<SEC-DOCUMENT>0001193125-22-173887.txt : 20220614
<SEC-HEADER>0001193125-22-173887.hdr.sgml : 20220614
<ACCEPTANCE-DATETIME>20220614164842
ACCESSION NUMBER:		0001193125-22-173887
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		129
FILED AS OF DATE:		20220614
DATE AS OF CHANGE:		20220614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcellx, Inc.
		CENTRAL INDEX KEY:			0001786205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				472855917
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265573
		FILM NUMBER:		221015462

	BUSINESS ADDRESS:	
		STREET 1:		25 WEST WATKINS MILL ROAD
		STREET 2:		SUITE A
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-723-6641

	MAIL ADDRESS:	
		STREET 1:		25 WEST WATKINS MILL ROAD
		STREET 2:		SUITE A
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d332508ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:aclx="http://arc.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1/A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:AccountingStandardsUpdateExtensibleList" id="hidden49526100" contextRef="P01_01_2022To03_31_2022">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden49526058" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden49526059" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="dei:DocumentType" id="hidden49526105" contextRef="P01_01_2022To03_31_2022">S-1/A</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To03_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden49525947" contextRef="P01_01_2022To03_31_2022">Arcellx Inc</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To03_31_2022">0001786205</ix:nonNumeric><ix:footnote id="FN_158911" xml:lang="en-US">These items have been reclassified to conform to current period presentation.</ix:footnote ><ix:footnote id="FN_158912" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="aclx-20220331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_01_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_08_2022To02_08_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-08</xbrli:startDate> <xbrli:endDate>2022-02-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_31_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-31</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >aclx:ChangeInControlMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:MD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >aclx:ChangeInControlMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >aclx:ChangeInControlFollowingAnIpoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >aclx:ChangeInControlMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >aclx:ChangeInControlMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EquipmentUnderCapitalLeaseMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:EquipmentUnderCapitalLeaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:LabEquipmentUnderCapitalLeasesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyCarryforwardMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >aclx:IndefinitelyCarryforwardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxPeriodTwoThousandThirtyFiveMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >aclx:TaxPeriodTwoThousandThirtyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LonzaSowMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >aclx:LonzaSowMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DividendsAxis" >us-gaap:DividendDeclaredMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:LabEquipmentUnderCapitalLeasesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DividendsAxis" >us-gaap:DividendDeclaredMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >aclx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:MD</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >aclx:RestrictedStockUnitsExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >aclx:ChangeInControlMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-08</xbrli:startDate> <xbrli:endDate>2022-02-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-08</xbrli:startDate> <xbrli:endDate>2022-02-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >aclx:RestrictedStockUnitsExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2021To06_30_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-04</xbrli:startDate> <xbrli:endDate>2022-03-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >aclx:TemporaryEquityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_condition" > <xbrli:measure>aclx:condition</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_DIRECTORS" > <xbrli:measure>aclx:DIRECTORS</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_49525090" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525091" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525092" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525093" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525094" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525095" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525096" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525097" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525098" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525099" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525100" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525101" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525102" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525103" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525208" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525209" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525210" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525211" toRefs="FN_158911"/><ix:relationship fromRefs="Fact_49525510" toRefs="FN_158912"/><ix:relationship fromRefs="Fact_49525513" toRefs="FN_158912"/><ix:relationship fromRefs="Fact_49525516" toRefs="FN_158912"/></ix:resources></ix:header></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 17pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the Securities and Exchange Commission on June&#160;14, 2022. </div></div></div></div> <div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration No.&#160;333-265573 </div></div></div></div> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom: 1px solid rgb(0, 0, 0); text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 4pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-indent: 0px;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">AMENDMENT NO. 1 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TO </div></div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden49526105">S-</span>1</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden49525947">ARCELLX, INC.</span> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Delaware</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2836</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">47-2855917</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification Number)</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">25 West Watkins Mill Road, Suite A </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gaithersburg, MD 20878 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(240) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">327-0603</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">President, Chief Executive Officer and Chairman of the Board of Directors </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">25 West Watkins Mill Road, Suite A </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Gaithersburg, MD 20878 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(240) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">327-0603</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 36%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 26%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 36%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Dan Koeppen <br/>Robert L. Wernli Jr.</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jennifer Fang</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">David Sharon</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C.</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1301 Avenue of the Americas</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">40<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">th</div> Floor</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, New York 10019</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(212) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">999-5800</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lisa Firenze</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Jeffries L. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Oliver-Li</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Wilmer Cutler Pickering Hale and Dorr LLP</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">7 World Trade Center</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">250 Greenwich Street</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, New York 10007</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(212) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">230-8800</div><br/></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public:</div></div> As soon as practicable after the effective date of this registration statement. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box.&#160;&#160;&#9744; </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;12b-2</div> of the Exchange Act. </div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 60%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To03_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div></div> <div style="text-indent: 8%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment, which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXPLANATORY NOTE </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No. 1 (this &#8220;Amendment&#8221;) to the Registration Statement on Form S-1 of Arcellx, Inc. (Registration No. 333-265573) (the &#8220;Registration Statement&#8221;) is being filed solely for the purpose of filing the Inline <div style="font-weight:bold;display:inline;"></div>eXtensible<div style="font-weight:bold;display:inline;"></div> Business Reporting Language (XBRL) exhibits as indicated in Part II, Item 16 of this Amendment. Accordingly, Part I, consisting of the preliminary prospectus, and the balance of Part II of the Registration Statement are unchanged. </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Arial Narrow; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(235, 0, 41); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. </div></div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(235, 0, 41); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subject to Completion </div></div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: rgb(235, 0, 41); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preliminary Prospectus dated June&#160;14, 2022 </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">P R O S P E C T U S </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 20pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">4,000,000 Shares </div></div></div></div> <div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 20pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g96c25.jpg" style="width: 360px; height: 72px;"/></div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 20pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div></div> <div style="font-size: 20pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 20pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 20pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are selling 4,000,000 shares of our common stock. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;ACLX.&#8221; On June&#160;13, 2022, the last reported sale price of our common stock on the Nasdaq Global Select Market was $21.71 per share. The final public offering price will be determined through negotiation between us and the underwriters in the offering, and the last reported sale price of our common stock used throughout this prospectus may not be indicative of the final public offering price. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under the federal securities laws and, under applicable Securities and Exchange Commission (&#8220;SEC&#8221;) rules, we have elected to comply with certain reduced public company reporting and disclosure requirements. See &#8220;Prospectus Summary&#8212;Emerging Growth Company and Smaller Reporting Company Status.&#8221; </div></div></div> <div style="text-indent: 8%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing in the common stock involves risks that are described in the &#8220;<a href="#toc129231_4">Risk Factors</a>&#8221; section beginning on page 15 of this prospectus. </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Per&#160;Shares</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public offering price</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting discounts and commissions<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds, before expenses, to us</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See the section titled &#8220;Underwriting&#8221; for additional information regarding compensation payable to the underwriters. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters may also exercise their option to purchase up to an additional 600,000 shares from us, at the public offering price, less the underwriting discounts and commissions, for 30 days after the date of this prospectus. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares will be ready for delivery on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 20%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 18pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 49%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 18pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BofA&#160;Securities</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SVB&#160;Securities</div></div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022. </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 96%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_1">PROSPECTUS SUMMARY</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_2">THE OFFERING</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_3">SUMMARY FINANCIAL DATA</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_4">RISK FACTORS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">83</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_6">MARKET, INDUSTRY AND OTHER DATA</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">85</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_7">USE OF PROCEEDS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">86</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_8">DIVIDEND POLICY</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">87</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_9">CAPITALIZATION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">88</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_10">DILUTION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">90</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_122">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">92</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_13">BUSINESS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">108</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_14">MANAGEMENT</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">166</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_15">EXECUTIVE COMPENSATION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">193</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_17">PRINCIPAL STOCKHOLDERS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">196</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_18">DESCRIPTION OF CAPITAL STOCK</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">199</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_19">SHARES ELIGIBLE FOR FUTURE SALE</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">205</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_20">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</span> HOLDERS OF OUR COMMON STOCK</a></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">207</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_21">UNDERWRITING</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">211</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_22">LEGAL MATTERS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">219</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_23">EXPERTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">220</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_24">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">221</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc129231_25">INDEX TO FINANCIAL STATEMENTS</a></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">F-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and the underwriters have not authorized anyone to provide you any information other than that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investors outside of the United States: we have not and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div id="toc129231_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PROSPECTUS SUMMARY </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you and your investment decision. You should carefully read this entire prospectus, including the sections titled &#8220;Risk Factors,&#8221; &#8220;Special Note Regarding Forward-Looking Statements,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes before deciding to buy shares of our common stock. In this prospectus, unless context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Arcellx,&#8221; or &#8220;the company&#8221; refer to Arcellx, Inc. and, where appropriate, our subsidiary Subdomain, LLC. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Though cell therapies have shown benefits to date, cell therapies have historically been constrained to existing biologic structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T cells (CAR-Ts). Existing cell therapy solutions, most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we can overcome these limitations by engineering a new class of D-Domain powered autologous and allogeneic CAR-Ts, including classical single infusion CAR-Ts called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), we announced positive preliminary results in our ongoing Phase 1 clinical trial for CART-ddBCMA for the treatment of relapsed or refractory (r/r) multiple myeloma (MM). As of the May 3, 2022 data cutoff date, 31 patients were evaluable for safety and efficacy analysis, which required at least a 1-month follow-up visit per protocol using the 2016 International Myeloma Working Group (IMWG) uniform response criteria for MM, which are further described on page 131. These evaluable patients comprised the dose escalation cohorts for the first dose level (DL1) (n=6) and the second dose level (DL2) (n=6) and a dose expansion cohort of DL1 (n=19). </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key highlights from the data presented are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the 31 evaluable patients: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 (39%) patients have extramedullary disease (EMD); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100% overall response rate (ORR) achieved per IMWG criteria with median follow up of 12.1 months; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 of 31 (71%) patients achieved complete response (CR) or a stringent complete response (sCR); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 of 31 (94%) patients achieved very good partial response (VGPR) or better; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 of 31 (6%) patients achieved a partial response (PR). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The longest response to date is ongoing at 27 months in the first patient ever dosed with CART-ddBCMA, a patient with EMD. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversions to sCR have occurred as early as the 1-month follow-up visit and have currently been reported as late as the 12-month follow-up visit. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the 16 patients who have had their 12-month follow-up visit: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 (50%) patients have EMD; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 (81%) patients reached CR/sCR; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 (56%) patients remain in ongoing response with a median follow up of 17.7 months. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA dosed at the recommended Phase 2 dose (RP2D) of 100 million CAR+T cells (DL1) continues to be well-tolerated. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), have been manageable, and all were resolved with standard management. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No cases of delayed neurotoxicity events or parkinsonian symptoms have been observed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No cases of grade 3 (or greater) CRS and only one case (4%) of grade 3 ICANS event have been observed with no additional cases from those previously reported as of the November 4, 2021 cutoff date. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All patients enrolled in the trial have poor prognostic factors with 21 of 31 (68%) patients being <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">penta-refractory</div> and all 31 patients having had at least three prior treatments, with a median of five prior lines of therapy. Twelve out of 31 patients (39%) had EMD, a condition in which myeloma cells form tumors outside the bone marrow, involving one or more organs, including the liver, lymph nodes, skin, lungs, and central nervous system. EMD is associated with worse prognosis, and patients with EMD have been reported to experience lower CR rates and shorter duration of response (DOR) in clinical trials of other BCMA-targeting CAR-T therapies than non-EMD patients. Twelve of 31 patients (39%) had greater than 50% bone marrow plasma cells (BMPC), which are the malignant cells that cause multiple myeloma. Patients with a high percentage of BMPC are considered to have increased tumor burden, which has been associated with poor prognosis in MM clinical trials and observational studies. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe our preliminary Phase 1 clinical data have demonstrated that D-Domains can potentially provide meaningful clinical benefits. Our D-Domain platform consists of structurally unique binders that are small and stable. They can be consistently manufactured and easily modified to generate diverse libraries of proprietary target-binding domains. The small size and structure of our D-Domain binders compared to other antigen binding domains used in CAR constructs, such as scFvs, are illustrated below. In our preclinical studies, we have demonstrated that CARs with D-Domains exhibit higher transduction efficiency, higher surface expression, and lower tonic signaling than CARs with scFvs, which we believe can lead to cell therapies with improved therapeutic benefit and reduced toxicity. Our D-Domain platform enables us to make a range of CAR-T therapies, including ddCARs and ARC-SparX, tailored to address the complexities of cancer. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g01a11.jpg" style="width: 304px; height: 195px;"/></div> </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the preliminary results from our ongoing Phase 1 clinical trial of CART-ddBCMA in an enrolled population with poor prognostic indicators demonstrate the potential for CART-ddBCMA to become a best-in-class treatment for patients suffering from r/r MM, including those with EMD. MM is the third most common hematological malignancy in the United States and Europe, with approximately 35,000 new cases diagnosed per year in the United States. Although changes in the treatment landscape for MM have increased the rates of and depth of response (antitumor activity), there is currently no cure, whether approved or in clinical development, for MM and patients typically have a life expectancy of approximately five years. In 2020, the size of the global MM market was approximately $18 billion. We estimate the current total addressable CAR-T market for r/r MM to be approximately $10 billion based on the number of patients who are receiving third line treatments and beyond. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are preparing to initiate our iMMagine Phase 2 pivotal trial of CART-ddBCMA in r/r MM in late 2022, and if successful, intend to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). We also intend to rapidly pursue clinical development of&#160;CART-ddBCMA in earlier lines of therapy through our iMMagine-2 clinical trial. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are also advancing our novel ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, our proprietary D-Domain based universal CAR-T cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. We believe that controlling ARC-T activation with SparX protein effectively separates the antigen-recognition and killing functions, which allows us to reduce toxicities. Our preclinical studies of our ARC-SparX product candidates have demonstrated that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells can be activated by different SparX proteins that target different antigens suggesting that ARC-SparX can potentially address antigen heterogeneity, and thereby address some harder to treat indications. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We initiated our Phase 1 clinical trial of ACLX-001, the first product candidate developed under our ARC-SparX platform, for the treatment of r/r MM in the second quarter of 2022. ACLX-001 is an immunotherapeutic combination composed of our ARC-T cells and SparX proteins that target BCMA. This trial is intended to establish an ARC-SparX dosing regimen and prepare for ARC-SparX trials in expanded indications. Our lead ARC-SparX indication is AML/MDS, for which we have multiple SparX in development targeting different antigens. We plan to initiate the Phase 1 clinical trial for ACLX-002, an ARC-SparX product candidate targeting CD123, for the treatment of AML/MDS in the second half of 2022 and plan to initiate a Phase 1 clinical trial for ACLX-003, an ARC-SparX product candidate directed at another antigen associated with AML/MDS in 2024. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have built a broad and scalable pipeline that has positioned us to capitalize on the potential of our proprietary platform technologies and achieve long-term growth and sustainability within the field of cell therapy. We believe our therapeutic approaches, ddCAR and ARC-SparX, will enable us to select mechanisms that are most appropriate for each target and indication we may choose to pursue based on underlying disease biology and patient need, such as in solid tumors, including small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). We are also integrating AI-powered discovery and computational tools to expand the applicability of our platforms. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have worldwide rights to all of our programs and have summarized our preclinical and clinical programs in the pipeline chart below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g15a69.jpg" style="width: 591px; height: 310px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pivotal refers to our planned iMMagine Phase 2 trial. Based on our current discussions with the FDA, we believe that results from our iMMagine trial, if positive, together with the results from our Phase 1 trial could be sufficient to support the filing of a BLA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our D-Domain platform has broad potential utility for additional cell modalities, targets, therapeutic areas and applications and we plan to expand our pipeline beyond hematologic and solid cancers to autoimmune disease, as well as to allogeneic cell types. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The recent availability of cell therapy products, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cells, introduced an unprecedented &#8220;living therapeutic&#8221; modality that offers benefits well beyond what previous oncology modalities offered. For the first time, these therapeutics directly harness the strength of the patient&#8217;s own immune system to significantly reduce, even potentially eradicate, tumors. While <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> and other genetically modified cell therapies have shown significant progress in extending the lives of patients who often have no other treatment options, there are limitations to their broader use, including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Limited Long Term Efficacy</div></div>: FDA-approved <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> may offer higher response rates compared to other available therapies, but efficacy as measured by the DOR is highly variable. For example, of the patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma with high response rates, approximately 40% or fewer patients were in ongoing response at 18 months. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Adverse Effects:</div></div> These cell therapies also have the potential to cause several adverse effects. Uncontrolled cellular expansion and resulting side effects such as CRS, neurotoxicity, parkinsonian symptoms and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;on-target,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-tumor&#8221;</div> toxicities stifle the broader use of these therapies in several key ways. Specifically, they limit the number of patients that are eligible for treatment, relegate these therapies to later lines of treatment, preclude the use of these therapies in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-academic</div> and outpatient settings, and increase costs to patients, payers and providers due to the need for intensive care unit access when they are used. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Narrow Applicability:</div></div> Currently, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> and other genetically modified cell therapies are utilized in only a few hematological oncology indications. Their activity in most tumors is primarily driven </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by a limited number of tumor specific antigen targets. Their utility is further limited by secondary resistance mechanisms arising in the r/r settings, as well as the antigen heterogeneity that is characteristic of some of these diseases. For example, within r/r MM, patients with EMD have been reported to experience worse outcomes in clinical trials of other BCMA-targeting CAR-T therapies than non-EMD patients. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our mission is to advance humanity by engineering cell therapies that are safer, more effective, and broadly accessible. We plan to achieve this goal by maximizing the impact of our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders, which enable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> to have distinct advantages including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Promising Preliminary Clinical Data</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;High ORR and Durable Responses</div></div>: In our ongoing Phase 1 clinical trial of CART-ddBCMA, for the 31 patients evaluable for efficacy, the ORR is currently 100% and the DOR is promising with more than half of the 16 patients with r/r MM who have had their 12-month follow-up visit remaining in ongoing response with a median follow up of 17.7 months. We believe these preliminary results demonstrate the capability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> not only to effectively bind target antigens and drive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cell proliferation but also to enable efficient killing of a substantial proportion of tumor cells. High cell surface expression and low propensity for tonic signaling of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> may enable more effective interactions between the CAR and the antigen as well as reduced T-cell exhaustion, which may explain the rapid and long-term responses currently observed in our ongoing Phase&#160;1 clinical trial. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Potentially Differentiated Safety Profile</div></div>: We believe the small and stable structure of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> enables a high transduction rate, resulting in a high proportion of cells expressing the CAR construct on the cell surface (CAR+ cells). A high proportion of CAR+ cells lowers the total number of T cells required to be administered which we believe may yield a therapy with an improved toxicity profile, consistent with currently available results of the ongoing Phase 1 trial of CART-ddBCMA. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity to Treat a Broader Group of Cancer Patients</div></div>: We believe the preliminary positive results of our Phase 1 clinical trial of CART-ddBCMA underscores the capability to apply D-Domains across a wide variety of tumor antigen targets in the future. Based on the differentiation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> and the breadth and depth of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> libraries, we believe we can expand to a broader group of patients, including those with heterogeneously expressed tumor antigen and antigen targets that might be difficult to target. We are currently developing therapies within both our ddCAR and ARC-SparX platforms to treat a broad variety of indications, starting with r/r MM and AML/MDS and, in the future, solid tumors. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foundation of our competitive advantage is our proprietary technology, clinical evidence, track record of execution, manufacturing success, and assembly of a proven management team. We believe these advantages position us to achieve significant market share in a large and attractive market and to ultimately transform the cell therapy market, contributing to a significant advancement in medicine. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategy </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our strategy to achieve our mission is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance CART-ddBCMA to treat r/r MM patients in the United States and abroad; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Develop comprehensive ARC-SparX AML/MDS program; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expand our pipeline to select solid tumor indications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Apply our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> technology outside of autologous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> solutions; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Enable greater access to CAR-T therapy through clinical studies in broader patient populations that support improved market access; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Invest in technologies that lower customer friction, increase capacity and improve responsiveness; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leverage novel AI and machine learning technologies to drive our discovery efforts; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunistically pursue strategic partnerships and collaborations to maximize the full potential of our platform. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Team </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our team and culture are critical to realizing our vision of reimagining cell therapy as one of the future pillars of medicine. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are led by a diverse team of executives with significant experience in business, discovery, development, manufacturing, and commercialization of differentiated and novel therapies specifically in the fields of oncology, cell therapy and rare diseases. Rami Elghandour, our Chairman and Chief Executive Officer, previously served as President and Chief Executive Officer at Nevro where he grew the company from a small private company to a publicly traded commercial organization with nearly $400&#160;million in revenue. Prior to Nevro, Mr.&#160;Elghandour was an investor with Johnson&#160;&amp; Johnson Development Corporation where he led several investments, including Nevro&#8217;s Series&#160;B financing. Our Chief Medical Officer, Christopher Heery, M.D., an oncologist by training, was the former Head of Clinical Trials Group for the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, and previously served as Chief Medical Officer at Precision Biosciences and Bavarian Nordic. Our Chief Financial Officer, Michelle Gilson, was previously a senior equity research analyst covering the biotechnology sector, most recently as a Managing Director at Canaccord Genuity. Our Chief Scientific Officer, David Tice, Ph.D., has over 20 years of biopharmaceutical research and drug development experience in oncology including 18 years at MedImmune, the global biologics research and development unit of AstraZeneca. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have attracted a diverse and talented group of innovators and company builders to help us execute our strategy and to build a transformative cell therapy platform company. Collectively, we are driven by our shared purpose and our values. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we had 78 employees and we are committed to continuing to build and maintain a diverse and inclusive organization. We believe focusing on diversity and inclusion is not only the right thing to do but is also a competitive advantage. We are purposeful in our efforts to seek and retain top diverse talent from underrepresented groups as reflected throughout our organization: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executives: 29% female; 36% diverse (racial&#160;&amp; ethnic representation); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managers and senior scientists with managerial responsibilities: 32% female; 45% diverse; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professionals and individual contributor scientific roles: 71% female; 49% diverse. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commitment to diversity does not stop within the walls of our organization. With our mission of advancing humanity, we believe in equitable access to healthcare. Inclusive research programs that encompass real-world patient populations can contribute to addressing racial inequality in healthcare. We are dedicated to expanding representation within our clinical trials. </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also believe deeply in corporate social responsibility and being conscious stewards in our society. We are devoted to leveraging our science to make a positive impact for the patient and local communities we serve. As our organization expands, we intend to grow our community involvement and outreach efforts, and establish our corporate brand as a force for good through corporate philanthropic, patient advocacy, and employee volunteerism. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Associated with Our Business </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our business strategy is subject to numerous risks, as more fully described in the section entitled &#8220;Risk Factors&#8221; immediately following this prospectus summary. These risks include, among others: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if this offering is successful, we will need substantial additional funding. If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and development programs, future commercialization efforts or employee headcount. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently generate no revenues from sales of any products and may never generate revenue or be profitable. Our product candidates are in the early stages of development. We only recently began a clinical trial to test our first product candidate in humans. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ddCAR and ARC-SparX platforms represent novel and unproven approaches to treatment, which makes it difficult to predict the timing, results and costs of product candidate development and the likelihood of obtaining regulatory approval. In addition, we may experience difficulty in identifying appropriate target binding domains and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ARC-SparX platform is highly dependent on the success of ACLX-001. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on third parties to conduct our clinical trials and manufacture our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical development is a lengthy, expensive and uncertain process. Our clinical trials may fail to demonstrate adequate safety and/or efficacy of any of our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may encounter substantial delays, including difficulties enrolling patients, in our clinical trials. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interim, preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing genetically engineered products is complex and subject to both human and systemic risks. We or our third-party manufacturers may encounter difficulties in production and sourcing and may be subject to variations and supply constraints of key components. Modifications in manufacturing may require additional studies and regulatory filings, resulting in additional costs or delay. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may receive unexpected or unfavorable feedback from FDA or foreign health authorities regarding satisfaction of safety, purity and potency (including clinical efficacy), amongst other factors, all of which would prevent or delay regulatory approval and commercialization and potentially impact the development of our other product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to significantly expand our organization, including creating additional infrastructure to support our operations as a public company and our growth as we advance our product candidates through clinical trials, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform and our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitive position may be adversely affected. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The price of our stock may be volatile, and you could lose all or part of your investment. Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our business is affected by the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and may be significantly adversely affected as the pandemic continues or if other events out of our control disrupt our business or that of our third-party providers. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Initial Public Offering (IPO) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 8, 2022, we issued and sold 9,487,500 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,237,500 additional shares of common stock, at a public offering price of $15.00 per share. We received aggregate net proceeds of $128.0 million, after deducting underwriting discounts and commissions and other offering expenses paid by us of approximately $14.3 million. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following are recent developments to our business and clinical development of our most advanced candidates, CART-ddBCMA and ACLX-001, since our IPO in February 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2022, we entered into a statement of work with Lonza Houston, Inc. for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. See &#8220;Business&#8212;Lonza Manufacturing Services Agreement&#8221; for more information. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2022, we issued and sold an aggregate of 590,318 shares of our common stock in a private placement to one accredited investor at a price of $16.94 per share for an aggregate purchase price of $10.0 million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, we dosed our first patient in the Phase 1 clinical trial of ACLX-001 for the treatment of r/r MM. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, we announced the election of Olivia Ware as a member of our board of directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, we announced the appointment of Michelle Gilson as our Chief Financial Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2022 at ASCO, we announced new positive clinical data for 31 patients from our ongoing Phase 1 trial of CART-ddBCMA for the treatment of r/r MM. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Information </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We were incorporated in Delaware in December 2014 under the name &#8220;Encarta Therapeutics, Inc.&#8221; In January&#160;2016, we filed a certificate of amendment to change our name to &#8220;Arcellx, Inc.&#8221; Our principal executive offices are located at 25 West Watkins Mill Road, Suite A, Gaithersburg, Maryland 20878. Our telephone number is (240) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">327-0603.</div> Our website address is www.arcellx.com. Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We use the name Arcellx, the Arcellx logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company and Smaller Reporting Company Status </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time that those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earliest of (i)&#160;the last day of our first fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more, (ii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, (iii)&#160;the date on which we have issued more than $1.0&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities during the previous three years, or (iv)&#160;the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering (i.e., December 31, 2027). An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may provide reduced disclosure about our executive compensation arrangements; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We are not required to hold <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stockholder&#160;non-binding&#160;advisory</div> votes on executive compensation or golden parachute arrangements. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;small reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements. Specifically, among other things, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div id="toc129231_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE OFFERING </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock offered by us </div></div> </td>
<td>4,000,000 shares. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriters&#8217; option to purchase additional shares </div></div> </td>
<td>We have granted the underwriters an option for a period of 30 days to purchase up to 600,000 additional shares of our common stock. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock to be outstanding immediately after<br/> this offering </div></div> </td>
<td>39,736,584 shares (or 40,336,584 shares if the underwriters exercise their option to purchase additional shares in full). </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of proceeds </div></div> </td>
<td>We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: (1)&#160;to fund the development of our product candidates CART-ddBCMA, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and (2)&#160;for other research and development activities, working capital and other general corporate purposes. See the section titled &#8220;Use of Proceeds&#8221; for more information. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk factors </div></div> </td>
<td>See the section of this prospectus titled &#8220;Risk Factors&#8221; beginning on page&#160;15 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in shares of our common stock. <br/>. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq trading symbol </div></div> </td>
<td>ACLX </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares of our common stock to be outstanding after this offering is based on the 35,736,584 shares of our common stock outstanding as of March 31, 2022, and excludes the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,113,589 shares of common stock issuable upon exercise of options to purchase shares of our common stock outstanding as of March 31, 2022, at a weighted-average exercise price of $8.83 per share; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">702,663 shares of common stock subject to restricted stock units (RSUs) outstanding as of March 31, 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95,638 shares of common stock subject to RSUs granted after March 31, 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158,723 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we granted after March 31, 2022, at a weighted-average exercise price of $8.29 per share; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">550,513 shares of common stock reserved for future issuance under our 2022 Equity Incentive Plan (2022 Plan); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">312,500 shares of common stock reserved for issuance under our 2022 Employee Stock Purchase Plan (2022 ESPP). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of our 2022 Plan and our 2022 ESPP provides for annual automatic increases in the number of shares reserved thereunder, and our 2022 Plan also provides for increases to the number of shares that may be granted thereunder based on awards under our 2017 Plan that expire, are forfeited, or otherwise repurchased by us, as more fully described in the section titled &#8220;Executive Compensation&#8212;Employee Benefit and Stock Plans.&#8221; </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated, this prospectus reflects and assumes the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No exercise of outstanding options and no vesting of RSUs after March 31, 2022; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No exercise by the underwriters of their option to purchase additional shares of common stock from us in this offering. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div id="toc129231_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY FINANCIAL DATA </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables summarize our financial data for the periods and as of the dates indicated. We have derived the consolidated statement of operations data for the years ended December&#160;31, 2020 and 2021 from our audited consolidated financial statements included elsewhere in this prospectus. We have derived the condensed consolidated statement of operations data for the three months ended March&#160;31, 2021 and 2022 and the condensed consolidated balance sheet data as of March&#160;31, 2022 from our unaudited condensed consolidated financial statements included elsewhere in this prospectus. We have prepared the unaudited condensed consolidated financial statements on the same basis as the consolidated financial statements and have included all adjustments that, in management&#8217;s opinion, are necessary to state fairly the information set forth in those condensed consolidated financial statements. Our historical results are not necessarily indicative of results that may be expected in the future and our results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the full year ending December&#160;31, 2022 or any other period. You should read the following summary financial data together with our financial statements and the related notes included elsewhere in this prospectus and the information in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The summary financial data in this section are not intended to replace, and are qualified in their entirety by, our consolidated financial statements and related notes thereto included elsewhere in this prospectus. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Statement of Operations Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">25,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;32,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;11,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;65,018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;32,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(32,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(11,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(65,018</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(32,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(11,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(64,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive loss:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on marketable securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(11,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(64,989</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share attributable to common stockholders&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(1.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(33.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(145.55</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(112.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average common shares outstanding&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,760,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">337,302</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">446,379</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">286,105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actual</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Adjusted<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance Sheet Data:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">127,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">208,140</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">243,390</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">324,370</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(162,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(162,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">221,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">302,571</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the sale of shares of common stock in this offering at the assumed public offering price of $21.71 per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June&#160;13, 2022, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Each $1.00 increase (decrease) in the assumed public offering price of $21.71 per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June&#160;13, 2022, would increase (decrease) the as adjusted amount of each of cash and cash equivalents, total assets, and total stockholders&#8217; equity by approximately $3.8&#160;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&#160;million shares in the number of shares offered by us at the assumed public offering price after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us would increase (decrease) each of cash and cash equivalents, total assets, and total stockholders&#8217; equity by approximately $20.4&#160;million. The as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of our public offering determined at pricing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this prospectus, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a clinical-stage biopharmaceutical company with a limited operating history. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, establishing and protecting our intellectual property portfolio, developing our D-Domain, ddCAR and ARC-SparX technologies, identifying potential new target antigens, developing product candidates and undertaking research and development, including preclinical studies and clinical trials of our product candidates, all of which are biologics or biopharmaceuticals and require approval under a Biologics License Application (BLA). We have not yet demonstrated our ability to successfully initiate and complete any large-scale or pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale product, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could be if we had a longer operating history or were closer to commercialization. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges that may adversely affect our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have no products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We have incurred losses in each period since our inception in December 2014. Our net losses were $65.0 million and $32.1 million for the years ended December 31, 2021 and 2020, respectively, and $32.4&#160;million and $11.3&#160;million for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, we had an accumulated deficit of $162.5&#160;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we advance our product candidates through preclinical studies and clinical trials; continue to discover and develop additional product candidates and expand our pipeline; continue to develop our D-Domain, ddCAR and ARC-SparX platforms; maintain, expand, protect and enforce our intellectual property portfolio; and hire additional personnel. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue, which we do not expect will occur in the foreseeable future, as our product candidates are in preclinical or Phase 1 clinical development. Our prior and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if this offering is successful, we will need to obtain substantial additional funding to complete the development of our product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in biopharmaceutical product development is highly risky because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional funds to expand our clinical, regulatory, quality and manufacturing capabilities, whether internally or with third-party partners and collaborators, and advance our product candidates through preclinical studies and clinical trials in order to obtain marketing approval. If we obtain marketing approval for any of our product candidates, we also expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We estimate that our net proceeds from this offering will be approximately $81.0&#160;million, based on an assumed public offering price of $21.71 per share, which is the last reported sale price of our shares of common stock on the Nasdaq Global Select Market on June 13, 2022, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the development of our product candidates CART-ddBCMA, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and for other research and development activities, working capital and other general corporate purposes. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities together with the proceeds of this offering will be sufficient to fund our planned operations for at least the next 12&#160;months, but our assumptions could prove to be wrong, and we could consume capital significantly faster than we expect, requiring us to seek additional funding sources sooner than planned, through public or private financings or other sources, such as strategic collaborations. Such financing may result in dilution to stockholders, the imposition of burdensome debt covenants and repayment obligations or other restrictions that may affect our business. Our future capital requirements will depend on many factors, including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope, progress, timing, results and costs of developing and manufacturing our product candidates, and their components, and conducting preclinical studies and clinical trials and other testing of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our ability to continue our business operations and product candidate research and development, and to adapt to any changes in the regulatory approval process, manufacturing supply, or clinical trial requirements and timing due to the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and otherwise, including our ability to comply with new regulatory guidance or requirements on conducting clinical trials during and after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs, timing and outcome of regulatory review of any of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The extent to which our product candidates, if approved, can be offered by prescribers in various clinical settings, including academic hospitals and community practices, the acceptance of our products, if and when approved, by patients, the medical community and third-party payors, and the revenue received from commercial sale of any products for which we receive marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effect of competing technologies and market developments; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The extent to which we acquire or invest in other businesses, products and technologies and any other licensing or collaboration arrangements for any of our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all, especially in view of the widespread impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic (as further described under &#8220;&#8212;Risks Related to Our Business&#8221;). If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to decrease headcount and/or significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable to us than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. Any of the foregoing events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we may seek additional capital due to strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities, which may adversely affect our ability to develop our product candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Development of Our Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our product candidates are in the early stages of development. We have no products approved for commercial sale and have only recently began clinical trials to test our first product candidate in humans, which may make it difficult for you to evaluate our current business and predict our future success and viability. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are early in our development efforts. We are still developing our D-Domain, ddCAR and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-SparX</div> platforms, and conducting drug discovery and preclinical studies for a number of product candidates while advancing our ongoing Phase 1 clinical trials for CART-ddBCMA and ACLX-001. We have treated a small number of patients as of the date hereof and our clinical experience with our initial product candidates are limited. Because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is a high failure rate for biopharmaceutical products proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of the early stage of development of our product candidates, our ability to eventually generate significant revenues from product sales will depend on a number of factors, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification of additional target antigens for desired indications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification and development of D-Domain-based binding regions that bind to the desired target antigens; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful completion of preclinical studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Submission of INDs or other regulatory applications for our planned clinical trials or future clinical trials and authorizations from regulators to initiate clinical studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful enrollment in, and completion of, clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Achieving favorable results from clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receipt of marketing approvals from applicable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishing and maintaining sufficient manufacturing capabilities, whether internally or with third parties, for clinical and commercial supply; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in combination with other products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials and commercialization activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effectively competing with other therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing and implementing successful marketing and reimbursement strategies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maintaining a continued acceptable safety profile of any product following approval, if any. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not achieve one or more of these requirements in a timely manner, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot be certain that our clinical trials will be initiated and completed on time, if at all, or whether our planned clinical strategy will be acceptable to the FDA or foreign health authorities. In addition, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic is still evolving, and it is impossible to predict the impact this pandemic may have on the development of our product candidates, our preclinical studies and clinical trials, and our business. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To become and remain profitable, we must develop, obtain approval for and eventually commercialize products, if approved, that generate significant revenue. We do not expect to receive approval of any product candidates for many years and may never succeed in these activities. In addition, it is not uncommon for product candidates to exhibit unforeseen safety issues or inadequate efficacy when tested in humans despite promising results in preclinical animal models or earlier trials, and we may ultimately be unable to demonstrate adequate safety and efficacy of our product candidates to obtain marketing approval. Even if we obtain approval and begin commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development, manufacturing and other expenditures to develop and market additional product candidates. Our failure to become or remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ddCAR and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-SparX</div> platforms represent novel and unproven approaches to treatment, which makes it difficult to predict the timing, results and costs of product candidate development and the likelihood of obtaining regulatory approval. In addition, we may experience difficulty in identifying appropriate target binding domains. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have concentrated our research and development efforts on our ddCAR and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-SparX</div> platforms, and our future success depends on the successful development of these platforms. Although there are other cell </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">therapies and adapter platforms in clinical development, our platform technologies, including our D-Domain technology, have not been extensively tested over any significant period of time. In addition, while we believe that&#160;our platforms may be capable of overcoming certain challenges faced by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">conventional&#160;CAR-T</div> therapies, we cannot be certain that our approach will result in the intended benefits or will not result in unforeseen negative consequences over time. As an example, we may not be able to identify D-Domain binders that can recognize certain antigen targets that we would like to pursue, or the development of the applicable D-Domain, ddCAR or SparX protein targeting such antigens may be too challenging or expensive to be commercially viable. We do not currently have any approved or commercialized products. As with other targeted therapies, off-tumor or off-target activity could delay development or require us to reengineer or abandon a particular product candidate. There can be no assurance that any problems we experience in the future related to preclinical and clinical development of our novel platforms and our product candidates will not cause significant delays or unanticipated costs or that such problems can be solved. We may also experience delays in developing sustainable, reproducible and scalable manufacturing processes or transferring those processes to manufacturing partners or developing our own internal manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because cell therapies represent a relatively new field of cellular immunotherapy and cancer treatment generally, developing and commercializing our product candidates subjects us to a number of risks and challenges, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Developing and deploying consistent and reliable processes for procuring a patient&#8217;s apheresis material, engineering a patient&#8217;s T&#160;cells <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ex vivo</div></div> and infusing the engineered T&#160;cells back into the patient; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing protocols for the safe administration of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishing integrated solutions in collaboration with specialty treatment centers and other clinical settings in order to reduce the burdens and complex logistics commonly associated with the administration of T&#160;cell therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conditioning patients with chemotherapy in conjunction with delivering each of our products, which may increase the risk of adverse side effects of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Educating medical personnel about the administration of our product candidates, particularly if our clinical trials permit expansion of participating physicians to those in various clinical settings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Educating medical personnel regarding the potential efficacy and safety profiles of our product candidates, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sourcing, supplies for the materials used to manufacture and process our product candidates for clinical trials and, in the future, commercial sale, if our product candidates are approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing reliable and scalable manufacturing processes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishing adequate manufacturing capacity suitable for the manufacture of our product candidates in line with expanding enrollment in our clinical studies and our projected commercial requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Achieving cost efficiencies in the scale-up of our manufacturing capacity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining and maintaining regulatory approval from the FDA or other health authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishing sales and marketing capabilities to successfully launch and commercialize our product candidates if and when we obtain any required regulatory approvals, and risks associated with gaining market acceptance of novel therapies if we receive approval; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining coverage and adequate reimbursement from third-party payors for our novel therapies in connection with commercialization of any approved product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may not be able to successfully develop our product candidates, our technology or our other product candidates in a manner that will yield products that are safe, effective, scalable or profitable. Additionally, because our technology involves the genetic modification of patient cells <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ex vivo</div></div>, we are subject to additional regulatory challenges and risks, including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genetically modified products in the event of improper insertion of a gene sequence into a patient&#8217;s chromosome could lead to lymphoma, leukemia or other cancers, or other aberrantly functioning cells; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although our viral vectors are not able to replicate, there is a risk with the use of lentiviral vectors that they could lead to new or reactivated pathogenic strains of virus or other infectious diseases; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA recommends a 15-year follow-up observation period for all patients who receive treatment using gene therapies, and we may need to adopt such an observation period for our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, public perception and awareness of cell therapy safety issues may adversely influence the willingness of subjects to participate in clinical trials of our product candidates, or if approved, of physicians to prescribe our products. Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Treatment centers may not be willing or able to devote the personnel and establish other infrastructure required for the administration of CAR-T cell therapies. Physicians may not be willing to undergo training to adopt this novel and personalized therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, in developing our product candidates, we have not exhaustively explored different options in the design and method for manufacturing ddCARs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells and SparX proteins. Although we do not currently plan to change the structure of our ddCARs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells or SparX proteins in the near term, we may in the future find our ddCARs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells or SparX proteins, or any manufacturing process thereof, may be substantially improved with future design or process changes. Changes in product design and changes in the manufacturing process, equipment, or facilities may require further comparability analysis and approval by FDA before implementation, which could delay our clinical trials and product candidate development, and could require additional clinical trials, including bridging studies, to demonstrate consistent and continued safety, identity, purity and efficacy. For example, we have used a lentiviral vector to transduce the gene for the ddCAR and ARC constructs into patient T&#160;cells. In the future, we may find that another type of vector or other means of genetically modifying T&#160;cells may offer advantages, particularly as we consider inserting our ddCARs and ARC-T&#160;cells into other immune cells. Changing how we genetically modify the immune cells would necessitate additional process development, comparability studies, regulatory filings and clinical testing and delay existing product candidates. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, the clinical trial requirements of the FDA and foreign health authorities and the criteria these regulators use to determine whether a product candidate is acceptable for approval, can vary substantially according to the type, complexity, novelty and intended use and market of the potential products. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">While&#160;CAR-T&#160;and</div> other cell therapy products have made progress in recent years, only a small number of products have been approved in the United States or other markets, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ARC-SparX platform is highly dependent on the success of ACLX-001. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ARC-SparX platform, including our AML/MDS program, is highly dependent on the success of ACLX-001, the first product candidate based on our ARC-SparX platform. ACLX-001 is an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA, or SPRX001, for the treatment of r/r MM. The ARC-T cells and the SparX proteins comprising ACLX-001 are entirely novel and neither has been previously tested in humans prior to the initiation of our Phase&#160;1 trial of ACLX-001. All SparX proteins are comprised of one or more antigen-specific binding domains fused to a protein that we refer to as the TAG. The TAG is a novel protein sequence derived from the 26kDA C-terminal fragment of human alpha fetoprotein (hAFP) and also has never been previously tested in humans prior to the initiation of our Phase&#160;1 trial of ACLX-001. The ARC-T cells are designed to have a binding domain that recognizes the TAG, which we refer to as anti-TAG. The anti-TAG has also never been previously tested in humans prior to the initiation of our Phase&#160;1 trial of ACLX-001. There can be no assurance that the ARC-T cells, the SparX proteins, the TAG, anti-TAG and other parts of ACLX-001 will not trigger an adverse response, cause unintended off-target recognition, limit the expected activity of the product candidates or result in other negative outcomes. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, because all product candidates in our ARC-SparX platform use the ARC-T cells, a failure with ACLX-001 will increase the actual or perceived likelihood that our other product candidates in the ARC-SparX platform will experience similar failures. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Phase 1 trial of ACLX-001 is intended to serve as clinical validation of our ARC-SparX platform as we seek to understand the pharmacokinetics, safety profile, and dosing strategy for future clinical development. Upon completion of the Phase&#160;1 trial, we will leverage the learnings from this trial to advance our AML/MDS programs utilizing ARC-SparX and consider developing additional SparX for r/r MM for a broader pipeline in this disease area. If we do not successfully complete the Phase&#160;1 trial for ACLX-001 in a timely manner or fail to achieve favorable results from the trial, we may experience significant delays or other issues in advancing our other ARC-SparX product candidates including ACLX-002, and ACLX-003 and our discovery projects, including AML-3 and AML-4. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical development is a lengthy, expensive and uncertain process. Our clinical trials may fail to demonstrate adequate safety and/or efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization and potentially impact the development of our other product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before obtaining regulatory approvals for the commercial sale of our product candidates, including CART-ddBCMA, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates have adequate safety and efficacy profiles, and the manufactured drug product has quality attributes that are appropriate for use in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during clinical development, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, particularly because early trials have smaller numbers of subjects tested. In addition, it is not uncommon for product candidates to exhibit unforeseen safety or efficacy issues, such as immunogenicity, when tested in humans despite promising results in preclinical animal models. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any clinical trials that we may conduct may not demonstrate the safety and efficacy profiles necessary to obtain regulatory approval to market our product candidates. As we continue developing our product candidates, serious adverse events, undesirable side effects, or unexpected characteristics may emerge, causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the risk-benefit ratio is more acceptable. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Treatment with our product candidates may cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of patients with significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> in our clinical trials may result in deaths or other adverse medical events due to an underlying condition or other therapies or medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance and impair our ability to commercialize our product candidates. Because the product candidates in our platforms share similar components, such as the D-Domain, a failure of one of our clinical trials may also increase the actual or perceived likelihood that our other product candidates will experience similar failures. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to a variety of factors, including, but not limited to, changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If our ongoing or future clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, or if we encounter safety concerns associated with our product candidates, we may: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incur unplanned costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Be delayed in or prevented from obtaining marketing approval for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtain approval for indications or patient populations that are not as broad as intended or desired; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtain approval with labeling that includes significant restrictions on use or distribution or safety warnings including boxed warnings; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Be subject to changes in the way the product is administered; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Be required to perform additional clinical trials to support approval or be subject to additional post-marketing requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified Risk Evaluation and Mitigation Strategy (REMS); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Be subject to the addition of labeling statements, such as warnings or contraindications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Be sued; and/or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Experience damage to our reputation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or foreign health authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA or foreign health authorities will view any of our product candidates as having adequate safety and efficacy profiles even if favorable results are observed in these clinical trials, and we may receive unexpected or unfavorable feedback from the FDA or foreign health authorities regarding satisfaction of safety, purity and potency (including clinical efficacy), amongst other factors. To the extent that the results of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trials are not satisfactory to the FDA or foreign health authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may encounter substantial delays in our clinical trials. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Events that may prevent successful or timely completion of clinical development include: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Delays associated with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic, as further described under &#8220;&#8212;Risks Related to Our Business&#8221;; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in reaching a consensus with regulatory agencies on trial design; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in reaching agreement on acceptable terms with prospective clinical research organizations (CROs), and clinical trial sites and obtaining required institutional review board (IRB), approval at each clinical trial site; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in recruiting and enrolling suitable patients to participate in our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to collect sufficiently viable white blood cells from patients, adequately expand or successfully transduce sufficient number of patient T cells for infusion or otherwise manufacture product candidates, or infuse patients in a timely manner with product candidate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure by our CROs, other third parties or us to adhere the trial protocol or the FDA&#8217;s good clinical practices (GCPs) or applicable regulatory guidelines in other countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or foreign health authorities for violations of applicable regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical trial sites, including due to a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or foreign health authorities to temporarily or permanently shut down due to violations of current good manufacturing practices (cGMPs) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Delays in having patients complete participation in a trial or return for post-treatment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> visits; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trial sites or patients dropping out of a trial or experiencing changing health or other conditions that require removing them from the trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discovering that product candidates have unforeseen safety issues, undesirable side effects or other unexpected characteristics; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent that we conduct clinical trials in foreign countries, the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receiving untimely or unfavorable feedback from applicable regulatory authorities regarding the trial or requests from regulatory authorities to modify the design of a trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Suspensions or terminations by IRBs or Data Safety Monitoring Boards (DSMBs) or internal clinical holds and/or clinical holds from or by regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lack of adequate funding to continue operations; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in regulatory requirements and guidance that require amending or submitting new clinical protocols and/or amendments to INDs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any inability to successfully complete our clinical trials could result in additional costs to us or impair our ability to raise capital, generate revenues from product sales and enter into or maintain collaboration arrangements. In addition, if we make material manufacturing changes to our product candidates or change manufacturers, we may need to conduct additional bridging or comparability studies. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we encounter delays or difficulties enrolling patients in our clinical trials and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until completion of treatment and adequate follow up. The enrollment of patients depends on many factors, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Inability to enroll, or delay in enrollment of, patients due to outbreaks and public health crises, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic, as further described under &#8220;&#8212;Risks Related to Our Business&#8221;; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patient eligibility criteria defined in the protocol; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The perceived risks and benefits of the product candidate being studied; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The size of the patient population required for analysis of the trial&#8217;s primary endpoints; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proximity of patients to trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The design of the trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to recruit clinical trial investigators with the appropriate competencies and experience; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to obtain and maintain patient consent; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reporting of the preliminary results of any of our clinical trials; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk that patients enrolled in clinical trials will drop out of the trials before completion of treatment and adequate follow up. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigation sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks, and acts of war (including Russia&#8217;s actions in Ukraine), relevant to such foreign countries. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interim, preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may publish interim, preliminary or topline data from clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data previously published. As a result, interim, preliminary and topline data should be viewed with caution until the final data are available. Adverse differences between interim, preliminary or topline data and final data could significantly harm our reputation and business prospects. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, preliminary, interim and topline data are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become available when patients mature on study, patient enrollment continues or as other ongoing or future clinical trials with a product candidate further develop. Past results of clinical trials may not be predictive of future results. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically more extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. Similarly, even if we are able to complete our planned and ongoing preclinical studies and clinical trials of our product candidates according to our current development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory approval. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our product candidates involve genetically modified T cell-based immunotherapies. A number of genetically modified cell therapies, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-based</div> products, have potentially severe side effects, including CRS, neurologic toxicities, Parkinsonism and Guillain-Barr&#233; syndrome, hemophagocytic lymphohistiocytosis/macrophaage activation syndrome, and prolonged and/or recurrent cytopenias, that can escalate and require intensive medical intervention and result in injury or death to the patients. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is no guarantee that our product candidates will not have side effects similar to those seen in other genetically modified cell therapies or that we will be able to prevent side effects from escalating to an unsafe level for our patients. Additionally, our initial product candidates are directed at treating patients with r/r MM. These patients are often elderly and/or have significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities,</div> and we expect they will receive our product candidate as a last line of therapy after most others therapies have failed, and these patients may be particularly susceptible to safety and toxicity risks. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy may be complicated and difficult to manage, which could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have designed a new binding domain that we believe should have low immunogenicity because we also removed potentially immunogenic sequences from their binding domains, which we refer to as &#8220;deimmunization.&#8221; However, it has never been tested in humans outside of our current Phase 1 trial and we cannot guarantee that there will not be any unexpected side effects from this binding domain or the SparX proteins that we plan to test as part of our product candidates. Although we have completed multiple preclinical studies designed to screen for&#160;toxicity&#160;caused by unintended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> recognition <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>by our novel binding domains, our product candidates may still cause unintended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> recognition in patients. Additionally, our genetically modified <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cells,</div> the ddCARs and the ARC-T&#160;cells, may still bind targets other than the target antigens or the TAG on our SparX proteins, respectively. If significant unexpected binding or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> binding occurs in normal tissue, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse events, undesirable side effects,&#160;toxicities&#160;or other unexpected characteristics. Detection of any significant unexpected or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> binding may halt or delay any ongoing clinical trials for our product candidates and prevent or delay regulatory approval. While we have developed a&#160;preclinical&#160;screening process to identify cross-reactivity of our product candidates, we cannot be certain that this process will identify all potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> tissue that our product candidates may interact with. Any unexpected or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> binding that impacts patient&#160;safety&#160;could materially impact our ability to advance our product candidates into clinical trials and ability to proceed to marketing approval and commercialization. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If serious adverse events or undesirable side effects arise, we could be required to suspend, delay, or halt our clinical trials and regulatory authorities could deny approval or require us to limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Side effects that are observed during the trial, whether treatment related or not, could also affect patient recruitment for future trials or the ability of enrolled patients to complete the trial or result in potential product liability claims. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, if serious adverse events or undesirable side effects are identified during development or after approval and are determined to be attributed to any of our product candidates, we may be required to develop REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these occurrences may harm our business, financial condition and prospects significantly. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development of product candidates in combination with other therapies could expose us to additional risks. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development of any of our product candidates in combination with one or more other therapies that have either been approved or not yet been approved for marketing by the FDA or comparable foreign regulatory authorities could expose us to additional risks, as combination therapies may increase the rate of serious or unexpected adverse events, which could result in a clinical hold as well as pre-approval and post-approval restrictions by the FDA or other regulatory authorities on the proposed combination therapy, including narrowing of the indication, warnings, additional safety data collection and monitoring procedures, and REMS, even if the cause of such serious or unexpected adverse events is not directly attributed to our product candidate. Any of these events or restrictions could have a material adverse effect on our business, delay our regulatory approval, and decrease the market acceptance and profitability of our product candidate if approved for a combination therapy. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will not be able to market and sell any product candidate in combination with any unapproved therapies that do not ultimately obtain marketing approval. If the FDA or other comparable foreign regulatory authorities do not approve or revoke their approval of other therapies used in combination therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with such therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain approval of or successfully market any one or all of the product candidates we develop. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with other existing approved therapies, we would continue to be subject to the risks that the FDA or other comparable foreign regulatory authorities could revoke approval of the other therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially. Additionally, if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies is prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing genetically engineered products is complex and subject to both human and systemic risks. We or our third-party manufacturers may encounter difficulties in production and sourcing and may be subject to variations and supply constraints of key components. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The manufacture of biological drug products, such as ddCARs and ARC-SparX, the components thereof, and the viral vectors used to manufacture these product candidates and components, is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production and sourcing, particularly in scaling up or out, validating the production process and assuring high reliability of the manufacturing processes (including the absence of contamination), in light of variations and supply constraints of key components. These problems include logistics and shipping, difficulties with production costs and yields, quality control, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">including consistency, stability, purity and efficacy of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability, purity, and efficacy failures, deficiencies, or other issues relating to the manufacture of our product candidates will not occur in the future. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, our product candidates are derived from cells collected from our patients and such cells may vary in type and quality as the patients may vary in age, stage of disease, and history of treatment among many other factors. We have strict specifications for the patient cell material and the product candidates we manufacture, including certain specifications that are reviewed and approved by regulatory authorities. The patient cell material variability may exceed our manufacturing process capability or deviate from the specified ranges, and result in failure in production of the patient therapy, lower quality batches, or even require adjustments to the specifications approved by authorities. The patient cell material may also be variable in factors that we currently may not be detecting with the analytical methods used or may not know how to measure and we may discover failures with the material after production. We may not be able to deliver the quality and consistency of our cell therapy products that we need or may need to re-collect cell material which can increase costs and/or cause delay, adversely impact patient outcomes and otherwise harm our clinical trials, reputation, business and prospects. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may fail to manage the logistics of collecting and shipping patient material to the manufacturing site and shipping the product candidate back to the relevant parties and experience delays or shortages of certain clinical or commercial grade supplies and components. Logistical and shipment delays and problems caused by us, our vendors or other factors not in our control, including the pandemic, geopolitical tensions related to Russia&#8217;s actions in Ukraine, the resulting sanctions imposed by the United States and other countries, and retaliatory actions taken by Russia in response to such sanctions, business interruptions, global supply chain issues, and weather, could prevent or delay the delivery of product candidates to patients. Additionally, we have to maintain a complex chain of identity and chain of custody with respect to patient material as it moves to the manufacturing facility, through the manufacturing processes and back to the patient. Failure to maintain chain of identity and chain of custody could result in patient death, loss of product or regulatory action. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Material modifications in the methods of product candidate manufacturing may result in additional costs or delay. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As product candidates progress from preclinical studies to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, materials and processes, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent purity, identity, potency, quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and could affect planned or other clinical trials conducted with product candidates produced using the modified manufacturing methods, materials, and processes. This could delay completion of clinical trials and could require <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> or clinical bridging and comparability studies, which could increase costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. We currently outsource all manufacturing to third parties, but we and our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not currently have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The process for treating cancer patients using T&#160;cell therapy is subject to human and systemic risks. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;vein-to-vein&#8221;</div></div> cycle for treating cancer patients using T&#160;cell therapy typically takes approximately four to six weeks and involves a large number of steps and human participants. First, the patient&#8217;s lymphocytes are isolated by apheresis at the clinical site and shipped to the manufacturing site. Under cGMP conditions at the manufacturing site, the patient&#8217;s lymphocytes are washed, and then enriched for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CD3-positive</div> T&#160;cells using specialized reagents. After overnight culture and T cell activation, the T&#160;cells are transduced using lentiviral vector transduction technology to introduce the CAR and ARC genetic construct into the enriched T&#160;cell population. At the completion of T&#160;cell transduction, the T&#160;cells are expanded for several days, harvested, formulated into the final drug product and then cryopreserved for delivery to patients. In the United States, samples of the final product are subjected to several release tests which must fulfill specified criteria for the drug product to be released for infusion. These include sterility, identity, purity, potency and other tests. We are subject to stringent regulatory and quality standards in the course of a T&#160;cell therapy treatment process, and we cannot assure you that our quality control and assurance efforts will be successful or that the risk of human or systemic errors in these processes can be eliminated. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prior treatments can alter the cancer and negatively impact chances for achieving clinical activity with our product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients with hematological cancers typically receive highly toxic chemotherapy as their initial treatments that can impact the viability of the T cells collected from the patient and may contribute to highly variable responses to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cell therapies. Patients could also have received prior therapies that target the same target antigen on the cancer cells as our intended product candidate and thereby these patients may have cancer cells with low or no expression of the target antigen. As a result, our product candidates may not recognize the cancer cell and may fail to achieve clinical activity. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to file additional INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to submit additional INDs for our current and future product candidates. However, our timing for submitting these INDs is dependent on the results of further research. Additionally, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once clinical trials have begun, issues will not arise that suspend or terminate such clinical trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that the FDA will not change its requirements in the future. These risks also apply to other clinical trials we may seek to commence under other INDs or amendments to existing INDs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The market opportunities for certain of our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small, and our projections regarding the size of the addressable market may be incorrect. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are initially developing CART-ddBCMA as a last line therapy for patients with r/r MM with plans to pursue label expansion into earlier lines of therapy. However, there is no guarantee that it, or any of our </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product candidates, even if approved, would be approved for earlier lines of therapy and any approved products may end up having a smaller market opportunity than we anticipated. Additionally, our projections of both the number of people who have the cancers we are targeting, as well as the size of the subset patient population who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. As a result, the number of patients may turn out to be fewer than expected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have limited financial and operational resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we intend to utilize with our clinical development strategy. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. As an example, although we believe that targeting BCMA initially before targeting other antigens will help us validate our platforms more easily, the risks associated with MM patients and the competition in cell therapies targeting BCMA, among others, could outweigh the benefits. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other products or drugs that are able to achieve similar or better results or make it difficult for us to develop our product candidates on a timely basis by limiting our access to patients, clinical trial sites, manufacturers and other resources. Our competitors include large and specialty pharmaceutical companies and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions. We believe the key competitive factors that will affect the development and commercial success of our product candidates are safety, efficacy, ensuring consistent quality and purity of the product candidates, delivery, price and the availability of reimbursement from government and other third-party payors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We anticipate substantial direct competition from other organizations developing advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> or other types of genetically modified cell therapies due to their promising clinical therapeutic effect in clinical trials, including 2seventy, Abbvie, Allogene, Amgen, Autolus, Bristol-Myers Squibb, Caribou Biosciences, CARsgen, Cartesian, Cellectis, Cellular Biomedicine Group, Celyad, Crispr, Gracell, GSK, Innovent, Johnson&#160;&amp; Johnson, Legend, Novartis, Pfizer, Poseida Therapeutics, Precision BioSciences, Pregene, and Regeneron. In addition, we expect to also compete with companies developing: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T cells with CARs that are reactive to tumor associated antigens; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">T cells with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> receptors (TCRs) that are reactive to tumor associated antigens; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cells</div> with adapter platforms; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bispecifics that bring T cells and diseased cells into close proximity with each other; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other immune cells that can be targeted using antibodies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Natural killer (NK)-based cell therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In vivo</div></div> CAR-T therapeutics; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allogeneic cell therapies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, greater access to clinical sites and patients, experienced regulatory, marketing and manufacturing teams and well-established sales forces. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see &#8220;Business&#8212;Competition.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business is affected by the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and may be significantly adversely affected as the pandemic continues or if other events out of our control disrupt our business or that of our third party providers. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While the extent of the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could have a material negative impact on our business, financial condition and operating results. We have experienced and may in the future experience disruptions from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> to our business in a number of ways, including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in supply chain and manufacturing, including the closure of apheresis collection centers, suspension of cell transport, limitations on transfer of technology, shutdown of manufacturing facilities and delays in delivery of supplies and reagents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in discovery and preclinical efforts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes to procedures or shut down, or reduction in capacity, of clinical trial sites due to limited availability of clinical trial staff, reduced number of inpatient intensive care unit beds for patients receiving cell therapies, diversion of healthcare resources away from clinical trials and other business considerations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limited patient access, enrollment and participation due to travel restrictions and safety concerns, as well as housing and travel difficulties for out of town patients and relatives; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in regulatory and other requirements for conducting preclinical studies and clinical trials during the pandemic. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus. For example, in March 2020, the FDA issued a guidance on conducting clinical trials during the pandemic, which was updated in July 2020, January 2021 and August 2021. The guidance describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report (or as a separate document) contingency measures implemented to manage the trial and any disruption of the trial as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; a list of all subjects affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic-related trial disruptions by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or trial, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial. In its most recent update to this guidance, the FDA addressed questions received from clinical practitioners who are adapting their operations in a pandemic environment. These questions focused on, among other things, when to suspend, continue or initiate a trial and how to submit changes to protocols for INDs and handle remote site monitoring visits. There is no assurance that this guidance governing clinical trials during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Other potential impacts of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our ongoing clinical trial include patient dosing and trial monitoring, which may be paused or delayed due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trial, interruption or delays in the operations of the FDA, or other reasons related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues, other aspects of our ongoing clinical trial and future planned clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial materials, clinical trial site data monitoring and efficacy, safety and translational data collection, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our trials or we may have to pause enrollment or we may choose to or be required to pause enrollment and/or patient dosing in our ongoing or planned clinical trials in order to preserve health resources and protect trial participants. It is unknown how long these pauses or disruptions could continue. Patients may need to withdraw due to COVID-19 infections or experience increased adverse events and deaths in our clinical trials due to COVID-19 related infections, which may result in increased complications due to immune suppression from our lymphodepletion regimen. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we currently rely on third parties to, among other things, manufacture raw materials, manufacture our product candidates for our ongoing clinical trial, ship investigation drugs and clinical trial samples, perform quality testing and supply other goods and services to run our business. If any such third party in our supply chain for materials is adversely impacted by effects from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted and our costs could be increased, limiting our ability to manufacture our product candidates for our ongoing clinical trial and planned future clinical trials and conduct our research and development operations as planned. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We previously closed our offices and requested that most of our personnel, including all of our administrative employees, work remotely, restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> staff to only those personnel and contractors who must perform essential activities that must be completed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> and limited the number of staff in any given </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">research and development laboratory. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors. Further, we and our third-party service providers, including our CROs, the clinical trial sites, our manufacturers and suppliers, may experience staffing shortages. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our employees and contractors conducting research and development activities may not be able to access our laboratory for an extended period of time as a result of the closure of our offices and the possibility that governmental authorities further modify current restrictions. In addition, when our facilities are open, we could encounter delays in connection with implementing precautionary measures to mitigate the risk of exposing our facilities and employees to COVID-19 or otherwise in connection with addressing an actual or potential exposure to COVID-19 (for example, temporarily closing all or a portion of a facility or disinfecting all or a portion of a facility that may have been exposed to COVID-19). As a result, this could delay timely completion of preclinical activities, including completing IND/Clinical Trial Application (CTA)-enabling studies or our ability to select future development candidates, and initiation of additional clinical trials for our other development programs. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Health regulatory agencies globally may experience disruptions in their operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The FDA or foreign health authorities may have slower response times or be under-resourced to continue to monitor our ongoing clinical trial and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any elongation or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-prioritization</div> of our clinical trial or delay in regulatory review resulting from such disruptions could materially affect the development of our product candidates. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The trading prices for shares of biopharmaceutical companies have been highly volatile as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could materially and adversely affect our business and the value of our common stock. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to evolve. The ultimate impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, additional or modified government actions, and the actions taken to contain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or address its impact, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, our business could be significantly adversely affected by other business disruptions to us or our third-party providers that could seriously harm our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our CROs, contract manufacturing organizations (CMOs), and other contractors, consultants, and third parties could be subject to other global pandemics, other geopolitical uncertainty and instability (including Russia&#8217;s actions in Ukraine), earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made</div> disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">man-made</div> or natural disaster or other business interruption. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As widely reported, global credit and financial markets have experienced volatility and disruptions recently including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, and increased inflationary risk. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including Russia&#8217;s actions in Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary equity or debt financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we had cash, cash equivalents and marketable securities of $210.9&#160;million. While we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents and marketable securities since March&#160;31, 2022, no assurance can be given that further deterioration of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents and marketable securities or our ability to meet our financing objectives. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment, which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior managers as well as junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior scientific and medical personnel. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We expect to grow the size of our organization, and we may experience difficulties in managing this growth. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, we had 78 employees. As our development and commercialization plans and strategies develop, and as we continue our transition into operating as a public company, we expect to need </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional research, development, clinical, quality assurance, statistical analysis, managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations, including for in-house manufacturing capabilities. Future growth would impose significant added responsibilities on members of management, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifying, recruiting, integrating, maintaining and motivating additional employees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Improving our operational, financial and management controls, reporting systems and procedures. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities in order to devote a substantial amount of time to managing these growth activities. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently rely and for the foreseeable future will continue to rely on certain independent organizations, advisors and/or consultants to provide certain services, including regulatory advice, clinical trial support and drug product manufacturing. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed and at a reasonable cost, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent contractors and consultants on economically reasonable terms, or at all. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do intend to transition some regulatory, clinical trial execution, and manufacturing capabilities in-house, but in order to do so, will need to identify, recruit and build experienced teams. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage, breakdown, or interruption from computer viruses, phishing, social engineering, fraudulent inducement, electronic fraud, wire fraud, human error or malfeasance, unauthorized access, natural disasters, and telecommunication and electrical failures. For example, our employees have received and likely will continue to receive phishing or &#8220;spoofed&#8221; emails to induce them to make payments to fraudulent accounts. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties to manufacture our product candidates and to conduct clinical trials, and similar events relating to their computer </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development and commercialization of our product candidates could be delayed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners, vendors and agents acting on behalf of us or our affiliates. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the regulations of the FDA or foreign health authorities; provide true, complete and accurate information to the FDA or foreign health authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will face increasing regulation as we advance our product candidates through clinical trials and pursue commercialization, if approved. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The laws that may affect our ability to operate include, but are not limited to the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal civil and criminal false claims laws, including the civil False Claims Act (FCA), that can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. No specific intent to defraud is required under the civil FCA. The criminal FCA provides for criminal penalties for submitting false claims, including imprisonment and criminal fines. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Civil Monetary Penalty Act of 1981 and implementing regulations, which impose penalties against any person or entity that, among other things, is determined to have presented or caused to </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offered or transferred remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The federal Physician Payment Sunshine Act, created under the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act (ACA), and its implementing regulations, which require applicable manufacturers of covered drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional requirements and regulations applicable to the distribution of pharmaceutical products, including extensive record-keeping, licensing, price reporting, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not realize the benefits of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">acquisitions,&#160;in-licenses&#160;or</div> strategic alliances that we enter into. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the future, we may seek and form strategic alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our existing technologies and product candidates, including artificial intelligence, machine learning and other technology-based platforms that may supplement our discovery efforts. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become exposed to costly and damaging product liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decreased demand for our product candidates or products that we may develop; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of our business reputation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Withdrawal of clinical trial participants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initiation of investigations by regulators; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs to defend the related litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A diversion of management&#8217;s time and our resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantial monetary awards to trial participants or patients; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product recalls, withdrawals or labeling, marketing or promotional restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss of revenue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhaustion of any available insurance and our capital resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The inability to commercialize any product candidate; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A decline in our share price. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients with cancer and other diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">significant&#160;pre-existing&#160;and</div> potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our product candidates, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent changes in tax law may adversely affect our business or financial condition. For example, in 2021, there were numerous changes proposed to U.S. federal income tax law, including an increase to the U.S. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">corporate tax rate, international business operations reform and the imposition of a global minimum tax. If these or similar changes are enacted, our effective tax rate may be adversely impacted in future years. Additionally, many countries, including the United States, and organizations such as the Organization for Economic Cooperation and Development are also actively considering changes to existing tax laws or have proposed or enacted new laws that could increase our tax obligations in countries where we do business or cause us to change the way we operate our business. Any of these developments or changes in federal, state, or international tax laws or tax rulings could adversely affect our effective tax rate and our operating results. We urge prospective investors in our common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of investing in or holding our common stock. On January 1, 2022, a provision of the legislation commonly known as the Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act) went into effect, eliminating the option to deduct domestic research and development costs in the year incurred and instead requiring taxpayers to amortize such costs over five years. We are currently evaluating the potential impact of this provision. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) by 5-percent shareholders in its equity ownership over a three-year period), the corporation&#8217;s ability to use its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> net operating loss carryforwards and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> tax attributes (including tax credit carryforwards) to offset its post-change taxable income may be limited. As a result of our most recent private placements, our initial public offering, and other transactions that have occurred over the past three years, we may have experienced such an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of this offering and subsequent shifts in our stock ownership. As of December&#160;31, 2021, we had U.S. federal and state net operating loss carryforwards of $117.6&#160;million and $116.5 million, respectively, and U.S. federal research and development tax credit carryforwards of $3.2&#160;million, which could be limited if we experience an &#8220;ownership change.&#8221; We also have net operating loss carryforwards and tax credit carryforwards for state tax purposes, which may be impaired or otherwise subject to limitation. Under the 2017 Tax Act, net operating losses arising in tax years beginning after December 31, 2017 can only offset 80% of annual taxable income for tax years beginning after December 31, 2020, but can be carried forward indefinitely. Our use of net operating losses generated in tax years beginning before January 1, 2018 will not be subject to the annual taxable income limitation and will continue to have a 20-year carryforward period. In addition, we will be unable to use our net operating loss carryforwards and tax credit carryforwards if we do not generate taxable income sufficient to offset our available net operating loss carryforwards and tax credit carryforwards prior to their expiration. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Reliance on Third Parties </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely and will rely on third parties to conduct our clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. We depend and will depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners to conduct our preclinical studies and clinical trials under agreements with us. We expect to negotiate budgets and contracts with CROs, trial sites and CMOs, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA or foreign health authorities for product candidates in clinical development. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or foreign health authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMP regulations and may require a significant number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us pursuant to our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and we may rely on third parties for at least a portion of the manufacturing process of our product candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product supplies or product candidates or fail to do so at acceptable quality levels or prices. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not currently own any facility that may be used as a clinical-scale manufacturing and processing facility, and we rely on outside vendors to manufacture supplies and process our product candidates. For certain of our components or product candidates, we rely on single suppliers or manufacturers to supply or manufacture, but we plan to expand the number of suppliers and manufacturers as we advance our product candidates through clinical development. Our product candidates are not yet manufactured or processed on a commercial scale and we may remain unable to do so for any of our product candidates. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although in the future we may develop our own manufacturing facilities, we may also continue to use third parties as part of our manufacturing processes and may, in any event, never be successful in developing our own manufacturing facilities. Our anticipated reliance on third-party manufacturers exposes us to the following risks: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must inspect any manufacturers for current cGMP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> of our third-party manufacturers with requirements of our marketing application(s). In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party manufacturers may have little or no experience with our product candidates, and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third-party manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing processes for our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our third-party manufacturers could breach or terminate their agreements with us, and we may be required to pay fees upon suspension or termination of the agreement even if the manufacturers do not deliver adequate supply of the product candidates or their components. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials and components used in the manufacturing processes, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to factors beyond our control. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our third-party manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over their ability to maintain adequate quality control, quality assurance and qualified personnel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place significant restrictions on our company until deficiencies are remedied. Furthermore, our or a third party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms or to comply with cGMP could adversely affect our business in a number of ways, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An inability to initiate or continue clinical trials of our product candidates under development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss of the cooperation of future collaborators; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Requirements to cease development or to recall batches of our product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any CMO with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">our&#160;know-how&#160;and</div> trade secrets, a competitor&#8217;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may in the future seek to establish collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may in the future seek collaboration arrangements with other parties for the development or commercialization of our product candidates. The success of any collaboration arrangements may depend on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">efforts and resources that they will apply to these arrangements. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision making authority. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborations with biopharmaceutical companies and other third parties often are terminated or are allowed to expire by the other party. Any such termination or expiration could adversely affect us financially and could harm our business reputation. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any future collaborations we might enter into may pose a number of risks, including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators may not perform their obligations as expected; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators may not pursue development and commercialization of product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators could fail to make timely regulatory submissions for a product candidate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if we establish one or more collaborations, all of the risks relating to product development, regulatory approval and commercialization described in this prospectus would also apply to the activities of any such future collaborators. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any collaborations we might enter into in the future do not result in the successful development and commercialization of products or if one of our future collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such potential future collaboration. If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates and our platforms. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any product candidate licensed to it by us. If one of our future collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our platforms and our business may be materially and adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain and maintain sufficient intellectual property protection for our platforms and our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our platforms, product candidates and research programs. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued that protect our product candidates or their intended uses or that effectively prevent others from commercializing competitive technologies, products or product candidates. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">into&#160;non-disclosure&#160;and</div> confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we, or any future licensors or licensees, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Composition of matter patents for biological and pharmaceutical products such as proprietary binding domains and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-based</div> product candidates often provide a strong form of intellectual property protection for these types of products without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts or administrative tribunals in the United States or foreign countries. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and in recent years has been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, that have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">third-party&#160;pre-issuance&#160;submission</div> of prior art to the USPTO or become involved in post-grant review procedures, derivations, reexaminations, or <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Any failure to obtain or maintain patent protection with </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respect to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The patent application process is subject to numerous risks and there can be no assurance that we will be successful in obtaining patents for which we have applied. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent applications may not result in any patents being issued; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Patents that may be issued or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> may be challenged, invalidated, modified, revoked, circumvented, narrowed, found to be unenforceable or otherwise may not provide any competitive advantage; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our competitors, many of whom have substantially greater resources and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our potential product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both in the United States and abroad for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations, and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely upon a combination of patents, confidentiality agreements, trade secret protection and intellectual property and confidentiality agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If and when patents will issue based on our patent applications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope of protection of any patent issuing based on our patent applications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether any of our intellectual property will provide any competitive advantage; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether we will need to initiate or defend litigation or administrative proceedings to enforce and/or defend our patent rights, which may be costly whether we win or lose; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Whether the patent applications that we own or may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot be certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts or administrative tribunals in the United States or foreign countries. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The strength of patents in the biotechnology and cell therapy fields involve complex legal and scientific questions and can be uncertain. The patent applications that we own or may <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Various post grant review proceedings, such as <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes </div></div>review and post grant review, are available for any interested third party to challenge the patentability of claims issued in patents to us. While these post grant review proceedings have been used less frequently to invalidate biotech patents, they have been successful regarding other technologies, and these relatively new procedures are still changing, and those changes might affect future results. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection, confidentiality agreements, and other agreements to protect proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> information, or technology that is not covered by patents. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The degree of future protection afforded by our intellectual property rights, whether owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed,</div> is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending patent applications that we own or may license may not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents, should they issue, that we own or may license, may not provide us with any competitive advantages, or may be challenged and held invalid or unenforceable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents that we own or may license, should any such patents issue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We (or any licensors) might not have been the first to make the inventions covered by a pending patent application that we own or may license; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We (or any licensors) might not have been the first to file patent applications covering a particular invention; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others may independently develop similar or alternative technologies without infringing our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to obtain necessary licenses on reasonable terms or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights, which will be costly whether we win or lose; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to maintain the confidentiality of our trade secrets or other proprietary information; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may not develop or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional proprietary technologies that are patentable; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patents of others may have an adverse effect on our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should any of these events occur, they could significantly harm our business and results of operation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when one of our product candidates is approved by the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we do not believe that any claims that could otherwise materially adversely affect commercialization of our product candidates, if approved, are </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications, which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing processes of our product candidates, constructs or molecules used in or formed during the manufacturing processes, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competitors or other third parties may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-grant proceedings, including interference proceedings, provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patents or those </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of any licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with any licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#160;non-litigious&#160;action</div> or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. Failure by us or any licensor to maintain protection of our patent portfolio could have a material adverse effect on our business, financial condition, results of operations, and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Given the amount of time </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, a patent&#8217;s life can be increased based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we or a licensing partner initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examination,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter parties</div></div> review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and any licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September&#160;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">relevant&#160;law-making&#160;bodies</div> in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect our intellectual property and proprietary rights throughout the world. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or may license. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although we are not currently aware of any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inventor.</div> We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may receive confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of these third parties or our employees&#8217; former employers or our consultants&#8217; or contractors&#8217; current or former clients or customers. Although we try to ensure that our employees and consultants do not use intellectual property, proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">information,&#160;know-how&#160;or</div> trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">her&#160;non-competition&#160;or&#160;non-solicitation&#160;agreement,</div></div> or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If we are not successful, we could lose access or exclusive access to valuable intellectual property. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to seeking patents for our technology and product candidates, we also rely on trade secrets, including unpatented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, any name we may propose to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Government Regulation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be unable to obtain regulatory approval for our product candidates. The denial or delay of any such approval would delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and by foreign health authorities in other countries. These regulations differ from country to country. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. To gain approval to market our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained regulatory approval to market any of our product candidates in the United States or any other country. Our business depends upon obtaining these regulatory approvals. The FDA can delay, limit or deny approval of our product candidates for many reasons, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to satisfactorily demonstrate that the product candidates have acceptable safety and efficacy profiles for the requested indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s disagreement with our trial designs or the interpretation of data from preclinical studies or clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the full population for which we seek approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s determination that additional preclinical or clinical trials are required; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The FDA&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-approval</div> of the formulation, labeling or the specifications of our product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s failure to accept the manufacturing processes, drug product characteristics or facilities of third-party manufacturers with which we contract; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA may also approve our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. If FDA requires us to narrow our indications to smaller patient subsets, our market opportunities for our product candidates, if approved, and our ability to generate revenues may be materially limited. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would materially adversely impact our business, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The FDA regulatory approval process is lengthy, time-consuming and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval of our product candidates or be unable to generate product revenue. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not previously submitted a BLA to the FDA or similar marketing applications to foreign health authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety, purity and efficacy for each desired indication. The BLA must also include significant information regarding the manufacturing controls for the product. The novel nature of our product candidates may introduce uncertain, complex, expensive and lengthy challenges that could impact regulatory approval. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or foreign health authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The availability of financial resources to commence and complete the planned trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining approval at each clinical trial site by an IRB or ethics committee; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recruiting suitable patients to participate in a trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Enrolling and retaining sufficient number of patients to complete a trial, including post-treatment follow ups; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trial sites deviating from trial protocol or dropping out of a trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adding new clinical trial sites; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for use in clinical trials. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We could also experience delays in physicians enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments or other clinical trials. Furthermore, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, or by the FDA or foreign health authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign health authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securing regulatory approval also requires the submission of information about the manufacturing processes and inspection of manufacturing facilities by the relevant regulatory authority. The FDA or foreign health authorities may fail to approve our manufacturing processes or facilities, whether run by us or our CMOs. In addition, if we make manufacturing changes to our product candidates in the future, we may need to conduct additional preclinical and/or clinical studies to bridge our modified product candidates to earlier versions. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or foreign health authorities may disagree with the design, implementation or data analyses of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or foreign health authorities may determine that our product candidate(s) do not have adequate risk-benefit ratio or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or foreign health authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or foreign health authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approval policies or regulations of the FDA or foreign health authorities may significantly change in a manner rendering our clinical data insufficient for approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have or may pursue Fast Track, orphan drug, and/or RMAT designations from the FDA for one or more of our product candidates. Even if one or more of our product candidates receive Fast Track, orphan drug, and/or RMAT designations, we may be unable to obtain and maintain the benefits associated with such designations. These designations may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that such product candidates will receive marketing approval. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, CART-ddBCMA has been granted Fast Track, orphan drug, and Regenerative Medicine Advanced Therapy (RMAT) designations by the FDA. In the future, we may pursue one or more similar designations for other product candidates, including ACLX-001 and ACLX-002. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions with an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being studied. However, if we do not continue to meet the criteria of the Fast Track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. Fast track designation also does not guarantee our product candidate will be approved in a timely manner, if at all. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. In the European Union, the prevalence of the condition must not be more than 5 in 10,000. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. If a product that has orphan drug designation from the FDA subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same indication, for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the product was designated. Even if we or our collaborators obtain orphan designation to a product candidate, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. The scope of exclusivity is limited to the scope of any approved indication, even if the scope of the orphan designation is broader than the approved indication. Additionally, exclusive marketing rights may be limited if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if a product obtains orphan drug exclusivity, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a product with the same active moiety for the same condition if the FDA concludes that the later product is safer, more effective, or makes a major contribution to patient care. Furthermore, the FDA can waive orphan exclusivity if we or our collaborators are unable to manufacture sufficient supply of the product. If we or our collaborators do not receive or maintain orphan drug designation to product candidates for which we seek such designation, it could limit our ability to realize revenues from such product candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A company may request RMAT designation of its product candidate, which designation may be granted if the product meets the following criteria: (1)&#160;it is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#160;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&#160;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites post-approval, if appropriate. RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy. RMAT designation does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may pursue Breakthrough Therapy designation for one or more of our product candidates in the future. Even if granted by the FDA, such designation may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although Breakthrough Designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. We may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. For example, the time required to identify and resolve issues relating to manufacturing and controls, the acquisition of a sufficient supply of our product for clinical trial purposes or the need to conduct additional nonclinical or clinical studies may delay approval by the FDA, even if the product qualifies for breakthrough designation or access to any other expedited program. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain regulatory approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety of the product candidate. The FDA may also require REMS as a condition of approving our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign health authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fines, warning letters or holds on clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Withdrawal of the drug from the market or voluntary or mandatory product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse publicity, fines, warning letters or holds on clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product seizure or detention, or refusal to permit the import or export of our product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA strictly regulates manufacturers&#8217; promotional claims of drug products. In particular, a drug product may not be promoted by manufacturers for uses that are not approved by the FDA, as reflected in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> labeling, although healthcare professionals are permitted to use drug products for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses. The FDA, the Department of Justice (DOJ), the Inspector General of the Department of HHS, among other government agencies, actively enforce the laws and regulations prohibiting manufacturers&#8217; promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, and a company that is found to have improperly promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses may be subject to significant liability, including large civil and criminal fines, penalties, and enforcement actions. The FDA has also imposed consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed for companies that engaged in such prohibited activities. If we cannot successfully manage the promotion of our approved product candidates, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. Failure to obtain regulatory approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to regulations in the United States, to market and sell our products in the European Union, many Asian countries and other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements, both from a clinical and manufacturing perspective. Approval by the FDA does not ensure approval by regulatory or payor authorities in other countries or jurisdictions, and approval by one regulatory or payor authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. A product candidate that has been approved for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities or payor authorities outside the United States on a timely basis, if at all. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also submit marketing applications in other countries, such as countries in Europe or Asia. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any jurisdiction. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we are unable to obtain approval of any of our product candidates by regulatory or payor authorities </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the European Union, Asia or elsewhere, or if we fail to comply with the regulatory requirements in foreign jurisdictions, the commercial prospects of that product candidate may be significantly diminished, and our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to market any product outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or fail to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business model. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, including proposals aimed at lowering prescription drug prices and increasing competition for prescription drugs, as well as additional regulation on pharmaceutical transparency and reporting requirements, any of which could negatively impact our future profitability and increase our compliance burden. We cannot predict the initiatives that may be adopted in the future, including future challenges or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The demand for our product candidates, if we obtain regulatory approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to set a price that we believe is fair for our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to obtain coverage and reimbursement approval for a product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to generate revenue and achieve or maintain profitability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The level of taxes that we are required to pay; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The availability of capital. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Commercialization of Our Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, existing cell therapies are currently offered only in tertiary academic hospitals that have intensive care units that can support the safety and toxicity issues associated with cell therapies. If we are unable to demonstrate sufficient safety to permit a broader use of our product candidates, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical indications for which our product candidates are approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe, pure and effective treatment; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The potential and perceived advantages of our product candidates over alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our ability to demonstrate the advantages of our product candidates over other conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The perceived prevalence and severity of any side effects for our product candidates compared to the prevalence and severity of any side effects for conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> products and other cell therapies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product labeling, limitations, warnings or product insert requirements of the FDA or foreign health authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The timing of market introduction of our product candidates as well as competitive products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cost of treatment in relation to alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The willingness of patients to pay <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> in the absence of coverage by third-party payors and government authorities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effectiveness of our sales and marketing efforts. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may face difficulties from changes to current regulations and future legislation. Current and future legislation may increase the difficulty and cost for us to commercialize our drugs, if approved, and affect the prices we may obtain, including changes in coverage and reimbursement policies in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. In both domestic and foreign markets, successful sales of our product candidates, if approved, will depend on the availability of adequate coverage and reimbursement from third-party payors. In addition, because our product candidates represent novel approaches to the treatment of cancer and autoimmune diseases, we cannot accurately estimate the potential revenue from our product candidates. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patients who receive medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A covered benefit under its health plan; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Medically necessary and has acceptable risk-benefit ratio; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Appropriate for the specific patient; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost-effective; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither experimental nor investigational. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> that patients find unacceptably high. Due to the high costs associated with cell therapies, patients are unlikely to use our product candidates unless coverage is provided or reimbursement is adequate to cover a significant portion of the cost of our product candidates. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA made extensive changes to the delivery of health care in the United States. We expect that the rebates, discounts, taxes and other costs resulting from the ACA over time will have a negative effect on our expenses and profitability in the future. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. For example, the ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by increasing the minimum basic Medicaid rebate on most branded prescription drugs. Additionally, for a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the enactment of the ACA, there have been judicial and Congressional challenges to certain aspects of the ACA. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial condition and results of operations. Complying with any new legislation or changes in healthcare regulation could be time-intensive and expensive, resulting in material adverse effect on our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 (the ATRA), which, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Legislators, regulators and third-party payers may continue to put forth proposals to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reduce costs while expanding individual healthcare benefits, including proposals that impose additional limitations on the rates we will be able to charge for our product candidates, if approved, or the amount of reimbursement available for such approved products from governmental agencies or third-party payers. Current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition. We cannot predict what other health care programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may have on our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in 2020, HHS and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements, and manufacturer price reporting under Medicare Part B. Multiple lawsuits have been brought against HHS challenging various aspects of the rules implemented during the Trump administration. As a result, the Biden administration and HHS have delayed the implementation or published rules rescinding some of these Trump-era policies. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. Further, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition for prescription drugs. In response to this executive order, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases. The impact of these regulations and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the state level, individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products. These measures could reduce the demand for our products, if approved, or impose additional pricing pressures on how much we can charge for our products if approved. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing approval, as well as subject us to more stringent product labeling and post-approval testing and other requirements. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other jurisdictions. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our product candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We currently have no marketing and sales organization and have limited experience in marketing cell therapy products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently have no sales, marketing or distribution capabilities and have limited experience in marketing cell therapy products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. We may have little or no control over the marketing and sales efforts of third parties conducting such activities on our behalf and our revenue from product sales may be lower than if we had commercialized our product candidates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house.</div> We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There can be no assurance that we will be able to develop adequate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or abroad. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be subject to or affected by data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including federal and state health information privacy laws, state data breach notification laws, and federal and state consumer protection laws, such as Section&#160;5 of the Federal Trade Commission Act, govern the collection, use, disclosure and protection of health information and other personal information could apply to our operations. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and its implementing rules and regulations. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, the California Consumer Privacy Act (CCPA) took effect in January 2020 and became enforceable in July 2020. The CCPA created new individual privacy rights for California consumers (as the word is broadly defined in the law) and placed increased privacy and security obligations on many organizations that handle personal information of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers a new right to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> of certain sales or transfers of personal information, and provides consumers with a new cause of action for certain data breaches. Additionally, California voters voted to approve the California Privacy Rights Act (CPRA) in November 2020, which modifies the CCPA significantly, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. The CCPA and CPRA may impact our business activities and increase our compliance costs and potential liability. Many similar privacy laws have been enacted or proposed at the federal level and in other states. For example, Virginia enacted its Consumer Data Protection Act in March 2021, Colorado enacted the Colorado Privacy Act in July 2021, and Utah enacted the Utah Consumer Privacy Act in March 2022. Each of these differs from the CCPA and CPRA and becomes effective in 2023. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our costs of legal compliance, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with data protection laws and regulations could result in government investigations and/or enforcement actions (which could include civil, criminal, and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A variety of risks associated with seeking regulatory approval for and marketing our product candidates internationally could materially adversely affect our business. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Differing regulatory requirements in foreign countries, including constraints on manufacturing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional trials in foreign countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Requirement to secure and validate region-specific manufacturing and clinical and commercial supply; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Economic weakness, including inflation, or political instability in particular foreign economies and markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign taxes, including withholding of payroll taxes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Difficulties staffing and managing foreign operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Workforce uncertainty in countries where labor unrest is more common than in the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Business interruptions resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">geo-political</div> actions, including war (including ongoing geopolitical tensions related to Russia&#8217;s actions in Ukraine, resulting sanctions imposed by the United States and other countries, and retaliatory actions taken by Russia in response to such sanctions), armed conflict, terrorist activities, global pandemics and terrorism. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These and other risks associated with our international operations, including relating to data privacy and security, may materially adversely affect our ability to attain or maintain profitable operations. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The European Union system for authorization of medicinal products for human use offers several routes: the centralized procedure, the decentralized procedure, and the mutual recognition procedure, as well as domestic national routes. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union Member States as well as the European Economic Area (EEA) countries of Iceland, Liechtenstein and Norway. The centralized procedure is mandatory for certain categories of investigational products, including human products containing a new active substance indicated for the treatment of certain diseases, including cancer, AIDS, diabetes and neurodegenerative illness; orphan medicinal products; and medicinal products manufactured using biotechnological processes. Applications for marketing authorization for such medicines must be submitted to the European Medicines Agency (EMA), in which the Committee for Medicinal Products for Human Use (CHMP) is generally responsible for conducting the initial assessment of a product. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The decentralized and mutual recognition procedures are applicable to the majority of conventional medicinal products and are both based on the principle of recognition of a marketing authorization by one or more Member States. Any national marketing authorization granted by a European Union Member State&#8217;s national authority can be used to support an application for its mutual recognition by other Member States. Marketing authorization applications can also be submitted directly to the Member State&#8217;s national competent authority under the national route (if the centralized route is not compulsory). Following Brexit, there are now multiple routes to obtain a marketing authorization in the United Kingdom, Great Britain or Northern Ireland, including national routes and international routes. The application procedure will depend on the relevant procedure chosen. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business. Further, even after obtaining market authorization, differences in GMP, pharmacovigilance, and other regulatory requirements in different jurisdictions can increase our compliance costs and exposure to potential liability. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission (SEC) and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as recent furloughs or government shutdowns, may also increase the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Separately, in response to the COVID-19 pandemic, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. As of May 2021, certain inspections, such as foreign preapproval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates and in May 2021 announced plans to continue progress toward resuming standard operational levels. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. As of May&#160;26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory authorities outside the United States may also impose similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations, all of which can subject us to criminal liability and other serious consequences for violations. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (the FCPA), and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. These laws generally prohibit companies and their employees and third party business partners, representatives and agents from engaging in corruption and bribery, including offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a government official or commercial party in order to influence official action, direct business to any person, gain any improper advantage, or obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with government officials, including potentially officials of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> governments. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in many countries, healthcare providers are employed by the government, and the purchasers of biopharmaceuticals are government entities. As a result, our dealings with these providers and purchasers are subject to regulation and such healthcare providers and employees of such purchasers may be considered &#8220;foreign officials&#8221; as defined in the FCPA. Recently, the SEC and the DOJ have increased their FCPA enforcement activities with respect to biotechnology companies. In addition to our own employees, we may in the future leverage third parties to conduct our business abroad, such as obtaining government licenses and approvals. We and our third-party business partners, representatives and agents may have direct or indirect interactions with officials and employees of government agencies, state-owned or affiliated entities and we may be held liable for the corrupt or other illegal activities of our employees, our third-party business partners, representatives and agents, even if we do not explicitly authorize such activities. There is no certainty that our employees or the employees of our third-party business partners, representatives and agents will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, debarment from U.S. government contracts, substantial diversion of management&#8217;s attention, significant legal fees and fines, severe criminal or civil sanctions against us, our officers, or our employees, disgorgement and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, financial condition and stock price. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our business. Moreover, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to conduct activities at clinical trial sites within regions covered by such sanctions. For example, as a result of Russia&#8217;s actions in Ukraine, the United States and its European allies have imposed sanctions on certain industry sectors and parties in Russia and the regions of Donetsk and Luhansk in Ukraine, as well as enhanced export controls on certain products and industries. These and any additional sanctions and export controls, as well as any economic countermeasures by the governments of Russia or other jurisdictions, could adversely impact our ability to continue activities at clinical trial sites within regions covered by such sanctions or directly or indirectly disrupt our supply chain. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to This Offering and Ownership of our Common Stock </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not know whether an active, liquid, and orderly trading market will be sustained for our common stock. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to our initial public offering, there was no public trading market for shares of our common stock. Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the levels of trading activity may decline. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. The lack of an active market may also reduce the fair market value of your shares. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of our common stock as consideration. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The price of shares of our common stock may be volatile and may be adversely impacted by future events, and you could lose all or part of your investment. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, many of which are beyond our control, including limited trading volume. In addition to the factors discussed in this Risk Factors section and elsewhere in this prospectus, these factors include: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commencement, enrollment, or results of the clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results from ongoing clinical trials and future clinical trials of our competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to achieve product development goals in the timeframes we announce; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse results or delays in clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in laws or regulations applicable to our product candidates, including, but not limited to, clinical trial requirements for approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse developments concerning our manufacturers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to obtain adequate supply for any product candidate, or any component thereof, or approved product or inability to do so at acceptable prices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to establish collaborations if needed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to commercialize our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unanticipated serious safety concerns related to the use of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Introduction of new products or other therapies offered by us or our competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions or departures of key scientific or management personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to effectively manage our growth; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The size and growth of our initial cancer target markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to successfully treat additional types of cancers or at different stages; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actual or anticipated variations in quarterly operating results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cash position; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in the market valuations of similar companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operating performance and the performance of other similar companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall performance of the equity markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The expiration of market <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stand-off</div> or contractual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of our common stock by us or our stockholders in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading volume of our common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in accounting practices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ineffectiveness of our internal controls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant lawsuits, including patent or stockholder litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">General political and economic conditions, including the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic and the ongoing geopolitical tensions related to Russia&#8217;s actions in Ukraine, resulting sanctions imposed by the United States and other countries, and retaliatory actions taken by Russia in response to such sanctions; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other events or factors, many of which are beyond our control. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our common stock relies in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May 31, 2022, our executive officers, directors, and holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 57.9% of our outstanding voting stock. Therefore, these stockholders, if they act together, will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interests as one of our stockholders. Further, the significant concentration of stock ownership may adversely affect the market price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The public offering price is substantially higher than the net tangible book value per share of our common stock. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This dilution is due to certain of our investors who purchased shares prior to this offering having paid substantially less when they purchased their shares than the price offered to the public in this offering and the exercise of stock options granted to our employees. To the extent that outstanding stock options are exercised, we issue restricted stock to our employees under our equity incentive plans or if we otherwise issue additional shares of our common stock in each case at per share prices below the price to the public in this offering, there will be further dilution to new investors. As a result of the dilution to investors purchasing common stock in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see &#8220;Dilution.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act) enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the year of our initial public offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of our initial public offering (i.e., December 31, 2027), (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which requires, among other things, that the market value of our common stock that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> to exceed $700&#160;million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt during the prior three-year period. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act (if we have less than $100 million in annual revenues in our most recent fiscal year), being able to present only the two most recent fiscal years of audited financial statements and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance, or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have incurred and will continue to incur significant increased costs as a result of operating as a public company, and our management has devoted and will continue to devote substantial time and resources to new compliance initiatives. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, and particularly after we are no longer an emerging growth company or a smaller reporting company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), which require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Stock Market (Nasdaq) to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing of our initial public offering. We intend to take advantage of this legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and regulations implemented by the SEC and Nasdaq may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We have invested and intend to continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from product development activities to compliance activities. The rules and regulations applicable to public companies have increased substantially and will continue to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these&#160;requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Substantial amounts of our outstanding shares may be sold into the market when <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> or market standoff periods end. Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after lock-ups and other legal restrictions on resale lapse, the trading price of our common stock could decline. As of March 31, 2022, we had 35,736,584 shares of common stock outstanding. Of these shares, only the shares sold in our initial public offering by us are currently freely tradable without restriction in the public market. The remaining 26,249,084 shares of common stock are currently restricted from resale as a result of restrictions under securities laws, market standoff agreements entered into by our stockholders with us or lock-up agreements entered into by our directors, officers and stockholders with the underwriters in connection with our initial public offering. However, subject to applicable securities law restrictions, some of these shares will become available to be sold in the public market beginning August 3, 2022, which is the 181st day after the date of the prospectus relating to our initial public offering. BofA Securities, Inc. and SVB Securities LLC, however, may, in their discretion, permit our officers, directors, and other stockholders who are subject to these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements to sell shares prior to the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we have filed a registration statement on Form S-8 under the Securities Act registering the issuance of 10,878,616 shares of common stock that are either subject to outstanding equity awards or reserved for future issuance under our equity incentive plans. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> and market <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stand-off</div> agreements described above. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of up to 24,785,564 shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements described above. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with this offering, our executive officers and directors entered into lock-up agreements with the underwriters under which they have agreed, subject to specific exceptions not to sell, directly or indirectly, any shares of common stock without the permission of BofA Securities, Inc. and SVB Securities LLC for a period of 90 days following the date of this prospectus. We refer to such period as the follow-on lock-up period. When the follow-on lock-up period expires, we and our securityholders subject to a lock-up agreement will be able to sell our shares in the public market. In addition, BofA Securities, Inc. and SVB Securities LLC may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements at any time and for any reason. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect that significant additional capital may be needed in the future to continue our planned operations, which include conducting clinical trials, pursuing commercialization efforts, expanding research and development activities, and continuing to operate as a public company. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities, or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior to the holders of our common stock, including shares of common stock sold in our initial public offering. If we raise additional funds through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our drug candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the 2022 Plan, our board of directors or its duly authorized committee is authorized to grant equity awards to our employees, directors, and consultants. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initially, the aggregate number of shares of our common stock that may be issued pursuant to equity awards under the 2022 Plan is 4,296,875&#160;shares, plus shares subject to awards granted under our 2017 Equity Incentive Plan (the 2017 Plan) that expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2022 Plan pursuant to awards under the 2017 Plan is 6,269,300 shares). The number of shares of our common stock reserved for issuance under the 2022 Plan shall be cumulatively increased on the first day of each fiscal year, beginning with our 2023 fiscal year and ending on the ten year anniversary of the date our board of directors approves the 2022 Plan equal to the least of 4,296,875&#160;shares, 5% of the total number of shares of our common stock outstanding as of the last day of the immediately preceding fiscal year, or a lesser number of shares determined by the administrator of the 2022 Plan. Unless the administrator of the 2022 Plan elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our 2022 ESPP, our employees may receive the right to purchase shares of our common stock. Initially, the aggregate number of shares of our common stock available for sale under our 2022 ESPP is 312,500&#160;shares. The number of shares of our common stock available for sale under our 2022 ESPP shall be cumulatively increased on the first day of each fiscal year, beginning with the fiscal year following the fiscal year in which the first enrollment date (if any) occurs under the 2022 ESPP and ending on the twenty year anniversary of the date our board of directors approves the 2022 ESPP equal to the least of 312,500 shares, 1.0% of the total number of shares of our common stock outstanding as of the last day of the immediately preceding fiscal year, or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a lesser number of shares determined by the administrator of the 2022 ESPP. Unless the administrator of the 2022 ESPP elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to establish and maintain proper and effective internal controls over financial reporting, our operating results and our ability to operate our business could be harmed. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. We have begun the process of documenting, reviewing, and improving our internal controls and procedures for compliance with Section&#160;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. We continue to recruit additional finance and accounting personnel with certain skill sets that we will need as a public company. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively or in ways that increase the value of our share price. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase or maintain the value of your investment. We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the development of our product candidates CART-ddBCMA, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and for other research and development activities, working capital and other general corporate purposes. However, we cannot specify with certainty all of the particular uses of the net proceeds that we will receive from this offering and our existing cash, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures will depend on numerous factors, including the ongoing status of and results from clinical trials and other studies, the product approval process with the FDA, and the scope of our commercialization efforts, as well as any strategic collaborations that we may enter into with third parties for our product candidates, any unforeseen cash needs, and our investments and acquisitions. The failure by our management to apply these funds effectively could harm our business, result in financial losses that could cause the price of our common stock to decline and delay the development of our product candidates. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending their use, we may invest the net proceeds from this offering in short-term, interest-bearing, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not intend to pay dividends on our common stock, so any returns will be limited to the capital appreciation of our stock. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could discourage, delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death, disqualification or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at an annual or special meeting of our stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A requirement that special meetings of stockholders be called only by the chairperson of our board of directors, our Chief Executive Officer, our President, or our board of directors acting pursuant to a resolution adopted by a majority of our board of directors, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance notice requirements for stockholder proposals and nominations for election to our board of directors, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than a majority of the shares present in person or by proxy at the meeting and entitled to vote, which could delay the ability of stockholders to change the membership of our board of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">A requirement of approval of not less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock and could be used to significantly dilute the ownership of a hostile acquirer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline and limit opportunities for you to realize value in a corporate transaction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court in Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any derivative action or proceeding brought on our behalf; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any action asserting a claim of breach of fiduciary duty; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any action asserting a claim against us arising under the Delaware General Corporation Law (DGCL), our amended and restated certificate of incorporation or our amended and restated bylaws; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any action asserting a claim against us that is governed by the internal-affairs doctrine. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. For the avoidance of doubt, this provision shall not apply to any claim brought to enforce a duty or liability created by the Exchange Act. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We could be subject to securities class action litigation. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business, operating results, or financial condition. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, plans for our product candidates, planned preclinical studies and clinical trials, results of clinical trials, future research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The impact of the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other related disruptions on our business; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The timing, progress, and results of preclinical studies and clinical trials for our programs and product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to recruit and enroll suitable patients in our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to take advantage of expedited regulatory pathways for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expected benefits of potential strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The size of the market opportunity for our product candidates and our ability to maximize those opportunities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The success of competing therapies that are or may become available; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our estimates of the number of patients who suffer from the diseases we are targeting and the number of participants that will enroll in our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug designation, for our product candidates for various diseases; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to obtain and maintain regulatory approval of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to adequately secure our information technology systems and the regulated data stored therein, as required by law; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The pricing and reimbursement of our product candidates, if approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our plans relating to the further development and manufacturing of our product candidates, including for additional indications that we may pursue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing regulations and regulatory developments in the United States and other jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our reliance on third parties to conduct clinical trials of our product candidates and manufacture of our product candidates for preclinical studies and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The need to hire additional personnel and our ability to attract and retain such personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our financial performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our anticipated use of our existing resources and the proceeds from this offering. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events or otherwise. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET, INDUSTRY AND OTHER DATA </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus contains estimates, projections and other information concerning our industry, our business and the potential markets for our product candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this prospectus from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USE OF PROCEEDS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately $81.0&#160;million, or approximately $93.2&#160;million if the underwriters exercise their option to purchase additional shares in full, based upon the assumed public offering price of $21.71 per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June&#160;13, 2022, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each $1.00 increase (decrease) in the assumed public offering price of $21.71 per share would increase (decrease) the net proceeds to us from this offering by approximately $3.8&#160;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&#160;million shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering by approximately $20.4&#160;million, assuming that the public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the public offering price or the number of shares by these amounts would have a material effect on our uses of the proceeds from this offering, although it may accelerate the time at which we will need to seek additional capital. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The principal purposes of this offering are to obtain additional capital to support our operations. We currently anticipate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approximately $55 million to $65 million to fund the development of CART-ddBCMA, our first product candidate based on our ddCAR platform, as a treatment for r/r MM; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approximately $5 million to $10 million to fund the development of product candidates under our ARC-SparX platform, including our Phase 1 clinical trial of ACLX-001 as a treatment for r/r MM and our planned Phase&#160;1 clinical trial of ACLX-002 as a treatment for r/r AML and high risk MDS; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining proceeds, if any, for other research and development opportunities, working capital and general corporate purposes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe opportunities may exist from time to time to expand our current business through license or acquisitions of, or investments in, complementary businesses, products or technologies. While we have no current agreements, commitments or understandings for any specific licenses, acquisitions or investments at this time, we may use a portion of the net proceeds for these purposes. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we believe that our available cash and cash equivalents, will be sufficient to fund our planned operations for at least twelve months following the date of this offering without the proceeds from this offering, this belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, any funding we may obtain through future collaborations, if any, and any unforeseen cash needs. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pending their uses, we plan to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DIVIDEND POLICY </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments and other factors that our board of directors deems relevant. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAPITALIZATION </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our cash and cash equivalents, marketable securities and capitalization as of March&#160;31, 2022, as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On an actual basis; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On an as adjusted basis to reflect our issuance and sale of 4,000,000&#160;shares of common stock in this offering at the assumed public offering price of $21.71 per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June 13, 2022, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should read this information in conjunction with our financial statements and the related notes appearing elsewhere in this prospectus, as well as the section of this prospectus titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="7" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2022</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Actual</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Adjusted&#160;<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="7" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands, except per<br/>share data) </div></div></td> </tr>
<tr style="font-family: ARIAL; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="7" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and marketable securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">210,929</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">291,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1.47em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; equity:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $0.001 par value; no shares authorized, issued or outstanding, actual; 200,000,000&#160;shares authorized and no shares issued or outstanding, as adjusted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $0.001 par value per share; 1,000,000,000&#160;shares authorized, 35,718,764&#160;shares issued and outstanding, actual; 1,000,000,000&#160;shares authorized, 39,718,764&#160;shares issued and outstanding, as adjusted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">384,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">465,071</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(162,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(162,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">221,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">302,571</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total capitalization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">221,591</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">302,571</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Each $1.00 increase (decrease) in the assumed public offering price of $21.71 per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June 13, 2022, would increase (decrease) our as adjusted cash and cash equivalents and marketable securities, additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital, total stockholders&#8217; equity and total capitalization by approximately $3.8&#160;million, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&#160;million shares in the number of shares of common stock offered by us would increase (decrease) our as adjusted cash and cash equivalents and marketable securities, additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital, total stockholders&#8217; equity and total capitalization by approximately $20.4&#160;million, assuming that the public offering price of $21.71&#160;per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June 13, 2022, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares of our common stock to be outstanding after this offering is based on the 35,736,584&#160;shares of our common stock outstanding as of March&#160;31, 2022 and excludes the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,113,589&#160;shares of common stock issuable upon exercise of options to purchase shares of our common stock outstanding as of March&#160;31, 2022, at a weighted-average exercise price of $8.83 per share; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">702,663&#160;shares of common stock subject to restricted stock units (RSUs) outstanding as of March&#160;31, 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95,638&#160;shares of common stock subject to RSUs granted after March&#160;31, 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158,723&#160;shares of common stock issuable upon exercise of options to purchase shares of our common stock that we granted after March&#160;31, 2022, at a weighted-average exercise price of $8.29 per share; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">550,513&#160;shares of common stock reserved for future issuance under our 2022 Plan; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">312,500&#160;shares of common stock reserved for issuance under our 2022 ESPP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DILUTION </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our historical net tangible book value as of March 31, 2022 was approximately $221.6 million, or $6.20 per share of our common stock. Our historical net tangible book value per share is determined by dividing our total tangible assets less our total liabilities by the actual number of outstanding shares of our common stock. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After giving effect to our sale of 4,000,000 shares of common stock in this offering at the assumed public offering price of $21.71&#160;per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June&#160;13, 2022, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2022 would have been approximately $302.6&#160;million, or $7.61&#160;per share. This represents an immediate increase in as adjusted net tangible book value per share of $1.41 to our existing stockholders and an immediate dilution in as adjusted net tangible book value per share of $14.10 to new investors purchasing common stock in this offering. Dilution per share to new investors purchasing common stock in this offering is determined by subtracting as adjusted net tangible book value per share after this offering from the assumed public offering price per share paid by new investors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table illustrates this dilution on a per share basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assumed public offering price per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21.71</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Historical net tangible book value per share as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase in net tangible book value per share attributable to new investors purchasing shares in this offering</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.41</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As adjusted net tangible book value per share after this offering</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilution per share to new investors purchasing shares in this offering</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">14.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each $1.00 increase (decrease) in the assumed public offering price of $21.71&#160;per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June&#160;13, 2022, would increase (decrease) the as adjusted net tangible book value per share after this offering by $0.09 per share and the dilution to new investors purchasing common stock in this offering by $0.91&#160;per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1.0&#160;million shares in the number of shares offered by us would increase the as adjusted net tangible book value per share after this offering by $0.32 and decrease the dilution per share to new investors participating in this offering by $0.32, assuming no change in the public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A decrease of 1.0&#160;million shares in the number of shares offered by us would decrease the as adjusted net tangible book value per share after this offering by $0.33 and increase the dilution per share to new investors participating in this offering by $0.33, assuming no change in the public offering price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the underwriters exercise their option to purchase 600,000 additional shares of common stock in this offering in full at the assumed public offering price of $21.71&#160;per share, which is the last reported sale price of our common stock on the Nasdaq Global Select Market on June&#160;13, 2022 and assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, the as adjusted net </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tangible book value per share after this offering would be $7.80&#160;per share, and the dilution in as adjusted net tangible book value per share to new investors purchasing common stock in this offering would be $13.91&#160;per share. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of shares of our common stock to be outstanding after this offering is based on the 35,736,584 shares of our common stock outstanding as of March&#160;31, 2022 and excludes the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,113,589 shares of common stock issuable upon exercise of options to purchase shares of our common stock outstanding as of March&#160;31, 2022, at a weighted-average exercise price of $8.83 per share; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">702,663 shares of common stock subject to restricted stock units (RSUs) outstanding as of March&#160;31, 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95,638 shares of common stock subject to RSUs granted after March 31, 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158,723 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we granted after March&#160;31, 2022, at a weighted-average exercise price of $8.29&#160;per share; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">550,513 shares of common stock reserved for future issuance under our 2022 Plan; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">312,500 shares of common stock reserved for issuance under our 2022 ESPP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent that any outstanding options are exercised or new options are issued under the equity benefit plans, or we issue additional shares of common stock or other securities convertible into or exercisable or exchangeable for shares of our capital stock in the future, in each case at per share prices below the price to the public in this offering, there will be further dilution to investors participating in this offering. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_122" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes thereto included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, include forward-looking statements that involve risks and uncertainties. You should review &#8220;Risk Factors&#8221; for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. For convenience of presentation, some of the numbers have been rounded in the text below. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Though cell therapies have shown benefits to date, cell therapies have historically been constrained to existing biologic structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> is designed to overcome the limitations of traditional Chimeric Antigen Receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cells</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(CAR-Ts).</div> Existing cell therapy solutions, most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we can overcome these limitations by engineering a new class of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> powered autologous and allogeneic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts,</div> including classical single infusion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> called ddCARs and dosable and controllable universal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> called ARC-SparX, to address hematologic cancers, solid tumors, or indications outside of oncology such as autoimmune diseases. We recently announced positive preliminary results for the first 31 patients dosed in our ongoing Phase 1 clinical trial of CART-ddBCMA, our lead ddCAR product candidate, for treatment of relapsed or refractory (r/r) Multiple Myeloma (MM), that demonstrate that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> can potentially provide meaningful clinical benefits. We plan to initiate additional trials with CART-ddBCMA including iMMagine, our Phase 2 pivotal trial in r/r MM, in late 2022, as well as expansion studies to earlier lines of therapy. We are also advancing our novel ARC-SparX programs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in r/r MM and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-003</div> in r/r acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). We initiated our Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in the second quarter of 2022 and plan to initiate Phase 1 clinical trials for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> in 2022 and for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-003</div> in 2024. We are also exploring indications in solid tumors, as well as integrating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-powered</div> discovery and computational tools to expand the applicability of our platforms. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our formation, we have devoted substantially all our resources to discovering and developing our product candidates. We have incurred significant operating losses to date. Our net losses were $65.0 million and $32.1 million for the years ended December 31, 2021 and 2020, respectively, and $32.4 million and $11.3 million for the three months ended March 31, 2022 and 2021, respectively. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2022, we had an accumulated deficit of $162.5 million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities. We </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expect our operating expenses and capital requirements will increase substantially in connection with our ongoing activities, as we: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expand the clinical program for CART-ddBCMA to include expanded enrollment of the Phase 1 clinical trial, the initiation of the planned Phase 2 pivotal trial and subsequent clinical trials focused on earlier lines of therapy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grow our supply and contract manufacturing infrastructure to support the continued development of CART-ddBCMA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Initiate or continue clinical trials to evaluate our lead ARC-SparX product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-003;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Expand our pipeline of product candidates, including through our own product discovery and development efforts or through acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Continue to develop our proprietary platforms to extend their use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Attract, hire, and retain additional clinical, scientific, manufacturing, management and administrative personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add operational, financial, and management information systems and personnel, including personnel to support our product development, as well as to support our transition to a public reporting company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Require increased manufacturing capabilities with third parties for our preclinical studies and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Determine and execute our long-term manufacturing strategy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursue regulatory approval of product candidates that successfully complete clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain regulatory approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtain, maintain, expand and protect our intellectual property portfolio, and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incur costs associated with being a public company, including legal, accounting and auditing, investor relations, and compliance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, we will continue to require substantial additional funding to develop our product candidates and our platforms and to support our continuing operations. Our ability to generate product revenue will depend on the successful development, regulatory approval, and eventual commercialization of one or more of our product candidates. Until such time that we can generate significant revenue from product sales, if ever, we expect to finance our operations through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, if at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, and could force us to delay, reduce or eliminate our product development or future commercialization efforts. We may also be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, we have not had any products approved for sale and have not generated any revenue from product sales and we have accumulated significant losses. In the first quarter of 2022, we received approximately $127.3 million and $10.0 million, respectively, in net cash proceeds from our IPO (described below) and a private placement subsequent to the IPO. Prior to the IPO, we financed our operations primarily through the sale of redeemable convertible preferred stock and convertible promissory notes totaling $234.8&#160;million in gross cash </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">proceeds. As of March 31, 2022, we had cash and cash equivalents and marketable securities of $210.9&#160;million. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities together with the proceeds of this offering will be sufficient to fund our planned operations for at least the next 12 months. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Initial Public Offering (IPO) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 8, 2022, we issued and sold 9,487,500 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,237,500 additional shares of common stock, at a public offering price of $15.00 per share. We received aggregate net proceeds of $128.0 million, after deducting underwriting discounts and commissions and other offering expenses paid by us of approximately $14.3 million. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following are recent developments to our business and clinical development of our most advanced candidates, CART-ddBCMA and ACLX-001, since our IPO in February 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2022, we entered into a statement of work with Lonza Houston, Inc. for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. See &#8220;Business&#8212;Lonza Manufacturing Services Agreement&#8221; for more information. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2022, we issued and sold an aggregate of 590,318 shares of our common stock in a private placement to one accredited investor at a price of $16.94 per share for an aggregate purchase price of $10.0 million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, we dosed our first patient in the Phase 1 clinical trial of ACLX-001 for the treatment of r/r MM. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, we announced the election of Olivia Ware as a member of our board of directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, we announced the appointment of Michelle Gilson as our Chief&#160;Financial Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2022 at ASCO, we announced new positive clinical data for 31 patients from our ongoing Phase 1 trial of CART-ddBCMA for the treatment of r/r MM. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not generated any revenue from product sales and do not expect to do so in the near future. In the future, we may generate revenue from payments received under collaboration agreements, which could include payments of upfront fees, license fees, milestone-based payments, and reimbursements for research and development efforts. However, there can be no assurance as to when we will generate such revenue, if at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Expenses </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with our CART-ddBCMA program, the development of our ARC-SparX product candidates, and the ongoing discovery and development efforts for additional product candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">External expenses include: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to third parties in connection with the clinical development of our product candidates, including contract research organizations (CROs) and consultants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments to third parties in connection with the preclinical development of our product candidates, including outsourced professional scientific development services, consulting research fees and for sponsored research arrangements with third parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laboratory supplies used in the preclinical development of our product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocated facilities, depreciation, and other expenses, which include direct or allocated expenses for IT, rent and maintenance of facilities. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal expenses include employee-related costs, including salaries, related benefits, and share-based compensation expense for employees engaged in research and development functions. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expense research and development costs in the periods in which they are incurred. We track external costs on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">program-by-program</div></div> basis beginning with lead candidate selection. External costs that are not allocated to a program are classified as preclinical and discovery costs. We do not track internal costs by program because these costs are deployed across multiple programs, and as such, are not separately classified. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially in the foreseeable future as we advance CART-ddBCMA into a Phase 2 pivotal trial; initiate or continue clinical trials for our ARC-SparX product candidates, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002;</div> continue to discover and develop additional product candidates to expand our pipeline; maintain, expand, protect, and enforce our intellectual property portfolio; and hire additional personnel. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The successful development of our product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing, and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. To the extent our product candidates continue to advance into clinical trials, as well as advance into larger and later-stage clinical trials, our expenses will increase substantially and may become more variable. We are also unable to predict when, if ever, we will generate revenue from our product candidates to offset these expenses. Because of the early stage of development of our product candidates, our ability to eventually generate significant revenues from product sales will depend on a number of factors, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification of additional target antigens for desired indications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Identification and engineering of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain-based</div> binding regions that bind to the desired target antigens; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful completion of preclinical studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Submission of INDs or other regulatory applications for our planned clinical trials or future clinical trials and authorizations from regulators to initiate clinical studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful enrollment in, and completion of, clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Achieving favorable results from clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receipt of marketing approvals from applicable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishing and maintaining sufficient manufacturing capabilities, whether internally or with third parties, or arrangements for clinical supplies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effectively competing with other therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing and implementing successful marketing and reimbursement strategies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining and maintaining patent, trade secret, and other intellectual property protection and regulatory exclusivity for our product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maintaining a continued acceptable safety profile of any product following approval, if any. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any changes in the outcome of any of these factors could significantly impact the costs, timing, and viability associated with the development of our product candidates and our ability to generate significant revenues from product sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses consist primarily of salaries, related benefits, and share-based compensation expense for personnel in executive, finance, and administrative functions. General and administrative expenses also include allocated facilities, depreciation, and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included in research and development expenses, as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our general and administrative expenses will increase as we increase our headcount to support the growth of the company. We further expect that our general and administrative expenses will increase substantially as we will incur substantially higher expenses relating to accounting, audit, legal, regulatory, compliance, director and officer insurance, and investor and public relations as a result of being a public company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income, Net </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net consists primarily of interest earned on our cash and cash equivalents, restricted cash, and marketable securities. Our interest income has not been significant to date due to low interest earned on invested balances. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of the Three Months Ended March&#160;31, 2022 and 2021 </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our results of operations (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,273</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,153</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(32,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(11,282</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(21,153</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(11,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(21,104</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">External costs:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">14,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical and discovery costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total external costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,768</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,599</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses were $24.4&#160;million for the three months ended March&#160;31, 2022 compared to $8.5&#160;million for the three months ended March&#160;31, 2021, an increase of $15.9&#160;million. This increase in research and development expenses was driven by $12.7&#160;million of higher external costs associated with our CART-ddBCMA clinical trial and $1.1&#160;million of higher external costs related to preclinical development of our other product candidates. Additionally, our internal costs reflect an increase of $2.1&#160;million in personnel costs principally related to the addition of research and development and clinical employees.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses were $8.0&#160;million for the three months ended March&#160;31, 2022 compared to $2.8&#160;million for the three months ended March&#160;31, 2021, an increase of $5.2&#160;million. This increase was driven by an increase of $3.2&#160;million in personnel related costs due to an increase in headcount, $1.3&#160;million in professional fees related to consulting and accounting and audit services, and $0.7&#160;million in other expenses.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of the Years Ended December&#160;31, 2021 and 2020</div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our results of operations (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">25,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,827</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65,018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(65,018</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(32,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(32,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(64,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,874</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The break-down of our external and internal research and development costs is as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">External costs:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical and discovery costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,831</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total external costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">33,366</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18,351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,705</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">25,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,827</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses were $46.9&#160;million for the year ended December&#160;31, 2021 compared to $25.1&#160;million for the year ended December&#160;31, 2020, an increase of $21.8&#160;million. This increase in research and development expenses was driven by $12.2&#160;million of higher external costs associated with our CART-ddBCMA clinical trial and $2.8&#160;million of higher external costs related to preclinical development of our other product candidates. Additionally, our internal costs reflect an increase of $6.8&#160;million in personnel costs principally related to the addition of research and development and clinical employees.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses were $18.1&#160;million for the year ended December&#160;31, 2021 compared to $7.0&#160;million for the year ended December&#160;31, 2020, an increase of $11.1&#160;million. This increase was driven primarily by an increase of $8.3&#160;million in personnel related costs due to an increase in headcount, together with increases in consulting fees of $1.1&#160;million attributable to new branding, marketing, and strategy initiatives, $0.7&#160;million in professional fees related to legal, consultants, and accounting and audit services, $0.6&#160;million in facilities costs, and $0.4&#160;million in other expenses.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have incurred net losses and negative cash flows from operations. For the years ended December&#160;31, 2021 and 2020, we had net losses of $65.0&#160;million and $32.1&#160;million, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $130.1&#160;million. As of December&#160;31, 2021, we had cash and cash equivalents and marketable securities of $104.6&#160;million. Our net losses were $32.4&#160;million and $11.3&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, and we expect to incur substantial additional losses in future periods. As of March&#160;31, 2022, we had an accumulated deficit of $162.5&#160;million. As of March&#160;31, 2022, we had cash and cash equivalents and marketable securities of $210.9&#160;million.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2022, we received approximately $127.3&#160;million and $10.0&#160;million, respectively, in net cash proceeds from our IPO and a private placement subsequent to the IPO. Prior to the IPO, we have historically financed our operations primarily through the sale of redeemable convertible preferred stock and convertible promissory notes totaling $234.8&#160;million in gross cash proceeds. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities together with the proceeds of this offering will be sufficient to fund our planned operations for at least the next 12 months. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of, and commercialize any of, our product candidates or enter into collaborative agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, we expect to incur additional costs associated with operating as a public company.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to require additional capital to develop our product candidates and to fund operations for the foreseeable future. We may seek to raise capital through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, and licensing arrangements. We anticipate that we will need to raise substantial additional capital, for which the requirements will depend on many factors, including: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope, progress, timing, results, and costs of developing and manufacturing our product candidates, and their components, and conducting preclinical studies and clinical trials and other testing of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our ability to continue our business operations and product candidate research and development, and to adapt to any changes in the regulatory approval process, manufacturing supply, or clinical trial requirements and timing due to the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and otherwise, including our ability to comply with new regulatory guidance or requirements on conducting clinical trials during and after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs, timing, and outcome of regulatory review of any of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The extent to which our product candidates, if approved, can be offered by prescribers in various clinical settings, including academic hospitals and community practices, the acceptance of our products, if and when approved, by patients, the medical community and third-party payors, and the revenue received from commercial sale of any products for which we receive marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The effect of competing technologies and market developments; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The extent to which we acquire or invest in other businesses, products and technologies, and any other licensing or collaboration arrangements for any of our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation, or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or we may have to accept other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March 31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(32,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(9,507</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(54,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(28,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(10,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,066</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(79,976</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(888</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">139,556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">81,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">118,451</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">41,656</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase (decrease) in cash, cash equivalents, and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">96,327</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">71,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(15,763</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities during the three months ended March&#160;31, 2022 of $32.6&#160;million was primarily attributable to our net loss of $32.4&#160;million and net changes in operating assets and liabilities of $5.3&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges for depreciation and amortization of property and equipment, amortization of premiums and discounts on marketable securities, and share-based compensation in total of $5.1&#160;million. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities during the three months ended March&#160;31, 2021 of $9.5&#160;million was primarily attributable to our net loss of $11.3&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges for depreciation of property and equipment and share-based compensation in total of $1.0&#160;million and net changes in operating assets and liabilities of $0.8&#160;million. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities during the year ended December&#160;31, 2021 of $54.2&#160;million was primarily attributable to our net loss of $65.0&#160;million, partially offset by net changes in operating assets and liabilities of $2.8&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges for depreciation and amortization of property and equipment, amortization of premiums and discounts on marketable securities, and share-based compensation in total of $8.0&#160;million.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities during the year ended December&#160;31, 2020 of $28.7&#160;million was primarily attributable to our net loss of $32.1&#160;million, partially offset by net changes in operating assets and liabilities of $1.7&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges for depreciation of property and equipment and share-based compensation in total of $1.7&#160;million.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities of $10.6&#160;million during the three months ended March&#160;31, 2022 was attributable to $10.1&#160;million in net purchases of marketable securities and $0.5&#160;million of purchases of lab equipment. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities of $1.1&#160;million during the three months ended March&#160;31, 2021 was attributable to purchases of lab equipment. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities of $80.0&#160;million during the year ended December&#160;31, 2021 was attributable to $74.2&#160;million in purchases of marketable securities and $5.8&#160;million of purchases of lab equipment used in the development of our cell therapies.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities of $0.9&#160;million during the year ended December&#160;31, 2020 was attributable to purchases of property and equipment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities of $139.6&#160;million during the three months ended March&#160;31, 2022 was primarily attributable to net proceeds of $129.2&#160;million from the issuance of common stock as part of our IPO, net proceeds of $10.0&#160;million from the issuance of common stock as part of a private placement, and proceeds of $0.4&#160;million from the exercise of stock options. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities of $81.6&#160;million during the three months ended March&#160;31, 2021 was primarily attributable to net proceeds of $81.8&#160;million from the sale of shares of our Series C redeemable convertible preferred stock. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities of $118.5&#160;million during the year ended December&#160;31, 2021 was primarily attributable to proceeds of $119.1&#160;million from the sale of shares of our Series C redeemable convertible preferred stock, net of transaction costs and proceeds of $0.4&#160;million from the exercise of stock options, partially offset by $0.6&#160;million in payments of deferred offering costs associated with our IPO and $0.4&#160;million in payments under capital leases.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities of $41.7&#160;million during the year ended December&#160;31, 2020 was primarily attributable to proceeds of $42.8&#160;million from the sale of shares of our Series B redeemable convertible preferred stock, net of transaction costs, partially offset by $1.2&#160;million in payments of offering costs associated with our IPO.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual Obligations and Contingencies </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We lease certain office and laboratory space in Gaithersburg, Maryland under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> operating lease that has a term that expires in 2030 unless renewed. Rent expense is recorded on a straight-line basis over the term of the lease. The total future undiscounted minimum lease payments are $7.1&#160;million related to our operating leases as of March&#160;31, 2022.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In September 2021, we entered into a manufacturing services agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (the Lonza Agreement), whereby Lonza agreed to perform certain process and analytical development activities and to collaborate with the Company to develop a statement of work setting forth certain technology transfer and cGMP manufacturing activities relating to CART-ddBCMA. In February 2022, and pursuant to the Lonza Agreement, we entered into a statement of work (Lonza SOW) for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The Lonza SOW expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. The Lonza SOW is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> for the first six months of the term and carries minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> costs including upfront payments, milestone fees, and fixed monthly payments during the related period. Subsequent to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> period, we may terminate the arrangement for any reason upon 12 months&#8217; prior notification to Lonza. As of March&#160;31, 2022, our minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> costs payable to Lonza was approximately $40.6&#160;million. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition to the arrangement with Lonza, we have entered into other contracts in the normal course of business with CROs, CMOs, and other third parties for preclinical research studies and testing, clinical trials, and manufacturing services. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice. For such contracts, payments due upon cancellation consist only of payments for services provided and expenses incurred, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> obligations of our service providers, up to the date of cancellation. We have also entered into agreements with certain vendors for the provision of goods and services, which include manufacturing services with CMOs and development services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement. In addition, certain agreements with our CMOs and third-party vendors contain development and commercial milestone payments and low single-digit royalties on worldwide net sales for certain products we sell that incorporate certain goods provided by our manufacturers and suppliers. Certain of these agreements contain development milestones of up to $18.7&#160;million in the aggregate and commercial milestones of up to $52.0&#160;million in the aggregate, along with royalty buyout provisions. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Estimates</div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles (GAAP) in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on a periodic basis. Our actual results may differ from these estimates.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing at the end of this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses, including clinical trial accruals and related expenses</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development costs are charged to expense as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, and overhead and facility-related costs. We account for advanced payments, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> amounts, for goods or services that will be used in future research and development activities as expenses when the related goods have been received or when the service has been performed, or such a time when we do not expect the goods to be delivered or services to be performed, rather than when the payment is made.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Expenses related to clinical trials are accrued based on estimates and representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies, and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, we accrue expenses related to the work performed by CMOs based on the progress of the work performed. If the amounts that we are obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based compensation</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We account for share-based compensation in accordance with ASC 718, Compensation&#8212;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>(ASC 718). ASC 718 requires all share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units, to be recognized as expense based on their grant date fair values. Our policy is to account for forfeitures as they occur.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We estimate the fair value of options granted using the Black-Scholes-Merton option pricing (Black-Scholes) model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> We will reconsider the use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. Our methodology for developing the assumptions used in the valuation model are as follows:</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock</div></div>&#8212;See the subsection titled &#8220;Determination of the fair value of our common stock and fair value of total equity&#8221; below.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield</div></div>&#8212;The expected dividend yield is based on our historical and expected dividend payouts. We have historically paid no dividends and do not anticipate dividends to be paid in the future.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for our common stock (prior to our IPO) and the lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us (e.g., public entities of similar size, complexity, stage of development and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate</div></div>&#8212;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term</div></div>&#8212;We use the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our share-based compensation related to stock options subject to service conditions are recognized as expense ratably over the required service period based on their grant date fair values. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or without cause from their position. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We estimate the fair value of awards subject to both a market condition and a performance condition on the grant date using a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method beginning when the achievement of the performance condition becomes probable over the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">applicable service period. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We granted restricted stock units (RSU Award) to an executive officer subject to service, performance, and market conditions and used the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Monte Carlo </div></div>simulation model approach to estimate the fair value of the RSU Award on the date of grant. We utilized<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Monte Carlo</div></div> simulation models to estimate the fair value of the RSUs on the date of grant. In applying the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Monte Carlo</div></div> methodology, the total equity value on various measurement dates were simulated and allocated to the various classes of equity in our capital structure according to the characteristics of that capital structure, such as the number of shares of each class of equity, seniority levels, liquidation preferences and conversion values for redeemable convertible preferred stock, and participation thresholds for common stock and each series of redeemable convertible preferred stock. The fair value of the RSU Award is the average of the discounted proceeds to the common stock across all simulated paths.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Application of the<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Monte Carlo</div></div> simulation model required various subjective assumptions that represent management&#8217;s best estimates of the fair value of common stock, expected equity volatility, risk-free interest rate, discount period, expected dividend yield, and time to achievement of a performance condition:</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;of Common Stock and Fair Value of Total Equity</div></div>&#8212;See the subsection titled &#8220;Determination of the fair value of our common stock and fair value of total equity&#8221; below.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for our common stock (prior to our IPO) and the lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period commensurate with the expected date of achievement of a performance condition.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate and Discount Period&#8212;</div></div>The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected time to achieve of a performance condition. The discount period is the period between the valuation date and the assumed change in control event date, with the assumption that all equity shares in the capital structure are paid out in cash.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Dividend Yield</div></div>&#8212;The expected dividend yield is based on our historical and expected dividend payouts. We have historically paid no dividends and do not anticipate dividends to be paid in the future.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Time to Achievement of a Performance Condition&#8212;</div></div>The time to the achievement of a performance condition is based on our best estimate of the period of time to achievement of a performance condition that attains the established market capitalization thresholds.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Determination of the fair value of our common stock and fair value of total equity</div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the lack of an active public market for our common stock and other equity instruments prior to our IPO, the fair value of our common stock and total equity was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, we believe that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date and resulting total equity value. In determining the fair value of our common stock and total equity value, we use methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation. In addition, we considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;our achievement of clinical and operational milestones; (2)&#160;the significant risks associated with our stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;our available cash, financial condition, and results of operations; (5)&#160;the most recent sales of our redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding preferred stock.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, our board of directors considered the following methods:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Probability-weighted expected return method</div></div>. The PWERM is a scenario-based analysis that estimates the fair value of common stock based upon an analysis of future values for the business, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible forecasted outcomes as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-marketable</div> indication of value for the common stock. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option pricing method</div></div>. Under the OPM, shares are valued by creating a series of call options, representing the present value of the expected future returns to the stockholders, with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hybrid return method</div></div>. The hybrid return method is a blended approach using aspects of both the PWERM and OPM, in which the equity value in one of the scenarios is calculated using an OPM. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on our early stage of development and other relevant factors, for our valuation performed on August&#160;9, 2019, we determined that the hybrid method was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock and total equity value. Under the hybrid method, we analyzed various scenarios, including one scenario where we would remain an independent and private company, where the OPM was utilized, and an alternative scenario of a liquidation where a waterfall analysis was utilized, with the outcome of each scenario combined into a single probability-weighted valuation. The enterprise value under the remain independent and private company scenario was based on a backsolve to our latest round of financing. The enterprise value under the liquidation scenario was based on the recovery of value of our company as of the liquidation date.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For our valuations performed on May&#160;31, 2020, December&#160;23, 2020, April&#160;9, 2021 and October&#160;25, 2021, we used the PWERM whereby our total enterprise value was estimated under various exit scenarios and allocated to our different classes of equity. The PWERM included various scenarios in which we stay private, complete the sale of our company, complete an IPO or liquidate our company that considered our estimate of the timing of each scenario and were weighted based on our estimate of the probability of each event occurring. The enterprise value under the IPO scenarios was based on the guideline public company method market approach and considered comparable publicly traded companies. The enterprise value under the stay private scenarios was based on an OPM backsolve to our latest round of financing. As a concurrent equity financing did not occur on or around October&#160;25, 2021, for the October&#160;25, 2021 valuation the OPM backsolve was linked to the equity financing on April&#160;9, 2021, adjusted for changes in comparable public company values between the two dates. The equity values under the scenarios in which we complete the sale of our company were based on the guideline transaction method market approach and considered comparable company transactions. The enterprise value under the liquidation scenarios was based on the asset approach and was based on the recovery of value of our company as of the liquidation dates.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The enterprise value determined under the PWERM and OPM was weighted according to our board of directors&#8217; estimate of the probability of the occurrence of the particular discrete event as of the valuation date. The resulting equity value for the common stock was then divided by the number of shares of common stock outstanding at the date of the valuation to derive a per share value on a marketable basis. In order to determine the fair value of our common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-marketable</div> basis, we then applied a discount for lack of marketability which we derived based on inputs including a company-specific volatility rate, a term equal to the expected time to a future liquidity event and a risk-free rate equal to the yield on U.S. treasury notes of similar duration.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Application of these approaches involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding our expected future revenue, expenses, and cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of future events. Changes in any or all of these estimates and assumptions, or the relationships between those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of common stock. The assumptions underlying these valuations represent our management&#8217;s best estimate, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the closing of our IPO, the fair value of our common stock is determined based on the listed market price of our common stock on the date of grant.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company and Smaller Reporting Company Status</div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time that those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earliest of (i)&#160;the last day of our first fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more, (ii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, (iii)&#160;the date on which we have issued more than $1.0&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities during the previous three years, or (iv)&#160;the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering (i.e., December 31, 2027). An emerging growth company&#160;may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company,</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may provide reduced disclosure about our executive compensation arrangements; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We are not required to hold stockholder <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory votes on executive compensation or golden parachute arrangements. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have elected to take advantage of certain of the reduced disclosure and reporting requirements in this prospectus. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;small reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements. Specifically, among other things, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited consolidated financial statements in our prospectus and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements</div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A description of recently issued and recently adopted accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing at the end of this prospectus.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative and Qualitative Disclosures About Market Risk </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a smaller reporting company, we are not required to provide the information required by this Item. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Though cell therapies have shown benefits to date, cell therapies have historically been constrained to existing biologic structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> is designed to overcome the limitations of traditional Chimeric Antigen Receptor T cells <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(CAR-Ts).</div> Existing cell therapy solutions, most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we can overcome these limitations by engineering a new class of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> powered autologous and allogeneic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts,</div> including classical single infusion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our lead ddCAR product candidate, CART-ddBCMA, is in Phase&#160;1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM), defined as patients with either minimal response or disease progression within 60 days of last treatment. Preliminary results from the trial have demonstrated that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> can potentially provide meaningful clinical benefits. We plan to initiate additional trials of CART-ddBCMA, including iMMagine, our Phase&#160;2 pivotal trial for treatment of r/r MM, in late 2022 as well as expansion trials for earlier lines of therapy. We are also advancing our novel ARC-SparX programs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in r/r MM and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-003</div> in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). In the second quarter 2022, we initiated our Phase&#160;1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001.</div> We plan to initiate Phase&#160;1 clinical trials for ACLX-002 in 2022 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-003</div> in 2024. We are also exploring indications in solid tumors, as well as integrating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-powered</div> discovery and computational tools to expand the applicability of our platforms. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: right; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g02s22.jpg" style="width: 245px; height: 157px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> platform consists of structurally unique binders that are small and stable. They can be consistently manufactured and easily modified to generate diverse libraries of proprietary target-binding domains. The small size and structure of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders compared to other antigen binding domains used in CAR constructs, such as scFvs, are illustrated to the right. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> platform enables us to make a range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies, including ddCARs and ARC-SparX, tailored to the complexities of cancer. In our preclinical studies of CARs with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> and scFvs, we have demonstrated that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> result in higher transduction efficiency, higher surface expression, and lower tonic signaling relative to scFvs, which we believe can lead to cell therapies with improved therapeutic benefit and reduced toxicity. </div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), we announced positive preliminary results in our ongoing Phase 1 clinical trial for CART-ddBCMA for the treatment of r/r&#160;MM. As of the May&#160;3, 2022 data cutoff date, 31 patients were evaluable for safety and efficacy analysis, which required at least a 1-month follow-up visit per protocol using the 2016 International Myeloma Working Group (IMWG) uniform response criteria for MM, which are further described on page 131. These evaluable patients comprised the dose escalation cohorts for the first dose level (DL1) (n=6) and the second dose level (DL2) (n=6) and a dose expansion cohort of DL1 (n=19). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key highlights from the data presented are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the 31 evaluable patients: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 (39%) patients have extramedullary disease (EMD); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100% overall response rate (ORR) was achieved per IMWG criteria with median follow up of 12.1 months; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 (71%) patients achieved complete response (CR) or a stringent complete response (sCR); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 (94%) patients achieved very good partial response (VGPR) or better; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 (6%) patients achieved a partial response (PR). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The longest response to date is ongoing at 27 months in the first patient ever dosed with CART-ddBCMA, a patient with EMD. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversions to sCR have occurred as early as the 1-month follow-up visit and have currently been reported as late as the 12-month follow-up visit; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the 16 patients who have had their 12-month follow-up visit: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 (50%) patients have EMD; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 (81%) patients reached CR/sCR; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 (56%) patients remain in ongoing response with a median follow up of 17.7 months. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA dosed at the recommended Phase 2 dose (RP2D) of 100&#160;million CAR+T cells (DL1) continues to be well-tolerated. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), have been manageable, and all were resolved with standard management. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No cases of delayed neurotoxicity events or parkinsonian symptoms have been observed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top; font-size: 95%;;text-align:left;"><div style="font-family: ARIAL; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 95%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:8.9px">&#9675;</div></div>&#160;</div></td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No cases of grade 3 (or greater) CRS and only one case (4%) of grade 3 ICANS event have been observed with no additional cases from those previously reported as of the November&#160;4, 2021 cutoff date. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All patients enrolled in the trial have poor prognostic factors with 21 of 31 (68%) patients being penta-refractory and all 31 patients having had at least three prior treatments, with a median of five prior lines of therapy. Twelve out of 31 patients (39%) had EMD, a condition in which myeloma cells form tumors outside the bone marrow, involving one or more organs, including the liver, lymph nodes, skin, lungs, and central nervous system. EMD is associated with worse prognosis, and patients with EMD have been reported to experience lower CR rates and shorter duration of response (DOR) in clinical trials of other BCMA-targeting CAR-T therapies than non-EMD patients. Twelve of 31 (39%) patients had greater than 50% bone marrow plasma cells (BMPC), which are the malignant cells that cause multiple myeloma. Patients with a high percentage of BMPC are considered to have increased tumor burden, which has been associated with poor prognosis in MM clinical trials and observational studies. We believe these preliminary positive results in an enrolled population with poor prognostic indicators not only reflect the potential benefit of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> but also demonstrate the potential for CART-ddBCMA to become a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> treatment for patients suffering from r/r&#160;MM, including those with EMD. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">MM is the third most common hematological malignancy in the United States and Europe, with approximately 35,000 new cases diagnosed per year in the United States. Although changes in the treatment landscape for MM have increased the rates and depth of response (antitumor activity), there is currently no cure, whether approved or in clinical development, for MM and patients typically have a life expectancy of approximately five years. In 2020, the size of the global MM market was approximately $18&#160;billion. We estimate the current total addressable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> market for r/r MM to be approximately $10&#160;billion based on the number of patients who are receiving third line treatments and beyond. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We are preparing to initiate our iMMagine Phase&#160;2 pivotal trial of CART-ddBCMA in r/r MM by the end of 2022, and if successful, intend to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). We also intend to rapidly pursue clinical development of&#160;CART-ddBCMA in earlier lines of therapy through our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">iMMagine-2</div> clinical trial. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells, our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> based universal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. We believe that controlling <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> activation with SparX protein effectively separates the antigen-recognition and killing functions, which allows us to reduce toxicities. Our preclinical studies of our ARC-SparX product candidates have demonstrated that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells can be activated by different SparX proteins that target different antigens, suggesting that ARC-SparX can potentially address antigen heterogeneity, and thereby address some harder to treat indications. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We initiated our Phase 1 clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001,</div> the first product candidate developed under our ARC-SparX platform, for the treatment of r/r MM in the second quarter of 2022. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> is an immunotherapeutic combination composed of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells and SparX proteins that target BCMA. This trial is intended to establish an ARC-SparX dosing regimen and prepare for ARC-SparX trials in expanded indications. Our lead ARC-SparX indication is AML/MDS, for which we have multiple SparX in development targeting different antigens. We plan to initiate the Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002,</div> an ARC-SparX product candidate targeting CD123, for the treatment of AML/MDS in the second half of 2022 and plan to initiate a Phase 1 clinical trial for ACLX-003, an ARC-SparX product candidate directed at another antigen associated with AML/MDS in 2024. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have built a broad and scalable pipeline that has positioned us to capitalize on the potential of our proprietary platform technologies and achieve long-term growth and sustainability within the field of cell therapy. We believe our therapeutic approaches, ddCAR and ARC-SparX, will enable us to select mechanisms that are most appropriate for each target and indication we may choose to pursue based on underlying disease biology and patient need, such as in solid tumors, including small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have worldwide rights to all of our programs and have summarized our preclinical and clinical programs in the pipeline chart below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g46h84.jpg" style="width: 593px; height: 310px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pivotal refers to our planned iMMagine Phase 2 trial. Based on our current discussions with the FDA, we believe that results from our iMMagine trial, if positive, together with the results from our Phase 1 trial could be sufficient to support the filing of a BLA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> platform has broad potential utility for additional cell modalities, targets, therapeutic areas and applications and we plan to expand our pipeline beyond hematologic and solid cancers to autoimmune disease, as well as to allogeneic cell types. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The foundation of our competitive advantage is our proprietary technology, clinical evidence, track record of execution, manufacturing success, and assembly of a proven management team. We believe these advantages position us to achieve significant market share in a large and attractive market and to ultimately transform the cell therapy market, contributing to a significant advancement in medicine. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Team </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our team and culture are critical to realizing our vision of reimagining cell therapy as one of the future pillars of medicine. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are led by a diverse team of executives with significant experience in business, discovery, development, manufacturing, and commercialization of differentiated and novel therapies specifically in the fields of oncology, cell therapy and rare diseases. Rami Elghandour, our Chairman and Chief Executive Officer, previously served as President and Chief Executive Officer at Nevro where he grew the company from a small private company to a publicly traded commercial organization with nearly $400&#160;million in revenue. Prior to Nevro, Mr.&#160;Elghandour was an investor with Johnson&#160;&amp; Johnson Development Corporation where he led several investments, including Nevro&#8217;s Series B financing. Our Chief Medical Officer, Christopher Heery, M.D., an oncologist by training, was the former Head of Clinical Trials Group for the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, and previously served as Chief Medical Officer at Precision Biosciences and Bavarian Nordic. Our Chief Financial Officer, Michelle Gilson, was previously a senior equity research analyst covering the biotechnology sector, most recently as a Managing Director at Canaccord Genuity. Our Chief Scientific Officer, David Tice, Ph.D., has over 20 years of biopharmaceutical research and drug development experience in oncology including 18 years at MedImmune, the global biologics research and development unit of AstraZeneca. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have attracted a diverse and talented group of innovators and company builders to help us execute our strategy and to build a transformative cell therapy platform company. Collectively, we are driven by our shared purpose and our values. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021, we had 78 employees and are committed to continuing to build and maintain a diverse and inclusive organization. We believe focusing on diversity and inclusion is not only the right thing to do but is also a competitive advantage. We are purposeful in our efforts to seek and retain top diverse talent from underrepresented groups as reflected throughout our organization: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executives: 29% female; 36% diverse (defined as racial&#160;&amp; ethnic representation); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managers and senior scientists with managerial responsibilities: 32% female; 45% diverse; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professionals and individual contributor scientific roles: 71% female; 49% diverse. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commitment to diversity doesn&#8217;t stop within the walls of our organization. With our mission of advancing humanity, we believe in equitable access to healthcare. Inclusive research programs that encompass real-world patient populations can contribute to addressing racial inequality in healthcare. We are dedicated to expanding representation within our clinical trials. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also believe deeply in corporate social responsibility and being conscious stewards in our society. We are devoted to leveraging our science to make a positive impact for the patient and local communities we serve. As our organization expands, we intend to grow our community involvement and outreach efforts, and establish our corporate brand as a force for good through corporate philanthropic, patient advocacy, and employee volunteerism. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategy </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our mission is to advance humanity by engineering cell therapies that are safer, more effective, and more broadly accessible. Our strategy to achieve this patient-centric goal is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Advance CART-ddBCMA to treat r/r MM patients in the United States and abroad: </div></div>Based on currently available results of our Phase&#160;1 trial, we believe we have demonstrated that&#160;CART-ddBCMA&#160;can deliver deep and durable anti-tumor responses for r/r MM patients. We plan to initiate a Phase&#160;2 pivotal trial in late 2022. We also intend to rapidly pursue clinical development of CART-ddBCMA in earlier lines of therapy and plan to initiate clinical trials of CART-ddBCMA in other key geographies, such as Europe and Asia, in order to gain significant market share in the existing $18&#160;billion global MM market. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Develop comprehensive ARC-SparX AML/MDS program:</div></div> Our strategy is to build a comprehensive AML/MDS <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> solution with development of various SparX proteins for personalized therapy tailored to the molecular profile of each AML/MDS patient&#8217;s disease. We believe AML/MDS is particularly well suited to the ARC-SparX approach given the heterogeneity of AML/MDS antigen targets and the high unmet need of the indication. We plan to initiate the Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002,</div> an ARC-SparX product candidate targeting CD123, for the treatment of AML/MDS in the second half of 2022 and plan to initiate a Phase 1 clinical trial for ACLX-003, an ARC-SparX product candidate directed at another antigen associated with AML/MDS in 2024. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expand our pipeline to select solid tumor indications: </div></div>As we validate the benefits of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> technology through our ddCAR and ARC-SparX platforms, we plan to diversify development programs beyond hematologic tumors to solid tumors. We believe this combination of </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">therapeutic platforms will allow us to select mechanisms that are most appropriate for each target and indication we choose to pursue based on underlying disease biology and patient need. We continue to invest in solid tumor programs, including SCLC and HCC. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Apply our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> technology outside of autologous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> solutions: </div></div>Since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders can be applied across cell modalities, we plan to expand beyond autologous T cells into healthy donor- and/or iPSC-derived allogeneic T cells, as well as other cell types such as natural killer (NK) cells. At the same time, we intend to expand our discovery efforts to generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders against additional targets which can then be deployed across either or both of our ddCAR or ARC-SparX platforms as well as any of the cell types we are pursuing. Ultimately, we hope to develop multiple therapeutic options incorporating different mechanisms, cell modalities, and targets to treat hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Enable greater access to CAR-T therapy through clinical studies in broader patient populations that support improved market access:</div></div> Initial studies in CAR-T have focused on demonstrating efficacy in patients refractory to multiple lines of therapies, resulting in approval and utilization in a limited segment of patients with late-stage disease. We intend to run clinical trials demonstrating the benefit of CAR-T as an earlier therapy option, supporting increased market access to broaden the number of patients eligible for the therapy. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Invest in technologies that enable access:</div></div> As demand for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> continues to increase, we plan to invest in technologies ranging from manufacturing to logistics and demand planning that enable lower customer friction and improved responsiveness. We believe these investments can help us provide much needed access to patients and clinicians and differentiate us in the marketplace. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leverage novel technologies to drive our discovery efforts:</div></div> We intend to invest in applications of artificial intelligence (AI) and machine learning (ML)&#160;to help accelerate our discovery pipeline by mining our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> libraries to identify indication-specific SparX proteins. We believe this investment has the potential to improve the efficiency of our drug development efforts by accelerating clinical trial timelines and increasing the probability of success of the programs that we advance. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunistically pursue strategic partnerships and collaborations to maximize the full potential of our platform:</div></div> Our versatile platforms have broad potential applicability in areas outside of oncology, including autoimmune diseases. We intend to evaluate strategic partners with proven clinical development and commercialization capabilities for certain targets or assets that do not overlap with our internal programs or our core focus. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cell Therapy Background&#160;&amp; Current Limitations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Background </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T cells are a key component of the immune system that can target diseased cells for elimination through the recognition of cell surface antigens. A growing understanding of the immune system over the years and advances in cell, gene and protein engineering have led to approved genetically modified cell therapy products. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genetically modified cell therapy involves isolating immune cells, modifying them outside of the patient&#8217;s body and then reintroducing them into the patient to destroy diseased cells. Such cell therapies have largely focused on using the patient&#8217;s own T cells (autologous approach) to express engineered antigen receptor complexes, such as TCRs or CARs. The extracellular binding domain of the TCR or CAR recognizes the antigen, and, after the T cell binds with the cell expressing the antigen, the intracellular signaling domain induces cell killing and activates pathways specific for the T cell&#8217;s proliferation and survival. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The recent availability of cell therapy products introduced an unprecedented &#8220;living therapeutic&#8221; modality that offers benefits well beyond what previous oncology modalities offered. For the first time, these therapeutics directly harness the strength of the patient&#8217;s own immune system to significantly reduce, even potentially eradicate, tumors. Initially evaluated in indications where patients were refractory to multiple lines of therapy and had generally exhausted their therapeutic options, adoptive cell therapies have shown response rates that exceed many other available modalities. Particularly striking is that these responses are achieved with a single, personalized administration of the cell therapy, generally achieving rapid responses and resolving toxicities in days to weeks. This transformative therapy results in extended quality of life benefits without maintenance or additional treatment. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of June 8, 2022, there are six FDA approved CAR-T cell therapies: Carvykti (ciltacabtagene autoleucel), which has been approved by the FDA for treatment of adult patients with r/r MM after four or more prior lines of therapy, Abecma (idecabtagene vicleucel), which has been approved by the FDA for treatment of adult patients with r/r MM after four or more prior lines of therapy, Breyanzi&#160;(lisocabtagene maraleucel), which has been approved by the FDA for treatment of adult patients with r/r large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> lymphoma (LBCL) after two or more lines of systemic therapy, Kymriah (tisagenlecleucel), which has been approved by the FDA for treatment of patients up to 25 years of age with r/r <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-cell</div> precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse and adult patients with r/r LBCL after two or more lines of systemic therapy, Tecartus (brexucabtagene autoleucel), which has been approved by the FDA for treatment of adult patients with r/r mantle cell lymphoma and adult patients with r/r ALL, and Yescarta (axicabtagene ciloleucel), which has been approved by the FDA for treatment of adult patients with r/r LBCL after two or more lines of systemic therapy and adult patients with r/r follicular lymphoma after two or more lines of systemic therapy. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hematologic cancers represent a robust and growing market opportunity for CAR-T cell therapies. These cancers, which include leukemia, lymphoma and myeloma, account for approximately 10% of all cancer incidence in 2020. We estimate that the total market opportunity for cell therapy in hematologic cancers is approximately $66&#160;billion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Limitations </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> and other genetically modified cell therapies have shown significant progress in extending the lives of patients who often have no other treatment options, there are limitations to their broader use, including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Limited Long-Term Efficacy:</div></div> FDA approved <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> may offer higher response rates compared to other available therapies, but efficacy as measured by the DOR is highly variable depending on the drug or patient population studied. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Adverse Effects:</div></div> These cell therapies also have the potential to cause several adverse effects. Uncontrolled cellular expansion and resulting side effects such as CRS, neurotoxicity, parkinsonian symptoms and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;on-target,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-tumor&#8221;</div> toxicities stifle the broader use of these therapies in several key ways. Specifically, they limit the number of patients that are eligible for treatment, relegate these therapies to later lines of treatment, preclude the use of these therapies in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-academic</div> and outpatient settings, and increase costs to patients, payers and providers due to the need for intensive care unit access when they are used. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Narrow Applicability:</div></div> Currently, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> and other genetically modified cell therapies are utilized in only a few hematological oncology indications. Their activity in most tumors is primarily driven by a limited number of tumor specific antigen targets. Their utility is further limited by secondary resistance mechanisms arising in the r/r settings, as well as the antigen heterogeneity that is characteristic of some of these diseases. For example, within r/r MM, patients with EMD have been reported to experience worse outcomes in clinical trials of other BCMA-targeting CAR-T therapies than non-EMD patients. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Solution </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our mission is to advance humanity by engineering cell therapies that are safer, more effective, and broadly accessible. We plan to achieve this goal by maximizing the impact of our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders, which enable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> to have distinct advantages including: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Promising Preliminary Clinical Data&#8212;High ORR and Durable Responses</div></div>: In our ongoing Phase&#160;1 clinical trial of CART-ddBCMA, for the 31 patients evaluable for efficacy, the ORR is currently 100% and the DOR is promising with more than half of the patients with r/r MM who have had their 12-month follow-up visit remaining in ongoing response with a median follow up of 17.7 months. We believe these preliminary results demonstrate the capability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> to not only effectively bind target antigens and drive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cell proliferation, but also to efficiently kill substantial proportion of tumor cells. High cell surface expression and low propensity for tonic signaling of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> may enable more effective interactions between the CAR and the antigen as well as reduced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> exhaustion, which may explain the rapid and long term responses currently observed in our ongoing Phase&#160;1 clinical trial. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Potential Differentiated Safety Profile:</div></div>&#160;We believe the small and stable structure of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> enables a high transduction rate, resulting in a high proportion of cells expressing the CAR construct on the cell surface (CAR+ cells). A high proportion of CAR+ cells lowers the total number of T cells required to be administered which we believe may yield a therapy with an improved toxicity profile, consistent with currently available results of the ongoing Phase 1 trial of CART-ddBCMA. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Opportunity to Treat a Broader Group of Patients:</div></div>&#160;We believe the preliminary positive results of our Phase 1 clinical trial of CART-ddBCMA underscore the capability to apply <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> across a wide variety of tumor antigen targets in the future. Based on the differentiation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> and the breadth and depth of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> libraries, we believe we can expand to a broader group of patients, including those with heterogeneously expressed tumor antigens and antigen targets that might be difficult to target. We are currently developing therapies within both our ddCAR and ARC-SparX platforms to treat a broad variety of indications, starting with r/r MM and AML/MDS, and, in the future, including solid tumors. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The foundation of our proprietary platforms is our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> technology, that has generated promising initial clinical data. We believe our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> technology is a transformational platform that enables us to take the right approach for the right indication within cell therapy. The strengths of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> are its size, stability, and structure which make it a unique and essential building block for making next generation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> to deliver on the promise of this therapeutic category which is poised to be one of the forward pillars of medicine. Our method of generating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains,</div> and the individual binders themselves are protected in our patent portfolio, which as of May&#160;31, 2022 comprises over 16 U.S. and international patents and over 50 U.S. and international pending applications. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We are generating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> against multiple targets which can then be deployed to create a new class of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> powered autologous and allogeneic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts,</div> including ddCARs and ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology such as autoimmune diseases. ddCARs are single infusion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> enhanced with our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> as the antigen recognition motif. ARC-SparX are adaptable versions of ddCARs where the SparX protein is dosed separately from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are dosable and controllable, universal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> designed to activate only when combined with a SparX protein that is bound to an antigen on a cell. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g22i15.jpg"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ddCAR Platform </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We use our ddCAR platform to generate single infusion therapies where our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binder replaces the scFvs. The ddCAR is composed of an intracellular T cell signaling domain similar to traditional CARs fused to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> which functions as the extracellular antigen binding region. Upon engagement with the antigen on a target cell, the ddCAR signals to activate the T cell to kill the target cell. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g33i14.jpg" style="width: 417px; height: 297px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> was developed to overcome limitations of existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies by employing a novel synthetic binding domain as a replacement to the traditionally used antigen binding domains for conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies, known as scFvs. The result is a structurally unique binder that is small, stable, and can be modified to generate a diverse library of proprietary target-binding domains. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Structurally Unique <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div></div></div></div></div>: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> are short polypeptides that spontaneously fold into a stable triple alpha-helical structure.&#160;The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> is derived from a 73 amino acid synthetic protein, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#945;-3D,</div> that has no known homolog in nature or apparent function as first described in a paper by Walsh,&#160;et al.&#160;that appeared in the Proceedings of the National Academy of Sciences in 1999. This domain is devoid of post-translational glycosylation or disulfide bonds leading to consistent manufacturability via microbial, fungal or mammalian protein expression. Additional key structural features of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> are as follows:</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Small Size</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">:</div></div> The figure below showcases the small size of the 8kDa <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> compared to other antigen binding domains used in CAR constructs such as the scFv and bi-valent camelid VHh structure of approximately 25kDa. A smaller antigen binding domain will decrease the overall lentiviral construct size which may improve transduction efficiency. The small antigen binding domain may also function to improve the immunological synapse formation and thus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cell killing. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g04a44.jpg" style="width: 495px; height: 301px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Hydrophobic Core</div></div></div></div>: The figure below depicts the three-dimensional structure of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> highlighting the triple alpha helical bundle with the tight hydrophobic core (in red). The hydrophobic core results in ultrafast folding kinetics of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> creating a stable structure when expressed in cells. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g43z54.jpg" style="width: 348px; height: 228px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stability</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">:</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> are highly stable proteins compared to scFvs which facilitates expression of CARs on T cells and manufacturing of SparX proteins. As shown in the middle panels of the figure below, using size exclusion chromatography, we have demonstrated that a higher level of monomeric protein content can be purified from human embryonic kidney (HEK) 293 cells expressing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain-based</div> SparX proteins compared to scFv, indicating lower levels of aggregation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> based SparX proteins and thus greater stability. In addition, we have tested the thermal stability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> as compared to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> binding scFv by heating them to temperatures about 100 degrees Celsius and measuring the retention of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> binding. As shown in the panels on the far right, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> that were heated to the indicated temperatures retained greater <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1</div> binding as compared to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1-binding</div></div> scFv, demonstrating the thermal stability of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g71l23.jpg" style="width: 605px; height: 351px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">When utilized in CARs, we believe the structural properties of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> translate into unique benefits of high transduction rates, high cell surface expression, and low tonic signaling. In the context of ddCARs, we believe the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> structure creates an efficient and scalable cell manufacturing process, as demonstrated by our high CAR+ rate, yield, and viability of cell product made to date. See &#8220;&#8212;Manufacturing and Delivery&#8212;CART-ddBCMA Cell and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> Cell.&#8221; </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">High Transduction Rate</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">: </div></div>In the manufacturing of CART-ddBCMA, we have achieved transduction rates ranging from approximately 60% to 85% in over 20 lots tested. We believe this high transduction efficiency may improve product consistency and reduce the number of untransduced T cells administered to patients that do not contribute to efficacy but may contribute to toxicity. Our high transduction rate compares favorably with previously published Phase 1 data regarding the transduction rates for Abecma (then known as bb2121) and Carvykti (then known as JNJ-4528), as shown in the left panel of the figure below. While we believe these data suggest that CART-ddBCMA has a meaningful advantage in transduction efficiency over existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies, these data are based on a cross-trial comparison and not a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> clinical trial and may not be directly comparable due to differences in trial designs and methodologies. As manufacturing processes and vectors can also be vastly different across cell products, we also engineered a vector where the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> was replaced by an scFv targeting BCMA while leaving all other conditions identical to isolate the effects on transduction from using a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> as compared to scFv. As shown in the right panel of the figure below, our CART-ddBCMA transduced T cells demonstrated superior transduction efficiency when compared to scFv transduced T cells derived from multiple normal human donors. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical Transduction Efficiency*</div></div></div> <div style="text-align: left; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g08a40.jpg" style="width: 343px; height: 286px;"/></div> </div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical Transduction Efficiency</div></div></div> <div style="text-align: left; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g08a45.jpg" style="width: 171px; height: 269px;"/></div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">High Cell Surface Expression</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">:</div></div> Coincident with higher transduction rates, the expression of the CAR on the surface of the T cell is higher with CARs employing a D-Domain compared with an scFv. As shown in the figure below, the CAR expression on the surface of T cells of six normal human donors was uniformly higher using a BCMA-binding D-Domain as compared to a BCMA-binding scFv. We believe that higher CAR cell surface density may help drive activation against low antigen-expressing target cells. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAR Surface Expression on T Cell </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g91e20.jpg" style="width: 224px; height: 267px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Low Tonic Signaling</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">:</div></div> Tonic signaling occurs in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cells when the CAR construct signals without engaging an antigen on a target cell, which can exhaust a T cell prematurely. Tonic signaling has been described in the literature for several scFv-based CARs. To determine the percentage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> that induce tonic signaling, we examined 42 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> isolated from two different screening campaigns for their ability to signal without antigen stimulation when incorporated into a CAR construct. Pooled data indicated that only 3 out of the 42 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> exhibited a level of tonic signaling above background, as measured by relative luciferase units, a signal detecting CAR activation, as represented by the blue dots in the left hand column of the figure below. In contrast, the 42 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> exhibited a much higher level of CAR activation in the presence of the CAR antigen, as illustrated by the right hand column of the figure below. We believe the low propensity for tonic signaling of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain-based</div> CARs may lower T cell exhaustion. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g26a01.jpg" style="width: 162px; height: 265px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Engineered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> Scaffolds</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">: </div></div>The structural features of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> make it particularly well suited as a scaffold protein that can be modified by inserting selected amino acids to generate diverse libraries of proprietary target-binding domains. We create highly diverse libraries of variants of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#945;-3D</div> by randomly replacing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-14</div> amino acid residues (blue regions in the figure below) on the outward facing surface <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;&#945;-3D</div> with one of 18 amino acids. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g11i15.jpg" style="width: 317px; height: 176px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We screen the resulting libraries for potential target-binding domains and engineer further variants with the appropriate target binding profiles to enhance target specificity, optimize binding affinity, and remove potentially immunogenic sequences, a process we refer to as &#8220;deimmunization&#8221;. We use rigorous target selection criteria applied to genomic and proteomic datasets generated from public, collaborator, and internal sources. We internally validate expression profiles for all antigens under evaluation to select the best targets. At the same </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">time, all the reagents needed to screen our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> libraries for specific binders to the antigen are generated and qualified. Over a dozen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders to a variety of tumor antigens have already been generated to date. We have also identified and characterized several target-binding domains for certain therapeutic targets, such as BCMA, CD123, CS1, HER2, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PD-L1.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-based</div> approaches are employed to assist in optimization and continue to be developed to enhance our discovery process. Applying all these discovery methods, the engineered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> are incorporated into our genetically modified T cells in our ddCAR and ARC-SparX platform. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARC-SparX Platform </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our ARC-SparX platform is a controllable and adaptable modular therapy that builds on ddCARs by replacing the antigen binding domain of the T cell with a novel synthetic binding domain that recognizes only SparX proteins, which contain the antigen binding domain. When the SparX protein&#8217;s antigen binding domain recognizes and binds to the antigen on a diseased cell, it recruits the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell to kill the diseased cell. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g09u04.jpg" style="width: 606px; height: 340px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are designed to remain in an inactive state, or silenced, and activate only when combined with a SparX protein that is bound to an antigen on a cell. We believe that controlling <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> activation with SparX protein effectively separates the antigen-recognition and killing functions. By separating these functions, our approach renders the killing function of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell dependent on the antigen specificity and dose of the SparX protein rather than on uncontrolled <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> proliferation as is the case with conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. We believe unregulated killing, which induces severe toxicities, can be mitigated with our approach by adjusting the dose and schedule of SparX protein administration. Additionally, stopping the dose of the SparX protein periodically can allow the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to rest after activation lowering the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> exhaustion, which is a common cause of rapid decline of genetically modified T cells. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Soluble Protein Antigen Receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-linkers</div> (SparX protein) </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All SparX proteins are comprised of one or more antigen-specific binding domains from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> library, fused to a protein that we refer to as the TAG. The TAG is a protein designed to be recognized by our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells, which have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain-based</div> binding moiety that is specific to the TAG, which we call the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-TAG.</div> This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TAG/anti-TAG</div> design is critical to the universality of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells as it allows such cells to bind any SparX protein, because each SparX protein contains the same TAG. As SparX proteins bind their target antigen on diseased cells, they display the TAG thereby &#8220;tagging&#8221; such cell as one that should be killed by an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The TAG we have built into our SparX proteins is a ~26 kDa <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-terminal</div> fragment of human alpha fetoprotein (hAFP). We selected and engineered the TAG for our SparX proteins for the following reasons: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Humans have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-established</div> tolerance to hAFP from experiencing high levels in utero and as pregnant mothers. We believe that creating our TAG from a normal human protein will reduce the likelihood of immunogenicity of the TAG and by extension, the SparX protein containing the TAG. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the small size of the SparX protein will allow it to penetrate complex tumor microenvironments with a half-life short enough (estimated to be several hours in humans) that physicians could manage an emerging toxicity by withholding or decreasing the next SparX protein dose thereby causing the ARC-T cells to deactivate. Such control is not possible with most mAb-based adapters due to their half-life of several weeks. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The TAG can also be readily fused to multiple binding regions, enabling SparX proteins to be multi-valent or multi-specific. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because the antigen-specific binding domains on the SparX protein differ by only <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-14</div> amino acids on the outer faces of the scaffold, the manufacturing process for each SparX protein is substantially similar regardless of specificity. SparX proteins can be readily produced in microbial, yeast and mammalian expression systems, and development is underway on subcutaneous formulations. We also expect the pharmacokinetics of all SparX proteins to be similar and believe that we can leverage the learnings from clinical trials of one SparX protein to inform the design of later trials for other SparX proteins. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antigen Receptor Complex (ARC) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The ARC is similar to CARs in that both are engineered chimeric transmembrane receptors, where the engagement of the extracellular antigen binding domain induces activation of the intracellular domain resulting in the T cell&#8217;s proliferative and cytolytic activity. However, in lieu of the scFv extracellular binding domain of conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies, the extracellular domain of the ARC is comprised of our proprietary binding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> that is designed to exclusively bind the TAG and not hAFP or any other known proteins or antigens. Thus the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> remains in an inactive state, or silenced, in the absence of our proprietary SparX protein. The ARC signals through a similar mechanism as traditional second-generation CARs since they share the same intracellular signaling regions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-1BB</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CD3-zeta</div> with the only difference arising from when the T cells are activated. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, because all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are intended to express a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TAG-specific</div> binding domain rather than a cell surface antigen-specific binding domain, the manufacturing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> is more scalable than in conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies in that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T&#8217;s</div> comprise the same drug product irrespective of clinical indication. The same lentiviral vector comprising the universal ARC and a similar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> transduction process can be used for every patient regardless of disease or target antigen. With conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy, different viral vectors, each with a different <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> transduction process, need to be used to make new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cells when physicians want to target a new antigen. This represents a significant manufacturing and regulatory advantage. In the longer term, engineering an allogeneic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell presents the opportunity for a truly universal cell therapy that could be manufactured to be an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-the-shelf&#8221;</div></div> option that physicians can use regardless of disease or target antigen. Moreover, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells could be redirected to kill cells expressing different antigens just by changing the SparX protein. This universal nature of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell can provide substantial flexibility to the physician and allow for dynamic treatments that can respond quickly to the changing profile of a disease such as cancer, unlike a conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits of the ARC-SparX Platform </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the key benefits to our ARC-SparX platform are driven by the controllable and adaptable characteristics and present an opportunity in indications where toxicities, heterogeneity, or on target off tumor effects represent a challenge: </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Limiting Severe T Cell-Associated Toxicity through Dose Regulation of SparX Protein.</div></div></div></div> Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells do not bind directly to the diseased cell. Rather, the SparX protein is designed to recognize and bind one or more specific antigens on the diseased cells and then flag such cells for destruction. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells bind the SparX protein and once the triple complex of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell plus SparX protein plus antigen-expressing cell is formed, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell is activated to kill the antigen-expressing cell. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell remains in an inactive state, or silenced, in the absence of our proprietary SparX proteins as it is designed to only bind the TAG. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are activated only when combined with a SparX protein that is bound to an antigen on a cell. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-D-Domain</div></div> based <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies bind directly to the target cell and kill it in a rapid and unregulated manner that often induces severe toxicities including CRS and neurotoxicity. In contrast, our preclinical <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro </div></div>and <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>data support the view that the killing function and expansion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell can be controlled by the dose of SparX protein administered. More SparX protein leads to more tumor killing and T cell activity while less SparX protein results in less killing and expansion. By varying SparX protein dose and/or its schedule of administration, physicians can control the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> killing function and expansion and thus control the corresponding potential toxicities in a manner analogous to that used for other therapeutics such as small molecules and antibodies. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have conducted<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>preclinical studies in which we have observed the ability of SparX proteins to control the killing function of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells in a dose-dependent manner, as exemplified in the figure below. In this study, mice were given a BCMA-expressing tumor followed by a constant number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells. In the first group of five mice (left), a high dose (3&#160;mg/kg) of a SparX protein that could not bind the tumor was injected daily (Control). Because the Control SparX could not bind the tumor, the tumor grew as evidenced by the intense blue, green and red colors. The second, third and fourth groups (left to right) of mice received a high (3&#160;mg/kg), medium (0.3&#160;mg/kg) or low (0.03&#160;mg/kg) dose, respectively, of a mono-valent BCMA-binding SparX protein. The low dose had little to no impact on tumor growth, the medium dose had immediate anti-tumor activity when compared to the Control, and the high dose cleared the tumor as shown by the complete absence of color, indicating that SparX protein targeting a tumor can modulate the extent of tumor killing <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div>. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tumor Killing is Dose Dependent </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g29n95.jpg" style="width: 387px; height: 248px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We anticipate that SparX proteins will be available in intravenous and potentially subcutaneous formulations and that physicians will be able to routinely utilize both forms of administration in the outpatient setting while patients may periodically (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">e.g.</div></div>, weekly) self-administer subcutaneous formulations in the home setting. In follow-up visits, the physician can assess the patient for adverse events (AEs) and disease response and then accordingly dose-modify or change the SparX protein(s) with the objective of limiting toxicity. Physicians are already well versed in managing the treatment of patients with an arsenal of anticancer therapies such as small molecules and mAbs, where dose modification is common. The ARC-SparX platform follows a similar paradigm, where the physician can control toxicities by dose modifying or switch to a different SparX protein in the case of r/r disease. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, intermittent dosing of SparX protein can allow <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to rest between doses because the predicted half-life of SparX proteins of a few hours allows the SparX to naturally decay and limit constant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> stimulation. The periods of rest may lower the risk of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> exhaustion. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Should we demonstrate the ability for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to be activated in a dose dependent manner we believe physicians would be able to better manage toxicities such as CRS and neurotoxicity as they emerge and before they escalate to unsafe levels, which should lead to an improved safety profile for our ARC-SparX platform. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expanded Access to Treatment</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">. </div></div>Due to the potential for severe toxicities, patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> or advanced age are often not eligible or not encouraged to pursue currently available <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies. We believe SparX-mediated control of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells may improve upon the safety profile of current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies thereby expanding patient eligibility criteria. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, less than 7% of oncology/hematology practices in the United States currently are authorized to administer and manage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies. If physicians are better able to control toxicities associated with cell therapies through dosing and thus reduce the need for intensive care support, we envision enabling community practices to treat their patients with such therapies, including in the outpatient setting, rather than referring them to one of the few authorized sites. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The figure below shows the general treatment plan, which consists of a single initial infusion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells in the outpatient setting followed by periodic administration of the SparX protein. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g98u89.jpg" style="width: 594px; height: 122px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Increased Adaptability of Treatment Regimen. </div></div></div></div>Because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are not antigen-specific, they can be adapted to changing disease conditions. Due to tumor heterogeneity and downregulation or loss of the target antigen, r/r disease remains a significant issue for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. On our ARC-SparX platform, physicians can administer different SparX proteins to redirect the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to new antigens. This is particularly important in the relapse and refractory settings where tumors may be heterogeneous or downregulate expression of the antigen(s) targeted by the initial SparX proteins. We believe our platform can address refractory disease caused by tumor heterogeneity by using different SparX proteins that target different antigens. This will be particularly important as we move beyond B cell malignancies into indications like AML/MDS or solid tumors. We believe that our ARC-SparX platform can address these issues because the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells can be redirected <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>to target different antigens through the administration of different SparX proteins for personalized therapy tailored to the molecular profile for each patient&#8217;s disease. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our preclinical studies support the ability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to kill heterogeneous tumors through sequential administration of SparX proteins with different target specificity. We used an <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>model in which NSG mice were injected with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NALM-6-GFP/Luc</div></div> expressing either BCMA (97%) or CD123 (3%). We chose this approach as it mimics the antigen heterogeneity often observed in many patient&#8217;s tumors. With only 3% of the tumor cells positive for CD123, daily dosing with SparX&#160;B had little effect on tumor growth compared to mice which received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> control SparX. In contrast, SparX&#160;A had significant anti-tumor activity by day 7 following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> and SparX administration, but tumors rapidly regrew. As shown in the figure below, the tumor cells that regrew were characterized to be completely CD123 positive. However, all the measurable tumor cells could be eliminated by redirecting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells through sequential administration of SparX&#160;A followed by SparX&#160;B. Taken together, these data support the ability of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to be redirected <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>to kill heterogenous tumors that are refractory to single antigen targeting. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SparX product treating heterogenous disease </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g15n13.jpg" style="width: 480px; height: 260px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g77g82.jpg" style="width: 315px; height: 318px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Custom Logic-Gated Therapeutics to Enable Selectivity. </div></div></div></div>The unique properties of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> and our ability to engineer them allow us to create mono-valent, multi-valent, or multi-specific SparX to optimize antigen binding affinity and improve efficacy. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bi-specific</div> SparX proteins can be designed as an &#8216;OR&#8217; gate to target two different antigens for broader tumor cell recognition when faced with antigen heterogeneity or an &#8216;AND&#8217; gate to more specifically identify diseased cells that uniquely <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-express</div> two antigens but spare healthy cells that express only one antigen. We believe an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AND-gated</div> SparX may be well suited for targeting solid tumors where it has been challenging to kill the tumor while preserving normal cells that also express the antigen. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AND-gated Bi-specific targeting </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g79z49.jpg" style="width: 550px; height: 358px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a general matter, SparX proteins do not permanently bind antigens. When both binding domains of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antigen are bound to a cell, each binding domain may unbind, but the likelihood of both unbinding at the same time is lower, and therefore, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> SparX proteins are more likely to stay attached to the cells. Through affinity engineering, we believe that if we decrease the affinity of each single antigen binding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> to its target, then the SparX protein will not bind or stay bound long enough for an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell to engage and kill the cell bearing only a single antigen. Thus, through engineering and controlled dosing, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AND-gated</div> bispecific SparX proteins can drive greater specificity for dual-antigen expressing tumor cells over single antigen expressing normal cells to avoid the typical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-tumor</div> related toxicities observed with so many conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> products targeting solid tumor antigens. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Efficient and Streamlined Manufacturing Across All Programs. </div></div></div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are genetically modified to express the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-TAG</div> binding receptor to be used in every patient, regardless of disease or the target-specificity of the SparX protein. We believe this feature may enable use of the same lentiviral vector and similar cell processing, resulting in a scalable manufacturing process that is applicable to every patient across all programs. We have also established manufacturing processes for SparX proteins utilizing a cost-effective microbial-based expression system and purification process. Because each SparX protein is substantially similar regardless of specificity, the manufacturing and purification processes for each SparX protein is substantially similar regardless of specificity. For more details, see &#8220;&#8212;Manufacturing and Delivery.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Efficient Regulatory Process. </div></div></div></div>Because the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell manufacturing process is identical across all ARC-SparX programs, the regulatory requirements will be shared across the platform. This has distinct advantages that will span global regulatory filings from IND through post BLA requirements. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Pipeline Approach </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are leveraging the full breadth of our platform by matching ddCARs and ARC-SparX with the indications in which they would be most effective based on the biology, patients, and market dynamics. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In MM, we plan to: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluate the efficacy of our lead product candidate, CART-ddBCMA, in our iMMagine Phase 2 pivotal trial in r/r MM and seek regulatory approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Pursue expanded access to CART-ddBCMA through label expansion clinical trials, which we refer to as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">iMMagine-2;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursue clinical development of&#160;CART-ddBCMA in other key geographies, such as Europe and Asia; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Evaluate the potential of our ARC-SparX technology through our Phase 1 clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in r/r MM. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In AML/MDS, we plan to: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Pursue AML/MDS with a library of SparX proteins beginning with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and ACLX-003; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Explore trials that evaluate the use of a single administration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells together with a combination of SparX proteins engineered to target different AML and MDS antigens, including AML-3 and AML-4, to extend the power of the platform. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In additional indications, including solid tumors, we plan to: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Extend benefits of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> platform by applying ddCARs and ARC-SparXs to new indications, including SCLC and HCC. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Pipeline </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have built a broad and scalable pipeline that has positioned us to capitalize on the potential of our proprietary platform technologies and achieve long-term growth and sustainability within the field of cell therapy. We have worldwide rights to all of our programs and have summarized our preclinical and clinical programs in the pipeline chart below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g46h84.jpg" style="width: 593px; height: 310px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pivotal refers to our planned iMMagine Phase 2 trial. Based on our current discussions with the FDA, we believe that results from our iMMagine trial, if positive, together with the results from our Phase 1 trial could be sufficient to support the filing of a BLA. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Multiple Myeloma Program </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our MM program is led by our CART-ddBCMA product candidate, which is an autologous cell therapy comprised of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> powered T cells that have been genetically modified to recognize and kill specific cells expressing BCMA, a target antigen for multiple myeloma. We are advancing our CART-ddBCMA product through our iMMagine Phase 2 pivotal trial in patients with r/r MM, which we plan to initiate in late 2022 and thereafter pursue U.S. regulatory approval. CART-ddBCMA has been granted Fast Track and Orphan Drug by the FDA.&#160;In May 2021, we also received Regenerative Medicine Advanced Therapy (RMAT) designation for CART-ddBCMA for the treatment of multiple myeloma. Following completion of enrollment for our iMMagine Phase 2 pivotal trial, we plan to continue to enroll more patients into additional clinical trials, to support label expansion to enter into earlier lines of therapy and include patients who have had prior BCMA-targeted. We also plan to pursue international clinical trials to expand into geographic locations in Europe and Asia-Pacific. We are also advancing our initial ARC-SparX program, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001,</div> an immunotherapeutic combination composed of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells and bi-valent SparX proteins targeting BCMA, to treat r/r MM. This program is designed to lay the foundation for our ARC-SparX platform. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Opportunity </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">MM<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>is a type of hematological cancer in which diseased plasma cells proliferate and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>accumulate in the bone marrow, crowding out healthy blood cells and causing bone lesions, loss of bone density and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment called a myeloma protein (M protein) causing kidney damage and impairing the patient&#8217;s immune function. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MM is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all hematological cancer cases, 20% of deaths due to hematological malignancies and impacting over 100,000 patients globally each year. The Surveillance, Epidemiology, and End Results (SEER) Program database projects that approximately 35,000 new cases of MM in the United States and over 35,000 new cases in six select markets within Europe and Asia. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The median age of MM patients at diagnosis is 69 years with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> and toxicities that can quickly escalate and become life-endangering. Despite the development and use of multiple new therapies, including second generation proteasome inhibitors (PI) and immunomodulatory drugs (IMiD), stem cell transplantation and CD38-binding monoclonal antibodies, the five-year survival rate is still approximately 50% and MM remains incurable in most patients. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most patients eventually relapse after treatment, and those who relapse following treatment with second generation PIs and IMiDs have a median event-free-survival of only 5 months and median overall survival of only 9 months. The outcomes of patients following treatment with CD38-binding antibodies are also poor with response rates of approximately 30%, median progression-free-survival (mPFS) of 3.4 months and median overall survival of 9 months. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Currently, multiple BCMA-targeting therapies are in development or under regulatory review, including T cell engagers (TCEs), antibody drug conjugates (ADCs) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies. Along similar lines, TCEs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies targeting CD19 and BCMA have been developed and approved for the treatment of certain CD19 and BCMA positive hematological malignancies. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In 2020, the size of the global MM market was approximately $18&#160;billion. We estimate the current total addressable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> market for r/r MM to be approximately $10&#160;billion based on the number of patients who are receiving third line treatments and beyond. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May 31, 2022, the two CAR-T therapies targeting BCMA that have been approved by the FDA are Abecma and Carvykti. Bristol Myers Squibb is currently enrolling clinical trials targeting expansion of Abecma, currently approved only as a fifth line of therapy, into earlier lines of treatment. Carvykti, developed by Legend/Johnson &amp; Johnson and also currently approved only as a fifth line of therapy, is also enrolling clinical trials targeting expansion into earlier lines. Carvykti has demonstrated an sCR rate of 78.4% and mPFS that will exceed 20 months. The BCMA-targeting ADC, Blenrep is also an approved product and has reported an ORR of 31%, which is considerably lower than the 72% and 97.9% ORR for Abecma and Carvykti, respectively. Additionally, the mPFS observed after Abecma and Carvykti (approximately 11.1 months and greater than 20 months, respectively) appear to be longer than that observed with Blenrep (approximately 3 months). Although Abecma and Carvykti responses are a step forward, there remains a need for improved overall response, durability, safety, and reliability. Across the clinical trials of Abecma and Carvykti, the presence of EMD has been a poor prognostic factor. In these clinical trials, patients with EMD have had lower CR rates, shorter DOR, and shorter PFS. In the Phase 1 trial of Carvykti (LEGEND-2), for instance, the CR rate was approximately 60% in patients with EMD (compared with approximately 80% in non-EMD patients) and mPFS was 8.1 months for patients with EMD (versus 25 months in non-EMD patients). </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The black box warning labels of both Carvykti and Abecma include delayed neurotoxicity events or parkinsonian symptoms, and could be a consideration for limiting patient use, especially as approved for earlier lines of therapy. Patient access is also limited by the consistency and reliability of the manufacturing process. In the CARTITUDE-1 study, 17 patients (18%) had manufacturing failures either because they received ciltacabtagene autoleucel that did not meet product release specifications or there were insufficient data to confirm product release specifications for Carvykti. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA: Phase 1 Trial Preliminary Results </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The CART-ddBCMA Phase&#160;1 multi-center, open label, trial is the first involving one of our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> and was designed to test CART-ddBCMA in r/r MM patients to evaluate the safety profile of escalating dose levels (DL) and to expand enrollment at a selected dose to further characterize the efficacy and safety profile of that dose. To be eligible, patients must have had at least 3 prior lines of treatment, which had to include an immunomodulatory drug (IMiD), a proteosome inhibitor (PI), and an anti-CD38 antibody, be refractory to the most recent line of therapy, have an ECOG performance status of 0 or 1, have measurable disease, and have adequate function of vital organs. If eligible, patients were enrolled, underwent leukapheresis (apheresis), and could receive bridging therapy while cell manufacturing occurred. When CART-ddBCMA cell manufacturing was complete, patients received lymphodepleting (LD) chemotherapy with fludarabine (Flu) and cyclophosphamide (Cy) on days <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-5,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-4,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-3.</div> On day 0, patients received an intravenous infusion of CART-ddBCMA. After infusion, patients were evaluated at fixed intervals for assessment of AEs and evidence of objective response using PET/CT scan, serum measurement of M-protein (including heavy or light chain measurement), and measurement of number of malignant plasma cells in bone marrow aspirates. Safety data are assessed for dose limiting toxicity in the first 28 days following infusion and will be collected throughout the trial. Long-term safety data will be collected for up to 15 years per health authority guidelines. Efficacy data are assessed pursuant to the International Myeloma Working Group (IMWG) criteria on a monthly basis for the first 6 months and then quarterly for up to two years, or upon symptomatic relapse. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g53o14.jpg" style="width: 605px; height: 205px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The IMWG uniform response criteria have been utilized in registration studies of approved myeloma drugs. The IMWG uniform response criteria assess efficacy of treatment options for myeloma and allow for a comparison of efficacy between treatment strategies in clinical trials, strict definitions for responses, as shown in the table below, and classifications to improve detail and clarify inconsistent interpretations across clinical trials. The IMWG criteria for sCR, CR, VGPR, and PR are summarized below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">stringent Complete Response (sCR)</div></div></div></div>: Complete Response (as defined below) plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry (kappa to lambda light chain ratio (<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div>/<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">l</div>) &#8804;4:1 or &#8805;1:2 for <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">k</div> or <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">l</div> patients, respectively, after counting &#8805;100 plasma cells). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Complete Response (CR)</div></div></div></div>: Negative immunofixation in the serum and urine; and disappearance of any soft tissue plasmacytomas; and &lt;5% plasma cells in bone marrow aspirates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Very Good Partial Response (VGPR)</div></div></div></div>: Serum and urine M protein, detectable by immunofixation but not on electrophoresis; or &#8805;90% reduction in serum M protein plus urine M protein level &lt;100&#160;mg/24 hr. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Partial Response (PR)</div></div></div></div>: &#8805;50% reduction of serum M protein plus reduction in 24-hour urinary M protein by &#8805;90% or to &lt;200 mg/24 h; or if the serum and urine M protein are unmeasurable, a &#8805;50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M protein criteria and if serum-free light assay is also unmeasurable, &#8805;50% reduction in plasma cells is required in place of M protein, provided baseline BMPC percentage was &#8805;30%. In addition to these criteria, if present at baseline, a &#8805;50% reduction in the size (SPD) of soft tissue plasmacytomas is also required. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall Response Rate (ORR) includes patients that achieved sCR, CR, VGPR or PR. sCR and CR do not indicate that the patient was cured of the condition, as the disease is currently incurable. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The clinical trial began enrollment in December 2019 and the first patient was dosed in February 2020. We have completed the dose escalation component with 6 patients each enrolled in DL1 (100 x 10<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">6</div> cells) and DL2 (300&#160;x 10<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">6</div> cells). Based on the nearly identical ORR in each DL and the observed potential for increased toxicity in DL2, we are currently expanding enrollment at DL1. As of the data <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cut-off</div> date of May 3, 2022, we have enrolled and dosed an aggregate of 25 patients at DL1, which is the recommended Phase 2 dose (RP2D). Most recently, data were presented at the ASCO 2022 Annual Meeting. For the safety and efficacy analyses, 31 patients who have had at least the 1-month follow-up visit were included. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The median age of enrolled patients was 66 years (range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">44-76).</div> Eighteen (58%) patients were male and 13 were female (42%). Bone marrow replacement of &gt;50% with malignant plasma cells was present in 12 (39%) of patients and 12 (39%) had EMD. The median number of prior lines of therapy was 5 (range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-16).</div> 23 (77%) patients had triple class refractory disease and 21 (68%) had penta-refractory disease. Taken together, these demographic data indicate the patient population enrolled in this study had poor prognosis with expected median overall survival in the range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-8&#160;months</div> based on published analyses of patients with similar characteristics. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g42q66.jpg" style="width: 594px; height: 257px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*Note: some subjects were not evaluable or data were not available at time of data cut on May 3, 2022. </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">**Data updated since ASH 2021 after full data entry was complete. </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">BMPC = bone marrow plasma cells. </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cells=CAR+ Cart-ddBCMA Cells. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A plot of each patient&#8217;s response and DOR with minimal residual disease (MRD) response as of the data cutoff date of May 3, 2022 is presented below. Of the evaluable population (n=31), the objective response rate (ORR) was 100%. The complete response rate (complete or stringent complete response; CR/sCR) was 71% (22/31), with 7 additional responses being VGPR, resulting in a rate of response at depth of VGPR or better of 94% (29/31). Responses are ongoing for 22 patients (71%). As a result, median DOR (mDOR) has not yet been reached. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g22s22.jpg" style="width: 605px; height: 338px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the time of the ASCO data cut (May 3, 2022), 31, 24 and 16 patients have had their 1-, 6-, and 12-month follow-up visits, respectively. As previously observed in this and other trials of BCMA-targeted CAR T-cells there was evidence of deepening responses over time with an increasing proportion of patients who reach sCR/CR with increased time on study and at subsequent follow-up visits as illustrated in the figure below, which is suggestive that patients treated more recently may still reach deeper responses. In fact, conversions to sCR have currently been reported as late as the 12-month follow-up visit. In the patients who have had their 1-month follow-up visit (n=31), the CR/sCR rate was 71%, but a cut of only the patients who have had their 6-month follow-up visit (n=24) results in a 75% CR/sCR rate, and a cut of only the patients who have had their 12-month follow-up visit (n=16) results in 81% CR/sCR rate. Of 16 patients who have had their 12-month follow-up visit, 13 (81%) have reached CR/sCR, and nine (56%) remain in ongoing response, with a median follow up of 17.7 months. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA Phase 1 Depth of Response Over Time </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g33h85.jpg" style="width: 585px; height: 259px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In those patients with at least 12 months of follow-up, the ongoing response rate at 12 months was 69%, similar to that previously observed in the Phase 1 results of Carvykti (LEGEND-2) and the pivotal trial of Carvykti (CARTITUDE-1) despite there being a greater proportion of patients with EMD in the CART-ddBCMA trial (50%) than either LEGEND-2 (30%) or CARTITUDE-1 (13%). In the United States, it is estimated that up to 20% of the r/r MM population has EMD. Patients with EMD in clinical trials of other BCMA-targeting CAR-T therapies have been reported to experience worse outcomes, including lower ORR, lower CR rates, shorter mPFS, and shorter mDOR, than non-EMD patients. In our Phase 1 trial, 39% of all enrolled patients, 36% of the patients at RP2D, and 50% of the patients at DL2 had EMD. The figure below illustrates the incidence of EMD in the patient populations in the CART-ddBCMA Phase 1 trial and the LEGEND-2 and CARTITUDE-1 trials, as well as the ORR, CR rates and percentage of ongoing response observed in each trial. We believe these results strongly suggest that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CART-ddBCMA</div> will have a comparable profile to Carvykti when evaluated in comparable populations, controlling for differences in key prognostic factors, primarily EMD. However, these analyses are based on a cross-trial comparison and not a head-to-head clinical trial and the data may not be directly comparable due to differences in trial designs and methodologies. </div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g11v20.jpg" style="width: 594px; height: 293px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the preliminary results for patients with EMD treated with CART-ddBCMA show a potential for CART-ddBCMA to be a best-in-class treatment for r/r MM for patients with EMD. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also expect that with additional enrollment in the expansion cohort, the overall patient population tested in our Phase&#160;1 trial will more closely approximate the general r/r MM population without adjustment to the enrollment process, but we intend to take operational steps in our planned pivotal trial of CART-ddBCMA to ensure the population enrolled is representative of the disease at large. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Of the dosed patients, 31 were evaluable for safety analysis. The rate of AEs of grade 3 or higher CRS and ICANS are of special interest (AESIs). A potential difference was observed in the incidence of these events in DL2 compared with DL1. In DL2 (n=6), 1 patient had a grade 3 CRS event and another had a grade 3 ICANS event. No events of grade 3 or higher CRS have occurred at the RP2D, and only 1 grade 3 or higher ICANS event has occurred at the RP2D amongst 25 patients (4%). In combined analysis of all patients in DL1, 88% had a grade 1 or 2 CRS event but 0% had grade 3 or higher CRS. The median time to onset of CRS was 2 (range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-8)</div> days and median duration was 8 (range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-13)</div> days. The median time to ICANS onset was 4.5 (range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-6</div> days) days with a median duration of 7.5 (range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-11</div> days) days. All cases of ICANS and CRS resolved with standard interventions, such as tocilizumab and dexamethasone. We are conducting analyses to determine whether any patients may be treated as an outpatient. Additional AEs, regardless of attribution, were presented at the ASCO&#160;2022 Annual Meeting and are presented in the figures below. The observed AEs are consistent with those of other autologous CAR-T cells in clinical trials and in commercial use. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g36a20.jpg" style="width: 394px; height: 394px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g20a42.jpg" style="width: 533px; height: 272px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to provide further updates on the results of the ongoing Phase 1 trial at the 2022 Annual Meetings of the American Society of Hematology, this December. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iMMagine: Planned Phase 2 Pivotal Trial of CART-ddBCMA </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our planned Phase 2 pivotal trial of CART-ddBCMA in r/r MM, the iMMagine trial, is scheduled to begin enrollment in 2022. We expect the trial will be a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm,</div> open-label, evaluation of the efficacy of CART-ddBCMA, as measured by the primary endpoint of ORR. Secondary endpoints will include sCR/CR rate and duration of response of a single infusion of CART-ddBCMA after lymphodepleting chemotherapy. The primary endpoint was selected based on historical precedent of the primary endpoint used in other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> pivotal trials and the selection of this primary endpoint has been reviewed and agreed with the FDA. Based upon feedback from regulatory authorities, we plan to include a total of approximately 110 patients in an integrated analysis of efficacy and safety, which may include patients from the Phase 1 trial, provided all requirements of the iMMagine trial apply to those patients. We plan to enroll approximately 100 patients in the iMMagine trial and expect a minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> requirement of approximately 13 months. This trial will be conducted at institutions in the United States only. Secondary and/or exploratory endpoints will include duration of response, progression free survival (PFS), overall survival (OS), CR/sCR rate, assessment of minimal residual disease, further characterization of the safety profile of CART-ddBCMA in a larger patient population, and confirmatory correlative biomarker analysis for pharmacology, predictive biomarkers of depth and duration of response, and manufactured CART-ddBCMA cell phenotyping. Assuming positive data from this clinical trial, we plan to file a BLA in 2025. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">CART-ddBCMA: Earlier Lines of Therapy <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iMMagine-2)</div> and Post-BCMA Targeted Therapy </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ultimately, we believe the use of CART-ddBCMA will move to earlier lines of therapy in MM so following completing enrollment of the iMMagine trial, we plan to initiate enrollment of a clinical trial designed to evaluate efficacy of CART-ddBCMA in additional populations, which we refer to as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">iMMagine-2</div> program. Similar to other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapies targeting BCMA, we plan to focus on enrollment of patients in earlier lines of therapy that have high risk of recurrence and/or presence of MRD. Additionally, we will enroll a cohort of patients who have been treated with prior BCMA-targeting therapy to determine efficacy and safety in this population. We will seek to demonstrate in the iMMagine-2 trial that CART-ddBCMA can provide clinical benefit in patients in earlier line populations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CART-ddBCMA: Future Clinical Plans </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also plan to initiate clinical trials of CART-ddBCMA in other key geographies, such as Europe and Asia. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> (BCMA): Phase 1 Clinical Development </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our first ARC-SparX program is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001,</div> an immunotherapeutic combination composed of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells and bi-valent SparX proteins targeting BCMA, or SPRX001, for the treatment of r/r MM. We are currently preparing applications for Fast Track, Orphan Drug and RMAT designations. We initiated our Phase 1 dose-escalation clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in the second quarter of 2022, utilizing our ARC-T cells for the first time in combination with SPRX001, which has the same antigen binding domain as CART-ddBCMA. This trial is intended to serve as clinical validation of our ARC-SparX platform as we seek to understand PK, safety profile, and dosing strategy for future clinical development. We intend to present interim clinical data of the Phase 1 trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in 2023. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Escalation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell dose and escalation of the SPRX001 dose may happen in parallel and/or in series depending on observations of safety and efficacy in each combination dose level. In addition, the clinical trial is designed to allow flexibility in the frequency of SPRX001 administration based on observed pharmacokinetics of SPRX001 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell expansion kinetics. Preclinical data suggest that frequency of dosing may be a key factor for the efficacy and safety of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> due to the ability to control ARC T interaction with tumor cells (via antigen binding) through SPRX001. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical trial design is intended to accelerate the timeline to meaningful clinical data as compared with more standard dose evaluation approaches. The primary objective of the trial is to identify a dosing regimen that does not exceed the maximally tolerated dose (MTD) and achieves clinical benefit comparable to what has been observed in our Phase 1 clinical trial of CART-ddBCMA. The primary endpoint of the trial will be to determine the incidence of treatment-emergent adverse events (TEAEs), including dose limiting toxicities (DLTs). Upon completion of the Phase 1 trial, we will leverage the learnings from this trial to advance our AML/MDS programs utilizing ARC-SparX and consider developing additional SparX for r/r MM for a broader pipeline in this disease area. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our AML/MDS Programs </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With the ARC-SparX platform we are developing a comprehensive solution for personalized therapy tailored to the molecular profile of an AML/MDS patient&#8217;s disease. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Diseased cells from AML and high risk MDS patients often have a complex cytogenetic profile that leads to significant clonal heterogeneity. This heterogeneity exists not only between patients but also within an individual&#8217;s disease. Traditional targeted therapies including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts</div> have struggled to drive deep and durable responses because they target only a fraction of the patient&#8217;s diseased cells. In addition, traditional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> targets in AML/MDS such as CD33, CD123 and CLL1 are expressed on normal myeloid cells, including progenitor cell populations, which may lead to prolonged myelosuppression. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We intend to build a library of SparX proteins targeting different AML and MDS antigens that can be used in any combination depending on the molecular profile of a patient&#8217;s diseased cells to combat disease heterogeneity. Furthermore, we believe the controllability of the ARC-SparX platform will give physicians the ability to turn off the therapy once disease is controlled to allow for faster recovery of the normal myeloid compartment and thus less toxicity. We have received IND clearance from the FDA in March 2022 and plan to initiate the Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> for AML/MDS in the second half of 2022. We also plan to initiate a Phase 1 clinical trial for ACLX-003, an ARC-SparX product candidate directed at another antigen associated with AML/MDS in 2024. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Background, Current Treatments and Limitations </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Acute myeloid leukemia (AML)</div></div>, also referred to as acute myelogenous leukemia, arises from healthy bone marrow stem cells that have accumulated multiple genetic mutations causing the mutated stem cells to grow uncontrollably. The aggressive growth of AML cells in the bone marrow disrupts the development of healthy blood cells including white cells, red cells and platelets. The net result is that AML patients often present with anemia (too few red blood cells), infections (caused by too few functioning white blood cells) or frequent bleeding and bruising (caused by too few platelets). The aggressive growth of AML in the bone marrow and blood, its disruption of normal blood cell production and the lack of durable treatments leave AML patients with a 28.7% five-year survival rate. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">According to the National Cancer Institute SEER database, there were estimated to be 64,512 people living with AML in the USA in 2017. In 2020, new cases were estimated to have been approximately 19,940, with 11,180 deaths. The disease accounts for approximately 1.1% of all new cancers, but is the most common acute leukemia affecting adults. AML also represents approximately 20% of childhood leukemia. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The standard of care for the majority of AML patients consists of induction chemotherapy (cytarabine and anthracycline) followed by additional rounds of chemotherapy with or without stem cell transplant. Although approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> of patients achieve remission, relapse often occurs within the first 18 months following treatment. The high relapse rate points to the need for new therapies capable of extending disease free survival. We believe there is a critical need to develop new therapeutic modalities with greater safety and efficacy, especially for patients with r/r AML. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Currently, new therapies for AML have many limitations. The lead candidates of small molecule inhibitors of proteins that are over-expressed or otherwise dysregulated in AML show only modest efficacy with short duration of response. Antibody-based therapeutics, including antibody-drug conjugates and bispecifics, have thus far shown limited efficacy and in some cases, significant toxicities. Additionally, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy is being deployed with specificity for various targets including CD33, CD123, FLT3, CLL1, CD19, IL1RAP and NKG2DL. Many of these therapies are in the early stages of clinical development. The common theme across the various therapeutic modalities described above is the need for new therapies with enhanced efficacy and improved safety. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Myelodysplastic syndrome (MDS) </div></div>is a closely related disease in which a population of abnormal myeloid stem cells develop in the bone marrow. Depending on the type of abnormal, or dysplastic cell that emerges, patients may experience a specific decrease in red blood cells, or one of the disease-fighting cell populations referred to as monocytes, neutrophils and dendritic cells. Like AML, MDS impacts the elderly with patients often diagnosed in their 70s. The incidence of MDS has been estimated to be as low as 10,000 new cases per year in the United States. MDS is considered to be a type of cancer because about <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of MDS patients progress to AML. Standard therapy for MDS is cytarabine alone or in combination with idarubicin or daunorubicin. Stem cell transplant can cure MDS but the advanced age of onset and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> often limit MDS patient transplant eligibility due to the toxicity of typical transplant conditioning regimens, especially for those patients characterized with high risk MDS. Thus, new therapies are needed for MDS patients as well. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> (CD123): Preclinical Development </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our first AML/MDS product candidate is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002,</div> which is an immunotherapeutic combination agent composed of the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells used in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001,</div> together with mono-valent SparX proteins that each contain a binding domain directed at CD123. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on the potential validation of our ARC-SparX platform in our Phase 1 clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001,</div> we intend to advance our ARC-SparX platform into myeloid diseases by initiating our Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> in the second half of 2022 for the treatment of r/r AML and high-risk MDS. We are currently preparing applications for Fast Track, Orphan Drug and RMAT designation. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro </div></div>cytolytic activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> was assessed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-culturing</div> a CD123-expressing human AML tumor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14-GFP/Luc.</div></div> For the negative control, we used <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells together with a SparX protein that could not bind the tumor (Negative Control). As shown in the figure below, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> exhibited dose-dependent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14</div> killing across a broad range of SparX protein concentrations (10<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">-4</div> nM to 10<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2</div> nM); p&lt;0.0001). In contrast, the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells failed to kill <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14</div> cells in the presence of the Negative Control SparX. Each data point shows the mean standard deviation for triple replicates where the significance of the comparison of the dose response curves for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> dosed together with the Negative Control SparX has a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">p-value</div> less than 0.0001. </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In Vitro </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cell Killing of Human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14-GFP/Luc</div></div> Tumors by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> is Dependent on SPRX002 Dose </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g39b76.jpg" style="width: 328px; height: 200px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>anti-tumor activity of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> was compared to that of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> cell with a scFv-based binding domain directed at CD123 (CART-CD123). NSG mice were injected on Day 0 with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14-GFP/Luc,</div></div> a CD123 expressing human AML cell line, the presence of which can be quantitated by a co-expressed GFP and Luc. We monitored tumor growth by using BLI to measure bioluminescence produced by diseased cells. Six days after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14</div> injection, the first group of mice received 5&#160;million CART-CD123 cells, the second group received 5&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells with 1 mg/kg daily (q.d.) of the Negative Control SparX that does not bind the tumor. Mice in the third, fourth and fifth groups each received 5&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells along with doses of 1 mg/kg bi-valent SparX proteins targeting CD123 (SPRX002) q.d., 1 mg/kg SPRX002 dosed every other day (q.o.d.) and 0.3 mg/kg q.o.d. respectively. Each treatment group contained 4 or 5 mice. Mice were imaged weekly for four weeks with an additional imaging on the third day following treatment because this cell line grows quickly. As expected, tumors in mice receiving the Negative Control SparX grew quickly while tumors in mice receiving the CART-CD123 were largely eliminated within 28 days of CART-CD123 administration. The CART-CD123 treatment group as well as all three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> treatment groups of mice were observed to have significant anti-tumor activity on days 3, 7 and 14 after receiving treatment (p&lt;0.001). Among mice receiving 1 mg/kg of SPRX002 q.d. or q.o.d., tumors were also mostly cleared within 28 days. Mice treated with 0.3 mg/kg SPRX002 q.o.d displayed robust anti-tumor activity but did not fully clear the tumors by Day 28. These results demonstrate tumor killing that is comparable to that observed with the CART-CD123 and dependent on SPRX002 dose and schedule. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> Clearance of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-14-GFP/Luc</div></div> Tumors is Dependent on Both Dose and Schedule of SPRX002 </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g40f82.jpg" style="width: 438px; height: 384px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> (CD123): Planned Clinical Development </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We plan to begin clinical development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> in the second half of 2022 with initiation of a Phase 1, dose escalation trial of both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells and SPRX002 in advanced AML and/or MDS. Escalation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell dose and escalation of the SPRX002 dose may happen in parallel and/or in series depending on observations of safety and efficacy in each combination dose level. In addition, the clinical trial is designed for flexibility in the frequency of SPRX002 administration based on observed pharmacokinetics of SPRX002 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cell expansion kinetics. Preclinical data suggest that frequency of dosing may be a key factor for the efficacy and safety of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> due to the ability to control <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> interaction with tumor cells (via antigen binding) through SPRX002. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical trial design is intended to accelerate the timeline to meaningful clinical data as compared with more standard dose evaluation approaches. The primary objective of the trial is to identify a recommended phase 2 dose (RP2D) that does not exceed the MTD and achieves evidence of clear clinical benefit. The primary endpoint of the trial will be to determine the incidence of TEAEs, including DLTs. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Assuming positive data from the planned Phase 1 trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002,</div> we expect that we will likely conduct Phase 2 trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> to further study its potential efficacy. Depending on observed efficacy, this trial has the potential to be a pivotal trial from which data could support the filing of a BLA with FDA. We plan to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-002</div> in combination with additional SparX proteins against additional target antigens with the goal of overcoming tumor antigen heterogeneity in AML/MDS. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-003 </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also identified a group of high priority antigen targets associated with AML/MDS through internal analyses and conversations with key opinion leaders and are developing additional SparX proteins against such target antigens. We anticipate initiating a Phase 1 clinical trial for our next most advanced AML/MDS ARC-SparX product candidate, which we refer to as ACLX-003, in 2024. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> cytolytic activity of ACLX-003 was assessed by co-culturing a CD123-expressing human AML tumor, MV4-11-GFP/Luc. As shown in the left panel of the figure below, ACLX-003 exhibited dose-dependent MV4-11 killing that was comparable to that seen with ACLX-002. A second AML tumor model, MOLM-14-GFP/Luc, was used to evaluate the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div> anti-tumor activity of ACLX-003. Six days after MOLM-14 injection, mice received 5 million ARC-T cells with daily administration of 3 mg/kg SPRX003 or 0.3 mg/kg SPRX002. As shown in the right panel of the figure below, tumors in mice receiving either SPRX003 or SPRX002 were eliminated within 14 days of ARC-T administration. These results demonstrate that ACLX-003 is capable of curing mice harboring AML tumors, and we are currently evaluating the anti-tumor activity of lower doses of SPRX003. </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comparable </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> and </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> Activity Observed Between ACLX-002 and ACLX-003 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g55z44.jpg" style="width: 588px; height: 229px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other AML/MDS Product Candidates </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have also isolated D-Domain binders to several other high value AML/MDS targets and plan to progress them in our pipeline to add to our AML/MDS SparX library. In two of our discovery projects, which we refer to as AML-3 and AML-4, we have engineered D-Domains into SparX proteins that bind to AML-3 and AML-4 targets, respectively, and both are undergoing further evaluation. Additionally, we are building a map of target expression in primary AML patient tumors to understand how our targets may eventually be combined to combat the inherent heterogeneity of the&#160;disease. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Solid Tumor Program </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to develop multiple assets and novel technology to combat a variety of solid tumor indications while leveraging the strengths of each of our existing therapeutic platforms. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ddCARs may be best suited for targets that have high homogeneous tumor cell expression with little to no normal cell expression with potential for a wide therapeutic window. We are continuing to build ddCARs where the target biology supports this approach. To this end, we have selected <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders to an attractive target that we are evaluating as a ddCAR to potentially treat patients with HCC.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some solid tumors have been shown to contain a high level of heterogeneity within an individual&#8217;s tumor. Where this heterogeneity exists, we believe a library of SparX proteins targeting a specific solid tumor patient population has the potential to drive deep and durable responses beyond those produced by any single targeting therapeutic. We currently have engineered novel SparX proteins for various solid tumor-associated antigens, some with overlapping expression in specific patient populations such as SCLC, that together may allow ARC-SparX product candidates to overcome antigen heterogeneity of the disease. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Targeting solid tumors with cellular therapy presents additional hurdles such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-tumor</div> toxicity as well as physical and immunological barriers. We intend to use a multi-pronged approach employing innovative technological solutions such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AND-gated</div> SparX proteins as well as technologies designed to enhance the persistence and function of ddCAR or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells in the tumor environment. We also intend to employ clinical and translational strategies such as combinations with checkpoint inhibitors to boost activity of ddCAR or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells to further overcome some common immunological barriers to successful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> therapy. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional Indications and Applications of Our Technology </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe our platform technologies lend themselves to a broad array of potential applications, including: </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Novel Targets</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>We believe our platforms are well suited to safely and rapidly explore targeting of novel antigens that would be otherwise challenging to target with a conventional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts.</div> We have successfully generated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> binders to over a dozen tumor antigens and are employing sophisticated tools, such as AI and ML, to optimize these assets. We employ <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-based</div> approaches to assist in the optimization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> properties and continue to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-based</div> approaches to enhance our discovery process. We currently use an in-silico immunogenicity risk assessment and deimmunization platform using an ML algorithm for predicting potential immunogenic epitopes. We also use <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AI-based</div> protein structure determination programs to analyze the surface chemistry of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> to better determine aspects such as library design and hit optimization. We believe further implementation of AI and ML can assist in other areas of the discovery process such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> affinity optimization from deep learning of analysis of thousands of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain</div> sequences from our panning and screening campaigns. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allogeneic Cell Therapy Products and Other Immune Cell Therapies</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>We believe it will be important for patients to have both autologous and allogeneic cell therapy options as both therapeutic options mature, including therapies derived from T cells and NK cells. We believe allogeneic cell therapies may not be a fit for all indications and as such we expect to develop them where applicable as another tool in our fight against cancer that includes our autologous ddCARs and ARC-SparX. While our initial clinical programs utilize autologous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells, we also anticipate developing allogeneic cell therapy technologies to target the broadest indications and/or create an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-the-shelf</div></div> universal cell therapy. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indications Beyond Oncology</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>As the field of adoptive cell therapy looks to apply the technology beyond oncology, including transplantation, autoimmune, cardiac, infectious and neurological diseases, so too do we seek to explore such opportunities. We envision expanding into treatments for antibody-mediated autoimmune diseases, such as refractory systemic lupus erythematosus, refractory primary Sjogren&#8217;s syndrome, or thrombotic thrombocytopenic purpura. For example, published scientific studies have shown that clearance of plasma cells within patients that have antibody-mediated autoimmune diseases have resulted in improvement in clinical symptoms. We can test CART-ddBCMA or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001</div> in these settings to eliminate normal plasma cells for patients with these severe autoimmune diseases. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diagnostics. </div></div></div></div>Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domains</div> or SparX proteins may be used in various diagnostic settings much like monoclonal antibodies or antibody fragments. As an example, we can envision labeling SparX proteins with a radiotracer for imaging tumors in patients as a patient selection tool prior to starting therapy with that same SparX together with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Antibody Alternatives. </div></div></div></div>Our binding domains have many positive attributes over scFv binding domains that we believe could allow them to be used as an scFv alternative in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cell</div> therapy applications and serve as the foundation to creating a new class of therapeutic antibody alternatives. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing and Delivery </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our manufacturing process is consistent across CART-ddBCMA cells and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells. This consistent process enables flexibility of cell product production within a site using the same equipment and consistent protocols, utilizing product specific viral vector input. As we advance clinical development of multiple product candidates across our ddCAR and ARC-SparX platforms, we have secured key components, including lentiviral vector, and capacity from our manufacturing partners to ensure we are able to complete enrollment for our planned CART-ddBCMA Phase 2 pivotal trial, earlier line clinical trial of CART-ddBCMA, and our Phase 1 trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACLX-001.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">CART-ddBCMA Cell and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> Cell </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We currently rely on third parties for the manufacture and release testing of viral vectors and product candidates for clinical testing. We also currently rely on third parties for patient apheresis material logistics, as well as to package, label, store and distribute our product candidates. As we progress through development to commercialization, we will leverage our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">best-in-class</div></div> vendors and evaluate other options to secure commercial-scale capacity. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current cell manufacturing supplier has proven to be a reliable partner for the CART-ddBCMA Phase 1 trial, releasing 100% of initiated cell product runs through June 8, 2022, and will continue to deliver cell product for CART-ddBCMA Phase 1 expansion trial. Of the 31 lots of CART-ddBCMA associated with patients for which preliminary clinical data was reported at the ASCO 2022 Annual Meeting, cell product for CART-ddBCMA has thus far had a mean viability of 98%, a mean percent CAR+ rate of 70%, and a mean yield of over one billion cells, more than sufficient for our intended therapeutic dose of 100&#160;million cells. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Viability by Lot</div></div></div></div>: Viability is reported as the percentage of viable cells in the drug product with an acceptance limit of 70%. Based on 31 lots of CART-ddBCMA associated with patients for which preliminary clinical data was reported at the ASCO 2022 Annual Meeting, we have achieved a mean of 98%, well above the acceptance level. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g41x63.jpg" style="width: 392px; height: 231px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%CAR+ by Lot</div></div></div></div>: Percent CAR positive, as defined by proportion of cells expressing the CAR construct on the cell surface, is well above acceptance level of 10%, as well as published competitor reports. A high proportion of CAR+ cells lowers the total number of T cells required to be administered. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g42b83.jpg" style="width: 416px; height: 245px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">VCN by Lot</div></div></div></div>: Vector copy number (VCN), defined as the number of transgene sequences per diploid genome determined by PCR, averages 2.1 copies per genome. The vector copy number to cell ratio is securely below the acceptance criteria of &lt;=5 copies per genome. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g88p88.jpg" style="width: 389px; height: 229px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Yield (millions of cells)</div></div></div></div>: Based on our CART-ddBCMA process, our mean yield is nearly one billion cells, surpassing the levels needed for both our low dose of 100&#160;million cells and our high dose of 300&#160;million cells. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g43n80.jpg" style="width: 389px; height: 229px;"/></div> </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are continuing to invest in process improvements to reduce the overall process time and improve costs. Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> due to its stability, has demonstrated a high transduction rate resulting in a more efficient manufacturing process. We believe this will translate to improved processes that will reduce the time to intervention for patients. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have established partnerships with established and experienced cell therapy contract manufacturers to supply clinical materials and manufacturing capabilities for our clinical trials. As we scale to commercialization, we will increase capacity with our current suppliers and evaluate other options to secure commercial-scale capacity. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The manufacturing process for our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells is consistent with the CART-ddBCMA process. However, cells are transduced with a lentiviral vector encoding our universal ARC, which is a CAR with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-TAG</div> binding domain, in lieu of a lentiviral vector encoding the CAR construct with a ddBCMA binding domain. Because our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARC-T</div> cells are designed to express the same <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TAG-specific</div> binding domain rather than a cell surface antigen-specific binding domain, the same lentiviral vector encoding the universal ARC can be used for every patient regardless of disease or target antigen. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SparX Protein </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We manufacture SparX proteins <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> for most research activities, but we use a third-party contract manufacturing organization (CMO) for most preclinical studies, and all clinical trials. We produce research SparX proteins in mammalian and microbial systems using fermentation and protein purification strategies that we believe can be scaled for commercial purposes. The purified SparX protein is formulated to the desired concentration and then put into the desired formulation buffer. Every SparX protein is monitored throughout the purification process and afterwards using an array of analytical tests that assess SparX protein size, binding activity and potential biophysical changes in the SparX protein. We anticipate the process will evolve over time to improve yields, quality and quantity of recovered SparX protein. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition</div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. Any candidate that we successfully develop and commercialize will have to compete with existing therapies as well as therapies that may be developed in the future. While we believe our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">D-Domain,</div> ddCAR and ARC-SparX </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">platforms and scientific expertise provide us with&#160;a number of&#160;key advantages, we face substantial competition from many different sources, including large pharmaceutical companies and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions.</div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We anticipate substantial direct competition from other organizations developing advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-Ts,</div> other types of genetically modified cell therapies, or other anti-BCMA biologics due to their promising clinical therapeutic effect in clinical trials including: 2seventy, Abbvie, Allogene, Amgen, Autolus, Bristol-Myers Squibb, CARSgen, Cartesian, Cellular Biomedicine Group, Gracell, GSK, Innovent, Johnson&#160;&amp; Johnson, Legend, Novartis, Pfizer, Poseida Therapeutics, Precision BioSciences, Pregene, and Regeneron. In addition, some companies, such as&#160;Allogene, Caribou Biosciences, Cellectis, Celyad, and Crispr, are developing allogeneic cell therapies that could compete with our product candidate.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot predict whether other types of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> or other genetically modified cell therapies may be developed and demonstrate greater efficacy, and we may have direct and substantial competition from such therapies in the future. Further, despite the unique approach that we have developed to address the limitations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> and other types of genetically modified cell therapies, we expect to face increasing competition as new, more effective treatments for cancer enter the market and further advancements in technologies are made. We expect market adoption of any treatments that we develop and commercialize to be dependent on, among other things, efficacy, safety, delivery, price and the availability of reimbursement from government and other third-party payors.</div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, gene therapy and cell therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercialization </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In light of our stage of development, we have not yet established a commercial organization or distribution capabilities. Prior to approval of any of our product candidates, we intend to develop a commercialization infrastructure for those products. We will initially focus on the United States and be prepared to expand to other key markets as subsequent regulatory approvals are received. While we are preparing to launch on our own we will continue to evaluate partnership opportunities to provide commercialization infrastructure, including sales and marketing and commercial distribution. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development, Evaluation and License Agreement with Pfenex Inc. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, we entered into a Development, Evaluation and License Agreement with Pfenex Inc. pursuant to which we obtained the option to obtain worldwide, sublicensable, exclusive licenses to incorporate certain proprietary SparX proteins into our ARC-SparX platform. Under the terms of the agreement, Pfenex is eligible to receive development funding in addition to development, regulatory and commercial milestones up to an aggregate of $19.3 million for each product incorporating a SparX protein expressed using a production strain based on the technology licensed from Pfenex, as well as low single-digit royalties during the royalty term on worldwide net sales of any such products. The royalty term is on a licensed SparX protein-by-licensed SparX protein and country-by-country basis and the shorter of (i) ten years from the date of first commercial sale and (ii) three months after the launch of a generic drug in such country. Such royalties for combination product are subject to certain net sales adjustments. Arcellx may terminate its licenses to individual proprietary SparX </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">proteins at any time upon prior written notice. Either party may terminate for a materially uncured breach subject to a disputed breach resolution mechanism. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lonza Manufacturing Services Agreement </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 2, 2021, we entered into a Manufacturing Services Agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (the Lonza Agreement). Under the Lonza Agreement, Lonza agreed to perform certain process and analytical development activities and to collaborate with us to develop a statement of work setting forth certain technology transfer and cGMP manufacturing activities relating to CART-ddBCMA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 12, 2022, and pursuant to the Lonza Agreement, we entered into a statement of work with Lonza (the Lonza SOW), effective as of February 16, 2022, for the technology transfer and cGMP manufacturing of CARTddBCMA and potentially other pipeline products. The term of the Lonza SOW commenced February 1, 2022 and expires December 31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. Under the Lonza SOW, we are obligated to pay to Lonza certain payments aggregating a total of approximately $24.5 million in 2022, including creditable up-front payments, creditable milestone fees that are subject to certain deductions and fixed monthly payments and which are payable over the term of the Lonza SOW. In the event of suspensions or delays caused by non-availability of materials we will be obligated to pay a majority of certain non-cancellable costs incurred during such suspension or delay. In the event of suspensions or delays caused by certain reasons outside of our reasonable control, we will be obligated to continue paying a majority percentage of the fixed monthly payments during such suspension or delay. The Lonza SOW is non-cancellable for the first six months of the term and carries minimum non-cancellable costs amounting to a potential aggregate of up to approximately $35 million in the event of termination. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the first six months, we can terminate all or some of manufacturing capacity for any reason upon a certain period of prior written notice, subject to a cancellation fee determined, in part, by the fixed monthly fees owed during that certain period. In the event that a regulatory authority requires or causes the withdrawal of CARTddBCMA, we may terminate the Lonza SOW, subject to cancellation fees. Lonza may terminate the Lonza Agreement or Lonza SOW for any reason upon a certain period of written notice; provided that any outstanding statements of work shall survive termination of the Lonza Agreement, until such statement of work is completed or terminated. Either party may terminate the Lonza Agreement or Lonza SOW in the event of an uncured material breach, where the cure period is subject to an extension for certain material breaches, and in the case of termination for the material breach by us, we would be obligated to pay for non-cancellable costs. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Lonza Agreement and Lonza SOW contain other customary terms applicable to the manufacture of therapeutics in the biotechnology industry. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing intellectual property is a vital component of our business plan for maximizing return on our investments. We actively develop intellectual property that we believe is important to our business, including seeking, maintaining, enforcing and defending United States and international patent rights for our product candidates, processes, and our discovery, development, and therapeutic platforms. We pursue, maintain and defend patent rights in strategic areas to protect the technology, inventions and improvements that are important to the commercial development of our business and our competitive position. We also rely on trade secrets to protect aspects of the technology, inventions and improvements that cannot be patented but are important to the development of our business and competitive position. We have spent considerable effort securing intellectual property rights, including patent rights related to our proprietary D-Domain binding domain, ARC and SparX protein technologies and to our product candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May 31, 2022, we own three patent families directed to the proprietary D-Domain binding domain technology. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The first patent family includes three pending U.S. non-provisional applications, and several pending foreign patent applications in Australia, Brazil, Canada, China, the Eurasian Patent Organization, the European Patent Organization, Indonesia, India, Israel, Japan, the Republic of Korea, Mexico, New Zealand, Philippines, and Singapore. The family further includes three issued U.S. patents (U.S. Pat. Nos&#160;10,662,248, 10,647,775 and 11,008,397), two granted European patents (EP Pat. Nos.&#160;3280432 and 3280433) and nine patents granted (or applications allowed) in other commercially significant jurisdictions (Australian Pat. No.&#160;2016246426, Israeli Pat. No.&#160;254907, Indonesian Pat. No.&#160;2018/07812, Japanese Pat. Nos.&#160;6871232 and 6873101, Mexican Pat. No.&#160;387517, Singaporean Pat. No.&#160;11201708257U, and South African Pat. No.&#160;2017/06875). EP Pat. No.&#160;3280432 has been validated in Albania, Austria, Belgium, Bulgaria, Switzerland/Liechtenstein, Croatia, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, and Turkey; EP Pat. No. 3280433 is being validated in Belgium, Switzerland/Liechtenstein, Germany, Denmark, Spain, France, United Kingdom, Italy, Luxembourg, Monaco, Netherlands, Norway, and Sweden. Both EP patents were registered in Hong Kong. The patent family broadly covers libraries of our proprietary D-Domain binding domains, compositions comprising our proprietary D-Domain binding domains and methods of using our proprietary D-Domain binding domains. Compositions covered by the issued/granted claims include fusion polypeptides comprising our proprietary D-Domain binding domain and CARs comprising our proprietary D-Domain binding domains. Methods covered by the issued/granted claims include the use of CARs comprising our proprietary D-Domain binding domain in the treatment of cancer. The issued/granted claims encompass CART-ddBCMA and universal ARC-T cells, ACLX001: BCMA and ACLX002: CD123 SparXs, and methods of using thereof in the treatment of cancer. Any patent issuing from the first family is expected to expire in 2036, not including any patent term adjustment and patent term extension. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The second patent family is directed to proprietary D-Domain binding domains that bind commercially relevant target antigens and fusion polypeptides containing these domains. The second family includes an issued U.S. patent (U.S. Pat. Nos 11,318,165), an allowed U.S. application, a pending U.S. non-provisional application, and pending foreign patent applications in Australia, Brazil, Canada, China, the Eurasian Patent Organization, the European Patent Organization, Indonesia, India, Israel, Japan, the&#160;Republic of Korea, Mexico, New Zealand, Philippines, Singapore, South Africa, and Hong&#160;Kong. The issued claims encompass CART-ddBCMA cells, ACLX001: BCMA SparXs, and methods of using thereof in the treatment of cancer. Any patent issuing from the second family is expected to expire in 2038, not including any patent term adjustment and patent term extension. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The third patent family is directed to proprietary D-Domain binding domains that bind commercially relevant target antigens and fusion polypeptides containing these domains. The family includes a pending U.S. provisional patent application. We plan to convert the pending application into an international application. Any patent issuing from the family is expected to expire in 2042, not including any patent term adjustment and patent term extension. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May 31, 2022, we also own two patent families directed to the proprietary ARC-SparX platform technology. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One patent family is directed to our ARC construct and SparX protein technologies, and to methods&#160;of using them in T cell-based and other therapeutic applications. The family includes a pending U.S. non-provisional application, and pending foreign patent applications in Australia, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brazil, Canada, China, the Eurasian Patent Organization, the European Patent Organization, Indonesia, India, Israel, Japan, the Republic of Korea, Mexico, New Zealand, Philippines, Singapore, South Africa, and Hong Kong. Any patent issuing from the family is expected to expire in 2038, not including any patent term adjustment and patent term extension. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A second patent family is directed to dosing regimens for employing the proprietary ARC-SparX platform technology in therapeutic methods. The family includes an international application. We plan to enter national phase in the United States and commercially relevant foreign jurisdictions. Any patent issuing from the family is expected to expire in 2042, not including any patent term adjustment and patent term extension. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to patent protection, we also rely on trademark registration, trade secrets, know how, other proprietary information and continuing technological innovation to develop and maintain our competitive position. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our trademark portfolio currently contains pending U.S. trademark applications for the ARCELLX, ARCELLX logo, ARC-SPARX, ARC-T, SPARX, SPARX PROTEINS and SPARX PROTEIN trademarks. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Therefore, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specified circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee&#8217;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent and other intellectual property positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development, commercial strategies, drugs or processes, or to obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For more information on these risks and other comprehensive risks related to our intellectual property, see &#8220;Risks Relating to Our Intellectual Property.&#8221; </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products. Generally, before a new biopharmaceutical </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product can be marketed, considerable data demonstrating its quality, safety, purity and potency must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. Potency is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Biopharmaceutical Development </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the FDA regulates biopharmaceuticals under the Food, Drug and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA). Biopharmaceuticals also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biologics must be licensed by the FDA under the PHSA through the submission of a BLA before they may be legally marketed in the United States. The process generally involves the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice (GLP) requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approval by an independent institutional review board (IRB), or ethics committee at each clinical trial site before each trial may be initiated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the potency, purity and safety of the investigational product for each proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Submission to the FDA of a BLA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Satisfactory completion of a FDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility or facilities where the biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the BLA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the biologic in the United States; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with any post-approval requirements, including the potential requirement to implement a REMS, and the potential requirement to conduct post-approval studies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The data required to support a BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical Studies and IND </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Preclinical studies include laboratory evaluation of product biochemistry, formulation and stability, as well as<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;in vitro</div></div>&#160;and animal studies to assess the potential for toxicity and to establish a rationale for therapeutic use for supporting subsequent clinical testing. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical Trials </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 12%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pharmacodynamic information is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of a BLA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the investigational product, findings from animal or<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;in vitro</div></div>&#160;testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the investigational product has been associated with unexpected serious harm to patients. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (DSMB) or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the biochemical and physical characteristics of the investigational product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the extent and length of which are uncertain, we will be required to develop and implement additional clinical trial policies and procedures designed to help protect trial participants from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus, which may include using telemedicine visits and remote monitoring of patients and clinical sites. We will also need to ensure data from our clinical studies that may be disrupted as a result of the pandemic is collected pursuant to the trial protocol and is consistent with GCPs, with any material protocol deviation reviewed and approved by the site IRB. Patients who may miss scheduled appoints, any interruption in trial drug supply, or other consequence that may result in incomplete data being generated during a trial as a result of the pandemic must be adequately documented and justified. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, on March&#160;18, 2020 and in subsequent updates, the FDA issued a guidance on conducting clinical trials during the pandemic. The guidance describes a number of considerations for sponsors of clinical </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">trials impacted by the pandemic, including the requirement to include in the clinical trial report (or as a separate document) contingency measures implemented to manage the trial and any disruption of the trial as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19;</div> a list of all trial participants affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19-related</div></div> trial disruption by unique subject identifier and by investigational site, and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or trial, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with cGMP and GTP Requirements </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA also will not approve the product if the manufacturer is not in compliance with GTP. These standards are found in FDA regulations and guidances that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products (HCT/Ps), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. In March 2022, the FDA issued a draft guidance that provides CAR-T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and clinical study design. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspection that follow a &#8220;risk based schedule&#8221; may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BLA Review Process </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">then submitted to the FDA as part of a BLA, along with proposed labeling, biochemistry and manufacturing information to ensure product quality, identity, purity and other relevant data. In short, the BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#8217;s FY 2022 fee schedule, effective through September&#160;30, 2022, the user fee for an application requiring clinical data, such as a BLA, is approximately $3.1&#160;million. PDUFA also imposes an annual program fee for each marketed human biologic ($369,413 in FY&#160;2022) and an annual establishment fee on facilities used to manufacture prescription biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;non-orphan&#160;indication.</div> </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information rather than accepting the BLA for filing. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;in-depth&#160;review</div> of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Before approving a BLA, the FDA will conduct <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;pre-approval&#160;inspection</div> of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes physicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase&#160;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan Drugs </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For biologic drug products, an orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">used&#160;off-label&#160;in</div> the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than the indication for which it is designated, it may not be entitled to orphan drug exclusivity. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and has historically been interpreted by FDA to apply to the indication for which the product has been designated. In September 2021, however, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the Agency to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; It is unclear how this court decision will be implemented by FDA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expedited Development and Review Programs </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drug products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. For biologics, the sponsor can request the FDA to designate the product for fast track status any time before receiving a BLA approval, but ideally no later than the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-BLA&#160;meeting.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a biologic shown to be potent can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, a drug product may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drug products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RMAT Designation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the 21st Century Cures Act, Congress created the Regenerative Medicine Advanced Therapy (RMAT) designation to facilitate an efficient development program for, and expedite review of, a product candidate that meets the following criteria: (1)&#160;it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#160;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&#160;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. A sponsor may request that the FDA designate a drug as a RMAT concurrently with or at any time after submission of an IND. The FDA has 60 calendar days to determine whether the drug meets the criteria. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may, as appropriate, fulfill such requirements through the submission of clinical evidence from clinical trials, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. Like some of FDA&#8217;s other expedited development programs, RMAT designation does not change the standards for approval but may help expedite the development or approval process. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Abbreviated Licensure Pathway of Biological Products as Biosimilars or Interchangeable Biosimilars </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Patient Protection and Affordable Care Act (ACA), signed into law in 2010, includes the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products shown to be highly similar to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;FDA-licensed&#160;reference</div> biological product. The BPCIA </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Animal studies (including the assessment of toxicity); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient to demonstrate safety, purity and potency in one or more conditions for which the reference product is licensed and intended to be used. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, an application must include information demonstrating that: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference product; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure and potent. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. In addition, the law provides for a designation of &#8220;interchangeability&#8221; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proposed product is biosimilar to the reference product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proposed product is expected to produce the same clinical result as the reference product in any given patient; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#8217;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#8212;laboratory, preclinical and/or clinical&#8212;required to demonstrate biosimilarity to a licensed biological product. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for twelve&#160;years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> pediatric extension. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-Approval Requirements </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as&#160;&#8220;off-label&#160;use,&#8221;</div> and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;off-label&#160;uses,</div> manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new application or supplement, which may require the development of additional data or preclinical studies and clinical trials. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;non-compliance&#160;with</div> regulatory standards or if problems occur following initial marketing. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warning letters, or holds on post-approval clinical studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refusal of the FDA to approve pending applications or supplements to approved applications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Applications, or suspension or revocation of product license approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product seizure or detention, or refusal to permit the import or export of products; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;off-label&#160;uses,</div> and a company that is found to have improperly <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">promoted&#160;off-label&#160;uses</div> may be subject to significant liability. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other U.S. Regulatory Matters </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services (CMS), other divisions of the Department of Health and Human Services (HHS), the Department of Justice (DOJ), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency, and state and local governments. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, in the United States, sales, marketing and scientific and educational programs must also comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Patent-Term Restoration and Marketing Exclusivity </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent-term restoration period is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">generally&#160;one-half&#160;the</div> time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation Outside of the United States </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions where we seek to commercialize any of our product candidates, including countries in Europe and Asia. Such foreign regulations govern, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of a clinical trial or marketing of a product in those countries. Certain countries outside of the United States have a similar approval process that requires the submission of a clinical trial application, or CTA, much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a CTA must be submitted for each clinical trial to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, the corresponding clinical trial may proceed. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP requirements, applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union Drug Development </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the E.U. Clinical Trials Directive 2001/20/EC has sought to harmonize the E.U. clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the European Union, the E.U. Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated, it must be approved in each of the E.U. countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA) and one or more Ethics Committees (ECs). Under the current regime, all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The E.U. clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation EU No&#160;536/2014 ensures that the rules for conducting clinical trials in the European Union will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the European Union. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">E.U. Drug Review and Approval </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of Marketing Authorizations: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or for products that are in the interest of public health in the European Union. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC) and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PRIME Designation in the EU </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority Medicines (PRIME) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Orphan Drug Designation and Exclusivity </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2) a life threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten year period of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Coverage and Reimbursement </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;payor-by-payor&#160;basis.</div></div> As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. The CMS has proposed to expand Medicaid rebate liability to the territories of the United States as well. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part&#160;A and B, Part&#160;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&#160;D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">from&#160;non-governmental&#160;payors.</div> </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part&#160;B programs, or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in 2020, the HHS and the CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements, and manufacturer price reporting under Medicare Part B. Multiple lawsuits have been brought against the HHS challenging various aspects of the rules. In January 2021, the Biden administration issued a &#8220;regulatory freeze&#8221; memorandum that directs department and agency heads to review new or pending rules of the prior administration. Under the American Rescue Plan Act of 2021, effective January&#160;1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. Further, in July&#160;2021, the Biden administration released an </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition for prescription drugs. In response to this executive order, the HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases. The impact of these regulations and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization. These and other health reform measures that are implemented may have a material adverse effect on our operations. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. There is an increasing emphasis on cost containment measures in the United States with respect to healthcare costs and prescription drug prices and we expect it will continue to increase and exert greater pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework could reduce our ability to generate revenue in the future or increase our costs, either of which could have a material and adverse effect on our business, financial condition and results of operations. It is also possible that additional governmental action will be taken to address the COVID-19 pandemic. The continuing efforts of the government, insurance companies, managed care organizations, and other payers of healthcare services and medical products to contain or reduce costs of healthcare and/or impose price controls may adversely affect the demand for our product candidates, if approved, and our ability to achieve or maintain profitability. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement, in order to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product in the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally, prices tend to be significantly lower. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees and Human Capital </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021, we had 78 full-time employees, 61 of whom were engaged in research and development activities. None of our employees are represented by a labor union or covered under a collective bargaining agreement. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facilities </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our corporate headquarters are located in Gaithersburg, Maryland, where we lease approximately 22,930 square feet of office and laboratory space pursuant to a lease agreement that expires on January 31, 2030. In May&#160;2022, we entered into an agreement to lease approximately 51,822 square feet of office and laboratory space in Redwood City, California. We will enter a portion of the space in June 2022 with full access to the space expected in fourth quarter of 2023. We believe that our existing facilities are adequate for our near-term needs but expect to need additional space as we grow. We believe that suitable additional or alternative space would be available as required in the future on commercially reasonable terms. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceedings </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers and Directors </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the names, ages and positions of our executive officers and directors as of May&#160;31, 2022: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 61%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Position</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1.47em; font-family: ARIAL; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive&#160;Officers:</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami&#160;Elghandour</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43</div></td>
<td style="vertical-align: top; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">President, Chief Executive Officer and Chairman of the Board of Directors</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher Heery, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Medical Officer</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michelle Gilson</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Chief Financial Officer</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: ARIAL; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1.47em; font-family: ARIAL; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.47em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors:</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ali&#160;Behbahani,&#160;M.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jill Carroll, M.S.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Lubner, M.S., C.P.A.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kavita Patel, M.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derek Yoon<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Olivia Ware<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Member of the audit committee </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Member of the compensation committee </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Member of the corporate governance and nominating committee </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rami Elghandour</div></div></div></div> has served as our President, Chief Executive Officer and Chairman of the Board of Directors since January 2021. Previously, Mr.&#160;Elghandour served in various roles at Nevro Corp., a medical device company, from October 2012 to March 2019 including President, Chief Business Officer and most recently Chief Executive Officer and as a member of the board of Nevro Corp. from May 2016 to March 2019. From September 2008 to October 2012, Mr.&#160;Elghandour managed investments for Johnson&#160;&amp; Johnson Development Corporation (JJDC), the venture investing arm of Johnson &amp; Johnson (NYSE:JNJ), where he led several investments and served on the board of directors of a number of private companies, including Nevro&#8217;s board of directors. Additionally, he led strategic initiatives in the development and management of JJDC&#8217;s portfolio. From 2001 to 2006, Mr.&#160;Elghandour worked for Advanced Neuromodulation Systems, Inc. (acquired by St.&#160;Jude Medical), a medical device company, where he led firmware design and development on several implantable neurostimulators. Mr.&#160;Elghandour received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering. We believe that Mr.&#160;Elghandour is qualified to serve on our board due to his investment and engineering experience, strategic track record, and his service as our President and Chief Executive Officer. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Christopher Heery</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">, M.D.</div></div></div></div> has served as our Chief Medical Officer since April 2021. Previously, Dr.&#160;Heery, served as Chief Medical Officer of Precision BioSciences, Inc., a genome editing company, from May&#160;2019 to April 2021, where he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. Dr.&#160;Heery also served as Chief Medical Officer at Bavarian Nordic A/S, a biotechnology company, from October 2016 to April 2019, where he oversaw clinical development programs for its immune-oncology and infectious disease portfolios. Prior to that, he was a Staff Clinician and then an Associate Research Physician and Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI), a U.S. government health agency, from April 2012 to November 2013 and November 2013 to September 2016, respectively, where he was part of a larger effort to create new immunotherapies for the treatment of cancer. He </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. Dr.&#160;Heery is board certified in Medical Oncology and Internal Medicine. He received a B.A. from Duke University and a M.D. from East Carolina University Brody School of Medicine, and completed his internal medicine residency at the University of Illinois at Chicago. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michelle Gilson </div></div></div></div>has served as our Chief Financial Officer since May 2022. From April 2021 to May 2022, Ms. Gilson served as a Managing Director at Canaccord Genuity Group Inc., a financial services firm. She also served as a biotech equity research analyst at Cannaccord Genuity Group Inc. from March 2018 to April 2022. Prior to joining Canaccord Genuity Group Inc., she served as a Senior Associate at Jefferies LLC, an investment banking firm, from September 2017 to March 2018, an Associate at Instinet LLC, a financial securities service firm from December 2016 to September 2017, an Associate Director at Oppenheimer &amp; Co., Inc. (NYSE:OPY), an investment bank and financial services company from January 2015 to November 2016, and an Analyst at Goldman Sachs (NYSE: GS), an investment bank and financial services company, from June 2014 to January 2015, covering healthcare and biotechnology companies. Ms. Gilson holds a B.S. in Business Administration from the University of Southern California. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ali Behbahani, M.D.</div></div></div></div>&#160;has served as a member of our board of directors since January 2015. Dr.&#160;Behbahani joined New Enterprise Associates (NEA), a venture capital firm, in 2007 and is currently a general partner on the healthcare team. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. He has been a member of the board of directors of Genocea Biosciences (Nasdaq:GNCA) since February 2018, Oyster Point Pharma (Nasdaq:OYST) since July 2017, Monte Rosa Therapeutics, Inc. (Nasdaq:GLUE) since April 2020, Nkarta, Inc. (Nasdaq:NKTX) since August 2019, Black Diamond Therapeutics (Nasdaq:BDTX) since December 2018, CRISPR Therapeutics AG (Nasdaq:CRSP) since April 2015, Adaptimmune Therapeutics Plc (Nasdaq:ADAP) since September 2014, CVRx, Inc. (Nasdaq: CVRX) since July 2013, Minerva Surgical, Inc. (Nasdaq: UTRS) since May 2011, and was on the board of Nevro Corp. (NYSE:NVRO) from August 2014 to March 2019. Dr.&#160;Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. We believe that Dr.&#160;Behbahani is qualified to serve on our board due to his experience in life sciences and his experience as a member of the boards of directors of multiple companies in the life science industry. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jill Carroll, M.S.</div></div></div></div> has served as a member of our board of directors since September 2017. Ms.&#160;Carroll has served as partner of SR One Capital Management, LP (S.R. One), an entity affiliated with SR One Capital Fund I Aggregator, LP since September 2020. Prior to S.R. One, Ms. Carroll was principal at S.R. One, Limited, initially joining as a Senior Associate in September 2011. From August 2010 to August 2011, Ms.&#160;Carroll served as a VP, Corporate Development at Limerick Biopharma. Between May 2004 and August 2010, Ms.&#160;Carroll was served as the Senior Director, Strategic Planning&#160;&amp; Corporate Development at Dynavax Technologies (Nasdaq:DVAX), where she was involved in multiple pharma-partnering deals, as well as substantial private and public financings. Ms.&#160;Carroll also served as a director at Clearview Projects from Sept 2001 to May 2004 and as a consultant specializing in health care at Mercer Management Consulting from March 1999 to July 2001. Ms.&#160;Carroll is a member of the board of directors of HotSpot Therapeutics, Ancora Biotech and Odyssey Therapeutics. Ms.&#160;Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. We believe that Ms.&#160;Carroll is qualified to serve our board of directors because of her substantial experience as an investor and her prior management experience as a consultant and as an executive. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">167 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">David C. Lubner</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">, M.S., C.P.A.</div></div></div></div> has served as a director of our company since August 2020. Mr.&#160;Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals Inc., a biotechnology company acquired by UCB S.A. in April 2020, from January 2016 until June 2020. Before joining Ra Pharmaceuticals, Mr.&#160;Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals from its inception in 2006 to 2016, as Chief Financial Officer of PharMetrics from 1999 until it was acquired by IMS Health in 2005 and as Vice President and Chief Financial Officer of ProScript from 1996 to 1999, where Velcade<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div> (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was discovered. Mr.&#160;Lubner serves as a member of the board of directors of Dyne Therapeutics Inc. (Nasdaq:DYNE), Gemini Therapeutics, Inc. (Nasdaq:GMTX), Vor Biopharma Inc. (Nasdaq:VOR), Point Biopharma, Inc. (Nasdaq:PNT) and several other private companies, and Mr.&#160;Lubner previously served on the board of directors of Nightstar Therapeutics plc from 2017 until it was acquired by Biogen in June 2019 and Therapeutics Acquisition Corporation (d/b/a as Research Alliance Corp. I.), a blank check company focused on the healthcare industry. Mr.&#160;Lubner is a Certified Public Accountant and is a member of the American Institute of CPAs. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University. We believe that Mr.&#160;Lubner is qualified to serve on our board based on his financial and senior executive leadership experience and his biotechnology company board experience, including serving as an audit committee chair. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Kavita Patel, M.D.</div></div></div></div> has served as a member of our board of directors since December 2021. Dr. Patel has been employed as a primary care physician at Mary&#8217;s Center in Washington, DC since January 2020. From January 2011 to January 2022, Dr. Patel has served as a Nonresident Fellow at the Brookings Institution. Dr.&#160;Patel has also served as a venture partner at NEA since 2017. Dr. Patel previously served in leadership roles at Johns Hopkins from 2011 to 2018. From 2009 to 2010, she served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House. From 2007 to 2009, she served as policy analyst and trusted aide and was part of the senior staff of the Health, Education, Labor and Pensions (HELP) Committee under Senator Edward Kennedy&#8217;s leadership. Dr. Patel currently serves as a member of the board of directors of several non-profit organizations, including SSM Healthcare, a non-profit integrated delivery system. She has also served as a member of the Health and Human Services (HHS) Physician Focused Payment Model Technical Advisory Committee from 2016 to 2021. Dr. Patel&#8217;s prior research in healthcare quality and community approaches to mental illness have earned national recognition and she has published numerous papers and book chapters on healthcare reform and health policy. Dr. Patel previously served on the board of directors of Tesaro, Inc. (Nasdaq: TSRO) from 2016 to 2018. Dr. Patel currently serves on the board of directors of Sigilon Therapeutics, Inc. (Nasdaq: SGTX), SelectQuote, Inc. (NYSE: SLQT) and Intelligent Medicine Acquisition Corp. (NASDAQ: IQMD). Dr. Patel earned an M.D. from University of Texas Health Science Center, an M.S. in Health Services Research from the University of California Los Angeles and her B.A. from the University of Texas at Austin. We believe that Dr. Patel is qualified to serve our board of directors because of her clinical and business experience and history as a policy maker, hospital administrator and practicing clinician. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Olivia Ware</div></div></div></div> has served on our board of directors since May 2022. Ms. Ware has more than 20 years of experience in pharmaceutical drug development, commercialization and healthcare management. From November 2019 to March 2021, Ms. Ware served as the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., which was acquired by Sanofi S.A. (Nasdaq: SNY) in 2020, where she was responsible for developing overall portfolio strategy for the company&#8217;s three BTKi molecules. From 2018 to 2019, Ms. Ware served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc. From 2011 to 2018, Ms. Ware worked in a number of public and private biopharma firms as a private consultant. From 2016 to 2017, Ms. Ware was the Chief Commercial Officer at CytRx, Inc. From 1997 to 2010, Ms. Ware worked at Genentech, Inc. in a variety of roles of increasing responsibility in commercial, team leadership and product development. During her time at Genentech, Ms. Ware played a key role in the launch of several commercial drug products, including Rituxan&#174;, Herceptin&#174;, Avastin&#174; and Lucentis&#174;, and as Head of Oncology Team Leadership was responsible for molecule, disease and platform strategic plans and oncology portfolio management. Ms. Ware has served as a member of the board of Ambrx Biopharma Inc. (Nasdaq: ADR) since April 2021 and Revance Therapeutics, Inc. (Nasdaq: RVNC) since March 2021. Ms. Ware holds an A.B. in Psychology from Davidson College and an M.B.A. in Finance and Marketing from the University of North </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">168 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carolina at Chapel Hill. We believe Ms. Ware is qualified to serve on our board of directors due to her experience as a consultant and executive in life sciences and biotechnlogy board experience. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derek Yoon </div></div></div></div>has served as a member of our board of directors since April 2020. Mr.&#160;Yoon has been employed as President&#160;&amp; CEO at Solasta Ventures (previously known as Aju IB Investment) (Solasta), a venture capital firm, since November 2013 and a member of the board of directors of Solasta since July 2019. Since December 2017, Mr.&#160;Yoon has served as member of the board of directors of Trefoil Therapeutics, and between December 2015 and August 2017, Mr.&#160;Yoon served on the board of directors of Clearside Biomedical (Nasdaq:CLSD). Prior to Solasta, Mr.&#160;Yoon was a Portfolio Manager with RBS Citizens from April 2011 to November 2013. From July 2009 to April 2011, Mr.&#160;Yoon was an Investment Manager at Berwind Private Equity. From October 1999 to July 2007, Mr.&#160;Yoon was Investment Manager at Kibo Capital in South Korea. Mr.&#160;Yoon received a Master of Finance from Boston College and a M.B.A. from Babson College. Mr.&#160;Yoon also received a B.S. in Chemical Engineering from Yonsei University in South Korea. We believe Mr.&#160;Yoon is qualified to serve on our board of directors due to his experience in life sciences and his experience as a member of the boards of directors of multiple companies in the life science industry. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Composition </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors currently consists of seven members. The number of directors is fixed by our board of directors, subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Each of our current directors will continue to serve as a director until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors are divided among the three classes as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;I directors are Ali Behbahani, M.D. and Derek Yoon, and their terms will expire at the annual meeting of stockholders to be held in 2023; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;II directors are Jill Carroll, M.S., Olivia Ware, and Kavita Patel, M.D., and their terms will expire at the annual meeting of stockholders to be held in 2024; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;III directors are Rami Elghandour and David Lubner, M.S., C.P.A., and their terms will expire at the annual meeting of stockholders to be held in 2025. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At each annual meeting of stockholders, upon the expiration of the term of a class of directors, the successor to each such director in the class will be elected to serve from the time of election and qualification until the third annual meeting following his or her election and until his or her successor is duly elected and qualified, in accordance with our amended and restated certificate of incorporation and amended and restated bylaws. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of our directors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This classification of our board of directors may have the effect of delaying or preventing changes in control of our company. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Independence </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock is listed on the Nasdaq Global Select Market. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors within one year of the completion of the company&#8217;s initial public offering. In addition, the rules of Nasdaq require that, subject to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">specified exceptions, each member of a listed company&#8217;s audit, compensation and corporate governance and nominating committees be independent. Audit committee members and compensation committee members must also satisfy the independence criteria set forth in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;10A-3</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;10C-1,</div> respectively, under the Exchange Act. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To be considered to be independent for purposes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;10A-3</div> and under the rules of Nasdaq, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To be considered independent for purposes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;10C-1</div> and under the rules of Nasdaq, the board of directors of a listed company must affirmatively determine that each member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining whether the director has a relationship to the company that is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (i)&#160;the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the company to such director and (ii)&#160;whether such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors undertook a review of its composition, the composition of its committees and the independence of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that Ali Behbahani, M.D., Jill Carroll, M.S., David Lubner, M.S., C.P.A., Kavita Patel, M.D., Olivia Ware and Derek Yoon representing six of our seven directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the rules of Nasdaq. Mr.&#160;Elghandour is not an independent director because he is our President and Chief Executive Officer. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In making these determinations, our board of directors considered the current and prior relationships that each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director, and the transactions involving them described in the section titled &#8220;Certain Relationships and Related Party Transactions.&#8221; There are no family relationships among any of our directors or executive officers. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Leadership Structure </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Elghandour serves as both our Chief Executive Officer and Chairman of the Board. In addition, our board does not have a lead independent director at this time, but will continue to monitor and evaluate the appropriateness of our board leadership structure. Our board believes that Mr.&#160;Elghandour&#8217;s service as both Chairman of the Board and Chief Executive Officer is in the best interest of the Company and its stockholders. Mr.&#160;Elghandour possesses detailed and in-depth knowledge of the issues, opportunities and challenges facing us and our business and is thus best positioned to develop agendas that ensure that the Board&#8217;s time and attention are focused on the most critical matters. Specifically, his combined role enables decisive leadership, ensures clear accountability, and enhances our ability to communicate our message and strategy clearly and consistently to our stockholders, employees, customers and manufacturers. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Role of the Board in Risk Oversight </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. The compensation committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial reporting. The corporate governance and nominating committee is responsible for overseeing the management of risks associated with the independence of our board of directors and potential conflicts of interest. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected the board of directors&#8217; leadership structure. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Committees </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has an audit committee, a compensation committee and a corporate governance and nominating committee, each of which has the composition and the responsibilities described below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Committee </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The members of our audit committee are David Luber, M.S., C.P.A., Ali Behbahani, M.D., and Derek Yoon. David Lubner, M.S., C.P.A. is the chair of our audit committee and David Lubner, M.S., C.P.A. is our audit committee financial expert, as that term is defined under the SEC rules implementing Section&#160;407 of the Sarbanes-Oxley Act, and possesses financial sophistication, as defined under the rules of Nasdaq. Each member of our audit committee also meets the financial literacy and sophistication requirements of the listing standards of the Nasdaq Global Select Market. Our audit committee oversees our corporate accounting and financial reporting process and assists our board of directors in monitoring our financial systems. Our audit committee among other things: </div></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selects and hires the independent registered public accounting firm to audit our financial statements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Helps to ensure the independence and performance of the independent registered public accounting firm; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Approves audit and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services and fees; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews financial statements and discusses with management and the independent registered public accounting firm our annual audited and quarterly financial statements, the results of the independent audit and the quarterly reviews and the reports and certifications regarding internal controls over financial reporting and disclosure controls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepares the audit committee report that the SEC requires to be included in our annual proxy statement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews reports and communications from the independent registered public accounting firm; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews the adequacy and effectiveness of our internal controls and disclosure controls and procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews our policies on risk assessment and risk management; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews and monitors conflicts of interest situations, and approves or prohibits any involvement in matters that may involve a conflict of interest or taking of a corporate opportunity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews related party transactions; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Establishes and oversees procedures for the receipt, retention and treatment of accounting related complaints and the confidential submission by our employees of concerns regarding questionable accounting or auditing matters. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of Nasdaq. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Committee </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The members of our compensation committee are Kavita Patel, M.D., Jill Carroll, M.S., and David Lubner, M.S., C.P.A. Jill Carroll, M.S. is the chair of our compensation committee. Each member of our compensation committee meets the requirements for independence under the listing standards of the Nasdaq Global Select Market and SEC rules and regulations. The compensation committee among other things: </div></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Oversees our overall compensation philosophy and compensation policies, plans and benefit programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews and approves or recommends to the board of directors for approval compensation for our executive officers and directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepares the compensation committee report that the SEC will require to be included in our annual proxy statement; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administers our equity compensation plans. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 9pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our compensation committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of Nasdaq. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Governance and Nominating Committee </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The members of our corporate governance and nominating committee are Ali Behbahani, M.D., Jill Carroll, M.S., and Olivia Ware. Ali Behbahani, M.D. is the chair of our corporate governance and nominating committee. Each member of our corporate governance and nominating committee meets the requirements for independence under the listing standards of the Nasdaq Global Select Market and SEC rules and regulations. Our corporate governance and nominating committee oversees and assists our board of directors in reviewing and recommending nominees for election as directors. The corporate governance and nominating committee, among other things: </div></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifies, evaluates and makes recommendations to our board of directors regarding nominees for election to our board of directors and its committees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Considers and makes recommendations to our board of directors regarding the composition of our board of directors and its committees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reviews developments in corporate governance practices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluates the adequacy of our corporate governance practices and reporting; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluates the performance of our board of directors and of individual directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our corporate governance and nominating committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of Nasdaq. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Compensation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2020, our board of directors adopted and our stockholders approved, an outside director compensation policy described below in &#8220;Non-Employee Director Compensation Policy&#8221;. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following table presents the total compensation that each of our then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors received during the year ended December&#160;31, 2021. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fees&#160;Earned<br/>or&#160;Paid in<br/>Cash&#160;($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Awards&#160;($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)(3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">All Other<br/>Compensation<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tiba Aynechi, Ph.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ali Behbahani, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raymond Camahort, Ph.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jill Carroll, M.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Lubner, M.S., C.P.A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">510,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">510,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kavita Patel, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">409,379</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">409,379</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lewis T. Williams, M.D., Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derek Yoon</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr. Ayenchi resigned from our board of directors on November 8, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts disclosed represent the aggregate grant date fair value of the award as calculated in accordance with ASC 718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in Note&#160;2 to our audited financial statements included elsewhere in this prospectus. These amounts do not correspond to the actual value that may be recognized by the directors upon vesting of the applicable awards. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, Mr. Lubner held stock options to purchase 110,825&#160;shares of our common stock and Dr.&#160;Patel held stock options to purchase 79,031&#160;shares of our common stock. None of our other non-employee directors held stock awards or option awards as of December&#160;31, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr. Camahort resigned from our board of directors effective February 3, 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors who are also our employees receive no additional compensation for their service as directors. Mr.&#160;Elghandour was an employee director during 2021. See the section titled &#8220;Executive Compensation&#8221; for additional information about Mr.&#160;Elghandour&#8217;s compensation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee Director Compensation Policy </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted, and our stockholders have approved, a compensation policy for our non-employee directors. This policy was developed with input from our independent compensation consultant regarding practices and compensation levels at comparable companies. It is designed to attract, retain, and reward non-employee directors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under our director compensation policy, each non-employee director receives the cash and equity compensation for board services described below. We also reimburse our non-employee directors for reasonable, customary, and documented travel expenses to board of directors or committee meetings. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The compensation policy includes a maximum annual limit of $750,000 of cash retainers or fees and equity awards that may be paid, issued, or granted to a non-employee director in any fiscal year, increased to $1,000,000 in the first year an individual becomes a non-employee director. For purposes of this limitation, the value of equity awards is based on the grant date fair value (determined in accordance with GAAP). Any cash compensation paid or equity awards granted to a person for their services as an employee, or for their services as a consultant (other than as a non-employee director), will not count for purposes of the limitation. The maximum limit does not reflect the intended size of any potential compensation or equity awards to our non-employee directors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash compensation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee directors are entitled to receive the following cash compensation for their services under the outside director compensation policy: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$40,000 per year for service as a board member; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$20,000 per year for service as a lead independent director; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15,000 per year for service as chair of the audit committee; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$7,500 per year for service as a member of the audit committee; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$10,000 per year for service as chair of the compensation committee; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$5,000 per year for service as a member of the compensation committee; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$8,000 per year for service as chair of the corporate governance and nominating committee; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$4,000 per year for service as a member of the corporate governance and nominating committee. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each non-employee director who serves as the chair of a committee will receive only the additional annual cash fee as the chair of the committee, and not the annual fee as a member of the committee, provided that each non-employee director who serves as the lead independent director will receive the annual fee for service as a board member and an additional annual fee as the lead independent director. All cash payments to non-employee directors are paid quarterly in arrears on a pro-rated basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity compensation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial Award: Each person who first becomes a non-employee director after the date of the effective date of the policy will receive, on the first trading date on or after the date on which the person first becomes a non-employee director, an initial award of a stock option (the Initial Award) covering a number of shares of our common stock having a grant date fair value (determined in accordance with GAAP) equal to $600,000; provided that any resulting fraction will be rounded down to the nearest whole share. Each Initial Award will vest as follows: 1/3rd&#160;of the shares subject to the Initial Award will be scheduled to vest each year following the grant date on the anniversary of the grant date, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date. If the person was a member of our board of directors and also an employee, becoming a non-employee director due to termination of employment will not entitle them to Initial Awards. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Award: Each non-employee director automatically will receive, on the first trading day immediately following each annual meeting of our stockholders following the effective date of the policy, an annual award of a stock option (each, an Annual Award) covering a number of shares of our common stock having a grant date fair value (determined in accordance with GAAP) of $300,000; provided that the first Annual Award granted to an individual who first becomes a non-employee director following the effective date of the policy will have a grant date fair value equal to the product of (A)&#160;$300,000 multiplied by (B)&#160;a fraction, (i)&#160;the numerator of which is equal to the number of fully completed days between the non-employee director&#8217;s initial start date and the date of the first annual meeting of our stockholders to occur after such individual first becomes a non-employee director, and (ii)&#160;the denominator of which is 365; and provided further that any resulting fraction will be rounded down to the nearest whole share. Each Annual Award will vest as follows: 100%&#160;of the shares subject to the Annual Award will be scheduled to vest upon the earlier of the one year anniversary of the grant date or the next annual meeting of our stockholders that occurs following the grant date, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of a &#8220;change in control&#8221; (as defined in our 2022 Plan), each non-employee director will fully vest in their outstanding company equity awards issued under the director compensation policy, including any Initial Award or Annual Award, immediately prior to the consummation of the change in control provided that the non-employee director continues to be a non-employee director through such date. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Committee Interlocks and Inside Participation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or more executive officers serving on our board of directors or compensation committee. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Jill Carroll, M.S. and David Lubner, M.S., C.P.A. have or may be deemed to have an interest in certain transactions requiring disclosure under Item&#160;404 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> under the Securities Act. These transactions between us and members of our compensation committee and affiliates of such members are disclosed in &#8220;Certain Relationships and Related Party Transactions,&#8221; and such disclosure is incorporated by reference herein. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Code of Business Conduct and Ethics </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The code of business conduct and ethics is available on our website at www.arcellx.com. We intend to disclose future amendments to such code, or any waivers of its requirements, applicable to any principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions or our directors on our website identified above. Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXECUTIVE COMPENSATION </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our named executive officers for 2021 are: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour, our current President and Chief Executive Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Hilbert, our former President and Chief Executive Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher Heery, our current Chief Medical Officer; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neeraj Teotia, our current Chief Commercial Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Compensation Table </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information regarding the compensation of our named executive officers for the year ended December&#160;31, 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Principal Position</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock&#160;Awards<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Awards&#160;($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nonequity<br/>Incentive&#160;Plan<br/>Compensation<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">All Other<br/>Compensation<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">470,272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">325,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,299,542</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,700</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">23,403,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">President and Chief Executive Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Hilbert, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">416,433</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">291,320</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">431,865</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92,843</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(9)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,232,461</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former President and Chief Executive Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher Heery, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">295,336</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">227,539</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,535,520</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8,700</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2,067,095</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Medical Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neeraj Teotia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">245,785</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126,937</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,535,960</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7,381</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1,916,063</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Commercial Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts reported represent discretionary bonuses paid in lump sum in March 2022 based upon the achievement of company goals for the year ended December&#160;31, 2021, as determined by our board of directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions used in calculating the grant date fair value of the options disclosed in this column are set forth in Note&#160;2 to our audited financial statements included elsewhere in this prospectus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts reported represent matching contributions under our 401(k) plan. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount reported represents the grant date fair value of a restricted stock unit award covering 952,804&#160;shares of our common stock granted to Mr.&#160;Elghandour on June&#160;9, 2021, as amended December 7, 2021, in the amount of $10,300,000 as computed in accordance with ASC Topic&#160;718. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount reported represents the sum of the following: (i)&#160;the grant date fair value of the stock option to purchase 1,068,005 shares of our common stock granted to Mr. Elghandour on February&#160;6, 2021 with an exercise price of $8.65 per share, in the amount of $7,784,451 as computed in accordance with ASC Topic&#160;718, (ii) the incremental increase in the fair value of the stock option originally granted to Mr.&#160;Elghandour on February 6, 2021 arising from the repricing of such stock option from an exercise price of $8.65 per share to an exercise price of $6.28 per share on June 9, 2021, in the amount of $213,700 as computed in accordance with ASC Topic 718, and (iii) the grant date fair value of the stock option to purchase 837,602&#160;shares of our common stock granted to Mr. Elghandour on June 9, 2021 with an exercise price of $6.28 per share, in the amount of $4,301,391 as computed in accordance with ASC Topic&#160;718. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount reported represents the grant date fair value of the stock option to purchase 81,757 shares of our common stock granted to Dr. Hilbert on June 9, 2021 with an exercise price of $6.28 per share, in the amount of $431,865 as computed in accordance with ASC Topic&#160;718. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount reported represents the grant date fair value of the stock option to purchase 290,692 shares of our common stock granted to Dr. Heery on June 9, 2021 with an exercise price of $6.28 per share, in the amount of $1,535,520 as computed in accordance with ASC Topic 718. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount reported represents the sum of the following: (i) the grant date fair value of the stock option to purchase 254,355 shares of our common stock granted to Mr. Teotia on June 9, 2021 with an exercise price of $6.28 per share, in the amount of $1,343,580 as computed in accordance with ASC Topic 718, and (ii) the grant date fair value of the stock option to purchase 36,336 shares of our common stock granted to Mr. Teotia on October 21, 2021 with an exercise price of $6.28 per share, in the amount of $192,380 as computed in accordance with ASC Topic 718. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount reported consists of (i) $8,700 for matching contributions under our 401(k) plan and (ii) the cancellation of $84,143 in aggregate principal and interest under a promissory note held by our company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Outstanding Equity Awards at Fiscal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Year-End</div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December&#160;31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 38%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="13" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;Date<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Exercise<br/>Price<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Expiration<br/>Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of Shares<br/>of Stock<br/>that<br/>Have&#160;Not<br/>Vested<br/>(#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market<br/>Value&#160;of<br/>Shares<br/>of&#160;Stock<br/>That<br/>Have&#160;Not<br/>Vested<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td rowspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2/6/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,068,005</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">2/6/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">837,602</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">952,804</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,345,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Hilbert, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9/18/2018</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">206,298</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">9/18/2028</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1/31/2020</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">375,485</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(9)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">1/31/2030</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">81,757</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(10)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td rowspan="2" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Christopher Heery, M.D. </div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">261,623</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(11)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,069</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(12)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="3" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neeraj Teotia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">249,632</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(13)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,723</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(14)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6/9/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">10/21/2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">36,336</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(15)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">10/21/2031</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of the outstanding options to purchase shares of our common stock was granted pursuant to our 2017 Plan. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except as otherwise provided below, this column represents the fair market value of a share of our common stock on the date of grant, as determined by our board of directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This column represents the fair market value of a share of our common stock as of December&#160;31, 2021, the market value has been calculated based on an estimated&#160;per-share&#160;common stock value of $6.66 per share as of December&#160;31, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/36th of the shares subject to this option vest monthly after the vesting commencement date of January&#160;22, 2021, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. See the section title &#8220;Executive Compensation&#8212;Employment Arrangements with Our Named Executive Officers&#8212;Rami Elghandour&#8221; for additional terms regarding Mr.&#160;Elghandour&#8217;s stock options. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This stock option was originally granted with an exercise price of $8.65 per share. It was repriced by our board of directors on June&#160;9, 2021 from an exercise price of $8.65 per share to an exercise price of $6.28 per share. No other terms or conditions of the option were changed in connection with the repricing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/36th of the shares subject to this option vest monthly after the vesting commencement date of January&#160;22, 2021, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. See the section title &#8220;Executive Compensation&#8212;Employment Arrangements with Our Named Executive Officers&#8212;Rami Elghandour&#8221; for additional terms regarding Mr.&#160;Elghandour&#8217;s stock options. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See the section title &#8220;Executive Compensation&#8212;Employment Arrangements with Our Named Executive Officers&#8212;Rami Elghandour&#8221; for vesting details of Mr.&#160;Elghandour&#8217;s restricted stock units. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/4th of the shares subject to this option vested on the first anniversary of the vesting commencement date of July&#160;18, 2018 and 1/48th of the shares vest monthly thereafter, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/4th of the shares subject to this option vested on the first anniversary of the vesting commencement date of August&#160;9, 2019 and 1/48th of the shares vest monthly thereafter, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/48th of the shares subject to this option vest monthly after the vesting commencement date of June&#160;9, 2021, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/4th of the shares subject to this option vested on the first anniversary of the vesting commencement date of April&#160;26, 2021 and 1/48th of the shares vest monthly thereafter, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(12)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/48th of the shares subject to this option vest monthly after the vesting commencement date of June&#160;9, 2021, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(13)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/4th of the shares subject to this option vested on the first anniversary of the vesting commencement date of April&#160;5, 2021 and 1/48th of the shares vest monthly thereafter, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(14)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/48th of the shares subject to this option vest monthly after the vesting commencement date of June&#160;9, 2021, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(15)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1/48th of the shares subject to this option vest monthly after the vesting commencement date of October&#160;13, 2021, subject to the optionee&#8217;s continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employment Arrangements with Our Named Executive Officers and Executive Officers </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into employment offer letter agreements with certain of our named executive officers and executive officers in connection with their employment with us. These offer letters provide for &#8220;at will&#8221; employment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with our initial public offering, we entered into a new confirmatory offer letter agreement with Mr. Elghandour, our Chief Executive Officer. This agreement has no specific term and provides for at-will employment. Mr. Elghandour&#8217;s annual base salary is $565,000 and he will be eligible for an annual target cash incentive payment of up to 55% of his annual base salary. Mr.&#160;Elghandour will also be eligible to receive certain severance benefits upon an involuntary termination pursuant to a Change in Control and Severance Agreement he has entered into with us, as described in more detail below under the section titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential Payments upon Termination or Change in Control</div></div>&#8221;. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rami Elghandour Equity Awards </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 6, 2021, we granted Mr. Elghandour an option to purchase 1,068,005 shares of our common stock at an exercise price of $8.65 per share, subject to the terms and conditions of our 2017 Plan and a stock option agreement thereunder (the Elghandour Initial Option). On June 9, 2021, our board of directors amended the exercise price of the Elghandour Initial Option from $8.65 per share to $6.28 per share. The Elghandour Initial Option may be exercised prior to vesting, subject to Mr. Elghandour executing a restricted stock purchase agreement. The Elghandour Initial Option will vest as to 1/36th of the shares subject to the Elghandour Initial Option on each monthly anniversary of January 22, 2021, subject to Mr. Elghandour continuing to be a service provider through each vesting date. The Elghandour Initial Option will, to the extent vested, be exercisable through the earlier of February 6, 2031 or the 36 month anniversary of the date Mr. Elghandour ceases to be a service provider, subject to the terms of our 2017 Plan. Mr.&#160;Elghandour will be permitted to exercise the Elghandour Initial Option through the issuance of a full recourse promissory note and security agreement in a reasonable form provided by us. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 9, 2021, we granted Mr. Elghandour an option to purchase 837,602 shares of our common stock at an exercise price of $6.28 per share, subject to the terms and conditions of our 2017 Plan and a stock option agreement thereunder (the Elghandour Second Option). The Elghandour Second Option may be exercised prior to vesting, subject to Mr. Elghandour executing a restricted stock purchase agreement. The Elghandour Second Option will vest pursuant to the same vesting schedule as the Elghandour Initial Option. The Elghandour Second Option will, to the extent vested, be exercisable through the earlier of June&#160;9, 2031 or the 36 month anniversary of the date Mr.&#160;Elghandour ceases to be a service provider, subject to the terms of our 2017 Plan. Mr.&#160;Elghandour will be permitted to exercise the Elghandour Second Option through the issuance of a full recourse promissory note and security agreement in a reasonable form provided by us. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 9, 2021, we granted Mr. Elghandour an award of restricted stock units covering 952,804 shares of our common stock, subject to the terms and conditions of our 2017 Plan and a restricted stock unit award agreement thereunder (the Elghandour Initial RSU Award). On December&#160;7, 2021, we amended the Elghandour Initial RSU Award (the Elghandour Amended Initial RSU Award). The Elghandour Amended Initial RSU Award will vest pursuant to a service component and a performance component. The service component will be satisfied if Mr.&#160;Elghandour remains a service provider through the date that our board of directors determines that the applicable performance component is satisfied. The performance component will be satisfied upon our achievement of a company value, as defined in the award agreement underlying the Elghandour Amended Initial RSU Award, as follows: upon achievement of a company value that is equal to $2,500,000,000, or the minimum threshold, 1/6th of the shares subject to the Elghandour Amended Initial RSU Award will vest; upon achievement of a company value that is equal to or greater than $5,000,000,000, or the maximum threshold, 100% of the shares subject to the Elghandour Amended Initial RSU Award will vest; and upon achievement of a company value that is between the minimum threshold and the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">179 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum threshold, a portion of the shares subject to the Elghandour Amended Initial RSU Award will vest between 1/6th and 100% based on straight line linear interpolation. Company value will be measured either (i) on a change in control (as defined in our 2017 Plan) based on the aggregate amount of deal consideration paid at the closing of such change in control by an acquirer for our shares of common stock or (ii)&#160;on June 30 and December&#160;31 of each year following the expiration of any lockup period related to our initial public offering, and will be measured based on the sum of our total market capitalization as of the applicable measurement date, based on the average closing trading price of one share of our common stock over the 60 day period ending on the day prior to such measurement date, less the aggregate value of all cash, cash equivalents and marketable securities held by us on the applicable measurement date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Hilbert, Ph.D. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into a Transition and Release Agreement with Dr. Hilbert, our former President and Chief Executive Officer, that provided the terms and conditions for Dr. Hilbert&#8217;s transition from an employee and Chief Technical Officer of our company to a consultant of our company effective January 2, 2022 (the Transition Agreement). During the period Dr.&#160;Hilbert continues service as a consultant, he will continue to vest in any outstanding stock option awards he holds subject to the terms of such awards and our 2017 Plan. In exchange for a general release of claims as set forth in the Transition Agreement, Dr.&#160;Hilbert is entitled to (i)&#160;a lump sum equal to six (6) months of his base salary, and (ii)&#160;a lump sum of $75,000, which is equal to his bonus award previously approved by our board of directors on March&#160;17, 2021. We will also continue to provide monthly payments for 12&#160;months in an amount equal to the monthly Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, premium that Dr. Hilbert would have been required to pay to continue his group health coverage. In addition, Dr.&#160;Hilbert is also eligible to receive a bonus of 40% of his annual salary for fiscal year 2021 (target amount of $166,400). This bonus will be determined by our board of directors in its sole discretion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher Heery, M.D. </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with our initial public offering, we have entered into a confirmatory employment letter with Dr.&#160;Heery, our Chief Medical Officer. The confirmatory employment letter has no specific term and provides for&#160;at-will&#160;employment. Dr.&#160;Heery&#8217;s current annual base salary is $430,000 and his annual target bonus is 40% of his annual base salary. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neeraj Teotia </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with our initial public offering, we have entered into a confirmatory employment letter with Mr.&#160;Teotia, our Chief Commercial Officer. The confirmatory employment letter has no specific term and provides for&#160;at-will&#160;employment. Mr.&#160;Teotia&#8217;s annual base salary is $400,000 and his annual target bonus is 40% of his annual base salary. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michelle Gilson </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into an employment offer letter with Ms. Gilson, our Chief Financial Officer. The employment offer letter has no specific term and provides for at-will employment. Ms. Gilson&#8217;s current annual base salary is $420,000 and her annual target bonus is 40% of her annual base salary. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">180 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Payments upon Termination or Change in Control </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Control and Severance Agreements </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has approved, and certain of our named executive officers and certain other of our executive officers and key employees have entered into change in control and severance agreements. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to certain of our named executive officers&#8217; change in control and severance agreements, if, within the 3&#160;month period prior to or the 24 month period following a &#8220;change in control&#8221; (as defined in the applicable agreement), we terminate the employment of the applicable named executive officer without &#8220;cause&#8221; (excluding death or disability) or such executive resigns for &#8220;good reason&#8221; (as such terms are defined in the applicable agreement), and within 60 days following such termination, such named executive officer executes a waiver and release of claims in our favor that becomes effective and irrevocable, such named executive officer will be entitled to receive (i)&#160;a lump sum payment equal to the sum of 18 months (24 months with respect to Mr.&#160;Elghandour) of such named executive officer&#8217;s then current annual base salary and 150% (200% with respect to Mr. Elghandour) of such named executive officer&#8217;s annual target bonus, less applicable withholdings, (ii)&#160;reimbursement of premiums to maintain group health insurance continuation benefits pursuant to &#8220;COBRA&#8221; for such named executive officer and such executive&#8217;s respective eligible dependents for up to 18 months (24&#160;months with respect to Mr. Elghandour), and (iii) vesting acceleration as to 100% of the then-unvested shares subject to each of such named executive officer&#8217;s then outstanding equity awards subject to time-based vesting conditions (and in the case of awards subject to performance-based vesting conditions, such awards will be treated as provided for in the applicable award agreement governing such award). </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to certain of our named executive officers&#8217; change in control and severance agreements, if, outside of the 3&#160;month period prior to or the 24 month period following a &#8220;change in control&#8221;, we terminate the employment of the applicable named executive officer without cause (excluding death or disability) or, with respect to Mr.&#160;Elghandour, he resigns for good reason, and within 60 days following such termination, such named executive officer executes a waiver and release of claims in our favor that becomes effective and irrevocable, such named executive officer will be entitled to receive (i) a lump sum payment equal to 12 months of such named executive officer&#8217;s then current annual base salary (as well as, with respect to Mr. Elghandour, 100% of such named executive officer&#8217;s annual target bonus), (ii) reimbursement of premiums to maintain group health insurance continuation benefits pursuant to &#8220;COBRA&#8221; for such named executive officer and such executive&#8217;s respective eligible dependents for up to 12 months, (iii) a lump sum payment equal to such named executive officer&#8217;s annual target bonus, prorated by multiplying such amount by a fraction, (x) the numerator of which is the number of days during which the executive was employed with us in the calendar year that the termination occurs, and (y) the denominator of which is 365, and (iv) with respect to Mr. Elghandour, vesting acceleration as to a number of the then-unvested shares subject to each of such named executive officer&#8217;s then-outstanding compensatory equity awards subject to time-based vesting conditions that would have vested had such named executive officer remained our employee over the 24 month period following the date of termination. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to certain of our named executive officers&#8217; change in control and severance agreements, in the event any payment to the applicable executive would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code, as amended (the Code) (as a result of a payment being classified as a parachute payment under Section&#160;280G of the Code), such executive will receive such payment as would entitle such executive to receive the greatest after-tax benefit, even if it means that we pay such executive a lower aggregate payment so as to minimize or eliminate the potential excise tax imposed by Section 4999 of the Code. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Benefit and Stock Plans </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 Equity Incentive Plan (2022 Plan) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted, and our stockholders approved our 2022 Plan. Our 2022 Plan became effective on February 2, 2022. Our 2022 Plan provides for the grant of incentive stock options, within the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">181 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">meaning of Section&#160;422 of the Code, to our employees and any parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (RSUs), and performance awards to our employees, directors, and consultants and our parent and subsidiary corporations&#8217; employees and consultants. Our 2017 Plan terminated on February 1, 2022 with respect to the grant of future awards. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">hares</div></div>. Subject to the adjustment provisions of and the automatic increase described in our 2022 Plan, a total of 4,296,875 shares of our common stock are reserved for issuance pursuant to our 2022 Plan. In addition, subject to the adjustment provisions of our 2022 Plan, the shares reserved for issuance under our 2022 Plan also will include any shares subject to awards granted under our 2017 Plan that, on or after February&#160;3, 2022, expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by us for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to or repurchased by us due to failure to vest (provided that the maximum number of shares that may be added to our 2022 Plan pursuant to outstanding awards under the 2017 Plan is 6,269,300 shares). Subject to the adjustment provisions of our 2022 Plan, the number of shares available for issuance under our 2022 Plan will also include an annual increase on the first day of each fiscal year beginning with the 2023 fiscal year and ending on the ten year anniversary of the date our board of directors approved the 2022 Plan, in an amount equal to the least of: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4,296,875 shares of our common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5.0% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such number of shares of our common stock as the administrator may determine. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a stock option or stock appreciation right granted under the 2022 Plan expires or becomes unexercisable without having been exercised in full or is surrendered pursuant to an exchange program or, with respect to restricted stock, RSUs or stock settled performance awards, is forfeited to, or repurchased by, us due to failure to vest, then the unpurchased shares (or for awards other than stock options or stock appreciation rights, the forfeited or repurchased shares) which were subject thereto will become available for future grant or sale under the 2022 Plan (unless the 2022 Plan has terminated). With respect to stock appreciation rights, only the net shares actually issued will cease to be available under the 2022 Plan and all remaining shares under stock appreciation rights will remain available for future grant or sale under the 2022 Plan (unless the 2022 Plan has terminated). Shares that have actually been issued under the 2022 Plan under any award will not be returned to the 2022 Plan; provided, however, that if shares issued pursuant to awards of restricted stock, RSUs or performance awards are repurchased or forfeited to us due to failure to vest, such shares will become available for future grant under the 2022 Plan. Shares used to pay the exercise price of an award or to satisfy the tax withholding obligations related to an award will become available for future grant or sale under the 2022 Plan. To the extent an award is paid out in cash rather than shares, the cash payment will not result in a reduction in the number of shares available for issuance under the 2022 Plan. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan Administration</div></div>. We expect that our compensation committee will administer our 2022 Plan and may further delegate authority to one or more subcommittees or officers to the extent such delegation complies with applicable laws. Subject to the provisions of our 2022 Plan, the administrator will have the power to administer our 2022 Plan and make all determinations deemed necessary or advisable for administering our 2022 Plan, including but not limited to: the power to determine the fair market value of our common stock; select the service providers to whom awards may be granted; determine the number of shares covered by each award; approve forms of award agreements for use under our 2022 Plan; determine the terms and conditions of awards (including, but not limited to, the exercise price, the time or times at which the awards may be exercised, any vesting acceleration or waiver or forfeiture restrictions, and any restriction or limitation regarding any award or the shares relating thereto); construe and interpret the terms of our 2022 Plan and awards granted under it, including but not limited to determining whether and when a change in control has occurred; establish, amend </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">182 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and rescind rules and regulations relating to our 2022 Plan, and adopt sub-plans relating to the 2022 Plan; interpret, modify or amend each award, including but not limited to the discretionary authority to extend the post-termination exercisability period of awards; allow participants to satisfy tax withholding obligations in any manner permitted by the 2022 Plan; delegate ministerial duties to any of our employees; authorize any person to take any steps and execute, on our behalf, any documents required for an award previously granted by the administrator to be effective; temporarily suspend the exercisability of an award if the administrator deems such suspension to be necessary or appropriate for administrative purposes, provided that, unless prohibited by applicable laws, such suspension shall be lifted in all cases not less than ten trading days before the last date that the award may be exercised; allow a participant to defer the receipt of payment of cash or the delivery of shares that would otherwise be due to such participant under an award; and make any determinations necessary or appropriate under the adjustment provisions of the 2022 Plan. The administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered or cancelled in exchange for awards of the same type, which may have a higher or lower exercise price and/or different terms, awards of a different type and/or cash, or by which the exercise price of an outstanding award is increased or reduced. The administrator&#8217;s decisions, interpretations, and other actions will be final and binding on all participants to the full extent permitted by law. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options</div></div>. Our 2022 Plan permits the grant of options. The exercise price of options granted under our 2022 Plan must be at least equal to the fair market value of our common stock on the date of grant, except that options may be granted with a lower exercise price to a service provider who is not a U.S. taxpayer, or pursuant to certain transactions. The term of an option is determined by the administrator, provided that the term of an incentive stock option may not exceed ten years. With respect to any participant who owns more than 10% of the voting power of all classes of our outstanding stock, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The administrator determines the methods of payment of the exercise price of an option, which may include cash, check, or wire transfer, cashless exercise, net exercise, promissory note, shares, or other consideration or method of payment acceptable to the administrator, to the extent permitted by applicable law. After the termination of service of an employee, director, or consultant, he or she may exercise his or her option for the period of time stated in his or her option agreement. In the absence of a specified time in an award agreement, if termination is due to death or disability, the option will remain exercisable for six months. In all other cases, in the absence of a specified time in an award agreement, the option will remain exercisable for thirty days. These exercise periods may be tolled in certain circumstances, for example if exercise prior to the end of the applicable period is not permitted because of applicable laws. However, in no event may an option be exercised later than the expiration of its term. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Appreciation Rights</div></div>. Our 2022 Plan permits the grant of stock appreciation rights. Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of our common stock between the exercise date and the date of grant. The term of stock appreciation rights is determined by the administrator. After the termination of service of an employee, director or consultant, he or she may exercise his or her stock appreciation right for the period of time stated in his or her stock appreciation rights agreement. In the absence of a specified time in an award agreement, if termination is due to death or disability, the stock appreciation rights will remain exercisable for six months. In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable for thirty days following the termination of service. These exercise periods may be tolled in certain circumstances, for example, if exercise prior to the end of the applicable period is not permitted because of applicable laws. However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions of our 2022 Plan, the administrator determines the other terms of stock appreciation rights, including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of our common stock, or a combination thereof, except that the per share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right must be no less than 100% of the fair market value per share on the date of grant. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">183 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock</div></div>. Our 2022 Plan permits the grant of restricted stock. Restricted stock awards are grants of shares of our common stock that vest in accordance with terms and conditions established by the administrator. The administrator determines the number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of our 2022 Plan, determines the terms and conditions of such awards. The administrator has the authority to impose whatever conditions to vesting it determines to be appropriate (for example, the administrator will be able to set restrictions based on the achievement of specific performance goals or continued service to us); provided, however, that the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator provides otherwise. Shares of restricted stock that do not vest will be subject to our right of repurchase or forfeiture. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units</div></div>. Our 2022 Plan permits the grant of RSUs. Each RSU will represent an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2022 Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. The administrator has the authority to set vesting criteria based upon the achievement of company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service) or any other basis determined by the administrator in its discretion. The administrator, in its sole discretion, may pay earned RSUs in the form of cash, in shares, or in some combination of both. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the vesting, or reduce or waive the criteria that must be met for vesting, of the RSUs or the time at which any restrictions will lapse or be removed. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Awards</div></div>. Our 2022 Plan permits the grant of performance awards. Performance awards are awards that will result in a payment to a participant only if performance goals established by the administrator are achieved or the awards otherwise vest. The administrator may establish performance objectives or other vesting criteria in its discretion, which, depending on the extent to which they are met, will determine the number and/or the value of performance awards to be paid out to participants. The administrator has the authority to set performance objectives based on the achievement of company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service) or any other basis determined by the administrator in its discretion. Each performance award&#8217;s threshold, target, and maximum payout values are established by the administrator on or before the grant date. After the grant of a performance award, the administrator, in its sole discretion, may reduce or waive any performance criteria or other vesting provisions for such performance award. The administrator, in its sole discretion, may pay earned performance awards in the form of cash, in shares, or in some combination thereof. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Non-Employee Directors</div></div>. Our 2022 Plan provides that all outside <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(non-employee)</div> directors will be eligible to receive all types of awards (except for incentive stock options) under our 2022 Plan. In order to provide a maximum limit on the awards that can be made to our non-employee directors, our 2022 Plan provides that in any given fiscal year, a non-employee director will not be paid or granted cash retainer fees or awards having an aggregate value greater than $750,000, but this limit is increased to $1,000,000 in connection with his or her initially joining our board of directors (in each case, excluding cash compensation and awards granted to him or her as a consultant or employee). The values of awards will be based on such awards&#8217; grant date fair value determined according to GAAP. The maximum limits do not reflect the intended size of any potential grants or a commitment to make grants to our outside directors under our 2022 Plan in the future. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Transferability</div> of Awards</div></div>. Unless the administrator provides otherwise, our 2022 Plan generally does not allow for the transfer of awards and only the recipient of an award may exercise an award during his or her lifetime. If the administrator makes an award transferrable, such award will contain such additional terms and conditions as the administrator deems appropriate. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain Adjustments</div></div>. If any extraordinary dividend or other extraordinary distribution (whether in cash, shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">184 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">merger, consolidation, split-up, spin-off, combination, reclassification, repurchase, or exchange of shares of our common stock or other of our securities, other change in our corporate structure affecting the shares, or any similar equity restructuring transaction affecting our shares occurs (including a change in control), the administrator, to prevent diminution or enlargement of the benefits or potential benefits intended to be provided under the 2022 Plan, will adjust the number and class of shares that may be delivered under the 2022 Plan and/or the number, class, and price of shares covered by each outstanding award, and the numerical share limits set forth in our 2022 Plan. The conversion of any of our convertible securities and ordinary course repurchases of our shares or other securities will not be treated as an event that will require adjustment under the 2022 Plan. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dissolution or Liquidation</div></div>. In the event of our proposed liquidation or dissolution, the administrator will notify participants as soon as practicable and, to the extent not exercised, all awards will terminate immediately prior to the consummation of such proposed transaction. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger or Change in Control</div></div>. Our 2022 Plan provides that in the event of a merger or change in control, as defined under our 2022 Plan, each outstanding award will be treated as the administrator determines, without a requirement to obtain a participant&#8217;s consent, including, without limitation, that such award will be continued by the successor corporation or a parent or subsidiary of the successor corporation. An award generally will be considered continued if, following the transaction, (i) the award gives the right to purchase or receive the consideration received in the transaction by holders of our shares or (ii) the award is terminated in exchange for an amount of cash and/or property, if any, equal to the amount that would have been received upon the exercise or realization of the award at the closing of the transaction, which payment may be subject to any escrow applicable to holders of our common stock in connection with the transaction or subjected to the award&#8217;s original vesting schedule. The administrator will not be required to treat all awards or portions thereof the vested and unvested portions of an award, or all participants similarly. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event that a successor corporation or its parent or subsidiary does not continue an outstanding award, then such award will fully vest, all restrictions on such award will lapse, all performance goals or other vesting criteria applicable to such award will be deemed achieved at 100% of target levels, and such award will become fully exercisable, if applicable, for a specified period prior to the transaction, unless specifically provided for otherwise under the applicable award agreement or other written agreement with the participant. The award will then terminate upon the expiration of the specified period of time. If an option or stock appreciation right is not continued, the administrator will notify the participant in writing or electronically that such option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will terminate upon the expiration of such period. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to awards granted to an outside director, in the event of a change in control, all of his or her options and stock appreciation rights, if any, will vest fully and become immediately exercisable, all restrictions on his or her restricted stock and RSUs will lapse, and all performance goals or other vesting requirements for his or her performance awards will be deemed achieved at 100% of target levels, and all other terms and conditions met. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clawback</div></div>. Awards will be subject to any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our stock is listed or as otherwise required by applicable laws, and the administrator will also be able to specify in an award agreement that the participant&#8217;s rights, payments and/or benefits with respect to an award will be subject to reduction, cancellation, forfeiture and/or recoupment upon the occurrence of certain specified events. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment and Termination</div></div>. The administrator has the authority to amend, alter, suspend or terminate our 2022 Plan, provided we will obtain stockholder approval of any amendment to the extent necessary or desirable to comply with applicable laws. However, no amendment, alteration, suspension or termination of our 2022 Plan or an Award under it may, taken as a whole, materially impair the existing rights of any participant without the participant&#8217;s consent. Our 2022 Plan will continue in effect until it is terminated, provided that </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">185 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">incentive stock options may not be granted after the ten year anniversary of the date our board of directors approved the 2022 Plan, and the automatic annual share increase will end on the ten year anniversary of the date our board of directors approved the 2022 Plan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017 Equity Incentive Plan, as amended (2017 Plan) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our 2017 Plan was originally adopted by our board of directors and approved by our stockholders in January 2017. Our 2017 Plan was most recently amended in June 2021 and approved by stockholders in June 2021. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our 2017 Plan allows us to provide incentive stock options, within the meaning of Section&#160;422 of the Code, nonstatutory stock options, stock appreciation rights, restricted stock awards and restricted stock units (each, an &#8220;award&#8221; and the recipient of such award, a &#8220;participant&#8221;)&#160;to eligible employees, directors, and consultants of ours and any parent or subsidiary of ours. As of February 2, 2022 our 2017 Plan was terminated and we will not grant any additional awards under our 2017 Plan. However, our 2017 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under our 2017 Plan. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the following awards were outstanding under our 2017 Plan: stock options covering 8,095,769 shares of our common stock and an award of restricted stock units covering 952,804 shares of our common stock.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan Administration</div></div>. Our 2017 Plan is administered by our board of directors or one or more committees appointed by our board of directors. Different committees may administer our 2017 Plan with respect to different service providers. The administrator has all authority and discretion necessary or appropriate to administer our 2017 Plan and to control its operation, including the authority to construe and interpret the terms of our 2017 Plan and the awards granted under our 2017 Plan. The administrator&#8217;s decisions are final and binding on all participants and any other persons holding awards. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The administrator&#8217;s powers include the power to institute an exchange program under which (i)&#160;outstanding awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type or cash, (ii)&#160;participants would have the opportunity to transfer any outstanding awards to a financial institution or other person or entity selected by the administrator or (iii)&#160;the exercise price of an outstanding award is increased or reduced. The administrator&#8217;s powers also include the power to prescribe, amend and rescind rules and regulations relating to our 2017 Plan, to modify or amend each award and to make all other determinations deemed necessary or advisable for administering our 2017 Plan. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility</div></div>. Employees, directors and consultants of ours or our parent or subsidiary companies are eligible to receive awards, provided such consultants render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction and do not directly promote or maintain a market for our securities. Only our employees or employees of our parent or subsidiary companies are eligible to receive incentive stock options. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options</div></div>. Stock options have been granted under our 2017 Plan. Subject to the provisions of our 2017 Plan, the administrator determines the term of an option, the number of shares subject to an option, and the time period in which an option may be exercised. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The term of an option is stated in the applicable award agreement, but the term of an option may not exceed 10&#160;years from the grant date. The administrator determines the exercise price of options, which generally may not be less than 100% of the fair market value of our common stock on the grant date, unless expressly determined in writing by the administrator on the option&#8217;s grant date. However, an incentive stock option granted to an individual who directly or by attribution owns more than 10% of the total combined voting power of all of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">186 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our classes of stock or of any our parent or subsidiary may have a term of no longer than 5 years from the grant date and will have an exercise price of at least 110% of the fair market value of our common stock on the grant date. In addition, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by an employee during any calendar year (under all our plans and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Certain of the company&#8217;s outstanding options under our 2017 Plan have an early exercise provisions pursuant to which the participate may exercise the option prior to the shares being fully vested. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The administrator determines how a participant may pay the exercise price of an option, and the permissible methods are generally set forth in the applicable award agreement. If a participant&#8217;s status as a &#8220;service provider&#8221; (as defined in our 2017 Plan) terminates, that participant may exercise the vested portion of his or her option for the period of time stated in the applicable award agreement. Vested options generally will remain exercisable for three months or such longer period of time as set forth in the applicable award agreement if a participant&#8217;s status as a service provider terminates for a reason other than death or disability. If a participant&#8217;s status as a service provider terminates due to death or disability, vested options generally will remain exercisable for twelve months from the date of termination (or such other longer period as set forth in the applicable award agreement). In no event will an option remain exercisable beyond its original term. If a participant does not exercise his or her option within the time specified in the award agreement, the option will terminate. Except as described above, the administrator has the discretion to determine the post-termination exercisability periods for an option. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-transferability</div> of Awards</div></div>. Unless determined otherwise by the administrator, awards may not be sold, pledged, assigned, hypothecated or otherwise transferred in any manner other than by will or by the laws of descent and distribution. In addition, during an applicable participant&#8217;s lifetime, only that participant may exercise their award. If the administrator makes an award transferable, such award may only be transferred (i)&#160;by will, (ii)&#160;by the laws of descent and distribution or (iii)&#160;as permitted by Rule 701 of the Securities Act. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain Adjustments</div></div>. If there is a dividend or other distribution (whether in the form of cash, shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">split-up,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">spin-off,</div> combination, repurchase, exchange of shares or our other securities or other change in our corporate structure affecting the shares, the administrator will make proportionate adjustments to the number and type of shares that may be delivered under our 2017 Plan or the number, type and price of shares covered by each outstanding award. The administrator&#8217;s determination regarding such adjustments will be final, binding and conclusive. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dissolution or Liquidation</div></div>. In the event of our proposed dissolution or liquidation, the administrator will notify each participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an award will terminate immediately prior to the consummation of such proposed action. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger and Change of Control</div></div>. In the event of our merger with or into another corporation or entity or a &#8220;change in control&#8221; (as defined in our 2017 Plan), each outstanding award will be treated as the administrator determines, including, without limitation, that (i)&#160;awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii)&#160;upon written notice to a participant, the participant&#8217;s awards will terminate upon or immediately prior to the consummation of such merger or change in control; (iii)&#160;outstanding awards will vest and become exercisable, realizable or payable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon consummation of such merger or change in control, and, to the extent the administrator determines, terminate upon or immediately prior to the effectiveness of such merger or change in control; (iv)&#160;(A) the termination of an award in exchange for an amount of cash or property, if any, equal to the amount that would have been attained upon the exercise of such award or realization of the participant&#8217;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">187 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">occurrence of the transaction the administrator determines in good faith that no amount would have been attained upon the exercise of such award or realization of the participant&#8217;s rights, then such award may be terminated by us without payment) or (B)&#160;the replacement of such award with other rights or property selected by the administrator in its sole discretion; or (v)&#160;any combination of the foregoing. The administrator will not be obligated to treat all awards, all awards a participant holds or all awards of the same type, similarly. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event that the successor corporation does not assume or substitute for an award (or portion thereof), the participant will fully vest in and have the right to exercise all of his or her outstanding options and stock appreciation rights, including shares as to which such awards would not otherwise be vested or exercisable, all restrictions on restricted stock and restricted stock units will lapse, and, with respect to awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met. In addition, if an option or stock appreciation right is not assumed or substituted in the event of a merger or change in control, the administrator will notify the participant in writing or electronically that the option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion, and the option or stock appreciation right will terminate upon the expiration of such period. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment and Termination</div></div>. Our board of directors may, at any time, terminate or amend our 2017 Plan in any respect, including, without limitation, amendment of any form of award agreement or instrument to be executed pursuant to our 2017 Plan. To the extent necessary and desirable to comply with applicable laws, we will obtain stockholder approval of any amendment to our 2017 Plan. No amendment or alteration of our 2017 Plan will impair the rights of a participant, unless mutually agreed otherwise between the participant and the administrator in writing. As noted above, as of February 2, 2022, our 2017 Plan has been terminated and we will not grant any additional awards under our 2017 Plan. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 Employee Stock Purchase Plan (2022 ESPP) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors adopted, and our stockholders have approved, our 2022 Employee Stock Purchase Plan (2022 ESPP). Our 2022 ESPP became effective on February&#160;2, 2022. However, no offering period or purchase period under the 2022 ESPP will begin unless and until otherwise determined by our board of directors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized Shares</div></div>. A total of 312,500 shares of our common stock are available for sale under our 2022 ESPP. The number of shares of our common stock available for sale under our 2022 ESPP will also include an annual increase on the first day of each fiscal year beginning with the fiscal year occurring after the fiscal year in which the first enrollment date (if any) under the 2022 ESPP occurs, equal to the least of: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">312,500 shares of our common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.0% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">such other amount as the administrator may determine. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2022 ESPP Administration</div></div>. We expect that the compensation committee of our board of directors will administer our 2022 ESPP and will have full and exclusive discretionary authority to construe, interpret, and apply the terms of the 2022 ESPP, delegate ministerial duties to any of our employees, designate separate offerings under the 2022 ESPP, designate our subsidiaries and affiliates as participating in the 2022 ESPP, determine eligibility, adjudicate all disputed claims filed under the 2022 ESPP, and establish procedures that it deems necessary for the administration of the 2022 ESPP, including, but not limited to, adopting such procedures and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-plans</div> as are necessary or appropriate to permit participation in the 2022 ESPP by employees who are foreign nationals or employed outside the United States. The administrator&#8217;s findings, decisions and determinations are final and binding on all participants to the full extent permitted by law. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">188 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility</div></div>. Generally, all of our employees are eligible to participate if they are customarily employed by us, or any participating subsidiary or affiliate, for at least 20 hours per week and more than five months in any calendar year. The administrator, in its discretion, may, prior to an enrollment date, for all options to be granted on such enrollment date in an offering, determine that an employee who (1)&#160;has not completed at least two years of service (or a lesser period of time determined by the administrator) since his or her last hire date, (2)&#160;customarily works not more than 20 hours per week (or a lesser period of time determined by the administrator), (3) customarily works not more than five months per calendar year (or a lesser period of time determined by the administrator), (4) is a highly compensated employee within the meaning of Section&#160;414(q) of the Code, or (5)&#160;is a highly compensated employee within the meaning of Section&#160;414(q) of the Code with compensation above a certain level or is an officer or subject to disclosure requirements under Section&#160;16(a) of the Exchange Act, is or is not eligible to participate in such offering period. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, an employee may not be granted rights to purchase shares of our common stock under our 2022 ESPP if such employee: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">immediately after the grant would own capital stock and/or hold outstanding options to purchase such stock possessing 5% or more of the total combined voting power or value of all classes of capital stock of ours or of any parent or subsidiary of ours; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">holds rights to purchase shares of our common stock under all employee stock purchase plans of ours or any parent or subsidiary of ours that accrue at a rate that exceeds $25,000 worth of shares of our common stock for each calendar year in which such rights are outstanding at any time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Periods</div></div>. Our 2022 ESPP includes a component that allows us to make offerings intended to qualify under Section&#160;423 of the Code and a component that allows us to make offerings not intended to qualify under Section&#160;423 of the Code to designated companies, as described in our 2022 ESPP. No offering is expected to be authorized by our board of directors under the 2022 ESPP prior to the completion of this offering. If our board of directors authorizes an offering period under the 2022 ESPP, our board of directors is authorized to establish the duration of offering periods and purchase periods, including the starting and ending dates of offering periods and purchase periods, provided that no offering period may have a duration exceeding 27 months. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contributions</div></div>. Our 2022 ESPP permits participants to purchase shares of our common stock through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator) of up to 15.0% of their eligible compensation. A participant will be permitted to purchase up to a maximum number of shares of our common stock during a purchase period as may be determined by our board of directors prior to the start of an applicable offering period. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise of Purchase Right</div></div>. If our board of directors authorizes an offering and purchase period under the 2022 ESPP, amounts contributed and accumulated by the participant during any offering period will be used to purchase shares of our common stock at the end of each purchase period. The purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the exercise date. Participants may end their participation at any time during an offering period and will be paid their accrued contributions that have not yet been used to purchase shares of our common stock. Participation ends automatically upon termination of employment with us. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Transferability</div></div></div>. A participant may not transfer rights granted under our 2022 ESPP (other than by will, the laws of descent and distribution or as otherwise provided under our 2022 ESPP). </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger or Change in Control</div></div>. Our 2022 ESPP provides that in the event of a merger or change in control, as defined under our 2022 ESPP, a successor corporation may assume or substitute each outstanding purchase right. If the successor corporation refuses to assume or substitute for the outstanding purchase right, the offering period then in progress will be shortened, and a new exercise date will be set that will be before the date of the proposed merger or change in control. The administrator will notify each participant that the exercise date </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">189 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has been changed and that the participant&#8217;s option will be exercised automatically on the new exercise date unless prior to such date the participant has withdrawn from the offering period. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment and Termination</div></div>. The board has the authority to suspend or terminate our 2022 ESPP and the administrator has the authority to amend our 2022 ESPP, except that, subject to certain exceptions described in our 2022 ESPP, no such action may adversely affect any outstanding rights to purchase shares of our common stock under our 2022 ESPP. Our 2022 ESPP automatically will terminate in 2042, unless we terminate it sooner. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Incentive Compensation Plan</div></div> </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted our Employee Incentive Compensation Plan (Master Bonus Plan). </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors or a committee appointed by our board of directors will administer the Master Bonus Plan, provided that unless and until our board of directors determines otherwise, our compensation committee will administer the Master Bonus Plan. The Master Bonus Plan allows the administrator to provide awards to employees selected for participation, who may include certain of our named executive officers, which awards may be based upon performance goals established by the administrator. The administrator, in its sole discretion, may establish a target award for each participant under the Master Bonus Plan, which may be expressed as a percentage of the participant&#8217;s average annual base salary for the applicable performance period, a fixed dollar amount, or such other amount or based on such other formula as the administrator determines to be appropriate. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Master Bonus Plan, the administrator determines the performance goals, if any, applicable to any target award (or portion thereof) for a performance period, which may include, without limitation, goals related to: (i)&#160;research and development, (ii)&#160;regulatory milestones or regulatory-related goals, (iii)&#160;gross margin, (iv)&#160;financial milestones, (v)&#160;new product or business development (including geographical expansion) or sales, marketing or other commercial matters, (vi)&#160;operating margin, (vii)&#160;product release timelines or other product release milestones, (viii)&#160;publications, (ix)&#160;cash flow, (x)&#160;procurement, (xi)&#160;savings, (xii)&#160;internal structure, (xiii)&#160;leadership development, (xiv)&#160;project, function or portfolio-specific milestones, (xv)&#160;license or research collaboration agreements, (xvi)&#160;capital raising, (xvii)&#160;patentability and (xviii)&#160;individual objectives such as peer reviews or other subjective or objective criteria. As determined by the administrator, the performance goals may be based on GAAP or non-GAAP results and any actual results may be adjusted by the administrator for one-time items or unbudgeted or unexpected items and/or payments of awards under the Master Bonus Plan when determining whether the performance goals have been met. The performance goals may be based on any factors the administrator determines relevant, including without limitation on an individual, divisional, portfolio, project, business unit, segment, or company-wide basis. Any criteria used may be measured on such basis as the administrator determines, including without limitation: (a) in absolute terms, (b) in combination with another performance goal or goals (for example, but not by way of limitation, as a ratio or matrix), (c) in relative terms (including, but not limited to, results for other periods, passage of time and/or against another company or companies or an index or indices), (d) on a per-share basis, (e) against our performance as a whole or a segment and/or (f) on a pre-tax or after-tax basis. The performance goals may differ from participant to participant and from award to award. Failure to meet the applicable performance goals will result in a failure to earn the target award, subject to the administrator&#8217;s discretion to modify an award. The administrator also may determine that a target award (or portion thereof) will not have a performance goal associated with it but instead will be granted (if at all) as determined by the administrator. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The administrator may, in its sole discretion and at any time, increase, reduce, or eliminate a participant&#8217;s actual award, and/or increase, reduce or eliminate the amount allocated to the bonus pool for a particular performance period. The actual award may be below, at or above a participant&#8217;s target award, in the administrator&#8217;s discretion. The administrator may determine the amount of any increase, reduction, or elimination on the basis of such factors as it deems relevant, and it is not required to establish any allocation or weighting with respect to the factors it considers. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">190 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actual awards under the Master Bonus Plan generally will be paid in cash (or its equivalent) in a single lump sum only after they are earned and approved by the administrator, provided that the administrator reserves the right, in its sole discretion, to settle an actual award with a grant of an equity award with such terms and conditions, including vesting requirements, as determined by the administrator in its sole discretion. Unless otherwise determined by the administrator, to earn an actual award, a participant must be employed by us (or an affiliate of us, as applicable) through the date the bonus is paid. Payment of bonuses occurs as soon as administratively practicable after the end of the applicable performance period, but in no case after the later of (i) the 15th day of the third month of the fiscal year immediately following the fiscal year in which the bonuses vest and (ii) March 15 of the calendar year immediately following the calendar year in which the bonuses vest. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards under our Master Bonus Plan will be subject to reduction, cancellation, forfeiture, or recoupment in accordance with any clawback policy that we adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable laws. In addition, the administrator may impose such other clawback, recovery or recoupment provisions with respect to an award under the Master Bonus Plan as the administrator determines necessary or appropriate, including without limitation a reacquisition right in respect of previously acquired cash, stock, or other property provided with respect to an award. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The administrator has the authority to amend or terminate the Master Bonus Plan. However, such action may not materially alter or materially impair the existing rights of any participant with respect to any earned bonus without the participant&#8217;s consent. The Master Bonus Plan will remain in effect until terminated in accordance with the terms of the Master Bonus Plan. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">401(k) Plan </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We maintain a 401(k) retirement savings plan for the benefit of our employees, including certain of our named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan authorizes employer safe harbor contributions. The 401(k) plan is intended to qualify under Sections&#160;401(a) and 501(a) of the Code. As a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-qualified</div> retirement plan, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> contributions to the 401(k) plan and earnings on those <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan. We contribute 3% of an employee&#8217;s annual compensation, regardless of the amount of the employee&#8217;s contributions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limitation of Liability and Indemnification </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, and may indemnify our employees and other agents, to the fullest extent permitted by Delaware law. Delaware law prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any breach of the director&#8217;s duty of loyalty to us or to our stockholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unlawful payment of dividends or unlawful stock repurchases or redemptions; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any transaction from which the director derived an improper personal benefit. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">191 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director&#8217;s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-monetary</div> relief, remain available under Delaware law. This provision also does not affect a director&#8217;s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Under our amended and restated bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we have entered, and intend to continue to enter, into an indemnification agreement with each member of our board of directors and each of our officers. These agreements provide for the indemnification of our directors and officers for certain expenses and liabilities incurred in connection with any action, suit, proceeding or alternative dispute resolution mechanism or hearing, inquiry or investigation that may lead to the foregoing, to which they are a party, or are threatened to be made a party, by reason of the fact that they are or were a director, officer, employee, agent or fiduciary of our company, or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or fiduciary, or by reason of the fact that they were serving at our request as a director, officer, employee, agent or fiduciary of another entity. In the case of an action or proceeding by or in the right of our company or any of our subsidiaries, no indemnification will be provided for any claim where a court determines that the indemnified party is prohibited from receiving indemnification. We believe that these charter and bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. Moreover, a stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">192 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers, including those discussed in the sections titled &#8220;Management&#8221; and &#8220;Executive Compensation,&#8221; and the registration rights described in the section titled &#8220;Description of Capital Stock&#8212;Registration Rights,&#8221; the following is a description of each transaction since January&#160;1, 2019 and each currently proposed transaction in which: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have been or are to be a participant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount involved exceeded or exceeds $120,000; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of Securities </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B Preferred Stock Financing </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August and September 2019 we issued and sold an aggregate of 4,986,153 shares of our Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> redeemable convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock) at a purchase price of $8.60 per share for an aggregate purchase price of approximately $42.8&#160;million. These shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock converted into an aggregate of 4,986,153 shares of common stock upon the completion of our initial public offering. The table below sets forth the number of shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Preferred Stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investor</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Affiliated Director(s)<br/>or Officer(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-1</div><br/>Preferred<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Purchase<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quan Venture Fund II, L.P.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lewis&#160;T.&#160;Williams</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,163,886</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Enterprise Associates 15, L.P.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Ali Behbahani</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,500,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novo Holdings A/S</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raymond&#160;Camahort</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">666,651</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,727,805</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR One Capital Fund I Aggregator, L.P.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Jill Carroll</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">666,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,727,805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aju Life Science 3.0 Venture Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Derek Yoon</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">581,943</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Takeda Ventures, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">312,503</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,684,995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2020 we issued and sold an aggregate of 3,989,432 shares of our Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> redeemable convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock) at a purchase price of $10.74 per share for an aggregate purchase price of approximately $42.8&#160;million. These shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock converted into an aggregate of 3,989,432 shares of common stock upon the completion of our initial public offering. The table below sets forth the number of shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> Preferred Stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investor</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Affiliated&#160;Director(s)<br/>or Officer(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-2</div><br/>Preferred<br/>Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Purchase&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quan Venture Fund II, L.P</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lewis&#160;T.&#160;Williams</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">931,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Enterprise Associates 15, L.P</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Ali Behbahani</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">698,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,500,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novo Holdings A/S</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raymond&#160;Camahort</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">533,389</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,727,804</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR One Capital Fund I Aggregator, LP</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Jill Carroll</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">533,389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,727,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aju Life Science 3.0 Venture Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Derek Yoon</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">465,614</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Takeda Ventures, Inc</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">250,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,684,995</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">193 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C Preferred Stock Financing </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March, April and June 2021 we issued and sold an aggregate of 10,396,707 shares of our Series C redeemable convertible preferred stock (Series C Preferred Stock) at a purchase price of $11.55 per share for an aggregate purchase price of approximately $120 million. These shares of Series C Preferred Stock converted into an aggregate of 10,396,707 shares of common stock upon the completion of our initial public offering. The table below sets forth the number of shares of Series C Preferred Stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investor</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Affiliated&#160;Director(s)<br/>or Officer(s)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares of<br/>Series&#160;C<br/>Preferred&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Purchase</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New Enterprise Associates 15, L.P.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Ali&#160;Behbahani</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,732,786</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">20,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novo Holdings A/S</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Raymond&#160;Camahort</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">433,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR One Capital Fund I Aggregator, L.P.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Jill Carroll</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">649,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SR One Co-Invest II, LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Jill Carroll</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">433,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Takeda Ventures, Inc.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">86,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Lubner</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investors&#8217; Rights Agreement </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are party to an amended and restated investors&#8217; rights agreement with certain holders of our capital stock, including New Enterprise Associates 15, L.P., NEA Ventures 2016, L.P., Novo Holdings A/S, SR One Capital Fund I Aggregator, L.P., SR One Co-Invest II, LLC, Quan Venture Fund II, L.P., Takeda Ventures, Inc. and Aju Life Science 3.0 Venture Fund. Under our investors&#8217; rights agreement, certain holders of our capital stock have the right to demand that we file a registration statement or request that their shares of our capital stock be covered by a registration statement that we are otherwise filing. See the section titled &#8220;Description of Capital Stock&#8212;Registration Rights&#8221; for additional information regarding these registration rights. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification Agreements </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and bylaws. The indemnification agreements and our amended restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware law. See the section titled &#8220;Executive Compensation&#8212;Limitation of Liability and Indemnification&#8221; for additional information. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Participation in Our Initial Public Offering </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Entities affiliated with SR One Capital Fund I Aggregator, L.P., a holder of more than 5% of our common stock, purchased 1,666,667 shares of our common stock in our initial public offering at a price of $15 per share. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Entities affiliated with New Enterprise Associates 15, L.P., a holder of more than 5% of our common stock, purchased 1,583,333 shares of our common stock in our initial public offering at a price of $15 per share. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novo Holdings A/S., a holder of more than 5% of our common stock, purchased 833,333 shares of our common stock in our initial public offering at a price of $15 per share. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At our request, the underwriters of our initial public offering in February 2022 reserved up to 5% of the shares of common stock that were offered for sale, at the initial public offering price, to our officers, directors, employees, business associates and related persons. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">194 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transaction Policy </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit committee has the primary responsibility for reviewing and approving or disapproving &#8220;related party transactions,&#8221; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. The charter of our audit committee provides that our audit committee shall review and approve in advance any related party transaction. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted a formal written policy providing that we are not permitted to enter into any transaction that exceeds $120,000 and in which any related person has a direct or indirect material interest without the consent of our audit committee. In approving or rejecting any such transaction, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">195 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRINCIPAL STOCKHOLDERS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the beneficial ownership of our common stock as of May&#160;31, 2022 by: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of our named executive officers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of our directors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our current executive officers and directors as a group. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections&#160;13(d) and 13(g) of the Exchange Act. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have based our calculation of the percentage of beneficial ownership prior to this offering on 35,736,584 shares of our common stock outstanding as of May&#160;31, 2022. We have based our calculation of the percentage of beneficial ownership after this offering on 39,736,584 shares of our common stock outstanding immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60 days of May&#160;31, 2022, to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table does not reflect any potential purchases by our executive officers, directors, their affiliated entities or holders of more than 5% of our common stock in this offering. If any shares are purchased by these persons or entities, the number and percentage of shares of our common stock beneficially owned by them after this offering will differ from the amounts set forth in the following table. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">196 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o&#160;Arcellx, Inc., 25&#160;West Watkins Mill Road, Suite&#160;A, Gaithersburg, Maryland 20878. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares Beneficially<br/>Owned Prior to This<br/>Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares Beneficially<br/>Owned After This<br/>Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Beneficial Owner</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5% Stockholders</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Entities affiliated with New Enterprise Associates<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,437,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">18.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,437,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Entities affiliated with SR One Capital Fund I Aggregator, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,500,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,500,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novo Holdings A/S<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,016,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,016,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quan Venture Fund II, L.P.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,095,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,095,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Named Executive Officers and Directors</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour, M.B.A.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,989,992</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,989,992</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.77</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Hilbert, Ph.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">869,838</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">869,838</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Christopher Heery, M.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(7)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">317,796</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">317,796</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neeraj Teotia <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(8)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">316,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">316,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ali Behbahani, M.D., M.B.A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jill Carroll, M.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Lubner, M.S., C.P.A.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(9)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,484</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132,484</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derek Yoon, M.B.A</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kavita Patel, M.D.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(10)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">79,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">79,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Olivia Ware, M.B.A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All directors and executive officers as a group (9&#160;persons)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(11)</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,519,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.59</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,519,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i)&#160;6,432,762 shares of common stock held by New Enterprise Associates 15, L.P. (NEA 15) and (ii)&#160;5,002 shares of common stock held of record by NEA Ventures 2016, L.P. (Ven 2016). NEA Partners 15, L.P. (NEA Partners 15) is the sole general partner of NEA 15. NEA 15 GP, LLC (NEA 15 LLC) is the sole general partner of NEA Partners 15. Forest Baskett, Anthony&#160;A. Florence, Jr., Mohamad Makhzoumi, Scott D. Sandell and Peter Sonsini are the managers of NEA 15 LLC. The shares held directly by Ven 2016 are indirectly held by Karen P. Welsh, the general partner of Ven 2016. The address for these entities is 1954 Greenspring Drive, Suite&#160;600, Timonium, MD 21093. Dr.&#160;Behbahani is a General Partner at New Enterprise Associates, Inc. and a member of our board of directors, and has no voting or dispositive power with respect to any of the above referenced shares and disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interest therein. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary interest therein. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i) 3,466,811 shares of common stock held by SR One Capital Fund I Aggregator, L.P. (SR One Fund), and (ii) 2,033,196 shares of common stock held by SR One Co-Invest II, LLC (SR One Co-Invest). SR One Capital Partners I, LP (SR One Capital Partners) is the general partner of SR One Capital Fund. SR One Capital Management, LLC (SR One Management) is the general partner of SR One Capital Partners. Simeon George, M.D. is the manager of SR One Management. SR One Co-Invest II Manager, LLC (SR One Co-Invest Manager) is the managing member of SR One Co-Invest. SR One Management is the managing member of SR One Co-Invest Manager. Jill Carroll is a Partner at SR One Capital Management, LP, an entity affiliated with SR One Fund and SR One Co-Invest, and a member of our board of directors, and has no voting or dispositive power with respect to any of the above referenced shares and disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary interest therein. The address for these entities is 985 Old Eagle School Road, Suite 511, Wayne, PA 19087. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 4,016,878 shares of common stock held by Novo Holdings A/S (Novo). Novo has the sole power to vote and dispose these shares, and no person or entity is deemed to have any beneficial ownership or reportable pecuniary interest in the shares held by Novo. The address for Novo is Tuborg Havnevej 19, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DK-2900</div> Hellerup, Denmark. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 2,095,114 shares of common stock held by Quan Venture Fund II, L.P. (Quan Capital). The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The principal business address of Quan Capital is Ugland House, PO Box&#160;309, Grand Cayman, Cayman Islands <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KYI-1104.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 1,989,992 shares of common stock issuable pursuant to options held directly by Mr.&#160;Elghandour exercisable within 60 days of May&#160;31, 2022, of which 1,037,189 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedules as would have applied to such shares under the options. This does not include 1,163,437 restricted stock units to be settled for shares of common stock held directly by Mr.&#160;Elghandour. See the section title &#8220;Executive Compensation&#8212;Employment Arrangements with Our Named Executive Officers&#8212;Rami Elghandour&#8221; for vesting details of such restricted stock units. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i)&#160;206,298 shares of common stock held by Jan&#160;M. Casadei, as Trustee of the 2021 Gift Trust FBO Jan&#160;M. Casadei (ii)&#160;206,298 shares of common stock held directly by Dr.&#160;Hilbert, and (iii)&#160;457,242 shares of common stock issuable pursuant to options </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">197 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">held directly by Dr.&#160;Hilbert exercisable within 60 days of May&#160;31, 2022, of which 295,933 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 317,796 shares of common stock issuable pursuant to options held directly by Dr.&#160;Heery exercisable within 60&#160;days of May&#160;31, 2022, of which 116,734 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. This does not include 67,666 restricted stock units to be settled for shares of common stock held directly by Dr.&#160;Heery. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 316,561 shares of common stock issuable pursuant to options held directly by Mr. Teotia exercisable within 60 days of May&#160;31, 2022, of which 111,972 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. This does not include 64,566 restricted stock units to be settled for shares of common stock held directly by Mr.&#160;Teotia. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i)&#160;110,825 shares of common stock issuable pursuant to an option held directly by Mr.&#160;Lubner exercisable within 60 days of May&#160;31, 2022, of which 28,595 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedules as would have applied to such shares under the options and (ii)&#160;21,659 shares of common stock held directly by Mr.&#160;Lubner. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 79,031 shares of common stock issuable pursuant to options held directly by Dr. Patel exercisable within 60&#160;days of May&#160;31, 2022, of which 11,525 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 2,519,304 shares of common stock beneficially owned by our current directors and executive officers, of which (i)&#160;21,659 are shares of common stock, and (ii)&#160;2,497,645 are shares of common stock issuable pursuant to options exercisable within 60&#160;days of May&#160;31, 2022, of which approximately 1,601,951 are vested as of such date and the remainder of which may be exercised for shares of restricted stock with the same vesting schedules as would have applied to such shares under the options. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">198 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DESCRIPTION OF CAPITAL STOCK </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our amended and restated certificate of incorporation and amended and restated bylaws. Copies of these documents were filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our authorized capital stock consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 200,000,000 shares of preferred stock, par value $0.001 per share. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the completion of this offering and the issuance of 4,000,000 shares of common stock in this offering, there will be 39,736,584 shares of common stock outstanding based on the number of shares of common stock outstanding on March&#160;31, 2022. As of March&#160;31, 2022, we had approximately 72 stockholders of record. As of March&#160;31, 2022, there were 8,113,589 shares of common stock subject to outstanding options and 702,663 shares of common stock subject to restricted stock units, or RSUs. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Voting Rights </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidation </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rights and Preferences </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">199 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fully Paid and Nonassessable </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering, upon payment and delivery in accordance with the underwriting agreement, will be fully paid and nonassessable. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has the authority, without further action by the stockholders, to issue up to 200,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Options </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we had outstanding options to purchase an aggregate of 8,113,589 shares of our common stock, with a weighted-average exercise price of $8.83 per share, under our 2017 Plan and 2022 Plan. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Units </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we had outstanding awards of restricted stock units covering 702,663 shares of our common stock. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Rights </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under our amended and restated investors&#8217; rights agreement, the holders&#160;of up to 24,785,564 shares of common stock or their transferees, have the right to require us to register the offer and sale of their shares, or to include their shares in any registration statement we file, in each case as described below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Demand Registration Rights </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of up to 24,785,564 shares of our common stock are entitled to certain demand registration rights. At any time beginning after 180 days following the completion of our initial public offering, the holders of a majority of the shares having registration rights then outstanding can request that we file a registration statement to register the offer and sale of their shares. We are only obligated to effect up to two such registrations. Each such request for registration must cover securities the anticipated aggregate gross proceeds of which is at least $5&#160;million. These demand registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under certain circumstances. If we determine that it would be materially detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve-month period, for a period of up to 60 days. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">200 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> Registration Rights </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of up to 24,785,564 shares of our common stock are entitled to certain Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> registration rights. At any time when we are eligible to file a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> the holders of the shares having these rights then outstanding can request that we register the offer and sale of their shares of our common stock on a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> so long as the request covers securities the anticipated aggregate public offering price of which, net of selling expenses, is at least $1&#160;million. These stockholders may make an unlimited number of requests for registration on a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3.</div> However, we will not be required to effect a registration on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> if we have effected two such registrations within the twelve-month period preceding the date of the request. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-3</div> registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under certain circumstances. Additionally, if we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve-month period, for a period of up to 60 days. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Piggyback Registration Rights </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with this offering, the holders of up to 24,785,564 shares of our common stock were entitled to certain &#8220;piggyback&#8221; registration rights, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this offering. After this offering, if we propose to register the offer and sale of shares of our common stock under the Securities Act, all holders of these shares then outstanding can request that we include their shares in such registration, subject to certain marketing and other limitations, including the right of the underwriters to limit the number of shares included in any such registration statement under certain circumstances. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to (1)&#160;a registration related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule 145 promulgated under the Securities Act, (2)&#160;a registration relating to the offer and sale of debt securities, (3)&#160;a registration on any registration form that does not permit secondary sales or (4)&#160;a registration pursuant to the demand or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> registration rights described in the preceding two paragraphs above, the holders of these shares are entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses of Registration </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will pay all expenses relating to any demand registrations, Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> registrations and piggyback registrations, subject to specified limitations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration rights terminate upon the earliest of (1)&#160;the date that is five years after the completion of our initial public offering, (2)&#160;immediately prior to the completion of certain liquidation events and (3)&#160;as to a given holder of registration rights, the date after the completion of our initial public offering when such holder of registration rights can sell all of such holder&#8217;s registrable securities during any three-month period pursuant to Rule 144 promulgated under the Securities Act. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated Bylaws </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain provisions of Delaware law and certain provisions that are included in our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">201 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, 200,000,000 shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of the series, the voting rights (if any) of the shares of the series and the powers, preferences or relative, participation, optional and other special rights, if any, and any qualifications, limitations or restrictions, of the shares of such series. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Classified Board </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated Class&#160;I, Class&#160;II and Class&#160;III. Each class will be an equal number of directors, as nearly as possible, consisting of one third of the total number of directors constituting the entire board of directors. The term of initial Class&#160;I directors shall terminate on the date of the 2023 annual meeting, the term of the initial Class&#160;II directors shall terminate on the date of the 2024 annual meeting, and the term of the initial Class&#160;III directors shall terminate on the date of the 2025 annual meeting. At each annual meeting of stockholders beginning in 2023, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Removal of Directors </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Vacancies </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Cumulative Voting </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Special Meetings of Stockholders </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, except as otherwise required by law, special meetings of the stockholders may be called only by the chairperson of our board of directors, our Chief Executive Officer, our President, or our board of directors acting pursuant to a resolution adopted by a majority of our board of directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advance Notice Procedures for Director Nominations </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders or seeking to propose matters that can be acted upon by stockholders at annual stockholder meetings must provide timely notice thereof in writing. To be timely, a stockholder&#8217;s notice generally will have to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of the company, with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Action by Written Consent </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amending our Certificate of Incorporation and Bylaws </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our amended and restated certificate of incorporation may be amended or altered in any manner provided by the DGCL except that amendment of certain provisions would require the approval of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> majority of our then outstanding common stock. Our amended and restated bylaws may be adopted, amended, altered or repealed by stockholders only upon approval of a majority of the voting power of all the then outstanding shares of common stock, except that amendment of certain provisions would require the approval of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-thirds</div> majority of our then outstanding common stock. Additionally, our amended and restated certificate of incorporation provides that our bylaws may be amended, altered or repealed by the board of directors. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Authorized but Unissued Shares </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our authorized but unissued shares of common stock and preferred stock are available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the company by means of a proxy contest, tender offer, merger or otherwise. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exclusive Jurisdiction </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim arising pursuant to the DGCL, any action regarding our amended and restated certificate of incorporation or amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing increased consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. Please also see the section titled &#8220;Risk Factors&#8212;Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combinations with Interested Stockholders </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are governed by Section&#160;203 of the DGCL, which, subject to certain exceptions, prohibits a public Delaware corporation from engaging in a business combination (as defined in such section) with an &#8220;interested stockholder&#8221; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (i)&#160;prior to such time the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">203 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">becoming an interested stockholder; (ii)&#160;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (A)&#160;by persons who are directors and also officers of such corporation and (B)&#160;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii)&#160;at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#8217; and officers&#8217; insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Listing </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;ACLX&#8221;. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer Agent and Registrar </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is&#160;150 Royall Street, Canton, Massachusetts 02021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">204 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SHARES ELIGIBLE FOR FUTURE SALE </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options, or the perception that such sales may occur, could adversely affect the market price of our common stock and also could adversely affect our future ability to raise capital through the sale of our common stock or other equity-related securities of ours at times and prices we believe appropriate. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of this offering, based on our shares outstanding as of March&#160;31, 2022, 39,736,584 shares of our common stock will be outstanding, or 40,336,584 shares of common stock if the underwriters exercise their option to purchase additional shares in full. Of these shares, 26,249,084 were originally issued and sold by us prior to our initial public offering in transactions that were exempt from registration under the Securities Act and, as a result, are deemed &#8220;restricted securities&#8221; as that term is defined under Rule 144. Restricted securities may be sold in the public market only if their offer and sale is registered under the Securities Act or if the offer and sale of those securities qualify for an exemption from registration, including exemptions provided by Rules 144 and 701 under the Securities Act, which are summarized below. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements and market <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stand-off</div> provisions described below and the provisions of Rules 144 or 701 and assuming no exercise of the underwriters&#8217; option to purchase additional shares and no shares of our common stock will be sold in the offering to our affiliates, the shares of our common stock that will be deemed &#8220;restricted securities&#8221; will be available for sale in the public market following the completion of this offering as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no shares will be eligible for sale on the date of this prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26,143,959 shares will be eligible for sale upon expiration of the lock-up agreements and market stand-off provisions beginning more than 180 days after the date of the prospectus related to our initial public offering; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">21,659 shares will be eligible for sale upon expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements described below, beginning more than 90 days after the date of this prospectus. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreements and Market <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Stand-off</div> Agreements </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with our initial public offering, our officers, directors and the holders of substantially all of our capital stock and options entered into market <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stand-off</div> agreements with us and entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of the prospectus related to our initial public offering continuing through the date 180 days after the date of the prospectus related to our initial public offering, except with the prior consent of&#160;BofA Securities, Inc. and SVB Securities LLC. In addition, in connection with this offering, our executive officers and directors have entered into lock-up agreements with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible or exchangeable for shares of common stock during the period of the date of this prospectus continuing through the date 90 days after the date of this prospectus, except with the prior consent of BofA Securities, Inc. and SVB Securities LLC. See the section titled &#8220;Underwriting&#8221; for additional information. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;144 </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;144, as currently in effect, generally provides that, once we have been subject to the public company reporting requirements of Section&#160;13 or Section&#160;15(d) of the Exchange Act for at least 90 days, a stockholder who is not deemed to have been one of our affiliates at any time during the preceding three months and who has beneficially owned the shares of our capital stock proposed to be sold for at least six months is entitled to sell such shares in reliance upon Rule&#160;144 without complying with the volume limitation, manner of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">205 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sale or notice conditions of Rule&#160;144. If such stockholder has beneficially owned the shares of our capital stock proposed to be sold for at least one year, then such person is entitled to sell such shares in reliance upon Rule&#160;144 without complying with any of the conditions of Rule&#160;144. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;144 also provides that a stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days and who has beneficially owned the shares of our common stock proposed to be sold for at least six months is entitled to sell such shares in reliance upon Rule&#160;144 within any three-month period beginning 90 days after the date of the prospectus related to our initial public offering a number of shares that does not exceed the greater of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1% of the number of shares of our capital stock then outstanding, which will equal 397,366 shares immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of our capital stock made in reliance upon Rule&#160;144 by a stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days are also subject to the current public information, manner of sale and notice conditions of Rule&#160;144. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;701 </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Rule&#160;701 generally provides that, once we have been subject to the public company reporting requirements of Section&#160;13 or Section&#160;15(d) of the Exchange Act for at least 90 days, a stockholder who purchased shares of our common stock pursuant to a written compensatory benefit plan or contract and who is not deemed to have been one of our affiliates at any time during the preceding three months may sell such shares&#160;(to the extent such shares are not subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;lock-up&#160;agreement)</div> in reliance upon Rule&#160;144 without complying with the current public information or holding period conditions of Rule&#160;144. Rule&#160;701 also provides that a stockholder who purchased shares of our common stock pursuant to a written compensatory benefit plan or contract and who is deemed to have been one of our affiliates during the preceding 90 days may sell such shares under Rule&#160;144 without complying with the holding period condition of Rule&#160;144&#160;(subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;lock-up</div> agreement referred to above, if applicable). </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Rights </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of up to 24,785,564 shares of our common stock are entitled to certain rights with respect to the registration of such shares under the Securities Act. The registration of these shares of our common stock under the Securities Act would result in these shares becoming eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule&#160;144 limitations applicable to affiliates. See the section titled &#8220;Description of Capital Stock&#8212;Registration Rights&#8221; for a description of these registration rights. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Statement </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> under the Securities Act to register all of the shares of our common stock subject to equity awards outstanding or reserved for issuance under our equity compensation plans. The shares of our common stock covered by such registration statement are eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration statement, subject to vesting restrictions, the conditions of Rule&#160;144 applicable to affiliates, and any applicable market <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">stand-off</div> agreements and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements. See the section titled &#8220;Executive Compensation&#8212;Employee Benefit and Stock Plans&#8221; for a description of our equity compensation plans. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">206 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> HOLDERS OF OUR&#160;COMMON&#160;STOCK </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our common stock acquired in this offering by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-U.S.</div> holder&#8221; (as defined below), but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the U.S. Internal Revenue Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought, and do not intend to seek, any ruling from the Internal Revenue Service (IRS), with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This summary also does not address the tax considerations arising under the laws of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.,</div> state or local jurisdiction or under U.S. federal gift and estate tax laws. In addition, this discussion does not address tax considerations applicable to an investor&#8217;s particular circumstances or to investors that may be subject to special tax rules, including, without limitation: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Banks, insurance companies or other financial institutions (except to the extent specifically set forth below), regulated investment companies, real estate investment trusts or other financial institutions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons subject to the alternative minimum tax or the tax on net investment income; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tax-exempt</div> organizations or governmental organizations; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Pension plans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-qualified</div> retirement plans; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid U.S. federal income tax; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brokers or dealers in securities or currencies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Traders in securities or other persons that elect to use a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> method of accounting for their securities holdings; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set forth below); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. expatriates or certain former citizens or long-term residents of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons who hold our common stock as a position in a hedging transaction, &#8220;straddle,&#8221; &#8220;conversion transaction&#8221; or other risk reduction transaction or integrated investment; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons who hold or receive our common stock pursuant to the exercise of any option or otherwise as compensation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons who do not hold our common stock as a capital asset within the meaning of Section&#160;1221 of the Code (generally, property held for investment); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock being taken into account in an &#8220;applicable financial statement&#8221; as defined in Section&#160;451(b) of the Code; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons deemed to sell our common stock under the constructive sale provisions of the Code. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">207 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if a partnership, entity or arrangement classified as a partnership or flow-through entity for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership or other entity. A partner in a partnership or other such entity that will hold our common stock should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other such entity, as applicable. </div></div> <div style="text-indent: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal gift or estate tax rules or under the laws of any state, local, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> or other taxing jurisdiction or under any applicable tax treaty. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> Holder Defined </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For purposes of this discussion, you are a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-U.S.</div> holder&#8221; if you are a beneficial owner of our common stock that, for U.S. federal income tax purposes, is not a partnership and is not: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An individual who is a citizen or resident of the United States (for U.S. federal income tax purposes); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States or any political subdivision thereof, or otherwise treated as such for U.S. federal income tax purposes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An estate whose income is subject to U.S. federal income tax regardless of its source; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A trust (x)&#160;whose administration is subject to the primary supervision of a U.S. court and that has one or more U.S. persons who have the authority to control all substantial decisions of the trust or (y)&#160;that has made a valid election under applicable Treasury Regulations to be treated as a U.S. person. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributions </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in the section titled &#8220;Dividend Policy,&#8221; we have never declared or paid cash dividends on our common stock, and we do not anticipate paying any dividends on our common stock following the completion of this offering. However, if we do make distributions on our common stock, those payments will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, the excess will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale of stock. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subject to the discussions below on effectively connected income, Foreign Account Tax Compliance Act (FATCA), and backup withholding, any dividend paid to you generally will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. In order to receive a reduced treaty rate, you must provide us with an IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN-E</div></div> or other appropriate version of IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8,</div> including any required attachments and your taxpayer identification number, certifying qualification for the reduced rate. Under applicable Treasury Regulations, we may withhold up to 30% of the gross amount of the entire distribution even if the amount constituting a dividend, as described above, is less than the gross amount. If you are eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty, you may obtain a refund of any excess amounts withheld by filing an appropriate claim for refund with the IRS. If you hold our common stock through a financial institution or other agent acting on your behalf, you will be required to provide appropriate documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries. You should consult your tax advisors regarding your entitlement to benefits under an applicable tax treaty. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">208 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividends received by you that are treated as effectively connected with your conduct of a U.S. trade&#160;or&#160;business (and, if required by an applicable income tax treaty, such dividends are attributable to a&#160;permanent establishment or fixed base maintained by you in the United States) are generally exempt from&#160;the 30% U.S. federal withholding tax, subject to the discussions below on backup withholding and FATCA&#160;withholding. In order to obtain this exemption, you must provide us with a properly executed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IRS&#160;Form&#160;W-8ECI</div> or other applicable IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8</div> properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits, subject to an applicable income tax treaty providing otherwise. In addition, if you are a corporate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder, dividends you receive that are effectively connected with your conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. You should consult your tax advisor regarding the tax consequences of the ownership and disposition of our common stock, including any applicable tax treaties that may provide for different rules. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on Disposition of Common Stock </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the discussions below regarding backup withholding and FATCA withholding, you generally will not be required to pay U.S. federal income tax on any gain realized upon the sale or other disposition of our common stock unless: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The gain is effectively connected with your conduct of a U.S. trade or business (and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by you in the United States); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">You are a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> alien individual who is present in the United States for a period or periods aggregating 183 days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met; or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock constitutes a United States real property interest by reason of our status as a &#8220;United States real property holding corporation&#8221; (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our U.S. and worldwide real property interests plus our other business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, as long as our common stock is regularly traded on an established securities market, your common stock will be treated as U.S. real property interests only if you actually (directly or indirectly) or constructively hold more than five percent of such regularly traded common stock at any time during the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If you are a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder described in the first bullet above, you will be required to pay tax on the gain derived from the sale (net of certain deductions and credits) under regular graduated U.S. federal income tax rates, and a corporate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. If you are an individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder described in the second bullet above, you will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year, provided you have timely filed U.S. federal income tax returns with respect to such losses. You should consult your tax advisor regarding any applicable income tax or other treaties that may provide for different rules. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">209 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Backup Withholding and Information Reporting </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, we must report annually to the IRS the amount of dividends paid to you, your name and address and the amount of tax withheld, if any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Payments of dividends on or of proceeds from the disposition of our common stock made to you may be subject to information reporting and backup withholding at a current rate of 24% unless you establish an exemption, for example, by properly certifying your <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> status on a properly completed IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8BEN-E</div></div> or another appropriate version of IRS Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">W-8.</div> Notwithstanding the foregoing, backup withholding and information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that you are a U.S. person. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Account Tax Compliance Act (FATCA) </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subject to the following paragraph, provisions of the Code commonly referred to as FATCA, Treasury Regulations issued thereunder and official IRS guidance generally impose a U.S. federal withholding tax of 30% on dividends on, and the gross proceeds from a sale or other disposition of, our common stock paid to a &#8220;foreign financial institution&#8221; (as specially defined under these rules), unless otherwise provided by the Treasury Secretary or such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities certain information regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. Subject to the following paragraph, FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and the gross proceeds from a sale or other disposition of our common stock paid to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-financial</div> foreign entity&#8221; (as specially defined under these rules) unless otherwise provided by the Tresury Secretary or such entity provides the withholding agent with a certification identifying the substantial direct and indirect U.S. owners of the entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The withholding obligations under FATCA generally apply to dividends on our common stock. The withholding tax will apply regardless of whether the payment otherwise would be exempt from U.S. nonresident and backup withholding tax, including under the other exemptions described above. Under certain circumstances, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> holder might be eligible for refunds or credits of such taxes. The Treasury Secretary has issued proposed Treasury Regulations which, if finalized in their present form, would eliminate withholding under FATCA with respect to payment of gross proceeds from a sale or other disposition of our common stock. In the preamble to such proposed Treasury Regulations, the Treasury Secretary stated that taxpayers (including applicable withholding agents) may generally rely on the proposed regulations until final Treasury Regulations are issued. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this section. Prospective investors should consult with their own tax advisors regarding the application of FATCA withholding to their investment in, and ownership and disposition of, our common stock. </div> <div style="text-indent: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their particular circumstances. Each prospective investor should consult his, her or its own tax advisor regarding the particular U.S. federal, state and local and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed change in applicable laws. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">210 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNDERWRITING </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BofA Securities, Inc. and SVB Securities LLC, are acting as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Underwriter</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BofA Securities, Inc</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SVB Securities LLC</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#8217;s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commissions and Discounts </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Per&#160;Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Without&#160;Option</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">With&#160;Option</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public offering price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting discounts and commissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds, before expenses, to Arcellx</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The expenses of the offering, not including the underwriting discounts and commissions, are estimated at $650,000 and are payable by us. We have also agreed to reimburse the underwriters for certain of their expenses incurred in connection with, among others, the review and clearance by the Financial Industry Regulatory Authority, Inc., in an amount of up to $20,000. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">211 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Option to Purchase Additional Shares </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 600,000 additional shares at the public offering price, less the underwriting discounts and commissions. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#8217;s initial amount reflected in the above table. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Sales of Similar Securities </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with our initial public offering, we, our executive officers and directors and the holders of substantially all of our capital stock and options agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180&#160;days after the date of the prospectus for our initial public offering without first obtaining the written consent of BofA Securities, Inc. and SVB Securities LLC. In addition, in connection with this offering, we and our executive officers and directors have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 90 days after the date of this prospectus without first obtaining the written consent of BofA Securities, Inc. and SVB Securities LLC. In each case, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">offer, pledge, sell or contract to sell any common stock, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sell any option or contract to purchase any common stock, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">purchase any option or contract to sell any common stock, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">grant any option, right or warrant for the sale of any common stock, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lend or otherwise dispose of or transfer any common stock, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">request or demand that we file or make a confidential submission of a registration statement related to the common stock, or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 8%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provisions apply to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock. They also apply to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasdaq Global Select Market Listing </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our common stock is listed on the Nasdaq Global Select Market, subject to notice of issuance, under the symbol &#8220;ACLX.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Price Stabilization, Short Positions and Penalty Bids </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">212 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering. &#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. &#8220;Naked&#8221; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discounts and commissions received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Similar to other purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on the Nasdaq Global Select Market, in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> market or otherwise. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Electronic Distribution </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">e-mail.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Relationships </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">213 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">European Economic Area </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In relation to each Member State of the European Economic Area (each a Relevant State), no shares have been offered or will be offered pursuant to the global offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the global coordinator for any such offer; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provided that no such offer of shares shall require the issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each person in a Relevant State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the Issuer and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-discretionary</div> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuer, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The above selling restriction is in addition to any other selling restrictions set out below. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the offering, BofA Securities, Inc. is not acting for anyone other than the issuer and will not be responsible to anyone other than the issuer for providing the protections afforded to their clients nor for providing advice in relation to the offering. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in the United Kingdom </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In relation to the United Kingdom (UK), no shares have been offered or will be offered pursuant to the global offering to the public in the UK prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">214 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and the FSMA, except that offers of shares may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent of the global coordinator for any such offer; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">c.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time in other circumstances falling within section 86 of the FSMA, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provided that no such offer of shares shall require the issuer or any underwriter to publish a prospectus pursuant to Section&#160;85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each person in the UK who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with the issuer and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-discretionary</div> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuer, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any Shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase or subscribe for any Shares, the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, and the expression &#8220;FSMA&#8221; means the Financial Services and Markets Act 2000. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the offering, BofA Securities, Inc. is not acting for anyone other than the issuer and will not be responsible to anyone other than the issuer for providing the protections afforded to their clients nor for providing advice in relation to the offering. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This document is for distribution only to persons who (i)&#160;have professional experience in matters relating to investments and who qualify as investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the Financial Promotion Order), (ii) are persons falling within Article 49(2)(a) to (d) (&#8220;high net worth companies, unincorporated associations etc.&#8221;) of the Financial Promotion Order, (iii)&#160;are outside the United Kingdom, or (iv)&#160;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the Financial Services and Markets Act 2000, as amended (FSMA)) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#8220;relevant persons&#8221;). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">215 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in Switzerland </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither this document nor any other offering or marketing material relating to the offering, the issuer , the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in the Dubai International Financial Centre </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (DFSA). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in Australia </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (ASIC), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any offer in Australia of the shares may only be made to persons (the Exempt Investors) who are &#8220;sophisticated investors&#8221; (within the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-sale</div> restrictions. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">216 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in Hong Kong </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in Japan </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&#160;25 of 1948, as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-offering</div> or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#8220;Japanese Person&#8221; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in Singapore </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i)&#160;to an institutional investor (as defined in Section&#160;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the SFA)) pursuant to Section&#160;274 of the SFA, (ii)&#160;to a relevant person (as defined in Section&#160;275(2) of the SFA) pursuant to Section&#160;275(1) of the SFA, or any person pursuant to Section&#160;275(1A) of the SFA, and in accordance with the conditions specified in Section&#160;275 of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where the shares are subscribed or purchased under Section&#160;275 of the SFA by a relevant person which is: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">217 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">securities or securities-based derivatives contracts (each term as defined in Section&#160;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&#160;275 of the SFA except: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">where no consideration is or will be given for the transfer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">where the transfer is by operation of law; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as specified in Section&#160;276(7) of the SFA. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notice to Prospective Investors in Canada </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-106</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prospectus Exemptions</div></div> or subsection 73.3(1) of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Securities Act</div></div> (Ontario), and are permitted clients, as defined in National Instrument <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">31-103</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</div></div>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Canadian</div> jurisdiction, section 3A.4) of National Instrument <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33-105</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Conflicts</div></div> (<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NI 33105</div></div>), the underwriters<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>are not required to comply with the disclosure requirements of NI <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33-105</div> regarding underwriter conflicts of interest in connection with this offering. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">218 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL MATTERS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Wilson Sonsini Goodrich&#160;&amp; Rosati, Professional Corporation, New York, New York. Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York is acting as counsel for the underwriters. Certain members of, and investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich&#160;&amp; Rosati, Professional Corporation, own an interest representing less than one percent of the shares of our common stock. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">219 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXPERTS </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ernst&#160;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements as of December&#160;31, 2020 and 2021, and for the years then ended, as set forth in their report. We have included our consolidated financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst&#160;&amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">220 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc129231_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WHERE YOU CAN FIND ADDITIONAL INFORMATION </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have filed with the SEC a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> under the Securities Act with respect to the shares of our common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements and other information about us, are available at the SEC&#8217;s website, www.sec.gov. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, will file periodic reports, proxy statements and other information with the SEC. We also maintain a website at www.arcellx.com where these materials are available. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">221 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div id="toc129231_25" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Consolidated Financial Statements</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_1">Report of Independent Registered Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_2">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_3">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit for the Years Ended December&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_5">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_6">Notes to the Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Condensed Consolidated Financial Statements</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_7">Condensed Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-30</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_8">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021 (unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_9">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit for the three months ended March 31, 2022 and 2021 (unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-32</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_10">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-34</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin332508_11">Notes to Condensed Consolidated Financial Statements (unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-35</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin332508_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and the Board of Directors of Arcellx, Inc. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Arcellx, Inc. (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders&#8217; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tysons, Virginia </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;24, 2022 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,357</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseOtherNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseOtherNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,477</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; deficit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent, current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRentCreditCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRentCreditCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent, net of current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A redeemable convertible preferred stock, par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,795,227</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020; liquidation value $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,795</ix:nonFraction></ix:nonFraction> at December&#160;31, 2021 and 2020.</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B redeemable convertible preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">49,402,623</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020; liquidation value of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,681</ix:nonFraction></ix:nonFraction> at December&#160;31, 2021 and 2020.</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C redeemable convertible preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">57,224,618</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> authorized at December&#160;31, 2021 and 2020, respectively; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively; liquidation value of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">120,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> at December&#160;31, 2021 and 2020, respectively.</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">233,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; deficit:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">185,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">98,973,453</ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">333,658</ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2021 and 2020, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">130,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">121,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">63,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, redeemable convertible preferred stock, and stockholders&#8217; deficit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,018</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,018</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive loss:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share attributable to common stockholders&#8212;basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">145.55</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">112.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average common shares outstanding&#8212;basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">446,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">286,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align: bottom;"></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable&#160;Convertible&#160;Preferred&#160;Stock</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series&#160;C</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,986,153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">255,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,047</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series B redeemable convertible preferred stock for cash, net of transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,989,432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock from vesting of restricted stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">30,433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">333,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">63,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series C redeemable convertible preferred stock for cash, net of transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock from vesting of restricted stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">200,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on investment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 7.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">130,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">121,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of premiums and discounts on marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on disposal of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Prepaid expenses and other current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,059</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79,976</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments under capital leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:CapitalLeasePrincipalPayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from the exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">688</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,185</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment for repurchase of restricted stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:PaymentsForRepurchaseOfRestrictedStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Series B redeemable convertible preferred stock, net of transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,801</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,451</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (decrease) increase in cash, cash equivalents and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, beginning of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash, end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures of noncash investing and financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment included in accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs included in accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredOfferingCostsIncludedInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredOfferingCostsIncludedInAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49526057"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of the Business </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;8, 2022, the Company closed its initial public offering (IPO) of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,487,500</ix:nonFraction> shares of its common stock, including the exercise in full by the underwriters&#8217; of their option to purchase <ix:nonFraction name="aclx:AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,237,500</ix:nonFraction> additional shares of its common stock, at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">128.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $<ix:nonFraction name="aclx:CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.3</ix:nonFraction>&#160;million. The Company&#8217;s common stock began trading on the Nasdaq Global Select Market on February&#160;4, 2022, under the ticker symbol &#8220;ACLX.&#8221; </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the IPO in February 2022, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P02_08_2022To02_08_2022">1-for-5.5041</ix:nonNumeric></div></div> reverse stock split of the Company&#8217;s redeemable convertible preferred stock and common stock. The reverse stock split became effective on January&#160;28, 2022. All share and per share amounts in the consolidated financial statements and notes thereto have been retrospectively adjusted for all periods presented to reflect the reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices were proportionately increased in accordance with the terms of the appropriate securities agreements. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to incur substantial operating losses to continue development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has funded its operations primarily with proceeds from public and private offerings of its common stock and prior to the IPO, private placements of its preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49526057"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company continues to closely monitor the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on all aspects of its business, including how it has and will continue to impact operations and the operations of its suppliers, vendors, and business partners, and may take further precautionary and preemptive actions as may be required by federal, state, or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of its employees, the Company has introduced enhanced safety measures in its facilities. Although to date, the Company&#8217;s business has not been materially impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> it is possible that its clinical development timelines could be negatively affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which could materially and adversely affect its business, financial condition, and results of operations. </div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525320"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and Consolidation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). The accompanying consolidated financial statements include the accounts of Arcellx and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Accounting Estimates </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates used in preparing the accompanying consolidated financial statements include, but are not limited to, estimates related to the fair value of assets, research and development accruals, recoverability of long-lived assets, share-based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents and Restricted Cash </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking and sweep accounts with commercial banks and financial institutions. Cash equivalents consist of money market funds. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of its lease agreement equal to the required security deposit amount. This amount is presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash on the accompanying balance sheets. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525320" continuedAt="TextSelectionAppend_49525320_1"><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company carries marketable securities classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at fair value as determined by prices for identical or similar securities at the balance sheet date. The inputs used to determine the fair value of marketable securities are considered Level&#160;2 within the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as accumulated other comprehensive loss in stockholders&#8217; deficit. Realized gains or losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, net. Marketable securities are classified as either current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets based on their contractual maturity dates. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At each reporting date, or more frequently if circumstances warrant, the Company evaluates individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities for impairment. In the event that the carrying value of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt security exceeds its fair value and the decline in fair value is determined to be other-than-temporary, the Company records an impairment charge in earnings attributable to the estimated credit loss. In determining whether a decline in the value of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt security is other-than-temporary, the Company evaluates various factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, the duration and extent to which fair value has been less than carrying value, the Company&#8217;s assessment as to whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, and the severity of the impairment. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525534"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts payable, and accrued expenses. The carrying amounts of accounts payable and accrued expenses generally approximate their respective fair value due to their short-term nature. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for recurring and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fair value measurements in accordance with ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#8212;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#8212;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525320_1" continuedAt="TextSelectionAppend_49525320_2"><ix:continuation id="TextSelection_49525534"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, and marketable securities. The Company maintains its cash and cash equivalents and restricted cash at two accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in highly rated debt securities consisting entirely of corporate bonds, which the Company has the ability to liquidate within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-day</div> should the need for additional cash arise. Accordingly, the Company believes the exposure to credit risk on its marketable securities portfolio is low. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost and depreciated over its estimated useful life using the straight-line method. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses. Routine expenditures for maintenance and repairs are expensed as incurred. </div></div><ix:nonNumeric name="aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated useful lives for property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful&#160;Life</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">3 years</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">7 years</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durwordsen">7 years</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment under capital lease</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2021To12_31_2021_EquipmentUnderCapitalLeaseMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</ix:nonNumeric></td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset group is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairment losses recognized during the years ended December&#160;31, 2021 or 2020. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525320_2" continuedAt="TextSelectionAppend_49525320_3"><ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company deferred certain legal, professional accounting and other third-party fees that were directly associated with the Company&#8217;s February 2022 IPO as deferred offering costs. Upon consummation of the IPO, these costs have been reclassified to shareholders&#8217; deficit as a reduction of the offering proceeds. </div></div></ix:nonNumeric> <ix:nonNumeric name="aclx:ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trial Accrual and Expenses </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company makes payments in connection with clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies, and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, the Company accrues expenses related to the work performed by contract manufacturing organizations based on the progress of the work performed. If the amounts the Company is obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical manufacturing, technical development, and overhead and facility-related costs. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed, or at such time when the Company does not expect the goods to be delivered or services to be performed. </div></div></ix:nonNumeric> <ix:nonNumeric name="aclx:RedeemableConvertiblePreferredStockPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s redeemable convertible preferred stock is classified outside of stockholders&#8217; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to not accrete the carrying value and related issuance costs of the redeemable convertible preferred stock to its redemption value until such redemption becomes probable. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-11 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525320_3" continuedAt="TextSelectionAppend_49525320_4"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525543"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for its share-based compensation in accordance with ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (ASC 718). ASC 718 requires all share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards, or restricted stock units, to be recognized as expense based on their grant date fair values. The Company has elected to account for forfeitures as they occur. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates the fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The Company will reconsider the use of the Black-Scholes option pricing model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. A discussion of management&#8217;s methodology for developing the assumptions used in the valuation model follow: </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock</div></div>&#8212;Given the lack of an active public market for the common stock (prior to the Company&#8217;s IPO), the fair value of the Company&#8217;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the significant risks associated with the Company&#8217;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#8217;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#8217;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. Following the closing of February 2022 IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of the Company&#8217;s common stock on the date of grant. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield</div></div>&#8212;The expected dividend yield is based on the Company&#8217;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for the Company&#8217;s common stock (prior to the Company&#8217;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-12 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525320_4" continuedAt="TextSelectionAppend_49525320_5"><ix:continuation id="TextSelection_49525543"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate</div></div>&#8212;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term</div></div>&#8212;The Company uses the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s share-based compensation related to stock options subject to service conditions are recognized as expense ratably over the required service period based on their grant date fair values. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Awards, Unrestricted Stock Awards, and Restricted Stock Units </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or without cause from their position. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates the fair value of awards subject to both a market condition and a performance condition on the grant date using a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method beginning when the achievement of the performance condition becomes probable over the applicable service period. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company granted restricted stock units (RSUs) to an executive officer subject to service, performance, and market conditions. The Company used the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model approach to estimate the fair value of the RSUs on the date of grant. Refer to Note 13 for further discussion regarding the terms of awards granted during the year ended December&#160;31, 2021. </div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525546"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">jurisdiction-by-jurisdiction</div></div> basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-13 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525320_6"><ix:continuation id="TextSelection_49525546"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes. As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> interest or penalties related to uncertain income tax benefits.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></ix:continuation><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities. </div></ix:nonNumeric> <ix:nonNumeric name="aclx:EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div></ix:nonNumeric> <ix:nonNumeric name="aclx:SegmentAndGeographicInformationPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment and Geographic Information </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. </div></div></ix:nonNumeric> <ix:nonNumeric name="aclx:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525554"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842)</div></div>, which requires lessees to recognize a lease liability and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset for each lease with a term longer than twelve months. The recognized liability is measured at the present value of lease payments not yet paid, and the corresponding asset represents the lessee&#8217;s right to use the underlying asset over the lease term and is based on the liability, subject to certain adjustments. For purposes of statements of operations and cash flows, the standard retains the dual model with leases classified as either operating or finance. The Company adopted the new standard effective January&#160;1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. The Company also elected the practical expedient not to separate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components of a contract from the lease component to which they relate. Prior periods were not retrospectively adjusted. The adoption of the new lease standard is expected to result in the recognition of lease liabilities of approximately $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn01_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.4</ix:nonFraction>&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets of approximately $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn01_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction>&#160;million, which include the impact of existing deferred rents and tenant improvement allowances on the consolidated balance sheet as of January&#160;1, 2022. There will be no cumulative effect adjustment to the opening balance of retained earnings as of January&#160;1, 2022. Adoption of Topic 842 is not expected to have an impact on the consolidated statements of operations or cash flows. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-14 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525320_5" continuedAt="TextSelectionAppend_49525320_6"><ix:continuation id="TextSelection_49525554"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div> (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The standard update is effective for fiscal years beginning after December&#160;15, 2021. The adoption of this standard as of January&#160;1, 2022 did not have any impact on the Company&#8217;s consolidated financial statements and related disclosures.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></ix:continuation><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13)</div></div></div>, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for interim and annual periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#8217;s investment portfolio, current market conditions, and historical credit loss activity, the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. The Company will continue monitoring through the effective date of the standard. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated all other ASUs issued through the date the consolidated financial statements were issued and believes that the adoption of these will not have a material impact on the Company&#8217;s consolidated financial statements. </div></div></ix:nonNumeric> </ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Restricted Cash </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction>&#160;million as of both December&#160;31, 2021 and 2020. This amount is presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash on the accompanying consolidated balance sheets. </div><ix:nonNumeric name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-15 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Fair Value of Financial Instruments </div></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:LongTermRestrictedCashFairValue" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:LongTermRestrictedCashFairValue" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the years ended December&#160;31, 2021 or 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="aclx:MarketableSecuritiesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Marketable Securities </div></div></div><ix:nonNumeric name="us-gaap:MarketableSecuritiesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div></div> marketable securities, which consisted entirely of corporate bonds, were as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross unrealized gains</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross unrealized loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities held as of December&#160;31, 2021 had contractual maturities of <ix:nonNumeric name="aclx:DebtSecuritiesAvailableForSaleContractualMaturities" contextRef="P01_01_2021To12_31_2021">less than one year</ix:nonNumeric>. The Company had <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2021" unitRef="Unit_condition" decimals="0" scale="0" format="ixt:num-dot-decimal">11</ix:nonFraction> securities in an unrealized loss position with an aggregate related fair value of $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.8</ix:nonFraction>&#160;million as of December&#160;31, 2021. All securities in an unrealized loss position as of December&#160;31, 2021 had been in a loss position for less than twelve months. Unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities as of December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> allowance for credit losses related to the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities was recorded for the year ended December&#160;31, 2021. The Company does not intend to sell these securities and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $<ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million, offset by amortization of premium of $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million, for the year ended December&#160;31, 2021, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-16 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Prepaid Expenses and Other Current Assets </div></div></div><ix:nonNumeric name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:PrepaidResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:PrepaidResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,551</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expense and current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:OtherPrepaidExpenseAndCurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:OtherPrepaidExpenseAndCurrentAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Property and Equipment, Net </div></div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment under capital leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense was $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525318"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Capital Lease Obligations </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company signed a capital lease agreement for equipment in December 2020. The lease term is for <ix:nonNumeric name="aclx:CapitalLeaseAgreementMaturityPeriod" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durwordsen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">thirty-six</div> months</ix:nonNumeric> with an option to purchase the equipment for $<ix:nonFraction name="us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1 </ix:nonFraction>at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in June 2021. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company signed a capital lease agreement for equipment in March 2021. The lease term is for <ix:nonNumeric name="aclx:CapitalLeaseAgreementMaturityPeriod" contextRef="P03_31_2021To03_31_2021" format="ixt-sec:durwordsen">seventeen months</ix:nonNumeric> and ownership of the asset will be transferred to the Company at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in March 2021. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-17 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525318"><ix:nonNumeric name="aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the remaining future lease obligations under these capital lease agreements are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeasesFutureMinimumPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Amount representing interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of net minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The capital lease obligation balance was $<ix:nonFraction name="us-gaap:CapitalLeaseObligations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million as of December&#160;31, 2021, of which $<ix:nonFraction name="us-gaap:CapitalLeaseObligations" contextRef="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million was included in other current liabilities and $<ix:nonFraction name="us-gaap:CapitalLeaseObligations" contextRef="PAsOn12_31_2021_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million was included in other long-term liabilities. The implied interest rate used to reduce the minimum lease payments to present value was <ix:nonFraction name="aclx:ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.0</ix:nonFraction>%. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made payments with respect to capital lease obligations of $<ix:nonFraction name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">0</ix:nonFraction> for the years ended December 2021 and 2020, respectively. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense in connection with the Company&#8217;s capital leases were immaterial for the years ended December 2021 and 2020. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Accrued Liabilities </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:ResearchAndDevelopmentAccruedExpensesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:ResearchAndDevelopmentAccruedExpensesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:AccruedOfferingCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:AccruedOfferingCostsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued vacation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:OtherAccruedLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:OtherAccruedLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525653"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Commitments and Contingencies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in <ix:nonNumeric name="aclx:LeaseExpirationYear" contextRef="P01_01_2021To12_31_2021_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">2030</ix:nonNumeric> unless renewed. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The lease agreements contain rent escalation, rent abatement clauses, and tenant improvement allowances. Rent expense is recognized on a straight-line basis over the lease term. The deferred rent balance was $<ix:nonFraction name="aclx:OperatingLeasesDeferredRent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="aclx:OperatingLeasesDeferredRent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million as of December&#160;31, 2021 and 2020, respectively. Rent expense for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-18 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525653"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2021 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing Services Agreement with Lonza Houston, Inc. </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Manufacturing Services Agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW), effective as of February&#160;16, 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW commences from February&#160;1, 2022 and expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. Under the Lonza SOW, the Company is obligated to pay to Lonza certain payments aggregating a total of approximately $<ix:nonFraction name="us-gaap:OtherCommitment" contextRef="PAsOn12_31_2021_LonzaSowMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.5</ix:nonFraction>&#160;million in 2022, including creditable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments, creditable milestone fees that are subject to certain deductions and fixed monthly payments and which are payable over the term of the Lonza SOW. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2021 and 2020, the Company was not involved in any material legal proceedings. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification Agreements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As permitted under Delaware law, the Company indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is, or was, serving at our request in such capacity. The term of this indemnification is for the officer&#8217;s or director&#8217;s lifetime. Additionally, the Company has entered into and expects to continue to enter into indemnification agreements with certain executive officers and directors. Further, in the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date however, the Company has not incurred any material costs as a result of such indemnifications nor experienced any losses related to them. As of December&#160;31, 2021, the Company was not aware of any claims under indemnification arrangements and does not expect significant claims related to these indemnification obligations. Therefore, no related reserves were established. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-19 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="aclx:DiscloureOfRedeemableConvertiblePreferredStockTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525940"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Redeemable Convertible Preferred Stock </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Company&#8217;s IPO on February&#160;4, 2022, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company&#8217;s outstanding shares of preferred stock were converted into <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,785,564</ix:nonFraction> shares of common stock. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,795,227</ix:nonFraction></ix:nonFraction> authorized shares of $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> par value Series A redeemable convertible preferred stock (Series A preferred stock), of which <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of both December&#160;31, 2021 and 2020. The Series A preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#8217;s control. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">49,402,623</ix:nonFraction></ix:nonFraction> authorized shares of $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> par value Series B redeemable convertible preferred stock (Series B preferred stock), of which <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of both December&#160;31, 2021 and 2020 from the issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> redeemable convertible preferred stock discussed below. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">27,444,339</ix:nonFraction></ix:nonFraction> authorized shares of $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> par value Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> redeemable convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock), of which <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,986,153</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of both December&#160;31, 2021 and 2020. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had authorized <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">21,958,284</ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> par value Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> redeemable convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock and with the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock, the Series B preferred stock). The Company concluded that the investors&#8217; rights to purchase Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock upon achieving certain clinical activities (i.e., clinically significant and meaningful biological activity with manageable toxicities from a phase 1 clinical trial, approval by the board of an acceptable clinical development plan, IND filling by a specified date and completion of other key analysis) (the Milestone closing) did not meet the definition of a freestanding financial instrument, as they were legally attached and assigned together with the issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, after weighing the substantive and implied terms and features of the Series B preferred stock instrument, the Company concluded that the conversion option was clearly and closely related to the preferred stock host contract and therefore would not need to be bifurcated. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2020, the Company issued the second tranche of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock in exchange for $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2021To12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.8</ix:nonFraction>&#160;million in cash. The Company incurred less than $<ix:nonFraction name="aclx:TransactionCosts" contextRef="P01_01_2021To12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million in transaction costs related to this issuance. As of both December&#160;31, 2021 and 2020, <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2020_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,989,432</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock were issued and outstanding. The Series B preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#8217;s control. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company authorized <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">57,224,618</ix:nonFraction> shares of $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction> par value Series C redeemable convertible preferred stock (the Series C preferred stock) and issued <ix:nonFraction name="aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction> shares in exchange for $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">120.0</ix:nonFraction>&#160;million in cash. The Company incurred $<ix:nonFraction name="aclx:TransactionCosts" contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million in transaction costs related to this issuance. The Series C preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#8217;s control. The Company&#8217;s Series A preferred stock, Series B preferred stock, and Series C preferred stock (collectively, the preferred stock) had the following rights and preferences, privileges, and restrictions. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525940" continuedAt="TextSelectionAppend_49525940_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of preferred stock were entitled to receive annual noncumulative dividends at an annual rate of <ix:nonFraction name="aclx:TemporaryEquitySharesDividendRate" contextRef="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">8</ix:nonFraction>% in preference to any declaration or payment of any dividend on the common stock, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis when, as and if declared by the board of directors. As of both December&#160;31, 2021 and 2020, <ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> dividends had been declared. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each share of preferred stock represented such number of votes as is equal to the number of shares of common stock into which such share is convertible. The holders of preferred stock were able to vote together with the holders of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis on all matters in which stockholders were entitled to vote. The holders of Series A preferred stock, exclusively and as a separate class, were entitled to elect <ix:nonFraction name="aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." contextRef="P01_01_2021To12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_DIRECTORS" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> directors, the holders of the Series B preferred stock, exclusively and as a separate class, were entitled to elect<ix:nonFraction name="aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." contextRef="P01_01_2021To12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_DIRECTORS" decimals="0" scale="0" format="ixt-sec:numwordsen"> two</ix:nonFraction> directors, and the holders of Series C preferred stock, exclusively and as a separate class, were entitled to elect <ix:nonFraction name="aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_DIRECTORS" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> director of the Company as of December&#160;31, 2021. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Rights </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each share of preferred stock was convertible into shares of common stock determined by dividing the original issuance price by the conversion price. The conversion price was equal to the original issuance price, which were $<ix:nonFraction name="aclx:TemporaryEquitySharesConversionPrice" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.51</ix:nonFraction> for Series A preferred stock, $<ix:nonFraction name="aclx:TemporaryEquitySharesConversionPrice" contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.60</ix:nonFraction> for Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock, $<ix:nonFraction name="aclx:TemporaryEquitySharesConversionPrice" contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.74</ix:nonFraction> for Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock, and $<ix:nonFraction name="aclx:TemporaryEquitySharesConversionPrice" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.55</ix:nonFraction> for Series C preferred stock. Conversion could occur at any time at the option of each holder. All series of preferred stock converted into shares of common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> basis as part of the Company&#8217;s IPO in February 2022. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Series C preferred stock were entitled to receive, before any payment of any of the assets of the Company to the holders of the Series B preferred stock, the holders of the Series A preferred stock, or the holders of common stock, $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.55</ix:nonFraction> per share (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of Series A preferred stock or the holders of common stock, the holders of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock were entitled to receive, before any payment of any of the assets of the Company to the holders of the Series A preferred stock or the holders of common stock, $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.60</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.74</ix:nonFraction> per share, respectively (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of common stock, the holders of Series A preferred stock were entitled to receive $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.51</ix:nonFraction> per share with respect to shares of Series A preferred stock. The Company did not adjust the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of preferred stock and these circumstances were not probable as the balance sheet dates. Subsequent adjustments to the carrying values of the liquidation preferences were to be made only when it became probable that such a liquidation event will occur. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption Rights </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preferred stock was contingently redeemable upon certain change in control events that are outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-21 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525940_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-dilution Protection </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of the preferred stock had proportional anti-dilution protection for splits, dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by the Company for consideration per unit less than the applicable conversion price per unit of any series of preferred stock, were to be on a broad-based weighted average basis. </div></div></ix:continuation><ix:nonNumeric name="aclx:CommonStockTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Common Stock </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the board of directors approved an amendment to the Amended and Restated Certificate of Incorporation of the Company, which increased the number of authorized shares of common stock. The Company had <div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">185,000,000</ix:nonFraction></div> and <div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">98,973,453</ix:nonFraction></div> authorized shares of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction> par value common stock as of December&#160;31, 2021 and 2020, respectively, of which <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">333,658</ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of December&#160;31, 2021 and 2020, respectively. The shares issued and outstanding represent shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s employees satisfied the exercise price of the options exercised by making cash payments to the Company. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. <ix:nonNumeric name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525744">Below is a reconciliation of shares issued and outstanding:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><ix:continuation id="TextSelection_49525744"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding <br/>(including shares early exercised)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesLegallyIssuedAndOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">544,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesLegallyIssuedAndOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">375,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: (unvested early exercised shares of common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:UnvestedEarlyExercisedSharesOfCommonStock" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:UnvestedEarlyExercisedSharesOfCommonStock" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">41,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesIssuedAndOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesIssuedAndOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">333,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of common stock entitles the holder to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2021To12_31_2021">one vote</ix:nonNumeric> on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. <ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> dividends have been declared or paid by the Company through December&#160;31, 2021. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;4, 2022, the Company issued and sold an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">590,318</ix:nonFraction> shares of common stock in a private placement at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">16.94</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49526046"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Share-Based Compensation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s 2017 Equity Incentive Plan (the 2017 Plan) provides for the grant of Stock Options, Stock Appreciation Rights, Restricted Stocks, or Restricted Stock Units. The aggregate number of shares of common stock available for issuance pursuant to awards under the 2017 Plan, amended, is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="P01_01_2021To12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,927,329</ix:nonFraction> shares. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49526046" continuedAt="TextSelectionAppend_49526046_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted under the 2017 Plan generally vest over <span style="-sec-ix-hidden:hidden49526058">three</span> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and expire after <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">10 years</ix:nonNumeric>. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price for stock options granted is the fair value of common shares as determined by the board of directors as of the date of grant. The board of directors determined the value the Company&#8217;s common stock considering many factors, including third-party valuation of the Company&#8217;s common shares, as well as additional factors, which may have changed since the date of the most recent contemporaneous valuation through the date of grant. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity for awards under the 2017 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding and Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div><br/>(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,952,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.6</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,145,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">288,557</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">210,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,598,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.9</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,696,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31, 2021. </div></div></td></tr></table></ix:nonNumeric> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.77</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.19</ix:nonFraction>, respectively. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate grant date fair value of stock options vested during the years ended December&#160;31, 2021 and 2020 was approximately $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction>&#160;million, respectively. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction>&#160;million during the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.6</ix:nonFraction>&#160;million of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2017 Plan. This remaining compensation expense is expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">2.8</ix:nonNumeric> years as of December&#160;31, 2021. The intrinsic value of the options exercised for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million, respectively. Share-based compensation cost is measured at fair value and is recognized as expense on a straight-line basis over the requisite service period. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-23 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49526046_1" continuedAt="TextSelectionAppend_49526046_2"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,930</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">551</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">6.3</ix:nonNumeric>&#8212;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">7</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">7</ix:nonNumeric>&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">90</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">110</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">95</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.83</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.52</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.42</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.42</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Given the lack of an active public market for the common stock during 2021 and 2020, the fair value of the Company&#8217;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports, described further within the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units</div></div> section below. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company granted 952,804 restricted stock units (RSU) to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions. All 952,804 RSUs were outstanding as of December&#160;31, 2021 and no RSUs were vested or exercisable as of December&#160;31, 2021. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Condition </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The service condition to vesting of the RSU Award requires the executive officer&#8217;s continued employment with the Company through the achievement of any of the performance conditions and the market condition. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Condition </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance conditions to vesting of the RSU Award include (i)&#160;the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii)&#160;a Change in Control following an IPO. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49526046_2" continuedAt="TextSelectionAppend_49526046_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market Condition </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the <ix:nonFraction name="aclx:NumberOfPerformanceConditionScenarios" contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_condition" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> performance condition scenarios is applicable at the time of measurement. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company value on a Change in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2021To12_31_2021_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon a Change in Control, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.</ix:nonNumeric> </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company value in the event of an IPO is measured each June&#160;30 and December&#160;31 following an IPO (subject to applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period) and represents the Company&#8217;s Enterprise Value. The Company&#8217;s Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> period ending on the day prior to the applicable IPO measurement date, less cash. <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon an IPO, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.</ix:nonNumeric> </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilized <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. In applying the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> methodology, Change in Control Market Capitalization and Enterprise Value were simulated and allocated to the various classes of equity in the Company&#8217;s capital structure according to the characteristics of that capital structure, such as the number of shares of each class of equity, seniority levels, liquidation preferences and conversion values for redeemable convertible preferred stock, and participation thresholds for common stock and each series of redeemable convertible preferred stock. The fair value of the RSU Award in each of the three performance condition scenarios is the average of the discounted proceeds to the common stock across all simulated paths. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Application of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model to each of the three performance condition scenarios requires various subjective assumptions that represent management&#8217;s best estimates of the fair value of common stock, expected equity volatility, risk-free interest rate, discount period, expected dividend yield, and time to achievement of a performance condition. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock and Fair Value of Total Equity</div></div>&#8212;Given the lack of an active public market for the common stock (prior to the Company&#8217;s IPO), the fair value of the Company&#8217;s common stock and total equity was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date and resulting total equity value. In determining the fair value of its common stock and total equity value, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the </div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-25 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49526046_3" continuedAt="TextSelectionAppend_49526046_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant risks associated with the Company&#8217;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#8217;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#8217;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for the Company&#8217;s common stock (prior to the Company&#8217;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period commensurate with the expected date of achievement of a performance condition. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate and Discount Period&#8212;</div></div>The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected time to achieve of a performance condition. The discount period is the period between the valuation date and the assumed change in control event date, with the assumption that all equity shares in the capital structure are paid out in cash. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Yield</div></div>&#8212;The expected dividend yield is based on the Company&#8217;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Time to Achievement of a Performance Condition&#8212;</div></div>The time to the achievement of a performance condition is based on the Company&#8217;s best estimate of the period of time to achievement of a performance condition that attains the established market capitalization thresholds. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company determined the fair value of the RSU Award considering third-party valuation reports. The Company considered several objective and subjective factors, including weighted probability of various liquidation event scenarios, operating and financial performance, discount for lack of marketability of the Company&#8217;s equity, and general and industry-specific economic outlook, among other factors. The discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the RSUs. <ix:nonNumeric name="aclx:ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525953">The assumptions used in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div>s simulation models to determine the grant date fair value of the RSU Award for each of the three performance condition scenarios were as follows:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><ix:continuation id="TextSelection_49525953"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 38%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change&#160;in&#160;Control</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">IPO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change&#160;in&#160;Control<br/>Following an IPO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt:date-monthname-day-year-en">June 9, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt:date-monthname-day-year-en">December 7, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt:date-monthname-day-year-en">December 7, 2021</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to liquidity event (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.56</ix:nonNumeric>&#8212;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">3.06</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">10.00</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">1.33</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">110</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">70</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">65</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.11</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.31</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.47</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.44</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of marketability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">26</ix:nonFraction>%&#8212;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">32</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of the RSU award (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:continuation><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance condition will only become probable in the event of a change in control or an IPO. Accordingly, as a performance condition was not achieved in 2021, the Company did <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t record any share-based compensation expense related to this RSU Award in the year ended December&#160;31, 2021. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-26 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><ix:continuation id="TextSelectionAppend_49526046_4"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Upon completion of the IPO in February 2022, the performance condition was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period (10 years) and based on the fair value (aggregate $10.3 million) according to the IPO scenario <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model as no other performance condition was deemed probable at the time of the IPO.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. Net Loss Per Share Attributable to Common Stockholders </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s potential dilutive securities, which include redeemable convertible preferred stock, options to purchase common stock, and unvested shares of restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,785,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">14,388,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,598,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,910,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of restricted common stock from early exercises</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">41,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">952,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">31,337,198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,341,001</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Shares of redeemable convertible preferred stock also participated in dividends with shares of common stock (if and when declared) and therefore were deemed participating securities. The holders of redeemable convertible preferred stock did not contractually share in losses and therefore no additional net loss per share has been disclosed under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_49525105"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Income Taxes </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s provision for income taxes consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current income tax provision (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax provision (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,954</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,090</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision (benefit) for income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525105" continuedAt="TextSelectionAppend_49525105_1"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State tax, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">6.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">29.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">29.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax rates and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The significant components of the Company&#8217;s deferred income tax assets (liabilities) were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,218</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-qualified</div> stock options</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredTaxAssetsNonQualifiedStockOptions" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredTaxAssetsNonQualifiedStockOptions" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">941</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">179</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred income tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,725</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred income tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">132</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred income tax assets (liabilities)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i)&#160;future reversals of existing taxable temporary differences; (ii)&#160;future taxable income exclusive of reversing temporary difference and carryforwards; (iii)&#160;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&#160;tax planning strategies. The Company&#8217;s net deferred income tax assets are not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net change in valuation allowance for the years ended December&#160;31, 2021 and 2020 was an increase of $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2021To12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2020To12_31_2020_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction>&#160;million, respectively, due to the losses incurred for research and development. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act) to provide certain relief as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The Company did not apply for any relief offered by the government during the years ended December&#160;31, 2021 or 2020. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-28 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525105_1"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had Federal and State net operating loss (NOL) carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">117.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">116.5</ix:nonFraction>&#160;million, respectively, as of December&#160;31, 2021. The Company also had federal research and development tax credit carryforwards of approximately $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction>&#160;million, available to potentially offset future federal income taxes, as of December&#160;31, 2021. Approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxPeriodTwoThousandThirtyFiveMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.3</ix:nonFraction>&#160;million of the Federal NOL was generated prior to 2018 and will begin expiring in <ix:nonNumeric name="aclx:OperatingLossCarryforwardsExpirationPeriod" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" format="ixt-sec:duryear">2035</ix:nonNumeric> while the remaining $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyCarryforwardMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">111.3</ix:nonFraction>&#160;million will be carried forward indefinitely but are limited to eighty percent of taxable income. The State NOL will begin expiring in <ix:nonNumeric name="aclx:OperatingLossCarryforwardsExpirationPeriod" contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" format="ixt-sec:duryear">2035</ix:nonNumeric>. The federal research and development tax carryforwards, if not utilized, will expire beginning in <ix:nonNumeric name="aclx:TaxCreditCarryforwardExpirationPeriod" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" format="ixt-sec:duryear">2038</ix:nonNumeric>. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">However, the deductibility of such federal net operating losses may be limited. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by <ix:nonFraction name="aclx:PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% stockholders increases by more than <ix:nonFraction name="aclx:MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% over a three-year period, the corporation&#8217;s ability to use its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> NOL carryforwards and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> tax attributes to offset its post-change income may be limited. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not determined if it has experienced Section&#160;382 ownership changes in the past and if a portion of its NOL and tax credit carryforwards are subject to an annual limitation under Section&#160;382. In addition, the Company may experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside of its control. If the Company determines that an ownership change has occurred and its ability to use its historical NOL and tax credit carryforwards is materially limited, it would harm the Company&#8217;s future operating results by effectively increasing the Company&#8217;s future tax obligations. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t identified any uncertain tax positions and did not recognize any adjustments for unrecognized tax benefits. <ix:nonNumeric name="us-gaap:IncomeTaxExaminationDescription" contextRef="P01_01_2021To12_31_2021">The Company&#8217;s Federal and State tax returns for all years, <ix:nonNumeric name="us-gaap:IncomeTaxExaminationYearUnderExamination" contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">2015</ix:nonNumeric> through <ix:nonNumeric name="us-gaap:IncomeTaxExaminationYearUnderExamination" contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">2020</ix:nonNumeric>, remain subject to examination by taxing authorities due to the tax attribute carryforwards.</ix:nonNumeric> </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DefinedBenefitPlanTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. Employee Benefit Plan </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sponsors a tax deferred retirement plan under the Code to provide retirement benefits for all eligible employees. Participating employees may voluntarily contribute up to limits provided by Internal Revenue Service regulations. The Company made contributions to the plan of $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-29 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts)</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(unaudited)</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">220,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development expenses and other long-term assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseOtherNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseOtherNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">243,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,874</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent, current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRentCreditCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, net of current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent, net of current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRentCreditNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Series A redeemable convertible preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;per share; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares authorized, issued or outstanding as of March&#160;31, 2022; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,795,227</ix:nonFraction>&#160;shares authorized and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of December&#160;31, 2021; liquidation value of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,795</ix:nonFraction>&#160;as of March&#160;31, 2022 and December&#160;31, 2021, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Series B redeemable convertible preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;per share; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares authorized, issued or outstanding as of March&#160;31, 2022; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">49,402,623</ix:nonFraction>&#160;shares authorized and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of December&#160;31, 2021; liquidation value of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,681</ix:nonFraction>&#160;as of March&#160;31, 2022 and December&#160;31, 2021, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Series C redeemable convertible preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;per share; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares authorized, issued or outstanding as of March&#160;31, 2022; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">57,224,618</ix:nonFraction>&#160;shares authorized and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of December&#160;31, 2021; liquidation value of $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">120,000</ix:nonFraction>&#160;as of March&#160;31, 2022 and December&#160;31, 2021, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">233,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; equity (deficit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;per share; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction>&#160;shares authorized and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of March&#160;31, 2022; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares authorized, issued or outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction>&#160;per share; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,000,000,000</ix:nonFraction>&#160;shares authorized and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">35,718,764</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of March&#160;31, 2022; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">185,000,000</ix:nonFraction>&#160;shares authorized and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">384,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">162,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">130,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">221,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">121,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">243,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the condensed consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-30 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,401</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,034</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive loss:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share attributable to common stockholders&#8212;basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">33.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average common shares outstanding&#8212;basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,760,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">337,302</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the condensed consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-31 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 22%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="26" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable Convertible Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/>Receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;<br/>Equity<br/>(Deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">130,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">121,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock (initial public offering), net of transaction costs of $<ix:nonFraction name="aclx:TransactionCosts" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,029</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,487,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock (private placement), net of transaction costs of $<ix:nonFraction name="aclx:TransactionCosts" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">590,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of preferred stock to common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,396,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">119,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,785,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">233,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">233,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock from vesting of restricted stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">286,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized loss on investment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,718,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">384,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">162,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">221,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-32 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share data) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="26" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable Convertible Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Series C</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/>Receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;<br/>Deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">333,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">63,720</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series C redeemable convertible preferred stock for cash, net of transaction costs of $<ix:nonFraction name="aclx:TransactionCosts" contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">814</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,970,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:TemporaryEquitySharesSubscriptionsAmount" contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock from vesting of restricted stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,173</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,413,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,975,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,970,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:TemporaryEquitySharesSubscriptionsAmount" contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">348,353</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">76,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">74,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the condensed consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-33 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ARCELLX, INC. </div></div></div><div id="fin332508_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncash operating lease expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of premiums and discounts on marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Prepaid expenses and other current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">392</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred rent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">467</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from maturities of marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,643</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of common stock (initial public offering), net of transactions costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129,156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of common stock (private placement), net of transactions costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from the exercise of stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments under finance leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash and cash equivalents and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents and restricted cash, beginning of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,032</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents and restricted cash, end of the period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures of noncash investing and financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment included in accounts payable and accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs included in accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:DeferredOfferingCostsIncludedInAccruedLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the condensed consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-34 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div id="fin332508_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of the Business </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;8, 2022, the Company closed its initial public offering (IPO) of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,487,500</ix:nonFraction> shares of its common stock, including the exercise in full by the underwriters of their option to purchase <ix:nonFraction name="aclx:AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,237,500</ix:nonFraction> additional shares of its common stock, at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">127.3</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $<ix:nonFraction name="aclx:CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million. The Company&#8217;s common stock began trading on the Nasdaq Global Select Market on February&#160;4, 2022, under the ticker symbol &#8220;ACLX.&#8221; </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has funded its operations primarily with proceeds from public and private offerings of its common and preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525753"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes to the significant accounting policies disclosed in the Company&#8217;s Audited Consolidated Financial Statements included elsewhere in this prospectus during the three months ended March&#160;31, 2022, except for the adoption of the new lease accounting standard effective January&#160;1, 2022, as discussed below. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525760"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (<span style="-sec-ix-hidden:hidden49526100">Topic 842</span>)</div></div>. Topic 842 increases transparency and comparability among </div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-35 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525753"><ix:continuation id="TextSelection_49525760"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn03_31_2022" format="ixt:fixed-true">adopted</ix:nonNumeric> the new standard effective <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn01_01_2022" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric>, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The adoption of this standard resulted in the recognition of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) assets in the amount of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn01_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction>&#160;million and operating lease liabilities in the amount of $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn01_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.4</ix:nonFraction>&#160;million for operating lease liabilities on the consolidated balance sheet, with a $<ix:nonFraction name="aclx:ReclassificationOfDeferredRentAndTenantImprovementAllowances" contextRef="P01_01_2022To01_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January&#160;1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components are accounted for together as a single lease component for leases associated with office space. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities. </div></div></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525348"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Restricted Cash </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction>&#160;million as of both March&#160;31, 2022 and December&#160;31, 2021. This amount is presented as restricted cash on the accompanying consolidated balance sheets. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-36 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525348"><ix:nonNumeric name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,160</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,651</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525172"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Fair Value of Financial Instruments </div></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets by level within the fair value hierarchy were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:LongTermRestrictedCashFairValue" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,007</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124,708</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:LongTermRestrictedCashFairValue" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525208">43,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525209">17,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525210">5,053</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525211">7,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,671</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items have been reclassified to conform to current period presentation. </div></div></td></tr></table></ix:nonNumeric> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of financial assets categorized within Level&#160;1 of the fair value hierarchy is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. The fair value of financial assets categorized within Level&#160;2 of the fair value hierarchy is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-37 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_49525172">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March&#160;31, 2022 or the year ended December&#160;31, 2021.</ix:continuation> </div></div><ix:nonNumeric name="aclx:MarketableSecuritiesDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Marketable Securities </div></div></div><ix:nonNumeric name="us-gaap:MarketableSecuritiesTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div></div> marketable securities were as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,814</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,081</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,007</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021 (1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525090">43,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525099">43,969</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525091">17,084</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525095">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525100">17,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525092">5,056</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525096">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525101">5,053</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525093">7,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525097">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525102">7,690</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525094">73,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525098">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525103">73,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items have been reclassified to conform to current period presentation. </div></div></td></tr></table></ix:nonNumeric> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt marketable securities held as of March&#160;31, 2022 had contractual maturities of <ix:nonNumeric name="aclx:DebtSecuritiesAvailableForSaleContractualMaturities" contextRef="P01_01_2022To03_31_2022">less than one year</ix:nonNumeric>. The Company had <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn03_31_2022" unitRef="Unit_condition" decimals="0" scale="0" format="ixt:num-dot-decimal">9</ix:nonFraction> securities in an unrealized loss position with an aggregate related fair value of $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.8</ix:nonFraction>&#160;million as of March&#160;31, 2022. All securities in an unrealized loss position as of March&#160;31, 2022 had been in a loss position for less than 12 months. Unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities as of March&#160;31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> allowance for credit losses related to the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities was recorded for the three months ended March&#160;31, 2022. The Company does not intend to sell these securities or expect to be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $<ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million, offset by amortization of premium of $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million, for the three months ended March&#160;31, 2022, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-38 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Prepaid Expenses and Other Current Assets </div></div></div><ix:nonNumeric name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:PrepaidResearchAndDevelopmentCosts" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,388</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:PrepaidResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expense and current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:OtherPrepaidExpenseAndCurrentAssets" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:OtherPrepaidExpenseAndCurrentAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Commitments </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the manufacturing services agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW) in February 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. The Lonza SOW is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> for the first six months of the term and carries minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> costs including upfront payments, milestone fees, and fixed monthly payments during the related period. Subsequent to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> period, the Company may terminate the arrangement for any reason upon <ix:nonNumeric name="aclx:PriorNotificationPeriodToTerminateArrangement" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:durwordsen">12 months</ix:nonNumeric>&#8217; prior notification to Lonza. As of March&#160;31, 2022, the Company&#8217;s minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> costs payable to Lonza was approximately $<ix:nonFraction name="aclx:MinimumNonCancellableCosts" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.6</ix:nonFraction>&#160;million. Variable costs under this arrangement include materials, external testing, and other services. The Company paid $<ix:nonFraction name="us-gaap:OtherCommitment" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.8</ix:nonFraction>&#160;million under this arrangement during the three months ended March&#160;31, 2022. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Accrued Liabilities </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:ResearchAndDevelopmentAccruedExpensesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:ResearchAndDevelopmentAccruedExpensesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="aclx:AccruedOfferingCostsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:AccruedOfferingCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">793</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="aclx:LesseeOperatingAndFinanceLeasesTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525527"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Leases </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in <ix:nonNumeric name="aclx:LeaseExpirationYear" contextRef="P01_01_2022To03_31_2022_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">2030</ix:nonNumeric> unless renewed. The lease agreement contains rent escalation, rent abatement clauses, tenant improvement allowances, and optional renewal clauses. The lease agreement also includes variable lease payments, which are primarily related to common area maintenance and utility charges. The Company also has short-term operating leases with a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn03_31_2022" format="ixt-sec:durwordsen">one year</ix:nonNumeric> or less. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the Company had operating lease ROU assets of $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction>&#160;million, current operating lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> operating lease liabilities of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction>&#160;million. The Company used a discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn03_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.2</ix:nonFraction>% in measuring operating lease liabilities. The remaining lease term was <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn03_31_2022" format="ixt-sec:duryear">7.8</ix:nonNumeric> years as of March&#160;31, 2022. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-39 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525527"><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s total operating lease costs were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">377</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">554</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, future minimum operating lease payments were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">939</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="aclx:SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to operating leases is as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 17%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CashPaidForMeasurementOfOperatingLeaseLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets obtained in exchange for operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="aclx:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525647"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Company&#8217;s IPO, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company&#8217;s outstanding shares of preferred stock were converted into <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,785,564</ix:nonFraction> shares of common stock. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the IPO, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-40 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525647"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the shares of common stock issued and outstanding in connection with the IPO and the subsequent private placement, total shares of common stock issued and outstanding includes shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. <ix:nonNumeric name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525654">Below is a reconciliation of shares issued and outstanding:</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><ix:continuation id="TextSelection_49525654"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesLegallyIssuedAndOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,736,584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesLegallyIssuedAndOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">544,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unvested early exercised shares of common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:UnvestedEarlyExercisedSharesOfCommonStock" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">17,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="aclx:UnvestedEarlyExercisedSharesOfCommonStock" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesIssuedAndOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">35,718,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="aclx:CommonStockSharesIssuedAndOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">544,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of common stock entitles the holder to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2022To03_31_2022">one vote</ix:nonNumeric> on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. <ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> dividends have been declared or paid by the Company through March&#160;31, 2022. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_49525430"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Share-Based Compensation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s 2017 Equity Incentive Plan (the 2017 Plan) provided for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, to the Company&#8217;s employees, directors, and consultants. The 2017 Plan terminated one business day prior to effectiveness of the 2022 Equity Incentive Plan (the 2022 Plan) with respect to the grant of future awards. The 2022 Plan became effective on February&#160;3, 2022 and provides for the grant of incentive stock options to the Company&#8217;s employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (RSUs), and performance awards to the Company&#8217;s employees, directors, and consultants. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate number of shares of common stock that may be issued pursuant to equity awards under the 2022 Plan is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,296,875</ix:nonFraction> shares, plus shares subject to awards granted under the 2017 Plan that expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by the Company (provided that the maximum number of shares that may be added to the 2022 Plan pursuant to awards under the 2017 Plan is <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2022_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,269,300</ix:nonFraction> shares). The number of shares of common stock reserved for issuance under the 2022 </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-41 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_49525430" continuedAt="TextSelectionAppend_49525430_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plan shall be cumulatively increased on the first day of each fiscal year, beginning with the Company&#8217;s 2023 fiscal year and ending on the <ix:nonNumeric name="aclx:AnniversaryPeriod" contextRef="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis" format="ixt-sec:durwordsen">ten year</ix:nonNumeric> anniversary of the date the Company&#8217;s board of directors approves the 2022 Plan equal to the least of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">4,296,875</ix:nonFraction> shares, <ix:nonFraction name="aclx:PercentageIncreaseInCommonStockReserveForFutureIssuance" contextRef="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the total number of shares of common stock outstanding as of the last day of the immediately preceding fiscal year, or a lesser number of shares determined by the administrator of the 2022 Plan. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense by type of award was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units&#8212;executive officer</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">755</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.5</ix:nonFraction>&#160;million in share-based compensation expense during the three months ended March&#160;31, 2022, of which $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million was included in research and development and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction>&#160;million was included in general and administrative in the accompanying condensed consolidated statements of operations. The Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million in share-based compensation expense during the three months ended March&#160;31, 2021, of which $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million was included in research and development and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million was included in general and administrative in the accompanying condensed consolidated statements of operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted under the 2017 Plan and the 2022 Plan vest over <span style="-sec-ix-hidden:hidden49526059">three</span> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and expire after <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">10 years</ix:nonNumeric>. The Company uses the Black Scholes option pricing model to determine the grant date fair value of stock options. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding and Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (1)</div><br/>(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,598,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.9</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525510">7,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,829,435</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">14.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">311,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,113,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525513">44,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,767,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">8.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_49525516">16,304</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March&#160;31, 2022. </div></div></td></tr></table></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-42 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525430_1" continuedAt="TextSelectionAppend_49525430_2"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs granted under the 2022 Plan generally vest annually over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. The Company uses the market price of the Company&#8217;s common shares on the date of grant to determine the fair value of RSUs. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSU activity for awards under the 2022 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average&#160;Grate<br/>Date Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">703,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">702,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units&#8212;Executive Officer </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P06_01_2021To06_30_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">952,804</ix:nonFraction> RSUs to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions.</ix:nonNumeric> All <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">952,804</ix:nonFraction></ix:nonFraction> RSUs were outstanding as of March&#160;31, 2022 and December&#160;31, 2021 and <ix:nonFraction name="aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> RSUs were vested or exercisable as of March&#160;31, 2022 or December&#160;31, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Condition </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The service condition to vesting of the RSU Award requires the executive officer&#8217;s continued employment with the Company through the achievement of any of the performance conditions and the market condition. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Condition </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance conditions to vesting of the RSU Award include (i)&#160;the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii)&#160;a Change in Control following an IPO. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market Condition </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the <ix:nonFraction name="aclx:NumberOfPerformanceConditionScenarios" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_condition" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> performance condition scenarios is applicable at the time of measurement. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-43 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(continued) </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_49525430_2"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company value on a Change in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2022To03_31_2022_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon a Change in Control, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.</ix:nonNumeric> </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company value in the event of an IPO is measured each June&#160;30 and December&#160;31 following an IPO (subject to applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period) and represents the Company&#8217;s Enterprise Value. The Company&#8217;s Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> period ending on the day prior to the applicable IPO measurement date, less cash. <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon an IPO, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.</ix:nonNumeric> </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilized <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the IPO in February 2022, the performance condition of the RSU Award was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period (<ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">10 years</ix:nonNumeric>) and based on the fair value (aggregate $<ix:nonFraction name="aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.3</ix:nonFraction> million) according to the IPO scenario as no other performance condition was deemed probable at the time of the IPO. The Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million in share-based compensation expense related to this RSU Award during the three months ended March&#160;31, 2022. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Net Loss Per Share Attributable to Common Stockholders </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s potentially dilutive securities include options to purchase common stock, unvested shares of restricted common stock, and redeemable convertible preferred stock. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">22,359,669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,113,589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,871,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of restricted common stock from early exercises</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">702,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units&#8212;executive officer</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">952,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,786,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,265,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-44 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 14pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">4,000,000 Shares </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g332508g96c25.jpg" style="width: 360px; height: 72px;"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock </div></div></div> <div style="font-size: 70pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 70pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 15%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PROSPECTUS </div></div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 15%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 70pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">BofA Securities </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SVB Securities </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 100pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022 </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 4.5pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information Not Required in the Prospectus </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;13. Other Expenses of Issuance and Distribution </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the expenses to be incurred in connection with the offering described in this Registration Statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the SEC registration fee, the FINRA filing fee and the exchange listing fee. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount&#160;To&#160;Be<br/>Paid</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC registration fee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">9,257.58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FINRA filing fee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,479.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Printing and engraving expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100,000.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">350,000.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting fees and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100,000.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miscellaneous expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">75,262.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">650,000.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;14. Indemnification of Directors and Officers </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;145 of the Delaware General Corporation Law (DGCL) empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any criminal action, had no reasonable cause to believe the person&#8217;s actions were unlawful. The DGCL further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation&#8217;s bylaws, any agreement, a vote of stockholders or otherwise. The certificate of incorporation of the registrant provides for the indemnification of the registrant&#8217;s directors and officers to the fullest extent permitted under the DGCL. In addition, the bylaws of the registrant require the registrant to fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the registrant, or is or was a director or officer of the registrant serving at the registrant&#8217;s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (1)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (2)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&#160;for payments of unlawful dividends or unlawful stock repurchases or redemptions or (4)&#160;for any transaction from which the director derived an improper personal benefit. The registrant&#8217;s certificate of incorporation to be in effect upon the completion of this offering provides that the registrant&#8217;s directors shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director and that if the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the registrant&#8217;s directors shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-1 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;174 of the DGCL provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As permitted by the DGCL, the registrant has entered, and intends to continue to enter, into separate indemnification agreements with each of the registrant&#8217;s directors and certain of the registrant&#8217;s officers that require the registrant, among other things, to indemnify them against certain liabilities that may arise by reason of their status as directors, officers or certain other employees. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registrant maintains insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities that might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the registrant would have the power to indemnify such person against such liability under the provisions of the DGCL. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These indemnification provisions and the indemnification agreements entered, and intended to be entered, into between the registrant and the registrant&#8217;s officers and directors may be sufficiently broad to permit indemnification of the registrant&#8217;s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriting agreement between the registrant and the underwriters to be filed as Exhibit&#160;1.1 to this registration statement provides for the indemnification by the underwriters of the registrant&#8217;s directors and officers and certain controlling persons against specified liabilities, including liabilities under the Securities Act with respect to information provided by the underwriters specifically for inclusion in the registration statement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;15. Recent Sales of Unregistered Securities </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following list sets forth information regarding all unregistered securities sold by us since January&#160;1, 2018. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(a) In July 2018, we issued and sold an aggregate of 2,271,030 shares of our Series A redeemable convertible preferred stock at a purchase price of $5.51 per share for aggregate proceeds of $12.5 million to a total of six (6) accredited investors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">(b) Between August 2019 and October 2019, we issued and sold an aggregate of 4,986,153 shares of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Series&#160;B-1</div> redeemable convertible preferred stock at a purchase price of $8.6 per share for aggregate proceeds of approximately $42.8&#160;million to eighteen (18)&#160;accredited investors. Additionally, in December 2020 we issued and sold an aggregate of 3,989,432 shares of our Series&#160;B-2 redeemable convertible preferred stock at a purchase price of $10.74 per share for aggregate proceeds of approximately $42.8&#160;million to eighteen (18) accredited investors. </div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(c) Between March 2021 and June 2021, we issued and sold an aggregate of 10,396,707 shares of our Series&#160;C redeemable convertible preferred stock at a purchase price of $11.55 per share for aggregate proceeds of approximately $120.0&#160;million to thirty-two (32) accredited investors. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(d) From January 2018 through January&#160;31, 2022 we granted stock options to purchase an aggregate of 6,109,152 shares of common stock upon the exercise of options under our 2017 Plan at exercise prices per share ranging from $0.78 to $8.65 for an aggregate exercise price of approximately $31.8&#160;million. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-2 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(e) In June 2021, we granted an award of restricted stock units covering 952,804 shares of our common stock. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(f) From January 2018 through January&#160;31, 2022, we issued and sold to certain service providers of ours an aggregate of 665,694 shares of common stock upon the exercise of options under our 2017 Plan at exercise prices per share ranging from $0.39 to $6.83, for an aggregate exercise price of approximately $1.0&#160;million. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(g) On March 4, 2022, we issued and sold an aggregate of 590,318 shares of our common stock in a private placement at a price of $16.94 per share for an aggregate purchase price of $10.0 million. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The offers, sales and issuances of the securities described in Items&#160;15(a), 15(b), 15(c), and 15(g) were exempt from registration under the Securities Act under Section&#160;4(a)(2) of the Securities Act or Regulation&#160;D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The offers, sales and issuances of the securities described in Items&#160;15(d), 15(e) and 15(f) were exempt from registration under the Securities Act under either (1)&#160;Rule&#160;701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule&#160;701 or (2)&#160;Section&#160;4(a)(2) of the Securities Act as transactions by an issuer not involving any public offering. The recipients of such securities were the registrant&#8217;s employees, consultants or directors and received the securities under our 2017 Plan. The recipients of securities in each of these transactions represented their intention to acquire the securities for investment only and not with view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16. Exhibit&#160;and Financial Statement Schedules </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(a) Exhibits. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">See the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</div> which Exhibit Index is incorporated herein by reference. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(b) Financial Statement Schedules. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(c) Filing Fee Table. </div></div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Filing Fee Table and related disclosure is filed herewith as Exhibit&#160;107. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;17. Undertakings </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-3 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned hereby undertakes that: </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-4 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXHIBIT INDEX </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 65%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporation by Reference</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit<br/>Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;1.1*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522173436/d332508dex11.htm">Form of Underwriting Agreement. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex32.htm">Amended and Restated Certificate of Incorporation of the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex34.htm">Amended and Restated Bylaws of the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex41.htm">Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, dated March&#160;26, 2021.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522022267/d129231dex42.htm">Specimen common stock certificate of the Registrant. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/31/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;5.1*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522173436/d332508dex51.htm">Opinion of Wilson Sonsini Goodrish&#160;&amp; Rosati, Professional Corporation. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.1+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex101.htm">Form of Indemnification Agreement, by and between the Registrant and each of its directors and executive officers.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.2+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex102.htm">2017 Equity Incentive Plan, as amended, and forms of agreement thereunder. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.3+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522022267/d129231dex103.htm">2022 Equity Incentive Plan and forms of agreements thereunder.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/31/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.4+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522022267/d129231dex104.htm">2022 Employee Stock Purchase Plan</a>.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/31/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.5+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex105.htm">Form of Executive Change in Control and Severance Agreement.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.6+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex106.htm">Employee Incentive Compensation Plan.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.7</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex107.htm">Lease Agreement between TPG West Watkins Property, LLC and the Registrant, dated October&#160;5, 2018.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.8&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex108.htm">Development, Evaluation and License Agreement between the Registrant and Pfenex Inc. dated December&#160;24, 2018.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.9+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522022267/d129231dex109.htm">Confirmatory Employment Letter between the Registrant and Rami Elghandour.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/31/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.10+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522022267/d129231dex1010.htm">Confirmatory Employment Letter between the Registrant and Christopher Heery, M.D.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/31/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.11+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522022267/d129231dex1011.htm">Confirmatory Employment Letter between the Registrant and Neeraj Teotia. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1/A</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/31/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.12+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex1012.htm">Outside Director Compensation Policy. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.13 +</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex1013.htm">Amended and Restated Restricted Stock Unit Award Agreement between the Registrant and Rami Elghandour, dated December&#160;7, 2021.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.14+&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex1014.htm">Consulting Agreement between the Registrant and Danforth Advisors, LLC dated January&#160;7, 2022.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.15+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522010026/d129231dex1015.htm">Transition Agreement and Release between the Registrant and David Hilbert, Ph.D., dated January&#160;7, 2022. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1/14/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.16&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000095017022009732/aclx-ex10_13.htm">Master Services Agreement between Registrant and Lonza Houston, Inc., dated September&#160;2, 2021. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5/12/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.17&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000095017022009732/aclx-ex10_14.htm">Statement of Work <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</span> between Registrant and Lonza Houston, Inc. dated February&#160;16, 2022. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5/12/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-5 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 67%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incorporation by<br/>Reference</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exhibit<br/>Number</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filing</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Filed<br/>Herewith</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.18+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522157549/d334887dex101.htm">Offer Letter between Registrant and Michelle Gilson dated April&#160;3, 2022.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5/23/2022</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d332508dex231.htm">Consent of Independent Registered Public Accounting Firm.</a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.2*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522173436/d332508dex51.htm">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, Professional Corporations (included in Exhibit 5.1). </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">24.1*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="#sig">Power of Attorney (reference is made to signature page hereto). </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document&#8212;the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Label Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">X</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">107*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1786205/000119312522173436/d332508dexfilingfees.htm">Filing Fee Table. </a></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Previously Filed </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicated management contract or compensatory plan. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8224;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Portions of this exhibit have been omitted in accordance with Item 601 of Regulation S-K. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-6 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="sig" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, Maryland, on June&#160;14, 2022. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ARCELLX, INC.</div></div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;">By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Rami Elghandour</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">Rami Elghandour</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">President, Chief Executive Officer and Chairman of the Board of Directors</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="text-indent: 0px;"></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signature</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Rami Elghandour</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rami Elghandour</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">President, Chief Executive Officer and Chairman of the Board of Directors </div> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Principal Executive Officer)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Michelle Gilson</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Michelle Gilson</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Chief Financial Officer<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(Principal Financial and Accounting Officer)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ali Behbahani, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jill Carroll, M.S.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">David Lubner, M.S., C.P.A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kavita Patel, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Olivia Ware</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derek Yoon</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;14, 2022</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="text-indent: 0px;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 45%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 10%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;">*By:</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">&#160;</td>
<td style="vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 0.75pt; border-bottom-style: solid;">/s/ Rami Elghandour</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">Rami Elghandour</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Attorney-in-fact</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-7 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d332508dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;24, 2022, in Amendment No.&nbsp;1
to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-265573)</FONT> and related Prospectus of Arcellx, Inc. for the registration of its common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tysons, Virginia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;14, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>aclx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-June-2022 [01:49:47] {AM}-->
<schema targetNamespace="http://arc.com/20220331" elementFormDefault="qualified" xmlns:aclx="http://arc.com/20220331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://arc.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
<link:definition>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
<link:definition>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" id="CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
<link:definition>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" id="CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
<link:definition>1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/NatureOfTheBusiness" id="NatureOfTheBusiness">
<link:definition>1008 - Disclosure - Nature of the Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RestrictedCash" id="RestrictedCash">
<link:definition>1010 - Disclosure - Restricted Cash</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
<link:definition>1011 - Disclosure - Fair Value of Financial Instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/MarketableSecurities" id="MarketableSecurities">
<link:definition>1012 - Disclosure - Marketable Securities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
<link:definition>1013 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1014 - Disclosure - Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/Commitments" id="Commitments">
<link:definition>1015 - Disclosure - Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CapitalLeaseObligations" id="CapitalLeaseObligations">
<link:definition>1016 - Disclosure - Capital Lease Obligations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/AccruedLiabilities" id="AccruedLiabilities">
<link:definition>1017 - Disclosure - Accrued Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/Leases" id="Leases">
<link:definition>1018 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1019 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
<link:definition>1020 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RedeemableConvertiblePreferredStock" id="RedeemableConvertiblePreferredStock">
<link:definition>1021 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommonStock" id="CommonStock">
<link:definition>1022 - Disclosure - Common Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1023 - Disclosure - Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholders" id="NetLossPerShareAttributableToCommonStockholders">
<link:definition>1024 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1025 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
<link:definition>1026 - Disclosure - Employee Benefit Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1027 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RestrictedCashTables" id="RestrictedCashTables">
<link:definition>1029 - Disclosure - Restricted Cash (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
<link:definition>1030 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
<link:definition>1031 - Disclosure - Marketable Securities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
<link:definition>1032 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1033 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CapitalLeaseObligationsTables" id="CapitalLeaseObligationsTables">
<link:definition>1034 - Disclosure - Capital Lease Obligations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
<link:definition>1035 - Disclosure - Accrued Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/LeasesTables" id="LeasesTables">
<link:definition>1036 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1037 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables" id="RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables">
<link:definition>1038 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommonStockTables" id="CommonStockTables">
<link:definition>1039 - Disclosure - Common Stock (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1040 - Disclosure - Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables" id="NetLossPerShareAttributableToCommonStockholdersTables">
<link:definition>1041 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1042 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails" id="NatureOfTheBusinessAdditionalInformationDetails">
<link:definition>1043 - Disclosure - Nature of The Business - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails">
<link:definition>1044 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1045 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RestrictedCashAdditionalInformationDetails" id="RestrictedCashAdditionalInformationDetails">
<link:definition>1046 - Disclosure - Restricted Cash - (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
<link:definition>1047 - Disclosure - Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" id="FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails">
<link:definition>1048 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" id="MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails">
<link:definition>1049 - Disclosure - Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails" id="MarketableSecuritiesAdditionalInformationDetails">
<link:definition>1050 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
<link:definition>1051 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails">
<link:definition>1052 - Disclosure - Property and Equipment, Net - Schedule Of Property And Equipment Consist (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/PropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetDetail">
<link:definition>1053 - Disclosure - Property and Equipment, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommitmentsAdditionalInformationDetails" id="CommitmentsAdditionalInformationDetails">
<link:definition>1054 - Disclosure - Commitments - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail" id="CapitalLeaseObligationsAdditionalInformationDetail">
<link:definition>1055 - Disclosure - Capital Lease Obligations - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" id="CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail">
<link:definition>1056 - Disclosure - Capital Lease Obligations - Summary of Future Lease Obligations Under These Capital Lease Agreements (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
<link:definition>1057 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
<link:definition>1058 - Disclosure - Leases - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/LeasesSummaryOfLeaseCostsDetails" id="LeasesSummaryOfLeaseCostsDetails">
<link:definition>1059 - Disclosure - Leases - Summary of Lease Costs (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" id="LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails">
<link:definition>1060 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" id="LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
<link:definition>1061 - Disclosure - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1062 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail" id="CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail">
<link:definition>1063 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" id="RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
<link:definition>1064 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" id="RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails">
<link:definition>1065 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" id="RedeemableConvertiblePreferredStockAdditionalInformationDetails">
<link:definition>1066 - Disclosure - Redeemable Convertible Preferred Stock -  Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail" id="CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail">
<link:definition>1067 - Disclosure - Common Stock - Schedule of Reconciliation of Shares Issued and Outstanding (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/CommonStockAdditionalInformationDetail" id="CommonStockAdditionalInformationDetail">
<link:definition>1068 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails" id="ShareBasedCompensationAdditionalInformationDetails">
<link:definition>1069 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" id="ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails">
<link:definition>1070 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails" id="ShareBasedCompensationSummaryOfStockOptionActivityDetails">
<link:definition>1071 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" id="ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
<link:definition>1072 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails" id="ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails">
<link:definition>1073 - Disclosure - Share-Based Compensation - Schedule of Black-Scholes option pricing model for stock options granted  (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails" id="ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails">
<link:definition>1074 - Disclosure - Share-Based Compensation - Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award  (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
<link:definition>1075 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1076 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" id="IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
<link:definition>1077 - Disclosure - Income Taxes - Summary of Provision For Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" id="IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails">
<link:definition>1078 - Disclosure - Income Taxes - Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1079 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails" id="EmployeeBenefitPlanAdditionalInformationDetails">
<link:definition>1080 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="aclx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_SeriesARedeemableConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_SeriesBRedeemableConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_SeriesCRedeemableConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="TemporaryEquitySharesSubscriptionsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_TemporaryEquitySharesSubscriptionsAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TemporaryEquityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_TemporaryEquityMember" substitutionGroup="xbrli:item" />
<element name="TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_TransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CapitalLeasePrincipalPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_CapitalLeasePrincipalPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentsForRepurchaseOfRestrictedStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_PaymentsForRepurchaseOfRestrictedStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredOfferingCostsIncludedInAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MarketableSecuritiesDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_MarketableSecuritiesDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="PrepaidExpensesAndOtherAssetsCurrentTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" substitutionGroup="xbrli:item" />
<element name="CommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_CommitmentsAbstract" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingAndFinanceLeasesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_LesseeOperatingAndFinanceLeasesTextBlock" substitutionGroup="xbrli:item" />
<element name="RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="DiscloureOfRedeemableConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_CommonStockAbstract" substitutionGroup="xbrli:item" />
<element name="CommonStockTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_CommonStockTextBlock" substitutionGroup="xbrli:item" />
<element name="ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RedeemableConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="SegmentAndGeographicInformationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="CapitalLeasesFutureMinimumPaymentsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" substitutionGroup="xbrli:item" />
<element name="CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PropertyPlantAndEquipmentEstimatedLivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_PropertyPlantAndEquipmentEstimatedLivesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="EquipmentUnderCapitalLeaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_EquipmentUnderCapitalLeaseMember" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentEstimatedLivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" substitutionGroup="xbrli:item" />
<element name="ReclassificationOfDeferredRentAndTenantImprovementAllowances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LongTermRestrictedCashFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_LongTermRestrictedCashFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtSecuritiesAvailableForSaleContractualMaturities" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_DebtSecuritiesAvailableForSaleContractualMaturities" substitutionGroup="xbrli:item" />
<element name="PrepaidResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_PrepaidResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherPrepaidExpenseAndCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_OtherPrepaidExpenseAndCurrentAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LabEquipmentUnderCapitalLeasesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_LabEquipmentUnderCapitalLeasesMember" substitutionGroup="xbrli:item" />
<element name="PriorNotificationPeriodToTerminateArrangement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_PriorNotificationPeriodToTerminateArrangement" substitutionGroup="xbrli:item" />
<element name="MinimumNonCancellableCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_MinimumNonCancellableCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CapitalLeaseAgreementMaturityPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_CapitalLeaseAgreementMaturityPeriod" substitutionGroup="xbrli:item" />
<element name="ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentAccruedExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_ResearchAndDevelopmentAccruedExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedOfferingCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_AccruedOfferingCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherAccruedLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_OtherAccruedLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LeaseExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_LeaseExpirationYear" substitutionGroup="xbrli:item" />
<element name="OfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_OfficeAndLaboratorySpaceMember" substitutionGroup="xbrli:item" />
<element name="CashPaidForMeasurementOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeasesDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_OperatingLeasesDeferredRent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LonzaSowMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_LonzaSowMember" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesLegallyIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_CommonStockSharesLegallyIssuedAndOutstanding" substitutionGroup="xbrli:item" />
<element name="UnvestedEarlyExercisedSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_UnvestedEarlyExercisedSharesOfCommonStock" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_CommonStockSharesIssuedAndOutstanding" substitutionGroup="xbrli:item" />
<element name="TemporaryEquitySharesDividendRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_TemporaryEquitySharesDividendRate" substitutionGroup="xbrli:item" />
<element name="NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." substitutionGroup="xbrli:item" />
<element name="TemporaryEquitySharesConversionPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_TemporaryEquitySharesConversionPrice" substitutionGroup="xbrli:item" />
<element name="SeriesB1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_SeriesB1RedeemableConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesB2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_SeriesB2RedeemableConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesCRedeemableConvertiblePreferredStocksMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_SeriesCRedeemableConvertiblePreferredStocksMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" substitutionGroup="xbrli:item" />
<element name="NumberOfPerformanceConditionScenarios" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_NumberOfPerformanceConditionScenarios" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnniversaryPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_AnniversaryPeriod" substitutionGroup="xbrli:item" />
<element name="PercentageIncreaseInCommonStockReserveForFutureIssuance" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="ChangeInControlMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_ChangeInControlMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_TwoThousandSeventeenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" substitutionGroup="xbrli:item" />
<element name="ChangeInControlFollowingAnIpoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_ChangeInControlFollowingAnIpoMember" substitutionGroup="xbrli:item" />
<element name="UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockUnitsExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_RestrictedStockUnitsExecutiveOfficerMember" substitutionGroup="xbrli:item" />
<element name="IncometaxdisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_IncometaxdisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncometaxdisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_IncometaxdisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_OperatingLossCarryforwardsExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_TaxCreditCarryforwardExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" substitutionGroup="xbrli:item" />
<element name="MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" substitutionGroup="xbrli:item" />
<element name="LossCarryforwardGeneratedPeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_LossCarryforwardGeneratedPeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="LossCarryforwardGeneratedPeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_LossCarryforwardGeneratedPeriodDomain" substitutionGroup="xbrli:item" />
<element name="TaxPeriodTwoThousandThirtyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_TaxPeriodTwoThousandThirtyFiveMember" substitutionGroup="xbrli:item" />
<element name="IndefinitelyCarryforwardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="aclx_IndefinitelyCarryforwardMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsNonQualifiedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_DeferredTaxAssetsNonQualifiedStockOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="aclx_DeferredTaxAssetsOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>aclx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-June-2022 [01:49:47] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" roleURI="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" roleURI="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" roleURI="http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" roleURI="http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSummaryOfLeaseCostsDetails" roleURI="http://arc.com/role/LeasesSummaryOfLeaseCostsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" roleURI="http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" roleURI="http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" roleURI="http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PrepaidResearchAndDevelopmentCosts" xlink:label="loc_ACLX_PrepaidResearchAndDevelopmentCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ACLX_PrepaidResearchAndDevelopmentCosts" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OtherPrepaidExpenseAndCurrentAssets" xlink:label="loc_ACLX_OtherPrepaidExpenseAndCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ACLX_OtherPrepaidExpenseAndCurrentAssets" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" use="optional" order="5" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesSummaryOfLeaseCostsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredCosts" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PrepaidExpenseOtherNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRentCreditCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="26" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" order="7" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeasePrincipalPayments" xlink:label="loc_ACLX_CapitalLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ACLX_CapitalLeasePrincipalPayments" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PaymentsForRepurchaseOfRestrictedStock" xlink:label="loc_ACLX_PaymentsForRepurchaseOfRestrictedStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ACLX_PaymentsForRepurchaseOfRestrictedStock" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xlink:label="loc_ACLX_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ACLX_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="25" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesIssuedAndOutstanding" xlink:label="loc_ACLX_CommonStockSharesIssuedAndOutstanding" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:label="loc_ACLX_CommonStockSharesLegallyIssuedAndOutstanding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ACLX_CommonStockSharesIssuedAndOutstanding" xlink:to="loc_ACLX_CommonStockSharesLegallyIssuedAndOutstanding" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:label="loc_ACLX_UnvestedEarlyExercisedSharesOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ACLX_CommonStockSharesIssuedAndOutstanding" xlink:to="loc_ACLX_UnvestedEarlyExercisedSharesOfCommonStock" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LongTermRestrictedCashFairValue" xlink:label="loc_ACLX_LongTermRestrictedCashFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="loc_ACLX_LongTermRestrictedCashFairValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:label="loc_ACLX_ResearchAndDevelopmentAccruedExpensesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_ACLX_ResearchAndDevelopmentAccruedExpensesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AccruedOfferingCostsCurrent" xlink:label="loc_ACLX_AccruedOfferingCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_ACLX_AccruedOfferingCostsCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedBonusesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedVacationCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OtherAccruedLiabilityCurrent" xlink:label="loc_ACLX_OtherAccruedLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_ACLX_OtherAccruedLiabilityCurrent" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>aclx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-June-2022 [01:49:47] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NatureOfTheBusinessAdditionalInformationDetails" roleURI="http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" roleURI="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" roleURI="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsAdditionalInformationDetail" roleURI="http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesAdditionalInformationDetails" roleURI="http://arc.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail" roleURI="http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStockAdditionalInformationDetail" roleURI="http://arc.com/role/CommonStockAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationAdditionalInformationDetails" roleURI="http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" roleURI="http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails" roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails" roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://arc.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NatureOfTheBusiness" roleURI="http://arc.com/role/NatureOfTheBusiness" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCash" roleURI="http://arc.com/role/RestrictedCash" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstruments" roleURI="http://arc.com/role/FairValueOfFinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecurities" roleURI="http://arc.com/role/MarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#Commitments" roleURI="http://arc.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilities" roleURI="http://arc.com/role/AccruedLiabilities" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#Leases" roleURI="http://arc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensation" roleURI="http://arc.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NetLossPerShareAttributableToCommonStockholders" roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholders" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashTables" roleURI="http://arc.com/role/RestrictedCashTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstrumentsTables" roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesTables" roleURI="http://arc.com/role/MarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilitiesTables" roleURI="http://arc.com/role/AccruedLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesTables" roleURI="http://arc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationTables" roleURI="http://arc.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashAdditionalInformationDetails" roleURI="http://arc.com/role/RestrictedCashAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesAdditionalInformationDetails" roleURI="http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" roleURI="http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSummaryOfLeaseCostsDetails" roleURI="http://arc.com/role/LeasesSummaryOfLeaseCostsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" roleURI="http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAdditionalInformationDetails" roleURI="http://arc.com/role/CommitmentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" roleURI="http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNet" roleURI="http://arc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#EmployeeBenefitPlan" roleURI="http://arc.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetTables" roleURI="http://arc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxes" roleURI="http://arc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesTables" roleURI="http://arc.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetDetail" roleURI="http://arc.com/role/PropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" roleURI="http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligations" roleURI="http://arc.com/role/CapitalLeaseObligations" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" roleURI="http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsTables" roleURI="http://arc.com/role/CapitalLeaseObligationsTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" roleURI="http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingencies" roleURI="http://arc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingenciesTables" roleURI="http://arc.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail" roleURI="http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStock" roleURI="http://arc.com/role/CommonStock" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStockTables" roleURI="http://arc.com/role/CommonStockTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CoverPage" roleURI="http://arc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStock" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStock" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_AssetsAbstract_120" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_AssetsCurrentAbstract_118" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_133" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_140" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_AssetsCurrent_145" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_132" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_139" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_144" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_DeferredCosts_149" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_PrepaidExpenseOtherNoncurrent_150" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_Assets_154" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_119" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_AccountsPayableCurrent_127" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_131" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_138" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_143" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_148" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_LiabilitiesCurrent_153" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_StockholdersEquityAbstract_116" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_PreferredStockValue_124" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_CommonStockValue_129" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_AdditionalPaidInCapital_136" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_141" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_146" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_StockholdersEquity_151" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_117" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_117" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_125" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_130" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_137" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_142" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_Liabilities_147" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_StatementTable_122" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_122" xlink:to="loc_us-gaap_StatementClassOfStockAxis_121" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_121" xlink:to="loc_us-gaap_ClassOfStockDomain_113" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_113_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_121" xlink:to="loc_us-gaap_ClassOfStockDomain_113_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_123" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_128" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_134" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_135" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_180" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_184" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_StatementTable_182" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_182" xlink:to="loc_us-gaap_StatementClassOfStockAxis_181" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_181" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_181" xlink:to="loc_us-gaap_ClassOfStockDomain_179_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_183" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_185" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_187" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_186" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockSharesIssued_188" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_189" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_191" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockSharesIssued_192" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_193" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_198" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_277" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockholdersEquity_285" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StatementTable_284" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementClassOfStockAxis_279" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_279" xlink:to="loc_us-gaap_ClassOfStockDomain_278" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_278_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_279" xlink:to="loc_us-gaap_ClassOfStockDomain_278_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_278" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_286" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_278" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_290" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_278" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_294" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_281" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_281" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_281" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" xlink:to="loc_us-gaap_IPOMember_287" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" xlink:to="loc_us-gaap_PrivatePlacementMember_291" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_283" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_283" xlink:to="loc_us-gaap_EquityComponentDomain_282" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_283" xlink:to="loc_us-gaap_EquityComponentDomain_282_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_CommonStockMember_288" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_292" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_RetainedEarningsMember_295" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_297" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityMember" xlink:label="loc_aclx_TemporaryEquityMember_1476434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_aclx_TemporaryEquityMember_1476434" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_SharesOutstanding_289" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_293" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_296" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_298" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_299" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesSubscriptionsAmount" xlink:label="loc_aclx_TemporaryEquitySharesSubscriptionsAmount_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_aclx_TemporaryEquitySharesSubscriptionsAmount_300" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_301" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_302" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_303" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_304" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_307" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_308" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_309" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_310" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_311" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_312" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_NetIncomeLoss_313" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_341" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_us-gaap_StatementTable_340" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_StatementClassOfStockAxis_338" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_338" xlink:to="loc_us-gaap_ClassOfStockDomain_337" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_337_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_338" xlink:to="loc_us-gaap_ClassOfStockDomain_337_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_337" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_345" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_339" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_339" xlink:to="loc_us-gaap_EquityComponentDomain_336" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_336_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_339" xlink:to="loc_us-gaap_EquityComponentDomain_336_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_336" xlink:to="loc_us-gaap_CommonStockMember_344" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_343" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_343" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_343" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" xlink:to="loc_us-gaap_IPOMember_347" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" xlink:to="loc_us-gaap_PrivatePlacementMember_348" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TransactionCosts" xlink:label="loc_aclx_TransactionCosts_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_aclx_TransactionCosts_346" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_394" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xlink:label="loc_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets_396" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_405" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_410" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_412" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_418" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_NetIncomeLoss_397" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_401" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_404" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_407" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_ShareBasedCompensation_413" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1476135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1476135" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_StatementTable_390" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_390" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476168" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476168" xlink:to="loc_us-gaap_ClassOfStockDomain_1476170" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476170_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476168" xlink:to="loc_us-gaap_ClassOfStockDomain_1476170_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476170" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476171" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476170" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476172" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_398" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_403" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_409" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_414" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_417" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_420" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_422" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeasePrincipalPayments" xlink:label="loc_aclx_CapitalLeasePrincipalPayments_1476142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_aclx_CapitalLeasePrincipalPayments_1476142" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PaymentsForRepurchaseOfRestrictedStock" xlink:label="loc_aclx_PaymentsForRepurchaseOfRestrictedStock_1476148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_aclx_PaymentsForRepurchaseOfRestrictedStock_1476148" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_399" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_402" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_408" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_415" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_400" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xlink:label="loc_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" xlink:to="loc_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities_406" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_411" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_419" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_598" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_604" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_603" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_603" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_600" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_600" xlink:to="loc_us-gaap_EquityComponentDomain_599" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_600" xlink:to="loc_us-gaap_EquityComponentDomain_599_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_599" xlink:to="loc_us-gaap_CommonStockMember_605" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_603" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_602" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_602" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_602" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601" xlink:to="loc_us-gaap_IPOMember_606" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xlink:label="loc_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase_607" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_608" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_609" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="loc_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_610" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1475964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1475964" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesTable" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" xlink:to="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1476121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_us-gaap_ComputerEquipmentMember_1476121" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1476123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1476123" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentMember" xlink:label="loc_aclx_LabEquipmentMember_1476126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_aclx_LabEquipmentMember_1476126" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1476127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1476127" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_EquipmentUnderCapitalLeaseMember" xlink:label="loc_aclx_EquipmentUnderCapitalLeaseMember_1476128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_aclx_EquipmentUnderCapitalLeaseMember_1476128" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1476130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1476130" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1476404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1476404" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_668" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_668" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_679" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LongTermRestrictedCashFairValue" xlink:label="loc_aclx_LongTermRestrictedCashFairValue_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_aclx_LongTermRestrictedCashFairValue_682" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_685" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_688" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_668" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_670" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_670" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_670" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_CommercialPaperMember_677" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_681" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_684" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_687" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_671" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_671_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_671_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_671" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_678" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_680" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_683" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_707" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_713" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_MarketableSecuritiesTable_708" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_708" xlink:to="loc_us-gaap_FinancialInstrumentAxis_711" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_711" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_711" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_715" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_717" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_719" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1475921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1475921" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_708" xlink:to="loc_us-gaap_InvestmentTypeAxis_712" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_712" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_709" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_709_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_712" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_709_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_709" xlink:to="loc_us-gaap_CommercialPaperMember_714" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_716" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_718" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_720" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentMember" xlink:label="loc_aclx_LabEquipmentMember_1475954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_aclx_LabEquipmentMember_1475954" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1475955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1475955" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentUnderCapitalLeasesMember" xlink:label="loc_aclx_LabEquipmentUnderCapitalLeasesMember_1475958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_aclx_LabEquipmentUnderCapitalLeasesMember_1475958" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1475959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_ComputerEquipmentMember_1475959" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1475960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1475960" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1475961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_ConstructionInProgressMember_1475961" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1475948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1475948" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1475949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1475949" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1475950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1475950" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1476068" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1476065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_StatementTable_1476065" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1476065" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476066" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476066" xlink:to="loc_us-gaap_ClassOfStockDomain_1476067" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476067_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476066" xlink:to="loc_us-gaap_ClassOfStockDomain_1476067_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1476091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1476065" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1476091" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1476092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1476091" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1476092" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1476092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1476091" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1476092_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_1476093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1476092" xlink:to="loc_us-gaap_OtherAssetsMember_1476093" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1476095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsMember_1476093" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1476095" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1476101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherAssetsMember_1476093" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1476101" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeaseAgreementMaturityPeriod" xlink:label="loc_aclx_CapitalLeaseAgreementMaturityPeriod_1476072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_aclx_CapitalLeaseAgreementMaturityPeriod_1476072" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_1476075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_1476075" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1476077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_CapitalLeaseObligations_1476077" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xlink:label="loc_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent_1476083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent_1476083" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1476084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1476084" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LeaseExpirationYear" xlink:label="loc_aclx_LeaseExpirationYear_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_aclx_LeaseExpirationYear_809" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_808" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_808" xlink:to="loc_srt_StatementGeographicalAxis_805" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_805" xlink:to="loc_srt_SegmentGeographicalDomain_804" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_804_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_805" xlink:to="loc_srt_SegmentGeographicalDomain_804_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_804" xlink:to="loc_stpr_MD_810" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_808" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OfficeAndLaboratorySpaceMember" xlink:label="loc_aclx_OfficeAndLaboratorySpaceMember_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806" xlink:to="loc_aclx_OfficeAndLaboratorySpaceMember_811" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_812" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_813" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_814" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_815" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_816" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_817" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1476167" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1476164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_us-gaap_StatementTable_1476164" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1476174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_dei_LegalEntityAxis_1476174" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1476174" xlink:to="loc_dei_EntityDomain_1476175" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476175_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1476174" xlink:to="loc_dei_EntityDomain_1476175_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LonzaSowMember" xlink:label="loc_aclx_LonzaSowMember_1476176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1476175" xlink:to="loc_aclx_LonzaSowMember_1476176" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OfficeAndLaboratorySpaceMember" xlink:label="loc_aclx_OfficeAndLaboratorySpaceMember_1476187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183" xlink:to="loc_aclx_OfficeAndLaboratorySpaceMember_1476187" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1476189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_srt_StatementGeographicalAxis_1476189" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1476191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1476189" xlink:to="loc_srt_SegmentGeographicalDomain_1476191" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1476191_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1476189" xlink:to="loc_srt_SegmentGeographicalDomain_1476191_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD_1476422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1476191" xlink:to="loc_stpr_MD_1476422" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LeaseExpirationYear" xlink:label="loc_aclx_LeaseExpirationYear_1476179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_aclx_LeaseExpirationYear_1476179" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OperatingLeasesDeferredRent" xlink:label="loc_aclx_OperatingLeasesDeferredRent_1476195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_aclx_OperatingLeasesDeferredRent_1476195" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1476196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1476196" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_1476197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_us-gaap_OtherCommitment_1476197" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_913" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_919" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_916" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_910" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_910" xlink:to="loc_us-gaap_EquityComponentDomain_909" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_910" xlink:to="loc_us-gaap_EquityComponentDomain_909_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_909" xlink:to="loc_us-gaap_CommonStockMember_917" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_StatementClassOfStockAxis_912" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_912" xlink:to="loc_us-gaap_ClassOfStockDomain_911" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_911_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_912" xlink:to="loc_us-gaap_ClassOfStockDomain_911_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_911" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_918" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_915" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_915" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_915" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914" xlink:to="loc_us-gaap_IPOMember_920" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_CommonStockVotingRights_921" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_DividendsCommonStock_922" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_935" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_939" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_938" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_938" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_937" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_937" xlink:to="loc_us-gaap_EquityComponentDomain_936" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_936_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_937" xlink:to="loc_us-gaap_EquityComponentDomain_936_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_936" xlink:to="loc_us-gaap_CommonStockMember_940" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:label="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_941" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesIssuedAndOutstanding_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_aclx_CommonStockSharesIssuedAndOutstanding_942" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1476281" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476283" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476283" xlink:to="loc_us-gaap_ClassOfStockDomain_1476284" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476284_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476283" xlink:to="loc_us-gaap_ClassOfStockDomain_1476284_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1476285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1476285" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_1476294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_1476294" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476312" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476318" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesB1RedeemableConvertiblePreferredStockMember_1476319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesB1RedeemableConvertiblePreferredStockMember_1476319" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesB2RedeemableConvertiblePreferredStockMember_1476320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesB2RedeemableConvertiblePreferredStockMember_1476320" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStocksMember_1476436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStocksMember_1476436" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1476289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288" xlink:to="loc_us-gaap_IPOMember_1476289" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAxis" xlink:label="loc_us-gaap_DividendsAxis_1476327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_DividendsAxis_1476327" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain_1476328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DividendsAxis_1476327" xlink:to="loc_us-gaap_DividendsDomain_1476328" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain_1476328_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DividendsAxis_1476327" xlink:to="loc_us-gaap_DividendsDomain_1476328_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendDeclaredMember" xlink:label="loc_us-gaap_DividendDeclaredMember_1476329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsDomain_1476328" xlink:to="loc_us-gaap_DividendDeclaredMember_1476329" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1476282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1476282" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1476291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1476291" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1476298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1476298" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1476308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1476308" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1476309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1476309" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1476321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1476321" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TransactionCosts" xlink:label="loc_aclx_TransactionCosts_1476322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TransactionCosts_1476322" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1476323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1476323" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesDividendRate" xlink:label="loc_aclx_TemporaryEquitySharesDividendRate_1476325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TemporaryEquitySharesDividendRate_1476325" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1476326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1476326" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xlink:label="loc_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock._1476330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock._1476330" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesConversionPrice" xlink:label="loc_aclx_TemporaryEquitySharesConversionPrice_1476331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TemporaryEquitySharesConversionPrice_1476331" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1476332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1476332" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1476188" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1476182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1476182" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1476184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476182" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1476184" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1476185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1476184" xlink:to="loc_us-gaap_EquityComponentDomain_1476185" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1476185_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1476184" xlink:to="loc_us-gaap_EquityComponentDomain_1476185_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1476186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1476185" xlink:to="loc_us-gaap_CommonStockMember_1476186" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_1476190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_1476190" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:label="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_1476192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_1476192" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesIssuedAndOutstanding_1476193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_aclx_CommonStockSharesIssuedAndOutstanding_1476193" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/CommonStockAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1476215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1476204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1476225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206" xlink:to="loc_us-gaap_PrivatePlacementMember_1476225" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476208" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476208" xlink:to="loc_us-gaap_ClassOfStockDomain_1476209" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476209_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476208" xlink:to="loc_us-gaap_ClassOfStockDomain_1476209_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1476212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1476212" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1476213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1476212" xlink:to="loc_us-gaap_EquityComponentDomain_1476213" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1476213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1476212" xlink:to="loc_us-gaap_EquityComponentDomain_1476213_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1476214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1476213" xlink:to="loc_us-gaap_CommonStockMember_1476214" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1476217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockVotingRights_1476217" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_1476218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_DividendsCommonStock_1476218" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1476221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1476221" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1476222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1476222" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1476223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1476223" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1476237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1476237" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1476239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockSharesIssued_1476239" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1476240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1476240" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1476241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1476241" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1002" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_991" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_991" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_990" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_990_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_991" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_990_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_990" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1004" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_990" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1012" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_993" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_993" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_993" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" xlink:to="loc_us-gaap_IPOMember_1005" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlMember" xlink:label="loc_aclx_ChangeInControlMember_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" xlink:to="loc_aclx_ChangeInControlMember_1014" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_srt_TitleOfIndividualAxis_995" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_995" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_995" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" xlink:to="loc_srt_ExecutiveOfficerMember_1006" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" xlink:to="loc_srt_DirectorMember_1009" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_PlanNameAxis_998" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_998" xlink:to="loc_us-gaap_PlanNameDomain_989" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_989_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_998" xlink:to="loc_us-gaap_PlanNameDomain_989_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_989" xlink:to="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1003" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_989" xlink:to="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1011" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenEquityIncentivePlanMember_1016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_989" xlink:to="loc_aclx_TwoThousandSeventeenEquityIncentivePlanMember_1016" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_srt_RangeAxis_999" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_999" xlink:to="loc_srt_RangeMember_996" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_996_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_999" xlink:to="loc_srt_RangeMember_996_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_996" xlink:to="loc_srt_MinimumMember_1007" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_996" xlink:to="loc_srt_MaximumMember_1015" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_AwardTypeAxis_1000" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1008" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1013" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1010" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1017" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1019" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1020" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1021" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1022" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1023" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_NumberOfPerformanceConditionScenarios" xlink:label="loc_aclx_NumberOfPerformanceConditionScenarios_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_NumberOfPerformanceConditionScenarios_1024" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1025" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:label="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_1026" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AnniversaryPeriod" xlink:label="loc_aclx_AnniversaryPeriod_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_AnniversaryPeriod_1027" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xlink:label="loc_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance_1028" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1476324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1476324" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1476341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1476341" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1476344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1476344" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1476347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1476347" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1476348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1476348" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1476349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1476349" use="optional" order="51" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1048" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1048" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_srt_TitleOfIndividualAxis_1044" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1044" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1044" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043" xlink:to="loc_srt_ExecutiveOfficerMember_1049" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_us-gaap_AwardTypeAxis_1046" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1050" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1052" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1476245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1476245" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1476246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1476245" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1476246" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1476246_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1476245" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1476246_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1476247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1476246" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1476247" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1476248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1476246" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1476248" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1048" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1051" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1088" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" xlink:to="loc_us-gaap_PlanNameAxis_1084" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1084" xlink:to="loc_us-gaap_PlanNameDomain_1081" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1081_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1084" xlink:to="loc_us-gaap_PlanNameDomain_1081_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1081" xlink:to="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1087" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" xlink:to="loc_us-gaap_AwardTypeAxis_1085" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1089" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1090" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1091" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1092" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1094" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1095" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1096" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1097" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1098" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1100" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1101" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1102" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1103" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1104" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1139" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_PlanNameAxis_1128" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1128" xlink:to="loc_us-gaap_PlanNameDomain_1127" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1127_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1128" xlink:to="loc_us-gaap_PlanNameDomain_1127_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1127" xlink:to="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1133" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_AwardTypeAxis_1131" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1135" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1136" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1138" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1144" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1141" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1143" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1476259" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1476256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_StatementTable_1476256" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1476265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1476256" xlink:to="loc_srt_RangeAxis_1476265" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1476265" xlink:to="loc_srt_RangeMember_1476266" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476266_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1476265" xlink:to="loc_srt_RangeMember_1476266_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1476267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1476266" xlink:to="loc_srt_MaximumMember_1476267" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1476268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1476266" xlink:to="loc_srt_MinimumMember_1476268" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1476261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1476261" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476262" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476263" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1476296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_srt_StatementScenarioAxis_1476296" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1476297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1476296" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1476297" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1476297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1476296" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1476297_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlMember" xlink:label="loc_aclx_ChangeInControlMember_1476299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1476297" xlink:to="loc_aclx_ChangeInControlMember_1476299" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlFollowingAnIpoMember" xlink:label="loc_aclx_ChangeInControlFollowingAnIpoMember_1476301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1476297" xlink:to="loc_aclx_ChangeInControlFollowingAnIpoMember_1476301" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1476310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_us-gaap_AwardTypeAxis_1476310" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1476310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1476310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1476313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1476313" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1476314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_srt_RangeAxis_1476314" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1476314" xlink:to="loc_srt_RangeMember_1476315" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476315_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1476314" xlink:to="loc_srt_RangeMember_1476315_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1476316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1476315" xlink:to="loc_srt_MaximumMember_1476316" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1476317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1476315" xlink:to="loc_srt_MinimumMember_1476317" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1476427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426" xlink:to="loc_us-gaap_IPOMember_1476427" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xlink:label="loc_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant_1476302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant_1476302" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1476303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1476303" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476304" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476305" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1476306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1476306" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1476307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1476307" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1214" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1214" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1218" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1214" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1217" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1219" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xlink:label="loc_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember_1220" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1221" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RestrictedStockUnitsExecutiveOfficerMember" xlink:label="loc_aclx_RestrictedStockUnitsExecutiveOfficerMember_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_aclx_RestrictedStockUnitsExecutiveOfficerMember_1222" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncometaxdisclosureLineItems" xlink:label="loc_aclx_IncometaxdisclosureLineItems_1476056" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncometaxdisclosureTable" xlink:label="loc_aclx_IncometaxdisclosureTable_1476054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_IncometaxdisclosureTable_1476054" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodAxis" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodDomain" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodDomain_1476070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" xlink:to="loc_aclx_LossCarryforwardGeneratedPeriodDomain_1476070" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodDomain" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodDomain_1476070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" xlink:to="loc_aclx_LossCarryforwardGeneratedPeriodDomain_1476070_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1476074_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1476074_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1476078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" xlink:to="loc_us-gaap_DomesticCountryMember_1476078" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1476087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1476087" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1476079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_us-gaap_TaxPeriodAxis_1476079" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1476080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1476079" xlink:to="loc_us-gaap_TaxPeriodDomain_1476080" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1476080_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1476079" xlink:to="loc_us-gaap_TaxPeriodDomain_1476080_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TaxPeriodTwoThousandThirtyFiveMember" xlink:label="loc_aclx_TaxPeriodTwoThousandThirtyFiveMember_1476082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1476080" xlink:to="loc_aclx_TaxPeriodTwoThousandThirtyFiveMember_1476082" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IndefinitelyCarryforwardMember" xlink:label="loc_aclx_IndefinitelyCarryforwardMember_1476111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1476080" xlink:to="loc_aclx_IndefinitelyCarryforwardMember_1476111" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1476090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089" xlink:to="loc_us-gaap_ResearchMember_1476090" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1476157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_srt_RangeAxis_1476157" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1476157" xlink:to="loc_srt_RangeMember_1476158" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476158_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1476157" xlink:to="loc_srt_RangeMember_1476158_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1476160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1476158" xlink:to="loc_srt_MaximumMember_1476160" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1476162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1476158" xlink:to="loc_srt_MinimumMember_1476162" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1476060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1476060" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1476097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1476097" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1476100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1476100" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_aclx_OperatingLossCarryforwardsExpirationPeriod_1476102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_OperatingLossCarryforwardsExpirationPeriod_1476102" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TaxCreditCarryforwardExpirationPeriod" xlink:label="loc_aclx_TaxCreditCarryforwardExpirationPeriod_1476104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_TaxCreditCarryforwardExpirationPeriod_1476104" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xlink:label="loc_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange_1476118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange_1476118" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xlink:label="loc_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange_1476125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange_1476125" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_1476140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_1476140" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1476149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1476149" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1476169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1476169" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1475938" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1475936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1475938" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1475936" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1475940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1475938" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1475940" use="optional" order="2" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>aclx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-June-2022 [01:49:47] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Marketable Securities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Total prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred Costs, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseOtherNoncurrent" xml:lang="en-US">Prepaid Expense Other, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseOtherNoncurrent" xml:lang="en-US">Prepaid research and development expenses and other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseOtherNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US">Deferred Rent Credit, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US">Deferred rent, current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity (deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, par value of $0.001 per share; 200,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2022; no shares authorized, issued or outstanding as of December 31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 35,718,764 shares issued and outstanding as of March 31, 2022; 185,000,000 shares authorized and 544,210 shares issued and outstanding as of December 31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xml:lang="en-US">Redeemable convertible preferred stock:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Redeemable convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Non-current operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SeriesARedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_SeriesARedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series A</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="lab_aclx_SeriesARedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SeriesARedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series A redeemable convertible preferred stock member.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lab_aclx_SeriesBRedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B redeemable convertible preferred stock member.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SeriesCRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_SeriesCRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series C</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="lab_aclx_SeriesCRedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SeriesCRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series C redeemable convertible preferred stock member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US">Other comprehensive loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xml:lang="en-US">Unrealized loss on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted-average common shares outstanding&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending Balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Beginning balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Ending balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary equity, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Series C redeemable convertible preferred stock for cash, Value, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series C redeemable convertible preferred stock for cash, shares, net of transaction costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of redeemable convertible preferred stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary equity stock issued during period shares new issues.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesSubscriptionsAmount" xlink:label="loc_aclx_TemporaryEquitySharesSubscriptionsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TemporaryEquitySharesSubscriptionsAmount" xml:lang="en-US">Temporary Equity Shares Subscriptions Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TemporaryEquitySharesSubscriptionsAmount" xml:lang="en-US">Issuance of Series C redeemable convertible preferred stock for cash, subscriptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TemporaryEquitySharesSubscriptionsAmount" xlink:to="lab_aclx_TemporaryEquitySharesSubscriptionsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TemporaryEquitySharesSubscriptionsAmount" xml:lang="en-US">Temporary equity shares subscriptions amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock, net of transaction costs, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock , net of transaction costs, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of preferred stock to common stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of preferred stock to common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of common stock from vesting of restricted stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of common stock from vesting of restricted stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Shares, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Unrealized loss on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid In Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityMember" xlink:label="loc_aclx_TemporaryEquityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TemporaryEquityMember" xml:lang="en-US">Temporary equity [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TemporaryEquityMember" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TemporaryEquityMember" xlink:to="lab_aclx_TemporaryEquityMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TransactionCosts" xlink:label="loc_aclx_TransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TransactionCosts" xml:lang="en-US">Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TransactionCosts" xml:lang="en-US">Transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TransactionCosts" xlink:to="lab_aclx_TransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TransactionCosts" xml:lang="en-US">Transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xlink:label="loc_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xml:lang="en-US">Increase (Decrease) Prepaid Expenses and Other Current and Non-Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xml:lang="en-US">Prepaid expenses and other current and non-current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xlink:to="lab_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xml:lang="en-US">Amount of increase (decrease) in prepaid expenses and other current and non-current assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US">Accounts payable and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Noncash operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on disposal of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock (initial public offering), net of transactions costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from issuance of common stock (private placement), net of transactions costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from issuance of private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of redeemable convertible preferred stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from the exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Payments under finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeasePrincipalPayments" xlink:label="loc_aclx_CapitalLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CapitalLeasePrincipalPayments" xml:lang="en-US">Capital Lease Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aclx_CapitalLeasePrincipalPayments" xml:lang="en-US">Payments under capital leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CapitalLeasePrincipalPayments" xlink:to="lab_aclx_CapitalLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CapitalLeasePrincipalPayments" xml:lang="en-US">Capital lease principal payments.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PaymentsForRepurchaseOfRestrictedStock" xlink:label="loc_aclx_PaymentsForRepurchaseOfRestrictedStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PaymentsForRepurchaseOfRestrictedStock" xml:lang="en-US">Payments For Repurchase Of Restricted Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PaymentsForRepurchaseOfRestrictedStock" xml:lang="en-US">Payment for repurchase of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PaymentsForRepurchaseOfRestrictedStock" xlink:to="lab_aclx_PaymentsForRepurchaseOfRestrictedStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PaymentsForRepurchaseOfRestrictedStock" xml:lang="en-US">Payments for repurchase of restricted stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchases of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from maturities of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental disclosures of noncash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Purchase of property and equipment included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xlink:label="loc_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xml:lang="en-US">Deferred Offering Costs Included in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xml:lang="en-US">Deferred offering costs included in accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xlink:to="lab_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xml:lang="en-US">Deferred offering costs included in accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase in cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of The Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xml:lang="en-US">Marketable Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MarketableSecuritiesDisclosureTextBlock" xlink:label="loc_aclx_MarketableSecuritiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_MarketableSecuritiesDisclosureTextBlock" xml:lang="en-US">Marketable Securities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_MarketableSecuritiesDisclosureTextBlock" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_MarketableSecuritiesDisclosureTextBlock" xlink:to="lab_aclx_MarketableSecuritiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_MarketableSecuritiesDisclosureTextBlock" xml:lang="en-US">Marketable Securities Disclosure [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" xlink:label="loc_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" xml:lang="en-US">Prepaid Expenses And Other Assets Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" xlink:to="lab_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" xml:lang="en-US">Prepaid expenses and other assets current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommitmentsAbstract" xlink:label="loc_aclx_CommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CommitmentsAbstract" xml:lang="en-US">Commitments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CommitmentsAbstract" xlink:to="lab_aclx_CommitmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CommitmentsAbstract" xml:lang="en-US">Commitments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xml:lang="en-US">Commitments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsAbstract" xlink:label="loc_us-gaap_CapitalLeaseObligationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligationsAbstract" xml:lang="en-US">Capital Lease Obligations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_CapitalLeaseObligationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xml:lang="en-US">Capital Leases in Financial Statements of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xml:lang="en-US">Capital Lease Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="loc_aclx_LesseeOperatingAndFinanceLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LesseeOperatingAndFinanceLeasesTextBlock" xml:lang="en-US">Lessee Operating And Finance Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_LesseeOperatingAndFinanceLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:to="lab_aclx_LesseeOperatingAndFinanceLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_LesseeOperatingAndFinanceLeasesTextBlock" xml:lang="en-US">Lessee Operating And Finance Leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:label="loc_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:to="lab_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xml:lang="en-US">Redeemable convertible preferred stock and stockholders equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" xlink:label="loc_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" xml:lang="en-US">Discloure of Redeemable Convertible Preferred Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" xlink:to="lab_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" xml:lang="en-US">Discloure of redeemable convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockAbstract" xlink:label="loc_aclx_CommonStockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CommonStockAbstract" xml:lang="en-US">Common Stock [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CommonStockAbstract" xlink:to="lab_aclx_CommonStockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CommonStockAbstract" xml:lang="en-US">Common stock.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockTextBlock" xlink:label="loc_aclx_CommonStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CommonStockTextBlock" xml:lang="en-US">Common Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_CommonStockTextBlock" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CommonStockTextBlock" xlink:to="lab_aclx_CommonStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CommonStockTextBlock" xml:lang="en-US">Common stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="loc_us-gaap_DefinedBenefitPlanTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanTextBlock" xml:lang="en-US">Defined Benefit Plan [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanTextBlock" xml:lang="en-US">Employee Benefit Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTextBlock" xlink:to="lab_us-gaap_DefinedBenefitPlanTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Accounting Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" xlink:label="loc_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" xml:lang="en-US">Clinical Trial Accrual and Expenses Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" xml:lang="en-US">Clinical Trial Accrual and Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" xlink:to="lab_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" xml:lang="en-US">Clinical trial accrual and expenses policy.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="loc_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:to="lab_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" xml:lang="en-US">Redeemable convertible preferred stock policy.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" xlink:label="loc_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Status Policy Text Block [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" xlink:to="lab_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" xml:lang="en-US">Emerging growth company status policy.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" xlink:label="loc_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" xml:lang="en-US">Segment and Geographic Information Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" xml:lang="en-US">Segment and Geographic Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" xlink:to="lab_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" xml:lang="en-US">Segment and geographic information policy.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently adopted accounting pronouncements policy.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" xml:lang="en-US">Property Plant And Equipment Estimated Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" xlink:to="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" xml:lang="en-US">Property plant and equipment estimated lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of Fair Value of Company's Financial Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xml:lang="en-US">Schedule of Available-for-sale Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule Of Property And Equipment Consist</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" xlink:label="loc_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" xml:lang="en-US">Capital Leases Future Minimum Payments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" xml:lang="en-US">Summary of Future Lease Obligations Under These Capital Lease Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" xlink:to="lab_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" xml:lang="en-US">Capital leases future minimum payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Future Minimum operating lease payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xml:lang="en-US">Summary of Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xml:lang="en-US">Summary of Supplemental Cash Flow Information Related to Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xml:lang="en-US">Summary of supplemental cash flow information related to operating leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of Shares Issued and Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Units Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Black-Scholes option pricing model for stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" xml:lang="en-US">Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" xml:lang="en-US">Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" xlink:to="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" xml:lang="en-US">Schedule of the fair value of the RSU Award considering thirdparty valuation reports.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Summary of Provision For Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xlink:label="loc_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xml:lang="en-US">Additional Stock Issued During Period Shares Exercised by Underwriters with Option to Purchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xml:lang="en-US">Additional stock issued during period shares exercised by underwriters with option to purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xlink:to="lab_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xml:lang="en-US">Additional stock issued during period shares exercised by underwriters with option to purchase.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Public offering price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Net proceeds from initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="loc_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xml:lang="en-US">Cash Paid for Underwriting Discounts and commissions and Other Offering Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xml:lang="en-US">Cash paid for underwriting discounts and commissions and other offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:to="lab_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xml:lang="en-US">Cash paid for underwriting discounts and commissions and other offering expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders Equity Reverse Stock Split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesTable" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTable" xml:lang="en-US">Property Plant And Equipment Estimated Lives [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable" xlink:to="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesTable" xml:lang="en-US">Property plant and equipment estimated lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentMember" xlink:label="loc_aclx_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aclx_LabEquipmentMember" xml:lang="en-US">Lab equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LabEquipmentMember" xlink:to="lab_aclx_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_LabEquipmentMember" xml:lang="en-US">Lab Equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_EquipmentUnderCapitalLeaseMember" xlink:label="loc_aclx_EquipmentUnderCapitalLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_EquipmentUnderCapitalLeaseMember" xml:lang="en-US">Equipment Under Capital Lease [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_EquipmentUnderCapitalLeaseMember" xml:lang="en-US">Equipment under capital lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_EquipmentUnderCapitalLeaseMember" xlink:to="lab_aclx_EquipmentUnderCapitalLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_EquipmentUnderCapitalLeaseMember" xml:lang="en-US">Equipment under capital lease.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" xml:lang="en-US">Property Plant And Equipment Estimated Lives [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" xlink:to="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" xml:lang="en-US">Property plant and equipment estimated lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adoption Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in accounting principle, accounting standards update, adopted date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in accounting principle, accounting standards update, adopted [true false]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of total operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" xlink:label="loc_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" xml:lang="en-US">Reclassification of Deferred Rent and Tenant Improvement Allowances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" xml:lang="en-US">Reclassification of deferred rent and tenant improvement allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" xlink:to="lab_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" xml:lang="en-US">Reclassification of deferred rent and tenant improvement allowances</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xml:lang="en-US">Unrecognized Tax Benefits Income Tax Penalties Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment of Long Lived Assets Held for use</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Money market fund (cash equivalent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LongTermRestrictedCashFairValue" xlink:label="loc_aclx_LongTermRestrictedCashFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LongTermRestrictedCashFairValue" xml:lang="en-US">Long-Term Restricted Cash Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_LongTermRestrictedCashFairValue" xml:lang="en-US">Money market fund (long-term restricted cash)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LongTermRestrictedCashFairValue" xlink:to="lab_aclx_LongTermRestrictedCashFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_LongTermRestrictedCashFairValue" xml:lang="en-US">Long-term restricted cash fair value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Debt Securities, Available-for-sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Marketable securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total assets measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xml:lang="en-US">U.S. Government Agency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xml:lang="en-US">Asset-backed Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xml:lang="en-US">Asset-Backed Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xml:lang="en-US">Marketable Securities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xml:lang="en-US">Marketable Securities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Amortized costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Gross Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Gross Unrealized Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xml:lang="en-US">US Treasury and Government [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xml:lang="en-US">U.S. Government Agency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xml:lang="en-US">Corporate Bond Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xml:lang="en-US">Corporate Bond Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DebtSecuritiesAvailableForSaleContractualMaturities" xlink:label="loc_aclx_DebtSecuritiesAvailableForSaleContractualMaturities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_DebtSecuritiesAvailableForSaleContractualMaturities" xml:lang="en-US">Debt Securities Available For Sale Contractual Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_DebtSecuritiesAvailableForSaleContractualMaturities" xml:lang="en-US">Available-for-sale debt marketable securities contractual maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_DebtSecuritiesAvailableForSaleContractualMaturities" xlink:to="lab_aclx_DebtSecuritiesAvailableForSaleContractualMaturities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_DebtSecuritiesAvailableForSaleContractualMaturities" xml:lang="en-US">Debt Securities available for sale contractual maturities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xml:lang="en-US">Number of securities in an unrealized loss position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xml:lang="en-US">Aggregate fair value an unrealized loss position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xml:lang="en-US">Allowance for credit losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" xml:lang="en-US">Interest Income, Debt Securities, Available-for-sale, Operating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" xlink:to="lab_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PrepaidResearchAndDevelopmentCosts" xlink:label="loc_aclx_PrepaidResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PrepaidResearchAndDevelopmentCosts" xml:lang="en-US">Prepaid Research and Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PrepaidResearchAndDevelopmentCosts" xml:lang="en-US">Prepaid research and development costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PrepaidResearchAndDevelopmentCosts" xlink:to="lab_aclx_PrepaidResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PrepaidResearchAndDevelopmentCosts" xml:lang="en-US">Prepaid Research and Development Costs</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OtherPrepaidExpenseAndCurrentAssets" xlink:label="loc_aclx_OtherPrepaidExpenseAndCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_OtherPrepaidExpenseAndCurrentAssets" xml:lang="en-US">Other Prepaid Expense and Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_OtherPrepaidExpenseAndCurrentAssets" xml:lang="en-US">Other prepaid expense and current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_OtherPrepaidExpenseAndCurrentAssets" xlink:to="lab_aclx_OtherPrepaidExpenseAndCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_OtherPrepaidExpenseAndCurrentAssets" xml:lang="en-US">Other prepaid expense and current assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentUnderCapitalLeasesMember" xlink:label="loc_aclx_LabEquipmentUnderCapitalLeasesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LabEquipmentUnderCapitalLeasesMember" xml:lang="en-US">Lab Equipment Under Capital Leases [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_LabEquipmentUnderCapitalLeasesMember" xml:lang="en-US">Lab equipment under capital leases [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LabEquipmentUnderCapitalLeasesMember" xlink:to="lab_aclx_LabEquipmentUnderCapitalLeasesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_LabEquipmentUnderCapitalLeasesMember" xml:lang="en-US">Lab equipment under capital leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PriorNotificationPeriodToTerminateArrangement" xlink:label="loc_aclx_PriorNotificationPeriodToTerminateArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PriorNotificationPeriodToTerminateArrangement" xml:lang="en-US">Prior Notification Period to Terminate Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PriorNotificationPeriodToTerminateArrangement" xml:lang="en-US">Prior notification period to terminate arrangement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PriorNotificationPeriodToTerminateArrangement" xlink:to="lab_aclx_PriorNotificationPeriodToTerminateArrangement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PriorNotificationPeriodToTerminateArrangement" xml:lang="en-US">Prior notification period to terminate arrangement.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MinimumNonCancellableCosts" xlink:label="loc_aclx_MinimumNonCancellableCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_MinimumNonCancellableCosts" xml:lang="en-US">Minimum Non-cancellable Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_MinimumNonCancellableCosts" xml:lang="en-US">Minimum non-cancellable costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_MinimumNonCancellableCosts" xlink:to="lab_aclx_MinimumNonCancellableCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_MinimumNonCancellableCosts" xml:lang="en-US">Minimum non-cancellable costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitment" xml:lang="en-US">Other Commitment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCommitment" xml:lang="en-US">Obligated to pay to Lonza</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitment" xml:lang="en-US">Other Commitment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeaseAgreementMaturityPeriod" xlink:label="loc_aclx_CapitalLeaseAgreementMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CapitalLeaseAgreementMaturityPeriod" xml:lang="en-US">Capital Lease Agreement Maturity Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_CapitalLeaseAgreementMaturityPeriod" xml:lang="en-US">Capital lease agreement maturity Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CapitalLeaseAgreementMaturityPeriod" xlink:to="lab_aclx_CapitalLeaseAgreementMaturityPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CapitalLeaseAgreementMaturityPeriod" xml:lang="en-US">Capital lease agreement maturity Period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xml:lang="en-US">Capital Leases, Lessee Balance Sheet, Assets by Major Class, Other Property, Plant, and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xml:lang="en-US">Purchase of equipment under capital lease agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligations" xml:lang="en-US">Capital Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligations" xml:lang="en-US">Capital lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligations" xlink:to="lab_us-gaap_CapitalLeaseObligations" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xlink:label="loc_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xml:lang="en-US">Implied Interest Rate Used To Reduce The Minimum Lease Payments To Present</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xml:lang="en-US">Implied interest rate used to reduce the minimum lease payments to present</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xlink:to="lab_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xml:lang="en-US">Implied interest rate used to reduce the minimum lease payments to present.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xml:lang="en-US">Repayments of Debt and Lease Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xml:lang="en-US">Payments to capital lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsMember" xml:lang="en-US">Other Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xml:lang="en-US">Other Current Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xml:lang="en-US">Other Noncurrent Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xml:lang="en-US">Less: Amount representing interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xml:lang="en-US">Present value of net minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:label="loc_aclx_ResearchAndDevelopmentAccruedExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xml:lang="en-US">Research and Development Accrued Expenses, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xml:lang="en-US">Research and development accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:to="lab_aclx_ResearchAndDevelopmentAccruedExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xml:lang="en-US">Research and development accrued expenses, current</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AccruedOfferingCostsCurrent" xlink:label="loc_aclx_AccruedOfferingCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_AccruedOfferingCostsCurrent" xml:lang="en-US">Accrued Offering Costs, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_AccruedOfferingCostsCurrent" xml:lang="en-US">Accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_AccruedOfferingCostsCurrent" xlink:to="lab_aclx_AccruedOfferingCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_AccruedOfferingCostsCurrent" xml:lang="en-US">Accrued offering costs, Current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued Bonuses, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xml:lang="en-US">Accrued bonus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedVacationCurrent" xml:lang="en-US">Accrued Vacation, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedVacationCurrent" xml:lang="en-US">Accrued vacation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent" xlink:to="lab_us-gaap_AccruedVacationCurrent" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OtherAccruedLiabilityCurrent" xlink:label="loc_aclx_OtherAccruedLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_OtherAccruedLiabilityCurrent" xml:lang="en-US">Other Accrued Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aclx_OtherAccruedLiabilityCurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_OtherAccruedLiabilityCurrent" xlink:to="lab_aclx_OtherAccruedLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_OtherAccruedLiabilityCurrent" xml:lang="en-US">Other accrued liability current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LeaseExpirationYear" xlink:label="loc_aclx_LeaseExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LeaseExpirationYear" xml:lang="en-US">Lease Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_LeaseExpirationYear" xml:lang="en-US">Lease expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LeaseExpirationYear" xlink:to="lab_aclx_LeaseExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_LeaseExpirationYear" xml:lang="en-US">Lease expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Short-term operating lease, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating lease, discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating lease, remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_MD" xml:lang="en-US">MOLDOVA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_stpr_MD" xml:lang="en-US">Gaithersburg, Maryland</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OfficeAndLaboratorySpaceMember" xlink:label="loc_aclx_OfficeAndLaboratorySpaceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_OfficeAndLaboratorySpaceMember" xml:lang="en-US">office and Laboratory Space [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_OfficeAndLaboratorySpaceMember" xml:lang="en-US">Office and Laboratory Space</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_OfficeAndLaboratorySpaceMember" xlink:to="lab_aclx_OfficeAndLaboratorySpaceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_OfficeAndLaboratorySpaceMember" xml:lang="en-US">office and Laboratory Space.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Through December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2027</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total operating lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" xlink:label="loc_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" xml:lang="en-US">Cash Paid for Measurement of Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" xlink:to="lab_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" xml:lang="en-US">Cash paid for measurement of operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">ROU assets obtained in exchange for operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OperatingLeasesDeferredRent" xlink:label="loc_aclx_OperatingLeasesDeferredRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_OperatingLeasesDeferredRent" xml:lang="en-US">Operating Leases Deferred Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_OperatingLeasesDeferredRent" xml:lang="en-US">Deferred rent balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_OperatingLeasesDeferredRent" xlink:to="lab_aclx_OperatingLeasesDeferredRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_OperatingLeasesDeferredRent" xml:lang="en-US">Operating leases deferred rent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LonzaSowMember" xlink:label="loc_aclx_LonzaSowMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LonzaSowMember" xml:lang="en-US">Lonza SOW [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LonzaSowMember" xlink:to="lab_aclx_LonzaSowMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_LonzaSowMember" xml:lang="en-US">Lonza SOW.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Shares issued upon conversion of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common stock voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends declared or paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CommonStockSharesLegallyIssuedAndOutstanding" xml:lang="en-US">Common Stock Shares Legally Issued And Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_CommonStockSharesLegallyIssuedAndOutstanding" xml:lang="en-US">Total shares of common stock legally issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:to="lab_aclx_CommonStockSharesLegallyIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CommonStockSharesLegallyIssuedAndOutstanding" xml:lang="en-US">Common stock shares legally issued and outstanding</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:label="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_UnvestedEarlyExercisedSharesOfCommonStock" xml:lang="en-US">Unvested Early Exercised Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aclx_UnvestedEarlyExercisedSharesOfCommonStock" xml:lang="en-US">Less: unvested early exercised shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_UnvestedEarlyExercisedSharesOfCommonStock" xml:lang="en-US">Less: unvested early exercised shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:to="lab_aclx_UnvestedEarlyExercisedSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_UnvestedEarlyExercisedSharesOfCommonStock" xml:lang="en-US">Unvested early exercised shares of common stock.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_CommonStockSharesIssuedAndOutstanding" xml:lang="en-US">Common Stock Shares Issued And Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_aclx_CommonStockSharesIssuedAndOutstanding" xml:lang="en-US">Total shares issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_CommonStockSharesIssuedAndOutstanding" xlink:to="lab_aclx_CommonStockSharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_CommonStockSharesIssuedAndOutstanding" xml:lang="en-US">Common stock shares issued and outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary equity, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary equity, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary equity, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesDividendRate" xlink:label="loc_aclx_TemporaryEquitySharesDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TemporaryEquitySharesDividendRate" xml:lang="en-US">Temporary Equity Shares Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TemporaryEquitySharesDividendRate" xml:lang="en-US">Temporary Equity Shares Dividend Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TemporaryEquitySharesDividendRate" xlink:to="lab_aclx_TemporaryEquitySharesDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TemporaryEquitySharesDividendRate" xml:lang="en-US">Temporary equity shares dividend rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xml:lang="en-US">Dividends Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xml:lang="en-US">Dividends Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xlink:label="loc_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xml:lang="en-US">Number Of Directors Entitled To Be Elected By Each Class Of Stock.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xml:lang="en-US">Number of directors entitled to be elected by each class of stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xlink:to="lab_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xml:lang="en-US">Number of directors entitled to be elected by each class of stock.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesConversionPrice" xlink:label="loc_aclx_TemporaryEquitySharesConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TemporaryEquitySharesConversionPrice" xml:lang="en-US">Temporary Equity Shares Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TemporaryEquitySharesConversionPrice" xml:lang="en-US">Temporary equity shares conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TemporaryEquitySharesConversionPrice" xlink:to="lab_aclx_TemporaryEquitySharesConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TemporaryEquitySharesConversionPrice" xml:lang="en-US">Temporary equity shares conversion price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xml:lang="en-US">Temporary equity liquidation preference per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesB1RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SeriesB1RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B1 Redeemable Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:to="lab_aclx_SeriesB1RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SeriesB1RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B1 redeemable convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesB2RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SeriesB2RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B2 Redeemable Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:to="lab_aclx_SeriesB2RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SeriesB2RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B2 redeemable convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStocksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xml:lang="en-US">Series C Redeemable Convertible Preferred Stocks [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xlink:to="lab_aclx_SeriesCRedeemableConvertiblePreferredStocksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAxis" xlink:label="loc_us-gaap_DividendsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsAxis" xml:lang="en-US">Dividends [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAxis" xlink:to="lab_us-gaap_DividendsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsDomain" xml:lang="en-US">Dividends [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDomain" xlink:to="lab_us-gaap_DividendsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendDeclaredMember" xlink:label="loc_us-gaap_DividendDeclaredMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendDeclaredMember" xml:lang="en-US">Dividend Declared [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendDeclaredMember" xlink:to="lab_us-gaap_DividendDeclaredMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock, number of shares issued in transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiration period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Time to liquidity event (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Restricted stock units, granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Vesting description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Restricted stock units, outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Shares, Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Restricted stock units, vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xml:lang="en-US">Restricted stock units, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments other than options, exercisable.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_NumberOfPerformanceConditionScenarios" xlink:label="loc_aclx_NumberOfPerformanceConditionScenarios" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_NumberOfPerformanceConditionScenarios" xml:lang="en-US">Number of Performance Condition Scenarios</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_NumberOfPerformanceConditionScenarios" xml:lang="en-US">Number of performance condition scenarios</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_NumberOfPerformanceConditionScenarios" xlink:to="lab_aclx_NumberOfPerformanceConditionScenarios" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_NumberOfPerformanceConditionScenarios" xml:lang="en-US">Number of performance condition scenarios.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US">Anticipated service period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:label="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Value of Award</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xml:lang="en-US">Fair value of the RSU award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:to="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, fair value assumptions, fair value of award.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AnniversaryPeriod" xlink:label="loc_aclx_AnniversaryPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_AnniversaryPeriod" xml:lang="en-US">Anniversary Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_AnniversaryPeriod" xml:lang="en-US">Anniversary period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_AnniversaryPeriod" xlink:to="lab_aclx_AnniversaryPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_AnniversaryPeriod" xml:lang="en-US">Anniversary period</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xlink:label="loc_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xml:lang="en-US">Percentage Increase In Common Stock Reserve for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xml:lang="en-US">Percentage increase in common stock reserve for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xlink:to="lab_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xml:lang="en-US">Percentage increase in common stock reserve for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xml:lang="en-US">Number of shares issued under share-based payment arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">weighted average grant date fair value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Aggregate grant date fair value of stock options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">unrecognized compensation cost related to unvested share-based compensation arrangements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlMember" xlink:label="loc_aclx_ChangeInControlMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ChangeInControlMember" xml:lang="en-US">Change in Control [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_ChangeInControlMember" xml:lang="en-US">Change in Control</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ChangeInControlMember" xlink:to="lab_aclx_ChangeInControlMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_ChangeInControlMember" xml:lang="en-US">Change in control.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Board of Directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Seventeen Plan and Two Thousand Twenty Two Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">2017 and 2022 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="lab_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two thousand seventeen plan and two thousand twenty two equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">2022 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="lab_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two thousand twenty two equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TwoThousandSeventeenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TwoThousandSeventeenEquityIncentivePlanMember" xml:lang="en-US">2017 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_aclx_TwoThousandSeventeenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TwoThousandSeventeenEquityIncentivePlanMember" xml:lang="en-US">Two thousand seventeen equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Options to Purchase Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Shares, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Equity volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" xml:lang="en-US">Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" xlink:to="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" xml:lang="en-US">Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" xlink:to="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" xml:lang="en-US">Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" xlink:to="lab_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xlink:label="loc_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award, Date of Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xml:lang="en-US">Date of grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xlink:to="lab_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award, Date of Grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Discount for lack of marketability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Fair value of the RSU award (in thousands)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlFollowingAnIpoMember" xlink:label="loc_aclx_ChangeInControlFollowingAnIpoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_ChangeInControlFollowingAnIpoMember" xml:lang="en-US">Change in control following an IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_ChangeInControlFollowingAnIpoMember" xlink:to="lab_aclx_ChangeInControlFollowingAnIpoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xlink:label="loc_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xml:lang="en-US">Unvested shares of restricted common stock from early exercises [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xml:lang="en-US">Unvested Shares of Restricted Common Stock from Early Exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xlink:to="lab_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xml:lang="en-US">Unvested shares of restricted common stock from early exercises [Member]</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RestrictedStockUnitsExecutiveOfficerMember" xlink:label="loc_aclx_RestrictedStockUnitsExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_RestrictedStockUnitsExecutiveOfficerMember" xml:lang="en-US">Restricted stock units - executive officer[Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_RestrictedStockUnitsExecutiveOfficerMember" xml:lang="en-US">Restricted stock units - executive officer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_RestrictedStockUnitsExecutiveOfficerMember" xlink:to="lab_aclx_RestrictedStockUnitsExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_RestrictedStockUnitsExecutiveOfficerMember" xml:lang="en-US">Restricted stock units - executive officer[Member]</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncometaxdisclosureTable" xlink:label="loc_aclx_IncometaxdisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_IncometaxdisclosureTable" xml:lang="en-US">IncomeTaxDisclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_IncometaxdisclosureTable" xlink:to="lab_aclx_IncometaxdisclosureTable" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncometaxdisclosureLineItems" xlink:label="loc_aclx_IncometaxdisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_IncometaxdisclosureLineItems" xml:lang="en-US">IncomeTaxDisclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_IncometaxdisclosureLineItems" xlink:to="lab_aclx_IncometaxdisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Change in valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforward amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_aclx_OperatingLossCarryforwardsExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Operating Loss Carryforwards Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Operating loss carryforwards expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_OperatingLossCarryforwardsExpirationPeriod" xlink:to="lab_aclx_OperatingLossCarryforwardsExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Operating Loss Carryforwards Expiration Period.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TaxCreditCarryforwardExpirationPeriod" xlink:label="loc_aclx_TaxCreditCarryforwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TaxCreditCarryforwardExpirationPeriod" xml:lang="en-US">Tax Credit Carryforward Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_TaxCreditCarryforwardExpirationPeriod" xml:lang="en-US">Tax credit carryforward expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TaxCreditCarryforwardExpirationPeriod" xlink:to="lab_aclx_TaxCreditCarryforwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_TaxCreditCarryforwardExpirationPeriod" xml:lang="en-US">Tax credit carryforward expiration period.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xlink:label="loc_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xml:lang="en-US">Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xml:lang="en-US">Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xlink:to="lab_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xml:lang="en-US">Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xlink:label="loc_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xml:lang="en-US">Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xml:lang="en-US">Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xlink:to="lab_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xml:lang="en-US">Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Income Tax Examination, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Description of income tax examination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationDescription" xlink:to="lab_us-gaap_IncomeTaxExaminationDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xml:lang="en-US">Income Tax Examination, Year under Examination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" xml:lang="en-US">Income tax examination year under examination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:to="lab_us-gaap_IncomeTaxExaminationYearUnderExamination" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodAxis" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LossCarryforwardGeneratedPeriodAxis" xml:lang="en-US">Loss Carryforward Generated Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LossCarryforwardGeneratedPeriodAxis" xlink:to="lab_aclx_LossCarryforwardGeneratedPeriodAxis" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodDomain" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_LossCarryforwardGeneratedPeriodDomain" xml:lang="en-US">Loss Carryforward Generated Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_LossCarryforwardGeneratedPeriodDomain" xlink:to="lab_aclx_LossCarryforwardGeneratedPeriodDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TaxPeriodTwoThousandThirtyFiveMember" xlink:label="loc_aclx_TaxPeriodTwoThousandThirtyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_TaxPeriodTwoThousandThirtyFiveMember" xml:lang="en-US">Tax Period Two Thousand Thirty Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_TaxPeriodTwoThousandThirtyFiveMember" xlink:to="lab_aclx_TaxPeriodTwoThousandThirtyFiveMember" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IndefinitelyCarryforwardMember" xlink:label="loc_aclx_IndefinitelyCarryforwardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_IndefinitelyCarryforwardMember" xml:lang="en-US">Indefinitely Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_IndefinitelyCarryforwardMember" xlink:to="lab_aclx_IndefinitelyCarryforwardMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Current income tax provision (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">U.S. federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xml:lang="en-US">Deferred income tax provision (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">U.S. federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total provision (benefit) for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. federal tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State tax, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred income tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">U.S. federal net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">State net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="loc_aclx_DeferredTaxAssetsNonQualifiedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_DeferredTaxAssetsNonQualifiedStockOptions" xml:lang="en-US">Deferred Tax Assets Non Qualified Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_DeferredTaxAssetsNonQualifiedStockOptions" xml:lang="en-US">Non-qualified&#160;stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_DeferredTaxAssetsNonQualifiedStockOptions" xlink:to="lab_aclx_DeferredTaxAssetsNonQualifiedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_DeferredTaxAssetsNonQualifiedStockOptions" xml:lang="en-US">Deferred tax assets non qualified stock options.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" xlink:label="loc_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Accrued Employee Bonuses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" xml:lang="en-US">Accrued bonus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" xlink:to="lab_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits accrued employee bonuses.</label>
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_aclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_aclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred tax assets operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred income tax assets (liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Employer contributions to the plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>aclx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 15-June-2022 [01:49:47] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CoverPage" roleURI="http://arc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NatureOfTheBusiness" roleURI="http://arc.com/role/NatureOfTheBusiness" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCash" roleURI="http://arc.com/role/RestrictedCash" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstruments" roleURI="http://arc.com/role/FairValueOfFinancialInstruments" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecurities" roleURI="http://arc.com/role/MarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNet" roleURI="http://arc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#Commitments" roleURI="http://arc.com/role/Commitments" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligations" roleURI="http://arc.com/role/CapitalLeaseObligations" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilities" roleURI="http://arc.com/role/AccruedLiabilities" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#Leases" roleURI="http://arc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingencies" roleURI="http://arc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStock" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStock" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStock" roleURI="http://arc.com/role/CommonStock" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensation" roleURI="http://arc.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NetLossPerShareAttributableToCommonStockholders" roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholders" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxes" roleURI="http://arc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#EmployeeBenefitPlan" roleURI="http://arc.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashTables" roleURI="http://arc.com/role/RestrictedCashTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstrumentsTables" roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesTables" roleURI="http://arc.com/role/MarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetTables" roleURI="http://arc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsTables" roleURI="http://arc.com/role/CapitalLeaseObligationsTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilitiesTables" roleURI="http://arc.com/role/AccruedLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesTables" roleURI="http://arc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingenciesTables" roleURI="http://arc.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStockTables" roleURI="http://arc.com/role/CommonStockTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationTables" roleURI="http://arc.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesTables" roleURI="http://arc.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NatureOfTheBusinessAdditionalInformationDetails" roleURI="http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashAdditionalInformationDetails" roleURI="http://arc.com/role/RestrictedCashAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" roleURI="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" roleURI="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#MarketableSecuritiesAdditionalInformationDetails" roleURI="http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" roleURI="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#PropertyAndEquipmentNetDetail" roleURI="http://arc.com/role/PropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAdditionalInformationDetails" roleURI="http://arc.com/role/CommitmentsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsAdditionalInformationDetail" roleURI="http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" roleURI="http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" roleURI="http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesAdditionalInformationDetails" roleURI="http://arc.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSummaryOfLeaseCostsDetails" roleURI="http://arc.com/role/LeasesSummaryOfLeaseCostsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" roleURI="http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" roleURI="http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail" roleURI="http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#RedeemableConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail" roleURI="http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#CommonStockAdditionalInformationDetail" roleURI="http://arc.com/role/CommonStockAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationAdditionalInformationDetails" roleURI="http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" roleURI="http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails" roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails" roleURI="http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://arc.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" roleURI="http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" roleURI="http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="aclx-20220331.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1476252" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_1476254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_DocumentType_1476254" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1476260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_AmendmentFlag_1476260" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1476270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_EntityRegistrantName_1476270" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1476272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_EntityCentralIndexKey_1476272" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_1476274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_EntitySmallBusiness_1476274" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_1476275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_EntityEmergingGrowthCompany_1476275" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_1476276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_EntityExTransitionPeriod_1476276" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1476277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1476252" xlink:to="loc_dei_EntityFilerCategory_1476277" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="loc_us-gaap_StatementTable_122" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_122" xlink:to="loc_us-gaap_StatementClassOfStockAxis_121" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_121" xlink:to="loc_us-gaap_ClassOfStockDomain_113" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_123" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_128" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_113" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_134" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_122" xlink:to="loc_us-gaap_StatementLineItems_114" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_AssetsAbstract_120" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_AssetsCurrentAbstract_118" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_126" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_133" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_140" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_118" xlink:to="loc_us-gaap_AssetsCurrent_145" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_132" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_139" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_144" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_DeferredCosts_149" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseOtherNoncurrent_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_PrepaidExpenseOtherNoncurrent_150" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_120" xlink:to="loc_us-gaap_Assets_154" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_119" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_AccountsPayableCurrent_127" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_131" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_138" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_143" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_148" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119" xlink:to="loc_us-gaap_LiabilitiesCurrent_153" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_130" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_137" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_142" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_Liabilities_147" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_117" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract_117" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_125" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="loc_us-gaap_StockholdersEquityAbstract_116" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_PreferredStockValue_124" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_CommonStockValue_129" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_AdditionalPaidInCapital_136" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_141" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_146" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_116" xlink:to="loc_us-gaap_StockholdersEquity_151" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_114" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_135" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_178" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_178" xlink:to="loc_us-gaap_StatementTable_182" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_182" xlink:to="loc_us-gaap_StatementClassOfStockAxis_181" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_181" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_183" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_185" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_187" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_182" xlink:to="loc_us-gaap_StatementLineItems_180" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_184" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_186" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockSharesIssued_188" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_189" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_190" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_191" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockSharesIssued_192" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_193" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_180" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_198" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_216" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_RevenuesAbstract_219" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_219" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_222" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_OperatingExpensesAbstract_218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_218" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_221" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_218" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_218" xlink:to="loc_us-gaap_OperatingExpenses_225" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_OperatingIncomeLoss_224" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_226" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_NetIncomeLoss_227" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_217" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_220" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_228" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_229" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_216" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_230" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_276" xlink:to="loc_us-gaap_StatementTable_284" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_283" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_283" xlink:to="loc_us-gaap_EquityComponentDomain_282" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_CommonStockMember_288" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_292" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_RetainedEarningsMember_295" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_297" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityMember" xlink:label="loc_aclx_TemporaryEquityMember_1476434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_282" xlink:to="loc_aclx_TemporaryEquityMember_1476434" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_281" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_281" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" xlink:to="loc_us-gaap_IPOMember_287" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_280" xlink:to="loc_us-gaap_PrivatePlacementMember_291" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementClassOfStockAxis_279" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_279" xlink:to="loc_us-gaap_ClassOfStockDomain_278" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_278" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_286" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_278" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_290" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_278" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_294" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementLineItems_277" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockholdersEquity_285" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_SharesOutstanding_289" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_293" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_296" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_298" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_299" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesSubscriptionsAmount" xlink:label="loc_aclx_TemporaryEquitySharesSubscriptionsAmount_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_aclx_TemporaryEquitySharesSubscriptionsAmount_300" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_301" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_302" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_303" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_304" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_307" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_308" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_309" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_310" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_311" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_312" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_NetIncomeLoss_313" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_StockholdersEquity_314" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_SharesOutstanding_315" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_316" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_277" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_317" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_335" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_335" xlink:to="loc_us-gaap_StatementTable_340" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_339" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_339" xlink:to="loc_us-gaap_EquityComponentDomain_336" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_336" xlink:to="loc_us-gaap_CommonStockMember_344" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_343" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_343" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" xlink:to="loc_us-gaap_IPOMember_347" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_342" xlink:to="loc_us-gaap_PrivatePlacementMember_348" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_StatementClassOfStockAxis_338" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_338" xlink:to="loc_us-gaap_ClassOfStockDomain_337" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_337" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_345" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_340" xlink:to="loc_us-gaap_StatementLineItems_341" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TransactionCosts" xlink:label="loc_aclx_TransactionCosts_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_341" xlink:to="loc_aclx_TransactionCosts_346" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_387" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_387" xlink:to="loc_us-gaap_StatementTable_390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476168" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476168" xlink:to="loc_us-gaap_ClassOfStockDomain_1476170" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476170" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476171" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476170" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476172" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_390" xlink:to="loc_us-gaap_StatementLineItems_394" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_NetIncomeLoss_397" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_401" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_404" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_407" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_ShareBasedCompensation_413" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1476135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_395" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1476135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets" xlink:label="loc_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets_396" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_405" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_410" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_412" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_388" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_418" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_389" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_399" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_402" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_408" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_392" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_415" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeasePrincipalPayments" xlink:label="loc_aclx_CapitalLeasePrincipalPayments_1476142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_aclx_CapitalLeasePrincipalPayments_1476142" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_414" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_420" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PaymentsForRepurchaseOfRestrictedStock" xlink:label="loc_aclx_PaymentsForRepurchaseOfRestrictedStock_1476148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_aclx_PaymentsForRepurchaseOfRestrictedStock_1476148" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_409" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_398" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_403" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_417" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_391" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_422" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_411" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_419" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_421" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_394" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_400" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredOfferingCostsIncludedInAccruedLiabilities" xlink:label="loc_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_393" xlink:to="loc_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities_406" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/NatureOfTheBusiness">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_427" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_427" xlink:to="loc_us-gaap_NatureOfOperations_428" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_433" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_433" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_434" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RestrictedCash">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_439" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_439" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/FairValueOfFinancialInstruments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_445" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_445" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_446" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/MarketableSecurities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_451" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MarketableSecuritiesDisclosureTextBlock" xlink:label="loc_aclx_MarketableSecuritiesDisclosureTextBlock_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_451" xlink:to="loc_aclx_MarketableSecuritiesDisclosureTextBlock_452" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_457" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock" xlink:label="loc_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_457" xlink:to="loc_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475923" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1475926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475923" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1475926" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/Commitments">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommitmentsAbstract" xlink:label="loc_aclx_CommitmentsAbstract_469" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommitmentsAbstract_469" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CapitalLeaseObligations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsAbstract" xlink:label="loc_us-gaap_CapitalLeaseObligationsAbstract_1476006" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_1476008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_1476006" xlink:to="loc_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock_1476008" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/AccruedLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_475" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_475" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_476" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_481" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LesseeOperatingAndFinanceLeasesTextBlock" xlink:label="loc_aclx_LesseeOperatingAndFinanceLeasesTextBlock_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_481" xlink:to="loc_aclx_LesseeOperatingAndFinanceLeasesTextBlock_482" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1476115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476114" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1476115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_487" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:label="loc_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_487" xlink:to="loc_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_488" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStock">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_1476271" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock" xlink:label="loc_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock_1476273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_1476271" xlink:to="loc_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock_1476273" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommonStock">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockAbstract" xlink:label="loc_aclx_CommonStockAbstract_1476143" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockTextBlock" xlink:label="loc_aclx_CommonStockTextBlock_1476146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommonStockAbstract_1476143" xlink:to="loc_aclx_CommonStockTextBlock_1476146" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_493" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_493" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/NetLossPerShareAttributableToCommonStockholders">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_499" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_499" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_500" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1475956" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1475957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1475956" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1475957" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/EmployeeBenefitPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1475927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="loc_us-gaap_DefinedBenefitPlanTextBlock_1475928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1475927" xlink:to="loc_us-gaap_DefinedBenefitPlanTextBlock_1475928" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_512" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1476021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1476021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1476023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_UseOfEstimates_1476023" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1476040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1476040" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1476041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1476041" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1476042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1476042" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1476043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1476043" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1476055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1476055" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_1476057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_1476057" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock" xlink:label="loc_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock_1476058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock_1476058" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1476063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1476063" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="loc_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock_1476076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock_1476076" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1476081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1476081" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1476085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1476085" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1476086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1476086" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock" xlink:label="loc_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock_1476094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock_1476094" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock" xlink:label="loc_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock_1476096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock_1476096" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_1476098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_1476098" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1476099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1476099" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_512" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_513" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1476108" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock_1476109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1476108" xlink:to="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock_1476109" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RestrictedCashTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_519" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_519" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/FairValueOfFinancialInstrumentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_525" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_525" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_526" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/MarketableSecuritiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_531" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_531" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_532" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_537" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_537" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_538" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475942" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1475943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475942" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1475943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CapitalLeaseObligationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476032" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock" xlink:label="loc_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock_1476034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476032" xlink:to="loc_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock_1476034" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/AccruedLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_543" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_543" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_544" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_553" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_553" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_554" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_553" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_555" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_553" xlink:to="loc_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_556" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476122" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1476124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476122" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1476124" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_563" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_563" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_564" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommonStockTables">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockAbstract" xlink:label="loc_aclx_CommonStockAbstract_1476152" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_1476154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommonStockAbstract_1476152" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_1476154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_571" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_572" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_571" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_573" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_571" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_574" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1476249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_571" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1476249" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock_1476286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_571" xlink:to="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock_1476286" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_579" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_579" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1475971" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1475972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1475971" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1475972" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1475973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1475971" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1475973" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1475974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1475971" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1475974" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_597" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_597" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_603" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_603" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_602" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_602" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_601" xlink:to="loc_us-gaap_IPOMember_606" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_603" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_600" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_600" xlink:to="loc_us-gaap_EquityComponentDomain_599" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_599" xlink:to="loc_us-gaap_CommonStockMember_605" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_603" xlink:to="loc_us-gaap_ClassOfStockLineItems_598" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_604" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase" xlink:label="loc_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase_607" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_608" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_609" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="loc_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_610" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1475964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_598" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1475964" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1476112" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesTable" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1476112" xlink:to="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476117" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1476121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_us-gaap_ComputerEquipmentMember_1476121" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1476123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1476123" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentMember" xlink:label="loc_aclx_LabEquipmentMember_1476126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_aclx_LabEquipmentMember_1476126" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1476127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1476127" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_EquipmentUnderCapitalLeaseMember" xlink:label="loc_aclx_EquipmentUnderCapitalLeaseMember_1476128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476119" xlink:to="loc_aclx_EquipmentUnderCapitalLeaseMember_1476128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems" xlink:label="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesTable_1476116" xlink:to="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1476130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1476130" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1476404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems_1476129" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1476404" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_620" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_621" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_622" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_623" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_624" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_OperatingLeaseLiability_625" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances" xlink:label="loc_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances_626" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_1476141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_1476141" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1476155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1476155" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RestrictedCashAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_631" xlink:to="loc_us-gaap_RestrictedCash_632" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639" xlink:to="loc_us-gaap_RestrictedCashCurrent_641" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_639" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_642" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_667" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_667" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_675" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_680" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_674" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_683" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_672" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_671" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_671" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_678" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_670" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_670" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_CommercialPaperMember_677" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_681" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_684" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_669" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_687" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_668" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_668" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_679" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LongTermRestrictedCashFairValue" xlink:label="loc_aclx_LongTermRestrictedCashFairValue_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_aclx_LongTermRestrictedCashFairValue_682" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_685" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_673" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_688" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_706" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaap_MarketableSecuritiesTable_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_706" xlink:to="loc_us-gaap_MarketableSecuritiesTable_708" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_708" xlink:to="loc_us-gaap_FinancialInstrumentAxis_711" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_711" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_715" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_717" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_719" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1475921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_710" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1475921" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_708" xlink:to="loc_us-gaap_InvestmentTypeAxis_712" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_712" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_709" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_709" xlink:to="loc_us-gaap_CommercialPaperMember_714" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_708" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_707" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_713" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_716" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_718" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_707" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_720" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_730" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DebtSecuritiesAvailableForSaleContractualMaturities" xlink:label="loc_aclx_DebtSecuritiesAvailableForSaleContractualMaturities_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_730" xlink:to="loc_aclx_DebtSecuritiesAvailableForSaleContractualMaturities_731" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_730" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_732" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_730" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_733" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_730" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_734" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_730" xlink:to="loc_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_735" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_730" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_736" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_743" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PrepaidResearchAndDevelopmentCosts" xlink:label="loc_aclx_PrepaidResearchAndDevelopmentCosts_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_743" xlink:to="loc_aclx_PrepaidResearchAndDevelopmentCosts_744" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OtherPrepaidExpenseAndCurrentAssets" xlink:label="loc_aclx_OtherPrepaidExpenseAndCurrentAssets_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_743" xlink:to="loc_aclx_OtherPrepaidExpenseAndCurrentAssets_745" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_743" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_746" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475945" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475945" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1475951" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentMember" xlink:label="loc_aclx_LabEquipmentMember_1475954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_aclx_LabEquipmentMember_1475954" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1475955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1475955" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LabEquipmentUnderCapitalLeasesMember" xlink:label="loc_aclx_LabEquipmentUnderCapitalLeasesMember_1475958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_aclx_LabEquipmentUnderCapitalLeasesMember_1475958" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1475959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_ComputerEquipmentMember_1475959" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1475960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1475960" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1475961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1475952" xlink:to="loc_us-gaap_ConstructionInProgressMember_1475961" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1475946" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1475948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1475948" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1475949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1475949" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1475950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1475947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1475950" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/PropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475976" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_1475977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1475976" xlink:to="loc_us-gaap_DepreciationAndAmortization_1475977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommitmentsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommitmentsAbstract" xlink:label="loc_aclx_CommitmentsAbstract_761" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PriorNotificationPeriodToTerminateArrangement" xlink:label="loc_aclx_PriorNotificationPeriodToTerminateArrangement_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommitmentsAbstract_761" xlink:to="loc_aclx_PriorNotificationPeriodToTerminateArrangement_762" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MinimumNonCancellableCosts" xlink:label="loc_aclx_MinimumNonCancellableCosts_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommitmentsAbstract_761" xlink:to="loc_aclx_MinimumNonCancellableCosts_763" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommitmentsAbstract_761" xlink:to="loc_us-gaap_OtherCommitment_764" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsAbstract" xlink:label="loc_us-gaap_CapitalLeaseObligationsAbstract_1476062" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1476065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeaseObligationsAbstract_1476062" xlink:to="loc_us-gaap_StatementTable_1476065" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476065" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476066" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476066" xlink:to="loc_us-gaap_ClassOfStockDomain_1476067" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1476091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476065" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1476091" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1476092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1476091" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1476092" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_1476093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1476092" xlink:to="loc_us-gaap_OtherAssetsMember_1476093" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1476095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsMember_1476093" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1476095" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1476101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsMember_1476093" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1476101" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1476068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476065" xlink:to="loc_us-gaap_StatementLineItems_1476068" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CapitalLeaseAgreementMaturityPeriod" xlink:label="loc_aclx_CapitalLeaseAgreementMaturityPeriod_1476072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_aclx_CapitalLeaseAgreementMaturityPeriod_1476072" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_1476075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_1476075" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaap_CapitalLeaseObligations_1476077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_CapitalLeaseObligations_1476077" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent" xlink:label="loc_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent_1476083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent_1476083" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1476084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476068" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_1476084" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_1476046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_1476046" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_1476047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_1476047" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_1476048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_1476048" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_1476049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_1476049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_1476051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_1476051" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_1476052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_1476045" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_1476052" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ResearchAndDevelopmentAccruedExpensesCurrent" xlink:label="loc_aclx_ResearchAndDevelopmentAccruedExpensesCurrent_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_aclx_ResearchAndDevelopmentAccruedExpensesCurrent_774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AccruedOfferingCostsCurrent" xlink:label="loc_aclx_AccruedOfferingCostsCurrent_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_aclx_AccruedOfferingCostsCurrent_775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_us-gaap_AccruedBonusesCurrent_776" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_1476103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_us-gaap_AccruedVacationCurrent_1476103" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_777" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OtherAccruedLiabilityCurrent" xlink:label="loc_aclx_OtherAccruedLiabilityCurrent_1476438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_aclx_OtherAccruedLiabilityCurrent_1476438" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_773" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_778" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_802" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_808" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_808" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_807" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OfficeAndLaboratorySpaceMember" xlink:label="loc_aclx_OfficeAndLaboratorySpaceMember_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_806" xlink:to="loc_aclx_OfficeAndLaboratorySpaceMember_811" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_808" xlink:to="loc_srt_StatementGeographicalAxis_805" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_805" xlink:to="loc_srt_SegmentGeographicalDomain_804" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_804" xlink:to="loc_stpr_MD_810" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_808" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LeaseExpirationYear" xlink:label="loc_aclx_LeaseExpirationYear_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_aclx_LeaseExpirationYear_809" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_812" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_813" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_814" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_815" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_816" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_803" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_817" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesSummaryOfLeaseCostsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_830" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_830" xlink:to="loc_us-gaap_OperatingLeaseCost_831" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_830" xlink:to="loc_us-gaap_ShortTermLeaseCost_832" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_830" xlink:to="loc_us-gaap_VariableLeaseCost_833" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_830" xlink:to="loc_us-gaap_LeaseCost_834" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_848" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_849" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_850" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_851" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_852" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_853" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_854" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_855" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_856" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_857" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_848" xlink:to="loc_us-gaap_OperatingLeaseLiability_858" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_864" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities" xlink:label="loc_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_864" xlink:to="loc_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities_865" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_864" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_866" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476161" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1476164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476161" xlink:to="loc_us-gaap_StatementTable_1476164" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1476174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_dei_LegalEntityAxis_1476174" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1476175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1476174" xlink:to="loc_dei_EntityDomain_1476175" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LonzaSowMember" xlink:label="loc_aclx_LonzaSowMember_1476176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1476175" xlink:to="loc_aclx_LonzaSowMember_1476176" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1476189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_srt_StatementGeographicalAxis_1476189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1476191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1476189" xlink:to="loc_srt_SegmentGeographicalDomain_1476191" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MD" xlink:label="loc_stpr_MD_1476422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1476191" xlink:to="loc_stpr_MD_1476422" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1476181" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OfficeAndLaboratorySpaceMember" xlink:label="loc_aclx_OfficeAndLaboratorySpaceMember_1476187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1476183" xlink:to="loc_aclx_OfficeAndLaboratorySpaceMember_1476187" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1476167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476164" xlink:to="loc_us-gaap_StatementLineItems_1476167" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LeaseExpirationYear" xlink:label="loc_aclx_LeaseExpirationYear_1476179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_aclx_LeaseExpirationYear_1476179" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OperatingLeasesDeferredRent" xlink:label="loc_aclx_OperatingLeasesDeferredRent_1476195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_aclx_OperatingLeasesDeferredRent_1476195" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1476196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1476196" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_1476197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476167" xlink:to="loc_us-gaap_OtherCommitment_1476197" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1476133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1476133" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1476134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1476134" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1476136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1476136" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1476137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1476137" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1476138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1476138" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1476144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1476144" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1476145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1476132" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1476145" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_908" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_908" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_916" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_915" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_915" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_914" xlink:to="loc_us-gaap_IPOMember_920" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_StatementClassOfStockAxis_912" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_912" xlink:to="loc_us-gaap_ClassOfStockDomain_911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_911" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_918" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_910" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_910" xlink:to="loc_us-gaap_EquityComponentDomain_909" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_909" xlink:to="loc_us-gaap_CommonStockMember_917" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_916" xlink:to="loc_us-gaap_ClassOfStockLineItems_913" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_919" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_CommonStockVotingRights_921" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_913" xlink:to="loc_us-gaap_DividendsCommonStock_922" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_934" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_934" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_938" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_938" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_937" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_937" xlink:to="loc_us-gaap_EquityComponentDomain_936" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_936" xlink:to="loc_us-gaap_CommonStockMember_940" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_938" xlink:to="loc_us-gaap_ClassOfStockLineItems_935" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_939" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:label="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_941" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesIssuedAndOutstanding_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_935" xlink:to="loc_aclx_CommonStockSharesIssuedAndOutstanding_942" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_1476279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_1476279" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476283" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476283" xlink:to="loc_us-gaap_ClassOfStockDomain_1476284" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1476285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1476285" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_1476294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesARedeemableConvertiblePreferredStockMember_1476294" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesBRedeemableConvertiblePreferredStockMember_1476312" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStockMember_1476318" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesCRedeemableConvertiblePreferredStocksMember" xlink:label="loc_aclx_SeriesCRedeemableConvertiblePreferredStocksMember_1476436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesCRedeemableConvertiblePreferredStocksMember_1476436" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesB1RedeemableConvertiblePreferredStockMember_1476319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesB1RedeemableConvertiblePreferredStockMember_1476319" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="loc_aclx_SeriesB2RedeemableConvertiblePreferredStockMember_1476320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1476284" xlink:to="loc_aclx_SeriesB2RedeemableConvertiblePreferredStockMember_1476320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476287" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1476289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476288" xlink:to="loc_us-gaap_IPOMember_1476289" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAxis" xlink:label="loc_us-gaap_DividendsAxis_1476327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_DividendsAxis_1476327" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsDomain" xlink:label="loc_us-gaap_DividendsDomain_1476328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAxis_1476327" xlink:to="loc_us-gaap_DividendsDomain_1476328" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendDeclaredMember" xlink:label="loc_us-gaap_DividendDeclaredMember_1476329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsDomain_1476328" xlink:to="loc_us-gaap_DividendDeclaredMember_1476329" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1476281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1476280" xlink:to="loc_us-gaap_TemporaryEquityLineItems_1476281" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1476282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_1476282" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1476291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1476291" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1476298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_1476298" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1476308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1476308" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1476309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1476309" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1476321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_1476321" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TransactionCosts" xlink:label="loc_aclx_TransactionCosts_1476322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TransactionCosts_1476322" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1476323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1476323" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesDividendRate" xlink:label="loc_aclx_TemporaryEquitySharesDividendRate_1476325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TemporaryEquitySharesDividendRate_1476325" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1476326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_1476326" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock." xlink:label="loc_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock._1476330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock._1476330" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TemporaryEquitySharesConversionPrice" xlink:label="loc_aclx_TemporaryEquitySharesConversionPrice_1476331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_aclx_TemporaryEquitySharesConversionPrice_1476331" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1476332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1476281" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_1476332" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockAbstract" xlink:label="loc_aclx_CommonStockAbstract_1476180" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1476182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommonStockAbstract_1476180" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1476182" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1476184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476182" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1476184" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1476185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1476184" xlink:to="loc_us-gaap_EquityComponentDomain_1476185" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1476186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1476185" xlink:to="loc_us-gaap_CommonStockMember_1476186" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1476188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476182" xlink:to="loc_us-gaap_ClassOfStockLineItems_1476188" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesLegallyIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_1476190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_aclx_CommonStockSharesLegallyIssuedAndOutstanding_1476190" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedEarlyExercisedSharesOfCommonStock" xlink:label="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_1476192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_aclx_UnvestedEarlyExercisedSharesOfCommonStock_1476192" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockSharesIssuedAndOutstanding" xlink:label="loc_aclx_CommonStockSharesIssuedAndOutstanding_1476193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476188" xlink:to="loc_aclx_CommonStockSharesIssuedAndOutstanding_1476193" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/CommonStockAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_CommonStockAbstract" xlink:label="loc_aclx_CommonStockAbstract_1476203" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1476204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_CommonStockAbstract_1476203" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1476204" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476205" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1476225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476206" xlink:to="loc_us-gaap_PrivatePlacementMember_1476225" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1476208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1476208" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1476209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1476208" xlink:to="loc_us-gaap_ClassOfStockDomain_1476209" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1476212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1476212" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1476213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1476212" xlink:to="loc_us-gaap_EquityComponentDomain_1476213" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1476214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1476213" xlink:to="loc_us-gaap_CommonStockMember_1476214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1476215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1476204" xlink:to="loc_us-gaap_ClassOfStockLineItems_1476215" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1476217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockVotingRights_1476217" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_1476218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_DividendsCommonStock_1476218" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1476221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1476221" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1476222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1476222" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1476223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1476223" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1476237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1476237" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1476239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockSharesIssued_1476239" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1476240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1476240" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1476241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1476215" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1476241" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_AwardTypeAxis_1000" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1008" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_997" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1013" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_991" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_991" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_990" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_990" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1004" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_990" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1012" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_993" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_993" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" xlink:to="loc_us-gaap_IPOMember_1005" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlMember" xlink:label="loc_aclx_ChangeInControlMember_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_992" xlink:to="loc_aclx_ChangeInControlMember_1014" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_srt_TitleOfIndividualAxis_995" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_995" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" xlink:to="loc_srt_ExecutiveOfficerMember_1006" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_994" xlink:to="loc_srt_DirectorMember_1009" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_PlanNameAxis_998" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_998" xlink:to="loc_us-gaap_PlanNameDomain_989" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_989" xlink:to="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1003" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_989" xlink:to="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1011" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenEquityIncentivePlanMember_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_989" xlink:to="loc_aclx_TwoThousandSeventeenEquityIncentivePlanMember_1016" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_srt_RangeAxis_999" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_999" xlink:to="loc_srt_RangeMember_996" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_996" xlink:to="loc_srt_MinimumMember_1007" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_996" xlink:to="loc_srt_MaximumMember_1015" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1001" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1002" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1010" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1017" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1019" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_1020" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1021" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1022" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1023" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_NumberOfPerformanceConditionScenarios" xlink:label="loc_aclx_NumberOfPerformanceConditionScenarios_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_NumberOfPerformanceConditionScenarios_1024" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1025" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward" xlink:label="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward_1026" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_AnniversaryPeriod" xlink:label="loc_aclx_AnniversaryPeriod_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_AnniversaryPeriod_1027" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance" xlink:label="loc_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance_1028" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1476324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1476324" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1476341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1476341" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1476344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1476344" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1476347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1476347" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1476348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1476348" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1476349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_988" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1476349" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1042" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1042" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_us-gaap_AwardTypeAxis_1046" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1050" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1045" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1052" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_srt_TitleOfIndividualAxis_1044" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1044" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1043" xlink:to="loc_srt_ExecutiveOfficerMember_1049" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1476245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1476245" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1476246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1476245" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1476246" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1476247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1476246" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1476247" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1476248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1476246" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1476248" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1047" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1048" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1048" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1051" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1080" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1080" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" xlink:to="loc_us-gaap_AwardTypeAxis_1085" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1083" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" xlink:to="loc_us-gaap_PlanNameAxis_1084" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1084" xlink:to="loc_us-gaap_PlanNameDomain_1081" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1081" xlink:to="loc_aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember_1087" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1088" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1090" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1091" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1092" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1093" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1094" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1095" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1096" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1097" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1098" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1099" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1100" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1101" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1102" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1103" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1082" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1104" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1126" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1126" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_AwardTypeAxis_1131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1130" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1135" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_PlanNameAxis_1128" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1128" xlink:to="loc_us-gaap_PlanNameDomain_1127" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1127" xlink:to="loc_aclx_TwoThousandTwentyTwoEquityIncentivePlanMember_1133" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1138" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1139" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1141" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1143" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1129" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1144" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1476253" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1476256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1476253" xlink:to="loc_us-gaap_StatementTable_1476256" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1476265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476256" xlink:to="loc_srt_RangeAxis_1476265" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1476265" xlink:to="loc_srt_RangeMember_1476266" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1476267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1476266" xlink:to="loc_srt_MaximumMember_1476267" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1476268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1476266" xlink:to="loc_srt_MinimumMember_1476268" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1476259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1476256" xlink:to="loc_us-gaap_StatementLineItems_1476259" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1476261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1476261" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476262" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1476259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476263" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails">
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract_1476292" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract_1476292" xlink:to="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1476296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_srt_StatementScenarioAxis_1476296" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1476297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1476296" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1476297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlMember" xlink:label="loc_aclx_ChangeInControlMember_1476299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1476297" xlink:to="loc_aclx_ChangeInControlMember_1476299" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ChangeInControlFollowingAnIpoMember" xlink:label="loc_aclx_ChangeInControlFollowingAnIpoMember_1476301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1476297" xlink:to="loc_aclx_ChangeInControlFollowingAnIpoMember_1476301" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1476425" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1476427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1476426" xlink:to="loc_us-gaap_IPOMember_1476427" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1476310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_us-gaap_AwardTypeAxis_1476310" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1476310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1476313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1476311" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1476313" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1476314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_srt_RangeAxis_1476314" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1476314" xlink:to="loc_srt_RangeMember_1476315" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1476316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1476315" xlink:to="loc_srt_MaximumMember_1476316" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1476317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1476315" xlink:to="loc_srt_MinimumMember_1476317" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems" xlink:label="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable_1476293" xlink:to="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant" xlink:label="loc_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant_1476302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant_1476302" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1476303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1476303" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1476304" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1476305" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1476306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1476306" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1476307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems_1476295" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1476307" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1212" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1212" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1215" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_1217" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1219" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember" xlink:label="loc_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember_1220" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1221" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_RestrictedStockUnitsExecutiveOfficerMember" xlink:label="loc_aclx_RestrictedStockUnitsExecutiveOfficerMember_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1213" xlink:to="loc_aclx_RestrictedStockUnitsExecutiveOfficerMember_1222" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1216" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1214" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1218" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1476053" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncometaxdisclosureTable" xlink:label="loc_aclx_IncometaxdisclosureTable_1476054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1476053" xlink:to="loc_aclx_IncometaxdisclosureTable_1476054" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodAxis" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_LossCarryforwardGeneratedPeriodDomain" xlink:label="loc_aclx_LossCarryforwardGeneratedPeriodDomain_1476070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_LossCarryforwardGeneratedPeriodAxis_1476069" xlink:to="loc_aclx_LossCarryforwardGeneratedPeriodDomain_1476070" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1476073" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1476078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" xlink:to="loc_us-gaap_DomesticCountryMember_1476078" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1476087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1476074" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1476087" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1476079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_us-gaap_TaxPeriodAxis_1476079" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1476080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1476079" xlink:to="loc_us-gaap_TaxPeriodDomain_1476080" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TaxPeriodTwoThousandThirtyFiveMember" xlink:label="loc_aclx_TaxPeriodTwoThousandThirtyFiveMember_1476082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1476080" xlink:to="loc_aclx_TaxPeriodTwoThousandThirtyFiveMember_1476082" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IndefinitelyCarryforwardMember" xlink:label="loc_aclx_IndefinitelyCarryforwardMember_1476111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1476080" xlink:to="loc_aclx_IndefinitelyCarryforwardMember_1476111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1476088" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1476090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1476089" xlink:to="loc_us-gaap_ResearchMember_1476090" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1476157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_srt_RangeAxis_1476157" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1476158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1476157" xlink:to="loc_srt_RangeMember_1476158" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1476160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1476158" xlink:to="loc_srt_MaximumMember_1476160" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1476162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1476158" xlink:to="loc_srt_MinimumMember_1476162" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_IncometaxdisclosureLineItems" xlink:label="loc_aclx_IncometaxdisclosureLineItems_1476056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureTable_1476054" xlink:to="loc_aclx_IncometaxdisclosureLineItems_1476056" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1476060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1476060" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1476097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1476097" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1476100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1476100" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_aclx_OperatingLossCarryforwardsExpirationPeriod_1476102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_OperatingLossCarryforwardsExpirationPeriod_1476102" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_TaxCreditCarryforwardExpirationPeriod" xlink:label="loc_aclx_TaxCreditCarryforwardExpirationPeriod_1476104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_TaxCreditCarryforwardExpirationPeriod_1476104" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange" xlink:label="loc_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange_1476118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange_1476118" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange" xlink:label="loc_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange_1476125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange_1476125" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_1476140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_1476140" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1476149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1476149" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1476169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aclx_IncometaxdisclosureLineItems_1476056" xlink:to="loc_us-gaap_IncomeTaxExaminationYearUnderExamination_1476169" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1475983" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1475987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1475983" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1475987" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1475989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1475987" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1475989" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1475990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1475987" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1475990" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_1475997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1475987" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_1475997" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1475998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1475983" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1475998" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1475999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1475998" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1475999" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1476000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1475998" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1476000" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_1476001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1475998" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_1476001" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1476002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1475998" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1476002" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1476003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_1475983" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1476003" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1476009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1476009" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1476010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1476010" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1476011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1476011" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1476012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1476012" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1476013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1476013" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1476014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1476007" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1476014" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1476016" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1476016" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1476019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1476019" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1476020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1476020" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1476022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1476022" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="loc_aclx_DeferredTaxAssetsNonQualifiedStockOptions_1476025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_aclx_DeferredTaxAssetsNonQualifiedStockOptions_1476025" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses" xlink:label="loc_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses_1476026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses_1476026" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aclx-20220331.xsd#aclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_aclx_DeferredTaxAssetsOperatingLeaseLiabilities_1476027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_aclx_DeferredTaxAssetsOperatingLeaseLiabilities_1476027" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1476030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1476030" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1476031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1476031" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1476033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1476033" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1476035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1476017" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1476035" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1476036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1476016" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1476036" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1476037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1476036" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1476037" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1476038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1476016" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1476038" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1475934" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1475936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1475934" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1475936" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1475938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1475936" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1475938" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1475940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1475938" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1475940" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g332508g01a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g01a11.jpg
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MM]$7(S<Y>(&TM;8E,C,V.'-ULA@D4G+!\/_$ !P! 0 " P$! 0
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M=K2 G,;'S(5RI!KG()YH]3NT#-%-<WCJ)$4H;9TDW+G&"D6Y<2QCR/&2IR
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MC>01N.6QC R?4X R>Q)/ [5LQ(%7:<''/'"Y)). #P,]@>P K9'/%35]QO\
MQV_VY_\ KGGE_NG\/W%*YGD-*<4IQ2G%*<4IQ2G%*<4K"=@ZXH&UJP=3-ET^
MNWFJ2.6U&0%HB0YF,==95G+!.!3FGFVBQEYRL8QG#90KF<K'=;7]^>)(TE4I
M(H93Z$ \^XSZTSC^L_IZ_2J5NZ/=;1/PWY^DZHU30G-F;;?KL?5=/::9GYZR
M,5T*7*+=(.?'?*G)H"-B6& @XF(CD(,?&ER11B00G!6WN=NYXK2ZD$,$EU/'
M!%&L;'=%&"S ,S'LZH2H5,OC&?2J;4]<2R/PUO"UW>* SQ(2JQ*02HE<;L,P
M\RQA=[ @@8.:KNV'\5OLF)KBT:[WAUCE:[2XF2@2)N<K50OT%(:X?DIU5C B
MYQBSID8]T<@1[ <-%/G0<@F/896TX=C/M+F\->)9+"^CEN[63X2V>:.1X@W5
MMR0YVLKC 15;"J<%4 7@X-<Y=ZKJUW!-%J.DFWMYC%TY4#JH&Y2"^_)&< [C
ML).3CU.].\>[9OL#U_ZJ ]8"0=L,T;33/8BU8KF6YV/7%TY=>A309()I3RD&
M198<Y&S,4I&9(5[)4:2RQ_\ K4H[ZUECEBO=0@E&R\NV@@9?*)DRTDC(P& &
MRJD?RG ('%6]['(^G6%Q;-N6R,4S!&#':H4<]\A1@G/H#WKEXX'7W=WXH&J;
MN<;-KUAM+IS5;XS'1$F2RTM\@&5@Y>N/&+-PY"K%*79ZC/+@$,&M%?4(]/R9
MY<@<CB9K-'U.7J!A]F$.TE2P&2R-@YP>2<8SP?:N_LK^9=&5H-I0OU1N4%00
M4.Y P"L\9=3@[F7)(  JZ7;O7;4HM9E[O(3-VA9BI1$I(0MDD;Q:KTY$FK0A
MUE0U=V#)7& E2"C&1!VHMZ#*^I._+@I8=4MIOF])!'AG.X,%X;+-C P, DY]
M./7MZUJP7=R\@A41E9G4.J11Q,5'?$D2QN@5<DD,%[LP)&1[:L&S%;!I <*$
M%"V"2UFJ1W]6:KE+=+A;GD*M/P[I$2.K,9 VLV1-L2!<!M"24[!,OOS7S[,5
M"O#H_OKC 8)F55P>3VW#'#'O[G)^1I<!NE(7)D03E+29R=[QH6# %AN9 NS
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MW!2@BHK-I5B,,1C++4Z(Z,E7 6D U2T^/L4CU"U *SM;@175G,"0HD&!%(A
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M5W=OJD]E:+IC%9FD,BB> AVMEF_EC>/ACOR6V,>Q"%FKDGABED-P!A4*##C
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M-<IP>7H<Z-FDMI'4B/C6W8IN3.."*"4.X2W29AMA=W <Q"-]VTD+$WF($>P
M*0ZC&XKD9SZ5TFKV(@TW0WMP_GM)IBB2,T:N-CSA8RY5&.%<QC;@D;  03:3
M0Z+5@M=I@!86'"B+2,?+3 ,$.U&@/OVC+AIR1W(]L-W*&6BD "&8]LO 8@F4
MK0IM&$7%N L2%0 &&_ Q@;_-@$ 9 !P"/0#N<D\_*QF9B_.[ .3G. .3G/)/
M)],DGUQ7(/ZEUJ5 .5@NDUTR$>%<#(%,CF"G26GD>A]91Q"7) @LC_ODG/%+
M-(>RI]XA;RLKS/D]LG'MFHC'&005!!X.1GCVY_*L^889&99&';2TP.TVRRTC
M'A#;32,(;;1C]24(3A*<?JQC',5[ P,#L.!7UXI3BE.*4XI3BE.*4XI3BE.*
M5''L06P#K%PTW&<1@%RUF=+N9PGVQH4/8]7)F#'\J\(2&''MOE'..*2VT&R^
MXM6$H^^GJH)M6&<@S6H9>YV_$1;LCVV@EO\ +DG Y&]IC!+W<<9-KJ 0G.1*
M;"=8=I'(?J[>GCDN0 "3BOG>*="CMS5]B+:3K6<"CU'R]J"/89@R@XD9Y8[M
MNB)+W:_+QP8B<-NDDLCRC "4-"2HB&VLIS-;H%DNTD:VE(SUMQ,,FTLJ=6/L
M5  PP(R,$YYJ.VNI,Q63Q+>1*S)';E,30]1@6%O(N&5V)/EP5!YVX[TX[G^)
M)OS=WN:@ZI4G->E4UQV7V'NB65[L'4H6/&QFQV* 44TD:'@1$^ZL:P6!I4F0
MVZRP!!HDW!L8YK_R66]1DTV,[XHF>\N'7;';K@LLBM]T)Z;F(&!GT!KM3X+C
MTPI/K4F([F18["TA;-Q<.3M$9BX9FSC*J&'<DGM59VE-R6N0O=\M%XL-RW/M
MVS4:=U+I(Z4*?ECG;'=OEZA(2\AEWVBQ"A*L^6[% 89>4YEQAA]].6O>7RL.
MHR-<W$C;[F[:*2UM<#?N:\!C>6,*,,0 "67.$ W<#CN9="6&QLDA:"STZ&>*
M\U4NPC:.&T>.<0-N(V,SJ#TFV>;D#)Y[4N@-(,:GZZT32\EG!;L)3TP\VZSY
MRV[*RV7SIY;"\(SG+.3CRV&5>GSEI+><_;[Y^FZ;9+8Z;;V/!VVQ65L<LS@J
M^1G&[+' SSC&17QG6]3.I:W>:FHP'O5E@7D!>DP:,^A"ML ;TY//%:XG[1:*
MW6XFFW*-F2[70;+!34#(L5JTRD!M2&KA*TQ#R9*MPDY]'GB48%>EHPP1+D?/
MA(*88(A21"G)[2[6Q9H;T7!!A>%9;:WDN/(X $GD4C( V%=P.P\'.*UY[07C
M&>Q,"1O(KM%<7,%N\;C!E0+)(K=,.6Z+[ N  02IKUU]$;8MY-SB7Z%+:WUE
M?9]BQ$IN!\8]8@$2"G?T_A(F'C'2B1P;>0RT8$1-K!*C,S5A<4*ESZ>&U)IP
MA@-U,-[1F5GM$>-D=Y9% ,TJMRJ*</CDEL(<+DTU!M_PL;NDEQ' (9WC=9(5
MAA.R&-'4E&(CR@8'&/4L:D[L;6M/VI3CZ1<(IHV%.P(\/E&<L&PTI%OM&PL[
M"&)0IR-FX&0%&D8>1'PET(T=IYM7C'IS/#-+!(LL;$,#GMPP]01_A/((]LUH
M/'&ZE6 /&/F#V!'L0<?C776["]=MD=!=Q4GL-+2!>]- 5B45D.6G(K+DCJU:
MS37H>/L<;&$" OP$7)R2I>OFC+A87ZDUF*4+$)?$RKN-/U2+4;2XL)F6RDE1
MMS1D)UBV%8 L#N9P0&!W, 1W!JFF@>VD250944@=ONC)QNP0,!N01M!P1@<U
M,#KE3V.\E\7NRZE?7=' %1LZ!79.PUF3;OMZ&":"%D)NM5@IZ.A(J%CV1QVX
M>0:>/=92,(4=(I6>YG0O[N+2K,6-LBI=/E6G",#'"3DJLKEBQ8D9.X9/(50-
MHV+=6N)#+(2T8VD(Q4[G ()V( % & ._IECCFT"VR"9VUPFH8HEJ+$,KI5FL
MCHSC0Q3E2C9 2&3 0S+>6W6E2QA"19.0$3YB(IEQ#:AS9&.?;YR-=L3W+#?A
M^DF<XZA4OU&YYV#S*IX9R.^"#O'E@@.,C<V!R%R 5Y'8YP3G(P2.YK9\%!0M
M6AHZ!KL3'0<-&CX' BHH1H$ )G"LJ]H85A+;;2,KSEQ6,)\K6K+BLY4K*LQ[
MC(S2.Q=RQ)9CEB2!R2>2?SQ\^]>P@Y&-H7&  !P<_7Z5KW=T+#V+5-VA+!6+
M)<H60B,,R5:J&&U6>2%P6,XYB$0Z4$AT\3T8.98R0G+^1LLH;?6M+#NO=P1W
M5M-!,-T4J;7 [XR#D<'L0#V/:O-RBR02(ZLRLN&5?O$9&0OS]OG5">NKI;ZI
M>K]2:%1KKN73VM9Y)DE3+*$5!;6HX3CC*2+!54P$FFY:\F&S6'1TS-?4*/+-
MQ^#R11VG<K8Y"W?4M%NG2T>2[L0HWP. [1J.[8(P>^,$'WXS7*66H21W4MK;
M1WEQ#;D$QW$0C>->0"A."23G("CR\X'&;C^MUFZN[GJV)/6E9K#LE'>ENQ0M
MCB0#[S!GN81[R;$5,)D)@\AQ:?2J6?/.2<XWE63'7$*3CI[358[]-T4[[UQU
M822CQ,, JR+M P>#@8X]N!TUM=P76YHB RG#QD8E0CDJP[@C)'U_6(W;>W7N
M@;2D1-(QIM>K5?K#!VZZI28N. L]_A'Q7B8V7UX)DB+".ML"A]T%H1TR/39V
M'#XHT].(>.]%[9+%,DD4X8S/@6DK/Y5EQG:Y.6*XYX(P?4<YK-0O)GNX[-;C
MX*WZ8DDNCQALE=G.<C:J\ 9))R?:"-_ZI=.-ZNQ>_.FN_7- 6B+K9TG:T,R$
MG!EP\["CQGR1MDJ8#L;:ZJ]*ICY=$I.P.#HXRP?3U#QQSTG[R[@ZCJNDRV]E
MK>GO=PW3""!I8]RX93)DRGR$80@9([X)'&-N6&V5#/%.L)A3<[*^-RC&,C@[
MMV,'VR><9K7VFOBR=G-='RNJ[<[5-Y"Q4>7'16PW&RD346F*4ZPU*GEC-C*L
M&#1Q\Y8#L($?/OG/,O'GYPI]K-G)X<T_4_MM,F%NV"\ENWF4-G#*H/."<X .
M,G VXQ5:FLRM;.5*S2J2B'!&X'LV-WHN.0![\FK6=DS.S$=>V=_T;1[-WO&<
MURZNBWFSKV ]8H65&>A6Y 6O4:-FW'H*$!LN;JFL5QN,SD6$\,"JD&VLIY:%
M(TO&MI9^F@9HV*J%)*G \S\#S#ACQD\D#FMU(I'A61K5^HQZC/,_4  ))*JI
MX'(\HQ[8) K(.F'8&P7.Y&U?8K^AIHZ8'FAJ->=.PLW4G"IBK-1A]YUK9JC<
M@(RW5ZR5R.E8*PH%."88D8<OYIG)*@"%,>]3LXX0&@2YA$>T3Q7$D<H/5W&*
M6-XP%*-M8<%@#P<<9V;=BV5=H7+C,;1HR$!3YU8,201Q[=AQZU9QRFK8K[I_
M#'[,?V<5.O8?0?M7GBLUI3>X<CBF.S\6@A]^MIE22@AEN)=+C)>!E:\;Z/:4
ME?D'ZJU)K4G.5I'#?]E*GLMISYD#O#-$F=TL3!0/YF7S*G_W@@9R,XR,4& Z
M,W 5ADGD ,<$GY#.3VXS4%W=<*VAV49M$@V#:=?"BG3H=+K%AB)(0N'BF@*S
M !3(QYP40WB6 91-2-6!20_].'CX^:;'((\(CMYV6QO+<,\D5S=12_#P +'M
M1%"27,I.Y^F4Q%;1D)N)=PV.?#0YE+R,!M[$Y(W DXP,X''! P>_;-:'V?K3
MK_0IC;D"S+/0DS>Y>0*UO7Z@&S%.55_$&F5L+UCK;30L>,@<^R*A(]B0#97D
M48A0Y0JDDO-<MK5O8?#R2N)BTC;41':((1C<TX)(;+ C##)[ 8)KJHGEO5TV
MVA@,4L5M+#,8F=VN%D\N40'!;I*%<Y'=EX7(,[?A]A;)"Z[Q"-D3$[,.XG9<
M:INV;(ZYQ%2BL#0P+ACHK3 ZD2)T=)2H2&&&QF@3ADBIP/[2$76C+*NG6XE8
MLVTD @C:I8[5Y))P,=\?3%4E]TQ<,L?(4*I;C+L  6(  !/KWYY)]!-[EK6G
M3BE.*4XI3BE.*4XI3BE.*4XI3BE8K( !2H),=("CG!F,/#$B&-(>$(8(;4R\
MR0RO"DNM.-.+0M"\92I*LXSC.,YQR5XTD!5@"&X;(SQ\@>,^QKSF16WHV"I#
M+R001Z\#/Z]_:J2^^/5/M'O#;^F=&:HV'L6N]<[%'2LEL^1/>>D*A!L GX=3
M"$EC.8F9HMMAA#M;A[(0D%;IC R90M@7 \3R^J:=>3S6UI!-(MC(2)\-E@,$
M$$Y!*X  48&,YQZ=;H^JV%E:76I3P6[ZK \2VZ,@42;]V9@I\H,?WG( +9&,
M9S4#=^ZQ@X7;1_77J.9L68#54AZ7>HL%<O+&626JY+RI^.-6TVR[,!LG1 QL
MFIT-J+8D,/HCO2'E+:N$U6S6#5;BTT)KB17@6&YMXG(+*C98D\@C:.000!QD
M\X^L^'[R6\\/VNI^*_A(!!-)/8W=R$ 4N-J%<X(;<Q"X(). 0&)JW3IATM:H
MQ=<W#M"E5VLW"&I<%4J!KL#T3 VNX\-"C9>Q2DR0$*N5V+;98PV0F9!MG#<,
MT2Y$A$/)RZMOO=(T1(GCOKB&$2F!$@AV\6Z*.SG&'EW.Q+@# VC (-?)==\1
M37:3:7:WD\MF;N>>>8YC-Q+)@$+@G-N(TC55).2&;L>;/E9QG/G'Y?X\Z=1M
M')'?^N_TKE  H]A_7O7KE.<^G^+^"L*SY3G.<XQ^K'Y?M_5YS^SF&3<<X!XQ
MR,_E[>G_ 'VK!/;# $'N".WK[BO;*O.,)_+\?MC'W^WWQC'X?S_AS(55P>V/
M7M\O?% #G)P?;'H.?D,UX\9_+/[N>L@=SBLY'N/SKB9ZOPUIAI2N6.)!G(&;
M )C)>(E!&38Z2CS&E,E!F"$)4R0.^TI2'&W$Y2I.?SX#,K"2-B'0@JRG!4Y[
MC'8XS7EPK!E;!!&"#V^A'U_+GYU1/L/X76V-1;O3L/I?/GZ_U]+RL7(6&K53
M9LE1[*R,L[#EBBXQ9@)%<.C'1?<Q#)G_ *LL)Y>$NMNL(;3CH(M9M9K0P7\$
M;S#(29X@PSV4L .6'!(XR>!C.*K3:21N7@;:#@E5?!&>3SSY>V,_B3G(FQUK
MZM?HYO::W_;-\;KV?<X:G':V:IFW2(=,G1FY>2!F)##N*XD2'/&.9C8U<:1'
M@XCBDY?DF"R75(2/67EWNMX[=88(XF(D#P#"3%3@-@A2#N'.[)! &!DUMQ1>
M<R%Y&8 C:_!7/)[<$>Q  P2<DYJ?-GME8IL2_/6R>B*["BIS[TE,GCQP:%>A
M3B6\OD.-XR\MM"UH91A;BDM.92C/HSXKXTED(CB1G=LD!06) P#P >!^'IZ5
M,SA<DD+CN6X![X'ZYSG/RQ7.A/L$I&)'=00.2TA]AYI6%-NLO-^MIQM>/ME"
MTJ2M"L><93G"L><9YDYPP(*D$@@]QCO[<]Z]$C;D<]B,=NXJ%/9#HU7=S76*
MW-K;8MOZ\=@H4-N/$VKKY;#F+  .E.!8?8-8*RP!<X87T^&&'B8\Q*/#"CEB
MH;'1HRV\<AZ@8QS#A'7N<XR#GN,<8X]/08JON;&.X<3QLUO<@8$T6 V.V)/\
M0/&!W&"14%YF-V1U:V()<MO=B^M(UZB(V3D</ZXT-<H38.RXTAMYMB*V#'P5
MV>KBQ9:14*>V^7&8+#-&<,B90<9DQLGU;>'+^\D6ZTZ -*LC(\C*523@X$C#
M RS$9/(W8Q@U73%[.0/+?6RS@;BRVX#S1D$;)"K!B2Q&6  P,^^8Z;$[C=HM
MCVP6]:_UAKRVQX@34>)+6W36R*ZR\+\QGU1,A9:UN:0BCVA9,AX<!U0*LDOO
MJ]D9A1.1L[\]E>VB!9+S31=J=L]E_P"SUX2.3EA$\9&#N#+)Z8X(S55<W]Q=
M.7?3X[J*)<"0">$MZD*N2&[]R?4# Q4 ]_TCL&;L.>NUTT1'ZG&M30H\M$T"
M&EP-=E2610E$A-D&K=8&EY);."[%79=YLAR26DEP5KYI2G+O1_'%E;"+3]<L
M[B33^MT4NYP]R]HLBL0\N/+&F>!(,[05![YK8N-1,"1OJ%BT-M,0DK+&7$0(
MX,@7<1Y@,'G'[S\Z@6O7_98%CKGA=9ZW;$R.6I5=IV@]:R=5O"(,++JI<R0L
MD4=:(RS-A**</&(DVA7$M.D1I8ZB<@-7M]"NEHNLZ?LU+2Y'"Q7*:G(#&\GF
M1#%#A0.0<#(&<-Y@:L8+>WN(@;61(D?G=';1E71A_,[<L0, YQAL@@ 9JT[8
M-<[5]:-85:O]9@:UN,,8]B.(KEFK+8;M0B5-(>>=K_T6TU[+T%@M#S(, H<X
MB*;/QAJ5Q'@C!8YRV?2]3O6?4Y&T]75FDGB9I>JPY!?<I(DQD;LX8XR,DFM^
M3XJW@Q !<.@ 4%%3  P57:1D>GNO[Z8ZL=9NPYW8='83?"%UU(<O>;HW!Y,
M<?E+I>*K$4/.&0039/$;78&I1 X,8$2;[K"F&<^DEQ\LE6_K5YHD>GQ6&CM)
M-N2*-I9$V].*"1Y40G RS22.Q(!!!';  @M$O6F-Q=[5 5@$!);+;<9'88 '
MK^N:MXQ]L8Q^6,<Y(=AGOZU8'DD^Y-?H3^&/V8_LXJ9>P^@_:O/%9K\Y@@YX
MA();2'Q3&'A26'<>IMX<AM33S2T_K2XVM258_7C/&6'*G:PY4CT(Y!_ TX/!
M (]CV-:#?%UI49^%9DK^_.35<E/?K%&+G*J1,B2\TE%9:>'#'$CK-+$X&FG
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M<XX.><9![5L;=T;+G&\'D<G!]N_Z<U^+6UI-N\%+!6"('C)>!F)2GV!,:_\
M-P)YX([/S9D 4K"'78HA!B4X:)::+CRT%1A:5$ N.N>Y8^BZE&W*RB1"PPP4
MDE=PSPPVGD<-C<.& 'D-NR6X[H2,$ @#)4\^I]1D<CN*T[L2H7RL5 (&4W-/
MCUTN3A*@4;%P%4@ *]47_P#,'S-BDS IJ36;B/'^FKF@I. "9.D!RODP6DK<
M;UKF:/82T"CJ,.K,&?*@MDDG=@ @D9()! .0!6U:1L9"Z2L7CA=XH@J$/(@\
MHVE23SC@<$ X!S@_M?Z^4K9M>KL)L$VF7?7586)(U: K%<16XQ!@3.1@I&0/
MC[%*XD$#!+*%2$'B-BR$$O+-%)RAA+$T<D4:.MNB!9%*.QVR!D(!*C<",,0#
MSDKG*G/-0S17$KJUS)-U4<. '>)A)[D+@9&2, 8/8@]JB3V&'W'K2_U0KK-M
MPJQ$3)Y,)7="QI"+"U&C 1XQ-GD2!I&5-CL5F.2V&Z>_+.0[5;=DP(Z#?'(D
MQV".8NXK^*97TRZ62,G:+1BSB/C)"[B2!SNP3C.,#FNRTN?2;FVF@UJQZ;E
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MK=<5Z?XWH]/J5C/R&>XFNY&FN97EDR278]L\D*.0!GV'/%=!%&L8*QH%4GD
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M.BAGQ4O C^V_88]">)DTRUAU+X:>W41775:SGB41F-F&X$A>-\,@"'T=94?
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MPZ2[)%01$B5!R VY0-H ;=DMCC@\8%3FOM;SJZ=8;N,&:' 0+!%LCI^<4_\
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M.1)(.@P);PTSER5CH(B-"D75M(<<,8>4[ZW/6XOJ[%)8[2!9G,D@0%F/)YY
MSZX&.??W[GF[ED>>1HUV(6.U?8#C]<9/SSCBM_\ -NH*<4IQ2G%*<4IQ2JZN
M]?5^P[_LG7ZR:QGK#KO=6K[9.2E#VT!$!6:M4L.41!(L#=JK$D"9'S7S;0 <
MC!,&%0#39D&3EJ<^?6#!SG3>'=7ATQ-2BO88[S3KVW6.ZL&D:&2X=&9H&BG1
ME>(QL61V02,4E*F/87EB['PEXC_L%=9AN!\3I>JZ<]EJ&F=66#X]&):)>K#+
M$\81P077JD"3'3"EIH<7OV@:5WJ,U[*F;\V'9M;@:QG:E;9[0=V_1S5>P;3'
MV0> OD/,1XSMBCT8F'6IB.-AV)!Z2"CQ'(TJ3>^3'=5IZ'XFM;6TGN])ATR[
M$NH;H);B,7LMN(1*$Z4RF+)MY  S% KR$/LY85=6NJZY_#A]8TR\\,6%EJE]
M\+*MGXIT=KC5--M+FV-U875F+E86@<PSPSQ7#0@2AXI47;Q5DT! PU6@X>M5
MV-#AH& BX^%A8F/92,!&1,4(T#'1X0[>,-L"AB,,CCLHQA+;3:48^V.5$DDD
MTCRRNTDDKM)([$EG=R69F)Y+,Q))/<FOF\DCRN\LC,\DC,[NQ)9W8EF9B>26
M)))/<FN7YXKQ6/\ -BE>4_CC]N/[>, ]QFL'L?H:CWMZG@#GUS;C,''R\G1G
M3&91DH ,PH^AS*F<6-@?)#>58+A7!0++&I1Y4IR)? :RW]2>5FONC-$8YT=U
M2!@90CNOV3 I(V =I*J2Z%@=K#=WQC8L.E*LMK)M!NE80.^#LN$&Z $X)VLP
M$;*,9W<8YSJ.9Z(]2=G.-V1ND# ,&2CDZM-#L\K"5B5)D$,/$E+@X:257,_4
M$Y3@PD&/&>+3X6I[/E*DWNF>);Z.(SZ=J27$=R@!FC,,X==NU )AO+*4VN 7
M;(8DX JKN=.CW]*ZM&BDA?.Q^I&5;&65HR0,JVY#QW!QC.*SGL470M(:$(EQ
M18.I0U/54J_!9"CHQ!T#"R-DA8>3$I8?M(=786Z\1*+@X^);?DB3F6ODQ#24
MH8<\65I+J>I()(?C9I&FF^U1)!O$;$/+(0.G$&"]1V9%5,Y95S4QD:&%DC=H
ME&U&6-V0%2P5O*A4' )P,-R/7-93#ZJ.U_\ ,FZB(C@19]P>6GZQ;6Y0UF6E
MU"CCN3CMC6HFQBS)@K Z)9R6;FTFNL8<4P,4IYYRKE-RTCR+*KYR-CXZ:,.<
M1*A4*HXVX)[Y[5MK+#L2&6-LIPLD3;9#'ELK*65@X)).3@X]>!CU+TY.8A*2
M_#V06/O=)*G),::.A\2\!(GVQU\BTMGP'U"-?6/(O/Y4$4+)ARL=A*6VS71G
MCACM06;*D!64=6)WD&\%ES(Q9MP4[B5#%4\_E&!SR:V#>JTUPTMNSPS(D>Q&
M$3HD2JJ*C@=,+Y%W[XVW8/ )!&?:UI!%)B9AJ2E'9Z?L,Z79K).N#L@HDY@U
MD413@<:PMU$9'!   1T>#D@MYH,-G)1AA:R"G=FU@Z"LN[>7FDF<XP \H&X+
MP"%\OE!SM QD\5KSW+7#1!D$:0016L(#;R8XF9P6(_G=Y9))#A07=B% XK8/
M-RHZ<4IQ2O/V_//[L?X\5CGV'YG_ (K[,8QEY&,9SY\Y_''\V?Y^88X4_3'Y
M\5@@D8X&?F3Z_05RGHS^>/Z_\.05YZ?S_3_NM;[7U%1=V4*R:UV1!BV*HVF-
M-C92.+QA2?08,^+\R.I2589,$P^IX(C"<K&(0V\WX6A.<:UU:0WMM/:W"[X;
MB-XY%]=KC!VG!VD=U(Y! ([5:Z+JM_H&K:7K>F3"'4-'U"SU.QEVY$=W8W$=
MU;N1D;@LL2EESAAD'O546H;1V$^&Y+Z&ZZ;]"U?L7J]>+PQI'5?86E*DZ[L2
ML34@VXUK&-WE59 -$$2N2"$&J;=BKQY#0HT:,7,2+[[26C>.L9M4\+OI^F:B
MMK=:3<7/P-GJ,'42XB>0GX9;Z)QTP6 Z8,9*JB[C*S(5?]'^)M*_A_\ QKMO
M&OCKP2^L>&?XA6&FS>,_$_@K5$L[C0M5CC9&\27OA/4H)?C-\4DC:E)::A"L
MLLDTD5M"L9W0W1IQA:4K0M"T+3A25I5A25I5C&4J2I/V4E6,XSC./MG&?./M
MSNJ_+>S/K^G_ '7MZ,_GC^O_  XIT_G^G_=/1G\\?U_X<4Z?S_3_ +IZ,_GC
M^O\ PXIT_G^G_=/1G\\?U_X<4Z?S_3_NOIC[8QC\L8XKV!@ >PQ7GBLTXI7$
MSD*#88HR'DDN*$,0E*U,.J8(9<:<0\.2*0CPX.6(0VT2*0WG#C!#33J,X4C'
M,JQ5@P[C((/(96!5E8>JLI(8=B#@T_VYY&>1R#S['D?/FL/KFMHR EPYUZ4E
M)J3BXDV#B'3F((!F-C)$H0PYAH:NPT(.0LI\$-;CQK9*V\M+^5^7^9*]_.X;
M=BHD:;MVQ,A0?D"3P,G'U-8QSDDDGN2<FH4_#2LTMMOKOG8>QU@6J^C;E[!5
MM5G.A85F7:BX7;]J CH_! ,>+Z6A@!A&O.$X<>PTAQ];KF/7GE?"MQ+?Z:US
M>,L\ZWU]$)72/>$CF944%5& JX ]<<DG-?9OXZ^'](\+>._[*T"R33=,?POX
M.OQ:PR3O$USJ'AO3KN[GS/+*Y,]U++*1NVJSD(JJ HL<YU%?&J<4IQ2G%*<4
MIQ2G%*<4JJ3X<:I'2NQ^WW1V=;"=SHW:ZMM:[G 7GO8FM4=CBI>^0(#HKX[*
MF96I2*3XJ;<:4L5P\O+0OJ8';*,X[PONL+K6?#\FT_V?=_%VTBD8>TU',Z)M
MV@JT)($F<@O(0I*J"?T9_'(0>*M"_AE_%NS:5?\ R[PX/#>N6DRIOM/$?@6.
MUT:\F61'8-;ZG 8;FT5@)%ACW28>0QQ6M\[&OSG3BE>/&/RQ^['%*>,?EC]V
M.*5XRA"L92I*5)SC.,XRG&<9QG\<9QG'C.,_KQGBGM\NWR^E= /XXUHL%)^.
M?U6UO2I<VFT+$IU5L3M0J+GZ,P!DY;=N*;LDG)1T)@$>4+F$Q,?\ZY(I*]Q;
M'N8PEQUY3E1I>@:)HDM_-H^E6&EOJ<R7&H#3[:*TCN[A.IBYGA@5(7N6ZC]2
MX*=:;R]5WV)ML[B_O=0AB%]=3WGPB216S7,C3O#$RJ>E')(6=8@5!2/=L3G8
MJY.?M\/ZW6R=_A26[ZQ-VFR3-9&[)]]6A:W+3LI)5\5$*#N-Z(P+"F%/1HV8
MUUIE8*F!FU"J8']G*/89]%VLLJ!U21T$B=.0*[*'CW*^Q@" R;T1MIR-RJ<9
M -:+1ITE;8N[CS8&>>"<^Y'!-=_?QC\L?NQR.HJ>,?EC]V.*4\8_+'[L<4IX
MQ^6/W8XI3QC\L?NQQ2GC'Y8_=CBE/&/RQ^['%*>,?EC]W%*\\4IQ2ND'_#!K
M59X&>Z)A0=CG840Z&W^^8-$RQT<R4Z/(:CPRLAL1]E+JDH6MORO"O4RXXTKR
MVM2<X(!&" 1D'!Y&1V/U'I4T(!9CZ[2,\@X;AAQZ$<$=B.#7<"ZJYSGJ_P!;
M\YSG.<Z$T_G.<_?.<YU[7?.<Y_7G/,U#6^N*4XI3BE.*4XI3BE.*4XI45^\N
MWK=U^Z8]K=YT%4>B\:@Z\[?V34')4-,A&MV6F42<GX5P\%:DMF"-R( ZWQ7%
M8;?;2IIS&4*5C*L@;B!G&2!GVSQGGVJA#^"Z=N=P=GM*]JXK9A\2]#ZYVO7)
M6J1L5#Q\>D&1VLY?;C=S7RQA6337)B9:&(PP6^Z)&X:RQ%,!"N*9SHZ?IUKI
MD#6UHC)$TTLY5G9SU)FW2'<Y)P6[#L!P!72^+/%&M^+]535]?NDO+]-/T[35
MFCMK>U466E6D=A8Q=*VCBC+16L$:-(5,DI!>1F<ECVE^;U<S3BE.*4XI3BE.
M*4XI3BE=([H;V7W[<OX3=V5UO9MLW26H:+KV@J"JJ_+.HB":OK0.UHH-?D!V
M,-9DH:H>4.5Z,D%DA1!#398+#!6%/*@6VMTN)+I((EN9D2.6=8U$TD:8V(\@
M&YE7 P"3C%6T^JZI-I%EH\VI7\VD6-S/=V6ERW<[V%I=78Q=7%M:,Y@AFN B
M":2-%:0(NXG KNX\GJIIQ2G%*<4IQ2OY\?Q[/Y0)U8_]GIG_ 'P2G%;$?]T_
M_P!?_D5[_#I_E5V]?]I?XA'_ "S<W%&_N5_#]S7]!GBM>G%*<4IQ2G%*<4IQ
M2G%*<4IQ2NC+_#&__,_0G_X'L+_S#4/%3P=V^@_>NX_U4_\ 2]UN_H$T]_=Y
M7>*@K??%*<4IQ2G%*<4IQ2G%*<4J OQ5?]6;W_\ ]COL5_=3:.*])]]?]2_N
M*ZXG\#J_T1=Y/Z1]*_\ 3%^XJ2?[X_TC]S7<UXJ&G%*<4IQ2G%*<4IQ2G%*Z
M#OPY_P"52=F?Z6.['_"VGBIW_N4^H_9J[\7%04XI3BE.*4XI7\^/X]G\H$ZL
M?^STS_O@E.*V(_[I_P#Z_P#R*]_AT_RJ[>O^TO\ $(_Y9N;BC?W*_A^YK^@S
MQ6O3BE.*4XI3BE.*4XI3BE.*4XI71E_AC?\ YGZ$_P#P/87_ )AJ'BIX.[?0
M?O7<?ZJ?^E[K=_0)I[^[RN\5!6^^*4XI3BE.*4XI3BE.*4XI4!?BJ_ZLWO\
M_P"QWV*_NIM'%>D^^O\ J7]Q77$_@=7^B+O)_2/I7_IB_<5)/]\?Z1^YKN:\
M5#3BE.*4XI3BE.*4XI3BE=!WX<_\JD[,_P!+'=C_ (6T\5._]RGU'[-7?BXJ
M"G%*<4IQ2G%*_GQ_'L_E G5C_P!GIG_?!*<5L1_W3_\ U_\ D5[_  Z?Y5=O
M7_:7^(1_RS<W%&_N5_#]S7]!GBM>G%*<4IQ2G%*<4IQ2G%*<4IQ2NC+_  QO
M_P S]"?_ ('L+_S#4/%3P=V^@_>NX_U4_P#2]UN_H$T]_=Y7>*@K??%*<4IQ
M2G%*<4IQ2G%*<4J OQ5?]6;W_P#]COL5_=3:.*])]]?]2_N*ZXG\#J_T1=Y/
MZ1]*_P#3%^XJ2?[X_P!(_<UW->*AIQ2G%*<4IQ2G%*<4IQ2N@[\.?^52=F?Z
M6.['_"VGBIW_ +E/J/V:N_%Q4%.*4XI3BE.*5T _CGU*U6C^$&=4A*U6IZP%
M$-].4,#PL1(2CSRAMM2Q)&&VPAWU+^7';<(?].,^RPVMYSTMH4K"IXR!$^2!
M][U_RBOI\.&HVHS^%,]BIT6M3Y,)!=A^_P!+S<PQ#R#L7$11V=J084E)'H'R
M*$"7,S,3$C%$NML/R,F $TM1!;#;BLL1T5&1GCCU]:[_ !Q6O3BE.*4XI3BE
M.*4XI3BE.*4XI71H_AB[;CUKZ"LLMK===A.P;;33:%+<<<7):@2AMM"<94M:
MU9PE"$XRI2LXQC&<YQCBIX.[?3_>NY-UB!-B^M?7J-D@RHZ1CM':F!D(\X=X
M0T$T2A0 Y09@I"&WQBAGVW&2!WVT/,O(6VXA*TJ3A4%;QXI3BE.*4XI3BE.*
M4XI3BE0%^*K_ *LWO_\ ['?8K^ZFT<5Z3[Z_ZE_<5UQ/X'5_HB[R?TCZ5_Z8
MOW%23_?'^D?N:[FO%0TXI3BE.*4XI3BE.*4XI70=^'/_ "J3LS_2QW8_X6T\
M5._]RGU'[-7?BXJ"G%*<4IQ2G%*_"N,C73&Y%R/!<D&L82T<L0=9C:4X5C&&
MR5-Y?1C&%JQC"5XQC"E8Q]LY\LGMGCVK&!["C$9&BDOF#1X(Q965Y)*8$89)
M(RM?N+R^^VVEUW*W,8<7EQ2O4O'JSY5]^*8'L*_=Q6:<4IQ2G%*<4IQ2G%*<
M4IQ2G%*X:4KE>G'1")J!AIA^/4I8#TI%@R#H2U*;6I8CA;#RQE*6TTM2F5(S
ME3;:LYSE"<X4KF>*4XI3BE.*4XI3BE.*4XI3BE:RW3J.F[]U!L_1^Q!SRZ%M
MVA6O6]S&BSW8N2(K%SA3("<9 DF<*> ,<CCR$#F-)RX.[E+J,94G'%9!((([
M@Y'U%1CZ)_#EZL_#EI=TH_6"I3E>CMA6$*S7"2L]IEK;.31\6 J-B673Y-ST
M#@10KQ> @PQAVTNGFOO9>=?RO"LLS,<L<_U[#BIT\5YIQ2G%*<4IQ2G%*<4I
MQ2HW47IYU8UEN.W]A:!H'5=2WC?G)QZY;7A*A$AWJPNV4YJ3L+LC84,9D'')
MH]EHF36EY"C'$)]_*T_Q>*SDD $D@=AG@?05)'BL4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5?=_.Z>U.K5I@8O7,'
M 3@Z.N^_=[R43*:=W#L\JVR>GK!J*'A:$NUZOFP(70U?LR-B2.)S=^T(B?U_
M1\A@R$^*S&H,6M7H#/Y@=P.^??OV["MYQ/:B LS&X:I7MG:>$VTS?KMKCKY7
MKL5&5./OMJBM5:]O%?!C T[-EYK;,.Q);"@GYZR4Y-.?)B91D :LQ+@HU@G%
M8P?8_/\ ,_EV]:TI#_$5#FHZFWT&BH(UPCKCK;:6V17[9K.E66D[1W99C8*B
M:T<L^Y=GZHUM%FTY>MMQ1NS(:7L#EE9FW=>,Q0K*9!YF54QC\R/EQW/]?.N
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5*<4IQ2G%*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g332508g02s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g02s22.jpg
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M=X&1)3(S0G(9HM+A\/_$ !L! 0 " P$!               #! (%!@$'_\0
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MG$ <6V(R)]]LXUD((P((:5$% 43"&3F#,6TUO;RW,@BA1G<@G"C)  ))/;
M'<D"JMY>06,#7%PZI&N!ECC+$X 'J3ZX )P"<5$_&>[I^E5^]6!;:0KC.KDE
M=JJ^J0-*R[A0ZU];/$.#7+&*%93@"'&C();8F FL#X[4B0' PF1EXGL\+0N(
MW&QL[6)(90=Q&<@X) !) /<$8XKVUN8[J,31/OC<!D.UD)7 .0KA6QYA@XQV
M]ZD/G]N2ZC5VF-[NI<='85 ._,E&[<25P0LL!A<DK=:NSOH7FK1-L'*DTL<&
M1A0P80<2?(_QY#(T?5=5PO)*H3Y@BX4$CWX!8_\ 42?6KFQRAD"'IA@A<*=H
M<@D*3VR0">3D\FI4QG&<?.,XSC^.,_.//*PKSXI3Q2GBE/%*>*4\4IXI3Q2G
MBE0KU5<6:C4DCKB&\:>RH'):L2&(HDP 0[6,SZ(<NVF#) H"-F48D>=B2-P=
M=!8YB,QP2QW:LRQ,J=013"62(#/5C1&+(1CS$DKA<$$X]1Q+:L@DF5G$1E@F
M@CE9L"*612$?.1M\P^88V D]LYU)]>+9R$]LD7\^L"(FSV BRB]NYUH1]PNO
MW@9? Y>3M:FSB@8UYPC;%C5F6*$$%>8G+"AD&+U7K)AM1IS0,8$B=9993(+R
MWQ_#D0.[D1/@)L#(IP!EF!].-UJ\=TGQ,DR/';0]/_#KG=D30N5BBVS*3U%?
M!D +%DVD''(J%._]<AKM']@5]18G5?*GG]D['RRG K]==W[--'K3G,@LFDTR
M]9BB7(,&\,Z-$(*U$:.$[=OB.*5FHBHWERRP:BD(1!' U[:V?\\Y5F@D9AV$
M:S;%:$@8.UB!D5L=-L>K=:3)+F;K7'^'W]X2-D2L%NHT5F\QFFM"Z1W/*N%9
M%)*9K[JG?+O2J;Q#TUC_ #J\=ZN592,.W7/:<G:"DU]W/N[N!5CL0A&')-DF
M7;_LX ?-OI-+*6L;&':R%!P$2PWLEG+8:,DC76H.([B_F +"&*63,SRC)#3,
M6.&(+,&R3Z5D=/2Y34O%732QTBWEDM])@E _?W$,?^5@B&W'33:&( V[T(SW
M)X/BRDSDM?N5BLN84EX:,>56:MN[$PS#*TN L::M]IKF9Y-HHXLPVX5RF;U,
M8C06-5$G+"A##&7GP]EKJ1-%!-;1=26WE,>Z!,.(Y+F-+4$( [)+!,2,Y5BC
M*V6R!QEA/=RO)#,RF.>.1F25BT9E$#RS2G<Q"R+.APX&[+!@Q#5NH#WM<R[F
MCKQC<M-77O++-8:>H,BC^M>L+VZ,J2T!+8QI&@\<*F%O'6PMM]6;T"-ZPE41
MP"*B"YO\.E&G27042&&ZB@F>/S+"SH_[LN"5)W;.KZ1LRKN+%L5NNIF5#CSQ
MLR X!<*RY/(XP,X&23SP,52ISI&R]S/?6Y)KQ75ENI.]Q9V)K8YF3H" +DW,
M] 9$]?7UR2?$HTUV-LW*5K2%G-F09;->A(1H3I"Y1>NNKU]'T6TAM)#;RF$J
MZ(OF>>0DN[2 88H-S*>W;!( K5H@NKF0RCJ(&RI8YQ&.  .PW9 ./KP"<"Z9
M?QCU!X=;A;HGIW)>:7>N(&I0QX.ZFMN!4$XLT34K\!J8+DD*2#6:*0J84C[F
M-=](I==M<?''O>ZM>1""6>[N87=1AVDD0R@AEY.[USY2?7!!%;18;6)MZ)&K
M 'L%4[3P?8^V2?;/&:EGC'1]^L\\4WO=6.GT;F/XA@PV>C@/(JJQ-5 A8K2*
M :$V(\, <[ZL,>PVLA$D0Q!<$<9<\$T'P\S1!RRI@9P5SE5."I.1@L1@\\<\
MFLXF,@WX(R3D>GJ!R.#V_P#WO4H^85/7+!__ $<?_EM_I\A?YC]WY"E?5YC2
MGBE/%*>*4\4IXI4%]DZ1U#GYU&UH/%&754CZPCK+N]76D!/MSU-.2)!M89*_
M^7M;!:X88YR)YP:^#*7%$)OM]W?;?33->>66,ITX3(&;#,"?)GUV@,S>I. !
M[D#)'H&3WQ^O6M>?9!#Q_P!D*?2JGUFV-.-;EV%FSHMC&N=6KMD%L*M<Y3ER
MR)+0*>M95QF-LR$'@=J")2]]@\$K$K&8/.BRU>2!XI0/AQ<*R*7< G +,KIP
M55BCA23@E0",LH-'4K*RO(1#>LH4.&7,@B8/@@%"2,G![+DCN,8S6E<FIG*_
M2SVF%GZ@ZLUFX7F[5-!U&V31YLQ6UM;$IG04QZ[$'X%&[V_+8%J,2*->HG4I
M"X9)I5L$T'9R+#'?:/<%%/7BCN[@$!ES&1)EHRN" %/NK+D?6M!8L;.WU-RT
MG0L;K$(.YB(0JQR;2S'(=1N"]@X!]343]'[4_P "?9R<3JJ)C<.E6?U^&Z4?
M;$4KMHR8U"VU7\F:5E"<ADF)91N!,-%;+,LL<*6(E>WA-BU6%:2<7KMX9]:D
M:* @23W$^8TV85W*A$B3Y589+ [5&.,<9^C:,L+:=<7!FC"2= 1QR$;"%!<3
M-N(.Z,NC* 26!=2&!JV"K=5VYZY-H87,+*I0M;1M/S_0VOE46NX"<""S[U$$
M]DM&JH5FE>ZN)42"1JOA:CF Q:$B,-BPQROL9E$;!2YVDC:O('E&> 20<#RC
M)YP<U6>%90LDES%N5=DG3/78E.!*P#!@C94,WG8 %@K>4':"I6I?<$\;=?"<
M)G4DL ]8U%R$V3M%\^XK!4S$SM)K"8&1'M'MM#*0(3%F(T$HL$D8J:=6##(R
M,$@@\$$'&"/R]".15&2-HVVM@Y 92.596&0RG R"/H/8\UDWF584\4IXI3Q2
MGBE/%*>*4\4K'_C&<?&V,9QG]_SCY_=__OU^/C/^/R<C/J0?<']?KU%8L,CL
M#[9&1]N.>1Z51O;.6S>I7OKTCVC;B36>LV3G-XZ>^99SN.TV02/*949*BBAT
MQHL/MU?9V2#13H;@(=A4-EH93#1M%DV/CIQ+I>K7&HRXDMA9W-S(V\AV3? K
M10J6"=6'"L2VW>C8RV"!W5H\6M>'K?2(E$5Z;^WM[=<#HH\<%W.))2>2MTJR
M*"FXB1!@+GS9'UTL?V)]?D7M#2%XB2P;7*Y74>F3;A[O6G(]DK'E?1E!8L>(
MQVC\^M+L6:>#;;:'<Q:M4P3E2A@S35KZ:.ZLK?454HTLLMRL(R'>Q$+0L5"G
M<1L;XN1?X;O'E 9,9]TY3IFJW&@RR[V,5M#'*_,:ZO'/\9;"0GE8LL]IO7$B
MQRL&VH/++?V;!TG6!>K^S#X:."R]+M8Z7$6<22;K!J^"'*>NAVGCTGBCC/+'
M!S%OI'OKHF&Q)'K]/[WF7A59;B75]7N"#+>72VR/@@,ENBDE2P&0P.PCC#*1
M@$ 58\>20V4/A[P_;!EM[#3OC)(PV<S74C(.HBDKU496\WJK<$J0:F7V(C04
MAS9.A,88B^<\_K0O3^HTLY?,_16YT6QV0UPK1+] S4!R&M"L+#=A'#JNG;#5
MQ@^%S&#LV"[JTWWE]!8*,.JAHIT?HO&T@E6-9&#(TD0*L=CEBN6*>?8#\^<=
M"RDNLX$\K1>89#1Q!'G( !VN1)&NX#G&WMOS7K[M>PG,5MU]0?<BD2%MDRMR
MHTL*$J+\"X<TXZ=RS4;*%1AF@LQZ?='?02?P4V,+K!J! WFBS^%^>QTBVNDM
MM9T*<;6E5S&RX*B=0@DY4%O.IB92P&5!_P"X5I+J6,O;72>;;QC&,H<GL0 <
M%6![C=CL,5GGV<%[@:F]9[9K1-QM^D7DCGU(%-*7*GD55YJ)""OJ@S.2#-6;
M6LD7\,:U (M2LH_97%L-JPPM*)AH:Y"P-O!U&9K:W$TY1#,@ZS &1A'O98P>
MS(A"A@K;<8J6S/\ $D*\.Q5,D X0< 9P"Q[D$C.,@'!KA_M5>DUB+DUNK4BN
MXI&7=T]4K*JQ-JZ36@Z9<>9V$RVX6NV3E;%DP2TI#2%&V413$4:59"204,O.
M_%38Z/:3OYXY(B;)Y) L<J.TL<\?+(BM_(8N"ZCABO##!SNI% (8,.H%7S*1
M@H<C+,!G=N(P"1Z=CQ=)27BFR5"NNT7T_P I/5"S":1_2QJ/KC3$4HF<09S#
MKN'/'*))K#MM%K)#MB/?;7XSYH'1XY)$DSO5SN))).3N!YYY!!&><8SVJ]$R
ML 5X! VCZ#OC''W#ZUD_F-2URP?_ -''_P"6W^GR%_F/W?D*5]7F-*>*4\4I
MXI3Q2OC8E2A+SC1P2FDX@9)4*T'(VIK"4>'>6,$/8P@0/!1>^F(!\EE##8FD
MT^N1#%]^77PG )P3@9P.Y^@S@9^^O"< G!.!G [GZ#.!G[ZTN>^W<EO1IE'
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M*^]R=JJ%PBJI)553R@!B26[9+$\DD\9Q6;^95'3Q2GBE/%*>*4\4IXI3Q2N
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M*&=X31.B%RL%MX4_B2Y#QR(W)+O0*63#4$(P%B*'RMY%<+/)))A@S+G=M65
M1A%DBX=#C"Y90I/(.""=A"T81 G&!@#.Y21G<5?LX&?0\9&><XVXSCXS\>5@
M<C/O5NHGFZDO==&:\>J=MIZR[5I8H?V5:W.#.LD:=WH1,!(EJ$+4%H3!-$/O
MF>P%XC4!29T'@A<%:FCK_6B*H)W5C&Q*J0,+E<9#/C // &21Z@8S&22Q ;D
M=P<8[#[?M_1S@G3.\V'CB:6[LDK'J'/U3#86VET2GV"*S517!/**QLT(N\IZ
M:YK4LT>=G0*<M6WB#B)(3!/C8=%,OD4<<[F)6Z,I4,@=@8Y&S@)N(!0M@JN=
MP+8R1DFHC.$&22RA@"P20J/0\JK+@'.22"!W%3GSGIE#Z[3DG0>9VU+=:98A
M?Q:>PH#XCUYD>-]HIH_OQ;9W'+$GCE%/ *TA.7F0SA&CCE030Z121O$[1R*R
M.IPRL,$'O]XQR".#Z&I-S8#!@P89!7!!'OV^M9Q\Y_CG_P!\^85YO;W_ *#^
MU8]8+;7JM$-*^;C+_P ;/^&!@WVWF-/(QKG?:   ?68TV;337,F\0H\V^D>/
MO[:XU_7SW!_7U[?C6+2[,;G5=V=H.,G'L,9/W5]*"PJK.KA<HS<'+B)2X(Y]
M=)HMM2%YDZ\X::"?2*<<D(X4D,L8B*.<<F"6":/22/;7 C'Z/_(%>K(6 8'(
M/;@?9SQP01@@US'SG^.?_?/GE>[V]_Z#^U87<.9<\Z"":!=:76K.,Q!*7&8<
M)P39I0CA]A2A\$RP[$Q:30;[1;?1FCVQKGYUVUVQKMB*2&*48DC1^"/,H)&?
M8GD'Z^E9/#%)_$C1^",LH)P1@X8C(^T'-5S=G^R[XO#Q>T5WUF32<EZ"(%LP
MJQ^'3VRK69J^#?>.M-Q;<T=PP*WN==0R& 6D+!=)O$8-OOB*48GEM4\*:7+
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M12C\_K^I*\^6.W:#3CXP.$U+@KR^7Z[054:6E6FUKT6Y4QPV%M8VV-]I''#
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M+!0 !@Q"HP8C) !\I&2#R!E0&B6Q?LPGK1D%DP!8 ;78+F/I 4)^*7EX/FQ
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M.*ZBR&FYNXKJTFNM/TN='62W<L'ZG[K?,D8Q(I="^_<,+@$X!%6%JJOTKEW
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M8\98@'[)^PF:\C\?6\5B(VGNM+U6!8KF*XFL)";8N%U!+92XM<IGJ%XE67I
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M^4V=4Z51?9S[*!%2[Y;*JF<]+O31LLK[U@J#8,P;OP]."Q)A#GBUW/"5OW8
MAGQ@D81JP@AETB+GUDP>..0H9(T<Q.)8RZ*QCD4$+)&6!*. S ,N& )&>:N6
MEU=6R7JVUU<VRW5H;2Z6WGEA6ZM)'$LEK<K&ZK/;O)##(\,H>-GBC8KN12.X
M%YG5.GBE/%*>*4\4IXI3Q2M0?M .V7#UO])/:?O//M%>]WY-P_H%XJN'0FQZ
MK5ZB0EEKI#PM98?Q8\1&NDNP^TF(Y<Z8TEQO'G;39]O;UK)<[EP<'<,'&<'/
M!QZX]JKI_DZGL!>?8G[-"E66]851$4SI/0.:UT50%J&.%5JUE*6N&FVQG:0P
MK!;AC-*81MM-)K-'%MG.D.GE.PL8--LX+&V#""V0I$'8NP4LS8+'ECECR:W_
M (K\1ZIXN\1:MXDUN2*;5=8N?B[Z2"%+>%YC'&A,<*>6-=J+Y1QG)]:O4\N5
MSU/%*>*4\4IXI3Q2NJA[!^RO;EG\J"]2^$+K\U"Y25Q8Q254AXPX@R5=GY7T
MV[/5Y$^H^"Y1&5JI%4=%1;S[8D+1+?G/TQ88](&MK=KB.[:)#<Q1/!'-SO6*
M1E=T!SC:S(I/'<<>N=M%JVIQ:)>:)'?7":1>:A::E=:<''PLU_8PW%O:7;IC
M)F@@O;J)&!&$G<$'(QVK_)ZU-/%*>*4\4KK@_P J@_FJ&_\ : XY_K++XJ6'
MYQ]AKKE>L/\ .V_84_V./4G_ &&ZCYZ._P!S?D:S/\.7_P A_P!RU_1S\\JO
M3Q2GBE/%*>*4\4IXI3Q2NE__ "I;_I9?9'?^/.B?[RO7CQ4L7:;_ $#\I*[H
M'BHJ>*4\4IXI3Q2GBE/%*KA^V _FN??7^R_UC_9DSQ62?.O^I?S%5L?R5G^:
ML!_M#]A_U-2\5E+_ !&^[_:*[(OBHZ>*4\4IXI3Q2GBE=-SV1_ZV_P"HG_E,
MM_W ]X\5,O\ !?\ U#\UKN1^*AIXI3Q2GBE=<'^50?S5#?\ M <<_P!99?%2
MP_./L-=<KUA_G;?L*?[''J3_ +#=1\]'?[F_(UF?X<O_ )#_ +EK^CGYY5>G
MBE/%*>*4\4IXI3Q2GBE=+_\ E2W_ $LOLCO_ !YT3_>5Z\>*EB[3?Z!^4E=T
M#Q45/%*>*4\4IXI3Q2GBE5P_; ?S7/OK_9?ZQ_LR9XK)/G7_ %+^8JMC^2L_
MS5@/]H?L/^IJ7BLI?XC?=_M%=D7Q4=/%*>*4\4IXI3Q2NFY[(_\ 6W_43_RF
M6_[@>\>*F7^"_P#J'YK7<C\5#3Q2GBE/%*ZX/\J@_FJ&_P#: XY_K++XJ6'Y
MQ]AKKE^L.,__ *MWV%./C/S_ ,#?U)S\?&?GX_87J.WS_5]W_C?/[OC]?W>>
MCO\ <?R-9G^'+_Y#_N6OZ.7GE5Z>*4\4IXI3Q2GBE/%*>*5TO_Y4M_TLOLCO
M_'G1/]Y7KQXJ6+M-_H'Y25W0/%14\4IXI3Q2GBE/%*>*57#]L!_-<^^O]E_K
M'^S)GBLD^=?]2_F*K8_DK/\ -6 _VA^P_P"IJ7BLI?XC?=_M%=D7Q4=/%*>*
M4\4IXI3Q2NFY[(_];?\ 43_RF6_[@>\>*F7^"_\ J'YK7<C\5#3Q2GBE/%*P
M+H_*^9=BK>U-ZUSRD].J.YPK/>K] JR2X5_9B#]3\$?LGL 3!?L8)]:7\,3D
M?,T'U9/I;Z_?V^5/Q'V$@_B*QX#U]X.KNE<Z0LXMRE?T*GUT.H5*\A<^J@MN
MK%47KYU(%:KUB@5:-TR$)622M$4+BQP!P")Q(8-()9(]E/Q^S)Q^';/U[U+W
MBE/%*>*4\4IXI3Q2GBE/%*B#HOKYP?KUFHETZOQ?E?3+?RYANWYK:+]0*M;G
M_/VLAJQE(RIC=^K/.K)V[!*G.V+3SAS[&*UQ.9/K!#[QJ<^Y'O@D9^T>OWU+
M_BE/%*>*4\4IXI3Q2GBE0W[#<-IOLSPWJWK[T,AX+1NQ4=_S^UDUDT5;8(4=
MC"D 82)SS0&@@C#6"7;(Q!"XV*.3XVW'EQC[N5>@X(([@@_A42>CGI#Q/[/G
M@:OUTX'BVR49=8[%;)3[R^BL5F:/K.3%.Q-8'B+DZ[3&D P0 HRU2O%B%"AW
MWAE-D++)4)+$DG)/]L5M_P"*\IXI3Q2GBE/%*>*5J6Y]%_5.P^UE<]W7?(53
M/VBJ*'%9K75"WMND,3IL)'%<U@#K?[08IFI&B2P.5^C':N;L8XCYM]"]9L1R
M:*]R<$9.#W'IGW]_0>M;:>*\IXI3Q2GBE8A>>A4'F%>(MW2[Q3^>50.6& NS
MWFRI:E7A9R,[:CPD.GYJ];!+/MKMB&.4G7>7.NV--=LXSXI6":>R?KK)LNTT
M[[Q7?9Q5V]W4ZZ=3HVVS2EU\=T6^MZ[7#W.3:ND%K=B);OQL2J5HZ%U,87#&
MK.V@5[@^Q]NWK[5(E/NM-Z$@$M=!MM9O%78;E1 62GOE5E0&R E2A&QB.$I9
MJXG<,R"<0K2$G?8<J&4>7&DL>^FJO*R;Q2GBE/%*>*4\4IXI3Q2L'JO3N;7M
MO;*_2.A4>Y/J$TV27I)5;8AL+>ENM#&:[=1;%JA@897&FK!*Y V <0AEZF*6
M8N8L3@%:1*8/M6<>*4\4IXI3Q2GBE4F<1]B?:&?K%V3V<VW]%KDW:M4RY2ED
M 8?L; J]ENZ5$ZO6,S;F?-1:*PLG-(.8YK%+:6WH*D]%6SKFRMU5PRD_/U9$
M#CG''K_I!]SZY]/Q[";>O=\]A*-T.V((T/1T%?95<+VD"E)HZ"\,J)S/EW.;
M4JZ=QF#2E/"*K96Q_7:7QA@2EUZ&+87M9]BKC'7+:G$J&3:RI@<8P><=^_X]
MN^.V./K4)!>\'LAMI'T3>F9A66$9)0"FA];"BY52XD/:?<RNQ]E(4,NW(ZAH
MNZ(CY3R9)K-I[%25^&7HE2<*+?:UWY*NL:O#C]=\G&1GZ?\ %9WTKVP]QH*W
MT@Y-5.>4+*NO$ZHS!Z'=.DSU1Y6>0^N/8;78V3K]J*^@NE3FQTWIM$5CKZ^A
MW'GIR^T[.F6\;>K0*<?4^P^\C![_ $/ZS5LJ0K8Y,H.V8 -MC%@!6S54/((L
M9[$"Q398+1)3F<HH!F=_Q(8\K)A) /)'%N<7MKF>17E<GXI3Q2GBE8#5>K<N
MO3RSUBD=)H-QLM).)67.O56XUVPO*BR#8&*3%]G4J&)AZ X5JO/6$B-1Q"(&
M )@4L>I(TT>BE*UU;EUSLEDIM/Z30;7;Z:02);ZK6KC77MDJA09TJLL:R(U;
M$IFB(%9P3KB86@HLD!T,HDNNI$>\>JF#[5GWBE<8Y=)JXJ8/K"V6(4:D68YJ
MY<GBJU2P(?7.\YC!B=+ &$+!IC.\Q!,T<,>N,[;[ZXQ\^*5R?BE/%*>*5#7L
M9SEQV'U[[OR2O&+5[_J7&NG\Y1GNI"H4X+B[TAY65AC:4$0\V):,:S@F/D#!
M-*T%TEV'$(EQI#NKT<$'V(K5/JOK1VFR*O=F@507DC&I>W]3MWX6]VBXVM%=
MN;6IQZHUWUW4H(ZFMYC:EEDJH[JDK;1^T<=YKS%4%=;6,/4&9BJ"2S* CCZ8
M^_DG_FMC/77CKGB:7I%=;O?VMTL?8+IT!1<6+ MC=+,IN,2=GI+T*65>N7:6
M6NGY/I"W"*.5831:M33YMX')C< -7GZ_7YUL+XI3Q2GBE/%*>*4\4JLV[>KO
ML0VZ3?+(J:U&P<Y?]AKW18^<VCO/5JTQN"P:@=FJ#%*YO=+Y9$QI-:KU@MG+
M.@4*B#J>C_E5AIK,;-\$6@T&"I*RR/;G'L/IWS]^?Q SFO:[]-NWC<U>(:!W
M)G6[G9O9'V(OAV^]F="5-!QWV/ZCWDRR+*GJDK@+<2^UBB=H5]&KL33#)7_A
MSYI5PX[ LJD[!U*ID9!([ ?B!^A]GIFK*!X(A8(!H-<Z0CPQP0Z9VWWSI%#I
MK''KG>3;;??.NFN,?>WVVWV^/G;;.<YSE6->WQ2GBE/%*UH6>Q!#6R=,G$YR
M_GY)RFQ/Z39.E $3OG9EPJRM:PL,5=Y;6T[FVNZPJ/8R50AT+OAWM:%37,%1
MFJ0\5N(5[C\?^*PN3W]]7?OH8@K=>GD]F  -3CU?A'?+61/,S#O+ -&1#6^9
M-)%]LW"YET$B>GL=1+.#%3WNQZD7\%M\J8//TX[@=OO^M?#9??KUZ$D+3T:V
MC="M\,= .$1 A690I:J+TWY5!J4JNQM9FJC%BHK78*A;2J\ Q*=97F;03B!;
M!MYU*@!/Y_G_ &/WU]-<]W.:VZY<+H-7$9V2P=@MLE6;G)DE_P!Z30I=N%],
M[J%$??VG/U-3/M)U?H*O,?/S65>N>B*XK;ANIRF@APR4P?\ GO\ 7'YUP-U]
M\J+0Q=MWU3;!&I;[T6I= #.<*5\//4//.U<YXW)>; P*SJ-$GL^G7N:]%K(D
MGX8PZ@V3=O)]#=4?#&IC\L_T)_XP?8U\"W[1+B;#HJFJ:?CRZ6[;]/KR[JE8
M$?WVI[N.=VCUXJ,$YY-$K5B7UZJO7/L"O"(NEI<(J[7#*],.U+S&SU(7J8./
MPX^W/]N/?-;^^*\IXI3Q2JZN>>JO90KT&UL5MJ_-%E%L?N&QHU[Y&Z'MG3[$
MK]HO9#7M(8+];T[C^U(IRVNH0Q%5@KGX7J(M@L<H3E8XKTM57EME9$CTY^7.
M1[#'O_7@_C4=V#TW]AWP4JH2P<TJ>*-TGVQZ#1+77K[>Q+GTU1[*>P3WK!O,
M+TT4\YKIG'ZFTIKTJJW1I1VO1VFUF@KMPKPP<U2"#9*\R/KV&?N&,]^??TKV
M*_1GKK0G!URZ!^!"&L?+CZM2:SV[MQ%?H5.7^SO4NC=:YXN:QCU0FU)[#P6Y
MI.4)3'J0/$P0[.E:+*G0QET<JF1[>A_( ?U&?OK%B_3#W%(RC%@[-6@<5_@S
M/D0]D"ZETS#AU(5R&6JKI+4,?0V3EPP4]+C!MHEU@OJ[.5<&DY- )NV&EJ?*
M<?WX'O\ ;QQZ>_W8G*C>KO>*#8;@_2=7UT(NYM@9/LGWSH5@T)-*[/VRYUZ4
M8.Q",@4^BGG5^HU-Q EB!'@@J0R&"*5#7:Y+E0G./I],589XKRGBE/%*>*4\
M4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4K6"X^H/%[P9?YW(]Z@7=.:!V.
MY51-T_H"6C-+@!K7]1;EM1UUA@JNK[YJM?(-URIV3MV"[+=RH8-SF9QJO<GC
MZ=O?\>]>:/Z><#YWO7MZK560>]7=#V%-N7;+0TDA;"J.LHX2B)F38J4W.%W;
MNC12:F;SZS2.1R)<;SJED@JF3^L?3^PKA:UZ/>NM0T-%KU6=+E3!;0@#$D=Q
MM$BB:7FPO/0*LU_"S-)-HVT(/+*0,>3%+I$TW5F'G#S-7UA/:J9/O[_U[_G7
M)T[TWX30;C3[M5$UI5,J,U@L2!3'T&\25+%K'Y@\XO'<&E0F?25QU:L<M?%4
MK\\:KBS-4XBO73?0E:,1HKS/]OZY_.LC9>KO%&UQZ=?3*I-O:.PL>1M[^PC>
MOHHV[3A[1.WY\>.%&QP$G*#)KM<A=3)QP=[2#74 %CRS%3+XAU>Y/;VS_7@U
MZG/JQQ1^ZL5A9UDR=K:9K1.Z(UL3^'4F6XN^36%_MI!"QTA'P6UXCSDB/ ^D
H>!=4Q$ V(H&S2,M3)_7W_P!S6P_BO*>*4\4IXI3Q2GBE/%*>*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g332508g04a44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g04a44.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M >\# 1$
M A$! Q$!_\0 'P !  $#!0$!              @'"0H" P0%!@$+_\0 5Q
M 00" 0,# @$'!@<*#0,%! $" P4&!P ($1()$Q05(3$*%B(R05%A%R-2<H&Q
M)#EWD9*AT1@E,T)B<;6VP>$F-#8W<W1U=GB"L[?P.**R.D-YD[3_Q  < 0$
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MA[/MM>Z^I*C+<6RJKL+3)JI:^UPZ>J(H2*38EB%:EV%0_H57;G'/'F[C!&T
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MN+1TU*.\EBF@^&T\649MI+@^)MHGB:[S-I-M?G39]"TV+35>\2.U6%=)\/\
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M6>7=-&D<85I YV-'EBH'IDG=@<,<=^*F?&6F065IHLEK$8;:ZEN9L<[%F60
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M^$].2QTBUF(/Q5PK2R.<A_,P8^VW! (^9..W'/\ CW7)=9U^ZC4"*RL2MM'
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M"!K:,"ZKXBHA+>M-IXQB[*&W$/"GO8(K)8&6#X94\ZD9-&36!;ECJ4%P#%*
M298'CC8)TPPV"-F91F1\@;AC.*]:@63Q$VCK=QLVEW&FN1$%#16UY',Z9ZI
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M=L P" %;Y\GGG%<+XEL+K3;F""8P-:11AK%K:031R1.V[>90S;G)R6R?*05
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M^&NPEO>1XV*.">FH"2*<+N&3YE;)R I'.3H-!+I\O4C9FC;);'/+'S*?5>V
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M\=698&W]+;TSI6IY/A2S"G"69C6N:YSHTF\T:BM[JU/O^^VX3JP21*!NDA9
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M#5V2ES-(8[2Z@VNBKB;I'.%$G+ @ <@ ^W8FIWQGXRTLA]-MK=KF]LI^)9)
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M/'/H/GNQE0.X/%2%SC8N*X!CKLER:Q:-6NEA'!0:.0XRU/*C?*)75(8C9I[
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MS3.B&@AB=(_P\EY#4+Z34;N2[F #/PJ*,*@  "J,=@><# ).<8Q4M# MM!'
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MN5Y 'BU,VP(C@C='8GGQ7$-%&15TMV7!,R@@L*9#FLF$C4GZ.Z805Z>TR9G
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MG(0<ENY/IP,QMR$>AJ:G)](XEIS(LU V!=YC=37M[A]\#!51!'D5-/BU5;/
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M\?\ 5_W\4V'W'Y_X4]O^/^K_ +^*;#[C\_\ "GM_Q_U?]_%-A]Q^?^%;G%9
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MMA<]MQQ@9^=;OR1D:]RD0(V->SW>['XL7\.SU\NS5[_L7LO*[TP3N7 X)W#
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MS\>_?Q[?\;MV_CRNY<XW#.,XR,X]_I\ZIM;&=IQG&<'&?;/O\JT_)&5K7H1
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M]=MC'+C3(?/M"DA<,Q3/ZP8!8 @@X(\N,8;FM46FS9''AKE$WDJTI8S7!RR
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M< 9-5*>&3+9-]I,0(3'Y@,*0IVB3"@1KYFP6P23@?=%=N [?D5G72/PJ-R_
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MUGD8_C\(8\K[BX$CN*F8ZOKT()!'LZ\@R." P>215V"5X]"2?EG&/WX-9_\
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M""-F"*TCMEB68X6.)))6PS*A5'*QVI:I9Z5$DMV[#J,4BCC0O)*X!8A5&
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M^YGK ;2U>*#7!2I !355M>W-C*%24-3:75B!7DP<<DD;!XI'B<<AXV9&&/\
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M.@ G5[10"2PN%4 9+,UK.%4 <DL2  .22 .34?JA L9R2 !TB2>  )HR23Z
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M3V!K]17D76U3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5^<W^4:_XTG:?^3O3?\
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M+/#,,I*B^L!>[5^/99%")]=LX4<QKDB/L26(Y/)&HO=>:]UJFHWL:PW-Y/)
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6R<[W)'W\<5<#YP==+3BE.*4XI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g332508g08a40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g08a40.jpg
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M_\0 'P !  $$ @,!              8%!P@)! H! @,+_\0 3Q   00#  $
M!04(#0D( P  !0(#! 8  0<($1(3%!4)%C:SU!<A.%57=7>2&!DB,E9R=I25
ML;2UU0HC,3E26):VUE%387B3E]'208'%_\0 '@$! 0 " P$! 0$
M  $("0(&!P4#! K_Q !<$0 "  ,$! <&#0\*!P$!     0(#$00%(3$&05%A
M!Q)Q@9&A\ @3-K&UT0D4%QA5='65EK3!U/$5(C4W.%)65W)S=K;3U>$6,C-3
MA)*3E+/2&2,T5&*RUD1E_]H # ,!  (1 Q$ /P#O\8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MOV>W-)1ISU-[]'K^HCUO1Z?53Z?1H"K8 P!@# & , 8 P!@# & , 8 P!@#
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MP^TM;3K2TN-J4A6M[ C5 ^A-6_,D#ZA. 2_ & , 8 P!@# & , 8 P!@# &
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MV]_V&LYC3I_X67I_8_B-F,8>$#PNO?\ *LGQ"RFWW.FG31@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@&._EC0[=U#QWZES^C"A1RQ6P%'$,"2ST"(B>-?+C
M5'V!4XLT^*&6C8!!-5/+%&EC1-K2&(SO5C175) UX<K\>_)/CEO =@"\GM%Z
M@!K5W:&*YIT3JW/#7<7@_9:;QQM%NZ/TQPRJGV^2*NG,)H=M+MG,V<;S4@$A
M,RC#X1D*@5X]75A\B.$9\!.@0J+S\75J\U!NW-.,4"=:38RXM.B.J]=#0Z,
M=K=5K-D(S*@";K%=YL%?7;+151S-J- N3CR2Y57!VP=(%3IR8YJM/%\G6;1.
M$Q.G0>25.+V.2[+Z&VP8V9=ER TLFW </%G:O$.S*XRQ7YME@518.#9IH-OX
M/,L$<E)&N/0W675CB\W]'5J)C0/H35OS) ^H3@$OP!@# & , 8 P!@&C+OWR
MI'8.3]IZ9S4'0N<SQ-)MA*O0)I1FR+(2H\%:4(?EJBGHL?;SGIWM7L8[2-?Z
M-)^]Z=Y Z#<!CTST:L.D,.D*L"MD5IA]*NP.>Y;L]HF2&^^*TR^,H^]\:G$5
M*TJZ5,&^&CNT;)P/<(5\:!3M K1?D=U2+MG_ %2E7]+L,$Y7C=]GMRA]+1W;
M:7 Y2G][;[[$HW#QDH:\56A_;B>Z_DVY5_-[9_U-G;?6QQ_A;#[U/YX>5_\
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M/X5_D!^DRP?6HS8'P&?:UN/\[>?E&TFBCNVONB=,/:&C/ZOW>8QYZZ8G# &
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M# & , ]5_O%?Q5?U;P")4#Z$U;\R0/J$X!+\ 8 P!@# & , 8!T^_-'\*_R
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M@+I%[3A_UY1U/37[!1^Z%T^4[*?I?Y@V>=C & , 8 P!@# & , 8 P!@# &
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M2WPF_D[Y"?WGQ?,C>Y__ *32?\BZ_P#VMQ]_1+PA?N-;?CUV'5%S),]1& ,
MSY^2S_UBOAQ^G6G?VAW.A\)W@+I%[3A_UY1U/37[!1^Z%T^4[*?I?Y@V>=C
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MOLQ=?OA9/VQGW\EBZVOY1;PW2AQ"E?=UI^_0E:5;]&GWM[WZ-;WO[VM;WO\
M[-:].=%X2Y\B/0?2&&"=*CB=CAI##,@B;_Y\K))MG6=+KTNRU7,Y-FO&P6B=
M%>%U.&5(M=GFS8E#>-FBB<,N7,BB:AA3BBHG2%-O!-GZ8680'21@# & , 8
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MJN-K2K7IWZ-Y'-F--.9&T\TXXFGRIL*&%8J&%/:DO,3+.!R& , 8 P!@# &
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MNF?KC_MV />7_P 73/UQ_P!NP![R_P#BZ9^N/^W8 ]Y?_%TS]<?]NP![R_\
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MB5'&3MQYKJ&%*/#!XY"JQQ6&91/NW\T^-0P_SDB:3,J5ANFC#BT,A(@>K&=
M3B"$Y]QK<">.)HFQ9D*4RVY#?&$(TW<:8PF.XH]FNG..,NJM=5#ULG;^;URN
M(LB[(.(,RF2#@V!"E,_$2#HHDT&(Q41GU,JB281E]D++;(>Z;CF7F!#WJ$GV
M8KA)MT[8]JX:L<B.))9I]NKG)I8+I5*H^,C60^,#/F'%MC6I\E+*I.FGX<5Y
M[T;].FH;$HB.BR)S^VH<>41'QWGVWIL5#JC==V9:I4WY' I'0*WT .3.U^0_
MN (LMLJT]<YK45;)&G'R-?)N[UMQQOW)]\:Y.@O[<TM8Z1&<E-1)6WXD<U3H
M3Z57MO"=>EKH+50O(^NDZ56;=" %F9%LN#%+&@S4\$!=ADB-<EW0 \=*$22!
M8EBQU!L86#,KD/3Y4JQ@ ON:2,UQN/>+C1O)5JL=WCS)QL$UK=,<.GFQWX;2
M3D.U  [=GT<%%@,ZJ\N"]1("#+HB&3W#,+NK6Z\TV@F_&=.CWZ008F>[RY Q
M2YD%4,C*8<V]J4Y,73Q=6)>,EGAA6CSUX<N!-#-GGPA(2>$JY>S3;!(B,1!\
M%R%%:@HDC915<\X2FOMQ1@R/'AKCKE:U)=>(R( ^+&??FM:T7+3MJWA[E7MK
M+7M>00:6-:.P*M8Y-?@5JNVRXE5/ VD5$/9)Y."PZ^WHJXDVH4V&(FC2P;TV
M*BN-1RH>4:V0'195XNJJKBEO:IAU].!.,J5HZ:]RQ5>K'<7#BW:3./WJM1:R
M2T5IH\&1BHDSA#3-E8/MF?<%CWF9LE,%"Y0.;&5\5U$>1_FWG([;:]9*8)[?
MX><M<6J94ZZ^8^7/[U(O";5J36YM><JMGD55_<D@-)Q"4Z$-&3B#HN:,>=9D
M1QLHDL'.VKU%QS@PL/6GVL%W#5*;U7DY?'R-%[=O%RG)Z-63ERJ!FK@CXZMN
MGH! .1($J^]8V]B"HR<-G-1X+!ZNK9G:3+1)A353G68[\=.I$":PXXSLG1UV
M=MY&JJFWMN+96+QY"'X<QCX\0@3-=,HW1@I.-%95,$[I]7H%/F5Y_P!9[310
M;9@=)?C$]O(82PX9;FQHVB(,;,TK3H:Z:^?J#5>E/HIYNLE0?F$C5@LEFMUD
M>-%C<ZMKB*K";!0HT(94FRZ D,BT+MLY\[)4LZ2<,*E2F 116XFDUN'J+KVB
MN%.7/'.F[#+EWBFU[-V5=G+R;B.!O'\)59UEFU6P'8B#5(!4\>-L<\K=1 YT
M&:M9W10B.LA>6S8-3YMG4J7&E[CS$J02EQRS) W*F,JY;G7"BV;%VYB<58[U
MKJ];>M]N<X13BEJ*^_O2;S6Y+EFM[UQO0>902KM,M4R/5*O30 UZOQ.B0".@
MHL55XTLB*,6.P0;"8D;D$&$CH8\5&M5LU43KBL6ZY4KCFDJ+?B*/;KJ\,'A3
M;EAE7$]C'")!NX[MDZP5MR3+LM!MDPCNB*7<A,^C10+&PM#N#UJ==J%-.+!R
M5SZ^\*//H:MMY9T6=W9''HJN%%76L\,:YJF+IXD.+CJU:L538ZX(DG0.5DK>
M5)D0]IB &K* K=9M4>=7'#[DP54K$5L090.0T?!I"3_;V [%(2)4<W'F1Y4+
M:(<9X<EQ\G2F%:5ICM5-@:K7'-4>&S%:T6_7XZ&G"IP\[T*-,.SR=?(CBI.J
ME"4E&ZQUD#U0.Q87)5Z6\78CN F:VW!!O5$- %N:4$$B--JCO.-EADFJ5PQ5
M'JKOQ;'%I7'.F+JW@ZJN/-J)K1N/SZI?S-]*V[5DF$H-F%M>W$D&2ON!ZTQ;
M'#9)F"%G-IE) LQ4!AD$2-KX*+ TC0\,.]#R'XWA2E,NI<FO7F5*CKR\N.UX
MUIJ+;53C!*V1FBECLXY4*O\ 3^BD:T+'5QU#C$3]E*+ZM.C'B,LY(;,OS'N<
MAQ,%V$+!,"&9Y%^5'/R&H3S5;IJU+7_XTV;SBE7&N%73#_RKCCN*]*\<(KA.
MUS&2U=EQ#Q&QF1D:QU,P>E"2EKN@N]E_;RDWL;$<@M'H+TH/\W!=1."Y&@T[
M5@D3P3,F4XV7R.F2HM5>M\A>+GCGM5==6L\NO><&%XSN1R&IT^\+/N38<?9J
M4?%'RY91F$'( X$X$1GWJ0U#B0QCPJ TBSP+I8UQ!2G'K6Z6(RBVG&V84RZ:
MXX5QUT:6XG$VNKVO/QTZJ[&L*3-/%G8QBK&Q]G;:DUHS4".VI@)R4Q.B5OG%
MNYI/A^B,<'/19!43<)LZ).2\\@21BQ%.PBL?3K#AQ5KAG7K:?53H+Q=]<LUJ
M2:VZZD0J'C?+HL:OKKMN#-&Z<Y78U:+$*>7))?"5RKW2HQ(%MC2+][P8E[%W
M@I*;D5TC3!,$NC4J  CP9I09-.*M:K.M=6+:;>6[75[PH:9/77J:VYXXTIR$
MWF<B)JY;SGFXVX^Z_,,=51<^=,$D715R@5JKOUU< ^%"6BN3MC"$A<8ZL8S8
MO<]SQT*&3;,"-SA\V5Q;IG7E6-<'MWTZ\2TP2V4Y'3:OXG,Y1RF1RV.P.8L4
M<P)8I'/*IIE8+8Z?N=0:U&JZ2VIC)B1#1#*08;#WP= O3D"5[7:2LEA;;#1N
MO2WTNI$J5QS270J$0!>/":HX.-5:]G1=SU7[8-L=@F)FV$;8S5QL0JZ&3>JF
M>-3P@)B;;ATR?,%!$1=OC+ ;'LD8I!^*<AUQ5SRPY:)42KN65:Y#B[\<:['7
M/![=U#Z5_P =P\&6,F'I%9+-0[]8+_(K8JD1PE&;G':-'I+D(!5IQJQ(!,*5
M'7:23RIY)TK:21LFKW79/;;$;\5,7777<.+C5T>+=*88I+?LZ2:P>:$*]S0Q
M0*=:$UB9.)W.>*L,8&A:0#-QNAJUNQ( B,3@)1\+B&WPP^1&(0UL;88),)8<
M;1&2KC5JNZN>%,^LM,&DZ9X\KJ4&#R>R!F:Q-K]GIH.QU.%;00^3"Y^9=KDF
MN7617"IQLF#F]'E&9]GDV.KC#CUK?MJGYSZIVB8^=)GRYKJJV.CIKV5W98Y4
M)3DKCJVTSQK7#.I4PG*YM9-<K>!6.&BM<QYW/YVV)* 'YYLS"()JB723EAC6
M ;"A3$_,L*K2/FW,;6MXJI>]^]Q-#U<]K=?'JYWK+3+8E3Q:^9:B'+X/#&D;
M):8\#F*[ 7@(K0B)#YI'#5J*(-7,-833EC&N&SLFT%9<T8-EM2')@X=#GP/?
M1HD?,)EY4R\;!+'#?S8;->TE$FWACAEM:SQQU;->MEQ;]1#EH*@C==LX^MD@
MH:V@5**5IRS1),&WMA42W$16K!7]L3(6PC#D1UU^7%4MQ6I,)]K6VUQ-:U7%
M/.F5=V\-5IC2E=5<\"WP[@I8#(TU7KZT.%!RDJS4UM^J:)&@5LWQ]7'!<XJ6
MD6)(^Q!AHAZ0:<#[ "ID\PIG3QQN TY$?O&KJY<=5:\W2.*]3PU8:^+3M@53
M7'[%OE-ZYINUU9J5=@Q01(M,>D'ESWG;"-<$6$]94E>DEB5JL<Z YI,8I(.0
M-1'F(J7H\Z!&9'H5Q3IEJKLRIA@N84=*5SUT_CGVH5JP<^N9^T5>Q2+A59,6
MMBQOJ5TM1#)$(FW,2Y$@E<A<6-T46W%(OL*@Q +9Q%GD5/41^2)(>\E23DB)
MK'!\SIAL>'T]!6FVL5AJ:JJ[<_H)$,J)N%TJU7F2>%21-AJE5J\:OL5V7$(C
MTU,G:"D*:_8'++,C3]R7KB<;E1VZZ/U[) K33S:X<Q9-7!+>WT_0M8IBWN2Z
M/I>H@=CXR<,6:>7$W_=<&3K.9O#;$.M^\689;2O&RO'69HNRNGFX+(X;"GQK
M)$@RJS-F:,PU,?%DBGF84.IK#"NK/"E:Y4YB-/'&FO+&M*9UYR,U_P =S-=7
M,FCN@11YHF?LAJ83%U4GI<?YQ\WJ_/G7A3IZ\V(O\X(BZD.L:+#8S-G<EDGY
MS4V"^TZPN->-NPHET-O4DM=,LJ$XN_;MUJFMM[RJ".32>><V[)$>.031&ZC#
M1>5)BBRPN,U,9Y^/JNEO.G+1=#Y*3+0$9($"A<^2(29DJ2I3FVM,M-RN*>.'
M/K;W;<BTP:VU\5-_.>E7XK((3JM=KA981@Y$ "A>V@U>=!#O@4:DVBMP8;*)
M!XU+9+-JO-AF33J):=SFWHL!@:.CQM;7*YI*BY:YM>;^):9-NKY*;::][[(C
M,;Q?D0:PV#@6\)%,0HP<8)N+54L[%G%#@(@N*%SH)N%T^&<'VEGXS,?7/#%Q
M-46A^9#U1T19\I"[QL:TPV8:]N&//CO./%PS\>_?O>[%U3U5T7XWQAI:;.U9
MF9+#EN;MH]^0#G/6)AV3V6K]H.#9Q9^SO!W81(W6FAC"057K6VH:X<HMH]/&
MMOON-XJ=3A75MKNH50I9;NIUQQYEESG(/>/.C3$F(BVZC1)J.G+E)6#?=D^^
MWOJ[/7@LB)*BV"!N.U6K!%BPI\=;4A5C%H=;:D5^0]I]LHJ:MG4FMF^N[8PX
M:Z]O6Z[=WT'"5X\$V1I:&*N((2_;1*@EU6Q2BDN&1@L'IQL<^!:(WZ84"E6O
MBQ2,3(&#=KT5]Y8>W&AI@0V&G&QJTW3)56'0MVX<7"B=*X/#^/6ZO'"A+^P\
M?G]7V/CZMV@PB.*+CIH>6)(&8,B40E"I,,[%B1;, ')-BM#GHT*6<'V)$-B?
M(<$,"9JWIDB)TU8X4YN;)ZZ4*U7M7G6Q[RI(Y@0USWH?/MVK3$:[%>F2X!D>
M'=AE*^/Z?8#UB)QMJ6:DM$28N792K0LNPD2TAE Y3HQQ^*^[-5Q3IE3GIYQ3
M!K;7K(VWPA-?39HM"LC8@'9WJY+)U2ZB)_3ZT4E" A6L%6SK-ELK9R>,+UY5
M0BQ1PT\#^$2J*(7J3/$S"(1^UK2NJN*P>W4MM=N;)Q<Z/.E:X[=]2BPO&*L-
M@CX<M,'G5F>4PN909!"KP'V:QJ.6Z.740K427+F*%BHKG04C0-<9E:2$"5H,
M.T6F^S2^RXV*PR=:5Y.O#/>.+XJ)ZUGBNG#D+EWR@F[75P-6$6B$%@P)<#=@
MCDP4\R.MP6",E1-UTK&%6BJD&14V>Y ($F(QC3)6,/6!*L3@9,I!EQ.G;+?K
M*U54Z=_6B,&N.%C7Q2,JU!1P>Y5BMU+H8<937XT0J*KKY1&VZAZ]L=^9VS 0
MO(KI),]-M;;'1AS@M V9'?D2R:6K+%?QPQIS=8:;UYJCP\6RO/J)H+J%@'WN
MZW!RQ!WX=H!U\..$-UF:Q*$.5MPT[ E3"RK5(9+I=6>G^]QV1 ?;B41-,R&-
MM/*DJX)<O73S"F+?)U5\YR:E3)-,KE.K0DTEU@(_(DVF>0&)D$;G*(PS4HX4
H==9FQFA!H]=2C=P*$$,$&7G$DAC<)K1-$^ ;JV^C=V0IECEMQJ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g332508g08a45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g08a45.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!#0"K P$1  (1 0,1 ?_$ !\  0$
M @(" P$            '!@@%"@$# @D+!/_$ $(0  $$ P   @@$ P,("P
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M:X"J,1U:C4I<ZVM$>3LAV"3)-@?]GT>L;9@>GTS[Q$>XMF , 8 P!@# & ,
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MU;UM9TU94S$9Q*G6M454ZVLHF(S3V3P;XG="SS(UA@# & , BED[CQ4"P3-
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M%Y'D\7&Q[B]C(Q>W[9]IDO6[V9E-R%& , E@GSML'TLI_P!VWG *G@# & ,
M8 P!@# -:>WTCN/04-0-0+Y2!5@K7SBW@DV3XO78'#Z#<JY>-!E-Q;>X[0DA
M)5] .W&5;>;!(4[Y>\)UK(YW1WO[#):JVS.?"(>7N+-2MW_<4]_$9-/3.>^N
M^[ZI2II<5^'>R8]C[;<ZA!FC?;^\^UTC6V/9>P]3?K^TRY[_ 'S]2(XW3',S
M#!!@# & , 8!IG/\DY[V"9[;'U-/7:(2Z:J%NUOI=L&BJG?[;N(83,1(=0LL
MA8JK)R\*(B)C)RSGT"/946]J+!LAI43*MQF4M1,/+*5FH>6>3[,]ACE+B5#S
MW)OAS_PSV%OXC99JT45HFS2DA)66*FY^O6!N:K<35IZ)E823?"(AYV-KTY8:
MX1(B)0VK<S6Y)4!.B/"R\0RR"8RC(]OALF/;Z6PJ[9]=Q7<A2:]+ZU3N3"UL
MBVJL;KMPL>JI68NJ4VVWN>F9[\$FK(L(* ID+.S#FF8.NS,D03[EH4<<%U3S
MR-[0E8J4^H]YQ=9[KS2W]!F>804S(/VV$9GWG62JW9(Z'D_A*2B86X,URS2,
M2+7;*53YF=B(>U"P,I($0$H>R!)-CE(>::"'ZY[/<?UB?.VP?2RG_=MYP0J>
M , 8 P!@# & , 8 P!@# & , 8 P"&S?%"'I^=L%*ZYU+E.[2:F6LT13%<YE
M8"6F-!BQ[TTW&]*YWT!,!)%A@B(/<K#L(+($-*DCA294@HYZSR3\?J:)'-^S
MR,_H5(@^?UQB @7I$YA9DE,R$Q-2+LQ-V":G3GY68GIF4>\E&'RAQ3Q"]M(8
M"%9VR!&" Q8@80YN7)5E]IF>0$'\0_%U=WH3E&U(5")22Z?ZTQ:N>L= ,A-2
M,#+P.YNE)>L5<55+S%-R[I-?MK;\A^&.I=:=B3F"G&]"IQ.W9&3CQRS7++M,
M)Y/X8/X7]!8MJN@2-G@J^/U=NDP$E#(:F8POMMNK%YZ#(6BW+ES'+<4_8*PT
MN!6U"U[<8%)2+$CN<(V*8*#<[N'L4+[2MB?.VP?2RG_=MYP0J> , 8 P!@#
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MTDA- 2%M8A(UJR&A:;#9]U*FD#)D7V-L1T<PIMTA25LQT>RO2FP14M 93@#
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M*3->BVB9$9IQY)6EM"MSN6[/LR[/""DB?.VP?2RG_=MYP0J> , 8 P!@# &
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MR_7@&YC);O9Z]9&>"?.VP?2RG_=MYRD*G@# & , 8 P!@# & , 8 P!@# &
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M6 B[!8WWW"]*DF'=Q3<6*66*^$Y1_B^$]FXR83YVV#Z64_[MO."%3P!@# &
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M&5F/E$/SZB_6<3%\THT+?;3T^+KPHE\NL5!PMGL2'C5DRL;7$.M0X[@SI+@
ERAFG=-.D!"#$G-#@-2#Q3<;'I&LN(W"-_K[#.<@& , 8 P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g332508g09u04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g09u04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &T"^:78X0DE-! 0      $X< @   @  ' )0  AR<C,Y,#DX-AP"!0 U
M36EC<F]S;V9T(%!O=V5R4&]I;G0@+2 Q,BXR,BXR,#(Q7U5P9&%T960@26UA
M9V5S+G!P='@X0DE-!"4      !#CXWV7 J;/C?(Q=/+68KH\.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'#@           *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE- _(       H  /_______P  .$))300-       $     #A"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #00    8              [P   :G    !@!G #  .0!U #  -     $
M                         0             &IP   [P
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   [P     4F=H=&QO
M;F<   :G    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   .\     %)G:'1L;VYG   &IP    -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $    #SA"24T$#
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M 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MPAU;ZR9:)^DV%!S6W-+7DV'1P<"6D'CW[#_G)P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 50"7@,!$0 "$0$#$0'_Q  >  $
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MW!!Y!SD$>.*V<:%N4+>]9KMBAM$+Y8 .DQPR13!1Y)8L>4X0I05\) 7"DA,
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M"1BMI_2UT==/O1IIUUI'3_HPM0I]CV"7LE[)D6$^[N[:?(<]L04^\MC2;.3
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M$8Y(R1(2S9 _*Q*X'!Q'D;3@'@MC(SR "1R2".T4B=D1/\)VS\]5JTQ2L)Y
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M9SO,SHX#2Q1EAPDD,-,D  CB-BR"L3W#I,+:)XTN+B."::*W,A]HE>)'6-F
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M+WHXA1QB(5DAKF(Z0QJD&2#Y>0L>V>"._P!^/VP3@8K#K6M0PYC 4R 86/<
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MVW3[R==0PHB]E]ECHM%M]<B)_N5Z2W#1O=RO1$7/#:[;1@-/::K ,<E]*O9
M.,\M;13J .>2<?!XK93\,-7NCC2^H>@M7)("I:]<=.V<S9X 6WUF^TNX))X
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M"2]7M!1[:EF1HCR/1L:0IY@E1S (16O0PH[W+'%-V,OKV\3A><8DY[;1Q_\
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MKIY2#D3X\>4PL99+R-!! 20(HP/F>Y&.,P29GMD1Y55QE3GCGD\8'!!^>//
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M@5(8<^[<VQV99&>3.79N>-4VZ;6[8]\KN40:UQCJECKDJ#%=54>CZU6U=HZ
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M,_I_\(<G\-U7)/+>Q<V;C>\?VD2T/%7>IUG3[%>[%]LJ+&PN:NR5T+5**+'
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M^H31M=SLWIP@'&<XVC.< <9)QN\<C%>FLLAQFQZZE@DBDIA/2<KAM8TH@/\
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MQ I&$V/#*17L^.5CO8C?U.A[J*:8%E9LJ. ..>#P0,X';.<X^:O>DW%E8MZ
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MU,2C.2<DX[<YS^P!P3C';MSBRZ=JS:3=-.85A239Z:3($D0\@ KQ@G( !_3
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M+BWTP,977B W CW/%&VT^J8_R2-G8-K 9;VC+9![K:[V??%GV$04RH@WE?\
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M@ GL*U[N[M;"VFO+ZY@M+2W3U)[FYE2&"),@;I)9"J(,D %B,D@#D@5[(5C
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M12H^4_U/DLE  8!HI3":I&L(P)AY(V5&)8;@5(\'!..>>*V[*XBMIUEFA6=
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M2:3K5#J6N0AU]%K517TE1#$UK61J^LBBAQ1(C&L:JH(35>Y&M\WJYZIW5<V
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M(+DPR)D_;-7/T#K^L3\D'XMY2XKD:_<QK!M6Z]U6Y)>TQC$1CHTUD:7 A%%
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MD: WIG2HK^6*:!=1(< I<I'/(S[4<RRI:D2116[13< V+KIJFXM;,,J"V:B
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M16ZJ2FR.-8X63C\J[5"L3D@A1RPSYP*SS8=69$O+ T$TPT4L<#&&E*]Q31$
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M0M9X;:RDBMY+DP2>JL-P[P.WTA _C!"LCH3&DJ;R:N)QG3"B1H]56:U=VFR
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MT:>(J.8<DR'(D126S0NM->Z=MY[;3[E!%, 4$\8F-K*%*B>U+<1RA#M!(90
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MF@*1M(B>K[2Z; K*^1P1@G*G@@C)P?TK\0V-K:&]A@O9(K9&F"2*[JC !U#
M!R.>#C:#C;[R<@U<;;.)>!H.B)+K]DJWVHQ>ULL-T"6=[T:JHJ@ -Y'JKNW[
M?8?BJN[D'V54IMOJ.KMJ'I7%HZVN<>Z$IMP1SN8CQGGG(&<$&NT7W2_0PT07
M-M<VOU21!M_U<<I]JY9MHWY*MG*X7M@E<$BH$+1K6YN04M%72;*?*DN R+$$
MCU"C2*O8[U?V"Q@T:5Y))!^ G-(]R,=[%M,YM(8&N)9%2)%W,YXV^,8/<D\
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MC&HC6-1&M1$1$S\R$EB6))+$DDG)))R22>22222>2>3710        !V '
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M,.U[PO:QZVOI;J"VT&6\>XM9)_J8XE22%E#Q&,N2NQR$99=R[GR&C,:X#*S
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M^1SFH%VVUURHUE\.H- ='??.K91GS8IILH GQY@2>R((8G#/X/<R5&4"C%$
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M+6N:59(WM!)5QWIE;U;\:>IUU34383P1PS1RV*VL5NDEG$RN4-_;M*IFW/\
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M%7![$]SM^.P//]/O7MH6LBC%VD!.22H4#';!/'SG/;'<=JE[08%;K&OV(Q!
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ME:K6JS\*Q&N1/X5(B[OEEC=3@@9&.^?MY'/P.#Q\<V6PT!K1X6<,T[A&(YR
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M3@<F,DDJZ^^%R7CR"\<GMU/<8>R)-@'CFIMEI7A!L&M3R#=959S->X!D</\
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M_H;R^OM2L[==/L+B>2YM[%4V+!'*S2")%!"I''NVI&N?34!<Y7-7>6_^G"6
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M-H*M6+XK""$P()\4,<S "*<Y$4+'E:QXG'5HD1SE4:)W553NGJV52V ",D
MCG [_IP >,'[DTUIYS;YFE,DI'ND!+$M@#)8\MV!)/WYS4\7X9>Q[&D9DD$6
MSUQ0UL=P1.>%X@)(5P97Q!$4Y6/E.0A'M>4:A41'-];42?BA+ $#&.03QG
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M9#!# CF,9^TC^SU\2PXC+(W(!)/8'MD??(Y''/'?BI2PNRLT:O[D;;SG)&<
M<]\'^W([]L2U'8K&ND';,K9AXT=/7-6(%'M&[S;Z9,1BM>AT*)5*-OB\;P.\
MNR*C7) /<S2L5A!RF S 8 !&!VSWQV./GXJ^S'3H[9!>21'U@3%"[)O8@!CA
M"0Q"CDX!P,'MS5F:R/84.FVP5##.39[AA CFPU9<UL52O>12O0;!Q/<.2QCA
MD>55]:-$C7A+VE+#>A+29/M)8G/(YY&?[<?VYJHZN8KDJL) 7*JH!XQD;?)
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M1R.[(O?NGZE3LU%[JG@*/!_7(QD#'&"/M_GR37MI"N2>01D8R,=\GCOP?OP
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MY)I<LAAST,_W-.3Y9W9UG1KQ%,UC=D21RK)-NGCF=-\<BS*J(T; JRF)!'&
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M_P"@,K-M4>%7"@<  5XM+&SL(A#96L%K$.R01)$I^2=@&YCW+-EB>22:IO\
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M%'O^C+KZSI@9+A-W"^\_R'>175.G>N0=.DM[Z\]#5;;<;&ZDRD=P^"8A-(H
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M 1_M? W'^Z7E/L.QQ2V,Z+";7J\\EXG6+([V.$Z<HU:IS#]KF(]CF*K7]O\
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MD16CM+Z"U?6^J6TZ.2:VM+60G5KLG<+:.)]IAB885YYO<L(RP !<X52:W?\
M%/$NB<+Z? TCCZD#34L/]X[O-TFQMK C&-E6UU9&\I=I:2U8U3RY3W.1C1QP
M-#%"  OS/J^KZAKM]-J.ISM<7,QY)&V.-,G;##&/9%"@)"1H !R3EBS']8Z9
MIEEI%G%8V$"P6\0 "CEG; !>1SR\C8&6;G@ 84 "2,C*WZ8I3%*8I14[HJ?Y
M3MBE:?>J/Z5\'ES9=JWSCGD,E%/V"SM=PG<>[C$E7NCW.WGCRB@<.2*:&?K<
M25.,K"D@@F"@1C&2-7D\E18NZTN&Y=Y [QNZD$J>-QQSC'G'//Z8/-=IZ6_&
M*^T2PTW2[[38;VWT_P!&".Z1]EP+.-AA6CD$D<LD*>V+W1(0JAP<%CIQI_HN
M\V6/.4:GTSJ+E\7Q>05LZOGFMTZWO9Y(]86!)7>!UD^":L!LD4,:9 HK!+:/
M%I(^T[I I0R[EU;L];4]KZ3Z_FT7I:+3-;T;3M1.F(JZ(QB210BX^D$RS)F&
M6-QZRS6[&9XHRTF']*22I];=8Z5JO4LMWT]/JLD%TYEO9+L+ _U(B7UQ"L<T
MK"-9"L>96(B?:51S[(N#VKZ"G*'#/*%!4:2._P">*B2R!*U[E2<.DI:35YX9
M<@BTVU:<RU//C1HKF1T=:K+N()X<A"QD@E'*B#K_ %M^*G6745L^FV,%E9Z5
M<H8+JWC"37$T#'E)[J>/<%![-;I"X0>GO*L^ZY?AK??AW:Q7&H]0W]SI^N6>
M^XMFN%EFMI70, +=;=.9)%(4),)']3<02"H7#>?^A7EO7=DU+1]SX[=I%K.K
M0SYVZ%DP@Z9*,Z.19-4"^CV%C76;8YHS'"&2>*V <Y0NB.$:O'G#+O3[JU(G
M*E0Y!=%?* \=CDJ,9.0.20"<GO\ H[I?\0^F^H+>2&UO()TA1E(D1H[J(]E
M@D1;@QNQRCX8)D@$(!BNL[I\E:;,KIL\,Z1)$$X"BUT4MYRNANDOL8H+-KF@
M*J0HTB>0_B@A0T]T@;$8B$V+28.0JAMZ@\C)_P#ESR>_@YQ]NPK=N75<R22V
M_P!.&3>'=4)#L$7&_N7)"J%&68A0#D9_-**3)B2H 8IJLYE.QIW"DG<>&AV/
M0 6B<X39#QB$'Y#',*I6O[*K3.R9#EHP&;:0#@^?T'G[?;G.<56VMEAN]]G;
MK<).V70RQ*D8)/N]SKP<CA,G/S67[!QW=:K/H$NQVVNQ]TA_?=>UBLII=S?6
M=+-,Z)#D2%BN/%UD4CW*4<G:9%*V2)A'1''\"-S$&@=6EN+A1':LNY#*BNYW
M<+&F[?*>#DQH^S W8R,R4$=P]U);Z/IL$TLKS+<2Q,=D3QQ[Y!)+L9%9%("J
MS %VV$@A@MD^C[Z70M3W6PZC.K.BYKG:S:78!T5E-H(\2'K]?87AZ]FQV6OQ
MH&ZQ@:Y1"]!+1VS?TM1?8Y)[*E)<18OPK&X37\NN64=G%%%IUI'#Z44$8"SS
MJJ >]YE5PTFTXPK/([DR$[MPX5U7^(,'1^J36^E&VZBNI9S+?O=R-+9:>"5>
M&&RN="UEX+AP[,T\C2QFW"+$8HI2ZUW!-0U>LTS6:75JCVK74D"- CDD/&24
M=(XFL=)ED$((BRY+T=(DD&$0WG(]PQ"8K1MBXHHX8TBC4*D:A5 ^!QG]3C)^
M3X':N&:KJ=WK.I7NJ7S*UU?7$EQ-Z:E(U:1B1'$A9BD4:XCC0LQ5%4$DC)Y"
MZI:C8:N;2WU9!N*BQ Z//K+*(";!F1W?EP9,62P@3,[HCD:]B]G(UR=G(BIE
M!96#(Q5U.593@@CX(_OW_2HYE5@58!E(P00""/N#Q5>NGS7IFK7W,]/$M9-M
MH[MWK;31I$TY9DSXECJM*Z\:2R,<YK<0;P,J&"YD+\ZW^(6QM9-M<2;"\M)+
M40VRR>2-8IV@<3*NT<I,X3<B@>D^PJS1D>P,@4(N$$5I=W!<O?);3&:&"X5$
M<JX5@T2,6CE8;;B/=N43H6#LC@LS LUF<C*EJ8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*P'D7C34N4J VN[;6LG
M1'^3HQV^+)E>=S59\B$=6O49%1?$C'-> [/VSB(SLF;VGZC=:9<"XM7VMP'0
MYV2IGE7 ()^Q!!4X((J/U+3+35;<V]W'N7.Y'&!)$_;=&Q!P2!AA@JPX(-==
M'D<6Q<>W?(]7P[QYM'*.HZ[;;HZ\U;[;'4D,>ESBUUKNE57LFQK>N5BPWH]*
MI)+;" Q"FKO)H""[Q;RO%:V%Y?7-M:F[CLFVF7<':^B66&(3 M&S;7!<.%*M
MD+]_S%I_46E:IKNL=.Z9;:I//IE]K%L)3; 0,FCW3VUY<+AS)"GJ1N4#H@?)
MVG<55H'T';:CDJ/1\HWD2WU2!HLVU5E7/<]D:<:V@0F*.P&$3YGP(P7CDLEJ
MU1#57H=CAI((&]PH(U@@V,9KE"Z;MJJ$.Y=VYB 68J1&O<E>&SZ8:@:SU%I-
MQU%;Z=)>O&;21[0W=JXFB2_OG@2"TECC!D)(5A-+E4@:6,$-F62WF&'R)%V.
M2?X_PGQ(\Q0=V-$QA1(!BO4+A]VD8A7>(U(B.\.Z+_9<V)+3T@IY#%>W) .<
M\_;MG'&<@<=[-:H^Z58W9TCF]-C(3RJJ,X&3G)(QG' )KA=CU23=5]^S4[*Y
M@[%85DD-."',6+%%8N3RCN:@T:-&D>B"<I6O:B$<YR^'=,]K. B).D8C7\TC
M#+!0IY[GD<>#V_+FHG6M)O9+._DTJ[O8-0DC8VP@D8*LP8%%V!@FTM[0&*C)
M!+8!%7@Z8=8UKD&RK=8V^T%36]7I[+>[DJD9U7*?4N#%MP0;=B"@>V(KF2S(
M048*PW'/ ]\>%*('GO5^JSZ/;/<6<#3E[L6J1D$-&SKN21XP-[)(X94VDG<
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MN1B2I+Y]DHA%L"C;S/5]5EU2:'=)(UM90K;6BR'!$:##RL@)59)V!DD [95
M<(*ZWHVDP:1;/%$B+)/-)<7#(#@RRNSE%)RQCBW%(]QSM&>"2*EW(FI>F*4Q
M2F*4Q2F*5\TP)),.7'"98Q3QCA%(:WR='(43AL,UJ.8KE$YR/1ODWNK>WDG\
MIZ1@KHQ4.%96*'@, 02I)### 8.5/?L>U8Y4:2*6-',3O&Z)(!DQLRE5< %2
M2A(8#<N2.X[U@'''&U/Q[ G?&CQ"W]Y-DV&QW@FS72;>4:=,F#4AK.=9SV1@
M/FR"AANG$CBE2Y\L;&R)THIMN^O#>3F0*8XE"+%%_# C545>T44,>3M[K&O
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MK/C@S2>I,PX>1J_6VC=/:5H,1CT^V".X'JW$C&6XE.!G?*_(4D9]- D8))"
MDYL+E?J;IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE/X_G%*\=T_P I^?X_/\XI7GNG^?X_G_IBE.Z+_"HN*5X[I_'=
M._\ COBE><4IBE>/)O\ ZD_[IBE%5$_"JB*O\(JHF*5YQ2F*5X[HO\*G^?Y_
MM_G%*\XI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*K%UD=15=TJ]-O*
M7-LJ&MQ;ZQ0K"T?6!!/*E[ER3LD@.N\=Z?"AQ&%G3)&Q;A9U%:X,$)Y;8II,
M@87H!R8H:T4LZYN;*[HIZ@>-;[J#Y(V/G[A3F3ID2+SKKW&EMI?)>^<)<]<M
MZ!5VUMJ&@[9Q]7S9]QKEM-Y)XJB-AZ-.;,6FUQ8PI\^T&A7^O[4KDH?6'U'5
MD7E;2M+Z@>8Z_@:QZH>F?INC]3O5-QQHFI\Y]/EUR-3;%=\SMM]0G:9I8H-<
M*.[C&DXZVCE[CRMAPMAY$)*8MW3089D?Z_R_]?CM]Z?Z_P!?WK:]H.SBZ88M
MY06'.W4AUMI=;9J]:"IAZKH_,'('#9+BIF2?D;E.XAU35+*NU+95 ZR@6.Y5
MKQP4BO!5220WO:Q2M?-!U'\]\%\U;5L74=R=S5L5SM-OU.R>$6Z3N'3]O'11
MR?"T;4N1-YT3CY=<U*A'SGQ?L6K:AJH4N)EW)9(F[316\>UVN='GCBO4K**+
MZJ7,E#I_'VS\OTG3)61^>.ER?U$\5V?'VX<F[G7Z'85MMQQ1ATOE^GI-7OMJ
MLG[/9<E5-3K$[1*LYI>Y1I6DK"*9&7V*5]VH?4RZFM_B4O'6K\/\4,YXD]8C
M^E>R=NG^JG'^@-@3NGBQYYK-Z/KE[4/Y(UJ95PP"@7.IVD.PD6'P9#:NR .W
M@SX"E<1Q/U'\UV_7>'I$V'J+/9<*:9S#R%LFO\R1Z1P;?F+>*/6:':+'H7+N
M9:$>JR9G#1]GL]EV2PJYC=OV?3::CU$\AMY0[N55/]?Z^:Y+KAYEY6J^N"XX
MJU[F#K,TS7:OH[UKD?2=1Z1.**WE>=:<KV')W(="&=NU5/XMY$APJ2;"JJFN
M::^G:Q0G.!@)%J!JG(U2O,'Z@_6=QAIW+,WFKA_B8\WI6Z;>G/=.=&EV2YH]
MON.9.=-1FACT<4-/$M]+UO5==W."^TW_ &8LHT+7M7%9+3U]F4##1U*R#8_J
M1]0&C;O8].VT:9TX77.]IO73OJNH<CZAO^V/Z;JN%U"U?)]M +R+83Z]^U4U
M]K8>*+J-"H(<IQ=[)LFF2*N12CMWA"I6&]*/6YS14\T[)H',M_HFTIRE]1GG
M/@NSOJ_>[Z_T+CBGXZZ4-%Y$J:+B:RO#1$@TUIMU;8JW6K(375DVZO(7C(M@
MGG&?'^L\G_[?M2LRT[ZEO-G--G0:7Q!K/3E0;+-J.J'D6=N_,N^;-KW%-MQO
MP)U";#PGKT#4+2B!8S++9=EA5,/:=JOW27Z[IM3+';?;K6+/B1&*58GI"YUZ
MD>3^I_K#TGE/8>'Y_&O%VS<=0M%H]+)/F7=,+<^*=%W>O2GOGUU6+:]5E1KN
MPDV-]:1EFR;XS4I60J%!00J5LNQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M5BFU:+IN\?T]_6.KT6T)J6SU6Z:PV]K8MFVAVZB4SJ79:ILL96PKNI?(,2NL
M0HR5#(1Q(Y!D[.12L6W/@WASD6\!LV^<8:/N&PQ:RLI8]WL6MU=M9BJ*7:ZG
M>JBL;,F1RG^#5[G0TVTU\97J&'?5D.TCL'+"TJ*5[+CA/A_897($R_XQT6[D
M<KT]1K_)Q+;5Z>Q3D&EU\$F+1UFXCEQ#"V*)419DF-6BM62DAQS."#P&C6HI
M7Q\0<!<(]/\ 1S]:X0XHT#B>AM9WW.TJ]!U>HUB+9V"#0+9MBVJBQG3I0PH@
M0FE.*0(40(G,&GCBE1'?=%G2Q!'RKMFL\$\7Z1OO(VE;]KFR<B:;H^K46[DB
M[Q1V-9LLR'>!J"/C6=F&:<LR6H2_.D*C[$<QBO&]7P\ GX!KAN"NAOI/XMX@
MBZ)KG!'&)ZW;^,=0TCD2RM-$U ]WRA2TU) C#_U#EPZ.#'V21./'2ULO=##$
MDW)36;8@I+T<U7VI8TGI;Z<.-65(^/\ @WBW3&46U,WJF36]+HJA:W=!ZQ(T
MMNV1'0X0G"V)=3ERM>?<-=\\E3)D0R'<(Q&N4KF8W3]P="US6M0B<2\?QM8T
MW=&<D:G1@U:H%7:[R RUFWB;M3QV14; VIUQ96-B2^C^NR++GS#%DO=),KU*
MS9FC::/=97(X]8HV;]-UF'IDO<65L5NR2=2K[.7=0=;-;H-)I*6);SIED"O<
M98PILDTEHT*1SE4KX#<8\=2)^]6<G1]5DV')]564?(TN31UT@N]4M+ L*NIJ
M=K<:.]+ZNKJVULX$2'9)(C@B3YD=@T%(*URE1;4](72O1<;;#P[3=._#59Q5
MML\=KM''T+CO5P:GL%H%P'QK*WI1UJ0I\^&Z+&6#,DB)(@I&CMB$"T D:I7R
MNZ->DU_'DSB5W3?PJO&%AL4+;YN@_P"G.K)J<C:Z^KKZ2%LCZ-*U('WV/3U5
M?6,M6A;-6#$%&<9P45BJ5^[SHXZ3]ET[6^/-@Z;^%+G1--NK?8=3U"QXWU25
MKNM75_8'M;VPHJDM6Z%5FNK&2>7;)#"$=B8KEEL,BHB*5(5?PEP_4<C/Y?JN
M,=&K>4B:M&T<G($#6:F'MK]/AN ^'K3[R/%'/=2Q?BQFQJ]QEC@%' $3&B"-
MC5*E#%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
5%*8I3%*8I3%*8I3%*8I3%*8I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g332508g11i15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g11i15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2N44&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
MIP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=7
M1P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %
M)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V
M]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M!"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M       $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M!"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M    !2<VQT56YT1B-0>&Q <H^%(         IV96-T;W)$871A8F]O; $
M  4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M           %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T
M!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$
M)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W
M!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24
MT#[0      $ $H^%(  0 " 2CX4@ !  (X0DE-!"8       X
M  /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M     )           ! #A"24TG$       "@ !          (X0DE- _4
M   $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M$ 6@    8       $ -0    $ +0    8       $X0DE- _@      '   /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H     /________
M____________________\#Z   .$))300(       0     0   D    )
M   #A"24T$'@      !      X0DE-!!H      S4    &
M(?   #U          !                          $              ]
M0   (?                      $                         $
M$       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F
M<   (?     %)G:'1L;VYG   #U     9S;&EC97-6;$QS     4]B:F,
M !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$
ME$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -87
M5T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M          3&5F=&QO;F<          $)T;VUL;VYG   "'P    !29VAT;&
M]N9P   ]0    #=7)L5$585     $       !N=6QL5$585     $
M!-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q497
MAT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&
MEG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$
M%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T
M-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
MET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F
M]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0D
ME-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M  !     @X0DE-! P     (2X    !    H    %D   '@  "FX   (1( &
M !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B
M 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0
M  ]M8  0    #3+4A0("
M                       !%C<')T   !4    #-D97-C   !A    &QW='
M!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !
M1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M   (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97
MAT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&
M%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !
M)S4D="($E%0S8Q.38V+3(N,0
M                              6%E:(        /-1  $    !%LQ865
MH@                     %A96B        !OH@  ./4   .06%E:(
M   &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %D
ME%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W
M=W+FEE8RYC:
M            !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D
M="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,B
MXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M              9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&
MET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:6
M5W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M               '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M   5A96B       $P)5@!0    5Q_G;65A<P         !
M           H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M\ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ?
M"! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
M  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!?
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MP'_)C]*?VZ_DO^W/]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M'_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,#
MP,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@
MX4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/
M_  !$( %D H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        _^$_5FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U
M-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$
M1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTP
M,2TQ,50P.3HU,CHU-BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@4&]W97)0;VEN=,*N(#(P
M,38\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C(M,#$M,3%4,#DZ-3@Z-#DK,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3 Q+3$Q5# Y.C4X.C0Y
M*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q
M+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!0;W=E
M<E!O:6YTPJX@,C Q-CPO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M
M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/E-A;F1E97 @5VEJ
M96MO;VX\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S
M9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#HV0C4Y,SA&-3DV-S)%0S$Q03E%1#DU-4(P,#0Y1$(Q-SPO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV
M.34Y,SA&-3DV-S)%0S$Q03E%1#DU-4(P,#0Y1$(Q-SPO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.C8Y-3DS.$8U.38W,D5#,3%!.45$.34U0C P-#E$0C$W/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV.34Y,SA&-3DV-S)%
M0S$Q03E%1#DU-4(P,#0Y1$(Q-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP,2TQ,50P.3HU.#HT,BLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C9!-3DS.$8U.38W,D5#,3%!.45$.34U0C P-#E$
M0C$W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3 Q+3$Q5# Y.C4X.C0Y*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV0C4Y,SA&-3DV-S)%
M0S$Q03E%1#DU-4(P,#0Y1$(Q-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP,2TQ,50P.3HU.#HT.2LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HV034Y,SA&-3DV-S)%0S$Q03E%1#DU-4(P,#0Y1$(Q-SPO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HV.34Y,SA&-3DV-S)%0S$Q03E%1#DU-4(P,#0Y1$(Q-SPO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.C8Y-3DS.$8U.38W,D5#,3%!.45$.34U0C P
M-#E$0C$W/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( + !
M/0,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0          "0H'" 4&"P0! P+_
MQ  X$  !! (" @(" 0,# P,"!P $ @,%!@$'  @)$1(3%"$5"B(Q%A<C)$%1
M)3)A-)$8&3,U0V)Q_\0 ' $!  (# 0$!              8'! 4( P(!_\0
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M"TYQG/Y-?(=(A"<*PG"5X? <^2<8]^\8QS R&&Q65W^OL+:[)&@\T*B5=_\
M3*H$JGYZ8=_%?>0P6(R0*9#%6,N]@SQQAYNS^X2 +("/X<:U\&I>M!>?:<UR
M@&'[=UQFV5O[6QW=DT8(:-MD>VM6$X(F*FE3$//-M?M3JX=R%+2RA2VPY CT
MVNN\O]*8KE)KG SFV=$:1K2[<O;D*-L([C1EB.^@)!*I) Y(*K7/?3"T=)KG
M 7+0-$A=K2]8F)PH_P#AS %XF;X23U%)(')1W4N7?S8L/LOIA61->3C9\'VQ
MM^C]<5">&2^VW(UG;-AAY5TQI*\-/LMG5 :0RXV\VEQ+3SC+S:5Y5A->^)VY
ML_(99KM &P%MDLA-&Q!U/C89 B;&U)2Y]/O>MKT=ZJOO%;5XO(#^H0H^*@R-
MW*.CZ4EE;RE2Q!T0LW ;WHG7YJ1R)C H2+C8:-80-'Q( <8 .VG"&V P!VQ1
M66T)QA*4-,-(0E*<8QC"<8QC&.1*1VED>5R6>1V=V/9+.Q9B2>]DDGNHH[M(
M[R.>3R,SN3[EF)9B?\R2:Y#GQ7S7S&&"QXA1YK[8H0(SYA9+RL(9'%&:4\0^
MZM7K"&VFD+<<5G.,)2G.<_K'/U5+,JJ"68A5 ]R2= #^23JOT L0H&R2  /<
MDG0 _P S4.>G-6H\E]SSVK[!@.R76>MV>Q1?5?1,@V\W7K-"0TB; %[>V9%D
M-I18"K00"\178@C"H\:*=RT\@T)2'#K!R5V?"X!@\3,4SDD<4F=RD+:DA>2,
M2+BK1@6]-;;G_P Q,O&1YE!4K[+-[S('Q:V?"XM6@RLT,8S>292EW%-R$OZ"
MS<-NWBB^P2R(0\K [T*SM9?%-TWDC7IBD5"X:0L*OL<$G=(;&N- >C"E_+*"
MHZ(#E":T,XRK.%--)A,C)^.$X8^']O-1:>:9^V00SW,65MP /T^8MXLC&0/;
M;W"M.2/?N7WK6+Y=GQH2WHNU&PRWD$%T'4GM']:-BRD;4C8/$D CK6,0/#GU
M^L-QJ5S[&;?[0=OGJ+-@V.JU+L=N$RW:WCIN+5E<;)D4")BX"ORY(6?6&T3
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M\E')+#&*=88)>:<('2[HLUXWF?'WC7*6;6XF'**19(YHG&R.GB=P"='0;B2
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MUJ=''=:]Y4X>D9Q*V"'4*FWT^63_ (FM)D=D2UCGGG*];B2,@HQ/6F<K[^Q
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MPV@2):EWUDY"PL5Y':X[+65@;J7)W]WD889)V=I1;P2$(\(=V/6V8<%.M;Z
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MJ$4XI3BE.*4XI3BE.*5A3LI;).A===]7B$<PS,T[3.S[1$O93\L-2<#2IN4
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M[G1]71_M@# G8,BZ!J'YWZCX?&!X,8?\5O!M=IR2TA8$[#S$ RZ/Q I4G?\
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M.-J:4#;ZY#V ;"%XSA6&VY40G#6<XSG^YKX*Q[SG&<9YD6M[>6,@ELKJXM)
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MQ[0^E!"6_P!L.D!%!GH8<QAQ(Q@Z\_)+B5*K3ZAHZ>6Y/DI'-;-T)_N0V5N
MP_(V"/X((]Q4#\]C>/RO*<P1S:W==_*-:P\=?D#6OX((]P:Y[R8^2/4WC9T:
MG8UU$<M^Q+B0=7M.ZKCRFQI.\6I@3+ZWS2%?)414('[12K1._2^L,9\<0$<N
M4.!$>CV'Q%UF;R.TME(Y,/4E()2)?EF(ZW^!\FH[CL?/DKE+>$'L_>^B0B_)
M.OG\#YJAAO[R =[N^5W?M6UMXW*MUM)V2Z[JO5TY,4#6M1:2IS(K <9#'L$S
M)@R7,HQ.6@^;G7U*]?G):^D=OH3QGZ<8BW@,MW$+AAQ#S3IS+L-;$:'[1HC9
M7O0[)'579@O K!>#R(9!Q3G+,O,%B-D*NB"._P!H]AK9^:VUZR>1CR$=4&H\
M:F;HM6PJ@A:7'Z;OR49MU44A"<LX'!)LYR[W#C_'U]3<),P8Z\H;6IIQ*$^M
MAD?IYX?>*R+9O%*2VI;"4QR*3H\F].&2%SL[T5D .]D;[W-[X!XY=AHQ83)+
MIO\ F+:=+71_ZN(CE5]G_JC/6CRU[SR:T_J/]2B@5P'LAUNW!K^:*PAB?MFM
M55G8VNAUI3G"I(7[)^%MK8S^<8>Q&,PLP4(A2FL&'9:^YVJ<E]*LU \CXV:"
M_MPSF-2Q2Z502566+C^_6@S* F^] '55MDOIEF8)7_PYEOH 3KD1',FO=9 -
MJ2.QS 56UOB >IO^L7;[KKW%I#E^Z[[-A-@0P3K0LX .DJ+M%6.?2M;,?:ZI
M,, V"O%O);<6*F3CV&CFFUO@/%,)^WE>9'%9#$SFWR%K+;2;/$2*0KA3HE&_
M:PW\@^Q!^14"R&,OL7.;>^MY+>0$@!Q]K:)!*.-JPV/<&ME.:^L&G%*QANZE
M/;)TQMS78Z_J(OFLKY31W/6,_6_9ZM*PK+GK*5XS\'34J]90K&?7K*<_XY[6
M[B.X@D)T$FC<G\!74D_["ON)@DD;'V5T8_Y*P/\ ^U>6]0.K=B:5@&^3JAPH
MUUT%4 P(0T6(\$\H=\8K#V4-,ELOM.-.Y=:=6TI&4_'&??QZ\MH.,$(DN!>6
M_H1O'&FTA >-7!)YGG]I'LHWWHCHUU'B\/&;>.2[NO6@FACEMH8^7!TE3FA+
M<@">)7?VD[]FT*F.ZP]U>Q_3J-CH?5&T;&NF17U)Q0KM(EW6G/,-Y2I8S,7.
M/DJA$/XQG#CE:(AGL8SGZG4>^:3*^)X'-@BYQT,<A'VW%HHMKA#[ F1 /5U^
M)Q(N_<5^9+P_Q_*Q&*?'P0R :6YMQZ%RI (Y-*IW+K0V)1(O\58+Z=>;O7?9
M8J]:RLVN9NG;QI&I[]M 42&_]<H=V#U]!*FI0&!-6^U,Q\Z\QC\ABOFC%_8*
MT0IF8>=;PVJG_*_I[=>.+;7:727./NKB.!6=&CG@,TA6,2]>D^P.W1E._P"P
M#1JEO*_!Y_&W@E2Z6ZLKB5(U<HT<T!D)X+-L>DQT/W(W\E%!%4!@HS<]DM5I
MO5@$F56&]6B:N<O+*"<,=F9JQ29,S(2#KV6W$KP488ZZIKTI.4K^"O\ &4\O
M'Q_%Y#&P"U1DMHX8(UYK)&HDT@&]\OL+:WK8(WWWHBV<9B\E964%O#ZD!95A
MVFE*KQXB0NIV P^[HJ1O6P1W=N\17DVZOV^(I'7;>VLM2==.RD<"#$05EC*)
M4*-1]NO81]8948?&QH(M8O$@WE.3Z^<H0*9/<<>KKZW2_P"%"J#SOQ+/8^62
M_M[S(9/%3L7(>ZFNI+=B=NC#FP>-6V%8+R5=<P=<S5_F'C6=QTTEW+=W-_;2
MDLS&XFG:+WZ8,[\D71'('KV(^:LPI^/K'Q]?'UCX_'UZ]?\ ;UZ_7KU_CU^N
M5-_G5=5I1Y(]GVK3'0?MYM&CSA=:N5+T%L>7J]B <4U(0<\FO%C1<K'O(PI3
M!X!A#1(1"<?)@IMI[&4Y1\L9V,B6;(6<3@,CW$892-@KR!((/1! T0>C678(
MDE[:HX#(TT892-@CD.B/P?G^*\]W7787<>R@4'; V[LZ]292$NDR%NO5CL1)
M"G4X^Q3KLM)EK<4KXJQGWG]XS\<X_?KG8=MC,=%C;5[6RLX0$*D0VT,9+*3W
M]BJ/9Q[]?]JZJP]E8#%V[PX^S1EVK%+:%&)&CLE$![W[[WUU69V#W26_F\\Z
MZ[G]_:XO*EYSZQCWG*_>??\ _N?\>L?X]>O$QA>@!K>@-<1[]=+H?Y[T/BML
MI UP41+T2%4,/]"X8_!'1_)ZUNMS/&?K"S;:\@/7)FN1!4O':YN+NS[U(M(7
MD*M5NKQ<B\.=)$X2IL?,A/N1,0 RO.'"S#4-MX^"7G&XUYOD(<=XCEEE98Y+
M^%;"U4ZYRR2NCMP'1(CC5F<ZTH/QT3#_ #^^AL?&,@'D0R9 +:0(3]SLSAW9
M0>R(T4\FUH$C?=7Q^<LUS)3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6BO>7H
M%U4[Q:\+BNQ55#%,K<3*$5_;D0:-6;OKQG C[I4B':5HR.Y"AXPJ1-@[*U*5
M1]P9!<C%N+';>:V^(S>2PTW.PG=1(0);<[>"X&P.,L)VK[Z .N7L ?BMCC\G
M?8YS^DF=5ETLD(^Y)AOI63O9.R 1WW53NQ]_M_>.=V1UOUA\I6FNW&I:^87'
M5ZN;6UULNWR==;"0MH6%AKF'49V'DXH=EIH43-?VQFO,NL^@8:,$6K&;3C\;
MM,W:#)YCQNYP<DH!-W92V\5C(6.^7Z4S>JCGLZ9!UHDD>U@)@(\O$+R; 75B
M[D?;#<V\?JG1+$1R2I(#\C<*D@C[CL5@+<?E)[6=TM?R>MNP';J@T[2=QCFE
MW_7.F=/VV/N4O',FM$9J2BY"I08ISA*V65D1[^WH:OFCIR)+2KX[KPKNWQWB
M&,QTRWEEXUE,A)$Q]*3(W]M90(_'IB?5.@-]D(S =@:K-QGC-M#.MS98J>[,
M;?8^1NX+2!&U^YF,Q("GW(0G\==GLO4?PY=C^V%<O6Q=0Q0.KM7A*:C]8V+>
M[4M4IK9\6O'V#YCPJU SK0T8R-A)9<H&B1@$'&-149-V$@*3D1I+D?J-AO'(
M[.SODBR676/5VF&,;V=KQ+&-#+*R$M]_[5Y'HLP!(J6R?4+$>/R"VGBM\C+-
M#PGEPS*PM@NRD2RS<0>).B%))*\WVQU5F/PV^-6V]"=?;0L&YGJR?O/;-D%&
MDW*G+%3<# :[J>"&ZG!@R!<?&+=,//D9F>F7$"(2K)<8$I:\QF,XI7SWS ^6
M9&&6'U$L;6,K;Q2#1#R'<C%?@^R_SHGYJJ/-O*?^)\BDT(D2S@3C!$_1#-VS
M$;.CK0'9^3ONIH^0.H73BE5(?*?KT;>O8;R5Q9K;2&]7=--?34<MQL;+V)6H
MW/1=_9?8<QG+B,J'<E!<OX<8*2A[(V&W1WLMNW7X\PM_&/#XSLB]\I!;L@*C
M/>Q>^QV&2-M:(V-^X&[=P+BW\7\;0@C]=Y:.1'7V".:$D'?9#!"-^Q4_(&\3
M>,OOQL[Q^T0.&[!ZGO<MH'<"@;K7+K"@-IAQK%E;E4E92L6"1;!KLR3*-UX<
M*Q4\V>BY6)/A6C@AUID7UG[GS#QO'^6Y"=,9?VUOGL6HAN[:4.%GA<>I 3Q!
M;B.1,4L4<NED]*8+QC-;GRC V7EUV5L;^W@\DQI-E?VERQC6X16)@DCTI)WR
M/!E5M!Q')QXH3#SY"MGW7O/W-V5V#V=>1XK6(LD_4=%U!PM@Z5K&K8DLC%?
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MR"Z _3VQUS,<".2@/7%41>1'_GNRDHMWXW$8OQBRW:0PWN1"@7^9N1NWLI-
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MB&;@X)@)*@$JJ@K][*\88UN?'[N2W23]0K0RK-'^@TZZR\?M)]Y DA?EWM%
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M$NV>-W);^M&2"6)(.]5EW4_DU[*Z%CEQW7K?_877B5_4A%%BYDJ9JK;R?UA
M<),KEZV.TC/II+Z !B$L>DJ^2<9PJ,W]KXCGX6>3!W*7^].B6AAU)KL)<)Z7
M)0VU!#<2.PH&@(WE8_%\N@D&(NTNY"6>W6U"!9'.^*72"-F7;'[BWX/9&SGB
MMTSR+>5&YFR]<JVQNR.S9S_3</?]GF 1,'2*8.,P-'1L3.W!;%>IL8FOA*4I
MZ, =Q)O92;(9 ?>?<6O\EROC'A.#3$6\ZQW%TYN+J)'::6+U1&QC/98LBHB,
M=[9D.CV37V<[A/%<7'B(6],N))9$C+S203S*ID0L27=DX*K<FUR!"]$U:#\9
MO].MK3K';8?>G:N7K>YMM1[(1D-18T%\W7-5FQU9=Q+2ATPVT3=I,9W#3@#+
ML3#P<<0UAW(<LZV*2/5OD?GLF0]>WQ$+6,$Z&*XNG8-=W,9.V )!_3J_LPC;
MD5)4MJJUROE;SH\&,22UCEB$-Q<2%6N;A0-, 0/Z"/\ *H2Q!*EM$BK-F,83
MC"4XQA.,8QC&,8QC&,8]8QC&/UC&,?K&,?K&.5Q4.K]XI3BE4Q_/UXXMD$]N
M*-W TG0IV?I6UZ@7"[[*J\03(#TZV:WA'BP;S96HT=Q<?#SM& 2&5,DHP*U(
M5A>#"VRI,-LBX_I7Y%#9W@QMW.(D9F>WYR!1([#2P*6.BTCE55?G>AHFK1^F
M^9CM<@EG<7"0J[:A+OQY,_0B!) +/(RJ@^.7MJH#)6]%9D0*U5I$QX3#[0A3
MC0J0LL+:=0VEX4IG*2VDH=3C.7O^F7C.?DAS"O2N="K$@W+/"CNQ8D$EP$8-
ML.C HQ]@5(92-@[J^C):RND,MLLJR?9."TI0H05;DO(J>]<@0$*DZX]"K$GA
M:\G-JU_L&N=5=\7<^V:IV1*(A]4W:SSCLS(:[OYSF<!4XR<+=(),J=R.<_!B
M?RRR,0EC>%8&=1&23^!*7^I?@MH;23/86U2VEMEYY"T@01Q2V^P/U,,0 "/$
M3_551HKV%!%5#]0?"K=+9LYAX$B2#9N[:!=1F '23Q*/;TP-2C6]:8^QJX/S
MG^J2J"7^H'U/'WOI_KVXM1$6_:-==A];HB)TU#3#T1';%3,:W/'5*K3E4=%&
MRUEKI,BM?S'PY&A/NM*4.VI-A_3')18WRA))]^E/8WD#E5+./L$H* $$M_2*
M@;[#$:V01-O <@F.S\<\Q?TEM[AV5!R+-%&9%^WKETK J"I(.@:@ZE_%!Y":
M@-G#_7J2GVVL>L/U.Y:^G$O)]JS]C3#-J:-4E7K&4X4*ESTK']O[SZM]//\
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M.<&>>&,3*I>0<WYQEU&U)4E]+H?:5)&XYFK;-VE_A;]K#)2C'$B>9;=N*\V
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:^4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g332508g11v20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g11v20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &-R^8V0X0DE-! 0      #X< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0 !I6:6=N97-H=V%R:2!#:&%N9')A<V5K87)A;CA"24T$)0
M    $/+!]326L >>*<V#4YT"IH X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q ::=4
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^
M-0 "  $X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              )S   $]0         !
M                  $             !/4   )S
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   )S     %)G:'1L;VYG   $
M]0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "<P    !29VAT;&]N9P  !/4    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     #G
M   !    H    $\   '@  "4(   #E0 &  !_]C_[0 ,061O8F5?0TT  O_N
M  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43
M$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-
M$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,#/_  !$( $\ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !
M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M.66.L1/L5NZ-S9CS0]X^"AE\7BO^:GU@_P"YM?\ [$7?^02_Y@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=G<D0G%S='6!E+.TMABQ"C-#<D5ED;+!\(*BI/_$ !P! 0$!  ,! 0$
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M(Q22ST(_..D*<*5_>TJ<5"G3N[FG"*W1A"M.,8K.W"BDEY#).=(Z@P!@# &
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M$O28_4]G_:^G_I'W7[E^-CO^0+YF/D='A+TF/U/9_P!KZ?\ I'W7[E^-CO\
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MOS1VA@# & 1$1RY27(3#^V[[GT@$.0](G, Y_P":'S#\!^;-S_J_W(^X$OF
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M&O#OH^DNL<_0\-2]9#K(I6&F??C%/W3)\QBI4_0]@==(0*\AB]( ]1SY )@
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M:EZR'6/<<U^1Y3\WN_)QKP[Z/I+K'/T/#4O60ZS=N'*8D1%$.4Q3EC6)3%,
ME,4Q6R0&*8H\A P" @(" " AR'MSPY_O2_O/WL^)KM.M6:>4ZM1IK<UKO:B1
MS)Q# & , 8 P!@# & , 8 P!@# & 0-D_BL/]Y0GZZ88!/8 P!@# & , 8 P
M!@%2<@'7J&'D;GU4L@ /^;R][U;F _>"/2Y\N7WY>SGS(?L$CI\?7_L"VX P
M!@# & , 8 P!@%/IX !++R P?NPGQ'I?./KDN8E^\)]Z/S?OO_O-@/J]Q<,
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MZ#1H@BU:-44FS9LV2(@W;-T"%210012*5-%%%,I4TDDRE(F0I2$*!0   ^V
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MP\K '6L.Y#XX>5@#K6'<A\</*P!UK#N0^.'E8 ZUAW(?'#RL =:P[D/CAY6
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M^Y08Q[A4@&0.8?A#X\OB'Q'X!_I' ',.T/B(!SY (<__ .C_ &]F 8_UOLJ
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MLEI9H/[=,Q%?E[K8&S&:;-[/>)2!A)"Z6-*5M#R)CW$LHU2 SQ@# & 5^O\
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M/8&/<VW@)_5P-2/#VOK'L#'N;;P$_JX&I'A[7UCV!CW-MX"?U<#4CP]KZQ[
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MQ]H6K(^VKBS@+!(1@BT:VZ/C#,"6R$()Q@9X[^(%9R#,KE:F7L;7 S#@# &
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M\S/.CE=S3A),3MV[>(S)@# *=3B 0EFY%Z/2N,^?_P"X3+I???\ ^6 7' &
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M'Q'X#\, FL 8 P#QS#GRYAS#M$.?: #\!Y8!Y 0$.8" @/P$.T!_XX P!@#
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M=HE;C9/<M3!.'B9^6L%@CHFQ2+^<;-@=/G<['HOWK\'4@51XQ>,W[H#;S &
M, RRU_@S?_4(_P#3+@&+WO\ #'?^TK_]4^ <; & , 8 P!@# & , 8 P!@#
M& 1LM_!"_P"V1W_?ML DL 8 P!@# & , 8 P""6#]TT</(/XBF@Z7/M#G(0(
M\N7+X#RYB/,/@ <A^( 3N , 8 P!@# & , 8!7Z^  $SR  _=!*#V?.(J)]H
M]@=H_/\ 'LY=HX!8, 8 P!@# & , 8!@#BK_ *->]/\ "ZY?J5W@&4-??R!I
M']T*U^I66 6_ & , 8 P!@# & 0,F8 EJT _$SZ0 /A\T._$?G ?@ _ #?\
M .W )[ & , 8 P!@# & , A(\!"6L CRY"XC^B(#S'D$<@ \PYCRY#SY?#F
M\_[1 F\ 8 P!@# & , 8 P#++7^#-_\ 4(_],N 1ZD%&*'.H= PG4.8YA]<L
M',QA$QAY IR#F(CV!V!@'IU?BN[F\=?S, =7XKNYO'7\S '5^*[N;QU_,P!U
M?BN[F\=?S, =7XKNYO'7\S '5^*[N;QU_,P!U?BN[F\=?S, =7XKNYO'7\S
M'5^*[N;QU_,P!U?BN[F\=?S, =7XKNYO'7\S '5^*[N;QU_,P!U?BN[F\=?S
M, =7XKNYO'7\S (6P0<8E' <B @;WA#EYBLL/8>78D-V"IR[2F$.?S<^8=N
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MN;QU_,P!U?BN[F\=?S, URXO86.;<+N_5T4!*HGJJY&(8553  ^YG(<^1CB
M]@C\0'!'N?DS]AE76,'&K:UUZLH@8RBM&J2AQ]<L',ZD!'F,/(#@ <S"(\@
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M?BN[F\=?S, =7XKNYO'7\S '5^*[N;QU_,P!U?BN[F\=?S, =7XKNYO'7\S
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MD"1\4R;I]3QL3:V62?D7OO"4LLCLJ\FF0='=PR\(QU^S SLQA?9M^T[6,$&
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M<^7P#[X_8'+L^& 6? & , Z:WOH;-?'XIML<5$!Q'[SHUOV.XW78(8:0TUK
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M_?&WC$^M@#WE']\;>,3ZV />4?WQMXQ/K8 ]Y1_?&WC$^M@#WE']\;>,3ZV
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M/8( 3V , 8 P!@# & , 8!7J]RY37]X97G\/CZQ/\ !\W+X\Q_M' +#@# &
M, 8 P!@# , <5?\ 1KWI_A=<OU*[P#*&OOY TC^Z%:_4K+ +?@# & , 8 P!
M@# (&4$ EZT'2$.D^D   'D!A"&?CR$.D',  !, =$_: #R#ET@ GL 8 P!@
M# & , 8 P"%CP_;6>[ #FX8=H?$W[7(!]\'X0^ ?V<L FL 8 P!@# & , 8
MP#++7^#-_P#4(_\ 3+@&&K3&'FV%CADI64@E)9I+QB<W!K-F\U#G?HN&I92(
M7>M'[-"48&5!TP6=,7C=)TDD=9JX3*9(X&L=-X.]-4>M;5I$2WL:]%V]1TM<
MV.G/IOI0S"G%A9R 6C(55HU9RZ:[N+L#]HM,2LI+3*;5*/9-)!LQC6;9$#WJ
MG"=2:[=:MLF9NNR]A; J-B8ST7;+Q-5YQ(JMXG6VP-6P=<=M:Y5:W$'@(>O;
M.N;]N1O&MI9[8Y969F):25$R1P,8EX)8>YW3>,KMVV6BQ:\V;NP-H--0,)M@
M37\F#;5%%H,3(VANI6DK6C,QLG79"5;Q<-<&]94>LZ]-.XYU*M5#% G8W@>I
M+*0]^O=L[QL%H:M])L:_9YVQTIU)5>*T!/W2?U_&0K-OKYI +)>LV!9F%C?3
ML+-3%A9.T%'\D:39MI%,"EE]&7PR$FV<VG'S?M",1&1C_P!>RU[(2,P\@JZ[
MJT'.N;9)T%[>HN3BH=9DDDTJ]I@*\\6A(AQ*03]1)Z+X#-4QPFZ[E+/4+DUG
MKW 66CQ^H(F!E(27AR*)QVEXS<$%7FSA"3KTFU6":@MY; B+,L"!'#AN\CG4
M*M!2D8WD, B*/P9ZNHNL-L:G:35VEJ[N4S@;>ZD7=7CY$OM,.WA%EHQ"J5*M
MP"$H[;MP=S%C>P3^SV:666E;1-33SU2B0=OL,CTWA^H=&FZE/PJL\9]3!W<,
M.#Z0;KH&'?VPV&S;U[8FFP0,N"5CC6Y(+H*(^[XT5&KCVY4P.2@8C:\#FJ$7
M,$+VR[)F8:D/HEQJ^L2D]!&@M5QD7MFD;E&N4XK*KLI1>$?6O7-.8+A;I2TR
MK*K0R5>@Y6(9K.!5 P'Q0<#-VOJ6R(K1MA7JC3B!IFT*-N"<=;$6K;L&VR9A
M_*^T.(4NL;JG:J[7EK#9W<;"0,WK*U =^YB%;TM$S3HT8!GZ:X']5V)W+DFK
M/LM_6'L[L>VP=#4GX4E4I-QVV\DWVPK75BIUDE@]ZSSF>LQDT+%/V&'A4[1/
M(P,7&).TB-P(K:W!O79C7T0QUXO*$O>O"W:3UD[F+:> 086&];SUYQ 2LFI.
MQ]5L)XZ6C;MK>$5J<DXK-CAHM(%&EDJEPBEWL<Y N/"-I2\Z9J6R%=E6 ]@N
M^V-PVC;4Z=2?):E8M2:@ZK6642M8T*G0V,LNE'5%F]<*15)JT,Q7?*1$1$)1
ML<V67 VNP"-EOX(7_;([_OVV 26 , 8 P!@# & , 8!!K"/66.+S[!@ID>C^
M$0D((.?_  Y\O^. 3F , 8 P!@# & , 8! 0!ND$QV\^4_*%^;LY*)]G9^#^
MWM_#@$_@# & , 8 P!@# , <5?\ 1KWI_A=<OU*[P#*&OOY TC^Z%:_4K+ +
M?@# & , 8 P!@# (.2Y^]:YR >7MK_I" \@ /=#[ES#F',!'EV" \AY#V" #
M@$Y@# & , 8 P!@# & 0<=R][V#D/,?:([F'(>S]K4.7:/8/,/P?^^ 3F ,
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M (&4Y>]ZUSY\_;I#ER 1#^)W_P"^^8 Y? 1^?D ?' )[ & , 8 P!@# & ,
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MS?Y?$DY>I*'_ ,V59)"//U@_ #B/+EVB'+ )CJHGWT_@%\W '51/OI_ +YN
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M)RHI@[,8%I&4*)O4E 2 2!D5.8!ZP>?,2@40YARY\^WERP"R]5$^^G\ OFX
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M7;K$.DLF10IB@!>, 8!4YS^4-)_??QG+\N0]G\G)3]]]\',/P<RF^^Y#V?'
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M^0F /Y.2G+F !T1[?AT^0!\0'GR 0+9@# & , 8 P!@# & , 8 P!@# & ,
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M'RT=996=B8*O[^UYK?AP1B BYQ)NM0IG6&P:A;9FNQ\0C+NWRL@ZCYMLK)J
M4,9^U+[<^+Q?[F<J3Q"[;L-FT)8K9)C#6AKQ+7GA1WEK!K7G]3C3]8-3R^VJ
M3-O*@[M^QH^'NU<;1%*E4Y*K[%N<(_IUMG#GF#JN2Q5<!KV[5T]NVP[0<$-;
M>,3^BOQ ?X4W+]3N<$EN?D?N,K:L_FPUQ_<.H?\ CT=@U+>_*_>7S!!@&NUT
MWC&K6V<TK0I=[!;E!BHK"3-STQMFQ:G8KMH8MF?.9>V1#>IU"3:1\)ZI-^@R
MV1%KLI:5A8Q=<LF_;1SD#KI#CKXHV5"<WU[&:*D8>DZQM/$18'S6F[ B"[<T
M>&X'] UP.L8Y?9,PI3K#<J;7I>^!)V"0NC5$+%18L:^A[Q?N6XN/'U?;XGUH
MS?1N,O<;[=]UT)L6@ZOIE\@27B9JT0YO\.U=WIBO#Q*^G:97/W2RB3VY69\I
M/RMJ4<GC'=<J#>H2\U4*X;859]I!^+L^GS<#<'ATMNY[QJ*JV7B UK%ZDVI(
M).C62C0T\C9(Z+%-RHFR50DT5%>?MS0J3M1FJ<R[!14[-4ZID?7JB/Q;3-^
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MER@W:&=*BLJL9-)!FT:LF#! R4?&,6Z+*.:M6J1$0 R#@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P",EV:K]D#=$2 ?VR.7YG$0+T&DBU=*AS
M!'I"FB<"ARY";D B #S "3P!@# & , 8 P!@# (-:-74LL?+E,G[,UA)>.4*
M(CZT5WSZ%<HB4.7(2 G'K@<1$! PD  'I#R G, 8 P!@# & , 8 P"!@8QQ&
M%F <"F/M\])R:/JS";DW>*$.D!^8!T5  H@<H<P ?@(\^>!V^PGL 8 P!@#
M& , 8!B'?U$F-GZ3VGKRO*LD9RYTBP5V)5DEE&[!-_*,%FS<[Q=%%PJDW*H<
MHJG306.4O,2IF'LP1K*:XK!>*5#NJ]3:E7WQD3O8.L0,.\.W,8Z!G49%-&3@
MR!SD3,=$RJ!Q3,8A#&()1$A1$0 :>UM\6RS8(, 8 P!@# & , @I..<.Y:N/
M4O5^IBGL@NZZ9A _JW,0]9)^J  $#&]<X3Z0"( !.D/:( & 3N , 8 P!@#
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MU$XHCF?I!=AQ40X32<K2Y95Q5@6>&11BEV[=PW/'N72+Y=D@Z ]YGB#IL'9
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M=O4RE,DY3*LT<J-Y6-<E683$='2#=9J01[#(6 , 8 P!@# & , 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
+, 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g332508g15a69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g15a69.jpg
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M0G>WU"0FAR4G*#E2<GB&DKA&:*?!T>'G_\0 '@$!  $% 0$! 0
M  $" P0%!@<("0K_Q !L$0  !0$# A *!P0$!@X(!@,  0(#! 4&$1(3(0<4
M%1<Q05%456&1E)6AT=,6&")7<9.QTM35,E:!EL'A\ @C4Y(9)%+6"3,U0D7Q
M)30V0V1T=86CI+.TPL-&8G)S@[6VQ#=$@H2RQ7;&XO_:  P# 0 "$0,1 #\
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MN>[^"JTT2SRE*0FE4E2T?30F)$-2?_:22#-/VD0MKT6-%MMMMYRW5LVVG?\
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M=UD_?N1?2,[Z1IX/T+@>F<QC=V&O!HI^<&UO3D[O@[K)^_<B^D9WTC3P?H7
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M "I4/^]O"@5EC5A0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M0*VFF)CT<XE,J!-2K/R4MP54YA!2*DN"MK3=1:?UM5Z&/"@H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % &6G!C_M3:N_\
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M8MRXY%AOOT5QERK0H4RCLHGLO:;.;48-+;9DN&RTF$:9-1B+4LR?3I9Q2_\
M'(..>N15S-MI:XJD')::=BH)Y"C<RK[,=*7#-*2:N<?;,S\O]V9JNQ)- N'A
MT?\ K*:ZJU2_U',4##O8,#UC,26TYB-E<=4&,3NX.;PN6DD=?LWQ5)LH$USQ
MZ"-"P!)S)\R,E +YPTZ\:2"SUU@G;.?$J%014HJFDPYE0BMTZ*Y'?)Q3-,LH
MY&0J8I#9J)V=6G5H>PQ\FP\1264J8P)MZJ/-OOD^WA)IQYLF6S0N\TQZ<I!&
MZ9)OQ.RE&2_((D*\M)&FXL80O%#49V-$=EM.2^:.I>^376NP<C=:3F.$N5VA
MLBT^781>30M$VNP$!@0K798\?EL7F,\:Y#"@1E'AQ^4VD4;CO0/6CJ;+Z("J
M#?4M+S9SK":M%TL5/@Z32N0Q*-HEN.O.36V68\B+$43C;JGULQS8?>S%37TK
M)DX?[_ ZZI)2&\&19R5ZT.8;U*4IU*$-K;:/$E1J4E&!:\E9'T>^N(4X<08?
M-#.P-N- 7-@*8&FP_>O"+R#C=/I;KN/RJ*EA<CL39JNWP(:]]09,F5%.52"R
MS]Z@S8W8NM"S;2=*),M<5J'35/65=:<9=TQ+R-<A1YS\:0TXQ@424.N(RS!M
MN))"20@U+Q)PTU5YS]XIM+3!JIRDFA6-S#+:0\M"TJ1<97*,L2+E$1%<6([R
MMLAT>4>>/=@9L.1(UU'=)'-O0S>)W+5TC:JQ::Z@UU,-CDF4*#N3B;J?QN0C
MX!+A0(\Y5AY1$H-;>K\7"L2HYVOGG;5]*(1+H;B7ZLS3)5)9*H,**1%J<V-!
M;7*=2T:8;[*YD9QUE)26S;<5D9#JVUH*\=561-7Q#)4E,=R,G+H/&V^\VR1N
M*))DTM!NMJ4DB<2:5'A6HTF0PTWSJ!OIJ7A0PJ6(SF+R^ P?9D,E.(5Q&WA.
M*ST"V-C<3,<=/">8(X.45<BBXU(L79IO6*JH\L18K-W:O44>IJJD9YUR,<21
M&FRX$J/E4OI;D0WE-.&T^E#9.M+(DN-K-MM1H61+;0LE)+81GSD-J4I&36VZ
MZRXC%C)+C2S2K"LB3C2=Q*2K"D[CN4E*B,BLI6U&0% &8>PO^PGQ8_\ Q(\S
M?\B<,ZYF%_NNM#_R'9?_ +W:@8#7^4IO_%*?_P!K4!AY73#/&Y73G";BW)FW
M$)K/9)) DDWW?C<_R1MO'69!_.RVTN3H?4\RUT"T:(A+?:L)&,]8YR6:#=MF
MY4ZC*)6/*@TVQ!^3:)-/+ZI:NT$<[3*AL,.L4?5U!'J3/0B&W3J"[48LUZK.
M2SI\IQ<\F(JZ:U'2^;;Q/&I"$*-7/R*C-0=0-I"%(BE,*_2SQ$T3$-3S;RI*
MG38<4;V!M3"6\=RR7>24G?96.<"X<]56'R7>N8J81[4FI.0<X@@C6Y4I@,U)
MN*6:L&QS"/SEP<9B#4V:1/;<7DAD4Z$#0[!VYL":&S#]L6L,VK]L9*$DXQ2"
M<BO5&I4:),<G-MY2I4R-4''\M$)I3K414FG2&&G$NN.K2G+*::0IO'DJJ;A$
M1HC8FUOO16W5/)3BD,(?->)O":DMFMA:$J)2C,BQ&E)&G%>*<\$./+2&;#8P
M+94ML_@G*CE1%)-L6<0QQF^C.D^*6LH5)94-&1J-3+U,E4K>GMAC![5[F)&X
MR]ZF*>XN-4Q\9([%M9$M?6U2H2YD"/DYEG[/2(\&)*3@D56T4^4Q'<<?D1<I
M&C(9A.+4@G'#C)-Q!IJ#SC!MV&JE*-QHW647.0X2VVFG"N7(FO.(0:EK;Q-M
MDEHU'<HS;+$1D^I2,-J0W1V"3"<'+8\@!K>,;@V/QMU_IDCGK4[F8EU^23F5
M-@Y*1 KGTTH4M#5H-*T9(P7+F6KM8>TSCQ<NP*LB&>P<MNXV<QK49PY%+@UR
M;5&]/,DU&U#*.IUMA[(F<LI12XYL+)IHTDM1/-MK;4@75U92<J6E5&N.S,=D
M%EDX6])X#42%8?WF4)Q!H,DI,KSQI2:3(4=KP5UY(!T5<PODPV/D-C/=U1/6
MXU_J&1@K&=C:! ,Y-.@,B>*25^E%XN6%FHQ:"RY' ^^,O#ET)+$H8D,?.<+J
MK7365R"E4%32(**5)G+14V'LE!K+RF(CS"<@@Y$AMQJ1IN,HV4-(9Q,29)N(
M2=9U)U!K)R&:2:*.MXRD(5A:E+-#2D%@+&LC2LW&SP$DD^0XX9D0UP5W(VPV
M9R__ +-/!W_P2VA_^[3D17*TC_+5K_\ EBG_ /TU0QY1:G_+4G_V(_\ W=L6
M4KHASP4 ;'V'&72LA*A=? &NR!NP6?''3O(,M*9!,0!G7L@RET-U[,I=$5HN
M*@4;D4.:J(S%X,BYS&=R1=4HV$AW+#-<WB2'>?N6BK##3T]]=/<@KK]6H349
MB(\S/CZ5ESXD64F2Y-D1Y:B.(AR2R<)A)-J<=2NYDVW)N+</8(SY",]K-L[.
M<>LQP#]7S;A*"[(CMWC_ '))(.\C8\.:/1_605ELV9PI%.7R9@3.R@,8'#(N
ME)&PV6Q,0VDP$H)1BTJE,H=Y!;T-6YR#*=.T^0:6Z3'F)D+=98?J+RZ=$EF<
M6.XVS&=9<=D*CJ<BRG51GVG3DQ8T=&5"[-??M_86?;/:^W-N&9BR0SCQJ@J#
MD>Q6_(!SCJ&,*08&4DJFGY)C-&<XV$0G+8!&G$&N>L*68XC-=R.3$9(%G9MD
MS#>IK*S9:6O,XNWW#E?J;3T>GJH:=59!37FXY5:/I-4. W#4_(3-R&42O*3V
M(Z([T)E:G<HO$45!25,V<S.XB+</9W.HSS7YMJ\[A=%7H[-@)3*T,[^HMFMB
M3(0-4WBV>8@4]T-M^BM!C]76=*JIN+O"CV21;8.!11HDX9:],J%G@--Z+?#L
M-:5OH)Q--Z2DW9-N:3.)!O'2%4-RN.5+"1&G TB/)@FV2C2N>SDD/*0XAPUQ
M\7YWW7>F\R^PQSD_!(%%6\GD!+?L>QAD1UY-)N9(-XX/,RE%Y"=C:DUTX$WA
M\6G<B[G'2A[N$"]A9XB<8Y$;#R[(\(C*S%XHU1K:O2E1F&Z&^<N7/B0V6U2%
MLQE(F0*I/)W3<F$Q>Y&12GD2V&V5Y/*-+9=D$M)*7<9;%^SZ-R_;/MN%BMV<
M:WNE0.<D)R]B9%'IB/$:O7:B5VEMC0=]KV-[)SV,T[:]6]2A: 2?:[:V'Y7(
MW6+R L.Q(8.8L0P7W5'M"BL/E':B+:<9B..U(E.I5J?,1.D4\J>NY!91U3T*
M>O'^[PM,-N&WADMF4>S=^PCO+=S&7^LKAC'71@,I.&W\NS7_ ,)^2/\ ^V_;
M-<U:[_(B_P#E.S__ -04L26S]BO88Q;KI1 4 9#\5]71?<FZ1$$F5R7>\O"]
MPREVF*E<>@CITZUUIN?;%$,59I+!1N-14<0,11@R,'S8QR/%B'#YXO=OBEW2
MCH;2U*32:0]-B9/+IETJ,@W(K\U*4SZK"@.K*'&<9D27$-25K:89<2MUU*$)
MQ&>$Y(KSY>+8*\9..N$NO9T2CV.H=QBVSB:;"UOJ0'#RQ(=LQJ*V1+(^+D4P
M&/\ <D'8@89((Y!!2Y)^ZDT=C:MB;E!I'PXXH\S<D4.<3;&?";?.JTEQ28D&
MH51Z6TVY3ENT^*^Y'B.(I,U;\MB1-=)M"8S\@LFDUONN-()+:EV>[C(MW9XR
MS?KTW1Z6<(H[" [Z?R3>PE#4XT>%P('!,7%2F?#I1()*2CHD"1U_%=A&AC-B
M[1$$)(F>SGF2>8!#L$Q^<DRM'+7XMLGYKJ(,>BNG4W''C;9=E.1H3D9B.W(=
M?;G28+3BEI-U$<V"A7D^=YN:7_K &5VV5WV&=^?-<1G=Z;]CCS"X<2X3PJ>0
MC5C&-R,=B?V%G"PSK9#M*7Y"DGTBY3<CM/(R<)%'S>/DD0KZ):PC3MP(D0EJ
M<;YX*JXM1I)R\;88$JV,R%-J*Y$=PV()2WDT]!Q,J:(]FZ#551WI2#?;4\B5
M49"4NL.J945Q&I;:4J-=F+C,BV=TU%FS;&:_/<?HOS1?7_"(7L6/XO=>SH--
M!FP@D-R@LPDH210A[%#*^]@VK)AZK1EB4/I.FK!JY5)-EK+FU28)\EFP%L9*
MG<:WR9]L78#^&?">AN0'I938D=Z/-1*:*BNU*)DI*VV#0I:DDVI.%DFWD&2W
M%QSRBEV<BVCNS^D[CS<76+/CN.^J"T?EFQF/(%QGJ:&M8DQ,R!74$E0F;::3
M<U*!4>C6<+S/>HZXY=E#S4D=R87.R;9@$Q:-'+#"5NTXQ;:N5^IM/Q:>NA)*
MJ2U2ELL%58ZHBHD-F,Z_(*63&52XE<IJ.F.[":4MW$M*SC).0%Q9\^;-M9[S
MVKK^*^^\^4>[E/QL#<=04+$I&;R25*;%W5#I)(FR;QD',M8'X.<P+L6'?XV=
MC,<DY21[?BYR[H6ZT;K)(9I73M39JT#U?>ENFSI>,4"D2X\=1H6ZRJ;J@3R'
M'D>0YGC-W82PI/%A4HC(P,KC,MP8:5UH@91P#_LB\EO_ !;XP?LGD-7-SO\
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MVP_\^-]5S=G_ /;=J?\ _)%__):(*E?YO_LE^(Q;KI!2% &0_%?5T8W)NH+
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M/?CI*?VX^K21?]K1_P#W#/\ V:0$+J^ 4 * % "@!0 H 4 * % "@!0 H 4
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M*247'N&/"_XV[CPO?.,P>3[%:,]7PO;TC(:[B<RDX^%PV<Q]&2"GDQ=(1Q'
M#BT8*YX$7[GL@6+ANY[@,$&R5W-Y34(G^^/-QS5)>BMID.LMJ>=8<-M9-$;A
MX[U%Y*2\NXRQ(29W!=^'6.^!<7>0&QW&O,H[J/8&$>VC)HY%(=/2L.DHS7)
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MMQ]6_B_[6C_^X9_[-("%U? * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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MN-MWFJ]#+:#)DS<N>6ES"F#._E,[O3]GZ]NK^NC$!0 H 4 * % "@!0 H 4
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M>[QBI^U!0/E^%_JS,OOYJ-=-? :>D3^!$Y/CZOS#VH*!\OPO]69E]_--=-?
M:>D3^!#)\?5^8>U!0/E^%_JS,OOYIKIKX#3TB?P(9/CZOS#VH*!\OPO]69E]
M_--=-? :>D3^!#)\?5^8>U!0/E^%_JS,OOYIKIKX#3TB?P(9/CZOS#VH*!\O
MPO\ 5F9??S3737P&GI$_@0R?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K
M\P]J"@?+\+_5F9??S3737P&GI$_@0R?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G
M\"&3X^K\Q2S'\$6!"V>+NW/8LO?)^(8]A?C2S3ZK%"S(9=7LO#MGU]HL\NM;
M#L?^DNGVOLL.R[/&2T4EG_H-.P?^D3VB,]XB#1=M[9%L;IW;HJGM04#Y?A?Z
MLS+[^:C737P&GI$_@1.3X^K\P]J"@?+\+_5F9??S3737P&GI$_@0R?'U?F'M
M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K\P]J"@?+\+_5F9??S3737P&GI$_@0R
M?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K\P]J"@?+\+_ %9F7W\TUTU\
M!IZ1/X$,GQ]7YA[4% ^7X7^K,R^_FFNFO@-/2)_ AD^/J_,/:@H'R_"_U9F7
MW\TUTU\!IZ1/X$,GQ]7YA[4% ^7X7^K,R^_FFNFO@-/2)_ AD^/J_,/:@H'R
M_"_U9F7W\TUTU\!IZ1/X$,GQ]7YBEK?P18$D8'BO7[%LK/AY9]=?UM+.UTKC
M' A"R5D_#M?L^W>JE\KY]GCVOM%L>QS[9UX3KI+N,]0T[)?Z1/;O_P" \0C!
MGNOVC/8W+N/C%4]J"@?+\+_5F9??S4:Z:^ T](G\")R?'U?F'M04#Y?A?ZLS
M+[^::Z:^ T](G\"&3X^K\P]J"@?+\+_5F9??S3737P&GI$_@0R?'U?F'M04#
MY?A?ZLS+[^::Z:^ T](G\"&3X^K\P]J"@?+\+_5F9??S3737P&GI$_@0R?'U
M?F'M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K\P]J"@?+\+_5F9??S3737P&GI$
M_@0R?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K\P]J"@?+\+_ %9F7W\T
MUTU\!IZ1/X$,GQ]7YA[4% ^7X7^K,R^_FFNFO@-/2)_ AD^/J_,4L?\ P18$
M^<F6]^>Q9+U)*8#K9VXTL\^WVS%"R?;KX^';'M=[7(W1[#K4Z[(V4[.W;.PP
MD]%)>;_8-.<N$3W3+>/$(P;.?8.[8XB/=XQ5/:@H'R_"_P!69E]_-1KIKX#3
MTB?P(G)\?5^8>U!0/E^%_JS,OOYIKIKX#3TB?P(9/CZOS#VH*!\OPO\ 5F9?
M?S3737P&GI$_@0R?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K\P]J"@?+
M\+_5F9??S3737P&GI$_@0R?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G\"&3X^K\
MP]J"@?+\+_5F9??S3737P&GI$_@0R?'U?F'M04#Y?A?ZLS+[^::Z:^ T](G\
M"&3X^K\P]J"@?+\+_5F9??S3737P&GI$_@0R?'U?F/,\_@A@%HT=.K<^2ZG<
MS9=QV'K9V>/9]I2S4[#LO#QEV/9=CU=EV-^KKZ^J_P""FNFO@-/2)_ AD^/J
M_,<6'\$. O6+)Y?GR73[K:-W7:_6T,\^U]O1P5[#L_#OCV78=GV/9=CCV75U
M]C;KZJ:Z:^ T](G\"&3X^K\QZ_:@H'R_"_U9F7W\TUTU\!IZ1/X$,GQ]7YA[
M4% ^7X7^K,R^_FFNFO@-/2)_ AD^/J_,/:@H'R_"_P!69E]_--=-? :>D3^!
M#)\?5^8>U!0/E^%_JS,OOYIKIKX#3TB?P(9/CZOS#VH*!\OPO]69E]_--=-?
M :>D3^!#)\?5^8>U!0/E^%_JS,OOYIKIKX#3TB?P(9/CZOS#VH*!\OPO]69E
M]_--=-? :>D3^!#)\?5^8>U!0/E^%_JS,OOYIKIKX#3TB?P(9/CZOS#VH*!\
MOPO]69E]_--=-? :>D3^!#)\?5^8O+Q]_@TX?AAMZ(\E6_,8EL5;6WJ_V$.6
MT,UBJ9COQC!J Y=D>PV_(<F'J?C*<BMNH.\[JR8V97[GLXNZ0UU7T055>GR*
M<=)3'*1DOWQ3C=-&2?:?^AI1O%BR6'Z978K\]UQLGQ]7YC]5\,_(^)_%H%^R
MVM>;JV3])^T7!):@ H 4 * % "@!0 H 4 * % $9:?ED>^+,2_:LUJ=HO2?L
M2(VS]!>U0DU0)"@"&[!V!#]5PN2[$GYM&.PV'B'9Z1FUVSYXF,$L<;9NWF;0
M8U>D'&"..6-\DV;1PM?KM;%/*]^JFR 2[8,.@CB(-98;1#N)Y,!L!B22C9\Y
MR,2XP/+E!H9/N%JYLU4=, )9Q@Z?7:L,+,E,%76"N:6"@!;N!\GN/.T9D^U[
MKO<NO9C,V")5QG'P$D8/WKUL >)CC[L)=)6Z$B:1\BJB//N@*Q)N$?K(LRBC
M1RJFED =CWDQH$?#IWL!SMJ%=YFL=A+:FV!(6QA%Z/B>S4#X:*JP,SDRLX4;
M2G"1R($%]1NUY/,B!9@WQ2OFY3MD 3S7NR8#MB,MIEK67@)M%W3I^/3-1TBW
M(L\"0EVJP*BW62.5\V144^169$QCS!!^/=I*-GC=%;#+"P!^=/I/>;G*/CSR
MQD4#TYMA_"HDO$(5(%0[:.0PJGF8(">Y7CWND_'"SZV2R ]FG=+%U9OA9&V2
M:6&>:F6?LEA[,T.K4,I=0@(DR--R&LHIZ2@\F@FS2G"T\VC,:E9\-YWYS,>S
M6#LO0:O0SEU&GHDR-.R&LHIZ2V>30ADTIPM/-HS&H\^&\[\YGF&#YSI'.DEC
M; <6-;IDS,,75LW%F[0;5SH&1>6!1Z2N!S(TSA;@6Y*C@<LC;\P*1=YD@N)I
M@B6:LG*UD;=2U8^QKREMM4UA3C98EMZ:FI=0DW7F4K4VJ22TMK=CO(;<-)(=
MR2S;4I)7CK6K&V+?6MMJFL*<;+$MK34Y+J$Y5Y@EJ:5))Q+:W8[Z&W#22'3:
M6;:E)*\<I'TBW28P]%!Q+-K3^,(.B#\2V6D&JX('2<%13(,2*#$5"&OV^*A
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M94>?7E#%_H3K#[$T\!K*\$-\YF_$AX"63X';YU.^*#V5'GUY0Q?Z$ZP^Q-/
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MRQT+PPX":-UAN]'BWJ;'A[R0WH'V4JII$+CLS<(OF!O2/)PEU(M\#28(R*B
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MFNG5.#('\\CO UUJKP93_P">3W@X7Z!/277?JWGM2UOYK7$Q*]_]M[,;=?\
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M]/X$)-4"0H 4 * % "@!0 H 4 4XQ^*2GZ.>_JRM '6"_$8;]%#OU1&@"JT
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MB#_8HO29_#!X]V@3_$MA]W4?,0]E>XH?GMC?0W#TQ3Q?-$'^Q1>DS^&#Q[M
MG^);#[NH^8A[*]Q0_/;&^AN'IBGB^:(/]BB])G\,'CW:!/\ $MA]W4?,0]E>
MXH?GMC?0W#TQ3Q?-$'^Q1>DS^&#Q[M G^);#[NH^8A[*]Q0_/;&^AN'IBGB^
M:(/]BB])G\,'CW:!/\2V'W=1\Q%&/]*?Q7(C\&S9;8?;,2@%W?MD/PQQ[2..
MCB#CW?5>_P#&[G:J]ACU?QL^QQZ[=?7:2_9]T02_S*+L'_I,]LC+>P@_V[=
MD_\ ?+8;)?\ HZC:,CX1%9]E>XH?GMC?0W#TQ4>+YH@_V*+TF?PPGQ[M G^)
M;#[NH^8A[*]Q0_/;&^AN'IBGB^:(/]BB])G\,'CW:!/\2V'W=1\Q#V5[BA^>
MV-]#</3%/%\T0?[%%Z3/X8/'NT"?XEL/NZCYB'LKW%#\]L;Z&X>F*>+YH@_V
M*+TF?PP>/=H$_P 2V'W=1\Q#V5[BA^>V-]#</3%/%\T0?[%%Z3/X8/'NT"?X
MEL/NZCYB'LKW%#\]L;Z&X>F*>+YH@_V*+TF?PP>/=H$_Q+8?=U'S$/97N*'Y
M[8WT-P],4\7S1!_L47I,_A@\>[0)_B6P^[J/F(>RO<4/SVQOH;AZ8IXOFB#_
M &*+TF?PP>/=H$_Q+8?=U'S$/97N*'Y[8WT-P],4\7S1!_L47I,_A@\>[0)_
MB6P^[J/F(J87I3.)YDN,$W+S038F_:,/50S%>Y!(^[M?!"SPF[3).,VK!O=2
MRCMS9!2R"&.:N6/8X97M8DZ >B%&C/R"C4R1D&7'M+QJAE)+V30:\DPV;""<
M>7=A;1B2:UF22.\R&;3OVXM BHU"% .?:2 4V4Q%T[4:&4>!$-]Q+12)KZ)C
MRF(K1J);[V36339*<46%)F6=ZZJ2\JC:Z"B:R*T;DZJ*R6>*B2J2CV(YIJ)J
M87O@HFIA>V6&>-[XY8WMEC>]KVO7C"DJ0:D+2:5)5A4E1&E25)Q$:5$=QD9&
M1D9&1&1E<8^NT.(=2VZTM#C3C9.-N-J):'$+)*D+0M)FE2%),E)4DS)1&1D9
MD8E54BX% "@!0 H 4 * % "@!0!&0'XQF/QF1_RK&*D]A/H_$Q!;*O3^!"35
M D* % "@!0 H 4 * % %.,?BDI^CGOZLK0!U@OQ&&_10[]41H JM "@!0 H
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M.S2Z'"JEH'JC+4_*6W%;?4V11*>F2ZTU)J<F%#-Q*I"18B4ZW&9%93-M8ZT
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M4*D)>9C)H%5DW&3606X2J$MQ1FN*B1 (T-P8J%;KZ^9Q^B04 * % "@!0 H
M4 * % $9 ?C&8_&9'_*L8J3V$^C\3$%LJ]/X$)-4"0H 4 * % "@!0 H 4 4
MXQ^*2GZ.>_JRM '6"_$8;]%#OU1&@"JT * % "@!0 H 4 * % %M=O\ \G<A
M_NG]N#*J1](OM]A@)+#/R/B?Q:!?LMK4*V3])^T!):@!2S9H3&PI>1'B#42"
M "R!HT5>JV19#!(IHJ^(D':V7\5)JS9H+.7"N7N)I)YYW]RU5(0IQ:&T)-:U
MJ2A"4E>I2E&24I(MLS,R(BVS,-@:F=.=-5Q+WCP\Y&\TX;&]T(:]XOD<6>QH
M,=C$.';4<L7@\ 3!2".@$]@.P#H#)VI[K NRTJ"KNLPYK%9JVLU0R=]/+LA5
M(55I](><AZ8J2;X[R'751242G$+;<<R!+)QM2+G"0TLDXT7*.\[K9.)-)J*^
MY.R5Q7^V[K%1W5TSW#S1O"+1G/.08[)D>J.0S\.'UY$8<%B1':"AMZQ/NCX@
ML#)S<-'&;J!.XP;"359M+7P\:<:)CV+PGD]8J.8AV1JTVLS:(WI=N5 2M<AU
MY;J8V!*FR0M"TLK<,GR=0MDC:2I2%8E)3<JZ3<2225GN/8(MGV[6WG&8G&KE
MQKCE*<Y'@-?A9H(><8>0<TXVSU67C@C!L7G$%;C7)8K$LP\A/*OHJYP*-[#G
MIA$$65RP6LY"M+8X74U-0I<BFHIZWULK*HP&:@QDE+4:67E+2E+N-M!)=(T'
MB2@UH+-<L]J4J)5]U^91I._=+\!C.$Y$;AV!TN4WXUQ26V:<=>/G#:-3K;,9
M0 QIRL7W]MG8"V,#:OI$Z#.),,9C]7CW9ILP%G1[-ZZ4OD]8.\,+*8[%<"*Q
M9=FHNM7SY]6<9BN&MPB3!BL%ES2V2R;4:I*DH-2D*-)%Y*BON$7F;AE?Y))*
M\O\ UC,[L]VYQ_B.C0_2[<3-_::Y>[N *3V(1OA(5EP_=82="8P/E6#2*B2I
M1N=C X',)"P*BI@N!/ H;@]*B2Q>0!GHY86RODT5<IMEJI!ETJ&X3#KE90RJ
M&ME;BFC-U:4X'5+9;4A;1+;6]A2M"&UI42E9R(3B5$HRON3LW^W[=H8\@^GJ
MX[30)H8MK#B]SEW 0Y!ZJG^YHI#M3Z@U_.)L#@FM-OSC2LI(2B."MP9.456T
MI@9)ZA@!S/H*!20155R@4>+BFF>NQ-097-1)J-%B)@RF(;KTJ6^RRM^1$9F-
M):<5$N,C:?21FYD[EI65QI(EG3E4YKB4=Y&9$1$9W$9EN[I&+ARKIN.)#:':
M#DFH8CO[DQ(^1(K99N&:IT5K=D9VF$':9;JN-IVFT7E\GAF( I#^Y7R"X1)\
M0+%E&>3L&T(AW#,HXQVK'U0W9S<IV#3FX"XZ'I4V0:(RU2SNBY%QIM[*)>(T
MF2\*4)(_+4E1&DIRB<UUZL5]Q$6?-L[-PV;:4VY&=\:I@FX(<PE(F-S\ V/C
M1,WC1.'S 19;)1!T(DL9+I)/@YD6]0<L'[7/MR%W#?-5D[>L5&SQ?GID5R%*
M?B.J:6XPLT*6RXEYE=V<EMN(,TK0M)DI)E<=QEB)*KR*LCO(C+;W=D71K&$B
M,M/RR/?%F)?M6:U.T7I/V)$;9^@O:H2:H$A0!\M:UK6M:UK6M:UK6M;JM:UO
M<M:UK>Y:UK?@M0 ZK==LNJW7:U[6OU6Z[6OU==K7_#:U^JW7;^?JMU_@M0!;
MS4NKXII76L)U1!D7K>(Z_C@V+1U(D\R($,!(E&R#/!X_4PP4=KXIV_CK9XXW
MSO>]^JW70!<.UK8VM;&UK6M^"UK6M:W]EK>Y0!]H _/ITC/'C=^UN2Q22:XU
MA+9D!;0^)B%RH(9F\9I$VS1=TX8YJXY6M9PDV?-%L\.KKM@X2O\ ]ZOKG0.M
MI96S]C'X-:KU.ILM=<G2$QY3Y-NFPY&@(0Z2;C\A2FW$D>V:%;@_*_\ ;.T(
MM$RW.BY"K-D+$V@M%2F[&4:"N?2X2Y,9,QBI5QUZ,IQ)W$ZVW(96I.R274'L
M*(8)6X6<K[>[;0FR+7]WW; E;?A]R_\ W_Y[>Y>O8]=#0]^MU%YT7NCY*+]G
M'1V+8T++8EZ*4[VCYZRSE=XA-C_,2O\ KIKH:'WUNHO.B]T/%QT=O-7;'HIS
MM#UEG*[Q";'^8E?]=-=#0^^MU%YT7NAXN.CMYJ[8]%.=H>LLY7>(38_S$K_K
MIKH:'WUNHO.B]T/%QT=O-7;'HISM#UEG*[Q";'^8E?\ 7370T/OK=1>=%[H>
M+CH[>:NV/13G:'K+.5WB$V/[GX/_ )"5_P!=-=#0^^MU%YT7NAXN.CMYJ[8]
M%.=H^WX6<K[_ (=";(O[EK>Z"5_!;\%O^O\ @M_-370T/?K=1>=%[H>+CH['
MLZ%EL3VO\E.[&YLCYZRSE=XA-C_,2O\ KIKH:'WUNHO.B]T/%QT=O-7;'HIS
MM#UEG*^WX-";'M^&WXB5_!>W5>W_ %_Y[>Y?^JFNAH>_6ZB\Z+W0\7'1V\U=
ML>BG.T=#CAIRG:)V6<Z)V(BE=5NA;-0&K;&ZSI=-JW3Z^S_ZRSA9)'"W_>SS
MQM_/37/T/OK=1>=%V!XN.CMYJ[8]%.=H[_66<KO$)L?YB5_UTUT-#[ZW47G1
M>Z'BXZ.WFKMCT4YVAZRSE=XA-C_,2O\ KIKH:'WUNHO.B]T/%QT=O-7;'HIS
MM#UEG*[Q";'^8E?]=-=#0^^MU%YT7NAXN.CMYJ[8]%.=H>LLY7>(38_S$K_K
MIKH:'WUNHO.B]T/%QT=O-7;'HISM#UEG*[Q";'^8E?\ 7370T/OK=1>=%[H>
M+CH[>:NV/13G:'K+.5WB$V/\Q*_ZZ:Z&A]];J+SHO=#Q<=';S5VQZ*<[0]99
MRN\0FQ_F)7_7370T/OK=1>=%[H>+CH[>:NV/13G:'K+.5WB$V/\ ,2O^NFNA
MH??6ZB\Z+W0\7'1V\U=L>BG.T/66<KO$)L?YB5_UTUT-#[ZW47G1>Z'BXZ.W
MFKMCT4YVBK >"W*\\;%!? K,@]BA!JQR+'1]QH89@Y6P2S?E'RF66+9@TPRR
M7<JXX*J623RLBBLK?!+/'EZ+&A[$BR)7A139.EV7'2CQ'<M)?-M)J)F.T1%C
M><,B0VDS2G$98E)3>HL^E?LPZ.U5J4"FEH;VBI^GI;$4Y]4AJA4Z$EYQ*%2I
MTI9F3$6.DS=>625KP),FVW'#2VK]&O'#CA#.,@.(06,8)O2SB/R4A,I4HABD
M0E4ANZB."SQ;W<\VXYI:^;4*,LIFD.8VZLLUWSA^]=_#]NK;5.W5;?JT\S:C
MH,V:93TK-3,"&1J-+:=@EON7$Y*?PDIYW8)#2&FF_P!F-!;0>L[H+6-B68HB
M4R9[Q)EVBKJVDMRZY5C0E+DAS.I3,-@C-BFPB6I$2,6=3LIZ5)D975Q8]>"@
M!0 H 4 * % "@!0 H C(#\8S'XS(_P"58Q4GL)]'XF(+95Z?P(2:H$A0 H 4
M * % "@!0 H IQC\4E/T<]_5E: .L%^(PWZ*'?JB- %5H 4 * % "@!0 H 4
M * +:[?_ ).Y#_=/[<&54CZ1?;[# 26&?D?$_BT"_9;6H5LGZ3]H"2U #!'I
M+-3\@]^<+MT:'XRJ1]CLW=(=AK%P>DYNX,1&]?RTLS&[/*J+)H+N'KA: YR
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M36;5>6CZ4"@!0 H C+S\KX_\7Y5^OQ*IVC])>Q0C;+T'[4B35 D* % "@!0
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M+IK?69WK(YX_[P8U;O478'MEKI7_ !KZT\RFO_1=-;ZS.]9'/'_>#&K=ZB[
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MQ*3S&HR/,9AC5N]1=@T&[(_E$GOQTE/[<?5W$7_:T?\ ]PS_ -FD4B%U? *
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M*5MH6E1K@RNNW3_6V1&6V-<U;\4A0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MK7>3/DZ[U\T<_P#L_35*G;_A<Z8[P ]:[R9\G7>OFCG_ -GZ:I4[?\+G3'>
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MU$EP[-TMQ3;S= C.%>6FEJ2V]6GVCP.RD-0VC<8@HD2=GE>+#Z^"@!0 H 4
M* % "@!0 H C+S\KX_\ %^5?K\2J=H_27L4(VR]!^U(DU0)"@!0 H 4 * %
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M+H58:2VJ73I*DI;-Q*<:7H<K)-)F0G6))--*<6RWD[7)#U(* % "@!0 H 4
M* % "@",O/ROC_Q?E7Z_$JG:/TE[%"-LO0?M2)-4"0H 4 * % "@!0 H 4 *
M (R _&,Q^,R/^58Q4GL)]'XF(+95Z?P(2:H$A0 H 4 * % "@!0 H IQC\4E
M/T<]_5E: .L%^(PWZ*'?JB- %5H 4 * % "@!0 H 4 * +:[?_D[D/\ =/[<
M&54CZ1?;[# 26&?D?$_BT"_9;6H5LGZ3]H"2U !0 H 4 * % "@!0 H 4 *
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ME+M"\N/D/L#OO!?GB'S$=]&TN/BY2[0O+CY#[!IWYO\ $C8O)O<N<VU\;B+
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M5V3T-IO9NG \.@^Y4PS"<6-=TKR5NLZPBC1AC,V"S6RKR/L&V:*^6*5HJ,4
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M2_(Q?IFF ]TNOL /#Y#_ 'MDOR,7Z9I@/=+K[ #P^0_WMDOR,7Z9I@/=+K[
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:X)96Q[%/+KROC:_5:]\K2E!D9'F_1>@!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g332508g15n13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g15n13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O&4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M    .$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             #+0  !=P          0
M                   !              7<   #+0
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #+0    !29VAT;&]N9P
M!=P    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   RT     4F=H=&QO;F<   7<     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !7 * # 2(  A$! Q$!_]T !  *_\0!/P
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M9ZK?2K]*IWT_1]B']8NIG$P=F/(NR [:YHX C<_^M[D94!U\.BZ$3*0B.O\
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M.H6556"+&!T<2)A#KQ:L=MQQP6.M]SC)=[HVAP8XGP_-1U:F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,8D!"%"1"$)*,(0A#&92E*4LXC&,8XSF4I9QC&,9SG.,8\\\) !)(  ))/@
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M!%'+W!(RET=0'G_I_P!7^F=M[';(+UPZ+5)'L5],WEO8J5FIV]BC4S8WZDE
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M]G%+NU"[5OEWND3>EJFT@G *O<S#*VT)WLKNT<3R$-NTV3G:H!.[&<X\\9'
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M^82.*A,../8>6!J-9B%$TELER+P1DF80QDD12Q'-U"^^6>.)4)#C:"HR,_\
M%P>!G]3DXX!-:[T_TW-U';WM\;RVBEL@QD69P)R)UD0"WC<^MI$1QW'VQ1CE
MFW[4?&3_ $]@9D)FF G*3PE7BMU XO-K*A;$.SKRF6*0(F!"54S-B.)S7)*,
M@3A')C87KF5II83%DYPR^ID& K\C(&/R@\G'])][1-+CM-/MM4>Y46BQ[K>Z
M*P6\TP[EQ9MVI-DCPSD[W V[QZ264U9__'7TSF][ZZC:U*H?VRJZ^V7;MLL6
MVMGND*_2JRPAU^.KN7M?@Q"K:P\E4[-4HI1G%MHMTCBSK\HUZACQ$-HLVNPS
MP1?@1HKONR!'(A'<(!&TG<Q0,H\X\@ UA=7:V-$^&O45GK&H"UN]3@&GV:Q0
M13S:D[_Q"*"V%R@W6X,265](KX,-O#+M8R3E3ZL<8\8QC_C&,?\ VQS=*^)Z
M^\4IQ2G%*<4IQ2G%*Z*RV?7Z9^OK+:W0K7K;#.:T#K UON94P*1X F64!R)#
M!QYB+WX(3&99'&?LG[;BPRM%+.J,88#&)I!^6/NMLCWGV#OZ0?&XJN<LH..]
MW;)=VM@TR"\OEN&L[;),MP+6,2W':4 EC%$3(RCU=M7< K&Y70_M/^1?J[K7
ML+7=''06>P"L+W9]7V.P%9U]8]K5_0S6$DM"G;C/%TM=F;7PH92Q$U[#BB!%
MQS!4AV6[HG2V[$AEDCCDC3**SB4L(@ S@ R;<KN*\,I(%='L/AUKE_;-.G;#
M-#!<0(H>6.6&9%=F>>/*P-$K'>DB_F4\A2KG3_=_YYO3?U?3:[+L?JCNG7-O
M>8MJS;-7#1USJ^B7-<R$"JEM=LO5<GU;@676*]FMJ3-0'6M_<K5<8A.6W].]
M%:WU19:I=Z:+43:6\4<FG7-PL-_<&0%F:VC(,;(B["7EDBC8R!4D9E8"/U7H
MZ^T>]BMKVYMDMIP&AU%1-):NA"G)[4;NK#=^4!LJ"X.S#&7MV_F ]-]/35-O
MKS[CP;!(##2[=1?GM:NQ,(CJM&^O45CFN)3N557%*RUL-Q14^^$T_@853/.6
MKN]E9R&/4I+F"0%T,,,*O(DB[TVSEF!A*N,E2C%E4@%=P88$71'66JW%[;:#
M;Z,R:?<QPSW^JZB]I:W"*\373:;"L)N+\112QJSQ =J27+)(8C%)VW4G\M_0
M/:FV5^OXH-HUBGL@5$0[/:,5#($WK'*H&(7%:FU)M*L2>9^O^95E8@F$<G&
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M\BN'U?U'CT_>G?MW1;7OC3S;;M%9LHJ>Z2NUJ!'6KAW7S5=:)0K]UAL=A-W
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MD9(3Y+G#:0KP=LFUFV&>%KF#A[-?PXL'!6V)"AF6<YTO^)5-LT62Z@1Y7<<
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MR;H#3%-YV9/3]7.Q57MI"RV%Z4(KHYS25EE]&&?DC(CEA]1$,,YF5F$8RSC
MOM3L=,2-[ZX2W2618HV<.0SLP4 [%;:,L,LV%4<D@ FMHZ6Z,ZFZUNKJQZ8T
MM]5N[.TEOIX([BT@=;>%'=V07<\'><A&"0P]R:1L*D;,R@S;C/G&,_\ .,9_
M?^?WS/K5Z^\4KYG&)8S&6,9QG'C.,X\XSC_UQQ7A (P>1]*UV?ZM[.U(]G'I
M7L+6M;URXNGKYS2]XTUW:$*9RU))JX'H-Q3[-K9M44M;,K5TPA=5&\5JUN^Z
M6J0KD38KXY_S4,[![^*:>4(B":.?MNZQ@*G?#QR&8H@$:E7A;8H#,Q&:@&TN
M_LU,6AWEG8VK2R2M97.GF>*$REGD%@\%S:BT#S,T[+-#>QB1WV1HK;:KZ],+
MGHF]8/JNW/M06J[/L7JV]+U@_J^W;1M*I 4!6J^XN=,J;BFA75&L:Y?SHYT;
M\=:M++4*/9ZH3HYL".=)%A'?=<3K#ICIBSTZ6XM[;ISJ.-+FWMK642R!7BBN
MI8Y'E::XA6=9HC<1QSR02E,<!G$DW9VU]9VI2\GFGDEE9F:>6"7&W**(!;V]
MI$D+*N\ 6\<F7)DW.2QN/_Q_CG,ZNU\QC&/\8QC_ -L<4K[Q2J[OY#NB]I[>
MTC2K356\$_H^[L\;3KN;I.D9OM+V.LE6;!"C-8M)5I]A5C%4B:CS0(-K3;7
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MRZ9V&=I #2TJ@2\EIU$:]J)<**D<8257) 0\P-C[XIY./$XQ>I.5@9=I&67
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MY<SF"!1BVB<#9QR#+SJVF=/6$6E)>P2B6^[[QRH\;FY'+!6#L,%<8P$)&6'
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M13H)U=76K"2KZY!8*B22@(8&!958$!A  0XX@,0H1A".,8QC&.;0   H "@
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MN1&NQAR. 9@(DHY QF481'G,%!8//?RVMO%-)-,_<B[:,Y*L.5 4,"=RD;2
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MHP(:*ZV)1]D(<CHK0P7+2+*KNT84E#E1R#@D<'&//. <_6IC7M6M]1@MHDC
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MZ.0G^H-60PK3F##C9!+Q8%C)"C@M<U^VT1(#*HFFN) J6XE$;F/G?+DJPPI
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MD81GCD19%+1LZ,HD4$J60L '4$$;ER,C&:[3GM45@V^Z87=:M>O#L5MK9EG
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MS1*3(\8MV5IY$9",E8W65X2#CMD[&8C>IP"OZ]HU2VT+*N4#%CKS$4245?\
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MDJ7<HC+95MWM;6Y8B2Z+K"I20LTBH3^&RJ0#SC<2 .>< FHZW'5#"H7%]6Q
MUZ+*]G*EM'&:LL !LPMPD.$HKSA/#&?G7"MF."9CF8RPD/)!PNH(LJA4=!(V
MTD9]().2<@GQYR/<\_6MJZ4U(17C'4X[KY )-&+B#8\[.(^RD;F12HRJHCDA
MCCU*K<BH([!WWL7JZPZ)EBTH]RK=R[+K-);TL )(;('(4ZR8+6M8KTX!(&P)
ML)T6,EL,E^TKG[R3.9P:ALNA=$6VM].]87]QJ-RU]TWH[ZM96D3VZ0.8K>YF
M$=RDB-*RR/#A.V4](D;>SA4&-J75<4>NZ!8V6@I86O4>I)IMYK4G>E:!;JZ6
M "VC+!0UNBK*2R<(P"$*[$6_>GGKS:-_[#ZV7VM9Q1.3(2PLD;B"EDS<69&5
MDZ,$ZD<UF@U.O$L[:P,[*I'.=7!;!32FXN7DT2F^,5EG EO S"-N%!XP ",J
MJECY ](&<9%3W4MY:],Z=K.H6:17$]OHTBK)<PB2-;>!D:6><2J#NN+GY6U1
M4CE8O=&0( H9/2$E*JKLIZ\H=4)E:X<E*V)Q_:A6JY@I \5\DRQ)8<_C!)C,
M<P^7,8RG[Y>,]/2(I$"L;"%-L08*>VI"^E-V-N[:,A<YP,XQ7P7+=I-=R++/
M&UY.)+MXBZ"=T:3$D_:!#=ONOM+A=BL0N0<"NUYY7M.*4XI3BE.*4XI3BE.*
M4XI3BE0)W]Z?=1[]U<%1=16JMAJ&H6&K;>.I1L;6@?'[O.!?9^$QJYG$O#U>
M)U/#&8"-%@3  EA=BE:)LKD@C#+D@,/H<9Q^N#CZ'Q698WTUA.L\)Y7RI+;6
M]^0",X]LY]_K4D=?Z>/1-)UW3?R3%U"AJPULK)T0@G>S#W9(4@!RF,49RG+$
M QF3 Q8@/)"9CF<K9P22%"@G(4'('VS@9_H*JU+4)M4OKB_N BS7+*T@C!"[
MEC2/."6.Y@@9R3ZG+-QG I1]3G3NJ]7=T=A0T^UL]/K-BUH6SPJ@-L#JAL7*
MCU=<K)+DE\,:]SX&5O=_K0KHOE4$&*L(CC(0S!UC5@"48Y.T9(R"/U/W_L:O
M6DEQ(I'<)48 !.?'/D\>/IC]:KGL]>4IMK *O51V1Q:P*.W/6*!:^RLX(L!N
MK#P',V3XEG!XBP*3,H8EY)YQ*.9E)@5"EL<8&,C[$9Y\_P"A5V1Y0VUF8C Q
MYP,GCV]O;C]O>LTI8HX8,),"B8Q3%\68B@ <\R@,A2XB(48XR..89\?J6<?'
MG/\ ;.$N75.0"3D??C@>W_G]3^M94,IV$2 X]C]3]SD^_P!O;GQ7(O[!"Z4=
MJW3X!&,?<*4H1EB9@$B0&9"SF$2"]\,9QC/]OC&)?W2C[<X]R[A<+R3^OW]_
MOSQ[G.<"I/3HT,N?!]LX]\XP." .??S]?%836]B70BKJ$65DO7+IUX)#AA3)
M05RH$@$\+^!3)D"\9&E,),LFE,I"QE/SG$AE>,E0#@$\G]<G&?'ZY^YJ2N])
M6=M_<&2!D\\>P_H/J>/IYJP_TT_T[V5A]O5]8;QOE+1K!L;RY=4Q45;!['%E
MEA6B"PR*QC:PJOQ^9.+P"-7! Q@!V8RGC-6O)E  ) W@XR<# QC.?&,\#C]?
M;#@TQ+:11<-MC(;&T@;PPVX)*[EVEE8E2"!@E@*KV]2PNW>L>_;2MJ0/04L+
MN%OK5,E6_-6!#L9"N&JP(L@. GL:>=1#\P\EBJLK@> 1B.$+MO+)/9B0.0^,
M9R000.?!X'TSG]JV33!IJW $\>^,':PR&E*XX;)&"?).!R2?KBK/JO5-6[&:
MZH)6@I+(D1ZRIO 4'(2< !V%:Z&K<)#_ $05_P ,K"L%\9O:D4BRD1C F,@,
M07,D4$G<)+,<+_Q-X/Z<DY\ D9^M8-XD2W-P\+%((Q,T;$!]BH&*EACU $#T
MD')]CGFUW1M+U&BUN&:>EQ7I&1"($#^[+@Z]4/PJX(?.9&P7(H?/,WN^;Y"2
MEF<IQQ+F%&B>J3 !;)Y\\^W'/[#D>*T;4-1OIYTADN"QB.P]OTHTC-EB5!P0
M,[ #D8'CDBM!Z3^5#J,^_P"WZ1>:?LE36:;;[A3,;2)]*SR[C3'+-9RRQ3_7
M0,)5M>K(X(<6S-Q^3"\52&]L990V[0=X&2 ,Y]63@<C@$GZ^?WK.7I/4Y(>]
M"(Y/2'*;MI (W$!B2"0/;/)KJNL/Y6.ONSNS$]/1Z_LZK6+2T_&5>PO; I.[
M)B4I8$ZYKH:[*JT)0CDA%07SA8#Q+XBL&Q@&<EH%$>\2AF_W0#C]FS_0D#/'
MBL0Z!?"%Y2%W(I8H.>!YP^=IXS@C(JU_F-4'3BE.*4XI4:;-N&[5#!8T/5EY
MMBBY98*PG?ZG5F."(QS^2N5N+A/+)<RD0<0MDKH2D/'^OXGCVY<<%NRJ9+V.
M)F7.TQ3OM.XC:[)&0.,-E0^!D8SC,'?:EJMO(1:=/76H1)*5DDCO]-MV:,(K
M=VWBN;A#*=Y9 DK6Y)7<&P16G_JN]9VU]7:'J0.BNHMS[,[7[.V..AZ[4MZW
M:(U?7NUM %,4.R0%BLS6.0P?)JVH.9)6W$LR_BY!3 R^75^J]0U'0;6#Y+3I
M-1O+ZZ2RLS 1):B64$I+)(F3V2%)#$(@PPD>-EV'MOP+Z-Z6^*.MZE_M%U9:
M=)Z!TSI,W4'427^;366L+/:;JTL[:Y54%W'NC65<RS;9HGM;>Z60.NV/13';
M[74NCF[[2UJO[>E2BQO"VHGFQ08M8%+")5)2D00C,*168L%DV&Z]2Q*VM7.M
MHB78)G:8VH/86S:K'!%J!C_Q4=L[/ L@)'H9@"<J%+#+*'+!690"=6ZTBZ2@
MZIUF+H6ZU2]Z36[/\%N=9@2WU&2V,<983Q(S>E)S+'!)((YI;=8I9X89GDB6
M4''$J]8KE@TJBF"/O,TX<2RP89SB/N*<\X"'',LQC[IRCCSG&//G..9Q( ))
M  Y))P!^IK6XHI9Y$AACDFED8+'%$C22.Q\*B("S,?8*"?I53?\ (UV9V+#7
M*"?4/86K-:=B=FCOE-^4I5T,N)6:059VFPMM@KL17M525F:6#\'R/P:#)0_U
MV8!U77[@R"."&965CZXUR02K D,V-K G"X!R&!4CR*[E\(-(L$NM0O=:T6[E
MEMX5^3N<$-"MS!(K.ELRO+GM.'^9[8BC22-C*C2Q;Z&PVM)N-)?;+8[8]:;1
M661:9)#94B66O62!8OVKV8V<X,U=98*SA$JRCK,_RQ'9Y!*5D1,4[-E,TDD<
M)M.]$21*44 1Y&%8GGC(Y/N/)%=>O-)73X9+J.\?29! )[#8[B\N"K0QL$5&
M#LFTR*[J,6[0H9%[4G<BUMVC<''6=C(J(M^O5J(S*=<8PDDJR<P0@".,)B7,
ML4AAP6 +R,>/A"/$LCQC/N9&</% OIC W*I.#Y 7VP5/D#VQ^M9^BZ;:VG\/
MGU!TAN+V>X[+2J9I89@JL;EP7 ;YE3L621F*L2[ 8+5&>JC;N-F&;V&/:ML.
MU*M4B*<6J\*QLSPX8T9>SV%^,TLRD?/NQ];,\0QG ^1]G:;)3-*.X[94*?Y,
M$G/OCDYW>3C .!FMMZ@UMQ8K96C_ "]I"D%R9V<,EPTT0#1JF?S1!]ASQD.!
MD9SGV]HT[E_132H*385=>N$[J\H!9G7T%FE3QFQ9:_9R7@!@"1_AA"S;5A+#
M&8&) +029R6]JEJ;J)(X$4,AW'<0%')SN( VJ&()X)R,XXK5^C=1&DS7DU[/
M=)'?Q+! 5+/<())(B)+0/O43/%&T$1 #JLA*8W#.>Z6YUDGOE]<YT0>-6NFV
M'2:+5["[E(0<F(,6L5VPP7C8*UU>&4I)6!,?',L/M,H&QCZ!;,=D8+5HK<J\
MTJ\RY)7)(R%(R^P ':<Y')]Q5O4-6DO+^![R.:&RM R")X4$[LMOM2\GM5,,
M/=FN MQ<VRO&NTM;1S1J%D7@L:I?L[166BDSE63K'PH8M;R@*M3(6U>SJ>?J
MFMZU>0WPU#05U_;@QBD$@^@6O9J5FT++6<<,D4B/(9(L;G5V3U@$-@X&W/(/
MD8.%P:R8=:%S9WUN$MX+::0XB-JTC]A)%FB28*TBW*I(L;(_;24%65BR2,IL
MH]"_<&Q=$]K]#ZMJ>S;=8]?]C[+K]'V70MCUP5;'8MO SKM0F9DD+'ZZM+9/
MUEN@;%\"S9BK95IA8F,DW)+37N[4QM-;K%;WMPRP[75I"Q)Y<DG@CE22&/)V
M@,">=_$G2M'UW3=2DM[CYK5M"TOYIYG2XCCCB18KJ7L1B.%1+(%FAF18YH5_
M"<7$KB1(/4WC/G'G_G]\V:OE:HB[YW#9]"ZCW?;=.6";8*:L"59MFHL-A3H%
M&+%)*WV][7:@RUKL:&E4[+^WO:[5M*V-^G2'J$6EFG!'&I6E^]>KHW4*]*EH
M'8VL>JD&PK[3<$W"^[&Z+TZAI;+54=3(#K..WZS'2=+'LF[#V3-U0"?6;MZB
MHJ[FU82V&K'C-<I_K_7]ZQNY]7G:77UQN;]N76K6BK[K8*WX-UO=0TU;5:Y'
MU#>KO5X6:T"-4SF[VB6I=3:-K']+4-J[>G2"WMR*5XW7VX+A2K.J"W6V"BI;
MY.69*7=376ZDI+NJ2DM9*!<!*2EDJE8JRR(T,R7?23=!G.1-*KGB0,%*[?BE
M.*4XI3BE.*4XI7R7GVY\?O/C/ZQ_OQ2O'[VWODA]S]C4VTP=H+;4K"\TEO8+
M1C-=MA+.-_D-O<,VYVG?@MKJP.85G;+#)D:EU(>61C<%81UB\M_\5*LVZ-I<
M21/)Z4RY(7R.8S@*K E<CG@$U]6=,VS)T_IMQ9.EU;R10S3V5N 2\4<628XU
M.6,39=XL!R58*-Z[3J0MH^P;#8VZU4:='%=M;9+?9ECY"TAXKTZ^5=+":JBF
M:BP<:-/V10F=' UZZ Y_4)EN*739S=A>Z0 W.P,6R2,*%!)8D^, D\+^O6K+
MJNRBTM^[:K=+*BP16TZQ=HD+P8@$7MJI!D8D[?5NSNJ5;6SW*C;UK5=B3V/L
MFKR%PNB%I13I=G"W-0$B6J51)6P=; N]#+[%2Z)&YL 3%:GRD9I4Z,K'97<T
MQBCA9YH7[4ELL@:=?4 @9<$"0@AC&3Z0=K'((6$'\.2*2XAN+:S6<_-R2-'N
MLG,@9GB@N,A$0ME5N(V:/>K;005W9OV1A1!X3FFW5OL.I52PA'CM5'C7=HI5
MA+#S9U+B(,6#"JNNL':K;#Q@,8/+/JC <456V=@UFRL+5%DLG.Z.("X1RY82
M(,$XDA@D0L ',3Q;X22K;7#1IJ>B2SW5Y#I5Y"L=Q<S&*&2%^]"6E<F(I,0$
M8.&5E;\K!@?)Q4/]3Z"MV]IN\;K1KL/*4\YX/2+A:KBFLE7)C^,ZK!ALSJZ8
M9E[8B\HE,P41&\P%A$T 0NG3]^.0-)(B3G#Q"1XXI%4G:)$#;9 N>-X.#D@#
MWW3J4W/35Y!IX6"1HHXS\R!#+)AD&YTDC0*&8@X$848P""<9YMAN:0MYZ[KK
MLA#W5M5M.7-I<H'M/LUB+/\ 3B=8$#N&E6&W&0OH9=(+ $F%@?WY^9AE.*UB
M;LS1FT+(8QN;W' &XC.?VQG]3QB4Z9TB>[T/4IKQ$,<EPL5JD+)&^9E,P+E&
MRI"%6VJJY#<_2L@[/V_?-J]0FB]?=2Z!94.A];49]DV_;-AU^NK$MU;7.Y85
MU?UV[8A&<64ZY3,+N3EHW"-L._A,!DE:>M;Z##'T;;_#B75=2U(ZCKVN3BTL
M]-L[U.]:/;]U;IM4MT0M#%V/Q8VD! $EFT)[\K[.=V]EUA)UHUC%#%IFF:;
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M20ZY.&4'&2/8'!*^V/M^]9VK7FGG5+F728NU82=EXXL, DH@B$^T,<A&G$C
M8_*0H& *IAGJ&R"NQT;5B9)V&5WE+$<IG*NPOGRK@9%HX+\ONCD@\CS+SG X
MQG+,_?B0#\D^1X\CV^X'_+W_ 'KU7-P@9MO'G@ X\\X&>,_M^AKNZF-NQKNP
M&1(M)R/VI7!QEP!I-HD9K*6$A!Q.,%F1!A[#!%'XY^,RC*>(SGF6]R#(L,H*
MG^0XX< CT X'/]L>X\U1N*$>ZC!  )QDY/'Z^_\ ?FN!INEWQJAQ9I,:QV6,
M&6=*W!F60X'/!!YC IL8P0GQRB3_ ,HYQ_=#/G'C+G 88'//N#G'MX]_Z^_O
M4C#<J&# X(QSG']OU_N//O6,4E+M%-L-C1;#52!$BTF:BR@^%VJ:E"4OF7PU
M$0)*GQ#_ %H@.+$S#B68\3E'$9XC1+Y##GR-IXSX''MY\9 R/O4J+K=APV[W
M('D8(&<9.?H,>Y^U;T="]B9Z9KS6]#4C-L-R+Z5H_8$;_%Q%$IL@A!59P>#L
M+9G\D)3]@\3SC&($S'))6KC2ENH]Q<$<9P"./8>/Z#'/VQ6%+J0E<1NOI!!!
M/[\Y(;&X>DC.<<9'%8[OFS7G<EWL&VW#DHV,QD3@U_;X1!\9L*JUXV,XGF(1
M2S-: 2><$C*7MAB4I#\@T_MHL,8+$@^D<G 'D\\^!]?[5<6X1 I4A50\8S]=
MV#QQR<GC]O>K<_2CIU23K;7K!QA9K8U:6GI9G7K!(X+BB1689E(J$08:GFX=
MQ+##;3+ ?@@J%G*_C$M>O+9XIF1R00?2.>,DGVX/('OG P:C=0U.0L4B'X+\
MS,6R69@%XW%BJB-6X4!6+9() -2+U;M/:-W"V2L:_P V0;G_ +@]MXKT8U1%
ME2JN52D2L-R#*93KM#G-B<"*Q]TAG8+B&"O<9BB8XP26\*./ \DDDYXX^O(J
M_J5MID"PRNKA.UL06Z^J28;BP=V&Q0F%(R0Q#$@,%J+<_P ;WIK=[ VOL'8*
MK9-A/N3=S8V^M/WY0:W"PV$IF+=A+%8!"]")@[+1 JDO# 6P>4!QS" 8CD=P
M[:Q[$&S&'P=Q(\9RQ''U !Q@9^L9'U#JL$30V]R8HVRH(53($.?3O*X\8!8*
M"<9R,G,>]=?Q2>G7K;LY/L.JM=ZLD*FS';TVF7%I7M4R302X,$#+HZP-K9UX
M)XQ@:S;63E'C GG'(9+@E]KD-$(Q!&K>\BE\D?386*@_H,>XY\6SKFHF%X.\
M-KKM9MJ[\8(.&QD9!QD<^_GQ9US&J(IQ2G%*<4IQ2JM?2UUIZC*#U[>M;L#L
MK6]UJ>G-QE3BZLL[C<4[/6+OZC2((,UFM+WEE]0F*A(6*]C*%>Q5)?;K+" V
M&@J+:II-MJZ=0:Y<7HN!I\HC33^Y<K)"0LC,>U )':(;6')6/!W C+<=[Z[U
MCH*Y^#_PRTG0)]$EZLLIKJ;J5+32;BVU6(R6[J5O=1>T@BN46;8K S3M,PAD
MA;M0LS6E?X_QS:ZX)6&=A:VMMFG7](PK-W+->8JBL+"PJOELD_:[5XF_5XD\
MN.-BNK,D@"8SF$<QFJU#,ER6+F%;B"6%P6612,!V3D<KZD(8 , 3@YP/?Q4K
MHFIW&C:K9:C;2"*6WEYD:WM[H"*56AN!\O=*T$A:"210' P2"KHP#KXWUEK#
M:-AV-&Y/&FS&X"79*-RQAKJ!'IML3Q11%9S(?$%;#.(R78"=N <DD0V+!G+$
M=)TZU:XE>VN(3&UOVP2!@;F+^A,G)0 94'['CG/VGU1KR:/9VU_I]\]T_4#W
MD\*I.LS-;0F(17=W% JVANF[N!MB6-67\% AXB;8=:M7:ZPS3VRRZLVUK9.P
M2 K7IM6.6,+C30H56@J#D[\."'(<86B+5RY(9*O]/)=N%D4B:"S 26106=1G
M9D<8P>23DY)R/J3XY_#KR&Y@N]6W7<=NG:[5Q-(S-&Q9G9I&#%47+D1J ASX
M7)-=CN'95 K;V#?]":GJ:\!K1=HZ/#%;2SN TOT$[(GSLG.')/V6>9LSA^0*
MP_//S2G*.+';Q:2C"YE$DTDFZ1R< ;AD(HRP ^I^OG[S4KW76<L3Z7;7 AAM
MS% F4N&95EDE=V>&WM48@N4BC6)=D$<48,K LW1:QC6<JV5QK%2OFP*<Q5F:
MQXQ?@RQGVR^$PY#)$X(SD3.1PQ+ XY)CQF.>2D/R$D9=%R3GD$'SG/\ 3Z#C
M']*UG4SK]G-'8WLK1)$ K0R1HA(7.,D'A&QC.2/Y?S9Q!M/8NDO+I,X4/CQ>
M9JB24Q.3RAB58UW(LSQ&6,+YB43(RQ!,1/=DDAYG,?R0T*//<7,1YC[FP;2=
MZC8 <GDD<Y]AQD^*Z-<PP6FE:'>0B>.[-B+N3YAP]M<[;B0Q]KGT2*!L=6;C
M;M! W"OWB'8>N%$Y_1)M&DH.DD>SK@P:M:TP3X^9<CRA,JQ6E,@AP:=B/Y<Q
M*'#(RC]O+#V<^GLN-TEL#GZLH!Y&>3@<>>1^G%9BZCI_54MU)<+'8Z_."<2.
M8K28R !9Q =I!))X7"Y.2N[BLAVSO4AM8;'445*1NP\EI_LY^S<U^490PQ,P
M1#@/!)#E$D<XED?C_2C)F6/,Z+[<\8>)0<C\ODXX&2 #G['G]S5K1-(M;.]=
M;V:<);S!9;G<D=LS/N"88G\N?*DY. #C.:VF]&U"GO._=$:U:;+J^G MMYU#
M:](K,[%-O<=GV6OW2G:CKKN8,P7<4'C4;,J58=*J: Y=@A ]IC%?!G6VN+A[
MRWM81*K-/;LD3/G!C;/IS@*&4'.,>1G@#,SJ<-MIV@=0ZRR+JD4&CZQ:7MP+
M54MX8Y+9X\RH48AD,\ =BTRE8W*I&.\R^UJ&,QA".<YSG$8XSG/^<YQC&,YS
M^L?O/^<_K'[_ -N=,K\_:_KBE<>*BD81'%9>,(F^Q&$0CQ")_DR7YXQQ'Q@W
MRYR3Y,8Q/Y,YG[O=^^*5_4UER1S @ DA+,92C,4)1E*)/EC+,91SC.8E_P!6
M.<X\X)_?CQ+]\4K]N*4XI3BE.*5C6S[?KNGHRL-@L<)B\3^( 5V["Q;S"/NG
M"OJJT#=G8$'#/R$&BHQ,0\9*2,1QE+&5:6-U?2=JUB,C94,S.D44>XX4RS2L
MD,08\*9'4,V%!)(%85]J-EIL)GO9UA0!B!AGEDVC+"*&-7FE8#DK&CD#D@ $
MU65U5_(3T]I5ON6N]U]FWN;![;VW**U;IW;>HK:)B4UU$""I%&K6H.(JI3,H
M-UT!K 84E' YS9QCHW4/0NHK'83Z;86T:"SCCGB2XC662X7!>4-)((9D;<%6
M5)269'!'"YXC\-/B(MW+U/::_J.I74]OK\_REQ<P!K:*RD0&"VC2)!<6[HJB
M:2"2%8DAN+9XC^(];EJ^KKTUOV$*93N;1<V["@FT:]R[6J364&0182C6EN95
MRKI'AD%E* &)99R2'Q^<9\\TQ^F=>C"E]+NL,VW,:=\#G&6$!D8 >6.WCFNN
MGJ?0=DK_ ,3M0(HWD;?((#M1=Q :X[,>XC@;G49QD@9(QWH+L;M+9ZO9-D[!
MIMBPG=W)BZ97?TQA1>IK_D8SE*3B\8V;*HX26&-Q^JE&4 R.O86)6"K*YW4.
MFZ7:36UMIT]N7AMU%[)\T9&EEPOK",.TKGU$HDV<D*8X@H9M%^'G4G5>KVFI
MZGU'9:@L-[?R/HEJ=*%NEI:;Y?P3-&!=31*IB"SW%H0RKOCN;EI&CBHX]2?\
M6'J$WSU&]@6VIZ_;;+JW;W8#W8&.S=BV+35:[5+/8W&;:YHKRD7V7^HT:>H&
M4Z==<T^M7;+\DZ5(B (3*<574D?3W4NBZ7="_@T[6]'TR#2I=/\ EKYX;^TM
M-Z030S+;&+YMRX=Q)+$JJ\F22BY^G.A.O9^F[=X[R%]@+/%'$5,BLP4<<E K
M,6.PRR%5&[<-Q1-5?5#HO;_HO5Z_ZYWS7T);)N<RK5NX4#=A<:[],MH*L4O[
M>S_$5X<YI8,3'=5[?R&"L.OLK1FO!9)2;CN@NBKWJ+5;Y'=$T[1[(WTUT91'
M+=,-_8L(!LD874IC<[S&VU%8JLDA4'I5WUUTM>Z=%=P23_,7MX;6710BI<1;
M@C7-UCNA4M&$BM&R%MTG<B0!4=88E7T[M3K^VJ]_WG92TW86O;-=UE[2:YF_
MJ-BH+9,;.4J].-D"+U>O8HY7K@RD,3LZX<C&KAD@16&LWUVMAJET=)LWBB69
MG,]X\=U/,O.))F,?;F+HWJ)58RI("CFM^LKO3-5TJUM0R/9&W6*TA1"(!D#.
MR-6?Q(3P"<,,;B<FNEJ-OV';/R*FT4C6RI[ 7<V-MV#7K4<BKLVLY$S;V9=?
M+ <=AS<N8 6E:/6KW.(UQG_>8D8LZN^HW&J:C*H+W N61>#MVL$5<*  %0*@
M4+C:H7"@J IVZ?2K70],MM266/3=0T^-2D4D:D20(!LVB0D1D ^B4(P)]#>0
MZ2'U7V%==%V#=Q#-B>O[#BTT$-16HLHI'IF1R3M2&-.8<89S.!#JF46PAE>$
MQ)_3SD8,YH3;3&TPSNB!Y)%4[%8X;:IQ^4#!YY)R#@8J&O3'U'IXU19(;017
M#QI'+,SW-P,YD$D9*K$\3ED4(NUE ;<?-<*ZH5[G-G?F@S<6S:\6,65?D*HD
M%!-@ <)5$AF%7)4\F_#T)P24&=&8XA!G$YDQK@1D$N?7C:<G) / /GP!@8QC
M@\5FZ;=RV\:6T 6*!'DD$2@J"P$DC2,Y"B261]S%V8R,6)8D5L3TS.Z[M[/U
M/KC5>N&;+;K^[J<M]BX7<7H*^OUY0.;XH($^RI7*-4>NF) 5@=2OLIE8 O6.
M3<7'F!M],0WZ10@EKE@ 2IV+'D"9W(SA4C7<%(]7 "MD [%K.N+H_3-_K.J7
ML4%GIEN97LP\9OY;BX""QBC4IB22:XN43? [/!M+M,G:9UN>_BEZ>]3_ $_Z
M?=S6]6V;A+M/<>Y]UV\6MVNST&VCUK665:2LJTJVSUM^UK!5K;598V*%>*Q9
MRC7,I+YB#,,@AWSK2;I=K_3[;I*&WCTJPT>RM#+!;2VOS5TC3/-/+'-'%(TQ
M$D:2R-&-\BL=S_F/P+KFI/J^J7FI2LSRW<S2.[DER,[(E8DG/;A6.)>>$15&
M H LYYIU1-.*4XI3BE.*4XI3BE.*4XI3BE.*5KCLW:VUU_>]-UD%.OI-4-J?
M]0GV.VK76IWCLW"+3K:AJ%G7UZ<*T<8D>,SADN"E$/ 8Q,',_>,??/\ ;%2U
MG8P3VES<.\CS0LH2VB959U(R6),<K$>0%5 <_P U3;K6Q5VRU\W:QS#P0-&2
M(U%<JPBF7SC$YA@7,LR#/$HR&6$YC)&6,QEG/G&*5.1_;_Z5CZA87&G3K#<Q
MB)Y(8[A$$J2D1R@E0S1\!P00RD!E(((]SQ=ZU-3>M/V34'BS75V*G=JB,#C[
MY ^V&0X&^/.8X+$1/828I2C$L(R'*6(RSGE2L58,,$@@\^*P1P0?I7G^[<]/
M6]])A%;]N%J0-3G95FG[-16!/PUG.N/AI4;D<BA-9UJO,UE9:P@NQ$JPB!FP
M,.8!E[9XY754)XP6##QGZ<G./!YP/W K+AN"GG  \C/G]/\ I_?QC7K7-BUN
MJ;MEW]?-,.R5=C4SL%I"$K&PB,#=>O)S$H0*<IQP^)>4#^(1)G(XX\SQ*2VX
M8QLI&8V5_N0"<_M@\GFLON[_ "1^@Q[GZ^P_7_E7;"LH+@B%5:*ZXH9]\R9E
M(V<8QYGC,OU'$(YQ+QX_MQC'G/MQR\W@$^,8)(_?SCQ_T/WS?@.XA1Y^F>1Q
MSSD''W\'R,\U@=Q$MG#.'%I86GF4AB+G(C>V,_D&2/MQ"8">81D*,988%G$)
M3R,L90AB2>^,GD?N??/V//V_:I:-0<*,[OTS]1]^/K_:I$IK.XSI-(BN"-C5
M!/:Q4=<!@#^+(,LYL1,6:^5\6DTLF$<>;:5A,"!D_9(4"P).A)^V2V_C&2O)
MW#^F.#G&/?/L*M21YD,04%CX.,%<^YP?&>3Q[?3-=/;ZDP]9*MUF^5R*>O6D
M6B?4:)BML1RG[)$/A.9G"OK"S(0U"(35A.;,O,\#$>5J>X:=5[&Z)CP&YW C
MC(QC@X^O]JE],-G8%VOXUNE*8"D# ^N  Q'MR1QCC[V$U_J@SK=QA#0Z^2%0
MJ",%U4\"7Q/#JM*NRPP.8Y834+&L%80D2!CRDQ(N98S*,>1[V\C)NF<&7PS$
M\D\^_P"O'Z>V>:BWM[>XF81Q@QEBP1LX #$KCQP 2 ?>K+^O24)Z3';=F>":
M?]++SC9M-X@FA1U]:)FY;) ,_JB -E9C!)DA[@C2D0>8"-F.8Y8@K8\MG&1_
M3 YQ_P O' Q4)J-Q)N-BIQ%%*S% /_>%F(!/G*AL$9QNSYP#73]%>J/JOU$%
MO!=='OIRH8C*QF\IY56&5C%D(32>,L'E(4Y1C+ V8K,XA.,I+X\$Q"\\3Q@%
M@/5XP?[&L.>RN+:..29-J2<*<@\XS@X\$CG'V/T-;%Y_6,Y_XY;K%K4FF]5
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M'JDE<CG9&@+$#EL!5!9@#@:GJ$.E6%S?W 9H[:)I.W&,R2N!Z(HQ[O(V%7/
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M18]SCT@':&\YPZ^5J0NMI;U1=;/EV+64;.HWH-CKJ^X.UH[2)QJ.98F#7[@
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M.CF4B%($L5F6%O?)<*4_EE#.<DB/&#=P1R&-TXF9B 2NY3P"I8#D$$\G!)&
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MQ2G%*<4IQ2G%*<4IQ2G%*XSB:E@HR@^LNZDZN91Q-L(V%6E613 PLRN:,Q'
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MVTO_ .;=1Z:AP2508SX;[5K8D7FD&YC '^(TFYBGR/YF>SO/DYX_M';O?.?
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MX8>1G'/NI/! &?.3L/1VD674NG:G&U\+?4XL-;*S;0#M!#M&&!:,LQ1Q'P
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MC]YQG././\_VYSB6<?K&?.<>?&>:=JVHJ"?46;G/N2<D[L >Q))^I)-:7/.
M"I/ R<'.>#[@#(!P<>.,DU-6B=>[#LUM7TM4&1VG9?6A&0L%&J"4_<4TY2@3
M"XP^Z9)&C\>89S*<)9G+SG34N9;F;MQ8(_F8GA5P?4,CP> & &XD '( JSI%
MM?:_J4&EZ9$9IIGVYVEDAC8A9)G(4K'&BDEI"05&"#NP&OG]/O2Q5UM=T[64
M\?,N!<<S!7AC)V\^S)772^X/][3&/>:>"S,..<0A#/QQAC*OK^WT^U>6=@L4
M2G))()..=H()+'G;E?4><X((^TNG^GX[*TT_1=+B):)(XR54!YYB!W)Y7_F:
M1MS.Q9L 8S@!1/FOTEY2>L3KK6]BDJV_G;;%UG$<X)%J>-3V-M@PXRE*>1C^
M$;.92C[!Y]T9^V><9S#ZI<P770M[>6>^.!K>"-!G!4"ZA0(P  4X!4X/G&.*
MWOI>PGAZLFL[PB6:W[LLRE=R?RC?N.0Q[CHZY')R3D\5KYZ\.T5 ]4UO2U@C
M'>)+=C6^P; _K':.J(TE!<=56+]N6Z?VNP>E>5.Y'LJEU^SHDD22^V9E &L*
MWV"A:^:.N=8MY[-UFC2YM[B=(I9K.3M/:);E2L$PC]$1B9!"WH8J55=X!4#[
M>_[/O1^HZ;KL&HV!NK.>STU^S9:S9SW7\6EUJ-HI+FS:17DNK::6Z6Z2626*
M-H=\DF(EN)4JN_J.?:4*;<14[^JAV9Z_(G?6_P!#6K?:?%41RQ95^@!=<-]#
M[Z&!/SIHE>.[\R7O'.+.-1TR>SO;.:31)C&4D"D.N2SD .0R\;?3A67.!@C
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MF$RJ;=[IUUD-G*(U3AE./EKZQFHU;B;3WSBKU5FN[F*(#(1=K#!&"3D$$@Y
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M8Q"3KM6HZV><2"H12EKAY'+^^,9PG@&1QE+&??'YO&<RGC$O,LYQS&D13DN
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M?Q3:3VMZ?^B]H["VBIL[#5NR>U@32H:[7R,7-MKJ^O\ XV._U6 1RW))FR2
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M4FH2QW%[%^+>Z;$DR+J-R$=89K5K9DN;*Y@FCE+)(,70N)#9R</K3N(U5O\
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MO!8<*@+<,3@*2(KT'U)[C?\ 8A0:9JT-JOJF1:ZAS<$\'8UNNBQ.OHA59/\
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M#&.3.YFR1O=U!7:XPB-OPRX#>:'J72G2_2FK7AAL>I-;N$GM#%J%N/EQ/ 2
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M' L<,4,:A%!2-<;28UZSVS7M@I [!'56KS3J.Q+"[-2)D9Q1*+D,V=2XBE(
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M8HQ;6T=L;B.]DM)6$5Y'/?,_R[PSQ,BVT*S1F&60M/;>9.!(#P&<U2!AB "
MSB'LAC'C Y#]N1$#XQC_ $IPS''C$H>PD83AN1'TX(\?;]O%?,BR$$E@) QR
MP?/J/G.[\RMGG<#GV.02#ULK8E=GVW0XK@\^V-J&,\UN<8CY]S>9YD2LSGQ+
M,I-9FE'R*&+ AR?#&DOM_/P/]X#*C]3_ "^"3N](R!N).*OK;B?_ +J2[_\
MP[$"X\^(APMQY  B F;U-\NJ*6KO(3@6$2#G$D)QQ*$X9Q*,HRQYC*,L><9C
MG&<9QG&<XSC.,X_6>5^?%8Q!!(((()!!&""#@@@\@@\$'D'BOZXKRG%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KKK;%:2N>!;& &N85.N[)@\5A85.*8
MCX(:4X8%&0I3QF>9Q]N,YSB6,X\\\) !+$  9)/ Q]R>*N1+*TJ"%'>7<IC5
M%+N6!&T*J@ECG&  <GBJI^RO0AUC9]9*;1Z1&ZA[>M9V.QL:^TG<T>[U6UY8
MQFIN*%INX8GKV"T_B1D,Y.#%>ZLX+WAM#Q<6P52(A;NQ-O/-%*)H7/:GB:>%
M@5#$Y0E'4><E&'^\!CK-KUGJ\&I2Z/UO%?:=I=_IHTZ^MHX;W2;VUL+F-F:6
M!(P+N'YV&1E<HFV5)(Y-K0@J])7=_6O975>$-?VM+8JYM(P<W% Q0(Z^VQ6G
MN?>Y645HE(KK5.U45U)E?8FPS<2M?R,4,LP5C.>IV;ZQJ":E:WMD\$\5RT]F
MTL>U)"/4%CF92NT^%D\ ^W%?1UY+T7IUSI/46A:OIU]I$UA#IMZUAJ4ES-\N
M;>.%YM0T^-XY8YHY9+KO6*S3F2V$+@J\I@CQ[?K.R:&2^IHETYG76"TV=2MF
MXMM5E$-4;X1VMDTM6Y=+[<DQ*U#7!<M\$PX.40G]T[$NK&Y4!94E:+=;2.BC
M:+F([9%.  2K#\V,.-KQDQNC-*],]*QZ8[R2*H-VL>I0HD@$KZ=,B%+E6:XD
MDC[A9P;*20S6SJUO<!9XY%&:[=UUGMS1:-JNL8ZYNNWZI-"N6UZ+=96_<J[J
M"R+97R,Q<2$^L.(6C""?!1%F\3,%R$-BL3W*Z+?1-,867=VY!G=&1ZD )&X@
ME1X!X/'!K&O1I^G=<Z1/!:IJ=LK"YNK>=$9)!+#(LZ,G^6SH)'(!&#/&&4+(
M!CLJ.PIZ0.A:MMMM*SV@(<Z7N33F#G*6WH&8+6(G;SY;A=^"#:2GUVL-O)F3
MPE:X*4!UC0GM)N!/IUK-.3O:- P?RTF,-QGWY((.#D'D$9T7J*UEM=:U5M*$
M)MHY6O+46L;0Q"SN_P#$0PB&1(GA>)9?EY(VB5HYHY$(R#6SZ1-16W#7^J*.
MHLV^M*_</R=HU1&M5B;B\Q))88K5"KGF5C$R8<Q"JJ07U V3N,L)C)(N+]]+
M%&RE0"YQ@'.2"<9  'TP/?GC!K7[.RO[NVN-4N)XTNGMG $NQQ;1HK,2DC@J
MA4D#<Z9=U0A#BKDNG^K;O\@L:]:"]1:]<6$JPHDA@4<1FB80J\?V<LF;$-I\
MA"MAE!7&5,JK$@+RJ"JUM#*RRR_D4Y5, *3SY'DXR,D^2./>N6]1:_!%:RVU
MJK1WMVL9E+L3+"N\-O<J=D;%8U"19WA9-SJ!@MN+"$!PB,<(CA".(PA".(PC
M&.,8C&,8XQB,<8QC&,8QC&,8QC'ZY,5S4DDDDDDG))Y))\DGW)K^N*\IQ2G%
M*<4IQ2NBL-8URUMZ:_LZ&GL+S79-2H+AVM2:LZ63PL =E5/G#-JORV'&!,Y5
M*+YQQC$GNQ''A50=U#*KLJN '"L0' .0& (# $9P<BH7]3FXV>C=9HW5=N\^
MMQ,]G=.Z[=[N/^F(RU[5]J[2U+7=H=^QN53>:REC-#9/@E86U8R!'!LM1P,P
MA%&JFM.;SU?=D]>-V]/K!JCO+2_SNU3T+NS<K;KW0==W7.M:KUW:%ZP!M^;C
MK7KR^V&RV3;=AK*?L#3:]U1.NU:YJ,Z%NFQZ9N%A%7A.!^O[_IXKE;'ZT^PG
M]FW36=9_H#4J_4MVT:#^X[:A!U/6M3+Z@ZOIO>*O=J9'L45E16*R+\-@%L&Q
MQTB *\-B12@?K,UVTD5[4_=(=H]L6NY2UW>A:_;:SM&Z>K*.IVZ([(&QTU3U
M#Z@K#3]50NY27#2V*-IJELH"K(DNBU7JZXF1ES:#W3;]:I6X?%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M=NTNF=E[:>L5[?>SZQ0(UEJ'3<:Q75Y
M+-&XO-;=U]RUO_SJ-FM8C5A9O2630)69*/"\)L QEO[5.I6NG:AI:69BG2Z,
MK22W6]"J@)/$D<"XR%*RJTH<$LZ@!MN )'HSJ+J'I+JZXUL_PO4M#:UM+6/0
MIXKN,7 AU+2M6DFO+B">&1;A;G3!%;/$[11P3,6MVDR6\:?KPZ*[2K=Z[>ZV
MHNM]ZTO7KKL&^UG4K#81&KS;O1:W=[ _35-4TT)2NM:>TPHK>'+6LOKVKA];
M$BQ 6)QESZ;3)8HM6!^9B@@25+1W7B:2*":X12X4+VC' P=U!(9XA^9L'[.T
M?J+3M4N.A=3%SH6H7]R;;4.H+*UFEN6T]=9O-+TV[O3$T\DHU**\U.-88+K9
MLB@U-RI-N"O1=/-T59UH[HLJP^B5VN)Z>/\ &960L<W4$-B.SL:,+/[-?:K;
M42;1!L'J@BQ=N3=7;Q7+$7'"-83K:0Q,PV-S&R/E]C85E.,$$'ZC).3D9YZ0
M#I]OU!<W=K&4>W$@F[\#QVZ2Q(989T5P4EB:-@"?4J[?YB!B7=#G;4O3J.F"
M)LH)K;$_<V6HW-G;JJB(W]MRL?L]<;3L!O- S\!4(6 \_3@Y@X?D)CZQIK3;
M."%!<GUK&A!!.YB%.2!N888\G<Q4 9)95)K6NI-9O[S53"62&ZF(2.YCMK=
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M1H7U&&;5+9[VR!:RC6[ADN+JYN)65&[ETD"2D8FNHI&WF>-C_C6QUGIX>O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g332508g20a42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g20a42.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[28"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )>:^EP(X0DE-! 0      #X< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   @  ' )0 !I6:6=N97-H=V%R:2!#:&%N9')A<V5K87)A;CA"24T$)0
M    $/+!]326L >>*<V#4YT"IH X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9?7"
M@         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ ! [_^
M-0 "  $X0DE-!"8       X             /X   #A"24T$#0      !
M '@X0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              'Q   #T          !
M                  $              ]    'Q
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   'Q     %)G:'1L;VYG   #
MT     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !\0    !29VAT;&]N9P   ]     #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     4X0DE-! P     &WH
M   !    H    %$   '@  "7X   &UX &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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MS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MK3^%IU'_ #T[#_6'CY)?!;[N=$_#,/\ )T^+>G_8\;^"G]NGV]'6G\+3J/\
MGIV'^L/'R2^"WW<Z)^&8?Y.GQ;T_['C?P4_MT^WHZT_A:=1_ST[#_6'CY)?!
M;[N=$_#,/\G3XMZ?]CQOX*?VZ?;T=:?PM.H_YZ=A_K#Q\DO@M]W.B?AF'^3I
M\6]/^QXW\%/[=/MZ.M/X6G4?\].P_P!8>/DE\%ONYT3\,P_R=/BWI_V/&_@I
M_;I]O1UI_"TZC_GIV'^L/'R2^"WW<Z)^&8?Y.GQ;T_['C?P4_MT^WHZT_A:=
M1_ST[#_6'CY)?!;[N=$_#,/\G3XMZ?\ 8\;^"G]NGV]'6G\+3J/^>G8?ZP\?
M)+X+?=SHGX9A_DZ?%O3_ +'C?P4_MT^WHZT_A:=1_P ].P_UAX^27P6^[G1/
MPS#_ "=/BWI_V/&_@I_;I]O1UI_"TZC_ )Z=A_K#Q\DO@M]W.B?AF'^3I\6]
M/^QXW\%/[=/MZ.M/X6G4?\].P_UAX^27P6^[G1/PS#_)T^+>G_8\;^"G]NGV
M]'6G\+3J/^>G8?ZP\?)+X+?=SHGX9A_DZ?%O3_L>-_!3^W3[>CK3^%IU'_/3
ML/\ 6'CY)?!;[N=$_#,/\G3XMZ?]CQOX*?VZ?;T=:?PM.H_YZ=A_K#Q\DO@M
M]W.B?AF'^3I\6]/^QXW\%/[=/MZ.M/X6G4?\].P_UAX^27P6^[G1/PS#_)T^
M+>G_ &/&_@I_;I]O1UI_"TZC_GIV'^L/'R2^"WW<Z)^&8?Y.GQ;T_P"QXW\%
M/[=/MZ.M/X6G4?\ /3L/]8>/DE\%ONYT3\,P_P G3XMZ?]CQOX*?VZ?;T=:?
MPM.H_P">G8?ZP\?)+X+?=SHGX9A_DZ?%O3_L>-_!3^W3[>CK3^%IU'_/3L/]
M8>/DE\%ONYT3\,P_R=/BWI_V/&_@I_;I]O1UI_"TZC_GIV'^L/'R2^"WW<Z)
M^&8?Y.GQ;T_['C?P4_MT^WHZT_A:=1_ST[#_ %AX^27P6^[G1/PS#_)T^+>G
M_8\;^"G]NGV]'6G\+3J/^>G8?ZP\?)+X+?=SHGX9A_DZ?%O3_L>-_!3^W7Z=
MO^ST;NW)N>K=4\C;VUMB;0?K]@U(P">V!<K!;W S)$;L!P@T+6>(3U0&YRX<
M1<M,7+6)*HL?+V%Y9;[G\$_],_2NF=+RN@+TWI^%@+;'Z@U5P\:.,*LE,4(:
M"*)S*AF"EM^/([;;G7R'PHQH8[878C./+VCEVT5.7$8^V^P&^W([?JW/Z]?F
M'ZY?_C0ZLO\ [C=S_P#ZA6#G[W\$O_FM\'/_ +$Z7_\ HXZ^OZ;_ /)^%_[M
M'_\  NN6.?0Z[=.--.--.--.--9UJ^O5^W;+UY5+:=35ZM9KQ4Z_9;*OO>$U
M\"9/0!Q<TK+V<,IP+'R9$W*GLX93WGNG?WF%<Y<^UL?!S,C'B<C(ABY%H8X.
MQO:4G><@?UT=0G_?KGRZTCBY-I+SI*%:338GDZ(S*NPW)W( V&OHJ8Z5LW;:
M=,UFOI2L'3I7'=Z/4?\ =8,WFTH$G-; X),[9R)V-?W98VQ%AU1$/VV1L.@S
MZU21X]6&)8'+1,3+9^"A\)!B=.R.I/\ "2'6;CHQSGZ7/$QUI#-HTYQ238H6
MF,C9-5Q!AYR7R:4.Z4#3HC<MLH2AE'&R1FNJP7'(1:4-LAS*/$0^;HEV^<2
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M_P##&U^=?KE_^-#JR_\ N-W/_P#J%8.?MGP2_P#FM\'/_L3I?_Z..OJ>F_\
MR?A?^[1__ NN6.?0Z[=.--.--.--.--.--760>.2DQ4RC1:2F!$<@04R"4QY
M,*"\G*'843#CRL1HCJ,Y0Y&9PAEQ.<I6C.,YQS)807EQC)>;!WXS0<W7Z+ML
M/4R_4QW(^HZ@ #8   'D  !LV^_(;>X[^=_?OKL?6_1QM+9.AVMQU:Y1/!?
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MI'VF=V[3'',_:,57G8(Q&1CE$=;2+XE8^CO?8"OW>UQAH]=-H2+;;GD%+[0
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M@M6)[<S0KZ@NW+2W"U?3O/$P,CJ&1LOK95I+%DDV)50QK<4?R24D9\0*&B;
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M=3G[]3,="E_OLYYZO2NGRZ5TW"Z;%B\\/'G .PV:C(OKHP'@&CEG*CPI;8>
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MUL#4G6L/V9L,!KQG6USS&)&R=#E7Z&),.@8]\K%)7;;&LA&P$4-"TUZ1!+
MQY^TRIKYZ/"A2@L2(7%DI?8\E-\E$W6<WZ@8%]]WE@]1KT]@Y(7C5WC2D@ R
M/.9W=*LD6X84=\7%J_%J4AT][A=@$IG84<U>V.3%T1;S6@/%U9]U2DDI5=U'
M]B6H1U-ZOU8RL0Y2KUIC<=UG,N#9&#L.S:UN&G! ]Z,722Q%4+(C-F3FI8YP
M1E]N4,BR6B.4/.QDY27G[9R/B$L1Y[>#O:UYTY'<[C9$*[ <2#N3OXM>AG3
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M0*R&J4?BY]1D+U3'L5(!G[1!9V5#N&1TLA[5D R(9:UF65^WVPQ0;!+&2/>
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M8%*E"00T(W0@;(RT>TRT&)+5QNY"B3LRS9JI>13YD._37(U.KV&_C2?[D?\
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MP9:0&4A1@2M.>*1DJ$+$XY%P.T0^J$A4YMZ5#,AY>"K);V=PZG9DXY![#%@
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M&RX]CL?)6.0RPLR[K*["5"M"%U!\!&)'&@0H=]PPJAK+R/ -9*U9@[&DU:B
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MRYTEE<M]_&2E:"X]U>;-0,QWU5251$7TK)8I,+XX+CNE,<#;8_,.B-'SO+B
MG$>-9!3=,:HUZ%/URE:]JE< VE*FK&('"(R8!J,J$L:F 1CNI=1)&,CG71\4
M4YC(Z'"==B18K,=UQM1@'EV''./J^;;U*2ZHCEN6_)F2:*S-NQ5$4G95  E:
M=U?33T[,H"D<69E"@;!0&=V 4 <F9MMV)-QU[J_7FIP\JOZVIP&EAIQ%9>=
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MTN:Y'2-S,A,I<;(QX<J/*CL:,C)1H,I%YHK6A[ZP)0NT[*N_!Y%72HW*J\Z
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M7%&0-V8Y^)A"0&[L,K'SK=Q -RQF<1>: ;B3TJ2%B0>40GV5O3JH=GF6RLE
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MK!=:]+/6'8-VS[@J]UZO5,*(UR+VG E#HES'Y&@9QNSBY@[)"V"AXK: X9%
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M0,+@SB4TM,+NO^-WW9RTB8TE69(I%^<G8ES/_:IYO%>?+:?M4DOV_H<U'IV
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M4RXW\#S+M)OOQ_\ I,LSWG_B8B G7_JHQH;#Z)X#<'=MY+$@@G<''IBGP/\
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M)C+F)*#Z7Z>.FYC%K[,52IS1ABHW1UL6G*7LQ#+U8MCJNINNNJ,!63=UV);
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MC-KCQV&TM,L,0\M,LM(QA*&VFFTI0VVA.,)2A"<)3C&,8QC&./\ S^[W:?\
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M15U4D47U('7U(2X##R&[23I8K];""UF<@KN(%U6Q1B!J38^L#I_K-Z#T"=L
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MOT"%83SE.![%F#@\6EF;HU1)VR7:^):?-HMI.,S5!I!U^V0:N_3&#<&;67;
MD["F0F,YGN.Z;%&5;.@?8=U<?M=YEV)XJO= 4TX=PJW;Y S-+T^;6;[AE<S5
MBIW[36:J25]]CR8R.ZJ&*!YLVP+%=W\G4:EO?R3O^&O\W/&FIJO;S_;G_?C3
M7G&FG&FM 2NHFL-W,C5!E1V19!@*ZC-<V6^5FK),4ZO7<JV)<0$EY8(XM!.,
M)\>"FK59*Y6#=3ILF3)CVHZ(=#6!(A+YT(P]*6I:4*-X2SX]:PMQ8;\$3(A?
M&-:]N1O&DPY(TI\WS!(+3G*M44^N261*S#*=N5'A2>0(H7J842G#9UWMLWK
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MDF R07+8<930'>/? 9I;(=U4DD41JR(3;D1>:M3';;CD("\2Z@G1@5J8MZ:
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MB9XBMHB0)G/#9.(92#ESN78A03,RV]B&7$3FHQ03+4R\F*1AQGU,NI;RVJK
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MT:X?3_BR8V!!I-\5J*ZLP;DRLM%* G555^Q]"*75*YKVO;HO#&OH-IT%?K<
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M5I=[ZS_"(_\ $[/X+/FX_&^YQIJ=W+WOJ/DL_2<::=R][ZCY+/TG&FJ$H2A
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MTTXTTXTTXTTXTTXTTXTU[G.<]G;G.>S'9CMSV]F.W.>S'N8[<YSV8_ISG/\
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M\>#^L>/=I_\ Q_\ <=Q^X^1^WSK&/).D^58^\>+!7E2( E:P)+=][%BP9XE
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M-(F((0%15NLQ'"#S:9"7LLJ<:@-.S7$87E3<1MR2K&&4*7BK>D$MZ0 Q);P
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MCB)>7JS8'(I.AXR3I^1D]P?Z;3R<*,5IX.\[>T/! HYME5Q5'H9]M6GMB"R
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MU5O:E+<C#)SQR"E%2.%B?!I^#;[\GI;K=*+3=1VE2;HE%8%0,K8_IV6^/B.
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M-I)F':1U;M1>53($"YAC:( YDL)' ]AA+8PL@('N,/1I$$C 1X*]WR***SP
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MWM)+9 (]Q%F8M0'P['DP+>=2AO2[J#$':,&V50)?4;>VO-W!<,V@()D)DVG
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M.S^-CL[.WM]GVOZ6FLL'_P QB?Y=K\S'&FJSC33C37-74ALO:6LHVLI.MA=
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MOI;2U(ZPMU;$O6Q:16J?042XD';,ZB/E@>T8<&-#U3N.)K*;/;,MP7QF^O&
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MTYU^0[?SQ9=V :RY&X)#+=# K6;#9IT'LT!R0J2DDF=YCCJP8@HPV!2+XXV
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ML7W"=43IENBU1V *LS8X5DW -XU]LFZN&IFEKI'7!.L,R.)B=2PRQ.$>I?\
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M>-RH?$=SCP034,KXR8S41:/A;X&3C]1ODQ%$E8;-&.&F.P=Z/D!JX^*8WGT
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MX)\ CPOJ4[D [E>/)2OO\;CW@BHJ([9D"UN12\^8H 0>)GI6)CD$C)BI8PF
M+%J)11L2%W93$E$F3&A)0J&D E:,Y43E/OW4CBJD>9I0DD'UO;+R74 D[D2B
M9GW[JQ"'YL(NLV'G<;^MU&Q()59QB&.P&PYUY@>[=2"!S#;67R9W#"&]R&(R
M8<GQ,F'(:?L<<K(F69H>12Q84R3\$S'AB%D'H&9HJ,VT]*;C8?[RCN7HTNB
MJBJ?)$T W/T759JY8[%G#;/L-_!V;<%R4NY4T=AOQ-JML/'*3THR*HWV0S4S
M&^WD<EV(50V41QU],A;-&+377),*RBV*\XA.!3TH>#.QRLLFM<>/$<R[+CNO
M!<-YPJ!.8#L2FT8;)OJ<G<[2<>\5#,-O/:G03(V/(%ZHCVV/I'>51L%&H.W)
MU'T2@'J^IW3F0"-O3-F68._+YLEB23J:=B[4>F5^579BF838&&LP/(O@TR'2
MK2G9$IA]YL6MM4N8CP>"IV(AB TYW<EC,-MIQH@&XH2=B@,O _U*ME-0N_D%
MY!E!)&Q(V(/T7@H/>KDT\_4-TVGN/U!_)&Q.WOWV\X07&;BCK*%'7W^\$2D9
MUP?%DP2\=H8M^9$B#FAK CPW$]EU\&X[/C26H2(D*<_,5W67G)4+R4("07YQ
M+,?HEN&*KD;%>*ATN[ @#@3Q +#A9BI)('@0LFV_G<-ENN^^X8LCR0;;'GMN
M65-FO8L1NSNV4'#B'VER)*',C'@D!;"U9$X1+=6\)(*D"5-H,89A1TQR+3KS
M65+1W3#@^P\C8^_8>?&P'$!@VQ!+%MV1E*[#PWU 5\!M_> Q)'ZQR)7COOL
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M[3#DT5,F$\-,-H[N=EV$MA;TI&;+OR1FV\#9U'D,6;%9OV\=DNJ[%67?<'U
MB6XE65?^<%6^L*HRU7<_K//'+;C9N/D'B0;\;%[6E6=S(HVJ#7G2\)2G&7@?
M<-U_N@.)4>+$E@Y<Y!='>K I<IZ8XPZF5&PTG&<-(A0N_JY>?2VP/UOWY%"-
MMMD]G%4<$EB[<E(/$K5MCL%\>/)_5\S4'<'?=N\9.I&RA5V8'8J_H03MA0HM
M&L%@83/D&@?@<P>T,:6P*:))585P\JB2FD-S!G8U :E,9E1W$N*QEEU:'<0
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ME]RH*>EP+;$^=B\J),-[U)5F!) *^[P2#J)\0S"FY0F8]/O(6TW?B20R@JI
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*FG&FG&FG&FO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g332508g22i15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g22i15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1P44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &_B^<6 X0DE-! 0      $X< 5H  QLE1QP"   "K&(< E  "')R,3DU
M-C<V' (% "U-:6-R;W-O9G0@4&]W97)0;VEN=" M(#$R.3(S,2!04%0@4DE$
M15)3+G!P='@X0DE-!"4      !! JZ[_;I2[4(NPW*\!.^-@.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0%D/.X         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !/@
M ;           0                         !              &P   !
M/@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M/@    !29VAT;&]N9P   ;     &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   3X     4F=H=&QO;F<
M  &P     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MAC.IMK9><L!C?3Q=_P"KFI]4.M>^AOV?T?\ V,_1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLL'1\!<T0U*"X0HD5)*3HL+Q&"8G@[/#TO_$ !T! 0 !!0$! 0
M   ! @,%!@<$" G_Q  _$0 ! P,"! ,&!0,$ @(!!0 !  (1 P0A!3$&$D%1
M$V%Q!R*!D:'P%#*QP=$CX?$(%4)2)#,6<F(7-%-C@O_:  P# 0 "$0,1 #\
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M/%.H'D*UYMA]EL./XAD3MM@6K++-&N#9N5ZN-SF35M(Q9B,J8VQ%5*G/,,.
MNMMNFW3]-O@A+CZ^I./4C_&^=C?CIO\ BOKYKZF1TWYKTU\E\-7C-N!U=1_!
MMUOU^QN_3>4N*BT9T.7(L%CGR3AU\N=O6B;$M4V?+N$HE'S;L=Y;;*7W_&/O
MIA/E'EZ[SU[GKYE47P_\8*1GO5MB_2/RCTT9EP7>>5+3G-RXNOMPY&P;+<AN
M3.%1ITB0,VPS'R[<\"N5QAQ5R[7%N$U:WD:#ZD_7N._?RB?OU4_.,X_S]GY+
M%#I$^+A<>.>E+AG+<U@]0G5?EW4'UN<N=,V%+R)KC^T9TUDUO9NMSQ.P0X]G
M>8MDBP+N$:'CEH>E7")+BQY;MRN;QC0WDJG'E]_9^J$GS(^@\@-Y^QM!VD]!
M7Q I/5;R7U#\$\B<'Y3T[\]]-MULD'/^.LDRNS9TVY:<CB-3;!>[;E%A4BW2
MTR(SC1FM,1DMJ>?;>3)EE2G Q,Q]_P *!,9R>O3[_=;/:*4HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$D#<POFQ^8_F*(M(/Q3NBGJMZDN6.BOG'I.OG&-JSWI/S_*<
M^98Y4_$38[I-NMKM[%K2Y%MZFG93278CQE-^JR2XL*(\BBCMM/7RQOZ;@==Y
M4GTW?#UZC,PZ@LSZM/B$9]Q_G'*=_P"'+SP/BF#</VRXV+#,+P;)6Y,;*7&I
MDR1(GNWJ],/A'SC$AM,8)#B-+HI((WPK&=87P6/D^">)./\ X?,:PX1D/'_5
M9A?4U<6N7<GR;);1<;YAMN^6M[*GI<I^6B.X_&@I?@1'F6G(H=<"D/)003:?
MB>GWCNKE<8_#WZP>H3J)P3J/^)#R+Q1?YW#F <@X9Q-QEPEC]RMV,V^Z<EV=
MRR9'F%\N5YDRW)UR3 ,=4 ,(8]%QIH.((0JAQN8]?TRH'?O]CNL?,<^#QU8N
M\<<<=#F>\R\87'H,XLYEM/+MMGVS'KJQS5D=LQ[(9&0V7 ;BYZWX-$BL2'UH
MFW:.R5NQ5=C+25A)$3.T?/[\_DI^X[^J[SD7X1?/.3<7?&BP2QY'@D>5\0;,
M>/;YPN9,BX)CX_;\,ND:3):RLAO;+\AF$$(^7!!<2TK7U&I4?K]>IQD;]-MI
M),*\DWX8G.,_JXX2YL9SNPXYC/'GPX7ND*Z7.R/S!E=MY%=Q->.LY+86UI2T
M;;"DE4IM]9]?L2".U9!J.8?]A\QE3!WCU/W]Y6'72)\$_JAX"ZDND_FO*;YP
M'<HO3W.Y3L&47;$[9>[?G_)]GS6QW:%;L]SS(+N_,=OF5+FSF4.1%$-0XJ7"
MA(*C4HJVX&^#AU&<7\6]$&&7K*<"DW+IM^)9DO6%F+L63.7'N?'MX$SY>U69
MSM^J^,I<07V7--+"74 _4E*B@B?3J#][R!]5LKZ5>BKDOACXB?7AU7Y-=L=E
M8%U,VWC2/A-O@NOJR"$YB5HMUON:[XVXE++7K.PBJ.EDJ2$D#?FB><_?3Y?7
MY+:UL?F/YBB2#L0?BOM%*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(N*TE0T" =_?S4&8]T
M@'S3'42.RE_16?NG^9_X5:Y*O_\ )]%,]@ .@@&/F%R+1^GPGZ1^9\^_^;^O
MY_I[5<AW_:?A]%3OT/E,=_*>WEF%R"-#]@ D>X/M_?K^6@:B'.D. &\'SZ=>
MWV5))]8^R<PO@:(.P='W\G?\_'D?Q\U!;4,>\!'WZ?,%3_;[DS"^J0X4Z[P?
MS&@-_P ?_M58)SS-![=MO7SZ_-4$$D08 ^]O[_#N+0*1H>1[ZT-_[J&8P8*D
M%S>@=(()P/I(_7X=X3K"E(TCPKP>[N\C\QKV_B#Y\_G0$M.1S;YV$$1D2/OO
MLH>WF!@\IZ'M!G$9ST[>65]2RYH;4"K[DD_P^Q_7^X^]"&ETEHZQCO\ ?\=D
M:'AL<W;(^LC] OOHJ_3[>Q/C\SY ]_XT,],^7?\ A5+[Z!\ *\>YWLD']/S!
MW[_H*I#3,EQG;'^/HH)(V$_$??S7$LJUX(V1_#?\?M_ ^U5;=S^_S/SV4[[_
M +?LO@9<^_:/XG_A3)$;=L#]B9/?92T,;,@YCJ?/S4TG?:.[WUY_Y_Q_6I4?
M>5]HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+4?UT?&2Z;>A#.X_&V:83R]RAEPC0
M9-X@<66/')D7'1<D%V!'NUURS*,5MHER6 7OE8<J4\RCM#Z&E+0E6X:)P-KV
MO6M.\LZ5%MM5J.ITZE:L&N>YAAT4VA]3E!P'EH:3(!P8VG2N#]:U>U9>VU*F
MVVJU'4J=2H^.=[=X8QKWALX#BT-)V.#%#]'7QQ.FKJTY#M?&,C!.4>%LDR68
MW Q"5R-#QI>/9%<)"GA%M#=YQK(;XW;+L^EM"&V;LU#B294B/#@39DEP-C(Z
MW[->(M$L:FH5A:7-"BWGKLMJQ=<4F #F>Z@]C'N8V27%@<6M!<X!H)7OU7V?
MZ_I5E4OZE.A6H46\U9M&H37ILZU#1<QKW,&[G,#N0270!*Z+K2^.YTW]'^>W
M;C-KC3ECF/)K+>W,9N5RP1G$8^(V_)(CBT7*R2[Q?\GM<U4N 6GF'G(-JF14
MSVE0ER$/(=#=K2_9WKNJ65M?4W6M"G=%AHTJ[Z@KNIU!-.L6,I/:VG4'Y>=[
M7&6D-AS2;=CP)K=]8VM^!1HTKQS1095<\5GL>":=3D:PAK*D>X7N:7 @@003
M%Z6_CN=,G4-,OEGRK!.3N#+Q9<:O&3L*S^/C,BRY"Q98RYDFU6&YX_D-T<>O
M;D9"EQK?/AP%RU#TXBGU@@7M4]F?$NF4Z55S+:Z95K4Z!_#52]](U7<K7U6.
M8UPI _F> X-ZX@F[?^SWB*P93J&A3N&5*U.@? <XNINJN#6NJ-<UI:P$CF<"
M0T9="U5=0W_I#?6#%Y7M^-=/G"?!N/8->G[BFPSN5+1GN?9%<8]FC"1-=G)Q
M+.N/[;9WGHY,]M@?B3;$=MUE4I];9=.X67LFL/Z U#6:Q=4835_#46TVTZK0
M":3'U&U>8D$ECG!G/R.!#3 6UT/9=094MJ5]J=3GKTWESJ# RG3JTPUSJ0<^
MG4))#B*;G!H>YI  P%WC_P <[J^RGA[(,6NV,\883S#<KO"_ ^2N.K!<V;%:
M,:,=[\3CC$\YOV<)7D8DH93!N3\^9;51GWU.6ME^(T9?O9[+=!M[^A7%W>7M
M@RF[QK2Y+*=2K6!:&'QK<4G"B07%[&AM0$- J0XEN6H^RW1Z-_1JON[J[L6,
M=XUK7Y:=6I6D>&!4H<A\+)\1H+'R &O/,2W7_:^4OBJ7?#L[ZCYW5GU -<20
M.286%1YD;/+G&CJO-YMKET3\O:8\./:(MI2M#L%KY()98DM*C"*TA"%'*TN'
M^!:.KNTIVC4'W3[47M&DZK7-+PP>2HP\U1U4O88/_L@M.Y*]E+AOA"EKE72*
MNFTW5W6K;VWI>)4Y/"!Y7L>7.\5SFR#/-/*3),J_E^^*'UI9'TW6_@:7S!DE
MMR6)?4O3.;+&]#LW*%XPZ-&;-OQ:9D5MB1Y$:9$NB$27\HM:(&17: PQ N]S
MEAZ[.W>Y3X%X9HZT=4;IM)UMX0Y-*J/K5+%ER'@FOR5*A?48Y@(_#U:CZ <Y
MQ%,-Y&4_=2]G_#]'6!J3+%CK841RZ;5=4J6C+H.!\;DJ.)J4RW>WJNJ4><N/
M(:9;39F]\.7*.L;BC%4=;',_4)RUS1T_Y!R*OCK.,"SW*LHRUS!,73;XT/\
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MS-MLUMHKCNL^IVOLN+;57J6FZ9Q%I]I4I56UG4+JUO;6ZMV,J.-2A5:^FYI
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M:KW%S<%KJU>K7<W#37JU*A:#N&EY<1TP,%45*M6J0:M6I5($ U'N>1.X!<3
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MB&TM@A._)V23LDZ V2?T '[A1%SHB41*(E$2B)1$HB41*(E$2B*&\HH:6L$
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M*9HB41*(E$2B)1$HB41*(E$2B)1$HB41*(I=:E[5I:4A)UY V?OX\'?BH/4
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M"/(]NM5<0Y1?,XX\PK+,GL:\=O.1XU;+O=+*YWK_  R=-C(><BI*M.)".\*
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MQO6,9>.92]VFUK@ ((D.:,DSD3]3G"^M-)-V;"DZ[<U]9P8\O(()#P\D1V;
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M6M:=GWT?8[WV@N:7D- ;(#HV@'8?4^798PR,&9!V/J9.YW@','.RJF*  YH
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M,6\RH';"F7BVQ&;A!7>8URMZT/J0=-O%U-4-,!VT@ST&9V@G^_<*D@\IC&#
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MA?B4!R,B02DA12EQ:7.TG^K4GO3I6C7IMJE2C<VM:V)%6G48YK6DM!=/4-[
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MJNI$P8!B?TD?#I\5FSA<&WPK/!_#8$>W1WH3#_RL0*$5MR0A#CB60K?:A*@
ME UVCP?:LFVDT5.< @MIBD!_QY 01 VW'W,)5=S&9F23Y]-SO/?TZ[JJ(W_:
M#[A9V*O*TIFB)1$HB41*(E$2B)1$HB41*(E$2B*4F>$(_P!:C_:%$4G)[7F9
M+;R26UL.(<)/:%(4VI*DE7@I':=$^X!V/M5L!QYFDDM@C;.1WZD#Y>:2)DD-
M'><#SWG_  ?)>/3ESB_D)_XA_/\ .R'ITNW)O'S/(,^XLP9=RG8_!O<"Y16#
M;[HF>VE#+4&.AM3JFUJ+3R$DJ6CR1SJYX/L-3U6O=WCJ?)0J&J0Z "&F0=NF
M,]-NZ^K]'_U%\1T.#])X%X:L+FVO+>A;VS;RG2>[F(MQ1\0N;O#MW;Y^78<[
M]2N VI>.6+@J->N%I&/,OVJ9AW',^#%B,7>'(4+Q+R6_($F9>FWBI+%H6)2O
ME&D*>0M"M5L>AWUCXITO37TZK6$L(I&>6!/E.T=?(]3SCVK<,>T"VM[75^+:
MUW>OU.C;5K>O7;4/("">42 06R9PT'SRLU_AB=$'(T;E]_J@YHML4PHF'W:)
MQ?<3=6[G>;S<,TD=UYRJ;-96IQ4^/:2];(CTEU]U2)3J$LH4 I.T1X1;R$<T
MY\C @&>\Q\5QMC7TW$O.33(Z8EI:[<S):2'$G&)$%7?Z[TX)TU\C7SJ$RW%H
M',%RRC"[=Q]C?'=TM[3]IL5K:EJDY!D=RG3&G'.Z6^\PSZT9MIQ!7V-NI40:
MT+B=U/37G5:U-E9],<S6QL9B,@G'PD3*^E/8Y85>/J>G>S>E?5=#HW-9[[F^
MIO+'W3<O92!!@B8#@9$#(,XTI\!W['>1.M#B[.H&+6/B?'8><6Z?,C6-VZ.X
MWCB%..>DS(F2W9 BFYOEN(CYA32%..!*  HZYI8<5ZMQ!Q%9O<PVUG2J.IAO
M*X!T$ <I _ZC: !(7UEQA[*>#?95P!Q#IEF[_=-:J:=5%4NJ4WUJU8L+6U2T
MD$D<Q=UV[;^UZ"M#C#9*QV/LH=!2K2=!.M#>CM:E%22/=)\'R#7T & TZ@#@
MY[FM(SEV_2/YW$K\NK@BG<O8T%C&U'3('NN(:",#<$3Y$9[+N8)5]25)[-#P
M-[\;&CO[_P#G55*13:TB"T01YR1V\NYS*LCF<7/=OS<HGJT 9^_)=C5Q2E$2
MB)1$HB41*(E$2B)1$HBE5H65J(2??W]JC,G..@[(8(B/B<S^PCSWZ=53\^8I
MR4+<@A/<")*@D]H#A'I->H/ <45)"M^WL?OJ>8MR 21M'Q^YZ(TM#FM<WF;U
MD2 !TWSYR.WQU&<G=$W''4YSWR#R=C?,MAG2K4+?9\AQ6 RBXIL]WM\),4,7
M-Q"Q]7=$?3Z2@"/36-@C5;E8<9:QI>B.TVU<]@J.YFN!,-:3@0#N 9( C'F%
MSG5/9AP]J_%C.+=0I,KW-O1;3M: :"UA:&PYX[R,[GIY*V>,=+S]GY O?%N2
M3F'+U96HV41%0FG39W\.C/A+#O;K3+KA2DK8(*=H4C:NW=8BMJOC4FON6^/<
M5#%5QDD$QS$]()W^NQ"VZE95FU:%$"G0M6G(I>Z T8 ) [8/EU"SEZ:^+9W&
M5UY'P9W,%Y#9KK<K;F%L;@PUPG,4_&4$N16$NE11'FIBN !D)#>U*  (-8N]
M<VL*(%,L+9G; D]/..A/3992E1\*I6)J<[7#W3Y[8^?6<3D+'#G'G.5-:ZB^
M,<BO5PM=\C76Y63$&8SDMJ4AEEEI, 0W4!):CRT'UV9 )2M+@\A6];'PM=V5
MIJMN^Z:QUHUS'/YL-\VG':=NRU'C>QO=1T&XHZ<7MO7-<&"GAX[.ST!C$SRS
M/=6;^%WP-F%HS_)^8[A?K2J5<X2<=O&/3VKF_D46WL2$/LS$7%\^DM4EU"4K
M004=G@'QJMQ]H/%VFZW;-TVQM11MJ1EA9 $@$#'83F1OY[\T]EW _$&A7;M2
MU:[\2O5!%1E2>?E<0XEIB)W&28C;JM]X0?8I/:!X/;LDGR?^3_#P?'( P@ <
MQ$??E_E=]))<9'QZ>@4-! ENJ)T"VE()\;((V//_ #^57$4Y1$HBXK!*5 ;W
MK[:/\-'QY]J(K?7[!+;>9Z;LXAV)+#8;>=C/*;4ZRGPE&@% %.S]B1OQ]J1/
MW\$5!QN)H"+I$R*"]+B7. \M,>ZS'$RG4,J4I#S!B.#T$M&,MWMEA0?22"4)
M'U"('7()DC'Z1!,@$'?S4.#B" >4]R.T'Y';X]M\>>OWJ(N/1_TR<A]1S&/0
ML]?XVM5ODP,6F21;8\J3/N#454EZX-)DO!+ =.EA&DG>B!YJEU0-.00,"8/I
MC !Z9GKE2QI."X3!,G;:8WS\2/ATR%X/S65S+Q!Q/R<Y$./OYIB%BS%ZTQG5
M2F65WJWLS5PQ(<2V768ZG>U+G:%. =Q2-:JIK@X2)^((53FQU!\P08)GL?57
M0N&.OWEYE%TD>I!;"N^(TE*&G_J!0'SK:DIT24>Q5V^? J53]A5-%83&0AAM
M!0RR@-MITE*4I3X2E 3_ &0 -$^?T\FB(P"''@1H]Q/\#K1_N-$4U1$HB41*
M(E$2B)1$HB41*(E$2B+X2$@D^P\GW/\ </-%!(&_HNOE/-N)"$*VM*TE2>U0
M4@>%;6"D% T"1WZV =>QHJAG($C?U']UUDM]IEIQ9DI9/:M14K1!2ELK5H+
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MUJOB$9F.O4]O+Y*W1;R@PWE&(Z3C.-X[3/EY90585]0ELH4>X@[_ $.M_O\
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MW_(_?1%*JF-)4M.EDH*0K0&@5>WNH;]O.MZH,[?+KZ&-CY*GF$D'!'?;OO\
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MTU@MH*VTAH%/A1(&AY[CX^VSW^#_ "\#S5?OYJ50<^9,]!) +C,S$R>I@XZ
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M_P VM<9A!<,B8VVA(&^\!:5+(\:(;"2HC\M#8V*]6JW5*UTVNRH1^3\TQL#
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MAM/LA*$^$C0'L/)U^ZM#J/=4>Y[B2YQDDF23Z_IV74:#!1HLH,:UE.F(:&P
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M3[JT-MD(!4A2O34VM+H)5_5J((84E.OVPXVA7@Z WH0'4NW3M$3_ /YZ=NF
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MQ6093<GKY*D+R],>XPDHB08YLJ&69KW>MQY'8V^GR/SZ)OD1Y'OG/;MZ8WR
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M9-U,6K(W[WE?55S'RRYA>.<CY [Q?R#B-ZS5.1<<W'-<2@38UEN-PCM*<?\
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7**GV'[A_A12H3?[9_P!$?XFB*-1%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g332508g22s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g22s22.jpg
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M.%%WA).4L[<F,S9289C3)7%"<W1VLD-%4V-RD?_$ !X! 0 !! ,! 0
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M.-LO+6$N.H6EYII:W&TJ=2E"NU46,;\F(I&494UMDH;S *5J2D)!UD*2E2B
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M!L$-@*4$H&9JENO1?1MBCFP]SV=O<Z()U091]C"96Q\H%[@J@<T5-CQ>PAS
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MI+BUK5WIN+X&2D,.%+KCS2G6@M3#CJM=9:)/\DK\((6%H"LU!.L23XP^AS5
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MRNCWJ>I%71%Z?A&)A9.[+3OMR',(LR0LF\7'0<CIM.1Y8QR%EJ16Y&LY3\=
M5Q64)+KR06^XWWQ,V_"&Y;U,-*VDM&U1[.%(04NIB1KPF^-*2X%YI?$](471
MMW+P D'PJZ]^O[GN8*0G>Z(V8!"MS1*$Q)"L\PL/ '6'_3LRY:@-<='&L-:V
M2BG85BVE:A>HXY"+I2C7N^3[-2-.,$0LNKN>T<5(CLSGY<&I$"-0!%+B4MA:
MMU4B1 UZ>,'$)C#_ '3L3SYS$ME3%OCN7)2%767$AH8EW,H>3(&^W HI"5R4
M(DO-QFX[;\A"'GD.+0DCF]/>>0ZDH90I\@R'&F@AR00H.?K% D %P)<4&TH2
MM:0M84H U")Z#.GA%:8J:0MAP'C]1_OHFF_;%*\?C8GDR@^!&7_%^%G7Z:>K
M&OL4S./8[-#0BMJ7F*GPL]IQ?>B^9!=9W55CX/D[@D#>6MNNZ:H.6_-\_P#&
M[Z_YF_/U_P#*KEW3EZY7K(UC$WD3J#_E9ZVME\KNGZW=./=/"XZW+YC%1]:9
MG.AG4AVQR2SEHVX.K4C==<ZBDZN$W^5#UG'W)7MA!]HN7)BOY@NS58L-T$*.
M6*MR"\BH2RQ4N>A@!]CD,&8N4,XMN3+"6Q'MJWTVI^R=T'(:53U6M^$[;Q%+
MP6$_J8CNXL/AL24--M,J>6PDM*D$W)]* G48*Q'7%W930+QCK:4SN97F!X#:
MM1"PD.!(2DK*!JG#6G^A"#+#[):W&7V;!$7?JJZA]Q']/#-D^.U3L,38NHF[
M7W5YBU@8"I[Z(A"INTV:<IHLX!!FLQ&X%^K129DM'?E+GB]:7(!MC4!;L3#M
MDM;-S<@97&$XQ9(D.X-1WEZB2I$D2DLRG&7GFM8KAR&T;F4W#]S(4R8Z62IJ
M%$CHD%G)]I2(C;3R4*.0S#FZ!+BDJ4G/-M8&KENIO32=*ZAM9G-57_)MBOFY
M0$DDG6"[U?M ,S6#PVS #E</1D+DARXLP)A28\QA.590EV.ZER/(>:7BMINL
MNRSVKA#W(O-)>;U'VP]'=:D,N,/-/LJ\%UIQIQ25)5LSR4,E)!$=&D.17DOM
M:I6D+3DM(4A25H4A25I.Q22E1!!^?C%6I8>ES4MBD#'5P#P)@'HP_P!.X*'4
MK*6JB .M[ 4I1=; *>!?@F@QP1+H%:R -C"D66*1$<PSX2W,+1<L8@N3"7 %
MLO%Z[L7MY4EAN27IS#<ML*>0\E;3K3B9LC=FG&U)<*AK;!D>Q,U]&MM0K6DI
ME*W1"5ZSJ4N)\(*!2I*@ZO62H$*SJU*_T;ZS$%XMH-6395]O#.SZ/M>9>KO:
M(9"QEC^MJP>J%(&$,"@@4&FN@0EE---#QP6!(FRYSQ G.G35K?5</8GGNMJC
MM,08<0P)=N3$B1U(8:9G2&9,MQ&Z.NNE]YUAK-:W5I0E 0VA"1E7-=P>4"A*
M&6FRRXP&FD%*$I=6EQPIUE*5KJ4A)S*B   D ;*RGI_2E8TC LX2EEK8[6K%
M;K)<H=7/FDF U0(V^Q&;;9(50P[#;(#@Q.R6 J64/G$":8KTG$> Y%@LL16X
M^YW61=EQW93<8/L1F(JI#+6Y.R6XK#49A<G)10XZVPRVWKH0V5!.:PI9*CTR
M)"Y)0IQ+86AM#96A.JIP-H2A!<VY*4$)2,P!GEF<SMK 5#Z!]-Z^;H(8;:-Q
M&->:TM<2_P!3U'9MC3C&M(>P1YE^RC+E(!KA,SYLT3:'\VL2!D&%TH7:VH]E
M@5:.<CLST3$O&%SF;\<7'MC4V?'5#DW)B"AJ>J$XTEAR*E[6*$(<CIWLX\EH
M2G(Y4PN0II10;EVYR'=U4I$=+KS9:<?0T$O%HI""WK9D *0-S4H)#BF\T%92
M<JOBL](^O*C;11X):MK1JE7KB9V%6-.8OT]&HZW=#\HJ0)&!M<CQV"KT#!4X
M7,#*<6L!*@@"TU,\!51<B"+7!M'\1S9,9QEV/;E27HS4*1=-YH-R?BLI;0VT
MM\J+87N;+33DEMEN8^TC4?D.!;FOUKG.K;4A2&"M;:6ER-R&[K;2$@)4LG5S
MU4I2IP(#JDC)2U JS_,WI!U<Y3:95 A6_4TGKB\;%V%K_8-1M&!5_J=AVM9;
M59[VU!*NCY8HD /R;B9@SJQ8@9JORH"!690Z01"BR,6J<2W 2I4AYN'*;G1(
M,*9"DQ]TAR6+<Q&CPRML+2XV\RF*TI$AAUI]*RX$N);=<0H)[VZ..*2TX'6F
MFG6G$:S2T,(0AHE((4E:0VDA:%)4#K9$!2@:^E=)VJ*(2U^>%9MA"S4"[; V
M3BTV*S2SMCNE]V=5)-+M]JOA2<VX^>(2Z^^R.'L,>QPT%!&AA 2 /!AQPN/P
ME8CN,QN:RYO9#$R)"@[W982RQ%AV^0F5&CPVT$)90EY)6X3KK>6XZZZM;SJW
M%4<G/NI=2K<PAUMIK40@)0VTRL.-H:2-B0%;23F5$J4HE2B31*Z1]>)NDRSP
M+5M8-62NQ$[<-ZA"WZ>,U.:V7DPU9)-KG@(T=)E*2MI8:M9^JP;'#HEDLN91
MJP58G.)%'IO(8DF[U0PN/;G7VX1MK5R=AH<N+4#<BPF.AY1+7ZN.3'8D*85,
MCL:K3$AM#;817?SNYA!;84M+6X)?4T%/I9U=0-A1)1X*/ 0LH+J$9)0M("0,
MFWO2M!V3;*C;[B->+S*=6=DU""+?>0H"2KVV!88-<QQP:ME:2+,X<#AQFDY=
M:2RAR5A27</=R;")=9D&-)BQ5AI$I^#)6X =V0];G'78JV7 1N90MY2B<B20
MG+++;TM2'64.-MD)#BV7"K+P@MA2E-E)SV$%1)X^3FK#5;Z&^GJMU2FT=%;*
MFZG3M.[JT=[#64[,--VNE]0MBIMKVW(NDV1W$S]EMI^D#B4RPN38\W$H@:?3
MGQTUMR-)OXLO3\B5+,AMJ1)N=JNVZL,H:,>796)4:VB*E/@,L1F9;C:&0DHU
M4-#B00JX7<I:UN.:X2MR1'DZR$A.HY%0XVP&P-B$-I<(" ,L@D<0R/O1^CFA
MTW8FOMI$-@[MV/<-5"+17->S-G;'E6N-6JU;A<807"1X61\%B=EZ+"A*?L)9
M)"Y%78,#)^R&&Q\%J/27B:9*A3+>B':H,6X.QWYB($%,=3[\9Q3C3JEZZU)R
M4M>3#91%;"U[BPV5J)HY<'7&76 S&:;?4A;NXLA!6MM14E1.9RVDY(&3:<SJ
M(3F<X_HLZ?Y&BZ-L4B=KC%3NFY]V;5W!8JQ'*LG(U-&6RXEGZ/1!Q*--(P4C
MJQ34A_'C@TKVNP[,2LSP*/&@S4-\[,4WE-WEPD,OJDQ;7:K=;&)"FRTJ4Y&B
MMIES%H*&UE<B5NN3CJ=W4PA@/*4M&=<KC*$EUH)67&X\=AA"RDI+A0VD..D$
M YK<ULBH:Y0$!1)%35JZ.]66VYG;1.,[(@@KC=:OLB^ZL#W>? U7?+Y3EUYP
M%9K)5\,N2,2,.U&KO&Q8,J%KUM>!1';<'.+>GJF=,?$UPC168Z&X*W8L61!A
MW!V(A=PAPY0?#T=B1F!JY29 :<=;=>C!U0C.L@(">")[[;:4!+16VVMEI]38
M+[33FN%(0O/++):PE2DJ6@*(;4D997W5]2'&-/6'6]VV5>3=@NC^Q)MCOH6S
M&A-F$O[&LA\^[ H)E^5,(U 52HAUJLT%@8XQBM@P@A$!J._'PK%I(N3*KFS.
MB0(C3$404,0W6&G6'!!899"YC02E$ER6MDR)A<!W=UUW7*DJRKK6^@R$O-,M
MI0WN00TI"5(4&4(3FZD !Q3A3KNYYZZE*SS!K%-'Z']34G5QW26+'M.T:E.5
M%ZG)H=FNOA!P<1T@R62<K<BOBZ^7"7".69P8C6V(3P>9-K<.)F^S*O+\2,O%
MEQEW!F[;A;X]R9DB5OQB+^M>4$%O<7TO./-.QBV=R5&4WN): 9U=R\"N]RXO
MN/)D:C"'TN!S=4M^$H@%.HL+4I*FRDZI;*=75 3EJ[*_DWHBUD6H>UJ2<O6\
M#L_=8^K@-C;'*;2+O;.-TZFO$':]0V;.S'8:%TF+@W9&I==%C8D,RBUVI9K!
M%^PE'I)&*Y[4RW2F8EI:1:ER'H,%%O:$!J5*" ],,<DER6K<F"A]QQ2VC'C[
MEJ!EL)H+B\EUEQ+49(CE:FF4LIW%+CF6L[J$G6<.JC):E$IU$!.00D"BLG0S
MKRWZFQI.R[-WL5UVV8J)-@$N_0(D)@?28\I@)3O8X?6H8:50?#>A2I]+("Y@
M A(" \28:XP],=?)C%LV-<>ZK$"T-S2U)07=YK4HKEJ2796NM]3J9F04E$I#
MB'FTNO:J@I>L*HN3K;^^$,Q@[JN KW(DE3A!4YK%94'=A <"@L!2LCFHFME=
M;4#W-Z^]7\72^7I+A)X@V6V&=8L!J*V[%A1$"XDR,.%M,B8V(7CXT3$;.6I$
MJ8YXU6'L(1!SIF_G@]O6'$R;""W"94RTHA2U%Q25..$N*U]52M;:E*!ELS-H
M\[NR@K<VFLDY:K22A)VDZQ!*LU'/(G/B YJR!RRKJIQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*YGWKM1-*:
MIWYNG2.T:U<JE&U&^/&0;UY"[.#; L<L'TX&GZU5H[D2 S.+QL=3U"9>8&%3
M'L,Q +DKK[3H!"FNVM7+5.0.S;]6T[?FV&LO:[Z[]+;7W'7M,4$?L$T;.Q-M
M2I)N149 036,:@CZTE&,6X8=DC;C7$6./M.MR*6\5JT9NR076#$+.0)RL%3:
MJ9'(G9LRY>///BY^(YUIW9^V-I%2KE#LA;06PU1]HU;2VU-?PA]CK!2:;TWO
M^C;ZO>MK)/\ 8_,F'7+L0@]/5M&$Z2<EPP84F9K"B.P6!;QPD"9_Y>7YJKJ^
M4<H\N8(!_?LRS)RXJW)Z2^LJO=6);=X@%1;)3UZ3OTVC3YAJ3&D0S[T6QW*N
M)DC\88@S&G_#ICY.0VF',#8&FP?L=82I#!R #50C++RC.OUU<=95<Z1Y&HTV
M2BVBXP=GVF<$FSZY\#-+""%A?9NVGG7(;\&"##1C;1 F6/3Z[6A0Z'.F&K(*
M9;:R\H!G]7U_O^8;>85ALWVL'2?!IDB[5V3L.\0%L7J0 BUVDRXKUR;U_7*I
M<"Z:A.LTH %/S)-3N RQQ! \F\<C"X-D<."P[U5L3 U3(_NY1R\^?%^><5'=
M2/:CZQZ:-A[%UC:M9[ ,VJH:TJ^R:I %O H[VR&);D<EL2OA&9TUI8PUJ6AR
MV]CVEHKXM,ZJ0; ^&\KD@9C.55"<_/D?)Q9>>L<M=KU4I:-DNC-!7XBSJJS[
M=@6A>+151.':GI.M;%M]T/!UV10-B<;;KNMB1 <#??AUXA@V CQ[TN2HZR"4
M">+:!GES\O%Q _GZ*Z\C9\<J.@%(>7,Q"4*+/BY>9=CO9CS&&Y#&78[R4/,.
M9:<3E;+J$.M*[T.)2M.<85QJMXI6+-?[(<O!R[AU"HL%%1*R1R940KDGEY4:
MU7.L+BDV<CX>!1A*:@V==&X=F>*$60(YX]>'4NO5(RR\H_/T;>/G!J@.9/D_
MS&WS9_,164^4JM.*4XI3BE.*5$GB60P0N6QB'E0P9.GI20G-#(*EQ8SCZ$2R
M+R5LP8ZU(PEZ6ZA3<=&5.K3E*<XXI4/0;0J[4FJVY<) UVQ@1A=\<W*S.;@2
M)L5MZ1#:G9CQ$SFHSRG&6IS<=MB8VA,F/A3#K:U#L)H-H%7=Q2G%*<4IQ2G%
M*Q?L;9**!.HT-P5Y<U<+3$KSTUR:U"9&-2%M->&PTM#KY@M(>D,H'@H*,S9<
M=LC-;\)L:ZT[4#//R#.J$Y9>7\\7&:RARE5IQ2G%*<4IQ2G%*Q?!V'+E;8*:
MT=!(9CP*W*L+)QLGY4XZS'74VF<2X#,++(Y)*58R<6 S))8(KS52,Q<#V/GC
MY.:Y;,_SR_NV><53/;EER9Y_Y5E#E*K3BE.*4XI3BE6_:S:JU6+#84H@NJ!A
M299+1,CD0/=R/AO2L-S2F(D_(^,YEKP'9>(4O+"59<\G=\'P,JH3D">89U8^
MO]H1;Z>L N![7WH8:OT<TF:&LB#,G$FWBY)=T43@I'Q,0'A\# J?'DL2I\8A
M -PGL*BO)<CXKE_'9^?I\U4!S\P/GY/+\XY_/ECE*Y4XI3BE.*4XI6.K]?<4
MB33F,QP\C%L/$@*/96Q, '&Y4:H66QP,0O*H;\:<N=/!1@[J'Y8]$1)-$W#L
ME3*8;]0,\_(,_K%4)RR\IR^H_959K:XKOU+#VEZ%'&R9ZR<::/AD6C$2$0#E
MYX4A&BEX[;<,M'9FCGVV2<#Q@Z>VE,H?(DPW6)#HC(Y4!S&=7SRE5IQ2G%*<
M4IQ2M;MJ=03>M"MD$Y"AC$D' IY)F.FUXB$)$>RQK]*FYG#L!9+@[(Q%(;RW
MAETBZ0C&H[T5AP@F$&*U S^DY<7S?OS\_P!7$JRSV<67+QYY^3R>:MD>4KE3
MBE.*4XI3BE.*5@>@;KCW8[7 ^&ZCY/9@VP2PLB"NJ3F"#=)LM="QW1D)P(,>
MEC3< X\6C$%.,.89&N.,090^2T1Q4C+/R9?6":H#GR<_+GQ$#9Y_)6>.4JM.
M*4XI3BE.*586SKLG7E'.V[* [SPIECR.$<-9K\$F1ERF(0X0DKB 3Q'FE9LA
M@>.\.&MIR=)80^MAE3C[850\6SZ_SR\GEJ@UYL1=\(7^)FOD@3-,MV:U"=)Q
MB<9X[#2&%$$G&VIXD<PW$FRIDS O$"478F!&Q1I<N.LO@=#J1EEY1G^^@.>?
MD.7^?V5DSE*K3BE.*4XI3BE8KO6R$U"Q5:O-JJRI%B@VLB_@[9U@Y(P96*_-
M+OG,Q4B"&)89F<R.%$WFGT3(>"Z)\>'-CCYR45RS^KZ2>3]]4)R^OZOHY\AS
M[>(U>-0+%3U6KQLX'Q7BQ<1!)S@?E+TM8EZ='1)]CWWY$(<\J5%0XEF6A<-G
M+,I+S./#2WAU=#QGEJHXAR5<?%*<4K\..-LMK==6AIII"G'''%)0VVVA.5+6
MM:LX2A"$XRI2E9PE*<9SG.,8Y4 D@ $DG( ;22>( <I-5 )( !))R &TDGB
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MKT5I_P ICQ\X4^VP\M'@X5C.&U=^<9^#F-7["V(,,.1FK_:I-K<EH<<C(DA
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M?H&0_>03RGFY=NVMT^K#_-PW#_\ LPA_S&.2]@_GFW?_ !*/W&I6P?SS;O\
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M<RME,V4I;![-)E.Q)#+E<%MF\P(4F21GXU L,JXJN:$80PQ$$>X-!M<[#$6
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MC3R,S"+BE^R!OX'G2$IV0U\!3'_<2%NL_P"G^3^'OS\/'!G _7#^PU]RG!C
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MC*E9QC&<\E[ ";S;0!F3*0 !QDG,  <I)V <IJ8L )O5M !),I   S))S
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M-?->]0'I+8'\/_' .R=>;1Z$3XO3@!9>O-G]")\6IYUWJ:^:]Z@/26P/X?\
MC@'9.O-H]")\7IP LO7FS^A$^+4\Z[U-?->]0'I+8'\/_' .R=>;1Z$3XO3@
M!9>O-G]")\6IYUWJ:^:]Z@/26P/X?^. =DZ\VCT(GQ>G "R]>;/Z$3XM5%,[
M5?J7=<@*7V8>_FLL34O(2HC?^]]>(TEO#*._0*?N\I=4Y\&%Y\%M7W/=WJ2X
M!V3KS:/0B?%Z< ++UZL_HQ/BU5OG7>IKYKWJ ]); _A_XX!V3KS:/0B?%Z<
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M"TX,PI<(:9#MA;8=W>4PXT)]R5JJC278^:@J4E2%+#866U#61K:I*LM8X?\
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MN%M$N0VFWI>9D;I:I:U1T-R4--;W5(EL[HH-[)GX7MUN39EWA[13;47"T37
M+MAZ[P4MW:#8;#B!=J@27;Z[$E6_>^)[8TU<GGK>[)D[^:@VJ26$*?U>]U&/
M\6&JOT<*?O\ YGO<%?3V(/;8_8ZT3PZ9ZC8"]S3OB]=RNR+LK=DI^ZG6ZW6*
MYB+9*@C+=9'R8#4KQHLTK"Y:9,Z=EQQKP/!:4A3>$I6O&<*SG&<>4?TC8*H5
MRPNDSI\W=(-R.M.>;>4WJOQ1DV4,M:H5GFH$*S(&1&5?43_9\WI%YPYI)<19
M;'9MPO>'T%NR1'XC;^O N"M=]+TJ45K1EJH*2@!)((.>8Z<UC8\*SWB]TED9
M,B/4G(G&2;^<^1FL$$2<2LC7,LHCRL"I4;,,AD?+))@2G$PBV191+@Y'FXC(
M \_Y_B/SEG]#@<R1S5I+U#=IKTY]*>U[#J?9P_9<FT,QP=A6Y5JR(*BO(#(0
M?F&E,N;9A3V9&,1G/'-^280CO3X+B^_/=EUEP5>+]"$^"N$&"ZXSD^^XVYKM
MZNMX*6'!EX0R.MMYA6963 ]YO\$7""N"E@NN,Y2'W&W-=K5UO!2PX,O"&1UM
MO,*PGY\CHP_)&[OT'KOKQR6[V&)/E+9[4]V6I?O6XE^4M?M3W9:>?(Z,/R1N
M[]!Z[Z\<=[#$GREL]J>[+3O6XE^4M?M3W9:>?(Z,/R1N[]!Z[Z\<=[#$GREL
M]J>[+3O6XE^4M?M3W9:>?(Z,/R1N[]!Z[Z\<=[#$GREL]J>[+3O6XE^4M?M3
MW9:>?(Z,/R1N[]!Z[Z\<=[#$GREL]J>[+3O6XE^4M?M3W9:\W>W%Z,5M.H2(
MW;WK;6G'?1Z]W=ZDYQCO_P"W&?@[\_#\''>PQ)\I;/:GNRT[UN)?E+7[4]V6
MO*%VX71G'AQ&'!&[<K8C,,K\&CU[*?#;:2A7@YS=\9SCO3GNSG&,YQ_-CCO8
M8D^4MGM3W9:=ZW$OREK]J>[+53Y\CHP_)&[OT'KOKQQWL,2?*6SVI[LM.];B
M7Y2U^U/=EIY\CHP_)&[OT'KOKQQWL,2?*6SVI[LM.];B7Y2U^U/=EIY\CHP_
M)&[OT'KOKQQWL,2?*6SVI[LM.];B7Y2U^U/=EIY\CHP_)&[OT'KOKQQWL,2?
M*6SVI[LM.];B7Y2U^U/=EIY\CHP_)&[OT'KOKQQWL,2?*6SVI[LM.];B7Y2U
M^U/=EJAF=M_T:/N0%($;L[HTY,ASPJ17L9\7B-*9^Y[KOGO5X;R/@SW8[N_/
M?\'=EWL,2?*6SVI[LM.];B7Y2U^U/=EJN\^1T8?DC=WZ#UWUXX[V&)/E+9[4
M]V6G>MQ+\I:_:GNRT\^1T8?DC=WZ#UWUXX[V&)/E+9[4]V6G>MQ+\I:_:GNR
MT\^1T8?DC=WZ#UWUXX[V&)/E+9[4]V6G>MQ+\I:_:GNRT\^1T8?DC=WZ#UWU
MXX[V&)/E+9[4]V6G>MQ+\I:_:GNRT\^1T8?DC=WZ#UWUXX[V&)/E+9[4]V6G
M>MQ+\I:_:GNRT\^1T8?DC=WZ#UWUXX[V&)/E+9[4]V6G>MQ+\I:_:GNRU1-]
MN!T:)(RI61&[/%/0H$=&,4BO>'XR,^2<<\+'MW[L)\&6UX.>_.<YPO&<8[L9
MR[V&)/E+9[4]V6G>MQ+\I:_:GNRU6^?(Z,/R1N[]!Z[Z\<=[#$GREL]J>[+3
MO6XE^4M?M3W9:>?(Z,/R1N[]!Z[Z\<=[#$GREL]J>[+3O6XE^4M?M3W9:BSG
M;6="]F#%:[8JGMTZ .CI@@T%+Z[JQ 66%D([D6>.(P)5T=C3(4R,Z['DQI#3
MC+[+BVW$*2K.,]C6C7%+#K;S$BWLO,K2ZTZU,?0XVXA04AQM:8P4A:% *2I)
M!20"""*Y(T88H;6EQM^VH<0H+0M$M]*DJ2<TJ2H10000""#F#6+-5=I_V7^C
MY)B;J73&P*'./L1(IF>!UI6F)Y")!<>=B0Y$YV]/2\PV'GWGFXB7DQL/.9>R
MUESN5B6NV$M(5^#(O-[;N8C:VX";<Y3Z6BO+7*$KCD)*M4 D#/(9<56T71#>
M(#2X]NB8:MK#CN[NL6QEFVLNOZH1N[S4&W1VW7@@! =<2IP(\$*"=E9G\^1T
M8?DC=WZ#UWUXY"][#$GREL]J>[+7?WK<2_*6OVI[LM//D=&'Y(W=^@]=]>..
M]AB3Y2V>U/=EIWK<2_*6OVI[LM44#MP.C2,PXVX(W9X2II*1CP:17LX\7+(R
MI37?G-WQ]UAIY&%X[N["_"QC.<8[\N]AB3Y2V>U/=EIWK<2_*6OVI[LM5OGR
M.C#\D;N_0>N^O''>PQ)\I;/:GNRT[UN)?E+7[4]V6GGR.C#\D;N_0>N^O''>
MPQ)\I;/:GNRT[UN)?E+7[4]V6GGR.C#\D;N_0>N^O''>PQ)\I;/:GNRT[UN)
M?E+7[4]V6GGR.C#\D;N_0>N^O''>PQ)\I;/:GNRT[UN)?E+7[4]V6GGR.C#\
MD;N_0>N^O''>PQ)\I;/:GNRT[UN)?E+7[4]V6J(EVX'1I+'S8K0G=F')$20R
MWE=(KV$^&XTI"?"SB[JSA/?G'?G&,]V/YL\=[#$GREL]J>[+3O6XE^4M?M3W
M9:K?/D=&'Y(W=^@]=]>..]AB3Y2V>U/=EIWK<2_*6OVI[LM//D=&'Y(W=^@]
M=]>..]AB3Y2V>U/=EIWK<2_*6OVI[LM//D=&'Y(W=^@]=]>..]AB3Y2V>U/=
MEIWK<2_*6OVI[LM//D=&'Y(W=^@]=]>..]AB3Y2V>U/=EIWK<2_*6OVI[LM1
M%@[<;I$4!-I"#MU1C2A!)(B0]1:TIF.4S#>P/>=2[<WVU-M2_%.+PXP\C*4Y
MPMIQ/>C/8SHPQ!NK6ZKMJFMT1NB1*>S+>L-<#*,#F4Y@9$'F(XZYM:+<1!QL
MNKMA;"T%P"4_F4!0UP,HP.93F!D0?*..M)>G/MY;L$BBQ/5#K6!=!WB8R9&P
M=8^25VT-H4A'A2"M+,3&JN;E.K7E;SX<Y2XS+:,(CAI#BOAR>\Z*XKJG'+'-
M5%7FK5ASM9Y@G,Y);DMI,AI( R"76I2B3FIU(K)+QHICN!3UCFJCJ(*A#G$N
M,[=N3<IM)>;2!L =:D*).9<2*^B'5NUZKNRITO9-*8M#%;L<>?('HM].M%&,
MY1B.C"U+"VP4)(.QO"SE,<I#9E!B2$YD"24^)E$A6G+C;Y%LENPI)8+S*M59
MC26)37DR=CN.("LMI;44NHXG$(5FFM.3X+]NE.PY!8+S*M59CR&)+>?D=8<<
M0#SH44N(XG$)5F*R]RRJSIQ2G%*<4IQ2G%*B1_X<=^DH_P"QA7%*EN*4XI3B
ME.*4XI3BE10+\1AOHH=^J,\4J5XI3BE.*4XI3BE19C\$9^E ?[:'\4J4XI6
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MO%F($)4ONBM6JE2M5,2WE1U03DD;T&9.60&8S/+4@C2[C5:T(WY"3KJ2G65
MCZJ=8@9G)!.0SS.0.RM?1.X>CX8:%!J)KW:3M9 2&ZV&NH3>VP*O3X +8UL+
MTN*FI.%M]@IDZ)>]ATJ\UEVOU\>N86+4(IB="<G$*C#L4:YBB>\IPN.M/;JX
MRMUQRVV=0<6@K;CN**XF;JT*#B&B05(U5A.04G7JYI#Q8Z'5/FSK6Z4N/)<L
M\-U;CC"-9"G?^'5K+9:6DH6L^ ES)) "R,;T';70WO*W:<HRNG+;;\S;3TB3
M5)5BV5;38>(Y/!/E9!>))'[Z-(+CEB:LJ+8"]8;*Y#RP#X@ZW&DUZ<R/YQ\9
M78+0EF4II3X !1 M2,TIUUI!+<7PDI*G#LU@A16#JJ*J[SI*QG%2\XW)M3>H
M$A>YVR,VI02HZJ3DRG^2IQ10E6SPRI/\O;OK[QOI,^)F%^GFV/7_ )(\*L0]
M)*]DM_9*M>^_C7QN'[!&^Y6KW49=:H.Z@-W#W-,:X)N0=L["AK(SRVWT3IZX
MUK*LJF3$#=J#QZ94G*,O/I@P(41+JU8C18[.$-(];X&M5P>P7A)U&)[Y'2YA
MNR.)89CX:+3*5VZ,H--%_#S[Y;;!U4%YYUTI W1Q:LU'\\FG#%5C9TRZ5V9&
MCC!MP?:TBXR;>G2Y^D)N5,=1B"X)<E2$0<=PH2'GU NNIB0XL9*U*#$=EL);
M3#:EN2"=K?C4K7^LZ*?9K-M+LEH]LZC \F9$KE>(60B&C3JYM>3+1)(P1#Z(
M[<M44:X\VA,R8QCP,YO,16PL6]#ETO-^NT-4^W1EQUV_!,E#3DZ:S!8DK:FX
M=0V4,/24%9;#CZ4DEMI>W*&T>XB3/Q Y'PSA'!.%KLW9+_<&K@SB#3';GY$>
MS6B7>9EN8DV?'SLA+TR+;W4M(?+$-;B$B1(:&J3ELW229!JI^V:H:4+1456:
MP-8(7O?4F76G =:KMJ]I ^#9=R"F\L0!UQ O39H-]VIA&7R<R42;C#\N2<<B
M72.TJX[PN6*8[AN#2WULVG""&YR94^;;NZKSL'#$A06\_;)B6FI:$W&6M$=I
MMA2WLF]AW/"\V8C#XOF']&EP838934)J7BK2L_(LSEKLMFOW!B'%O>D> G<H
ML+$5J=DR;8ZNP6QIR;(?F(9B:[^J_NA5'XB]6^F-V?;!S8'<:X];,0>S85_]
MLUH3A?A[_P!+,"^\M)O_ .T2NY79%GA1VG[J<%TJM4Q$>R5!#S%;EW&6U/4X
M+-*0[*S<+9:GD.,X2I#>(+T-K*7%9>;=7A"D>4?TC8<B)<L+B1=)]T*X-R*5
M3F[8VID)?B@I;[FVZW)*5Y@JW5+J@4C54D$@_47_ &?%U@77#>DE<##-DPVE
MF]V!+C5ED8CD(E*7 N!2X^<17^_.)6V 4H$5R,@A2BXAQ6JI/32JVRE%KY?:
MZ%#-C;6&P*>LQ!4 /$E'&UYF1(4A]R'*=-.MP\QG68CEAAC_ "F*\S,">7BW
MTR\^;LM@//GE]'^O)7T.!&9&6WEV?GZ_G&RM1M[];/11H?:%AH.]SHT??6F0
MQ=R/*U?9K:[@02"#\C5^RXJK%XBDJPR]W1L3,N,=V?#;1X6._*;/AG$MUAB7
M:FEKBEU;>:9S,<;HC5UQN;C[:N4>%JY'D)RK+;/A?$UVAB7:F5KB%UQL*3.8
MCC=$9:XW-Q]M6S,>%JY'D)K$'G0.S"_.L+]1-X]0N2G ?&_B[GO2+VJI3@)C
MCQ9SWK%[73SH'9A?G6%^HF\>H7' ?&_B[GO2+VJG 3''BSGO6+VNGG0.S"_.
ML+]1-X]0N. ^-_%W/>D7M5. F./%G/>L7M=/.@=F%^=87ZB;QZA<<!\;^+N>
M](O:J<!,<>+.>]8O:Z>= [,+\ZPOU$WCU"XX#XW\7<]Z1>U4X"8X\6<]ZQ>U
MUYO=I]V8BV74IM07*E-K2G'N$W?'>I2<XQ\.:%W8^'/W\\<!\;^+N>](O:J<
M!,<^+N>]8O:Z\87:>=F,S"B-.VH+AUJ+';<Q[A5W5W.(:0E>/"Q0\X5]UC/P
MXSG&?OXSGC@/C?Q=SWI%[53@)CGQ=SWK%[755YT#LPOSK"_43>/4+C@/C?Q=
MSWI%[53@)CCQ9SWK%[73SH'9A?G6%^HF\>H7' ?&_B[GO2+VJG 3''BSGO6+
MVNGG0.S"_.L+]1-X]0N. ^-_%W/>D7M5. F./%G/>L7M=/.@=F%^=87ZB;QZ
MA<<!\;^+N>](O:J<!,<>+.>]8O:Z>= [,+\ZPOU$WCU"XX#XW\7<]Z1>U4X"
M8X\6<]ZQ>UU03>TZ[,=YP>IJU!<I8GI>>_Q%W=/<UB+*;SGNS0\>%_*.-X\'
M'?GX>_N[L9SAP'QOXNY[TB]KIP%QSXNY[UB]KJO\Z!V87YUA?J)O'J%QP'QO
MXNY[TB]JIP$QQXLY[UB]KIYT#LPOSK"_43>/4+C@/C?Q=SWI%[53@)CCQ9SW
MK%[73SH'9A?G6%^HF\>H7' ?&_B[GO2+VJG 3''BSGO6+VNGG0.S"_.L+]1-
MX]0N. ^-_%W/>D7M5. F./%G/>L7M=/.@=F%^=87ZB;QZA<<!\;^+N>](O:J
M<!,<>+.>]8O:Z>= [,+\ZPOU$WCU"XX#XW\7<]Z1>U4X"8X\6<]ZQ>UU0M]I
MUV8Z24N0JU!?$.P1[+>?<+N^>]UA\FM['@>T/O3W(D,?=9QC"N_NQG.49QAP
M'QOXNY[TB]JIP$QSXNY[UB]KJN\Z!V87YUA?J)O'J%QP'QOXNY[TB]JIP$QQ
MXLY[UB]KIYT#LPOSK"_43>/4+C@/C?Q=SWI%[53@)CCQ9SWK%[73SH'9A?G6
M%^HF\>H7' ?&_B[GO2+VJG 3''BSGO6+VNJ KVI79EP!9*=#.B"<N' F2XHU
MK2%PBN$9,>.X\Q!;DRJ*B-'7+=0F.A^2M##*G,./*2VE6<<V\"XU6XA"FEH2
MI:4J6;G'4$!2@"LI3**B$@YD)!)RR )KDC >-U+2E3+B$E20I9ND900DD J*
M4RBHA(S.202<LAMKF.([2;<4*^L; /4[5!+7*BCA8EJ&+KNF18,>IOI6I043
M=$UY-L4>&CU)>AGB$Q^"0-,9?E@8XJ5[$Q/2%PT"V-C"SZV+O=TWR/;E2.Z+
MDMPQ7)#+9?<SA Y)9<"2V$APK0DA045C.OGUAG],"ZXBTOVS )PI#C85OF+8
MN#[=<D3[NK%D:1<+DS9H%UGN+NB[$\T9SJ94VVQK4RMJ$XJ+'N#TB.)DGZ??
M<\H'YC4_]&0O]RYXVWW+\9D>N<^]7LO?<OQF1ZYS[U1@C7M!S%=SFCU#.?9,
MWCOS6@N?@P9GXQCX87WL8QC&,?S8QC&/@QQON7XS(]<Y]ZF^Y?C4CUSGWJD_
M<\H'YC4_]&0O]RXWW+\9D>N<^]3?<OQF1ZYS[U/<\H'YC4_]&0O]RXWW+\9D
M>N<^]3?<OQF1ZYS[U/<\H'YC4_\ 1D+_ '+C?<OQF1ZYS[U-]R_&9'KG/O4]
MSR@?F-3_ -&0O]RXWW+\9D>N<^]3?<OQF1ZYS[U/<\H'YC4_]&0O]RXWW+\9
MD>N<^]3?<OQF1ZYS[U1AK7M!P'*9Q1ZAC.!\O.,XK07&<9\0OX<9Q"[\9XWW
M+\:D>N<^]3?<OQJ1ZYS[U2?N>4#\QJ?^C(7^Y<;[E^,R/7.?>ION7XS(]<Y]
MZGN>4#\QJ?\ HR%_N7&^Y?C,CUSGWJ;[E^,R/7.?>I[GE _,:G_HR%_N7&^Y
M?C,CUSGWJ;[E^,R/7.?>I[GE _,:G_HR%_N7&^Y?C,CUSGWJ;[E^,R/7.?>J
M--:IUV;#E@S],JT=DN-G#'I$6M@T26&I\5V*X]'6L>M"'VD.Y6RI2%I2XE.5
M)5C&<9YM3Y;3C;HDODMK0X IYTI)0H* 4 L$@D9'(C9RUS;G2VW$."2^2VM*
MP%/.E)*5!0! 6"02,CM&RM7^G/LY^DGIBP-(4+6$ [<QB&?$['V(MNZW=$EE
M.$)FC9I&.D35I2T)PEW-,#5MEW&,^,95E2\JG;SC'$%\+B9<Y3,9PG.%#!C1
M=4\:%I0HNOI!)($IU\CD/%4W>,7W^]ZZ)<Y;<96?_!Q,XT4)/_0I"#KO)')O
MAQXCD-;G2_QF)_V_]73S%ZQFI3BE.*4XI3BE.*4XI42/_#COTE'_ &,*XI4M
MQ2G%*<4IQ2G%*<4J*!?B,-]%#OU1GBE2O%*<4IQ2G%*<4J+,?@C/TH#_ &T/
MXI4IQ2N.8PH2L?:&A#MWNU=N;U:V)?:3K#7QF4%B[EU0&S5+$P2*Q]65:V@7
M(^JSZ1;Y$5MRZU^\6<F&.5^:W'#UXXQ)&*Y?])V?.?IXMHSSXM@.7+\^Y5VC
M.W[;L@?=.DF5LL3K6WUV/K_:<A>NXT"!!+ Z-:RQ!MB[VL(=+1@5M;;E2T5\
M07#N$ZH'<CID6H!EN JGT\GE\HRV?QRXZMSJPL74.UH'J&C,:FU'(JKFI=JQ
M9)M&]K6FPQZTY4#K,HTW5WM L#9!>,)4Y/17_;@Q&?G-X&XL#;2_9+&3V%FT
M&ZVE2I]P2^)\%0;[EQRR7A(:*6R^+L5I;4YD@N[V*@DE>XDC4.3V!FSF[6A2
MKA<$R!<("@UW*C[BIX2&BEO=Q=BL-J<R07M[E02=?<2? J([0[=&=!=*DS8C
M5;;MV(=AHXM(B04<!I=24E>3XD*F,PB:FU,XQA?B<,.87G.4^,3W>%SLPC;.
MZ]]1#+QCZ[,E9<2@.Y;FG6RU2I&8/%GF,N/+DJVP_AQC%5U%HDR'8K;C;[Y=
M82E:PI@:X2 O))"CL)(SRY*^>S/:IOYQG&="CLXSC.,XSL:=G&<9^#.,XS4.
M[.,X^_CFVN *>EE^QI[16P.\;9^F[CZB/7CK78VM-FAM9) ]%W3\%&5^] M3
M:7'';C'#X7;RI\-86JU38D374IN/&!&RP*X3ED/(! TO*%E(+SUD<A-JAYN$
M+= 44.SGW#%ANSG=PMC;@C1&M=6Z.9RDY!:VEAM* M96VI9"4I*Q93M%EE@+
M?2[?;XX40W9\Q3,:.X&8K:'$[J\5+3_S TXVA*-=:M1>L VE2AZ;/ZL*[J2]
M"J?;.DC7*;)KT'K]NLR(-RDJ57@,$3$M5"B"L3:% +@/86 =0['#3H HF$>E
M3!\T?$=5)CYN8&"H=QC-2X]S7N14MM&O :"DF,ZME02I,E:%)2XA6HMI:VU#
MPD**3G7; T062XQ1*CWZZ[D\M]*@MB*"5H<4R]F4*6VX"MLY+;6MM8"5H6H$
M&OWYU21\0P_ZQYWJCR_X IZ67[&GM%7'>-L_3=Q]1'KJ?LGHRT-=-AWBX&6]
MD(+VJVV&QE$#[D#CP$D31641FIAQWZ/+>8BXD27,,-.RI#C;7@H6\XK&5YB;
M7I[QK8[9;[-$B8>7%M,*-;8RWX,Y;RF(3*([2GE(N;:%.%MM)6I+:$E69"4C
M8/FQB[]!C0YB[%6),576Z8\1<\27VZWRX(AWJSLQ$3+K.?FR4Q6G<.ON-1TO
M/K#+;C[RT-A*5NN*!6<86GI[Z>>G&G7;=6"N^0T+7].LE@-2J?;PLVR/ 8(N
M0^7@"($6@HD$)A"$V[#:'M+2J<I[$7.?!=5C/.=I_P 7W..8MPM&$YD<N-NE
MF1;)[C>Z-*"VEZJKMEK-K 6@\:5 *&1 -6UC_06T3X:GBYV#%&E"TW ,/Q1+
MA8CLC+XCRFRS)9UQA?/<WVE*:=3Q+;4I"LTJ4#@&H&^B?J.V#2=65Z[;^OQ!
M=+]EZC/*;$I;(.'3(@Y3L)X/'/ (9\C%=ACHT/#%= %I(IED:T>;$0&HSC5(
M>GW%MO5)7!LN$(BYCRI,I4>TS6E2'UJ4M3CI3=05*4M;BSG_ .8XXO+7<65=
MEX_08T67YJW-7O%VE6ZM6B&W;[8W.Q3:9*($-E#3+<:,ES#2DM(0RPPR G;N
M,=ADG<V&D(V8]X9TZ?\ EVI^G%>^S_E[_O'X]\2PS[ON'Q:H/_P]]!O2VD7W
M]9/_ &Q6_G1]JC6/3E2=ID:KFWH#//#SM@6:F(M4Y#(,827E8Z& K8V8YX$9
MQ]2XS,.=(?7A'BL)SC*5:[QOI!OF/W[?(O3-N9<MK3[,<6YA]A*DR%MK670_
M*E%2@IM.J4E  SS!SS&_]#.@?!>@J#?8&#96()3&()4.9.-_G0IKB'8++[+(
MC*AVVW!M!0^LN)6ETJ4$E*D@$';&J62AF;/945Q&<V!R/ =,D7!A"-@I%@N2
M8K34(I,CHCD8P2<_-BS(8]]QD05FRTR&6)DY]3V"_GC_ #E6Z003LX\OJX_X
MBM0=[;"[.NM[/L SJ98Z='-G)9#/NJV;K^MV2S^P3P0?D1A9(I6BLK,#&$R?
M)&,R\MM=[G@-H\+/?E-HAXO?AA=E-XWENJTC>4MYEC=1ENF2$/MIU]J=8ZN9
MV9DUEEGAXQ?AARR&\B#NK@&\9;[+&ZC+=/ ;?;3K_P G6.KF=F9-8A]V'L:?
MZ)T9?5!2?4CDIW-TC<^(_>,GM52G<W21SXE]XRNU4]V'L:?Z)T9?5!2?4CCN
M;I&Y\1^\9/:J=S=)'/B7WC*[53W8>QI_HG1E]4%)]2..YND;GQ'[QD]JIW-T
MD<^)?>,KM5/=A[&G^B=&7U04GU(X[FZ1N?$?O&3VJG<W21SXE]XRNU4]V'L:
M?Z)T9?5!2?4CCN;I&Y\1^\9/:J=S=)'/B7WC*[57F]N'L:\M.X1$Z,_#RVO"
M/!U!2L*\+P<^#W9Q2/@SW]W=G_3QW-TC<^(_>,GM5.YNDCGQ+[QE=JKQ@[@[
M&U,*'A^)T:^.Q%CX>\9J&E9<\;AI&'/#SFD9SE?A]_A9SG.<Y[\YSG/'<W2-
MSXC]XR>U4[FZ2.?$OO&5VJJKW8>QI_HG1E]4%)]2..YND;GQ'[QD]JIW-TD<
M^)?>,KM5/=A[&G^B=&7U04GU(X[FZ1N?$?O&3VJG<W21SXE]XRNU4]V'L:?Z
M)T9?5!2?4CCN;I&Y\1^\9/:J=S=)'/B7WC*[53W8>QI_HG1E]4%)]2..YND;
MGQ'[QD]JIW-TD<^)?>,KM5/=A[&G^B=&7U04GU(X[FZ1N?$?O&3VJG<W21SX
ME]XRNU503=P=CAEP=EB)T;>"F>E4CQ>H:7C'B/)9>,^,[J3CPF_&Y:[TY[\>
M'X&>[OQC.'<W2-SXC]XR>U4[FZ2.?$OO&5VJJ_W8>QI_HG1E]4%)]2..YND;
MGQ'[QD]JIW-TD<^)?>,KM5/=A[&G^B=&7U04GU(X[FZ1N?$?O&3VJG<W21SX
ME]XRNU4]V'L:?Z)T9?5!2?4CCN;I&Y\1^\9/:J=S=)'/B7WC*[53W8>QI_HG
M1E]4%)]2..YND;GQ'[QD]JIW-TD<^)?>,KM5/=A[&G^B=&7U04GU(X[FZ1N?
M$?O&3VJG<W21SXE]XRNU4]V'L:?Z)T9?5!2?4CCN;I&Y\1^\9/:J=S=)'/B7
MWC*[55"WM_L<,$I:E1.C;R;,$>EGOU%2LM>/3()YD> GVD]V'/%JB^,5C&,J
M3XK&<YPG&,.YND;GQ'[QD]JIW-TD<^)?>,KM55WNP]C3_1.C+ZH*3ZD<=S=(
MW/B/WC)[53N;I(Y\2^\97:J>[#V-/]$Z,OJ@I/J1QW-TC<^(_>,GM5.YNDCG
MQ+[QE=JKFU=NMCI[SL6?(U3T+](=ATR/,IB#)%@T[4HUTNP0?+\01-C2L& D
M'6$'4MR':S&G@#SD:'Y!.,Y1(F2A O?%BT*8BN6&V+C.QO>H=XEQ52&8;<N2
MY$94XC6C-2'52 ZI0.0?+>0224H)U=8^0,>?ICVS1]I'F:/;I$QK.:LD]NU8
MFQ-%Q,Y&3:;AGE/1!PZ[ ??O3-K*D(>=5>K2J8\B4W$:++4:5,[GZ]Z=^C79
ME H^QJ_TMZ$; ; I]:NP1HEH_64<@V'M86$=&MD([("2RQ-1"GLIE,M2)#;;
M^'$(>=2G"U>:YMUQ);YLN"_?+KN\*4_$>+=TFJ1NT9U;+A0K=4E2==!U59 D
M9'(<5>G7K[B%AYUE5^NRE,NN-*4BYS]11;64%2=9U*M4D9IUDI5D1FD',#'0
M#LRND6M[)A[)&T0AAP8?59A-&DG),G6HHKAU4J'B#3G&_)$"Q,Y6)X4 Z\\!
M$OL0VH(UB% @Q(V2R=*^.I=C.'G[VZN J.F*XO<T":XPDC]6Y- W=>LD:BU%
M6NM&84HYDG7$? >!HF*W\=Q<'V&/C.2MYY[$K49X7!4J2UN,J<AHR#;V+E*;
M*Q)N4>$U/?<>DR')*I,J2\[O]S7-9546'_!'OI0Y^VB'%*E.*4XI3BE.*4XI
M46;_ !,5^CY?_(<XI4IQ2G%*<4IQ2G%*<4J+E_C,3_M_ZNGBE2G%*<4IQ2G%
M*<4IQ2HD?^''?I*/^QA7%*EN*4XI3BE.*4XI3BE10+\1AOHH=^J,\4J5XI3B
ME.*4XI3BE19C\$9^E ?[:'\4J4XI7)NNU&^M]9,6UIU<:&T5&X[@[(VT5IT6
M'M^Q+,1=H@AU2D;"C6TC)LNCQA2L%YT6D$J77T5;7#FD[!"-FG"[C E53EEY
M?GV>;Z>?8<]@V5D??74Y5P/53IS4D#:>QJP? 6H:[9*'7273^)J6Q$':Z_W5
M\_(V=81%S8;%0[96+'+DCTQ!)F'GV$UV^>VQ";&"5 -A/D\VWCXN4C+G^BMI
M.JC_ #8>H[_4-M__ *>V+DI8_P">K/\ UI;_ /%LU*6+^?+-_6MN_P 6S6E7
M:V.U1GH=)KN<&PD0>+?K?#L:L%1H8JJ1F?\ X.MN<5#'8:64+^%YM0]:W$_<
MH=:S]US)< !\XG;$93*'=[S,B^A;C>6IX0*6W&E9Y<1"L@>,&LGT>B0<4-B*
MIE#N]IN2GVUN-ZNIX6:6W&E$GD.N .4&ODW]D.G3\T=U?6)1OLNYOS4O/R]L
M]DE=MKT!J7KQBU^QR^W5M'ILG)" FI6NJ-N('4X).'MD3:;Y;M ":D)-U"P!
M:^Q;:E>]N:CC@0QEJQR0-;F*K!R)/-RU#P)%DBVRW#;@KDA+KI3-DVUV0I"K
M>Y'BLW=R0XT^RZ^8\B);YZG76RREUY(?:4AM.NZDHS*C W- ==*9LJV.R%(5
M;W&(D>\.2'&I#+KRH\F+;K@77&BREY](D-*0TD+=04$E1LK=U<K-:)5@KN2C
M[G23.58(/ $$;;TR:<E *B&%UX0/GRJGKX@VR3! XX8<]".K:L,:$@>D@UA*
MF%*N;6^^^A]NVR;9J-/NK=1O"Y-!+TAQQYQ:$R)2"4.NEQ84T"TI17J'CJZM
M3TA]M]NV2K9N;4AU;J#;[FT$O2'''G%H3(EH)0ZZ7%A36;)45ZASSK"/LATZ
M?FCNKZQ*-]EW)34O/R]L]DE=MJ4U+UXQ:_8Y?;J^A#:'7O3Z9LF_5!_4MD)/
M5:XV2O.D&K^+B-3G Q>6.7+;BKI$E49$A4?+R6%27U-87A&7G,I\/./V3]':
M1?;-:KT,6,QA=[="N0CFRK=+ G1VY.XET71L.%O=-37U$:V6MJISR'PWQ_\
MI_0,$8ZQC@US1=,N3F%<3WW#J[@C%S,5$Y=GN<FWJEHC*P[(5'3(,<NI9+[Q
M:"P@NN$:QL9WK$I.[A-FUO(Z>K#9A)VJ65=B"2=N@@K<ZL#@\LC8D8G/5,2[
MA;8F-+=2Q FH)R,H\4/;=E*;;5WS_P!')%L91(FXW:99<DQ8B5IPY+?_ .(F
M/HC1D*3'N3JT)<?<0@NK2EIO6UG5H0"H15B_V@KF)9CT"RZ&)<N8Q;[E=7&E
MZ0+7#R@VB$]<)[J')V'XS3KC$..\ZF,TM<J04;E&9>>4EM4'0&-8:RN;&Q]?
M='=WI1RS0K3;)<RK=0A3-:*9M<J=>2T&UTJN0)]6=-S"=^=- J=:*UDL G66
M#* A@Z,Q'8\,="5F!?2-(<4KCRDQ7&UX=E1U*6I]Z.IYDRKDPB1"0Y&DA<]A
M;D,;V> ?4I&J<R3^F5B]28;BM =R#$ZV+NC+[6/[9.;;91$B3D1):;;AZ:]
MO#\>XVY3%DFM,7=8N$12H26W=<3?G'*7\3-H^L<3Z@\R;_=AD]<V/<3GQ:M:
M?^)+;?\ TBG?]ZQ__:]=%^B_J"I._M:[JGDJL5I57KF(,*R^76IXF]*%D@Y9
MV:['G !%=)0<MQ([S7@PLNS75.IQ%<0[X*%:DTE:-W=',JTQG+NB[&Z,27TK
M1!5"W'>SC3>J4JE2MTU]U!!!1JZN61SS'JO]'7](6-^D#;,3W%C"KV%DX;G6
MZ"MIZ\HNYF&X1Y+X<"T6VVA@-"/JZI2Z5E>>LC5R5N]2 6NA)@]BG84HO'A
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M;^,*]UQ>S4\U9V:?YK1_KMN/KAQP\QGXR?=L;LU.'N-_&%>ZXO9J>:L[-/\
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MA4_97"VZC7"D)7W964-@*3JQP0AI>Z*0D;JH#7+W+*-\I+2WH+J)^P/DUO\
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MGV=72YU&!U&]*]H)MR_,,LMOSQPNP#H]E"H=SC#>+#4B:8-HKRUY5C"&S0B
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MSAZ[[<G,2+F/OG0"6,QF,L)4'I7A)9RTG+6%=^F59\+"/!QGO5G/?]_.?O\
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M3XG#R>[.%8\)2?N>_NSAOS1?T5=_62/B5-^Z+.B;QZR3\3JM]SKMS_CZZ?\
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MXPA..:264J6M2$ZB5*44H!*@A))(3K*\)6J,AF=IRS.VM*+*5+44IU$E2BE
M)4$)))"=96TZHR&9VG+,[:N#G&N-.*4XI3BE.*5%F_Q,5^CY?_(<XI4IQ2G%
M*<4IQ2G%*<4J+E_C,3_M_P"KIXI4IQ2G%*<4IQ2G%*<4J)'_ (<=^DH_[&%<
M4J6XI3BE.*4XI3BE.*5% OQ&&^BAWZHSQ2I7BE.*4XI3BE.*5%F/P1GZ4!_M
MH?Q2I3BE8NW3[86=6W@G5B%YAG0%;-6,=#UNQ79%SLD@",EE&JB#39J=>X*)
MMH=C("L/1*W,,-/2VUB%LSL,KXI6)>DHA=+!1BUEMY_8$SRXSD<*KMY5:96
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M23GGGMSXZ^!>G63<TZ:M+:6GYP;3I)QJ$!MV0$!(Q%<0 D)5JA( R &P<0J
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M1^!3WY?:M_-]!O213UJXX.8#ZW.>@C\"G!O /7!SU2/P*T>[0GJ:Z^KQT[R
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MGV:?YTQ_J2N/J?QP#QGXL?>4;M-. 6-_%U>](O::>=3[-/\ .F/]25Q]3^.
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M;36(?=Z[&_\ \G2)]3%:]0N2G<K2+^T/O%_M52G<G21SXB]YO]KI[O78W_\
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MB+WF_P!KI[O78W_^3I$^IBM>H7'<K2+^T/O%_M5.Y.DCGQ%[S?[73W>NQO\
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MXIUQ9YUK65*4?*234YSJKJJ+9_'1#Z+#_K9SBE2G%*<4IQ2G%*<4IQ2HL/\
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M]AIYM/LLOS.J7_N V%]IG'#7'/C+_NF'V*G#;'GC,CW1#[#3S:?99?F=4O\
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M\22(F5^+:TQ5M"((3 =J*DY;T@X1;Q#Q93HI4]D% U;BUZ\:2[W>,6VJU_\
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M2 AA86ZWHEBTVYRKU>FF'XL8CKJ9&058!UL,VP-&,JF IDPE*A.QO9-#3$/
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M\"=3CZ;7XE>4/HH[41R)%6SVAK332XS"VF_8\W_)MJ:3E"/@%Y_R$YPG[_\
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M<@7"PIS0PLP9LDV?8]IW1P@8\L5RU\N<[!]6?'MY0>/GVY5VW]KT_P#I /\
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MM=7[S7D-T@NN$',%Q9!'$1K';6M?4)IS:-_#T"-2D[)"3!6UM?D+(Y4+9;J
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M;!R7F2!H,JTV'Q(E(43PN+8PW@^28<RIV=';2G/CF<N,CS?/Y/GYOIIF.?\
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MSWIJK9;\*A$^G>NURN66KXN)0X2)U6L2 !^3-Z:2XTY:R?M5+AP>N;6Q<!,
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M&W/PI>,SL98C3UC(+,<F>?/\PRR^8GC\F6RJ%).7%D,\O/R[.;\[:_C.ESC
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%4XI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g332508g26a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g26a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2184&AO=&]S:&]P(#,N,  X0DE-! 0
M    )#R^DG8X0DE-! 0      $H< 5H  QLE1QP!6@ #&R5'' (   (8 !P"
M4  (<G(R.3,W-#@< @4 (4UI8W)O<V]F="!7;W)D("T@04-,6"!.;W8@,3<N
M9&]C>#A"24T$)0      $#!\G[*1_+!;,KY,L(0V*,\X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O
M;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T
M=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E
M='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#
M35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I
M;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.
M9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J
M8P    $       !21T)#     P    !29" @9&]U8D!OX            $=R
M;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT
M1B-2;'0               !";&0@56YT1B-2;'0               !2<VQT
M56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N
M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ .__C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"
M24T#\@      "@  ________   X0DE-! T       0   !X.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             #.P   ?L          0
M   !              '[   #.P                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   #.P    !29VAT;&]N9P   ?L    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   SL     4F=H=&QO;F<   '[     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    %.$))300,     !F^     0   &(   "@
M   !*   N0   !FB !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"
M$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-2
M1T(               $  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M*%5U5<)6#U8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M              #_X4 !:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \
M/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P
M,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3$Q+3$W5#$T
M.C Q.C0P*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TQ
M,BTR,U0Q,CHR-#HU,BTP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C$M,3(M,C-4,3(Z,C0Z-3(M,#<Z,# \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N
M,38@*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(R.3,W-#@\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R
M96%T;W(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!
M;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(^36EC<F]S;V9T(%=O<F0@+2!!0TQ8($YO=B Q-RYD;V-X/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*
M(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C4V-4)",3 P,C8V-$5#
M,3$X0C@R0S-#.3$R,C1"-SA"/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C$W140T-$,Y-T4T-T5#,3$X
M,T,R0T1#-T%%0D$V,T8P/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,3=%1#0T0SDW130W
M14,Q,3@S0S)#1$,W045"038S1C \+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C$W140T-$,Y-T4T-T5#,3$X,T,R0T1#-T%%0D$V
M,T8P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(Q+3$Q+3$W5#$T.C T.C0U*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-T0R1#4P1#1&1C8S14,Q,3A".#)#,T,Y,3(R-$(W.$(\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,3(M
M,C-4,3(Z,C0Z-3(M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C4V-4)",3 P,C8V-$5#,3$X0C@R0S-#.3$R,C1"
M-SA"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(Q+3$R+3(S5#$R.C(T.C4R+3 W.C P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C=$,D0U
M,$0T1D8V,T5#,3$X0C@R0S-#.3$R,C1"-SA"/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C$W140T
M-$,Y-T4T-T5#,3$X,T,R0T1#-T%%0D$V,T8P/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z,3=%1#0T0SDW130W14,Q,3@S0S)#1$,W045"038S1C \+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @
M(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO
M9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!"0"B P$1  (1 0,1 ?_$ !X
M 0 !!0$! 0$            (!08'"0H$ P$"_\0 2Q   00#  $! P@%"00&
M"P  ! (#!08  0<($1(3% D*%2$T=7>U%C$W.+87&"-15Y67U-<90521(E9A
MEJ'5)2<R6'&!A)BEL?#_Q  < 0$  04! 0              !P,$!08( 0+_
MQ !,$0 " @$" @8$" H'!@<      0(#! 41!A('$R$Q-744(D&T%391596Q
ML]46(U)45F%TE-+3"!<8<9&6U#(T1%.3HV.!H<'$T?#_V@ , P$  A$#$0 _
M ._C & , 8 P!@# *9%%.F#O.O>S[2#I(9/LZWK7NQ) H5KUUO>_^E[ME'M;
M^KVE>N_37KZ: J> , 8 P!@# & , ^;NW=-.;8TA3VD*]TEU2DM[<]-^QIQ2
M4J4E&U>GM*2E2M)]=Z3O?IK9;;]O=[=N_8\>^SVVWV>V_=O[-]NW;Y2.IUR[
MP#<J]35UKD[A=B@;3/CF)MEP2P,Q5C:N$0.\WNH[6MTI=I&6RI&](0D5[2_7
M:T9DHT:?*BV_K<Q*JRFMKJ:&Y.Z-THM?CUMLJ9;]_>C7YYNN0S,?#>+I7/D4
M95\9^EY?+&.)/$A*+7H>^\_2XN+7=R2W7:B0,:J14 'N6;#9D]C,;/;CWGB
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M2-+TR\X.]L8X%Y\5_33[3K#FVG5Z0\VXVKT6A2= >> ^QD_>TW^<'X!7, 8
MP!@# & , 8 P##\_^W3F/X;]?_/N0Y>U^'Y?[7@?9:@8C(\<TOR[6/M]',P9
M9&7& , P1TCR7XOR2PHJU_M9L+..1PTJV&/3KQ/(4 6X0RP_LVNUN6 2I;@K
MZ=L**T0C2-*<:0E;>U@9'H=\JW2ZQ'W*F2#LK7)51:0#WXR6AW']@F$ %>U'
M3@$;)L>[+%?:UL@-K3ND:=9VXRMMQ0%<G&RG8:5:"!&DS'(XQ L:85H$0\A0
M[FF0R3%!R"1&"7-I9=(4 8EE"]N;%?TG;:@-;$EXI==DM]&<]U75C]3BNFU9
MIJ:LBC)^BCW^6YE)(N,G+A5]@:S38A-1G"FQHUD!\0-FE03,@\Q'$GB ?6$\
M6>NUZU\>M^HVHRRN&@-5QR(W921W.P#[8ZX NUS)3T&\-$R@RK_'6,<>2;DB
M%S)=N967ZKCI T"R0?!_KL9SVK<Y;-IYRZ/:HSHC-L<FI)E5O=CN25#G[G+9
M 1R&>+"K1Q\,<RY(DK/%8K<96D?1;Y*B@@ -@W$Z3.4N%MSEA8#CY&Y])NU^
MW!QQJI$& 'L\I\0+&-F[&$:?)4RTF2E5C#H&W,R,CH=9#6DE/ 9*@/L9/WM-
M_G!^ 5S & , 8 P!@# /S>]:]/7?Z_JU_P!N ?N>;KY5_B@8?G]?^O3F._\
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M_P -_%>3_A@C)AZ&?'=4\J?O>.9#AWXV:7Y;K/UZ<<E6='DP# & ="?S>/\
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M&=K9:6"-A23#8Z)".-%?"DHXM0H;S@9K.B0Q"4O#M@7; ?8R?O:;_.#\ KF
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M5VF_/]%AT4.OV^_1M,@X6Z.3<76:XBYV4H"O"1GQ\U)FN$&O@3'P!@# & ,
MH<!]C)^]IO\ .#\ KF , 8 P!@$+?$ZK>8M=L'9WO*6[UBVP<E9QG>6,0*8O
M:P(]!DXJ2)&3&5V <BJZ9&O5D>)@)IZ>G #8^7=,ER$DMD%[3Q)D\*WT:*N&
M\'.P[ZM/C#699EG.K\Y<J<ZEUDUMNK'*4%7"4904:XN,M]1X7QN,,>_7I<5:
MAIV=CW:I99H,,"ATRQM,:?)5DMP@YV+U5VN;WC*7/M)14TLU8VXY]/G"_P"[
M_P -_%>3_A@C)AZ&?'=4\J?O>.9#AWXV:7Y;K/UZ<<E6='DP# & ="?S>/\
M;KWW\+(;^+!LA?II\*T3S#)]VB1EQOXYH/E6O>]Z =9N<[FN$-?*HFR3J(>B
M?S/NF^2=/=0-9'Y:C]3Y-SL"'GQG9$%B-+U=.O\ ,[*26T$ZHO:PAS85QDYI
M"GW#!W&AP*_X95&W4CAH<!<>5!<2*1?NMR<!R\,BF'/U2DSO4;=-TD6;E*#+
M3U;F;076)",DK3-LSLS(R\^9(2,W*'3!)Q#@$IGWV!6'B27FAQAVG'R"'W$-
M,L,M)VMUYYU>TH;:;0E2W'%J2A"$[4K>DZWO ,; =GY7+-U9V'O5?FFKMJ57
M4W(4OZ81/,04LQ!31<>J,05IX&*F2AHR0/\ J#$,(99??0MQ&M@>=SN?(&_I
M72NBU7:X8M@$]EN49>)2429*1S#(HK.UD2.W#X.<"2J.:*1\5"S#&U:<BSDL
M ?O\N?'/>NM?RFTK?N87](EO)L$>H3Z&^B0)[XU!J7MANI^@I6+FO<M/K(^B
M)("3]S\$8.^X!>U:M-=N,6B:K$P#-Q:R30ME@O:=0T=&EO 2()"-Z2Z*='G,
M/AG!D-M$B$M.,/M-N(4G0']P'V,G[VF_S@_ *Y@# & , 8 P!@'/Y\X.&<*X
M%P]#:QT;3U637O9!(XJ/359?UZ:<)<:;VKZ_J1I7MJ^O:4[UK?I+_0Y-0US4
MY-2:^"]O4A.Q[O*H]E<9-+L[VDOUE72<VG XFTJ^ZO+L@\#6*^7#P<S4+N:7
MP>TW1A4WW*M<K4K.KY(MQ3:<DGR;?1!/_$1?]\17^<SHOKX?DW?N^1_*)+_"
M73_S77O\L<1_=8^B"?\ B(O^^(K_ #F.OA^3=^[Y'\H?A+I_YKKW^6.(_NL?
M1!/_ !$7_?$5_G,=?#\F[]WR/Y0_"73_ ,UU[_+'$?W6=!?S>T%T3N?>5.."
M.:=Y9$>S\,:(7O7LVL3>_;T,\[['_MZ]G:_9]K_I>SZ^RKTAGIFMC/3-%C%6
M)K/R6W.JVM=N/%+9SA%-]CW2>Z^0T'BC5,?4==T=459]74Z3K3D\[3-1T[FZ
MS,T395?"&+C=:X]6W/JN?DWCS\O-'?K!SGLQIKF^5#L'1*QXR/RW->C.<UFF
MK8.R_*HZ$1R%$E\15;:S70#.LZCR8R@Q4=>5U.US)UBDZQ7;%$ULVCR]C#&M
M.Q3@)*>+LQ?++Q^*MG1)2"DIVXV2_7$ >MW**Z%#UZHVJ]V.=I%0&N\&,+"V
M9RHU$Z&KQ<C#I(BM%QSPD=(RP0S$H8!GPQ+BQ"D-#CENK'>2V*6YMD0AQ3:M
M(8)=2.6IH=U6](><2*2I#:E*T.]O6FU 0E \>.E-5FM@-N5"K7:#M?1Y.-Z+
M5[U>-256@>A]9;Z=)QH4$Q7*_$7(8IK:((^O6K;,$2]$QTL]HEDA^(& M6%\
M1^A5VS\AN(4_2SY'@,:W6*3%D.S8 EW@%@]+AB)&YR;,6<] S:(R^ $BCQD9
M916Y6'EW/C4CVC:(4"SPO RW1=#J_-1+Q6R(:AW",ZC7K"^#*CRTM=(KFE;H
M35;FHEM1 X-+?+B9*5>+$FI U,>5$0K4.G<*J1/ G+R*A2E%BK4N=(CW9NZW
M^VW^4%B'2B(B)(LQK;C41'%&CA$G- @BB-D2+D?&;D9#9I_T<%HG3"0+\@/L
M9/WM-_G!^ 5S & , 8 P!@# .?3YPO\ N_\ #=?[OY5Y+_PK!&3#T,^.ZIY5
M_P#+QS(<._&S2_+=9^O3CDI]-?U:_P"6LZ/)@'IK^K7_ "U@#TU_5K_EK .A
M3YO'^W7OOX60W\6#9"_33X5HC]OPAD^[0_\ I$9<;^-Z%Y5KOO>@'6;G.YKA
MK)^41[;7**!1N6V_N7*N*B=5G(\2!W:_)2<\<;#<F8B%O4O>865N%=HMHL=:
MHJ8R,KS2+%5)6N3!EB/9@%V*#<*C1K$!G'P+<Y@KQCI+/'*[S6M<_ FNA1<2
M'R&PV6X\ZD#(OH=H G;'6KM;8*O3EX&L\\/)3Y-R)!?:LQ\@7+BRLP,4U)E
M3%P!@# & , H<!]C)^]IO\X/P"N8 P!@# & 6_!VVJV=Z8'K=E@; 17I)V&G
MV827CY5V$EV-)4_%2[8)#ZHV292I*G03-,E-Z5K:VM:WK*EE-U2K=M-M2M@K
M*G97.M65MM*=?/%<\&TTI1WB]NQE*NZFYS55M5KJFZ[579&;KL7?":BWR37M
MC+:2^0N#*95.?3YPO^[_ ,-_%>3_ (8(R8>AGQW5/*G[WCF0X=^-FE^6ZS]>
MG')5G1Y, P!@'0G\WC_;KWW\+(;^+!LA?II\*T3S#)]VB1EQOXYH/E6O>]Z
M=9N<[FN&MCY0OH\<+6:WSZD>2_#. ]E:ES[$U/\ 0+;Q*,O%4@R^;]+C*S8:
MM$]CBK/%,CR71552#L9R*T2>702KO'PA0TDZA]D#,?@99[U<?&*CV3HES_3Z
MQ24M?7&K*[:>/7.1?K[5^LS%7CYNQ<!#"X^?.PM=;C8>851VEQ;1X+[+S[T@
M@Q> 3$P!@# & , H<!]C)^]IO\X/P"N8 P!@# 'Z\ B;XU>''*_%F:Z=.<Z.
MMYI74Y0(Z7;L\L#(L10<6=/24;#Q"0(F*<=&%-LTT[N3G')FQ&((9:D9HM(K
M'L[+Q!Q7JO$E.DT:EZ-R:-A+!Q/1\>-$I5)07-<XM\\VJXKU5""V;C!.4F]6
MX;X/T;A6_6LC2HY2LU_49ZGG^DY5F1'TB?-NJ(S[*JUS2VBMWVI.348I2RS6
MC:2'?F1X5\S\V*A5*9TZ7M41%U"P$6./<JI@ 9+QI("X]:"EG1Y^ELH97M2$
MMZ:W[SUVM2]>FM;'PWQ/J'"^5?EZ=&B5N11Z//KX.<57SQL]5*4=GS1CN^WL
M6Q;SAF0RL;-T_4+]-R\:&15&^FG#R.:K)ZKK:YUYF/D5]KIK<91@I1<7M+9M
M/7A_L!O$C_KKV/\ OV _\@S<OZW^)_\ E:=^[R_F%W\)\5_I7F_1F@_=A8TG
M\A=XJ!=&J%.;MW65 V&IWF>))5.POQ;)-8DZ*&&TSO4%IG3+[=G,43I;:U[6
MP/[M;:=.:<N(=+/$TL:Z]UZ?S578]27H[Y6KH9,I-[V;[KJ5MM\KW]C5C;KO
M%T-1Q,-<4Y?5Y&)G7R?P7H7,I8EF#""6VF;;265+FW3EO&.S2YD[Y_V WB1_
MUU['_?L!_P"09;_UO\3_ /*T[]WE_,+[X3XK_2O-^C-!^["8_AM\F[Q?PEME
MMM_,+!>9>0N5?&KDFS:I",,%:#%D&Y)IT9 48$Z@C3[6D>TIU;>VUKTIO:O8
M4G6N)>-=6XIHQ<?488L:\2V=U3HJ<)<]D%"7,W*6\>5+9;=_:6LWJ>7ETYFJ
M:ODZG9C8^1C8T;<;3\:%,,JW&MO:]"Q,>4Y3EB4)=8Y**C+E2<F;#,T\KFM7
MY2N<L>N51],Y#TFET_ND^7+S5<II/5>;\EZ9T> KE0M;^@J-8.@%AM("K5S?
MJ-OM^FBHT:0IU?L4 3,@M3#B" )">&MZE.F\)B;]*354F-6RY=2FH=JF6RJW
MN$K=8.Z9;7JM2M7&CJ=J%BDJ97U1U:F9"N&RT1]*QA8P4]86!T3D@!)B3VE,
M<?M1;P"=!D[4<,EI9 2=-+]2V$/CEL+>&U_3-)>%):4M"=.,/(VIM0&JA^W]
MF*H48+#V7KTC*15>[RW091MBV;F;'UJ*[HR)RF/NCHX J9>+-YV6$0%&6)A%
M1D:V5*R;XRV(EHB- ^479>VNV3G3=JF^R"TB8:$3Y/DC)O8BZC>$_P K[@T=
M29.,:3,5J =L4=4(XUFA.CQ>Z\BFDONN!6<TZ3 M 2V^62*77C9D_KS76$R,
M:%TN*9A[ D".X>OCU,-E;/#0HH2Z\S?V+D44\U)0@KUN<M+MI@Q=.!PWT6"!
ML?\ 'HBQD5.S;FB[#(0S/2+V-0)"UN2Y$^;S]F:<1 /FFS^U3<B.ES1[$-)2
MSCQLA!-1A:B"6WFR' ,O0'V,G[VF_P X/P"N8 P!@# & , 8 P!@&'Y_]NG,
M?PWZ_P#GW(<O:_#\O]KP/LM0,1D>.:7Y=K'V^CF8,LC+C & :Y?+OY.Z#\L[
MP[=)'LEMH#4A4^7U.?K$;SSB=^@)P7D/4Y7KM0)>;ZMSFZ& [<L\JZ-9(Z-+
M%B;1!LLQ$T$4+MU+H$UN4TRP<^HD'4;/?9/IDO#MDL.7"8KE,J1T@,LTA^/%
M57^?P%8J4<Q$@NCQ0C<5"!I<%#:>)T\6X^^X!D3 & , 8 P"AP'V,G[VF_S@
M_ *Y@# & , 8 P!@# & 8?G]Z_ETYC]>OV;]?_/N0Y>U^'Y?[7@?9:@8C(\<
MTOR[6/M]',P>NM_JWZY9&7& , 8 P!@# & , 8!0X#[&3][3?YP?@%<P!@#
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M,=US.,'ID%)I;[1<X)OLYH]ZRS_\<QYD1@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , CKY.>6/C_ .&_.QNK^2/01^:T
M NR1M1&L!,#:+$AVQ2XLB;'1J8^HPD_*Z60+$R#WOU Z%:2,K3S[:EM)6!$G
MCORS/R:_?>G4SC?)?)>-MW2.@S"(&H5IKG77XER8EG!WR4!HD9_GT5#B*4R,
M\O3I\@*SZH]CWGMJ0E0&T# & , @/\H?Y[\]\ O'#I_;9K=1N=SH,'7IZ'XR
M=T6#I=MN@4[<H>I;>B6RQIB5V*'](FGK*%K\@VYJ)+'_ *+V'GF ):\TZG0N
MMUH6ST"XU*X1ZV0DR#U1L\+:1(J2* %D%Q1IL(64RR<PP6RM8[_N']M.-N[9
M0AQ. 9#P!@# & , 8 P!@# & , 8 P!@'G)#$-;]T8,P4UZZ5[HAI#S?M)]?
M95[#B5)]I/KOTWZ>NO7?IO /*S"PX[J'AXJ.8>;WZMNLA#MN(WZ;UO:5H;TI
M.]ZWO6]ZWKZM[U^K> 5+ & , U*?*N?)7<A^43X9T, +G7'QO*:1I];I_+^\
MWVO/%S5'B(6]!6DF,9G(P0N:%C2 B+.(RR*P]IM^>*W[O39#^\ FYXR^)_C[
MXB45ZA^/O(N?\AAIDL.=M<=SZ!&@(^PVIF'CX8F>.9'2G9)KPD<,QIYW>UI8
M:;1K6OK]0)'^NM_JWZX P!@# & , 8 P!@# & , 8!BOL=*L]\I14-4>O=!X
MG+L$LR:;GS0'FTA9-L!,D[<B-C]5Y_TNK?1T@IQM1B_T;^DT[&9T'(B)V^EX
M#3!P?S9Z[P7P<\=O*3O'6)'R-L/D1RN*O<Z/W'KWB7XU5&D241%;DI6%YAJ-
MYOSN:M<Y:M22?@8&03:AAVX1.S[)6E$,[F@)GU;Y0Y/3.D\_J/(^#72\4NV^
M+W&?+VQ=)(M%:KHE(Y%V0J]#Q0Y%5)T=8+'>1&Z6X2+5X!LEJ6;=D6]R\<_&
MAM30$=N=?+.4FV5[J72[1Q\:M<5YCXS07D\=?*OW#GG3Y?5>ND^17Z'SZT5B
MKCMQU!ZE.DB/ZE*O9K>PW77-MI)D"Q69,V- M&X?*^7&S\SN!O >0<TM?6>?
M];\2Z]9H<#R I'4.:*YUY+=F!YA'G =)YPDB(_3GZ2%EJM*54Q(Q5*,E8*\/
M(ME8]P++ 3D\ONZ=FYWR'@L-1A(3F?;_ "7[=R#@@TO):&Z)!<;D^@-R,Y=;
M"A"QXB+NI]5K-:LH542>S'0\Q9W8-^0"=CU$19(&->U>1Y_R=57J@O9N[R_D
M?,]MOS-.X[OMLIP?@RX25B*C8K==7;UUROUKG'.0*8+$022(=3M">M+<R2)7
MQ=VE^9$U% 0]Z%YMR7D5K74^2VFY42OE?)M?*;R$A6X"^Z/A8SKO$;_Q*EAV
MV"L5,E7*M;7J[([GR.==*@'G=D0$YN2AR8_Z4+$;\W[OUO;_ -&__8$U>-^:
MA1'5.'^+A%*?EK%(\!XW>;)?[AT^IUBP6#5PHC\F]-4"CV@ANT]ACX4N&6ST
M.=KIJRZ[)2C*'@)-U!:FO0;+L 8 P!@# & , 8 P!@# & ?$AE)+#PZ]JTA]
MI;2]I]-*TEQ.T*VG>];UI7IO?IO>MZUO]>M_JP#7COY-+CD?2N"4VF=)[GSA
MWQZXW:_'VJW"E6JI"W*?X]>7*T_;*?9Y*:HDX RJ8+J-?+_2>FQ50N,6\$I,
M+88U@HIEX"ZJSX,T3DU+L<;R.5FG+4OPQH7AI4W.A2#4O6VZ;R&*Z QSB2L@
M\%&0LH5*.2-_D56\^--#1) M,(BX^*);4Z\!!KQ*^3GZM7:M9>']TBS:[XR6
MGQ_(Y-TSF!OD7-=W/Z?TIMVFB0'6JE82.:\[F>0HJT- V!,>S%2Q!D@?.PI"
MHF'>J$>4^!/6?\)8R\<BN/(.G>1'DET\*SRW.IZ&N5LL_.A;ISR;Y/<(B_4.
M9I#]1Y?5ZTB6B+? Q$T7)6NLVHRP.@,"V)Z5CT:#P#*G6?&FC=SXO&\5ZI,W
M6T"1"Z=+1O1&IYJL]3C;U0CH^8JW3X>U4^/KX\!?HR?C1YQN2@(B,B]F*)$^
MAM0Q3\6X!A.4\"*[80Z_)VKR)\H+5UFEW0*]\^[O,WNFZZ'SR7#J]EI+P=/K
ML7SJ-XO'0DW4KA8X.V1)')S1[DS(,FVK<Q*0\$?%@7-/>$M"N38I%^Z+U^_6
M)OQ_[IXXR-OLU@JZK!.4CR$E:E+WF3D=0]-B(4>R!OTN&'JRX:'B:]!@:?#3
M726=CZ' ^$KX/4"?N_&K18.C]?G:QP>3HEEYUR>3FZ>]SR*NO.:HFG5FYI=1
M1VN@"2;<8A)4G"P]\BZ5,2VWI&2JI#I9J2 )IX P!@# & , 8 P!@# & , 8
/ P!@# & , 8 P!@# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g332508g29n95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g29n95.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2^*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +VZ^$A0CA"24T$)0      $                      X0DE-!#H
M   1D    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O;
M$     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D
M)I=&)O;VP     "W!R:6YT97).86UE5$585    !L 0@!R &\ = !H &4 <@
M @ $T 1@!# "T 3  R #< -0 P $0 5P @ ', 90!R &D 90!S       /<'
M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0& C2\         *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      !  @1I>  $  0"!&EX  0 !.$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         !.$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     !30   @@          0                         !
M    ((   !30                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   !30    !29VAT;&]N9P   @@    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4T     4F
M=H=&QO;F<   ((     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    ).$))300,     "4_     0   *    !F   !X   OT   "
M4C !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ,"
M@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,#
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M=P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ ^ &# P$1  (1 0,1 ?_$ !\   $$ @,! 0            @ !@<)
M!0H#! L" ?_$ %80  $$ @$# P(#! 0("@8'"0,! @0%!@<("1$2 !,4%2$*
M(C$6(T%1%Q@D,ADE)C9A<7:U,S1"@9&4H=/4\"A28F2TQ!HU15-4AL$W1$9U
MA:2QL^'_Q  > 0 ! P4! 0               @,$!08'" D!"O_$ %D1  (!
M P,# @0"!@<$!0@#$0$" P0%$082(0 ',1-!"!0B46%Q%2,R@9'P"19"H;'!
MT20S4N$7)9.4TC135&)CDM/Q&$55<H*#LN)#=,(F-F2$HK.TP^/_V@ , P$
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M15  8"6<*07DRV[)XR/'V=6\1FIH9JBV4$T=%3?+&G$6R.H # 2S8W;I 6#
MXQN'X]/U<+V*/9+\J!M.6[!VZ^3&H^O)>/5AHR9@R4XS,YDW8U!8F.\"LCGJ
MF>U$>C7.8X:N^T3YBD-'Z!HE^9^;]8UBS.&^7*@&F6,YC W#<),%AGW]XGS-
M&:,0&A45)J_6:J69PWRY&#3+&054?9^2,9Y).6M6T?)*IQ375=(S77.3Y7#R
MYI=F7T^@M*F%:82^5)>6+C5=!(;XU\*(Z.(1I3A17F9YO[-1WN2'DL\D]8ZT
M]9! U.111+*DK)4[0 TSL%S$6R2%!8#CDXZ>>6SR3U;BFJX8&@Q1QK(KLE1@
M?5*S9S&3DX&<?;[9>;>;SKEW+-;A>(74*EB0I&E*VOOI,:TRTS:N26SB9664
M'XU03ZHV,&$L?NP@7E1[VJC#*VL5K?\ 1RFIJ(FD9Q<G>)6CIQZ@$;4X4[I!
MZ>6?/(.,#VZ9$=N;Y!?7G1G+"X.T8*P_4NPP@<N-N[)/@X./;K)1,XSUM_KJ
MBL]76+ 93CDVTS#(X%S!D4V"74.( S:.4QXV2+)TV00D:-( X7]U'H,K6E\$
M-34OI5DJ5R$P3+'30M$PDJXF8CU1SB,*H#,IW>XR/IRAJ>F].JD2L0^C,$@B
M9&$E1&2?U@Y&T 8R"IY\[1U@/Z=$AX5:YI>ZQV?2CK<^=@HJ!^-/GY#8L?:1
M:N)E4*O@F*Y^,2W2D.RP>YJ-$$WY7_NE*]^BM]5'2PUU!*9*3YHS>N$A0B-I
M&IW=@ *A0NW9[DKR.<*-!F=8(ZJFDW0>N9!(!&OTEFB+<_K%Q^S]B"<<X>;]
MJ8>++<DPN1)GQKC$\7!F%V\]7.971J,_GV.RP]E8YBC:-7$CC<XO;R1J.<,J
M,C_(5)IX:I51HJBH:FBQ(F]IE_LE"00#[,>/<D C+'RLQBCF 4I+(8D ==Q<
M'&-N<XSX/CW\<]?57MG75Q5X3<0LLJO@['(\.$NDF6&;(9 FO4T:!&DM$=\@
M*L<PPG#:\9/$;D1[V-<26ZMBDJXGII-]" :O:-X@4D ,[*2H4YR#D@C)\ X\
M:FG1I5,;9@P9<<A >021Q@CD?AS['KBBT6J'9[?[0AP\,=L6OQZ/KW)LS 2L
M=D,#&HED2\C8G<V3"K(AU\>UD%LAULMXFLED>9&(]57U',$X]/,,H]9=T68W
M'JK_ ,4>1]:_BN1TT4<;<HPWC*94C</NO'U#\L]2,A&*K41[%5[?-J(Y%5S/
MM^=J(O=6_=/S)W3[I]_OZ;P?L>#@\>#]OS_#I/7VBHOZ+W_U>O.CI>CHZ7HZ
M.EZ.CI>CHZ7HZ.EZ.CI>CHZ7HZ.EZ.CI>CHZ7HZ.EZ.CI>CHZ7HZ.EZ.CI>C
MHZ7HZ.EZ.CI>CHZ7HZ.EZ.CI>CHZ8>T]DXGIO6F?[:SR>^LPK6F'9'G65V Q
M>\6)C^+5,NZMC!!YC]\[(4,WL!]QGO&\!^;?+R0Z.JX,9W[U,<AP;#>1$7CA
MHJPU?ERX]E']7*OS++!<EZS6&3.AEBSOVJL(T;5TW9%92SQ9!:80X$&I58\F
M@BY86P]N2\Z.I@V_U%M-ZAS?+<$_H^W_ +3L]7T=/D>[;/2^J)VP:#1M5>P"
M6M>NRK*'90W1[1U0$]Q(QS%HV4Y+$J1LL9-.*+*A%DF?/X='6.SCJ7:&QO,<
M8P' \0W?R%RK--(X_P BL6KN/>N/Z0@W&H,DM951!RX-H2ZI:F-&')B^106$
MZ)).V1&#6BGS2.BC\SG^?S_TZ.HCR_JHXN[9W!VGTQJ/:>[=6\P:+;MRW+,)
MPPTC(,8-K1M=7GJ34%O<4)H5MC^0EM8>Q:ZU&.5B\6K.]HY,IKXZ>_S_ #_/
M_(ZE:FZGW&BWQ_>^;%A[;I-<<=;[)L.V#LN]UE=0\(EY[BVP#:SF:^PBS"25
M*SO,YV5-B0ZFFQBOL'376E;&4PK,[Z\1T=-+*NI-BL_5G(IV-Z^VKIK?VJ>.
MFPM]X5K'DQK@^$6.9XSBU'./"R^CA5^0V,3)<7B7@X%?D4.!?0[^F=-BAN(%
M2^?#(4_G^<='\_SGH^-.Y99Y[J76.<70X@KC,< Q#*+44 1 P1V-]05]I-9#
M"8T@HHK)$HC0#*<Q&"1K7E(Y%<IT=2/Z.CI>CHZ7HZ.H5WU%V%+P80M9Z_P/
M9.2-R;&BNQS8LYL"@95BMHY+&V8=T66WZE4@:LV WVT=[PO(?N%:P!:C;#2"
MI)K*NJHX?1F'K4B;Y2YC(2,C<GT2-]+\XP><#)%5L[425;&OK*RA@^7J%$U$
MI:8R-&0D9P<[)"=K<8\9*C+":6]^R>2(CNR=T:JJB+V^Z(JHBJG?]%5$7M_!
M/5.ZI7Y?S_CU^^CHZ7HZ.EZ.CI>CHZ7HZ.EZ.CI>CHZ7HZ.EZ.CKX<(3T>CQ
MC>A&>V1',:Y"#_-^[>BHODS\SORN[M_,[[?=?1D_?QR/P/WZ]R>.3P<C\#]Q
M^/ _AUACXQCDE]*\]%4%=CAW2:!75\5?HLAPG <:K3VD2"11.4:NCH-?%>W\
M$[.B>=1*%FD G7;-AV_6KG.).?K&><-GGI0DD&\!V_6 !_J/U@'(#??G[]-F
MQU3KRTK,LIYF*UCJ_.I;9^6@ TT1UW-8]A&RIAXA0G]Y",0GF(@U4BO>O=Q'
MJZ0EQK8Y*:5*F024:[*9CAO17&-J!@1C'&"#QQ[#I7KS9C;U&)B&V/.#M7[
M$$8_//M]AUVFZZQ<>4U&8!C3 7-'B[\/K/9LYXX$>C<3W&A^G-D?$)(&O=HI
M91/D-9XIYJHQJSSYZH--+2ED,4U0*J3,<9=I@,9]0KN"GR5!"D^W)RDR,5*G
M!!<N20,ECCW^W'C_ ")ZP$;50ZW&Z3&JC,\SA!ILG9DCK$UJV=:V2?.+./43
MI1@M0E:9QE%[7A]AM;[B&57*Y]KF9*B:HEI*1S+3&G],1%(H_H"+*BACB1<9
MSGSXP.O&;<Q8@<^P&!X X'[O\_/6<-CV6)89G/A9J<8[RLB1L8KI-9#D0<3L
M8T0HB6 D<GN6"2I+QR2@D+[:>"L5KV^*-96HI?3HXWHU)@E=JF1975ZN-G!$
M9YQ'L4%0R\\YX.<MD$@X."1@<>/Q_G_GU]QX&>QSX>,E[2SH4*(869G/6O!.
MN)7Q4;'DU;(ZI&A(LI/<*-48WP5>R*G8:>M);V6M(@GCD=U-"%E#1PIORRS%
MOK<E/I!YY^WDIQ+NCPR[0#Z@*\L<<;><#!Y/71-.VA$I;Z1]$QBUNQW_ +>.
M5\.RDQ(\C&W%BM21929C&M'9C&Z61X@K[+FL$C55ZJQSJQVEYZ93/5Q4YILU
M4CQ([K5;7)2%$/,1.Q0S?5DMGCGIEFJUCD98XI)?4Q$@<J#$6 R[$?M 9)QQ
MQ]^.LXMU>LOY-:_&CNIX]"RR9="EB<V3:>9$)4!C.1KO<1K$5I'/:BJYJJB,
M<BHR*>F-*DOS:BH:I,1IVC8;(< B=G&0!DG*@'P0#D<^F683M'\N3$(1()@P
M.Z3G,04XYX&&) YZZ,?-".@8W+FXOD<&1D=E]-2 L-ASU+E,03)=JK",2-">
MUC3>ZJ*]H7^;A)X.3TZUN7U:U(JVCD2CA];U?4*+4 *K&.G!4[Y025VYP6&
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M<CIQ]1B-KJS04[T]$B&A>.OIWDN4A0F2-(@=T)CD_5_6#N/(SUR@V34.F8[
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M;OD;/X+W_P#P'_-]NW_/Z0=;WH^?E?\ L3_X\]-'5%P/E*;_ -Q_X_[S\/\
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M-SF^2HB_9%7U:5^LU5IZ\7*RUCH]3;:EZ:26('TY=H5DEC# -LE1D=0PW88
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MVFEEK*ZJ8K%#&,^!EGD;]F.)!R\CX11C<<D9(XA(<8  4NQ)("J ,ES_ &5
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MM4L<MI%CN9\+!V.>-YQ,<C_'%/+Q<URI]OLJ_P >_JC'.P,-I!.,9&00N<X
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M>B?5'6_T6CIJ[WUGV;Z^#5OL+^0D408QYX0#<50O5=J.R+TVGH*B"Y@05UZ
MK($8!U%%"(EBE>=%,<:U!G!AC]5RQ1RP0X7JN"UR34")#*\%5(XG=E8$FG51
MM 4'!4LZD\@G!.> .HGY0:[U";1]1GXY<NIW1C&7DQ*],QYY5!L2BDH8]4^
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M=5OOO-36O4-''JRQQB26@K/T9<98(W;YJG,89:B:0B-%6BG#4PD7U6+2B-V
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MR'QP1+*0BD"!A'ZJZ;LE;>+O#2A%I4HI$J;K/4QN8;=202H9GJU'(#,OHA&
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M/DP_GR9A(SII<RW:P+H/3%]O=QJJ47.\TU6E73@/)')65[!9**@GF1]T51A
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MDZ_IEJB)LJKHZNI+9 P00WD^^2,>0/RQK,D@1^1'%G:EAB89U3J:UI#96RO
M%JW,'%+B1>UQIC7,%'9+=[XH+"E=W(5C".>]55$UP[E=I+C?]74=;;'FD6_3
M&.YRO@Q6R&DIH568<;O3=4=?VO\ >/$B(.2;P:LI:J.GJW<QI'&BU+YW!1MP
MF !NW$\<\%B#XR39_P!3?J-Q^;-_BE1@V%%P;4^#U\5M'77@JF3E]I?(.='L
M;VYM*P;6>S+CRFLBUONRWQE8]Y9TCS$P.3>V_;]M'P3R5=4M5<)VVR-$9%IH
MX%">G#%$Y\J5)=\*#].U%&=T*\7.*FH3# QE>H^IG(95522J[02<+LX' .?M
MGFA7D("42KQ@PX9B1(Q[%TF>WLX(2R6@8",5$17"<1!O(Q[O%A>WBBJYGVQS
M\1T%7)2Z>E2DE:B@FJO6K5 :&*:18UB@D]U:0%F1N%;:5SN"]0+25_1R("&<
M2O(XW<JKX5=R^V=N0Q\YX\'JYGGK'F?T,=#>SA__ &%P$A6AW.1SF()MQ(C(
MQZM3NB%?(:-O=S%55[H]%1/6%NUFGY;_ *RML2M(D%N/Z2JI(R$(BIF4JA)5
ME(EE*QLA&UU9E.?!K%O98ZI9&)4(Q/'DMA@J^^<GR,>/.!SU#/$;D3DO%G?N
M$[FQ<I/DXQ;M-.B=B%!854A?:L(4F(V1&'-$2.YW:(<PPE>UJ/=XIW7=C5=A
M@U'8ZFV5 4B>';&^<&.9>8W5BK;"#QN4%@&SP>>FK/,@JZ^G<N(JEY/4VY']
MK<-N<C*DC;G&.<'V+/ZW')W6O-+E3CV^=78/<X<*]P2HQ;)X=K'@"/9Y+5V4
MPJ2P.@'.A@D#9(**LI6RFA8T3F^(VKZT>UCVVO>B:FWQU3P5L5ZED6ADI!(5
M$ZR(@II?41%6:3=&X"LP().1@CI<PA61X(IA*T!VL2-I&XDKDM@8VD XXW>3
MXZ''$0VF-832XX225/"LKPVX$=Y!),AO>837?=6N6&0Q!"(GZ)YM:JL<O?=W
M0=DJ+!I*R6BN.^JHZ%!-N8.8I)B9Y8488_5PM)Z2X&"J <^>K3O@IYJJCJX4
M!EI8S"9ASB16PP##@@X"Y&0=JD$X'4W;1WON+9G'4/'W*<XGV^M<;'(M<=I+
MCXTD5%+AC9+@*"UDA)91JRN/%8^+7MF,@0A/D-"$8RO:ZV]:]N=+WF@OU;-;
MZ.*Z26VLDIKA)F,4U6E/)(E40&5%;<!Z\NW<T>=Q(SU<<%SJJVDIXS"DLV4$
MS%>1".=^[P&P#@G[ 'VZ8N"FQ[^J]IRN]U&YS43\X2YC^P1A4H[7(I5GCROD
M.3P*T8"$48V.11MDJCF=U5WJT^Q%IU#:;-4FZPO%;KD\5?:4>16*PRILE;T?
MVXA,ZB4!^6!5L ''3]QP]E4^LI:.H=8PC LC#);(\CD%<9YS]P,$0W>P;CA3
MMSBI>54BT9F-_59!B%I*DC-!QVQ!(AR9$A()8KY('Q#5S9$1U;-C)(D6$I)P
M9 QB\9W<?M)%K2\4USAK8;?51T+TS2^CO,DB&22E#LKH#&[R>E-O5W2)5,+(
M<@^T59'66QWD]5I:=2B#!+R D'"^Q"%LL"2QSA=N">BKDW@,3Z+G&?6\ND@%
MR'(-T9_9R+QO@R?60<6MKB#(@M<(#_DP;"TF&*KC2A(*3%>K $<1SV8O[%62
MNMNM]305;-$UE62W3P@AH9*OUUCD=&W>42$%&"MZD<@W, NTR/2;]'UC%RJB
M*-"AS@M(6?<<'@A5 \<@[21C'0XZPNL#R'B/R_TQD<.K%EF48+'RW![6:-WR
MYESBGOAB8M"DK*:())<NT':B[QE+[U<B#D-:YX2WOWUTC>M1KIZILT$M9)2U
MLM/)2(5 'SD614'*Y_:@6 L7"*9 S# +(BU[ZFUI3J2SPM,2&9=BJ5 R"?J#
M J  "1]7 \XNO_#0YGH/4'"O?MCMB=B<"RL\IS:9FE/DIJY)YJS&Z]L8$694
M37LDR:U8?NQSQF,*Z<DH\40#,4Z)JS;[%?9;N*>&@KXIXJI*(NL,J&"M24;H
M/5 PDT;88C/ZL[7RHVGKV.GJ9/1]%'#+(P9@&&TAAD;@#@@8/X<$CQG7:V=D
M438NPLWR.36UE9!S"VO9CZ>EC_%JH4*R*?VX=?%>YRBBA Y@PB>]ST:U.[E=
M]_70&JL_KZ2J;*ZM5+):Y*/_ &@[VF=J=D!=@%RS/ABPP-V/L.E&6-M0$^H6
M$T<L4HW<.K(4&6 4'>!D\9W9)\\%UQ4A&K?P[W5#KY(GA/"Y=:,BE"]JM()X
M0X<Q1D:OW:YO9&N1>_9?LOV3USOJZ6HH:FHHZN%Z>II99()X9!M>*6,D.C@C
MAE;(.1[9'!'4!UVRE3Y7(\^X)]QU5YQKA1I&F,SDDF$=81MBT@(,#W N8"!(
MQVR/+E^VY?DC::4&,%'B5([WC<AD4K0^M@_AVFJ([S?XO3Q2/;J69I2) &F%
M2T<:EA^I?$?JE0_ZU0',9*M)U+^7:JMM9$N[*/#*A!; D7<0I(P 6&<<Y]QQ
MG-Z? 'J=VO%+4&X]*YWCC=CX!E>&W L%QRV:676U&37,V"RZKB"%(B$B5U_5
M$M'$L/>E_!F-0#(+X]G.>W*'<7MA3:SJJ2HAF^3E:58J^6,J)):54<1NI97#
M/#((PJ%5#KR7!B0&=3HE530BH9U:(*Q8#,A 1@8_JSP'P1SM'/CCH1NF]6:,
MU55<\-I[)QNGMZJ+"'BVML%LC->%]G=C+<TL+Q(T:RZ^GE6=6XD9J-=.# ;'
M49!I(\-?[)HS4=F[E1V"U5<_I4-8D=5=H$*)\D42H.0-P2=J9@K<D1L^XD90
M]*I(Y(:B5XF=*='R[LA!,8 <1E0>9&SMQC'(/C!ZZ/$*ZQINULJJLHOX>(4.
M>:UVAAA))V-)7GDY+BUC$K* K9;)+&1[6P?&KV'*ON@<\9&2!E[$];$=X[17
M770-=26^ADN=;$]%4) C'UL05$;2U"!67>T,6^4QCAP"I1@2I9H7>J>X".,/
MOD 1<D;,%"0BEL,1CA3G.,\GJ)=;S,3QC@'5ZZG"CR\Z-R5V#=5S5(]LK'L>
MJX J*:1!(]!O!?&! 5CG#>UZP6.$]OMKY8R^'_3]]HKK<[K505-';JRWTZ1)
M,A1:J6.IGBWE'4,KT[Q3H<D'#D$$,,1*N(QVFK]4;0YV*#C.5D.X[22RD ;0
M<8)/D=0=D45N1:DV%A7BOR[R)3S:HJJUK66=%:#FQQ'>Y'*T$@+I0^S&^3C^
MRUSV#5_?+?=G1-5K2STU+0S1155!4R5T/JA]LQ2EG3T1M(P\C,J;VW*BLQ*L
MVW;#LDL;6:HAED"")A,K/['<5"X!X#%F^_N=OCJ0>&M_KS&.$W*&@O",%M/9
MVT-4"PR&6OE/,_$L):>==V$>P#VBPD'92)$,C)*O62Q[V 'YHI!X)['Z3O@U
M'0:KDII([*E-<Z19_5C7UZC"P.K0G]9)$DA(5@ HDB;D[<&H0*#2UI]3:1#)
M'M1P&WL(RHD\D)@[OQ(&,^.N_KS+:N@JMB45S7R;.KSG7V68>>/'D)'<*7;U
MAQU$LRN5K31HELD*6<3E<UXP=T&1R-:NP_<O2=3J_3TUKHI:6&L:2":FDJT9
MX T;@.IV!GC+PF1$D0;E9@=P&X]0]/U$1I*NE<A=VY\L"3'M)W'CD[ER PP?
M!^PZ(?I_\D=8Z:Z;O-+C=F=(Z^V9MK94$&)"5C(8L52CI8D:5EHK$K1FD2G2
MA#IQU4<C2GK)=B<PWQ6EC2=<NU.@]01ZP>ZR'Y6CL%RGMM6PRPJJNG9DFIQ&
M1N$85A*DTB8W>GMVO@B; @$-1,9U14AF0)N(:;>A"X& -@)#'<"3Q@><!)8@
M?9X?G- P;"ER#&[*MC-*HF-9+<X9X9O<*QZ#\9$<;7O8K'HQ[^S^RJB[&]T-
M+5.K=+3VNB8+6K+%4TH9G6.2:#<!$Y1E^EU=POJ;XP^QV0[>*/IZ13%<H))5
M16620-(2J@QG(8D$#'&#GZ02"<^.BT_#CP9E;U:]10;&+(A3(^M.1 SQI(GB
M,)_]!V;N\2#(B.;W14<GV1%14<G9%[^M!JRAK+95S45?2S4=93,8IJ>I1HIH
MVP#M9&^KD893@*5(905/4F12 01@_2?OQD'CVY]B/S'08:^AEK,<RD9 J,MS
MLO++UI'-7W'QOE,KXJM56HJB<V(8C'>2]U>JHG945VV/8'2\]KM=;J"K&PWY
M*=*6,A@?DJ4S;9F!./ULDK-&5',:C).<"15 QVS*Y]66H1\#) 1#])8'Z><D
M@_EGSUL7=+'J=:CX8:0V=KO8N)39LO+5LC5MW3V4B98RSS_IT4=7+QI*N+!C
MQ8,1)TROO3WTH[)9Y$1:X4<SRK([I=M[KK.NIY[=4QJ$A,31SHJ11X64B43B
M1Y"S.462)($ 14;U"PQU5#%'5V^DD>H2$Q';Z;(<@MDY5_J;!8JN, ?CQS1E
MQ,VC0X#D'4#:UP; VT,;N,(Q8QE&!_:\V@"[-8!8YA%20*D@R>PA.:Y$,\7D
MK%=VPQVBTM7UVM::J8%*?352[5SQMOC:=4FAC@W!AE&E0OO*[2$&<':2U1Q$
M/4R%@GH;P2#G<[!DVK[GW88\%1D@X/3TXV[ELN/^Z,/V[45=7<V.'V,V4"MO
M(Q9E5*'85LZHDI+B!/$))\(U@4P1I("BR1A>]_BU6NW%U;88-3:?K;)4R210
M5].L,DD#JLJ[720%&9)%7ZHP"=C<9_#% L3H*ZK64R!9GD4LGTL 2"3XP6/V
M. 20"1CI@87-Q83N6LLM;!IK/8.R\:RC#:2""1\"JKYUA?W]W$@F\W)'6+]6
MC111C*5/C+]GHY&*[!/;GM_=])=P+J\$DDVGZ.C-'\T\D9>IDJ8X9Z>.5 B;
MW@ ;U"@ 1GC!W;F K^Q5BN2HY"$+L1FQ))A\@\*,C"L"5X!( ..>CHZ?_,VH
MXKVVT:;.<.C9OKC:F%2,=OH'QV$OJN?"CV7TN7C<LKF#@NG/L30[<95=$F1U
MCOD#5\0!!W]W4[?/KJUTU/2U@HZVEJ/6A>0DTTBR[5D6I1%+.L8Q)$5^I&4@
M'ZFZBVR0UE.U/)++#Z#94_44RN1AD//ZP?M$9*L%;')ZK)XW!UMBO41U_D^P
MQ/I-44VTIFRY@5C&LRQ<>!\N\KX(P1F,)-D"E$!!3VVC&\HE<BL8G=-5;OVR
MU!2:KFT7;%%UKA215<%0=M+#/1O"DDM2P>21(DB<O"PW,Q=, $L!TWA/7)#A
M%RV&F_5C/(R<Y RQ^D#=G(QY'5F?5'Y=CYE\F)FPZZMK:C$L8Q/'->X'7UZ1
MRJ/%J-9EA&/.L!!"6?.E2[>9)DND>7PB%=71^T>*Q7;?]K=)G2&FX;=(SO42
M2RU58SEE"U$H1&5(R2J(J1*J[<;POJ-RQQ"U"L$%-3T:N7D#J[$\!G<EG*8)
MP@^E1DY^DYY)ZBS@=D&!XKS1P#+-FY7*UYK^TX_<@]4Y=FL!/&5 =EV!7L3'
MX\=(\4QEG7,Z:E%&\A%>9TKV_>%Y->S$O<_1.HI-=V35%EH'NT,E3;UF@&YT
MHYZ%@S/4!G"I3/%^M5E(421LI1F;ZZS$?4-N= LCI#$&BDP %610I(8C*GG&
M!DL,8).3"&(94_5.Y*7-:%L.T)@N<0;ZH;.B"DP+']GKEDR"DF#*&4!02&Q1
MJ^/)$1BM=XE8[LJ>MA:^B%WL51;YR\(KJ&6GE:*1HY8OF(6C<JZ$,K+OX92#
MQD'JF0!*:_5)<MB7*$)](*\C"E<!<#]G)^P_'H+>6MBS*N4.7[.BQ"P:_:>9
MLS440\CY4@$ZQEQEN?>?XM:-QK5)4L8!=Q $=@P_NQM3UHAKW0U1H6XT]#+5
M+64]93&IIYU0HV Q66*122?U4A*JX;=*@5V"L642ZV...H81DLC!6&?(XP1[
M@8Q@<GCD^<=>R?B7^:F,?[/4O^[8WJQ^J7TX?1T=+T='2]'1UX_W4KRB5A/5
M8Y99A!8CYF+\JLROH[%\>Q25>5.E^W^=%:BO02L:YR*B.5JK]N_;Q6*MN4C<
M <$C<.<CE6!!&#@\''(R..I,;;"C>=N#@];T73UYW:*W,V@QZAS"ICWY==0]
MC'P>[E"I+:$V5C\F(6?.KSJ"1' $KY\ATTX"JQR1I,1PQ0XA"Q(JCY:!H3&(
MV:9\3)R$1F5B@W$@*P555$9>%</NWMF5-RA*^25P1RRH7!. <D X'VX+!B=W
M5)_X@[G%HK9E+QHB:QR.%LZ7%S#.9=YD%)Y6E/C=-4,CXE85 \B")0I9+9 >
M:+7N.:5+!#)./_9Y0'OO?MSJZ326JJ6[R1AJ-A\M<(B-I,,Y*M4JNUCZU.KO
M(NU1N7=$, GIO "/%)D1R, ^TD$X).\E2<$'&0 "1].,<=4RR,1K5/@4*OS+
M"[&YV/CT'*,3J@WL41;6KL+$M7&2+-E?'JWSOG!-$D5!)@;>+)$4<BO8U!O+
MMU2]X]"5-7)1B\B(J&/KSP3QTI*J"5]8IL## P#A3D8<M](J3T=%*T;1SPF=
M0&&XE,KP<+(XV,.<^0<Y\> ZN2F?ZDP75IM.ZVP5).\]2Y%A=QOW+RV]A.6P
MKXK\B+D%/B@&O! ]BDE6]%3Y4)T1P8TF%&E19<H03E9@K4W>.[G5*5%HK?F+
M);;HM11PA88H*V 4\4<D4LBJ\Q#R&<QR;\['.8L#:?:FI54^6C19(HW0R@*G
MZU  Y!?#'Z'S@KP%(R"H'3M@:LU3M#,JO%M+[-:2<[5,/<.05FTH4;"+.GQ6
M6!MG(C0O9FVT*WLZ*E4MC<1_E0WI'"DJ*QX#HUF2+%\0%@JJ=Q>::IME266.
M-(T:IA=Q$[.SS!4$:F1?33()(=">-V&9*>@J98G_ -TXPS+*#_NV]MR+@X P
M20 "<YY.14WG:ZUR"OQ6?H2VL,XH=99+(M=I6TZ/])N"!@E'60LCI<<(5\PV
M&RQ$F2EG@/*/#4PF608@RM<_&5\[QUEZU%I^I6,T-JL]ZIKEM4L\LJQRE'$I
M79N*4S/M5"HD+D%.,=%6]/- M+$@-/G,S<B1@4],D GA,$GZ2 3X''7::V)9
MQ8DVLD!EQIL./917A=YJ2OD*YH)/AW0C D>CAHY[41"M<SOY(K4V]M6I+/=X
M*2HHKA33QU\#U5&HE19IX58)(Z0.5F*Q/E)2$ C?Z7P>J!=+ Y2.2G(D0A6!
M!#$1\@,1D$*3^]2,'D\,*3D<)^QM;T4.P?,BW]G<XP<,#RE"6\/\:# CR1H4
M;?W5@6.(A%\OC,(XRM<C53UA_6O<JWVC66E'I;O#-;:>6ZT=^@I9DE$#2^E"
MC52#(4TT@]0#A_I<!L$CJJT='!3P04TY1TJ"ZS@'<$=<!-P/(],XQX..<8X,
MC6 X[4(44N')BA/*CGF1I8),():\SP36.EB(^.GQBB>TJH16L[([OX.:JYBM
ME\MEPHGN%)<*2HHH]^ZICFC:)2G+B20-M0KY;<1@'G&>J?>+41- E.OJI.1R
MIW11J&(8%N1].TY\ $#W(Z&ODG>I4F!K]JI]0"L"VNVC((@H[),(4RJB*X3W
M-62X$MDHXT[>RCPL>ON>36:S][^X-KO-'1Z;LU6E:BU1J[A/ 0\"M 6CA@24
M,?4<2!Y'*@QA AWDMP^*&.W[XPP:60()-NTJJIDH,C(SECD*<>,X(QU;;U(,
MP!A?'?HE6LY"?2S< *J!:N&CB$!!E9*U"2F!:OD9\56I(03?S/1CFL_.J)ZQ
M'V_U>-%:ABNTD$E32R024E9#$5]5X)=IW1!W1&EC9%=5=E#8(W#V72O&DQ,@
M.P\-@!BOGZP"1DJ>1S^ Z$(4>I?9E8/(*H=0@HLUV16!25M4&JFQ V$.VF+)
M'[\6+)@2 R@L>%YR(5@A"*=R#7=*EUO8*S3!U0E8GZ.@I5J*A6:-IZ=C&'%+
M+$'(6JRPC]/=]3D!3MYZJ$5+&M9(ZG$4D8E,H&U%X#?6?J"D@?LGC/!YSU%W
M*?$8SJ#7=[J*UD[3Q0N/QLTOLUQRED#AXU<G(^.N.SXR2ID^,>I9#=,E2)\2
M"UHY8%>-B(]$U3[E=T!K">S1VN.>AIK5,]=$9GB>1JLR$4\I4(?3>*- 7B+L
MN7QAL!BBL%.=K4L>=_URS;<,V/I12,DC !8@GR<XXSUU,&S:%9ZPLLZSM[,6
M%63X]3 /)BE:+-9QY012$Q@3$5\PU5'*Z;>J-OPZ\8V^4A"R Q_64-._$%:_
MD:2+4=-6I<XFBAJ9Z**.6GFCPX-6J&57C(*J)X"N<N6@W@,JQ116V:F99E,#
M,_A8_H)8D[U(Y&#RP  !Y4$<"9<RKHM%K[)L5!%AV.QMA:8M-AX,Y30IU0FO
M615/:38KQOE,E7^08^MR2@%[<:75RJ;W&$;+.Q@Z'W4[NT=RHQ9=+UHJ:6X4
MLB7*MB]1"$G;TS1@EH9(G" M,")4ECE,+H 23*2.&CIS!#L:9HR/47./3 Q^
MUE?K*DD9!QXPI8GJ.=<W^.7.I:;*YV0UE=*!>MPJTJYH941L:Y;7OF52MFO#
M\)ZWE?'))BC:]O@X)Q%<US&^=]:)[N:>KK19Z2ZUL5NND<=):Y(I6 1YU#PP
MRH% V4\D<4;F5PL<;N(V;A2TBF@HFI#AXD:25C)!)G_>MG+ G(.]0#[)R0Q'
M ZE?"I.N8]K/AYQ/O728N+YADE1CV.PXY)]V_%\=L[IPB3I$AC*\'O0XX5>V
M-)+(84WL>#P+YW%W)U_!HRB@*&&2Y5Z.:**1F;]@H&E9$4KZ9W, \CHA=0HW
MY.UJ@C@HH763&Y))2L8'+$9)!XX55P-Q(R>/8X);BUQ^W=R5X.W6P<,GVF<4
MF!Y5,0.N8U_/\Z:T,8<[*KV!0/B%J;&>M?)!(GB%-KIX89)%HT,T"&\+!T#W
M&T^8[2MP^4H;Q5K4Q7:YF"G1ZBH:IEEITJ)D=9H_6>3Z9&C=))#Z893CJH(8
M:JWB&1EW3$9!  4J2=IP=^7SB,D!<L1N\ Q)JS6:Y2W+;&XNJW%L>Q3'K2]M
M9%U*?7.N&U"C/*QZ@1[52SRDD1LF;64XV%))6"5'-8UBO3)^N=<6_2%NBK:K
M,U14-+#0T\2K,[3)2SSB22)3Z@I5]()-,H_5B13[XZ;HJ:*@BD9U98Y#*@4!
MCO=5)*D9! 4#)/('((^X\\7Q9'LB'D,; BRB6P[ZXL[:"VR;6/@UU[8%^%/G
MD/+C#% 0"L#,EF(V%$,B!E/8XH6DL+M;K*P5FG:AKG4T<%\GN]RN5RIV5]SS
M5DY>%J99"YE!A6)(UB9GRF ,@DL4"5$TTDB3A4VM^H!V@-(2=P'DLRX QS@
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M;U21+2)/+405$B1U*10L^9?EPSLZL$+QB,,S*4&T,=O3KT43R"=&B=U4;V!
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M4WJ5QRHJI*&$#WHCF-1KBU=73T\U''53I25;AJBF$C>A*T67B9XCE2R,!L8
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M@G]G_P!;[$@?;D<^"3T!\*0!C+?4P(\$^ ?./&?&?PQU-TR_90\<>/Y; !+
M;]Q[&R*6)CA@ES:?&1X=$K:KYA F<L6-*D6I(;",,"*>88C1J[[)*EN-?/3Q
MT$U=5RT-*-]+22SR24].[@AFB@9RD;,,#*KQDXP"V7VDD,42%V9$9F5,\#&,
M#D^<G.3X]L<]->MVQBYLNWIL*?2%KL@SVCRH."Q(HUDAH+7+;$8)CR2VO"H"
M@H#SXS9S&/\ <(4K/::A_P L0(WT GPP+'QG;GGP?)Y&<?W#IM6&78YRX.W
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ML0,LP &3C+$XP//.?X^.N78GX@'F5A=[-PZYXS\! .H32EB5TOB?BY Q$F2
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M5S_/\//4@UW7WYH-P^7D4+C/P(;7V<A*B9\+B5C+138;$%,>.4 -LWY4)LL
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M/15-.PJZ>.HC J87B+".570E"RR+N1@610<#),^&I:CC,B*K-*'0[USE2I'
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MLWIHQ7:(-\D6["D:_7BX-:[?45T2"6?;(E+$[B)):B0!85>1P52,NX+DJ0J
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MCC.?/N<X P!^7XGI$[%I&!/@E<#&, 8!YSSY)_S\=:$_XBKE:+.^:%YIW 9
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M@AL1&JE\KJ"EJ>[=+HYTI6M-BMH>UTI@@ I;S'1K(&A8CU"T5$6BC13B+D@
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M#.E0U-\I5T\R.(WC^5F!8>2O#2?2=3VQ[K]V^W]YI9;??+3KO4#2TLL$B_\
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M)"2FG\&_?\K"17"[->[\C6+^JJJRH,"(H5/J+-(&Y&W8V  @P"#DL22V""N
M""2^64K&P]U0G ^P8?@#XQGS[_;KT'.G/O.QVUQ6UU#=7PUL8F#U4*%/"OYK
M(HH0S199D:J.&7VB15;Y=^WM_IV1?3$$IVO#MY7<%(SR<\9./;./'L/.<!JH
M0)+D'AB&P1X' _+!\_O_ !ZUK_Q1O%.+>ZVPKE:"GD?M[@UL+#,TL(@BO#^R
M5[,7X+9;1#5OQZ^W,]XI;G=A>^\;GHQW9OL)83E'(7U W+#Z0RKGC"DX.<8
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M7-;(=$:]6*K4[4"9RTT1W84.P*^%#8;:=N<8!.%XXSQ@$]4^!F/J#)^L<$9
M&,G QQP"<<^_''52_P"$GX[8WDF$<IMZ7M;63YP<AQO!Z61("P\R. -22PGB
M$PB*@V22'%XN\55Q M1.[?-KI$5141NT44KQ1,(I)8T8A)'C9C$7 (+!-\FT
M9P"Q/)P0IIGC0!"5WN&;''^[&%!((X&YCC QG[@8N#ZK_#&GL.!FX=1:WQX
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MJC>I[R_T"G5*X26^5S*T]%BVE<SCVV55;GW./T-[L#(9$7!/F7$(4BN@/F?
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MGE$8  8G@KGE><GB-/%$[N1[O'P:Y7-[M^R:R1/2*Y^H\C'G'MC\<XQ^/2(
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MYUK$CGC1@)!C6D@<LK&1HR)!9*]L2.]I'+( (4#/(XSC^'GS]O/3+%3*&"@
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M0TR:AJ/4DJ7HG+4E*IBD^4:JVLIJ]S%HP%"QAY%+!MH4%@ZM$^=AG(;<5;*
M*I*EADGG!  &,$'^]SQN5'2\@UEA5Q.D/K %5:/"V?'_ *=-Q.;(<%W<2.*M
MRY[7,7\S4&1OZ]U_O=UNVB[*U5!;;C9J36%3%0754:X4@M=(WS"IC8S/(SSJ
M%9  T;H-V<<ELPW"B;Y4W*@$RON^7>0&H4M^K#>F%+@,#P>0,Y]P>FR7E#TH
M0R&!7H\:P5I)((@B)OS<:D,4K'O>H@)>.\A :PCB.<]KD]HZJC4$JOM2;L/1
MQ5'HG4$[9GB@4BBCWN[AF8H@G)98P&W'(_9<8 3)E)1LP!^8W D ,@R&SG+
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M5M[<T]\IJ :<,%*L%9IZ684M34W4-%+*]?/%(U:91.312*D=.RQQL).GES^
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MM9W,[/V".HNUSTY7]Y]-P4<U2K37:Y:=HM6Q3VU9X$8GU):&CIS- "5@@#Y
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M)?W="GL>B+;H#3]OMC36ZSV^&QJ9UA>::R4$5+$E*M4T):.H8P*TDD:Q@AY
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M&/"'\ 0&)'\1S_#VZWV-([SC[.PG,1TUN&FJ\*F7%%'QI_@&15UE/$=5URP
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M24,%E@]VNY<&K)8++:2#::2JGGDJ5J(W^<FIV>"-TBA+!:4[W>-Y&_7%5D1
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MMJK$(R$K;G(KP\8TRRBO8C3#JA_+=/$!1O47NN9XQ_=>SHE\:&HUT]V"[?Z
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M#3(\15&1K#*411#X6U5KO]JJ:^DO=EJ: T-TKK2MR@+5^GKG56Z4PU?Z%O\
M#$E#<A XQ,D16:$D;XPI5SWQ^&+XPNU?Q26RX/I!ZVPZGLS/^E]&W^2A%XAI
MXVBC:YV]Z*IJ(+I9S-*D(KZ<KLD9%GA@,D6_Y9BF<UFOMIW&/XQ,D997820T
M5DMK(R5>,W,8P\AO(XSM<Z1;"HGD=6P'#89\23*M J[X36$S%\/%NT_5=WNW
M57JZ"]Q6>INIJ=*5--9ZZ:SWC5MOE#6>"NNB1B"GMD%5%-,:Q#+3-<J6EHZB
M2,2-UIU_2/\ ?W3]X[=VSMWH?N'H.XV:LUW'8N[=!;]46FIU32&S34]7;[ E
MB65JUZ.>\Q1->JVF.^@:AAI9$*U,SPS)U8=<LVU3="3!)DU(=C=<.'OJ71NW
MQY.15T+$[*G@$*1544.5-B,$<J->_P!KR\6]W=TV:U\SQZMU2T@&\7RX^H #
M@9JI-V,Y/ X_$^W..N60"/5R;6#(7RC*<A@,E2,^01@\\GR>>.MRG@-C]0;C
MSJEI1,G0;#7F/R8!I3VOF5TCZ7$K[VG4["._(DIA',%W5XBH]6*Q$:C;-I54
MCG# [BI..,DAA]R/<<?CSP>H\Y)=O8@\C'MD$<>,$8_NZU7NMEJK'J;K:<$,
MM44<-7LRHP:GDOEC^+'FIBV<934#, OO>#@*RX$(96.%[Q&_W6.8GDY/$85F
M3<I+(LN%.=H<$;&  PX*Y(YP#YZ?ASM3=PRE@<^<8)&<\C]HG\O!QUL^<;M-
M8BR'EHBN! N+$Y:JWE,<HD.RN]^$%Q'C(T9#/ T"I(5@S&\?=>KU(]/4.FB5
MPP+ $<>W !(XQ@@G@_QQD<!J:1SMQG P03SY SG(/[L\>W6FGUZN/>*8=S<X
M9Y1$N/IIMC9W28K9W2HCXU=4U&T:D%=8%5"H-QH"EFE<OY'J)H_=<[NGBY3@
MJLRYR 6*X/L0P..,GQG&><<\G'3^=PC<@Y5U5B![D!N!QY^_\/MUN!Z\XVX[
M2[ G!CV->^/!HZ>3#>4Q!C&GM?(DV04<OBT4I9JO,UJ*K^[?+LC?NQ'!E]NX
M8"@DD\#('/!\?W><_BT\[,N<'DG/@?N_,'^!^W5!/7NXLZAE:4FYC(DD+F]3
MOS5D?%+>,TB1(L/+K00;(!G%(UIFRHT\Y1A:,@AN1JHC4:U?2X@(YG4-D$,"
M.<$ 9!SQSXQ^[[=/1L9516&  #DG)# @8Q[C&0<YYSP<];*NK\,%%UYKBB-<
M ""BU+@V.S9$P;IDF5)I:&K5;"!)*95%^01'*4B*@!%4+1-$C.SY_6G<Q5,J
MH(5549'(V@8 ^Y/ODGG/4,L<L0"1O8CGDY)SGC/D_;[#/MUI?_B(-+8Y P6V
MV.60V;=P=UTT.B.!ZH)D;+@V:6;%1CO;.BB@QO)[O)S2#<K$1JIZ8I6(G=0?
MI(8GWY!(\#@^Y(/[LY&)KD- N?*[<'V!\'/V\_PQ^_;%Z6F"8E1]-;BA#MBP
M!2@Z6J44<<PG(^-(++FA,SNJ.4K1G8LC]5%)0HN[?'[2\(ZN\C9=BVXEB2<<
M>_)_?R/'@=0YB1*RKD#<, _D!R1[?A^//W&N[^(>J,8)Q/S>X!+0$B!G&"UU
M4QS>S[)Q\GBRG1D555',$)TF4G97*UZ$5$[*KO4*E(^8XY!W$>V% _< 0?/W
M\=3#GT#GVP/.2#D>>??!_=@^0.J=N,Z>7X=[J'-5?UYK: :B_P .[L;IT3]?
MM]OXHO\ VKZJWW_#[_D/Q _P&>H?]L?_ '/']_6U9T+]60,-T!KFPCRBJ"CP
MVDIKJ*%4\209IQ2 292.*UDF#";8S"J5WC^Z?(>B&* 34A12R/4.-P'I9;<_
M)5> R*<$C.Q0!D# "J54G,JI<A%13R!E21SPO('!PS$ #/ \9P3UR?B>=9XG
ME' 3#[1X@E%0;ZQ-Q9\8B*ZMAVE%D@)RA]M5$-9"B BN>-Z_E7Q5%56NN"Q0
MT57?+30W*:6*VUUQIH:UX=AE5&;TU=68$K@OACGA23@E5PQ2(LDOU\D(RA@2
M"%9E+C[')523@G[ >[CZ3>J!2<!P,TO#X-''RK"(U;(A7E%3GM*YT6#&=*<8
MTD'OL&:PB.1616(J&,%IQQBC5R.ZHAJK9J6^6N&[S5=%35TD<#I5U+QRP' @
M_;D;>Z1%49W8EPK,C.K=5&X-)&SJ9'^DJ=GJ,<!E&%)]V48!SYP3GGH _P 4
M5QCBX]P[P'8S),8\[#=NTT:=+(5Z27Q;Z/;5$80F)]FB0,@**GY6HHE155R-
M3U;,</HRC))W(V??)!!'L>,<<CC^/4!9/41E/&T@C[#) 8_OS_B<X/5XO3UQ
MG%]5<#]"+>372JZDT'@-X\T1S'R3([$JR<6O\#$8UPW$E-(PA7,$$3722&$
M1",D4%(U;4K31D;YY"%)X RQ&#YSY)X!).%522 4LC2SK&O!8[,DG;@8&<YS
MXP3DG)QYZKKZZG'/5>0=,SD/N.0.+&LZ>DPF[@2C-<A@7-A<T$^ ,2I)D,85
M_P I\0C!R"HKW*UI"M5'JW)2K2UDJHV?2J'@.#D,5+*3_9X^GC*@^"0.<.;R
M'> Y*KZ@Y]MGN.!GGQG'&/'@$MT<>*E-0],OB] ^2,Y;O$KC)[2$<A1$E)?V
M%Y[@1D$\9D <!F,</R1G[OR3LY[NZ!$7;U5?:XD#KSA@5P%(/D'(R,8&1^&
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MQ;6U_E.1 HL+V+D^0;(P_"ZA%BDA46*V$6NP>?D R%*9UL94)8KXJ.*)WMA
MURQW.5V"-59LY9@NUCY!+#G''@>.!D>_VZ\?Z43:-N>1C). 3C..>3R1[''N
M.KS..O64S/7.@<JMM\^6P*^LX[Z_V#JW+\<"..:5*O"0\)/KO+6.>L1;6MRY
MT2+'MVM#[T.08$\"/A$DO8,9+[5+;BYC()X7 +;E_ KSC^_GH:-3M;@*0&./
M?/L,>!G/O[_AQ0GS4Y%77(W8(,$Y![T;#P7%\2E[8NZ; Z^+<.D[/L8J)1X!
M4L))9"E6=;6R(D!D^=+2' 8ZQF/ PI4CM>@41(?3B&YF W,,-M7(+9X*J23]
M(."0N<D CV4J?H. JKNXQNW \#SSR>/8\>..C2X(]<7<N+9?QBXT3L<EY#J6
MDJZK43C6]U$;E#B2I;XU)?PI-;60*^$*  @X4VK.*?\ /"BRW31R&*TGLU.G
MI.X>19=Q95&!&(P"67:<L7+<JV=H7(QDCI *,0"OU$XW'!/YD#SG[C\^<CJN
M_DUSBS'GG?[>QS>&9!P['L9/DN7:3JHIW0,=A6.,FDC'C=^%SGMO9V1U8W"@
M27H*5&NB,=$[1U?&>I(A $*C);ASY;!]P?[(!QX^^#[=!8.&4X4 $H<D?LG
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MT>9L>*!5>@0^Y1*@@"<1SFB9XC:YSE1/)RJJ@%'C@Y'W!R<8S[GV\_Z]>$R
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M"@'6<)A9"E U1KGGM.*G3W8'OSK"FN5ZMU3<&M6C*1:2X*UMG6O%M$TK6R:
MPPUX2XS437%)6G-!5R11")PK]<Q/B<IJKN9_2)Z#T!/14=PM=B?MA;I[=)00
MQTUPMET^8U3?#>*F*+YJXQQTE(T<"5,A@I86D@C6-*B=I.JJN>]7/5SG/<JN
M<O=SG*Y>ZN7NO=SE5>Z]U[JJ_=?X^M6P J@* JJ, #"J !@ 8&  !C@8 ]NN
MWX 5<*  HP!X  X &!@ #\, #]W4;<P5JJ[+\.PB"EVV=A.'0H5[]99#&Q;6
MXDEOO*".+(DN")(4V)&D!,97A/'</P16N<_J1\#.G9;7VFK]2"NMUPH==:AE
MU!;9*.AK:&JIZ:&@I+3-1W U3O'5M35U'5_)U=)BGJ*619P%>5XXOF'[Y=P*
M[NKWH[G:LK[+:+$M-JBITO2T]FKS<Z.I@TO755!)<XJHVVTO)^E9Q)7N\U+Z
M[33R-+*R[ LQ6D<]=5X74%L33VUV!X<B",\[W5Q3X]7%+ ?[\B0[W8R*,*^'
MLL:,81#C &(8TYV]T:PW+NQW4N+P01RU'<'5,/JP+&L=1#0W6HHJ>5?3CCR#
M'#]3,9&DE]65Y7:1CUVP^ 6GA3X6.VE6EMGM\MPCU%5S/4OO>O,^JKY.M? 3
MS%051F>HHZ?A(DE8IG>SLV[&XH,?JI-ID^/)EE4:774;<<=,% ';6%V4@(H2
MRB"D. R,(4J=[PPJ\98PO$H7.0J9!^''2NHM6=T:"#3&J9='W&Q6JOU/->8:
M/YYQ;[;44%+44+4[2PPR0U\MQIZ:I6=G1J9I@(G<+MQE_2;:UMFF_A[BT[4V
M6TWBZ:YU&EIM$]S5GFTTUNM-SNM5JJTA%WBZ6Y8(:&F8/&@%UD]8R0EX)>TZ
MOCU'C40U\HE2UM;%7LQ.\>"GQA*OM_D<JL&BN>G_  CE5ZKW<OK$6HKY<]37
MV[7^\5;5URNUPJJZKJ29-LDM1,\GZI)7D>&G52$IZ<NPIX52%250'K<GLSI*
MR:([6:$T[I^QQ:<M])IFT3M:(YEJFIJZNH8:VXFIK%2,5M9+73SRU=8(T%34
M-)*J(K*BLK?E$!FK=;9*V:4IB9MF=*2$L=HPQ6_2<<FH1LCLI)#RH%KW(KV"
M$B^#6*_S?ZW=^ FZU4EU[OV4TD*4E/3:%N:UHG9JB6>8ZFIO1:G(")$J1.0Z
MDON3ZLJZ!>0?])%*8_B0T'%Z38J.TK$OZL;J4I]47$HR1*BO$P:>19!*T@D"
M1M$8\.&=O7Y-&_HWZ19SL=(B?U%,/*88W>#RQDDU+C,8Y>RL>42.8QZI^1RH
MO9%3U4]=<ZQU0/O>[E__ )4G^?6@D_\ Y349S_O3G[^3U>UT5-:IMGB9C-SC
M&J,8U10WE==6%' KX?O./70K(L-9%A</>69,=/8UKCV%E(^4IVFDA"$+V!3'
MLT7J3NI)<KDY9<^!X^P'O@>PS@\GI]Y%1$..#_8R. ?W$G@C\^<GC'5!'79X
MB9!IV]QS>V:T,"@O,LNI.JX<6MR*+?U%M#QV'89-#S"GL8K8LJ0PM5*922(M
MK7PC0S![^V1OM%?*I25W0GD<-D9X!P,?;&<9(R"#C.>D2M&ZAA^UPON/;/(^
M_/Y'D\YP#-Z"7'J53CQ*TGTU)DU=F1191DUJ*'+'(QZOG1H[JN/(L1L0LMT.
M.A5#&1&1GS32AHYK6N,YFJ822!>0 0/N,9Y./8\?@<8/X]. >G!DG#X) &/[
M0X'/MGC./&>,<]1A^(BXX:EJ<C_I5USCY:;*,8R&EQ7-3FF&:EP'(CE-66\!
MI6O'814.J@]L3T^(I7JTQ48]J.4TI#M%@! ,+MP,E%P3@$8S@$G.6()\D]-L
M&:%78_5D<^X!.-N>!QQ]ACP1CK83Z0/$9VLN(&)9=E<*TRJ^R:LJ:*DC&;'C
MAM6CC$ESC1&A&,4:(*0@$?/1?-7BDC1Q4(1R-E!(SR%<@OMC7[X\G.#C!XR,
M8!^_1/(0R1AL;%!8\ @\?N\>1_)UN_Q >*:Y%>@V4_"(6/;.R#-)6M7JQ2L&
MRDQ=D&X;<06-5JEDN'(2"5\QBN4$YSD:[P$15T;-EE'[*_5CP <,-N3^0..<
M8R??I4H7TP3]1. &)Y'OG&.<^P]O/MU9#T@NFV"KX1X%R#Q.ZAW&;[0^'L')
M?:JXJEH*'ZX:-54I[@[G$=!$YC)MG!CIYN*,;FH0??P14AY&8#E8^"/  X&3
MSSYXSR!CDCGH61$.P@@MSGW8GD #G.!X(Y\@XZD3\0@SAOCFL=:XGM>"++\A
M,K:!F7XN 'S-9FGUED6#:030B_/E%9/C(^QK/(T:6 C5)'(P?DGL:LLH$3[B
MJ@L.-IY&!^?))/@>WW*(_J1S*/H+D#\R",\Y/MC(_'JBGH0Z'O=BY=MS/,'-
M1SLYQ"?@5-05D\4=UK]+G'FV5Q9 CD:92Q2"@PH\R"QBH<:E[O1PD55UISZ:
M8)#9) R>1QC _'R?R/OTJ A5<MP#@9^WGW]@21^?]QVU.LGK37F =/W;&Q-A
M:_I;I1%Q<J8]*AQ3LO:B0>/%L8TN9&,.;2D!*G(6HL(A2%@RA 8X)6-<C4B$
M(T9Y1V8;""/&,L2.3C). !SDC\>FXI&9RI.Y0K9!YY'GC')XYSY]R.M4_B+<
MQ*C\/CU%;(<9WM.YG:3%#"1WN+'65BU6.,IE\F>_[ R(UZ+]BJWNYKN[FK>N
MEKQ#8[F;A.K.4HJR*+ ) GF@*1LR[DWHI)+)D9 /!(VE,3JDVXCC8P^^,^_M
MG\O<]!OP:V=BF%T]W-V%"N;6CS&':4,^TI$&:\H90[.ME5]E$%+D1VRH@!1%
M9.KWG5\H*^#5\T8JY4O';"N[Y=E#9*?4'Z.OZ:D:_P!#5U@FGM\M70)54M-0
M5\*,9_DI()PH8&62DD$=2BRO&%-RZ-[BZO[0Z_T5W6T=16N[7+2E=7/56>[[
MA172W7"F>DN%#ZZQ3RV^IGIG_P!CN$4;RTDI#;7C9T<O]P9WI8FK+K'L,S.5
MF]]D]QCTR(-^-V-*/&JRE+)DSY-H>>40V6,E#K#"&&V<%\=QG/(+NB^K*^&?
MX=.YG:WN+7:RUS/IVAM]-I6ZV.F@L5VJ+FUUJ;I76VH:283VRA-/14<5K65=
M^97J)4^D)&V<T?$_\7%7\6%-VVL5-VQK-#4^B[M<[]>JRYWF@NLU95U=L>V1
M45JEH8T,=M"2R5=2]2(II98:11&-C=!?KG:=75;!KKZJ""YDZ]N*6Z/"E,[P
M;!C3>\T+"(QS'IV8K6F:Y_@16O:B^"]]Q/TG:]7QZHTC!4SQRR6N:BJZF.)L
M0I=:66%9(9"BQ2&)9 VT.2S#!^DY&K^L+8MZLM931U!B$<#0,RMC"R*RC: /
MJVDC)SDC/(X/5K,_?'&?-"UNUQY+<ZPR $EUA?8<N/S+*?>RA%\S)128;1U#
MSS!(H"F(HXLDTA_SAB52D)S&NGP+]X-.76V6G1E\L6H+ 4ILZENMSGL]PL-=
M%,TOSBT$=-5SSPPL(9:2"CJ7D@DA"QR11E!'L_VT^//7%@[-Z\[(=U= Q]UZ
M&YZ>J=-:!JS6T<-MMEHJK:+53634XJE-QKK?;/HJJ6KWRW/TH5IDE>00SQ5'
MV=KCV0;0VE-QJM?61?J<"1&D'E--8!KIDFSE55.88/[-&)6QT\S(!ZJL@W94
M[";X]*=([*345[I)G6XW2WV/2M'=[P)"165D-#+'(JP^F/0Q,DU3*ID=R\ZD
MJN.M9J"V54NFJ>AN31PUM)3TE/.P9G23THL;5WDG8%08W$GD!O?J>IFU-V9;
M@\3%\AS*VL\$N;&)CH36SJ\CI1\?(*R!5FNSC^K)$KG6(Y?A)E)%:A$7R5&*
MC7Z/MCVYLNM+GW%M>D;/1ZWN5+)%<[[2PR"NG@J$IXIBT*N*;U:B.WT\4T\4
M"U$RP())'R=UN6>FM]174&F5NEP2ALU967VVV):RK6T4=PNB"EK[C24"R_(T
MU9614ZQ3U4<"321Q!6<J .LMP))19S6[1HY-I7OV1:(>+ATBS+&JJF17T5A%
MGY'!KCE>\<6QE0  9#&>0C)D=)3&D:I6C74CXC:#5NM^S*5FF:*NU!#9M?25
M>I**TPD5;4-!1UE/#)#;(I))*N"BJZJGJ)($>6?Z$J88&*J$V([!]T]*=F_B
M+[7:^[AUD]'H.SQZHH[E74M"]S-!=;U9:NRVBX55-&K3)04T]3NEJJ=))J;/
MJA"N_<5NPOV1UAJO8D?-;2FM,NS2B)B>)8K0W$&TLX%B25&GEO;A\1YH\"#7
M)&BE\$.\TKW?8\&^3FKB?X7NR/<2/N1I;N'?;!6Z;TK8Z*Z7%9;Q'\G77&:N
MH)K;34\-M=Q608CJJB>1ZV" J(U*1N2I&QGQR_&=H?OQ;M-]I.R-5=KY0VW5
MEOU)JO5T]NGMNF:R"U*[4%KM#U@2KNLDE6[R5$[4=/1T_HQO#/4L28AOX>'Q
MN9O+!&7HZ@U;<,N:NOBWT$,VKFW-I62HM1&*$[>XS2;$HTBR&N!(%*0;@F"9
M6.];I]_Z34=Z[%]QJ#1"537BXZ=JZ:C-)5K0UGR,LT8N<M/4R,OI2?H[YPD,
M6=P6"JQ(#:$:ON]18*?36J%%2JZ=U-8+[4?*0P51@BM5PI[A,_R5212UX04[
M%:6KS2S% M1^JW#HL6:VNB[)+KL4RH%;"LWQ73H\UQJH#6#;*<84AC7'<@ .
M1/9\/DL.U8Y6L,U_CQ+M5>MWH;7-2T\\LEVJ*2WTE-.BQRRUE;5K;X8Y3DQ+
M')4."TREXC"?6CWJ5#?2WJ7XA-%:5^'VI^(6YTU^;2$&CXM41V^KM;T-_JTJ
M85%';YK?+E:2KK:EXZ<O(QI8A+Z_J/3@,Q!=("?C-_U*\ER#%H4^)3S-*<B2
MP$M61DLGHNKKEDPDKX[SL9\F>LN6P0Y)$&TR-4CE1WKLOJVP7O3G8VQV34UQ
MHKOJ"R4.G[/<;G;Z=J6CJFHIE@A:"*7,ZHD"11DMM,CH\I1"Y4?-K333U-OK
M*V6B@M\-SN=PN5!;Z>HDJX[9;KC<9Z^DMOS<L,$E2:&.=:83-%&9!%NV#CJE
M+A#N'^B3.:?-HV+R[YD&^R?'9=,'V%G7?SQNC")7*011,<TY8X/ @B->$<@+
MFJAG=XM+H&U=Y_A^U#V]N+5=GI+U3?HR6Z _6LU#44U;3UT2QO &IX9HDQ$)
M$R(W!?=]9M?64=>M':KE:[J]GN5JN-/<[=6*[(:2MM\T=1'6 )@Y0*P4@@J2
MK*V03T7/.#9&Z[_)Z 6TL;!@6.I1&R?'L9BSH%HJH,9H\VQLIT!GD6R$QKX@
M8#_W=8!S8T0+?<>I)?PY=N>TG:SMW4T';BKMNH9+*U59]1ZKHZ-(ZV[5]J+5
M$U-/,N]YHZ5Y]L4:U$R,QW&5Y,L+9[?5QOEZNU]FOU=?;U<:^NJ[G<Z\U(_V
MBX.E15R4U-,S1PBI,2R22QHAG=(RX/I1A>KHJZJ<BU9CU-\"NQ6/37:!DV[(
MIY$FY)>,D6<^UMD")TURTD5];6P8;&D50>?CXD5Z^M0?C9MPH=2:0U!35=SN
M57>=+U+1:>EJTBH;13VXT$=+%;:6=D2FENU9/7SUU5*P+M#"C\0J#U]_HPIK
ME2ZO[_+%04MSII;?I&O6J1(H+E350%QIZ2Q15,TFUZ*HCAGK'W&*."J#.P;U
ML(2M(V$W4.^"U-15SGUN(V$J3<Y$ 1)#*L@/BPXM1$''D)\XDYSI\MDB0*.*
M-%$5".D 8,^#?AQ%MD[]=MX;ZFI)+A5550+-3::JE@MM+74]'5U=;6:CE>:G
MJ7MD=-%'!&M*':>226GFA>"9BM3_ *5Z/6#Z8[.^IJNUV[2-5K&DAN&BZ>:N
MBO%^U"DHEI[A'+S15-OLM&SY$D4-13SU!F2219 D5?&E;&54[=UY)B-8[W,K
MIH,A'=E86':315<R(5O?W$27 FR J4:L<)CO<&YA$8Y.O/=33,&M>V^N=*U2
M+Z-ZTS>:=)MYC^7K$I6GM]1E26$M+6PTU4C@% \*ET924;F=>[E6Z>H*N_VI
MDAN=ACBO-OF9$E1*RVRBKIO5@D5DFCD:,)-'(/3DA9XV^EL]&;G 71LTRV.^
M-%AO!DMX%\6%W6''<.RDM4,57.>J@&J> E5SE5B)W7OW]<)+89#;J#UJB>KF
M^4I_5JJEM]342>DF^>=P%#2RMEY&P,LQ..OIU[2O;9.UG;>2S1^C:)-":2>V
M1;2GI4#V&@:DBV%F*". H@0LQ4 *6;&3AJB"'-]@Z?P*UI:6UQN!9Y?F5ZEN
MID >'6TWNS:V0Y'!:L=P(,<XQ *A)$DHF/\ NQK';F_#_>X>V7:'OUW7BKJY
MKC1V^TV:BM<000)7[*B.SU\)+,6J7K[L(I"ZJ(H*;*EM_'&3^DDL=^U+\2.A
MM,V^*6BGU=IG1FDK)7T4I^9JUO.KZJ&[22;(6>F-OB9E1P)BD<CSJ5&0'GLG
M!['7][%J;BU@6%U,J8%W8QX(Y@24Q;-BR05EBR9%B/#9"C*$T@ AN%'0PQM*
M]47MH]IO4,6I:.IKX*6IAIDK:BEBGJI89S</1;$U9%)#+.)(9)BZB223U)&5
MW=5)Z[$]GM6Z:U=HV)]&6:OM6DM/5U7H^P-5QTB4MTH-,%+2+C9325-2E19'
ME@DIJ&KD]%ZH4TDJP+$T;O"-[K*&/E-@%"^SK+!E[-QK+LF2(,<^/7OC0W7V
M2U\R&%OB22@:J6Z1%5J.(^3W?_PB*O7CMAW&NUH^$V;6>K+?744VE]'WF*W_
M #<K)47>UTL+P:4K()MZ%4N-+56VG@?U0R$ LZ.K$?-+W:J+3J?N)W4T_P!M
M*&:"V7;NS>M&Z02J62BC-7J+4*VB,1>HNZ"@BOM74QQ%%804(4(H$83H@\SK
M<;RK-U77TXIZ^_N11!R+Y(=&BVUM*>56Q:YDB26#2PTD!AA-(>KU0/N.&)"-
M$SD-07.\I2U=3J2G"5W^TUS1435%>PIE?Q/62A5J:^9MTT@#, 7(,DA1I6^C
M#M4MZ[0]CK';>Y%%;[;)VST#315\6ES5WFFCLNC;%#33U*S_ "E'\W7UB6ZI
MKUI*:G!2.>* &29'=JTN:;J;'MPI%QVXJ\JA'D8]$M),+WR5[LC!1U0;A8C5
M6&=5KYK)?E+$CA!DN4!@JJ?NNQ';F+4^G>Q/;*@U1:UH;W#9ZJF:U>N*IX*5
M;A73V&64TTS 3I9WHWGE@EF6*<LI#H05^=B\:OM>O-8:[UGIVVUULTMJ;7>J
M+]IFDN:>C7"T7:YSU]-+41+)(8Y)'J)9$42.%615W,%RWK+8I_FOC?\ _(*?
M]51R_P#U=&_54^R_ZT^R_KZU\?.]\^=S9Y#<Y.?J& WYC@^1U:AR"0?()S[\
M_G[]:3]EDCL&T+RPYGXQRHW/3\VM;=53--7Z8URWD'EEI0; Q1^_,"Q>#J:7
MH:??3*:ZQRWQ?(,F$GPZ**:*.&V<*:(,![50?Y_G[_F#]O?KS[9_C^XX/[_P
MXYSX'5@6(DD9;U=ZJ#QZYF;7RO-<'SC8M[S#9M#<\!--T?[::ZL&:MX@ZHT6
MD^NB97<X-<NC9/<W>/4Q)N+UU69N0Y))OK+X@/>CV_,<9S_/\_?HM.E)(WG5
M\L.JIKS?&],FWQE&![QTL)F06X?HV.U!,FTI29/8TF!X;'DR:W$,3KY=DZ%5
M5D1Y)!8D0$NTE3+$LB20_?\ AT?;CV_CY_GV]^.M5#DD6LC=1CG&2>Y(]B[*
M-K-HU53$5TZ1EE3'E-\V*Y!F+4/FL9Y(P:,(X?V?]URE\2C5Z_#%8Q1EUAEO
M6B$N7I.%WT&^;='(-V7B-7'2-)&!AE5200">MDOA7@M]1\3O8:&[0)44?Z>N
M4U.CH)$6[0::N\UKF9#D9@JXTE1\ 1NJN<,N0V=44D?)-DX522P#E1;'(*\,
MB.9Z,$8*%0CQD<[\O@YK%1S7?E>G=CE1KE7UR]NH=J&:*.H^4DJ3#2)4Y %.
MU9/'2B8L2 @C]7>7) 0 N2-O7=KXAM77/078SNUK.RU+T=WTUH'4UWME5'"M
M1)3U]):ZB2EFCA?"2/',$95;C< ><8Z"W<=I=S-Z9C;YA23:*Q-F9SEI5AEA
MS(M8&Q8&N%'CO\G>3JH$90/:KV%<K2"<K7)W[SZ*TS;;)VVT_H[3]:*JVVW2
MM+8*"X-4I6>JL-N^4%3)41$QRLTN^60H%7)( 48 ^7'3]52SZ*-=3UL-;55-
M!6UU34,X=)[M6S/55SS$  &6ME?>#A@K8/@DEGEM(_'LAL:MY7'8QP)48[W^
M9#0K&,&P@E-W:QS3DB20N.-[&$$97C>UKFJB<+ZREGH*^XVVK"BKM=SN-JK!
M&#Z?S=MK9Z*I,1/[4330.T3@D.A5AYZ^H_X?.XUL[M=D^V?<*T1>A1ZCTG;)
MVIO3DC%)6T49MESHU60!F2DN5%5TR2 %)DB66-G1U8Y'-=9Y5#=JC+P.@VV,
M&P7)(A)$0XI!ZFSDVTR[(&5%7N80WPV,CBGL:H$E>4<CQ%<)I-A--:YT55?#
M!KK0U-<Z:#7$&L:'4ERLDCS05<EICO%GL\%:K21K3SD>G"TE)%,\T<+Q3-'L
M?=URRI=7?,?THUZOUYTSJ2V6==56+M[:[A<;7506^:\Q]L:FU6Z6&L"?+[+E
M.E9<*&%Y \U YJ44JL@CZ.%R:N'EN.2KJ,*95 N8!)\8Q$"$L9)#/-"E5%1@
MV]_-[G)XHUJ^7Y>_K66ZQRS6ZMCA>2.1Z>0*T0S*!C+", $[V0,J8!.XC )X
MZZ\=S*74E;V\UQ2:.J9*35=1I6^Q:=J80AFBO#6ZH% 81)A/6-1L6(L0JR,K
M$@#(@W96NK>^Y,SZ^[RRA- SC-K6]BYBDR1;TT>C)9R90TGN&Q\D#X,9 P3Q
MGC1H?(+AJZ,YKO77[1W?KM)9>Q<>J]+0W<Z6T%;K#I6>PTMHEI+U05?R5-3T
M=-'150I%G5T#U'SD#,E2T52T9DJ%:/KYEK1V,[[1T]M[=5/;*_6ON9>M-7&_
M6S3E\FH;9<-04])#/+=+G13RU34\U3+/'52>C)+'6RSL$>"-Y5S.F;6,&WR[
M([*L^]=+MIA8*^/@BQ/=5H%:S[>#5&UJL9V1&,5K41.W;UR/$TM0TM3,)!+5
M3U%5()G]28/53R5!$S@G?*#)B1LG<X8Y.<]?27V*T?<^WW9CM9H>]I3QWG2F
M@M+V&ZQTK!Z=+C;;12TU8D+@*'1:B.1=X&'(+#@]0=NA\VHJ=>U\F,V*/(<@
M'DT8YP-88\*G.^HC& =R^:0GRY=@U[5:C"EBL>USO:[^MZO@OL=/);.\&M05
M>6WV&?2<$J3AQ \M!+?+G$\$8+QR8@M#&0LI*$HBDAB.4W])/KBVZO[I: [6
MT$K7&?1-";G?;<L3R0"YZRK+;24%(W&)JA[51S>I%%N*15JH^'D4"2WN<][W
MO7N]SG.<J_JKG*JN7_G557UHHH"JJJ,*J@*/L , ?PZ[500Q4\,-/!&L4$$4
M<,,2#:D442!(XT7^RJ(JJH]@ .F]R#B&DZ>U6>N&TT6NRG-3Y&L=Z$)!E3OH
MT2HDSQ,<XD84B. D<!GL&%[T8Q'*1[/+?'X";G;HKMW>M%360QW:M?1M7;J*
M0B.>IMM%1WA:R6EW*OS$=-550-0L;2- TJ,X56!ZX0?TB]#?8/B>L-\N=NN$
M&G*CMS:+#IZ\302BUU5QAN%VN-TMU)5#]0:N(5,4\L#.LS*6=59(V9<YU^6,
M/KSI%#,G=AN#6%B>G=5:K"S*EA$5R*BI^1R_=$[_ '7[]O5:UU_^^&J,<?\
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M)_M*R@G*^",$8^QR1XZ8BW9+*,;2..<$%@,'[\'^?/7G\Z @_2?P_P!U*JM
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M%;9T:0?[=+&ZPDK]1D*GZ<C&.<\[L^% YZ8.C<8L+;5O[0P(4A\5F16\*QE
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M[%636TUTTAEBIBRQGUG5O3CA8LGZLJ$C?;ZFP 9P%'5NBKEA0I"1N8EP&4.
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M\%561V^FB55C6I8N]00)3V^@E:UT;J:1:*D:5L2=H?D[86*%:-OG('J:^:-
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MQC(HY&,G(-)@CK"D.%&(V'=, Z9 ^4&/*-!49F@+'\3$CQF2GWY *#'(&=I
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MVY8?2H4$#V!R ?&<??R?!Z#-XPON?\<CQ_?]_P >NNGX./8R+W_KKX5^O?\
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M.+8TF?,F_P!=;"$^5*DR4&[5E\Y&I(*0B-7_ "B3NK//]4[)W1%[=D[>L4
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A%Q6M\&E6)&%'4B,555J/4?DC55?%%[=U[>HOY=,=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g332508g33h85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g33h85.jpg
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M&B4R.4)8D9<8)C5#14938F-T@V9S@J'!\/_$ !T! 0  !P$!
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M_P!@FSK_ /6;.SM[)'\U8KHO16=%547H9MT5WNE1=5S*[95,Z[),O_&(J_\
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MH'$O>J*K")R)1TY(C>317RJ,Q%1$Z2-B1'+X7<U\.@/N/65PO^2@!#JG-><
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MMDN8R-V4^-J(YZ1T;(6/<V5787O_ /O;_J\'_=K,S(QH"EV[?XL#_P ;B?Z
MO5KQ?J5ORS/(D+;BG2&_*)Y+BW#6-EA-@'_@S4[Q_55<!E8,06Y-H=Y$ZD9(
MEE7GCH_-R==+#'R;XUYR(OM(NL0T;]89?EZ?E6F/:*.M$WRL'*M/TG.]R?(-
MS_1K?2.M+&L!WN3Y!N?Z-;Z1T [W)\@W/]&M](Z =[D^0;G^C6^D= .]R?(-
MS_1K?2.@'>Y/D&Y_HUOI'0#O<GR#<_T:WTCH!WN3Y!N?Z-;Z1T [W)\@W/\
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MQ W*[LK&:*Q"D)E"-JZ2<V2N"("D,,>') .Q1'%E*/U?:)NG,;1TC9I*AM-
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M2"9FUI'3BF)ABD;SRS(W)TF/>US>:*BIS1.:*BIX%UH?16J?G!B.=.FLV?\
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MY-PW_P G%?\ VT_7..BWWR8QWX_R6GT*TK?@]T)[TQ<I(7FZQTSX: : : :
M: : : : : : : : : : : : X54:G-51$3QJJHB?]ZZ \$]O5C+R(L08G>X>
M5"CU7Q<D9T^FY>:+X$:JZ \OKAJE\+9B)&^P^*NLI6+\;9(Q'L<GQM<J: >N
M"L]V9YJM?V+0$$R:^K7XWD#&O+5SJ.V:WG66C4YJ 0B<W.#1K4Y^-7*B)XU5
M$U54/5M'WU3^.9A;\6ZU8GO?6KP4TJKF3.O<1+[1KV:[&/EN- - - - - -
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MO[?0#UN4WO1?I)?V^@'K<IO>B_22_M] /6Y3>]%^DE_;Z >MRF]Z+])+^WT
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M[]O&_D#G_P!5P:PG3 ][DW?5)RBFX](CX0J/>S$^2C-O[6A3N4: : : : :
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M_;QOY Y_]5P:PG3 ][DW?5)RBFX](CX0J/>S$^2C-O[6A3N4: : : : : :
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M[0NFLQY1R+IDK'#V ),/25O0D1B21N=&]KE>NZGQ"GS]?NP]C*W]L'_0S?Q
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M>(4.TQL;=O<*ZR'&A;W&'YZ%#NADD0^<.IL9W+$N,GA'J!:RR@=>7N18I-.
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MFW5I>91G0-58)41=D+P2TKCJB623I ".?GS_ +=LR,: : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : ZM:UB=%C6L;S<[DU$:G2
M>Y7O=R1$3FYSG.<OC<Y55>:JJZ [: : : : : : : : : : : : : : : :
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M[>7<ZKP')0[;:/%#\F(Q#)B\<$*M!TV]K]QJ4IME0WN0UL-<=1VHDAB(5);
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MW*:D1L/8D.FL:HQR6DI<4 E,.;'(A;P)E+XK<7+/R.JH*#*56@R4#'8\E-I
MRL:M"X-UL2VKR42#LV1!V(!0-SDRQ@=^153[*"OL[BI%N@JN0<L"-W>_%J5P
M^[C[WX=A18:X91YG?TU7GY0=;%DM7@PA)=M9C>MD[(2A@S'5MN#3Q6+:TTXL
M%A$T =2:'9S 5SI,GJL@*O ZYERR;';.6HLEM,:R.A@>9"KVO=5%WM56B7X*
MJQW5VM#/954J=%T1CT>Q7 6VXAQ+NN,WS6MR.B+HL4I;#<RJQ=0<3SW(,ER2
M7:;/P=NLJL (Z2BL1+F!+@MI3ZRF&DL*T H"57VBQ9#ZWP*D[C;WTFWD53(N
M,Y9E$MEAV5[BD!T8U17&5&"8/'C\N4Y!9#YA<XN]DE;ZZ*2)M!!U^1$SEOCC
MJT00Q\ '?&-VIMPJ'<.UPG&+(=,.LKW'Z:UR^0*LQ_*[NBD-@,DK^Z3+F_AI
MQ9AA^O+L:6NGE4M!Q1Y2!3FB 4UQG?[++:QVO*,Q_'"L=S3:ZJW'RD#%)<IR
M/-,(ICMOILK?DEK3U]&1$E4?D\3<%Q?&Q5L,ER@F=UO3.,[KNZFN B-YQ15%
M=D$>/TFV>YV5R%'550":$!B^-QD7EW@USN)7U,U7GN4XCD=61ZU\>NBC7V](
M!$&0'&$]7E&#1/ \$W%[@<=3)DT.*YR3A[*QDR91&+C3 W9!-LZW?0;$N[)L
MFCR!MK/@,D,R6*U'K;CMYF5DMVU6S3Q 0BXXJ[!I,E?2[5Y,/8@P[D0Y"/D=
MEB4,F-G8=MEANZ5&45'3Y39#6M3>X[G5&20E18SV0+D+">*AD'0<!,</$687
MLENUN1%@EQ799M+AQ=_:XC=$T3(CS&[;56X]:2(?47]P)W$=57(DLB2'LNA&
M0FBR5ZG101D@2UDG%.7BV%9078X5<QY5C>*YN&VY,%H!<*L-W,#V@M-VKK"W
M5M5G619.")#54]ETK#I&TLDE<8 %E!LLE4;: 1)G%.#4MRU,@Q*[LO6=:YZ=
MD16*MJ.R8SM[A5^-12Y7<,R#(*LVSG<^>8B:JQ<:XLY!Z\U\%:DRUPMB![ZG
MBYVXM\P;@T%1F3,B2ULZ&4)*<<M\=[C$F7/SRGBBKCS23K' ZO%8;O(!*X<N
M>2NRO$$IX[0RZC$C FDKB,P@<Z0*.KRV3H%X&&QYE 3CY#W[@NRYE2^6GR=U
M)?@H([#+3O".QJ0YT9,%*'$9#+))$!]-N=^J[<FKMS:W!LUJ+$';S$-T:G'[
M;UJ2VF3X?GH60$XD73R4>47-9 ;;$XO<UW=ER?5&ADPCR&Q0#%1S(!)?_E68
MQ91 W>*T&69/C)%)E=N,^EH(+*RR=<<Q; ,FGBQF.*^@EZ5<[.64EJPNNDZ%
MY3WH3I0V5#R# /.)Q.R7&;8!CV.8>7?UF=Y'A]*^<6SQ9)L<%R7;G=7.B#IK
M(3+;*HOYZ[[FI+3@JUP_8P8+6. FUO$K:8L"L^T^Z57NUCIF05M+>XV^ON)Z
M6PH,H2I&R6J-A!KK+L]Y3UEK:$X_8=DM!'S4]XE?<0=))W K7DUQYP%&UXN\
M3:74BOV_W+1+FZRH *2.NQHJ2:EP[+P<%N<M@ $R@BT)IVY(60.(%""[(BP:
MBSLXJ11'T[K@"*IQ/U)%DM!5[;[@V>4R9K?82'BO6X'47\Y%#19!D<ER4!D.
M;5+Z:DLZG&K,ND*NUKY;D?LT]; 5%)*Z " A<:.UMBP^P!I,[*QNOP^++9\E
M@HP7@M[1MO3[K#TDHB6_>@-@3B=[7H.;9 AX^^[D=3.N6$N&<2![,TXC,GQ,
MNV#LMI\CQME7M'ENYAIMU983=2U$N-74=3$"558YG,T=F/8,F&GA?7W<<[7G
MAQ$((QEA."![,@XL<&Q\RUJ),<S$V_I;R3&;2D&'HHR:^^)RJYQS' CB#+T4
M$1F6UN.7V:T!4Q+89\0K>U3K!:G5M08!"&<6F.UZWMWDN/9!3X>/78Z;4DS5
M;1KT(RXVSO=QGT.3UI-E^YKHUN/'X]1PUS213\A<!4L+FEM:V8D"MV=[E,P2
MFQ.P(Q3([NUS+(JC%*G&:B7'8[6.]N:VQLH1CBKB^JJ,>(5M83":2RVF8V5&
MJ,A3515 HR)QA8 =8 5X>*Y^0Z6E;9W<T572SLQ0YZ93'W'=1CW\\TI,!V(6
M=<9;4T=KC0Q)-7-WW+7$%G  3[/OG#%@6V^;MV]SAY.ZMW7TF*8<^3#1LE66
MYJKV]I3+60G+8L>K1+"EHW62QR7K[$&(X44X >S897C 22#Q9XO;N9'2X!N)
M922 X6C$;#AH<?KISW(3\8H<(<0?F(P_?K+.FOG61\4LV+AA4A)*7\[CZ*&W
M \</%@!+<V$*;=9<M(#0472F:7B:74>X=SO+DFQ;=O9P9,E97(4NX%#W,/D
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M!E4:&+IB61P[N<14S'@>EN&8@VONZEN+X^E7DH+*S(JWN<#L-[6Q4T..Q@7
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M!PYMM=R5\UO8ICE2AMG-5'UUK6S&D=DZTF4.SIZBQ@EE<Y[#:JL*Z77@"/A
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<..NLC@H^B,5/&\#Z?<EVM_@ZPG]&*;]CT!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g332508g33i14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g33i14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1YP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'E2^=V0X0DE-! 0      $X< 5H  QLE1QP"   "K&(< E  "')R,3DU
M-C<V' (% "U-:6-R;W-O9G0@4&]W97)0;VEN=" M(#$R.3(S,2!04%0@4DE$
M15)3+G!P='@X0DE-!"4      !! JZ[_;I2[4(NPW*\!.^-@.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&:FL"         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             ",0
M Q,          0                         !              ,3   "
M,0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M,0    !29VAT;&]N9P   Q,    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   C$     4F=H=&QO;F<
M  ,3     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   %.$))300,     !/H     0   *    !R   !X   U<   !/, !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !R * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M*2K?M'#_ 'S_ )KO_(IOVEA_OG_-=_Y%)3:0+OZ1C_%W_4E0_:6'^^?\Q_\
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M<D6..H;8TL'P)_\ ()XP&.D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MV[AI%VT"BW/;\UFIT&X:53JY1:E&5WQZA2JM$9GT^:PK RU)B/M/-DC/8L9
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M:92$^3;H"P.5*6A)WF.2H[IQ&>I))K/M+M1N5O9<<.S-J[)N"^;DEE/93J#
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M #]B2<>>=7>VW>:B!/S"/>?[9_[JY-R% B-Q4 !]1UP!TR2!S-?H!=$M)J%
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MU$ GBNBKMT4>V:54ZW7IC%+I%'AR*A4ZC+=2U%APHK1?D2'G#^%MII*EJ./
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MA6YUL2< X@\$F".F2 .>SL?K!LO<&#59M'MRDVDFF("'G+F4_5O661W-AAN
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MNH5%@KMG:ZV(CR5LS:S<KG_XU*=;=BT2G)==D_7PG:_@'P]<"_L=0?8\P.N
MVK"B)4A*PE;RQ/RI$RC=$S*1&1@/BW5+:Y87IH>#1 5O<3U5R$''<D&8'2:Q
M3ML>K/\ R5[G6WN!8\A=CSX-=B.,-,2),V/39:W?0EON%/KO.Q%%2EOP'(SD
M3M=4&&%-AL#J?5?#6GZ[I*[34$MI>6T5*7M2E4[0 E.$I)3@#,2!@X-:/N=2
MO_#=VT]8E:T+=E.TE0C<4@DC<KYAGCF#(K//Z9-V:SO)L3MKN9<%%_8E4NV@
M1JE*B#O;94KO+*9K+;J4.M,5 (^:8;<0%I;=2%!)/;KAOQ)8-Z1K-YIUNX7F
M[=Y:4KP<(4/E)XD<8/UKICP_>.ZII5M?/H\IUQI)4@\DYDCH!(XZ9X&*D2@]
MR0?N >1@C(SR,GG5KJZC\>?Y_/SK5I4::4II2OBO!_0_RTI4=MN/\^F^G_E[
M!_V/)TI4BM*4TI32E-*5;^^))UU6S\/SIUE;QU:@KNZZ;@N.F[?;:6B'S%C5
MV^*S!JM3B&KS$!;L"@TFE4:JU:JRF6G7W&XC5/C)3*G,+3D'AC0'/$NLVNEI
M<\EMT[WW@)4VRA2=ZD X*R2E*0<29.$D&]^'M'7KFJ6]@ESRD.*!=<$;DM;@
M%%(.-QD)$R)(D$5A=;H]2F[?55>;VZ>\]S"X[FG-*:A,Q8<>FT6WZ:MTO,T6
M@4R,E*(=-BDA+?JN29C_ &^M-ER9*G'5=/V>AZ=X?8.GZ9;^0RE0WJ4HK=?6
M!!=><5)6M7, )2F2$(2G%=/Z;HNGZ';BSTYCR&4@%1*E../*B"XZX9*E*,]D
M)G:E*4C/@UX[5=V,=ISG@8_,ZJ:K\B>D>TSD>^/3BKQ?P)ML]S!U@W3NI%M&
MY&-K8^Q]X6K5[TD4R1%MF77:M==CSZ+1(E2DH:8J-2<%%J$PMT_YE42/#>5*
M4P'V@[KKXJWUB?#MMIZKEE5^=59N46B5A;Z66[:Y;<=6A();0/-0D;RDK*OD
M"@DE.L/BG>69T6UL2^T;T:@T\BW"TJ<0TAEU*UJ2#N2G<XD#=&XD%$PHB\1\
M0SXK^T/1)<%*VA5:4S=S>:YZ BNFQ8L]BCT"W[;J*Y<*'4KSKLB)4?0355Q9
M0@T6#3*A.FQF77I28$1V/(?UOX-\"7_BQ-Q="Y18:=:+#;ETIM;CKCN#Y=NT
M%("BD*$K4XE*2" 5*!2-=>$O!=WXF4X\+A-E96Z]KCY27'%K 2=C+8*<B4RL
MK2E)5C<016(7N?6+'W2W$N?<.A[3V?MI"N>HKJB;.H =JM)HTF0.^0BFRZLT
MJ8W%6]W.M11V1H?>6(+,:(VS':Z'L&KJPL[>T=U"XO5L("/M3T-NNI&$EQ+?
MR%0 @JDJ5$K*E?,>B=/M7+.T8MG[MV^=90ELW3S:$/NA.$%9084I*825JE2N
M22HDF#>]6\MN6E*N"WI%K.SV*6RE"IL>HB,#,5$0_P"D8BFVTI:8+@;6L2%
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M S!XQW$DCO\ 7O6\VE"5*3GM /*AVY/@C R,8/!/CC.->"M!D)2I /J1GWQ
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M"25)*4J)(''-9SC2&(45IM"6XT:,RAM#:0EMEAEI(2A"0D)0VVVA(2D !*$
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M@+8M$I*FVAM"N5020J I<0.$X)K4OBCQXO5 Y8:>/)L4%:7K@E6]8&-P ^4
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M<N!;^=9.K;,2I;C*D+"$"4RO:5+ "I"4.*@A)C%.V^Z=K&LYAAZ:V_<L]&'
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M7(RU%:UK/*U*4?0J,F/K79:\UYII2FE*:4II2FE*VTK)"LX&,D?I[$\G_=J
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M<6HA2OO24PE4E.V%9J'FX;^W,B^KF=V<3=J=LWZB](M)N_HM-B75#ICZBZU
MJJ*14:I"DN0>XQFYJ)27)K3:)#\>.\MQL959IO4VC U(VQO@@"X-FI:K=:Q@
MN-^8VVM(5&XH*2 HD)40 :SRQ%Y]D8&H%C[8EL)N%6REEE2TF"6RXE"@%CYM
ML0D_+*@ JJ!WO0P8TVJ1UPH-1+1)J2*>PN9VI0$!)D*4VZ1V)" 2[PD8P4!2
M3>+-W_<2@@J2?E"2HP,$R4\$3!C ,=#D5B!\\[4E9!0%0)$SDD95&X_+V,@@
MUF^?!8G;E5GX<'3K<6Z5SW'=E=N*EW76*)4[JD+E59%BOWG76+$B?,.@R':<
MU:T>FN4GYAU];=,?AL(=+#;*$<H^-W;)[Q3JZ[!MMNW3<E'^TVAI#CR$A-PZ
M&T (25O;Y"0 8DRHJ)Y7\7/6S_B+4UVB4):^T*22A"6TK=3AYS8B$ K<W*44
M@;C*C*B5&3W7MM!5M_NBCJJV7M^*Y-N+<C87<ZU[;AM(#CLNY)]J5(6]&;;/
MXW'ZRB"TA.02I8PI)P1C]B\+>]M7U':EI]I:B>B0H;C]!)^E62S<2U=6[BC"
M4/(4H]@%"2<' &3BORW[$A;B;9R)=JWE0JC:ETVY-DT>MVU<%.E4VO4.J0'E
M1YM-J]/G-1Y4.?%=0MJ3&?80XTZDH(.,GKWPW>NKL&BDM/6SZ$K04K*@09,A
MQ)$D<'!@@CFNDO#U\^W;!2"VXR\E*A))W'T6DC,B,<=QR).677K\NV>U%AO-
M1:?'6VJI5%48EAB.% K;"RH!R0ZC*6F$$*)/>LH:"EIOKJF$(WJ:2%*G:D%1
M).8(,G[I^:2"!V,UE2'W7R5>6V <%7S$@C)@E4$D' (,*Y!D!6:+\'KJHZ2[
MCIJ=D++VIM#8_>_]F"34W*6#+_RL,4M*#)GP[HK#\RY9E4B-A4V3:]5J$Q,2
M,)$VD.R8S,U,/F_XB:%XA9<_U2\U"XU32_,VMET[?]/4X?E0IAL)80VLD(2^
MTE.Y4)< 4I&[1OQ#T'76'?\ 4[B^N-3TLN0WO&S[!YF4H6PV$M!"B0A-PE"2
MHC:XE)4DJOZZU76K*:4II2FE*:4II2FE*Z5<U20LCM4@*4A*AE/?QVE2B< )
M0KN2K&1@)5P",22ZI1(;0I9!VD01D<CZ?GTJ*@$ %1@&#D](GD]8C_)F-+4X
MN));*%)*CA2>U2$GN[22YW'*L@I"!R<^#XUZ <__ *ME$@F#SB3G@P!Z=:\I
M6VO[JA[S(YB,#G_/:J=[MW ;<VYO"L!Q++L:D2$,J42GM??'RZ.<@D][J0C'
M/'Y#%ST=CS[ZV2 5!3LQ$&$YS$<]9('-6S77_LVGW*P8(9(GU4=O'I,_YS4
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M/3/ZG-5Z63(2"09 ^N?P)[R9YKK77 0 03G)P,]V?N,'SXR./(_/5,XM4Y,
M$?GG\,Q[>U79M@%'$F(408)$XD_E^1S KS\I>5%0*DE*5?6@$@8(&58!_"2
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MXB#GZ8[]8_*IJ6TJ(=5\JT@0(G(GJ>.08],^OC[NLN15(-3H[[:5%YMU3:"
MX7"SW.94@8#C9<4%*[\X'T@$ 8Q5PJMG"Z@0"=V#D=2<SP1/UZ<CW<VR=7MU
M6;ZAM4-A,1."#)Y',&/?)Q49:30FZ"VJG2*<B*(S?HB2\V&6$/J>47%O)'+B
M%J4"D@)[D?3@$C5,]?KN5PM0*0!SVQZ<1QR/<Q$NS\.6NCVK=K:(2I2%J65
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M&&V5*!!"'7"$KC)2" 02",N\$Z/;:SKUM;WB=]HT?.?1) <VD!#:B,[%*/S
M$;@-LC=6&O3KKJ5V2)=PUVK3ZY6ZW(=J57K-6F/3ZG4Y\M9=DS9TV0MR1*DO
MNJ4MUUYQ2UDY)R<GIEVV1;0PRVEIID!MIIM(0VVVG"4(0("0D  !(QQ%=-^4
MA@):;0EMML;&T-I"4)0D0E*$B$I2!@ =,]:YU3?;C4RISG4.KBTNEU*LU%QE
MEU_Y.E4>$]4:I4'TLH<6W$I\&,_+F2"GTX\=EQUQ24))U3J<;93YCKC;3:2
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MLAU6]QMU*4()P H;A(&"9D''!.1S5=.DS;JRYU<NJZ[J@TURM52K56BV>MT
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M3@R1T$C&?7 (J,FX.Q%N]/$"@V3:%P-UF\Y]&NFM5NH-J0FH_--R43Z"AY+
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M=0T+5KBU7:)O;NW=" IHVMZML(),)7L0ZV2V2"#( 5"@0E0!'Z/'2K?72KU
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MB $F4#.3WCZ3.#@<^N< O0IMP[N5=0?O0,DP)XQ'MSTZAXN-I'*^W(':E*0
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M'L4?N.0!GW_7I4LAIM*=H4MU"5;H&XI4"1\TR8_7\:X\OW24 )<4 ATJV@X
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MM;P'<HH2C:,E(2E,R!,')$D@D=JY.\3:,O3-9U*T42&K=:]LB$D20G:<!0@
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MWSZG@\@]/<D:LTNV+AJ]%MRLUVHP(7R\>GT*FR*G-3,JX," KT(?KO--ATK
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M.J[ITW#MI+DEJ,IR?3[\CTQYEIQ]:&RLP*K)=*"05-LKQW8[3E_@D%W5;NS
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MN$ E*05XS@!& > DC(\#!PG.=4"WD\XF#'RR1Z]^,2*NS=D]!\M$S ."8SQ
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MSZ!^!">/&,^#@X_]11/MB5.*(VI02>@F<=8Z"3R!4]QP,,>:!+F\A*2 4E/
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MAP+<3GZ2I)2D>P^H>#^IU,=U<.C^H\G[L8B!')YP<_6! LK7PY;:5O"FC)G
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M!MFSN+:[2K^I(0W"<#Y@DK!!Z  =8'2O7A^\\/:C?/7.I6SENNW5 2N9)!/
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MY9*UJ/<I6<:T#K6KKU.Z>>. ZN2(@D R">@YB(X&:Z"\-^'VM&MTQ!=*3)'
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M/6<\UY6 VJ%^L#[W$$\CU]>OO5=-MMOYMQ5N(U\MA"E$^L6P?30E?<M12YA
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M>2GL2D82E/&,$8' U0ZZM]Q;JRHJ6HDE7))ZUN-AM#+2&VTA"$I 2D0  ,0
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M*0VTTRS1W)].:71X$F.^IU[Y:H%![QE62K [)^%=WX?U#PW9V;3MLV\PDIN
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MPCY^!%C2E3ICD<.MI6TVRLE2R!K#XH^(;)>GJL6WT/W+WWU!84H)W221RD
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M^6A06DPWE28R$PXZ$,2' X'WV$(;"6'G@\ZI;K(0XI3B@I12I65*[_M_U?\
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5-*4TI32E-*4TI32E-*4TI32E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g332508g36a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g36a20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2_ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +Z2^$AECA"24T$!       /AP!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP"   "   < E  &E9I9VYE<VAW87)I($-H86YD<F%S96MA<F%N.$))300E
M     0\L'U-):P!YXIS8-3G0*F@#A"24T$.@      Y0   !     !
M +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M!);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G
M1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $
M)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M    (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $
M-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V
M]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M!%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %
M)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M        !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M       $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!BP
M          "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M   %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4F
MQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H96
MY0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W
M)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M  "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )8    !  $ E@
M    $  3A"24T$)@      #@             _@   .$))300-       $
M  >#A"24T$&0      !    !XX0DE- _,       D           $ .$))32
M<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M   0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0
M M    !@       3A"24T#^       <   __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M X0DE-! @      !     !   "0    D      .$))300>       $     #
MA"24T$&@     #-0    8              F<   )H          $
M                   0             ":    F<
M   0                         0     0       &YU;&P    "    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P   F<     4F=H=&QO;F<
M)H    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6
MYE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&
M5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M      0G1O;6QO;F<   )G     %)G:'1L;VYG   ":     -U<FQ415A4
M   0       &YU;&Q415A4     0       $US9V5415A4     0      !F
M%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96
MQL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W
M)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC95
M9E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4V
MQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M  "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M    MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M   #A"24T$$0       0$ .$))3004       $    !3A"24T$#      E-P
M    $   "@    H    >   2P    E&P 8  '_V/_M  Q!9&]B95]#30 "_^
MX #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1
M,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@
MT0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,#
MP,# P,# P,# P,# P,_\  $0@ H "@ P$B  (1 0,1 ?_=  0 "O_$ 3\
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MY_Z.W]-_H]BM9'3^ITMM(ZEEO LIKQG;[ UXO _2V;;'N:VJSU:G^EO_FU@
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MG,153U$M_>;_G#^]-(_>;_ )P_O7/LJ^LC<H!P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &* 8H# 1$
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MCEN$57F@>?:<;!&MED0OB%62,W4YXRRV93?G"H8_"E]\OR^S?T U3^XG/2_
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M^HS'7V;5"D6WN;T/;?G61!!$BO8BFGS[^ D-F;(E&U+AX,M,,OS9,A>68O\
MM7W7%>7GV\'P<DP?"#RLN(C;#C9D6SUA*$3%HDA3C6*A8N>8RQ"@"[: #0>Y
MA-@/A-O-M59T.'\E0[-2'):7-$8CQK%56(!A&;JBJ 3H -*COIWV?F]4]K/W
MA5;8N56LM8*T:^5-^1B(LW5#3L1^6S#F*:>3&FQY<"'*84MO+;Z&G83JFFI2
MWF]WA%L-=O8!<-QQPT\$\>*PLX7,(YXPRC,MQF5E=@=;@D,+E;'9X0[%7;N
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MCO\ Y4M?R'>$2_\ 6QV)_P">\_\ 91//T'P0_P"[6Q__ "O_ /EDK]"<$O\
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MX3!8W&;8X2[3F&)Q,6R=@JV'3#03211XO%B^9\0J,HF499"JO=;+'I8N&XK
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MZ%N$!N/7^X,YM@)U^X4;Z48>N%%@PH.5'E0(JP \>S <&.!D123#CFMP=/\
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M.X_&+PB^3<!W&+^\T_&'PB^2<)W.+^VI^!GZ?_EKVG^DVO\ ]SN/QB\(ODW
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M;-G:-=N<FQ2LAIAZ=6Q5?FJF+^A"P]V&39-YCMM3<1$BGUCVIKLMF"P*E@2
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MH2YZH4=J.FK;.F8W,D0.ZXXP&W5\U89-DSR-F,L*M:Q*K("1U'G'HT^:MO\
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M <<0^-\AQ<.0Y'6M'E(PKR5J;RI/E8QGQ9QX\8S^+D)@YW1'#P@.JL 0]P&
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M0V%*S:@]*V2%KRBHF#*S*C1TL2(.)5\[!2CIF%U+9.<+ FP#LP(!O9E!L"2
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M LP*"0%==00>D"M?(/A"(EM?A0=3=;MZ;=(YT7IGL.=BU/V;C$5S7FZ0A<Z
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MD@\V>CO./WRX4Z1:+,>K/F[''I51CFK*T%E#I<J"RLH-8E"XN JL^@)9,I4
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M%0-S74 7N+7TW&D>'>/B+2*QB$J.60\])91*Q4!QE<90 267>2*DLATS)R]
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M*!:UV!O<$96@DES<;(I(BECCR1E0&E7*TC7=B2   H( !;4WJ2MW]3"FVW-
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M$HJ]9BKI128:Z5(2X3G4M$%@F+LPDD.6<%P2S/DPL3 LUD<'F,%&51JI8J5
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MLY4K.<YSGD)?(O/D'-702. -!N :P'H&E5B4F*,\9,/R::":0 <T: !@ !T
M: :"J+SK'NL%\A#_ '+EN=Y\G>2>]63(>UG[^7WZ>=8]U@OD(?[EQSO/D[R3
MWJ9#VL_?R^_3SK'NL%\A#_<N.=Y\G>2>]3(>UG[^7WZ>=8]U@OD(?[EQSO/D
M[R3WJ9#VL_?R^_3SK'NL%\A#_<N.=Y\G>2>]3(>UG[^7WZ^/28G\+_\ 3J__
M  /_ )__ -#"_P #_P#M_P"2_@__ .?%QSO/D[R3WJ93VL_?R^_1$J(YX_('
M5]?B_C\@&%5XO_Y\4//BXYPWO(/_ .R3WJ9;[I9S_P#WR^_43VG>% J>TM;Z
M8E0(Q78VT(=E,@Z\!IXHFX)JE0BL/6"Z6V2F*U%K-4B3)HP'%)DGFU%["5@!
M0T<A.6\TPU\^3O).C_W?1\Y Z:J19E7C9R6O8">70#>3S]!T7Z]*EOSK'NL%
M\A#_ '+CG>?)WDGO5;(>UG[^7WZ^/28GG,M?1U?\[A/EY;^@POG,(SGQ85E'
MH?E>3G/XO*\7B\?XO'QSO/D[R3WJ9#VL_?R^_7WYUCW6"^0A_N7'.\^3O)/>
MID/:S]_+[]/.L>ZP7R$/]RXYWGR=Y)[U,A[6?OY??J+MR[DI6B->'-J; %-,
M4:JYA2;:9#TP:9]5P,F='AS[68A1(>9R:U76I'TI9)\*/,=$A8\TJ[%5$AR7
M&UR 3GDT_P#^DGO?]"JL,HS&7$6&\B:8V])LU[==21")#"4.(1'Q:U.@3XL>
M;!FQ P.1%F0Y32'XTJ,^U#4T_'D,N(=9>;4IMQM:5H5E*L9RYWGR=Y)[U6RD
M[I9^_E]^JGSK'NL%\A#_ '+CG>?)WDGO4R'M9^_E]^GG6/=8+Y"'^Y<<[SY.
M\D]ZF0]K/W\OOT\ZQ[K!?(0_W+CG>?)WDGO4R'M9^_E]^GG6/=8+Y"'^Y<<[
MSY.\D]ZF0]K/W\OOT\ZQ[K!?(0_W+CG>?)WDGO4R'M9^_E]^GG6/=8+Y"'^Y
M<<[SY.\D]ZF0]K/W\OOT\ZQ[K!?(0_W+CG>?)WDGO4R'M9^_E]^I@A9QF'$S
MA*$8S&8SA+:$MH3C+2/X*&T82A",?Q)0A.$IQC"4XQC&,<T&^$>G4ZG4[^D]
M->+)I(XU//;4FY.IWDZD]9.^HQL/\LS_ /ZJ?^DWS;B_-K]/UC7K8;\Q'\Q^
ML:_FN[M]XZ[0N]3FQD=G*W0J9T,+Z>I]VT5-OPX)-W0]OB8MG>LM-->E-O6Q
M>K]<637!^N2,^3]'6$1:&&FE/Q_(E7S*#JULMKC34-OZ;&PRD7(L;Z'2^.22
MTI.< 1E05)^%F^%<7OH"#<BVAK>C8>U.YEQW1W!KFF-HZ;U[1>M-4UC;*E&M
MNJB=^*WNQ6+71BZ$JM92<2[5IL+2)BQ\9$HJ%B2K5C$[&!,L>B OZ1DWW6 M
MU@W.IO?G"UM-PK*6D9I K*H0:76Y)UWZC337IUTM6J43PF6_]\E!SFF %LUZ
M'$==.M^WIV*YT]W)VG19-@[_ -3CMN-U@^7H1T&/I^O (<Z&$XD15YN9@FV;
MD1I<*' 8Q)@W^FRGX+,.<H8#0CH(OTWN-+7-..9KY;@A%;1&?5A?4BP &[K.
MIN-*G#778[NYVEV!7ZS09]#ZML3.F>E^P%EKFR=5%;_=J_M:\W/8X.?178,F
MUU)J'4Y"*<VT3G36I!V- 2TH2U#GSG)D6?-T NJL;W)%R=-"NH L?Y6.M2KR
M2$VLG,4FXN0QS BU]VGIT'IO6/:N[@=PB.K>H?:G8YW2JM>]A=O432EUT54=
M>6*/*K+5T/6"CPK[4MFE+U*(RCN+>*AEYP$W7W0+-1E/A8N'#T5-AE0"3:]M
M;"VO3N-[]9%Q;=Z=2623*DC%<K$ H =+FUP2;DWUL;"U6S4&\-OV&Z0>K_7W
M&I=%V38V].^>P+=LJ1KF18X0RE:3W<'I;ZJS3$V,**L.U;D>O5?G&BQ\BX+C
MAX)XBH4[*<'M,V(U(%A;,=VX!NH6U)8"Y-M#TV%0K-?BURJ2TA)M>P5[&P)U
M)N+ZZ:]8MNGTSW#O38=V[=:\WN8US8#77_>8/6M;-ZT!$:Z(+5N=J'7MX8)$
MQ90S8)D _.E6B3),#,EIT<1-<>&0I4B'%8=4Z-;;^B^[*I&\GK_Z%9(V8F0.
M02K6! L+90=VIN3<G4CH%;W<BLM.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI51$_WN+_ 'AG_J)Y#;C\Q_M57^ W[+?V->Q3^4B/]^E_YASD
M)\!?V5_L*K#^:B_=I]450\M62G%*<4IQ2G%*X =A]4EC6VO"^ZXU.F&+.[!Z
MX]+[1''FKT_4J[.N]GNF]46"<_8#)'Z.J[UFA!((R;+BYBLO89B,X8<7AMM5
MB---Y3KZ?RJCT#0 ?16LZB\P WB,[^DEKZG=>P&GHZ*VTZFA$Z$[,FM V;KS
MH#4]MV)HZ?N2O6GKW8;D<&3ZS2+Q6ZA8JC=F+I7P$V.4%%[T F5\R-:6./Q'
M"ZG(0>3!Q%>BY-P;#2^EM;6!Z!J+Z;]+G2U7097*E$4E2P*$D6! L00-?3T[
MA4BZ<<@3>_'>RW6!UO!.B:\ZOT $[*5C*A&O%5&Z;&GR(:%^-V-%,W"RG_I)
M]C"6"#U:A-.><?$>)IOL!J=UOI-O621] HOYZ4D:!4%_1:_][Z^BW17*M[O5
MIW?O=3IKOI_L_4:Y6G^QMYU/K71<;9@T:\.U,[I'<$1.R]N4QN?B1%O>U]HM
M5:)7Q1O&?5NL0J(-;@P;0=L#3E;J0#F%\P %^@JUR1UW MU"PWWK%QBN\;9@
M.?8+>UA9K$B]LQ-OFL/35M#M&H#FN>P;^K;$(%EO""SE2_"+-;'5/MUCUM9.
MPAZF5>K$=6+).6IG7MS<GU_KI$ 3$OTP&"FP[U$#1VTM>CR3SC86YU@UQTM8
M#?<BQ"6W6LPW5%SHX4_G-);VTS6L1>X!/-(/-^C2NA_A#>V6NJK9:QT_-;PK
M>@)FTZ80OFV-HV&X#J'-JND(<R:&D@-=G23S>'=I[/.0GJJ#S!:>?K%78MUN
M6[#(CJ^B>N 0&-KZ]7-O8V.NN\;M-3H0*RRR*#D+9;B[$FW-Z0#;>V[3<+^B
MM$M82IMIZ$]/.V]5[#PS-/TMH;3=./CAYRT62ZP=L5N^T\E/ Z\<!GV!QG;&
MXY"A>BK&,NZ966QQR+A*GFY)081*192#S<JWL-^@OTBQ8\T]!TOTWH-8D<,2
M J#3>""+Y>C,QYIOU_.#U'Z7V2AWO6]YH=LV5#VON&ZRK+L/L ,<3:'JLW/O
MQ(K52P'6J[0/AP3VG*@_6I^JZX5J,@O6GW:>1;D$7CCA3RESI?4C?U?_ &-+
M C>!UWK+&05*DW8W+[[78F]KZ6%[ C0VZ;&KYX-(G/)]%>M^)\]XI@+1G:@+
M)OKPZX1K=(L!JGU2=YW&,>=;EUD&)?9<\2?.,K0OR4^/R<.@?,+?-;3^7KJ8
M23&M]+ @==@2!?Z!\U;S\5DIQ2G%*<4IQ2G%*<4J9H/^Y0_[K'_Z*.:#;S\Y
M_O7A2?G)/VV^L:P$V,G/E9KK3&5MK<3E*L.-8\>/-HQX_$IS&<?CQG^/&.;4
M3 (H)UUZ#UFO2P\J+"@-[@&^G^\:UU'=3]/#*?M"ALZT&2JON>Q[$MNSX)>>
M0.2;>?VJ_)?O$T@6,E)YAI!1,E4*%"A3XL&OBHX\/78PH4,'0XM\ZF^HUO?3
MK^C_ /!H- *R9X;$6)S7O<7))WW._7^71:JFE]7M::^BW.)5JA.B-["K%1IU
MR=GV^TGIIVOT6I*HU8B22!^Q$YS<@?5U*'.DXLA@H27G) I,FDL^F<9UZ_Y'
MPH)(A>U]; WN= +#>>JH2+>#7ZP%0=,KC.NK76A5%U)5M$"6Z)NG<6OYA74%
M)'8$U2AW8K2MB@2NP@X,?YR- =O,VP$FFY9''IV<%"7I8NIM<WL H^$+ ;MU
MMWIN-2;7)-5)A( YPL,NA8:#<#KK;TZZFI_IO7+76O;2JY4FB0JT=SK:FZA;
M6*G3(XR+KK7\TX0J%9@ ,$<@8$8-+LAE;4N$-8(R$2TL39DEB+$:89UZ_1N/
M63U=9-7$D8)(N"0 =-+#<+=%KGU_-;$X?3O3$#6>L]/1->K:UWIZYUW8.NZ_
MZV6E>:_;JH?EV@ 6R6<L:S9;$$Y.E3<P#9$D-E8=]&F0Y$1#;"&91;7=:VAZ
M-W15<\64)8Y18@:[P;C6]]]8A;>@77BY@AP(IKLP/^A-GW/<@"PU39>QJ3>:
M[L789$@5NQVOW^HW0+= T6S3"DWZ7K@\ZQ5YL1U YX*H>PQ%:9U/3TWZ1K]%
MK?10M"=X-[DW%P;MJ2"""+GHW>BU9SH;J5J3K-!N,#2]'E59K85CBV^[29]Q
MMER*6>U1*^)K/K&8,W>RV,M,-31(0=@N2=FYEFR")!HN[.,SY\^2S+U^G<=]
M@+[O0+]>_?>I5XDOEN+FYWG7=?4DZ].M3Y]#$O[-GZUG]9QG7K_D?"K<<GI]
M5/H8E_9L_6L_K.,Z]?\ (^%..3T^JGT,2_LV?K6?UG&=>O\ D?"G')Z?53Z&
M)?V;/UK/ZSC.O7_(^%..3T^JGT,2_LV?K6?UG&=>O^1\*<<GI]5/H8E_9L_6
ML_K.,Z]?\CX4XY/3ZJ?0Q+^S9^M9_6<9UZ_Y'PIQR>GU4^AB7]FS]:S^LXSK
MU_R/A3CD]/JI]#$O[-GZUG]9QG7K_D?"G')Z?53Z&)?V;/UK/ZSC.O7_ "/A
M3CD]/JI]#$O[-GZUG]9QG7K_ )'PIQR>GU4^AB7]FS]:S^LXSKU_R/A3CD]/
MJI]#$O[-GZUG]9QG7K_D?"G')Z?53Z&)?V;/UK/ZSC.O7_(^%..3T^JGT,2_
MLV?K6?UG&=>O^1\*<<GI]5/H8E_9L_6L_K.,Z]?\CX4XY/3ZJ?0Q+^S9^M9_
M6<9UZ_Y'PIQR>GU4^AB7]FS]:S^LXSKU_P CX4XY/3ZJ]XH@BF3'4J-G&$OM
M*SGSC/XL8<3G.?Q.?^V,<AG6QUZ#T'J^:JO,F5M3\$]'H->I$20<(3G$1\J0
MN9)6G/G&<>-*GEJ3GQ9<QG'CQG&?%G&,_P!..0K+E77]4=!ZOFJ(I4$<8-[A
M$!TZE JC^AB7]FS]:S^LY;.O7_(^%7XY/3ZJ?0Q+^S9^M9_6<9UZ_P"1\*<<
MGI]5/H8E_9L_6L_K.,Z]?\CX4XY/3ZJ?0Q+^S9^M9_6<9UZ_Y'PIQR>GU4^A
MB7]FS]:S^LXSKU_R/A3CD]/JJ#;!U3U%;#VW[):-;#;"3WW1*GK3;:#1$B2%
MW&DT;-JS5@DH%+*NA!R12KK97$3PP\<3DNSVW9LV2Z/&KASG7KZ+;N@$GJZV
M/KJIDB.:X)S !K@Z@7MZKG=K6/Z1Z8:;Z\FC5FUG4;*W:#X0=6"%JO>U-F;=
MM**L(D.3!M5&63;5XNQH)5XDYUV>W7 TZ &R0<<GKA*EK4]FH91T^NY_O_:H
M5XDU&:]K78LQM>]KL3I?6VZJ(QUTNH[M17NQ= )!Q\"SZZ7J;?M2,9?QFXUN
MM3#%CU3:*W*B)D-1K91;"?M I^+/;:@&ZM<B27)T6:$&-RISKU]%MQOI<C^9
M/K)&N\9%SAP=XRN"-X%RI&F\$G30$'URC;-!46\636UNLU+AD+!J*U3KMKX@
MU,DCOH&S$JI8*3,)+BC)\.&7P[6;2='IA&XY(>TN8F>S%;)0X4N,SKU]-]QW
MV(ZNHD?34EXB5-C=3<:6UL1_8FH&C>#SZ^Q;6.LS=1N2QX?8+VUQ&MW]N;+D
M::%[)>,2+#FX0-0/W-S7D<@Q8I3UC@P4U[Z"&V52+*.$Q3[31)#.MK7Z;_K;
M_FW?R]._6JW@O>S:&]KMEOOOEO8:ZZ :U/E*T34Z!57:97@$]T"]/L1)QNRV
MBP78FJ3:2L\T93BP7,X>/IB.D"4Q<* DGB"(CN-P!$:# CQHS4YQIKN]!Z[]
M76:L'B L >G>"3J;[SK6$B.H.G 5/T?K\9KWS%+ZY%!)K4%;<L]DEBZX6 @"
M=9!$"4>98'\7&4%%EYJQ+UUS85#BV8M@B9:/#QY*-&9=-=UK:'2PL.CT^NQW
M@&F>*RBQLMB!8[P+"^NNG7?77>!42V;I(Q3:)M&#U;:C:JVAL^M9U\Q?K1:+
MI<H.MJ69M!@^=]GU8,G3 P*H-,MENLU5J@9NO5I=K(1%$5M"HK<=IG7H-KD$
MG7K.H!T! )L!8:#2JLR6.0E6(M<YC87N;"^GT6%]];,ZETP%TKK#7^HJ()6/
MIVM:@ I5;BN2&77T":Z-CC(CDI[+F,R)LAN/B1-DJQY<F6Z\^OQK<5GC,O0=
M.C0[O55UDC4!1>P%AIU5(7T,2_LV?K6?UG&=>O\ D?"IXY/3ZJ?0Q+^S9^M9
M_6<9UZ_Y'PIQR>GU4^AB7]FS]:S^LXSKU_R/A3CD]/JI]#$O[-GZUG]9QG7K
M_D?"G')Z?53Z&)?V;/UK/ZSC.O7_ "/A3CD]/JI]#$O[-GZUG]9QG7K_ )'P
MIQR>GU4^AB7]FS]:S^LXSKU_R/A3CD]/JJ58B5(B14+QXE(CLI5C\6?$I+:<
M9QX\>/&?%G&<?BSG']'-([S\Y_O7CR$%W(W%V(^8DUI'L[^?ME_OR/\ *Q^=
M+@OT6']D_6:NQV?^A8?]V/[FM#U=Z>J*=E.Z?SMX;[2V3+P!VH8KEU43228-
M+KCJ?&FM9B*A)-H4.^EDR<B5/X_@3E(SA><W&QAS'G7.&*E;ZY@;$>O2LW*(
M>,XKC!QE\N6S7O?+U6M?2][7Z:G?6.RJCM^D!MAT0@Z4JI]99L9.>B2(+CZ@
MIHC7R'E192&WVL-%!4UE.5H3YQ+:74>-"TYSDTZ"#J1<=8-C_.LB.KJ&4W4W
ML;$;B0=" =X/16>\5:G%*<4K!#>R:E7KY1];%)[K%NV+"M9&J#TQ)#K4Z+2H
MH^;87'9;:%1XN8D<I#4VB0M"I&7%)9PO*%^)]/I Z[6O;YKB_P ]5+J&5"><
MX8J-=0MLVN[2XWUG?%6IQ2G%*QBUW2J4:".)W"P"ZY +V2M4\9++2D1&)UHN
M1N#6JJ"C+<SC#I,^?)0! R,GQN2ITMAAO&5N8QQU:@7( N0+DD #7I)( &\D
M@#4U!8+8L0 2J@DVYS$*HUZ2Q 'I-9/Q4TXI3BE.*5AIZ[BZ]:*-4I@ZR2B%
M_F'80F:)KI4J"&.5\'(/3';0;A1G1U9C28L9447(,/QFR9-QD=#4[*<2CCZ#
M:]K@$@:$ZGHO;2_3IOJ"UF5;,2U[$*2!E!)S$ A;VL";7.E9EQ4TXI3BE.*4
MXI3BE.*4XI3BE.*5<PO\L"O^(PO\RWRDGYN3]AOJFJ2?FI?W4O\ PVJOM_\
M.VT?\Q&_^YRN5@_,0_NH_J+6/"_HV'_<0_\ #6L=YEK/3BE.*4XI3BE:ZO\
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MWP9,2$=2+VRY6(RVL#9OA:UDS6OI=6ZJ; VQ#F[7R_?^Z.RPG9*Y@+5L(G?
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M?LO&Z$ZUM&)C]L8U$@[$TE'VU,I)/%4!1)MR=:?'LJN<AI<93D+<4'0,06L
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M?%OZR^Y3V5A_B67\H3]]XY>_8#O/\:>49/BW]9?<I[*P_P 22_E"?OO'+W[
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M&T6Z]L@- BL5HIK>;IR-2I"\RA^(1?*-G.1TC);\F.N7(:3#=R7-]PZ+&_0
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M#1@^<HE)E%1,,00(0U15X2ZN$M2HR9)!)O>Q%CKK8BQL>NV[TU/%DB0$Z.
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MDS195DQDC,JLE+C\=VK-AV# SKE:]T$R!;F]R-<U[G-;-DS:E36-EPC!UY4
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MHU\D;&GK/0R(<F2 6&HUHT&R])C,0RSK:<<"]TZ@1<Z?J@KH 2=;WU Z>K6
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M,2A@Z&\U+GRHT9:7<SIUCUC^77]%7+H "6%CNL;W^:U[_15/8^X?5NIA]<6
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MV(Q,CJ6TXIB4PW(94XPZA]A>6GD+1E;+S;;S2LI\IMUM#B,X6E.<*54>+/\
M1G_#/%*>+/\ 1G_#/%*>+/\ 1G_#/%*>+/\ 1G_#/%*>+/\ 1G_#/%*>+/\
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M'),-V$?LBG(\)\6@[I/"GK_=_BH[\QD_;XY)ANPC]D4Y'A/BT'=)X4]?[O\
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MW<!/.R @9]]Q;KSXH<\\ZXK*EN.N1&5N.+5GQY4M:U94I6?QYSG.<_CYS4H
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KH/7/YO
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M^[\<OA\V7V![U/*>'\R?N_\ *GLFL7O&M_-\?=^.7P^;+[ ]ZGE/#^9/W?\
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MHVN$,MX@'Y]A$PPD[+N%J:Q#*R);<&3ES#:\MX9?7E>$+RGQX2KQ35[@"Y(
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MY82_4\<GQ/8GVT\:<GQ?Q?\ JQ>]3UKI7Q,W\L)?J>.3XGL3[:>-.3XOXO\
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M42J 2"DC1297 L48,HL0+.C,.@C5;5>^H.IMA=;M?B]=O:J'0A]N+[FW#:E
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M02C1W&VIKHN N0ES,1CR'*,3VWT\7'>QM<9LM[$@$K>Q(!(N!4<=B"P<S',
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M)PI6<JSXO&K.<^///,8DLQ.I+$D^DFYKG923)(2;DNY)ZR6-SIIJ>JHTL/\
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M=;!KNF,%!EF"+* [1#J]A58WZ?:!$I8BQ BL,XU&PS/:99LMB/HD]:E1H>D
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MCHI%$7'0UOF(]-B+WL=?2#I<:5)53?+*JY@ WP3>PM<7.A].M6.O^#+J5?J
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ME1]%NH5)P%D$8-Q&^3,#\$ ZFVM916&G]R[(V]UBL796-N_60O5^F]_-;EI
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M!%C8:8AQT-CCH""#%*00 042Q   !&>U@  .H #<!3EV'RE>)ERFP*\4N4@
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MM+,:'!@Q![4:)$CLH0TQ'CM-LLMI2AM"4IQC$\OA&Z.;V%]^K#:$(  CG
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M$0=O%#++IFXCK?V*V5O(O1=YZ1A;,UV6AWV&-9&")4%RPC3PBU4J<-21 W,
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g332508g39b76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g39b76.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &V"^< @X0DE-! 0      $(< 5H  QLE1QP"   "   < E  "')R,CDT
M,38U' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !"(I_Q8^.6%LSJ+P9N2=X]_.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "<   !      & &< ,P Y
M &( -P V     0                         !              0    "
M<                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M<     !29VAT;&]N9P  !      &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   G      4F=H=&QO;F<
M  0      W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQLNS)LJ]"VC]-D+HNK_7+I'2[<9CWB]N12_*-E3V$"AM5N15<R7_ *?[5]D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_5U$L@^J_;^!B3!Y,1B(Q$8B,1&(C$1B(Q$8B,1&(C?GQOQ]=^/I_?B)K_\
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M92DUH:TK>8H++&(0RRSA)]F@ (0A "+01;WO6]YZ/PL<XN'B8K,';&Q:,=G
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MNHK5U2]"69899X"'%GC2M,PB'O\ WI(\[ S,&@A\^3/8ZKTIY@0_71))H]^
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MQH(0!UH(0ZUXUK6M:^FLM%5"J%4 *H"@    #@  =@ .P [2X@ H"J %4
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M'()_1V9R3_5C_=\_G\9X0NV7O#VJTG;^N6'SWYM_1>4 YZS^T'[+@!C[X'H
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M%F]+3GI,)'N426UYX6B+))*0R*9E$-P2""PE%)BR65J;%9"8H( Z**)7@T4
M(2PB]@=:Q7X7;?:P6YV=K&I6<@O[5FU]+GD\EC517=R>HCD7<_7W/,T^"VU"
MZOJ69N#66''*ZAJK&MN..Q%%5-G'(!_UO(('>0(=]&TU0_5=DU=&Q%1!EC),
M.VWL1*61N@$@'2#QQV.,TN-(<C5 E:E:>K,$8L-%HP\0?T/;HL.(S/ ;Q$UK
M,RL_9NS,S/VW;8B:?DU9^GBMS3135E #4-2KRB5S5R QL7NP/0S)TF4'XA>'
M^=C[LU&C;6C-3I-"82XRTV+T!FP,9KB#D7^:Q:UG9F8GEB>#VX$UOIQ4#S_8
M?$JEV.AJ9X;^F$#^W6\H$ZRM#]_&^,2J615I*4$[=$9[+I"UDC;@C8BF8U0
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MJX+V6$$\ DA5"J"SN[*B("[LJ@D<]MM=%;W7.*ZJU+N[>BJ/4]N2?J !)/
M)($L+1<Q],OO.45LV0!EU)IMRFV-IU4,<D.L2)/<3C4?7L06Q\8T1KXC)D[2
MC<6MB+..=QO"],8!(!X3)P+PZ5;-N;8>Y=I4X^1K.$E>-DL*TR<>^O)I2\JS
M^SVO43Y=W2K, PZ' ;RW?H8#I86JX.H,Z8MW6]?=D971NGD#K4.!U+R0.1SP
M2 P'(YD)CO/5.Q.Y)MT#'X6G;K?L9E01V:3(#L_GJ'MF;"VDI"A,:E3J>PI
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MPD4D/\]:U[&RL;LZE(G-_=433$FQ>H2I?B$(@[*<$H$REP3K5 QIDQI1FZ;
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MT]:K]Y5RY_ A_.W$2W[]PYZJTJ<SWJ3]O\.2-Y4A) H=G[TWHZ\.9X$Y0""
M'+W"W%"HT!!( %$A&:()90 E@T$(=:UWZ-5U3%K%.+J6?CTJ6*U49F354I8E
MF*UUV*@+,220!R3R9QM32YZGJK=CZLR*Q[>G<@GM*L9>6/6/C;8E9([ZB7)#
M S(0F 1-++P D:VQ& TXQ0:!*@0W.0E3A,/--.&$DH&A&F&&"UL8Q;WU;K[L
MFU[LBZV^ZP@O;=8]MKD *"]CEG8A0%')/   [ 3[554!54*H] H  Y/)X X
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<@DM$EIQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g332508g40f82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g40f82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3>F4&AO=&]S:&]P(#,N,  X0DE-! 0
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M)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M   $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$
M1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M   $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M  0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'*P
M     *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&
M=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M    H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "
M]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M &       !.$))30/X      !P  #_____________________________ ^
M@     _____________________________P/H     /________________
M____________\#Z     #_____________________________ ^@  #A"24
MT$"       $     $   )    "0      X0DE-!!X       0     .$))30
M0:      -!    !@             $K0  !50    & &< -  P &8 .  R
M   0                         !              54   $K0
M             !                         !     !        ;G5L;
M    (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&
M]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $K0    !29V
MAT;&]N9P  !50    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6
M-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M  !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T96
M0     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T
M]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G
M1L;VYG          !"=&]M;&]N9P  !*T     4F=H=&QO;F<   54     W
M5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;V
MP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T
M53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
M /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G
M5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&
M]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&
MQO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M   C_P        .$))3001       ! 0 X0DE-!!0       0    $.$))30
M0,     "TD     0   *    ",   !X  !!H   "T( !@  ?_8_^T #$%D;V
M)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#P
MP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,#
MP, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,#
MP,# P,# P,# P,# P,# P,# P,# S_P  1" ", * # 2(  A$! Q$!_]T !
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MTG<8VO]5MMGT?W-JTB]@>&%PWN!(;.I @.='\G>U9?7::KWX-5K&V,=<_VO
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MD.NAK0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &
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MA7_6^XO?Y_M4_P"EG331_/BX5_UON+W^?[5/^EG331_/BX5_UON+W^?[5/\
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MLSP_!<OT1KVNR;TNB<&J_'<7JMD5V&8]LN?OM-T6F55$+(+#.<DCZ]*IYT4
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M_J08)_ESN/\ UC]--']S[^CM_4@P3_+G<?\ K'Z::/[GW]';^I!@G^7.X_\
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M331TTT=--'331TTT=--0][I^/45VIV54[\->+R+\KV5%W1S"3LJ?HOQTUV(
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MS*M'Z?R8>?LVLW(=9X/=ILX46#"%L%;7&ZV<[,Q0JRHQ^OABR1QUMQQ8E'4
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MNKM9K'=.H*P4%II7JJ@HSL%PL<2*I.^>9L10HV-JM*RAY"L:[G=5/-$9R0,
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M$N(1L)C$9IZ,O<LN:\+?A+WNKGB1K4:G=/+Y3Y^.J%59V5$5G=R%1%4LS,Q
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M-/1>ZO8X+1>2)>_IY$5OPJ>7;Y_=W 9( \R!P"?$^@!)^@!/H"<:C\_P&3^
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M>KTG=F01"10[O5F$K,J(JH7!@R6!=N0DI34R4/>__-CB64ID&,[@6[L,""9
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M%4K!/!&E*Y)V*LSS N&#;HHI%VD-E>7>)"DLSJ6$*-*%'B[*5"IY$ L1DC)
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M5%0S;X):FAHH0$*<Q1&>I8@E]Q5NXC!5 8WD9>\##%SODLD%GK&B4F:933Q
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M0P,KJ=H.UO!<_P#$!?4:8URSTU38+,A9EB]$"%0Y/(E0+9P9#GCC9*][K49
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M6XVN%8<C5@Z/F0)*)7"A@X3+8 W*0/ZB%QN(^GY:CSXS8D6[V]06LA%#!Q"
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M:A'9+];H\1J[+45"4S*K $?_ 'F-2RYPRJ69&RK@$:ZJFQ4\G=M%/ ^,,_\
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MB1N&03P05X!R!LV=Y]CF(XEG%T*=!LK+!*0-K-JHYED&AGGR$K*-M@*)YEC
MF7#P17O<C5"CU<11HJ.7OZAZWLW3L%;)4UU,:V*FDE2VI41??:EF!$,20;C(
M.]=E7O&3:B,96RBG**Q)LA-4518BDJ1EU5_A'\O:FX.%9EP#M*XR3@ XZ+/$
M.6ZPXI<:)[VM8^?H/4$US&+Y,8Z5K_'S*UJK\JU%>J-5?E4[=_GKQE7UAN%?
M6UYC[K[[5U%7W>[?W?WB5Y>[W[4+;"^-Q5=V,X&<"ZN0SL578"Q(7.=HSP,X
M&<>'@/IIQ'5)KCHZ::.FFCIIJ.#U?E[>F%SE3Y[KQTV#V[?'_P!6+^_IIKE/
MX=6RKO*<:I8C'$F6]_3UD8;47R?(G6,:*%J+V^55Y6]OU^?UZ@_/RY]YTTL.
M[K=)F\=J7-5+*YA-D95(@3 O5AD]F\EL!(&03D5'-4;7#>-R=NR/:Y45%Z'D
M@\Y'@?IR,'RP>0>"#G&I&<CU\OP\/]:4[0V4X.7.#9#L256U-U%N39B/*BC+
M%).D5V*9- C8R ==%444=K>VL"QGF>WV9SH38TP;VR%<E;07&MM=;#<*&=Z>
ML@9FBG4!F4R(T<@(8,&#H[HX8$,K$'SUR21XVW(<,,\G!!]<@\'(SXCZ<XUG
M]?Y3E5]Q[WW$DY!8G7$(^ SJMQ2O?(#6Y)G\7';^%]WY*9D0H9<438ZN<$;)
M$@3&-:1K$RU.T'J,V&OL4U7-4)4! E<TY6MIH&D7OH!(0SS03@&+;N5X5=PK
M]R=B]ZSML=BBM*/"H+$2KN<$\^+$DL-V=P4D9QMQ@+[--5Y#NO"<MNJ*RE8%
M446"5V30(T,8Y=K(QK%XU9-:V.DL*N&>9'#%-YG&LB&(BM5K2L\<)EEEF<RS
MRRS2MC=)+(\LC8&!F1R7;:,!03P  O@!KH=V<Y=BQQXL23P !DG)X  QX #
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MQO+#-*J00N)G@9V'>]XCY$F\I+MVF2-41B0HU!G;N^ZVH4]&17R,GQWAL$Y
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MPOEKV29%'BT0PW1J/'()Y18MBUHW3;V4!"SR,",8$O\ 9^K>H["HBMEUJ8(
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MG(GRB=XJ+:E+%(YN5NEE0(4IX6JGDF2384>&3[JM.4VOE@TRNC))&P$JE">
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M,#!SK/(KL076LHS2E8YS/>*@XOM!\844;&^V/Q9U8& V,P<*P. "K$\JWQ^
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M$<.2%J(Q!FD!BO,KFHU2N56^*N3MULS,=SLSM@#<[,[$*,*-S$L0JC"C/
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MS%?Q,3W^Z=T-\&RANK!B(]"#C"?9'BA<-SP,>AW-&KSJP;\Q[0IJ&CZ2O*U
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MS5%3&D1F>.)W0PJB8",Y$JO(DF48C5(?NM,JQTJAR#*TLS>$CRJJ,$7<<Q;
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MND\;]UZ(P"QRO+=D0CYHJY*0U?287"'.L<7N( ZE9$V-.L*JX:4, ;U&/V8
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M(ZK[K$E1&#)C<5D0EV4!#(S[,J-S9[4! RA&+A8XT!P1@*NT#GT 'AP#N'(
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MR9/DL/V5HFF;,N;:HQQJ.&Q1/C"FJ9?<4/=II&2?2J<MWN<J\F^-2=VHB?\
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M55#6Q&2"JHJVED=)H=\<U/)N$<L533SQ,HV;FR5#+N;J>0,C([N' @A'*L9
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MXXUSNDE8J@QC R%9LMX *I/CP "1]]Z9#N;6.:W..-VQL)@!#@SH;(N>Y28
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M!5 C>=C)A<,P8G:"PV@@ $\@<G./ZO,G U4Q]2SBWK?CYRBG:TUQ/M_N<BE
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M ). =4SN&5!W2(47874MER"2"P)*[L$Y(QY<<<OF^F1U_</T_G^6 G+")<;
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M\.\ F66$RA/NZ!#N40N7E65U)9048[L+W;::>GEI:AYHEE96$T&TR(5W?#L
M7<C*26/>!E;D*1N!T/U1..%UPWU=,I,EO:S.ES' Q-G%QQ6OCTUU<7LW'0@F
M(IRG9#AGC@F@GR0Q%E2ARX+8XSQG*[:-?U_:;YT=U-5RT%1!O6:UT4-3'AYY
MZRF AD7<-JF RM+(N24CA5D9F>/-4U.\--'-322)2Q;J>H$R!7J&>#$1C&3E
M&W;FR=R[68C^D%=?0=YC7&IN,N\]<X[C-CF.<0MHTC-<8W4JKIDZ]V.]T6 X
MC_LIK Q($VKL97:2(D625Z07NC+/0Z:(Z9LT=[N:T]14QTE'302UM=4R-@)3
M4VTR +N0L9"P3X6#(&+@$J%/50TRU%0%8@)&G?.,GXD1D!7Q7&[<,L64(F6+
M< ' ^I]CG+39VJ.0F6<KJ&9.M\2HJ"ZK2V4&G@-QF9/MVRZ 6)I"]J2RI'6@
MMHYZ^.62HXY(Y;=KI"A(79W6#]*TW1D%'TS)$5J*N$&(-42O5I321B=Y1_29
MXY&AE[Y@H")(L?PDJ+A4I)'121AH33ETDIQ .\!=642*)0=^$#G?O+[BH&<@
M:8]Q$57>AKZJZ_*]]R<2U5%7NOSF%5^OPG]O]G;O\?'SI$#'OWSZ^IU8_$\^
M9]^7[?AJ*OC90CO]Q84,Y?:!6SBWS^X%*A/P6,:>P*HB*T?N% QJ&>G9CE3M
MW>K478'9C;4NG6-NAD8!*>.IJVC:/O%G$<1C$1!^$*3,"Q?C@*,LPUS25:42
M5;AMM+&T^1P 5'PDD@C"L0P!X8C'GJ9N#%FWE@LBIA6]O,(Y%(*!$ESRD(7N
MB>: $5ZN>J.7\SOER.7_  D5>O8SK]UI3%.U/3P+C,L[QPHF">-[,%'D/IP/
MEKVX=162DKC=JRYI32.I^&HG6*.3@$[1*54XW<@$X]/,L\DZ\SC*N7#<@LJ"
M;%JL'C02Q$-7RGGL1AI;&-'B1P(Q2$LXUY,M2R?R(L05<Y7,3LQ7ZJEZ:NMR
M[4H[M-!'!;+);8UHZGX6CKEJ*255"/O.)X*RLK&9BJA(8H0%+3*YRY;_ &N&
MPTU_>J5:)X@B5+3QM#(U0TJ1@2;@J')/FR&-D*G^:-/5IH=ED-@*IH:R7;6A
M$)XQ(XE\F(%%<8LDC_ 46.%J*\\B0\01-15(]$_785VJ:"Q6ZLNU\N%)9[1;
MX6J:VX5]1%34E- OC)++(P11X*H!W.S*JJ68*;'4]6VNBBCJ"[33R2)#!'#'
M+45-34RN$BIJ6G@1YJB:9G"PPP1R22'B-6/.HO\ ,=1Y+3<O*/&LV^X=,R79
MS[1G]*685]<2>&5#CM*QGVLE&,:.$-T(IXA&-:T!%^4Z\U4]JH:WM'Z;O%'<
MZ"Z=.]45_P#[/9;I13&2FJ+;&&NL!:1HXP$#Q",A7<+$0)"FUHQ?ZVXN;-67
MJ6*:"2.DNDU31UT,E%64=9;8Y5K:*OIJI(9Z2II:J)X9X*B%)(I$=9D5@1J8
MO=6OL>U5L*-AV*7LVXC+2PY5M'GO 294VD@DA%A'/%&$"H:(V++8'Q4@62D8
M555%3KT98KK5]0]/0WJY6@66HGEJ#!3??:>O$M&D[I25BSTN8F2L@5*F,*Q_
MER(2<G&M0]DG55]OT3O7"(QO6RT\,M-3S4L,L21PAE6.>::0&"I:>DD?>$D>
M!RJIAAJ+SE?I7*;3E?JO5>4$9BTK,Z7#@LMK"4$E=64%O?7LJ3?_ '4,QHQX
M<2I&>>U0%(\R!:)K7%>-CO.G:E/%U!U3::6R(U94&U0T1@@0B0U:UE<[1%7"
M,KB-@Y[S:B*&8LJ!BN\?N]2C"&:H%1(7F96+*>[5Y79$9L@ ( Q))'CDD@9%
MB;,?4>I+O3M1QP_D2Q7)]>4%7CF/S9F87UQ+O+R/B4VO+7VL6=5!J)5%82 U
MRM<6+)*1GWQVD4X'%BES[ISLCJ+))!=8KW60UPB/=M3P0A(N^IFBDCDBD>:.
M="[]YM=2"47!!"L.J*]V6FJ)J1FFFEB=DE!D6.)C@A]BE'RO&\$[B&"D@XYK
MF^I(9V:[.Q?;,"@K<;H[3&<=P,%162YLL,,N)-L5A"8^<I)2A;4FA@ ^3(D2
M7_:$]XYGIYKKCM)Z(J.GIUO+5TE='=*N45+3Q1131UTH:?\ _)"1NDR+*4VH
MC((6!5L[CVF:GJT:JIG9D+;&$C*\@)'P\JD0P%7:/@& HX/B>GIPU_\ 5$XM
M_P#)WTOV_P 7\G.-_P!B?O\ [/\ H_3K56NG49^(^F]R0D3$UEG>P=,U''VI
M]0G8?/:+98C'S3(-M9?:6FV<CVYKG7EG!NZK'L3PNNQ_)K.EEY3<5]CF$J^B
MTYJ6%'K 3S3^FFF)Y!Z2W*W1.BN5>VS9M1;2Y%U^N>.&5<>"ZBI<OR?))_(K
MB_MO--B8AE$3 K*II,:PBASIF7CQ&5KS!0#PW L3L,AA =8U8Y<V<TU,+1\0
M]L:^],J'Q"TIFM)A.[K?29L+N]J9 ZQ4,#9.S5-8[MV:Q::++G&R2PR+*,ZR
MFA0;6,3(9=;[\P$89)#6FGO:9U1B&BM2ZUTS@%<.JPO5N#XS@6,01L:SV:;%
MJB)3P7%\41"23AB-D3#N3W),HII!7.(1SE::9=ZOG^]B<X_^3ML'_LMW337/
MQ]&=:2GY84N8Y1*CQ,?KV0L8DFDJQ@12<N.2+$-*>1S1BA!)"_IR.1>WN(OP
MC7/9E%@Z:EO]NZ@JJ:5C4V6FI:J.D2,R/51R_>S,J!06WJM,!&H_J9P"1P=5
M<%/W\4[ X>/9L!QM<L)&VDGX@2(V"E0<OA#RPU<PY6>E%7\EMP5&]Z/:P\9K
M[FOQO]M,6L:R182F_L[2!KRRL4LA3?M1$L(E?7L6MG0V1XLHTRQ9*-YI"7,>
MD.U*7IGI^6R/;5JB@G-'4PRHBE9I#)MJ$9 S;6>0AT<NRB.(J,"35.\5%42T
M,]4LS26\EHE1O@<EMX#9_H'/_%7# YP&Y->7T]=+5VN/5LY5:]FJ^128]-R!
MXI<=GM BQ;_,*J_AL,X**,)&P[A(2M:J(OD3Q1K>_;4[,SL[MRSLSL1X99BQ
MQDD^?F3]3J&;<S,< L<D 8&3R<#G SX9).,9R<G5YC%\.JJS60\4C &2M;%D
MM%%<]Q?#[E??8ORON/:9IF*_M\^:(OSW=U&N&<^'KC]>=44=#7F/\.O5&YV9
M=DU-<20U&5W3<7J*,(8CW3LASP^50XD@YB!!!BI#BO%),B')[1FD#%/Y*U,M
MZ2Z.N76$U6E%)%3P41C6HJIPYC624Y6)%3XGE,2R2;5/P[4WE0XSWQQQL"\L
MRPQJ54N5W'+9P H*D\ DDD*. 6!(&I .27JM9EN%B4F*:YQO%L5+$D5TV-DD
MDV5V%U'*U\<9)+0BIH5>CHGMH6*-D]/>]QR2GM7YW+:.Q6UI$PN];55L^0X-
M*6HHXP4"N@^.9Y06+$,Q4@8^'QST35UNI@HP]07;:'+;%Q@\[%)Y.,C+G XY
M/.JX_&'36>U'-J55X+7WLJVQ7$MH[$QTV/@DCL?P=V-V+8<RO2*GNJZ!(LV1
M6MCHCS3(2QXR>Z\;5UQ4=,4O3?:-;;5<'!M$EPI*NDFK ABFHY&9HXI\ (^V
MH1J*21E5&=&ED78=NJN'89H73XD==Z A6)8Q%HT__1SWH"!6R2"#MYP7_8=B
MF99ODU9BV)5-G>9+<31PJNLJHYSSS22N5KD[":KA#8USB29#U8&,%A3R",$,
MCV^HZZJMU%22U-5+%%31QLTLDK*(PH'_ .L<,3X*O);A1S@:I:5+N]1ND=T5
M&#AB<%(P3DL1R %QD^'UR,M?]8OB7D?&KD#C626\L%@#<&&UMK*DQXPXC"97
MBM=6TF1G$,;G,6/8.^TG#>B,[$,=JI\(O7AFNDIYJVMFI(ON])-65$M- 228
M:>2=Y((CGDF.)D3)!8L.<$'7;,ZO([H-JL[,H\" 3D>?'.3M'"YP"?'2WZNA
MI8\=.'-<XZ1AS=/7,8LI1D*D4!.0N[VR)3A"8\KVQ0^Y(>QC'.5@E3M\]NO0
MO9U?J+I7LPZ@ZFN2RR4'3[7Z\UD=.JO/+!;J..JDB@5F16FF$?=1!G13(ZAF
M5<L*>6U7F_UEHZ?Z=I$K[_?JFGLUBH'J(*5*R[W2M^Y6ZE>IJ6C@IUFJYH8V
MFE=4C4EF/D5KL70'SI2U821ZUIGCKPE>I"CAB_HXR%>J)Y%]EK%(O9$\U=V1
M$[)U\@NJ^I;AUCU+?>JKJ(UN%_NE9=*J.%0L4+U<S2B",#QCIT*PHQY=8PS9
M8G7Z%NQCH*7LN[*>S_L^J:T7*LZ4Z7M=IN%>HVQUESBIU>YU$"[5*TTM?)4M
M3(RADIS&K98$ZV6VM(^9:TKM;2@3RWM?E )>)V"28PZV$"UD"C6$.P9(/'1D
M1GW,R:INT@HWKV"UB*09O0GV4^V6#LJZMNEEO@MM-T7U<?OUVNDS215MJNUI
MMM3]TJ495=*BFK(X8:&2!C&Z2M%+$23(LGSK^WS]E6^7^^W/[2G1=?1O+8>C
M::V=9](M15<EROE-;ZB2*"[6>II(JD/<(()Z&&>FJ(J> 4-O>5JK.WNL+?$@
M/M90ZISWU,+V:RI<1K6D=558!5U<YZ-8/N]T.,%SW/8A'.57%52*Y5T!UGU+
M+UEU=U+U9/3BDEZCO=RO+4H8O]V6OJI)XX"Q)RT,3)&Q'PEE.T!<#7OK[._9
MW7=E'8GV<= W5H'O5AZ<IQ?FIN8#?[E+-=[X(6'#QK=:^K1)  )%42!5#;1C
M$D%9"MH"+WBW-::KGB1K'.+%(4,AOMJ]KO;.&5&CR8Y6]G,,%G=5&I&.K>SS
MJVHZ#ZZZ4ZRI5+R]/7B"M>$,4^\T<B24=RI&(.-M7;:JKILL&5&E64#=&I$]
MOO8]9>W'LROW0UUCA6M>,W;I:XS&919>K;=!4&QW0F#^:T$51*U/7PH&-3;:
MFLIMC=[C7NG/@BKL8JH+$5:+&H%7.DHUK?O+/WY<^>9/%.[V"DSWPAD>YRD%
M%8]BH)1L;D/;=UA2=?=K'7'5=M8/:KC=H8+5( RF:W6FVT-GIJDJQROWP4#5
MBKA=J5"JRAPVM8?8H[*^J.R3L+MMDZQ/<WV_=07SJ^>U>)L=->Y*=:"V.W!-
M0**C@K:M2%,-76ST[+NB9FWYF:5]OJ2ZU7=QI*$,=).,64)D,8HE@Z:VQ'^+
MOD*CW1/OF(V1( CI:0BO"Q7,CC$^Z_9Q[0>G^R+M-GZJO=DCN5)?:6EM-5=#
M42K6]-Q2304]7<J&%8I4J86H%VU5'_+=^ZWP2+)(ZR>>/MT?9#[0.UWJKIWM
M@[,+C;ZFZ=)]/5\/472%SJ*J.?J"DMD%;/01=-=U3STYO-1%65M+!25DU%1R
MU7W5GG7OYI8]!7&+G5;KG!9%L*1+LHU)*R<<! F@K("%T^% '.0+2E9#9/8I
M6C,X!I"/*SW!>VY=H?:\[5:#M%ZOM5EL-1+-T[T>D_=S":6.GN=WND4$L]>E
M(PC$L5-2K%34E3(L@ EJ7A,8G8-9?_&WV2V2NZ1;MUZAZ<AEZENMSO5MZ!N5
M9#525=BZ<M<CV*[.H<F@H+C>+DMPB81K]_\ X; L4DBJ9X]8L:.#*#,"1XS@
M1/;<Q43LYI&%&]?A5\A$8CF+W1$\G=T7O\>6EN]8MCK.GMR-;*ZY4-UFB9,N
MM9;Z6XT4+Q/D=VKT]SJ4G4 ][MA)([H9^F]PZ7LETNU->J^ABJ:^ELEZZ=1Y
M &1[1U!+;)KI1S(1_,CG>TTF 3\*]Z /YI.G+\'J\D;G+J*W'#;#@9*NR[
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M/=*KU:SQ5B(N\NJ+O+8'L24/3M9?'O-\I;14"DE5/X733Q2RS7*?<A!AIQ$
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M$CJ>1)><$:2UY;7V?]64O2MUJ:FX+/)1U% :<K31))*)8YQ/"0&>/Q+2H<N
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MZCV&(EA)J=CP)AFQ0FQEA9)(T,IRD9'&1XA>97-:-KGK/OW[/[!I.HG'SG;
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M\'5*O1Q5W45@ZBHY+"1<Z.^W:FJJZWS6Z&HM%)%16J.C$D51<_O-9/&VV%)
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M(<0VE*U'=7>@L-XNE'65]NMU364E  :N6! _=Y4.0L>>]F<(0[1PI(Z1_&P
M(UW)"\BLR -M) 7<N]R!DK''DO(P'+! Q QIMTCZJ'U.@G4+:_C<Y1D4+W)J
MR[5%<V>R,JM[9RB=D&O?OW7OW\E^/CJT9S_L$?W_ %]#P>==1!'CQ]>#XXQC
MU\\>FGI9!]1)Z@-5P7U!R)# T,[8&=<F=SZFN!.UY<K0MQ3 <"U?D=(Z+7)E
MZ&!:NLLOMTFRUF$&>*R(,<<+@O>1J--%+]4EZF;9+0-K>.+O>6.,+6ZMO7/0
MIC.8J+_MX17+V:Y&M1._?MW[_"(]1@DG 7&/'(R,>))'"X\_+P.N0 /G@G
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ME1^ ECEC9IA..N<&SC@;[%J.PMSQ75,IZ/<]&Q(XBSXI'=F!17!8JJ9[6:1
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M&9MK1+'[=V&2J_\ #YA@294PL*+$M8SE>I*Z=. :N:^*203\.KX##L"Q6/\
M0ER[)>FA;Y32RU5)4(FX5!D,ZJ5*NQ='!(7:I7(?$6YW W<ZKH#3U,QIEH>Z
M4Y59C(=__$@YD.QFXQM &X,0B[R-0L^I)L?%=T^L+D%]AS(*50+O J [JX*I
M&F6N*X37K8O8)6,:CQE$.*=6C;V+&<]/T1>M1=(4;6OKJR4MS(IY(:F.0[B
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M*J-16_X7DU$5R6?J>JFH+!=:ZG@EJI:*DDJQ3PX,LRT_\V1(]Q4;C&K$<^6
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MI_L_ZCZ@KZVFJ1+:(Z=A)635D32.TE06FC2.#?$U06&YVF,@56.68NQ353)
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MJG]P3WQ UIC6-9&M9(L,;N<;9CMW "S[4\<]/+<T3HSY B*K(\R,(S7L1PY
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M-82C1&9("LL:*DZ01J\6-JH&6+NP[!HIZC#+%( 8G<[SL#.J.%$BH20"&"X
M<-_^J.6SI6Y^0.3[,@P\;*)*NAK2JZ5$$=#%N)X"%:R;/*@(Z> D<OL0F#0#
M'?TJH\B,5E5UCVCU_5M-'0)3"W4"2B6:%)S-)5R1D]TTLHBA41)P_<*A5I0K
MLS=W&%X2R0C>M/ L*O@.0V68*3A<!5V)D!MIW$GQ)QJ3KB0JKZ''JL]OU_EE
MXF_/;^.95??O^O\ 8J+_  ;\?V:YU3Y.<^?[YSJ'C5EYBN,9E5WF:8T++Z*
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MXW%@PHV6AEE%X-FI(L!->1QB$)**YY?)8/AY_7Z>?L?AC33=R;:^E*^X8PF
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MX:F6G$@B('>J$;*@Y .?/S\?]X&J@?U'.B(.KN4^!YOB&.#J-?[ QFZ?4RX
M5%4K8QI\:<> !B=V!*QLDQG!1>R$26C45K%[4#.\C,\CL[L2S.QRS$DDDD^)
MYY/GKJ+%VW,<YSD_AC/ ^GEQQC@ :MU_3V.\O20XK.^/S#VT[X_@NZMA]O\
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MR58?;J]>YVQA0XDL<?Q<&6:-[*%*XOD)I[_Q^N--5^FLT;1YYMK8VTI\BO\
M?P)TF <4BFCG-#K),2FLGF99-&^<TL] $A18XW""UK#.5"$*US(_'T_3/]]/
M[_G[^?/Y:F2]:_"XX>,I!XYCD2WH\L)DM%DI9%5(=%I:U:8T^NGV!XK7.K5/
M8+'BP[$YFO"4+DC>4A6(W.NA>G;7U)5W.EN-6U-)!;I9Z%4GCB,U3M< D.K-
M(D VS.D0#8&6;:-55-'')OWJ\C!HE"(P#!9'*O)C!W"/@8X W9;.HIOITM,8
M;98GD^U950%<IA["MVVEZ='-1N*T-!1.BT,=1O&DALFSD23N&]51A>Q?%O@C
MDP4'(!]0#^8U2ZD.]8'%:[^:IL>PC2H4B&M+DTRPI5$,H6PXT(TH_N!50^1D
MG1*WVI@S-GM^U$X3O!'(^=-0X_3K\3XNZ=H9_LF>[["9A]CB]'2VL>;*9-A!
MGP+V5D".KXYF EQ)<<4<:??A-&9("I$5CP*JM2>>?7^^K1'J$8OA^/<0N15>
M^U@MFT.O;C):[[^I9D-9/F4D3[5XK2G<>*]]7;UY),>;+C$84"G?)"U7,8BP
M,^9'X#W[\]1Q\_GY_EX>_/50'B*_W?0V]5A[!L&U^Z>*+FC$JH,;'9E6^+&>
M:N>K&-_*WW'.>J-3R<YRJO3_  .?S]^)\?S'W[]_/&L%Z!>J<:V+SWQW*<ZE
M8R'!]0XU;9S? OHCY$P[XD<JUGX"7V7@BV+)XA*I2$&]P%>$#7O)Y#G4^7]_
M?OP^8UT&<]QC6>]*2DRV]@A'"I_N'5 W$6/*CDDJ$Q6H@1O0AB'2.)XWHUX7
MKYL(SN]%C..?\>^=1JC[R5H=>T_,[EI,UU48T)]=MF#3^5*V/*D5ZQL PEUE
M%'8#5QF +<K8E+'8YC!SDF#*UYA%5/4W8K26YNFIIG$ J9J^K2IF"QK4!$6'
MN89).6:,)B:-2=H$O_Z>[-)=*FOI:.GEML322F5^\4*?B.5^$G.3L7&-IX!S
MR=.WXE9=8[4V%B.J-N9*23@;\=R^IJFW4MGG63&8I92,>I:ZREH]! /;1((@
MUSGHU[3RX\1PBS'J_K[4NG;:.G[E74%&KUL4M/4]Y F"5^\1I55+HN-P%.TI
ME;G(5"P)166[TU575UL85T"I*FR52P/>[@R!E+#&_";C_,\  W&P$0Y<=\+#
MDW-_;^2Z_H(^2Q]>95:T^"P'TXOPT<1,F%C= XT%$8 8EKJT4%KR.8XJ&(1Y
M4*YY.M2=F]NZ?N-;=#>W0FFH8YZ%2SJ599=\]5$Z$*TM,B1J$^+*5#,4("E:
MBUJ6F9A'$[1J) LN$7;DAGWY&W8>[Y&/ZCP03F8G* \T)6=DLLXQ[9<J%72U
MJ[./&I[-V$AJ'&'#G0(?V<8^-K6GC <,,P/W/W+?;FBDRB$8<NXY*'LXFL4M
M(G\'CCEAW(TCP1U0=$+0N6+1U"21L01$#&$ ,6V- 53M*5IJ KBB:VL%1EAV
M@*#DG8[A6W)AL.S%@W_+G)A@T?EFOY?JO5LB]J8U7@%MN^_PJ; FH.?&@H&,
M2E@2!DGK[4?RR&L@R@N'X?:(1!1NS$:WKRMQS@EER=I8!6*^1906"L1R0&8#
MPW-XFS^N"<<X)&"03P2.<$@C(SCR!/&NA%CVM-/WVHY&(3*<MAA.2XXZ58E&
M3[B'#D&C,?\ =PC&&BGD)V4KAJOM(SL->SOTC'.<>1Y]!Y8'J=1KFO\ J2:C
M;I'FEM["XYBR*UUQ$N:B8^)]I]Y6V"'9%.C$\F.561FM(5CG->5'KW\E7O.F
MNIKPT_\ 5#XM=_U3CMI9%[_KW_DXQO\ 7M\?]'QT]^NFH6,KXH\IL[G\L./4
M7CMD-'7[K]4S#.6V(\G;[*-7!U]@6I,-R'1>42LIQJ)79Q9;5E;+L1:NO,8I
M<<#@M1&</(4/:9'#KVS0/::;5?Z*]1_#_P"?'OK9,O8VD*/"-19GOS%#'W5<
M6>K)VY>.O(UFX\"KZJ58\A-LY5<8EL'3%&?%L@N+K&-95IJ_);O%2X#&JJ2F
MC$::E'T;;\O=<>F"3=6,:MN.0',G? \EY(U>ILCRJ&R!B69\B<N/G&+8>DS/
M+ZCB5^'Z'Q+(\?J28[$L:,TX&&2H54*JGVGNQVFF@Y'Q@VY@' #B?H_5G$_D
MAG6Q<(YD:LY![8E9.O&K'\QFV&(\C<:Y [KS.1"A\@)F*TL'9-O-R#^3C$L=
MR:V;$93PZC)24@(T2WG--2->K/,+8>EAS2L)%=-ISS>,^;3#U-DL-;&K+(HV
MF)7SUKI<^ LV$][HTI8,^;#4XR?:RY(/ SVFN9GPGRC'\*Y8<?LIRMGN8_5[
M(H?Q)&IW<T,L_P!F)Z(B*J*.1)"_NGRK45.Z=U<C3R_;Z?\ ?'XZZHO'N@IK
M37$.RIBQS4^305FQ)85:YQ1RVJ8P%>O=$(-2((C7=T[-1414;\--5<OY+,>U
MQZ_^Y)=[/?,LKC0=;D>#A>)CU<ZUB46+W(5>CD<A8=563$:UK7.>*09CORM7
MN_73W[]_VU90B:NF/I[-:DK LL'N$LJ211.EQS!&W[?VU3P(Q6>;!]U\7^;N
MZ]_E8_M_UC]_QT^?_6JD?#33O[+>NAO/%LBL6W%I Q>^M\>ER!M>_P ):4+
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M7Q]XIG)^JIU.N0\1CU_?4R/T\KD?Z17%%4__ $&V/G^U-U[$14[_ +^WZ_\
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M6*IB:)VBD!V.H8<J<$<'*L"C8964<Y(GB;;(NTD9&"K9!\^"1P<@C.58$'#
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MEQH;BB"1Z&K@JT0MM#O!(LBJ6VM@%E&>.1D<9SKFC=VZOM#;2?A)X/!!&<'
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M#L?*@9PVHW_3FUQA&G/6)W+KC(<OK/VBI]?1*^*6)*5*^TR5^.XY+R"# <=
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M?OZ::U;ECS>R_<?(+<-3N>DI]C:MK]F9954^+G$>+.H*NDG2ZFOD8O;@E,?
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M%Y0T%O9R)*JC5BY--C2J^D)%>IHK FL2/1?8'TX_+V./[?34_F><#]<_CX<
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M04'[AE5(PWL<-J-&R=-:WGOTQ6T]GSZNQS?U!<"OI5-20,=K7R]/V!?M:RM
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M&4Y;Z?N:;X9E>3/S7'\L%?UQG9K<1;$^(M#74<V ,!++O8^4P\BV031-="%
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M9%5Q(+'1A/#8IB3 3"-0GR1[62K)!N$3Q8B,>]J*J=TD#)&2 ,@$GP )&3^
MR?33CZ9_''ZY]^>I_P#U+K;<LSA%R!D5<VTGVUIJJ]!%@!D.CD;3&@L)((V,
M-[6->&O',>QJ.3W%1R#:KFIW;2$1L@[LAMH8A) JNR,Q& =K*X&<A67<%) U
M)1EP?$'.",XX)'CX9XSP3@8SK+^D'B%-J+@+I1,9$QEQL:CMM@S[<B*DYALA
MS>\B*.,H_!_MN^P>C'*U48 7EW5"(Y>(]\>.?/\ SP-<3^?OC&?WTG/K;5,_
M+>$6WE+*.GV% R;'(1J-=*-53(E@1GN$3Q>A @.-[6.\U5&JG97*BAQ[/O\
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MYJ>/9'?_ *R)W_MZ::CG]7WLGIA<Y$__ '==@]OC^%8OZ=D_A\=/?YZ:H_\
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MJ/<K1_E<Q%6./\?I^GAIJ+'Z>; )$'B5R9HK*-X?:[YV74.B/16C:7'R@ 0
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M$2H0[9 ?_)"GS$&%%&QKNITU=2^GI_WHSBDBIV5 ;71?[53=.PT_7]_PG?\
MY_X]^FA]_OZ^_34T_331TTT=--'331TTT=--'331TTUJ^<+VPO+U_P#V7O\
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M<XR>MB4MQ.R2[J'U,%"LB5\+&B#I:R,)#O(]O>+6 <_N[LXI7.8GBJ=/?O\
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M>].8M&XF<C9$Y^9[6R^VK@Z=SLLBM=8)AU#6_?!92.)%)*CT<DT=IVL<4/\
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A5V 8_$GU\^'(8.1$F0Y0BQY,8XV% 8;QD8U[51)U&O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g332508g41x63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g41x63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,"^8S8X0DE-! 0      "X< 5H  QLE1QP"   "   < E  &E9I9VYE
M<VAW87)I($-H86YD<F%S96MA<F%N.$))300E       0+FK@VU9<7P"=]+%7
M/L_T(#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $<   !XP    8 9P T
M #$ >  V #,    !                          $              >,
M  $<                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $<     %)G:'1L;VYG   !XP    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M-ZK7A;<=E/VAE?HCU UNZZ&U_O[GO=\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,C4W05:6IK4B6')S=).7L;;"(S95E;0D,T)1)6&!4__$ !P! 0$  @,! 0
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M,YV)UK7J_6VLQ8Y2SV)K E2*+ZS32WC$K*R?0HHJ>0>K!UKJ+&ZQY 4  I0
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M*-_VM?O+ /.'BP\)=J[A*V1$ZNM;:9MEF<L&,M/IU>):BE5XV3YF8*/Q?S:
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M-IPC*I!M3DEEXRW'.&T\H]??%Y__ %*-_P!K7[RSS4UL>+S_ /J4;_M:_>6
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MPY93:PCVAX19+:DQPVZ@DMV(OT-G/*@R5M1)9KXE+"Y$ZQ6BDLT$B9F\FM'
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M2H5X\,X^)YC)/E*+ZXOJ?]S)^8!CC /*CB?\$WIWB;W<.ZY2]W"F/9D8D+Q
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M0DFL/,9^Q\"W"L>*%/<)-N";5Z%_/L1O1QKZWNH3>>5QGD*Z,_Y3%D:+0D1
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MU)R47C3*2>-,X.>M=W-Q&,:]Q5JQB\QC4J2E%/&,I-XSC3//&F3)>8)CC &
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M$WC:TMGO9DTI4''@CW)T;@Y.?$N#H^'5I+BXWK%1XD]6L_J1SP,T,8 P!@#
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M"V65 )BKI*MF[9LJHBA(I(.![=EXFX5$1 VJ12*BBDB01$B29$B"81,82IE
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M-8])PH!#O' QBY010 ?CG$RB90+](G /IP"<17R7&_L#/_CIX!7X P!@# &
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MQ2F$M5L E$Q0$2CY*=>DHB \A_\ L, DD5\EQO[ S_XZ> 5^ , 8 P!@# &
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M.7(YBF,43<Q P@// /O@# & 0[8?^0;K[*6#\*=8!(HKY+C?V!G_ ,=/ *_
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MG76W#C4H.@6ZG-TY&)#9O$3ONI:NJ5LBECM5D'KBI0$%9%S&$WBS%HY=JNR
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M%?@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MS-R,F3\HOP& N_N+G/6-;OW<!W-@'!J7.@41#8MN$0 1 .S@/2/+T!\C_2.
M6J"J%R<0T8O.WVT,YA5FB>2:MRP!D$'AB *R21O)*G-,A^8%'M#^C_R'X< N
MWN+G/6-;OW<!W-@%H4J-S"=;MR7RT&@S1CE5P\$L!XPG)%<H%;MRE\E!S24;
MF7.8W9CR,0H=8<^0@7?W%SGK&MW[N [FP#J>ESP$.)-BVX3@4PD 4X  $P /
M2 CY&] "/(, MD'4+@XAXU:;OUI:2ZK- \BV0) &10=F( K))&\E*<R%/S H
M]H?T?^0_#@%U]Q<YZQK=^[@.YL M U&Y^7TVX7VT# C#K+*/.F \8++E>H)H
MM@+Y*_[)F9EU3&[,>1R%#K#GTB!=_<7.>L:W?NX#N; /DO3+"5!8R&Q+:=<J
M2AD2&3@ *=4"&%,IA\CAR*8_(!'F'H$?2'PX!10U0MR\5'K3%_M+645:(GD&
MR)( R*#LQ %9-,1B3\R$/S H]9N8!\8?AP"Y>XN<]8UN_=P'<V 6;W(W7W0@
MV]WEG]S_ )&,N+WI@/&?+/CQ4RM>GR5R[#Q(3*]79?\ <]':?^(@7GW%SGK&
MMW[N [FP![BYSUC6[]W =S8!9X"HW1Q$M5I^^6=E+'%SXTV;%@#(I@5TN1OT
M&\E*\^MJ5!0WY9N1SF#T<N0 7CW%SGK&MW[N [FP"T/JC<DY*%28WVT+1RZS
MPLRNH2 !1JB1H<[,Z >2B]1E78$2.'0IR(81Y%Y<\ N_N+G/6-;OW<!W-@#W
M%SGK&MW[N [FP"T0-1N;B(9+3M]M#.64(H+QLW+ &12."RA4P(;R4IS 403,
M/Y9ORC#\'P !=_<7.>L:W?NX#N; +0]J-S3E(5%E?;0K%KGD F7"A( %6I$V
M9CL!0#R47J%9YTI*?D*<B"(_D_&P"[^XN<]8UN_=P'<V =5*7/=!^G8MN$W0
M;I 4X  $W(>0"/D?X!'T8!(:@WE&E9AFTV A*HLR)ON8IF$5RF. F,*/)(3'
M+TF-V8 7J$>0 'H "S;3^;#8_L';_P"GI' .-5?-AKGV$J/X!'X!/< 8 P!@
M# (A>+G&T.OJS\DW?/@%[&Q4?&1B:"LE+3$P^0C8J+8E=.&C4'#UZX22*H[=
M-FJ)1.LY7213.<H%'0;\POT?*N6T9*P4C7YZ0K4_ S8, DXB8CNR.LV7/%/Y
M..735;N&SMJY9/W*"[9PDH4X")BE G> 8R=;-0CMAP>OI.K6:/-:#S+>M6A<
ML(I7IA] PY)V29(D;3*\\U.2.\841=/X5JP<*LG*"3LRO8D6=NW[C7V=NW,R
M;@%JG9N-K<++6"8<D:14)'/)21<J" %19L4#N%S_ )0@ F!-,W03GS.<2D+S
M,8 P"*:OV)&[4I43>(F*FX1E+'?IDB[&V:M)EFI'2#J-72?-F;Q^W15[=JH8
M$RNE#%()04 B@'3*#T_@R!@&+EMJ19MA+ZXBHB4F9:-2C5; _;.J^RC('RLB
MHY8HK>5YJ.D91V=HD+M=I Q\JNT;*-U'1$0<H <#*. 16[V^+H-2G[E-)NU8
MNNQR\F]28I$6=J(H ',B!%54$>LPB =:ZZ#=,!%1=9)(IU"@6#6NS(W9;*=<
ML8B6A7%<FP@91E**PKPH/#Q49-)*,96N2TY!R;51A+,Q.JPDUQ;.O&&+LB#M
MLLB0#) CR 1'GR !$>0<Q]'I] !Z1'_Z#X< U_8<157D8JTOTJQ=FS^M[.0U
M*VKTC%QT;.62UO8V'EHX85N\ETFZ46_833=TD^FW,1V+9!TY=I-VZ9%5 ]6O
M;LC)=!O4;L&$7F(]E)12S&8EJ_+P\N1H23B)N#>*,9*/>>(.W[%0Z*R?4FLS
M>N6SA!1)=%8Z:A1P&L=N?I+1L#:43KJ3HT9*0EFE#7RT,JJR?0D:BZBX9X_4
M(BV=V!^Y=LT6#-5=5)!(J(NGSA0YA;LE4T5SI!V^O^/9UX.J>SD";&8:XDZI
M9X9U-Q]BD:W8'Q8-2!L"56/#EF"- 8S;R99J)%FVBK8TM$1Z+Q,C@6ZIS)E*
M<.W;M_.3C& I3&'F(%*)AY )AY ',>10YB(^CT  "(CZ ]. 82K^^:I.5G9%
MJ<Q-IK4?J^PO:Y/-K+%(QTJZ=M8F'F&RT;&IO'+@Z,LUG8TL4D\*R?N5W!$S
MLD1.F)P)QKB],-ETBN7J+C9:'8V1@#]"+GD6K>88!VJJ)VLB@R=OVJ3I%1(Y
M%2(/'!"F#D"@^G +)?=K1&OK#KRNR<':));8UF2JT;)P\:BXAH9\NW<.$%K!
M(.7C--F@N#91-!)L5X]6/S,FT,DFLJF!VK.THRWVJ<KD#$2;ME79"0B)&S'>
M5U&+\K19DTW[)I''F_=,[3;N%/%#R*4#Y,%VFN@5X)D3\@,G&,!2F,//D4!,
M/(!$>0!S'D <Q$?_ $ !S$?0& :ZH<2E5<5*8MGN6NK(L3L5'6)86:90L%+O
M+"[7;(L5Q\K3K2-B8IX5V@NF\L$C$J))'*5TW07.FB=I_GT#'^>W;GIS,JZZ
MO<9LJGQ-SAV<E'L94TBD1E+HMTGS=>*E'L.]34%FY>L7"0/6#CQ5\P>.X^0:
MBB]8NG#1PBJ<"S;$V>VUL5B_EZO9I"N+/H2/E+-$DA58V!6L4ZPKD6+YJ\F6
M4P[(I)R30K@(:,DU&K90SE8A4R&Y!V[=O5J66"WC7IZW1U80@[&U93TG:X6K
MVUVC$A7;++TE15*QL(X$)=>:1.S4:O@;KR4.Q;2!(]VJQ671(F=0#,BZ@HHK
M+ DHL*22B@(HE RRHID$P))%$2@913ET$*)B@)A !$ 'G@&&X?<2\XG;6C'6
ME\]U5,E8>+EJ<LI34Y42ST0C-QLBA(A;35OQ%1@L K=O-HNVSA,[99J17H X
M$LUGL>N[7IL1>*MX\6(ETNM)&3:BR?MEBE(*[1TAUJD*NV4,**ID5EVYE"&%
M!=9/I4,!SL6\GU[7G5D&JV.U,HYN^?RJ-<&#*XC(J,8N)!])N!GIF$;J)(HM
MQ(FV:N'#]RL<A&[50 .8@$4D]YU&.M.K:FFSG))_M=)-S$.6#1J+*#9NH)_/
M1KJS*.7K9=@25;QKQNP1:MWSE5TW6ZD$VZ"RZ;F#,PCR 1Y"/(!'D <Q'D'/
MD ?2(_  ?2. 8"DN(6N5Y6VM+;6+=5I&K1]9DT8V21@7+JRM;E8'56K!((8F
M>D6X/96?:C'$82Z\4Z:F61</$T&ICK)@9?K$VM8H5I+KQ#J#.Z[00CGK^"DW
M"1"*&(4YGE;E9J(5!4 ZR^+2*XE >E3H4 Q #MI_XB.[)OQM<5Q]9U*G9;5'
M1+"3EYDM;\A M%0\.Q6D9"17">FX1%8J39!3LFC-9P_=* ";=LH//D';MC)C
M\W$;3ANL?3&L18GIG\A5HH9E L(1HV?W&'\NP95(AS-H6I=FK'B4SJ595]U%
MLUNU1</"':N^P#MV[?SL 8W24QN1C=)1-TE#F8W(!'D4/I,/P 'TCZ, UY'B
M,@$7=CBGM0M[2=@W=48LH8IZI(.+&^NLFZB8!A%O(JSOHMI(JNVBQGS">?0[
MJ,;%\:?)(H%.<H&3M?WR/V##/91G'2D*\B)Z9K$] S9&1):$GH)V+5_'O?)K
MV1CU1$!1=M7+)\Z:NV+IJZ16,18.0%MVCLMMJVON;*^KLU/QS!E)24CY&=UI
MJLT8Q;0[UR<A;)/P)'[M1%,Y6<9&J.Y%XL )(-C&$.8%N6V\P:VFG5YY5;6R
M87PY6M9M+EO$)P[V2-!>Z+R<JR\L#9&:I8\%2F<NX))B#Q!=H+KM2<A D&T_
MFPV/[!V_^GI' .-5?-AKGV$J/X!'X!/< 8 P!@# ,>;.HQ]@5E.(:R1(>5CI
MR!LT')*M ?-VLU6Y1M+1XO&?:H&<LE56_B[M)-=!4R"J@HK)J@0X ?'6M$<4
MEI9'$I)HR]AN-HD+;87K1J=C'C(/46K--M',E%W*K=FT8L6C=,%G"RRIB'64
M.)C\@ R3@&$FNN;=YYGNRI:Q0,Q#)QGD*KPCB'?IR%1AW#= \NG%O"RHL#R$
M]*-V[B4DE8[QA5@U:1J?0B@(J 9MP"%WZB0^Q:^-;G',NU8>5(>8!2%D5(UT
M+R"DFTO' HH4BJ;AJ1^T;+K,G2*[1UV14W"*B?,H@634.MQU534ZB-AEK/T3
M5AE_*DRH11X/EV8=RGBW,A"%!-OXST?!^6IVJOY/:=!0,GX!K%:>'1.?V3(7
M9K,13!I.V*CVJ7.:!(M;6LG1R((H-H"RE=)*1T7,MF+!M)ME&RYNR*\*B<"O
M#%([>WMGW@V=P"";.IBVPJ'9J8WF%X)2PQQF R*"8K="1U$SK-G")54#KL7Z
M)#L9! BR)UF3APD15,Q@. $-TAIYMIR)L44P4AF4;.SI9IG5*E%*5^CU0"QC
M&/<-:M J/'H1B<LX9J3<N5%5-!U,OGCPJ!%%E3J 9M'GR'ERY\O1S^#G]'/X
M/1_^X!JB.@;@Y=W*4>7*NEEI?;\+N:L+M*X^!O#ST-7X:K!%2J#F96-)13R&
MA^A<S91B[3<O5UD52@DB0)CQ\_IZ@9IUE1%*#!R+)W)$EYB?LD[;9^01;"R:
MKS-@>F=NBL69E5SMF+<O9-FR2BZRO9H@=54ZASF&CM[BP[?U_:=@(TUO79Z#
M@TZS<H.XNAEXA[*G?.:\\3=LF: M)..*W16'MB.CG!8X@9,4@()3=0)M9]*P
M6V UY;(S;T]L6RVJO3S>7:*P-9CUHEZTE*K7!!LZ/!0:YI=5B(R$DT1DIYX6
M/\;E#MV2:IB(L&I$P,Z&Y\AZ1 #<AZ1$.8 /+T"( ("( /PAS#F'TA@&LL9H
M*4D%=AEO-L*Y:W79,1L]D%+1D*VZBIR$@H&#CVSE5V_EF\JQ;A78^430=-13
M"4*5UV?6U:&2 REJ/7HZLH$%1QGI*RC# ]#RO+'*=XX\<?N7W2/24H%31\8[
M)(OI$"E])AY^@".[:U_9MB.=>N*U8X"';TB[QUU6"3B7DN:1>PZ+UH@Q349R
MC C9 R;]SXP8P+*@J1'I H%4*8.O/HPO;C/T]!#*OPZ)UO8S:X(2\2E%QUOM
M]U9IQ]?(PM+Y_<V[I-_#V"QINC#*5YFYD'CQFR%HF<RI(\%U#^)%,=V]..V,
M\^0-G1Y\AZ1 #<AY"(<P >7H$0]',.?PAS# -/Y+ANM%BKUU@+39Z?-,+=M)
MILQW!.:F^7J\RFFV*U>5"VQ+J<7\MUUP*#)\5 %4!\H,FRBY%T""@9V[>\9>
MGH_SG^YG74&O!U708BD>5E)9**<2ZS8W9JH,(MG)R[V3:5V":+N':S"M5MN\
M3@Z['J.G!F$,Q9M04$B12E CVQ]<V^ZW"DR[2QP)*E4703*M-G(9^^92MG06
M*:*G7JS*58E=&@"=;F%8NT%VC29\6F1(=XP9'0 L%2T6]KMIKKYW9F[^JT:P
MWRSTN&1BA:2;:2V J_5DDYF3\;50?M8P)>6;Q96[)HH9%PB9X=99N"AP-A'9
M7)VKDC-5-!X=NL5JNLF*R*+DR9@0551*=,RJ::HE.HF50@G* E Y1'J #5=C
MH[:+36MHIY=DP:%KN<\C+VR^LH"8:S%C3=\D;"BZ5+8!<QJSV-1:0D0O$.6H
MU^(0(VCRD42073=NW;^!L)2(%U6*U&0+AO76A(INDQ9-*K&+P\*TCVJ2;=FU
M:,'#IXHB5!NF1( [80Z2%    P"%[GH%HV37XRMP-CC(*)/--W=O82<:]?H6
MN ;(K&&LKJL)*-<LX]^^%JI*BDH8[Y@@K&FZ$':XB!%)KA[83%UIM_):K##S
M<#9JY9)N-BGRA:S*&KM/G*LUC(R+=%74AX\H3:RR:"+HZ0(G>D.D9P^5<A&N
MWJ]>@-BC=0E,!1 #<AZ1$.8 ;EZ!$.8<P >0B',.8>CF&4&HKOAPL=C@[JTN
MUKK-AL5GN-6O+>SJU=THKY2HMF96&GU^6C'TNZ9+TR*1CTHKR$P!B51)Y*R
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MHV=81TC7'SED\92[EG*/$BI"^/MC5?RO7KZ#U$P08 P!@# & , 8 P!@# &
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5TT4^T64(3M%E$TB=74H<A $P ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g332508g42b83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g42b83.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1FT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &9B^95(X0DE-! 0      "X< 5H  QLE1QP"   "   < E  &E9I9VYE
M<VAW87)I($-H86YD<F%S96MA<F%N.$))300E       0+FK@VU9<7P"=]+%7
M/L_T(#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))300-       $    6CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             1P   'C    !@!G #0 ,@!B #@ ,P    $
M             0             !XP   1P                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   1P     4F=H=&QO;F<   'C
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $<     %)G:'1L;VYG   !XP    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !3A"24T$#      /+0    $
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M58E_[OXI*6]"G_1M^X)>A3_HV_<$\O\ W?Q2E_[OXI*6]&G_ $;?N"4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC0K@\9/6E/KS9VT=MJ](K-G35RC'$6;N&ZQ"*H+I'(JDJ0JB9BF* @!/=/\
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M[BJW'N37_$%I?92^Q3S]]CK/::6]BZXX>1-^ID^P8&"I]O>E1;L$CI.FR?;
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MA=L[(@!?[9;M+=!QU*S?KT4UNH<$*1PCUA /U2Y"F.4BJ?/HJ%*<P%. @!A
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MX_?@#Q"W]^RWI%Q^_ 'B%O[]EO2+C]^ /$+?W[+>D7'[\ >(6_OV6](N/WX
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MC*/*4)?TR2?%<FFGQ33+WS4F(, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , P<!^:.O\UE/: /]<5]H.[^N_OP"+;@]B7:/S=7
M;[-2> 0&/1=+<--1*TD;E%J%U;2%57NOFS%Y=$VB4!#G>EKK>1;/&RDBHT*L
M1, :N'/1$XLD5'G4%$#0Z5A]7*[1@4Z-;-TRQY\M=['9B<0>ZS6R;D[&LO&R
M;JK4E=61HW:JAU!CVJ+G8EH6&=)N4Y&'C"%;JKB?L_7_ #]OYG5NO1;J$A(R
M(>S4C8G4<S1:*S<N#0)23,B7H [?BQ;M&AG:I0 5SMVJ":BG2.5(G2Z("#*+
M+(MD57#A9)NW03.JLNLH1)%%),HG4555.)2)ID* F.<Y@*4H")A  $< PWJI
MK'BWQSZHX'Q1UH(>-?&\?XMZ\P@4J/;NT=EZTQA  3ZWIB(@ !S' /93G819
M9=LC,Q2KAJT3?N6Z<BT46;L52]-)ZND583HM%2?EIN5"E1.7\HIQ#OP#))J$
M5(15(Y%$U"E.FHF8#D.0P )3D.41*8I@$!*8HB @(" \L KIO[+,I_N-$?\
M697V_P"N7_''C]<_+_7;':O<_D61@D8 P!@# & , 8!SAX[O!VU'C5<TZQ*V
M][1+I3V;N(1EV[!&3:2D&\<$=]@?M5#)* =FZ!99DLBL7H"Z<E4(<#E$EVZ)
M=-+KHLKJC&VA=VMU*-25*4W3E3K0BX[X22?]4<1FFN*C%KD;K2M8GIL:E)T^
MMI3DII)[90GA)M-IIJ244\K*VIKN-CN%+AIJ7"?IN$U%47[^8;LGKZ:F9N2
MA'4S8)7J?&#\4$O[%JB)&S9NW;)\RIH-T^D8ZACG-I.D.N7/2'4ZNI7,(4Y3
MC"E2I0_II4:>=D,OC)IRDY2?-R?)82PM0O9ZA<RN)Q4,Q4(P7';".<)OM>6V
MW[<=ALAFD,(8 P!@# (&]VGK&.MS6@2&QJ&PO;TA5&=*>V^OM;:[3.7ID.VK
MB\@287(<GY9#),S@8O,Q1$ YYEQL+Z=M*\A97<[2#Q*ZC;5I6T6N:E74'237
M<Y(]U:W,J3KJWKN@LYK*C4=)8>'FHH[.#X/CS)YF(>!27$9NR%X==+WS<<\P
M=2K"EPYGQ(MGS!>2?+K),XYB"G1,5 CI\X014<'#JT$S&5/^24<VFBZ75UK4
M[/3*,XTYW550ZR?]-.*3E.;7-[8)M17%M87,R[&TE>W5*VC+;UC>98SMC&+E
M)I=K44\+M9S6X!?"FRO%GMZ3U!=M=1E2EGT1*3U2D:\^=O6BC:&3%S(1\P1\
M('37!H(*MG3?F110ATE$B=,A@O/3#Z/X='-.IZE:WL[FE&I3HW,*T8PFI5'M
MA.GLX-.7"47R6'E]NZU;0J5A;*YHUIS491A4C42R][Q%Q<5C*[4\+'+CP?9;
M.9%:& , 8!R@L/A@.&FN[]7TDXC;8YC&%H/3);9K5*//5V$\D^",<G*T%R$B
M[A64AUC=W+($$ (BJX:M72 )G4Z%0^C;7:^CK58SMXSG;^54["3GY1.BX[TL
M[=D:LH8E&DWVJ,I1EE*PPZ.7D[55^LIQJ.'6*WDI*6,;E%S_ *5-K'HX:4GM
ME)8;75TIBG*4Y# 8AR@8IBCS*8I@YE, AW" @(" AYPSGI7FFFTUAK@T^:?<
MS^L 8 P!@# & , 8 P!@# & , 8 P!@# ,' ?FCK_-93W!_UQ7VPY!@>.XBV
MX/8EVC\W5V^S4G@%/SJA4^$:&Z=I=4HJFI:*D:T-&,S(&B2'AX(%%'*-?$LT
ME'N4^FQDWL8JV>1\>Y<OF[MJJW*X3 UDU;8=-Z\:&LSKB:UC7=BOII:=M,92
MIV6G*Q+0SCLZAH!W7;?,2MHEG:;9N<[.<<*(V)HJL9N03LD$F@./;\/<#I17
MYZ-L\+&6"'466BY=HB^8+.&;M@JLU<$!1%8S-\BW=H J00.4CA!-3HF 1*',
M, J#B<8R,IH39T5%1$E-O)2NFC"M(E1P5\W0?O6C1Y,D1:(.G<@WKS-9>>>P
M[5LNXFF,:XB445%'I2B'CQRYFC5#K;R FH>6V/!DO.LFU]O2DU9X76\E!5:R
M6"8US#,*M-DU6#9^>%:18LK%62O&K=]''G)-L]!PBNX!1(/'^??[.[V]F A=
M*7.H5U.69LK 956!4F+RREHA9=**K=LF8AO%4CK(HC:R65LW@ZXQ?2T(C("2
MMQ#-Q'-C-W$^F"3Q_GYCQ[/'+'Q.H&L9J5L6OZE-3<$2M2DA"M5G4&DBNV18
M" &31(@U= #IF@L@1)R@R=<W+-)8C9P8RR1S"!%ZTTG6FSYHD_,-)AT:G11T
M%VD7XJ330&7E !$R/:W@*'*("(J]87F \N@'=COX]W#Q\?&2.U<._P""X?/!
MJ%QW>$:IG!,^IM87H\IL6\7%@YG4H5I+H5^.B*XU=BP"2D959C)J'</WR;EO
M'L6K!7I@R>+.G+4I&Y'=VZ)="KKI5&ZKQNZ=E:VLXTI59TY5IU*TH[]D*:G3
M24(.,ISE-8W148RS)QWFDZ-+4HU*DJRHTH2ZO*COG*>U2:2W12C%2CEMY;DD
MD_2<;MTEQDZAW)PX(\32TB-#HK-*42MI;2LD16J2D&L5O*QSMPVZQ-[T5#H*
ML%FA#*2#9VT,1LDX5.U2U6J]&M2TS6Y:%L\KNY.GY/Y.FU<TZJW4YPC+#CE)
MJ<9?T2C).324GC76EW%O>JRBNOJ3494G!8ZR$LXDU)^@TXRC)2>(N+PVL-RG
M0W%AP_\ $RE-*:5V)'W%6O*)DF&(,)B%E&1%A$J+D\9/1\8_.S6,4Q4GB3<[
M8YRF(57I (!CZMT>UC0G26J652U59-TI.=*K"37.*J49U(;UP;BY;DFLH\[O
M3KRQ4'<T=BG_ $R4X5(Y6<Q<J<I)26.3><<38K-,8)KUOKBKT'PR-(5WNS84
M?3/5$JLG",CL9>9E9$K82%<N&\3 L).1%FV,HF1P\,V*U1.H0AU0,8 '<:1H
M&KZ[.K#2K*I==2DZLE*G3IT]V=JE4K3ITU*6'MANW/#:6$S-M-/N[[?Y-2WJ
M&-\G.%.$6^2W5)13;[DV\<<8+5H-_INTJA!WW7]@C[14+(S!]"SD8H*C1ZWZ
MPZ1Q+TRD52516340<-UTTUVZR:B2R9%"&*&!>6=S87-:SO*,[>YH2V5:-18E
M"6$^/----.,DVI)IIM/)CUJ-6WJSHUH.G4@\2C+FNU--<&FL---IIIIM$PS&
M/(X*;<\-<VUUQ%3>M8O4C69UG4+6XJ5BLKJ9>-;2\7CWPQ\K+0[%-L=@@U:+
MD6%NQ=IKN'I$>8N&PJE*7KNG?1;.^T2E?SU%TK^YMXW-"W5*,K>*G#?3I59N
M2FY26$YQQ&#?*27&VT.C,:EI"K.XG&O4IJ<8J,73BYI.$9<=SYI.2DN><<,/
MN_'/D)2/8R;43"UD6;5\V$Y>@<4':!'"(G(/,2F%-0HF*(_DCS#VLY).#ISG
M3EC="4H2QQ68MIX?:LHJ<HN,I1?.+<7CEE/#/<SY(& , 8 P!@'R4[O\'9QO
MV7C.M<K"UB>F$;-LU2UP6[$Y)JE7V$0YE$W\?-O9479%XIY7V94TC0O5%?D5
MCRM8QLY2.T.K^B=*Z:]%+?HO;TJM>E3E0L%;UM+<).M4JJFX5*48*+52-:;;
MZW+AMGNJ.+4U'H=MK&F1L:<G5IPZNC&#MGQJ)QBHNG&FTW--K":S"2PY22W8
M^L]JFHBU;)*GZQ5)!%-53O'IJ$3*4Y^8]X](P";O[^_OS\[MIMM<$VVEW+/
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M_P#;&WVF8M/O70\I5M5ZC&[K,<-O_EC.[;_[8Q[2\<U1AC & , 8 P!@# &
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MN:E8*&RDVL*HA&P,]89)I8&<M+2JC)1%G!*$8/&SLQ7BRY$%&J1B"L?-Z:=
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M# & , 8 P!@# ,'7_P T=<_TK)^[[\4]W^O<[L BVX/8EVC\W5V^S4G@'YJ
M '4FKP$ $!US20$!#F @-9C $! >X0$.X0'SX!SUKB$NXV38X..VQ58!?2NR
M(,&,/3[VJBUG'.S;ZX=RLCLZ'9,R,5SC"J>I2MU)\L\0;2_;Y%,&;XS55!GQ
MV]WV/' >/\?KQ_/V=4, 8 P!@# *FAS2H[;L?C,C$B85.*"-[&HN<YV(2LET
M#/ 5*4I'/6=/F5+I)]'H\C<P$ CM?COXY]V/=@CM7N?R[/GV?$MG))& >-9,
M%D541$2@JF=,3%[C% Y1*(@/NASYA\>2GAI]S3X\N!*>&GW/)\SU-\#1O:$X
MGXNR2%PKODEA]@DMJ=P1FEE+B\C&DN$PV:GB3-BJ%F7/(K5R[.Y%OUO6N.8D
M,!<[G<_2=I-70*EO"UK^<:ED[9VTJ45:QJ2I]4Y*HI-.E'^J,=N<8CQPR\5>
MDEG*TGMA/RB=)QZK8U!3E'#6_.-B;;X9>%C&3Z9<X648@FR]9T;<-(GM<[(K
MS*TTZRM0:2\,^%4B:Y"*$70627;J(NFCMJX32<M';59%RV73(JDH4Q0',NQO
MKO3;JC>V5:5O<T);J56&,Q;3334DXRC*+<91DG&2;31[4+BK;585J,W"I!Y3
MPFL/@U)/*E%K@TTTRD^';@OX=^%H9=?3]'+$2LZHD>2GI:2?S\XJD@1=)NT1
MD)-9=1FS13=.2%0:%0*<%U16%43B.;36ND^M=(.J6IW;JTZ*:IT:<(4:2;V[
MI.%-14I-QCF4MS6%C&#*O-4O+Y1C7J+9'E""V1;X<9++<GE)K<VEC@D;3YH#
M7C *&XH-OO=!</VV-PQD(:Q2="J+V9C8CHJG1=2(J(,F)WH(""Q8MHZ=I/99
M1,2G2C&[M4IBB3I!MM!TV&KZQIVFSJ]3"\N84IU>&8PXRGLSP=248N--/@YN
M*XY,S3[:-Y>4+:<MD:DGNDN>V$)3<8YX;I*+C'_V:X,XY>#<\)OOSB*XB0TU
MM^/KDW%6V$LTU"2U;@C0R]3>5]@I+BV=BDX72=03IJ@K'HJO ,_2DEV!3/5B
MKF3#IG3CH'I&B:*M3TVI7I5+>K0I5:=>LJJN(UIJGNCF,7&M&34VH^@Z:GZ*
M<<NQZSHMG:V4KFW4J4Z/5J2<Y3552J0IO.YY4TYJ68X32EZ*X-6!LKP*U&OO
M$));/;;+?1&N;'9C6JPT8(P5Y8'#IZ+Z4B(J9!8J:,8]4$Z::ZZ9WK1)8X$,
MH=--0<.Q^E&\L]%IZ>[&%2]H6_D]&[WXI[8PV4ZE2EC+J17%I-0DTN"3:/*C
MTFG3M(TI4-UQ""A&IE*#PL1E)<\KM26'[%P)!X3GP=VT^*>=UM=-.2T(I(4^
MMFI[ZLV:64BVGBXKHSMK)L'AD7")7!>D*#M(Z8'7*1 P'YI\L\.@?333^CU*
M^MM3I5>KN:RN8UZ%-5)=9M494Y0S%X:68O.$\IXSD^-%UBWLJ=:E<QE'K*KJ
MJI"&[+DDG%I//!I-<TEGM9N[P&\-\_PK<.-6U1:IIK-V1O(3,_-JQYCJ1K%_
M.N@=*1<>JH4AUVS(I2)]>)$P66%50I *8,JW2[7*72#6[C4:%*5*A*%*C24\
M*I.%&.U5)I<%*>6\9>%A-Y-7JUY3OKV=>E%QI[8PAN6)24<^DUQPVV^&3<G*
MR:P8!\[OAMKCQ&UV>U@SJ,I<X/33J,74<NJDM)LV3VZIO!.FA//(H2*"Y0:$
M(K%-7*I41 %ED$S+%,<.S_19;:)6I:A.ZIVM74HSBHQN53E*-KL])T85,K:Y
M-JI**SP2D]N$7/HS"UE2K2:C*Y4UNW8<U3_MV+GMS_4TN>$^PZ8^#9FMTS_"
M1KN3WL>>7MZQI0L<[M!5BV![4B.S%K3N3,Z_OBJJT=T#)+O0[4LWZE101 2F
M&C=.*6ET>D=[3TCJ5;+J]\;=IT87+C_\\*>WT4HSRG&'HIY2XY-'KD;:.H58
MVRA&*4>L5/&Q5>._"7!//]27#=E\VS?'*B:@YJV?P47"5;=XNMYRL):0DI&S
M&N,Q26TX@E0I>QJO#23MX\BQC3R96S^2,9\^C&TPWCEUC*)=G(S54;&O%O\
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M\7&U[3H_AQVQM.E1!)NTU"LJOX=FJB9RW3=*NFS/Q@Z;D$#KM8Q-R>072 0
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MZL)0G%]THR2:^*/&I3J4IRIU82ISB\2C-.,D_:F?S ?FCK_-9/\ YQ3X@_\
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M[C8 P!@# & 5RV[]K2O/VJ/$<OBYS,ISP?+>'%=^<^W"+&P?0P!@# & , 8
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MR9U!F)0!4.5$A"F4$.0"80$W( [Q#'?\/?V_X[^/P([5[G\O'CC:N"1@# &
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M5O-(O:F61D&QNI*LL@=V"R1< ZKX!BIR8:U^(D)IZD]7;1S<[E5"-9.)&07
MH@!46;%H11RZ<JG,5-)%(AC'.8 [@YB %3!Q!Z[/$I222EA7>+6.5J9:PC6I
M96VEGX-@>5F6*E?*@+TGBV+3-(NW E[,1J*9P6,99$B@'H0_$UIV=%\>.LJJ
MC1A$N)<\BI%R",>X*R3B5)".9.E$"E=S4<,[$(OHE$#/$'+]%N*8K"8A0+V:
MN".VS=TF15,CE!)<A%TS(K$(J0JA2JI' #I*% P =,P 8AN91#F X! &WLK2
MW^X\/_UF5P?+_JC_ /M^A8V#Z& , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&#@/S1U_FLIW=_OQ7W>_
M^N[NP/S(MN#V)=H_-U=OLU)X!7[:)JL[PL1D/>9P]9ILEHR(9VBQ)R+6(4@H
M):CM"R<N24>I+LX\T<T%5V5VZ06;H"D"BR2B93$$#1S6[*+?;>KR^G]B\96P
M#70["T2MVMTO3JGK2VU>J%BHP\AVV:UQ%3ELBFS)]$,T"UUD@@_0>H*MI(Q
M7<)O^>/<.1UHP",75Q:VE3L+BBQL9+W%**=FK4=,OC1L2ZF!3$K(DB^(BX.W
M9E6$JBYR(J'%,AB$+TC ( :H5S46R:J?7=U85]G*WBOR^PG5\;3-H9$4N#W8
M\+&DDK,R?LV1F$<:.EX.):,H8Z )I0!54$E>O3(*P$%2X1)^+A&2D*WA8ZRQ
M4>VFGKZ+E'#5S:KO*31)&:53<.D7+"!0B(YN@RCY!&.[9+2249(R)^4%'@$+
M/'/C\W\A_K\C=O7$?:XJBU>.O,B65MK.);H3L@50BW:'I.ES$[@B2!'2R:0I
MHKNRHI [634<]63K>B$@B5:AU879\TV6FYJ<,K38E8KF;<-7#A$HR\F'4)&:
MM&9"H@)1, &3,<3"(B<?,$+F^?9S_7_79CVD=J^+[>[&>[N7'LY&1NNZ]3ZY
MNFL]=7B^UVLWG<LK+0FKJM)O.JF;O*0+%*2F6T&S(0ZCCQ8S7;JO%S]4W1,Z
M:HF6!=TW34DDM' & , PDK9JY!/8*-FY^%AY&T2)X>M,)248L'MAEDV3F14B
MX-JZ727E9!./9/'QV3$B[DK-HY<F3!%!4Y0,W@# & >)==%L@LY<*IH-VZ2B
MZZRI@(DBBD05%55#F$"D33(4QSF,( 4H"(B !@%3*[ZU$EK:I[?&[QJNMKTZ
MJ#*H6MLWDG;"P.;]+,8*GIQR+5BL^5">E))BU9*"T*G_ '@BRQTFX&5*&/G^
M7,M[ *^M.U==TBP1%7MUMB:[-3M?MELCD)915FT&LT5LR>6^=>RJJ01,5%P#
M609KR#R5?,D4TURF*8X%/T0)G&2<;-1S"8AY!E+1,HS;2$9*1KI!]'R+!XB1
MPT>L7K515L[:.D%$UF[E!11%9(Y%$SF(8!$#WL 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# ,'7_S1U_FLI[GOQ7W.[^N_ (MN#V)=
MH_-U=OLU)X!"HB?C:KPQPMFF(HL[%0&CXB8DH0R!')9=C'T9JZ<QIVZB2Z:Q
M'J*1VYDCH*D.502G3.41*(% R^N]<:Z0U/N:@N9?7CN1EJA K5&AW(CNC+QN
MPI*-"4C8JI2*+^"606?#&N'059G .7;>+2<D4*#82' WXP!@# & , JY1VV8
M;.GG[Q4K=FRU]'.W2Y^?01;MI27675/T0$W132(8YN0"/(!Z("/<+_7S_7Y=
MO9':O<_U1P%V].[]VAL1CQSR^A6CS441Q#:$8Z,V0^NX-;O1=#5#9"4!.OXK
M5)ZL:90';%AGI>?L3[Q^S</ZTVJ*CQGV6!00&/'Z</C]G?[?KEV^_N?_ #]>
M*?=9M;WK-V+7O%CQ!H;5W3-<:NKF_$S,5_AB835Y;TO7E8H,Y9:CK2'E]/-V
M9*S+ >%;05S\<O2N)NUO9-1:)?NV9$&J;]>/V</]#'+'+@LOO[>/Q^Q'H[$V
M-'T/AMHEFX=^*;:NT8O:VV=<T3B(WQL';%^1JE/9IP$C;[<YAK.ZJ\ZUTTYO
MLHDPI9GM3KY8FJK3[.(11@I(K1TW9X/''_(?/E[ECOY<N?/G]I";)L0*8_X4
MM:[>XS[_ %[55Q7XD.(NQ6C6%_VG+NY*@-&$51]8Z6:[3>M9"[2\>\G[7+R4
M9.3XLU968A&L=6E$)0T&F$^/'YD\\M+CA=GVO@L)+E\<\S(4&EV.Z[K\'-$\
M2]TW='V> T=Q$;6I",KL+8M:G+5-!?:\ST_3[&K'R#,TIL1IK:POSVKQRH$]
M(Q:*T=+BJU6=HC'CQ\^[["._W\^'MS[./9[N#X&!T1O:>N.U^'/;,EN;B.L%
M];4[B)XA.,;7Z-AOS+3VOTZ35ICU/Z+5HL@Q95J'FJ<ZDFK)M7HT%)N07KP3
M<\=\+UJY7?-][_S^G/MX#QRY\NW\^/P/YU9#<7E W!P'3:6Y.(C8UGG.';9.
M_.*2O6&XSUAHKQ2R:HV+8=841.GO1\41:L=;R,X1GV9,DRNY28"[<JBW;$38
M?#C[_;_C'_27CC[^&/S[^SC^G:2%#=<W'\%EIXB=1<0^WM@\2%E8:LKW$"-D
MN%^5U]H5]M2WLE+:]1I;NMR<)K)_K6-1F8L%8&O.G]<C&P/[#'NDE&[HQY[.
M?MY>/=_R/8^6,\,9X\>?^?<N/ O"(L=TUIX/;C?W4ANTNT8&VT^VM]1,V>P+
MUM^)H+\*.VUVH1IL>ZMT;+/J3MQ=!8I<6;)G7H-THNG#M&R";G'?Q[>WL[_R
MY?X"3;2QQ\/C_P ^!,9[<=10UAP'ZXX:-G!8*#KFP%4V/.ZRE7HQRM#X9N'V
M?GY*IR[J+*EU[6;LQ*2F]A7!NHED3*-'*2R:ITC%C'#EV#OSS^>?^FI6N=>[
MUG9'0TM?^);BE9EN/!EQ <4'$6QCMH6=BP/$SUJI3W2^MZRU0 3T64B33,JJ
M6:@1;V]:-KLC A()L'1TTG->_'?\^Q^Y91/8^7!I+@O;GC_WV=F(1LJ5W;>.
M'"\U':FQ=NKU:B^#\X;:AL*9-8[=%.7.P^)/;<XYL=RM"T6JDYF'E.U/4&"=
M@DGY72K>/F'Z,D)$)9R18_;GNSRY_P"/R[^9'NYY[L>[ERSQX)GT.:!IM,H.
MFM=U77DY.66DQU9CU*S.V*SSEPE).(?I^,&;D]@L3M[+/&8I.BEC4EUQ291Q
M6K%JFBU;HI$D@N# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M^%CR'5?7=7[C8_P#S+TO^NK_  _I7[1Y+>(C]9UQ^R:B?PL>0ZKZ[J_<;'^
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MBL2JRC&#F\OTG&"C"/NBDEV%HL:-S0M:-&\NW?W,(XJW;H4[9UI9;W=11_\
MCI\,+$>'#/-GH[@]B7:/S=7;[-2>>AEC3_L2ZN^;JD_9J,P"Q< 8 P#PK.&[
M8I3N%T6Y#G*F4RRI$BF4/SZ*93*&*!CFY#T2 (F-R'D \L _070%0Z0+)"JD
M0JBB0*$%1-,W/HG.3GTB$-R'HF, %'D/(1Y#@'D*8I@ Q1 Q3  E,40$! >\
M! 0[A 0[P$.X< KEM[*\KY__ ,'B/-YO\9E?/_\ Y\>"'S7+MY\_A\RQ\$C
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MRH&!);D[$.FYZX02YJ$'FF;D!O: SG8]I_INF>AY7^>P!V/:?Z;IGH>5_GL
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M*EV+Y]'@1<S8XNFS=915$I')3(',<H%(L44C"!P$N 2T1  $1$   $1$1Y
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MQSG.80*4A"@)C&$0   1$>6 1.O7^CVQE)R-9MM=GF$*<R<N[BI=D];QAR(
MZ,5^H@L<K00;"#C^W$@"B(* (D[\ RE<LM>M\,RL55FXNQ0,D50\?,PKYO)1
MCTB*RC=4S5ZT45;KE37251.*:A@*HF<@\C%$  \-EME8IL=XVMD_$UR,%8C<
M'\R^;Q[45SE.<B(+.3ID%0Q$SF @#TA*0QN7(HB &+?;(U_&MH)Z_NE9:M+0
MFBM7'"TTP*E.HN"IF06BC]?R?(K%52%-5N*B9@4)R,/2#F!- $! ! >8" "
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@['XXC'4?VOLWJ3;]H[/VCKNH[0AUW0ZOKDNETR@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g332508g42q66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g42q66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2=Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )UZ^$ >#A"24T$!       /AP!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP"   "   < E  &E9I9VYE<VAW87)I($-H86YD<F%S96MA<F%N.$))300E
M     0\L'U-):P!YXIS8-3G0*F@#A"24T$.@      Y0   !     !
M +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M!);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G
M1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $
M)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M    (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $
M-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V
M]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M!%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %
M)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M        !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M       $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!CS[
M9         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M   %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4F
MQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H96
MY0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W
M)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M  "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )Y]L@ !  $ GG
MVR  $  3A"24T$)@      #@             _@   .$))300-       $
M  >#A"24T$&0      !    !XX0DE- _,       D           $ .$))32
M<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M   0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0
M M    !@       3A"24T#^       <   __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@     _____________________________P/H
M X0DE-! @      !     !   "0    D      .$))300>       $     #
MA"24T$&@     #-0    8              :D   /4          $
M                   0             #U    :D
M   0                         0     0       &YU;&P    "    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P   :D     4F=H=&QO;F<
M/4    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6
MYE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&
M5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M      0G1O;6QO;F<   &I     %)G:'1L;VYG   #U     -U<FQ415A4
M   0       &YU;&Q415A4     0       $US9V5415A4     0      !F
M%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96
MQL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W
M)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC95
M9E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4V
MQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M  "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M    MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M   #A"24T$$0       0$ .$))3004       $    !3A"24T$#      <\0
M    $   "@    10   >   (%@   <U0 8  '_V/_B#%A)0T-?4%)/1DE,10
M ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T
M94     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                          $6
M-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M  %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
M)4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6
MD   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&
M=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2
M Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D
M="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M    !865H@        \U$  0    $6S%A96B                      6%
ME:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M     DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F
M-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                               &1E<V,
M  +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U
M)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W
M5R('-P86-E("T@<U)'0@                            !D97-C
M   "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,B
MXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($
ME%0S8Q.38V+3(N,0                                  =FEE=P
M  $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M!7'^=M96%S          $                        "CP    )S:6<@
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MH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$?@2,!)H$J
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MJFBZ;P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&)86(5.8UADB5)33)#%WMS(T-SA!=K8E-5%R=+&S(S-A)E)U@8+_Q  < 0$
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MQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIKM,?^NL__ *IO_P#FTYQO<?\
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MHP421>I[M>>9)TWQ<$])+<5FC#<HS7#+<BDBEKO!8-=JTM41O*9"REPZDIP
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M<2AB$)UVMTHQ;08YKMNK5M7ZT-@0K,TL48F/"A:<Q1K&CM[*O,L0)W&Y XC
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M.2[(QUC(&M+;2LO'+'$\:,L0_ER;R$ J@[R!NQW[E/?JY4>\F=+#01SAU<<
M"V$=*78SJ2MWPX]N4M,?0STDPF)9D401V'QU)RX#D]0S<IA3=W^&SG=1+_\
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M3.1(IB>QOR.9&R"5$FV)CD9 C\+<+'A.T;V)UBOJJYO$:XG-8R,3-)\D,5A
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MG]6U_1-.--.--.--.--.--?Z!75O_NR]=/\ @347_+^/<_)F=_KS,_[UR/\
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MJKKKJ[[JK+*;;***;;;[[9VVSG/I(!&BQQ@(B*%1$ 5$51LJJJ[!54
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M V!V &P ]P'NVV]VVWU:UDDDDDDDDDGO)).Y)/UDGO)^LZE41<T^::PL5(9
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M-M4DD$DM=E5%=]]4]$]=M]ML:XSGD'_A%Z6QJSOEE14#,[-2QRJJJ"6+$U0
M% )).P !)UU>GO2URJIE&=G("!:E-BQ8[*% KDL6)  &Y)/=JN+/J%Y%A_%)
M7.&K2'J16$N(TWDQC>U[;01'ZS0EJ'A;U-%>5).R(B9D]\,8@;%MWH>4.,;:
M GQ#T-\ZF_A$Z7(D<CY4*LLJPIO0H!N<RJZQ-'U3CCD,;+)P2*K<HB3;@]K0
M=/>EI=XQE"6CC>9MJM(KRHV97D5Q7X'1&1E=D9@K*5)##;76)=+/)5I#ZJEL
M?I%Y+JQM"RV=1>(H6RK8T%12;GG&!40:GAY&5LR&HF22;*,33+H:;),#Y,&W
M<);MB>SMI)?X0>F!G@A;*A.M06):SM2Q_#+)71YC7 %7B626""V\)(X7>OR=
MQ)-"'X>GW2ODSS+E2_57AYZ"I2XHX966-I^^N.)(9):_-5=V6&5YS]'!*5L]
M_8^^3W]Q2WS*M3^M.<_C#Z7>*CR./]+I^'W2SQ4^5I>GT_L??)[^XI;YE6I_
M6G'\8?2[Q4>1Q_I=/P^Z6>*GRM+T^G]C[Y/?W%+?,JU/ZTX_C#Z7>*CR./\
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MLI,L$-U,PC50419;<3)$Z+')5QET=9.PI6L+;@-CU!>G8^\917M+BJ8ND5/
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MV&^P[.H;#<ECL.T]ANQ).WO))/>=.7T<)W-S-[]PW[-H;[   ;]J_4  /L
M'=KD3.]UEM,*(U_U65TSG?7&Z=SVOOIG9/?9/?7&VM%YQY]-]=M-\>?SZ[Z[
M:Y\V<9QAR^C7WO.=X!'^CJ'>"-P?ZS]Q'>/[M.7T;^^9ON[C_HVA[_L_K77W
M[8[M^[OJS\Y+9^Q7'+Z-?>\Y\.H?O/3E]'/OF;^&T/WKI[8[M^[OJS\Y+9^Q
M7'+Z-?>\Y\.H?O/3E]'/OF;^&T/WKI[8[M^[OJS\Y+9^Q7'+Z-?>\Y\.H?O/
M3E]'/OF;^&T/WKJR(C<_N*&;GFPAL<W'LMC+80]>OA3<KLV2R10&/7@\>\>#
MTGF5DV3ITP8N7#;5)5=FV5WV1T\:3EB1Q$7:(.W+,BJLACXCP%U5G57*[%E5
MV4-N S  GR)!%QORFD,7&W+,B*KE-SP%U5V57*[%@K, =P&([]9?D-5Z<::<
M::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<
M::<::<::<::<::<::<::<::J%W%F\XKR-4K(H-+B,7</>SU PJ1-6K($]'RB
M(6#8(J&R, 9U,B2+E!HH.,*O&SL&[#%&Q%HT5P0V:ZN6CF=5!)D\?"Y)BG7*
MI)&=@C&'!Y.[#(2-G#0V*D+KPNJL.-9 RD 7A%;'Y:78B6K3KV(7!/$KG*8^
MJZ['=65X;4@(*E@P1E9=CO#U43>Y0/;<17\QM>56! ;'K&Q)N(.R$153*L9@
M<"R*(N!P_KKI76C^8!QM?@)"Z%SI"WI _>G]7 (K%7!;9M('C6NF&9+D,JL7
MK5:,R-*-K$[2.J6;R<L"NN-E>>)(H#O:A:2KOQ1EYYZ;>RO7EB(6.6Y;KNB;
MF* )'*]>G*7WF;(**TSR2+PP.(;>ZQORH(H-&]_[6":]U8G*Q,=?V%%+=L.%
M=-VZ3+=@QGVC&5-:O$QJ083WV_%OJ_GKL2=G9!MZ"C>OY(.+KZ:_A7BNN:65
MSBEDA94R)-]FXAQ1I26_FXZ]_EG8R+3JX7(M:B0^WU&/<K)<CXM:QQ)E3%,K
M=GI'CPS*VSO;?%X>W8IAR=DDN39>G'49]AQV) "4K.5X8=Y0R^'/6&1W:WJJ
MOK UZ_=:JGLR^B1>?N:Y*RZ?36B8[=!II6\>;Q&0B6@ :'D0U?\ %'##')%\
M[>@@[?=P)W6<[+<D4!>P$=*;Y&MC:PXA)/S)NST>>= %X8XY<@B<L;S2JCS1
MIRV@$V&HDT\==&*&S+3LWI-@5B$<-G(P+#&>\F1^S9B)&VA3BC#OQ&8P_3+R
M@MC1V83.N48\E.IJ:N.^7<45-A;&=1F(U75;.HFJ8!7%+559,J?%W4@LT:T'
M/24>08-V6Q)^7-^N;BQ)+'4ED>NO$.8T#9EK$IW0R\GI/F\;0@CV0QJ>J8]@
MTCD!%KIQK))/Q:OD0&260>Q$S8>**-=FY36>CF.R5F5MV$CJ9YV(10S,\QX>
M"*/83U>5LOKPZ:U6>Q'Y=5K/LM/J!KJ9@)"B]!RN(Q*SK1C<;GH!_E9 >]9+
MF 6Y:*-WVS9FNH@>;O$D&ZJJ6FFR:"(Y/%TI.&>K:L&:57"[2Q5L-=SL52=%
M:6/BL2TH:-JN6=&YLU<L>+BU7!-(E/)6E80V*=>>.*3=PJ3M?AQ1LPLPBDV0
M3O;I2E8VXE@F*#8IJ,;%GEXU+?<UD)!Y:P/JE5TYHF&!A%7R#K<.@X*,RH1!
M8WJR+00[!9#;99NE-I%JW.M!$GACEC$E&;F(-BCA'9!2JG++)+))?=GDN9N>
MC7DG)DCD:Y%CZ^/!$ 651)D;4B23/*SQSR(\\:U$D=9V8HDBACIKP+6PXN6%
M39".JRY&:WP&3=3P4:L;)&J*KJCI')SV"ZV;)?M.I=L_KZLKYTM0\WKVRS=G
M-B<7AXBJZ-F!B4QU>@81!23&-J&VTP>0C>::R(=,3EC[I^RPDOD8L&Q,A1IQ
M ':JQ)+I"V.2Q:)59+%L68GR]?'MP\D1)3-H*)8IC1E.,CFGED>UQIP%=2O#
M'-,]LUJY#20Q416G6E9OJKK.9FNBEL8GB2Y&,FT44210!.WU^ME;LFK9]*7]
M+(+)P9&-FZN'PEJW:J.[*U%$)(RL&:/2K=@/8NL-D-6T0$Z!&8)N9>0J7V*
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M_2UW660".-CJBO"1"5C:2Q+U>2Z@)XY[Y=Y999$(V$DUEDLO&0 L]A##'L[
M"U""Z+E%%RW537;N$DUT%TM]5$ED5=,*)*I*:YSKNFIIMKOIOKG.NVN<;8SG
M&<<@RLC,CJ59&*LK AE93LRL#W@@@@@]X/<==1UD571@Z.JNC*0596 *LI'<
M0P((([B#N-<O(ZEIQIIQIIQIK&F3 R/""AXV]0&APH]V5*D'.V=6[$<P04=/
M':^V,;9U1;MTE%5-L:YSC33.?-GS<B[I&C22,$1 69F.P4#WDGZ@/K/U:DB/
M(ZQHI9W8*JCWLQ.P _O)U4NT /22R8S#^SUL.:A*PEP(B7[.6Y))(R#PV31T
MN90)0469+*%!H";1YS(R2!"* )1J:%)GB'XL0P3)/-U%)%>J6 Q AL.\14-L
M"\L*//7E6-MU:>"/CFKS!3- H,L3IP\0BK=:@8(3+ JS<14$A(W806$9P R0
MRMPPV(BPCE/#'*K'8:EEQ%:%[%B LXV90:VH\O%9["0DA9.VDC!/(C8#=F!L
M("U=,7*PUX-D+<(S&F$?.KZ6K'5'&R>==\9A/61Q(L\6XLU6KR"13]+4GDAL
M%>_WI))!!*&'^M&K*WV]CE*F-HWV->PL\94_S=B*.6%7V]Q98YY4V(*\,C C
MOUKY3J-UN+BGH9U4<619/1=:A]<C$WP9Z+9TXV)LZMWCI00\8DXP_@C0R5;Q
MLM'78LJ.1(.DTGOHJ[8S.3>65IG+-,]N2\TG$P?K<U>*I-,&4@JTM6&.M*J[
M)) IB=2C,&ZK%(D@7;DI!U58V5600<XV!&58$,%L$SJS;LDP656$BJPXHYT^
MZR11LLS!TO"6[-WI.]"#1T/5*M2WB@) @[&W,MRSAZB95FXV,A$)0L4T=K&5
M&673[=9VY=KN.L>*,PD*(C6DI\M55$%66\,D\"JH 1#> LJ$"\$BKP%54 26
M616+J[!S8KVB^Y+M8JU7I03,YW9G2K(\&Y)XD8\88]^LG5-?4#2\J/5Q6C(.
M#GAF/")M(A3@X9D4U(1)HZ=1:.D2!:3$C!]6,"G3-Z$CS#<AD2'SHZ:BV;35
M1;&\P\CQR+Q,R12I),=]SS[:R!)9F/M236$INHFD+2.E;@+%8@!2456CD*A3
M*DL4)VV4QU&B>6&%1LJ10/>B=HHPJ(UD-P@R$G34.I%6MV,_%255^5A1NV#-
MYPX>D2*Q$W3<UD@]3$X?UY/8D6!RB-LI"4=R(^XP,?CW3=67RX8J]=@B_LUO
MF C@K0(QX5H+;6"8,8S%1G9I6J,4(XH(C)80*Q*&L8*Y3AJQDW,SRSS.%#&X
MM43Q%5D6:U75(DL@.#PS,D-8[K[76(Y+ 823R;UKC[#R?UC5]6&9I7L-@D=(
M +9/TT)EA=X*D-G4L%*;R:<3M_H,*Z&)K [$333LJ2 ITZ/J2=B4:R>9BERA
M%UC2?$B<NPRI#(F-Q]J:MRU05*(D1<;%9K!>2O53/7$<+1MU"S8-<<N8R!HE
M6+R5U9I0V0MUXY@S,;%X1.;[5YV/-+2<JPCRHZ]<AK<Y#) (F$D.YMY/"[]9
M1NXG=-GUWQ.O@LA>)S+:-%VSX>(E#*O1#8@B3"%0S?4$O-FXX>(79,7(I]*]
M7*2K5^8]?+E\P@$"0VK<Q*,0_6[3UZ]2Q'+&2>M"6O/6KRUY5DBE6Q'$T;&P
M Y)7B7Z-VB6&K'&"NZ+#66P]F(H0 (@EF%YUD3A='KB0,!74IFWK^M.OLOF]
M^JE-YN'E4RJSK_(",;6!XCW6^!1M+>/1B-JCFKM15("-L*4;OIPXTV]K#7,R
M;OB#%M'HOKJQE"[.T<3,SR9C(33&XYW6S<]NG4K\?U1B>O-1A/%(.U;-@.4-
MEUABZ($8JJQIB<>JI50!>35/!;M3A1L.,UWAM.-E)QM2N(PYA4SWBY'33C33
MC33C33C36*.G!$8"EI&?(-Q0,$.>%BY-WMG1J/&CT%'3UXYWQC;.B#9NDHLK
MMC&?1TTVSYL^;D))$B1I)&"(@+,S'95 ]Y)^H#ZS]6I(CR.J(I9W(55'>6)]
MP ^TZJS:79'IA(82PAMIW#4I2$7?7S<RT"E)0S683"K9BGL/;R=QJR<96:00
MSJMEGI*WV[ #E7?U&2>BV<:\L*$6>K,I%B&6NQC8;&*<RH]4.Q]A)9)E0P1N
MP:9P%C5R=B@G9(DO02;1LLPCF39N-1&RS\ V)=4B+\XJI$:$ERH[]8NS(+TH
MJN<QRU[9)UQ7<@D$D926.YF5BKQ:(2F=Q 0R0'35""$I(R@LFGT9#-QF&4R5
MCQ"4"&K48NB40_",E$N*YBG8 \-AVMS!&[WC:R>3>EAC;?J[3FSRK3PK&9#9
M9)238</$KS($V7B@05H0ZC9&6+>:G%+(NW.$7(,E9)6?@$(:, 1#AF*34?0]
MPZE)1*8'#I^WL&/5\U)E"+=,PPD\;@A][.ZZQMG*JC)TQ"'S;T^'71T\VRS_
M '4V461WUTQ/A>O(1PF*6&[#;(*\+I=IAHX9&!&XDA!=.$]VQ964@D'C,)D
M8B2-JUFJ =F4U;W!UF+["D_+C+?7NBE2" =8>4]4NO<RQOL>K(,H[WF1Z?\
MM88\-1\\G*I6S;#Y400D( F,-MF\H'LF;&2"&Y!(,=:-6S<H/=)():Z5(B1B
M(*H"PK9C12 R&*Y<>_:AD1MUFAGNR-9DAF#Q--POP;HG#(DGFDD[S-7D=O\
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M86C(,3 . 0K117&*IUWC1+"9#'2NL;$BLL6%SU>66+<\+K'/:@@ D$@(G5N
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M:7[#6S9NEICS:)(((Q'1))/7'[M=$]-==<?NQC''4<&=M\^YV  _T39[@H
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M_;IS)/[1_P!)OVZ>S1W^ 9?Y5#_3XXW_ "F_2/[=.9)_:/\ I-^W3V:._P
MR_RJ'^GQQO\ E-^D?VZ<R3^T?])OVZ>S1W^ 9?Y5#_3XXW_*;](_MTYDG]H_
MZ3?MT]FCO\ R_P JA_I\<;_E-^D?VZ<R3^T?])OVZ>S1W^ 9?Y5#_3XXW_*;
M](_MTYDG]H_Z3?MT]FCO\ R_RJ'^GQQO^4WZ1_;IS)/[1_TF_;I[-'?X!E_E
M4/\ 3XXW_*;](_MTYDG]H_Z3?MT]FCO\ R_RJ'^GQQO^4WZ1_;IS)/[1_P!)
MOVZ>S1W^ 9?Y5#_3XXW_ "F_2/[=.9)_:/\ I-^W3V:._P  R_RJ'^GQQO\
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MELBH5CDE]A6(KAD-BIC9Q,T/:5V)8I)9&"K4CI23W6?AXE^AEMXKC.Y]B5^
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MTYDG]H_Z3?MT]FCO\ R_RJ'^GQQO^4WZ1_;IS)/[1_TF_;I[-'?X!E_E4/\
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MK8!4Q2(_)6RDO)%N [PQ6 HC:*H(RPRQ\0,DN0S%X2,">4V6S$V6)A/%S$>
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M\K,@=^("R!)Q'?52A%EQPE)L5Z5'EL-Q"[VK-IWO$%4VC$U>MC$)52 T3\L
M:T&O.GM_Q""G1QZ^*HE]I$+(C=N[V>8Z]^UW4RG8=!ZQ)N+'%RJR)+G88[$K
M,0T50K%_6;JN!8QF-A[IF)T5&+\]E(ZB1(J"I--(JL6=7%FM-7LR-(2+'7)F
MF:5[0F 8*M1H31'5M<[WDLO,Q<68HD)4*ABZO8BGJQQIL8.K0B(1B!HBQ+R6
MA*MYNM"5A/4KS]8KLH25S) R>OS6XRLWEH./8C )A)[AR44>KQ.)8)E_8@0!
MN]::CV*Q<B]>JLUBA0@Z*$GKC>FPDG4*]2DYBDHQ2&E-*>-EM-D+.66:0J%'
M F0M.8XD4"*LL4"\7+XFT5Y^'(-=M*)5EEK\^&,<*FO!3KX\1+QEB7:G602/
M(S<<S.^RH0BQM8]!=A>S]-PX!/I+"*N(FJ_WAEM5_*ZWC]KLH[-6B[D<O<-)
M2X;(8^6C$TU1R]=0LN6=E63$:^"OW<6$2 >00=:+*PV+33Q\^"M,:UF&.-^3
M?QSK(;$E>*TA= YXQ5FE"RC\7CFKLH:19,U4R5ZZ0ORK$T'.@DD<,]/(Q<*Q
M12V*[<#E-XQ82(-$=YIH9@^T3Q]QWT?*_M\NH,L2.M*B,WI">R$F"N:ZT=W
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MTA)32%8EEC2]T3KS#24A!U;2!1U;=@!F*+EC+H\+!DQ"#8-LO'VRKGH2,&*
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M#8=LO1R;Q$O8^'?KMOP/X[\9ZAUZC\.KP#:>I-]UMU[7#^6('#E-_P#5XAN
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MO4DZR'01).R+((FC"]*(V5VSE47+B(?;]KYC9R==2(T9EB"TNGUC1$U.;L$
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MAZ2#FJLLD:T<!%A4>R3W]E8;MJ\I"]K!O3'*FR$E'*12L!PQ2F>U=;'02'9
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MKLCA+\2TWSA;6!0$U/LJXC"8O^]^R+W1:X9@>_A$XZ.-&$V;EFVK;L(2LG.
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MCUJRBH"[H&VJ:DNP$FOZMPI*IWK^<."$DWL(DA$9C+,3A%@0%1X[81!=N:%
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M]#5/UBF=<8RIOZO333T]O/MZ&FNOG\VN,8?_ ,_\22?^))/^))T_O^ON[_\
M#N'_  '<-<G&FN-1));&N%4TU<:*:*Z84TUWQHJGGTDU-<;8SZ*FFV,;:;X\
MVVN<>?7.,\?W_6-]C]FX(/\ Q!(/V@D>XZ?:/J/O'V]^_?\ _(!_QUR<::<:
M:<::<::<::<::<::<::<::<::<::<::X\I)95U7RDGE;33=/1;.FN5=$U,Z;
M*)ZJ9QZ>NF^R:>V^F,XUVSIIG;&<ZZ^9IKDXTTXTUQ[));*)K;))[+):[ZI*
M[::Y43U5]'UFJ>^<>EIJIZ&GIXUSC&_H:^EC/HX\S_\ N-C_ (;[[?X;]_\
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MUU_=I)/A[E5D_9*J(5VIHF[8O$%FCQOOG"S9RBJ@MIHJGOIAVGC-@?P=H[,
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MNCKP&2;B"Q*LMRR7M!=P9 K. (P-0S:7;\ 0D]F%@LBADAL>-]&!5\SK QW
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MJJBJ%4#3M:S\G3H/]D:2&G-0V]6(4L["8O)Q[$*ULS>D"0H"=#?M_P"S#[H
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M%.O BT['#"E-69>#>(DF2Q+/9?BW',F8 <(&LA4JG2FCU3[FN+-K,<0E&@E
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MAHO]+X[1R'WZYYF?_/IVED?O]WS4_P S3P:J#W4UM^AHO]+X[1R'WZYYF?\
MSZ=I9'[_ '?-3_,T\&J@]U-;?H:+_2^.T<A]^N>9G_SZ=I9'[_=\U/\ ,T\&
MJ@]U-;?H:+_2^.T<A]^N>9G_ ,^G:61^_P!WS4_S-/!JH/=36WZ&B_TOCM'(
M??KGF9_\^G:61^_W?-3_ #-/!JH/=36WZ&B_TOCM'(??KGF9_P#/IVED?O\
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M@ EG=V(5(T4%Y'8A40,S$*"14/IKV2L'L"=["H3\1%XTE")]$=(#%@ZNZTE
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M>D,B"'9--DQQ]HW4 9VS?2*A'%L>&>?)Y._8Q%U5/LLE>-<A:G9=UFK5JJ
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DC33C33C33C33C33C33C33C33C33C33C33C33C33C33C37__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g332508g43n80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g43n80.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1RH4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 7<8DP         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  $<   !XP    8 9P T #, ;@ X #     !
M  $              >,   $<                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   $<     %)G:'1L;VYG   !XP    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !'     !29VAT;&]N9P   >,    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     4X0DE-! P     $BD    !    H    %X
M  '@  "P0   $@T &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( %X H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"
M! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"
MDD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _
M /3J::33636TG:WL/!3]"C_1M_S0E1_,5_U6_D57(R.I-N+*: ^H.C>1PW:P
M[@W>WU/TGJ?N)*;7H4?Z-O\ FA+T*/\ 1M_S0@X]^6:=^34*WEX;L!X!VM_E
M;MECMG_"?SJL2_\ ='W_ .Q)3'T*/]&W_-"7H4?Z-O\ FA2E_P"Z/O\ ]B4O
M_='W_P"Q)3'T*/\ 1M_S0F=34&DMJ:X@2&@#4^&JG+_W1]_^Q*7_ +H^_P#V
M)*<1GUCZ00++:334^ S>R;"Z7UV-]&MMCOT+Z;V6._[KV_X+TK;4SKV$_P!K
M<7](VJ^VP0-K32&O]+U=OIOLMKL99['?HOSUHNZ;@NB<2G0[@8$@ASKI'M_T
MMMC_ /KCTF]-P6V&UN)2+',-;G!K9+#]*OZ/T'?G)*:^)U;I.5950UFS(M@>
MB^MS7 [7VN:[>QOT&5?3_ET?Z>E L^L/1J\:O(=4\FVAF2*F5;G 6,-[*2YO
MZ+U_2999Z7J?0J5ZCI>'CW5748[*C0RRNIK/:UHN=79=#&M^E8^BM1;T7I;&
M[&X- ;L=5&T?S;Y]2KZ/\V[<[V)*;8HH(GTV_P":$O0H_P!&W_-"<;@  T #
M0"?]B>7_ +H^_P#V)*8^A1_HV_YH2]"C_1M_S0I2_P#='W_[$I?^Z/O_ -B2
MF/H4?Z-O^:$O0H_T;?\ -"E+_P!T??\ [$I?^Z/O_P!B2F/H4?Z-O^:%"ZFD
M4V$5M!VN[#P19?\ NC[_ /8H6DFBV1!#2/P24__0]0I<T55-) +FB!W,!0LS
ML:MYK>2' [8VNU=#7;6Z>]SO49]#_P!%V*C>QASNG;F-(+3+B),M -?;\V7?
MZ_I6:+\;&>7%]3'%Q!<2T&2!M#C_ &4E(OM6/DTMLI>'-]2L G29++&[9_>K
M=O9_(5I LKKJK#:VA@-C"0T:27MGA'24I))))2DE0KZ-B5]9MZRTV?:KJ10]
MI<37M:0[VU_O>W_7WJ%V&S&ZG9UN_.MKQZ\?T[,=[P,=H!WF\@_G)U#OT[?I
M?NIH=V?V/J7[:^V?;/\ )_H>G]AV#^<F?6]7Z7T5><YK&E[R&M:"7.)@ #DD
MJ%%].12R^A[;:K&AU=C3+7-.K7-<%1R>@X65U/\ :-[K7...[$?C[_T+JWSO
M]2K\[=N_>2W/JTH5H%>;;-YR,)UW3K*K76,<<:V=U1=!]-SG5?2JW_3V(?2A
MU(=/H'536[.V_IS3.R8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME:&RQM<C-3=%1G5WMB0R4[,E)D-Q@;%"1&-E_\0 ' $!  $% 0$
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M&O/,JM^C, >*+4_O8:\\RJWZ,P!XHM3^]AKSS*K?HS 'BBU/[V&O/,JM^C,
M>*+4_O8:\\RJWZ,P!XHM3^]AKSS*K?HS 'BBU/[V&O/,JM^C, >*+4_O8:\\
MRJWZ,P!XHM3^]AKSS*K?HS 'BBU/[V&O/,JM^C, >*+4_O8:\\RJWZ,P!XHM
M3^]AKSS*K?HS 'BBU/[V&O/,JM^C, >*+4_O8:\\RJWZ,P!XHM3^]AKSS*K?
MHS 'BBU/[V&O/,JM^C, >*+4_O8:\\RJWZ,P!XHM3^]AKSS*K?HS 'BBU/[V
M&O/,JM^C, >*+4_O8:\\RJWZ,P!XHM3^]AKSS*K?HS 'BBU/[V&O/,JM^C,
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M.OH< >$\-[I/\F=?0X \)X;W4?Y,Y^AP!X3PWND_R9U]#@#PGAO=)_DSKZ'
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M94XSZ=,R44WCHGDY.\H*UN[BWC+G&C6G34FL-J,FEE+IGR/'3.<'U[RW%5=
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MEGDBQ?MY(AUTU4 .O. >)22CDDG"RK]DFBT4%)TLHZ0(DV5#D(I.%#* 1%0
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MV0QHC & , UBXTJH;"K[ZJ7FM0EMK4D! ?0=AC6LK&.NK."B1E6CM-5(3IG
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M,F;2.9M(]@V19L6+9!FR:-DRHMVK1LD5%NV02(!2)(H(D(DDF0 *0A2E*
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M;SHW>FLN(S74-M/4MB1LE1F^N30=%25:NV;QJ?JGD=),'!2.6+]HH'07;KD
MP<RG*)B&*8=/5=)O]%O:NGZC0E;W-+'*+:E&47UC.G->]G"2ZQDNC,-W9U[&
MM*A<0X3CUZ/E&4?)*,ET<7Y'W^=(E[(XUA@# & , 8 P!@# & , 8 P#S.WC
M./;J.W[ILR:(@!EG3M=)LW2*(@4!466.1,@"(@ "8P (B >N.71C*;481E*3
M[HQ3DW]"2;96,92:C&+E)]RBFV_H2RV?<FH14A%4CD424(51-1,P'(H0X 8A
MR'*(E,0Q1 Q3%$0, @("(#E&FFTTTT\-/HTUWIKR-%&FFTUAKHT^]/S,_O*
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M]RK].?X/P"XVIU4D-1ZS6643122UU3#J*JG*FFF0M:C1,<YSB!2%*'E$QA
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MR;DL9Z)1SWYPN]N>0G(C & , 8 P"/;OJ35>RW$0[V+K:AWQU7U5%H)S<:E
MV5>&55.DHJ>+5F6#Q1B951! Z@MC)]8=%(Q^9DR"&Y:ZCJ%C&K&ROKRTC62C
M6C:W-:A&K%92514IP4TDVDI9QEX[V9Z-U<VZDJ%Q6HJ>.:I5)P4L92;46DVD
MVD^]9>'U9L\\FFE7I1),A$TDXQPFFFF4I")ID0,4A"$  *0A"@ %*  4H
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MDJ='M(AX50P*';IG'K!$" ;I"F \P 0'F'DP_;\_J!*> , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@'Y->Z/<%_'ILSCCGKKKVI7RY5NPR%<7U=<J
MY**I0=)CFS9D@DR=21'C8E36AY1%T]<*J]F$>L!\DJL*@''Z(V/NG9^G[3I6
ME]<6=K<485U?VU:FG6NYRE.3G&'"3N%4IRC"*7+&.+2PST+1]3TNCI=&E.O0
MH3A&2KTYI<ISS)N?#&:G*+\F>6>&.F#]4U-8SL94*I&VA^G*V:/K<$QL4HB
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MUF39609D4M,04Y&KQ1,7#<AP4."A4E"](ICAR'I<A ES & , 8 P!@# & ,
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MDOH2N[NW9N6LU76%JO2+*01K+R\:]H:5UMTZ1NY;3<C%2-4B;$](TEXGD?\
M'I^Y^W4&UVGC+XHJ3K7?3IOO*I;)HFD.(I*M27$76JCJN/V+9-*P&I*G<=N2
M6L]8RTW'Z_V#/ZLV'..ZA*%AU7+N0BF4@RBV,A;&145*@D"L\7'%MNOB3\!M
M*R#-37NK=L:@US9GMBK^JJ]%;*JRU2J=VW7>;(SL5Y1VW79TT#9P0US5*'0S
MLDY-NF\FYEY'*NFT>]NX$S\4VP6/JJ7<I:U4C:RX&N$/8/%S-1CHZ8,)3:%K
M<66IZY?.TS#TSFJE6H6RG,<< $B4G8&RX%[2V:J)@<^Z0QTWPNTS@<V+K<M;
M#?=!TCL#B'XR+5291!Q(2FKX[1]CM]Y)NF3BW2C!R6>VI+U^/JI+-SD59QFZ
M-70*5A)BE3N\O=]K\G7SY_>P7-U[?N'G2O<Q^'^ XDG$)M9W;:!1FTGJ\LO&
MVNR[:WG>F25^?T!JP"4[)*3SVT2[Q:3++.T8&(9(.9:><LX1BNY3J"+*?I^P
MZ2U;W.;3<C)0*VPK]QV3&ZV-1I4R>>J6LZ66$VKL:V46C2)%E2.*+K>LR#.F
M$>H_^%'7D$R-$T$W[!$ .XUB_J*7_P N=_\ 9/\ E#_[P#*(?:$?S2?[A< Y
M\<>?W*OTY_@_ +;Z[(U4TA14WW7]B/JNL%=]E14<.>S&J3$%^S((I+K+. 2$
MW4I)(+***=$B:2AA A@*>:DC^)24FT9!QJ76\[KTDU$'@K_NZ!BM?;V?P"2A
M2.Y23JM-@Y:*+(M6R29X9S)%J$J\Y)#)0,4H F,^D'1C -"V2$H:K.$XB*M<
MJ\5=-$REI"]0;V=@F*O,\E%'O*B5<,LTY )R.S@H*1U!; *Q2%$#GG#:%W)!
M4*:J3G7II,UWU58-=0"K27J(KZ_5=;*M=@AIB]*.YE))>:>P=@C)VVR%*"=;
M+V^-D 8,@;J,5A EKAYU'LBHSFF65KK"\(&E]57O7UEMZ\E7W:.SIRQ6"LNF
M<[%%BI)[+JLGI(![9))6R,H=\C+2XH U<*=I<F L3NB)D7=:5>M['*1[1%]6
MT%8=JA#G8O%EK1$)I.G"SR-<ORJ-C'*HFFW>((G,D4JJ:A1.4UT6HRC)Q4TI
M)N$FU&23RXMQ:DE)=&XM/#Z-/J6SC*4)1C-TY2C**G%1<H-II3BI*47*+:DE
M*,HMK#BUT,(?4.S#&,8O$OM A3&,)2!6=1B! $1$"@)M>B80* \@$1$>0>4>
M>=6MPZ+A9V5H3>$L^[=PK./+TUA+KZ#A7M/<3;?^T7<BRV\+3]L87H7P)W+_
M -S^?%!LW\9G:/FQJ'^7N/&'1?D5H7WW<7KDIXI;C^<;<OX?MCU(/%!LW\9G
M:/FQJ'^7N/&'1?D5H7WW<7KD>*6X_G&W+^'[8]2#Q0;-_&9VCYL:A_E[CQAT
M7Y%:%]]W%ZY'BEN/YQMR_A^V/4@\4&S?QF=H^;&H?Y>X\8=%^16A??=Q>N1X
MI;C^<;<OX?MCU(/%!LW\9G:/FQJ'^7N/&'1?D5H7WW<7KD>*6X_G&W+^'[8]
M2#Q0;-_&9VCYL:A_E[CQAT7Y%:%]]W%ZY'BEN/YQMR_A^V/4@\4&S?QF=H^;
M&H?Y>X\8=%^16A??=Q>N1XI;C^<;<OX?MCU(/%!LW\9G:/FQJ'^7N/&'1?D5
MH7WW<7KD>*6X_G&W+^'[8]2#Q0;-_&9VCYL:A_E[CQAT7Y%:%]]W%ZY'BEN/
MYQMR_A^V/4@\4&S?QF=H^;&H?Y>X\8=%^16A??=Q>N1XI;C^<;<OX?MCU(/%
M!LW\9G:/FQJ'^7N/&'1?D5H7WW<7KD>*6X_G&W+^'[8]2#Q0;-_&9VCYL:A_
ME[CQAT7Y%:%]]W%ZY'BEN/YQMR_A^V/4@\4&S?QF=H^;&H?Y>X\8=%^16A??
M=Q>N1XI;C^<;<OX?MCU(/%!LW\9G:/FQJ'^7N/&'1?D5H7WW<7KD>*6X_G&W
M+^'[8]2#Q0;-_&9VCYL:A_E[CQAT7Y%:%]]W%ZY'BEN/YQMR_A^V/4@\4&S?
MQF=H^;&H?Y>X\8=%^16A??=Q>N1XI;C^<;<OX?MCU(/%!LW\9G:/FQJ'^7N/
M&'1?D5H7WW<7KD>*6X_G&W+^'[8]2#Q0;-_&9VCYL:A_E[CQAT7Y%:%]]W%Z
MY'BEN/YQMR_A^V/4@\4&S?QF=H^;&H?Y>X\8=%^16A??=Q>N1XI;C^<;<OX?
MMCU(/%!LW\9G:/FQJ'^7N/&'1?D5H7WW<7KD>*6X_G&W+^'[8]2#Q0;-_&9V
MCYL:A_E[CQAT7Y%:%]]W%ZY'BEN/YQMR_A^V/4@\4&S?QF=H^;&H?Y>X\8=%
M^16A??=Q>N1XI;C^<;<OX?MCU(/%!LW\9G:/FQJ'^7N/&'1?D5H7WW<7KD>*
M6X_G&W+^'[8]2#Q0;-_&9VCYL:A_E[CQAT7Y%:%]]W%ZY'BEN/YQMR_A^V/4
M@\4&S?QF=H^;&H?Y>X\8=%^16A??=Q>N1XI;C^<;<OX?MCU(/%!LW\9G:/FQ
MJ'^7N/&'1?D5H7WW<7KD>*6X_G&W+^'[8]2#Q0;-_&9VCYL:A_E[CQAT7Y%:
M%]]W%ZY'BEN/YQMR_A^V/4AJ2_##(NDK@@ZW-;'*.PA(-\27H.E%$[D*<6WA
M"#9B&UN))H20[1M%E[X OT8]NBT#D@F4@/&#1.J\2="P^_\ WW<6?1A_IG*[
MEW8Z]>\N6U=R+&/"-N3IW?!NUOWYT/KW^7)%FU> Y3:5<=UI??\ <J\TE;#"
MV:>49Z?X7[#W^E:[#M(& =R32[:2LT>=]"14=&,X>41:(RD:VC&+5J[3:( @
M.AJ&K:;=T8T[7;>EZ9.-13E6M;C5JLYQ4)1[-QO=0N::CEJ>80C/G%/DTY*4
MKI6B:Q85YU;[=VL:U2E2=.-O>VFBV\*<W.,E6C/3]-M*KDE%P<9SE!PG)<5+
MC*.2UCP*0NHZ#4=<5';UX+7:749:CPQI:H:>EY3P:L+]26LL8[DGNNE'+AI9
M)99:3FV@F*S>NU.D9N4A$DR;E/7M%A3A"6S=$JN$(P=2I>Z_SJ.*PYSX:M"'
M*3S)\812;?%)=".J[8W'4JU*D?"#N"A&=252-&EINV>RI<I-JG3[31JE3A!/
MC%3J3EQ2Y2D^IM]LX2$[Y3VVO;MM:?ME#9#&&9TVP:XT?*UEH,)T>\XMX9YK
M15BB,7T"=[Q31*+3H%ZCH=$,O>X-$:QXE:'Y.Z^W$OX:PG^_Z<F-;5W(FY+P
MC;DR\YSINUFNO?[UZ&X_N,>VX,81EK]WJAGL%\UUC(%4*_U\WU7H9*G/NM43
M55,[KQ-8!&.%#JHHJF65;&5%5)(_3Z29!!XP:)QX^).A8\F+[<2?V_IGD_M'
MBKN1RY?[1MQYSG_X9M7'V?H+'U8P8I_P*TN5A:A6Y.UD?U[7[KMU&@W>G^']
MQ$U%X*Y')G5>CU-6&:Q*ZCE,CA51FDD95<A5E>FH &P]P:(TD]DZ$\/*_P!^
MW%Y//\,9E];:?E15;6W(LX\(VX^O?\&;5_=\!=/JP9SU'<=XP0VR794L7:(-
M$V ;#+K'17AEV-%N9HDV&P^++OF*230YFJ91<_8-A% H@E]CE/&#1.7+Q)T+
M.,?\;N)+NQW?IC'[L^DIXJ[DX\?]HVY,?_;=JY_S?H+E^\PTMP5'G]@W#8L_
MOG8\Y([!U7%:<N\/+U/3DC7+/282<L<]&1\O#N]<JM774+VVQ-52G**+IE)*
M-W*2A2)B6S]/:/VW:>)^B\.R[-T/=>N]GS4U)5N7Z5[7M./O,=IP<</CR63,
MML[@5NJ*W]N#M8U^U5U[@VXZW9N'!V[@]'=!TN6*B?9=HI97-QDXG]5O@<J-
M-JMEH]2N2E:IUS:KL;=6(/4NA(R#M#)RW.T<,[!'--7I-I=JJU44;';OTUTA
M0.=+H 0Y@&];@T1+"V3H6/3>[B;^IO66U]3[^OE,3VMN5M2_VC;CRO-IFU4O
ML6A)/TY75='T-24[F_IQ6#:5A5Q"J5UA+.)YC"'TGP]FBV<V[9(QSJ6;,AU6
M*"$@X8-T&2SM,A5E&J*:!CBF0"A3]/:'\BM#\O\ ]?N3/7KW_IK+^LKXL;F[
M_P#:-N+KT?P7M/'V?H''U]YEX3@2:5W9E6VE#[UV3'3.OM<26J]:PS"KZ?8U
M/7=2L$NPFK6C5*XSUTC&1\C:GD- )3$H*"CTT?!L(UJLV9"[1<V1UW1XUJE1
M[/T:4)PI0A0=YKW9TI4W5<ZD6M6564ZRG&,^TJ2BE2AV<8-U'/+4VUN"=O2H
MK?VX(5(5*U2K<QT_;?:UXU%25.E.+T;L84[?LYNGV5.$I.M4[64TJ:A,<SJ3
M9*,3(JK<2>SW*2;)P=1N>M:D(18A4C"9(QD]?D4*4X!T3"0Y3  CT3 /(<R^
M,.B_(K0O-_QNX7W_ $ZS@UUM/<6?_F-N9>E:=M=M>E)Z)C/FR6/; )6S<!,)
MQ!!(!,/(!,()E 3"!0 H"(^4>0 ',?( !Y,Y-O+;223;:2[EGR+/7"[NIW:3
M22;<FDDY/&6TN]X267WO"2\R1SYX\_N5?IS_  ?E"I<G47]D^L/]/*5_MN,P
M"0\ 8 P!@# (FW*E(GJ)56CYNV9MYRMGDVRS(SA9^B-DARH)-G)7*(,%$G'0
M6,J9!V"I"BCT$^EUI3]'H_CU_<"6< 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P#'3$DVAHF4F'JI$&<5'/9)VLH(%31;,6RKI=4XB( !$TDCG,(B  4!
M$1 , Y:Z9XM-CUW@JX<=J3T;(;=WAQ;W9?Q15&:DO!EDY5VI.6V]TJ)E)DT>
M_5K]0I>K6:3YXZ&/D'Z49$F20;.W:J29@, '=1)*HN(*,VYIZ/KDBCL/B;U3
M<W-2N;NU0HWS0E"A[S6H?7KM>LQ+NWJ[,&5-68]JX91,A'61JK' U?' PE?N
M^GV_@"=.#GCA?<6TA ,V.MB59-CH:G;&VVN-B&5)KO:USL,Q$-=-I&)&-4IF
M1B8^KV&8FI3K&9F;8T!_P!DYE)4@%"PV-NIGJ5/CCBN)/<G?O8/&H[I.KM+3
M,W"R>E[9IF3X@5=30]09T%S75'Z+IYK^'EKBTL4'-MI5D[05FQ=+1J3I%1_K
MZ?S^H%G:OW1;8\].:OG1X;W,AJ#B*HV\+QPYO:K<%IW;EWB=0T]Q>H.3L6N#
M5QFSKL1M2OM4C4]5I9)A\WD;!5(R69-GDR*3<#26G=6 5USJ66=5K4C;9&ZK
M3;HB!KA]F6I.MZZC=>P45)[!:[E>.-:HW"F7VH34S&4R0H84YW*JV*19]$Z3
M 5W*+K^7M[>;T@L*XXR;J3@,V#Q56#6+B@W6#B+TTJE2D@FC1UGFV5N?436M
MAA"V*"K%F4JFQI12OS5=">K<)+.(F9:G6CTR*I*J@52CJ'M&9V)9M.V/BSW]
MK:!X6N$FFWW8EZHETBH56>WKM:<NMWLEHN*\_ 6"/E8R&9P3AS&UET@2)90L
MBFQ!L#0K4$P).X%.(;=W$)LO72NP+(Y,UK? UJ"^[#AH^-3B8:=VAN6V6-6%
MLC]@4@D82+FE48)AK%H"D1@C8UR]4"2B % EO1T]NB8X^N+&NVW<$M=-9:XU
MGIYK"41M7(NMTRCVS8,C<+0FPC@:@\EIN>:T1A5W$[-3LR[7=N)L%&#"'C#-
M8]$#0I_N@VPS[=J<)0=*5:Q:2M/%4GPFL=AS>SC5^YRULK)'SW;ETK="+5I!
M"4I&O&4#:V1G"]B92<I+UF0_X%I%&;R*H&@57NIUF!:/NVT]$1]"T58=:<2V
MU*S<&&PPL=U>TWAP>.@>6A_34ZVR:,H&\1Y&1ZR*4^ZD^VOFZ+IBF@LDN(&X
M:$W)Q%;QXWXF*VO1XK4$#JWA42V:O1JELMQ=47SSB!NB$;0VNQ6G>* ;1UQK
MD)K*XB:/0)*Q[=1^LO'2[M-0PE I"RXA>)'9/'""=5V!Q 4RN6?C)M]/UO(R
M\]44.$RP:!X<H"&8;LIC>K*MIFQ2>S9][%W%Q'.W0ULP/DW$S#/G#.!?)*/;
MV]NX&]<!^S.*7?.P]<[D87/BP9ZQNZ&^+ENR2WC ,:[H*+HUAE)4_#^PX?6-
MJKC1],2T8R[URJEEKSN0JQ(%D])85G2LM') !X5-I[XA]6\7TSJ3B'W=L#36
MS-A<.N@N$W<FQI6OSET=[4N5V=TO=VP-33D;5(!F^UPV3F(9*FOB13N 5FZQ
M/RM<$\$JFHN]O;'M] -MWK=-I</B''_IB W_ +8VI2:!P.PNZ86T[*L<;/;#
MU!O&S6.\UVH5.,O$1#0+YVPOC*O-9YA!3@2#Z,=0XGCW*;"<,W,\X.U:"[]Q
MKIFXE Z,FO46*TB'E\CY6*1.\#RB(^1P90/*(C^7G@&YH?:4?S2?[@8!SXX\
M_N5?IS_!^ 7)U%_9/K#_ $\I7^VXS )#P!@# & , AK>P60:"\"MF@BK#(09
M51G"R!DNO-/118P2!'JHGZH) 4!? 8_2,SZTJ("J)0&V?+C+AQY\9<.6>/+'
MO>7'KQS^MCKCNZF*OVSHU?<_9*X[.?8.NI.BJW%]DZJ@U-T^?'GP:EQSQ><&
MC=1QF_?'AE_5.TO2^1GPYY5I7VWGY'$X\)OQFQ/V.X/ZXZCC-^^/#+^J=I>E
M\?#?FTK[;O\ (8\)OQFQ/V.X/ZXZCC-^^/#+^J=I>E\?#?FTK[;O\ACPF_&;
M$_8[@_KCJ.,W[X\,OZIVEZ7Q\-^;2OMN_P ACPF_&;$_8[@_KCJ.,W[X\,OZ
MIVEZ7Q\-^;2OMN_R&/";\9L3]CN#^N.HXS?OCPR_JG:7I?'PWYM*^V[_ "&/
M";\9L3]CN#^N.HXS?OCPR_JG:7I?'PWYM*^V[_(8\)OQFQ/V.X/ZXZCC-^^/
M#+^J=I>E\?#?FTK[;O\ (8\)OQFQ/V.X/ZXZCC-^^/#+^J=I>E\?#?FTK[;O
M\ACPF_&;$_8[@_KCJ.,W[X\,OZIVEZ7Q\-^;2OMN_P ACPF_&;$_8[@_KCJ.
M,W[X\,OZIVEZ7Q\-^;2OMN_R&/";\9L3]CN#^N.HXS?OCPR_JG:7I?'PWYM*
M^V[_ "&/";\9L3]CN#^N.HXS?OCPR_JG:7I?'PWYM*^V[_(8\)OQFQ/V.X/Z
MXZCC-^^/#+^J=I>E\?#?FTK[;O\ (8\)OQFQ/V.X/ZXZCC-^^/#+^J=I>E\?
M#?FTK[;O\ACPF_&;$_8[@_KCJ.,W[X\,OZIVEZ7Q\-^;2OMN_P ACPF_&;$_
M8[@_KCJ.,W[X\,OZIVEZ7Q\-^;2OMN_R&/";\9L3]CN#^N.HXS?OCPR_JG:7
MI?'PWYM*^V[_ "&/";\9L3]CN#^N.HXS?OCPR_JG:7I?'PWYM*^V[_(8\)OQ
MFQ/V.X/ZXZCC-^^/#+^J=I>E\?#?FTK[;O\ (8\)OQFQ/V.X/ZXZCC-^^/#+
M^J=I>E\?#?FTK[;O\ACPF_&;$_8[@_KFLW6E<66P*;;*'97G#@O7+M69VI3Z
M+!+;\0^6A;)%NH>5292L9/-9&,=J,7BY&\@P<MWK-82.&JZ2Z9#E?#GFTK[;
MO_I"7A-\M38G['<'U?\ ?_:4]B^YRWR*UE!:E2D:*[JE/G*O8: XD]Q\5TC:
M-;2=-@WE9KY]=6USL0]@IK=I /WD2LR@W[5H^8N%$'J*Y!Y!3X<Z]-)ZKKUO
M/X\?Y="YKPF96)[#27D['</7Z?\ >6_L:-H=\!%J?5[1]7=TCAF7A^'G92VX
M-:)*O]\J.6VQW:4F20M5GD%+:>0N\C*KR[V0EC6YS,)R4F9&0>$6=MFZJ;X<
M\VD^CWUYW97_ (?+C\BG'PF?&;%_8;@Z?_L+/F_U))T=PQ;GX<:M:J=IZ"X8
MZG"7:XVN^V<A0W3*/Y6T720<24Y(+2LM9'LB1,5W)THUDDY390[(B#&+0:M4
M$DBU^&_-I7VW?Y%./A-^,V)^QW!YO_/^OZ?1T(9TSW.RW:+=T]U4(W34XGKI
MF\8ZYB]E7[B6V? Z]3?MG;)ZYI4!>+U-0]=DW#&0?L3R\>R2E 9OGC8CLB3I
M<JE/ASRK2<?\UX__ $KV^CK<UX3'W3V(OHH[@ZOZ[B7D\V.I\4KN==OUXC-I
M5)AJ"+/)U"0U]"._&/Q0.7^MZ+)R[&==U'43UUL!9SJR -)1<4JG'TA2&231
MBHUD4 9,6S=.OPYYM*_S7G_26X\)G3%38G1=?['<'7KWY=PWU71]WV]3SF[G
M)<DXFNLHLFKZ[.UN=NED0V-6=H\4D#M:7E]B%BBW9>T[*C=@(6^TI6,("O\
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M>R'E_9@&'0O&Q'$Y(U].@0W;XN/C))R)KGR0%O++2"#3JE.\/V2@&C'(JE$
MZ =7Y1Z?D>7[/Y^WU@S'?S:'X!0'L_XU^+^X/9_9@&OVNT;$CZU.OI"B0R;%
MK%O5W:C:X=H<$;)HF%4Z* P:8+*@3I&(D*A .8 *)R\^8 3&U,!VS8X ( =!
M$P /K@!DRCR'\OEP#GUQY_<J_3G^#\ N3J+^R?6'^GE*_P!MQF 2'@# & ,
M\B$>P:KNG35BS;.7QRJ/7"#9%%=XH0.B51TLF0JC@Y2_8E,J8Y@#R (!@&,L
MMCK53AW,[;IR%KL"S,CVN6L$@RBXML=58B3<%WD@JBU3.HN=--$#J 8ZIB%(
M G$ P#(QLE'3#!G*Q+]G*1<BV1>1\C'N47C%\T<$!1!TT=MSJ(.&ZR9BG261
M4.FH00,4P@(#@'MP#5(*[4BR2LU#UNUUB=FX%4B5AC(6:BY&3B%ND= A)9FR
M<K.F1^FBHB4'2:8]-)1(/LDS% #:\ QLS*0\)$R,S8)".B8.*9N)&6E)=TV8
MQ<<P9)F<.GT@]>'2:M&C5),RZ[EPHFBBF0RASE*41 #TLWC21:-9"/=-WS!\
MW1>,GK19-RU=M'*95F[ELX1,=)=NNB<BJ*R1S)J)F*<AC%, B!Z< U=Q<::T
ML[2HNK-7&]QD&@NF5;6EHY.Q.V)14,*[>*,N$@LU 4EC=81 4N::@\_L3" &
MT8!B)Z:@J[$O9FS2L5"P;%+K9"3FGC6/C&J(F*3INW;U1)LBF)S%* JG* F,
M4H<Q$ $#Y@YZ#LT4SG*W,1D]"R"8JL):&?-9*->)%.9,5&KUFJLV7(50ATS"
MDH8"G(8@\C%$  RIC%*4QC& I2@)C&,( 4I0#F)C"/(    1$1'D >4< T1Q
MLW6;.MFO#F_4EO4A>JQ1K:K9H0E?-(-GJT<M'=_!>A'G=MY!%PR5:@Y%5)VB
MNW.0JJ:A2@;JU=-7S5N]9.4'C-V@DY:.VJJ:[9RV7(55!PW72,=)9%9,Q5$E
M4S&(H0Q3%,)1 < Q;NPUQK,1]9?3<,WGYIJ^=Q5?=2+)*7E64:4AI)RQBU5B
MO'K5B15,7JR""B+8JA.O,0#EY@>"MWFDW!:5:U*W5FS.(%P#.:;U^<C)=:(=
M"94A6TBE'N5SLEC&06*5-P5,QC(J 4!%,P '\NG=@V955)!)19=1-%%$AU55
ME3E32233*)CJ**'$"$(0H"8YS"!2E 1$0 !' -5"]43P76OP6^J>!B+55RO<
MPG8GP:39-ESH+.%;!VKO85J@Y!1$ZIG?5)K@=,3 ?F& ;4BLDX12<-U4UT%T
MR+(K)'*HDLDJ4#IJIJ$$2G34(8IR'*(E,40,41 0' ,0_L%<92L77).:A6LW
M/D>'AH)](,D9293CTRK/SQL8NL5U()LDC%5=F;(JE;$,4ZPD 0$0/''7:G2\
M_*56*M5>D[-!D*I,P#"8CWDS$IG$H$/)1S=PH[9%,8Y2@+A)/[(P!ZX\L V4
MYR)D,HH8I"$*8YSG,!2$(4!,8QC&$ *4H (F,(@   B(\@P#0G>TM71U=0NK
MW8-&9U1^Z/'MK4O:(-*!>O6ZR[8[-O-&>@P<N$'"#I$Z"3@ZB2J*Y#%*9-0
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M:]7K=69R>KAP3L$+$3D9(RL&<53H 25CV;E9U'FZY)1'HNDDAZU,Z7_.0Q0
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M/CS^Y5^G/\'X!<G47]D^L/\ 3RE?[;C, D/ & , 8 P!@# & , 8 P!@# &
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MK8EWQIQ&#U0T>_B8Y[(5D7Z:RM>< R^QRH.AV , 8 P!@# & , 8 P!@# &
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/=[O_ .W6]=_Z?5_9@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g332508g43z54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g43z54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &BJ^9I@X0DE-! 0      &8< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M @   A_]' )0  AR<C,Y,#DX-AP"!0 U36EC<F]S;V9T(%!O=V5R4&]I;G0@
M+2 Q,BXR,BXR,#(Q7U5P9&%T960@26UA9V5S+G!P='@X0DE-!"4      !"/
M[#JE+Z5W+!=]7H62\*>K.$))300Z      #W    $     $       MP<FEN
M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  @.__C4  @ ".$))300F       .             #^    X
M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             "\@  !'\
M         0                         !              1_   "\@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "\@
M  !29VAT;&]N9P  !'\    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    (
M.$))300,      ^3     0   *    !I   !X   Q.    ]W !@  ?_8_^T
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M2222E*KD=2Q,=VU[BYW@P%W_ %*)DOVL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D 5P# 1$  A$! Q$!_\0
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M<S-E3S/:R)C=",D48*R.<C6ON ZT=5<U&DO<JM2OZGT/JUBAFM6CU.!5+/\
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MABC3S]WO>UJ+]O/GFNJL[!45G8G 5068GZ  $D_H*P*K.P55+,Q "J"223@
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M%]?I*,:"21_CP^T%AKCF,C1/+5A97I*J(_RYTR?S:Y45TGJD(6Y5P"0(&?\
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M1A#"+$FEMHX?IFDM\DL+=.;8$1/;(96,D>D;96'3-2BF9^S#;1J/Q9)03*P
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MJ?*Y'0^Q\CWK6S^9$#4A7-D)8Z*6&=\;'?&Q722.O-KI%KJ2(\N8KE5VB7
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M*6 I0'N6-LYX\G+>6FMQMI[W/9N1)W(90FVU?:=J6R!G$DNU&V*\BJ\FW</
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MGQQDR/3UGJ?1VLM>:[IM[IK:1!=7]U:W4#V]PWR,#W!B$<_;):5HPJ;BJLQ
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M;,/+&[\M<UWA/>W[M5/**UWXW+2.4R)(BAER0P\Y4@A@1],>0<9KLGG//'G
M_P _S)]JT'1^I</+6C,YV*SV@_*T<;6"1/E1ON>J,==B1M5WL8W[2'BHYR>U
M'2BJGR3I/3].M<1&XT_EL%GM7(!/&<0N< D^T;D?16X"UD,1/*XSQZ??./TP
M/T/&>,YK0W?A\>3OH>Z\WVWUMJNU:X&IM<54"8VW/T-GD(#M+7B5"S5'8!=0
M)FY8=)?B6E]-G:F$PV 2.PMA2(!70=+!6>*73Y[&\CM\R"X+RQHL4^(CW KV
MRMW=T46Q.\Y",VU'#&K5TKIIU6_M-,OR]KH]W=+!>7LK]BWM2<2&3NF&4B4*
MF$5$E?!)6)QG$3_5AZ@)^ONJJ^:7ITJVI;BQO0M4/V!8TX.E3LBFG)/.?C!L
MT=>J7IQ;BI/O  ="/3Q'""#Q"%M"G1(=JTP'/<NHE4%%B,8D*O 1E5)<* "G
M'I8^K)(W>?3OAQT*_4_4UV++6KJPOM/@$MK-IL8DLX-*G26 7.I22]F1=,E,
MUM;7,]J))81=]\12M&L;U_T/ZSWI,ZQ=?X_N#TU=P6$^D *:PD&+/4]?8C:%
M92+:R $M;L6U$8P\HV*ILFVQY@0X@;8'A$"Q0!9WL+R[8'3KN-HH9-K,CF0+
M(F,*Q7T@! I:,J,DDD$')LNN? [7(];AD;KKI][FT:&.!IOFY'M4B([<;FWL
MS'*R+@W#]M3-(TI8,#EMSE?_ !&G75?64^=ZB]-=G+6U@ -76OV78H8"C A#
MQ"B0_M])G[ATGQ01-9[UMD5?:BN\JJKS'_X2E(:2>^3N,2QCCA8Y+>HDLS*H
M&2>%! QQQG%QT3^$V/7&:YO?B5ITMS<L93;Z;HTK,\TI+LHEN[NU"Y);@6V
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M?VK\Y",$@^0<'W\?<<']JZ<?K0JX]Y^K%9@;"=P ]KVKUY#437##7AE9?-"
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M*JI+> IPIQ@@8]1>W[@CM\%4&&<?ZF .3['&0<#GWQ[YLIR@1==F,]7GJBG
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M7[>%7PJ+^5\*B_T3\<GO7;Q$G*\9)QSP!X\CC]SG-8.XCKSC'G!()SD^V?/
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M$8GF0,Y:YW*S.BRK&Y+%=IPMMZ6^*FN=)ZK>Z3,@UE)+N&VLK*Z>.6*1U_\
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ML>LD-T-G B;85Z^?*AV)["S _/E?L+/$GW7[?=>99;NZG&V6>5U_])<[>/J
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M#E1LP\C&Z5T D=M$CET2$F0@.(Q<O(S2IZ@%=HU[<9=<JVP$$C%<7D=S'9V
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M<K&VE1)*OOE FDC<QRO>&2)+))(_>L;^:Q?*>J-B-\3$A6^X(Y5\<;AY\,"
M!2JK=9Z/>\\<?)%89^7:T[)7?3W6/1;19V-7RQTU/Y9<C2>/'R-<#+"UR.;&
M3,GM>ZYVG45NZX[O8D(P5D.P#_\ OG81G@9(.!D@9Q6"1&P< -DC(\?O@?\
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M$<+.J%BN)@>R69I<_P \JG>R=9EGF61ZR.;)(KO/.[3RR3&>5RSN068^& /
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2I3BE.*4XI3BE.*4XI3BE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g332508g46h84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g46h84.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MJ4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 8L            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  'E   #GP    8 9P T #8 :  X #0    !
M  $              Y\   'E                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   'E     %)G:'1L;VYG   #GP    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !Y0    !29VAT;&]N9P   Y\    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     4X0DE-! P     $.P    !    H    %0
M  '@  "=@   $-  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( %0 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M *JM)N54\M:RXN<\PUK1823^ZUH8N:LZOD6D&W(%A&@+SN(^&YQ3#JE@B+6
MMU!$ Z^<H\4?%7^C^6_?R_XT?^]>H];C6S60/T=VL<_X),S(K>TN9=(!VGZ8
MUB>[5SAZ[G'0YCCQ^>>W'YZBSK-S&EK;:X<[<9 )F(0X@@_#^7K266_[T?\
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M8#/[OT%/!M;]OQ9LG]/4(]W^D9XM7,?\Y>I!NS[9[?W=VF@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                          #_X3Z.:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C$M8S P," W.2YE
M9&$R8C-F+" R,#(Q+S$Q+S$T+3$R.C,P.C0R(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @
M(#QX;7 Z0W)E871E1&%T93XR,#(R+3 V+3$Q5#$R.C,S.C4X*S U.C,P/"]X
M;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y-:6-R
M;W-O9G3"KB!7;W)D(#(P,38\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @
M/'AM<#I-;V1I9GE$871E/C(P,C(M,#8M,3%4,3(Z-#DZ,S4K,#4Z,S \+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R
M+3 V+3$Q5#$R.C0Y.C,U*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO<&1F
M.E!R;V1U8V5R/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^5FEG;F5S:'=A<FD@
M0VAA;F1R87-E:V%R86X\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^
M:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.C<S,&$X9&,P+6,X9C<M.#@T9"TX868X+3 P83EC,#$R
M8C!F93PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.CDU.3%F,F5D+6,W8S(M9C(T
M8BUA-C U+60Q.&)F-3(T,CEB8SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C5F8S0S861D
M+3 Q-&4M8S T.2TY-F9F+6$R8F-E.#$V9C<P,CPO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-69C-#-A9&0M,#$T92UC,#0Y+3DV
M9F8M83)B8V4X,39F-S R/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 V+3$Q5#$R.C0Y.C(S*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N,2 H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.F,W.34Q8S%C+65E.# M,6,T8RUA8V9B+6,R.#9E,SDR
M,C4T8SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,BTP-BTQ,50Q,CHT.3HS-2LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(S+C$@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<S,&$X9&,P+6,X
M9C<M.#@T9"TX868X+3 P83EC,#$R8C!F93PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP-BTQ,50Q,CHT
M.3HS-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C$@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII
M;G-T86YC94E$/GAM<"YI:60Z8S<Y-3%C,6,M964X,"TQ8S1C+6%C9F(M8S(X
M-F4S.3(R-31C/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YX;7 N9&ED.C5F8S0S861D+3 Q-&4M8S T.2TY-F9F
M+6$R8F-E.#$V9C<P,CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C5F8S0S861D+3 Q
M-&4M8S T.2TY-F9F+6$R8F-E.#$V9C<P,CPO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X
M<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 38"40,!$0 "$0$#$0'_Q  ?  $
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MXSN>7P'J/7N!J;G\COLOT)NU[+\()+RARHUZRPY3U [C20/"#_YZST^"6'G
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M!"#>U[X]35GO5:]RMI>I/7M0QSPLWN>A:*50Z$HVH!E)4@E2-QX#DG^2/V6
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M S AA,Q>4,#X1([%W!ZF<EC\(DY-O>I.125RL\R'.,D?7>RA"K"Z.\]>W%P
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MLHWV#';K8=9/A/@RKH1K*CL(G\:R0#*\8D\AB;ZXREF#,),K?$1,F<RS!'2
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MIF..#L@8L;R+) (TW*EDL=,?1^2.S+&UB)XEK0H9U+DXLS04Z+KVAKNY)#6
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MBF,4QBF,4QBF,4QBF,4QBF,4QE]]+/\ SG]-O^?_  S_ +R(U6#JG_-6J_\
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M,Q'2@+S0$;;MO&3LX*_5 0H3JWU*K2GE*4JF.]L)E!!@#2#R#EA!A)Q)I=Q
M,*-+$$99@!7", K"#>]KVO7A# JW*P(8<P((((((!!!ZP0>H@]8.>!,K*Q5@
M592596!#*P.Q!!ZP0>H@]8/4<J*F1BF,4QBF,4QBF,4QBF,4QBF,AF3[RO\
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M,M'%'88LH,QLUNQ_Q5J4=V>KH=RC5DFDKQ0KT]?G,-?M2:6.O96K=YF>?48
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M%6D,2&IRU-RRAR01$L^WZ)W>-''7SO'$D[! -V?:&1) 5!#*=U)V.T@$R]"
M>DY0Y3P%5,K0[N3U)^E1D(8@@CK !!-&,VK33E()/#H8T99C*N2SYG8'N)MN
MUQ(X41RID*D<<3B6*4)*!O>7MA/)=6V.N:I$_JT1H#BFT016VUF*033UROZ:
MM++#,@*DK- -YHP02)'B7X4BQERB_";9>O*'8(D<C[K'*JLC," 4=S&CGJ^"
MCR HCORJ[#923G+)-5VG2),@)&_Y=B"-D'.'W&O")*PYP)!.8NF6K9''#K-J
M=8:0M8D+>M7.HSBP)D*).-6H/+3W":*C8@UPP*=M0FS7,@,8EKAQ&9U9^4="
M'95Z4D)NR_"^$-\EZMF-K$<E>9)*O:O;$;1N)(NW:\5NGS1D<_\ 2JL\%BOL
MIZ:"6.6/F1U8WZ0K4;DB1N+<J3KF]P2IUJ%:D. H2K$:LH!Z94F/*$(HY.H(
M, <2<6(0#"QA& 5PBM>\NC1NR.I1T9D=6!#*RDAE8'K!4@@@]8(V.8ZLK*K*
M0RL RL""&4C<$$=1!!W!'41GS\[L+J(SA@B>8T*P]DV48\+DB"0FOP(XJ(3A
M=36XN.EH3%?9DQ]QB2@5* $[VX;!L</;:][[:]-['&D:9JGNO[HTH+G0M3Z'
MIU+=&'6QS\NS+MS<JD[[^ 9ZMV-M'TO58M6.HT:]PPS5%B,R<QC#QSLX4@C;
MF*J3X?!FI97K0W0A%&$TT/SWE6\54]H!L^)G=G6(4QSJH>T[8C<1HTQXFMP<
M!1QY.2-[B!,M-2([+;$=J*DAQ_HXX<X1:PU4:30[97GWA,4JN1&L32,G,P$B
MH)H@SH64,W+OS*P'HZ<,\(O,U==)H=,O.3&T3(Q6/HP[H'*F2-3+&IDCYDYV
M*<W,CA9&0:MMTDBA:0V29?S@S 7O94:1]O73E#4R$]F9Y"2R%%V;A&W=#&1_
M97,*+>6473.246\WXA #1#H'!E@NL&GZ5*4C,S\G,0L*RR0-*3S@=&)HI(RV
M^W,A^+KRF+AW@V<,T6FZ9(J1=.[*NZK"7EC$I;FV$9>"50^_*3&W7MD"]ZWM
MT#C3@[M3_G7,K2X,#HN97M.L&2#@MW;#1$.+:M."UB3DK$)P1%JB!';\D5ON
M[6MLO5Z+AGA*=(Y(=+TR1)HTEB*[_I(Y.M'53(&*O_JG;K^+?+L7"W"4R1R1
M:5ILB2QI+&RKOSQR+SQNHYN8JZ]:G;K&$NM_7\K"O$7G_+!-FUKN\J@KW%O;
M#!-_;"%*$Q$4XH4IKF>:<YH>P(FT"I:H*/LH)3C3EFF@'AGA)>7?2=.//)T2
M\BM(.D(8[,4D81@!'YG<JB\I#,#L,'A;A,%![D:>>D<HI6-G',%=R&9"P0!8
MWW9RJAEY=^8@'H6UXZ]+J^T+9^S'=?VOVWVC_P#6]J=C[-VU9)P1VQ=+V'^.
M[8['V'L/\;O^Q_=55W+<*\O/[DZ9R;\O/N.3FWVY>?I>7FWZN7?FWZMM\J[E
M.%.4/[D:=RD\H;E'*6WVY0W/MS;]6V^^_5MOU9W(OKCU]31^;XQ%=0657I^=
M3#"D+<F=6HH9MR235*@TU0K2IT:-(D2DG*EJY<I3(4*0DY6L4D)B3301/PQP
MI6A>>QI%"*&,!GD:.4@ D  !69F9F(54169F(55)(&4S\+<)UHFFGTBA'&NP
M+&)CULP5555+,[NQ"HB*SNQ"JI) RM6_5/NBJG)B?$[EJ%R(P2L5['N'"<D8
MC6EH9@LEY.JDJMY:D[DVJ8\DBX#)%=T:E+@F6-(+'MPU=S20F8K:'P<*+:@F
MD4IJP!"]'#,LDDO2] L"Q2F-UG:?:'HY%1E<[.%V.V._#_""T^W8]'I30DA8
MA' _232M+T"0HCE&$KS$0\D@0H^XD"\K;4(OUZ:X"%(K-VI3+;JU*'!2A97D
M)5T1#]8@^Y)9J%.>V#,[,>'L9ET%C#52<1H23@V-M>U92<*\,E1TFB:='*$5
MY8BP=H>8 D.1(/@@[CI-@C;;J=LRAPGPN1\+1M.5U56D38-T1(W(9@P&P.X#
M$*& Y@ #G=9];&Z#R!\;XTSYRS,M?G5Q1-"!KL80G4'.3DL"WH4@[JVQ.2E&
MI7"LE 8K-3DA.L,)AH.QF7#3)PUPC#$\TFEZ8L4:-([]; (B\[,.21BW*@YM
MD#$C;8'<;T2\,<(PQ//+I>FI#&C2/(5W544<S-\%B2 OPCR@G;K .<;KK?U]
MLUPA7ZA,H7")K;G@TU \M#NG2-[L"XD!CBI:4JU.V''V^YNC7FIEA([A+.(+
M&(-KH^&>$Y=^32*'5(\0#QR1EGC_ %Q&LC(T@ (^$@*GKV)V.2G"O"C[[:/1
M'PW0!XFC9FC8J_*KE2Z@@_"4%2.L$CKSCC>M'7V[*@1R.YURR8K1,+N^ ;;N
M#>@N1'HTUK'=X<;"<D:4NR-M:VY:J,%<VXS IADIPGJ;@)'$G#/",$8DDTK3
M4BZ2* ,%=QTLTBQ11_HW<\SNZJ.KJY@S$+N<B3A;A*)5=](T]5:6.!2(F;>6
M9@D2 (6.[L0!U;#<$D#KSR^:Y-?,<5KT;OJ$RH0)M<3FE4K(=&U>TW<$XA@-
M3)7IO1*FA?>PBS-X-"M4%&A (10QA#>]JHN&.%)U5XM(H,'02*IC=).0^!FB
M=UE0=8_60$;CXB,F/A7A2559-'H$.@D ,3*X1@""T;$.G41N'56!ZF .XSIC
MUY:\RC5))N?LQ%'(B JEI)FPLU$E'8(@*E90V@(TJ881@$!0>$LD5A@N$=[#
M#MK[E>%=E/N3IA#,44@@AF'A12)2&8;$%1N0>K;*APGPJ0I&D:<0Y(0A1LQ!
MV(7X?PB"#N!N1L?$<J>;:T]<D+!#%)FJC(#L@G,'9YTS+$3@F*WJ%R6NC0L;
MUB<]N[*0X-#ZQ/#2K#?:4>)$%8G$),I)O6/6X;X7LFTHT&I&]2W)4E5D8@LB
M1RHZD, 4DBECD'QCF*GK4Y8J\,\+61/MH5)'KV9:LJ-'ORR1!&W#!MBLD<D<
MJ$?ZL@!^$#E#<H7K:Z2V3?*2'U?65W(\,^1*/H/]_,KN/X8\BT?HS]['*%ZV
MNDMDWRDA]7T[D>&?(E'T'^_CN/X8\BT?HS]['*%ZVNDMDWRDA]7T[D>&?(E'
MT'^_CN/X8\BT?HS]['*%ZVNDMDWRDA]7T[D>&?(E'T'^_CN/X8\BT?HS]['*
M%ZVNDMDWRDA]7T[D>&?(E'T'^_CN/X8\BT?HS]['*%ZVNDMDWRDA]7T[D>&?
M(E'T'^_CN/X8\BT?HS][.$_= M::H  *-2.2S0%G$J !&Y(M@3DYH3B#+;$%
MONBS0!&';MMMM;;:]0>$>&#U'1*/A!_4?PCK'^OCN/X8\BT?HC_']KQYS<H7
MK:Z2V3?*2'U?4]R/#/D2CZ#_ '\=Q_#'D6C]&?O8Y0O6UTELF^4D/J^G<CPS
MY$H^@_W\=Q_#'D6C]&?O8Y0O6UTELF^4D/J^G<CPSY$H^@_W\=Q_#'D6C]&?
MO8Y0O6UTELF^4D/J^G<CPSY$H^@_W\=Q_#'D6C]&?O8Y0O6UTELF^4D/J^G<
MCPSY$H^@_P!_'<?PQY%H_1G[V.4+UM=);)OE)#ZOIW(\,^1*/H/]_'<?PQY%
MH_1G[V.4+UM=);)OE)#ZOIW(\,^1*/H/]_'<?PQY%H_1G[V.4+UM=);)OE)#
MZOIW(\,^1*/H/]_'<?PQY%H_1G[V.4+UM=);)OE)#ZOIW(\,^1*/H/\ ?QW'
M\,>1:/T9^]F:&AG=6LP8^S(A;-2N1Y%D3$\V$C8G9RD(TZI; ' 1X@-TJ0&)
MT91PFHLP\1$D1;1V$WB+<2 ]G;;$J><XGX$TZWIS/HM*&GJ%7GE2.$,JW$"[
MO X9B!)L.:%AM\/=#U/N.<XHX"TZYIKMHM*"GJ%;FFC2$%%MJ%^'7<$E>=@-
MX6.VSCD)Y7)'U9)%B1Q>43@@4D+4*V-V5HUB4T!Z94E4*TYQ"A.>4(19Q)Q0
MPF%&%B$ 8!!$&][7M>O!&5D<HP*LO,K*P(964@$$'K!!!!!ZP>K/ '5D9D=2
MKHQ5U8$,K*2&5@>L$$$$'K!&V5+3*<4QBF,4QBF,4QBF,4QBF,4QD,R?>5_R
MR[_3CJ@>%OX_Y#)/@7^'^9R9J<C%,8IC%,8IC%,8IC%,8IC(M\]Q7CY+</HA
MU,E?"/XC_'..F1G$P?S=?\LNOTL=,9.TQBF,P%RMN:NE?-<HE\NR1&'V0NDU
MS?C/4 \%G/QH$()[BJ)I81'P(TH4^]*CSC&DEFV2,9@CD[T4<HL>( 3+!!MZ
M.N:AIW:7:DB1F@NH) >3<E=299)Q(=_A<DT<5B C8Q30QR#=D&566[;CDBG"
MLDM&#3R-OU8*]B>PC)U_!F)M6(GE'6T$KQ$<K'?'G4SN84.R7 L.8%@L90+\
M3+M< M5F=GF:R4\^1-K<L5R*531FA!92*PU-\@.S@3"U;:?>R%%$'9Z">,\S
ML K96CZW)0NTKDK\ON+H5G3=-2.,,)I.5EI16MS\*&*>8W97W5FEJP!=CD3?
MI*^M;$]L:U+5$YWY5C515BFL1'9N2:.K36*$#P/.[G< C,F<N;GM@3,&5C<O
M.+AE2#R![:X@Q9$:,5Y,D>/8OEMD@*H2J&->2F=@.3W?2(]OQHT1Z12V+AM8
MN"5:M2VA E!A4M8MT8Y(D6O8C:R]V-+D"65KW9(UBEMUUDW"2RHD?2 AXW:-
M)&C,@+&)/TL:1GX)CKO425/@RBK(S,U?G'_J^9Y"O5SQF1^1UYL@YMN:NG69
MJ9"^$+LIP:>O>;93GYNRCCC(;G#LC0Z=S:+M,,EI$0DK:38UMC,ACC*A;W2.
MJB%Z!58NR@8>V2DYI,PZS<A6K&.ADAJT)M,->:(20VJ4]R6^\-M"?TNUN9IH
MW!1T95Y6 Y@SX/Z;=$83RU9R&4'HYZ=>.K7FAWZXY$@CZ,L#\)7D# JVPJ_%
M>@+3GA=QA3GCYCD+2J@V(Y_AQO&HDBYS-=V+*,I1S6>R*3*W"RA<_3B32E'=
MZ<Y,L5"5*%BM8,9=[&A"79NZC9OI>BG,8BO14H'CBC6*."OIR31TZ]5%^#!%
M#'.Z!0#N NYWW)JC=XS W,TDD%^?4NEE)>6:W95%FEG<D=)S=&NR[ +MLH"A
M0($G<W]+UX+A'&KK&WV1PC N&LBX&A[ _O@ER5RQQE.-D1.7M<H-"E(4NJA8
MS)P%$*R3T(TYU^V A$:62(JY-J]V>WJ%YF1;.I1TXYY(TY"G:%JM<JR0$'>*
M2*Q4A<,"=RIW!ZMJX)I*\*P1<BHNK-K(8Q1-+VX\6IPNHG9#,M62+5KBS54=
M89P8>G60P0\G6TZ[G)@O33E1NS+$93FV9SUFQ:HPLRNN6<KO^1 ,V,1/#8\M
ML2:B'NP@H&Q@/:DY#.6F$6(I,8H[:$L4'7/MD7-?NWJ]FM+'3C2Y/%;MM7JI
M#)9MQ"0=LS.GZTLG2'I#L%) Y53X7-C&)"*ZA0B5'L-6C7<)"ME(UDB1=]A&
M.B4H#NRDD<Q4*JY]UI,N8IC()Q]V([^?<OU:=3&3M,8IC*&R;'TTLQU.8LL4
MOR)+)(F_,2A7%P#,D28EV;%*$PYD 6 P0W(L)]Q) [P0;G6#8>P&^O;%NQ+-
M4L1,90KQ,I,(+2_P11UL6_5*[CF!*[C?<9FGJS7:JH\$3-/&HELS+7KQDL!T
MDL[?!A1-^8R=93;F ) !T]H=&2Y,Y*9,8T$"?SDD98RXN3I66%8L$UL..I%C
M$QV.B-YP(1DW-;WHU0U2(QZ)1-"]*Y6$D.C#ZWKSL:QJ"V#9)HZDK7VU(V%6
MD>CA]TTTU).TU)"QM%)I@C5IC(&KR,LFT1AD;J8>#I(.TP.*N$'2@*G0L>(X
M>:84Y;TJ&[M'SS Q7ULND2B3IRBQ*UV&W5@O;AK$L_P)$F?'./WN9\0DR...
MKH-]TY+W:4'3*-XYCL(LL:EP9(G3-\8<+1AGEXFQ0QKY2V;Y7$V9[3N78&UL
MNW=9-Q[!-/5(D:75)JK)2<S0'5+=W4)#([J>D:">_/-"5CC9E,=652R-$U,/
M!123F/$7!C,_::V8WXFK!).U(JU54A.YCB,JU(J3DR/6C=7U)2*4J738Y;H-
M:KQ%#"$$UU.$-B.YCX-1: ";'XS("K$DEQ0\/)SQ#E<81+VF1V=6 Z2M2Z[@
MG?KHEXG%X4,JQ8[-5CM^-78IIMYD598X*\U%YH1"[:0!4L*S='/6/N6(Y(]T
M1Q:FFY@JM,,V+AF81R+)Q/P:>G,#R6$XBABE#16+MKMJ!5B%B"<)=FGC+)T\
M?:T5;HC:>&G/N<AB,AMB$6;DR(IM3-T=94!#<0U&,9" E$W)DI:-.RFC-,:2
M$P"K$D-HS31(B@ 3W,,['OQ;B2;MB22QM(.G=Y2)MS*#(Q<B4D F3K^&2!NV
MYVZ\X%ZQI,U,R02FJ>U^EJNLM:3H?T?/7D1G1X6Y>:-E9@4(ZSGS6[N]^'^&
M?DR7?^D5KUWL4>#7/^M0_P#ALY[+V)O]#K7_ &]+_P#*L9KO9]7<<:\=(L=G
MXTL[M*%AB00)7%R(&W'S2!1V$HHC)E:(*6X5"9!)&F</:QLN(-G)+,3&P\\)
M850S^XEX>FDO/=6]T<CS6&W1"'6O;FL&Q K$G8M7>K$KC8(]?I #\$#O&T*5
MK361;*N\EE7*JV_:MNS<L3UT8MNA<2U8^D!^"*W.JEF'+6;AKO;W=Y-=G;'Z
M]R.3Y*-R\Q*53TE$M9LC*'Y:WCE1=[HA)U#DFQ<>A8$=SBA%%RQD9I$, TR
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MGIK02]*(EI?F\YN"H6"UE\W&%I(*TE@V*<E>.5[,4:0L]>:N%*LPD>!4E+=
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M8UB#1@RQSV&1$F<_H!+S+'9B++N_24Y76.P FRNP )&Y%*R?=>M-$<TB:?\
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MBF,@[_A*#Y#-^GDU'QC^!_Q7&3E3C%,8IC%,8IC%,8IC%,8IC%,9#,GWE?\
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MGLU_Z5[HU#%J#<QD2M#8BB4K(CG,O1^PWV,-/CX('$<E2]'P]=UV#LL6Z7$
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MH9$Q#7D)%";M]*D>&U$L,;U=SD"RY 25J900(90KU:Q-4LP6Z[F*Q6=I()0
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M*RR=3<99JLWL9]Q6L95>K7FU:_<O2QK&;<A8PH24CCY1&D2G8'ECC544[ [
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MAM8\NZ=ZO8^]CN.G^6Q_0GVF/;.V$NBYE7STB'[M3O#:QY=T[U>Q]['<=/\
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M/"CC48(XU#96DMI"9&K@9B"FU4O2J2&L*,I828A HL/@TFYF"FGV(^EY-3N
MSS/8F8B F262*O"Y8F+<JR5HMTWY"40\NZDMT'=+HQ<R-P1P\QZ.*%1T^MA(
MXH7G=%B0:IRQLK3 JZCF!-@G?M@B.HD& RFL1G!D\?FTHT]0>:!NCF/T)I@U
MEE9"TT1Z>)@%=4J1*1%'*Q!$:8I4NRTS?C=U)=I]SY^4(=2ME I3EY*VW(=@
MRC]"0 55!X-N92VQYMA<[JM(YND[A^&S-OS](9-9/Z4 LKE3J?6JS26#R<W7
M \-?F"UU9[EPJ&J(B4M ID2Z1&+.U+6.7-K$W"3%I2;EA3DA9&UN")* 0QV1
MISK&A0)NQHTUPDE6WV77AEB#]+9ELEVY]Y1&NS$ .1T:J/A$#P[D*%7<A1FC
MUC4J6I/ U+1*&BK#&T92E+=E$RAOT1D:Y8L-SQIL&9"@ED,DSKSR$"N*R,TV
M?&;N]>F;4/F;6+$9/B;"F3,CQU%A5E95;W#8B[O[8F=DT^R(K4-IRQO3'$EK
M24RY&>8G$*Q@"E)([AL$P-[_ $QV&=>T72^&+U?4M5H49WURU,D5JS%#(T34
MZ""0+(RDH6C=0P&VZD;[@YWO#%RK7HR)-/'&QL.P#NJDCD0;]9'QC_SU[:3.
MX2UP;XH?<MZ@-^0 )9 _8ZE.^) #;O0%"[3VE@#MOO0@O:UMM]EK;:];[K^$
M^O\ ](-%^$=V_IU;X1/A)^'UG^.='[I:=MMVU7V\.W21[;^'?];QYZ=P=K<L
M$8;:6,^[TV^TP/L<2?>F7\.T=NTM@[[?QBVT[K^$^K_T@T;J\'].K=7\/A]7
M^S'NGI_RJO\ 21_>P9H.UN&WL(W2OGPP5@A!81F.)..]@!ML"&UQ(KWL$-N\
M$-N]:W>M:UJ#C#A0>#B'1AU[]5^L.L^$]3^')]T]/^50?2Q_>ST[@G6QT4\\
M^C62_N-3W8\*?.+1_7Z_M,>ZFG_*X/I4^]CN"=;'13SSZ-9+^XT[L>%/G%H_
MK]?VF/=33_E<'TJ?>QW!.MCHIYY]&LE_<:=V/"GSBT?U^O[3'NII_P K@^E3
M[V.X)UL=%///HUDO[C3NQX4^<6C^OU_:8]U-/^5P?2I]['<$ZV.BGGGT:R7]
MQIW8\*?.+1_7Z_M,>ZFG_*X/I4^]GN5H%UM'&E$@TIYWWYQA9(-]CB1EAWYH
MPE@L(PQ$$LL-Q"M81A@@@!;:(8K!M>]H/&7"@!/=%I&P!)VO0,=@-SLH<D_P
M W/@'7D'5* !/;4)V^(2Q[G]P^%_^CQG/MAW+C<W&/0;IW=G27(F]QU$Y,C_
M  ADQ_ 6D4CC*0:4M0EQPPN15AC&S,QQ83W0XDZY+P^=F6?=)D[>$GY/[)''
M$O%^IE*SR)HM%C'0A/,O3L&(:]-&3L)90=HU(WBAV3]8N3Y[K6KOJ5@(C$58
MF_1J"W+(W6#*00#X"50$;@;GJ+L,W"%_>R_\@/\ JVKSS-#GO3&*8Q3&*8Q3
M&*8Q3&*8Q3&0Z[W59/SCA]"'3)^(_P 1_@V3%,C%,8IC%,8IC%,8IC%,8IC%
M,92+/^%<Q_T!^K14QE74QBF,4QBF,4QBF,4QBF,4QBF,HS'?X#1;Y&1_W=,9
M6=,8IC%,8IC%,8IC%,8IC%,9 23W/)^567]:I*8R?IC(6.^XK?\ F;_WIE,9
M1V987(,C8IR% XK)6^'R.6Q-Y8663.\7:YLTLS@XI#$Z=8ZQ%[_Y)DC:$8]X
MO9UUPD+D@SB!#+N,(P@0&C8JL@26*1HV)"R+'(KM&67X2!U4KSK\)"0R]8&7
MH)%BE21PY5>;?HWZ.0$J0&1]CLR$AAN""1LP()&:1X=N1.:&*%RE8DR)@+&,
MX9\VX S_ (9Q)B:$3DC2JQ9'P,-V./>Y1!'^0&NQ \K&/:LN5)(>)F1,%T+(
MO9R5RYLL8;V4G$M<34F2*];2(ZI#/-J$T,EZ/3]6I=I2T*=I$Z0K54M8KSV6
MDD:9GC(CBE<"TQZ:-X)DA2(Z>M/I:T$,$]B=-134TO7@B*EJ4211U^27GY:P
M*I(O)$([CLFY?YG<LB1[.61<K8P497D&I3*FH3++9"(S(V3'J:TRTQ/VG6+1
M?'J1R5N+R<:U$K6Q]D<@D:@M8_'A7&6((-"G+%AOK-.*G)IU."T:BZ!JNDP2
M6GB-AK6K:K3U.:Q,(@L:5XS6>**&/F8<P9G8D@6F$DMNC:E* T]<X>U$(@)#
M5-#6TIBYV/,;$_;',"=HHP.0#8;FT9>Y)ZHX-B*1XIQ+FS3^%)FO1'!-(^=5
MN2L<RV2J6U9CN-2:--<NQ2H;W9NL0B=V^2'%+F>4)%"=N<"2I"G3KE904(\N
MUQ!IUZS;>U4NB \11\14Q7FABEZ98:4+UK3,D@Z,FC$\<L6\L8:1$Y><N+U,
MFJ^G2_K2T8[E8]0,3U[=V>YS\AV;I8S.ZM'SB*?91(=M\V,9CT>RK)>YN*]$
M:"7,#;,%.G&!84M-%:5Q,C87B(QZ,,RIZNC*#=SNVJSF(XY.3O+J@EGE6-MO
MPCK63:O%)Q5W0"*00=TT6N]KDKTO0QZNFI&#F!Y.E,:]&#OR\YWWY<QTB*T9
MZA(YIM*O:>&'@5[>G3TED/QE4>8.PVW*@@#?+1ZK=$&H7(^7'#+.GS*.)(JO
MG^D&4Z/LEMF6HC*Y$E11A\<U3VWSB#F15[9S+R) M7K4IK6^[]J4)AD*!#N8
M0).=9ANT6IZUI]Z"S)5U2]6U%36ECBF6:K%;KBO(TD<BK!/!<D5Y45I(7 =$
MD\ RJK)6DT2R 3;T6241'?>"2*PU&27G3=7+QS4()$ 90Z<T3&/F+Y8)EW)7
M(;;@K4GBE3DG'JIWS?H*TTZ0V9X$S/)B1DD6#8*[15VDKG8U/=4?'GE>X$N#
M:C2A[=) 3<2DH)]@;-WJ7$]>]:[82M.@[K[/$O*S)N89S1*0=1(Z9#5DV;<J
M.D'*WZV]G05&D5^'()0)SHG#\^C2%1U32S6M1L":,-MRQ[78U96V8F(G;]7:
MXFHO<OYCFF>.TVC62X;"5*33%IVQ9#BCHPM=4(,GZ=<UEYBCSE+68@YO3/.-
MGLQ&ECKNQDK"7/@X]58BX-X4$6#3U\4[-BT(9)7EXF]W%1I.5>@ETS4-+LPL
MPYBMEH;Q:*95(CDC1^LJ!E4'/##4@66:$1Z!K6A6):S]%,8=92I'*8FV^%"8
MX)HK-:4]';@L2UY=XI9 ::2[F'F6=9?9M1N=,B8:=<JO6JW".=<BQ. P^1-V
M*2H3@C&DPQ_%HW&$,B4NKNZS%P.DX7IVD\BN2 8DJ5$0462VHQ"O0:[2H1P5
M*$-WM2"OQ"5DL2Q=MF[KT%:%F'0\D<=:N*L9"J6=V:61B6D(RQ;26U#/&61&
M>#2*D15>HU].U(ZA+TS'=V-CI)8EB!,42E5 (+DW29= ^:8]KO4:D8YDW',,
MQ$YY(?,FR^)PUHG3?(LE*7>$"BI##.H8YR1WQ(-_0+KDNH\R1MF8)ZY(D29E
M6IA%&*E9^)4U:K#HSZ?/!/8G6K8J5^9H37@Z>VMI;,$G1BW6Y 94>BDCU)F<
MS$(6*B_;_3F,Q*$8/4:21O\ 2<M:(QO&>CY5L++RQ]$TZF2LHY$9@BYMHKG\
M91@/\82C^QR7]=*JCXS_  '^+95_J?\ O?Y96=3E.*8Q3&*8Q3&*8Q3&:A]8
MVZ\Z>M V5$V'LL07+TFD3^P7R D7P%HB*]F*:'>0/S*G2J#W^91U8%P ICZP
MPXLM$8G"2:GN!2,8C"R_0^$NQMK7&.G3:GIUO38((;DE)DN2V4E,L44$S,%A
MJSKR%9T"DN&)#?!  )W>G:%:U.%IX)($57,9$I<'< 'JY48;;$>$@_NVZ\Q/
M]LM:*N:/4MYMXU^U"NH[Q7%7E'0OI[WX#-AW(:A_7U/3E]ECVRUHJYH]2WFW
MC7[4*=XKBKRCH7T][\!CN0U#^OJ>G+[+'MEK15S1ZEO-O&OVH4[Q7%7E'0OI
M[WX#'<AJ']?4].7V6/;+6BKFCU+>;>-?M0IWBN*O*.A?3WOP&.Y#4/Z^IZ<O
MLL>V6M%7-'J6\V\:_:A3O%<5>4="^GO?@,=R&H?U]3TY?98]LM:*N:/4MYMX
MU^U"G>*XJ\HZ%]/>_ 8[D-0_KZGIR^RQ[9:T5<T>I;S;QK]J%.\5Q5Y1T+Z>
M]^ QW(:A_7U/3E]ECVRUHJYH]2WFWC7[4*=XKBKRCH7T][\!CN0U#^OJ>G+[
M+/<O^$KZ*!F%@'B?4H2 9@ #.'&<<" 4 0K!$:()>3AF""6&]QB"6 9@K!O8
M 1"O:UX/8+XJ )&HZ$2 2 +%[<D#J WH ;GP#<@;^$@=>0>$=1 )Z:J=OB#2
M[G_^5_Y^+<YO0BN2X/F/$+9D_&TB;Y5!YM%.'HX_-AP#TJYO6)1#!?:&][DJ
M2![],L2&V"H1JR3DJ@LL\DP ?'M1HVM,M6J%Z%Z]NI*T,\,@(9'1MB.OP@]3
M*PZF4A@2"#G-RP2UYFAF4I)&_*RG]QZB#\:D=:D=1!!'4<ND7][+_P @/^K:
ML;+.>],8IC%,8IC%,8IC%,8IC%,9#KO=5D_..'T(=,GXC_$?X-DQ3(Q3&*8Q
M3&*8Q3&*8Q3&*8Q3&4BS_A7,?] ?JT5,95U,8IC%,8IC%,8IC%,8IC%,8IC*
M,QW^ T6^1D?]W3&5G3&*8Q3&*8Q3&*8Q3&*8Q3&0$D]SR?E5E_6J2F,GZ8R%
MCON*W_F;_P!Z93&35,8IC%,8IC%,8IC%,8IC%,8IC%,91@/\82C^QR7]=*JC
MXS_ ?XME7^I_[W^65G4Y3BF,U=:IM8^4<898]C^&M<63)(].<.-PX\J,=5>5
M<IL\PVO;\M@+.!H6L=XJ00D4PI:Y*3K+$S^!R.NJ;KHV\AUQA*_2QL0&1+5N
M*2!#\+HJVCS75DL.1O%%/,T:1-$)&!@;82R.:Z7+$)%>+HYT@DL=H;6)0.BC
M-K7JNFR1H.;=Y8H&::3GV CL1L>C5.F-BHUK=S;D"8@;77*>+L8X]?T>*CGK
M+4(9#9I$\4GRN'Y)E0XVL635L2MR25NCHRL,1='*366L+*M;5:8UN;'I_;$1
M&4D6SW8Y;48[6L2I7F1"8M0Z&II\@2JY)18I>V+5M2Y>:6.N8H&YB_1UR\@@
MK/' 3*R-T\1D=I*ZO;GBY[*!5 FK]'#"1&>C_I*2RHJI^EN),-;64(I-,8-3
M ]MV2<>-<#"#+.3FC$,R:V=_EV4B)2@PL_-QP[JFV)(FEVB[*;+&Y4K-3/R;
M(30L9!)D 4818=JQ(D&I2QQ]&Z:;+VDI#;+JE?29M8E+)(W2F&2)(:\563]+
M'+:033EX)%DKA@C,E1'D+<]SFL ;$^YYU"+3EV:-2O2AI)[$EA%,314)62-$
MF1EO]H"S+FG,D#F2_-G;A;_'WJ+(4J=^88Q')079Z@<<E2Y0K;X6K71HZ.+3
MWL"F(+TR@3D>V#-(>@%.*0TH&RE14# <I*6K4 V9BX2NT:!;(("+9Y^D<B'>
M!ZSU98V)D;-96DEE2"23D GHU+.R!@I><2,YBYOA] %"1@2_I4G2Q&_Z@S/B
MK&9.?"[_  C0(QZXH. L-QF#P''@E@#;:(8Q9'R=8(;6MX;B%>UK6_'>^ROJ
M[L%';A+4"?G!;_\  Z;GHG"C!-+L.Q 5+$K$D[ !8HR23\0 '6<QV0Z'L%#F
MN0(X"9.TK5PI5!HDH@D0,DQ,Y*R%'L-2_)>58B0O?X>EBSN_2IZQS((M&2&%
M;("&$]V)-*(=AI$9*S<S<8ZRE2G96K''':;4;*6YTA--].;5:^G:99VAM-:2
MO7CU"I:M2210M-'$1S1+*S+MX+,\\4"R/#5EFT^A(TLTD2B*?4+-,K.859UV
M6"6>&.OTHVG9#.T9ADC6UR'!D0=HW(,A+=*N2H_((?"F9U08,03&5.2C( )?
M-5D9CV1E;>H:S\EQZ$Q@II<FV7D)U!(Y'(G&*G,BJ-M*Y7>^TDUBU%8KT8^(
MJ-F&W<D@DU9JD$:Z>:]+MN:FLJ2+0GM6N>-J?.&->*.R)Q8=(U-M+,C.(6L*
MD>UBPEL\H$L<#5(FICG8%IHVL//-/'"L;0(RQQ!TD:/"W-#,UQ[)$B9FJ!/N
M+RD'!A*V 2.1%2IUB[S=I0C>VTQY F2GF)@NHU9J%$Y%C>6E$:0U/2A4Z(E:
M@WJM(FDGH12R7H=2YVFZ.[! :T=B$32"%^BYF7G$857DB(@F8&6%5C=0-M%S
M&&%GZW:)7=@.5'Y]V22-2[NJ20F-PLC%U+-OL-E%K:V>5XIC%,8IC%,8IC/H
MHW!W7AD+'>2S]&;ZWO\ -,69: _.,3 @*5.:K&,R*;;*ECMO+B,"B@KLC1&A
MD!1=B4[:ZF)GL-P]G<[*?#.S-PA2NZ5)Q/"\%6_IR1QV><K&M^J6*I$-MN>W
M$[@Q$[EX0T/^K'R\GQ+I<4M=KZ%(I:XW8G<"5-_U.H'X6YW0G_6++U\XY?MU
M+^]@_P @/_I:OEK/.\]Z8Q3&*8Q3&*8Q3&*8Q3&*8R'7>ZK)^<</H0Z9/Q'^
M(_P;)BF1BF,4QBF,4QBF,4QBF,4QBF,I%G_"N8_Z _5HJ8RKJ8Q3&*8Q3&*8
MQ3&*8Q3&*8Q3&49CO\!HM\C(_P"[IC*SIC%,8IC%,8IC%,8IC%,8IC("2>YY
M/RJR_K5)3&3],9"QWW%;_P S?^],IC)JF,4QBF,4QBF,4QBF,4QBF,4QBF,H
MP'^,)1_8Y+^NE51\9_@/\6RK_4_][_+*SJ<IQ3&6P?L8EOSRH>A3:>MAY^]"
M%*T/:9&C2DV[" PA&7=N--3%'$%F$FA+.M?LIXG$NY;J0C7)L&6CTLC2"Y=B
MYMMTBG"( ".H+R'8<O,OAZN;G&TBJZ]10XF6C4AJGAWAFZ80P%F_ICV+4A8N
MP::3ME!(RRE) 2NQ6):SAJCS5Y8*V$T]B#$]\C9-$2?MNI+N_-O85(S!&&G#
M.369+)1"/4]JJ1VL18 1I.Q%A G7NQ+A:]S3L!V_J)VVVWL+\6Y\'1[#KY2
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MZ1>KJ*L4KJ?U8OA'9I& \^UW6&U"<01-_187&VQW$L@)'2;]6Z $A/'UO_K
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AW"&US 6WU[;16MMO3Q?O^PG_ "QU>,^;_P#3E=TR,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g332508g53o14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g53o14.jpg
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M2?#CZ39SHSVDM._FLU]\TH@"DN+\[]I:8$
M
M                                    :L^4M_ K^D?^ P,E?7Z/U,^=
M&>TEIW\UFOOFE$ 4EQ?G?M+3 @
M
M                           #5GREOX%?TC_P&!DKZ_1^IGSHSVDM._FL
MU]\TH@"DN+\[]I:8$          'RX<JIQB<3NF>+ZRT;5NZ;I2:BTIM&?MH
M&$>-T6"+R1ABKOG!$U6JIL*.5O\ Q%<]'G&3>OC&!^X\Q.;O(G*7-ZG*SN3<
M;*R)9.5!VVQ;FXPLTBFU);HK<MQ^[<PN;?(7*?-VC*S^3,;*R)9.5"5UL9.;
MC"W2";4DM(K<MQKC[8SQQ>Z6V7\I,_Y >R\#N;'D7"]27OGL_ SFMY$PO5G[
MX[8SQQ>Z6V7\I,_Y / [FQY%PO4E[X\#.:WD3"]6?OCMC/'%[I;9?RDS_D \
M#N;'D7"]27OCP,YK>1,+U9^^.V,\<7NEME_*3/\ D \#N;'D7"]27OCP,YK>
M1,+U9^^.V,\<7NEME_*3/^0#P.YL>1<+U)>^/ SFMY$PO5G[X[8SQQ>Z6V7\
MI,_Y / [FQY%PO4E[X\#.:WD3"]6?OCMC/'%[I;9?RDS_D \#N;'D7"]27OC
MP,YK>1,+U9^^.V,\<7NEME_*3/\ D \#N;'D7"]27OCP,YK>1,+U9^^.V,\<
M7NEME_*3/^0#P.YL>1<+U)>^/ SFMY$PO5G[X[8SQQ>Z6V7\I,_Y / [FQY%
MPO4E[X\#.:WD3"]6?OCMC/'%[I;9?RDS_D \#N;'D7"]27OCP,YK>1,+U9^^
M?</37;E_4*J^>+'<.WM;@W;IPIG&5%W+B,:K+K'SC&,9.JJ<QS9QC&,F-GUA
MS%D14<B^,4E&-UL8I<$E.227<DM#EW)C&&3D0BDHQOMC%+@HQLDDEW))(D@P
MF  #Y$./;CAXM-:\8&]J-1-\7RL5&N6]%C!P$6^:I,(QH:"B')F[5,[-0Y4\
MKKK*YP8YL]$H;//S>L.@N:G-CD#-YO<E965R5BWY%V.YVVV1DYSETMBUDU);
M]$EPZCH?FES6YO9W-SDK+R^2<6_(OQY3MNLC)SG+IK8ZR:DEKHDN'48A]L9X
MXO=+;+^4F?\ (#T/@=S8\BX7J2]\]%X&<UO(F%ZL_?';&>.+W2VR_E)G_(!X
M'<V/(N%ZDO?'@9S6\B87JS]\=L9XXO=+;+^4F?\ (!X'<V/(N%ZDO?'@9S6\
MB87JS]\=L9XXO=+;+^4F?\@'@=S8\BX7J2]\>!G-;R)A>K/WQVQGCB]TMLOY
M29_R >!W-CR+A>I+WQX&<UO(F%ZL_?';&>.+W2VR_E)G_(!X'<V/(N%ZDO?'
M@9S6\B87JS]\=L9XXO=+;+^4F?\ (!X'<V/(N%ZDO?'@9S6\B87JS]\=L9XX
MO=+;+^4F?\@'@=S8\BX7J2]\>!G-;R)A>K/WQVQGCB]TMLOY29_R >!W-CR+
MA>I+WQX&<UO(F%ZL_?';&>.+W2VR_E)G_(!X'<V/(N%ZDO?'@9S6\B87JS]\
MF.N^4*XUI38%&C)#B/V.[82-QK#!\U5D6>4G+-Y-LF[ENKC#'&<IK(J'3/C&
M<9R4V<8S@:V;S1YM5X>7.'(V'&<,:^<)*$M8RC5.49+QN*:31K9G,[FQ7AY=
MD.1<.,X8U\X249ZQE&J<HM>/Q32:/MZ',IR^
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M7  ^&;E+OZ=?$C^7+?YMP0Z@YE_-;D;ZJ_SK3J;F1\U.1?JLOS[C!@>H/5
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MK52BUJFFFFFGHUO1DC*,XQG"2E&24HRBU*,HR6JE%K5------IIZH] DD
M  GFK/;/UQ^7E0^<,<-3/^0YOU3)_)F:F?\ (<WZID_DS/T1!R$<=
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ME1R9R_EU684HY$+[<2W >!">3=R?0LGHNENK4Z*80R8QTG.YJURA,+5M?VN
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MU3)_)F:F?\AS?JF3^3,_1$'(1QT
M                                :L^4M_ K^D?^ P,E?7Z/U,^=&>TE
MIW\UFOOFE$ 4EQ?G?M+3 @          ^-SEH?Z=-M_(+7/_ & HZ+_TV^:]
M'UO,_-.D?]-/FKC_ %O-_.-40]Z>_   #VK.%W!B&<+*KF322;IF64.J8B#=
M,J2"),G,;)4D4B%323+S$33*4A"E+C&,0DHZZ)+5MO1):MO5MZ<6WO;XM[V0
MDHZZ)+5MO1):MO5MZ<6WO;XM[V>H22          ?HJ4+[Q:7^2=<_[.S''V
M5\IR/_?=^9(XWR_E>5]8N_,D2P8#7  ^&;E+OZ=?$C^7+?YMP0Z@YE_-;D;Z
MJ_SK3J;F1\U.1?JLOS[C!@>H/5%WRVE'Q'LW#5F8S8IZD8E\;&8N(PL(RJY(
M#$>E,2S&67DG;>>K3!\\78KRV$XQZF9H1VM#I,9"/<+_ "J^5(;%5M]?0U97
M1O#E&?2SOZ5SZ.N5<81E5?.,8R5?CQ>TXJQRA-+Y5?*D7&JV^KH:LKH_@4HS
MZ:=[MZ1UUSK5<73?.,%*->MD7M.*L<H32]-*U(UM;^DQ+NT%B)*_0CR8@42L
M(UPB7*-KF*DU:.E9.R0*[ETY?5^57]3*\TGK&[3S%LZW7[)+2)XYG;*Y0ECQ
MRK(X[LKQ+(UVO;L3WX]>1*25=%RC&,+:UTETJJ8OI)76TUP4Y3E<HRQXY-D<
M=VUXEL*K9;<U+?CUY$I14*+5&,875KI+I54Q?22NNHK@IR[X^CHQI#S,])71
MVA'4YC&JWG#.JIO7L7(S!Z2WCV5>;JV9DC96V'5S*D^D%G<%U.G#/UT&CTKJ
M**_Q+E2<K*JH8T7/)E-8NU>XQG"M9+G*YJB;HEIC/9@HV[3L@G*+5FQA7*TY
M6555XL93R96?!-K(<(V5U?"G.5SZ"4J);.-K&"C;J[81E*&S8X1YOHRWN9"V
M,>KZPU+3[-8JM)NW\T1F@N_JKA!*<78)J(Y=NF;)!PD\RIAL559$Q$&R*T@L
MW9+99<JXT88\G"^3R:*<B$85;4HPO3=2FT]F,I-..FTU%ZRDU!2FL\N5<:,,
M>6Q?)Y-%.1",*G)QAD1DZE-ZJ$93E%P2VM%+?)J"<EWI>&O8J#B+9RZ<9$OY
MI<D?&1ZSY(ZZTN[DZ?#1K%5V8R$,DW</[]4S.I,DJNSCV;]Z=8YW\+*QK7'_
M +WAR5DJG.R%2<YS46DJXUY-LYJ.^QN,,3(2AT:E.4(I>);7.6'_ 'S"<9SK
MZ2R%:V[)[+25<:\BV<U%;5KE&&)?LUNM3G*,=$H60L?'C-#R&)B#8V2PL8Z,
ML37+F-F:ZW3M#=)+$;3;&=[,X5D(!M 0C*EWF#NDO,S#]FWAX0[AN^33G&CV
M(:S/E6'1VSIHG.=,MF==S=#;V\FG9KTA=*ZR63BVXU==4).RU)Q;IE&V5K.5
MX=';.BF<YTRV9UWR>.V]O)I4*](72NMEDXMN+757"3LM2E%]%*%DJML=9S Y
MKJJ4@E)1]F@&L[&O4D%&W1DS(R4%)HG;K&RJ3#&PPDRP;JJ=+,_9M6TCTAKA
MYAJCOTW]+TR<'"=%LJIQ;4M'L0M@]I;O'IMJFTM5&4G#66SM/?HOZ97IP<)T
M72JG%M/>H0M@U);O'IMJG);]B4I0UEL[3MN_:&5JTE?H^OV4EHSKJ>5@9Q51
MO7F::JC1M:WK]XQ6@+E<&)V[9K6<&ZD<OFLQAP],U=Q;)=F8J_SL7E97QQ)7
M4=!\-J5M24KI-;4J(0C-78V-).3OWR495Z1UC.:EJOG8O*ZOAB3NH="S*E;4
MD[I-;<L>,(2C=BXTM92O:VXQE5I!2C9)2\6CYR&?UV;F*_*)D1DX*4D(:123
M5(LFD_C':S)XF19/)DU2$<(*%*JF8Q%"XP<F<ESC(^I5;"ZJNZMMUVUPM@VF
MFX614XMI[TW%K<]ZX,^M59"ZJNZMMPMKA9!M--PG%2BVGO3::W/>B4:L]L_7
M'Y>5#YPQPP9_R'-^J9/Y,S7S_D.;]4R?R9GZ(@Y"..@
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M/Y,S]$0<A''0
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MJ9/Y,S4S_D.;]4R?R9GZ(@Y"..@
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MS4S_ )#F_5,G\F9^B(.0CCH
M                            U9\I;^!7](_\!@9*^OT?J9\Z,]I+3OYK
M-??-*( I+B_._:6F!                    !4VE2.B4R4*\3?)K9VEO0Y2
MR",T@XRV4W;L)1D<B<]'1;_+-5F9!2.52:GB5X\[5> ?RL$I&RCP"V0
M       'P[\I3$2SCCGXCUD(N1714O"&2*HLG*B9\=;D'CG(<B1BFQSXSCGQ
MG..?&<#IWF9;6N:_(R=D$UBO5.<4U_FMXILZCYDVUKFKR*G9!-8LM4YQ37^>
M[BF]3!SU"F_[&E?DYW]2/3]-5]+7Z\?W/4]-5]+7Z\?W'J%-_P!C2OR<[^I#
MIJOI:_7C^XZ:KZ6OUX_N/4*;_L:5^3G?U(=-5]+7Z\?W'35?2U^O']QZA3?]
MC2OR<[^I#IJOI:_7C^XZ:KZ6OUX_N/4*;_L:5^3G?U(=-5]+7Z\?W'35?2U^
MO']QZA3?]C2OR<[^I#IJOI:_7C^XZ:KZ6OUX_N/4*;_L:5^3G?U(=-5]+7Z\
M?W'35?2U^O']QZA3?]C2OR<[^I#IJOI:_7C^XZ:KZ6OUX_N/4*;_ +&E?DYW
M]2'35?2U^O']QTU7TM?KQ_<>H4W_ &-*_)SOZD.FJ^EK]>/[CIJOI:_7C^Y.
M]6P<T79NNC&B)0I2WNHF,8T>[P4I<6"/SG.<Y1YL8QCU\YSZV,>OD:F?;4\'
M-TLK^29/_?'Z&?>:F?;4\'-TLK^29/\ WQ^AGWGZ& Y&./@
M                                                   #5GREOX%?
MTC_P&!DKZ_1^IGSHSVDM._FLU]\TH@"DN+\[]I:8$
M %.:*9]04:50Z@Q'=%MK?[OJ?$42&P?J_?&R'_5O49-6:=PIF2ZI]4<R6:A(
MGFLNLS*FRMTJ/S;COC^_W^_:2_T7L\[_ +U+@7&!
M!!MGKIMM:[#<K.$FB3>C6U=5TN[:L$&R:4!(*'<+/WUEIC%DDB4N5%';RX51
MJV(4RSBRP2)#RC4#ET!8CBATEPFLFX37J-;63<(N6[U%<BL,R.59)XSGK4T=
MIJE-@Z;EK:+(W7*;"J$],)'+(. )<
M                                           #5GREOX%?TC_P&!DK
MZ_1^IGSHSVDM._FLU]\TH@"DN+\[]I:8$                    %,:%*T+
M1);#(K$J/9>XA3&Q'DA4V^7)M^[+,],<L W;,,O#O,KFD3JI9EE)#+I2?7<S
MII)RL)?Z+V%S@0                    0S8RBJ.O;XL@LNW72IEH41<-G+
MQDY05)"/C)K-WD=.5B0:+I'Q@Z3EC9:\\04*55K.1*Y"/VX'+HZBBM*J"JJJ
MJZJE7KZBJRZ[ITNLH>):&.JLZ?2]@>N55#9R=1=Y/3;I8^3*.)>25,=ZL!*
M
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MWS2B *2XOSOVDDO'L"K[Y;?KY @I8            !8&O?9!_P"\R_MR "V
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MW,3KJ"95R)K,6VP@G6XS*"Z9!#UUW\>O_P"^U]YE$!!+*3]\#;\2Z_8' %V
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M#.F^#V*J99:S;-L5UE:U 3&JG.T(Z/L=VG7F<V'$$^E'TRR=W*6$[?IX=?\
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MR\<(I/G_ $O"B[2$9PT&@?)BQ\0R1YDL"92<GJ][+;V#[*,O>!?WA<""!
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MTH@"DN+\[]I)+Q[ J^^6WZ^0(*6             6!KWV0?^\R_MR "V
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MV7](+&D;J,TFH.6JTZWKKP[=5O>]+CN77HS<*!4 "[:5][S7\:Z_>% !*P
M       8\3'LM*?XB]_>50!UP  #7YM#@&C=J;@OVQ)7>&R8"E;,M^B]A7'5
M57BJ*TC9>[<./J3(:GE%;;*UN9M#>.@K;7Z]<G4)'NF3:7F(*/:R*J\,>0C'
MPLI-+31;M5KOUT?'KTWK5<.OMT:Q^HG)9)T/;6E+4\V)*[-B:1NAQOW8E\OE
MCD>R%;K+"Z:USK2IT<T C 2+6?@I*]:AU'O:TW&S[!4F4;]K"+;M*[)HS2,G
M51+EQW::K3\6]>[1-Q22TT?49:7O@OK=ZWPEN1;8=QB(&3N.F-D7O53!E6E:
MU=]B</2TDZU-9W$V\B%[1"%B7;F#<ST3$R:3*P*4JIESB/31GB3XKKN[]^_N
M?%=G_P"ONTS0 @ #R7[>/[\?Z@#)<         '263V"E/>BG^P H(
M      !+*3]\#;\2Z_8' %V          KG8?W/%_CG/ZB( JT
M  !:^O?N&0]]D_8E %@@#5GREOX%?TC_ ,!@9*^OT?J9\Z,]I+3OYK-??-*(
M I+B_._:22\>P*OOEM^OD""E@            %@:]]D'_O,O[<@ M@
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M           /)?MX_OQ_J ,EP         =)9/8*4]Z*?[ "@@
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M (# R5]?H_4SYT9[26G?S6:^^:40!27%^=^TM,"
M
M                                         -6?*6_@5_2/_ 8&2OK]
M'ZF?.C/:2T[^:S7WS2B *2XOSOVEI@0
M
M                                !JSY2W\"OZ1_X# R5]?H_4SYT9[2
M6G?S6:^^:40!27%^=^TM,"
M
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M .V6^!7RC^@8 =LM\"OE'] P [9;X%?*/Z!@!VRWP*^4?T# #MEO@5\H_H&
M';+? KY1_0, .V6^!7RC^@8 =LM\"OE'] P [9;X%?*/Z!@!VRWP*^4?T# #
MMEO@5\H_H& ';+? KY1_0, .V6^!7RC^@8 =LM\"OE'] P [9;X%?*/Z!@!V
MRWP*^4?T# #MEO@5\H_H& ';+? KY1_0, .V6^!7RC^@8 =LM\"OE'] P [9
M;X%?*/Z!@!VRWP*^4?T# #MEO@5\H_H& ';+? KY1_0, .V6^!7RC^@8 =LM
M\"OE'] P [9;X%?*/Z!@!VRWP*^4?T# #MEO@5\H_H& ';+? KY1_0, .V6^
M!7RC^@8 =LM\"OE'] P [9;X%?*/Z!@!VRWP*^4?T# #MEO@5\H_H& ';+?
MKY1_0, .V6^!7RC^@8 =LM\"OE'] P [9;X%?*/Z!@!VRWP*^4?T# #MEO@5
M\H_H& ';+? KY1_0, .V6^!7RC^@8 =LM\"OE'] P!KOX]N/?KQ[%'_PH]3O
J4[KZ_P#OKJSIW5G6=_\ QS7I?2^I?_WZ/H__ )>A_P"H6C+9UW:ZG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g332508g55z44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g55z44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    * :^$"1CA"24T$)0      $                      X0DE-!#H
M   1D    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O;
M$     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D
M)I=&)O;VP     "W!R:6YT97).86UE5$585    !L 0@!R &\ = !H &4 <@
M @ $T 1@!# "T 3  R #< -0 P $0 5P @ ', 90!R &D 90!S       /<'
M)I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M     *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V
M]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6
MYT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M    !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8F
MQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M      0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M      0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M          4G-L=%5N=$8C4'AL0&9#&J         *=F5C=&]R1&%T86)O;V
MP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'
M0               !4;W @56YT1B-2;'0               !38VP@56YT1B
M-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%
M)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
MUC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M X0DE- ^T      !  LAC5  $  0"R&-4  0 !.$))300F       .
M       #^    X0DE-! T       0    >.$))3009       $    'CA"24
MT#\P      "0           0 X0DE-)Q        H  0         !.$))30
M/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #
M(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M!P  #_____________________________ ^@     __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@  #A"24T$"       $     $   )
M "0      X0DE-!!X       0     .$))300:      ,U    !@
M     !J0  !$,          0                         !
M    1#   !J0                     !                         !
M     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   !J0    !29VAT;&]N9P  !$,    &<VQI8V5S5FQ,<P    %/8F
MIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W
M)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M  #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M!);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   :D     4F
M=H=&QO;F<   1#     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M      37-G951%6%0    !       &86QT5&%G5$585     $       YC96
MQL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W
M)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "7
M9E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F
M4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M  #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M  .$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!
M0       0    &.$))300,     !W7     0   *     ^   !X   =$   !
MV[ !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B
M!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M    $  /;6  $     TRU(4" @
M                             18W!R=    5     S9&5S8P   80
M!L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   B
MP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M   TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&
M5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M@,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($
M-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M     2<U)'0B!)14,V,3DV-BTR+C$
M                                   %A96B        #S40 !     1
M;,6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M   !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#
MHO+W=W=RYI96,N8V@
M                  9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6
MQT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.3
M8V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                   &1E<V,         +%)E9F5R96YC92!6:65W:6YG($
M-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V
M4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                    !V:65W       3I/X %%\N !#/%  #[<P !!,+
M-<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                */     G-I9R      0U)4(&-U<G8        $
M4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@
M!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .
M4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@
M%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B
M8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#
M,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!
M,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%20
M58!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L
M &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@
MAN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"C
MT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0P
MQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#I
ML.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q
M$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^
M44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA
M;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&B
MH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1
MW#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((7
M4AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"
M67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*=
M J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"
MZ"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T
M8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#
MB,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>
M ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4
M/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:
ME)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5
M G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5J
ME6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%
MW)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.
MEE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5V
MRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='
M!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7
MSA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4
M>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_X
MYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW
M67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*
M%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP
M*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[
M6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MY0), P$1  (1 0,1 ?_$ !\  0 !! ,! 0$            )!@<("@0%"P,!
M O_$ &T0   & @$# @,$ P@)"PP-#0$" P0%!@<(  D1$A,A"A0Q%18B01<9
M41@C)%A987&6,C,V.8&1T]3P)28G*31"=GFAL<$:-3A)57-WLK2UMK<H-T9'
M5E=FAI67I]'50T124U1E<GB$HZ3A\?_$ !T! 0 !!0$! 0             !
M @0%!@<#" G_Q !%$0 " 0,# @,%!P,# @,&!P ! @, !!$%$B$&,1-!\ <B
M46%Q%(&1H;'!T3+A\14C0C-2"!8D)28T4Y/2)S5B@I*BM/_:  P# 0 "$0,1
M #\ W^.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*5%=U5]Y<R::8RQ7%:OXVI^9-G\YW^=K.,<;789L\$]KF/,<7'+&4
M+(^;5R7A)E9*"JE/,R9_+R*"(34Y$@Z$S<52BI5J,H]75K&:)Z7;*X-QC&Y?
MS9OM9<78IP3B(UI+!5IKE^]1<BM;&=SL_H/'L95<8R\#8(FRK-F2TM]H-6<<
M=%D=RY>,5/7KU]*IG+^\/4?U+I^!_P!U/A;4G[UYBWFUAUK86["5RR=9<>3N
M/,Y_?PER=1E>N)*O=ZID3'J]6AB(/)I2=J4\E8"K,FBIV+Q!NI5V^H7U(;/T
MXLU8$MV::= +:%92@;O4;]EV%A[3)Y'Q9G:%B96S4:-E$F4BK7W-*R-&, K\
M,D,(E*-[&UD7+F7*Q(@V.Y]#^]*RHT#S+L!L1JOC;.^R6.ZMB.]9;;2-]@<:
M5E*<(O3\86!^N]QBPMZT_)R+EQ>7M,/$S5I%LG%,FC^4&,3AV"S%P0RE0[V+
MK1;1QC^6VBB=?<'2?3:K^[Y-))&Q'O5T2V?>/$K^GC%_G&/B"Q@XX3HR=G5*
MHRJ+M0+,\;F;MU9!F1PI)M%*6_K1;1PC^Z[0PFO^#97IN8UW;2THM-B5O5T+
ML_(OD+VPQO,9K@8=.-#'"5*86649@TJ<@J-BDDS)(C(LT%UI1@I5_MG.H-OA
MJ/N/JY0LHX5U:L6L6W.SI==,81N-\@9)F=HXZ-?N4T(W*UFC):#B*&,"R8.&
MD_9X6 93(0#9PG%/[&V<+M'[I2IU>*4XI3BE8W[@;&UO435[.^R]K2*[A\,8
MTL]W",,H"9IV7C&"@5VMH&%1+^%V6PJQ<"S*"A#'=2*12F*(@(*5&AIQU7[?
M:=2=T\O[RX[JN(,YZ"2]P/GS%>,C2QT355I0F.1<>R=;C[;-R<J#J^QCEU P
MPR$J#%]/QS@I%F:?K-VBE=#1-X.J8ZUNNVZ&4-8=3JGKW+:MY@V'QO6*_E3(
MLSFO&1:GAVT92Q@7-4;*PT'4KK$WIS#PD),,,:R\-.UW[P).G  DR?J-5*NC
MD??79Z,Z4&'>HABO$./KY>%\:XBSQG#$I6=N<(+8CFH]G)9?+BP6-@2DV=FJ
MD2^4LD(M8G%@8$AH662?,9%T=N<JE5UT[NH/9>HK?-A<F8NI\+'Z-4!_3<?8
M.R=+1-EC,BYER9]WVEARQ*IMI"02AF-"HR\K%U)B#>%5>2EA+*'&9#[,=QJ"
ME6@W'Z@VW=?VLR%J9HGA[ N0;AKWK&WVISW8]@[;>(")5KLI*2K*OXLQS'45
MFHZ5O\W'Q0S",Y87:=7:(OFK9V1-0BB@J5C.PZS6T&US/&K#IYX"P=+VU'2"
M&W>STTV-O-S:1=;BY64F*^EA/'2E CD'<W>G<U7)<L;:K 6+K9F*D8XD6$>=
MPX(V4KJ-@^M?G>&TVU_W=PHTT'QU0LJZ_.,P*XCVNSU;H?/^4KQ6IJ1A+_AK
M6^A4^+C%+S+0+YI&L(VSNU3HR+VR1(/J_$D(H"RG]O7\?&M@G ^0K!EK".(<
MI6NBR^,+/D?&E'O%AQQ/F4--T.:M5;C9N3J,L99LR6&0KSQZM%.Q79M%_6:G
M]9JW5\T2*5=?BE.*4XI3BE.*4XI3BE.*4XI3BE4S=;=!8_IMMOMH=_9]9I%9
MGK=8GXE$X,H*MQ3N9EW?@7W/\M'LG"WB'N;P[![CQ2H(\;==N/M&"=B=C[OJ
MK9:CBS%6(:5F/&,C6<SXPR;*9$8Y.N04C&V.LB158< XP-EZW/I&M3S>D6[[
M348U*;7FWSY$(E9NX4K/73W>Q_GD^Q-)V$Q$GJ9G+56V4FOYHQY9,EU>]U>&
MA\H4>%R#C:VQ.3XAO#5V3BK)!3/RCA Z#1U$3D<]C'93'%N=52LNXW.6%)F0
M8Q,/F'%LM*R;MNPC8R-R#4GTA(/G:I4&K)BR:RZKEV[<K'(BW;H)J++*G*FF
M0QS  J5=+BE<&4<.F<;(NV+,TB]:L7;AG'E5!$S]T@W45;LRK&*<J1G2I2(
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MW>5=@,F5/$N.6,E&0[NXW22)%0B$I,K_ "L4Q4=G*8 </G "DW3 HB<P#]
M1XI6$7ZZGI0_Q]M<_P"O"'^0XI3]=3THOX^VN?\ 7A#_ "'%*_/UU72A_C[:
MY>WU_P!?"'^0XI7[^NIZ47\?;7/^O"'^0XI3]=3TH?X^VN?]>$/\AQ2GZZGI
M1?Q]M<_Z\(?Y#BE/UU/2A_C[:Y_L_NX0^O[/[1Q2GZZGI0C]-]M<Q_\ GPA_
MD.*4_74]*+^/MKG_ %X0_P AQ2GZZGI0_P ?;7/^O"'Y_3_\AQ2LGM>MU]4-
ML6]@=ZVYZQWFAK573-C9'%"FR3*4(\D$%G3!O(F33)\NJ\;MG"K8I@$5BH+>
M'<4S "F<59S)W5:Z<6%[]:<6Y6W(P;0\B4B44A;;3[';D6,Y7Y9%--51A)M#
M(F,W<D2624$@B/X%"& 1 P#Q2J$_74]*'^/MKG^W^[A#Z?M_M'%*?KJ>E#_'
MVUS_ *\(?Y#BE?GZZKI0_P ?;7+]O]W"'T_;_:.*5^_KJ>E#_'VUS_KPA_D.
M*4_74]*+^/MKG_7A#_(<4I^NIZ47\?;7/^O"'^0XI3]=3THOX^VN?]>$/\AQ
M2GZZGI0_Q]M<_P"O"'^0XI3]=5TH?X^VN7O]/]?"'O\ _P!CBE5CC[JT=-;*
M]WJV-L<;HX'N-\NTTQKM2JL)<4'4Q/SLDJ"#"+C6WHE%=X[6$$D$@, G.(%#
MW'BE2'\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*U@^O+W_6"_#T]OY0!/O_1^
MD;6C^;_[O\?%1YC[_7Y?E6SYQ4TXI7P<N6[)LX>.UTFS1H@JY=.5U"I(-VZ"
M9E5EUE3B4B:229#***'$"D(43&$  1Y4JL[*B*69V"JJ@EF9CA54#DDD@ #D
MG@4) !). .23V ^)K@P4Y#6>%B;'79-C-P$]&LIB%F(QRD\CI2+D6Z;MB_8N
MD3'2<-7;95-=!9,QB*)G*8HB \KGAFMII;>XB>&>"1XIH95*212QL4>-T8 J
MZ,"K*0"""#4*RNJNI#*P#*RD%65AD$$<$$$$$<$<UVO/*IJR.?=CL+:OTIAD
M/.UZC\?4^4MM=H["9D&DJ_3<6:TNCMHA@1K#,9%Z"8E1=OY%^9L6.A89A)3<
MPZ8Q$<]>H*5RLU[ 8AUWK4=:\OW)M5(R;FF]:K;-&,F[)9K;97;=P[:URFTV
MJ1DY;;A/N&C-V[3AJU"2DB+1JY=F;E;-UE2*5;"I[R:O7:I.;G Y,[1L;EC&
M.#IV*FZA>JK=*OE7,MTK6/L94^VX_M%9A[Q57EOM5OKK**>3]?CXI5G))S1G
MY81)>124J\&5,UXRPFA2'N4;.C48W(>0ZSBJKR[]C*+0ZU\N:CEM4X.5EF+)
MU'UT+%(M@A8F3L+B,B'<^]B8$C_[7F8ID\4K[5[,>.;7DV_X?KEB),W_ !9$
MU*8R%$L8^469U5&\DE5ZNPE)\&7W?3GY-E#O)0:VG**3[*(/'RTA'-8Z7BG+
MU2K/95W>U?PGDQAB+)F4$*[>'3>J/)!JG5KM-P-09WR9=5VD.\C72OUN5IF,
MVUNG&3J-KBU_GZVG+N$3"S,JB)514K^K-N[K!3LU):^V+)Z3#)XSE6JKYB2J
MW=[5*_;[Q'H2U*IELR2PK;K&]0N=MC';!]7*G9[9$S\NWE80[./5&=A0?J5\
M87>35NPYJ-K]$922=Y-&W6/'K5H-3O+>H2F1*='O)2VX[A,G.JRCC.=OU981
MTBO.4V(MSVQ1IHR5;.8XCN*DD&BE99<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K7,^*:3(MTG;8DJ0JB:F=\#D
M43.'<IR'N'B8IBC[& 0$0$!]AXI7FQ0]"0L=@AH"%B$WLE..VS%HS1;D.8ZZ
MZZ9>X?A$P$*F"AE#'[$32*=0WB0IA"\L+"[U2]M]/L(6N+RZD$<$*XRS8+,2
M20%1$#/([$+&BL[$*IJI%+L%7N>!D@ <9R2>  .23V -7KVHP7$X@RDO HQ4
M6W92\15;.P1CA0<1B+:Q1<>^=LF*J0% Z,;(J2$8=-0I5DE&AR+ 54O&H:?>
M:5>W&GW\#6]U;.8Y8VSC([,C8 >)QRDBY5QR*F2-HV*.,$<@]P0>S*>Q4CD$
M=Q5A20,0U*9=.'CW!3'3*<KD@F GXNW=, 'Z=A_&7N'<"]_VCRS)&!QC"D$Y
M.6YSN(\B!Q[HQC![DU3Q@<<^9SW^[^*OA9\,&JN,J-D1U3HI-&T'D$WS9\V\
M!:]E"K0B[=(ARJ_+2L:)G)#JG$XG3. $(02"?.:CTSKND6%EJFI:=-:V.H;?
MLLSM&2Q>,R1K+&CM) TD8,D:S*I903@%2!6T3*I;*D J#AE+*6!*!U!+(64$
M@,!P".XQ6-+4S)26F3A!0XID08G3:'04%NAZ+55504B^H)@,N) ];W'S,81+
MX?E@_P Z\ZR5I6#B7?$V4LG-&E29%QFK7?6B',:[%279S4@M'.EVSA-4Q4EX
MY7Y50R!TSE.@X,H=5($R@>0"=Q 8A "Y )"!CA2Y .T$\ L0">.34@$Y(!('
M)/D/J?*K 1T+$OG$N*T>R2\7:94B(H 4B!!8MU/%$#F,(%$QA,(&$>YC&'V[
M^T5%9+8@P1'7'&F7K$_J0*(Q5;8.ZU+BP_?E)B+E6;B0;1QS)"4Z2L6+TTD=
M,2^FF@5(AA44\.;)IW2'46K:9=ZQ8Z=+)I]G%)*T[%8_'6(%I1:1L0]RT2JS
M-X8VG&Q6:0A#ZI$SCAD#$$HC.!)+C.?#3^IL8/. "?=!+$ XO)Q[!K(O&Z47
M&*I@9@)0=-?6,45111.4GN';OZQC&+[!ZA"^X=NPZV#D9'8\BO*LFPU[25UQ
M-GHGW;350O"E9<5H\2 K*09HY!9G86JB:@J>B,K\W%N_5*"15 ;"D<1%0.77
MV&]^Q_ZC]DN/L'C?9_MOA/\ 9O'QGPO&QLW^6,_U>[_5Q5?AOL\78WAYV[\<
M9[=_KQGMGC.>*VX/A%RIDJNX)$6K-H4+_B\0*S1] IO&NW%$!,7R/W$/2\OK
M_9',/Y@'+4>7EGZ? \<_Y%>3?3X?J./O_:M>;JW8_;Y$ZRFZ5;,F(N)W992'
M35\U0](CN(A?4.)4S@)B)ID.H80#N4I>W<!'V];>"2YGAMH5WS7$T<$2Y W2
MS2+&BDG  +L 2>PY->BJ7947EG95 S@98X'R')[UA9MI@/'F)<JRD-0V<R2G
M2#-E)U\TVKW=%25(V2?H%\'3@WHH2 /$4 <.%U_E@0.JJ*@F'F;ZDZ9U/I:]
MBL=4%N9)[9;J&2VD:6&2-F:-@&>.)P\<B,CAD'.&7*L":I(C%M]Y65PVUEW8
MRCE&&&"M[K#X 8((X(JU&#<5PN2<ET"HN8Q=^WL-G@V+]HT<*MEG$>LN@I))
M$6,L3T3G9^L(+"<H(]_+Z@',-;6UQ>3);VL,EQ/)G9%$A=R%!9VP <*B@L['
M"JH+$@"HCC:1U1%+,<@!1D]L_<!C)/8 9\JJ;9K ,?@G,N3,8&;N"#3;%-L6
M9G*X+K#')?/N8DZBB*IDE3J,BM#B<H]O(3 /N(ASR='C8HZLCCNK @C(!&0?
MB""/B#D9%4D%3@@@C@@]_P ZLA3ZFRGOLINHW56<2*A40*F8YE3'5D"-"%23
M(("8YBCX]O$?V_4.W"(\CI'&C222.D<:("SO([!$15'+,[$*H')) HJEB% )
M+-@#')).  #YYQC\JRDVKU_Q]B>\PS"EM)5. GJ;4IE,DDY76%M-KPT(E:F*
M*JO@J<K*Q&E4R%5$XD1,CX*&3 AN9;6= UCIZ>*VUBQDLI9X1/"'9)$EC)PQ
M62)G0M&V%DCW;T)4LH5D+5/&R=]I!)&4=77<IVLNY"1N4C#+G(X)&&!.'-<C
M63Y\[1<H@J5,Q"I%$RA?'NN)!'\)RB/X0]^_?N'OW]O?#UYC//?[\?M_'XUE
MM>]8F=+P;B3,9EV[@N2Y&R,'<,=NY(I"%C3MS0;LRQ9 YU6\ZU5=*I&6;M!
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MDEC:6+<4\2-6!>/<.5WJ"NX<C.1R*A@2K!3M8@A6QG:2.#@\'!YP>]:R6_\
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M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6N=\4O[=*"U#[>V><#?7\O\
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MB-_$_P RH=\1 $FHE[.5/% 1*"GD%AJLMU#IFHS6*;[R*RNI+5 -Q:X2%VA
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M6<PSLJWS@E$B3R43<M".F9E!$"G<G;HI.2)ID,H*2**A_$A1[CE/8CJ>F_\
MEX62"WCU"VOKL7,8*"XF$C+)#=2*??8-&X@#8**+<*#Y5K_4=I<7NEI]G+!(
M/$\=5[$EMX=@OO'(*H#CLN,G&!?/-:R,5AR[_:;@C9H\A7+5,JAQ(HL\<%*#
M)L@7V,=0ZX$[D ?=,IS"42E'MN_M#NM,_P#*?4C7K )_I%[%'R!ON)(FCMD7
MD$O)<-$J!<G>5QGFL9T[9ZI9K%M&+60,UT)%<$PLA!16QPY) 7_]1  .36*N
MNT=C^9RG?EV*<4VAV,%@>7AD6[I #HV=O OU3-BJE. KRX.#/4WZ!C'776!P
M*Q/,IO'2.BXNGKW5]1_TZ"T%E'I?1EQIZ12*RVMZFG:@3N='RUW"&D282$R;
MC)XH)+"MIDDO;>*XF $L,<TCR(J'/V5_$%N%V'B2*-E!;&[(8DDELR#.".@D
MTUT@$2G* ]^P]NWOW*<!_;[=O?V'W["(#V[+&T'V1HI",KQR<')/<<Y&.2>W
MP^%:/<QWHUB&[A#A9 &W ,?=VG*. >,Y!';GYBL-:!:H>#V0V*K4FFC&%DG4
M/91F13*FV:!%UV),^"1>&_ U;*B]^9]9<4T1=>0&,"BI 'DNC=3Z/H?7_5>D
MW4EK9&^;2[V"YN'BMXY7&G6L,T!ED9%\8M()8D)R^9L$MPVT:C87&N:8UM*Y
M2Z603@%PJR! 8T1LE=[*NPHHR3R16<5NR'9K6E%O+?,F>-*M&))%=/7#=L8D
M6U33(J8S_P 2F!J1 I"@X5.<B9>QA$>_OV)Y[.&)FD>)(BK.S/@1QJ-TC-(2
M0JD89G+$=F8G@FN0:#T1-HLNH-H>FR6$T]V[3>")%#74F0S(I8J!DDL%VK@8
M_IQC # +;&EBSG>["P%(TZG:963J20*=E3P[B,72>N54A /4;$4=B+10Q2&$
MZIC]NX'*7@G18Z2U/J7JC5;+[/)J*]0ZG<:1*'"S/936EI;W\\42GWK66XGD
M:*1@5_WR4.6-=PMEOD@S(\<LR6<45P5R7:ZVQ)<31D'E'+,KY)4ELCO6?";9
M0KM4_8!!4H=RE+['[ 8/Q?D/M["'Y]_YQ#G9Y)4>W5?^S."QR1VX';ZYS\<\
M&M?M[:XAU*29 0[E3A <,RL2"Q\B#@<?Q4Z?PW59B:DCMU%0CHCN/<9C@I3R
M**:AFSM[6G7SC ZQ [*"R73.CX"'=$0%,W<X'$?DCVG=-:3T]J-K+IDAD_U:
MZU6ZN$W[EM73[$?LB*IVJL,LUPP']06548GPP!M%TA6.-VC,<LK.\G.1D^&=
MJCC #%F^/OX/88BIV=8EE-^^I4M&@S,O ;82@SY!?,47A2S-4JZ4&J9FJN1X
MX(Y4:/&K4R"2H"LBHD7L<>P[[[*-?T2UT./29[VUMM3DU*Y<02NL<UQXRP^$
MR!MH<L%,8&2<H<=A7I#$TL6U9022Q\ R!6R ,&-"079AQ@ GC '>L1,_ILHO
M ^2K#/-FRT&A!JQP).W""9G<Q*E5;0K9HBH<%UUQ?%!8IFR:@MP:J+B8A4C&
M#>NLNH>G]*TC4;;6)8)3>6%W#%I[>_)=N\#A(E1 S1AWV;9B%$9Q)N7:#7E'
M:F.$2O((T8DX)]Z;:#E%0^\RMRK-P 3SSBJ;U_EX*PXN05J[@YX@EBGE%@26
M<BV-)K+)?-O$47!A^7^TFZ3-V9,J:?<ABB*8" AR\Z+U30]6T_\ UO1[..S?
M59Y9]1B.TW!U!2(9FN2I;_<;PT=0"%V.K( K<V^JPR7-H@CWQVX)=6'];N%
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MYI%U+3#%(#NVA+>&ZNU?((+7,0."!G;=*N)[NQ+7$(0V\<<<;*3APZ[F8C/
MB9"AXP3*N3D+GT,MK]8L:;EZ]Y*UGS":QDQOE6,C(JSGJ,N2!L::$18(BSL5
M8J7492";)PE*PC!05#LG!3I%42,GV4$0^8JN:Q,PCTDM4,/W"9R39I#.6S&3
MI;&\]AQKD;;'-=SSG:JOB>TQKB(L6/Z8>P.F\158&9CGCUD_/#Q#:679OG;
M9,&"YVHJ53.L?1NU,U-R]1<VX[L.P]LM>+<?77$N-X;+F;['DVGTK%%S*W\\
M8U:NV9!PT@:= G1<'K["-4;+)JR;]6:=S1C-A;*52O10Z=$OTY=7KI2[Q 5&
MMY4R_FW(F6;K"4B<<VBN5B(D996)QQ28JRO6,:ZF&57HT?%)F<*,6Q2R3^3
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M?BV]9QU-7 KR5B$W[I%*"KSM\Z7=-6+UJB9R51@@<X1O@CXF73;(G*")CB&
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MF'^0YX?:+C_Y\W_U7_\ NJ=B?]J__P 1_%?U]W*]_P!PH;_Z+8_Y#C[1<?\
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M>DYJI6B#AZE3ZA7*G.X3:(PJ["5C;"Z.E+S$PB@4)HK@GILW:4G-J.D47*"
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M<SIK9@UYQ/T\Y'"5\86UK;]C9>?FKU<:K'LG*M4A_O8U;5I4R+ITT6E'*<+
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M9CT_UQHM*PNK TQ[,S"U_M,J->CY>6L\I)G=I()RZDPBZ1&.)#K-FI&B*"8
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MEW<6VCUE3)G C=XJ8"&, =\_TWU'?=,:B=0L521I+>6VFAE.(IHI,,JR$ L
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M(CDVX?5=.CUR"2!FW2K<--&,X=T"A1LSW\-$ *GG9C (#$5E3J.-A?$COM>
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M&#R.\K*B1JTKM(5CC4)'&I<L52-5"H@PJJ J@  "2S,<LQ8@  DDD # '/D
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MC2&*VA(\2=PN<11[UWMV7<">*J5'?=M4MM4NV/)00"Q^0)'XU@8+5J3Q-Z1
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M4_=GUWJW7Q .'\$XZI[1PO2%&UW3C4&]'ND!)?PA-T\53^88RS-5R5*3AWB
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M2H6/A;,-)S#79;8AX[,X=1]JK%363.5,3>)F[V77D5'"O<2BJ[E"E4'Q'W3
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4JD[[_<+=/^"=C_\
M,[SBE>65T:V5"D=UZ\SNLC&QCY:N67[E+S$@G&L%;,0A%4VAG"IBI^LY9D<$
M1((^1OQ@F!C]BF4KT9,>;(8^KN%%']HGXV/@:A!@G+2S^49I)1:[%,I53.%S
MJ CZ*AA\T%4S=E/,I"D$QP*,9[C:?/!!&/\ )/[_ %$$$^?'&01^.#YY'^<<
M'6^Z8-BRK(WVPA2:4VN&NN9-Q<K3I)TYCGC:]&D>QL9**R"7JE0;E40;C)-_
MFVQSNC&!- I@(H0-MTG3M FT/4]2O-9EL]9L6D%C8+)'%]H+1*T$D3;!,[F3
MQ$98Y%"A06[@U?V\=N89)7E9)4$FP+(B>\%!C(4CQ&R=PRAP,<]Q4TO5IJ-5
MMNF.Q<3+K(@W;8<NKPADBD(5LX2K[A1L?S #!Z;59HW5( ]@#R$W?L)@YJ9[
M^7D2?GC!^'/S\^<UCU[?#G'<\\]\'MD^7>L4^@O1&N,M0=?"S":#<]BJ$W<&
MZI@_>7CFSS+YZ\,*AP],'B"0("0H" *HE-V-Y%\ CS[_ !XS\L?#YC/RX'<F
MI/8_=]^"#C\N_EWJL>MC3Z[,Z+[%N5I!HS;-*#)*%<+B5/LHQ(+A%L3N8 $Y
MW:")$C 'B<XE G<1[C/[^L_M^%!VY]?C56]$3&-8Q?H)KNU>?**N)>A/K090
MIB&.+NR3KV<<B8P=^RG\. #$#W$B?L'<0Y (R1QV^//\Y^'!'-&SCCO_ ']?
MOQD' [KU8FH-MTKSW:7+XK9:B3,3;JNH*)2E&>3>)-#MD5#F #$>INSM! @B
M8PK#XE$3"''K./P!S\O0R*FLZ.D2PAZ/TT]<V,LJ**88[>2P$$@#W3E7#B07
M*)3>Y .8 $I@'L)C>0=@ W=GY_(>8)/\>ODJ!WK^TFD6C RN3XX%FCVLY+K3
M*LG]5,"OT9-*193:!TC&$ZZ21%VQDUDNY2*(^(C[''@=A^?G^?KZ4JJOA-1[
MP>]@?7_5S67W'^><O/8._P!/R_H_9^?)]?IZ^_FE1R[3889Y^^(&SCC*1?$C
MX^3V(1F'RQP 2J(UFE5J<^4\1$._S2K)- ?$#&\#F[!W]^/Y_+R]?F:A>P^@
M_2M^C6=: KU6DC>NFI(/&R")'!R@!3?(MRLRIIAV$"-R BFH0H?[PQ/PB8>0
M#GG]^WTQQ]_\8 _B.Q'U]?+ZC%:[M@K$I#=>C(\R;Y&5AW&L];D)Q(#%6/&M
M7"YD4!7,/D K'<@=50QQ*<QCD3 .YR\8&""VW@D$@G)P2!P#W(QVP!R< 9J0
M/N']C@??C%;1A)6"/3 9/3M@;)0)5@$ )\H]24CU>[%8IOP !BF.B8HA^$%"
ME/V PEY4"5P5)!&"""058$$$$8(92 5*\J0"#D50,@Y&X98\C@C!# CZ'D-_
M:M83I[8]<0757ZA.1JQ*L'4.RD\<PTD<4B^DU3EH)LZ&%!,IS 51J8BC=8P!
MX^)$/'L B 06))+$LQ))).68D\L23DDDY))R3WYJL\Y)))/<YY.?//?/SK8'
MV;A6.0L>V&)CU@(J>M/VITP /!7P9'!!45#AX*I@05$Q /Q& IR]^QBB(X)[
M]CGR'T^GT_49JE<@=L>8_CDG']_(YK6*^&\Q1*U.7VNFGP(*TE[G!]0V<@B)
M")K2M6>3:3D&YS#XB19LJW]R=P ABE$>YP[1P<?C]?6<_7%55/EOMC\EHQ_:
M6+<&[N.<5"UME6'X#F,1O#/5D@<)"(E !%-/TQ,'B41()0 1X(&2?\#YC/(X
M_O4#MY_#GO\ #\_SJ"7X9;'"KG6G+SU];I"KL3[!R$H_AHQPFDC:F=;@U(!:
MNSQ#@/KPZZ[TSI $?%5&2CVC@AA%, &ZMYTA2[22WAG^T6K0(\H.ZVD+HZW$
M!&=LJ["G(P4=@3@FO5) @D!C5_$C* MWC8D%9%/Q4CL.X)!XX-W>N'C()C5_
M.<A'D351CJ<QFF20G\S-TVUBCU5U14-^/N!$E$@ 1\A >W?L ART^'D"1]>P
MX QQ\_AR?IY^O7QK7=^'&-WZN6NH>_8:_ESM^SVQS-_X_;M_-[C^??E5*]-+
M(F-\>9>ID[CC*]$IV3<>VELBSLU%R!68:XT^PM&[MN_;M9NM6%E(PTJW0?-&
MKU%%\S733=MF[@A2K(IG*I5O,-ZM:S:ZMIIGK_KO@[!S2R 0+$VQ#BBB8W0G
MBI@)4RS*5/@8<DF5,IC 0KT%RD Q@* =Q[J5T>-M-M1L,6HM\PYJWKIBB]IC
M8#HW/'.%,<4JT)*6HC4EE.6>K-=BI8/O"5BR+. 5Z3[6*S;%>F6!!+P4JT_3
MQT7J?3\P"[PQ7[8?(<Y9<FY'RYD'(B]5BZ4XN-UR-9'4T\=_=B&>2$="LHB,
M&+KD5'M'JS=".B&YDP2%4R1%*RHDL1XJF<DUO,DQC2@RN7:;!2M7J&4I&GU]
M[D2K5J=%09NOUVZ.8]6QPL++BJJ,I%QLDV9/Q44^:05\S=U*N'Q2G%*<4IQ2
MG%*C,ZQ.<,FZZ]./9+*F'9]_4<AQL31ZU!7&* OVI4"9!R=2Z!+6:*5.FHFU
MEHB&LL@ZB'ZA?"/E"LWH@86X$.I6'6K&=\CZ:6WJK86G)7;O>W'&DMHUBLF)
MXA '.Q&U]B;9^PQ4;3<*#".G#J&>7@(.QO%K7%1CITS6@:S(ORIG5:-FX'4J
M'GJ$[\+[J=17H7,%]+]ZM3?T>;ZU1X1[N1@,^%6-X&RY-P&B+6@+GLL_]X7<
M"$("MC1 K48Q&7A3B*OSO9-4?#O^7Y_VSYUN'S><&\)6LR64V*\VRA,-S9X1
M:$A<<2,E9,EF)"5^;^T\/1"3@%K]"G^\!8DDBQ,W3&:AY]AX@,6HH=4U6A;V
MF;(R&.?NG>2J+T12]_?4U:<EQVBFG.MX+[IKVP5?E4KR<SC[63K0HBY-!HN)
M(%?32$HJ51,/G)O,5/$EM+BK-\:3+=O2J"->F,;R+"V8[.JQM+X+'EB"4<F7
MHU13"K&:JSKTZZ";V?J[<4Q&91$BGK\*^\QFI"'B<URQL89GD@PH?P7CHC'D
M@_E<H?ZUHVT@;"[$C@I\AD\9((#R8&; %H8R4,/[ZT,H92JI#(*8WV H/W.R
M "D_2).[EMPU5T%#ATXV2AXT:M/V<5?EHN[/AEP>QM<52,Y=QT;+NRJ%(Q.!
ME*I*.S>A(T^B7 ,69K9$O>1 QVG6I#',@TM]35&S3M9^^=Y@#N!7K6/0-!&G
M1M;E11J%:EH.8]+TI),A5*YTOF%&(2S>J;&V7I']"$*E-+IQ-"?/E<J%5I(7
M8(S"9"+E_2+,ID'[K*Q\>+8Z=T[UXQ_7#U>*5V+G*<<RLM1KS^K7N.:6RC3]
M[6N,A65V5'IS6OJ5LBM>OEE<+IM*M;9,MD!>'@WQ15?(05D."J?V2H"E$DB1
M(TDKI'&BEGDD8(B*!DLS,0JJ!R22 !W-422)$CR2NL<:*7>21E2-%')9G8A5
M  R22 !R36#=@ZF>.IULO6L!T+(.6LO.IVT5F)HR5;=LD&[JMSTE &L,K)-#
MOD7-6D1CAGHA]#+/"/Z\Z92#US"(.3+M]"U;V@:?#+_IV@12=0ZO)E88+%7E
MM589!>2XC!$J(?><6WB *#XDL*D/7+-?]JVCVLYTGI:";K#J&4F.WL=(5KBT
MC<$@R75[$'C\*/!:3[.9<!3XKP(3*M!8LPY=+-DO)^>-QJQD3(&2L,UB(MM1
MQ] TES(XW1;2,1-69M7\1>#E5CDN]0ZD*6-?0D6;T8JS/H9!Y(S<C(-'C*WT
M;I&_O=07J'K&:.\U$;6L],3#V6G $,H*Y:)Y$8 K&A>-&!D>6X<JT=OT]T%J
M>HZM%U=[0KB'4M:BPVF:-#A])T1=Q= J'<D]RC;2&!=$=1(TMS($DCDB:Y/1
M=3.+88*)DQN.4JI.6I&3<TUXC#4(L''5R1&O9/D!5%.EVF5+8P9PD*]*LK(R
M,)8F9%"*19_4Z177JZ <VH!3W=P_1;FH2-,I+8M&M%QU(&M[A5'(88]^_P T
M@0<>NXQ>H<WWT2N9%/E#X_ ;." (@+?BE5$ODM)"QY%K@T?)*IL=5*%MJLTA
M3WBM=NA)IO8' 5W'DL"H(VRV180 HS,&U*DM'N)F 144,,F02*5PHW+*,DXP
M\W#'N5F0YA@)"?16D:.]:-\;%CZVRL@Q&7E3KB%"GGA7H0D?&/@<*NK&U>Q!
M3%5;B<RE=4\S:@SJ-IMPXMS4Y)5LH)8O/76F.I!>VSZJMYAJ-]_:O! X!>:Q
MBF>8"V*7)%0C0M'C)BQ^B*+ Z)E*JI7(B25UMM*&F9".>I4:$O)[0E5'1Z98
MDYM]9V(52IV$%?0G;Q%#6#.YJMH)D<1[*>K+@ZIPETRIJ5T$5F-"5986>AC7
M+\?^FE ZZ#64H+]D\Q@!*B\MPHYF0.N8<>KF(S&ND2?F<">V.6D& ^LN50%*
MX<GF]",J.2K<.+,V/B8UO"M'5KD;CF0>6V\*).ZZT&UXW@B.07MU(4&Q%<HV
M-HHBW4:0U@7!(/LI4IU*K0MZ3'(DECO[J7@%(VC1EY&YFK3D,>O4Y.;F80*I
M&VH%!;/+NP&&&5DZV1$'#2$DX:1,H<C\A"*51L#FU">@<*3Q<79IB"YK7*W1
MB)W'<A&SN+A-5IBTBKFB-.X.ICU H0XU\RSX[DH6>3B(@.YWY%2J5_,QFY"'
MKF6[&.+<UR1<26(*XM"Q&.9%_8LBF&.KTC]M8GB4W *WFO %A*R&59'02^T(
M:?:^'E&',=2JR+?4SY$2QW]TKV516B'O?WS/6'1<>IIDFT(3[IJVH5/E27DQ
MG 2I*T*7S)H5)>0!02)'("E47$9Q;R]4Q):RXKS;&DRW:TJHC7Y?'$BPM6.C
MJL+.^^\.6(0[@RU&JJ?W8,S5FWAW"!'T]6D/ 2RZ:B:E?>8S4A#P^;)@V,,S
MR0837,@O&Q&/)!]+Y1$*E#VT%<+,2."FR&@8LP%<!1@=L'WKC)>%$ .R%8ZE
M547("1K["T+[GWX%)JD/;N6W&JSHM#C$V4G&Q@U:9LXJ?+1]V=#(@^95Q1(S
MEQ&LI%X50"-#E%2J.89P0?U3'MK#%>;69,A9!_1\G7W^.)%K:J:I]KV"(^^.
M080[@5JK0/*OFD?O2Z.JV^R9B ?@D*<HF!%*YLWF1"$9YN>#C3,,H&$(I.57
M;0M ?R#O*8*4U.Y?9^%$"+E-D64(13[LJ,X\6QB7$BD )O6(*HJ54!<B)&N5
M,IH4S(0'N=*G[J2S&JCHM.K*< ZJS4U8N5@%7Y>OW.8&TE7@:\NFHXDVT!9U
MDU"!#*@HI5)-LX-W-0K]O#%>;4"6#)J>,BUQSCB11MT.JI<7M."]3\"+@5XK
M&A#LALBEP5.9F2H.F4\9+T'!2 I5=PMU3FKG=J86KW2+/24:RN>S35=<1U-M
M 6=D\>D2I=@44,WL2T$#(6ME3;IIC#O7+-NJ)Q<%$%*K7BE.*4XI3BE.*4XI
M3BE.*52=]_N%NG_!.Q_^9WG%*\<_&F3V^,XVR.X*OMCY)>R++[L7MUZ3E6EL
M$#.#2*T$R63,1M8'2HH UF@$56"1% 0 BIBJ I626/\ -&19[6K.]#GKK:):
M!86_$^05&3V9?.2*D&UN8F=:']=P *-I)228NUFYCD14=-4E3]A*)@CUYGM^
M_P //ZTJ1K7'J@&T5LS+%V/7*V4,9R>7D,DVEPL#)FVK#>P,&2<S7Z>X9K.?
MMD47"R+ER]=K)-3':K-6R8F5.L5CY>O[^=*RYZDO56S)F:C;?XDQ[$1%-QC!
MSM Q7+R+SU7]ILL1<VCY:?*W,)P:L$G**39%F5L!W -A< L!O4]G;CR_G/;&
M3YCX8[BE8TX=ZN>RVC>+];M?SHU6V$Q,N\E[5#N6(?.(X]LR;-[5Z,[FO(%T
MK;!-5WT@X<MTQ9(MI%A%.2N56RRA1_SZ[_A2NUZF?5$L.S>1;]KA>HJ4JN!T
M96H,57%.F"(6!,Z3.-FY.0D$GC5VQEXT[MXF)XSQ:J?+,2(D6[G.!F,#\>>/
M/[L>N:5W&".JAG+3<VLNI]>F*SE:IU&U-H:2DSQJT>]?8ZR'-L?T=P2KXQDU
MS6&NPDLA+NECI@DT^;+7E"N"M#. D_/^:58S=+J$V_>')5]U>RC)KX_Q(7*#
M^%I4E570J(H3<!)/(J(6N\>Y34)/0LG*MT5Q*R.T>1ZRC8Z1W!4S%%2NRP'U
M/=E->,H:[:XUR\QMEIF.&\=AW)+=V3YZI3K9W8# ]6ATS>D= U,BU5HU";()
M0F%$7"SE K<J/+BSL[F_NH+*R@>XNKF3PX((E+/(^&<@ #/NHK.YQ[JJS'@&
MJD1G94499C@#@9/U/  &22>  2>*CXS=MO+[%W_-S+/EBF']/LDW9IO'A8SU
MEV] L<$9^WJ+>)CB&!,8"5;D)&RK,2^EYNBR0&(HD90?!E9&964JRLRNK##*
MRDJRL.X92""#R",$ C%0002"""#@@\$$=P1Y$5L.?"9=_L3>T!_[MZR>P#[!
MWG+SW[=P[_Z?3D5%1/[^2_V!UU<]S![*I3T8_9:'<.;&1X+ L:U)5*P9R=5W
MZB((H+I +5<3J$3%-8Q3CXF$15 X 'P K)R#ZU6T^+=0%&5?E:],WE?.5LH<
M!?))@990]2AH]O-*28M4%DTW3U1%^QCTU!$4O3/ZX@)BE \=_(]LX_GY_+/U
M\JFK.8\W4SO'98OW4;2R)'/F<[0GU R%198S1W-'FCH,XRM4:*2,FFJG ?;9
MT9YC8EB"X28HNV;@KEVHGY3QZ^/E^U*R<F^N1LS9M,)!TQC*M"WN$RU6*)*R
M#8KQQ%NJO*5^3L1UT&2ZXK-E9/[$<0[E/US$226,NB(&[$ I*$,I(8$,I'!#
M#D$8X!!YS\?/M0'!R.XY%8UZR;F9GU8M.R>S-.M,3>*IG''U>N-DBK$^2?SL
M=DN7M#J.JT!)@W,F+9>/.A8A4$R11<U=LQ< 0C@"%%\_.E2,[&==>^V3'V"J
M15JVCC/]-F(2R]POP+!./*<\EW\W4VAXB+4%)-\V:2\0H]>&7527".43! HN
M"F T=OO^.!S\./P\_OI6+NB&_DQTS,3Y1Q+GFI%F9)[DDMTJ)H6::.K'=238
M-QF)QK']RK-8E0$!EHVQ2BC5K('<&8(D4<(''C&>_;)[C[O[@_"E2,[?=8ME
M=\=DHVN=9DIO(.3==IS,3)_94P;DCJO(PRXG:^*"@N%K$+!&5<-68%,W*=H4
MIE!%1/N[>?T^.><G[\_=2H%=1>HWGOIQ8JIU)KC2"G4[S=6^8YZ%D$S"Z+0)
M>.301BP?)B"S.8L+@%K R5 IBLT2MBKE5^:,5,/F/Q_+S//SI68O4#ZFL_LE
MD;*^JL $3C:HY"I-0@V5HF3@Z1)8G\5%VE]"S2IU@^S(^6(NE"%D$3'^SY(Q
MEUT#H',*;\?AZ_3)Y_'E6+GPZ+55EU@-?V2IDS*,XC,;50Z"A5D3*-L?3R1Q
M163$4U$1,0135*(E5((&*/8>_)I7J!\4IQ2G%*<4IQ2G%*<4IQ2G%*<4JWF6
M<3XZSKC6Z8?RY4HJ]8UR' O:S<JE-IJ*1LY"OR@5=HN*"B+A$Y3E37:NVBZ#
MQD[10>,W"#I!)4BE6FU8T[UYTOI4Y0M=Z&:F0EILJMPM3R1L=GN5FM-D4C8^
M%3E+%;KG,3UEEU64+$QD1&I/915M&QK%!HQ103 X'4J"#KR]_P!8-\/3V_E
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M.!5.Z1=T=\I8<;5$D3LQ"K[V UG?-[89;2>\U'6.C.D;"VB:>ZN8XYKN6")
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M06S8'"WA*Y+[)%\"&,900G3=B)^8 81[ (]@ P=P'D<^AY<<=^_P_2E=8O\
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MC$4-U=]E?2,!3_=G!0 (@(^WZ$J+W* !W[F'Z%#M[]_KW#BJJDCZ5W15?/\
M6N=S'DRPUZ5D\S5AJE&UU.NMI9.K1<HP2=HD&7=*&$DVB@H0DBFS(G\HX.HR
M.8ZI1$D9Y['X9X _,Y[_ "Y^?%*UVMIM$KQ@+;>(UG&9861Y;K'"-Z388\R/
MR,G'S<FY:)*.1]42H.8AV15O*-%1340.V$!*'J$[S2ME2&Z#*-!U@E:&K:6K
MZW6ZJ.[0\LMBK8,OLIXU;+F9ND%&KA5X@R.J1,P-E3+@5L85S$\OQ<>O7;]:
M C\#@UK$1VC&7)#:V#U0^3+*71_/(-E9*I';SS(E<<-$4SV)MXJMBJ-DFBPJ
M'2<';.45C BJ4#^(F4K9\R#T=HBE:@OL<72[S54BTV[9D@_=,HIPTCYYLF!T
MI0K5%JB\<+J*E$SXA7YDCB8R9%#>'F,9'XC/8]J5J^8HT]L&6-H$];JO8T+0
M+&U6-J_N%79JR#-> C6T>JZE6C00 Y55"@B@5LJ<?1>'.B*J@)B<9I6P_NQT
M0I&"UGHI<;+R"5[BHP5ZS7)U%H1]9E&Z23AQ$,@:M4%2RDFMZH,B/%%DSK 1
M+UNQ@,#UZQ2M>K0_5BP[&[)0V/OLJQ SKB\E8K8E%0Q'Z[9.J.SKHQ3PCGLR
M:C,2Q"0YRO# F8552$*<Q?'BE3\]53I<91MV*\<Y4@3U2/R94:6]DG^,V%99
MUZ2L-:*B9=\TA7;=<YYF8A4TSF1:.^_KI(J)LU ,*:!GKU^=*A>Z3Q%0ZF&C
M *$,FHGLEC],Y#@8IR&3D%2&(8@@(D$# ("4WN @)1#VXI7K><4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*U<.IA@;J2Y)LFJF9]@H )[%^O&R5ND7S7I9DRB?
M9V'Q-D6@3E74MS9ID)VY<*6F(=M(.+=OJ&1)]%Q=AL+MBLS\4G2*E3 ]*6#V
M)K>@FO<)M1'V")S,PA;4G+1UQ814;?&E3/?;4KC%+(C.%0;1Z>1?T:*5(U[,
MF@FY6M1I5:0+]HJ.Q%2I#N*4XI3BE.*4XI6.>S9MM"T..'3@FO1\G?>1D$J&
MR9,BGHWW1^2D?M 8\,9N6T]]XOM'[*^3%PH,;\E]H>L45_EQ!2M9EOJIU/8#
MK-:5;4YLUXQ7?YJ>V%V-4M6;,=Y(NLY3:'KI)82F,:UFERK)SC9)KBB)Q[C^
M9L-AQW"R,W+.<OYBFI*-G)J'<31)"/>O7>GKUZ_>MO+BE.*4XI3BE.*4XI40
MNYV=]_-=:_L#DQ;7'"6T>*8MO%,]3L4X;HF9;YG]SE=].UPE6MF98PR,I5&U
M%H[0MLM-A?TADTGA6BZ_'0CYB^D#NDU*[+I P+1CA#*UOG:[L<USAEG-U@RE
ML;>=DL'/-?9S(^6;- UY-W*X^QTY=/$H?%M<@&$)3ZDU;.%A03A')G[AS*+O
M5COVI4M'%*<4IQ2G%*<4KXN4C+MUT2*&1.LBJD58O?R2,H0Q"J%["4?(@B!@
M[&*/< [" ^_%*U0.F;K?LQ6LY=.#"%^URS#B\W3/ANHHSS=F>Z5A.'Q)DU?8
M[(R#O%C+"MS(\6')#6Q1;L]BF%$6[1.$0AB%D"&='03(I6V+Q2G%*<4IQ2G%
M*<4J,7JG['YAUQPC5)77K7>^YUS;=;RWJ%+L5*PU-YJ1U_:/X]RE9LWR]6@6
MQGTDO589=5*NUE*2A/O=.O6L4[E&\.25'CUZ_&E5=TM:-1,=:7XXJ]"K.>ZZ
MV3F\@3=M=[-8]4Q=FBYY)M=XG;3D?(-KI)Q%.$2N5PF):9@633^ LZ^O&,60
MJ-FB:IW[4J0SBE.*4XI3BE.*4XI3BE?)?^T+?]Z4_P#$-Q2O,IZ+K&92W\R_
M:H SHTG%+6J'23:&62.1.QW)\T45463$HB@84BMSH&[%4!7N;N!.PCZS\_7W
MTK>[S'7[?CO62V22#U;YO[@6IVX55[D-&N25N5.V<CV!1-4$EU$E2 )?(P%\
M.P]_((P>.?,G'\_=Y#/)X( X>OK_ (J';HBXI:5[1/#MCBCB[D\G*6JUVI=(
MI3J*R[F^3T8F=ZN0I#+.#I11S"FIYF233(03&\1["?QP<>L_3X?=FE==\0+]
MZ([2*_Q\9(2$)"2J$$K*HME139R@PUBB_F8MPF;R3*B\266.)2@4YS-R%  *
M)@$/YY/S[_/'PY_8TKD=#/7N.Q[HWCZ39(NWMCOK67R&\<' ACI.K&M\XBU;
M$ ?%-)NT!(B9SE\_83A^+N #SQ]<^6>/EGCZXQ\Z50/6SD++":49>K;)=<(R
MX5-D\EC^9P1^:C+%%N3)";\(F]=DBNB F[E\R]A*(#WXX[_=]?/CS/W'[LTK
M(CH>T2.FNF9A$C$PE4!E:9%9!,X^7VDI89-=R8"$$0.=4_@<Q1\#^F7OW[$[
M<@YR,=L$X^/R]<#Y]J5!K\1?5)I"4QI9&I7*M?8S$S"RO=0XILI9W%G5:D41
M["02+ @NB0YC=TC) F CY\GN/\_O^^?GD4K8#Z.-5C8[I0ZZ,Z\'I ZK4O=I
MWT%#JJ2,]*S+U1Z*I3&'L+5%$K=-,.Q4#' 2!^(P\$X]>N!48[^NWUR/C6MI
M\016+>XM6-+V#F1<4A-_)0?HJ+JJMV\DX(<[85DS&$K=3P06!,HAV$55/3'W
M'O/K^U35\_A+N_[JG:SW]AP93/R^G^R K[_7Z_E]0#W']O ]>L&J6[?>/C\1
M\.?PY^%8,?$>H+ONL'L1&M>P.7\-K^R0$P^)15=88H**?D8?8H 8X")A'V#O
M[]OHJJMWSIS/I/'NK^!L%QK4DX2CXKIYIF:60:K-W4TNP;.Y$H_+M&J0,CK*
M*%1.4JC@Y ]=5RJ8X +/?'?\.?\ 'UX^ZH('GCZ\=OGG/GS^%:\>7:Y7<[?$
M!132/;(U2,UUQV>2LA(V*: FZE"'?N"^B)@.@91P:?; I(.2F64*02E(8Q2C
MR#QZ\_[U-;0&1+HNCC6Q*RS..?I/:^Z9E;?)D,J@4(TXH-2E(!3 DHP2%(B9
M2F2./?N0#B A'Q\R//L?B,?<<<\=^]1CZ_CZ]<=JTN.C;'3>9.I1LCG&"@CP
MT;7C6%-J5N51P6$<6"X(0L<P3,^,Y.10(^$=+JI@J $ I_$"E A2R>QSVP<U
M-;2>[,K8ZSKKE&WSL0I/L*A2).P1+%R!'"[AS"L5CE R)D_0516(84W1/[8D
M!P5 P>(CQQG//;[O7'Q^?GFE:N'PUTZA.[U9;FS0,<:7E*+8K:B)H\CF-@FC
MN;;N9$"'<)J$;@FH\;-FZ9P$5A*  (F+V!Z\^W\_XI6QOU5[?:;#KME)BH"4
MB\:X^FY5HY2(NV=1ZS5HZ<IA&O6:K9=JX1]$1%1%0A^WXDC!]> <\_=\,XR/
MD,G^Y[\,8[5K_P#PLL?&R.>-D)N930DBQE+K;[Y5XU&05=NBRTD9)54%A.!2
M%7.4YSG!13R 5"F\B^0N_KU]X]%4K?Q &8))CJC9YU%@F2SQ<S$-H"<8I'C)
MFG.DY-J*+R*>M#)N&X)E'Q]0B_[ZFJ)%DCD%0!??G^#V_P ^?/R 5J%]*I=5
M?J<:-KK*F447V3H"RISB)E%55I%4ZBAA[]Q,8YA,8_<?<1_/Z3Z]>OIBE>FM
MU'ML9O1K2G.VU5<ID7D&;Q%!UV3CJ=-2SJ"BYMQ/WBL4\$7LJQ:/W;-%N6PF
M>^:#18ZAFQ4>Q04%0JE8>XGZDNQ='V.P=K;O_K9CO"3O::H6ZTZ\9?PAEV6R
MQC6RRM#KK2UVK']M96.CTFT5:U,JZ[0E&;HC.1C)$5TF3<?(JKDJGU_(?MS7
M>M^NOTY%HG),PODO(\2VQC0QRG)H6' N9JU(V;&2=BC*P[R!CV.GZ7'/+W4X
MZ1F(Y:2EZZB]08Q;@TJX\&#=RNBI6>$'MK@JS[ Q>LE;MYY_+4O@MAL>UC(B
M(E'T(EB.6GFM<AK&]LZ#4\$R5FI)X@,3%N7J<B_9&%\W;G:@*G%*Q&WVW[RU
MI_EK4>DUK7$MVQOL1M!K]KI:LSV.]QM>A:O)YTN3VMMV%0J<<A+6:TV.#BXN
M1GY1>51KE<8IC$,4G\HZE%B1BE6TZMO54F>GA48]IB#$$=L!F-*F6/-%XITE
M9EZQ7\;:_4U_&5N=R3;9=@RE'S968O-FJE+I425B'W@E'\NJ5RDE!N"+*5+Q
M5I@]BK%<L"B!6RD[ Q$P=L0XJ$;GDX]N],@10Q2F.5(RXIE.)2B8"@82@(]N
M*5WW%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MKY+_ -H6_P"]*?\ B&XI6@ET)<3U^"ROD+-L[)@V2MV8+K4/F%0$T?&K0%N%
MRS1=@/8/F/$[MRF41*7R=-OJ)>X*5MX;V7JM,]1\ZK2TLS:-4<)7T5USNRI)
M$4<5QXV9.TC%$#*"=4Z1TR$_%XG[=@[ /![?,_/M\_G]Q!'/GQ5.<D<$ ?$'
M.<'Y_J,? U'9T1:^\QSH'A.HW R:5G<-D+O&L@,7N6G6Y6:F($6O?^V',:5>
M*."D$PHG(0IOQ#R/A]><<_7\_I\<]ZDY\O@<?7U\JL]\04#>Q:(92;QIDD_0
MF:BJ_P#5,4X).EYJ-:LFC?Z""S]7NH<"=_8W=0!$0X\\\8P?NP?6?H*#C ^7
MP]8^E98]+6JAB+6C%E%?^L65C,75!1<7 #V6*K%-5!71*/E^\%]0R!P2]_/\
M1P ![\?IZY/K]JFL1>NQ7&CC1O,;MHJW0-"PR)@3!0$B%9"Y X$1$1_$94RH
M) 0/Q''\/8>P\#@G]?N ^.?6?E2JP^'FDU(?0W%9)--/Y18;.JT]4P>Z)I=T
M=$/Q"'XC>2A1*/N<O< [_3@=\GX'.?(?#.#_ )Y^D'D?>/U\^?7?O5DNN'KU
M Y'U?S]8W+UBP"BL9&\-GAB@5 '\(I\TR2 P=A(JX2$&Y1* B<%CI^/OWY/H
M5([#]^_WUD/\/=--0Z9V'"3*8*"HE<V+4ZY_4*9)&8=K(MP >_AZ1E1\2CV$
M0[%+_O1Y''GCM^0[_+'/KFH.>,?'GT/T[<Y/ J+#X@BGQ<?J2[?^NFD[;YN@
MGD28H$\GJ!TW2,BU[&[G+\F=RDH0P#V[* 3ZB("';UY^OQ\_.IK'GX2KN;:?
M:PXB'O@VE]P$??WOZH]_'V]OR$0_9V_(.5 <;LC@XQV.<9R!WQ\^V< GO4,/
M=/U QY]_(50G5<Q4GF?XC.=H;N,=2T0]F];)"?:-4A5,:%B<.4!\\]0"@(E1
M4%-- XCV[@KX]P[]^4XY/U_8?Q_?C%36\WKA1HFH4FQK,6;=!-]*NG#5FGV[
M,F<>4S=@T37*8QA;H)I 1,A#>F4I1(0!* <D9[_A_?(_$521GCY??W_M_:M>
MK6V-@T^L)U )=W#"[0=16-:RQD@;^H<9QO$I.W106.!C)HIIJ$4533. '],I
MSE'Q#M3QCCGG/'S/!\^Q[_0\>555L&SF.XL^,UVSI-.177AEY$JJG8ICG9D5
M,)D51#NFH*"IQ* =^Y2$\RB =N58X^\'D=A^''PQQY>9R*<^]C\/YQ]WS^6,
M\ZN70_B(!#;WJ()PT>BTKKK-:+6(%!NFBAYHR,F=PB@1(OI%$KM95SXE_"3R
M.80 1]H^'('KR[?$<_ES57E6R3N! 1\O@C)+1RU%W$MJ=+'<LFY$#F<,W<>>
M.>)@@L!4W'K"Z*5=$Q?463,?TQ!3MRH^7R _O^>?\52..#W/X^>,]_(?$UJ*
M?"_5R!A-PMNH5Y&$4E(>FFA8MHZ\TBHL&5Y42?MU /W$ (1LU3,0YNX@00'O
M]>1Z]>OQJ3V[D?''?'X'UYUM=;X8LKDS@/(*X,TE6D_3)>-<&(F4QFH+,%TT
M3-S%]P*/F8"]@$X"4>P^_;CCU\/+OS\>]!\/U(S\QQ\,C\:U/?A6'B-4VVVK
MQM),SHO7M$2 /F42@LU3@;!(HJ)K%,4?3$0=-U!^@#V'L @;@'D?V^_OQ\CW
M'/PHW8^O/Y>C4]?5DUUA<JXGR-6)5N1VQGZ!9)4R"!0$Z:T8S6?L7:8!V B[
M=XV253$ #R$#]S 0QN1CG\Q\.?U^/(R#^0$$9%:(_2G2,UZG&CK1;N"S39:A
MM%2G#Q.51O*+HG X&#N!@,G_ &/?N AV^H#Q_/KU\>34UZ5?5:UCR9N3T_=C
M]:L.GK:>2LH5ZJ,*H:WRKB$K@O(+(M/MCDDI*M8^5<,DE(^!>)I*IQ[D1<F1
M(8A2',H2:>O7QK U#1_J%;8YQP#FK;.5P)K/&Z;XRRU$:XTG UMMF7["\SCD
M[')<>L<QW:WV6KT6+1BJ2U;L).#J#&"='7D&SDCUXHW>F.FIZ]=OQK!/3;H=
M[2P.QT#>]QXK%TW0I?5;9/6[82\L=F<[YUR;G:;S%&$BW&69-GF1JM7J*$]'
MO72(56E(1+.%<QQY26-,NGS8&*E7U^&APK>'&#\M[?9=N!<F6S(<K6-7<.9
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MN\1(U7"&&ZI,P;:>AV=G>H0\?>K@A#U\LU/C6V8_;\I(E)'MUE$E0(J/7?\
M?U\*D:ZO6M.6ME,/XLBL(X,D\L9&H&17MVI=PI.RX:N96P9;T:C-0]<R3CVZ
MNX>7A)KTW$FO#V>L3*?H/(1\=9JU=/&Z(MU34%S6I=0K'/4PH&/GF+\/;C;A
MMNAPZH^9V-FO</C2L+&L.P+&$=6J$GW];4@IZ;K[^3JL+:$5&-;0N,*O<Y6-
M59NW;*+<JC\.WKXX'X_E7#RGT:>I_4];< ZK46:?YAQ36M'K?B28J>/=JW&M
M],I&R5\R5?[[9[-D6-+7QE,^8U80MZ1IU1JCMPE&&0@G",BQAF$R]=NE34H>
MC6A&Q^N^U&/L]Y"Q?796-QQT>M9-6(]-C;*7(3RV?L4NW3^Y4:&67D0+',W0
M(,F25L4<M*P^,J@89,Z""ITE*QYUMZ9N^F MK,*=35^W@[=M7L3F/*\;U$<-
M)7RKH4^L:\Y.D8YGCN,QC-KJ-H>9D\!0U3JT@HFS>JR5L<B:*;NGK9HHNZ4K
M:/XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7R7_ +0M_P!Z4_\ $-Q2O'!J
M4,TGMG3L9#TABFV6;+.S(J#V3)!5FP2MBF3'[ /8H1L6Y[]P^O8OU$.RE6ZM
M-A4M-LLUD7[%4L$_+S*A0'N #(OEW?@ F]NQ2JE('<>_8.WMVY'S\_GP?T^_
M!\_NI5\=;'IHZY6JV*&%3[FXFR5.^H<YC&(L[KZM89?C,8#>0N; D0@B8>QN
MP '8.W'X$<_/C\.<^LTJRR;LS4I%FZQDG#99NJBL0XD,DLCZ2B2A#@/X3IG*
M4Q3=^Y3D P>_)QZ]?A2LE==[0_=YU8W6>D74E(1$+D&Y24F]7,X=.7472IYU
M\TX6.(G.H=P9/N<1[B/;L'?MVCT?B/7H_%6-GJIE( %$O<P=Q]P[B<?Q"81_
M_2'O[C[^_P!??MQW['^_]OI^-*[IN^GKA(05>>OGDJHH>*J%?;N516!BR>/$
M6C&.9]S?O39-=T(II (%+YF^@<>8 ^/ '<Y^ ^))'^:56VRDZWF<[Y*=QZW=
MG'V%:!CE0$"F!G6"I030Q!#Z% D:4R8E$ +V*(#]!Y459&975E920RLI5E(X
M*LK88,/,$9S]PJ2""0001W!X(/S'[<8KB:_E-.9MI4O.+K2*,$^>WR;</'!E
MUUVE(AWMI74<.%U!.J8QXE%,1.H)A\@ .YNQ1JB=HY$D23P7C8R)+@G8Z LN
M,*Q!) 525V@L,D+DB4)5@P;:1R#SW'([ ^>/+'G6/E@E%YJ7E9AR85',O)OY
M-P8QO(PK/W2KM0PCW'N(F5-[B(_F/]%'Q^9S^/?\ZIK:I^$B'_V56UH=Q[?H
M*I/;OV]A'(*O]/O_ #A]?;^<.!^'?]/W[52W8_=^M8:?$>3TTEU9]F*VG*/T
MX!S%8$E7$.1RH2.<2*.#**@D]5:E,"2KE)$PI$5.4QB$'L AQ551B9!?K/->
M=9TE#F4+%*YDCT"&,(E2(K;(M\ %+W_#[N.X=NW[/R#D'GCRI523>=9C)F*Z
M-A]6-3+9_O+%L)NU)MVQ)&SP[,R;"E1L@^2$'SQ6&<OGRG9T)TO(6ZB?[Z0P
M@^_XGS_GG'P^G;BE7 SQE^85VSD[N>0?2K7'-M@H"#:N72[ELVA*(QBH)>/:
M(J+@FFV>!&OC+HIBFFY,Y4]0W[Z8>/GS\.W?]\#[OCVI72R<^VSWD2JXUIL<
M$#0BW&<-58XZ";(T/!V"55GK+(RQ$5EFH*1S8'YRN"]P0C6B" G$J7'W?I\S
MGOY_/'/?O2K=9SO1<AY<O%G9>(P2CQI"5CNH8PDK%6CFM9KH=A3*4?4B8EJX
M.!1[%47,8 [F'@_?Y?D?\_+OFE=%8\LWBU-Z_!R\\]&#@HAM$LH5JY7;L%$F
M22:!7#Y(JHA(/EB]O6=O3+' I$T4O20232*.?+\_H?A\\?YI5Q]@)Z27Q3JO
M57[QRN2 QS8YE!JX7.J5LC9<@39V  0QC%* ,F!01\2AV0$A0$"=@X]>7\>7
MW_3XJMDEEA6)QBC3X,9-O:W;^69S=G7<F5<-:0\;MRMZA67!ES+PL;(.3/7%
MC09D;A*E53;K**-P.D9^G?/K^V.,>=*[?(D_(,-7L%4-P[=BTD[OE+(Z#%19
M4S9%JJI$55@HB@)A2(559A)J$$I0#R%00]Q-W>CCUS\/G\,4J\O2HF99]U*=
M"HQY)R#N/B]DZ&:.8N'CA=HP%U("+D6;=0YDFWKBDF*WI%+ZG@7R[^/M/^,^
MOC2O6[XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI71V"
ML5NV,1B[37H.RQ@J$6&.L$2PF6(K)CW35%I(MW+?U"#[D/Z?D4?<HAQ2K%9R
MT_U@V71IS;/>#<>95;8]75=4=M;H%"0;U5TLHR5,Y@T %)*/<%4CF*B*Z!"*
MMSM4C('3$O?BE<EOJ1K"US+%[#H8$Q4GG.%B&<'%98"F0IKVPC8^%6K;%)O8
M3-32!%VE<<.(!L_]49!&$77B4W16"JC<RE7X8Q,5&*2"T;&1\>M+/3R<JJQ9
M-FBDG)*(HMSR$@HW23,]>G0;H(G=N147,B@BF*@D3(4JE=AQ2G%*<4K\,4IR
MF*<H&*8!*8I@ Q3%$.P@8![@("'L("'80^O%*_>*4XI3BE<!Q%1;M['R3N-8
M.I&)^:^RI!PS;KO8SYY(J#W[/=*IF79_.(D(BZ^643^82(5-7S(4 !2N?Q2G
M%*<4KK0AH@)<T^$5&A.FCPB338,6H2YHL' .PC320)?.#'@Z '(,Q6%L#@ 6
M]/U  W%*[+BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?@@ @("
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4N*5*AQ2G%*<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g332508g71l23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g71l23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Y 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'B2^=Q8X0DE-!"4      !                      .$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $( <@!O '0 : !E '(
M( !- $8 0P M $P ,@ W #4 , !$ %< ( !S &4 <@!I &4 <P      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M    !(P   ?9          $                          0
M   'V0  !(P                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P  !(P     4F=H=&QO;F<   ?9    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   2,     %)G
M:'1L;VYG   'V0    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MZ?\ PB8_5SH)V[L"AWIL]-NZMKH;+G[?=_*>]$Q>F=/Z<YC,''H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  #_X4"!:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D
M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q
M,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @
M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O
M;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R
M5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,#$M,3)4,3$Z
M,C(Z,3$M,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R,BTP,2TQ,E0Q,3HR-#HU,2TP-SHP,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C(M,#$M,3)4
M,3$Z,C0Z-3$M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P
M<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O
M<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.D8X,$$T-T0X0T4W,T5#,3%"0D$T1$0P1#<Q0CDY-D%&/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.D8U,$$T-T0X0T4W,T5#,3%"0D$T1$0P1#<Q0CDY-D%&/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z1C4P030W1#A#13<S14,Q,4)"031$1#!$-S%".3DV048\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYC<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1C4P030W1#A#
M13<S14,Q,4)"031$1#!$-S%".3DV048\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#$M,3)4,3$Z,C(Z
M,3$M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@:6UA9V4O<&YG('1O(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D8V,$$T-T0X0T4W,T5#,3%"0D$T
M1$0P1#<Q0CDY-D%&/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 Q+3$R5#$Q.C(T.C0S+3 W.C P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1C<P030W1#A#13<S14,Q,4)"031$1#!$-S%".3DV048\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C(M,#$M,3)4,3$Z,C0Z-3$M,#<Z,# \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D8X,$$T-T0X0T4W,T5#,3%"0D$T
M1$0P1#<Q0CDY-D%&/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 Q+3$R5#$Q.C(T.C4Q+3 W.C P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D8W,$$T-T0X0T4W,T5#,3%"0D$T1$0P1#<Q0CDY-D%&/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.D8U,$$T-T0X0T4W,T5#,3%"0D$T1$0P1#<Q0CDY-D%&/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z1C4P030W1#A#13<S14,Q,4)"031$1#!$-S%".3DV048\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? ET# 1$  A$!
M Q$!_\0 'P !  (" @,! 0            <(!@D%"@$#! (+_\0 81   00"
M @$# @(#!Q %!0H/!0(#! 8!!P ("1$2%!,5%B$7,=<*&")W>)>V&2,D,S4W
M.$%15E=9F+2UN#95=9:W)3)VD=0F0F%Q@;'!Q-7P*#0Y4E188G-YDY6AT=+Q
M_\0 '0$!  $% 0$!              $" P0%!@<("?_$ %T1  (" 0,# @0"
M!@8%! T&#P$"  ,$!1$2!A,A(C$'%$'P,E$5(V%QD<$D0H&AL=$(,U+A\34V
M=+,6%R4T0U-58G-UE9:T5'*3LM/5&$1%5E=C9(22E**UTM3D_]H # ,!  (1
M Q$ /P#O\<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1
M'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$H9W-[V
MUSI[8=*5\CK\]L)W9EDS*O$D"3ACFM/Z4$V:E4N[;PLB9,:4LA7:=:=ET&#.
M%1OB29,,P0)(FM,!925HDG[;[I]9M&7@1K?9VSF -U-3*<.B X-7NUI<C$=A
MEGP5!'&9E1K9T=7B-U+19<&J03TP;+/NQ)61;,IN.ZM")PB>^W4IS9)'4K.X
M!\B["X>R9\N-%K%XE /BZ<8DO[6<BW:-67:205KM<5Z!<6H%ADN@3/T@)!#!
MJ0Q <>T3CHOD,Z<$**'V4,W6,+TJQES(:M& U7OA=5G77!(L]8C-9&#:M*+V
M&G@ QD81-WH- FTP5&E(7./,92YA")R>P^^O4?5Q:HA+?N@(@A>H- )UE-;"
MVV]1)L#:TUP=J^5*)4:OV,:(;V--9?CT;[S+@+M:XTK(-,Y$9]3:)QML\@'5
MJIQ-L9>V!,)&=/4>]; L%<A4R\-DSM?US(CC[=(H;TZMQ!E_;!F)PT.8E4V>
M<A!9I&'DQ)@QG,OI1.%UAWXTWMB!J"YA#M<K6LMI=<K]V,DF=C&3-#N54K.O
MIE CV%Z?43U4CBGJO7D75>+5=';C &CI$0<L)%LH<NHR/1.?&>0?IF5H]UV.
MWOZG#J9KJ32&+N7L;)ZJ*K<?91=@%KTT2&6<.(+MU>[%)#<:K6U$!RLF\)??
M'EGX\62ZRB35IC?NH>PH S9=/72%<1=;L<RH6-+< P%*UVS0(D$A("'Z_8QP
M@^%GJ&$QA6,R3&1<S1),<4A9D#YT62ZB3!Q$<1'$1Q$<1'$1Q$<1*5]Y^R.W
M^J.G#F[M=:6I6XZK10Q0[L2'9MPD=5F!4)B8%A!TUB/#U9L:-99!%XC-S-;G
M2ZX@:W!84TX05-4F(B0E:_(DK0.WZ+K3N-7=?:-:M6@MB[DGRJ5;;UNM ^12
M=BU6KMQXDT1K"KEI5?CU([.MUP-R:7"'5"./<>)E$BV7IV4??W][_P!DM'<^
MYO637]GK51M&V L0O:Q=..CY \;8C]=' MB$5"-?G+9;Z^'*5.C!;P42H?4"
MMT- 8%CEI6R(D2U(7[43$[+Y!NGE/.[2KUEW:$$3=)$((?;4R0"N"J]KXV3M
M=6I0\#9[6S77:P-/S;!=:PS&!NE_NSPXJT>1#4!:DDF43BZ7Y'>EVP+?6Z%5
MMVCY=PM-Q7KN$ (5+8%?G";^I,IT=2+DFPU,6W0+;8X\.3+I]=O+E>+7*$WB
M;5HA>*XTZM$X/:/D(T> H78R5K.SQ;;MC1FCMM[F'T*R5R]4V%=!NJADK):=
M6#=AK@8?=JM L>!H$^?H<^P0A4DE%;?DM.28WU$3ZNS7<LGH6%UC#@:-4+'?
M>TEJ73*<O9&T$:<U4$/1:"0OJQMDV*Y4;U)BFK R.=!46O0JN0(6@ZZF&TN*
MEEYW")RP+O5JU>^[%UCO(NUTG;]&TA3-TWQ'X6N)[78*+9(5U(&P4/94.K1J
MZ3_"T2CSY*SKBAPFP?,CC0*Y=A@G @E$B_<'DUT-3]63MG4"U"S42E[SZZ:P
MVT-OP&]ZT,Z\JN]-D5^I(NA6L72N5NTMPEUPF3L%1(Y$.!;,L:ML?+F-H>2E
M$FJO]SM1[(?U4]J*VU2V"M@[2O&IB[-@D7&CW.N6ZC:QM>QRM931#='P<:N<
M2%7X<TC6;KBAJCU2>[9(D\@M(L482//C^_\ R^_R_;*CK\KU.HG6P9V-W%5A
M\88ST^TGV@LM+UO.M-LV+&E[@LQ>KQP\.IJIZ!$6G,D!3C0^XD+QF0Y,9(Q"
MX01%B1"A-)EU('=+K3/JFP;FK9*!8;556I%TV&S8JM=:P?JM;V2S)>HA C5+
M#7!EG5FTKAS(0B'%$2)THK$DB$QON;+D1*):-*L*2E2?7T5C"L>N,ISZ9QZX
M]<*QA6,^F?SQG&,X_5G&,\1//$3K8VNE]A>X?F#\@O7H5WK[=]:J5H+KSU9N
M.G0VA]@!0]/"738U7(NFBUII%DK-A#VX:\2@1Y\T0IP0X1PY+CNDFT.LKC)/
MC8?GY_W?SDM>,GR_:UNW3S2,[OYV0TA0.RI_96VM%12)RP5ZC)WP;U#LIW7;
M%[J5<PJ'#^I9,R@+)-H-&C"%V21-R+ACH;[ V&D36Y4B'=#:.@_-#W@I_D3[
M5ZYVQT0[[=[:YIK6\VX56V=99.JNMH*H[,#ZZM>IK=42C;\0J--G:G&(P+ /
M0(CY!R61TA0Z6R31+S5[S3=C]P5:FPNK73:G;NV-1N@&AN\_;!%SWFYI>M4Q
MG=&N(^P!.IM5-YH.PB=NN)L4R5+A)YM02OP1F!K!"?(FRG4QT?>WUG)&_.1L
M38[FN173WIM%V^4V'XWX7DA<([+WT/U2)I=#&7FXTB^:].0XVNK=,+V@*6J2
M ]<( 9;T&QG#;*IT>N5X9+//(_M^_P _O_AE/5WS/;.WUN;IS5KOT[BZDU)W
M_P!![AV_U@N*]\@[==9IC0U3'6N^ ]D5:+31("G C$:<O\''D6TC+6-P))6$
M0&G%"X"IH^S(/H?F_.;QV'O3J[?:'I,"3*=-NRV[*E?^DO> )ONPT*?J:IRW
MC5#LUX$:E#5ZE;-9@29!:KWRK9NE?%'1D9488<2W)5$1]_?G]_\ =^<^[1OE
M0WX)U5TIZZ]<.L5L[-;8V=XO*MWA:OG9;MY$_$D0 +-YK!X-M;8:M,-D]CW"
M4M$1N%<A0$*]9K,:'1RM;JX-LO9AJ)]1GS^&CX3H3/U5UQUJ'E]U- E-YQR'
M9KLS"Z_:Y9/5R^.:Y-=>=;;2GZRL=7N6XYAZ&0( 46=5"$R*^NOS)33,VR,C
MX"3MY_C[>?;^4V^=].T5EZBZ'5MJK"-&DIR[>!JS\_L7V' ]:-4UJ$;BEG<V
M$Y?C-<MTPK(9EP(8T92JM7"MIL<PHU@<TU&ASI3"1-/56_= UFM?5:F[AI_4
M0+MO<UJ\CO\ 4U(&M-5]BQ4[7-KV:6UQ8+U2=E:[V\8UQ$B'M?VR5!KXK"3=
M?K;HD>:('Y!60V%;@%43'^RW[H/N76._;&U?>.O7783L+JMJ_35U[<42[=W*
M-KN\$KIM2MP[>5U?T\JIVDO3^QIJAU:=#.%R3"J_'F2I4>L,Q(Y26,DDTG;V
M_;][_?Y2RGG4WO<0?C/H>[=#V"]"2=I[!=-;#5U4JS3J':;+7K?M"IE(]647
MB$AOP6K2/EQQ1"*0G)%JQ*RT2RJ*EW/$@?Y_X>)5#N7Y1-R%^J_D\U)V)TSL
M_JMO7I44Z4G2DSIMW 2&M1ZB]G=ITMRFO4GL!)TC(DU,R,C-S0FQAZM:%8=D
M$.% 0R6/C%LDH:!][_LDX[W\WNR-;=H;IUXU5UDU%M&?3^VNH.E8N@7/M@[J
MOLK>]A;:J8"W1-OUW3\;1>P\8Z_ H1OX<R[2#:G)_P 24;2W '1IC45'W]_X
M?OE*]+>3_M+T\LOD2V'<](3]^=4*SYMMS:,N&U[3V(FQ[YJX)L6[T>C5>HZB
MU25JUF00J&MUR!I64+>M5/#.N6R &K<!E+-@-"D29]1>1B[=1^PGD!L&T0=N
MVUI&S>:"C=5S]P.[3*QAO5>F;2U12858N8ZN%@5EA2-?0[?\8:; C"E+AC7C
M4>>S)F2G\0W43=%TY[L)[@X[86"O:OFU[6O77LMLOKC1KLQ:4V61O67J&&-C
M7FZ5\$BN!&0(5JWRB%4K[+)RT-'7!$@A@E"RM4!A$T76GSI]L=W^/+NMV>Z]
M:-T'KJT:4IDXR%'H[/@+MO;0285RGU0M(["=>+?I@;*!W09$'XL(&M^PK4[0
MT_,$HLT>:*RN:B63WQY@.T75SJSUZVSM[0W3NH;$ONBB.W;74]M]_*Q1SUT;
M 1OE0 VF*J(TI+L-UMFP*\F!:'6\UX!3:$9L4"C2CIN:TJ=E$KN4[^]L=L>2
MGK1N?IMIHEMX;V!\&0WL/#ZU[&W],U=K*DR[/V" V>5=[#(CU^SACMX%PH\/
M4X.>(J#!8M/M@W,LO7ZBT:EPD3B:1Y80V[.Y/3GO6N?LG7_7$CX=^XW9':.D
M(ML(FA0RP:-VC/@7IO[*PZ&KEPL(*91[ 'JMEEA1L\I 2/=PP(Q,7"CI.W^.
MWOX^_P!O^<N+XZO.&UW6[&:[T%<=9Z)J$K>^C+#OS4<O17;2F=E;#3AM9?#O
M$M5]DZI6ZO7)NGMKHKIEBPI%R7I\7WQ"E?=0T7$D41DB1=V&[^.=%O(GY5M[
M[.*WR[:>Z]] ^G=N :@AVV=&KTJ^7[:UCH &,$'DGY=;JL^WVVR5P.<M;0EU
MZ&/?=(S&2#<'$1Q'T_C_ "_M^_'UF5: \Z9O;,3M333.LNHTC<77G2-![! R
MNK_('JZ\]5[%0[O<!]--#]@]FLU"#6M36G51$G%<NPJ>&L+Q1CV.5MB1DF"0
M51]_MF T?]T.H):)[BVX[HC6E^W-UBV;UIU+0Z_UP[#M;1TIV#M_;*5,'ZP8
MJFWBFNJK)KK(,B*.1KWDA4R61_V=Y _,N<_D?%1]_P /O[$H/V#[@]LJSL#S
MFVCL]&WCH.QZ=ZV>.N3$U?U0[DE RZC-L6T1H:1;M#[IG:R,0Z&B_12T>3;5
MKTZT=FC'K!4B:7')+-BPD_Y_Y??_  FT'LMYI-XZ2NW?:I:EZ2CMN43QG#.O
MUI[!;,MG96#325DU[NC5]9V#&=IE33JDS.F7Z T2L:)$*:34 =&5*49<--EC
MHRJ)2)Q7:KSQ632VU-BTG4'7'5VSH^M1W4)$.C[.[..:3W[O>P]SQP8C06.O
M.KQ^F=IN78!0&CXUK9!E1!+\:3@JP-'+0&<D2TG;[^G\?S_9+%>:'N5W!Z<=
M7-&[.ZT4BIXO-U[&:)UYL%9NW5YV+7HMWL@R ]0QS=AHE@A'8]Z)OR*9(NT>
M&&F4V$K\5PX,Q[+<!I(F#[C\KG; %L7<VH-'=%Z-L?9O3?K/KSL9W@!V;M&Q
M5P>N"=_J!2]PM(Z?LT'4!E6V+A^%P9@I#MY,'1ZW)3$;C.P&)DMECB)MGZL]
MA*CVRZX:1[+42"4%5+>.LZELD*(-I929"Q[0(C$7097XZW(JR(64Z^+FO1''
M8;\B(X]$==C.-.*1)[XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB:Q.P?CKSVJW%
MOF\;;V_L"MTF_:&"=<]?U+4]KE5KXFOY[5@-;,7?VI0B3&,2;;<3D!3<(>^F
M/@)40.9,C,S.6XB//^7[YJP/:F[A4#LS7\;-HUS["':LKH;&*5*N5'L0,U=V
M+O.D!5<1+WBWM*H!9FF@2M<7"1)NZ8&[9(<FW9JFE@PQ*K[5&DY1[?>WOXV_
MM_OGYZH:/[#$=GVW7UQU;?9LG8$7R#TN%.V!2-_T*M]11/8&V;!N4>R#B=@"
MKZ_W^/LTNU2 \Z+J,T2G,QBRRE8PD%%L:9:-_?\ 9-BFTO'SL,H#Z7SJ=+IU
MH/\ 6;KD8ZZ6RDDMP[RZ_5>U"K&#U.S,LE?ONCV9-HB.BC>JX^&ZV>K!,,="
MFI"9&1!,?"E81-=.Q=!;FU%V\='U/KU:K5K*E0>@ ;7V@*E6>Q?Z(=G3=!0H
MKL2Q"-RUB :UK!$:0LQ5XL$>[$$QQU^758Z+,T_7T5C*GW^^1_O_ +_O_/S+
MQ5/QV]E3&Z'=@[HV_7[3&CZW[>ZU?MKFSMU7<_;8G8UR)%J!:%JZUI'ZITS!
MU]71HX'+J6O69[!E45N;]^;0TF$I)GQ67QG;KV]JG5="V;?=94XM0_'5N7HX
M0)T1RTVT?,-VHCHS%#V)'B6 '5'9(5R!IUR;=:C,4TMMPVJOCBQ>&ATPM$R"
M_P#0/L;V#LMEVKNNR:)JNQ)T/I91@U4UBJZ&J'FA]8NT0CL;=#ALO8ZZ!+2[
M)?'V2 6J5A %8>DPVX\%ZQF_NA,DVC[^_O\ W7^TIHPWJ_<G;;9)$N(GB^PV
MTZ+?Z^.'-RT30D.JZ1UQJZ;%-9?9;CN3I9.E2R#"X2WVOMTB&EUQ,A+C3:)9
MOB(XB.(CB(XB.(CB(XB5I[BZ.,]E.LFXM%UXT,KAK955^P#S9EJ4^+'/_<Q\
M[Z\QJ$A<M;7LAK1[6$*7[EISZ9QC/$3 -L]7#NQM\&-MQCX"(,)=,=O=8FA<
MZ)+>(-'ME6RK6&-8%.MM+C_8XD:ON1B$5*_F/.N,9;:6VA64HFOX%XI;I52M
M<CD6]3[JJ%ET;U:U9M<+?=H]AM>P1!_KU1!.O2AVMU76\[-4V?6;0)$02<"J
MWZ%798D['D2'K#+@%'!T-$M?:NCEF/ZLW=K^-::I&F;8[ST#M;'FNP""HD6L
MT_<6FMC2:P52EC+TH_)#:QF!XTE.'8")$T?AQW$5EWV(GFT='K4=-;P+Q;=5
MHBMJ=^^L';X;E< A]896-$!NN LW5YZVV?Z[8CGZ%SZA<IG*Q[31T>B6ZGVS
M,)0?,I2OQ6]IKA;KM:MK[ZJ%Q/&.KG<OKNU="]RW7;C%R*]E9X9^I7<E3K3/
M>H.I U/%A8 .=K_5XI0Y3<-$V*7EM+B"QB)LI[-:6VOLC3]8U+3J-U>VW5I%
M?76=D4?LV'MDVJED,!X$($? 2:\,L6&9@0A'F2WAI&NJ?)-R(JAUCK4R%F3)
M1*V:[Z-=DM-#(->U_OD 4G$^@-*ZE'-R6M-G<V75=G:I<W,8H&UJD+=2<@6
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M)'W]_P )(NOO$AUWU3>05KUY8[_7@]8\<;GC3!4_$L%-'QM3NW$C=G[]*(R
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MCU?>/IDSJJJ;RD]K>N\/3U[8LK](V5.W%08-.M_X,&DS%PC5DW,/,0CI"J#
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MRD85AI"EY2G-NUQ55;82 *ZW<D@D (I8DA?40-MR%\D>!YE=:=RRM "2[J@
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MON:E0I"ECQ#-X )%5J\>*4_K+_T:^I.C>A>VEVH(:U?U;N4T^Q@2H 9E'F7
M[==_]3=3ZE$ED!%VV!L*TZ@VCN.A:^HM+M-JFD*CJVLPSQ^SVV56A!?-,I(^
M28KPPO9B+#J(3QEG,>)-6TZVFG*L;&^<0)SMPZ+;[025JK".:JQ;=L5K%UX[
M5;'W(9CLJLPJQE7(&(Y8K5F7U4UL &L8V)W6[=6X:PUT[V,!MXV4;LR@Q%J#
MRX=7=D1-90C$NWU^P7:/KVL'C<"B70UIRK;TO6K!^UF]#KW D%%JTS8,<',<
M:CC5.1_D3FVA+ZXIR0@7S*R42B[*K5RU5%FII5:X%7S0TDVG--"L?UK4+3<6
M5">1IN%9?M/M8J+V)2S* ]B8+V*AYB@:BU:X9O*_ZM;VNIXLX  MK+<0Z[XX
M%\V'2$TT$F8<WT)$GJ[J>\1#QWKQM,6 CZWW9<&]>:[V<1,O@,P(% -WYU%/
M:L$AY+;AG.<169,!"YR:*U:RY*%&UCY&/B<6]/#(S*!DX55A.W!LND\Z ?Q
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M:/[-8>BN26\/9:BG]?6;4W &-B9G%_38<7.#?+9 0^>V[*R>=F# 'B497,W
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MF_?)==O]/FEOYTZ-_P#;O-;^G=$_\LZ5_P"T<3_[:=G_ -JSXG?_ *..O/\
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MQEIC.'5ISRW:66JQD(5A6Y5F5G56"DJ612&< [$JI#,/ .Y$KK +H&!*EU#
M,JD@D @,VZJ2/ 9AQ!\GP)UR/'CO[9IGR";#<[+;_P!8[CM-_P!/UVF4,CH&
MR4QBJ+LX2WV F>%7W2HJDT;>M'EPZZ0 (I[6ZQVP(U$R-V(RC9,)=G7#G9&&
M%.)E(N[W6V8]Q<.E]+5U4/WG2ZA5H5N?'9GKIM:KA1O:R@&WF'MW8W,@(C9%
M2KLR6*;;!V*V1^5CA0+0YJLLI9]KBJ!2R[5>_?7>_=CJ%KJM:XKU/GV>M;2J
MMQ&V^UW8S5'-8S0).&18NX8:,JUE1;9+#464(G VY-2/K%E9:ZQ=*X25F<FW
M4 N;A9#>E,>ZJUV4L6:NO*QK[<<("H*Y-5+U,W-?++5:+,2[*JLFP!\3+I\L
M]]%M2(?2A:W'R*5L9]F*M2]J6+^K?;8V5\,BJBQ9OK8JSCM]%5V"UHLC<C5;
M*X+2 $(+\!E5SE90QE<62^J7]-/JCZKOM4OU]V<8SC\T#V\^3]3[;RP?$1Q$
M<1/1*BQIT63"F,-28DR.]%E1GD8<9D1I#:F7V'4*QE*VG6EJ;<0K&<*2K.,X
M],\AE5U96 96!5E(W#*1L01]002"/RE+HEB/78H='5D=& *LC JRL#X(8$@@
M^"#M.K+W:K8[QP>0[K1V\J#,6GZB@FANL]G,Q'IL8<QHV^?.&.P9 ]"U(+0J
M:5(6XNAAK*V@4*K:X<7!7@3#D,;WI@)D:#KW2! 7]$$=2]/HJC=,5UL74L4,
M=V-:/WN-:G\=V FP"*#P.-A4:!J55>)2E./I=E.)556KA!TQU#E!4KX\BA&B
M=4!!7:=ACZ?JYQP "FW:=9>:D--/L.(>8?;0\R\TI*VW6G$X6VXVM.<I6A:%
M84A2<Y2I.<9QG.,\T<] GLXB.(CB(XB.(CB)#M/_ +\.YO\ L_6/_"#_ !$F
M+B(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(X
MB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB:?/(OH?K/M;8CQK;';G=?6ZV
MB>H.](%Y"Z5367Y=GZJH.5B9MPK;XY/5&QR^ 0\D\$BQW1[XV?[WIR #+TC[
MNO")L)ZQZY@ZIT;KRDA]LW'=M=& (3M4V)>5T]PV7J,YAN75X[2Z)5J;65!1
M@)V#  Y@@(ROM+$3Y#LE[WOK1)ZXB8I>W+<U3;.Y00U:L5U0$(*JP*Y&)U?J
MA8YB.O(Z!8C8P)9"(H1)D^QJ=.A #$F,PI;C0Z4M.&E(FEKP,+LKFF.\[ES%
M@@EN7Y2>Z:[.&JY.8:K0H^JU@,EQP P0$@)Y0-#GY?CC"$T&(E3(;;,A\;"=
M<5&;1-Z'$1Q$<1'$1Q$<1'$1Q$<1*+]'?[=W'_ET;Y_W*D<1+T<1'$1Q$<1-
M&NNNVO<FU>0*R:"%M:[.U"G;7N4/9M>8J^GXDX!IG\0L1J)91%R!]D#6QSA6
M/5I31.WX-:8!+!6AP15)8KVF&RK3 (OJYV;FM%R:[W X]O)K&H"@($-B/6]M
M6)3R)#$W6,5K(=:9ROU;LM9'(_+/C@G<6T.,(7*W,(RVIWLJU57=1506!<A!
M=O*XD2)4_P!_9[^*6+_3&7Q$EKB(XB.(CB)JN\O^B!&Z>H=M<*LLHB53&99\
MFF.Z\2&4^?EM@U.&9CQWY'R!\UD.0D(PG+3P>,7BO)4U*<0K)TS.MTC7=%U2
MD*17F+@Y:OQXV86I%<=E<L"O;KS/DLA^1"!*6+>!-%K6+WCBDE5HRFNT347;
M8$:=KB##%@?QP.'JGZ+U#F705KB._($ S*_$GV")=B>BFGS=GF,2]@:R:,Z&
MV0MK,CZZK=IP@Y3DSR2):UR6B]BK<*NVHHT[]/+<T\\E#++>$-(S-;P1INJY
MN&AY55W%\=_'KQ;U6_%8[;CD:+*^8!(5^2[[J9E:/E6YFFXEV0AJR@C49E1!
M!KS<5WQ<Q!N 2JY--HK8@<Z^#CPPFR;FJFSCB(XB.(CB(XB0[3_[\.YO^S]8
M_P#"#_$28N(CB(XB.(CB(XB.(CB(XB.(CB(XB.(F.6FW5JDB%';69A!!>)<
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M@C&K37'21.,U,&CVS@Q<XA$?1EUB5!B)E9D2XSS>,N-/L-N-.(QE:%93^?,
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M'W]BLT2SSB(E4UB"<GEDRX45296&-OG:K1K-.EYR!QEW:=2-05@0*\Q.0OI
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MU';F9'K?<GQ4,HGX5A&8*W5.X0F9A><(S&RK#V%9PG*/7\N(F"5/;E.N!+8
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M1X\.Q^C+GU;L/82SZ-;%=->N6T>OVL86EB=XLAO9"MLVVJ'SEPV,;N5,H;8
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MCW&L=ZO4'[P.V2>\6R J<G-^3D9C%D*FG=,G*R;:MJQVS<RC=%K5+Y0(,47
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M5&UUKK+UXE-]H5K&5>?#@I8!F&XW]>G]RZYWU2(.Q]5'GK-2R<J?#'&W =@
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M%[;++'IV)=G)'E4154<554Y'?8EBUCLS-8Y.[>E5"UHB+(]BK@&W!9]<LXB
M> E6D,$A!2,W+@3F6WFY"&Y,9U*FW4)>9:=2E>,XPMM*OUXQRJNRREULJ=J[
M$.ZNI(93L1N"/(\$B74L>IQ96S(Z^5920P)!&X(\CP2)K_J/BGZ3TOL;>^S
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M;-RK 58!73""J6'AE[>(C<D]U#,RD_C5AXGY'TVQPXI2/)VSL LZ0B)CQ)I
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MT?\ XK^'C_\ /_$WW#_+.Y'S>/\ +]C]%X/=X</G.YJ?S'+_ ,;Q_2/RG/\
M9\KV_P#]7'8M[O<^<R>'+EV..)VMO]C?Y7O\?V][G_YT"*H>&F%$YFS+O8(2
ME2<XKI>!KAD.C#^%_22E\#K\)8,IA>[&8V5G5*7EM'S%2\97A:[+Q[:14FEX
M.._H_I--FIM<>.VY*Y&HWX_KV]>V. -SP">-E=%J6<VS,FU?5^JL7$%?G?;S
M5BUV^GZ?K/IZN7G?A;M2;U9"\2?6-RVO7@YB"S%D @=8UP:A393<J4\X2>EV
M^H'RK4A]AYB&MB-.9A(:AM.M1VY+LEYZK$R\.BIDR-+QLURY8779&=4ZJ54"
ML+C9--952&8,R%R7(+%0H%C+Q,R^U7Q]5R<%%0*U-./@6H[!F)L9LK%NL!8%
M4*JZJ H(4,6)X^QZ^V,8/NE0N^;I4Q+F8?TZP,J&JB(]CX[#+4G")Y^C%#:_
MGNMN2'OJDEY9<D+1%^@RAIMNNC-P:J17;H^+DV#EO?9DZC6YY$E=TIRZZAP!
M"C:L;@ MN22;=^%G6W&RK6<O&K/';'KQ=.>L<0 WKOQ+;CS(+'>SQN0O$ ;?
ML_0-B%;,\9$;VN=8".2(;S50'U'5D\7'9CML(D14$C=()6%;4];3KKSCI9<A
ME4EQ,5UA#;*6U.9A5XXJLTC%OM"L#DODZ@EC%BQ5C75EI0"@(  JXGB"P8D[
MS?A9UF0;:M8RL>DLI&*F-ISU@* &4678EEY#D$L3:2.1"E0!M^BU!V'/M:CH
M_>=R!@,SX4I-*AU+5TL0B)&^/\D9@J3I,VS9CD?I/9??49S.9^4Y\.3'^FQ]
M**\S"3&%+Z1BVW<'7YMLG4%M+-RXV=NO*3'Y)N.*]K@>(Y*V[;K,+.?)-R:Q
ME54\T;Y1<;3FJ"KQY5]RS$?(XOL>3=[F.1XLNR["%!V%+MJCT3>=Q%U[).)-
MQ1XU2U=(#I@L*8S(#X+3J3*M&8L[#3J7I.362+6)+F8LMC*&<MDS,)<;LMI&
M+9=VW3YMLG4%MYMRXV]M,M<?DFX(7M<#Q')3N=SX>:V3WEU?*KH[B/\ )KC:
M<U7!>/*KN/B-D<7V.[=[F.1XL-AM^':!L1RV_?F][7-BO_>6R'X'14=6+#X&
MHD(=6 P6=I"[/\)UE*HJIF362R6UY<1.2_A+F)&9A#&[)TC%:[M%/FSDZ@+>
MX5(%W;&6,?F#ZN':[9(V*;>(;"SCD]X:QEK3W0_R8QM.-7;# FGN'$.1P(W7
MEWNZ =P^^QC&O]BXMOW[.][GFO\ WO)+\#YJ.J\!_MF967\5[[MBD8L_P4L9
MQ"Q-^]?=\M8^KF?F3ZO9?.87RW9_1&+W^UV_F_F=0[O<X[=_M_-_+\^7KX=K
MM;^.''Q(^2SOF>]^F<OL]TV?*?*Z=VNWRW%'<^3^8X!?1S[W=V\\^7F>8M V
M(Q;<'G][7.;7\%WY^:.]4=6-!U#W7G7&@>2T:D,V?$.,TM##<O!K!1:&4K>F
MN.J<6N&S,)L;LKI&*EW;5/FQDZ@;>8 !N[;99Q^3$$E>UVP20$   E<+.7)[
MS:QEO3W2_P H<;3A5P))%/<7$&1P4$*&[W<( )<G<G\"]?;&A6AHW.WS=#()
M!*1,<ILNH:JBB7H3RGLLB5E!U'B6-$6+AQM#<AHN@@YAA&7Y3JENY7-F;A/C
MFI-'Q:KC6JC*7)U%K X WL%;Y;4<FV)*FHH-SLH  $5X6<F0+GUG+MI%C,<5
ML735J*$G:HV5X:W\5! #"T.>()8[G?\ 8:@;#'6ELV2WK<CX)$R9(739M2U;
M#%.QI"9&(T!1032(-C2Q RZTMAY!=,MY49O$M]]+CZ78MS,)\<U)I&+3<45?
MFDR=0:P,NW*P5V9;T<GV.X-10!CQ52%(FK"SJ\@76:QE75!W8XKXNG+45;EQ
M0V58B9&R;C8BX,>(Y,=SOYK=!V&'L;9@UO2XVT,A<U2ZF4J6KAPQY,AIY$9M
M1&OTH4?2D>XXV\PILJA;RXZ$2U/M+=0M?F85M!JJTC%QK2%VR:\G4++!Q(+$
M)=EV4GF 0=ZSMN2NQ V8^'FU7BVW5\K)J!??&LQM.KK/($*.Y1B57>@D$;6>
M=MFW!._YK6O]BACS90WO>YVX2E,W"ZT4J.JQH]Q4EAUJ,M4^OT@4:3D>ZXW)
M8P@BE+SC"$2\2&5NMKF_,PK:375I&+C6;IM?7DZA8XXL"PX7Y=E7K *GT;@$
ME>) (8^%G57"RW6,O)KV??'LQM.KK/)2%/.C$JN_5DAE_6>2H#\@2"K&O]BA
M2SD\YO>YW$>N)-CH"%:CJL9#:D26\HBSDRZ[2!!-3PY><.L,N3517U)PF8S(
M;SE&61FX5M82K2,7%<,A-U>3J-C%5.[)QOR[:P''@D)R _"0?,8^%G56E[M8
MRLI"K@4V8VG5H&8;*_*C$JL)0^5!?B?9PPGKK.O=CA9TF2<WW=;A%>&SH;(X
MK3]4#&(DV2UA$4NT_7:,)F.2AR\9>8C2)#H]]6<IF1)#?HC#(S<&U%6G1\7%
M86(QLKR=1L9D4[M41?EV(%<>&95#@?A93YD8^#G5.S7:SEY2FMT%=F+IM:J[
M#9;0:,.IRU9\JK,4)_&K#Q%;U[L</((/&M^76VLRPY ?#BDZ?J@<T+(RD)3$
M/1G %%%OR)HQ25.1X<YV2*D*6I,Z#)1A*4K\W!M5!5H^+C%;4=FKR=1<V(I/
M*EA=EV*$L'AF0+8NWH=?,48.=4SFW6<O)#5.BK9BZ;6*W8;+<IIPZV+UGRJN
M6K;?UHPGFN:]V.(<+J,[[NML1/!SQ@]HG3]4CD@RDK+.8ECAJ 486N7/&8;<
MQ'A%%30S_P A>9HZ3E#7TU^;@VBL5:/B8Q2Y+'->3J+FVM=^5#=[+L"I9N.3
MUA;5XC@Z[G=1A9U1M-NLY>2'I>M!9C:;7V;&VXWKV<.LL]>QXI87J;<\T;8;
M &OMC"F#K1;?5TL[I,/('BI)&H:I@.5LBZI.63P] 2C#69TV+C"DMPS39$4Y
MA><OP7583G"[-P;&I->CXN.*[5>Q4R=1<7H/>ES;EV%$;W+5%+!MX<>8IPLZ
ML7"W6<O(-E3)6UF-IJ&BP^UR"G#K#NOT6T/6?ZR&?L!K_8HJ'88Y;>]SL\DL
M)<@!YY&HZK@/58@OW>PV.9"4@;%(3&O7'MB'6"8Q7MQ]2$KU5ZKLW"L:EJ](
MQ<=:[ ]J)DZBXR$'O2YMR[&13]6I-=@^CB*<+.K2];-8R\AK:BE3V8VG(<9S
M[7(*<2M;''T6X65G;RAGY":^V,-&V*&3WS=+#-+P&XH<M.J&JH4JJRT.*6LF
M-C"*./'D)#J,X:5'/1"D)*4X4W&2YE2LK<W!LLH:O1\6A*G+6UIDZBZY"D "
MNQK<MW10?.]+5N=_+;;13A9U:7K9K.7>UJ!:K'QM-1L9P2396M6&B.Q&PXW+
M8@ \+N=X%:^V-!"V,;/WU=#1,NS!;#6&74-4Q9U4<C25/2GQL(;1H8@BLDSG
M$20@] *-,-)PY#;CR,Y=RLS<%[:+$T?%JKJ+FVA<G463(#+LHL>S+>U!6?4O
M9>LD^'+#8!5@YZ57UOK67=9:$%5[XNFK9C%6W9JUJPTJ<N/21?7:  "H4[D^
M!>O=CP@EA&SM]W4P4+(@)$6*53]4Q9U65%D*=EN#H0ZC1 Y!1-G.(LC!T>30
MPVG#D),9_.7<K,W!>ZFQ-'Q:JZR_=H7)U%DR.2[*+'?+:U.V?4O9>LD^'Y#Q
M%>#GI3?6^M9=UEH3M7OBZ:KXQ5MV-:5X:5/W!Z6[U=G$>4XGS/S!UYLB+7S@
MF5ORZDBY-X<X+M,BG:H8)5QN&ZMR;'@#X5&C@IS99M26)*S P@]&0C"X#D5W
M*EYE\W!:ZJQ='Q:ZJPXLQURM1-=Y8 (SN^6UR&L[E158@8G9PP\2$P<]:+JF
MUK+>VPUFO);%TT64!3NZHBX:TN+!Z6-M=A4>4*GS/,/7NR(]<,!Y._+K/,D)
MD"0.MCU/U0R3!1HN59EP(8Z+1F $Q@EC.,2'B@J;+8PG'PGX^<YSF&S<%KZK
M5T?%2I%=7QADZB:[F;\+L[99N4I]!78BG?U PF#GKCVU-K68]KNC5Y38NF"V
ME5_$B(N$M#BS^L;*G9?ZA6>8VO=CLU@B%>WW=99R62BS(=Q=I^J6RHJ$PC"9
M F,,8HS5=D19JL?4=DSQ$H@TK.4QI3*/1.#9N"<A+1H^*M*ULK8HR=1-=CD[
MBUK#EF]60> J6*A_K*3)7!SACO2=:S'N:Q77*.+IHMK0#8U+6N$*&5SY+/4S
MC^JP$_36O]BHJ<D$O>]S>L#QEL@Q=UU#5:2\,:B.VTL T);I"*P["=>0N4J9
M(#/%4N.J;;G)82VTD<S".2MPTC%%(J*'$&3J!J9RQ(N-ARSD!P"%XK:*]@"4
MWW)#!SAC-2=9RS>;0XS#BZ;W5K"@&D5C#&.48@L7:DV G8.%V$8U_L7%34"S
MOBYJL"C/W%-WS4-5X+H&_&2S]@P*Q2,5G,++V,R_F*#9+?55EOYWQ\):P^=P
MOF>]^A\7L]KA\I\SJ/;-G+?O=SYOO\MO3Q%O;V\\=_,?)9WRQI_3.7W^[S^<
M^6TWNBOB!V>W\G\OQY;OS[/<W.W+CL)X<U]L9548!(WS=&S[1M9)V[)J&JE%
MY Q41QA-><%+HZJRB"B0I$U,UD,V7RZVEI4]492V5!FX(R3=^B,4TFH(,0Y.
MH=I;.0/?%@RQD%ROH*&TU['<(&\P<'/.,*1K66+Q<;#F?*Z;W6KX%>P:SA_+
M! VS\Q2+=QL7*^)^7M>['<J\((UONZQSL8M)G2KDW3]4K*D1[S.6V0CXMZC.
M5QF)$<_LAN7#$1R;B\>Q^8ZUZM\#-P1D/:='Q6I:M47%.3J(K1P=S:+!EB\L
MP])5K6K \A0?,@X.><9*1K68MRV,[98Q=,-KH1LM)K.$<<*I\AEJ6PGW<CQ/
M,O7VQWZR*#1]]72$;@SILF?;V:?JETH:BR?7XPV6-DT9ZO16!_KZ,/C!,.8]
MZ8^7(?SZYR7-P1D66MH^*]3HBIC')U$5U,OXK%L7+%[,_P!198R#^JHDM@YS
M8]=2ZUF)<CNSY0Q=--MJM^&MJVPFH5:_ZIKJ5S_79I^9FO=D2*X&#QM^76 9
M'2R+Y*V,4_5#Q,_'EN87#A3ATNBO@(;(I&,M1G1(N!)D)S[I[TE>,*X7-P5O
MMM;1\5ZG5!7C')U$5TLH]3HZY8N8V>["RQU7^H%$A\'/:BJI=:S*[:V=K,E<
M73#9>K'THZ/A-0HK]E-52,W]<L9Y):]V/, @!<+?=U$E162'W>RQJ?JB20L_
MRWTNP\$($^C2@L#[6UA4:/\ 9!PW,AM>7)WR7L)<PKS<%;KK'T?%LKLX=NAL
MG453'X@AN#IEK:_</J;NO9Q(V3B/$68.>]--::UEU65\^[D+BZ:UF1R8%>XE
MF&]*=L>D=FNOD#N_(^9[2] V(0!UP:.WK<@100S,;,V.%4=6RY]K<D.H<C/D
MH)2DS@XY<!M*F&4 1XMIY"\KE(>=PE>(JS,)+K['TC%NKM*FJA\G4%3'"C9A
M6]>6EKASY)N>P@C92!N)-N%G/3177K.7394&%N0F-IK69)8@J;$MPWI3@/ %
M%=0.^[;F?@QK[8Q 378(W?-T SQ$20P8-PJAJJ9,M4AYY+C,XE%*T><,'O1&
M\98:: PA<5Q"\K?9==PE:9JS<%++W?1\6Y+64U5/DZ@JXZ@;%*VKRTL<,?)-
MSV,-M@0-]UV#G65T)7K.70]2LMMJ8NFN^2Q.X>Q;<*RM"H\ 4I6I!W8$^8.Z
M_P!C$X->C"M\7.MRA(O$(P1@5#54Z1:9V%)5DR28,T<C#'RLIQE&8H*.,'>B
MLYQ$PK&,X4YN#6][6:1BWK99SJK?)U!%QT_\56:LM'=?KRN:Q_'XHNP<ZQ*%
MKUG+QVJKX6V5XNFNV2_C];8+L.Q$;W]-*UU^?PS)A]8M40G6)LO9)\I!"@UC
M#@>0"ID>+<"BFUH38RDF#7HQ 9/;6I+N(->EB0RE(PE0_*%*3G'?(QVKO5<&
MFM[;A958MV4S8U>X)HK5[F2Q#[<[ULMV/A]_,R$Q\E;,=FS[K$JI-=U34XBK
ME6;;"^QDH5ZW'OPH:JHG^IMXF=\Q)F1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q
M$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'
M$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$
M<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$
M1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<
M1'$1Q$<1'$1Q$<1(MVENW4NDH]*E[:V!6=?1MC;!K>J:,]9B+8YNT;%N"Y2*
MS4!*G,9Q(,F50I?PX_\ !2I,=U:UH0C*N(DI<1'$1Q$<1/3(D,1&'Y4IYJ-%
MC,N2),B0XAEB.PRA3CSSSKF4MM---I4XXXM24(0E2E9PG&<\1,$B[5UW/.42
MO#;8*+$MFU4U>* H.XZ7%VNI5]-=<*'Q!T:U*!OCFFK97GXSV2*/N,<FS('8
MELH?6TC[^_X20>(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(
MXB.(CB(XB8K=;U2-;5LC<MBW&JT&H"$M++6JZV$15JV,0^\B.PHB<.3( R$E
MY]QMEI4F4UAQYQ#:,Y6I*<HF)6+?.C:A4JY?[9N;5%7HEQ<A-5&ZV+8E0"5*
MTND6_K#VZY8R1B,'..3V?Z["0,FRE2F_X;&'$_GQ$U[6#RL"<]PMS]-=2].>
MVG82X=?9FF&-M;!U,.T@YK6IPMYU$==J:9D$+KNJGV*4*0#F3'2+T*MOO(="
MDTQ&);6(3LQ$V9-[ H;P>'8F;M47:^1+MU\>=;L@98><>=(+$M!(9-,W,*47
M=*-N#6QK#ZYBR"%PTLYDI4WA$XFJ[>U->K+:*92-H:[N5PH[_P :ZU2JW6M6
M&RU"3]94?X]H!""<PI7W_KI4Q](M%B.?62IOV^_&4X1/-CV[JBG6VL4"W;/U
MY5KW=EX;IE*L=UK8.VVY>7LQ\(K%;)DXI@^O,C&6,)%0I><O8RUC'O\ X/$3
MX0&\=*VR\&=95;<&KK+LFN(D.V'7H#8%3,W@"W$<2S*<,U,<6DGA:(SJT-2%
MSH#"67%I0YE*E8QE$]H_=6FRUI"T85MK69.[605..UVG#[Y5IEI/!!<F7#)&
M M>C%7"Q04.EP)T6<0@Q'XD23"EL2'FW8[R4(F:S3X$<4#@R!L1 -6+,]-?$
M324.*4.J%1TRR> X]]YN63R-B+1*GXA,OYAQUI>D?3;5A643&IFT]8CH#I4A
ML:AP!;+]BBO$IEOK\6 U)J$61.MD=V8^11';?J\*'+F6)I3F' D6+(D$DQFF
M'5I1*!=\?)MK;J'H;3VW-9P*+V5L'8S>.O=!:'KH+==.IE%N5MOI>4,6?+;:
MQ#N(4!0ZIB!)5:+5&"G88B8Z/A$$PT352XR)<4+V"ULP[K2H;*O^IM<;LV'5
M:V<9TU+VW32MG47-#8\B<(J:%RQ).]CX!)<L:/L04$W$.MQ<3XL5A#^&&T2!
M]-][J)M'>/?'4%A"Q=7".B%TUC4[GLNX7$/$JMEB[)UE!V2BP+=G1A46HCP3
M,S(F7]U*36Y#C:9N)4=#GQFT3Y.M_?O7W9OM?V\ZRZ^$0R@OJG7NN-C:W!7[
MH$MU,VG [$T(K>AKU8P$CN1XD:MLBU#)$Q)DLR5D.*>8^(EG+:T??W_&6F?W
MCI2+L2/J&5N#5L;;,M&'8FKW]@5-G8DIM4?,M+D>E.%TV5Y&8J52<+;&*3F/
MC+V,_3QE7$3VS]U:;%6,'3BFVM9C;=9S9.LUJJS[Y5H=CL-D"K::,5\&#D%6
MR98V)<?8;)BH$61/@+>:1*CM*<1C*)4'R'>1C3OC\Z^;9W'8)%8V3>]5C->'
M'] B=D5:M[.. =@[5I&K&#L41-^Z&8@87+NK)>0377Y$)]@>]$0\TZ\AYM'W
M_"?GNKW-M/7J\]']-ZHI]?O>X>YW9.O:O%5ZR2R3$6LZ>KP.9>-^;6RT)<9E
MSEZWI,2,[&B?5;BNE38S,O*HR76UHEOQFZ]-&[^4U.&VWK(OM,(TX^:UH,OM
M5GW\0PRA+CSQ2FQ"KMB@---J2MQR6-:0A"DJ5G"<XSQ$Y0-L_6EBLCE-K^PZ
M,=N#0>;87:H&MH G9&@ XXY6"!QP%"(/E$!X%E9>KTTFJ+B%%.-."7WVYZ%1
M\(G#S]XZ4%["@ZC)[@U:.VL32VL;K&?L"IQ-A$$/,_(95!I<@NW9):78^</M
MJCC7,+9S]5.<H_A<1/03WUHP+=7];&-SZG$[%BH@.2:"3V+3X%UCME5M(&./
MU:48:.LH)+?81 6Y 2F8MYI,?+F7$8RB?I.^-'+NTW6B-RZI7L<;.@C".OT[
M$J"KM )%,XP,'S:I@QD[%G$<YQB#$?@-OR\YQ\=MSUXB>YO=^EG?O_TMO:O<
M_"E;:N5H^G?ZHO\ #=0?E38+%J/^TMG[/6WIHPC#:.$?C#')0^;'1*4[$?0V
MB>N-O72,S7+VX8FX]5RM1QD..2-IQMA5%_7,=MF2F&ZMZ[M%U5EI#4Q:(KBG
M":4HDJ2PK.'583E$XB=V5ZY"Z@K81+?VDQU!1-C#5WB=M6BQ*@DC-C)FPQZK
M+(/-A4S9<-:)<:+F;A]^,M+[3:VE87E$C#9?>_J=J/8G735]ZW34!EG[6_BI
MS1[T6<DM6K7!I]=7:"IB1;A?RZT!!2!C:T S9PH/%V$BE0H+*G$$+CI1)TD;
MBU'$V'%U'*VGKF-M>="R2A:QD7>LL[#F#L,+E9GQ:6X339)$+$9M<C,ID:MC
M#"%O?4^FG*L(DC<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$1Q$<1'$31;Y&M$
M=H.X&^#&N]0ZFI-DHNF>M-IA +9M^^7'5=?$=B-\3<8K&R=8SPNJMBQ+K=-(
MUO749YE6'P<8#,V,Y&63Q+?>3%1*&;OW]M[>VUZ,:W0-WEHZE M0]$;1NVYP
M3O:NI!NJ=Q:V3:[)V#K1^EZ/KTRGS,[6%"(--FF-S6.GX"U"<#N$-TA5),"1
M)1,LTC?;YLOM^6NEYL^XJV.QN_R!4[2=[5>^T)2E]E38R;LX%I[5->$"P\3J
MT&;U/3:-8B=877;I8B]E>K'M=$,VA=C4Q'\?K]_Y?VQ_Q]OY3.S>H]\ZVZV^
M/9)FS]BV*GL'3DZY]N3UYE=S-S6]GL@9U9JANG8O@/1^P0&XZ<+@+C[%B0@X
MAT?KX-;X@M-BKGWIX?.1,2!=\V_;3FRJ+K';VYMW676VG.O'0TWMSM)!?[:Z
MN1IUQS9%[N6VK-?]6Z=%F5"K-NK5P2M5JWM]C++3"]2%N1[.J0_ =G.*1+$@
MV]W;F[=DZ[%UKO\ H.OM@Q>[NK]T5(D=[BD($D'!K9V/I:P'=G7DP-TF+Q>2
M84=9=9Q]%,LJK@0T@#FVRVI3T1Y$XW5U9[,T_JAT^JG46L]@JG?:;XU^Z%5/
MUR\C]LBHX3MX"H/6(53!9>%MSVC6B<.Z0;O$U4EWUI6%1SR:0K[&DEGB)\%K
M$[F/4#;3749WOR%UT3T=UI%[ D[1D]C1FQFNR4KM!K/\4%-9KVXI=XB64=J/
M-_7N4E0&4ZY3'57LXR_]";AM]_W[??[)']OMY_Q_=_?_ (^9MTZA:^MVI-V=
MR=;YE;7FZ;%733Y_3KVS[=?=@-H59]2B7]C,5*Z;#*GC9,0JX07)Q$>R:F0!
M!Z<2;89A*DKCX?G]_0?P^S]9,OYQ$<1'$1Q$<1'$1Q$<1'$363 [3]SY/= I
MU:D==.N[-;"TD%N4AL!GL=?GS'Z&C^R[!0(L^+4U]>&(;VPFH]<F%WJF[9(X
M+ZKL>"BX*0IR6VC]T\=*O)KI;LSK6A2[M: E!V\>US=]CV.N2*_>*U14A-<'
M9 J_3*;?+B)BU2W1:$RL4Y>4U^T&Y%5=GX2:3"PEQ+*)+C7D5Z?9HMYV1.VN
M[7Z?KJ#035I(VVA['J$EBJ[3L:*GKJ\B0]GJ0DU9*#<CZECP-WKH\I6)SD>4
MI!/#<5]2$;_Y??\ "<)8O)ITRISD5FY[..TV0NN5&Y&HULU-M^NR*)3;T<*U
MNK6_:#1:BQ5ZMJY0Z'FC&SVP<5L8S)^/A^2TB2PM:)GH'O)USM%&MU^K=AO!
MX;1K>+HMEKHK3.Y)NR(%E/B(=BKL5.JV:&K8TJ%8JV0AV,$;C5AT(3 R$EHI
M%<)#KK:)C5"[D5_;?8335 U8\%M>H]M];=O;LA7?,4Z,L$<]K':VM]:/5EX.
M69'21#D*;;+#!LP@X(B'P]@!Y&2V83\:;&RC\OOZ&1#3/('9;5LKM<T_K*CP
M=.]2#6T:UL-B#LT\>[2,S-:A\%H5J5UR$ZRD+Q1-E(2X_KPK$O,V8;!/C; W
M$4W*D0(*))=9\B_7DWU\UCV1+1-R5:C;.JBKA%B3] [L+':R%@@15@L)>U#Z
MY02[@FJUZ&7BYDWMW_W$DVO?, GBD)*I&$C?[\>?OS_ R,$^3O3E5[-[UTOM
M6PBJS1J&-ZUEM>;!"5F^V4,1$[]K<HA'L>Q[:!#FJ=0:H\?="!:W9K/-K(6:
MZ1RVN?(6T\Y'29DA+NZ=;W)KC6P<7K<L*M/:#L-H"R$QIFXS95=B:7T'8-NP
M7B2B%8KS0ZV2B8N% L4 7%N-?AB)7U QPI.6K$5(W]_V?N_;_E]?']^V-4WR
MGZ.F6*BTF[C[?$+V/I^,[@F[_K_7.W+OI:#2'AKQ@F@/<%:[$FID",)AS"40
MP8K(-A]:8U=DM0[C*9KRD?E_P\_?[Y>.H;YU)?K:/HU,NHZR68IJBJ;PAP!3
M,^2RO5EYGS1M-MSI%,3[;'AV>6-)I"19$MHB0:&D),>&N-"DNMI,E[B)I5\Y
M^H*KM_K#J=FQ1=[**Z[[(4?:=#)Z:ZLO]SZV*O50JUY4%SOGKLPQ,<O.G#+<
MZ;7B:<0)*8-G+5AV0IN$N6EU'W]_X?NFE*GT;:<'=?CP[+^1+Q=6>Q]:E^/+
M<.HH'5?0/4XIMW7VB.T=C["V.R-6(CU@AQK+G5,_<NF\@WF6C0YEBNGK-^&Y
MLH1BJ3G R)>3K'T$VQ??+%W^WP]8N[?2#3" GCE-:CK&J2%7UEK7<PVD=>A4
M"R:LO2SFO[\&O@?54X$S0+"&H-E&M@'#%A$NEW%SA\F*B5QH'13M -\E$#HT
M5TEL-GQP:=\A.Q_*W4MQIKY5C64]XWK,38-8=?JO8%1VP,F92.P%GL,I^IN3
M5$,PX$HKF,\RWB6RD_?W_O\ S_MDG>#K5=PT3VYV/JG777'8+O5L-H^ZEQ?9
MSLUT=D=3^V5"OUPW(*L4CK/?-J2$1D=I(+['S+9+NT9HFB \"$,L%H@YB%!F
MI'W_  \3.QVN@FM_,+W?M';SHAM[M 8["['Z6E^C6[0O71S=6O-?5"@ 1XHP
MU%VD0C2:UUX<U5L!#=ZN<N>7K$TA'!O61AHK)6!BEDGZ#[/^_P#E^7U.O?J-
MJ'L]?O(WX^]UG.D=JZXV+5G97MK"[)5G5W0>-U^U%ID#<*-M0/1VR79>*Y*L
M_9B#L*%#'GBEW)RR%+@'[#&B-S8)*RB6#2/I_+[_ )_GXG-=2/')LO5_6SPY
M;-C=.[Q2>TM3\O%DM/8BY_HD."-PUGKR3NV_ASQ79I=P0U9@FH9-4A:^2WDV
M]%J'P)HN6RC"CKC\](FX;RJQ+]K;OAX@NX0[2^[-PZ@ZX77N/6]O(T)K*R;>
MN]7D;[TG5Z;KL@Y2*C&FGGPT\^$G0YY9J-\ 8K#"9;[;TR&U(1-/W7#HGO'9
M1GQX"^P_3+:,>@-^6SR1;LW+KO:NLY94'4-;[$I;QS79;:3#3!6INTX]98L$
M8.)2YQ&DW"?&S @33@^8A$I$]13QF6HO10^N2W1\L9HU'_=/]IL]%J!C13Q<
M!6/'K=38;-P+5X40KTF(,ZK6R%7*_FQNPVFM;&F HK)+$E,"-])'W]_O^]I&
M_:7J'<5"?*QUD,^/W<^S.]?9#NS7+ET&[+TS0) MKRD]>HAG5*-+-5?L] A9
MK>AJKHRFUBQACM<Q8ZXV'A2X]=<A/PFIN!B3_EY^]_W?E^Z2YW0ZA]J2)SR8
M68[UWW1M_4I'R1>+K<FV:?5*$?)SNU'6C3FE!HG>T/6@!$>-G:4"%;\AY!D0
M!5-;BRA,CY?QUBY"HZ!_#8'^?]_TW^G]DV/>'74+-9[^^5?=^M>H&TNHW5S?
M@_IV8T$ V%I0EHD9:,5>E[)#;&,5JB3(D)JM(GW-4VR2:RN&*+C(5F$$3( *
MZ;8BY??W]_XR)JR[;:C[/[K[W$)PGI%::!>-2>7/1&P@AW2_0B,Q%N/6JM;$
MJ+;7:>]=\,+DV>WF;<Q/D2+)KJKOY@5D0+?G6,3#%UB>0$(_+[^_O]PYS>OC
MDV8<Z_\ DKVV*Z=W@MVK+>=N1M70][AZD.3=QRM 1]X:U,P;SJXPV)<LN-5K
M'G+X<>-5EU%9EH66,3'GECODQ4GQ_<?X['\OVR$?('U,V';1_F*U%:?'KV&W
M]W:WCWAI&^.J?9.H=?3M_KHOJZ*+ZNE!A]=W=$C.10\>I4 )?* 2UL((23,X
MK:QH[%<FX"39@!'^_P"_'W]/83?-J2*7[@^8;L[M\5(;Q2/&SUN#=/=.DI;>
M989KM)OT7'V/N^UCOUX;,4*I1*7K2S1L?2<2F<MA6',Y5EM'T^_[-O[]YHWZ
MM]4=E2P_BBT+6NA^_-3^1?J_Y#U[M[Q]O+=HTQ5JV8T^'OFTCFU"1?M;-BM"
M=V#-NU\]38U8"0++8D&HX9\''C,P'X6221]_?O-Y_@QZ1A.OFNNP&Y]B]=W]
M8]G-F=K>VD4I>[W3)H3:!G31?=#IBF"!A(]%:,Q=8'&086V"!0M3%9,DO_=2
MTQ*G35SW433+WYU)V?WAW0VFBO\ 2*U5"]ZS\D/6[8%!LVE.A$8A)V-H6JV[
M7S:NSMV[X?4DV0J>F(=>A%-:4E:55<*+4JP"?M5=LQD C[_Q_P O\)#M DZ>
ML_=*RW'M;KZY#^JPSSG[IOE)W<)ZA4W;E1ON\B%Y,:UUCK>Z=TD[AE3EZ;<-
M_;"4JD1^NDW\.%AT*O9O;Z /S0;[,3[/'6]IVP=M>G>S.T&O[K7M=9\A?=29
MU*V>CJ-3[7KS=G8_<>W=I#:0(N?>>)MVRD]Q,5&16OO>MB<+05#R+V!7FGT6
MV:"I \TA'W_G,JA>+S;-'\'.DS%0ZCVL!V8*]V .S>[=6FZ/*7C>^R^M5![%
M;06.JM@T\5)U.V;:HP(;$U-?AFD8QT"&L@@1)-0%P7RI$V\B1YMK4Y34VH:W
M<M55?<=SF=A_+KU,V92>OM@\<CW6'7!"X:KT#NO%LDZ?Z*W_ 'R*,;LI-G=Q
M55[0&9MVH!,2SBA]E@V7#01MV$C[^]OY;S.Z&,U\+TGJRDZ3ZI&]EYE][^X+
M_D+V+;O%/6MP;EZL=@K340-NINN-<=.V;-L6M5&EW!HX(UO6+87N.QAE)K C
M$)XP,R\Z*9??WY^_\9^QO_#[_=.&U-T;LVJM)>$38O;+H#M#9-:T)V([_:_[
M)T&;U5D[<V,#UE?+AM IUS#V[5(4!9YTS6<2[FY5QI[<=HE0Z[.,?B.O3/\
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MC^Q.$H^_O^Z>JI=A?%;1=A8VG4=;;%!7ADS9+) +0^F_<3XH2R7+)#-NL=:
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M:J[LN/:LZHVB-%@-A#IYVBVYVEV63$!RK'2[HY"$/JFCPV)$9]:1]C]_\/\
M/]TX#Q-/FI/42=(L9BMV&P/]JN]SQP]3H,H94C19SNOOQ9 K61TTS8YD$#/E
M9=E"8DH^;D1X+K#3Q6>XA4IU)FROB(XB.(CB(XB.(CB(XB.(FN/Q3_X'L7^4
M=W:_YSM]<1-CG$1Q$<1'$1Q$<1(7-]@]25[==:Z]%+;#9VQ::#9]GPJTA#KN
M8%'J1 0+)'C\]"<P0$:5/,-1PB"K\9TXJ :4,1);"DEQE?ZUKU3U'&J2Z[WV
M1++4I0<CZ2Y>Q3P!+JA#L K*6IL85=CGX^9L>JG\W9*K+6.WN$"5N.9 4L.
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M>%*=GMX)F%QQ\?&94AMK-%)%U-5RG@F0E3XXM_5O?W[TQZ:Z4;U66VW.$2M
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M$_'7TS,T[8&OR>DATJH;3[0_OS[Z&5;MAMMV#LS]TKQG.T'9;-N;GP9:B55
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M]12*L2L>01,?/*K4_P#=70[]L>RK,=!S,?\ K/+R8V18C6UT765H"7L2IW1
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M 5(((!$[#!S,?4,+%S<5N6-EX]5])XE#V[4#*K(P#(R@\71E#(P*L 00.2G
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MSKBE+<6I6<YYYUUU33C]9=44455T4U:YJ5=5-2+7576N58%2NM %1%  55
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MXXPZE+K+BV<J:<2E:,I5C&<9_3.5E8?1G7E^'DY&+>MO286[&NLHM4-J&>K
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M$LZJ::Q8Q!+"NBM0-E.QV3@QL"U<F<J*JDK5!M[YC2N1!JW_ *0;O_C=<_\
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MEC! J@LQ)(554;[  >)L:ZTIK2JI0E=:*B(/944 *H_8  !,JYBRN:X_%/\
MX'L7^4=W:_YSM]<1-CG$1Q$<1'$2"^SAJ #Z\[KDSFJE,7)U7L$<-#7D@,&U
M6R&)U1,L"ZR:D&#M8'Y'GI>6QLQF380C;L5]Y*BH]/NELXF=YQ,E %+/1<JJ
M[!0Q[3LWDO7X5%>QB'4JB,W)0I(RL'_OS%)9T5<G'+/6I9T!NK7DH5+"6Y,
M@".6<JH5B0IUC>&&G4.5K'8NUHN56394ZVYIY^]EK14KK99 IFLTR<FOS;14
MNT_;)LG#'JA"X0]PY>A!J.%#@A2*]&""0[S^WM)3&K5&8UWV66.6#!KGIMO[
M=MI*!7N'S5Y9ULL9C:181Q0#7("UN[CU55*J*&+)4MH3G55NQ*4[T5\*^"(I
M5G0<[;2;Z&NI0VR]I_WS=EV=>;$W&UI*U>"T^8AU*9KJHABJ5KLI2H.JK^+7
M7;%<):8#UK-CK T0-0PP<)(?P#@H'*Q*3V?FMO4<H5JS,3RKKK[16FLKMM27
MK:UZVW5[7%C\C31VK]OZT8RGTKC,[JJCP]C\U-M@.X-HK?LH_O75R6OCW;C9
M(&D*Z&K!#=8L%!0/@-;>>RW&;<?=2G*M<:X4KT5(=><_-2LY],KSC\_RY$@?
M7]A_D#_.3SQ)GA7N]JO;Z>[TS[?=ZY3[O3\O=C'YYQZ_K]/S]/U<0=]CM[_3
M?VW_ &S6YT2VCV L=MWMIW:.OZS5*GH&YFJF)-0)1A\D9(6 _/M ,:.Q,5B*
MNL!J<1'K&R5-8F.BB%=2XI3R)BU\;TMEZL]VI:;FX]%6/I5UE*65\P[677V7
M55)NQ4T58[#@Q56-;4$DDM/*?ASK'4V7F]2:%K.EXF%A=,ZAD8-&179>]N3;
MDY-F9CU5=S9#AX^!;4:7XAVIMQ0?4+-]DG.RGJTU:^1B41U4:T+V;@QVI,/4
M>RJ:4.X6AQUV(%@6#,"[D6484EEE$30%P[ Y=EN*2F-)6/>=RIAIQM?4:>$S
M>FM9PO\ \9TW)Q=:H.R^K%L T[/KY'U!C=;I;H!X(1P?)$X[4N[I_6&@ZAO_
M $36,'-Z>R%Y-XSJ2=7TNSB-U*C'HUFMV/D-94 0"9M)QG"L84G.,XSC&<9Q
M^>,XSCUQG&?\>,X_/'.7G8SSQ$<1'$1Q$<1'$2+-3_W-N?\ &GLK^E9#B)*?
M$1Q$<1'$1Q$<1'$1Q$<1'$2.=P_;_P!$VS<E?I_;4T"WKG9=],-XC( 3U.J5
ME7JE.$HQE7NS^2?3W?EZ>O,S3F=-0PGKW[BY>.4VWWY"U-MMO/O^4YWJ[Y?_
M +%.I?F^/RHT'5CD<]N'9&!>;.1/@ *"23[>^QFCO4L>%VBVMU7U*$C9QK'3
M.K*A8K; PK+T)#X6+%GEHTE.?1MQ\W9WAXIU3F,JD,19ZE8SC*^>L:BS=-Z%
MK63:2=1U_4;ZJ[&\.* YXD'R1LH9QYV!9?J )\.]/X=?Q+Z\^%/16$A'2_0'
M2FD:MK%*[-1W<.C&NMJLX[*SYVIV8N*X;S951E;C8G>UC.M[#TBWE;++KN>P
M1TUM\&0?;U_*FN-1ZA<X4W$J*0A0LK4AL?E$Z9'R['0A4IA;$-]2/@,*SIL8
MT]:8F%3E(V-FZ8U=61F(FXRL<KQ')S[7,54<3X#$N 0QV]JR=+S/@WU3JNJ:
M)?7E].]58^58FA6/P&!JE=M=M62$!\UUBVZMK%"M;2U5+GE2&;7;MNJ.V+?'
MZ6Z]]HG;&G9<+W.JQE089"U@FI47#\^,SGZ:<38:F(N&<+^GB7B.TVIW&4J4
MKUW0VQL/ ?3;*3\ICUBO!R63DV-8P:M5:T^KA8 ^_P"1)(! V'R3UUIN?JO7
ME'5FDYF._4&5:N5U#H:WK0VM:71;6;;ZZ%/'NXQ[#*K)M8*JAR##=MJ%'O(3
M6/6>NQ?NL 7;-P.6BP@Q\N2S&(R@KC_LF%&8[J_J.MPP*!^7'DXRAG$ME6<X
M2G\O*K,,ZWUIG9#JUV%I5E"VLJLR&RH"NBIO'@/<K$_GP8#<D3Z\T;6<?I/X
M4Z72,BK%U;J[])YF%5>Z5Y#XU[/9=D+66)84:>*22/"]Q6_/;A>L^GY=D"6.
M\6<U/KVDS<U@\U5<R\C8-U^RL.H<LIV3E;3T:HK0G.6Q67&HIAJ*W.F85"RV
MT[?ZUUW%IS:,7!IJR-9QJCCOF\>X<,6.2*,=#NIRQOZKO4U18HNS@D:[X3=%
MY>9I^J:UJN9?IO16HY2ZA7HYL^7JUIL6K@^IY]Q9;*=(=00N$62K+6KOW@T,
M*VYMCM"C;-I-ZJZEW#4$](H213%3!(0\N-1!\12)A&$Y$E89A2G":OM0.*T$
M*-MJB2S)7+4%$=J1RWZ%NP:OTKU)B:B*S:H5;4M'S-S,&%=EC*2*PN[VL'5C
MR%=>[$E?;J.J^C-7HT_I?H?7-,NU3.QCDY.=I%^!=B=-Z5R:I;:M-7BV;J#A
M>=- *5U@K9=Z%V>9>MFZ*1;VLT*I5DW7(M=!NS)LNQY8^8</1Y_Q;4ZU(84Z
MDR[&*N+<)'''48)2).'XS:F,Y7C2:N,A\@9.2];MD@NBU BNFE=A34J'Q4@K
M([=8_"@_/>>H-\/[.CM!Q.TZ78XR10[UEK+GLR*CDC-S["%;YK4&[ES<@69^
MX&(("SK4=I),6'W+*7X$-C5EI-QJ]PKT$?C+8V!'>2,FPIJ8.%XAXDSF66R!
M!2480[)DO*4A7OSCG0T44U81LL=V:NFWN,UK!3LA+@@'CLH\#P1LH)GVAT6M
M^=T'B:3D.<\MAY.G7-=6+,FRP675FI;=N\178YJKV8%:T"D@C8[E:KO%OKW?
M*GN_;*4-U3MY\%O)GU?R_3GAKTIP(S/PZC#;8U(@D-0AF/[6T1X[S_K]1O#:
M_/Z*7_6Y"5V/W.5EQXANW6&(J.X&Y4*?(V&P\@$^)YMKO3R=9:%F]%:#;6-0
M^%K%:,975:M8&314FIM0A8<LGYW&N=K26=G85G=.+#;I$EQI\6--A2&I4.8P
MU)BR6'$NL2([Z$NLO,N(SE+C;K:DK0M.<X4E6,XSZ9YD^_M/F*RNRFQZK4:N
MVIVKLK<%71T)5D93Y#*P((/D$$36AV8[.3C6Z*UU:U?:H4 I89H8/="HB2E9
M^&\:GK8D!ASOU&T1WH QM<XJME2WVF7/HKRUG#B<Y^%4G-[+ALM59L57  <<
M7.XY?BVX@#8'8LI]]IZ9H'25N+T^>K]0P;+*1\U?IXO0_)E,!*G[]X /);;G
M[=*OLKFMB P\S8Q5JV,I]<"5<,RE@8"&Q!D-M*4(SEJ*REKZKF$)2E3SRDJ>
M?7Z8RX\XM:O52LYYA.[6,SL2S,=R223^S<GR=AXGG.9E79V5D9F0W*[)NLNL
M;Z<[&+$ ?11OLH]@H '@3G^4S&CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.
M(CB)UP?.EAP?==*&#UOU77:[)U;M0-KQNP[BZKZ8LXO?ZBU8DT*ZWJ9V5'RU
M[!Z_UR"HFFY46E?/??(3$.E:V=5*&9@(G8"U8N0[K'7+DLA62\IRB5!<DK2F
MV&:<3D*KX]3Q"IM1<8C-5J8YE4@$W'QAA MR*EG&&\)QQ$J7VYZ.#^VEVU#8
MC6SIM/K.O2PF7:JE"UOK6R3[J. WVG;)$Q06Q+"!D; U8238Z2,BD2U*/,MD
MP$HA!>&((_ ,0$2NFNO%IH_1&K]J0=GQKYW"K[(NAQ=>Z[FA*\'L-:UQHL;?
MHVI=955D"8IT.UV0)$V5<AZ;19S8UVP9)0D$,0LPL2'$3._#["#C>E,8?7J>
M6U\!@]F>\40+1#S4=DW3!<?N=OAJ!5R[,4H;C-$@,5#0R:W',E6428SB6B,Q
M&$R'$3:!Q$UH[S\?^QM_Q;O7;IWB[ )UW=3^3+NNH=9T^W7Q$6)8X]F A1\K
M%&095!K\Z"-3!=D$')CZ(#.9S\E3C^7?1]$Z\T[06PLC#Z)T ZAA4=D:B^3K
M!R+F?';&ONL7Y\TBS(K>SF%K"*;#P50%VT^5I=^6+4?5<Q:;'Y=E*\(*@#AT
M16.,;"J$#;DY) ]1/F6#T7H';6I[.0-7CMKM[? ::$=%L5+8-=UB-%CIZID.
M0P=AS:?4 1=,V-'CRH*8ZYRH#S$]U;\9QYB*XSH-<U[2M5QJJ<'I32-"NKN%
MC96GY&IV6V5\'5J'3,S+Z>#,ROR""Q60!6"LX.5BXN10[-;J&3EJ5V"75XRA
M3N/4#314V^P(V)(.^^V_F6KYR\SHXB:Y/+%_@+[4_P#2G27K_P#)O'76?_G_
M /\ '/0OA;_SVTO_ *+K6W_L34?Y;S4ZY_R9D?\ SL;_ .*HFQI/ZL?_ !8_
M^;GGLVT\\1'$37'XI_\  ]B_RCN[7_.=OKB)L<XB.(CB(XB5?[HZUHVUNK>[
MZML4K8*_5F-=VFRRK'5R5T''*U*J@6=8!]BA)U\: 6PMD),@-$7JX,)M9LC,
M=P'(:DQY[L=S$SAMBW6!BCTUVV5N S!7[-B M6I L79V!1@5.X)&X!&5AD_,
MTH$%@MMJK:LD+S5K4/ 6'_5LQ  L4AD/D$2D7ALUL_KK0^T%KJ.P*%%MNVFK
M",IU[#[J@)$0&M;4$'B36R>^; >O9\38I0B79Y4M>!HL:9,D@(^*^T+S/E[>
M\D8^-6RJKI9F%D!4O5SOY"EBJAG6H>FNVP\K!OZ$4!9KJQO8[@EE:G'57]6U
MO%7WNV)XHUA;<UH.*@*>3,QVV^\PY?D0:M_Z0;N_C==_\-M;\1]_NDO\1'$2
MOT_X]&[#A2"8_P! ;O"I2*Q.DMMJPSF^:T1-L-=2_E*?IYEFZ23N"%2'%)=6
MQ38,;'U4(;PQIWXXFLU/MLFJXYQW8;\?F\$/=1O].5V+9DCEX)&*B^=AMS5O
M'3^I\>T+QIZ@PGQ+' /'](Z2+,K%#$>GGD:?=G#D?45T]$\@+QL#S<3I95SN
MCK>'M7K-MFHSE+1&?JQ"9+4U'7*<4(C1W$V:(B,WG#K^2E4>.B5--Y]ZT3U)
M3A?KE"NCZ5>O]-8^'<%:G5:LC2+ Y55#:C2^-C6EF](^7S'QLD%O :D'<>XY
M3K5+%T#(U"@LN1HE^'KU10,S,FDY-69F4@)ZS\WI]>7B,%\E<AAL02IX_HKL
M\QM[J7I&W6>2N9=853<H&Q)3B$MN2-F:F,$]6;(?4VC&$(2_>*<>?;2C&6\M
M.-J;4MO*5JT%M9JMLJ8$&MW0@^_I8CSX'Y?E.GJL6VJNU2"MB)8I'L0ZA@1_
M89;/EN7(XB.(CB(XB.(D6:G_ +FW/^-/97]*R'$24^(CB(XB.(CB(XB.(CB(
MXB.(E*O(99Y=:ZC[<2.)9&$[&%:JL!]#?U77G#TMB$]":3[T>U4^*MZ$IW/N
M2RB0IU:%)3E.>JZ+P1G]2:94RAD2];[-R0 M7JW.WDD$ A=P6(XCR9XM_I"Z
MI9IGPBZP-.0V-?GX'Z,J=$[ECC.L2FZE%W&QOQS;2;"2*E<V$$*0:D^+JL#*
M!IS96Y3R/9]T--5$;,SC&7IX>EQDM/(B>[T]_P NQSB,=/L_@K7#PO/\%/NY
MTOQ NLU'7L72,<AOE:]F'D*EMQY.2=]@%0*23Y!.V_MOY1_HQXF%I?275?7N
M72:AJ>HKIF)<Q5K,C T*GM$5$;;]W5,C-K4>.1J!(!W S&R/V[>VQ<P8"6<D
M9Z5.^DIW*1E5K$9S&'B$Q?KZI8B)7_ 0G"5D""\(1E.%+<;V^/;@],:.>8YD
M^E0NW=R\I@?2!L#YV!)_\&@&P)(!R]3;6/B!U-V,<*+[AS/<9OE=)TNI]GR+
M3_LU@^E1LV3D-QW5>;UZ.^V^P?WL5M,VH0?02MB=P61 K[ZA>#Y;6V*96':B
M6B1UY9<77S;I(]':E-(S"==8RTE/JUG&.MT'67NISZ<K&YUWZ7BU6"ICVZL]
M;;VM3D"0MM+&MV!.Z@$#<-/D_P"(VB6]/=1TZEHN?<VK8?66<^$^4@&7E=,_
MH/25Q<BP.JN<#.;(U*L-6JUV.%XJ7I&\?:$MO8KR5]R]7#I0#Z>LM7!0(HH/
M .S0E=H6L1;K*"0UHPWA];)2PHPZ/>4]EV455EW",)CLIPQ@YEF'T1INHI1E
MK7EZA7;:V5;6M]^1G,A*FNH$;=NUR%W(2I07)9]@>IT+"ZI^-76?2HS<2V_
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MX6YW"OF5'8/Q-E=R\VK9G*O4P9"CJE1)#AE8@,<%1QR;UV&W;H9"&#-V^5Z
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MF+"Z!CN/O.>W###D9O"6?X&/,>E<K4>J>H<W7]8O;(.GXEMH9@%IQRP(K2I
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M2; -(U&2/>7,JX8K!<E5:PS7DYRY]8U)B-Q<9CM1W17W,=*R\K*7LIQ-1OI
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M:3=.HL8K,N5F&9A.XEA:Q%!D!1B0;(,^Z./:&$H,U<A:$QY3+F4KPB4(\/Z
MS?2N.W7:[8ZB 1V:[Q("U6X,$8UKK8I/<_?&( .RQB\TD58.BHN&H15DD0G3
MFIS#Z)<N0_A;JD39_P 1(0W5V7Z]]<(M;G;]W3K/3D2XDI0>J2-CW$)4F[&4
MA,-R9@\*HS,B?<9<6.ZT_(9B_56RTXA;F$I6G.42:F'V9++,B.ZAYB0TAYAY
MI6%MNLNIPMMQM:<YPI"T*2I*L9SC*<XSC/IGB)[>(CB(XB.(CB(XB:X_%/\
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M.<1'$1Q$<1-;/EC VZQ],[*.HE$LU\M:=G:-("&J<%VG9+1371>VZB0?V:#
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M&R'4D5+MW" .+>.?!?I'JG6>J:OB3UDN7J_5^I"S*Z/P=35F55O#UW=4:H@
M&#H^!7:U6F4$4G)M++C(QX6IV'=;ZXA4&$1DR)KMAN%DE_=+C<)S+39*P%%)
MPE/JEO'MABH#?I$#B6,XBCH:$--IRO+CCGA^?GOFM6JH*,7'7MXN*A)2FO\
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>XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB.(CB(XB?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g332508g77g82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g77g82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[42:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    1'Z^%U-#A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      $+    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    4 $, 80!N &\ ;@ @ %0 4P U #$ ,  P "  <P!E '
M( :0!E ',       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &
M8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
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M0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8IXU0
MIV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M   $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M       %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F
M=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&
M5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F
M5C=%1O<&QO;F<      #A"24T#[0      $ "4\:H  0 ! )3QJ@ !  $X0D
ME-!"8       X             /X   #A"24T#\@      "@  ________
M X0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M           0 X0DE-)Q        H  0         !.$))30/U      !( "
M]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M &       ! #4    ! "T    &       !.$))30/X      !P  #_______
M______________________ ^@     _____________________________P
M/H     /____________________________\#Z     #_______________
M______________ ^@  #A"24T$"       $     $   )    "0      X0D
ME-!!X       0     .$))300:      ,U    !@             ![0   >
M@          0                         !              'H   ![0
M                     !                         !     !
M  ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   ![0
M    !29VAT;&]N9P   >@    &<VQI8V5S5FQ,<P    %/8FIC     0
M  !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F
M<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96
MYE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P   >T     4F=H=&QO;F<
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M]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M     ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M &.$))300,     #HK     0   )X   "@   !W  !*8   #H/ !@  ?_8_^
MT #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0
ML*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,#
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M^OWU.<\,;U2DO)VAONF3IMC8F;_C ^IKW!K.J4N<>  \D_]!)3/J?UPZ=T_
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M>^KU63]8.L](IQ[/4QCZ;&^J&"NG=NO:ZQS7>H_P!2NIF*_9L]3^=_5_YMG
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MG\XJ%O7+;+68]F5./0T4,<'0W8S7;Z;!^D8ZQGZ/\ /_F%OT_6OZU5]"
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME>PUJ\#),P1SJG6$R_IG[6W8FSLFY(\K*/8^U<NT!2\<,*RW"N/K-88O@^#
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M"GRC$XE7<S<>F.AGGP(\P#I((TA[5>(9W*1K>R/7R[HA_7]?U_A]+PFP/.O
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M.RB[DSZ]IL?KE3Y%['D7%1\NI?D4FKF!R*C$1Y7R6><=6C%%]Y[STN3<7QG
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M^8E+? ?7:=['Y^/J /'0T\!(]T/J;\/FY$!\7( \Q--"O8I&HQ\:V%MBB2Q
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M&!%*1SVR /1RCU\N7:U:OQBFV/:6%/O-N]&LD\<SQ]S"JD<Y1?9D\+)*'$A
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M/C8R0K(4.JMZ]TF0884BR!E1542,(ZQ5*ER>W3L3HG7R #YU]#O_ %^O5WN
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M_?Q^?\E!U\_W6^^\)T]MOA_$KHD'0)UHG\@-@;/C\R /U('UZ13P#H?'Y >
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M<MFX='LBDEBEC,<"_BE_"269$^.[5&E6K&L\L;,KR"*) 2A=W8C\)(/A!Y)
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M?WR2([#K$2V]1^U&>W1);2L2H\^2!^_3C^H&17=7OF2U$5ROS?%6(C?RY?/
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M>GCRSPU(\E7,0R$Q;VX&A97AC8]I2))2\WN3,R* B=Y"C9E!CG7V9X?"R2H
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MR%:*3':V/( QR#>D><CQ'TT]>_3*]Q'DMQFE1WN_V;F+J/#@\A+"U."3&QS
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M=1;*\=U+LZV'FO*+,\<J9U3@F53XMEC9[>3?VEA"F0ZLT:3".6!2Q6&"1PY
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MMQ:HFZZQ2YE0HDW#\>M3L+96,$TN4Y\Z?)*CC$541_@U$:U$]'\_Z_K_ $Z
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M@CDFDCACEEU&TK!%;OT.A8)]31U>F$<-V\,-&[W6,\5U+A'=OG++'5$[UO\
M$J>VJ)^_\2>N9D1T=E=#&P9@4((T0Q4@;\D!@5WL^01O8/6R* ?(T2?@;^K$
M>/S^"/K\?GOHHL:Z\G5UON-.1[J?R JH^1U>90:ZLI_Z",9=CEABRTEO(LII
M[YN/.A1;E+6-!960GSD2;"9/5!H3V7ITF-XEELG#)+7%$RIB[68CQDF4H09J
MSBZK^S-DZN)EE^_3X^"<JDMH0" M_=I+WLO5GN5$EBK2V84M6%D,$+,5DE:-
M0Q1?';W!65^QRKLFB  P/0LI]39U>>R?^SCA?=R-=^=2X3^.\0LA4_\ <]%3
M^)B)_P";_G^W,$$?.Q^G^?U_3_(_MU=VZ'D?3?G]%+'\O_(U]>ICLOJ(NKE%
MU'1[$A<@,-E3Y-W;5UY4NTUBB?;X8117U%D&2VH6.6-*>Z9'E*4P7BD#"T3"
ML>][.@/&.0?V&>0'$6UPXF6,7_8?L;99"YV21 L@$9F]L1F1E'N$D]*E(PO;
MW1>\!W^U[@,WM_\ .8M]_8#H%BO;Y !^>HIC?4U=7<I@A=NS"%59Q(Y.^IL,
M;Y#:2,-$_$#^%R>Z]55$_FG;^7KGR""0=C7T.AK]"-;\?OTGV^2.T;VWYC8&
MM:V20/)_?X^G5W/7EZS'/?@[RNUGJ[CQLS'L5P_)..VO<_MH%C@F-Y 4^47T
MN\%9S!S+6&>0()F0X[6Q6.00O!/!O=SNY_/_ $_[=6J =['^O^N_^GY=4ZZW
M^I(ZN>3YYBM))W9A<JOE7]8VW:356%1PI3#F126KCG9 8X _@J=%*A&*WNBM
M>U_94V6*PV4SMQ<?B*<MZY(K.D,(!;M4?B=BQ554;&RS ;(&]D=*Q1>XX4=H
M\[+,P10HT6)+L /&P-D;^AV1MU[^^HFZN&J-OYO@T3>N%R*JFO9244T6I\))
M%L\>EE?,H[.#(?7N^5!G518\B'):XC3A<UZ%+^7.PIX)ZTLM6U"]>U6DDKV(
M9%*RQS1.RR)*K?PR(P*,-#7:-C>SU66,1R,A VO@@?Y;.]$D;^-@_GKY*_IE
M=:OJJ\S-\S\"S?D9A%!AU1@>37EI9OUO@-<0-K]CL'4*!<^M4DA[)XFROCB:
M[S2-XG5 />JJP4;=N*5ZD9F:)XE:-%9I )N\+)VA2!$C(!([,O;W+K9.NKZ]
M8S=S!2P3LVH/U<D#?Y*/&]GZ_78Z!W9/U'76&USGN<8'9;QPU+'"LGO\;F)_
M13@9?[>DE%BN52!@/"17/&CE<-ZL555&KV[>L13L ^?YC1_78/Q^WS^QZ1>,
M*SC_ )20/I]-C>S_ $?GQ\%UQ ZUO6%Y.8ER,MX^\\4C%U5K:1DU)/35>$BC
MKD4*8&P'7%7[0^/(^Y54"RKF (\1EDS8BQ?<.B-]6.Y4J I8D%CH$_@4$LW@
M'04#9/@#\^E8H.\'0W]-Z)\^#OQOP/KX^#\_/0*D^IIZO W^V[>.'HY'*QR.
MU+@[7(Y)S8SNZ+6KXJC5<G9>_9WY7]NWI3I#M ^?SUKR/^(#\_R\?S^>B4P#
MKZ]7K-./.YMOLW=CS9.L[3!G1C-U-@:5DRLNK&=47\7Q)6C>>?#/.Q^<WXQ2
M%!#',(^&^.X\J%:205V0 Q*CR-E@-_'S\;UH:\'S].E5B!0MKP-Z/G]#^^M?
M7P/!^NQT-#?J:^KPY"(F\\-_A6,J+_1+@WX0L0IW=_\ L=_-S43O^R(B^KOK
M_C_TZ1T-'X_X3^_X23]? /\ V_7KI(\)=E9=N7AWQ;VWG\X-GG&S- ZFSK+[
M&-$! CS\DRG"*6YN9@849K(\04FPF'*R,!C0A:]!C:UC41 >?Z_K_P ]6D:)
M'Y$C_ ]%!Z.J=+T='2]'1UQV>HE2GR'J5<RZ8!1@)8\J]S@:8KF^ F.V!>>Z
M54<]B*HAM>1!(OF9S4&-%>]J+O>-8.7DF<QV%AE2"3(6(X5DD*@*A<>ZP#.@
M9TB$DB1[[I601J-N.LA0.W;'M54+L?DA4&V('U(4$A?^(C6COJW_ $'Q-RS7
MO'K6T?$8E98S<R@Q<MR:0IJZM]VNL8H8^-1I[YIPQI4,T9\R1.B&]UK)TTP3
M*<3 +Z83[4O/+>%]1:'"<?)E*_'O2_"4(L=D</'8+6.3SRNV;S<JXX-)3R,=
MFK6H5)782I]TF$,@:21>I.?8I]9?LG<=M>L4GK]FL=C<MF*];A.#I\AP.0RE
M%^+"*8Y>3&2T,7D#1R=_(2JMJ99()A7J4'A<!'< ;O7@598YRNPC&(=6R-AF
M?9'5V54D$T0[5J7E5;F0!$1$<"HM66#CMD(C?BQU*C_C%1?4RO3!*'JWQ;A'
MJ?I#(F+6QRO'25AC!_;=&JT@ 4PE9HKN1CC=O9>PJ"Q+$2G:\0AE-SO 2XSE
MV4P\\EBGQK*9:G1:WOW[%-+5P<>>T54=T]VE'5:4A?Q2NP*KO0M7R'C+<CU9
ML2%KN-39%@Q,!F:_PJLIC!EV4H!+.+)*,B(V.K[J(@9\LH1-^9+DB2" ,9RA
M8R+W$,3SB#[3& Y7ZS8N;B$$G*+TSY*U+"N M2V\)D\-Q[ X-JUB1EJRUY(8
MZ[,L<,1@=YBT\Y[WUY?]K#T2F^R-Z<^AO%\;RB#U(/-L/SKU$MY> 4\74SM.
M&:;,9*"RLDOWVCDK$U;'XNI''!%2HJ;,\@:NJ6==:\T=;8%R7#K;.RSJU];?
MQ)%V0DQK;%E":)"(X@G.&0YY#JN8WVPE"V0@O<]QHVH[QEK!Q,VO4RD,5D&O
M5[4=C+4K4]R-/O$%2LR1(9]2RV6,K1PR;C5S![C([1@.&CCS=?*<?_M_%,9D
MGHV9JR-O1GA5XA&^CMBLZE"=ZT-ABHWULY-XU )C&U<+CU]%.P+(<:H*C%:K
MLL.T6)!%"6BBM+*B/+&GMKVL;&D^U(C'MU!+EQU"CQL\]?3/D^3X7]H./EOJ
M<R4<CA,[R[&\O:"W5M";+<E%N,/B<#4G.1RF/:RXD]BC5=H,>4@5B[(LCI>O
M7VL?2;U!^S+]GWTWX/3YKC>>>EM_&6\S)E:JS8"!AB[T&?8WH;OW>]]^RMA)
MJR258GCIM/7B: [+TRP^GO7IS ?JV9;N?CT8P\FR<9)57 ?78K-B0+2X=.EM
MF' &4#YBP"1*Y7D6;(;\=Z,_*>CK<=P^5Q&1]2,#5N07,G1RUOC7'K==U3)Y
M6T]JMC)I"PDF@Q>2LJ+T0:*M*M2XHLM6E651'B7U'C3@D'*3#JW9FM8X+#&[
MQM?1R@:NI0,Z,/[Z/N6-=*58[WW6>99QBR?,:7:>)Y775L.C_3%F>A/#E0I1
M(=GAH/<Q(%< !GS(<2,&(V)(<2)W^ ,L=R>\]BKYO>B'/L]2]=^*OD/[0L9G
MDW(+N#YT+</9%+%G991FK%F2)33-BOEHX+-/V)/:AG2-D4UU9#Z'_:;^T5]D
M+/\ V5_2WB?HOR.67D_!,QQJSQKB3T<S4R>,K9H2KS#^WK-^BM&]-,MNW-<E
MK9*=9<O+#<@EFB0[HUZ?6-)BG4NX64?RFRO@<J](L:Y&JB^";4IG!:1%:U4,
MT9E:9$56M*UR-7\>I<<TXW_NGR"[AQ;CN)#+*T<J;#+%[TJ1+." !+[<:LX3
M:[;QX'4.UTT<4BGQ+$DNOJ ^V ^A^/\ 'Y&NB2^H%_XWOF7_ /OGC/\ L]Q+
MURO]?U_7_3JH^!^P_P!.I2Z+&HM+/S]-S[8F384VGMH-512+"KC2J>LCV=S
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M1A\^K80-7C-;=7=-0BQT 25%1[ X/QBD0 !.@B$\:0_;\C(NZY?FL!FKM2;
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M&%.A'M\>RM9BK"YK6Y(UDDK1SK";/8ZQEYA(T2M\A'=(Y"J%CX1M=P7?2SH
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M\9M<+H;*%;PU.,ZR;"NL#74R1CKW"2+:2ZFPR%@[D13!8)GQ9$8DQ@GC<KZ
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M[WVOJ'%L:N1YUJ"SP/%':0%3SP'6VJ6X!77F4.:-9#Y$W(RVE);@( W@"58
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M"/,XSD<]/+V;"PR@W(8 QJ^[(D56H'D!2>,LIL.C1>XS1A3L)&%X*D$"*>Y
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MSN&;UKY%AY*4<V0N+R[A6+M2U<!R[+6+\:PY'(21;R,-AH9^VY7HV*M;)>W
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M,U79[2&-B6$G@OKR&.P 1KR- >1\_P#*.D54'M*Z7L'\!.]_/<>XC0/Z:^@
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M0VY$R9]W&28R;CZ2;+G'SR.D\ZSF1#-7AEUOO5JM^1/('.N0N\,7R?/9=1C
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M,=J3('?<G]UL;!< B100/##O57(;8[E!T.T$6]G:P[?X67N;9V"&_#^(^/H
M5'UT3^O6P'D_U$_&?(^(F:[2?C>4,OX^U)FL*'#I@#NLLD$Z,ZRA9 Z1\-(L
M6/.H?"XLV$1IXCT)7*TDAXD*DT<KZBT-L.XOL:U\,/G9._RUOY'@'I)8U5@_
M=M03\+Y+?':/KH#R"/\ IUJ+=4'D58\H.0 ]F0:,59K.125E;J^;$DI)BWU'
M4#(*QMW^#O&OG2;B3+691/''D4RH,,N*V48I2YM<R)76N9#V(Q;V] *'.]$A
M0"[ ,0KL6/:2%8*==*3,Q[1K\ _$I\>3]2?'G1\:.]:.OTZC733_ .+RX/\
M_-3T-_LTQO\ Z]_Y_OZO'P/V\?M].L%OXF_^X_I]?RZ-SU7JWI>CHZ7HZ.N<
M]S7U5T7K#F+R=D[/Q;J#R=DR=Z;--G4C#<LTA'Q(N5FRVT?>%QN/:TY;,%(^
MQ=(=6BL"$ELAJ)LA[BHY5?+%>@W(LMBL?EXLSA88,C4@NQ12M;]V..Q$LJI(
M%JE>Y58!NQF&_ACUCQWA).U=(97:-^QF5-K\@?\ ./ _/0UYZ'ZRQSH38[@\
MR@L</ZD#*7[C]U?*_5>B2S&27( 36,<&G<+VG*!C$0@555>[^+NK>W2W/3WE
M>"X5D.,V<SQK^QK-M<G/*(,H]V.:)H&41RI![83===H\;$@MVD[&MC]WF=XW
M>+L]GW%5F/C4G:&VJLS>>P$?!_0^ 6;BN#]!3+8K)-?B?4L"YS%4D>7F''\9
M1/:0[%:JMIG,=W6.Y6*URJ1"-1J(Y51.#PWH_F<U"DM?*XR%BW:T-A;22HW=
M(I+!('5E_!WAT8JRL"#L,!EPU)I" C1 Z) ?O!^N_P P#^'Z'SX \G768R*O
MZ$V%8W84<G!^I?+AV4D$PBQ<IT&0C3PE$@PL*^H&-J&0S'._@(OB!RH]OBOE
MT5[@O+.,\:RG&3D<5/CLK<K7[7M5[LM@3U/96-(93$JA'U&9/P,2(]AE7N#)
MRU)5D21WBW$KZ[>YA_>A"V_C?A1Y'@>2>O[6:OZ$=K"'-CXAU*6#*JHK"9EH
M)'-5A'!*GFRC43U&5CFN\".[M3R[]OQZUM3T,Y%<A2>'*8H)(Q'D6]KVN8VV
MRUF1BK]W<%=OX202/!52M.R]RF'1\>1(-_B8'R= Z(((!WYV!YWUY<M@="6D
M@4&*%U]U,9J#E%E ?6Y/H5Q$=8R0QE?,.ZG<Q5:_P03&#8JL:Y.ZN1J.R>0<
M&Y36P^"XC+-B[%6G=GN034:ETS>]D95AD:Y-(@C94[E 5(@_MIX+E0"DU.2.
M4R$Q&22.-2%#$%59^WP>T[/<0VB21K].LDW5?0F)$9-_274J8P@O-K'YAH%A
MNZM>[P\'4J)W7Q\6.1RM=Y-<CD;W<B2^A'(VKI8_M;$JCKL*WWSO[M.>S1K$
M;)4 'N[3L'8&STL*DY4-WPC?_"3)W?!/P1^G[>0?@[ZAV]V1T%K(%33R-9]3
M-D;'H;XD48,UX^,<]3#')(\R+3$<Z49&L16M5&=FHK6M5R^7"\ERN2R$>%X]
M>DJ1P\8I/1QZ5()E642I%,[2=QD>2U,_:K:5$!.P%!ZP1'[3R@=O?*_NN2&/
M<WMA0!^+>@HTH^/)^/'1C\$,3Z.TOEIPHR'6VJ.H[39+G/(C!HFH\FSG,-$S
M,"=G6+9I2/C"RD5'4):_;(5D6M+:PXKX]D6MEM+$[(<1%XQD>,A6)!8*YCV-
M@$$J77P0=,>W>_!W\'JKJX79T ?Q: (/C^'8[OYC8^#OSO9G3K:.Z.N#=2??
MM=R>UOSHR3=US^ALHS&VU!FFIJW7QGWV!8_-K!T<')H#[F/\>J2(*8V60G>:
MP[@N4+F(EOY_H='_  V/\=_Y=)@G0\_36M$_&_U_3\M]5UUF5=!? P8#M&LU
M%U*R$;>NMZA4S_1CD@VV(V\:0(,Q4K6->KR,BR?;&1CUC'&Y5;[C7)8?Q=RD
MGXT?CR"/V_(_E^YZ4_$H#[70/Y$G8\Z([O\ M\_/Y-.VVOT K^\N+L^E>I8"
M3=64ZXDQXV?Z)%%":UG%E$%&&^"][ ,))5H!N(]6":U%>YR*JU"Z V2=#7[C
MQ\_ \Z\_O^@U3W"23I?/G^$@:)^/X@#Y_P ?H?IU+!,\Z%NJ\1L(;-,]1XM+
MN[!JH1Y:Y]HPL@5/'RBLO'1XSO@B2/,%:T,:/,<01QDCJ5@NZO0C;2 Y!V?P
M,?R^=$?E^_\ A\>>E"9% WV_B _X3L G\^X:)UL@'QK\]=1/7[3Z!U<R:&NU
M3U.X;+6N'76+(VR=%!;/K)I@G6#+0<!OOQ2&C1S$ 7N-Q C<J*K&]KR ?D_!
MW]#HC?Z$>/\ IU:)'\Z*_ WH'R#]#^+X^O\ AU.%QE'0[T=CTBHGZ6ZC\C'M
M[ZYHSFCR\[T>01JU]O7WE=)$WX $!<T%W7,2/):XS!JIVN&K9#Q^K!IR&\_A
M)UH^-Z(/T!\[._\ XZN)D3R>W3 #X/YG7CN^?UZ@!-@_3^O:Q4TYU,NST8YJ
M?T@Z'5>Q#/$U._VW^:C7\+^5143]^Z>KP!YU^W[?7QX_7_QTF)"1X[=?(VI^
MI/\ ^=^?119[3]%CCM@&+2\NT'U)WX7R0P"'>U39^=:/+'$ZON?**<3VUX60
M\HH#,&=CV%*K*^W<"5'>&842V;5VV"=QGZ$>?S!^=C^M[Z5+2(-'LT=;':?!
M^1_Q?(_P_/J'-09ST%)&V-5IC>H.I(&_-L7"6T!K3/\ 1A:P-PN5U@*PMD*/
M7,.2 .=[))8PO:=\5"-$YI%14OU^9.A^WD:^3X_?Y^O\ND>XG1\:\_1M?.O^
M;Q^8^/KOJ[+KM8ETG2<Y\SR?F%BW,>QVE%UI@1[BSTQE&LZO"%HH]9+;4!A0
M,FAGN'VC8Z/;+1SU88SF(!$:J^G)PWIM>R_%9^7-E\70QE8W/>2U]Z:P!27N
MD*1PP2"0N/X$1BQ/C72<(+NR@$!%+L[ ]H4#9^#LD ^?'U\;\ZJAU5;]!F=B
MN84.-ZNZB7Q\HBOJK<MAF6FRSXT=I E&^&8,-L0)3"&[P5XR$49I+?%R-1S.
MJXEPCD.>XUEL+B,OA%Q]^[6LWVECOFRQI/W55]V*%X%@8ZF12.]SYW^#0S=&
M*,=\U:-9"5[Y6*@[T0.]CV#?;X&P2"?'UZ8V4T_0#PX7_9/7'4M*1_O+'#&S
M'296&((*D54*M>T345/;:KU57,]T;E9X*J^N=Y%Z793CD?\ Z[)UI23(4BJU
M[TH8HBEW!:!8T&C&A=BI'>G=I#W ,,RCS[>O.@I9@P(WW+Y ^/V/XA]#X>N.
M5W09RC#ATT+7/4;CUP[4EV+Y>9Z69,(<U=&8-B&' +&0)8DD4@;7^!/-2-4B
M^*#7KL5Z=\JSG$8./U<GAUQ+90YR(R07EL//-2C17:=8G@%=H)59$UW]Y)W]
M!>L#OK<U925(4.74N#IM#0()^"!OX!(^1MHYO)Z"-22.*^USU,)AJNMB1(_L
MY=HY$'7LEOB 3W%KA*00SO\ %AGHY2(1B-<YKFIZYGEO".0T_NYSV:BN''4J
MM*!EKVY?9IQ3M5@1=UT+11S.(_<(+,73RQ/5)4G7M[S'^%0J@*0>WN_+P2-G
M?<=[^=G73MKHG0LJ<1MWU>GNI-8XWDCJ2!96),RTF(E=(DRK!E4P0RQ N::<
M2',097B)'<P8U]T:G$I-C3X#R;"U+=2M<Q\]3E..6E8>2M=TD8O1&+L+Q1&*
MQ]XC4Q/YA9">XGN7:BUK+(Q C9 58MVN0""R*0?H-LPV-[.@>H;@9+]/]*G_
M &F7J_J85H?>3S<;/=&$&,RJ\0WGC"A*C556O8KT4A!JBHY$9_$O#5.+7K-I
M\4^16H!.GN0SB<(LC%EBFDKJK%1^%U,A4O'V%9 HUM$),25!3Y!.PX'U .B?
MKY \?OK?4^PL<Z$$?#[&M#KSJ)+47/Q;0LEV;:868UL= G&T/MP?;_C0+4<(
M@R.=W<C?%W96O'3],>85.)9+ 0YGCXQ&:FJY.R[QY#[UW5>R6)(I%A"A6$0#
MQLCEP3H@>1?_ &?*S+.3 66-@IV_A9"I;P!Y/X/(/TV=>.AKG9;]/S763H;=
M1]34Y 3UB>[^N-%B'[HG"555'5RN1$<[LK57OV;W\D[_ (8#+8B3$VIZ;R-,
M]>=Z[R)%,D1DC168(TJ@G0<'00?ATX_"5)QG5E.CHD'MV%<KX .@Q;]1]!^?
MQU=?]0/<]*^'RZU<SEQAG-.[V$3C9KDE#)T9DNI:K%!X4^;D'V6/9 S*MF63
M\A&3Y7W$X",@O:H$ WNTB^M7LC>CK8U\ _O\@Z^GGY_+7U13ZZ(W^Q_EYV/]
M-]4ZZ3R?H4/VAB7Z2UAU+ER1)LQ*AEOFW'TL%9B5DU&H=D:F:5.Z*Y D1S&"
M/[9#.:%CU]'8)2$+)&'('>[A$3R/+.WA5'RQ)\?Z+)WEQV]H).AL$ 'XV3W?
MZ^/SZCN=DO0/KI<F+*UEU/&R(A"M,U,ZX[/3S"]6/1%2E[.7NBJG;]T7NB]E
M1?5-'SY^OY@C6Q\$#Z@?&SO\_.^J$LI(\?KX/GX\G\?Y'>OJ-[WU/>IYW1!S
M76>\L<Q;674E=4U5%CVR,G!-S?CY]UD0,&G3D\:8C*EHAK&CWTZ=/8<1%,"*
MP8GC=^'V%0&1OJ-@? &B-'Z?L?GYW\=7*S$$#L .CLAO';] .[]?_P!$_EOH
M?5S'H%-<K/Z-.IXBHK6JGZYX[IV5YW [+VI%[IYHJ_G\=D_Q_"WZ_4_K_6O\
MQH_Y:L]Q_IVZ&A_"=>3V_P#-]-;&OY]3OK^\Z)-/JC;&P,>U9U)96'V$2IU;
MF+)N>\>OGQ@95+;>5TZ!';4!1[A3<8$%3J\_LO,-'Q7L(A1V, 64'Y4AOIKP
MI\GQ^OP/'U\'J]6DTS#MT1KRI^/S'XOTW]?GX^>H8;L[H1-B2X#<)ZIOPIX8
M<:9$_I$X^K'EQX373H,<X5J/ H8;V*6,)Z.8 W9PFIW54N*@_P CL?'@_G\?
M/5GNO^8T?IV_IW?\WR!_1^>I7M\DZ)$70N(&EZCZF ];2MC9;-K+,.<\>EG2
M<L;0X]$GQ+#_ +$^VT(*L$<E6B!8YRFLE4KT1K!V@#W"=_B*@'R/ !/GX^3X
M/Y=*%I @.EULM_"=GQH$?B^OD?3\ORZB0FP^@W(KHU*7 .J,6KA3)LJ'7/S[
MCRZ+%F2/C!F2(P74JL&24@H[3.:B>X@6>:+X-7U?VC>_.]:W]2/U_P#&CTF7
M)\>#K>AIOD?/_%_+9_QZZ:7">-@T/AWQ9C:Q!DL77(^/FH?T)&S,]?)RZ/B+
M\#HB8\#)Y%2,56>^%5.BCMBUPQPB3FG=&8T*L3U4? _Z_/\ /I!M]S;^=G>O
MC>_/1/>CJG2]'1TO1T=<V3DU@=1/YG<VLQNX(+5D?DQM+'JJ%+9[L04^5E=S
M8R["4'R1IG@A,$"$$S7!<64:0K".BM1KD?:(]8^4< ]/O2_C?#[UC"Y3D>&B
MOW,U6$9LP8K$U:D#4J3R1N(9[EV["\UE )H:]9XHV0V>\2W^Q3Z#\6]</5?-
MX[FH>UQ7B/&DY%D\+7OV<=:S=_*Y!L?B*TL]&:O>3&U1!=MW?N\L1DG2A \G
MM2R+(&&W-.&F4MAF%/2QOTC7RJR+?1@J(D>#8S7&;7R'5YO<(R!(,%@S/$UT
M<,H@F=@H9C'9/V:?7B3U(BL>FW/<F<AS&&&?*X.[:K0I_;6(IK"+%:T\4:0S
MWZ+R-,S-&L]FF6D=I7KRN_4_;2] ^*^@/->&S</M35.(>H,>4BQV!O6[>1L8
MO-X58)KE>M>MB6=\=/6M5YZD=JU8LQRQVHQ(8A$!]./>I\<C:^R&_L\;A&8&
MUJ,:K'2O-PW2#Q+*QN9;/CK&]^6,8JQ@))4<R,.080&^Y_&S&^T[ZK9_TE@X
M#Q/@M]./YG*KE<[EY:]>C9L_V=B9J=2C#+][K3(M:];MV&*)$K2+2,1<0AED
MTGV-O1/B7KUZJ\FPO-$R5SBO#^&+D;5/$9.[B"_(,MDXJ>*-G(8]H9V2"I6R
MD\=/WE1Y%C:9)8XF1VWM#2;(-63)0Q&6N*GGAHS-.@7RJF=-')G1JU[G*266
M)8 @2$'-$-B=PDC'<AUCO+W'H-Z\8CUKBL<7Y'2KT^>XK$F]:ABC9:&=Q,5F
MK6L9*D61_N;QVK->&_0$K,@L1S5^^!F$&M^T_P#9[L_9VYGCL<<P<UP_E\.5
MO<3OV4$>0JP8B2O]_P 1EF1%BEN4X;M.1;D*QI<KR-)[4<D4J+,&$:TC4F$0
MHN3XS##-OWS9KA6$)J6<6OBS35<2,UY&I+JG,DP)IU'&=%,]IAJ?R1!L8POV
MD?77EW'?5>KA>!<FNXK'</Q6*-BI2=3BKV5RL"Y:8V8F0ULO4_LRUC(8Q,)J
M\3?>%@$<AE8R*^PY]G#TI];O2KG?,.<8R3D,F4Y/8XKQ_*0Y"Y3L82GA\9C[
M%B]A35F2*O;L9').)9YH["SQTH87C:MWQR,FYXXV9B4UO%?$L,6GY%)@"L?;
M5;''Y59!)D*LF0T1YWM96QC%C3@><,Y8CQ'+'*Q6^GGX=]JGA7+N)<ER>3PU
MJARW@W&(>27L3*J18_,30214T?"97S706,Q+5JO3L,E^LERI)[$\;K(8Q^JG
MV=N4^EWK)Q3T<N9G#9"UZB9S&X[@V;%N!I#1SF?CP>/L9O&K[5RC8IM(+%N,
M0_=KGW>P,=/*8W6*8*C56,6T8^'U%#&)*O(DB#"F3!AFVZ6CXRK"D!L#-$^*
MYTP(4>.,H(S0D,- JQ[D=$VM]JGU'L^H6 Y1G\\]+C-3+4X<CQK&*U7!#!6;
M8@N13U![LEVQ#5L/+';L/)9$\,31/$JJBSO]6/L1^E?IW]F[U R5"+(9OU#X
MUQ^SRR#FV1NV8KINX2*.Y:H5,=4DBQU;$6ZD%JJ*#5IF?WUFGL26(XYHZ3MS
MX@_'[V98A%\:-93P"B@]IPU#[%8 )0L558[PCJB=W-:JM?\ V!'?P]DEWZP<
M:BP]^?,1@(;]V".O&B.%CBAQ\"%(Y ZKV(8PYD",W>1$S,@ Z\@9BCJEB/92
M=8Y(G'\+1R1AAVL-;[5(_/9\$Z^+"NE5M&XO><'3DU)(:,-+AW+W"<F@%]U2
MN).R/)\>9+:U%&J@:HZN,-XPD:$SQ!(\;3-<1S&%S^,%='R%*LN],RMVLR[$
MB#7A=^#Y!\=O5CM_=LI&CVMY!'GX.B0?Q#P?G_+71%_4D8Y;Y?UIMV8Q0@')
MM[O'=(0( 2G%'&Z0;4N,L3S,5S6,:UKE>JN=W7LJ-17.1%NJ5I[DZ5JL3SV)
MI"L448[GD;6^U1ORQ )U\_0#?CK&C1Y&B2,=S-L ;'D[;]CL#SK9V/C70VS>
M, ,XXV66#8R[%8&?:VRP$]66(RUV03YEU3)!LZ0+G,0DR,>;0#0BRV!;!LC!
M0;40TA6O+ZE<+BPM+CTV)Q$D,*XMX[MZIN6.Y)"@GEL7E1':-Y-;@82NCJW:
MV@JMUO[=1%B6.$+WHAVR^ V@6.P"22VB01\[ ) '5<6A-(;$WMM_%-1ZXQ*=
ME^97\Z+'900R" 1T>"K)5H21(,4(8D>+'"9\F00PT8U.S%4BL1S18UJ29*A_
M:2EJ'WVLMQ 7#/7,R"9 8P9 63N'X!W_ /+^+76BB7<BJ5!T%# G0^=G9'QY
MU^N_C?5EG+CA9M^IU?CF2LUUEV,4VLZB5CYERN77ACS65+IEW?'Q>![$"T=0
MQ_=23";*C&E^)21WG<J" %U/4REQ"K7CDQ3XBME&R$TM:EA*U[L?!310"NN6
M>66>K%EZLZS&4P/'#+#(O9&"I)MJ5,S'%<.8LXZ5S:,E):,<B,E0^1'9/E&=
M?!&CO0(\[V:T-.:VE[$S$,%C)CJ.D@1[J_G18#YC 0JR%(GB8=/)C(HIYH_P
MU.=R#&I>Z^;T:)[:\?Q;9S.8G#+*L#9._6IB5PS+&LTJJ[]JC;%4+,%\;( )
M V0K#&9) /)155F.OE44N0/H"=%1OQO0)'5O?(#CQ-V[J.IM<FS.U-D>!8!7
M95C4D=371\+IJFQ! G@Q4"Q(PCN&X!F#^4TRLE73"B$#R5QW*6N:\;Y1ZT-Z
M+87@PPBP9K+<=J\F2[9?+R9+&4K-JQD\KBY(6C?"S3U6CC F2Q!6F@NI8:.1
M:G3NW_2JS!]GC$?:%N\WXDD&9Y0V"H>G<"H.3FJN>?CK64MG(=UK(5IT3*7<
M4N.'W7#N++VA(!'U6%HKB]F^Y=I%US72@5OZ:CNN,IO?C+.A45%7_*L'7TEB
MFCC=7,8P/NJXJ$\9+/$;E1Z(AG<-?P67M8.U$)K]>PM94K$S+9:0*T#5R@+2
M+.DB-'H;_&%8*P(Z:1*[EU0@@Z0_PC9[B672^/)V!HC?_2Q/EEG>?[LP#%N/
M666."R:_4UA6LQ.^QK#VTI#6[*J/76DH97F+(2KN"Q@FGB4[1J9!2X8_;>YK
MY$8OT,PV3X72R7WFYB^1343;G>>19*WO,H<Q350%]J+\/X C++$&;W0\@*FE
MZR8KU7'&I,186,M<'E$DWH@J!KL&QX&B%WLEAKJM[76 Y%K;E)JW \LCAAY#
MC.Z<$KK(,>0.5&4@\SHI83QI0'O%(C2XY0R8Y6*J/ 9B_P *]T2,1(/< =Z[
MAOR/@D;U\CX^HW^G2;*R,4;P06W\_1@?\#O_ #_?J^#ZHO(;&?U2,IQD3G"@
M0-2:K+[3'*Y)DN75RW-4PT<ODUCD$(*^TO97D:KD1_='%P^9R-W"4>.0LT5.
MK9GG"*=BU;N2:B26/O<E!*D*HQ@92[/&S('#!>L3V +H>6V=;V2= 'R=>0HW
MVZUX)_%Y&WBSA$7 M1UN3Q'(R]S"46,V6V */*B55(,3#,^4\3)094Z9,:&0
M,;1.;%K B*Y6E<)K5_:JYC=PS\-]+L38OXZ"A@JW)^02UIY: RUC*%JN%JV8
M*_LF:+%P8ZY+V3DQB>W$5B5ZZL/0K_9Y^C7%_4GEWJ%SCFN"X[R?"<(@QO&,
M%A,[2KY:*+D&5B.2R&9DQEI9:']QC5AI4YK%>:026K;UWB,1+,'DGIXI65^3
M2:<4>DS*%8OI98(X1117<%K8-LH6C8H8\E_FR0P2- S^]F<-B>+U]/S]FCG=
M?U9]-+G&\Q=FRW+N!V9,7?GON9KTN/RD,LN$O&Q*&DL,M0V,9]XD=YNZHQF<
MM*KR,/\ :LX/Q/TU^T%S;B/$Y<;3PQI8?D-/CU!G"<=7+TP]C'&&10T$8LQS
M6ZL$3/!7HWZD<)1 (HYSU1KE^N]7XO#M<;B0)V21762BL(,67(?CP@@@54&0
MLAIFN 5PIU@0*L'\ALX!9#7K[7MQZ^T]ZFYFCSW!<3X=R')8?%\'P.+?LP>3
ML5('Y!:>P]BS[].2,734JPU*:O(\T4<ZWX4 [I>^37^SV]%?2SU=XGZH\UYI
MQ_"<UB&?C]/\3!EJJ6QA(<=BJV3RUS&,X]S'Y&Y8S4$"Y.FT-N-<:GW:>,;+
M0WLCC46994-K&C0YU+GL^;6TXFO DRG2B..TG19@G^<MD%J(8D&0AGK*C0)(
MPJ.:(Z.D7Z9^OO$O43@?)N1<OHW*68]-\)BSRZP:?=3RI8/8AM8BU'#'#)9R
M,\$:VL>IC?&SV*N^RM8@F>)'K5Z,7O2/UQE]&*>1BSMK/6<!/P6>6S''+8QW
M*<G)B<%0RLDAW4O5+JQT\A9E[()U*WXB(I6CB(K7FD,1LZ>ZQN7CL:]L&8GE
MEFRX?*M(E@ZVKJ:9/KWU(!SOM["BE1@OC5YXAT.GR&D<]Y$\(X0?:H]1^3^K
M7$8<5D:7'N&93F.!QDG%K%7#ST_["M7XX<@^4RMNJ+_WHU'GL?>:ERM'%:2!
M:\! *RR>^T%]DO@GH!]F#,\\Y!G^09/U5H2\<7^T\9;E7C=;)Y3,4J<U#^Q.
MPH<!'!/+#:R5PM;>1([,;4S(M9:Y<3X_/O=GO$2GE5H 5%=;!),"K8@ @:Q?
MNA(QFH<C")(BO A2><R80*-,\14?ZF)SFQPWTZCY!ZCYJM]^QV*BHPT:M2>&
M:3)9J*[]PCHPEC*B6/O#J;;3=[UC5L33 B%P81>G'#<CZK\UXYP;AT]"QF^4
MWYL9CYYK"K0KRT:-O)9*U9F3O(BQF.HW;L\40>Q*M;V88WF>.-CRA::Q:PQJ
M[QP./DO;=^*Y0>+*"V4ZVGVD*GL;*"R-$#*6.Q"%CBAK$ %[21GD:YISN:7U
M$'#_ &K^><@]4>--E\MA^-\!RO(\3A\C@+$- 8FEA<G8CQMF2YF+%:.\UE%L
M&R+KV:T,=A(_[J*J'B;T3]:?L1<"])OLY<JY@N2Y-R+U*XW5Q>5DSE:[8K8R
M:5LO0K9"C5XW%WU1B7J6;"_^H%K(J%$ZVE<>WU2]L[$4H\HF211RQ&'R9WN1
M2E5$CE>&(1_ML<_S\/>,\36N&Q[/;5K_ !1KFH_OJMQ^KB[]G(UE<19#*2L%
M%CW81WTHID> *2&B?N/8^OX0J["D >6\G9)&DZ,K+-VR!E)9"KQ@JRZV-%>W
MSH$@@>//6P']4^JISPTOV7LO]4+4O;_^?RC_ */Y_C_#OZ9SK#3Z_P O^O48
M]$?I?Y[R(V?CN^<@_3(\-QT:7^.8]91?U),NV1+!X375A2P9(W1:F&6)(&QD
MXT>1-=V4(G >A'XLM@ O"JEF*G9T2$.M@@;7>B &^0 3XWHC+B"Q*9)/(92%
M&]>3OS]0 ?(\@^-_\740]47I,;&XS[V>'#,@Q;+(VV<BF2\3PJ$CL>R&']XF
MF,1(4.U<*),IJ]6*Z2:-,>^J"1KI0FQO"2\CL+V]C!AV*"SE- L0.X>-G08'
MLW\CSI=D=6NGN_BB(/=X[25!VP7?G9V!H[^/V!/1_<8>F!*XZ\?;?8]R9,UR
M[<D*XUG;28E;"/"Q6DOJN5#LW0_>%8^ 3L.V.V<K>Y4*PC5&Y&-'C26BY_".
MU5;>R-EB /'R/!V#HC>P/RZR(D1?P,06.F)UY/R0!H^ ='P23L?F1UK>[*XZ
MY_K7;T+3N106U>8WMK51ZVNL&%ADC1[S(9T2C/8M*QK1,GQQ!M6*%2B2OE1G
M^?FKVMV =2G>"" -DJ=C^$$Z(^==8CQE7[=@EF77C7RS;W\^1\D?3Y ^.MB'
M:'1]M.,?"%@?UH#8%WN")6S,ME0<>>VIQS*:ZO)<X_75UF\T@@D@RW,!(F/!
M&+,"LX3"^T0HF8@L]S@A= DKW$G0![2-#7\8 ;>^Y=-\ C?60BH5:(#3@$;;
M6B/ !77GY.M$_GOK5VBX]:R+F'CR0YC;>=:UU4&"V'(+.4\\;8@1,@C8L@IW
MM.UXQ,8XA7.;X,7R:GK-WKS]-$[_ &_HG]O/QUA]AWVG8)8#X.]$=OQ]#Y^?
MT^/@=;CN;]'(F:=.+%<1I<MH:J7C]97["AY;:8ZX'LVD.G<*P6U,%J3X(IC9
M<QDH)&M\W2HQ2I(=% C=:+3!^\JW:201W;708G\((TI\@'1T=;^OC-;M=?9\
M@@:!W^A).O'S]3Y_EUJ 9C@MUK_+\AP[(7P5NL8R"=53E@21S81_#XYQ2H,T
M#WBD0Y(?:/'*Q7(0)V.7LJJU-BK!E##P"-^1K7[@Z^/KUB=A5M$CN#D$'?@$
MJ?!\?'S\_/\ CUV.^G^Y7\%>&KU_=W%W0[E_/?\ +M88PJ_G^?[_ +^KA\#_
M *?'\ND7_C;_ .YO]3U &Z.KCP]T%NK9&CMD3-O0KO39\##MW-Z;2VP,EU+J
M\6RJF+=XC.S[95'43L;Q:ML*Z4T[IUM)C1P("7[CT;%,YAU37^A/^&_^W1$1
M>;_&.RY,8IQ$H=I463[XR[6]KMF'B&,&9?-JL&K TTD=KDEC7//#H"7,*^K[
M#'X5B0,NXKGNGQ!.B>V8AU3IPZBY::%WOMWD%I#5.<Q,PV!Q?M\-Q_<\*L <
MM9B]]G5=<65-3,N49]NL[( J&UCW,6 <Q*:PBDK[! RVO$TZ.M$/E*V36<A^
M7<4\<3191R_W'D$(ZHUQ_B4E_9T+U8Y%\V"//).&]CT[.?!8YOX;^>+^U?DH
MK>6])L7&7]S!^F<%BP1,_M-)GKRF*-H/_;$L,.(602?QE+84Z7MWZA_[,#A<
MECEGJ]ZE"RRU:>*X[Z?QU%;:379"O)+T\@()W6@?'1PZ8 &U/M20"(5"V-$U
M1O.YLD\*\&OEJ0D)\A!.NKR[JX-4%G@J1R25(]ZC;(5WMM5Q1L\T1[&I^S[C
MLGEOM ^DM;$SM!)0S>2SF29'"M_8N,P>1:]')I7D]JT9(JA [$D>54=PNP7@
M_P!I_P @QE+T<X/QB5()<YRGU/X^,0IBJ2VJU?"1V<KE;L+2N+56-*T"UI;-
M1&#FRM2<B.SVL^-/VGS>#\B%-@U325^>_&K+*Q&@;*3'CVQ3B;1R")Y2S ;8
MV,*1&#W0=< SG/:V*@U[3[<U'!P_:'X1=QUVVV:L<1O-R#&T[!EJP^]$D%.S
MDZHD;[O[]:C2:.0K$G?%394DDM/(L(?]FH<W2^UISRGCAEGXO;X/-/EGHTII
ML5%E$DKG'P9>VC"O25_<N6*ONJTL]SL2/M5GW &R9:IIK+X(F&20F28=:J4"
MD;VB1$O81?E*UR,='9,LJ]1M>WNDD@WM<U6_G>?8R=HO71"6A]FSP/DU3ME2
M-I/O R?&[<7W5V4R1RM!7M>[V.JO C*ZMI2LP?\ :>X![/&O1[DP25XL5RGD
M^#9NZ,UHY<_QF6["&A;\;6)AQ^58I%!58TFC?1E4,2.VH%748?I"J#-@V%Y%
MUM5FO)$9YOE/2PBP+&(6<%S&!828:58V##-<^5+660TM>ZB56)]6N20\J]=O
M6+*8^"S#B(.2U\+3:3VVK2V<!3&&O-3<$/[<348(##V+#7]M8H>XB4BG^R;P
MG+,9Z#<MR.<BGK<>Y'ZBYC*\/K2Q0K%]SA1,7DK4$JDSNLU['B I,?:B6I&:
MX'N2[9,>?AD?.]'V4BJ,#[-K[;$C)Q17RV?J=XV2HU?72BH4C&AEE.0)^R#&
M!DGS(%H_;4CR^G>2;&_90^T'6LO%9GRO.<5BL69RNJ4V9QG%X*5E%58V[\?-
M'+;A7;&1ZP7W-E@L=OM1>GGJ/S7[?W'<#@^124\EE,AZ.YGB.:^[Q2OPO#X.
M[F,KE+M:$*!,]"7$Y&[&LWX+<TJUY7[68AV:)QXF4;6I718+75],:7DUA'4K
MW-BU57_:]D*X1GD<,Q8H!N(SL][FN*\;5<]L/.7WA0P'L260MO)35,35E(5#
M-<L';?A[T"]T,,\A5&) 4JBNW:I]+?MF<UI>GOV7?5K+96S::6UP^[QNK-5K
MJ]BQE,] <57<Q(\4<49DG>>RX=4@@61U5NU4:FOGQ+JI&X]@1ZP<4=638F3E
MKFA<X18SPF?]P1(C$8P032C-*C7*JO')$C6L:G9WLGRZ>S/Z<<%AS%A;5J7C
M^&GEN1LSV%G''ZC6)>S<8*3//$'#E0YG0$@$@_./PH3CAG&4M,9'_LJ JP<L
MZ(5)C0_3Q$T2G9^FMD ]9#I,(B=3?@DK?PK>4&HT5$3LB)^K("?NG9%555?V
M[]D7\K^Z(P,PC\,I ;0#QA0@7050P8Z[RS]QT%.D"_B+%@N\E [20?/:?'@?
M*Z_[_0[ &CO?5L76BB!L/J%\Y@F/1Q7RJ+4 8<R])($&'8NTI1K7F@$BF"9E
MRDQH4J7-5ZMFN"J#<Y&^MIQB[4QV=QMV^CR5:UR.25457/:NOE6TI3Z.&VH4
MGN\ D74&1;,!?RH[B=C^$Z?1!^=^//Z?D>@WU'0X9<;JB8YM"7:,CS+J75L'
M2,?,D2\EFSVPX$=Y)3"'^*289Q"&*)YR*P;"(Q2N(V>N7N7(N//D<1%"^J:V
M@;#"-%J+ 99#^':]WMKKM!"CN.NX* =W \ MB.:97M1EM)LC1([B1\Z.CX\G
M0T?@>8_Z>.U]4\5NHAG.RM@8S:6]#J;*,ME5D;%YY1SC+3W\^K;CU>QTK[<6
M/=%=&&:7/G$%'@Q#()3D.Q_J$?'^*Y+GG)+-'$AE62:S<L6YD58ZL$DQ_O9Q
MV *[L_:B(@<R':JH1BNF=XEEO2NWMQJKO[FM]H+:T$ &V.]* !Y _AT3UN"+
MRSX?=2KB1R-S>)A%O@N:ZAUY=.NL5OYX9 JR'9UN2/K;N <!CQI+)H*(:R9[
MPM.RS-,CO&X;GF*IZD<#R_!K%:.]9ALULE,9:UF =H>>!(5F1PRAU(]W\*!B
MC1]I.B %1BD258K,$@EBD$L89E['7^#O1E[B-=R@@[^%'GY'6K3T&-4Z"W?O
M;8NJ]V F6-7G%=C5;)JJZ9-K[%^(@2TFV,N):0GB+#+%N08\KBHG;Q7\M<A%
M8[D\;F,CQW*8W,XR5([E6>0Q$QI-IF0QLKQR*P*2)(R^"&T&T1H=*02/&)F0
MCN[0 &&P58%6!'GZ>"!\=PT>IPY#\*-^::S78&#6^);BCZ?Q"XR65C%A:PK8
MF+7U52G6QAI$(TSJ0$E*N;!,]P33D$ABS/X2(8 YD0>H/$DPYY=&_'O[?GQ]
M6/(3QI7CR@C"E/9GF6$WYX8Y4D$4#Z#%1&GXBK&^+C'&OO8RJ4ZHM,/?,R!2
MRR.-2MH#O1B412-;=5 )/:.@%Z?&7$EXGSIK:JC:>QR_3M5-A2@CG2IU36QM
MB1%GQH0X@G%:"4&<R/-,7VHHHJ$21XB=XK'CA-V'*>J^'R,BI#6L9K(6HHGE
M010))%;EAC0S=H_ 6 C15#!M&- V@%(7,DEAHMJS),8M@G3&.4(-'S\D#0'C
MSH>.O13X=G+\N9BP<=67?1XMI.D4=W'&P;X='63+2S=)#8>P$D4=;!DE]M[E
M&9C$8)SE(SO-V_+B;6+L-/9$-&RB4VL12,A+7I$IPA)(RS!Y);$<2]H#!W'D
M=<KD,OD.)]L^6F5ZKS1H.]&<_P!_*D$:(0._99PH.O'\0T!OH)L IY]-RGU-
M"L9Q+0W]+FOY 9A9R6$@L,F7T_P6R3(8[QG#%&(+XI7H2,T;0JUJ,:B>>?*,
M2F"Y#F</$[21XZ_8K1R/KO=$?\+.%\=Q!!;7UW^_6_;R_<I)1T[U).SVN@9-
M_4$*=$?\)&OIU=G]3R1L;JTYU+1S?=CZETZ1&L:A'^*51T17(KV*QCB.8Q5'
M_&J_MXJJ.]9_')(H/_5B0"U6L0/%'&BR2=GNQ*2_N21^W$\CHG?$?<[AVAD#
M#NOJ]O:22.X$ * "=$@$G9\ _0CSX^1ORYN)T>3M#A_D9+P@HYM=VZW.+6 X
MS/CM'/I4O[RE*]",.-AWE.3WR-DO?.?#"]S1HU1,[]N;"-B^6^E'J15]EI^7
MX<\9Y-5]]EE?[M+4.$LU*Y1_<>L]ZQ%8!DC18HI&4^XY#R3^PAZOS>EOVL$X
M)!7RN3Q?K7CJ.*NX^E,33Q^8H"W;J\ALUY2ZG[M5@EJ.\3(R5[$[$O[:QLS=
ME$D6V@,LIQ0?N1\<R_%\I$4CN_V:ID#LZ.TE [-<1HI5E84<:4UJH-$.TJIY
M=U6S[&>;IX7UFNT;%UJLW+.'9'&XVJQ[:V3RV*MT\LD,A+ "U%BH,G-78(6>
M*&=.X=J RT_VF_IX!R#T=]5:>.K0Q@<DX'R/+0PLMJU)>BHYCBU/(2HH66K
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M0=O_ +/OA<W%_LZ<?S5[%XZCDN?9++<S%NLL+Y'(87*VB>/29:S$O<\Z8J.
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MDZ.PKH$=D<!U23*F!"P;BM:%GY>0C$:GI3BV,CS'(L/C)E)@N9.K#8 95_\
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M6KK=\=[33G4-X.;<R%ZV#,WSVKJ[:0B_W(5E1[,B2@0A(O<B!8*Q)(9Y(J.
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M-<R<UE,YE9\75S5=O]W.)1I6IS8/#4\Y),$K5<]3^^BCCVB,-3)8FU![T/\
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M77DQJ1+R00<:+)9"@Q#0F3?DB6Q&YHWMP98#+()%/80-#>SW$;/P/CZ@[V?
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M'SXWOYUKZ?!._KTI[BF-5[C^$L?X3K1U]0/IOQX^IV?C;C#]/?U!:<%-=XU
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M.SG".)7N,\GRV;YQ4NWY\AB[>/JX_A^-@DCABNY&O.DTN2VTT<]^O[M%H*I
M@:>RP@.')F\!67.16N08>IF,7#A)*/&[*9>7-\G_ +8R#5+2X#^S\;;QL7]@
M58GR>6DS%['H:[)'4]^9BJUK/RO9Y,B7'HN99O)LWVPJH4862WRO++)8OCB&
MQCIJ/7W?%G@BHG\+V]^WX1.,DQ-Q<Q)A40R74OOCPA_N^Z99S "Q<@1H2.XL
M[!43\3, ">LXG\1UX4'R6.@%WL,23X';Y/P #HGQH'#.T7NK"= Y%EN;&S1,
MFM;V +&;.#L6R.;&WUK)$FQH;VC#9&.PV0P7N)6E.V,01Z[Q:XO>0)N_X]QW
MCW*TY95P'-\+E^3<1HIDLGQ_%16K,"4I9)4[X<S(L./N%&@D5SCI;T43"-)Y
MD:1-[C.8+/<6EP5?D_'.0<?/*L?8RG&;.6Q<]"IFJ-618IY\?+8]N25(GEA#
M'VP2DT,J!HI8Y" :[#V#W5%SO,VJWP:J+E%YW1Z07KX*GSN_E[WX_*(ODB_N
MOKC.M-Y^/KH:^=G\)_3?@^1OZ[UY'1-V%)GS./U9G$;(-GLR4.2VI+B<3*+Q
MU&3&Y%'!E4\>.ORFM'>1RBGSSQ?<(4U;*"96,4/@YR&]*^5+Q@<I,57[M]S_
M +1-+WB,BF/\D637,>BK(5E"+(7$9&T[MJ$VN8]; QWWR+^TO:^\?==DS"+^
M'9&M'R0  3^+\)_%O4>:$V#GQM\Z7 7.\S( FWL"&\;\HNWB(/\ 6E$Q6.8Z
M<K7,<Q5:K7M<US57\?GTV^A^75^SL>3Y8CY^@(_Q_+SL=;(?U..]LLPKJ*9=
MAN&Y3>5$Z3JO6CIB0+6RB"AQI=-9*Y8H8T@(F3#*T:>^K7-:Q[E[H1%<UX\7
MSA,)Z?5\'C$KMFKMO(>Y/)"DLU:I*DFFA)4]LS2(%B+GM79;QV]9L,JI6[%1
M3*[-^(Z)"GZ@:V#L:V3KR?IOJGOB+1;0SBDRC( ;5OJR#7/$ZP9.R3))/NR#
MD9'K@A" AWI)EJ*84OFHF,C,][W5\F"=;1]1>+>CO#\;R;E<-^\W*<[9QM.A
MB*L%RR[4:R36+5AKTU>*M$(XVD8^\TLKSPB)-,YC<3TI],N:>KW,H.#\$QE'
M(9R3%9'-V&RF1CQ>-IXK&O3KV+-BU)%8E9GLWZ=:*&O7FE:6PK,(X1)+&U^5
M<'<./L@S#YEF1X5>8H_E0<FO?M4])311XIH9B2XDESR&5HC1G!0XR,8KP,\D
M<[><JSW&/5?AN,YIPFXMRG4F:+(8F2*"IE*%N<QUXJV1I13"2"225=Q&(SPV
M5TU620-W#5\^X'S'TYY'>XASOCMKC?(,?&D[TYGBGJ6JDV_8N8[(U7DIWZDJ
MD?WM:5PLFX95CL))$LU<?.-&Q+3!%RS--@9:"3F%/+J\=J3VU_-G%]Z)!DDN
M!QX]T"761JB=!=%2[;[PIGR)0P19  R2,9?F/,_37TJR_'^+<C@R_(^4S-1R
M'(H<-<KXZMQ>KD?N)K4,A-+%:-[*G_U$R8NI)5F:J_N3SUWFJ!^L]+_1'G'J
ME@.;\MP"8?&\5X!BK-W)\BY-<LXK%Y7)UT]Q^.8.ZM66M8RJI&??>66.K6EF
MK5II!-84)7%F-UL3'\EGT2Y_FAI )[HI>V4W:)%>RVE >$P_F.5SUC CR_-'
MHQ!E\D1[7M=ZZ/DG'8\;G9<3#,UF6>W&L<H?L2N+%RT$BGB:)G=S5^ZV>\O&
M$5V?MD#KIFQVS!'39298W4'QH2$,-[V2 A\[U\;_ $)[X%QASO(M;&R";MS*
MHN46D.3/Q>K2^O3).#6FFN8YTD5NT$-;E M%";*:]Y',1[EBB,-ZZGD?)O2[
M@W.L5Z?9B3-7\K)+CZF8SU)ZL&%XU<R4R-CDNP.IM9!7K6*=G(RUI66A7G1E
M629)JT+X\7^SYZG<M]+>6^L6%PE.3AG#UMS6I;=]J^4S-;$(TV=N8"BE>6*[
M7PT0<6VL6:S3S5[-:FDTT#+T,.K8^YI&SXU) SG,ILNIF54FP!!RV\<T\B4)
MQV5*-=/4<E_R_P"[.'XHBJQY'.:QB*KK\,X9;Q?,)Q<O004N/_<LEG+GNB"E
M$DE?[W+!/-,3 \$$RM#+OMVH:60H J%DF=:Z2V&W(D064HH9_>)_$L4:J&,K
M.S!(T1&:0L H/C=D2XELB+CTRXM-G9! LXM?(L/LJ6612"#4 ?DI!DSF6#6A
MG.8BB<T<4X12441BL:UY&Y(^U5Z<V_4+&^G^&P-[,5LCFJ?'(^5U_P"S5QC7
M[ME:,=FM6?\ ]1;H);D0-;#1]\?=8KQ6(NPO)I_L@^LE;T=RGK=F:/'L)@<;
MB'Y4>.9*Y:K\K;C==GL39!ZR4I*E:?[A&+L6-M6XK<L#I')'!:/W<57;/R_:
M\3,9$J;L#/21960RA03$RK(/;='4L&0, F/FH@AA#+8)!C<X/DCT&J*QZ>N4
M]6</D*&<M6;C2R029._7JR.Y,7M*M>PJ11&-%A6-9_;TCR1MV=JD&-AU&68]
MX252W;+IUWO^%PK %2/PD[/@; .P#K?6P!]4AE>5T_.?3<2GR?(JF._B-J<[
MP5EW90!$.Z?DWF9XHLD3'%?V3S*K?)?^4J^FHUOZ>.L51L'7R/CX^3O^OTV?
MSZIFXV8%L+;NM^0>2KDN=V,_"L";88>^-E>1^X[(H5U1'L C&*:0<IQ,>=9L
M411N[/(T[7!:(AV).X5E!( /D[.O'^7QK8_/1\$Z'65%&65F^5^/D?E]-[WY
M&OW\?/0<)GFQWV;8@LTSDAG&]EL5F27[SN,U[T47M-F*]2*Y4;[:,[]U1J-[
M_LKUC:_$1KP=C0V/T^FOG0\:^HW].K"[_1.SL:X20]RY!F&8T><CSJ01E!+R
M3)&9!8XC8U4,?R9$$E@U\:+4'@?,4WL)XMLB,,Y55JL1$JF7M!!V"/&OPZ_/
M]_I]?SZRC$5A)/@]O=\'8\$:/S\#3#R2-G^=>;=@[",;V19SFKR$<5H6"RF^
M>][W'$%C6-9-\G.54[(B(O[JO;NJ^EOIO?\ 7Y_EUC_)U]3O6B=_.AX U]/C
MSKZ_7HYN0NAMC:6T)H?;H-IYO9R=ALN8F:UC\DR".3&K<$F#(JF,&2<TA($J
M#*.!9/@@EF02^!7L(UHTHY0[,OU7\M?I^OZ_E]#TO)%VHI'Y@-Y(\G]OR /U
M._G7@] ]!SW8\R3$CASK.3&DFCA$,64WSR$>8TAK1,:DYWDYZHQB?PJO?M_T
MK+KN7N!9=CN 8*2-^0&(8*2/'<00/D@_'2"@EE&S\CX^NRVQK>M_3ZZUKXZF
MO=;,SUT?$DIMI;$LH]QAU-.M?N-U<5LFKRS[4I<CI6A9:R$EPJVP<UD*R[M2
M:%R.\&J-WK?9WC.5XXU-<I%7B-Z#[S7%>W7M:C\;60P._MR+WJ"K:WLD;&^L
MBQ!) (V8:#!@IV?E =^"!]='8!!.]$]1GB>6[/RG)Z/&XFQ<R')O;:HIX[SY
M1=H!I[0T&()YG)+<K1(:3Y%<UKG>*.5K57\>N?( &]#QO\OH.D%V=>=?!W^R
M@GZ?^?RZ[(7"["[;7/$/C#@%]8CM[O#-":GQBWM1&-(%8V5+A%+7S9@CR?[P
M8<B0 A6%-_:D:Y'O1'*J>A3M5/Y@'_$=)/KO?7@=S:'Z;/1,=T[]NZ=_\.Z=
M_P#']OW_ &_/JO5O7][IW[=_S^_;^?;_ !]'1TO1T=<M3GN5\KG/RY))&YCQ
M\BMNM&!&%>QCOUM<,\VF>QG9SVHU7*QB,'_:C<YWBK_4\>!R?>.,\=:<-W1X
M>@B($=E!$$:!DE?M[20$.T7L4!D8G7=UTE?7L1'\7A/PC7X>XJ1L$^5/YZ&A
MIMD:ZF3"\;Q>LXTZSNZ:>PUM>Y5EY[^.=J).=/&R!"(H4\U4=97LKX\,*>*(
M<Y"'5?)7-;Y?_;"Y!FK_ -H"W@LAC!3QV X3A$PUJ*82Q6Z5RY=M>_-J-"EB
M:>6RGM=SB):C?B/N>/1+_927\M9Y-]HNO?K6A7AM<)6O9$DIQZ>W%G.VLB%!
M%][>.;WY'#F01=B,H01LT);(H5RVTP#&(PP_=;[)H]3%E/&WW(\26\0)3B'\
M?-L..X[)1F*Y&,09"]D[.7TY_P!CCE-KC</JKDK^1F7B_'>)GDES'/,?NXN4
M3-,;,$;L(HK,M6O+79E[6F+0J_=V)KI?]I]Q+!UQZ:<NQF&KQ\PS-S,<<L9&
MM"D=G+P?=J"XJC<,8#W)H+<JQT&D#R1)++"C!'"=31,A" -TBO=''619KJBM
M ,PVG!$KP";"\([?%Z1FQ4$,1F,]M'#5KE8]6HZ%>8SMODF<RV9R?N/D<[<N
M9R\[J2K6,I;FLV$9O(#+)(P[#H!-!!VJ0OHSZ18"AZ=<,X1Z0Q5+S6.(>G?&
MULY#^S+$>%O2K')CLCV9!O<K-E)LC5LWKN/>7[PL-V&PHDB=F2)H-#@E3R%U
MA:9O5,EXU>S$NLGK'JSV[$8B60034$X@6^[,L(GDX9BL'+DQU>]'#D.\Y_\
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MCU+$8R/#8G'1R67L7YX<?#8L1-=R&JJ6[ 97EBHU8>T)"HZ V3K7$&[NFQ[
M;9(FXQ"SQU?$,/XS[NS=#E"@3XS6-=&C@')><D81%4Z$C/50A*HV-AC."8C,
M>KF8XY&(ZV%Q,\ED5ZLC.KPUUJ$5C+-[K=S2V MH$_A*31Q]H"ZP"(T,MB50
MGLU5MF% 6'O&-9/:93Y #,0=_0:)/@]'&7$-XR-2Q<?_ */+:3KDUW:;!69
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MLE<NXUS#[.OI-:XR:D4&%X7Q_BN5QE64R'"\@XWBZF*S6*L!M2K-7O5Y'!E
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MGK+PW-N2VN"\[DM92W-<ALXNQ6OO(S6JW]IWDBO15[&^Z".98H]0Q%550X4
M$CI-\1C[%NODY*E<V\=%+'5L&)/<BCG9%=$?MVJMH-H$? /Z=89<]DS(E."H
MB28.73IU:*]O&>(RVBU[FAK%0@RM<CGN<U9C7#&PKF)Y.>CE\1?4^YD*N%I8
MJM)C^59#(8F#D&=1^V3++1ECCHCOCE1]2]__ *V*1$24=P)=&8=9;PUY(U22
M,./*]CHIC12#W]JD?\0[AK7U/YDF:,LY&[$L-J5DG)KLN5Q<<6-C:?JEC[T
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MC1WO8^OS\]4A+'1A$<B+V5J]_P *G957R_'X7LBJY?Y+_+\_GUF>?\_\M_\
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MY6-$,38;B/>1RL8,;45SG+V1%5R(G1M]G[BZ2,7RN52-4#,S-4 4$$LS,8@
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MEQ R!A+Y-:<0B(B/8UWI,@?/CQ\$CX_/?G]3_CU< 02-MHZ&N[Y!)T/CY\;
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MQLX9S>;@UCD%FM TMOD/$L_Q"M*JLRTVY!7CJV;C,K(8VAH"W[$@8%+30'3
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MB5N)X7D? \Y?LD1!L=)BN=<<MU<@994?VJ]:S'&V1* /+C#=K;*SLI;W?O\
MGOW[_P _W[_]/JP@J2I!4J2"I&B"/!!!\@@^"#\=/'#+%/%%/!)'+!-&DL,L
M3*\4L4BAXY(W0E7C="&1E)5E(()!'4:;PC!+AV$2I30%,3*[F%#>^*U#AAP(
M5++D@=.[(X@"R[*(8,8ONMB&"60!HUD&]V>/V';5ZQ<]3,9)?L'#4Z'&;:XR
M6=I*2Y'(6LRK7(:[,4K3M!C$BFFC5??'M>\)#!'V^+W^T>J<:J^L7!#C<-7I
M<ER/!<AD>39J)"CYBE'EXL?@*]I5;LEGQS5<H4L-%[HAL11M))'%$D=FW6_T
MO&WMUC.,^%S)# 08?$K6V4RV/5&I)CX[89+-=&\N_DB/3^-7,1RM0:N5OCW5
M-;D)/;>RP_\ \T@'_P"E(P_K_OUYO5U[I3^0VQ'Y]OQH_'U/[:'Y];@/#F+4
MX!HNLP8<@$.=C4M@4CP#!*WXOP(]A'>+R[L $L0S(!7.[=BM=X_QM]8-1P(B
M"WXN[>B1\$=WQ\#8V#KXWOQTG8V920/D#1_;8U^9 ^GU.O.M^=$GKABM-V]:
M#76HZ\4% 07:ZIJR+ ]LJC+D&5V5U9B.5B(XIW(K7=G_ ,34<BJC>ZKZNCTL
M5AQK1=SH;UX&CK?@_7^?^ 70$F($_"[WKR!L[\_R'U[?W'SOF<6&TD+2GZ60
MS8!:2',J+-2#0 XY7L+7/4;#.0I$%&&R4YZC]M[2-<UZM7\6U"OL,I_"?Q=Q
M)^-@C\_H!L_N/KTA8W[O=X^0RG6P1KX\?'[?MXZYV/U$]7BM!SLJ\:Q>RC6B
MT&FL7AW4N,1"L?;-L+U#N5_DY?[1!H1K'(US%>J(U&(SU?4 6-@#L!];'P=#
M1UX^-Z_+7UZ6<E@A;QM=@ ?0DZW]/C7Q_P!>K[OI;=?Q(7&&SSAW]XD3MZ2+
M"6T+T585378]*H'I*;^%1CBG)(]MG='IW>_\B8GJR3\5E=_\':?S&CL'?C?R
M?@?4^=ZZI(=1JH/\:-XW\G:_'U^@U^_CX(ZM5ZTO'N+M#B#N:EK(,28/(-:W
MTBE"\O9E5<T04RA]JUC"-4I(\:NG(%ID7V6$>UKD1HVMMG41S12+Y!8:'QY)
M'R//C7U/QO0.^K:S=W<K'Z$$_GX(^=^/)V-_('P/GH8_IEH5@G3^H#W%S6$K
M2Y1ET2M$A *Z/]CO[6#\4J^3G,.H2E=_$Q7]D ]&.9XIZ5 W/-LA00A&R/+:
M_7SL@[_3X_3JE@_AC&CM?!._H3X_PT/R'GSX\]57?4\<?R5F(4.\95XRWF6&
M:P83Q^3$/"?/II(%$KA>(R (Q1O&WP:\7LIV1&N>B)P=RV'&P0X+'6M;&ORW
MK>]_(_;X'2H8/ 0!V]@V-'YWL?GX/T)W]-^=[ZW&.GS_ *"'#'_FLZ$_V7XO
M_J]9_P#7]?/6&WR?W/\ KT7WHZITO1T=+T='7,RY9930X7U#.7=_?,NS#'OK
M;D4$6I;#+$FCDYG;LFP[N-)+%+)@G"C5%\27'D1Y3!2FO<\+$]2UYIP?,>I'
MHCC>'87_ ';6QE,+C1)-R6/)F*K[5'W*=W&6,63+4RE2^*T\,\U>Y6:))X)J
MLB3$==OP;/6>&<YXCS5),]"O&;,.5K3<5RE#$9^*_ 0(A#8RN*R^,L4;$#6:
MF2Q]NH%O5)Y*YL11O(6:B9#2/Q@>:-GB'C95(Q\XB%58<MA/;6KF"&,I1V;?
M(2I%8TJE849P/+'>AO7F=<]!?4JEZBP^ES8F&UR:Q4&1K35;!_L>YBQ&6ERU
M?(68JP^X12*]>5Y8HIH[*?=FA$SQHWN?A_MT^A61]*LKZI7,AE\3'A,G'@\C
MPNW7QTG.'R\P5JM?'X>ME):]ZO>A+VJE];T=+[M!9>U-5>K8BBC6OWLV22S)
M?_>R89"KC5^'TL<0'2'9$R2R8>;[D@BQH,1PIQW6S0J62=CZP:#<\2%#,^;[
M&%6;TMQ'&AE\/3Y]4SLV;O<G2G9L4WKWX8JUS#!.ZM;L5A#3I_=9Y!%[=FLT
M_P!W5)9(7\NY/MU<HQWVH.1>LO#>)R2<>Y1A<5QO.<%S.:D@:WQ["5C'B\E+
M8IP6*]?D$%W[S9IA:]BK6BNY"F9I!8DL/+4&ZQ0EJV'+R"N)!9@5AL&180;"
M&D0%=&KCR8%08\EXU'D%I8)#JA5"!?+CR)B+(:QXO9)'' _9&]4\M#;ER->'
MC[U^55^-Q5[D4]BQ<JB[%%D.1UQ7#0K@H*/WBU2MR2]]^:*.!:\4<OWA95^J
MG^U3X1@L3AF]+. YWF&8RAKU<@.0%L!1P&4MQ.IQKQPQW;>5GQE@"3)6*WL8
MLUD/W+(69)=P#&?;KXP 2J&@; R&RF&EY=8V$T]C"M4CR3LIHU; 1L<M;&@5
M9&0C>],F%.07O">!'/8LW+OV8>-YU:>'Y+R3,9#A/&\;5Q_">)T$IXB'"RMC
MXH<OE,C?ABFLYC)9/((V1]T?<H('E>%Z\\0"KY^\/^TQZN\'S'+^5\=K<.Q_
M-^;9;)93.\\7!7+G)[M?)9&+)OAS%D<G:X[3Q=2Q$\51*V 6W]UD"37))(UE
M+HW-E&6XGES<?K;*+%BLHJ&W8>N1#J<63T4&]C*XLD:O$6+$L@A<UK&%CRAE
M=[KW-8]K:_9V^SQZ9Y/A:\BY7@?]X\NW*.2TX6RTEA*L4'&>0W\!%']P@FBJ
M6:]J;%2W)!;CG2Q'8$;((=Q=.SZP?;M]8?4_*2MZ>\HRW ^%3X/%XR;'8B&E
M2R=C*&C"_(;3Y:-;.1K$Y2:W2J&ED*W90K5V*1V))R92XZ6QMI+:XGF6Q7,R
MB(.&/ X^43))QSXJ GGFU4>Q,ADA18+PI/>)WB(;)$N2U/-7^YPGVSO22;%8
MSBW,/3K@^-CP6%AOT>5U>.U*>-FIP6;M:3&6H<97%>"X9[MRU78Q#[Q[T\7>
M'1MI@_98^V!']FS-<HK^H-/DG(>)<_R^%R.4SL5A\E-@\S'+'C<EG,H]VT;5
MD6L.U5>Z+[Q/-)BZM72HZR1XZ_V%'@:UFYSB%S4@NVY<''J2--+%DWSEKG@G
MR[N'1&&[V:\X7,%&FS&'\$:]CV E'&T&)Z6_9@?!>LF,P/J!AI.4X&IP3_>C
M(VUISIQ.'D%O("C5P,]J4@9B6K''8G>LT<,4VUDFKM FG[;[0GV^LYZS>GF0
MX7PF'.^F]_)\HGK9"C1FL?VME?3B;"M]W:WR*H(XJ%Z]E_=@R>.Q<L;K5:&H
MMNU!]ZFF^G B9,M>>/%"UL3/DV%ER8U/8SI)/R21,F;!II$HSU_'\9#$<YW9
M$3NO^7;U/GE\%:GPGD%*E!%6J4^-Y"K4K0(L<->M7Q\D4$,,: (D44:+&D:@
M!%4* % Z@UC<>*F.CB"E1'75"&))\(-@EOQE@1^)F)).R23Y,.=>NT?2]8WE
M]:BCQ)98.=XO(''G"4\5[VZ\Q-&*432"5W@Y4>SL]OB1K7?GQ[+ G"Y23"92
MEE8:U2W+1F6>."[$9JSNH(4R1JZ$E">]"&'9(JOY[==7(W;VG0/X=>?U4C8_
M(C>P?H0#U&G$#G/9:BS"<M9CX+(615Q6V>+W<DJT,R?7HZ76VD:9&<*3$LX"
ML(HWJ%/>BEEQ%>J%;XR&OY7TX^T!5Q_$>:8*>ID*LYR6-M)[3_=;%,&23[E>
M/=-$9($+21R1*D@3L?N T6[YGZ>P<LAC%:S)6N12%TF"H\WMN=30@LO:Z2C3
M%3VE71779&BQ]V<K\_Y)[6%F#KVK6TC3G0&4LYSZB "ECR?^Q=7B<DA#D0,,
MD@YA/>1MC(-_>",D.<K5V^-YOBJ)P_&O32SBJN/P$SU[]/D#FD<Y63V*PFHV
MSN.61R&DVPBF)57$94E3N.)<%QG'\0^'A1)39D$EN5R/<FE"A7F:0@!I&)T5
M51&$544=@UT1VQ.HOO*TUKF^#R'5M>F*/J,9R&_IZ^779%?I,>P=>DRX2S*&
M,^4L(RVA(E?!DG&,S43N<[7MY1XYZ%<"Y=S3U3XYQ&2+FT5_^RV3[V),5<O7
MQ8E:U2K)(8HD_!8^\N0S1*@$2*\@UAGTU@B^Y4;><S.1X_@;MJYB>/W;KV,1
MBKF196M28VBRM# \_M1M*P/XFB5W5VC4]5NR=@3ZRYK]AU  &DST;%KY4B3-
M#-QX]<P19U8QL&5%:[SDR!642>]7$>Q[7HP1QN1F3D_52U7SL7-L?4QN0GR5
M*'')#>EG6?"PU0S7L.]>G:C66K-/,+4-RPC&=9-=BM"0O;/BZ H?=#&):LX=
M9%9E+ Z[9$D4HRD$!2K: *D+X(/1>1><G)_*]09N4&P;T$'7P,7C2/8LE',)
M79'9?98SIEO'#'OIH(\@30N8:T7NL@"/5S5?WU5;G_"8/[6Y!7],^&X_FTTD
M+8_(Q8BM*DS32%KEB=BD<Z3Q@-(6C8&5F0,X();C8?3#A2V)+_\ 9:-+W(XK
MR,9*Q=F)+K 3[4>M#PD:C\F&^@9D['GK:UN<P/FTVSL?R&HOJG**J7)8%A*D
MS)D8Y02)9R!GQ9D:,4#HRL"5BG4[/-W=_#\JY=9YA,;N5QU"/)LRK+D*CWD:
M:%8VC6!JMBY:KHB_A*F!(NT@[![W([>..&&%(H(5B]K2Q]GA510?PA/CZ [\
MD^0?KJPC?744Y8[0XIZJQ.]VS?1(-[E6R8N5+CQGTGWF+3&HUJJN7\%['-BB
M!</>437H^2C(CC$<@NSN*2")9&.B0 " V_!.RQUK0\ ?7Z>.E&D/:&&E9@=E
M?PG\.AH>?'S^F]>/)WU69KMQ3;(P4QRE.<N8XRXYC.4A"F)D$0I2$(Y7.(][
MGJY[WJKG.\G*J]^_K*(\'0'Z#^6OTU^7[=8_^?6S']0WE:4G5 N %&9[).DM
M,1W/$]G>/X8V62SO'EF8!Z'#\CS.-X5&C&^(W$17%D;Z3YE,=BJ\; L)KMB%
MRLJ=T;*!8C'L3.J'W8A.QE5D91&-*S#SG4G[8QY.B6'QO1/Z?4MK6O!UY&SX
MZ&C$=IUV5Z;M5H<>KJ>)K;%\<BDN3E9\RQR*4>VBO+!(91M)76?E%L/MXVE<
M6<>7-:<@B@8)E?5OT-PN=]5N'YBYR+-YK*>K'J1?KVH6'LU\3PO#<>AO28^M
M#%[B:Q]6D(H<O)K<4U6!8T8L9I+?9Q^T-ZG>CU/F>)Q^0QAXWAO3_D][%8FK
MCV%>?F?)N8X"G@N39UIY96OYV.3*35WD!CJ' 8:.I'5 @FD;*8'N;'LBH8./
MV-;<,RO(TELR*?1/2OHD!BT2;-QR<['VO#73%GOER6VQ&_&?6MAK/BI(=(]C
MUK_7#[,]7!<?Y;R;C64HXSB."LXKD'%>.S5Y;MM<MES#@.2XZ3*3F7()7F2'
M%6,+W360MF>Y5=(Z\GN#J_L[?:']4U]?_3G(\N@K<YM-C[OIQ?Y7R2W)9Y!=
MXUG,U_;T=RM82G+)C\CQ9_[6$DZ#V\WB+%?&W/NZT(+74.;0V1#R:) HL=6?
M#K61X_WP9X\:(ZRGPF-&B^4:=-=+A-D*:4USW1FG<4#R1&/C@]M[OL[?9\;T
MJR.:Y/G9,7D,QE*M.M@EKO:M6,-C9((I,B99+M*HU7(7K)1;<-3WX((8!##:
M>.:1.N<]??M#\C]>Z''\-FHK,..X[R+E^<"M;C-7(S97-7!QTPX^O$D4-;CO
M&&J8RF;<EFX;,V3G:4_>#)+"*B:JJB=N[>[7(OX[*J-7M^$_P5%[?Y^I8B3^
M(!MD, ?T.@=?EO3#_'7S\1N>HC%25![59?YD+L$?L/CR?._TZGC65_$H,/RB
MSN\FB(&C?#BXSA36L?>7EM;?()[XC.[.B8U6#A&+:F:I",DRXH8PFDEN?ZBS
MZY^A>-]4.4\7>AQH4[V2LEN7<^BO"LN.P6+6$+2&+7O&9S^3$B5,7//"D%*M
M!/-;GE2O7JN]OHG]I[U-] <A-Q[C%R_EN/Y2EDKM/BV3@2WQ2IEY%]DY*:S(
M1>Q(@DE2[+0Q$L1S4T2PRFL&FO12[E&78W#T 25D>)V2YOMR$8.%V57/)%HL
M<@X]D,05_*>Q]F^QD_=XON5XXLD,]GM^^-YV#(]SF6]*/0*GA_M*YS(\<Y1>
MAXUZ-Y&@)<-DJ=._:Y!9Y=PB\\$%G(BK62!L)/?AR$$M2**1BD'NJS%'7M/6
M[[67J_ZQ^F/$_3;,?[JI3S2WKWJ)?I4+%*YE$PG*(I^,)2IBS8K55,^&=L@@
M(CED5;$*1]L<<?GP'(Z/,MD8)K;%BO%BSJ&)"G9#=MD.N[:]B41;FVD*C2%8
M(?RQ'HZR(,2(]@HIB%<YZD6_UV^SWCL9P#U"]3+!KGG$W)?[:@K<>U6XU2P=
MW+U,16QR4'AB[IH\?-'F<O>/]]+E3=,9>!PK:'T*^VIZX>BF%A7F>5_WGX1@
M<=R/&8WB>0C6S/1CFDMS<;FAS<A&39:>1:E3CBELS4:V DDIUZ*RPUWB@+?^
MW:7*LGA1L4K+RGU_4I[%#3Y!+BFF0I<QK'VUM8DA-0#Y]K-CQ([ ,*0K(<:O
MBH9Z@_$@?1STM@]$.!CCEVU0Y!R3)7+5WD7)J>-&,6[W]RX^FO=)+9DK8V(+
M#6264!I)YYDAA-B10T?-O4OG7K%S2[ZG^H[8G_>+,XG%8N*G@OOHQ&)Q..B8
MU*6/2]-/)%%)//8ORH&U+;N692.YR>K1_J#\QAX+U6..V5666SL*!7<.L-?]
M_@.,Q\>:>KSX-> R">Q71I-D2*,HR(\3W>VPK'-<[M%JV"[S;4,3*VQ]/XR3
M\[_7]>F^@8+(6+=HVW^.CK8^?)UOQ_X9$[Z@K=6AL1TU@E)@E=+R:RU_BV3[
MAR*5,.6:PN358IC:_&('O@C#DI6OB6#W6QR>PDI(8#,;_>!X"5F<N4<JHVH"
M*1M4 !=_V \D>"=DZ)Z78H2NU9B0&;SX 8DZ!\^!OP 5 &@-#75&N1[FL,UY
M7TW)3.ML65]-RO-FYG9976#GU638K,#8?(%72:PDB7)JOLPW1APWUT^TA$AH
MCHLR09DD;,A4[8VC"^=?4@AO&B=^-[^OD?38\C0-"16)VI&@!H:UKP!\ZU^6
MQHG]>K^<:Z^_(3%N-O'S!%AU5MLS9]CDV'W&UK9BI)AXS1Y0/$Z_*R5T4@!3
M;VP%(1Y4*P0%+!FE>QWR!B9B& ]T@#Z10#H;WY7N[=_\H_/]0/'QT!(RRL1L
ML3X\:':VMZU^?TV ?CK64W]G&Q]E[=S[+=J9-*RW/IN1W(,BNY97$9(F0["1
M#>R$-?X8U>%1/9!B":T80(U&M15<KLZ-55 J@!1K6C^@.R?&R?D_GTFX8L1X
MV/  /P!O_#^?SOZ^>K=NF)U/MJ=-G7-I:RZIV8:HV/E\2/3X:"P6%=*>G<X&
M9WU21Q&1HX(L>6$(F2?-MC;*L5WLA::2)"6,O)N-BKA?Q?(!'_"#K7U\_H"=
M_(Z4* H WQO2D?.AKN_E_P!3_/JT7JC]<^JV; Q;2VG#6-1CVVM85]CE&PYD
M)DIN'U&PZ$L*#$J*=\P;I,@<62\V1E*=7 &XC(:R2->)R*1/(3)(?$;:5 1H
ME='>R#\_3>M[\]"*L7C>^X?Q_D#_  ^-C?U/R/C0ZJ3X)<]^173QQ[>^/X7E
M-'GVOL(RS$;*?B K*0:JLFY%8%@7.18O:1WH>"I(\.$XS7#]MLLZ#EC85Q6O
M4DC69D8=R,P(V-[!7R P_G\CX\_OT!0ON!].$(/CS\_)'C]O'QL'X^>LYUCN
MH5FG*V\H==K=AB8A16+<BDXC &]ZJZQQ.@L,?M+6:\Q6FD&'=S718L=6B#'$
MPY/)Y1]J58BNY&WW-L$GZ>?( W\>!LZ^3X_/HE[5 C4^#_$->?X=@;WOR3Y_
M;?SUTBNGTG;@APQ3_P#99T)_+LO_ )+\8_=/\?\ '_/UF]8#?)_<_P"O1?>C
MJG2]'1TO1T=:WN\?IR=1[PW-M3<EMR.V)36.T<\R?.IE/"Q+'9$2JD9-;2K8
MM='D&EL+(!#++($!BC85XVM4J.?W7T^>%]<LIA\71QB8.C86A4KTXYI+$Z.\
M=>,1H75%"[.B? 'SHDZV<]+[*BI[2'M4*"20=*- $#QX_/P?U\=1ZWZ8_5 Z
M27C@^5^U&4<ZRB6\NM;A^,?&/8PH\F+&DO'\S\O$&49C55>W\2*J*YK7)L3Z
M_7382X>*X@W8H9*T=PS3&U'6E=)9*Z3F,R+#))'&[QJP1F16*[ (T\U*G-E%
MRSUU-E:C5%\GM$;.')'_ .=^$#9WX)UKN(.)3Z7'2#>ZIR@V;_/_ .)F,=NZ
M]NZ]OF_S[)W[=N_9%_DGI<_:(S!\'CV/(_(V['TWK_@^1OYZSXWAC<R)7C#D
M=I;_ (M#R!W:[M;\ZWK?GY.^OR/Z7'20T>G]:+9JHY[G_P#B9C'[*Y'(WM\W
M\HBHBHB]^RHBI^43M<WVBLP=:X]CUTH70MV?('Y_@^O2$,<$08&".4FQ)95G
M )C>3Y">/  V/S\_GU^D^ERTCW15Y0;.7\HO9<,QC\]OY?\ AOX__P"^K/\
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M:\CO&%=O_3S),% D!73,@!)!U]!TS?\ >N>D?Q_W4&S?Q_\ J9C';_T?-_\
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MC&U/K]9[NY>-P*>_N&LE(= LS%1_Z7X);N/YOMB"-*+O[5T=B ;!V"7.]?\
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MXT 1X \'7Q^1Z:3?H[=$-[]^9&UE_?\ _-YB:?G^7[6OY3]^Z?Y_Y>C1_3_
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M6O:B]VM>B6R(YK7(CD1R*B.:BI^4]7:/G1U_(?S/[G^75/>^?P_0#^+Z#\_
M^?._CIV9]](YH_/,A9D4KEYM&#*^PXK2'&+ ,6,TZXOC%3C YCG$M$5I)L>H
M#(,-.[6%(]K55J(OJU5*C0._)/D'ZL6^A_,_S^O5&F[B#V_0 ^=[T -DZWLZ
M\_Z];4NB]6PM':5U'IBNM9-[7ZFUKA&MX-U, *++MXF%8W6XY'LI48#GACR)
=HJYDDP1/<,1".8QRM1%]7])$[)/YDG\_D_GU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g332508g79z49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g79z49.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1[H4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M    .$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             $8   !K<          0
M                   !              :W   $8
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   $8     !29VAT;&]N9P
M!K<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !&      4F=H=&QO;F<   :W     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !H * # 2(  A$! Q$!_]T !  *_\0!/P
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M.4S'MH?1D-%E5S75OK(G<UPVO9M_.]I4,5F170VE]YP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!9@(F P$1  (1 0,1 ?_$ !\
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M>0-KFHJX?*\5?\+R%UQG)V\EK>6LC1R1R @$ X62)B )(90-XI5RDB,&4D'
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MB;=D8:E<K&I&/[U6^-W>E5_!^U](+RGJQN>Y+U/?QW]M'PUC,(8N,8PR"SY
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MK"24I[C:/XD^C?27I+T_PEI;WC'U5'%&+E(&>5>2C?8W-W<1N1])''(&^BD
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M#-&S1SP2C) E@F62*4 L Z-AB,&KRZCZR::4II2FE*_#R,9QV54Y_;AKG?\
M_*+_ .NE<$@?/Q7S^2%/W?T_;[>US$7G_P#S1NN<'Y_V/Z_M_G7&P'R<?U!7
M_P#ZQ_K\?S7U8]CT[,<UR??VU45/K_+7%<@@]CL?N/@_T/\ T_KFOUI7--*4
MTI32E4QF<;%Y6,7#<S9!?C$:&^RMWV3D9"BQJES;-+ IE5JQGUA8@["/,8\9
MH4F,*7'*(X1$;Z1&19$,)829PFOR2P*Z_P A@Q!!Z()!R":]K>6>&>.6V=TG
M5L1M'TX+ J0/W# E64Y#*2I!!(K76\<**AG8SN1D5E5"OZPMDM=%_,BMGO@5
M]Q.E3Y4@SW*0ORXD&O@L0[3+*%)(4*F>X_9]ZY>]N&ELXU=H2-WU(T8ZM[0<
M!0(SG;'>$!*KJHK<UN;N""&*[G)N#B9F((9YG5.R.@1MG!"G(RR]8J+.]5+4
M4^2V%EBT8 L=D%&L6("5*F%K7L&T9!S'SB%D,0Y$]HBJ1PW-D#:Q?I!NL'$,
M;F$0R$_4*H)\@C0.F3VI71GUSLPP==26QG%9L<I !E8/)@@_(;4MG&",9R"!
MC [!^.Q#W.XQ+)JJ1[D)ZU<]KT5>58C7/:B/>JHKN&=U5CD<J(C%<YC%;9((
MA;,%D S@EO=DA2"H8+J<Y)S^L_(]N>AY3_FA2C,1^K)SDX_4>\#)P!GO!+8.
M:C1E<V95/5WVTC53I)<K^K4:SE&JY$Z]W-3NCFHYJ-]G#GJ[IJ9M(FN6R[,5
M)4DJ,$Y; 7 '^$_  &!\8J'N)3&J=9( PS!5&H)*D-]V)&?>.L$GVJ35B,RR
M^VR%(OYI8V5@VKA#KZX4N5)D,A00%<P<,*F,=0Q1L+W#%B-;&8UWT)6.5'>T
MS+'Y1;JB1HQ9WCC"H\H8@L^BDL<8[/;8P<D=8TEU)<HHEG>0(B 1DF1439U"
M %VZZS@QCVOA1T%JR]@0AB=B&&)K?2Q1L<<@_0)K6-:J(Y[E5ZI[7O>B-5G*
M(5_9C%\$E;1RQ/:^WW)EG&0!@$L >RS,-@H95[;!Q"4,@.5S'XC_ 'A()4D,
MHC7&C.B,ZLP7# M@X -R]ULKVERG):"7M-M].VYQR+AN/5]S56%]*R.1;93$
MB^K(\A#,FDE+%!9R2JX4%AT&/T^]HPG>Z..'G$L2R">=)W$LS@QQP0$0M(3'
M%HI/OC0@!B2?=KK@!CD7CVD\RFRC>.'5U()VVD\N!E%=_P!*,BEW90Y5YG5B
MS9KO;;)IN Y+5%?R)"J$L243N@75\A/4AHC&D8,!QD:K6%9R]KDZO1&NX97Y
M'(E+EP3@H=@'8%B"''N!";-_B8MA<!>\UCL985EFCR'2!M2<#8I$P(&I!& N
MJMC^G>*WYO!/.*?<;QHV]S2#"JH=U=0SLS)]4 (4L<KJY):>PN9B":U5/<!@
MQ;(+7HU@(,J)&B#%!#%"/5O*+(E[-&[LXC.L88DZ1G+", DX"$D'!.6V8DL2
M31^3ENI;HM=232MXXS$T[,["!E\D85C\I[S[AD,Q9B2Q8F8#FHY.%_E_]M1]
M1]4W6X7B%-&M8=/BV.U42]*8]Y%K:2L@Q[D\ECAR#6H8T40[$L@;G#,28TSR
ML<YKU<CG(JE=B#BN-5D"%5UN/TM?65HI *ZN@U<&)!@ EM(R6&'$!'''BBE,
M*5D@8!C8=A'M*UR/<BJ5[(0BCB&  V!"%C!"$)C1C$,;4:P8V,1K6,8U$:QK
M41K6HC41$1-*5]=*4TI32E-*4TI32E6HW&W)%BTRAQ&A05KN+F!R#QK'&QS3
M7_ A*TMUD=N..:.E=CM/%1R2+.=+@0S6)Z^HCR"65A$C%E..X_ZH375PQ@XZ
MT&;JY)T'D928;:(Z2%[F=AB.-8W(0/(^D:,ZU[G>8DL!!8\<B7?.7[*+"Q(#
M?DK(@NKZY7R0^.RM(BSR2O+$'D\=O&S32QQM<Z&LMT4#I[ "F*$2RAQB/+&9
M(4;5.T!2,$0@6E[H)Y!C(X:-5[&N542-;79M"Q39M"P"L4R==@"P#8QL 2 <
M@$CNIV(RF*,S*BS&-#*L3,\:RZCR+&[*C,@;(1F1&9<$JI) [.NM>E-*4TI3
M2E-*4TI32E-*5U)T^'61)$^QE A08822)<R48<>-&CA8I"GD'*Y@Q"&QKGO(
M]S6M:U7.5$15UU=TC1I)&5$0%F=B%55 R2S'H  =DG%>D44L\L<,$<DTTKK'
M%%$C222.QPJ(B L[,2 JJ"2>@*BSN+YC;3X!DD?%ANNLNLRU<*XEGQ2/63JB
MG@6/I)#D6UK,M8$>.V1#D"GC;'26]T1["(Q7%$-\-<\_QUN2%E\[  XA*L,D
M A2Q8#)R.P"H+*&() -WXK\.?4_*VC7RVBV5JLSP;WQ>"1I(F99%C@T:60HZ
MNK!4R"DA("QNRX*/Q"?*65OC/LXU)@,1V&XCN)'P0-[8ODRK"1>4>,5F67;7
M >Z/7Q:0<FS6E63!+-/9V,";&>.+%#'FRH*RNY.8Y:1FLY=%M^V1D AC!!B$
MI92'=I6D+>T @JJE@-J^@?17I.'T?PIN7]1I'?7BR:V<-NHEFEDN);5Y8I!.
MQ>V%HMLQ60031&<L?=F-879'Y*[@95@R[?7SJ6OQJ# I8QVU=;#@2 TF-S9%
MC14$>T>0[*RII"SI;(D>"P:R6SBQSE*DD;V[JX2ZF)BXJPX=K_DY+>9(@DSF
MW5)X3#<.;8QJK3)'J))IYPH9$8@L3M%75I:\;*]])=^)6EEFGNKIR7E>9DE$
MLS)(OFDN'AB@<")F8$E3T:[VQ/G)DFU^88KM17^2671<:SC*X<%N&X;8&O*W
M&0%<UQ*];*_KOR['VW\YH8CC87*.<1Y<A\AT52?+9ZWGX8>N(;"_]07BVO'<
M=QD#7UW!/*)+R:V@827/TR1).I>*W$D@61T$F/9ECJ:OZDN?1O*\9?0\7Z>;
MDO5%Q"]M8WZ6PM+,WLWDAADF"7$3,D4\L;2R7$#^.%0Q#*@42CW?W4=>TF,[
M&1,@Q7']P;R4*5&E6EC!AP\P'(CO@'#+MRR3^D\#X9H[J]SP2'%>-CF$G'>!
MNEY^2X^.\MIKNXACN.44YM9)?^*\T)\&!"K1S#R1K#+&6&K^0B,,58";]%^A
MN8CL^8GL.#Y+D> ](3'-[;6+SVMM97[#E$D>81^%F6[GO+>Z"J[QQ6WDE2*"
M59# ;,MK<7Q[.)VWN$W%9?&CJL2ZNG DMQ1N:6D<"2FUGRD-8OQVKD)'],B:
MGN,^#(:UK4<C5FGNVBX:YD=YD4&2;SO&DEQ*L;:+%L<?J]T99 /'[5VW7N_6
MP?E><X_D^3XE7C>TBBM>.6YEAA%K$)GCN'6-M9)5FTN C'63(R41U=;/9[MR
M-9NX$_#[:*F+[/87,)DUG>P)=/"OFXO%9!)-JDFO0KO[17;R5U>,CWK+64&2
MV(%">@'?T#9W'/\ .\/P5C<K#)RUS(]RTUNTXAC8-))K$)8FF141LJ'S&60R
M.$)<6_UU+)QGIQ_4?/\ %A8+:'CK/B+2POD>1TGG*1"\F\<OT]S"+B*:?"#9
M?/XR"HQ+[\/]^#;7Y=5V%CB4:U2XGU.,[@1V !D4L&06$0[+C#*%)71L(>,U
M-S,J,IG,C)9%GRI(J@G0,=DF_P#J6(^@VY6S@@DY%)H;6:PN()9+22=#/*8;
ME;/=A)"D<9O%#73@CPHJL7T/SAQ_)\E^)4MA_9_,1\%;WT?,WMJDG@\5IQ/%
M VT')WW)26GNNO4?-I#;<1!$D%O_ &2D]U=3-+KX+L>7N6[59/N%/D;0PHN&
M8=CL(--"J*[&A4SW3R/D/LPK *Q&$ X<<*#L@O)&<<)?6Y[?00M;N>6N+^07
MA6:VNY+>"*66]^G>6X=8YI6=TS(D?C2>&,J[&3,6V  M2OHOTG<\%Q)L.;Y)
M/44M]S5_R)%M=<A(EC"KVUO;0QW]YX[F\626"YNV>%$BC^I>%"0RN8.T9*Z3
M:^ATT+GRGSG'EE:(Y(K($5WQ#-5')TEG+'CP&'D*1!EEI(>SHQ!.B9_)L/"L
M<LS_ /#$Q[;Q0 1QBY7L*'0,0V0%99=LKH2-PVMK%-;R/>1R6UM9PK?11W*J
MR33L996X^0L'?P.S^3\K,BF(=R/+*U98/ [?W<.DW.VVVTK-V+>70/RG&,8'
MB626MH:B?66@SAMJVJK99R0QNK_2=D&:)&2BVA:SX[60T.LC#E>ZM>3@A1Y)
MK:8.HCDE29X2KE"99-5<.RA) JL5[8 X)44'U7Z<X#E_1W.<U=<-96G+VD,M
MV+^PL)+1YT6%+B"1?>1+&TCM:R22H6D2-FDU=0TNS:U>6M7^K47_ --3=?)]
M<Z4II2N%^T5/ZHNE*P2>3OX+=GY:;Y;N;H[E>7.[M3BF56E-/VSV_H2GLZC!
M4#%KDN628N0VTFO=&?)C26TU;C\2E# 0HYTB1+,BQ&[@]._BN/3'#<9QO'^E
M^*DNK6.:._OIU5);W9G\)5H(UD!"LOE>=YF?&@55]QRDN?&B*JG*YSDX'ZB0
M0%QD@8&3]P3V3D4_YNP?/KPHW1V\\BO&ZWD;O>.--#P;;;)/&RBQN_L;F7,-
M7UF/3,LO:NCBV +NWR.=7US!9A _*9])-/$A/@'B'L#6WSAZRO/58OH>:XV9
M9X(YF#\7'%(R2BYE>1XYPJR,80[E8)8RCVQ*@;*S*WT'^"=G^"W.<3SOHKUM
MQ0X3EN8$W(6_K/ZVW@;C);.+:%N,\YACA,=O$$NN/N3<V_)QJ[,T-PL4T&=O
M$K:SOL6QR\NJ&7BUQ<4=59VN,V!XLJ?CMC/@@E3:*;)@D-"D2ZF24D"2>(4D
M8IH[R >X;FKJU0/))#%)+$897C1Y(2P<Q2,H+QEQTVC$KL.FQD=&OG[D(+:U
MO[ZUL[Q>1M+:\N8+7D$BD@2^MXIG2"[2"7\V%;F)5F6*3+QA]')92:J'7K6'
M32E-*4TI32E-*4TI7F7,N;!JY\NNKGVTV/$.:-7#..,^8<8U<.,PYD40G%=^
ME"/_ $M7[5%_;7I"D<DL<<L@AC=PKRE2XC4D L5'9 SG ^:Q[N6:&VN)K>W-
MW/%%(\-LLBQ-/(JDK$)']B%R H9L@9S@_%6JV)JKV#AMC8Y1'9#R')\TS7)[
M2%'BV$&#%6UR*=^7"@1+1@IX@?DH*QYGR1")+G.ESE$/Y/K;(\S],+T1V<C2
MVT%M:0Q2.8B[:6\9DW,+-&6$QD&58^T#)SD5!>E&O9>*-SR5N;6^O+_D;F>W
M"W"QQ;WDR1"%+J*&=8W@2*3$D2,7=V*^[N]&HJK+32E-*5P[]EX3E>%X3^OU
M^VE*UW_(K\7GR#\/?.7^QOD[XT7VWGA/>3GX5B&Y0ZXEW>6TJ+)5W^M.#D5+
M86./VU>8+ED6.W$9!994XVX-@\3[R.>JG;IX7\->#]2^D1=<!ST5[ZMB07=W
M8&010Q(ZX_LUH)52>*16 5;]E-M+<;(&\!65.W1 P"/L6(Z)(_<' &0< ^X@
M;=?%9XH.Z.W-EM]7[K0LUQ8VV]K00,IK<X_.H#,7F8[9QA2Z^X%<D,R$L&7'
M.%\<JE3V>QC$3V.1FM0O87T=Y)Q[6EP+^*62"2S\3_4+-$2LD31 %PR%3L,=
M $GH9K&N;JVLH)+J[GAMK>)=Y9YY$BA121[F=R%4$D 9/9( R35#TGD5L1E$
MPD&KW+Q5MHP#Y;($R>^CMI,(:,4D^#!MAUT^?6C:YBNL8(9$!$>SDR=VHN4_
M"<Q'G/'W+!<;F./SI&6?15D:+=(W9O:%<JVW6#4&/5/IIE5VYBQ@#L1&;B9;
M1Y=4,C&);@122H(P7+QJR:*6+:C-7G[E!P]'+*!PG)$3DS$7[Y5&)U*Q$5%X
M8C7HG[-(OVD7@$_L?V^Q/QC^#_7/?[=5/;,O?;IUV![@.^^OU#[] ''?>17=
M&1A6->QS7-<B*BM5'(J*G/TJ?NG]%_GKC^M>@((R#D'X/V-?O2N::4K'Y^(;
MN-2XKMCBN%Y!;GH\?W(RUM5E4V*3T'?BE-7R+>P@,D(]CXS+6T91UDDK%<_X
M<N0SH1'N$^7X>WEDEFN(D1WM41D5]B/*[Z(P48+%0&=1T"5[('N$WP*9O#*%
MVEA0&#K.LS,H67'[1J'(/V;'1.*QS96?%IN/Y3F>/;D7.02)DM*)"#<Z+'2-
M05U:'%2%AC:$R))J(;4%*:UZ.($KI#RR3&(::AEN'N;6UNK&.-%)D.%)9?*S
M><#9B QD<L5+$!7 &!A*W':R&76 PQHX03AM$]QE:1Y-)$+(5$CNQ4G8!P J
M(%48T-R2V*Y!/DC[RBS"D,<0T54>]/LCWL&_ES$5O)E17#Y[]?5PU$NW'A$5
M%0,JJ3XLD@>/O5%)PV0<C'R01G^>+A4B(R5 56RI5@26.!CL;#/SJ5[.!4<\
MAMRO:JO,_LC7_9.6$16JK7<%>]R]2=T5HVM;V>WIT?RKS6FVLKBZ=-5;L9+N
M#J%!)V4N[$ZDD#/:X!R<$U&37*11Y?5>P%"_J8G8==Y]Q;O(53C/9[J-F>6S
MI8BBY3[8P?=4&A"*]%_O\$>UCG#<UK'='=VJ][5X5BK-R61@A9UD73X#$,3(
MP!8+@*26V1B<LHP/U#!J&DNS.=%5MB1E59L%5]IP"VV ==2 ,#8Y.H-6RS3:
MO<#&]N\.W6MJM(V [AS;JJQ>[':U%@^=(Q\B#NH\F'!G$FUQQ%,QPV6<>(Z2
M%#R(O<;7%?"BZBGFFM$8O+;A))8V#*L:S,Y61RRA9&< %5B=PI)4ML,'F2":
M*V6X,BLDH0Y5V\BF4NJD855U81S%0IDU5?>4;(J.LU[F@<1KE5S?6B*-W=WV
MY1HY'-8UCG$<U%'S_)Z\-ZE?UR%BQ$6V5<CMR%"_)UQ@? 8#4'O .25(%1OE
MU* $A?EP@;(&$[P1L8USJ$)9R2 0PZKL8J2E#?5/]H@GET4>9 ?>QJ\P8=I(
MIFS(ZV$6ODR!2 1YY8C3QHDEXR#CE>Q'L(QKF:@;B57+@-DZG;RD,TA. &'N
M)!VP"J%&*IL,9&,BUT5XRXW@'C,J^PNR;#8KDCO0A%5&7W !3L0PE#FMIMK=
M;DV#MHH66U^UD"Q61A\#.I<*?E,>K'&C>W\Q+7/^"U9MI[I*"'[DCQSB":68
MHO>2#&5*22E'=55IO#GPLQT*^,2;R#W$JQ?[GX  49%VT#.QB7\MVC4JBR J
M@C FT$CNZH,MKNV<G! )"C8[\%]P<R\??[.9*&VGGP7*\>QNO-B?PI=Q&RRY
ML9]11T,*O'7R72JK)7L6PE!M 5]PQJ + D@,&8)4H<OCY"[NK>=O"Z/-].[L
MBZK&S&61F/3ILA B+(2)!(#E2#-\[Z9L[C@[:YEECM6MHXR;MR@6&,PL$C?K
M9U9U0&),89S+M&JE6V6V+RU%_JG/\_Y_Y\KJN5I2OUI2FE*:4II2FE*:4II2
MN'.:Q%<YR-:B*JN<J(B(GVJJJ\(B(GVJKI_[]4J(&X'G[X8;7W4;'<T\E=I*
MV]E3HM8VJAY7#OYT:;,E-A!'9QL<_-R4X6R'(V3+M4AQ(;4<68>.$;R-LUEZ
M+]6<C"UQ9^GN4E@5&D,K6SP(412S&-KCQ"5B/TI%L['I0QP*[^-ON O>/>RH
M>NSTQ!Z'?Q5L=K_)'8*5Y7[N81<;J8BNZ][.I:/ L=DS939%OB</&Z:W*^BL
MY$(=(]+*;*]$6DB6A9MH['IE_!B28<UTLL#R_.<=9MP_IB:[BAY)[:6_>P<,
MDGE>>2,1R'!C%RD:>;P.ZW2PW$9,6FK5[^FOPV]:<QP_JC\4[3TWR-[Z0L^0
M@X1?4,*QS6\<,=M%+)/%#N+T<4]R3:MR4=NW&/=V4RB[,VZUD-14=]HJ*G^&
ML>L6N=*4TI32E-*5QRB?NJ)_QTI7X(5@QD(JJJ#8YZHU'/<J-155&L8CG.=]
M?36HKE7A$155-*X) !)S@ DX!)Z&?@ D_P! ,D]#NO&H<FH<G@ML:&V@6L17
M*Q2PI S*(C?W#(&B^V-(9^Q(\A@S,=^E[&K]:]9898'TFC>-OV<$9ZSD'X8$
M=@@D$=@UB65_9<C")[&Z@NHO@O!(KA6^Z. =HW7X:.0*ZGIE!!%>XBHJ<HJ*
MG^&O*LRL<'G%Y"AP?"\DQJ/D>+5,4LH=!?$GUTRSMX<EYL:M(PPPK*$E#*#/
MK)TD*",V5'.5R.%-$2MG 6E<]RTWU*<2L<1CN9&B=@L[2*8_IY(V+>,1IW)G
M*[Y*8W74YWI^&GH1KV%_4<T')B:RLSRG'213VD=A/$/[0M)XW\-Q]>)EN(8E
M0*8I5#JK6\BW=O)6$Y-Z9^^>.1*;"J^R'(J))H>0V)U8RQNK"18,/$LD@P?D
M +.)"9"CM8Z0^-'%'2*G6*P DCK);7C6>WGA$CGW>7"LON35-MB'T'3XU(9\
M-L=7%;_;C5XH6_+7UP!Y$7Z2Q"LT<(B0+)$LS*N(A(S,S*N\C.WLRS,/:W.Q
MRDW;M:F0!;>6/ VXG%R[%*WVS8UH]L<D8?P&QR"AB,-!+%FSC*5T5DD"1R2%
M<.&W-LH;JV3QX1(;Q'>*4E5U:-E!9F"NP"]@ ZAF7H$8JJ0<S:6:/.(A)<K+
M,T$S(JA206(V9481ERKJH5UDPPROZC'7>'QYR7)S93M[4K0QR%B G$K,7GF/
M8T<)9L>QB_,@I'EK%8X0X$>7$G21E>5DDH$ !0H/;GHWU2_"7?'<C;1Q275L
MLT#17K2^&\5XVB)$T4:RH0""A:/V/"O;*P+T&]:UNS.E]=WCV]VP=I/$OD@D
MCTR$,N(W"N6D 4QAD8HP#@,T?L=\:7XMY#T.0R=B;*JQ^M_,R8@S%+V-?ULW
M(B3(8,2G29Q11)D,E*"G_-)TB9)>LFYNI<DLN5U:5EL]5_B%S]]Z:3B[*_G!
MO?J!SKQM!+&+9P_F@@F8-+#%+Y&4^$0F*)/ OMS)7GZ>L.-#W$LU[8136L8-
MO%=F:/R^21CGP2)M+,L: Q1 E5>88#,H+??RAQ2CR"WS2LH<6R\.;4=B%E/"
M,&NDT0QQH!5N8D2ZG2AWXRR;P\PB^S\S@3YP?= 97#L9%A#^3_4OH^XYB['(
MVL-U(/IU1E\KI'(T)61);15ADTDE4:ZRM''O(QFU Q7US^$?XHW?HOB+3CKC
MDN ^BN[N5[@263O=-%<&:%1R8,UM"D=NC(T<UK"UU%;QK'(+A(U1+O\ C+AC
M]M]N;3<#>FIR)F02(#;#"H9*X\R<X:EA5L^7;%?&E18<J.Q2QHLRT:55 1ZN
M#(D( ;9#T<_-7/%M9<]&Q2*]D%M;3Y%RUHHTC,Z#$C2%T=Q$P5RH1W7X8QOX
MW2^D[CUA:)^'7(V26L_'6W]OWT-Q$>,M^5<7-Q)!QSH&3PA)85N&MMX3<!HX
M<+Y$JTGDOD%ONSMSG9;IXJNBQ>DAR8EBV5+AD:L*P+'JHLIT821[ EI=W< I
M*V7!D172X\620L(Z$G-V?Z;]7Q_A9>OZFDL&GM+9;F**Q*QF03W[)"BPEVB)
M<0Q;L#-D1; OD #7,OHJ3\2KKBO35KRT"<M=NB_6@3"U\-M;O+/<WL409U@L
MAY2KB(J2P2)45U*TYL'D]-MQMIA5K@ECDTJ=#L,DM[NYN!/%=6V96U<5]Y<R
MY 9IHAG(Z:&)#(R3(8VLBPW2GDG$,Q/;E_Q"LOQ,G_MA5DCME_X"/CF1('M/
MI DQBPKLKJ6EB*GR,NK>U58.BP@_!7GOPEN>4XGE_H1><C#:7EI>V'_$V"^G
MDFFL>&MK?\B&2#P0V][=3PB%=;V2Y16>!K>63OV%O77%G3.9,EM<94FV<HX6
M*>8:,"0WWCCD/W1$]70"<*UHY F\#,TJK 7$N\C3,0%__$9)*EBS9U!]FJ1^
M./(1F#*P+ CVVKBK8Q6QM %":LG'%=2T<$<.T32'42&269I9G61D5E.5";KO
M4./[;EE3;C*<6@2H]/!JPFF L@*QKU)W1WQV>D1FLE())2.,S@+1]6G<1P&O
MX,+B1!$TJ%F A*JZ(P[V"LV&]W0.21G'6#61+RRQ6+Q7GTTLQ=I)QY87N%.%
M,9GCMR80R,=0(PBLP.Q!!(^F/9Q&J,HIGU-$VN/-+'D1;$$J;&G19U-,C6+H
MXW/: J$,(;A F0I37QD<3D(R1E>W"%TK7@CT9PQ;6Y"?=#@E1D#6/W]DC#C.
M!D@=YN$9N%GGFNXE\0*3\.)58207>\<8$N &DD=P6B*$-"Z2)*P-;<_BSYD;
M7>3./C2JD_V1SJ'+L*J=M]E-C2QLIG.I8\(T^_QVOC6<N1>XL0<V.45Q#:\8
M'/?'G-CF'^NSVWDN8)[B.WN1#;3_ $T\K0N(XIR RQO*%\6SHRL@#>X'H?('
MQ3ZL])7WI.]MK>[FMKJ&^LX^0L[JT9VC>WE>2/219$CDAGBDC>*6)T&&7*EE
M(-2_UVJJ4TI32E-*5PJ(O'*(O'[<HB\<_OQS_72E<HB)^R<?Y:4II2FE*:4I
MI2FE*:4II2BIRBHO[+]+I2N$1&_2)Q]JO_%=*5SI2FE*:4II2HF^7GA]X_\
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M?T#0KT>9 #Z.8A'$Z/\ IK'O55>]O93NT<QD*2QR^< $A- RL4(]QRH&W6H
M#G.V]8Q+LBQ@L(DW:.$R-JI;#DJO2(%=<DA "6PWS5'RD4G\5Q/:U%1?M7.]
MC>7$_2T2-17,:K6M>K?61R]6.[$:U,&>X:8N/<RE0,8UP%"+@% $SD$8)!)0
MY5@2#U4=KA58EP<D#W;9)*G'N!*_/9& ,@X!\YP2'>%S^41C5%['HBOZ,7LQ
M7(C'-X8GJ8K7>IRNZ?3U5RI 7!<:9'SD80HS 9P-P') 7!U!6/[DJ <UU(RT
M8#*,-KLV2P.NQ1P=]<-C;K]2ZL.U(NIC)_B.4'K&CRL<-%[/<Y'N57]!HQ5>
MC7\HU&(YRHJ\*J]#)J)F=?S&4@ ,V-!L2QQE!@GO!8G#=>X:MU7. H5&30#8
M%LDMDJ0N022 S8!&"0 I  V%;!6UN;3K7#=F3QYC_P O@%V\GPF,,K%%*C2:
MZ7*"][6/3V1YT>6QSE9V:0*-=P[LYE:_)+Q@)F6-KV"48&64+.5(/M'O01R_
M )5QTH&*NG*&6YX*X5GS;2VD#Q]G3W1ITQ.3^7JZ'K(?/V 8[=@UY8U?\/Z<
M?S_I_+5,K0M?O2E-*4TI32E-*4TI32E="TKP6M=.K)**Z-81),*2UKE8YT>6
M$D<S6N;]M5PB.1%3]E7G]TUV1VC=)$QM&ZNN1D94AAU_! /\XQ2M>;!/]'$\
M88%E+M=TMW-V<^>^UDRX55CY*/!J<5:^:\\>KG?[!D=M,5D96QS2H=G5*]5(
M\(0*YO3>=[^/7J-T6/C>+XJR B57DG$][*9 FK.GOMXD!;+@-')]@Q89SZK,
MZJ%7   &  02!@L0?N?V['WJ_'G%^#1M=Y*9':;P[49%9;5[]61J!9=\>\N3
MXG9LQVD!1UQY%7'%*EUUL&'758FV5>[JK(YB$B$E&60GRUZB]'<?SSW%WEK;
MDIY!*;H%G0R+KAFA+!5SHA)B\;;*&SD9/T#^%?\ VB/5?X>16/#73?VKZ5LQ
M-&.,$<,<\<5P\CRQ1S^P2Q'SW(6&X+QIYWQA24.6'97",AVUVDVYP#+<QL-P
M<GP_#J#'K[-[5QGV&46E76QXDRXE/DE/*>28<3R(^7(DS'LZ/ER3R7%*^R<?
M;S6EC:6UQ<O>3P6\44UU(,//(B*KRL.^W8$_)/?9+9)TSZKY:PY[U+SO-<5P
M]MZ?XWE.4O;ZQX2T8M;<9;7$[R0V<3$+E848*2JHFV?'&B:HMPYUA"K0/E6$
MN-"C#17$D2SBC@&B?S>4SV#8G^+G(G^.LY59V"HK,Q^ H+$_Y#)/^E5N6:*"
M-I9Y8X8E&6DE=8T4?NS.0H_S-6AM?(';"O,Z'!NI.3V2+U96XE6S+^05W*IU
M&:&)8"KRG'#IK?M=2$?$WT@W:(01XSY+AUB4?Y,=L]? 7-56Z]<>G(',,-X_
M)7 .!;\5;S7\C-_RJ\*&#;^#,#7C+NKN7<I_^4=ELC<-Z)ZYN7VE5C#&\K]/
M?",0TES>/U*UI.WTJ)]Z]!8V,?=QRD.>\I;123G^/?[5_?/77_6L8^I?4-T/
M_LOT=R!4_IEY6ZMN- '[M [/(1]\!L_;&:_*?_B7N.50NUN)C<GZ6HV[N9H^
M?V15<QT,CD_FJ?I5>>&\<+KG/"1]8O[DX^?RHD_TZ?\ H>_]*ZD?B'<Y(?TS
MQBG[ 7U[,HZ_<"'(!SCX)'[5\7;<[Z6#NUEOB*$BHO(J7#:L36\_R84CA%X3
M^3E_5^^NPO.*3]'%E_CN6YD)_DD#(_W_ )5T/ ^M)N[CUFD.?E;/A[91@_\
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M'W'.YC#(!'(OZO&557<,O1#%00YR<^X;)Y'U!P36#WD8%OM:2P1ZJT>88W5
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M4II2O/C\#G31)S^ML>3_ "__ *@_C\?U_P#[15_X_P _M4Y/P/\ ,?\ 7/\
M[UY+U+(!]]'/_P#4"IZ__MC]OG->AKBO6N%3E.%_Y?\ ?_V_P72E84?/K\.:
MOR'#+_<G8.B;&RRHG6642,.KQ16(5T\H)=P7&VLANFJQ# +8MQD4EL-IY5@:
MIBODF% +8N+YB9+A$N)LHR+'Y)-B 5.4)U=%#$X#2.&!(!;';5-\3R2VK^*?
M8Q.0-L@A!KJ<JV1KC ('V'V)).O78GSJE-\'<*KGX[9(-A@)<UI(:V-><#'Q
M+*.1PF@FQI0NI&6$)KX<T;0F&\B*PCIIP'!6+,F['=(_;HX+*3J"=,E>XV(
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MP?*430V]Q8R%YT=PMO%:* A8DL6=4A)EV7V@*R^]ML$# JZUW8_M\^]#1W)
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M#,R:$:]="K]Q-MZVCVWP$\*G<*BK,ERJAO Y#ET"V@7T3'X]9-R68I_O_?\
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MD*XJ*Q!N>@K/<1-Q</C@62;Z@/+*QG;5)I=CA-@I"INP4JJA6V8]GNF6<O\
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M2-]921_I#U?Q_K+CIN1X^"ZMD@NY+5X;L1"4%<-&_P"3)*NLD;*V-LJ2RY8
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MP,QHV.0;F?K0$AJ>A[7M(YR-:]T;<6,RS12("T>&)CW9WD)& K3QD%LG&PU
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M2U]G6VDF_D6EM8*5 W &G@Q"Q9,LL=T&MA646)*J6NF3CQ6#C1".KGHOT_\
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M#+)<1"**[.)5B)S--EVU9:TY32E-*4TI32E01\\/P_MF//K;BKPC<MDRAO\
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M"LZ"*[B,4N%)4JX]K*Z,IRNK;1LZ/=W#L!P_ ,)HMNL/H*^APO&J.)CE)CT
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MTXSM9;RL?CD6+/-7B+;RH%BDI7CC$223V0Y$4AG.AO5@C1U;$?Z3.5DA&%(
MO?%M;*&U9SE<F0*T)+%D!PZF,E% U\BY(&&^<]G''/\ J?\ M V@ACP88%$M
M[$L:B0PJZ2).5F9BK*K,@=3+&-0"RJ"WO4ME<[4Q;#*,)I!3[5QS/F)9M($5
M<DI?8P@QAG132SB;(C!4$CY$*1"1'NCE*-S7\WW&W427$]H5;RJ)9U(5UD9%
M;)*_(=4R1H Q;H@DUZ\7SG$^H#QO%<S-);06CK:VDH9HGC$I7,9VC92LCM&
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M@CQI<3(T\"1*RE00LDDF^P\:@5"R\C>27,EOQW&^;PI')-+?W#\=$!(TBK%
M%M;V>:8"-F/DAMX"I0B<[8%[*\\N3%&6=#2!)<CO;%0Z24$J/<U&H=!A0G+4
M:_L@VI^KK]\<K#.%5B$?R*,8;4IGK/Z26Q^V,G!![-2<#RO$C31""4YWB$@E
M"$$C'D"J&R #D*!W7=UUKUII2HA>:&W'D-NSM0W;_P >LQQK"+/*+V)49U>7
MQ+*--CX#.CR(]V_'IE=#G%98L>^.XT5HXAY\!9,:-:P2+TDT[UOP_J'G>''%
M^G^5AX=[JYCBY*Z=)#.W%NKK<Q6DL?OAF8E"675GC5XEDBW+5N#\$_57X=^B
MO6/_ 'F_$3T[R?J:VXFPFO?3W&6)MC;/ZCMY(I+!N4BN98EDLP!)ALS""?Q3
M-:3Z )6VU7C]1[4[*8OM)7W-S?R\2HQUU?F^0.%*RA]H SYD.V26@NP!UTTC
M6U4!GLCP*R-&JD^1&"[VVGTY"_IWCN+XN.ZNKVVXVUCLS]9,TK7-NJ&.6.4$
MA=9$9T"@?EH5","JL-<_B;S"?B5ZI]4>K;CB>*X/D?4?(2\FL?#VJ6T7'7?M
M^FG@8+N]Q&\4<T]P_=W<>6:9")G0W_B?(2.%LI1K(:(:&<%KV">5&HCW#8]7
M/8Q7(JM:YSE:B\*YW'*Y+:[-KG7)UV()QGK)'1./D@ 'Y 'Q4%'OHGD*F34;
ME 0A;'94,2P!/8!)('1)^:[&N*[TTI32E-*4TI32E-*4TI7AY/DM%AN.7V79
M1;0:+&L7I[+(,@N[,[8U=44M1$-/L[*=(>J,!$@PHYI,@KOI@AN<O[:4J$V-
M;8Y#Y? %N3Y#P+FIV1N4;8;7>+\Y9=36V^+G49ZC-?(VN$0,G+\GR&.C;2%M
M);E?@F$5DV'!R:AR'-HLBQJE*FM5XMCU%0@Q?'Z6IQ_'XD+\NA4U'60:NJ@P
M4"L=D2%6P@!A1HPQ<#& 0&A:QK6=%;]*'1!^X((_RKD$@@@X(((/[$?!_P J
MT(/)K;@=#YCYSLODU^V^QK!,OO<7 7X,Y#BDUU+.+1W,5E?);*BF_-#0FRU@
ME@S82R#K%M(P@(9OSUR'+<['^(5Y;<3+R$THY;_@+,73/;3*(XVDM9+=V@BP
M\0F<NS.@ \A&P6OUZ],^E/1O/?\ 9@]/\QSW$^FXFN?3-M-R?)3<9%%R]C-/
M>"/^U['EHXI;F.2!A'K%"L,\N^AF*M)OY>2CK,0K=N:N'9)/I\PCI4I>SP*/
M)<<R!PC2+.JR]X0N@6]C:@'/L<0R@1 EGUL5*?*(KLFKOSK,]O3VLGBVFD2W
MWF'U$@;R1B-\++((R7D3"2(IC?V+NTRL55]?EW@+\\;SMM;WD4W*P"WVX*2:
M(13S7MNC7-IQ%Y, IF4B";Z>ZC7SS+";2<F\:-I[DBR*FVYO*.TH6$EI!6&"
M5 %'(:)91(BL]U<Z0]'&*@Q-4:RQ#8A%#((,S.Y4=DVLUK921PVZ2216XBC:
M6'*PNWC=?RF[5@@'O79E9ON2Q063E;#D/4/&SW7)2P0W?(RW4ZPSIM=0B1]A
M-/'^48HYI>E#>.94&"D8\3271K=SLAQVP<L2!"(^V5+6-3V))#VUS%A%>&R2
M0T981C*&0H8HBJ]X9@&FDQY#N0+8H;A+60)&-OJ(#"[LS12:R>XQ= *H<!3[
M0K(0P1F1CC7K<?)>6SR2L(YN,N&D55@-U;2^!S"+@Z.TDC0RH22[+',KJ98Q
MXR3:+,9%N^4"UKP+7S;,Q9SH3"NE%CPXXGM-.F.>Q3N--E/X0L9@H_#1@:CT
M]RMZW+O#&I01I<$.QCA!4);QJ%R5)<!\LJ]R_!4 'W&EK MZ93(9YK)L1+=7
M4D8-U<R,&"H\8MR$1DE<AXF<@,W6%!O1CM_?%5P;+XEK < RP[ X0R8,B39S
M*F1,%)4JCD(*,VO8@4:YI!G:AA+PXJ.Q9(DGN(UD9(!XEDDD6<,6BB#E2P!(
M1FW)8Y(  [)J:XZ6*UXZ\>UCFO"THMH+0VSJ$GF\2;(&C.X)3I&4 9R%A5B#
M$'./*(>SF]0<4E1),2/B^04QO1#Q5]]-E5TAL"QEF8:3:P:P-?9Q^P^T&JN#
MJ%2#:QDOL$&\/2?X8<9SW!6G/PW88WAGEBS<PVUM%- [0F&4&UGED:1K<I(6
MFMP&D5U. 7.M/6WKGG>-L^8X""S)Y0\7):1R2.S!);B%I[9XT]@'B>4+&ZR1
ME&!7<,@ G&??[/\ S$Q[.=Q-R'T6&H^P=B.- Q"IL(U-_9AU*9Y)DEF25=7>
M7\V$YLUTR8U15QO:&+']T^+,(*L_B'PW&64Z\3!<-<6_]DR),MS.KSQ2S3.)
MB_TUW+"L,NY9(H]7"J6]T3QEZC^"/'7WI*Q@Y(2<_:<J_J:#DI(I+/B[:*YD
MM8^.2S"0+QUW<Q]6[Q&2XO':0(K,1Y6=\;1_&J/,I@Q\URDTZ!225E1"8O0N
M$])3D*Z.)]C:3FO P@FG>O6FE/.-6,9_O(ORE9_AO!97%U=W7)3CS*(REM%%
MXY!JQ\BO,[.,D(!F$%<[:'(!_27F?QYY#U)QW#\'8<#QI;C[D7<=S?W-RL]J
MQ&!"(K2-(W94>4.WU!#EE3R:ABTLML*?'K:ADP9;I)+.%6?%K!SC1  BP:F&
M$*FL9<J1'1QUK1O$P(!=#R3GDO>%_K&ZU3^..,),6'T\=O$C,1Y&552.,A>E
MRVGO?90,*0B ZBHPQW,+EK*.,"]DNYYUB+F,R33M/(@*^]0C/A0"\>@0,Q(9
MJF;16<7%J'%).%7<C(<@N3BKH-,8,XH1"L8CRHWX_P <5;92XMP9D2')--ER
MBM:-R,;)"]HK#;S))R$=M)<3/:>-92SB/R?DH-&$[$:H\8R1JD@)9<8PS:EO
M[*5N)N.0DXRWL+V&<Q,$F=H(VN)L3M]&IF9621BT>GEB4>.8$C*&NH-$R[G3
MJ^2LB#96+QQK"$]$04?W341O,=/:Z.R(\+E>S]?5%;S[$812V%)O'!DZM#JS
M+)T6.59<ECUE@<L0,$_UZH#V_P#Q:F(MYEEB21 6"8$@F5@  5"R(K G# _(
MSG'J3MY)>!/@5TEPK&[Q'IB%$6>&.VM.#I& I50:LE29*# 9(XR,X(64<JKZ
M!L".KS\?;^98GE2&WN':1'Z)8X:0*%8,BD*V&)QC4@!CJR[+L8I.2L[JXAMY
MI)]5?D(8RV4"R)$\Q91N5\D8RRJ&8D :%V5K-U^<557EE_G=_5U,2OKI%G9Y
M)*I0+Z([)H75<.J'&>YH"2;*Q."#*9$5GH99O49XKT0C(^ZOX;5%FLDFN;6-
MQ$#*,9N%Q+$ZD$;K"8UU$FL;#7<2 8-GXST;=\LZ\5>W"6_+<A:P&U19%)^D
M5Y%NDN"ZR$));23N70O<!XF"Z&49R6>%.+V^8Y#@.]=7A.X5Y<V&7RIEK^;8
MO#I<%AX?<!ET5A>BR7(WN9-M*X9*R\K:G%&O-"2GDT$668)WL9@\>>0Y+E+2
M]D@N)K=)B$0PHMG#;:O&9#=3L#+,K,)L11;22JV& 8JNNOQBGXGTKP'J3T(.
M9].64!XNW<O:<I/<>I;_ -00-:7MM8R\/QZDVG&O"MQQ\LO)RB+Q3VURT2O'
ME\ZS&M8U$:B-3A/I/_?_ !_]=;%^/BOACY^:_6E*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*ZLJ%%FC0<H##-:Y'
ML[\]AD3GJ03T5""(WG])!N:]J_;7(NN5)4DJ<$C!Q]Q^Q'P1_!KSDBCE7610
MP!R,CM6'PRGY5A]F4@C[&O-^!:1N?@V32#_E'LQ+*1K4YX8*4-P9+?W^R2EG
MO_X?6NVRG]2X/?:'!_J5(*_Y*%%>7BF0DQ3;#KV3KO@#_"LJE)!_+2F8_P#6
MN'3K:.[J:G^2G]:Z?'*K45%7ER6#:OA$XX5$5Z_:<<_:HU0_$F#C_&I&3]\:
M;_ZX']!0RW"XVMM^\?DS1M_G^=]/^WP"?FOU^;R?Y4-PJIQRB.J.$Y_9%<ML
MC?\ UX_QUSHO_P"=%_3\W/\ IX\_[/[5P;B0''T5U_D;7'^OU./^M?);&W,[
MJ&E)'Y541;&?!"B_7TJ+7+;.1.?I.6HO[\\<<ZXU08S)G^$C9C_^V8Q_UK@3
M7+?ILV3!_P#'GB4?'S^0;DD?;&,Y^U<NAWTI'-DV<:")Z\H.LBH22Q/_ *?G
M6"'"]/Y*K:L+_P#>:YJ_6N08U_2A?KYD8XS^^JX/] 7(_<$4\=W)^N=(0?\
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MKV*50@>@^[$>J*]B.S[#B^0Y1WCL+62Y:-0TFFJK&I. 7>1D1<D' +9."0,
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M_@_Z5T((^01_4$?L?_0@_P"8KNZXKBFE*IJ]A95(<%^-W=/6*CD;)%=4,R[
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MVXGTA;VGU'+W]H#$S1VLJ0FQ@2Z!S&KW!U]C:_W4T1!]I+:Y87LI:!7-HMP
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MD :=B BLN35)]0>KN/X^WNU1WE,44P9H64&69, 6MJVP,DS9)=T]D,:NS-L
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M*R]J[(S*&5@VF,'8_"^HK?EU\;QFVN1L#$7#QR:XV:&0 ;+WT&"M@@@$$&H
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M510K&/ (17&@G&*5M8;J"":]B@,DRP-):1;*IN)%1Y(H\E@%$LB1IA^G5L8
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M8WGA.6KAR6Q,*O\ (/N;W LRH2P&00!A,@9Z8D-DY+'!O)65V21&C\A94W!
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ME./A8H@\C-U@+UWBHWE^1BXGC;R_E95%O [1AB!Y)B"(8ADC+22E4 S]R3@
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M>T+1\I;V\=U:+=P-%_<7"@Z!B;HN\<A/NAF7M$(8L2 /;BL,,&U]&2OE&]9
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M]/9.IY$P#$<J>N4Z.955[6N3K<0)/!-&=F$@QJ0<(0K,KJ #\,!U\!1WWD5
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M*4TI32E-*4TI32E>;<54*\J["FL@#E5UK"E5T^*5J.%)A38Y(LJ.1KD5'#,
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M,3AB-0KD>U5];'<$5WK:[SM0RJSAUW **C; 3;/U)A"$(AZD"3'8*VP4ZC3
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MTK8OP)#84FEEK'<2UJ/S)D2-ZG/.X0C<L3@! MK-Q MP7FBU".<MIC4MWL"
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MSFMLMKL!A'T  &,9 &2-2!\]9[^VW=7/AWM%B<3E2!(N4=M!TH)88_D97KY
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MC;5V%<Y>S9IW#0M'.$VD< :S# "EE(202O'DL64X"D,5)5*C!Y0XK*Q+/GF
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M\KRU.&\4B0&29"[LRA6$:E"[A&9RN5U7507"O&5)<L(PX,NT?=G8JI/;?^;
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MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*X5$<BHO[*G"_\
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MIV:2YAG==]481^^++L )7BRX.SB/5")/8A@+-[H]CMQ>E=.H8<1TR)DB _\
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MH9ACVRH<D86173V' 5N5X@;B^-\*WQ_=7$9UEMVXZEH]W<+@DOJNL+ROK=<
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MHCW3>-%I?9,S,]\]P'Y+,15(E-62'MB(QBHK(TBQFL&GP6)RBP(< 3"M<O\
MM'3LC_8&.(DQ(/L29-@-L#H*&#$9VQV ,X;8=F(@]"SWMV+[U)R+WKE<?2PL
M71PK,2LDC*B+$>BT4< 9OTEPN%J].0Y_CV%3(;\+D5;6##%KYV)A0,.GE@CJ
M*,(S#B_AU$J)'_0AD ]D@2,20->KBNDK9+6_@6QY+*D,7M;Z$>2]MBQSH<[&
M2VV)D:+&VP(1@2&6!]8>B.3GO(^9]&(#=)#%;\APEQE.-Y*U@20+]/J52VY#
M#K&L[XCD4*D@&#O>#'O C-_,&J#.H84C#ZMU]'DFR:[=*=AU''*B%MI>&O9
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M!QP#:CSRY9514#$BB-),O*"$]47C*L[*[Y&X2UL;>2ZN),ZQQ+L< 9+,?A4
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ME5[0+RQ$:B]$1O=K.R]6]G*FJRK3N3L6.W?9^_R /W^3W\# ^QZVG;6JH[)
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M[C[_ /3^?]Y&#G/8\N-H)+[+-]RH,?*I<JVV0QG;3;:KVQP3(<TS&BWGV_W
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M9XI;.PXL'Z7AY8@4//7-_,GBBXZ6"655MW/U)\CQ3^".)KM<*^6T&7[;1+;
M]QX$RER_%+@]-?4E@P(IE=(C=%9'4P5>&7%*%S3P)D=SXLR(490F+&<)^MOQ
M7UGRG%Q7EI*MQ;S*NK(2I*$9PP/N5P5*E3V&.I^*^%KCTSSGI+US<\-REB_&
MW]G*Y>.12\3/KD2QR!V1XV9U971BAP65@&!7-K^%3EV[VX,>]-#%)'1X[50Z
MQ,YN(A9%5<!%-8H\9D&:@EF7,0,E9$:Q AWB@Q&QK!K2?$,_4/KR'A[."W\A
M$DUS,[?21R!9X0JDBZ 'M$;$B/O D+EE.$U/WW^"5QZJY99YO=;Q6-K%"O(W
M$+2VET&:,26)+%9'F0*9%D0MXA&BR*#(#4Z:?=.EV=\FK6%OCEU/@UKO73UE
M;@%;8@<*FMY6/6,^.B?VN>5E7%L)["_[)2R1@(OOB,=)6;)!'D46_CAN>'MF
MX]O/%8R,DWRLT6ZASF(C9DRV#(#@,K#! )K;_"75Y8^J>0@YJ(V=QRMN)[5Q
M^9:7)CF-NJQW"L8XY%2)66%@79)U+ZG56R#-<CT[-^T7]E_DJ<<\I_@O/UJK
M5LFHZ>6>93L#\?\ <C(ZUC'S(U!+"'V+PQ%DC<-5<J_7"HO5?W7AWTBKQKJY
MPK'^#_7_ *]9_KU6?Q<(GOK>,G +@]$CX[^1V/\ ?VK1_I7TF)W=OG^:V YN
M29'+ESX-! 8EA93723.4#0PQ.<HFN1[V>\RACK^KARN5&NK$MI=7[D1J$16)
M:60ZQH/@Y8D!O:.P"2<#O )K<-]S5KQ\$5HTK-JBK% I:2:1P,!5C4'W,>LN
M,=YP3@FHK7$+C<*LN\LRV-#QJJJX)3T^*U8ANE$(Y%04O(IC&-<\B-=W=%:U
MG5SFIZXCAD:?S^HMK >"Q/U-PQ"2W<@!11GM(4[R #TY^?C,BE0D1'#R%[/%
M)?%[2S,BR16"RN'=D[5[AX]60YR0J^]<C7QG.T+<1Q38JJW<PZ'N35 %67=E
M*-*2+\R,%@( 3G$4X(;QB5)DMK .7U/<J*]R,:[E^O%^!M+A3>1VL3W*/LK:
M*HDD/98H"(VSDDAU8D@]BMM__P 0_5W%*EAQ_.W4"FW&J2)#<L$&=0DDT<CQ
ME<LP(?.^I!7[^ONUNMA6;V59CV-8Q2XU38C+2#1,IXP:\(H'OE'DA(,/+WOD
MD-(D/.4A#',]2%4KB.=J:MN$DX^&*5M5$S8:(1C;+J69_:>NR5;VDD,"6&*K
MQN^6N9+CD[V_FO;N8B:XN9Y7DF,L9U!9R6)73(U'Q%A%"J=1YJ[@3_R&=A+I
M)#8VK6$6&$JL$&P(Q.)3'(Y&N>@_M[%1&M5B(O+E14DC!';2V]PB!GBURN!H
MR9(P!MT0,X8G _402!6!:2M><C<W=PS)@E589/6JJ3C (R6/0+ XZ)Z)HBHJ
M8XZB</VE(8\I9$)7.>O#7EZ?Q!.5$0:H-RJ_ORG='-X1J\V0\WQ<@1A;E)8E
M 91C!;KH'O#'OYP<9Q@5,P64ZVS,';WRD1$LP)4MGWIL-5()PV".\9SG%I,Z
M:.JD-C$:.-[%<8Y6M>WV,:BN5BL8CV\N5J*J([]+&HBKS^T7=<E+=AHF13&'
MRF0"0H)!^0<?/>, 9QUCJ Y2T2!NV4?J)8+C;H$#(R "?C'RW\?%L(YX=@1/
M;)>Q$3@;45S_ &%1Z*WE5:B?7'WRO3A>%=U1>(YLK^P ^0!C(^!@? QW^W[C
M[5&6T:2.0P;&.AL2 3DMEB<C/R!]CT#D8'<CN;^81@F=[AL[NZ(Y$0?VC!HY
M45R.55>YJ-:G#>/_ #$14Z^#$X;*YR"@)[QT#CKO. =L@=$9!!J5ED"E$R%P
M5RRD=@#H'[ '(^.\@]X(SEH_!NLF5WXF'B3-BO<U9F5;E4LMC>6M>.PV&W7A
MHUR+PYR>Q0D^N6<L:B(B)]]K=660DDX*_L .@H^P!S\ CX! Q\54_6C))P\8
M'S'?Q'!.<$QW*D@YQ@Y.#\D=G[8_H2ZS:U732E-*4TI32E-*4TI32E-*4TI3
M2E1,\D,FRXN:;";.X]G-AM95[RY9F%;D6X5&&I7*TCX;A-CEL3 <(G7\"WI:
M?+,T?#D3?S>53VDN+B.*9@RDCP[T]==5*E6CW"W/S7QGO,*V:Q'*<ZWARC<@
M6?YS79'NOCF9;IDP3$\"'@59:8\R!L1MP;-\B-:W6;54FKDY2\;:>++N94S)
MI0H=!C-@KCK_ '_O_I5DLI\@MV<JR21?'9GFTDFQQ[\.F5-VZFS[^L?C=MG'
MG3FVW.XZ1HEI78]:)79SB]0"J-+M*"BM,BPDE2&\I:]7DK(ZA/1/\'_I67S2
MN::4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2N%^D5?Z(NE*P\[N4?D-FNZ^9^6.'[(?G9]A<WKJC8XL[-K#&\TM=K]KI5
M_2[^U53MQ)PV22VE[[MN]PJ7&D-D=;7Y*#&-E<J8Q&5%?),K@Y_G_I_I_3[_
M +_]!5O]QL(W4S/&O-(4'9K&3[8;H>3N.32[M6E9F,S>S!<-OMH_':!+W=VP
MVL3;H$G))VVTF*3(*&PK-P*^YI+^CM[*)3V%OBKL>M5<_P"_]YQ4A,3/L[@-
MQO;A/D9L]D66[G[B[SY]=R;B;L'F6[\+>; KO*Y<C9QE+DU%AN649JG"]O#8
MO@Q<5M[*J+A%ABUG*F5D*JDQ[^U4JYWF)B^Y&<>*_E74Y+@.&W1_]6N;P]K(
MN%'OLVRRV%*KIXP_.I[#$*PE7?R!#K497XW)O4+)?("V6YL8!9"E3EK:JLIX
MR0ZF!#K8:.<1L6!%!#C->1RN>]H(XQ#1Q'*KGNZ]G.7ERJNE*]#2E-*4TI32
ME%_9?^_^NE*T=/Q5X/\ 9OS_ /*NQ-_#E3LKVOM(8B<H*3"G["[4PT+PC>Z(
MLF%/8CT<J.4#V*U.J\W?TU.(+<RA5=HIW94(!!+)&HR&&,C&?D=_Q5(]1VIN
M;P0Y9$FME5W1M6 6:1NCV<$-V ,_T!),/]G(V23[(UK539=6V/(":)/JW?&D
MB.%POH<E.KF>ECODD<-$<Q!(YKT4B*MA6;SEWE.6,C$_"YR?A0N,8.,?U[S@
MU7;V**V"0HI8A$75CW@ DE\'LGL'8Y)SU60>+'S;<&L=-W,KPYZ&'"9%#E<=
M$I\TA,>KBB.:UB,1;,@VQ6,82S0QSQGN17,:O9OI&Z!L+C&?@#('\$DD$D?8
MY^?GYJ"FVB&(P4^Y& R9/8P.L='['O\ SJ%NZFW?D#D7YEAM8.TRFB+,'\9M
M3#-86-*2-V8!IJN*-\P?(%,P\I!G%U60C3(7U(RV\7+:QYN(LHZQ&.6.0!0V
M<;#<@IC(4@ #X P36J?5$%_R>.-Y>Q@FMC>Q75G=6ZO+#%XV9098HP9XI!Y&
MW+))$8F?/NQ693\-3QFW9\5XH-W(<ZF)%R?'CRCX=8AF1<UKI519QQS,;L&2
MX07+07U64M@AHDJ8!)S**8P:SX,@4;%YSD..YJUDX2Y^H/YBK%<% ;=&=6,-
MU"59O'/%,ABEC<(6C\L>?'(&KQ]%\/ZC]*\N/5$2\4GE27>SM92+F2&"54EL
M;HLJFXM)[9Q<6\\;2(C^"7Q)<P2(N<C-/&KQ:\M8F,;EY[MK19C-D5H%AW!'
MV%5:NBA(1JT]R:IEP33DJY22(SX-DZ0V%)&<0D&G9%U%#RO/>FIKKCK>[EM2
MDK"2(!)8BV!K-&)$=1Y(RK+(H!="#DBOIF^]*^BO7<7'\YR7"V?)2- IM[J5
M&2Y2,A@]M,\+JS>)R\<D4C.J2*P'8!J2>'87BFWN.5F(X1C]3B^,TT=L6KHZ
M2$"OKH0&I_=#'CL8SL]>7E*[L4Q%<0KWD<YRP=Q<3W<TEQ<S23SRMM)+*Y=V
M/\DDX ^ !@ =  5<+.SM./MHK.RMX;6U@0)#!!&L<<:CX"JH _J3DD]DDU8_
MRJ\5=KO+O:JTVNW.@&0)7+/QO)ZQ #R'#<@8QS(UY12C#>UA&HY0S816OB64
M)Q(LD:\B*'O:W<UG+Y86(^ Z?X9%!!U<=9'71^1\@BO.^L+?D(O%.@)4AXI
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M\.>%KAL<[A7)VX58RXMI7CD^IE@0$>R-G"Q1$9(+* H)^=222,C["ME<9R?
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M%-8\C%1KQJ=\BJMFC>0HBC&57L*G\1XT*L3;<9-:7?(2"XC>&YN#*D3!B<.
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MJ[ECOM<>J5+K'"0L:G]>,D_? /7\C)!^<_85Y)//-JNRHA &BYW##)0Y_P
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MMR7F!<'9@H!(QJRXV/1*DG(^^ .AG'WC*(W58T*=86,\\>%$K82+)E3ITA[
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M7+U_WE7^2-Y1?M&_:,1>ZHB+T@N$*E#G?&>_^8?'[?'8SWT6&.\UF36;;^3
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MYD<2,>,4:*)?DJYQ45416N>UI%141R,1JHY%1;EQ%A:V-T 95EW5DZ&REW!
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M-3[@XS)I\RK(JJJN?#B78X95^C1RMY:OO;75S93+<6EQ/:SH<I+;RR12+GY
M=&4X/W!.".L8KPN+:WNXF@NH(;F%_P!44\22QG[9TD5ES_.,UAJ\@?\ 1],&
MW R+(<WVB\G=T,.R;(Y[K6T@;JU==NO0SIC47U,^962<!R@+&*@D'(LKC(9
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A32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g332508g88p88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g88p88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 7<8DP         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  $<   !XP    8 9P T #, ;@ X #     !
M  $              >,   $<                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   $<     %)G:'1L;VYG   !XP    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !'     !29VAT;&]N9P   >,    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     4X0DE-! P     #YT    !    H    %X
M  '@  "P0   #X$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( %X H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M:7$5[3+F?:'.KK<W>_TV?3:IMZMTRQCG45^ILLIK=[0V#?;]FK^E_P!O[?\
M0>E9_A5;LPL.RHTV8M;ZG'<ZMS&%I=&W<6'V[MJ8X&&YM[+,=MC,IXLO98 ]
MKG!M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M8)=PY<+P3!5===95B919994QE%55#&.H<QCG,)A$1 W;O4ZO]3>A^]"O_1^
M.]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO
M]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]
M"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^
M.]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO
M]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]
M"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^
M.]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO
M]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]
M"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^
M.]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO
M]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]
M"O\ T?@#O4ZO]3>A^]"O_1^ .]3J_P!3>A^]"O\ T?@#O4ZO]3>A^]"O_1^
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M , 8 P!@# & , 8 P"A_&U^+/],_Y4P"VFK/O8:X]8=0_AZ.P#?, 8 P!@#
M/$QBD#I',4I0\\3"!0#_ .1$ P#U]H;^71]M)\K(RNU>* [0W\NC[:3Y6,KM
M7B@.T-_+H^VD^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+
MH^VD^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+H^VD^5C*
M[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+H^VD^5C*[5XH#M#?
MRZ/MI/E8RNU>*!B)F'K-B1:-[!%P4ZW82#668H3#)A)HLY1D)Q9235)ZDN1N
M_:"<XMGB)2.$!.84E""8>;*[5XH&1<"P=H+-70LW+9RDH@X;N.I60705(*:J
M*R*G23525(8Q%$SE,0Y#"4P" B&,KM7B@<*&C:_78QG"U]A#P4-'IBBPB8=J
MRC(QDB)S*"DT8LB(-6R8J'.<4T4B%Z9S&Y<S"(LQ[5XH&3[0W\NC[:3Y6,KM
M7B@.T-_+H^VD^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+
MH^VD^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+H^VD^5C*
M[5XH#M#?RZ/MI/E8RNU>*!AHB$JT I)JP,1 0JLU(+2TPI$L(Z.4EI1R/-Q)
M21V:2)GS]<?&L\="JX5'QG4,.,KM7B@9GM#?RZ/MI/E8RNU>* [0W\NC[:3Y
M6,KM7B@.T-_+H^VD^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.
MT-_+H^VD^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+H^VD
M^5C*[5XH#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@.T-_+H^VD^5C*[5XH
M#M#?RZ/MI/E8RNU>* [0W\NC[:3Y6,KM7B@>[)!0_C:_%G^F?\J8!;35GWL-
M<>L.H?P]'8!OF , 8 P!@$>;' #1U<3,'235O5-25(/C(JDI--RJ)*%'[4Z9
MRB)3D, E,'B$!# -Q[C0_H5&^X6OS6"<OM?BQW&A_0J-]PM?FL#+[7XL=QH?
MT*C?<+7YK R^U^+'<:']"HWW"U^:P,OM?BQW&A_0J-]PM?FL#+[7XL=QH?T*
MC?<+7YK R^U^+'<:']"HWW"U^:P,OM?BQW&A_0J-]PM?FL#+[7XL=QH?T*C?
M<+7YK R^U^+'<:']"HWW"U^:P,OM?BQW&A_0J-]PM?FL#+[7XL=QH?T*C?<+
M7YK R^U^+'<:']"HWW"U^:P,OM?BQW&A_0J-]PM?FL#+[7XL=QH?T*C?<+7Y
MK R^U^+'<:']"HWW"U^:P,OM?BQW&A_0J-]PM?FL#+[7XL=QH?T*C?<+7YK
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M<AMQ$ZGN!U*Y 3<NYEY1LZ09(.:9=(U%14&ZB@E.]DH!HR0#HD,/2<.$B"(
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M^EY&-A-DUQO*P\DK!S;R+8/W[)LO%R#P)%&">OP@960(DBT3G&SIBD=4R)C
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M8P%*!C\A.8  !,(!R 3" <S<@\0<^?(/$'BP#RP!@# & , 8 P!@# & , 8
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M1ZSD'/HY''/5CY<?[@EK) P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , Q,]_@LI_D7/^D; ,DC]R2_-D_=# *)\;7XL_TS_E3
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M>=(:-Q:5:5.A45:O2=.6]QV0WQVU&FFW+@Y*'!<TVEC!WXYY"5,8 P!@# &
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M.ZI8!;G&62NM,9D<=J=@0&YIM(HD%H"_8S#R4/R4,W%0.8"!P$ Y 2S@# &
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M>148\3=@_3=1[)R1\5(J)7A%VR2I7942\RI X*8%@2*/13 _0#Q!@&0P!@#
M(]V-_<*QZ_J7_OC; .OGS67=N]M&\/$3/Z/<R4$K+VYO#W"Z0[8%Y*K0IVJB
MS0[=8Z*Y(X)5^0C!22$@&0YE11527<IG"_?P[TK2-6UJI1U:,*L:=M*I;6M6
M3C"XK;E%J23BY^C@W-4T\2PW)-1:.]H%M:W-U45S&-24*>ZE2GQC-YQ)N/\
M];$T]O+BVUPRO1YDKN[?&\N'R=G=X.I*P&A[BM$4R[3+<J$G9X8&2*[XCA4B
M*!)(D,_.+-*4 ACN.L.W66569J&R?XB:5H^DZS2HZ3&G152UC4NK6E)RIV]5
MSDH;<MN#JP6YT\^[A222FDIZ06UK;7-)6\84I5*;E5I0X1@]V(24<^[O6Y[4
MDDDN'$[/F,Q$R:KQ"-E(Z06CUNSOT6+UL[58N.72ZAXF@JH=LMT?'U2P$/R\
M?1Y90YTZE-1<Z<X*:W0<XRBIQ_\ U%M+<OBLHX<J<X*+G"<%)9BY1<5)=L<I
M97Q64>X6#$70/19-!>@7H@[%LB+H"\N71!QT.M O+Q<NGRY>+(W2V[=TMO/;
ME[<]N,X_H?.Z6-NY[?\ \Y>/#D=!GFP_%#Q1Z.V'JRMZDLMBU]K^5JG=U:T5
MUL4BL]<23DHU=0+R35;KD!*,BVL0\+%%$@.RR:BC@CA(H$3]>_AKH'1_5K/4
M*^I4*-[>4[CT2MZ\GBC:^AA*-:,(RCQJ5)5(NK_\>C23BWEVWH]965>WK5:U
M*G<5E6=-PJ)35.ELBXM0>4G.3E_Z8X;<)K#SNO$EQ/<7E9\S5U!MV-;2E9VG
M;E89GLBTL(@J$Q 5UPA)]EL968MC)0SB>.VBRKN.S)@R-("*(-SF3,35T/0>
MC=?ISJ6FU)4Z^GV_I96-O4J[J5:M&5/=0<]R=6-)2J.,<O?L2;?'/Q:6.GRU
MJZH;85*5*#G1I.6Z#J>YOAQ_G5/,O=>>6'G!O'F8N^>*3=G"IN:=O+A];K;6
M5)N/TU;K*@1!S:9;[%'3QM'/W((MR2;2+L(1B!I0P',J5^LU664.S.(:G3S2
M.C^E=(=-HV<8VUM75*>IVU!MJWI_:(QE."<I>CE4H[VJ:PDX*26)HPZS:V-O
M?V:C&-&%647=4Z?",*?I(+>H1_DW0=3W5_\ E-)9XT,\S>V'QY3G&6A';"F-
MR3-7=&GAVY'[#4L9ZU%-4FSH45VS27 (F*D4)4&Z$2E$$;])$RC= AF?3)EN
MZ;V/1"CT9=2QI:92N(^A]73LE15>I)SAN4I4_P#TJ0=+<ZCJ[GE)MJ1U=8HZ
M?'3JCC"V@X*/V5TE3C-R;22BX+=*+CQGG*;Q)O/$^H3/!BBC & >ATZ;,6KE
MZ\72:LV;=9TZ<KG*F@W;-TS++KK*'$"II(I$,HH<P@4A"B81  ')C&4Y1C%.
M4I-1C%++E)O"276VVDEVDI.348IMR:22YMMX27Q;X%(M0>:*\*^\MMNM+4"[
MO'MQ*I(I1"C^%>QL)9U8HBBCY.NRKDH)/E"(HK+H)JD;'>H)*+,BN$R]++5J
M70OI#I.G1U2]M(PM6H.HH583JVZJ-*#KTXO,$VTFTY*,FE+:V=6XT6^M;=W-
M2$'"*3FH34ITU+&'..$L9:SM<L=>%DO)E4.2, 8 P!@# .KWS2?CYL7!;$Z[
MC:53HVS6W8BDZY;O; HY+!1$57#1B;SK$6:B+EW(.UI9L5LF"R2*2*:ZJ@F-
MU9#7WH/T/H]*:M[.ZNJEO;62HJ4:*BZU6I7](XX<TXQA%4VY/#;;26.+7=T;
M2J6H*M4K5)1IT7".R&-TI33>6WG$4H\<8;;6&1=:>.S<.VO,V;1Q):AJ:U7V
M>Q?GK,\2+;GF4:\BRDTV5@MD 1RBJ95LV8*IO$3.T7 1IU%NN%8&@JCO4.B6
MFZ;TXH:'J=RJ]A*"KTI5)*DZV^FYT;>LTUB4IIP:@UOQ';C=@V:>E6UOK-.U
MK2]+0G2=:E&?NN;P]M*?'#>Z,DL?S\.&7@U+S&_B-XD=Z1VW6&XYR=O51K1H
M!>LW6Q)%,]0FY!1^62KJ4F5!$91#LB*,@8BIUU8PP$3$Y$GB*9=K^)FB:'I%
M339:71HVES7597%K0?N.E!0=.LZ;D_1MRDX<$E-<><6SZZ16EG;QMYT*<*%:
M<I*5.FML94TE[^Q<([98CPQNW-OBLG>!GE15Q@%5N)KC+T3PE,JZXW!87S)[
M:EG!(*#@XM::FWC=H)"O)$62!DP0CFIE")J.W"J9#K&!! %5N9 L&A=&=7Z1
MSK1TRA"<;=)UJM:I&E2@Y9VPWRSF<L-J,4WCB\+B="QTRZU#>Z"@H0X2J5).
M,$WRBFHR;EAIX2>$UG&433JW:%'W/0Z[LK7,XA8:A:60/HF21(JB8Q .9)9N
MZ:KD3<,WK1<BC=VT<)IK(+)G(<H"',>7?V%UIEW7L;VDZ-S;SV5*;P\/&4XR
M65*,DTXRBVFGE,UKBWJVM:="O'94@\-<T\K*<6N#BUQ37]S9['.L*M7IVS2I
ME"QE=AI.=D3(IBJL5A$LEW[LR20" J* W;J"1,! 3FY%YASYY@HTIUZU*A32
M=2M5ITJ:;PG.I)0BF^I;I++ZC'3A*I4A3CC=4G&$<\%NG)167QPLOCP.G+AC
M\V"K_$%Q'1VE7NJ754K]SDY&)H5H3G DI$SQJBX<QY++&=C01;EET&IP*I'N
M%@CG2B""Q7*!E7B/I6O?PVKZ-HD]5CJ$;BM;4Z=2\M_1;(*,G&,W0J;FY>C<
MEE3BM\4Y)Q>(NQWG1_[-:3KPKN=2C#?5A**4)*/\_HVN*VK+2EG<D^*>$=TV
M>8%9.M#S3KC%V%P@:GJ$SK.$C7EHO5G<P2$]-M%'\17FT<Q+(.%%&)#HD=/G
MY3%09D76(D0B;I42*G(0 O/03HS9])=1N:-]6J0M[2W5:5*E)0JUY3GZ.*4V
MFXP@_>FTFWF*RLY.WHFGT;^M6].Y.%"$9>CB]KFYMI9ES48XRTL-Y7'":><\
MS4XN+QQ>Z1F;;L2 8QEIJ%L7JKZ7AFZC2%L9>Y[221>M6JAU>R/&R;L&T@V2
M641*8&ZQ.AUXD+BZ<='+7HWJM.VLJTJEO<6\;B%.K)2K4/?E3<)R26Z,G'="
M32;3:><9?SK6GT;"O35"3]'6@YJG)[I4W%[7[SXN,N<6^.5)9>#L3REG&*+$
M\T<X45-\)\.Y+ZX->59].II/PB'?V)'M2JX-25XMBY=F[>9X(,04$@,1>F!H
M#L5QZ&6Q]"ND*TAZT[-?8U1=PX^EA]I5NEN=;T'\VQ1S/GOV)RVXXG6>BWZM
MOM7HX;-GI-F]>E]'C=OV8Y8XXW;L<=N"].5,Y(P!@# & , Q,]_@LI_D7/\
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MX1BL1BN"21\UZ]:YJ.K7J2J5)83E+L7))))1BNJ,4DNI&YF #%$H^<8! ?\
M]"'(?_\ ,U3"='*/F,L*EQ2I;L';2A]>(['2V3]A!H)4+$J^3F26$88]A+(
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M6TA;SMU4E2BXTI*>V+CEM*HL-\&^<6LKJ[.WV A(^LP4+6XA(4(JOQ$;"1B
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M^1<_Z1L R2/W)+\V3]T, HGQM?BS_3/^5, MIJS[V&N/6'4/X>CL WS & ,
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M/7]2_P#?&V 2%@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MCP#%3JJ8PTH *$$18N   .41$>K-X@ !P#*H_<DOS9/W0P"B?&U^+/\ 3/\
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M.. 3O&.PD(U@^ R1@>,FKKI(F Z(]>@1412.!C 9/F;[0P&-S+R'F/GX!SL
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M@7F6T)*N*ZUCGLZDR7/%-9=XX81:ST"#U /W;1H^=(M"GY'6,W:++&(42)E
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M(;D AS >8#R&I_@'QA_WP#\\-8@CS'6!1'I ;G]F(<^D <@-_P"D_P#F /$
M^?R\7/ /'PU4@Y\M7)AS'F/_ !@7QCSY\Q_X3\8\_'S'\/C\_ /(>-8@\^>L
M"#S-TAYW$/&8/.,/_"?_ #?]_/\ ^^ /#6('G:P)_P O1_\ 6(?\H><7_P!)
M_P#*'_3SO^V >/AJI='H]ZY/H\P'H_9@7H\P\X>7V)\N8<@Y#RYARP#]'C63
M'I<]7D'I !3<[B4>D4/.*;G4_& ?@ ?$& ?H<:Q 'F&L" /C\87$ 'Q^?XPJ
M?X>0<_\ K^' /$>-1(0$HZN3$IB]$0^S O(2ASY%$/L3\8!S'D'G!S' (&IE
M[T=K^[*[#JO#Z5A:!<3;MBNXVC996+@'-E6%>Q.*K7I:,?5^J+3RPBI+JUV,
MC#R CR<F4#Q8'GSY_(GH>-5,3 <=7D$X><<;B43!R\[D;[$^8<O_ -X #C63
M #%#5Y *<1$Y0N)>1A'SQ,'V)\C"/X1'GSP#]+QK$*(B76!2B(  B6X@ B >
M( $0J?,0 /$ ?@_!@'EX;7Y,_P!L_P"E, >&U^3/]L_Z4P!X;7Y,_P!L_P"E
M, >&U^3/]L_Z4P!X;7Y,_P!L_P"E, >&U^3/]L_Z4P!X;7Y,_P!L_P"E, >&
MU^3/]L_Z4P!X;7Y,_P!L_P"E, >&U^3/]L_Z4P!X;7Y,_P!L_P"E, >&U^3/
M]L_Z4P!X;7Y,_P!L_P"E, >&U^3/]L_Z4P!X;7Y,_P!L_P"E, >&U^3/]L_Z
M4P!X;7Y,_P!L_P"E, KCQ \0/?1^Q+_A+N'W#[O?_?NZ?:NZ?<7_ /I8_J.H
/[G__ ,W6]=_]/J_MP/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g332508g91e20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g91e20.jpg
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M(DCA@@C?+*]D;'.2IC'RO9'&QTDDCFLCC8TO>][R&L8QK07.<YQ#6M:"7$@
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MKGXY]>%E%AEEIIT_/S0+D?X^9E\%F/\ B?9M9J0#*KL5R$9ES^RZP_1Z#3%
M:ITF7?\ 1#O,UNI!8F,3)O@I;TJK@?$.)4?;8OX=.FGV&M]/%+=3\?ST^@MR
ME= 9<V21"M#KY0A#+JUR59]50,"P5[=ZZNW4E[EW,SC3);&MT]4$=2,TY>DK
MZH=DM2,"E,1/7R-[H.'/.PMSY'A9+=3Z<_"_3]\UL?(8\7(P7/MM+:^M-'=R
M:'0WUXM8EG;VKJRKHQYIX:2LI:<:,&BHZ:F$@KJH*) ZP>0AI!TA9A(FZE9!
M'^I%_L:[^1:<A%7<(G")PBCQY5^,W6_E[T1O>@^T@?GYS:5;H@[:"&*2VR6E
M#]2,[L*"27T2&YSUFV$T=%<V X="JFP;/5V!PT^;V>QZNV:Q>CQC#WVGI9+N
MC)(CJ8'>[/33 :Q31W:[(ECMV1EI&,</70ULU!5154!L^-V;3^F1AR?&_P#[
M7MR/$&SA9P!'6I\*_P F>R,KH=U\-/RT-^3Y+>, Z"8'2G32_([LZ-$9"W+Z
M6C-+5)+<VAIIZQ'/?[+(W*E51)T$MW2;"47>NT+ :"H@H]N]FV7P''W%U93L
M WL)Q=Q)J*>9C,HF32B2P%XV5#9&L(AFI0[,8Y1PR,BQF@'^CK3>5@M>FJB2
M7L<!^D/<'99@/#@"&NC![LN<J6N)PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MHR>1F@OJ<CK8,:\[(S&5M;VY33:+J?J5_;FPJC:VF=8YB5]3/UEVO6U%#-80
MD#GVKLK-;-M9:*&M(%#?<%C2..GF;?49^FO103IK;/,"_AP/R65]'6,%G3WQ
M$.[[>WKG7$;I['N'JB'J>Y&F^@&C2"MK(NF^F?O +H8HE?9R5%P^.5OT?W.-
MD#!(A\AX&_U*#Q)\1;Z!;PY"E.$3A$X1.$5#'^I%_L:[^1:<(J[A$X1.$3A%
MU%?%1\.MWVIG\/Y=>+ZRT?F=XG$KL>N#ZN#WF]BXZNDGL-'U;901>U]TA@TM
MB3GJDGZ@:RF.OLD^!@NU/)@Z3V>[3TF'35>S>T%I=EMHF^S5[)#[E#5/ 9!B
M,9-^Z+'"-LTC;.C#(:D$NI&-=G\#Q"*!\M!6V?AU>!',''*&0Y,F!_IL;![A
M8MLR2]X@#+'P5\QL)YQ^.^1[MQS8JNXG:[/]DXET_P X_K_L:J@'_$>8,1_M
MG<*V2>&TH#9XX9;/.V-6?+ ,3.0(/KNUVS%9LEC=3A55>2('OJ"KW;,K:&0N
M[BH;:X#K QS,!(CG9(P%S0USO!B>'RX;5R4TEW-'OPRVL)87?H>.%[>Z\"^Z
M\.%R+$S$YK"QZ<(G")PB<(G")PB<(G")PB<(G")PB<(HD^7%-V'?8\.NP;-M
M:+-4;QLV:ZTW;.O]P?HY,J3!AKT>U9I\<?:9K+Z&5A6ES]=H(9COK*LR>MO
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M>\YC&ODL VS6U-. 6T]*U^UUC6X]APQ&)H_Q*A:V.OB: #/" =VH:T:D $@
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MW9L&VNQK J9]'ATT+('S.G+9*:*4]XYK&.(>YN]8MC:+$D"V5KF^T8+MAC>
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M[YBZSC6,N:MK.JIK3=]J7\5M;^Z=/N,JU/9(]T='DW6TB;2D*"@E(K31M+!
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M)$K(1QQX6.DFGGFD<V.*&&-KI)99'-9&QKGO<C454D N(:T%SG$!K0"2238
M 9DDY #,E2 7$-:"YSB UH!)))L  ,R2<@!F2HOXW9>(7EA2:_.]?:/J+N"J
MS]M)!JQ,>?3V)-)<E_-B2Q>14/BL:\HWZ8A@E^%-$AWTY#!3YTAF1N;JJ3:#
M 9*>6MI\0PY\T8?3FI9+&)8FV]T"0;CVMN-Z)P.[<;S1<*U5X5"^)[*FEA?$
M9Y89"SNGB.KBW1/!))"XF&LAWF=_"]S*F+>;WK&[POK&;H_O/Q_EEM/'772;
M7%,D>05T[O26D)%$KEDFCS5L^02&*1?<Y8V1S4LZJR-2I+R;TB?Z!B.'8F S
M%8/9Z@C=%?3#=N= 9F6<2- <I +G=$8S&O'#L1PPE^%3^T4UR305+KV''N9"
M0!SL#&=-XR%;,ZP\LL#MK/\ !^R%/ZF[)'D8*9CMNUU=\TUWHB0U5L7"&.6Z
M17,0<8V&ML27/3Z4$B-$F=Y*S!*FG9W].YE=2$$MJ*8A]F\WL:7$6SNYI>QM
MO><#DO71XW35#_9ZAKZ*K!#705 ++N-LF/<&@WN+-<&/-\FD9J4)(PQH\X9@
M\!8A4,@Y0I,4<XY(\S'1S03P2M?%-#+&YS)(I&N9(QSFN:K55.8EDCXGLDB>
M^.2-S7QR,<6/8]I#FO8]I#FN:X M<T@@@$$$+*S0PU,,M/40Q5%//&^&>":-
MDL,T4C2R2*6*0.9)'(PEKV/:6N:2UP()"Z\NR? @"LTA':?B=MS_ !T[23W3
M2@4KI7]::5R.65 +G,M80/7!32^SWCB V-!$C?>N5G(=\]O9<#[79IZ%FS_:
M'A4.VF 9,;-5!HQV@%MTS4M<2Q\\K6WL^26&L=?=_P 08P;A^1=L_P"%2DHL
M9FVZ[!-IJKL>VZ&](^EPTO=L7C;@[O/9,3P0-FAHZ:23=WHJ>FJ\*8&[QP*:
M4]Z+%E/.+:=0WP'7'F[UP9U?=D2_1T_;F;#)M^KM6K/1K2GRA?7/K)I&?+F*
M6OFL6#.G62TJ\U SY3/7B'95AFTE)-C?97C<6/4K&][4[.5TL=-C^'7S+ V7
MNFSL:;MC[YL)DW=VGGKGG>.*P+^)S:7L^Q6DV._B:V-J-A\2F>*;#NT'!8)L
M0V&QXMR$SY*;VEU#*]NY)-[++6-A=*7UU%@L3>[;V-T-_1ZFH T&:N:O045J
M.PNLN:4\6SJ[ 9_K[9PS@Y9AB(E5%3WQ2O;[D5JJCD5$XI5TE505,U'74T]'
M5T[S'/3544D$\,@U9+%*ULC'#(V<T&Q!T*^Q<+Q7#,<P^EQ;!L1H<6PNNB;/
M18CAM5!6T57"[],M/54SY(9HS8C>C>X7!%[@A7;GG7O3A$X1.$3A$X1.$6K=
M]T=TMVK<Y71=G=1]9]BZ##&?<,7=[C"YC5VV3.^;%/\ 59RQO:PXNFG^H@')
M^97S#N^J'&)]?GCPR1Y"CQ;%<.BJ(</Q*OH8:MG=U45)5U%-'4LL1NSLAD8V
M4;I<VSP[W7.;HX@WXJFI@;(R"HFA9*+2-BE?&V0:6>&N <+7&=\B1H2MI<QZ
ML+'I<EE)]"/KILQGIM6(/]*+IY:6MDT(PORB(/IA[IXRV4(_R"RX?DQDMC^4
M41'[?9/*CESI?+DBA+ONN^DJ?N/8]A;7#^1>1V5], V/LGKF3N'1TNDKQ*<"
MO'97%],S:,_(0"Q#?1D4>DK,M'-8QEFU\-DP_P"O+J!-K BW(V^NOJJ"!<GW
M@>8N?@0"?+X9+??1Y@+TO!<W2=Y+E7.A-@UW=UEM$-M;!R-'=79S/]GV"]BU
MH T$?U!9%KG<]4D330.JW6LDALH<'R\K?3)2.69',^60X^BD!R%4H]?V^0FV
MNJJ*/+36,M=<8>CQII5O'7UFW)V5_J,Q+8LG97'$T^?H[7%Z:4BT^CM);>GJ
MW6]"#8CG5++";:9ZWOTL+^>7V47S.6EO.YM^<^"MTGD&8P?63IB8?7JVG/O^
MVXWZAS%SU17Z;89^4G(JW.R?C.2<3 Z;1B06"8^1]0VHBG^FMK*:MKYMUUR'
MP&O+4#CG=+]+VUMKY<_3+1<IWD#-7(&83C46HU=O<9KK<R+1(\O2:2OW=3U[
M6 7X+Z2.+*A:2XN(+2ILA3]-\G.CF&W E79L@I28MU\=--<L\[<>J7Z7OI:_
MVROPX=5MK$ZTO3MTP-K4P4FAQNE=E]" #9R7=6TZ6@H-6#/56\U92D'AEY[4
M4A+WDT];.,;*6 \=_P!(A,XCU_M]%/E;\_.7@LIC_4B_V-=_(M.0BKN$3A%@
M_9V#K>TNMNP>LK@P^OJ.Q,3JL-:'U<J0605?K*,ZA-+KYE16QFCCGR3#/>US
M$F8SWM<WU:OJHJI]#6TE;&UCY*.I@JHV2#>8Y]/*R5K7CBUSF .'$$KT4E0Z
MDJJ:J8T/=33PSM:XN <Z&1L@:7-(<T$MMO-(<W5I! *\_P#XN? C[*\29]OI
M^G/.;98G?WQD$%9:Y[#O@I3LV!),0-5:VJ=KHV6JEE/@GFAE:< %**R91[1Z
M0_3]<V@[5J/:04D.);+4M320-<7LEJMZ5LT@:'R4\OLY,=FM(!&Z]P)&\P7O
MX.S? MDNS:''*.DPS$-H*3'ZREJZEN.5\#Y*,43:IE+'1&FH8FB9C*VH;4UA
M$<M9>$%E.V$-?+S\1?%^Z(_7,=T7YAY<3^N8_+G0]?=@RB1_DBN'ECR%.PMS
M4_O!JW+Z:9SU:L4DRI(BZUW/9[BG_*J,4V=G=HR=AK*,./(@U$I;R+YX0,[@
M9+I?<]G>*_\ *J<5V<G=D&5##648<>3@:B4M!_JDG@&MP!9:^W/Q"?&_:1BX
MWS=\8>[_ !UT3D<.)>:S%6=D%5/=ZJZ2AU]6#4ZTL='^I*1AY$JJ.8QLDT)3
M/2-?53;'XQ!>IV:QK"\8AU='3U3(WR6RM+3R/? TVR.]4->PW +3FL?7]EKL
M7A=)A=?@^T$30=QU+4L@K67Z.<Z.,@ZL?4_JR<PV6Q>J>^",XT>3QG[_ ,%Y
M6];M1KV=5VFH#![BH:]$]60U-%8*)JGMCB:V&"**GEB5R/8-DXW-DF;CZ["7
M/WAC.%5>"5=S_K6P/=02NXE\K Z#4W)[P<+S:!<\K]F=L-E=XRX?655 S_VZ
MB)Y=&WE%51B2%X %@&/>,\H!JIZ=2>3/6';LOVBNL9\UM8'.A/PNKC;4Z& N
M'U:1")%*[Y%JD+VR(YH,LA<,;/>:&$Y?EIK%=A%90C?>P34YS;4P'?B+3H7$
M"[+BWZ@&DY-<[56J'%Z.N.XQYAJ 2'4T_N2APU#0<GVL?TDN %W-;HMQ:O(Y
M;=4)^7V>>I]3G;./Y1]+>UXMG7$M3\V.D%+CEC26)WI)!.UK9AY6ME@DCE8U
MZ6,/Q&OPFKAK\,K:F@K8';T-523203QGB&R1N:[=<,GM)+7M):\%I(-&.[/X
M'M1A=7@FT>$8=CF$5T9CJ\-Q2D@K:.=O O@J&/9OL/O12 "2)X;)&]CVM<.N
M2^\,^VO'^W/W?@]V,10"SSOL+GH/?'3W'7^A<GHKQZ@VPG<^O)DC8T>!]G/#
M9-1[DCV=8,B0+VND[3=G=L*:'">U;!65DC&"&EVOP>%E-C-$#HZIBA8!-&'$
MO>(&NA-A?#)Y#OKXZQ3^'';[LGQ&JVI_ACVQEPF"68U>)=E.U=5+B&R6+D9N
MAP^JJY'/HYY&M;#$^LECK!O.#=HZ* ")<(/Q-\MBO7*^1/3O:/5O:560,+>Y
MZOIP;>H<+,LL::2K.L[>E*(I)7CRR1L&@LW21NC2I,OHVRDM\6)]CKG]SB&S
M&UNSV,8!7B4X?6U%144]298]POHJF&FI*MD51&V6,223/IXV./\ J649+6'+
M;._Q:MB-5@/:/V5[>[)[<8*:<8]A-#0X?6X<RFG[YD>+T%7B6*83-54%0^FG
M?#3TD6(3RL%L.FQ5L<DS>RS/WU1J:&DT] ;%946CJ*V]I;&!'I"?4VX<-A7&
MQ)(UDB1%!D0SL21C'HV1$>UKO5$XY64E105=50U<3H*NBJ)Z2JA<070U%-*Z
M&>)Q:2TNCE8YA+21<&Q(S7UMA.*4&.87AN-854LK,+QC#Z/%,-JXPX1U5!B%
M/'5T=2P/:UX9/3S1RM#VM<&N <T&X%WYYUD$X1.$3A$X1.$3A$X1:1U7?V+Q
M]_8YNTS7=9Q]8^&,@K+>._?&TH9EG%@+8M?I\CUU=YVU8V(AC)I*RT+8.2V8
M.=T90\\,<V\/B/NJ2ZQT<? +,L%V+1=C@G6-%5[JK@KRVA3Q;SK7L+K,Z65\
M+)TD!K>P\SF+"Q$1CT:XX 8D-DR/@=.D['QMBUO[@_)2#?@1XBRSM41R*U4]
M45%147_!45/147_[3A2M'1^.W60!!QF;K"<>:178FNKBLU*,*N<;U]=65[FB
M*$0T.PKAWP%V<HY8A@1U2=5Q151-:\"0P<J;GY^=["Q^"BPY<O*QODOE_0.5
M? :/]]UK6:(,NM[!5#*-7]F5Q^CO=06!KU?GWI +-9ZG41-CR"93Z>IOSJ45
M8*J&M$!7_;7+AEGT&M]$M^XX'XW]/LN4GH3)&2$?56^IF"A)N['+5CC:I@6#
MNK[5U^X+O,JZ*E8<MF+JZH"VIW:,W0B4;(75-0('1$%5<Z_0>/2UK?#E;XI:
M^OPY=1QOUODMAY+(B9(>V2*QM+NST%S+H-#?W;Z];6ZMGU];30DEQU%=45 Z
M!TE-3TP@];5 #1@58J.AD)4@F<3=2K]'^I%_L:[^1:<A%7<(G")PB<(G"*WV
MM14WM>34WE977-6;&L1E;:A#6->7$O\ C&2&9%,-/&O_ '9+&]J__'*XY)(G
MMDB>^.1INU\;G,>T\VN:0X'J"%7'))$\212/BD:;M?&YS'M/,.:0X'P*@EVM
M\,'PE[:<078]*4N+NIE<^.]ZN)+Z^*&F<OJXB.JS\H^6(G5_I(LEAGS5^9ZO
M_P"ISE=M-!MOM-AX#68G+4Q 6[JN:VL:1R[R8.G  R 9*T6RT6U8?MSM/AP#
M8\3EJ8@+&*N#:QI'+?F#IVCA9DK<LM +0WU?PDNR\O8LN^B_*S3VD8+8HZ_&
M]]A%Z@-L ZHX4>':YXD0^EC&5K4A6IR3',7T?ZJC5BDS\6W=!4QF+%< @C<X
M'>JL)<VG?O'5QIIFN9*3F3WDYY<;BC%L3V7VHB+=H=EX*:MM=N-;//90UT;P
M+!SHI6/CJ@.#*J:5K1^C<-G#?F!W?G3T%53!]O=6M[7RM..J/N,YK!M*7#%
MWVK/67L(;=@370M_OR/Q=B(R(XD]D5A#!!(YN'JJ79K$GAU!7&CED/\ RYJ<
MPZ\)(B\TX>=![/5.;?,M)("Y[61UF"R!U/6.Q["2[];J:2GQ:FC/_P!> ODB
MD+1?.&IJ6.L"Z2 $!931_%)\9&E#UW9TNUZ9,)E:- ?M,P79Y(TI5]/8'K<8
M[2UXT3O1SFNTD><):QJO(#'16HZV_8G&7M<^@%-B+6C>,=/.UE2UO-U/4=R]
MQTOW!G;?1[K&VUX1ACMHH#-L_54>*O8S?FH(YVT^*4S>/?4%7W,KPTD-,E(:
MJG+CNLF>59?(Z+X=WD4[KW?]E^1W6E2]9FY;-Z/-=S86H_$@SR5L/PM8O-EM
M(U@"*-FGD^5%66=3+93-E/$^J1BYS9C%]MMF8JW#:'9]]=#WAKGTN(X37SMH
MJDQLB=60>SR4SMZ6.*)CXYG3TM0V"(OIY#&".1]I/\/V%=H6*T&)8Y#M7@6+
MT-/'A$E5@LD.'SXGASJB>II\(JQB.&XA'*UM1/6R4$M REQ2)U56>Q5C!*\+
MLASE-2YS/4.>S8HX.=H::KIJ (1ZR"ATM6# %5BC2.?(Z0<<&""*%[I)'/C8
MURO>JJY>>UE54UU955M9(Z:LK*F>JJIG@!\M342NEGD> &@.?*]SG   $FP
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MAF<C<9E6I8(9MWOH8I=P[S.]C9)NNYMWP=TY#,6*R!$1$]$3T1/R1$_P1/\
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MW#Q8<QZ_9+GD?3[I]WL?\K7G^IS7^X>+#F/7[)<\CZ?=/N]C_E:\_P!3FO\
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ME^.9"S*8P46JCKZB/^V^@(SRR'F..>>GQB_7(#(\#J#?0'A^%<0>BL:.XB#
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/B<(G")PB<(G")PB<(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g332508g96c25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g96c25.jpg
M_]C_X0FD17AI9@  34T *@    @ # $   ,    !)*X   $!  ,    !!UD
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ *_(
M   G$  K\@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M,3HQ,3HQ." Q-#HU.3HR,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   %HH , !     $   !(          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MQJ=S9;[/W8T+8^C_ -MKU;H?4AU/I6/F?X1[8N TBQOLN'_;C?9_(4?Q/EN
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M&0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
M  !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET
M8F]O;      +<')I;G1E<DYA;65415A4    &P!" '( ;P!T &@ 90!R "
M30!& $, +0!, #( -P U #  1 !7 "  <P!E '( :0!E ',       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <@            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $@     0 ! 2     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      W4    &
M  !(   !:    "  00!R &, 90!L &P > !? %  <@!I &T 80!R 'D 7P!,
M &\ 9P!O %\ 4@!' $( 7P!- #  ,0!? %8 ,  Q     0
M           !              %H    2                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    2     !29VAT;&]N9P   6@    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   $@     4F=H=&QO;F<   %H     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    ".$))300,      @Z     0
M *     @   !X   /     @> !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O
M8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,
M# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4
M#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,
M# P,# P,# S_P  1"  @ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$!
M 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&
M!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q
M0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$
MP]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G
M]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1
M\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C
M\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!
M  (1 Q$ /P#U'(OJQJ+,BX[:J6.L>[P:T;G+R;J.>'W69V<[8[*L+W:.< 7>
MYM7M#OYNO]&S_BUW7UUS?3P:\!A]V4[=9_Q=9#S_ )]OIM_J>HN+_9-G6".F
MU?SF1)83P"P&W=_FL]/_ *XM;X= 0Q2RG3BZG]R# .;C'F8XKK6(E7>;T7U)
MZKT'$Q6UNR/U[J-H.WTK!H3Z6)5ZGI^G]'])]+^<O7:KQJ=S9;[/W8T+8^C_
M -MKU;H?4AU/I6/F?X1[8N TBQOLN'_;C?9_(4?Q/EN C,"9<9J?%^C+]'A_
MJNKSW+>W60$RXC4N+][]%OI)+/Z_U>KHO1<SJEL%N+47M:>'//LHJT_TMSJZ
MUFM%T$EYW]5,;-^J_7\''Z@][C]:,0W9+K2-PZC6Y^3<QW'I_H,CT_\ ALA;
M7^-#_P 0O4_^L?\ MQCIW#Z@+WZJ>J27)O\ \7/^+]K2]^ QK6B7..1<  -=
MT_:/:F^H6=:.C]1-V39E=-P,S(JZ?F7'>Y^+5#FN]6/T[*_TFVW_ *U_@O32
M,15@GZBE/6.<UH+G$-:.2= DUS7M#FD.:>"-0N(Z#T1GUQH;]8_K*'9%62YS
MNG=,+W"C'I#BRMSF,]/ULFW;[[7_ $V?^!7;OJ6>E9-74/J@YO3\@6-.5AV6
M6#$R*N'LMKVY'HW-;_,W55^Q"AM>JGJTEPWU_P ;I.5]8OJS3UGTQT][LWUS
M=9Z3 !54YFZ[?5L_2MK_ ,(H-^K/^*!Y#&V8#G., #/=))T@?K:<(B@==>P4
M]XDN/^N>/31D?53'J;MJIZKCLK;S#6M+6-U_=VKL$TC0'NI22Y/ZP#_L^^JG
M]7J'_GAJZQ(BJ\1:E)+D_K7TS+Z;G5_7#HE(LS<1NSJ>*V0<K$TW_1^EDXVW
M?4_^1_A?0JQU4QBWZ]]:JSG,+OJOTEP?BM?N:,O+C^>?2X,_5\/=LVO_ ,)_
MI:[;Z:CPZ7T4_P#_T-+KV<W.ZI=<#-;#Z57?V,G4?U[-]BV?J5@?S_4GCG]!
M3\!#[G?VG^FS_K2ZI)6Y\YQ8?:C#@%"-\5^D?X+GX/AYAS!SSR^X23+AX>#U
M2_PY?*^9_6SIW[/ZW<&B*<K]8J^+S^G9_9NW/_J6UK3^H'4A5E7],>8;>/7I
MX^FT!ES?[=?IO_ZU8M;Z\]-^U=)&6QLVX+O4TU/I.]N0/[+=M_\ UA<)AYEN
M#ETYM,FS'>+  8W ?SE?_7:B^M:6$_>N2X#\X'!_U2'R'_HO48OZ3RG"?F X
M?\.'R/KRXSZX,=U_K_3/JG3:ZJMH=U+J-M<%S*ZIKQ&^_=6[U,AWT+*W_P"
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MC^;?:\O_ %;,V[]S_P#"?Z*NJVV[MTDN+2NBG__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-! 8
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MP  1" !( 6@# 1$  A$! Q$!_]T !  M_\0!H@    8" P$
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ME0'U$#Y LM:^H4 UH.K1BLD8I@D@XK4%2:?($@?;2G6QM_)SW1O+>?\ *N^
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M5"::/'X:B)(Q^'HZ: EY%DEDAGF?F&ZYFW:?<;@D15I&A-=" X7[?-B,%B:
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M)H=1-1QRQ-,J?S^SHS'^RW_\+(/^?N;U_P#2@/AO_P#6'V7?O'V7_P"4=/\
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@[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g332508g98u89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332508g98u89.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1*<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $H"^1S8X0DE-!"4      !                      .$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&F-<*         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,[    !@             ! P
M!/     # #$ ,@ S     0                         !
M  3P   ! P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   ! P    !29VAT;&]N9P  !/     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   0,     4F=H
M=&QO;F<   3P     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 'H"4@,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M        !@<%" $$"0,""O_$ % 0  $$ @$" P0%" ,," <!  0" P4& 0<
M"!$2$Q0)%1<A%C%1E]8B05AA<8&6UR,H\!@D)S(W1DAF9W>1L30V.%97H<'1
M)29"AH>WX4/_Q  < 0$  @,! 0$             ! 4! P8"!PC_Q !1$0 "
M @$# 00%!PD%!@0% P4! @,$!0 1$B$&$Q0Q!R)!46$C57&!D9/4%3)CE*&Q
MT=/P%B1"1,$E,T-2X?$T8G3$-5-S@Z)4=:2"A(62M/_:  P# 0 "$0,1 #\
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MB]^.2S\A:*I/S@UR<+' "EYO5@=G+#D:W=0XB-B0?I51HG+DLQC :/=,S&R
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M6W;[ZI[5L*^QO4"U71+<=FM?2VGQ/N ("#(@QHV<U]:Y8N/F3GH7WP+9%S$
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M::<::<::<::<::<::<::<::<::<::<::<::<::TQ]HAGP]$G4EG_ &:R6/\
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M=?94,\MKZ)%7Q][.]F[V5%<X;)8:*&1[%B2M66?$XE\;+!-8B^4@>.U4@D/
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M1V=']/->LVF(;43NG6Y61F,J05#U>8MT?L#/T25*>6$8\PEQ3;/@PG*KJ?\
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M5?(T(+#68O\ E[^I6E0;*QE.[GFX,KV[Q'*IE^S4?:>.(<8<UV:O8^C-<4=
M]W!YJW22C/MMW@J92_!(V[H(%(B6DWA]IU[:A>TFM<R;-3M=F@56.#<A:S;+
MT&P'2W()1D2Y7CY(B/ ;>AHO+ZDR:U*>->;]+Y:\O9Z96P-W Q8)\S V1Q]&
MV*5I;-ZABI'DRBVQ'8%R"%)I62S8X[PJ.,2MWG(!#P#Q=L<5VRL=L4[+6XL)
MFLQC6RN/>AA\UVCAC@[/-C#8I-B[5J2I622A1[P^,D9GL2J( C&069I*D6EH
MI>S[JZ+'6&S5S$2[5!*>!5500K4](23"9!0A3[LA(+;>:\UXIMIQ.%9QG'?O
MCE)VGR= QC!8M9)J=&Z;"Y"3(RWQ<D:I# [0B2-%@@!5N*H6!Z=?+76^C[L_
MF%G;MAV@:"KE,OBA2;"P8.MACC8$R5JY&MHPSS26[3)(G.28(P'^$$D:R^Y=
M+*V.16;C4+,[KK<6OE2*Z!L86,:F4@B3*1F[!5;1 /$ACVJCV=H,1$W $%B.
MME!QTW#2$5/14=)#T6-R?@EGK6(!=QMS@+E)I#%S:+EW-B"8*QKVZY=C%,JL
M.+R12I)#(Z'[!3N>'$D4L0L5)PHGKEBG(IN8Y8I "8IHR24< @@LCJR,1J Q
MNW>I6NL9C-@]+<I:I<561\672FQ=>RU3G<-]D)DFXS95BUU9JYDS.,OJAR1I
MQ,?A>!\3DEE&2%3'QV$F/>4\]'7C;KW&4I7(K$._7NS)1ANP3\?+O5,7/;EW
M4?YNI!J8Z0\H,FL2'8]W<KSK*F_7CRKI/')Q\N8*<C_@ UY]00O5ETY&;D<%
MT)(6*M;2J_4[<=:Q$'K2H;$N\)M.\WL2^5" VI8Z8<0&15Y.4N%K!]VF2TL%
M[I@8]1)HZ\X%9["5NSN;3&!\ND$^/GP%6])+=LTJLN/ITVIV9J$%I.2SQQU:
M[]XD<;]Y,_&,_G&]<XJ^M3>\(Y*LU".P[V9:\+UX8FAD>K'*JE9 L4;<E1'#
M.>I))/HSTP:+FM,1%]DK/:8NS6C;%LB+]/I@J#$ZWA8(T77].I*(6.K4+(R0
M;:6!:FP067YZ7"CB27%M)SGNKC,[EHLG)3C@KR05\=6EIPF6Y)=EE1KEJWWK
MSRHC$EK+*JA=E15 .N?R=U+CPK%$\<5:-X$[RP]EW!FEEYF1U4]3(0%V.P '
M(]-MG^4.JW3C371DXR/F8XZ(E0QY",DQ" ) $MM+PQ@932F"!GVEXREQIYI:
MD+3G'S2K/-L$\U::*Q7D>&>"1)898V*R1RQL&1T8=596 ((\B-1[E2K?J6:-
MV"*U3N02U;5:=!)#8KSHT4T,J,"KQR1LR.I&Q4D:I4".VEK'#41!@-;3H@Z<
M,PXI,P-"7VKQ[.$H%B<FRN?=-Q!%9PE@,V0/AIEIAI#9Q$N_E16>FEFP.<Y6
M+4S8'+.>=F1*SVL1?E8DR6!%7VL8R:1CSDBAAM57=F,254VCU\_K5.V79 1T
M<;6C[9=FXAW="&:_%CNTV&JQ@+#2-FYO1[05X4VB@LV[6.R*1HBVI<A*6L&H
MMQA[=O#\)<*=JZ1A9RA05W]*'=T4.P S"IB/CGVPPXB.G)U\J0>+A!10\IP)
MC^^G<J):[)\70]FY.SV+2UC<GG8+53+VL5WDF+.6J35A6FG1I9;$U2JB0I%:
MDDD&TI/=IM&WLX?M]6[<=H9<=G^S_8^U0R?9G&=I.X@[1CLUDZUYLA4J2I!!
M1IY/)2S6I+&-@@@V:L )I"TR=-Y-"5RV[6V"+;YT$NE5JASU4EZ_&3.OQ(NR
M6&0%K!0TMEV<(,Q(L18TE($L,L('<:6VVSA.?#CD&U<QV Q#XZI+'D[V5J7Z
M]RQ5R\D]*G#)>C>N%JI%W+SO!"CLQD#*S'?KTU;T,7F^VG:B#.9"O-@,/V:R
M>%O8NG?[-04\ME+46(L0WB^1EL&U%3AM6Y8TC6(HRHH!*DZN_:&LJEM^E2U#
MNH3Y4-**"*:) +?C)F$F8DUB3@K'7I<1;9L-8:_+""2L-*AN-D!'"LNIRI'C
M;7QM"]9QMJ.W5<++&&4JZB2*6*13'-!-$P*2P31LT<L; JZ,1T.Q'W"M9EJ3
M)/"0'7<$, R.C J\<B'H\<BDJZGH03Y'8C7^*LG5?JA>:[;M?"=2U;#;2F(V
M7KZ>J-"V*:,GLAL>[ZYMY]>J+LPTG&<E6"HW 6/E5Y\YJHP7=0V+>2#L_D!W
MU:XV#G8GO*%R&Q<I(?\ FJWJRS6>Z/LALU6DC'0V)_SC/:/%VOE(ISC7._*O
M.DL\ /GO#8B5Y0I\@DL193T,C>9U'V;%]2[74 SU1U70<]#UE8>EJA>Z7;*[
MJ_9>Q3JY5-B22I.1UU'TRR6F2B)$6NWBQ2IAK4R$ZA<+'89#,4I61^BHRX-L
M/^0+.7AEF#92S4LUYK]&DD]BDG=I=>U!7CE1IZD,:*8F&TLF[J-@;6LV-\"<
M=+>1Y#XN2&:*2S6KK)+  JV#+'$KJ7B10"K#9VW(\C>?3GJ[8MXVT;U2;*2F
MDN,R6]J=1-7$ZAB:!:F*+9]@1*JY8[Q/M2A$U.S,G7:5!R269,%AQA^6.7E7
MB7\ZK-7Z53'I@*)\4I3$VK=]<C)<KM;@I2=_!4B,:Q0Q1SVI8R8V8$1J.NVH
M>1M5X:@QE;Y<%*4LUH6WGB,T4#"2.",H%C022.NZML0J^J-M>@O./U0:<::<
M::I*1IEQI4S*635.8<Z.GCW):S:WG2'HN,/F"?#@Z>K$^PR;FN2Q^$H>D@7X
MTR&E2D+,4B.D"C#B.GAR6-R=:O2S_B8IJD2UZ.:J(MB>&LFYBJ7JCO$+M>'<
MK!*D\5JO&1&#/#'%"GSZW@,]V?OW,MV+\!8K9*R][+]D\G-)3IVK\Q7Q.3Q&
M3BBLG$WK/%9+E:6I8QUZ<-8*T[<UFU-"=I.["V=29&DL:BM4))EFUR3'DI*:
MUV9 ,'5VQQ-B&04M-E+(+CWB8IM@I/NA;C@KCN,#*7G#>;/ KA\'E(<F_:&A
M9KQQ78)(8:V9CN-%=I6:;F,>"B2.94L%HSXD*L@7=P/6%!VQ?M/VN[/6L!'V
M'S-"Y-8Q-R*U:R'96?&1VL5EJ.6A6=AEYY9ZCS4ECG7P#,\+/M$6(75?CQ.V
MK_'1>IY^ 'J?E.;.C[;;UZNC2:QF+R2D&L.553Y(8#)<P ^00LX)+;JG&FWU
M,H5^1BW>?L_B)Y^T%.V^0W&"FQV-&=F2^+ 3OKXR 6*25HJTR+&(I"5XN5#L
M!N>7CI]MNT]6KV*RF-APO%NV%7.9UNQ]2;$&GXCPV&;#&2>*M'/?ISR2M9A4
M,7C#M$C$J-S0(@8.#"@7TH/#%B1HAY)++:VS!F T!.)('5XVE((:3G#K*O&V
MI*U(SXDYSW^:3SM-8EL_F/+-)/ZI.Z,\AD]5NA]4GH>AZ;^>OT!1K^!J5*J.
MS>#KUZZ2?FLWAXTC5]@?58\ W0]#Y'6H,5KW>'37EN$T?#0NX-$MO+3"ZAG[
M(FH7W5(3J\OKBM>726:D82VT\=U;Z8:G7!VOEUP9QB-B[<Y"B!1070R7,5G-
MY<K++C<L1O-DH8/$U,@XZ"2Y5C,<M:RPV,MJMWZSL"\E82N\K= ]BGD?7N,]
M2Z0.\MQQ][!9(&W.>%2CQ2D;%Y8N8D(+-$')8TWU(QW4-U!C:Q^A/3S:-?63
M5U_?O(LMMHK1]KI9""Z3;J3)"E5V)O-Q.FW6XVV&&Q3+,2RIV5%!3DD)*U%,
M66$?#8=K_BLS7N07Z8J-'CERU>T"MJM:1EGDJ54B!>LJ2%I& C9CQ8@*9N.;
M'T#8[[(16([4(A9:JW(IAQFCF5A(T,2H.48#'G^:Q\^HU$*E4MX=6,YK4385
M4-T=5]64?IIM]LQ:NG^)C)RU[@I5\<NUQJE$LLC,,FUJGQIE1K@S*H1@P7T,
MT6TTE6%9PJ39L8KL]%>:E83*V+]O.UJ_A\Q))%7QMJF*E:S;@CBX3V9%LSL1
M*5;E$I;RUMEFI8M+!KRK=EM3Y&./NK[LD56:$112SQ*K+)*PE<GF0W) 2QVW
MUZS\^>ZY73C33C35772@R,E,"7:D3 ]8OT<#[KR<8&N0@[)!8?R7]'+1'-OC
MND!(*RHB.DPWF9:%(=?6&\X,4<"9>XS+0P5I,7E*SWL1-+XCNHI!#:I6^ C\
M;0F9'5)6C 2>"16KVD5%E59(H98N/S_9JU;OP=H>SUZ+#]IJE?P?B9Z[6L=E
ML;WAG_).9J))$\M=9B9:ER"2.]CIGE>N[PSVJUC#IO6S&AE!3FE)UZ1<0L=P
MJIVRFRT$XI:<HR0R7.2]8E&F59SXO 3#H=;Q^3G#G;Q*DG%81I!+4[35%A!#
MA,AC\E6MJ =^+QU:]^N6'EO'98,>HV!Z05[1=K4A:#(^C_(O:8/&TN$S> O8
MYR1Q[R.?)W<+=5&WY<9<>KJ-QLVP+:QU:.W5K2LS6O%43!N3X*GATJ2 H\-8
M0PEKM!X<TB]'QCK4;(%1\ D63\LEY]EM][/EF/94K..WOR]F,W?KYD97NA%:
MR4N4@EREBG+,!1AEJG%13J\\,<UPRU]T 8HHWC78;_(<-6]('9'#WNRW]G%G
M-G&X&OV>M5^S]'*05F;,6ZV07M'9IR15+4M7%K7N<97:-9)&"3R;DC<#6%"7
MKNNE0CTLU-$G6">L19HT.- B^JGCW#WV!(D1\@<,9A;F4--MNJQX<=\]LY[<
M^=9S*C,7$M+7:JD5.I3CB>R]N3NZD*PJTEB1$>1W"[L2HV\NH&ON?9#LVW9;
M%38^2ZF0FLY3)Y6>Q%1AQL)GR=I[4D<%*"22*"&-GXHJN>@W/75,7C3VQ*=>
M)_<73?)UP&RVQ09>S]3711HNOMLGQ8@\<!/CSD:R=(ZXV$Q$C-Q2[9&P\W%S
MX8\<-:J](N1T=)Q\BIDJ5FK#C<U'.T%?DM'(U>#7,>DCM(\+0R%4NTVD8R>'
M>6*2%V=J\R!W1^]AMUYH$J9!)&2+<5K<.QGJJQ+-&8VV6Q 6/+NV=&C);NG7
MD0:MW?/[MW9I796EY3I4VA7I;8])G:<1-QE\T9-5>*>F@'0LGCRIVP8R2-#8
M6YYB<%544AYK'9P!M2LMXGXJ+%XO*4<G'V@H31TK4-I8I*F6CGD$3A^#1I2=
M$9@-CQL,H/DY\]2:4=*G;KW%RE:1:\J3!&@NI(W [\2JP,JL?+I(0#_BVZZU
MPKB.KJ4BZUTX6;6<%6+"3NE>+)M(/IWKUDTS"ZH5ILB9][@8]7#5B5M3>Q?)
MIV95#0)CPRENI%2GLG-U-_9R-[&;@O2SQ+B_D*#9F:#)RY'\J+$(WV26Q' :
M1-KNRSJI '/??5C(V*1Y,A%8>6,5!PK'(216WL^* XD[/*L7<[R<3R4';IYZ
M]0-+ZV'TYJ76^J195V=&UW3*_3V9E\-J/>E&X&-8CTG. L.O,AJ)PQYN1FGG
M6V?%Y:7%X3A6>$R=ULED+N0:,1-=M363&K%Q&9I&?@&8 L%WVY$ G;<@:YJY
M8-NU8M%0AGE>4H"6"\V)X\B 3MY;D#?SVU9O(.HVG&FG&FJCW+IFJ[QKD75+
MBLWW+'3Z)YP<%;;2S7$0DY"8&<>6A;C"$LSCQ31 JFBF"QAGF7491GO.Q^0G
MQLKSUPO>/%W6[ D*.]BEWVWV;<Q!2K;J59@1JRQ>4GQ,\EBLJ&62 P OOL@,
ML4I8 $ GY(*0VZE68$'6MU<Z5=>0DW*P%'W+9X_9D,Y%66SR27ZG8;4C%EJ<
MQ4Y>4LD;*Q)HV"+]A^3GG#"@VG42[*28S#8+:AG+>;-6I8TELX^!Z<@>&%.,
M\,'R,\=A(X7216XU=HXN(8CNSL^[$$7T_:*[-#'-;Q<#T)>\A@3:Q# 3!9CL
M1)#(CJQ%3C'#Q5B&3H_K=1D/[BFCQ$ < /?[7%B.Q]E!F)%]%=4EZO6+4%*U
M+."$+*C?($;]T4"%G$2#66'A9'!B<KR [Y"/']H;,DBL:T#L&A:-5[T$2PY"
MS?B8<9-V^4MRQ\#N"A7_ !#<Z_[56I9PYI5Y&+P-'&IFW[Z#(VK\+#B_)CWE
MN2+AL0RA3^<.L+J_3!#[7C-E(E=M+G-=3NR=BS=8A:-(4J;B1RK-0<4 >PDV
M*/CBI/$N)"2LFZNO/R;@31S@Q1#2V?+&Q)GS,E%Z?=T>ZMQ4Z<<TEI+$<C""
MUXHQ+"SJG=M+&@$H0,5#*-CUU+L]H),=+1:/'=U>BHTHIY;:6H7XPW#<:!('
M98S&TJ)M/PY%>2@[CD+*HO3MJ#4NX'+L'=4JFYZPV5B"JTN]7'"!+I=8Q=AL
M+<<<H3$_DX^+&DYD6*22WEJ-,,6K!4<T"V)#LY6_?H"LU?Y.**$R31B4!J]9
MNYA+KR[H*CF.,OQ.[HODY8M7W,UDLEC?#-3VBCAA::S$LX5JM6411%UY=R%2
M0QQO)L09%'YKEMXA:^D"88G(BR4F]R;=C/VW2K=.3ZH.A0[T3#51%Y*9E78N
M,K <-<K3@RTLQYDU8@2IB2AQQA5%M+%]0O?!GD,4D-BLAA6A9KQ1"2S('DG-
M4% \D[25X.,!98X76-)"6XD-L)5;M-$8I8+=-# N-M5HH>^MRB66P:JF)9))
MGEJURL#.L4+K&DC%@.NVNSGI!H<)'6!8FX[+#1)\Q"6'<;Y"J,X-:;36]@2&
MVVYB<+,A<(IJW9RR'/'1T&Y#QZ88P)MD8?#2"7O/Y>LRO%SH0R2)')#0 \2#
M!!-42AW<:K)O.!'"@5Y>\<R*Q8MN0//]I;<KP!L7#+*D4L.+"^+#5Z\]5:!C
MA19/[T.[@ 5Y1(QE5]R>JB>G]-5%M-4JE"&OEAP-JF?F[3"J@I2,9DX+8L]*
M.6^MVV2P&SGQ2=9:G#'H2)D651,C'3/J90"00L9Q,9,O9AGFM&M$3=BCAD[Q
M',<M2)!7F@3D>B3=VHDD0]XC1[1NA!&HBYVW7L6+C4H0V1AA@D[Y)"DM*"(5
M9Z\?/;U)S$HEE0\XY(N*,I!&MK6TK2VVEQ>75I0E*W<I2C+B\)QA2\H3V2G*
M\XRKPI_)3W[8^6.4A\STV^'N^&N<.Q)(&P).PWWV'L&_MV]^OWQK&G&FG&FG
M&FJ!ZJ=;2&W^G#=>M8=ELB:MVN;-&P0[KCC3;\ZF/=+A&5N-9PM*7)48-&?\
M9&?%V<0MO*T*ML#=3&YG&7I"1'6NP22D $B(2 2D ].D98_N(/75EB+,=3)T
M;$IVBCL)WIV!VB<]W(>O3HC,?,>70@['7\%DG%R$.>=%2H)<;)QIA($C&GC/
M!G1YP;RQRPS!"$MD"EBD-N,$#O-MO,/(6VXA"T*3C]<03I*B21,LD<BJZ,C!
MD9&')61ANK*P(*E20P(VWZ:^M6J@(W&S*P#*RD,I##<,K D,C#8J02"#N"1K
M:[6&;-:M150/5X0,OLS0NX9C;B*:D(>2F+=!3D525CSD;7G%N/V]NF26O,MV
M>&$%?(8@9L,WTST>S+/AT]R2O7R=E\C(\6/S.*BQAM\RD5::*2V&ADF&RU3;
MCO P2NP4S1,FZN8U?C<C3$;L6&RR*H# =%92Q.Y&W'GS]4D]2-MPQ4'9*/WO
MU$;^VMJ/</4##QU.UQTT69B[35SBZ"'KL8<*#-B9-VI"F>2"W/VV>=J8E8I]
M;86^:D\A:4C,@,R#XM=^2<%AL9E,7A)9+5_M#6:G#4DNO>+/,DL8LLF[F"K
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MX\'Z/_G;-_<+Y?J7[/VZ>#]'7SKG/N1Y?J/[/VZX^(_MB_T?^F'^)2/L[_\
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MO6< 57A8BN6,1DT^1C&CQGK**Q5920=771YI)HSV5:X\!\F7D:QWJP5IVB,
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M$&S(( 6\X"@[+*,EI#<(;:?<$21YF!UOM-O+9PA3C:%Y4G'.-QY'COQW/'D
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MNYL0/ J(@G:XAK@/+W8@5RVP83!08]@%)60[1D/K&Q/U=-]QT&^VV_T[?O\
M+4DO&[-7TF:T9.P>N2]@M;6KEFDJ)8M<T]%AL8U=C:[&VMIR%$"CL'8B9F)E
MUFK[&QK&$)\K#99YHP;VJ"E:G2]')9%?PLD:SQV)3'$9#(T1YL6X\XW7B/5<
MG?ILJD@!ON-_X>X?O^/V==*%MOI=VBN*@Z7#UB:^F-A;2)&9H(XJ9$QFAQ6W
M [.> =%,+1&JK-PB)02>.'1X):P-1N5M3#Y Z4]7*5>3S/+'W,?5N_)*J9WJ
M&)65SZW>0NK1J?S(RW5 "74;_M^W;;I_K_#66K?4KI.]VE,-&,RY<B/LP_44
M3-R%+D&HD^[UU5Y?E8N'G"!,LX]Q'ZWMC)>'G!'QB@0C&AU 3$.>=XDQMR"+
MFQ0*:RVV19E++#((.#.BG?Y1;$)78$$,5)Y(ZJV/]'Z.OU[ZUSJ.^NFBP[8V
ML:32K/,0UQDM+U67N$Q3"IW6XSTK-6F&I0,N&N#1%5!).QIRQCY/D,R9LA/6
M#,O+&Q\8_'K;L9:&2CJU56:)'A6[*D*3".RW%(FG*$2%YBM:.,\5"*L<?! S
M<@<[';SZ=?:/@??O[/+;IJ^ZIOS0]TLM9R!5I<.5V7D2JTBS3VL)")"V!6Y&
MJV^X1I,#9C(Q+$I4#Z_1["6P.^6TM#34>X3%L"S,2^9!EH7H8I>4J,E8-+/%
M':5S7D66&%A)$K;K,LD\:DA2-RP#DHP&.OV=?/Z/XC^AJ!1?5%T\3CR! -96
M Z-BG]<&ZZ+%UD 6S<;+>X61)KD7KR.;QDY-EC(&J2+YZWA(I$3"5\PIPYF.
MBUN-[WQF00$M9C5G%A;(:T088H742-8;?B8FDF4#8N6>0#B6;JV/P\B?HV_Z
M]/IZ>PZS4/UI].\C- 1\>)<1GD2L='2DL3K"QQ<?292];9M6G(]NWF&1@SU9
M*LFUZ?,5HALME)*I# \A*ML1[JSVO#8;(*C%C"=T9D06HF:9(*D5QNY4.1((
MZDR2C8[<=U3=ME+B?A]H]P/U]#[-8V*ZO>EN8DS7:Y&&3MKN!T,FO1\%KIP^
MT[A;1B8D(>:J2!A<D6:+CF:O+RZ9.5(!;A8^-;FB<A1Y<887Z?$91%42,J10
MJ_>&2P%BI[\ Z3;G:)F,J)Q0-WC-P')@P#8^[;SZGX?UM].K8@NJC2UDKY5H
MA[&:5# S="KAQ&8*78?"G-C2[<! Q9@+XC9PIXLVMR)GPWQT%0,@(8)(LLOC
M.(Q$DQ=V)Q')$%=DGD4=XA#)60O(RL&*E2FSQL"1(I!0D'3;]Q/V;_PU,=-;
MGIN]J<Q>Z&F>S7#'6L1YD[ GP?O4,H$23 E8K):,,R46> <*^R6&\]Y#RGXV
M00%+ G@"Z;E.:C,8)^[[Q1ZPCD5^)!*LK;=5964@A@-]@R\D96(C;^OCM_IJ
MV.1=8TXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTUAI&N5Z7-C
M9*6@H:4D85U;\/(2,6":;$O.8QA;T:42PZ^"ZO"4X6X*XTM6$X[YSVQSVLDB
M*RI(Z*X =59E5P.H# $!@#Y [Z:^**I5VSY*4;K< W)S*PW)>11#QR3Y5R/<
M0\ Y)&)&P0<L%UIIT-93CJAG&T+9RA2$YQDRRE50R2%$Y!%+MQ0-N&"KOLO(
M$AM@-]SOOIJJMK7S5NLR:Y])ZD79+'//V20KL'4Z(Y<;2\/&""&W2PL QX3Q
M T?'!.1[D[)+<:44Z1&1S6#I0Z.!(E58+5D2=U*L<<8C$CRSB&(%B5AC+,P!
M9F#"-=CL S'BJLPR 3]H^T^6HC$[[Z?+M3MHV0$1N8UKJBL#'6VSD44EZEEU
MV:IL/L]P.NOO1JV+./\ 1:5@)V5 B1BF6'3P&2D>\$J99VO0R$,U6)B4LVI2
ML40G F61)GK!I &WB/>I(B,Q!(5B/5V)$$;>\^SZ]OWZJR0ZF.G,MR$B)O55
MKCJV]KJ:M4-/G:Q0"'&M3-R$ULFI5U ?><S9KO8)N-!KN:>.4%9%346[&RQ&
M3FG,2EQV0',QVHFD%A(GC6SR+%(39,TF_J=U!'&S2]\0T7!@R#B1IM\0?+V]
M?+?[!Y'W:S!G51TVCA1D 93[82_KJ.F)>2J;VHYF2E--QNME00$W)V4!<<2W
M4\5:.GH"2&?%?>)D*](A3%:][Q[J7\^1B\D6>19H1XAD19A<C5;C6>;(L3<P
M9N]:.12" %D4I+P8;:;'_N1[1N/MUMZ/%U>8#9D1XN#D I8<@YHK$>"^R>-/
MBM8-)\>658?1,!9928M65>N'\"",NHQC&*@M*AXEG5D(7;DP*F,GB//IP.^W
M_*?+;6-? ND4L]3BSJC6#5NR(DPZHN BB5.RX Z! 91Q3PB\KD0Q6VQA#E9R
M2..A#++J&TI3C(GF7;C-*NR-&-I'&R,2S(-CT1B267R)))&YTUQ,4JI6 8,.
M9KL2>*!-!V,-AT-I+8\X#."68>31AI+?]\XL (DP\I6<I*D!VR2DO.)[\)-+
M&6*2.I9#&Q!.Y1D,17K[.[8H/<I(&PTU*.:M-.--:]U?I>T[3@1XZ"@I$<46
MZTO8#*'9Z6)4FST"+$AJR9E;Q2UJ9$ "':?#SG(QBD9<);<6M6<SY<G<F8M)
M(I)AFKDB-!\E.Y>1>B^98DAOSAOL"!K.Y]_LV^KR^ORUT[)TGZ5MUHGK+8X.
M:E![/)2E@GZ<_;+'B@2=MFJ6_KJ3N+].:DFXA%F*I)+\"L]AEIO"'<RB1L3J
M42J?4>5NPQ1QQNB&)5CCF$4?B%B286%A$Q4OW0F D"DD_P" GN_4TY$?Q]NW
MNW]VH5/=%NM3J]+LQ\Q?B;JZW*%PUTM6PK9890>5*UK-:L#8DW##W42%<34Y
MEZ+/@UCY&-1C,@ZE<RX[(N[DS-D.O)8!#ZH>&*O%&O$64M%D"J.,O>H'63?<
M?F ]WLH;G;;V?0-?FJ]$^K(.$K.39789=^K,-28F(V0WLBXN6^L"TF!GH"-A
M*?-'21)455DA6^X"NPSZ"T28UC-S,JD"6PWQ,RYJT[R\4K+7E>9WK>&A$,IF
MDCD9YD50'EWAA(<$%3&O#B-P6Y_?O\=_/]P\O=[]99GHIT$R %$*@K$9"C1]
M6C3(>5NEGF(^>9I=_G-EUMZR(E9(QZ;.C[39[&\X><^X7) S9\?*O&CJ92SX
M.9OEF?G&'9I7#I#$C1F:!*\G=E%7@K1Q1CBH"JT:LH!WW$D_OZ=/=[OH&LKK
M7I$TGJB2AI>I1$ZB0KI;[\&1*6B9E/=HSE8D:</&,-$DY9< !@):0%&]2V^8
MZ^0H^0,-/PDG'FSE[MM&29T*N '"Q(G(]ZLQ<E0/6:15)VV4 <555Z:;GK\3
MN=2"@=-FL-90%FJM.9M,76[;4*K2Y:(1<[+Y+<=3Z-&:WB)&)+;D6Y."L.:;
M"0D29/0QP,B0N( D?.1)M+,<UV,E9LR12S&)I8II9T?N8MRTL[675U*E)(^^
M=W$;JRCFR[%3QT))\_ZZ[_ZZJX+H(Z<@<0;C,!9,FPY\@<7)KM\Y[QLB).<&
ML9D=82&R6\/QCDN*V2@2.;C,-)>D1VEI&F9EF0E'/9$\_E(PKJJA1"G&/BAC
M#1@@D-P)!+%]SQ8@LB%6Y]_];$?N)U*$='>F&G1\M,7)L04N<?;B\7FQKBU!
MSU^!VB]"NANFN(=A8Z^@(L4*$M6<Q1!!@HKJ8XA0>-7Y7N;$$PDD1@L8(^7*
M.!JHDWX])&@;NY&'YX"DCD.1<COO[>G[/^G36%V=TF56:IM7!UV(+#7+7 0L
M?KF8F;'=0/<(>+K"7.2]#.U>7#FXB;+)A\"A6%34XP(R20#+UVRU\V4@)#W5
MRLL<\C629(;!+6$6.!N\;N)(5Y)*C(R /NT8,9) 9)(Y%216Y.^Y\_/H-6%T
MU:</T;K!-,EYQ5AFY*Y[$OT[(Y.EI1&)C8UWG;J>"S+3SS\W+LQKTWD!,M*J
M;-E%#J.=%!]0D(>/DKBWK7?)&(T6&O7C7BB^I6@C@5BL8"*6"<N*[A=PH+;<
MB)W._P!'[!M\-7[R!K&G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FG&FM<MI]*FFMT6UBW[)AIJR$LUR4K&85ZTSXM:<CYB#L-;.=]SA'CM#&
MO0EIF@W7P7!,$K>".,;)D8>&+C[&KE+E*(PUG2,&1)>8BC,@9'CD7UV4D@/$
MC -OMLRJ0KR*V02/W_U_7O\ >=1:(Z*-!P3D0>F&L1\C &.20DI(VF:*-6_B
MVZLNS6'D,O,C.-"S6E]?+8'9$;0MF),2^@@B;F2#]KYJ_)S'.-5D4*42)%4#
MNK4)V)!;<I<GW8L3NR[$!$"M_J^CI_7F?W>6I/?GM*;?J<'(2UH/ )K(C6XJ
MP159R6JNT:RD&M%.N3T?"QRA[<,2Y5K(;&R4,;#O>LCYUR,.C75&MM9U5Q=I
MS2*D2,)&-.42QI-5EY2#:-G;>$CO8E=7#CBT896'$G0;]?L/_7?RZZJH3I,Z
M7&8S%>CYZT1<7  0\];J\C<MM%7*A!["G]Q5R7V>*7852<C[NNMEGIH:0L3C
M;IHY;L7,/244*P$/+.6RA;O6BB9Y&:.&0THCP8UTIR)6(CX+RACC0K&" 5#(
M%8DD"1Y#J?([?N_KI[-M]?N7J'1\D!G6#EACI5R3TO.:S%K$!;9.?G3=0]0=
M[C(V2.$&A2CI$B+F[?%BL(M;&'$0; A;RC@H]HAW&$FR_(VA&RA;B63(\*1Q
MBWCZ[.BDNJJ'2%R>Y/60LHXLQ&@W]GT_9OJ6M:2Z8P -D+3*0S(%AE Q-@D.
M[ _H I:$VI=MZL@'D.2O@@S1KW>+5-/AK6,][N?3'NM^[066FM1N9-VK#@Y:
M-6:N!7ZLCU8*/)0$WD4P011ANHY#EOR8DB3[?J_=_IK 3'1_TPXC!K/-O2P]
M5B]:%T2/--VC8!*M$5&9K#E4>D8XY<VR+'/E5XS++9XIC(#A:VI[ RYW")3G
MM,ODPQB3@96M"=U%:,RO,DO>A77ANP$B[E2I8*#'OW?J:;GR]WP^@]1]77V^
M_7Z>IW3=/6Z7UV'>[.)L37$>%NNS6FOWVR0UEA8B[5QBGD2T[>HTD81(-UKM
M1:*EHI9N,/HCQ+6D8(IN*E6PFR21+8->(U[+&C'%)7C>)WAD,P2.!PS<H))=
MD<#H6,6[#FFFY'N]WL_=_KMJO:5IGH8M=/;(K\\@W7M:C:U4#(FRWNUQ$ I$
M#J63UE!'2@5O-C3B39/4M\]V-V+QX18X@R&FFC#26Q9%4B>YG(YB)(RMF5I9
M@\<$3R?*6ULR!#$K*JK;K\C$!\FX="H!*ZSNWG[^NX ^GV?1OM].^KMA-%Z(
MJ5Q EC[/)SNQ\Q,RD>8O>S9"P7$^NV:)"J61\^]I51+\&."(T##(8&2(/(ER
M,BA3LW+R9ID*2[?FA*K$J5@R[I!66.%9(W:;?U$V$A8EG)/(J%7I&BJ,;G[?
MZ_T&HM/5/IAF6=3ZX"V5(5V9TS#5^G:QQ0=ESD-:XZ*N$4]08<,8^#-618VI
M>-I\G$NDDXDVPGX:3DGG0)&,R>)MCER:&W9:LLJ7'DFM>(K))"S1,)W8JZ[1
ME&F5P!Q)#JHY(_%G7S(^/4?U[Q\/+4>UKKW56M.J+8\E7XR)KT!JKILTQKE,
MDZ62#"4>&&DK>4'&RLQ-R3[4K8I> CX-R2DG/)-BZY 5GWQ*2:YX9L'W9L6K
M.,KK(SR26LE<L<0 SS.RQ E$1=UC21GXI^:TDDG!5"$LWZ?22?V#^.I7*=,'
M3L+(2^P#;'88:9O=LKUFA[PK;,V#(1UC&+LIT%BD3Q,QGRT%8N5G!$CL/23)
M$!,O5L1G%=' BQ-2Y3(,L=<1Q.E>*2-H/"1LK1D1K)WT83J5[J-F?92)$[UC
MWA9RW/\ I_I_H/LU\ZOT6=.]38C9: <N;5:%S2Y\V.?VM<I&FVC&O95ZW4F8
MM@ALZ0!8TP4T_FP(D)!UWWJ\V.Y.O2H8[#+>9,SD)"R.(>]/?(K"I"LT1L*(
M9TA*Q@Q=X@[LJH' ;B,(227(_#[/+IMT^H;?NUW&^F31$?#QL0Q<;P +39B&
M-HCZ-T6EI[5JH"MV%,7#4;+D[D:O1K-)LUB$?#6.2\?4#O(D'BHF+B/=V/RG
M>9V<PP,9DD6<>"B(M"26,N\^T>\C=_'$P.X"S*"H#L_)N?M^&^_V_$?;Y:Q,
M;TT=,8$)10*[:Y2)#5'4N*UE*0^WY7,BY):\8GV*W8:?,.S11,I;1X2QV&"E
M)85X\B>KLI(1DZW("/O)5Z;)Y-I)WDB1SRF>TKU$X\;)C,D<R! $A+Q1R(A"
MB.1%>,J0--S_ $![>O[^OTZC5*UIT;"PT''U^<)-$W@=492,>G+I;).7LTA2
M-IW#J$K9DB?/G/3 Q9.PIVSS7G3;[#]C4]B%RLUM# O-DUG,,[M(@4TEE5@D
M,2I$LU6''R!5C7B0*\<2;("(]N>RG<Z;D_OZ#X >SR&W_76- Z:>FRG;-@M:
MU^&N-9E9L*4MFMK=5=@S *Z'-Z[]3'35-JRX\UIZLE#5C99&4QQS<HU/560D
MXD].8VOQHC?MLGDIJSV9'AE6-EBLQ2UT;Q"6"&2:7DI$H,M8 LO#NY55AZTC
MDMS[]_>#U^C?W^73?H-OCJX1NC31\>5!O1(-RA@X4JGR;T+%;!N(<-8Y^B3Q
M-EK5HMHB)?*['9AILXZ1-FY%]TV9,*R9,N'F"QY <0YF\P<.T+LXF4.]>%GB
MCGC$4D4+%/DXB@"JB@*@&R!06!;GW_UMM_7V^>K)TYHVA:+B9Z(HK4[ENSSN
M+'.G6*PRMDE)&41%QT(P^^=*D/NJ4S%1,>*M[_I)SC"Y&4(/E2C3R(UR]/>>
M-Y^['=1]U&L4:Q(J<F<@*@ ZL[';R4$*H50J@23Y^S5P<AZQIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIJJ-G:;J.UE014\7:H68K2
M9EB&L=)MDY3;")&V04<*R0WO6"+%?>B)T8,))X3_ )J$D@1TF&H25C8\X:56
MN2U>8C6)TDX%XYXDFC+1DM&_!P0'0LW$CV,RMNK,I:^5;T;K>G4NU:]JD,76
MZG<&T-2<=!S4S%O"--4RO4$9$')@G,2D%D.LU:$#$=BS!GQWQ,FMNX+===5F
M2]9FFBL2N)983NK2(CAB9I)SWBLI63E+*Y8.""#Q(X@#3?KO]>JD!Z)-#1\*
M#!L1MLP,$Q84K)3=[(.<:=8;?"[ 5-D$!G"X'G(*[5Z'L]5DHQN/=KDJ&EZ,
MPPAUYMR6V:O-(TA:+DQCZ=Q&0JQPO!W8#*=XY(9'BE5RPD0[-N0",[GX?8/=
MM_0\M1<[H;U\?=W9MZP7WZ/S-'N%<O26]B7-FV['E+O-UTFPOWJ?9DVUST/)
M5ZMQU:S'N89]T1($=%USW/&B('QL&;L"'@(Z_-)X98/[O#W5984D$8@CX[1L
MLDC2<AOS=F>3FQWTW/\ 7PWV_?\ QULO6-80]3F/>T7/WIYI#4D.- 2EUL$I
M5@!I$W)B!8^NFF.Q80T4G*0(-EAA"(B+;:CP\-C-H1BNEM/*G!XX =U)D6"-
M9F*KQW:55#L7_.D))+ONS;DZ;_1]@U9'(VL:<::<::<::<::<::<::<::<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::_#B?&A:._;QH4GO]?;Q8SCOV_/V[\#H0?=IKRAGN@<RBZ0MH
MT#(1]MV$(<W9P38*H-"V6SXB>BB+Z4@J4T<]*>>R/+RL8FSY?+.S&  F*")'
MSEAV15U4>>$UV$R*8:Y4Q,LDI:*/GFFRK3LH0;E$<Q[!>98;J>H37KEN?=[/
M/R];E[OC_7EKX!>S<L"9ZPV%[9T47DB>G+Y5@;'!6"75FR6O952VE+U78HHM
MO!@[=1&3JPU4<@-@,EE5EJ$PR]'F0"'I++=HXS''&*K+LB0RM')&GR<5::JD
MM<F%GBG(F,VY8A9>>X=9-D<O+I\/9[!MN#MOOY^>X'[K3.Z*+)+68*TNSVI*
MP7+BT?-S"H.LY"M"BR=&ZB<;Y'+ICJK0<Z([/Y,E(:S&2J"")286S9VVQ,OD
MQ*8JYF)(VB$=N54,_<&Q964E9\<:!6;Y)01'LC1JFP2,=UNVP<M_I/T_1MUZ
M?Z_ZG6.I_046!,ZH*N,_K:8A].O:ZBHJ/A-=$QQ&PZ_K<2VIB9_:CTG89<6P
M["7*6$:8&EF0V0HJ37:3V6B7K,E$3ZFSO)+0A2RCVQ99V>R&6O)9,/..J%C0
MQUPD90H6)=>Z4["+UA;?W^WX^?NZ=!_6^K:/Z7)8;3>KM=5ZPU1Z3U!LV3V'
M60;55S)77,L&]+WMV$I\]5@Y@$G$/6(6YCMUQ09Z6H2=J]>E1 %C -QV(BY-
M3<LV)(Y0MNLM>5HI0MA"$@#S1RLC#G*\)[SDN[QRR*6#-RUC?S\_+;SZCZ]O
M=T^C7XZ=^D=C136PL.V"!L+^P*;!5LA+5/9!B(=T2?V?9)&*BX8J2DTHU^ _
ML9NOTZF$FDH@Z=6X>!*D)'#."<,CEC>-?:.2,5YI)%)F+.X,=:-7=PJDV&%<
MR33 #O)I'D"KOMH3OMT\M_COO[_C_736O371_NFLSNJQQ)G5MS!KMHO,S$5^
MV4RZ6O3FLXDG5L71A8FO0%MV3.VR 9L!*9&1"AX6PYJE72\[7H& !!*.D2['
M\KTY([9*6H6DBKH\D4T$5RRZVGG+R20UHXI#&"JL[Q][*1WDDA8*JYW\SUZ]
M#L1N=_J V]_V]?+7?A_9ZSU;#JU7CM@4:=K<%8=)W%^T7#71<KM(29T]0ZEK
MU$!4+&S:&(^L4R6C*I[R$CL1YY,,3/V:.0\8++Y)&\R=H$E,LK5YTEDCO0B*
M&RJ52ER>:QWDT9A+2S(TW L74.(XF]4IL7+S^((VWZ=?J^W_ $'35E4KHJ?H
M]AZ7K#"VJJQ^>E?6=:UC3H:,H@ $7,1TE MU[<4K+NH(4>U)VL<&&D*BN.)%
M369,"1>D\S[-DE6<QILR)H\I&\4K?E2S+9E=YV9D99.\IJ@V"E8BSK-R![U&
M4+W9C0Z;^8V\SOY]?A^WSW_?KJ;RZ4KKMBU[3 B[ Q6Z[<[5I3=5=L"O,+&1
ML75<>[49>F6Z)%D8V5?KLK QM1L%<D8MU:HJR@&R)25JCH\"24<I#4BJL\9D
MDABNTY(QT/A[9$JS1.59>\5VFCD1@.<3*@(#,RX!V_:#UZD?6"/L_P"](; Z
M6=DZQH^IH*"AH+;X],J>[Z@F)>UA([#KHY&[71+):#R:]9MN!2H4DY867X"A
M'"$$5J!JLA,5VR>X(4\60CY]?*5K,]N1WDIF:6E-S%I*\A%$&.)1)'4*LO=G
MO+ .TLDP22/O74JV=P?IW'MVV]@\A[/:>GT=-;K=.M%VO3M;TK5>T :(13JC
MHS5-('8BASGY4VP1=08KMUB9Q9,H9%FQ068UE I0H K<JW*.(\IM *U%TN1G
MJ369[55IQ-->M3DN5"+&\QDA=-D5U=N6Y!8\./F2WJX.WL/O_P"A^OW:TY>]
MF,^97IR&.W(4\5.U$80^0Q7WL*D;[4)H6,UO<)-/OGSB&0M-@CZ?N@#1+!5H
MKSA*V)&+2X@=%N.TO&1'6F (Y257O!ZM>9"UF%?4V!:V3;A;8B*0#=7ZDYY=
M02!T/_?[3U^!\M8H/V8]A1-@V S;0#Q%ADFBMC1;0EZ1&(:&O(EQ;,HCR;TU
M(1$X8D(5F6+\\$(N?#C[8U'C&#%A27L]I8^#1BHP6-2*[;P<B3 82)QW'%T7
MDQ0;,1&S0EB"&5R]NW7KUW'M]_3V>S;;W:DD5[/5^G:KDZ9+V_-YC8I.Q[<.
M7"5WT6T)6QVC6DW6HP**GI":< P719M4$?J-TE#'T78BHJ%<=6W',2:M;Y\3
M6DF6(P,WAH2KR[U4CBLI(S,BH&VGCYK< W[UF:3;=BNG+<[[>8V^'GO\.A]N
M_O/75\:>TEL2"D>GDV[L *F*?6]C[1W#9!'16T6/J"W"V*W8X^&!9*));@(A
MR8NN&O494()%M4Z-CRB_1$>F@7+M=UR"P\N$TM>M3C(/R="F3W;.=E'>.$AW
MV&Y8S,P7D-V_G\=A]0]OT]!]IUN]REUYTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
MXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTT
@XTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152702472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcellx Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001786205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149209080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 127,160<span></span>
</td>
<td class="nump">$ 30,833<span></span>
</td>
<td class="nump">$ 46,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">83,769<span></span>
</td>
<td class="nump">73,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,974<span></span>
</td>
<td class="nump">8,192<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">220,903<span></span>
</td>
<td class="nump">112,809<span></span>
</td>
<td class="nump">49,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,127<span></span>
</td>
<td class="nump">10,318<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,172<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid research and development expenses and other long-term assets</a></td>
<td class="nump">8,913<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">243,390<span></span>
</td>
<td class="nump">128,782<span></span>
</td>
<td class="nump">57,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">13,180<span></span>
</td>
<td class="nump">4,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,808<span></span>
</td>
<td class="nump">14,845<span></span>
</td>
<td class="nump">5,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">4,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred Rent Credit, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">21,799<span></span>
</td>
<td class="nump">16,918<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,379<span></span>
</td>
<td class="nump">114,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value of $0.001 per share; 200,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2022; no shares authorized, issued or outstanding as of December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 35,718,764 shares issued and outstanding as of March 31, 2022; 185,000,000 shares authorized and 544,210 shares issued and outstanding as of December 31, 2021</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">384,095<span></span>
</td>
<td class="nump">8,615<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(162,496)<span></span>
</td>
<td class="num">(130,111)<span></span>
</td>
<td class="num">(65,142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">221,591<span></span>
</td>
<td class="num">(121,515)<span></span>
</td>
<td class="num">(63,720)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)</a></td>
<td class="nump">$ 243,390<span></span>
</td>
<td class="nump">128,782<span></span>
</td>
<td class="nump">57,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,894<span></span>
</td>
<td class="nump">28,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,367<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149412024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">98,973,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">35,718,764<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">35,718,764<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,795,227<span></span>
</td>
<td class="nump">29,795,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary Equity, Liquidation Preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29,795<span></span>
</td>
<td class="nump">$ 29,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,402,623<span></span>
</td>
<td class="nump">49,402,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary Equity, Liquidation Preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 85,681<span></span>
</td>
<td class="nump">$ 85,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,224,618<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,396,707<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,396,707<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary Equity, Liquidation Preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149370920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,401<span></span>
</td>
<td class="nump">8,521<span></span>
</td>
<td class="nump">46,883<span></span>
</td>
<td class="nump">25,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,034<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">18,135<span></span>
</td>
<td class="nump">7,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">32,435<span></span>
</td>
<td class="nump">11,282<span></span>
</td>
<td class="nump">65,018<span></span>
</td>
<td class="nump">32,096<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(32,435)<span></span>
</td>
<td class="num">(11,282)<span></span>
</td>
<td class="num">(65,018)<span></span>
</td>
<td class="num">(32,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,385)<span></span>
</td>
<td class="num">(11,281)<span></span>
</td>
<td class="num">(64,969)<span></span>
</td>
<td class="num">(32,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (32,409)<span></span>
</td>
<td class="num">$ (11,281)<span></span>
</td>
<td class="num">$ (64,989)<span></span>
</td>
<td class="num">$ (32,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (33.45)<span></span>
</td>
<td class="num">$ (145.55)<span></span>
</td>
<td class="num">$ (112.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">20,760,722<span></span>
</td>
<td class="nump">337,302<span></span>
</td>
<td class="nump">446,379<span></span>
</td>
<td class="nump">286,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141951448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A</div></th>
<th class="th"><div>Series B</div></th>
<th class="th"><div>Series C</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement</div>
</th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>Private Placement</div>
</th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th">
<div>Redeemable Convertible Preferred Stock </div>
<div>Series A</div>
</th>
<th class="th">
<div>Redeemable Convertible Preferred Stock </div>
<div>Series B</div>
</th>
<th class="th">
<div>Redeemable Convertible Preferred Stock </div>
<div>Series C</div>
</th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="num">$ (32,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 42,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">4,986,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable convertible preferred stock for cash, Value, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable convertible preferred stock for cash, shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, value</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="num">(63,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">114,261<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable convertible preferred stock for cash, Value, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable convertible preferred stock for cash, shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,970,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquitySharesSubscriptionsAmount', window );">Issuance of Series C redeemable convertible preferred stock for cash, subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, value</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="num">(74,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Ending Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="nump">$ 91,186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending balance, Shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="nump">7,970,812<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">(63,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">114,261<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series C redeemable convertible preferred stock for cash, Value, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable convertible preferred stock for cash, shares, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,396,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,396,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, value</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investment</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="num">(121,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,111)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="nump">$ 119,118<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="nump">10,396,707<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">233,379<span></span>
</td>
<td class="nump">$ 28,894<span></span>
</td>
<td class="nump">$ 85,367<span></span>
</td>
<td class="nump">$ 119,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of transaction costs, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,283<span></span>
</td>
<td class="nump">$ 9,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,274<span></span>
</td>
<td class="nump">$ 9,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock , net of transaction costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,487,500<span></span>
</td>
<td class="nump">590,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock, value</a></td>
<td class="nump">233,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,894)<span></span>
</td>
<td class="num">$ (85,367)<span></span>
</td>
<td class="num">$ (119,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,785,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,413,272)<span></span>
</td>
<td class="num">(8,975,585)<span></span>
</td>
<td class="num">(10,396,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, value</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vesting of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, value</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investment</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 221,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (162,496)<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,718,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TemporaryEquitySharesSubscriptionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares subscriptions amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TemporaryEquitySharesSubscriptionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682153769656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 15,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682148291528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,385)<span></span>
</td>
<td class="num">$ (11,281)<span></span>
</td>
<td class="num">$ (64,969)<span></span>
</td>
<td class="num">$ (32,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Noncash operating lease expense</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,481<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">6,754<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="num">(8,423)<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="num">(6,059)<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="num">(1,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">7,764<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,586)<span></span>
</td>
<td class="num">(9,507)<span></span>
</td>
<td class="num">(54,238)<span></span>
</td>
<td class="num">(28,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(467)<span></span>
</td>
<td class="num">(1,066)<span></span>
</td>
<td class="num">(5,783)<span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(27,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">16,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(10,643)<span></span>
</td>
<td class="num">(1,066)<span></span>
</td>
<td class="num">(79,976)<span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CapitalLeasePrincipalPayments', window );">Payments under capital leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PaymentsForRepurchaseOfRestrictedStock', window );">Payment for repurchase of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock (initial public offering), net of transactions costs</a></td>
<td class="nump">129,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock (private placement), net of transactions costs</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under finance leases</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">139,556<span></span>
</td>
<td class="nump">81,628<span></span>
</td>
<td class="nump">118,451<span></span>
</td>
<td class="nump">41,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents and restricted cash</a></td>
<td class="nump">96,327<span></span>
</td>
<td class="nump">71,055<span></span>
</td>
<td class="num">(15,763)<span></span>
</td>
<td class="nump">12,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of the year</a></td>
<td class="nump">31,032<span></span>
</td>
<td class="nump">46,795<span></span>
</td>
<td class="nump">46,795<span></span>
</td>
<td class="nump">34,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">127,359<span></span>
</td>
<td class="nump">117,850<span></span>
</td>
<td class="nump">31,032<span></span>
</td>
<td class="nump">46,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities', window );">Deferred offering costs included in accrued liabilities</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CapitalLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital lease principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CapitalLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_DeferredOfferingCostsIncludedInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_DeferredOfferingCostsIncludedInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses and other current and non-current assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PaymentsForRepurchaseOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for repurchase of restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PaymentsForRepurchaseOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682253061432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of The Business</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of the Business </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;8, 2022, the Company closed its initial public offering (IPO) of 9,487,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $15.00 per share. The Company received net proceeds of $127.3&#160;million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $15.0&#160;million. The Company&#8217;s common stock began trading on the Nasdaq Global Select Market on February&#160;4, 2022, under the ticker symbol &#8220;ACLX.&#8221; </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has funded its operations primarily with proceeds from public and private offerings of its common and preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of the Business </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;8, 2022, the Company closed its initial public offering (IPO) of 9,487,500 shares of its common stock, including the exercise in full by the underwriters&#8217; of their option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $15.00 per share. The Company received net proceeds of $128.0&#160;million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $14.3&#160;million. The Company&#8217;s common stock began trading on the Nasdaq Global Select Market on February&#160;4, 2022, under the ticker symbol &#8220;ACLX.&#8221; </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the IPO in February 2022, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-5.5041</div></div> reverse stock split of the Company&#8217;s redeemable convertible preferred stock and common stock. The reverse stock split became effective on January&#160;28, 2022. All share and per share amounts in the consolidated financial statements and notes thereto have been retrospectively adjusted for all periods presented to reflect the reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices were proportionately increased in accordance with the terms of the appropriate securities agreements. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects to incur substantial operating losses to continue development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has funded its operations primarily with proceeds from public and private offerings of its common stock and prior to the IPO, private placements of its preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company continues to closely monitor the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on all aspects of its business, including how it has and will continue to impact operations and the operations of its suppliers, vendors, and business partners, and may take further precautionary and preemptive actions as may be required by federal, state, or local authorities. In addition, the Company has taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of its employees, the Company has introduced enhanced safety measures in its facilities. Although to date, the Company&#8217;s business has not been materially impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> it is possible that its clinical development timelines could be negatively affected by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which could materially and adversely affect its business, financial condition, and results of operations. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682253061432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no material changes to the significant accounting policies disclosed in the Company&#8217;s Audited Consolidated Financial Statements included elsewhere in this prospectus during the three months ended March&#160;31, 2022, except for the adoption of the new lease accounting standard effective January&#160;1, 2022, as discussed below. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (<span style="-sec-ix-hidden:hidden49526100">Topic 842</span>)</div></div>. Topic 842 increases transparency and comparability among </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The adoption of this standard resulted in the recognition of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) assets in the amount of $3.3&#160;million and operating lease liabilities in the amount of $5.4&#160;million for operating lease liabilities on the consolidated balance sheet, with a $2.1&#160;million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January&#160;1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components are accounted for together as a single lease component for leases associated with office space. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and Consolidation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). The accompanying consolidated financial statements include the accounts of Arcellx and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Accounting Estimates </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates used in preparing the accompanying consolidated financial statements include, but are not limited to, estimates related to the fair value of assets, research and development accruals, recoverability of long-lived assets, share-based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents and Restricted Cash </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking and sweep accounts with commercial banks and financial institutions. Cash equivalents consist of money market funds. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of its lease agreement equal to the required security deposit amount. This amount is presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash on the accompanying balance sheets. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company carries marketable securities classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at fair value as determined by prices for identical or similar securities at the balance sheet date. The inputs used to determine the fair value of marketable securities are considered Level&#160;2 within the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as accumulated other comprehensive loss in stockholders&#8217; deficit. Realized gains or losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, net. Marketable securities are classified as either current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets based on their contractual maturity dates. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At each reporting date, or more frequently if circumstances warrant, the Company evaluates individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities for impairment. In the event that the carrying value of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt security exceeds its fair value and the decline in fair value is determined to be other-than-temporary, the Company records an impairment charge in earnings attributable to the estimated credit loss. In determining whether a decline in the value of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt security is other-than-temporary, the Company evaluates various factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, the duration and extent to which fair value has been less than carrying value, the Company&#8217;s assessment as to whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, and the severity of the impairment. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts payable, and accrued expenses. The carrying amounts of accounts payable and accrued expenses generally approximate their respective fair value due to their short-term nature. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for recurring and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fair value measurements in accordance with ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#8212;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#8212;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, and marketable securities. The Company maintains its cash and cash equivalents and restricted cash at two accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in highly rated debt securities consisting entirely of corporate bonds, which the Company has the ability to liquidate within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-day</div> should the need for additional cash arise. Accordingly, the Company believes the exposure to credit risk on its marketable securities portfolio is low. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost and depreciated over its estimated useful life using the straight-line method. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses. Routine expenditures for maintenance and repairs are expensed as incurred. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated useful lives for property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful&#160;Life</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">3 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lesser of estimated useful life or remaining lease term</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment under capital lease</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lesser of estimated useful life or remaining lease term</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset group is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were no impairment losses recognized during the years ended December&#160;31, 2021 or 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company deferred certain legal, professional accounting and other third-party fees that were directly associated with the Company&#8217;s February 2022 IPO as deferred offering costs. Upon consummation of the IPO, these costs have been reclassified to shareholders&#8217; deficit as a reduction of the offering proceeds. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trial Accrual and Expenses </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company makes payments in connection with clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies, and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, the Company accrues expenses related to the work performed by contract manufacturing organizations based on the progress of the work performed. If the amounts the Company is obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical manufacturing, technical development, and overhead and facility-related costs. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed, or at such time when the Company does not expect the goods to be delivered or services to be performed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s redeemable convertible preferred stock is classified outside of stockholders&#8217; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to not accrete the carrying value and related issuance costs of the redeemable convertible preferred stock to its redemption value until such redemption becomes probable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for its share-based compensation in accordance with ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (ASC 718). ASC 718 requires all share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards, or restricted stock units, to be recognized as expense based on their grant date fair values. The Company has elected to account for forfeitures as they occur. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates the fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The Company will reconsider the use of the Black-Scholes option pricing model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. A discussion of management&#8217;s methodology for developing the assumptions used in the valuation model follow: </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock</div></div>&#8212;Given the lack of an active public market for the common stock (prior to the Company&#8217;s IPO), the fair value of the Company&#8217;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the significant risks associated with the Company&#8217;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#8217;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#8217;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. Following the closing of February 2022 IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of the Company&#8217;s common stock on the date of grant. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield</div></div>&#8212;The expected dividend yield is based on the Company&#8217;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for the Company&#8217;s common stock (prior to the Company&#8217;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate</div></div>&#8212;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term</div></div>&#8212;The Company uses the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s share-based compensation related to stock options subject to service conditions are recognized as expense ratably over the required service period based on their grant date fair values. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Awards, Unrestricted Stock Awards, and Restricted Stock Units </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or without cause from their position. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates the fair value of awards subject to both a market condition and a performance condition on the grant date using a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method beginning when the achievement of the performance condition becomes probable over the applicable service period. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company granted restricted stock units (RSUs) to an executive officer subject to service, performance, and market conditions. The Company used the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model approach to estimate the fair value of the RSUs on the date of grant. Refer to Note 13 for further discussion regarding the terms of awards granted during the year ended December&#160;31, 2021. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">jurisdiction-by-jurisdiction</div></div> basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div> (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The standard update is effective for fiscal years beginning after December&#160;15, 2021. The adoption of this standard as of January&#160;1, 2022 did not have any impact on the Company&#8217;s consolidated financial statements and related disclosures.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13)</div></div></div>, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for interim and annual periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#8217;s investment portfolio, current market conditions, and historical credit loss activity, the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. The Company will continue monitoring through the effective date of the standard. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated all other ASUs issued through the date the consolidated financial statements were issued and believes that the adoption of these will not have a material impact on the Company&#8217;s consolidated financial statements. </div></div> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes. As of December&#160;31, 2021 and 2020, the Company had no interest or penalties related to uncertain income tax benefits.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment and Geographic Information </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842)</div></div>, which requires lessees to recognize a lease liability and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset for each lease with a term longer than twelve months. The recognized liability is measured at the present value of lease payments not yet paid, and the corresponding asset represents the lessee&#8217;s right to use the underlying asset over the lease term and is based on the liability, subject to certain adjustments. For purposes of statements of operations and cash flows, the standard retains the dual model with leases classified as either operating or finance. The Company adopted the new standard effective January&#160;1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. The Company also elected the practical expedient not to separate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components of a contract from the lease component to which they relate. Prior periods were not retrospectively adjusted. The adoption of the new lease standard is expected to result in the recognition of lease liabilities of approximately $5.4&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets of approximately $3.3&#160;million, which include the impact of existing deferred rents and tenant improvement allowances on the consolidated balance sheet as of January&#160;1, 2022. There will be no cumulative effect adjustment to the opening balance of retained earnings as of January&#160;1, 2022. Adoption of Topic 842 is not expected to have an impact on the consolidated statements of operations or cash flows. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232146856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Restricted Cash </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $0.2&#160;million as of both March&#160;31, 2022 and December&#160;31, 2021. This amount is presented as restricted cash on the accompanying consolidated balance sheets. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">127,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">117,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">127,359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">117,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Restricted Cash </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $0.2&#160;million as of both December&#160;31, 2021 and 2020. This amount is presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash on the accompanying consolidated balance sheets. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">30,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">31,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232002728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Fair Value of Financial Instruments </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets by level within the fair value hierarchy were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">124,509</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">124,708</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,053</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items have been reclassified to conform to current period presentation. </div></div></td></tr></table> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of financial assets categorized within Level&#160;1 of the fair value hierarchy is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. The fair value of financial assets categorized within Level&#160;2 of the fair value hierarchy is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div>The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March&#160;31, 2022 or the year ended December&#160;31, 2021.<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Fair Value of Financial Instruments </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the years ended December&#160;31, 2021 or 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232146856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_MarketableSecuritiesDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Marketable Securities </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div></div> marketable securities were as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">50,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">50,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,814</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021 (1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,053</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items have been reclassified to conform to current period presentation. </div></div></td></tr></table> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt marketable securities held as of March&#160;31, 2022 had contractual maturities of less than one year. The Company had 9 securities in an unrealized loss position with an aggregate related fair value of $24.8&#160;million as of March&#160;31, 2022. All securities in an unrealized loss position as of March&#160;31, 2022 had been in a loss position for less than 12 months. Unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities as of March&#160;31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities was recorded for the three months ended March&#160;31, 2022. The Company does not intend to sell these securities or expect to be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $0.2&#160;million, offset by amortization of premium of $0.1&#160;million, for the three months ended March&#160;31, 2022, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Marketable Securities </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div></div> marketable securities, which consisted entirely of corporate bonds, were as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross unrealized gains</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross unrealized loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities held as of December&#160;31, 2021 had contractual maturities of less than one year. The Company had 11 securities in an unrealized loss position with an aggregate related fair value of $30.8&#160;million as of December&#160;31, 2021. All securities in an unrealized loss position as of December&#160;31, 2021 had been in a loss position for less than twelve months. Unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities as of December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities was recorded for the year ended December&#160;31, 2021. The Company does not intend to sell these securities and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $0.3&#160;million, offset by amortization of premium of $0.2&#160;million, for the year ended December&#160;31, 2021, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_MarketableSecuritiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_MarketableSecuritiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232059176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Prepaid Expenses and Other Current Assets </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expense and current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">9,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Prepaid Expenses and Other Current Assets </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,551</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expense and current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other assets current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152403672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Property and Equipment, Net </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">9,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment under capital leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,162</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense was $1.0&#160;million and $0.6&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152403112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Commitments </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the manufacturing services agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW) in February 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. The Lonza SOW is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> for the first six months of the term and carries minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> costs including upfront payments, milestone fees, and fixed monthly payments during the related period. Subsequent to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> period, the Company may terminate the arrangement for any reason upon 12 months&#8217; prior notification to Lonza. As of March&#160;31, 2022, the Company&#8217;s minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> costs payable to Lonza was approximately $40.6&#160;million. Variable costs under this arrangement include materials, external testing, and other services. The Company paid $5.8&#160;million under this arrangement during the three months ended March&#160;31, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152578808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsAbstract', window );"><strong>Capital Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock', window );">Capital Lease Obligations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Capital Lease Obligations </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company signed a capital lease agreement for equipment in December 2020. The lease term is for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">thirty-six</div> months with an option to purchase the equipment for $1 at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in June 2021. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company signed a capital lease agreement for equipment in March 2021. The lease term is for seventeen months and ownership of the asset will be transferred to the Company at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in March 2021. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the remaining future lease obligations under these capital lease agreements are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Amount representing interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of net minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The capital lease obligation balance was $0.3&#160;million as of December&#160;31, 2021, of which $0.1&#160;million was included in other current liabilities and $0.2&#160;million was included in other long-term liabilities. The implied interest rate used to reduce the minimum lease payments to present value was 5.0%. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made payments with respect to capital lease obligations of $0.4&#160;million and $0 for the years ended December 2021 and 2020, respectively. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense in connection with the Company&#8217;s capital leases were immaterial for the years ended December 2021 and 2020. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for capital leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209026<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682154303960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Accrued Liabilities </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">793</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">14,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Accrued Liabilities </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued vacation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152564904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_LesseeOperatingAndFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Leases </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in 2030 unless renewed. The lease agreement contains rent escalation, rent abatement clauses, tenant improvement allowances, and optional renewal clauses. The lease agreement also includes variable lease payments, which are primarily related to common area maintenance and utility charges. The Company also has short-term operating leases with a term of one year or less. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the Company had operating lease ROU assets of $3.2&#160;million, current operating lease liabilities of $0.4&#160;million, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> operating lease liabilities of $4.8&#160;million. The Company used a discount rate of 8.2% in measuring operating lease liabilities. The remaining lease term was 7.8 years as of March&#160;31, 2022. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s total operating lease costs were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">377</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">554</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, future minimum operating lease payments were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to operating leases is as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets obtained in exchange for operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_LesseeOperatingAndFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Finance Leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_LesseeOperatingAndFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152545784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Commitments and Contingencies </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in 2030 unless renewed. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The lease agreements contain rent escalation, rent abatement clauses, and tenant improvement allowances. Rent expense is recognized on a straight-line basis over the lease term. The deferred rent balance was $2.1&#160;million and $2.0&#160;million as of December&#160;31, 2021 and 2020, respectively. Rent expense for the years ended December&#160;31, 2021 and 2020 was $1.2&#160;million and $0.6&#160;million, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2021 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">917</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing Services Agreement with Lonza Houston, Inc. </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Manufacturing Services Agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW), effective as of February&#160;16, 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW commences from February&#160;1, 2022 and expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. Under the Lonza SOW, the Company is obligated to pay to Lonza certain payments aggregating a total of approximately $24.5&#160;million in 2022, including creditable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments, creditable milestone fees that are subject to certain deductions and fixed monthly payments and which are payable over the term of the Lonza SOW. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2021 and 2020, the Company was not involved in any material legal proceedings. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification Agreements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As permitted under Delaware law, the Company indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is, or was, serving at our request in such capacity. The term of this indemnification is for the officer&#8217;s or director&#8217;s lifetime. Additionally, the Company has entered into and expects to continue to enter into indemnification agreements with certain executive officers and directors. Further, in the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date however, the Company has not incurred any material costs as a result of such indemnifications nor experienced any losses related to them. As of December&#160;31, 2021, the Company was not aware of any claims under indemnification arrangements and does not expect significant claims related to these indemnification obligations. Therefore, no related reserves were established. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152541256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Company&#8217;s IPO, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company&#8217;s outstanding shares of preferred stock were converted into 24,785,564 shares of common stock. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent to the IPO, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the shares of common stock issued and outstanding in connection with the IPO and the subsequent private placement, total shares of common stock issued and outstanding includes shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35,736,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unvested early exercised shares of common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(757</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35,718,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No dividends have been declared or paid by the Company through March&#160;31, 2022. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock and stockholders equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232223656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Redeemable Convertible Preferred Stock </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Company&#8217;s IPO on February&#160;4, 2022, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company&#8217;s outstanding shares of preferred stock were converted into 24,785,564 shares of common stock. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had 29,795,227 authorized shares of $0.001 par value Series A redeemable convertible preferred stock (Series A preferred stock), of which 5,413,272 shares were issued and outstanding as of both December&#160;31, 2021 and 2020. The Series A preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#8217;s control. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had 49,402,623 authorized shares of $0.001 par value Series B redeemable convertible preferred stock (Series B preferred stock), of which 8,975,585 shares were issued and outstanding as of both December&#160;31, 2021 and 2020 from the issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> redeemable convertible preferred stock discussed below. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had 27,444,339 authorized shares of $0.001 par value Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> redeemable convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock), of which 4,986,153 shares were issued and outstanding as of both December&#160;31, 2021 and 2020. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company had authorized 21,958,284 shares of $0.001 par value Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> redeemable convertible preferred stock (Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock and with the Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock, the Series B preferred stock). The Company concluded that the investors&#8217; rights to purchase Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock upon achieving certain clinical activities (i.e., clinically significant and meaningful biological activity with manageable toxicities from a phase 1 clinical trial, approval by the board of an acceptable clinical development plan, IND filling by a specified date and completion of other key analysis) (the Milestone closing) did not meet the definition of a freestanding financial instrument, as they were legally attached and assigned together with the issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, after weighing the substantive and implied terms and features of the Series B preferred stock instrument, the Company concluded that the conversion option was clearly and closely related to the preferred stock host contract and therefore would not need to be bifurcated. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2020, the Company issued the second tranche of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock in exchange for $42.8&#160;million in cash. The Company incurred less than $0.1&#160;million in transaction costs related to this issuance. As of both December&#160;31, 2021 and 2020, 3,989,432 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock were issued and outstanding. The Series B preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#8217;s control. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company authorized 57,224,618 shares of $0.001 par value Series C redeemable convertible preferred stock (the Series C preferred stock) and issued 10,396,707 shares in exchange for $120.0&#160;million in cash. The Company incurred $0.9&#160;million in transaction costs related to this issuance. The Series C preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#8217;s control. The Company&#8217;s Series A preferred stock, Series B preferred stock, and Series C preferred stock (collectively, the preferred stock) had the following rights and preferences, privileges, and restrictions. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The holders of preferred stock were entitled to receive annual noncumulative dividends at an annual rate of 8% in preference to any declaration or payment of any dividend on the common stock, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis when, as and if declared by the board of directors. As of both December&#160;31, 2021 and 2020, no dividends had been declared. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each share of preferred stock represented such number of votes as is equal to the number of shares of common stock into which such share is convertible. The holders of preferred stock were able to vote together with the holders of common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis on all matters in which stockholders were entitled to vote. The holders of Series A preferred stock, exclusively and as a separate class, were entitled to elect three directors, the holders of the Series B preferred stock, exclusively and as a separate class, were entitled to elect two directors, and the holders of Series C preferred stock, exclusively and as a separate class, were entitled to elect one director of the Company as of December&#160;31, 2021. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Rights </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each share of preferred stock was convertible into shares of common stock determined by dividing the original issuance price by the conversion price. The conversion price was equal to the original issuance price, which were $5.51 for Series A preferred stock, $8.60 for Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock, $10.74 for Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock, and $11.55 for Series C preferred stock. Conversion could occur at any time at the option of each holder. All series of preferred stock converted into shares of common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-to-one</div></div> basis as part of the Company&#8217;s IPO in February 2022. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Series C preferred stock were entitled to receive, before any payment of any of the assets of the Company to the holders of the Series B preferred stock, the holders of the Series A preferred stock, or the holders of common stock, $11.55 per share (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of Series A preferred stock or the holders of common stock, the holders of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-2</div> preferred stock were entitled to receive, before any payment of any of the assets of the Company to the holders of the Series A preferred stock or the holders of common stock, $8.60 per share and $10.74 per share, respectively (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of common stock, the holders of Series A preferred stock were entitled to receive $5.51 per share with respect to shares of Series A preferred stock. The Company did not adjust the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of preferred stock and these circumstances were not probable as the balance sheet dates. Subsequent adjustments to the carrying values of the liquidation preferences were to be made only when it became probable that such a liquidation event will occur. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption Rights </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preferred stock was contingently redeemable upon certain change in control events that are outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-dilution Protection </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of the preferred stock had proportional anti-dilution protection for splits, dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by the Company for consideration per unit less than the applicable conversion price per unit of any series of preferred stock, were to be on a broad-based weighted average basis. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloure of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152629400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Common Stock </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the board of directors approved an amendment to the Amended and Restated Certificate of Incorporation of the Company, which increased the number of authorized shares of common stock. The Company had <div style="display:inline;">185,000,000</div> and <div style="display:inline;">98,973,453</div> authorized shares of $0.001 par value common stock as of December&#160;31, 2021 and 2020, respectively, of which 544,210 and 333,658 shares were issued and outstanding as of December&#160;31, 2021 and 2020, respectively. The shares issued and outstanding represent shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s employees satisfied the exercise price of the options exercised by making cash payments to the Company. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding <br/>(including shares early exercised)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">375,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: (unvested early exercised shares of common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(757</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(41,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">333,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No dividends have been declared or paid by the Company through December&#160;31, 2021. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;4, 2022, the Company issued and sold an aggregate of 590,318 shares of common stock in a private placement at a price of $16.94 per share for an aggregate purchase price of $10.0&#160;million. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682153648440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. Share-Based Compensation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s 2017 Equity Incentive Plan (the 2017 Plan) provided for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, to the Company&#8217;s employees, directors, and consultants. The 2017 Plan terminated one business day prior to effectiveness of the 2022 Equity Incentive Plan (the 2022 Plan) with respect to the grant of future awards. The 2022 Plan became effective on February&#160;3, 2022 and provides for the grant of incentive stock options to the Company&#8217;s employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (RSUs), and performance awards to the Company&#8217;s employees, directors, and consultants. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate number of shares of common stock that may be issued pursuant to equity awards under the 2022 Plan is 4,296,875 shares, plus shares subject to awards granted under the 2017 Plan that expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by the Company (provided that the maximum number of shares that may be added to the 2022 Plan pursuant to awards under the 2017 Plan is 6,269,300 shares). The number of shares of common stock reserved for issuance under the 2022 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plan shall be cumulatively increased on the first day of each fiscal year, beginning with the Company&#8217;s 2023 fiscal year and ending on the ten year anniversary of the date the Company&#8217;s board of directors approves the 2022 Plan equal to the least of 4,296,875 shares, 5% of the total number of shares of common stock outstanding as of the last day of the immediately preceding fiscal year, or a lesser number of shares determined by the administrator of the 2022 Plan. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense by type of award was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">696</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units&#8212;executive officer</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized $4.5&#160;million in share-based compensation expense during the three months ended March&#160;31, 2022, of which $1.3&#160;million was included in research and development and $3.2&#160;million was included in general and administrative in the accompanying condensed consolidated statements of operations. The Company recognized $0.8&#160;million in share-based compensation expense during the three months ended March&#160;31, 2021, of which $0.2&#160;million was included in research and development and $0.6&#160;million was included in general and administrative in the accompanying condensed consolidated statements of operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted under the 2017 Plan and the 2022 Plan vest over <span style="-sec-ix-hidden:hidden49526059">three</span> or four years and expire after 10 years. The Company uses the Black Scholes option pricing model to determine the grant date fair value of stock options. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding and Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (1)</div><br/>(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,598,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,829,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(311,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,113,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">44,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,767,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March&#160;31, 2022. </div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs granted under the 2022 Plan generally vest annually over three years. The Company uses the market price of the Company&#8217;s common shares on the date of grant to determine the fair value of RSUs. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSU activity for awards under the 2022 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average&#160;Grate<br/>Date Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">703,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">702,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units&#8212;Executive Officer </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company granted 952,804 RSUs to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions. All 952,804 RSUs were outstanding as of March&#160;31, 2022 and December&#160;31, 2021 and no RSUs were vested or exercisable as of March&#160;31, 2022 or December&#160;31, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Condition </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The service condition to vesting of the RSU Award requires the executive officer&#8217;s continued employment with the Company through the achievement of any of the performance conditions and the market condition. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Condition </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance conditions to vesting of the RSU Award include (i)&#160;the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii)&#160;a Change in Control following an IPO. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market Condition </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the three performance condition scenarios is applicable at the time of measurement. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company value on a Change in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). Upon a Change in Control, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company value in the event of an IPO is measured each June&#160;30 and December&#160;31 following an IPO (subject to applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period) and represents the Company&#8217;s Enterprise Value. The Company&#8217;s Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> period ending on the day prior to the applicable IPO measurement date, less cash. Upon an IPO, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilized <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of the IPO in February 2022, the performance condition of the RSU Award was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period (10 years) and based on the fair value (aggregate $10.3 million) according to the IPO scenario as no other performance condition was deemed probable at the time of the IPO. The Company recognized $0.8&#160;million in share-based compensation expense related to this RSU Award during the three months ended March&#160;31, 2022. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Share-Based Compensation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s 2017 Equity Incentive Plan (the 2017 Plan) provides for the grant of Stock Options, Stock Appreciation Rights, Restricted Stocks, or Restricted Stock Units. The aggregate number of shares of common stock available for issuance pursuant to awards under the 2017 Plan, amended, is 7,927,329 shares. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options granted under the 2017 Plan generally vest over <span style="-sec-ix-hidden:hidden49526058">three</span> or four years and expire after 10 years. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price for stock options granted is the fair value of common shares as determined by the board of directors as of the date of grant. The board of directors determined the value the Company&#8217;s common stock considering many factors, including third-party valuation of the Company&#8217;s common shares, as well as additional factors, which may have changed since the date of the most recent contemporaneous valuation through the date of grant. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity for awards under the 2017 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding and Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div><br/>(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,952,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,145,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(288,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(210,552</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,598,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,696,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31, 2021. </div></div></td></tr></table> <div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2021 and 2020 was $5.77 and $3.19, respectively. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate grant date fair value of stock options vested during the years ended December&#160;31, 2021 and 2020 was approximately $5.3&#160;million and $1.7&#160;million, respectively. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded share-based compensation expense of $6.8&#160;million and $1.1&#160;million during the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, there was $19.6&#160;million of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2017 Plan. This remaining compensation expense is expected to be recognized over a weighted average period of 2.8 years as of December&#160;31, 2021. The intrinsic value of the options exercised for the years ended December&#160;31, 2021 and 2020 was $1.0&#160;million and $0.5&#160;million, respectively. Share-based compensation cost is measured at fair value and is recognized as expense on a straight-line basis over the requisite service period. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">551</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,051</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.3&#8212;7&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90%&#8212;110%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">95%&#8212;100%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.83%&#8212;1.52%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.42%&#8212;1.42%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Given the lack of an active public market for the common stock during 2021 and 2020, the fair value of the Company&#8217;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports, described further within the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units</div></div> section below. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company granted 952,804 restricted stock units (RSU) to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions. All 952,804 RSUs were outstanding as of December&#160;31, 2021 and no RSUs were vested or exercisable as of December&#160;31, 2021. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Condition </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The service condition to vesting of the RSU Award requires the executive officer&#8217;s continued employment with the Company through the achievement of any of the performance conditions and the market condition. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Condition </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance conditions to vesting of the RSU Award include (i)&#160;the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii)&#160;a Change in Control following an IPO. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Market Condition </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the three performance condition scenarios is applicable at the time of measurement. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company value on a Change in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). Upon a Change in Control, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company value in the event of an IPO is measured each June&#160;30 and December&#160;31 following an IPO (subject to applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period) and represents the Company&#8217;s Enterprise Value. The Company&#8217;s Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div> period ending on the day prior to the applicable IPO measurement date, less cash. Upon an IPO, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i) one-sixth</div> of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company utilized <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. In applying the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> methodology, Change in Control Market Capitalization and Enterprise Value were simulated and allocated to the various classes of equity in the Company&#8217;s capital structure according to the characteristics of that capital structure, such as the number of shares of each class of equity, seniority levels, liquidation preferences and conversion values for redeemable convertible preferred stock, and participation thresholds for common stock and each series of redeemable convertible preferred stock. The fair value of the RSU Award in each of the three performance condition scenarios is the average of the discounted proceeds to the common stock across all simulated paths. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Application of the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model to each of the three performance condition scenarios requires various subjective assumptions that represent management&#8217;s best estimates of the fair value of common stock, expected equity volatility, risk-free interest rate, discount period, expected dividend yield, and time to achievement of a performance condition. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock and Fair Value of Total Equity</div></div>&#8212;Given the lack of an active public market for the common stock (prior to the Company&#8217;s IPO), the fair value of the Company&#8217;s common stock and total equity was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date and resulting total equity value. In determining the fair value of its common stock and total equity value, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant risks associated with the Company&#8217;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#8217;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#8217;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for the Company&#8217;s common stock (prior to the Company&#8217;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period commensurate with the expected date of achievement of a performance condition. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate and Discount Period&#8212;</div></div>The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected time to achieve of a performance condition. The discount period is the period between the valuation date and the assumed change in control event date, with the assumption that all equity shares in the capital structure are paid out in cash. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Yield</div></div>&#8212;The expected dividend yield is based on the Company&#8217;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Time to Achievement of a Performance Condition&#8212;</div></div>The time to the achievement of a performance condition is based on the Company&#8217;s best estimate of the period of time to achievement of a performance condition that attains the established market capitalization thresholds. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company determined the fair value of the RSU Award considering third-party valuation reports. The Company considered several objective and subjective factors, including weighted probability of various liquidation event scenarios, operating and financial performance, discount for lack of marketability of the Company&#8217;s equity, and general and industry-specific economic outlook, among other factors. The discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the RSUs. The assumptions used in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div>s simulation models to determine the grant date fair value of the RSU Award for each of the three performance condition scenarios were as follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 38%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change&#160;in&#160;Control</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">IPO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change&#160;in&#160;Control<br/>Following an IPO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">June 9, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">December 7, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">December 7, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to liquidity event (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.56&#8212;3.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100%&#8212;110%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.11%&#8212;0.31%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.47%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.44%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of marketability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26%&#8212;32%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of the RSU award (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The performance condition will only become probable in the event of a change in control or an IPO. Accordingly, as a performance condition was not achieved in 2021, the Company did not record any share-based compensation expense related to this RSU Award in the year ended December&#160;31, 2021. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Upon completion of the IPO in February 2022, the performance condition was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period (10 years) and based on the fair value (aggregate $10.3 million) according to the IPO scenario <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model as no other performance condition was deemed probable at the time of the IPO.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152605336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Net Loss Per Share Attributable to Common Stockholders </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s potentially dilutive securities include options to purchase common stock, unvested shares of restricted common stock, and redeemable convertible preferred stock. The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,359,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,113,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,871,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of restricted common stock from early exercises</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">34,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">702,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units&#8212;executive officer</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">952,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,786,876</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,265,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14. Net Loss Per Share Attributable to Common Stockholders </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s potential dilutive securities, which include redeemable convertible preferred stock, options to purchase common stock, and unvested shares of restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,785,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,388,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,598,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,910,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of restricted common stock from early exercises</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">41,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">952,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,337,198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,341,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Shares of redeemable convertible preferred stock also participated in dividends with shares of common stock (if and when declared) and therefore were deemed participating securities. The holders of redeemable convertible preferred stock did not contractually share in losses and therefore no additional net loss per share has been disclosed under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152921016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15. Income Taxes </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s provision for income taxes consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current income tax provision (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax provision (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(9,625</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,625</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision (benefit) for income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State tax, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(29.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(29.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax rates and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The significant components of the Company&#8217;s deferred income tax assets (liabilities) were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24,692</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-qualified</div> stock options</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,665</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">941</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred income tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,724</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(38,725</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,635</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred income tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(132</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(89</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred income tax assets (liabilities)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i)&#160;future reversals of existing taxable temporary differences; (ii)&#160;future taxable income exclusive of reversing temporary difference and carryforwards; (iii)&#160;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&#160;tax planning strategies. The Company&#8217;s net deferred income tax assets are not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net change in valuation allowance for the years ended December&#160;31, 2021 and 2020 was an increase of $19.1&#160;million and $9.6&#160;million, respectively, due to the losses incurred for research and development. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March&#160;27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act) to provide certain relief as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. The Company did not apply for any relief offered by the government during the years ended December&#160;31, 2021 or 2020. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company had Federal and State net operating loss (NOL) carryforwards of approximately $117.6&#160;million and $116.5&#160;million, respectively, as of December&#160;31, 2021. The Company also had federal research and development tax credit carryforwards of approximately $3.2&#160;million, available to potentially offset future federal income taxes, as of December&#160;31, 2021. Approximately $6.3&#160;million of the Federal NOL was generated prior to 2018 and will begin expiring in 2035 while the remaining $111.3&#160;million will be carried forward indefinitely but are limited to eighty percent of taxable income. The State NOL will begin expiring in 2035. The federal research and development tax carryforwards, if not utilized, will expire beginning in 2038. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">However, the deductibility of such federal net operating losses may be limited. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation&#8217;s ability to use its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> NOL carryforwards and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> tax attributes to offset its post-change income may be limited. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not determined if it has experienced Section&#160;382 ownership changes in the past and if a portion of its NOL and tax credit carryforwards are subject to an annual limitation under Section&#160;382. In addition, the Company may experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside of its control. If the Company determines that an ownership change has occurred and its ability to use its historical NOL and tax credit carryforwards is materially limited, it would harm the Company&#8217;s future operating results by effectively increasing the Company&#8217;s future tax obligations. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has not identified any uncertain tax positions and did not recognize any adjustments for unrecognized tax benefits. The Company&#8217;s Federal and State tax returns for all years, 2015 through 2020, remain subject to examination by taxing authorities due to the tax attribute carryforwards. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152391000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16. Employee Benefit Plan </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sponsors a tax deferred retirement plan under the Code to provide retirement benefits for all eligible employees. Participating employees may voluntarily contribute up to limits provided by Internal Revenue Service regulations. The Company made contributions to the plan of $0.4&#160;million and $0.2&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 715<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472162&amp;loc=d3e58407-109430<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235042<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149427336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and Consolidation </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). The accompanying consolidated financial statements include the accounts of Arcellx and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Accounting Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Accounting Estimates </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates used in preparing the accompanying consolidated financial statements include, but are not limited to, estimates related to the fair value of assets, research and development accruals, recoverability of long-lived assets, share-based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents and Restricted Cash </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking and sweep accounts with commercial banks and financial institutions. Cash equivalents consist of money market funds. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of its lease agreement equal to the required security deposit amount. This amount is presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> restricted cash on the accompanying balance sheets. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company carries marketable securities classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at fair value as determined by prices for identical or similar securities at the balance sheet date. The inputs used to determine the fair value of marketable securities are considered Level&#160;2 within the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as accumulated other comprehensive loss in stockholders&#8217; deficit. Realized gains or losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, net. Marketable securities are classified as either current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> assets based on their contractual maturity dates. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At each reporting date, or more frequently if circumstances warrant, the Company evaluates individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities for impairment. In the event that the carrying value of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt security exceeds its fair value and the decline in fair value is determined to be other-than-temporary, the Company records an impairment charge in earnings attributable to the estimated credit loss. In determining whether a decline in the value of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt security is other-than-temporary, the Company evaluates various factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, the duration and extent to which fair value has been less than carrying value, the Company&#8217;s assessment as to whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, and the severity of the impairment. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts payable, and accrued expenses. The carrying amounts of accounts payable and accrued expenses generally approximate their respective fair value due to their short-term nature. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for recurring and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fair value measurements in accordance with ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2&#8212;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#8212;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, and marketable securities. The Company maintains its cash and cash equivalents and restricted cash at two accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in highly rated debt securities consisting entirely of corporate bonds, which the Company has the ability to liquidate within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-day</div> should the need for additional cash arise. Accordingly, the Company believes the exposure to credit risk on its marketable securities portfolio is low. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost and depreciated over its estimated useful life using the straight-line method. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses. Routine expenditures for maintenance and repairs are expensed as incurred. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated useful lives for property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful&#160;Life</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">3 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lesser of estimated useful life or remaining lease term</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment under capital lease</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lesser of estimated useful life or remaining lease term</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset group is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were no impairment losses recognized during the years ended December&#160;31, 2021 or 2020. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company deferred certain legal, professional accounting and other third-party fees that were directly associated with the Company&#8217;s February 2022 IPO as deferred offering costs. Upon consummation of the IPO, these costs have been reclassified to shareholders&#8217; deficit as a reduction of the offering proceeds. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock', window );">Clinical Trial Accrual and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trial Accrual and Expenses </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company makes payments in connection with clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies, and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, the Company accrues expenses related to the work performed by contract manufacturing organizations based on the progress of the work performed. If the amounts the Company is obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical manufacturing, technical development, and overhead and facility-related costs. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed, or at such time when the Company does not expect the goods to be delivered or services to be performed. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s redeemable convertible preferred stock is classified outside of stockholders&#8217; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to not accrete the carrying value and related issuance costs of the redeemable convertible preferred stock to its redemption value until such redemption becomes probable. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for its share-based compensation in accordance with ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div> (ASC 718). ASC 718 requires all share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards, or restricted stock units, to be recognized as expense based on their grant date fair values. The Company has elected to account for forfeitures as they occur. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates the fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees.</div> The Company will reconsider the use of the Black-Scholes option pricing model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. A discussion of management&#8217;s methodology for developing the assumptions used in the valuation model follow: </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock</div></div>&#8212;Given the lack of an active public market for the common stock (prior to the Company&#8217;s IPO), the fair value of the Company&#8217;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the significant risks associated with the Company&#8217;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#8217;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#8217;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. Following the closing of February 2022 IPO, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of the Company&#8217;s common stock on the date of grant. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield</div></div>&#8212;The expected dividend yield is based on the Company&#8217;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Equity Volatility</div></div>&#8212;Due to the lack of a public market for the Company&#8217;s common stock (prior to the Company&#8217;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate</div></div>&#8212;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term</div></div>&#8212;The Company uses the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s share-based compensation related to stock options subject to service conditions are recognized as expense ratably over the required service period based on their grant date fair values. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Awards, Unrestricted Stock Awards, and Restricted Stock Units </div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or without cause from their position. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company estimates the fair value of awards subject to both a market condition and a performance condition on the grant date using a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method beginning when the achievement of the performance condition becomes probable over the applicable service period. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company granted restricted stock units (RSUs) to an executive officer subject to service, performance, and market conditions. The Company used the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div> simulation model approach to estimate the fair value of the RSUs on the date of grant. Refer to Note 13 for further discussion regarding the terms of awards granted during the year ended December&#160;31, 2021. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">jurisdiction-by-jurisdiction</div></div> basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes. As of December&#160;31, 2021 and 2020, the Company had no interest or penalties related to uncertain income tax benefits.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment and Geographic Information </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (Topic 842)</div></div>, which requires lessees to recognize a lease liability and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset for each lease with a term longer than twelve months. The recognized liability is measured at the present value of lease payments not yet paid, and the corresponding asset represents the lessee&#8217;s right to use the underlying asset over the lease term and is based on the liability, subject to certain adjustments. For purposes of statements of operations and cash flows, the standard retains the dual model with leases classified as either operating or finance. The Company adopted the new standard effective January&#160;1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. The Company also elected the practical expedient not to separate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components of a contract from the lease component to which they relate. Prior periods were not retrospectively adjusted. The adoption of the new lease standard is expected to result in the recognition of lease liabilities of approximately $5.4&#160;million and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets of approximately $3.3&#160;million, which include the impact of existing deferred rents and tenant improvement allowances on the consolidated balance sheet as of January&#160;1, 2022. There will be no cumulative effect adjustment to the opening balance of retained earnings as of January&#160;1, 2022. Adoption of Topic 842 is not expected to have an impact on the consolidated statements of operations or cash flows. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div> (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is part of the FASB&#8217;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The standard update is effective for fiscal years beginning after December&#160;15, 2021. The adoption of this standard as of January&#160;1, 2022 did not have any impact on the Company&#8217;s consolidated financial statements and related disclosures.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13)</div></div></div>, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for interim and annual periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#8217;s investment portfolio, current market conditions, and historical credit loss activity, the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. The Company will continue monitoring through the effective date of the standard. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated all other ASUs issued through the date the consolidated financial statements were issued and believes that the adoption of these will not have a material impact on the Company&#8217;s consolidated financial statements. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases (<span style="-sec-ix-hidden:hidden49526100">Topic 842</span>)</div></div>. Topic 842 increases transparency and comparability among </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The adoption of this standard resulted in the recognition of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (ROU) assets in the amount of $3.3&#160;million and operating lease liabilities in the amount of $5.4&#160;million for operating lease liabilities on the consolidated balance sheet, with a $2.1&#160;million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January&#160;1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components are accounted for together as a single lease component for leases associated with office space. </div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. </div></div><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trial accrual and expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting pronouncements policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_RedeemableConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_RedeemableConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment and geographic information policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152526248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated useful lives for property and equipment are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated&#160;Useful&#160;Life</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">3 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">7 years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lesser of estimated useful life or remaining lease term</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment under capital lease</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Lesser of estimated useful life or remaining lease term</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152589608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">127,160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">117,651</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">127,359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">117,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">30,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">31,032</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">46,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232053560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Company's Financial Assets</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets by level within the fair value hierarchy were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">124,509</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">50,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">124,708</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities <div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,053</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items have been reclassified to conform to current period presentation. </div></div></td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (cash equivalent)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market fund (long-term restricted cash)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682154693048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div></div> marketable securities were as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">50,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">50,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,814</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,797</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,013</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,812</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">83,769</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021 (1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">43,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. government agency</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,056</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,053</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These items have been reclassified to conform to current period presentation. </div></div></td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Available-for-sale</div></div> marketable securities, which consisted entirely of corporate bonds, were as follows (in thousands): </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortized costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross unrealized gains</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross unrealized loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">73,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232053560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expense and current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">9,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,551</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other prepaid expense and current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,049</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152607336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule Of Property And Equipment Consist</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">9,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,514</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment under capital leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">142</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation and amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(2,162</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152569336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock', window );">Summary of Future Lease Obligations Under These Capital Lease Agreements</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the remaining future lease obligations under these capital lease agreements are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">160</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Amount representing interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of net minimum lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital leases future minimum payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682153665944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">793</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,478</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">14,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities consist of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,429</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,113</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued vacation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">578</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149336392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating lease costs</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s total operating lease costs were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">377</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">554</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum operating lease payments</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, future minimum operating lease payments were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2021 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">917</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to operating leases is as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">206</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROU assets obtained in exchange for operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of supplemental cash flow information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141769128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, future minimum operating lease payments were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,033</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,846</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2021 are as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">894</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">917</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141824808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Reconciliation of Shares Issued and Outstanding</a></td>
<td class="text">Below is a reconciliation of shares issued and outstanding:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35,736,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unvested early exercised shares of common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(757</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35,718,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">Below is a reconciliation of shares issued and outstanding:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding <br/>(including shares early exercised)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">375,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: (unvested early exercised shares of common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(757</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(41,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">333,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152573096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Reconciliation of Shares Issued and Outstanding</a></td>
<td class="text">Below is a reconciliation of shares issued and outstanding:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35,736,584</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unvested early exercised shares of common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(17,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(757</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">35,718,764</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">Below is a reconciliation of shares issued and outstanding:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares of common stock legally issued and outstanding <br/>(including shares early exercised)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,967</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">375,492</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: (unvested early exercised shares of common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(757</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(41,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shares issued and outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">544,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">333,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149305032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Compensation Expense</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense by type of award was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">696</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units&#8212;executive officer</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4,481</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">551</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">6,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,051</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding and Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"> (1)</div><br/>(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,598,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,829,435</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(311,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,113,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">44,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,767,303</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">4.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March&#160;31, 2022. </div></div></td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity for awards under the 2017 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding and Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div><br/>(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,952,145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">2.66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,145,794</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(288,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(210,552</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,598,830</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,349</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,696,109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">5,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31, 2021. </div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSU activity for awards under the 2022 Plan is presented below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average&#160;Grate<br/>Date Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">703,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">702,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option pricing model for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.3&#8212;7&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7&#160;years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90%&#8212;110%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">95%&#8212;100%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.83%&#8212;1.52%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.42%&#8212;1.42%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">&#8212;%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock', window );">Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The assumptions used in the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Monte Carlo</div></div>s simulation models to determine the grant date fair value of the RSU Award for each of the three performance condition scenarios were as follows:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 38%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change&#160;in&#160;Control</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">IPO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change&#160;in&#160;Control<br/>Following an IPO</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">June 9, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">December 7, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">December 7, 2021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to liquidity event (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.56&#8212;3.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100%&#8212;110%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">70%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.11%&#8212;0.31%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1.47%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.44%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of marketability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26%&#8212;32%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5%</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of the RSU award (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">10,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of the fair value of the RSU Award considering thirdparty valuation reports.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152389272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,359,669</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,113,589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,871,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of restricted common stock from early exercises</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,820</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">34,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">702,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units&#8212;executive officer</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">952,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,786,876</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">25,265,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">24,785,564</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,388,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,598,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,910,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested shares of restricted common stock from early exercises</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">41,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">952,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,337,198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,341,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232032040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Provision For Income Taxes</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s provision for income taxes consists of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current income tax provision (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax provision (benefit):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7,671</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(4,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(9,625</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,625</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total provision (benefit) for income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State tax, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(29.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(29.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in tax rates and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The significant components of the Company&#8217;s deferred income tax assets (liabilities) were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. federal net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">24,692</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">12,826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State net operating loss carryforward</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-qualified</div> stock options</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,665</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">941</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">570</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">556</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross deferred income tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">38,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,724</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(38,725</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,635</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred income tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">132</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(132</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(89</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred income tax assets (liabilities)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149393608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of The Business - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 08, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders Equity Reverse Stock Split</a></td>
<td class="text">1-for-5.5041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="nump">$ 127.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses', window );">Cash paid for underwriting discounts and commissions and other offering expenses</a></td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">9,487,500<span></span>
</td>
<td class="nump">9,487,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase', window );">Additional stock issued during period shares exercised by underwriters with option to purchase</a></td>
<td class="nump">1,237,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="nump">$ 128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses', window );">Cash paid for underwriting discounts and commissions and other offering expenses</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional stock issued during period shares exercised by underwriters with option to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for underwriting discounts and commissions and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141898600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Property and Equipment, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems', window );"><strong>Property Plant And Equipment Estimated Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems', window );"><strong>Property Plant And Equipment Estimated Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems', window );"><strong>Property Plant And Equipment Estimated Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems', window );"><strong>Property Plant And Equipment Estimated Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_EquipmentUnderCapitalLeaseMember', window );">Equipment under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems', window );"><strong>Property Plant And Equipment Estimated Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_EquipmentUnderCapitalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_EquipmentUnderCapitalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149467992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adopted date</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">$ 5,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances', window );">Reclassification of deferred rent and tenant improvement allowances</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized Tax Benefits Income Tax Penalties Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of Long Lived Assets Held for use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of deferred rent and tenant improvement allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232059048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash - (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash reserve</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682148277032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 127,160<span></span>
</td>
<td class="nump">$ 30,833<span></span>
</td>
<td class="nump">$ 117,651<span></span>
</td>
<td class="nump">$ 46,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 127,359<span></span>
</td>
<td class="nump">$ 31,032<span></span>
</td>
<td class="nump">$ 117,850<span></span>
</td>
<td class="nump">$ 46,795<span></span>
</td>
<td class="nump">$ 34,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682145328680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 83,769<span></span>
</td>
<td class="nump">$ 73,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market fund (cash equivalent)</a></td>
<td class="nump">124,509<span></span>
</td>
<td class="nump">26,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_LongTermRestrictedCashFairValue', window );">Money market fund (long-term restricted cash)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">124,708<span></span>
</td>
<td class="nump">26,671<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">83,769<span></span>
</td>
<td class="nump">73,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">50,904<span></span>
</td>
<td class="nump">43,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Corporate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">14,797<span></span>
</td>
<td class="nump">17,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">15,061<span></span>
</td>
<td class="nump">5,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Asset-Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 3,007<span></span>
</td>
<td class="nump">$ 7,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These items have been reclassified to conform to current period presentation.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_LongTermRestrictedCashFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term restricted cash fair value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_LongTermRestrictedCashFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682147870728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">$ 83,812<span></span>
</td>
<td class="nump">$ 73,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">83,769<span></span>
</td>
<td class="nump">73,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">50,904<span></span>
</td>
<td class="nump">43,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">50,904<span></span>
</td>
<td class="nump">43,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">14,814<span></span>
</td>
<td class="nump">17,084<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">14,797<span></span>
</td>
<td class="nump">17,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Government Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">15,081<span></span>
</td>
<td class="nump">5,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">15,061<span></span>
</td>
<td class="nump">5,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 3,007<span></span>
</td>
<td class="nump">7,690<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bond Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These items have been reclassified to conform to current period presentation.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682148276024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>condition</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>condition</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_DebtSecuritiesAvailableForSaleContractualMaturities', window );">Available-for-sale debt marketable securities contractual maturities</a></td>
<td class="text">less than one year<span></span>
</td>
<td class="text">less than one year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in an unrealized loss position | condition</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value an unrealized loss position</a></td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating', window );">Interest income</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_DebtSecuritiesAvailableForSaleContractualMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities available for sale contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_DebtSecuritiesAvailableForSaleContractualMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income, amortization of premium and accretion of discount on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale); classified as operating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149284968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs</a></td>
<td class="nump">$ 6,388<span></span>
</td>
<td class="nump">$ 6,143<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_OtherPrepaidExpenseAndCurrentAssets', window );">Other prepaid expense and current assets</a></td>
<td class="nump">3,586<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 9,974<span></span>
</td>
<td class="nump">$ 8,192<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_OtherPrepaidExpenseAndCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other prepaid expense and current assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_OtherPrepaidExpenseAndCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research and Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682147883576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule Of Property And Equipment Consist (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,480<span></span>
</td>
<td class="nump">$ 6,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(1,126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 10,127<span></span>
</td>
<td class="nump">10,318<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,115<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,355<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentUnderCapitalLeasesMember', window );">Lab equipment under capital leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentUnderCapitalLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_LabEquipmentUnderCapitalLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149375480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682232075608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PriorNotificationPeriodToTerminateArrangement', window );">Prior notification period to terminate arrangement</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_MinimumNonCancellableCosts', window );">Minimum non-cancellable costs</a></td>
<td class="nump">$ 40.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Obligated to pay to Lonza</a></td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_MinimumNonCancellableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum non-cancellable costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_MinimumNonCancellableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PriorNotificationPeriodToTerminateArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior notification period to terminate arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PriorNotificationPeriodToTerminateArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149392056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Lease Obligations - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CapitalLeaseAgreementMaturityPeriod', window );">Capital lease agreement maturity Period</a></td>
<td class="text">17 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet', window );">Purchase of equipment under capital lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent', window );">Implied interest rate used to reduce the minimum lease payments to present</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments to capital lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CapitalLeaseAgreementMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital lease agreement maturity Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CapitalLeaseAgreementMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implied interest rate used to reduce the minimum lease payments to present.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of leased long-lived, physical assets used to produce goods and services and not intended for resale meeting the criteria for capitalization, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682145298120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Lease Obligations - Summary of Future Lease Obligations Under These Capital Lease Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: Amount representing interest</a></td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of net minimum lease payments</a></td>
<td class="nump">$ 326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682148324904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ResearchAndDevelopmentAccruedExpensesCurrent', window );">Research and development accrued expenses</a></td>
<td class="nump">$ 12,129<span></span>
</td>
<td class="nump">$ 6,626<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_AccruedOfferingCostsCurrent', window );">Accrued offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_OtherAccruedLiabilityCurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="nump">$ 13,180<span></span>
</td>
<td class="nump">$ 4,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_AccruedOfferingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued offering costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_AccruedOfferingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_OtherAccruedLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other accrued liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_OtherAccruedLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ResearchAndDevelopmentAccruedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development accrued expenses, current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ResearchAndDevelopmentAccruedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682148251720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Short-term operating lease, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 4,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease, discount rate</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space | Gaithersburg, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682153772200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149396616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Operating Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Through December 31, 2022</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">7,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of total operating lease liabilities</a></td>
<td class="nump">$ 5,214<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682153955320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 3,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for measurement of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682147795864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_OperatingLeasesDeferredRent', window );">Deferred rent balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">MOLDOVA | Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=aclx_LonzaSowMember', window );">Lonza SOW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_OperatingLeasesDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_OperatingLeasesDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aclx_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aclx_LonzaSowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aclx_LonzaSowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141898472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">894<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">2,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">$ 7,060<span></span>
</td>
<td class="nump">$ 7,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682147753736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">one vote<span></span>
</td>
<td class="text">one vote<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared or paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion of preferred stock</a></td>
<td class="nump">24,785,564<span></span>
</td>
<td class="nump">24,785,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682149421304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details) - Common Stock - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockSharesLegallyIssuedAndOutstanding', window );">Total shares of common stock legally issued and outstanding</a></td>
<td class="nump">35,736,584<span></span>
</td>
<td class="nump">544,967<span></span>
</td>
<td class="nump">375,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_UnvestedEarlyExercisedSharesOfCommonStock', window );">Less: unvested early exercised shares of common stock</a></td>
<td class="nump">17,820<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">41,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockSharesIssuedAndOutstanding', window );">Total shares issued and outstanding</a></td>
<td class="nump">35,718,764<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockSharesLegallyIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares legally issued and outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockSharesLegallyIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_UnvestedEarlyExercisedSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested early exercised shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_UnvestedEarlyExercisedSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682140437432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock -  Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>DIRECTORS </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock shares | $</a></td>
<td class="nump">$ 81,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquitySharesDividendRate', window );">Temporary Equity Shares Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member] | Dividend Declared [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,785,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,785,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,795,227<span></span>
</td>
<td class="nump">29,795,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="nump">5,413,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.', window );">Number of directors entitled to be elected by each class of stock. | DIRECTORS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquitySharesConversionPrice', window );">Temporary equity shares conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Temporary equity liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,402,623<span></span>
</td>
<td class="nump">49,402,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="nump">8,975,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.', window );">Number of directors entitled to be elected by each class of stock. | DIRECTORS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TransactionCosts', window );">Transaction costs | $</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,396,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.', window );">Number of directors entitled to be elected by each class of stock. | DIRECTORS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquitySharesConversionPrice', window );">Temporary equity shares conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Temporary equity liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStocksMember', window );">Series C Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,224,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TransactionCosts', window );">Transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesB1RedeemableConvertiblePreferredStockMember', window );">Series B1 Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,444,339<span></span>
</td>
<td class="nump">27,444,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,986,153<span></span>
</td>
<td class="nump">4,986,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,986,153<span></span>
</td>
<td class="nump">4,986,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquitySharesConversionPrice', window );">Temporary equity shares conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Temporary equity liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesB2RedeemableConvertiblePreferredStockMember', window );">Series B2 Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,958,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989,432<span></span>
</td>
<td class="nump">3,989,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989,432<span></span>
</td>
<td class="nump">3,989,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TransactionCosts', window );">Transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TemporaryEquitySharesConversionPrice', window );">Temporary equity shares conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Temporary equity liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of directors entitled to be elected by each class of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TemporaryEquitySharesConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TemporaryEquitySharesConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TemporaryEquitySharesDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares dividend rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TemporaryEquitySharesDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAxis=us-gaap_DividendDeclaredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesCRedeemableConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesB1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesB1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aclx_SeriesB2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aclx_SeriesB2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152699368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Reconciliation of Shares Issued and Outstanding (Detail) - Common Stock [Member] - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockSharesLegallyIssuedAndOutstanding', window );">Total shares of common stock legally issued and outstanding</a></td>
<td class="nump">35,736,584<span></span>
</td>
<td class="nump">544,967<span></span>
</td>
<td class="nump">375,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_UnvestedEarlyExercisedSharesOfCommonStock', window );">Less: unvested early exercised shares of common stock</a></td>
<td class="num">(17,820)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
<td class="num">(41,834)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_CommonStockSharesIssuedAndOutstanding', window );">Total shares issued and outstanding</a></td>
<td class="nump">35,718,764<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_CommonStockSharesLegallyIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares legally issued and outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_CommonStockSharesLegallyIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_UnvestedEarlyExercisedSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested early exercised shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_UnvestedEarlyExercisedSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682147824008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">98,973,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,718,764<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,718,764<span></span>
</td>
<td class="nump">544,210<span></span>
</td>
<td class="nump">333,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared or paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">590,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 16.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682144891736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>condition </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>condition </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 6,754<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aclx_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,296,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,269,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued under share-based payment arrangement. | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,927,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">unrecognized compensation cost related to unvested share-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_AnniversaryPeriod', window );">Anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of Directors | 2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,296,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance', window );">Percentage increase in common stock reserve for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">600<span></span>
</td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">weighted average grant date fair value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.77<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate grant date fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 and 2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 and 2022 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2017 and 2022 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | 2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,329<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702,663<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted | shares</a></td>
<td class="nump">952,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units, vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Restricted stock units, exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_NumberOfPerformanceConditionScenarios', window );">Number of performance condition scenarios | condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | IPO | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon an IPO, (i) one-sixth of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon an IPO, (i) one-sixth of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Anticipated service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward', window );">Fair value of the RSU award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Change in Control | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon a Change in Control, (i) one-sixth of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon a Change in Control, (i) one-sixth of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | General and Administrative | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_AnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Anniversary period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_AnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_NumberOfPerformanceConditionScenarios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance condition scenarios.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_NumberOfPerformanceConditionScenarios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in common stock reserve for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, fair value assumptions, fair value of award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aclx_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aclx_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aclx_ChangeInControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aclx_ChangeInControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682140331832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,481<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 6,754<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Executive Officer | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682147828104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">2017 and 2022 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, Beginning balance</a></td>
<td class="nump">5,598,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,952,145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">2,829,435<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,145,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(3,504)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(288,557)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(311,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(210,552)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, Ending balance</a></td>
<td class="nump">8,113,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,598,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,952,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="nump">1,767,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,696,109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning balance</a></td>
<td class="nump">$ 5.36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">14.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">11.38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending balance</a></td>
<td class="nump">8.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years), Outstanding</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Exercisable</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">8 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 44,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 16,304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,011<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682145309368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Stock Units Activity (Details) - 2022 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="nump">4,296,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="nump">703,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding, Ending balance</a></td>
<td class="nump">702,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aclx_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aclx_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682154135720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Black-Scholes option pricing model for stock options granted  (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.52%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141667864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award  (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.52%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant', window );">Date of grant</a></td>
<td class="text">Dec.  07,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Time to liquidity event (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Discount for lack of marketability</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of the RSU award (in thousands)</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=aclx_ChangeInControlMember', window );">Change in Control [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant', window );">Date of grant</a></td>
<td class="text">Jun.  09,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of the RSU award (in thousands)</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=aclx_ChangeInControlMember', window );">Change in Control [Member] | Restricted Stock Units (RSUs) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Time to liquidity event (years)</a></td>
<td class="text">3 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Discount for lack of marketability</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=aclx_ChangeInControlMember', window );">Change in Control [Member] | Restricted Stock Units (RSUs) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Time to liquidity event (years)</a></td>
<td class="text">1 year 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Discount for lack of marketability</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=aclx_ChangeInControlFollowingAnIpoMember', window );">Change in control following an IPO [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems', window );"><strong>Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant', window );">Date of grant</a></td>
<td class="text">Dec.  07,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Time to liquidity event (years)</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Discount for lack of marketability</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of the RSU award (in thousands)</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement by Sharebased Payment Award, Date of Grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aclx_ChangeInControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aclx_ChangeInControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aclx_ChangeInControlFollowingAnIpoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aclx_ChangeInControlFollowingAnIpoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682145378152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</a></td>
<td class="nump">9,786,876<span></span>
</td>
<td class="nump">25,265,910<span></span>
</td>
<td class="nump">31,337,198<span></span>
</td>
<td class="nump">16,341,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,359,669<span></span>
</td>
<td class="nump">24,785,564<span></span>
</td>
<td class="nump">14,388,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</a></td>
<td class="nump">8,113,589<span></span>
</td>
<td class="nump">2,871,594<span></span>
</td>
<td class="nump">5,598,073<span></span>
</td>
<td class="nump">1,910,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember', window );">Unvested Shares of Restricted Common Stock from Early Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</a></td>
<td class="nump">17,820<span></span>
</td>
<td class="nump">34,647<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">41,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</a></td>
<td class="nump">702,663<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">952,804<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aclx_RestrictedStockUnitsExecutiveOfficerMember', window );">Restricted stock units - executive officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</a></td>
<td class="nump">952,804<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aclx_RestrictedStockUnitsExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aclx_RestrictedStockUnitsExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141540424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">$ (19,090)<span></span>
</td>
<td class="num">$ (9,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange', window );">Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange', window );">Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Description of income tax examination</a></td>
<td class="text">The Company&#8217;s Federal and State tax returns for all years, 2015 through 2020, remain subject to examination by taxing authorities due to the tax attribute carryforwards.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income tax examination year under examination</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income tax examination year under examination</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 117,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_OperatingLossCarryforwardsExpirationPeriod', window );">Operating loss carryforwards expiration period</a></td>
<td class="text">2035 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_TaxCreditCarryforwardExpirationPeriod', window );">Tax credit carryforward expiration period</a></td>
<td class="text">2038 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Period Two Thousand Thirty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Indefinitely Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">111,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_IncometaxdisclosureLineItems', window );"><strong>IncomeTaxDisclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 116,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_OperatingLossCarryforwardsExpirationPeriod', window );">Operating loss carryforwards expiration period</a></td>
<td class="text">2035 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_IncometaxdisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_IncometaxdisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_OperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards Expiration Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_OperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_TaxCreditCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_TaxCreditCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=aclx_TaxPeriodTwoThousandThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=aclx_TaxPeriodTwoThousandThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=aclx_IndefinitelyCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=aclx_IndefinitelyCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682154091752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Provision For Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current income tax provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred income tax provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="num">(14,840)<span></span>
</td>
<td class="num">(7,671)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(4,250)<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(19,090)<span></span>
</td>
<td class="num">(9,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">19,090<span></span>
</td>
<td class="nump">9,625<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682154100856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</a></td>
<td class="num">(29.40%)<span></span>
</td>
<td class="num">(29.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682141670360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">U.S. federal net operating loss carryforward</a></td>
<td class="nump">$ 24,692<span></span>
</td>
<td class="nump">$ 12,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">7,592<span></span>
</td>
<td class="nump">3,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">3,218<span></span>
</td>
<td class="nump">1,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_DeferredTaxAssetsNonQualifiedStockOptions', window );">Non-qualified&#160;stock options</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses', window );">Accrued bonus</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aclx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">38,857<span></span>
</td>
<td class="nump">19,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(38,725)<span></span>
</td>
<td class="num">(19,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_DeferredTaxAssetsNonQualifiedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets non qualified stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_DeferredTaxAssetsNonQualifiedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits accrued employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139682152525688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions to the plan</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>d332508ds1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aclx="http://arc.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aclx-20220331.xsd" xlink:type="simple"/>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="P01_01_2022To01_01_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="P02_08_2022To02_08_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="P03_31_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aclx:ChangeInControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aclx:ChangeInControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aclx:ChangeInControlFollowingAnIpoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aclx:ChangeInControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aclx:ChangeInControlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EquipmentUnderCapitalLeaseMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:EquipmentUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:LabEquipmentUnderCapitalLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyCarryforwardMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">aclx:IndefinitelyCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxPeriodTwoThousandThirtyFiveMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">aclx:TaxPeriodTwoThousandThirtyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LonzaSowMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aclx:LonzaSowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendDeclaredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:LabEquipmentUnderCapitalLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DividendsAxis">us-gaap:DividendDeclaredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aclx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aclx:RestrictedStockUnitsExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aclx:ChangeInControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-08</startDate>
            <endDate>2022-02-08</endDate>
        </period>
    </context>
    <context id="PAsOn02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-08</instant>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aclx:UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aclx:RestrictedStockUnitsExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P06_01_2021To06_30_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="PAsOn03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aclx:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aclx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aclx:TemporaryEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_condition">
        <measure>aclx:condition</measure>
    </unit>
    <unit id="Unit_DIRECTORS">
        <measure>aclx:DIRECTORS</measure>
    </unit>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="P01_01_2022To03_31_2022" id="hidden49526100">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="hidden49526058">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="hidden49526059">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="P01_01_2022To03_31_2022" id="hidden49526105">S-1/A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2022To03_31_2022">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P01_01_2022To03_31_2022" id="hidden49525947">Arcellx Inc</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To03_31_2022">0001786205</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory contextRef="P01_01_2022To03_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To03_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To03_31_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To03_31_2022">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">30833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46596000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">73784000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2761000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">112809000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">49357000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10318000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3172000</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1761000</us-gaap:DeferredCosts>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2284000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1477000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128782000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">57694000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1333000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">504000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13180000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4576000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">183000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">171000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">149000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14845000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5271000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1895000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1863000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16918000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7153000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">29795227</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">29795227</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">29795000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">29795000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">49402623</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">49402623</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">85681000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">85681000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">57224618</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10396707</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10396707</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">120000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2020_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">119118000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">233379000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">114261000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">98973453</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">544210</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">544210</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">333658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">333658</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8615000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1421000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-130111000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-65142000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-121515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-63720000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128782000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">57694000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">46883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25056000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18135000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7040000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">65018000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">32096000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-65018000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-32096000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">49000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64969000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-32095000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64989000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-32095000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-145.55</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-112.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">446379</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">286105</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5413272</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">4986153</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">42566000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">255771</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">308000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-33047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-32738000</us-gaap:StockholdersEquity>
    <aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">3989432</aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">42801000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">30433</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">47454</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-32095000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-32095000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5413272</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">8975585</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">333658</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-65142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-63720000</us-gaap:StockholdersEquity>
    <aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">10396707</aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">119118000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">10445</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">200107</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">432000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">432000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-64969000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64969000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5413272</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">8975585</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">10396707</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">119118000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">544210</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-130111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-121515000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-64969000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-32095000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1041000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">629000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-210000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6754000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1051000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6059000</aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets>
    <aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-331000</aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">974000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1333000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7764000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2776000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-44000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-54238000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-28662000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5783000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">888000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">74193000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-79976000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-888000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <aclx:CapitalLeasePrincipalPayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">387000</aclx:CapitalLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">432000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">688000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1185000</us-gaap:PaymentsOfStockIssuanceCosts>
    <aclx:PaymentsForRepurchaseOfRestrictedStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-24000</aclx:PaymentsForRepurchaseOfRestrictedStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2020To12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">42801000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">119118000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">118451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">41656000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-15763000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12106000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">34689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">278000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">311000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <aclx:DeferredOfferingCostsIncludedInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1301000</aclx:DeferredOfferingCostsIncludedInAccruedLiabilities>
    <aclx:DeferredOfferingCostsIncludedInAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">576000</aclx:DeferredOfferingCostsIncludedInAccruedLiabilities>
    <us-gaap:NatureOfOperations contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Nature of the Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;8, 2022, the Company closed its initial public offering (IPO) of 9,487,500 shares of its common stock, including the exercise in full by the underwriters&#x2019; of their option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $15.00 per share. The Company received net proceeds of $128.0&#160;million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $14.3&#160;million. The Company&#x2019;s common stock began trading on the Nasdaq Global Select Market on February&#160;4, 2022, under the ticker symbol &#x201c;ACLX.&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the IPO in February 2022, the Company effected a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-5.5041&lt;/div&gt;&lt;/div&gt; reverse stock split of the Company&#x2019;s redeemable convertible preferred stock and common stock. The reverse stock split became effective on January&#160;28, 2022. All share and per share amounts in the consolidated financial statements and notes thereto have been retrospectively adjusted for all periods presented to reflect the reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices were proportionately increased in accordance with the terms of the appropriate securities agreements. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects to incur substantial operating losses to continue development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has funded its operations primarily with proceeds from public and private offerings of its common stock and prior to the IPO, private placements of its preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company continues to closely monitor the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on all aspects of its business, including how it has and will continue to impact operations and the operations of its suppliers, vendors, and business partners, and may take further precautionary and preemptive actions as may be required by federal, state, or local authorities. In addition, the Company has taken steps to minimize the current environment&#x2019;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of its employees, the Company has introduced enhanced safety measures in its facilities. Although to date, the Company&#x2019;s business has not been materially impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; it is possible that its clinical development timelines could be negatively affected by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; which could materially and adversely affect its business, financial condition, and results of operations. &lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9487500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <aclx:AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1237500</aclx:AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">128000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <aclx:CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">14300000</aclx:CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P02_08_2022To02_08_2022">1-for-5.5041</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation and Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). The accompanying consolidated financial statements include the accounts of Arcellx and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Accounting Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates used in preparing the accompanying consolidated financial statements include, but are not limited to, estimates related to the fair value of assets, research and development accruals, recoverability of long-lived assets, share-based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be material. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking and sweep accounts with commercial banks and financial institutions. Cash equivalents consist of money market funds. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of its lease agreement equal to the required security deposit amount. This amount is presented as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; restricted cash on the accompanying balance sheets. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company carries marketable securities classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; at fair value as determined by prices for identical or similar securities at the balance sheet date. The inputs used to determine the fair value of marketable securities are considered Level&#160;2 within the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as accumulated other comprehensive loss in stockholders&#x2019; deficit. Realized gains or losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, net. Marketable securities are classified as either current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets based on their contractual maturity dates. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At each reporting date, or more frequently if circumstances warrant, the Company evaluates individual &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities for impairment. In the event that the carrying value of an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt security exceeds its fair value and the decline in fair value is determined to be other-than-temporary, the Company records an impairment charge in earnings attributable to the estimated credit loss. In determining whether a decline in the value of an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt security is other-than-temporary, the Company evaluates various factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, the duration and extent to which fair value has been less than carrying value, the Company&#x2019;s assessment as to whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, and the severity of the impairment. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts payable, and accrued expenses. The carrying amounts of accounts payable and accrued expenses generally approximate their respective fair value due to their short-term nature. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for recurring and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; fair value measurements in accordance with ASC 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements and Disclosures&lt;/div&gt;&lt;/div&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#x2014;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#x2014;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, and marketable securities. The Company maintains its cash and cash equivalents and restricted cash at two accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in highly rated debt securities consisting entirely of corporate bonds, which the Company has the ability to liquidate within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-day&lt;/div&gt; should the need for additional cash arise. Accordingly, the Company believes the exposure to credit risk on its marketable securities portfolio is low. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at cost and depreciated over its estimated useful life using the straight-line method. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses. Routine expenditures for maintenance and repairs are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated useful lives for property and equipment are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 29%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated&#160;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;7 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;7 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment under capital lease&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews the recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset group is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were no impairment losses recognized during the years ended December&#160;31, 2021 or 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company deferred certain legal, professional accounting and other third-party fees that were directly associated with the Company&#x2019;s February 2022 IPO as deferred offering costs. Upon consummation of the IPO, these costs have been reclassified to shareholders&#x2019; deficit as a reduction of the offering proceeds. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Clinical Trial Accrual and Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company makes payments in connection with clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies, and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, the Company accrues expenses related to the work performed by contract manufacturing organizations based on the progress of the work performed. If the amounts the Company is obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical manufacturing, technical development, and overhead and facility-related costs. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed, or at such time when the Company does not expect the goods to be delivered or services to be performed. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s redeemable convertible preferred stock is classified outside of stockholders&#x2019; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s policy is to not accrete the carrying value and related issuance costs of the redeemable convertible preferred stock to its redemption value until such redemption becomes probable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for its share-based compensation in accordance with ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt; (ASC 718). ASC 718 requires all share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards, or restricted stock units, to be recognized as expense based on their grant date fair values. The Company has elected to account for forfeitures as they occur. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company estimates the fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees.&lt;/div&gt; The Company will reconsider the use of the Black-Scholes option pricing model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. A discussion of management&#x2019;s methodology for developing the assumptions used in the valuation model follow: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Common Stock&lt;/div&gt;&lt;/div&gt;&#x2014;Given the lack of an active public market for the common stock (prior to the Company&#x2019;s IPO), the fair value of the Company&#x2019;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#x2019; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the significant risks associated with the Company&#x2019;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#x2019;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#x2019;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. Following the closing of February 2022 IPO, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of the Company&#x2019;s common stock on the date of grant. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Dividend Yield&lt;/div&gt;&lt;/div&gt;&#x2014;The expected dividend yield is based on the Company&#x2019;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Equity Volatility&lt;/div&gt;&lt;/div&gt;&#x2014;Due to the lack of a public market for the Company&#x2019;s common stock (prior to the Company&#x2019;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-Free Interest Rate&lt;/div&gt;&lt;/div&gt;&#x2014;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Term&lt;/div&gt;&lt;/div&gt;&#x2014;The Company uses the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s share-based compensation related to stock options subject to service conditions are recognized as expense ratably over the required service period based on their grant date fair values. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Awards, Unrestricted Stock Awards, and Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or without cause from their position. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company estimates the fair value of awards subject to both a market condition and a performance condition on the grant date using a &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method beginning when the achievement of the performance condition becomes probable over the applicable service period. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company granted restricted stock units (RSUs) to an executive officer subject to service, performance, and market conditions. The Company used the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation model approach to estimate the fair value of the RSUs on the date of grant. Refer to Note 13 for further discussion regarding the terms of awards granted during the year ended December&#160;31, 2021. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;jurisdiction-by-jurisdiction&lt;/div&gt;&lt;/div&gt; basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt; (ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The standard update is effective for fiscal years beginning after December&#160;15, 2021. The adoption of this standard as of January&#160;1, 2022 did not have any impact on the Company&#x2019;s consolidated financial statements and related disclosures.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for interim and annual periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#x2019;s investment portfolio, current market conditions, and historical credit loss activity, the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. The Company will continue monitoring through the effective date of the standard. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financial statements were issued and believes that the adoption of these will not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes. As of December&#160;31, 2021 and 2020, the Company had no interest or penalties related to uncertain income tax benefits.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company Status &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment and Geographic Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic 842)&lt;/div&gt;&lt;/div&gt;, which requires lessees to recognize a lease liability and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset for each lease with a term longer than twelve months. The recognized liability is measured at the present value of lease payments not yet paid, and the corresponding asset represents the lessee&#x2019;s right to use the underlying asset over the lease term and is based on the liability, subject to certain adjustments. For purposes of statements of operations and cash flows, the standard retains the dual model with leases classified as either operating or finance. The Company adopted the new standard effective January&#160;1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. The Company also elected the practical expedient not to separate the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components of a contract from the lease component to which they relate. Prior periods were not retrospectively adjusted. The adoption of the new lease standard is expected to result in the recognition of lease liabilities of approximately $5.4&#160;million and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets of approximately $3.3&#160;million, which include the impact of existing deferred rents and tenant improvement allowances on the consolidated balance sheet as of January&#160;1, 2022. There will be no cumulative effect adjustment to the opening balance of retained earnings as of January&#160;1, 2022. Adoption of Topic 842 is not expected to have an impact on the consolidated statements of operations or cash flows. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation and Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). The accompanying consolidated financial statements include the accounts of Arcellx and its wholly owned subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Accounting Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates used in preparing the accompanying consolidated financial statements include, but are not limited to, estimates related to the fair value of assets, research and development accruals, recoverability of long-lived assets, share-based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be material. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking and sweep accounts with commercial banks and financial institutions. Cash equivalents consist of money market funds. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of its lease agreement equal to the required security deposit amount. This amount is presented as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; restricted cash on the accompanying balance sheets. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company carries marketable securities classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; at fair value as determined by prices for identical or similar securities at the balance sheet date. The inputs used to determine the fair value of marketable securities are considered Level&#160;2 within the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as accumulated other comprehensive loss in stockholders&#x2019; deficit. Realized gains or losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, net. Marketable securities are classified as either current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; assets based on their contractual maturity dates. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At each reporting date, or more frequently if circumstances warrant, the Company evaluates individual &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities for impairment. In the event that the carrying value of an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt security exceeds its fair value and the decline in fair value is determined to be other-than-temporary, the Company records an impairment charge in earnings attributable to the estimated credit loss. In determining whether a decline in the value of an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt security is other-than-temporary, the Company evaluates various factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, the duration and extent to which fair value has been less than carrying value, the Company&#x2019;s assessment as to whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, and the severity of the impairment. &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts payable, and accrued expenses. The carrying amounts of accounts payable and accrued expenses generally approximate their respective fair value due to their short-term nature. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for recurring and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-recurring&lt;/div&gt; fair value measurements in accordance with ASC 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements and Disclosures&lt;/div&gt;&lt;/div&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2&#x2014;Fair value is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 8%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#x2014;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, and marketable securities. The Company maintains its cash and cash equivalents and restricted cash at two accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in highly rated debt securities consisting entirely of corporate bonds, which the Company has the ability to liquidate within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-day&lt;/div&gt; should the need for additional cash arise. Accordingly, the Company believes the exposure to credit risk on its marketable securities portfolio is low. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at cost and depreciated over its estimated useful life using the straight-line method. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses. Routine expenditures for maintenance and repairs are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated useful lives for property and equipment are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 29%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated&#160;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;7 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;7 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment under capital lease&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated useful lives for property and equipment are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 29%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated&#160;Useful&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;7 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;7 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment under capital lease&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2021To12_31_2021_EquipmentUnderCapitalLeaseMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews the recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset group is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were no impairment losses recognized during the years ended December&#160;31, 2021 or 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company deferred certain legal, professional accounting and other third-party fees that were directly associated with the Company&#x2019;s February 2022 IPO as deferred offering costs. Upon consummation of the IPO, these costs have been reclassified to shareholders&#x2019; deficit as a reduction of the offering proceeds. &lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <aclx:ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Clinical Trial Accrual and Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company makes payments in connection with clinical trials under contracts with contract research organizations that support conducting and managing clinical trials. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies, and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, the Company accrues expenses related to the work performed by contract manufacturing organizations based on the progress of the work performed. If the amounts the Company is obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. &lt;/div&gt;&lt;/div&gt;</aclx:ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical manufacturing, technical development, and overhead and facility-related costs. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed, or at such time when the Company does not expect the goods to be delivered or services to be performed. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <aclx:RedeemableConvertiblePreferredStockPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s redeemable convertible preferred stock is classified outside of stockholders&#x2019; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s policy is to not accrete the carrying value and related issuance costs of the redeemable convertible preferred stock to its redemption value until such redemption becomes probable. &lt;/div&gt;&lt;/div&gt;</aclx:RedeemableConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company accounts for its share-based compensation in accordance with ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt; (ASC 718). ASC 718 requires all share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards, or restricted stock units, to be recognized as expense based on their grant date fair values. The Company has elected to account for forfeitures as they occur. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company estimates the fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees.&lt;/div&gt; The Company will reconsider the use of the Black-Scholes option pricing model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. A discussion of management&#x2019;s methodology for developing the assumptions used in the valuation model follow: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Common Stock&lt;/div&gt;&lt;/div&gt;&#x2014;Given the lack of an active public market for the common stock (prior to the Company&#x2019;s IPO), the fair value of the Company&#x2019;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#x2019; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the significant risks associated with the Company&#x2019;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#x2019;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#x2019;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. Following the closing of February 2022 IPO, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of the Company&#x2019;s common stock on the date of grant. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Dividend Yield&lt;/div&gt;&lt;/div&gt;&#x2014;The expected dividend yield is based on the Company&#x2019;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Equity Volatility&lt;/div&gt;&lt;/div&gt;&#x2014;Due to the lack of a public market for the Company&#x2019;s common stock (prior to the Company&#x2019;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-Free Interest Rate&lt;/div&gt;&lt;/div&gt;&#x2014;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Term&lt;/div&gt;&lt;/div&gt;&#x2014;The Company uses the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s share-based compensation related to stock options subject to service conditions are recognized as expense ratably over the required service period based on their grant date fair values. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Awards, Unrestricted Stock Awards, and Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or without cause from their position. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company estimates the fair value of awards subject to both a market condition and a performance condition on the grant date using a &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method beginning when the achievement of the performance condition becomes probable over the applicable service period. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company granted restricted stock units (RSUs) to an executive officer subject to service, performance, and market conditions. The Company used the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation model approach to estimate the fair value of the RSUs on the date of grant. Refer to Note 13 for further discussion regarding the terms of awards granted during the year ended December&#160;31, 2021. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;jurisdiction-by-jurisdiction&lt;/div&gt;&lt;/div&gt; basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes. As of December&#160;31, 2021 and 2020, the Company had no interest or penalties related to uncertain income tax benefits.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <aclx:EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company Status &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/div&gt;&lt;/div&gt;</aclx:EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock>
    <aclx:SegmentAndGeographicInformationPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment and Geographic Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States. &lt;/div&gt;&lt;/div&gt;</aclx:SegmentAndGeographicInformationPolicyPolicyTextBlock>
    <aclx:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (Topic 842)&lt;/div&gt;&lt;/div&gt;, which requires lessees to recognize a lease liability and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset for each lease with a term longer than twelve months. The recognized liability is measured at the present value of lease payments not yet paid, and the corresponding asset represents the lessee&#x2019;s right to use the underlying asset over the lease term and is based on the liability, subject to certain adjustments. For purposes of statements of operations and cash flows, the standard retains the dual model with leases classified as either operating or finance. The Company adopted the new standard effective January&#160;1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. The Company also elected the practical expedient not to separate the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components of a contract from the lease component to which they relate. Prior periods were not retrospectively adjusted. The adoption of the new lease standard is expected to result in the recognition of lease liabilities of approximately $5.4&#160;million and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets of approximately $3.3&#160;million, which include the impact of existing deferred rents and tenant improvement allowances on the consolidated balance sheet as of January&#160;1, 2022. There will be no cumulative effect adjustment to the opening balance of retained earnings as of January&#160;1, 2022. Adoption of Topic 842 is not expected to have an impact on the consolidated statements of operations or cash flows. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt; (ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; is part of the FASB&#x2019;s overall simplification initiative and seeks to simplify the accounting for income taxes by updating certain guidance and removing certain exceptions. The standard update is effective for fiscal years beginning after December&#160;15, 2021. The adoption of this standard as of January&#160;1, 2022 did not have any impact on the Company&#x2019;s consolidated financial statements and related disclosures.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;</aclx:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn01_01_2022"
      decimals="-5"
      unitRef="Unit_USD">5400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn01_01_2022"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for interim and annual periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#x2019;s investment portfolio, current market conditions, and historical credit loss activity, the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. The Company will continue monitoring through the effective date of the standard. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financial statements were issued and believes that the adoption of these will not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $0.2&#160;million as of both December&#160;31, 2021 and 2020. This amount is presented as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; restricted cash on the accompanying consolidated balance sheets. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,032&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">30833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46596000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets by level within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (cash equivalent)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company did not transfer any assets measured at fair value on a recurring basis between levels during the years ended December&#160;31, 2021 or 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets by level within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (cash equivalent)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26472000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <aclx:LongTermRestrictedCashFairValue
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">199000</aclx:LongTermRestrictedCashFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">73784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26671000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">73784000</us-gaap:AssetsFairValueDisclosure>
    <aclx:LongTermRestrictedCashFairValue
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">199000</aclx:LongTermRestrictedCashFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:AssetsFairValueDisclosure>
    <aclx:MarketableSecuritiesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities, which consisted entirely of corporate bonds, were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross unrealized gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross unrealized loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;All of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities held as of December&#160;31, 2021 had contractual maturities of less than one year. The Company had 11 securities in an unrealized loss position with an aggregate related fair value of $30.8&#160;million as of December&#160;31, 2021. All securities in an unrealized loss position as of December&#160;31, 2021 had been in a loss position for less than twelve months. Unrealized losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities as of December&#160;31, 2021 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities was recorded for the year ended December&#160;31, 2021. The Company does not intend to sell these securities and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $0.3&#160;million, offset by amortization of premium of $0.2&#160;million, for the year ended December&#160;31, 2021, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. &lt;/div&gt;</aclx:MarketableSecuritiesDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities, which consisted entirely of corporate bonds, were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross unrealized gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross unrealized loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">73804000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_CorporateBondSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">73784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <aclx:DebtSecuritiesAvailableForSaleContractualMaturities contextRef="P01_01_2021To12_31_2021">less than one year</aclx:DebtSecuritiesAvailableForSaleContractualMaturities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_condition">11</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">30800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Prepaid Expenses and Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other current assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid research and development costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other prepaid expense and current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total prepaid expenses and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other current assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid research and development costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other prepaid expense and current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total prepaid expenses and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,761&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <aclx:PrepaidResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6143000</aclx:PrepaidResearchAndDevelopmentCosts>
    <aclx:PrepaidResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1551000</aclx:PrepaidResearchAndDevelopmentCosts>
    <aclx:OtherPrepaidExpenseAndCurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2049000</aclx:OtherPrepaidExpenseAndCurrentAssets>
    <aclx:OtherPrepaidExpenseAndCurrentAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1210000</aclx:OtherPrepaidExpenseAndCurrentAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2761000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment under capital leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(2,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,900&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization expense was $1.0&#160;million and $0.6&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,514&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment under capital leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;58&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;96&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,026&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(2,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,900&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">9115000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3514000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2355000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2345000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LabEquipmentUnderCapitalLeasesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">58000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">58000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">109000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12480000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6026000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2162000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1126000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10318000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Capital Lease Obligations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company signed a capital lease agreement for equipment in December 2020. The lease term is for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thirty-six&lt;/div&gt; months with an option to purchase the equipment for $1 at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in June 2021. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company signed a capital lease agreement for equipment in March 2021. The lease term is for seventeen months and ownership of the asset will be transferred to the Company at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in March 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the remaining future lease obligations under these capital lease agreements are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 93%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Amount representing interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of net minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The capital lease obligation balance was $0.3&#160;million as of December&#160;31, 2021, of which $0.1&#160;million was included in other current liabilities and $0.2&#160;million was included in other long-term liabilities. The implied interest rate used to reduce the minimum lease payments to present value was 5.0%. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company made payments with respect to capital lease obligations of $0.4&#160;million and $0 for the years ended December 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense in connection with the Company&#x2019;s capital leases were immaterial for the years ended December 2021 and 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock>
    <aclx:CapitalLeaseAgreementMaturityPeriod contextRef="P01_01_2021To12_31_2021">P36M</aclx:CapitalLeaseAgreementMaturityPeriod>
    <us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1</us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet>
    <aclx:CapitalLeaseAgreementMaturityPeriod contextRef="P03_31_2021To03_31_2021">P17M</aclx:CapitalLeaseAgreementMaturityPeriod>
    <aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the remaining future lease obligations under these capital lease agreements are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 93%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;54&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Amount representing interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of net minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">160000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">130000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">344000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">326000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeaseObligations
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:CapitalLeaseObligations>
    <us-gaap:CapitalLeaseObligations
      contextRef="PAsOn12_31_2021_OtherCurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:CapitalLeaseObligations>
    <us-gaap:CapitalLeaseObligations
      contextRef="PAsOn12_31_2021_OtherNoncurrentLiabilitiesMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:CapitalLeaseObligations>
    <aclx:ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.05</aclx:ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="P01_01_2020To12_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Accrued Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued offering costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued vacation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued offering costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued vacation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;578&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <aclx:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6626000</aclx:ResearchAndDevelopmentAccruedExpensesCurrent>
    <aclx:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2060000</aclx:ResearchAndDevelopmentAccruedExpensesCurrent>
    <aclx:AccruedOfferingCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1301000</aclx:AccruedOfferingCostsCurrent>
    <aclx:AccruedOfferingCostsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">576000</aclx:AccruedOfferingCostsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3429000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1113000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">344000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">249000</us-gaap:AccruedVacationCurrent>
    <aclx:OtherAccruedLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1480000</aclx:OtherAccruedLiabilityCurrent>
    <aclx:OtherAccruedLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">578000</aclx:OtherAccruedLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13180000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4576000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in 2030 unless renewed. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The lease agreements contain rent escalation, rent abatement clauses, and tenant improvement allowances. Rent expense is recognized on a straight-line basis over the lease term. The deferred rent balance was $2.1&#160;million and $2.0&#160;million as of December&#160;31, 2021 and 2020, respectively. Rent expense for the years ended December&#160;31, 2021 and 2020 was $1.2&#160;million and $0.6&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2021 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 91%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,972&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Manufacturing Services Agreement with Lonza Houston, Inc. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the Manufacturing Services Agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW), effective as of February&#160;16, 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW commences from February&#160;1, 2022 and expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. Under the Lonza SOW, the Company is obligated to pay to Lonza certain payments aggregating a total of approximately $24.5&#160;million in 2022, including creditable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments, creditable milestone fees that are subject to certain deductions and fixed monthly payments and which are payable over the term of the Lonza SOW. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2021 and 2020, the Company was not involved in any material legal proceedings. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Indemnification Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As permitted under Delaware law, the Company indemnifies its executive officers and directors for certain events or occurrences while the executive officer or director is, or was, serving at our request in such capacity. The term of this indemnification is for the officer&#x2019;s or director&#x2019;s lifetime. Additionally, the Company has entered into and expects to continue to enter into indemnification agreements with certain executive officers and directors. Further, in the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date however, the Company has not incurred any material costs as a result of such indemnifications nor experienced any losses related to them. As of December&#160;31, 2021, the Company was not aware of any claims under indemnification arrangements and does not expect significant claims related to these indemnification obligations. Therefore, no related reserves were established. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <aclx:LeaseExpirationYear contextRef="P01_01_2021To12_31_2021_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">2030</aclx:LeaseExpirationYear>
    <aclx:OperatingLeasesDeferredRent
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">2100000</aclx:OperatingLeasesDeferredRent>
    <aclx:OperatingLeasesDeferredRent
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">2000000</aclx:OperatingLeasesDeferredRent>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1200000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum lease payments under noncancelable operating leases as of December&#160;31, 2021 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 91%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;917&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,972&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">830000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">851000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">872000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">894000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">917000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2972000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7336000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OtherCommitment
      contextRef="PAsOn12_31_2021_LonzaSowMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">24500000</us-gaap:OtherCommitment>
    <aclx:DiscloureOfRedeemableConvertiblePreferredStockTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. Redeemable Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Company&#x2019;s IPO on February&#160;4, 2022, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company&#x2019;s outstanding shares of preferred stock were converted into 24,785,564 shares of common stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had 29,795,227 authorized shares of $0.001 par value Series A redeemable convertible preferred stock (Series A preferred stock), of which 5,413,272 shares were issued and outstanding as of both December&#160;31, 2021 and 2020. The Series A preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#x2019;s control. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company had 49,402,623 authorized shares of $0.001 par value Series B redeemable convertible preferred stock (Series B preferred stock), of which 8,975,585 shares were issued and outstanding as of both December&#160;31, 2021 and 2020 from the issuance of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; redeemable convertible preferred stock discussed below. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company had 27,444,339 authorized shares of $0.001 par value Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; redeemable convertible preferred stock (Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; preferred stock), of which 4,986,153 shares were issued and outstanding as of both December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company had authorized 21,958,284 shares of $0.001 par value Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; redeemable convertible preferred stock (Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; preferred stock and with the Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; preferred stock, the Series B preferred stock). The Company concluded that the investors&#x2019; rights to purchase Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; preferred stock upon achieving certain clinical activities (i.e., clinically significant and meaningful biological activity with manageable toxicities from a phase 1 clinical trial, approval by the board of an acceptable clinical development plan, IND filling by a specified date and completion of other key analysis) (the Milestone closing) did not meet the definition of a freestanding financial instrument, as they were legally attached and assigned together with the issuance of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; preferred stock. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furthermore, after weighing the substantive and implied terms and features of the Series B preferred stock instrument, the Company concluded that the conversion option was clearly and closely related to the preferred stock host contract and therefore would not need to be bifurcated. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2020, the Company issued the second tranche of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; preferred stock in exchange for $42.8&#160;million in cash. The Company incurred less than $0.1&#160;million in transaction costs related to this issuance. As of both December&#160;31, 2021 and 2020, 3,989,432 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; preferred stock were issued and outstanding. The Series B preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#x2019;s control. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, the Company authorized 57,224,618 shares of $0.001 par value Series C redeemable convertible preferred stock (the Series C preferred stock) and issued 10,396,707 shares in exchange for $120.0&#160;million in cash. The Company incurred $0.9&#160;million in transaction costs related to this issuance. The Series C preferred stock was classified as temporary equity as a result of certain redemption rights that are outside of the Company&#x2019;s control. The Company&#x2019;s Series A preferred stock, Series B preferred stock, and Series C preferred stock (collectively, the preferred stock) had the following rights and preferences, privileges, and restrictions. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The holders of preferred stock were entitled to receive annual noncumulative dividends at an annual rate of 8% in preference to any declaration or payment of any dividend on the common stock, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis when, as and if declared by the board of directors. As of both December&#160;31, 2021 and 2020, no dividends had been declared. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Each share of preferred stock represented such number of votes as is equal to the number of shares of common stock into which such share is convertible. The holders of preferred stock were able to vote together with the holders of common stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis on all matters in which stockholders were entitled to vote. The holders of Series A preferred stock, exclusively and as a separate class, were entitled to elect three directors, the holders of the Series B preferred stock, exclusively and as a separate class, were entitled to elect two directors, and the holders of Series C preferred stock, exclusively and as a separate class, were entitled to elect one director of the Company as of December&#160;31, 2021. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Each share of preferred stock was convertible into shares of common stock determined by dividing the original issuance price by the conversion price. The conversion price was equal to the original issuance price, which were $5.51 for Series A preferred stock, $8.60 for Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; preferred stock, $10.74 for Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; preferred stock, and $11.55 for Series C preferred stock. Conversion could occur at any time at the option of each holder. All series of preferred stock converted into shares of common stock on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-to-one&lt;/div&gt;&lt;/div&gt; basis as part of the Company&#x2019;s IPO in February 2022. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation Preference &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Series C preferred stock were entitled to receive, before any payment of any of the assets of the Company to the holders of the Series B preferred stock, the holders of the Series A preferred stock, or the holders of common stock, $11.55 per share (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of Series A preferred stock or the holders of common stock, the holders of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-2&lt;/div&gt; preferred stock were entitled to receive, before any payment of any of the assets of the Company to the holders of the Series A preferred stock or the holders of common stock, $8.60 per share and $10.74 per share, respectively (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of the Company to the holders of common stock, the holders of Series A preferred stock were entitled to receive $5.51 per share with respect to shares of Series A preferred stock. The Company did not adjust the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of preferred stock and these circumstances were not probable as the balance sheet dates. Subsequent adjustments to the carrying values of the liquidation preferences were to be made only when it became probable that such a liquidation event will occur. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preferred stock was contingently redeemable upon certain change in control events that are outside of the Company&#x2019;s control, including liquidation, sale or transfer of control of the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Anti-dilution Protection &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The holders of the preferred stock had proportional anti-dilution protection for splits, dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by the Company for consideration per unit less than the applicable conversion price per unit of any series of preferred stock, were to be on a broad-based weighted average basis. &lt;/div&gt;&lt;/div&gt;</aclx:DiscloureOfRedeemableConvertiblePreferredStockTextBlock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">24785564</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">29795227</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">29795227</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">49402623</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">49402623</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27444339</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">27444339</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4986153</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4986153</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4986153</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4986153</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">21958284</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2021To12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">42800000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <aclx:TransactionCosts
      contextRef="P01_01_2021To12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</aclx:TransactionCosts>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3989432</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2020_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3989432</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3989432</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3989432</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">57224618</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">10396707</aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">120000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <aclx:TransactionCosts
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStocksMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</aclx:TransactionCosts>
    <aclx:TemporaryEquitySharesDividendRate
      contextRef="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</aclx:TemporaryEquitySharesDividendRate>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="PAsOn12_31_2020_DividendDeclaredMemberusgaapDividendsAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.
      contextRef="P01_01_2021To12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_DIRECTORS">3</aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.>
    <aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.
      contextRef="P01_01_2021To12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_DIRECTORS">2</aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.>
    <aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.
      contextRef="P01_01_2021To12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_DIRECTORS">1</aclx:NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.>
    <aclx:TemporaryEquitySharesConversionPrice
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.51</aclx:TemporaryEquitySharesConversionPrice>
    <aclx:TemporaryEquitySharesConversionPrice
      contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.6</aclx:TemporaryEquitySharesConversionPrice>
    <aclx:TemporaryEquitySharesConversionPrice
      contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.74</aclx:TemporaryEquitySharesConversionPrice>
    <aclx:TemporaryEquitySharesConversionPrice
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.55</aclx:TemporaryEquitySharesConversionPrice>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.55</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2021_SeriesB1RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.6</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2021_SeriesB2RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.74</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.51</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <aclx:CommonStockTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the board of directors approved an amendment to the Amended and Restated Certificate of Incorporation of the Company, which increased the number of authorized shares of common stock. The Company had &lt;div style="display:inline;"&gt;185,000,000&lt;/div&gt; and &lt;div style="display:inline;"&gt;98,973,453&lt;/div&gt; authorized shares of $0.001 par value common stock as of December&#160;31, 2021 and 2020, respectively, of which 544,210 and 333,658 shares were issued and outstanding as of December&#160;31, 2021 and 2020, respectively. The shares issued and outstanding represent shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s employees satisfied the exercise price of the options exercised by making cash payments to the Company. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares of common stock legally issued and outstanding &lt;br/&gt;(including shares early exercised)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;375,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: (unvested early exercised shares of common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(41,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares issued and outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;333,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No dividends have been declared or paid by the Company through December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;4, 2022, the Company issued and sold an aggregate of 590,318 shares of common stock in a private placement at a price of $16.94 per share for an aggregate purchase price of $10.0&#160;million. &lt;/div&gt;&lt;/div&gt;</aclx:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">98973453</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">544210</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">544210</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">333658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">333658</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="P01_01_2021To12_31_2021">Below is a reconciliation of shares issued and outstanding:&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares of common stock legally issued and outstanding &lt;br/&gt;(including shares early exercised)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;375,492&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: (unvested early exercised shares of common stock)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(41,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares issued and outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;333,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <aclx:CommonStockSharesLegallyIssuedAndOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">544967</aclx:CommonStockSharesLegallyIssuedAndOutstanding>
    <aclx:CommonStockSharesLegallyIssuedAndOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">375492</aclx:CommonStockSharesLegallyIssuedAndOutstanding>
    <aclx:UnvestedEarlyExercisedSharesOfCommonStock
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-757</aclx:UnvestedEarlyExercisedSharesOfCommonStock>
    <aclx:UnvestedEarlyExercisedSharesOfCommonStock
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-41834</aclx:UnvestedEarlyExercisedSharesOfCommonStock>
    <aclx:CommonStockSharesIssuedAndOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">544210</aclx:CommonStockSharesIssuedAndOutstanding>
    <aclx:CommonStockSharesIssuedAndOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">333658</aclx:CommonStockSharesIssuedAndOutstanding>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2021To12_31_2021">one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">590318</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.94</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13. Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s 2017 Equity Incentive Plan (the 2017 Plan) provides for the grant of Stock Options, Stock Appreciation Rights, Restricted Stocks, or Restricted Stock Units. The aggregate number of shares of common stock available for issuance pursuant to awards under the 2017 Plan, amended, is 7,927,329 shares. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted under the 2017 Plan generally vest over &lt;span style="-sec-ix-hidden:hidden49526058"&gt;three&lt;/span&gt; or four years and expire after 10 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price for stock options granted is the fair value of common shares as determined by the board of directors as of the date of grant. The board of directors determined the value the Company&#x2019;s common stock considering many factors, including third-party valuation of the Company&#x2019;s common shares, as well as additional factors, which may have changed since the date of the most recent contemporaneous valuation through the date of grant. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity for awards under the 2017 Plan is presented below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding and Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"&gt;(1)&lt;/div&gt;&lt;br/&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,952,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,145,794&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(288,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(210,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,598,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,696,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2021 and 2020 was $5.77 and $3.19, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate grant date fair value of stock options vested during the years ended December&#160;31, 2021 and 2020 was approximately $5.3&#160;million and $1.7&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recorded share-based compensation expense of $6.8&#160;million and $1.1&#160;million during the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, there was $19.6&#160;million of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2017 Plan. This remaining compensation expense is expected to be recognized over a weighted average period of 2.8 years as of December&#160;31, 2021. The intrinsic value of the options exercised for the years ended December&#160;31, 2021 and 2020 was $1.0&#160;million and $0.5&#160;million, respectively. Share-based compensation cost is measured at fair value and is recognized as expense on a straight-line basis over the requisite service period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,051&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.3&#x2014;7&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90%&#x2014;110%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;95%&#x2014;100%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.83%&#x2014;1.52%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.42%&#x2014;1.42%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#x2014;%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#x2014;%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Given the lack of an active public market for the common stock during 2021 and 2020, the fair value of the Company&#x2019;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports, described further within the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units&lt;/div&gt;&lt;/div&gt; section below. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Company granted 952,804 restricted stock units (RSU) to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions. All 952,804 RSUs were outstanding as of December&#160;31, 2021 and no RSUs were vested or exercisable as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Condition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The service condition to vesting of the RSU Award requires the executive officer&#x2019;s continued employment with the Company through the achievement of any of the performance conditions and the market condition. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Performance Condition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The performance conditions to vesting of the RSU Award include (i)&#160;the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii)&#160;a Change in Control following an IPO. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Market Condition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the three performance condition scenarios is applicable at the time of measurement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company value on a Change in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). Upon a Change in Control, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i) one-sixth&lt;/div&gt; of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company value in the event of an IPO is measured each June&#160;30 and December&#160;31 following an IPO (subject to applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period) and represents the Company&#x2019;s Enterprise Value. The Company&#x2019;s Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60-day&lt;/div&gt; period ending on the day prior to the applicable IPO measurement date, less cash. Upon an IPO, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i) one-sixth&lt;/div&gt; of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company utilized &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. In applying the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; methodology, Change in Control Market Capitalization and Enterprise Value were simulated and allocated to the various classes of equity in the Company&#x2019;s capital structure according to the characteristics of that capital structure, such as the number of shares of each class of equity, seniority levels, liquidation preferences and conversion values for redeemable convertible preferred stock, and participation thresholds for common stock and each series of redeemable convertible preferred stock. The fair value of the RSU Award in each of the three performance condition scenarios is the average of the discounted proceeds to the common stock across all simulated paths. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Application of the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation model to each of the three performance condition scenarios requires various subjective assumptions that represent management&#x2019;s best estimates of the fair value of common stock, expected equity volatility, risk-free interest rate, discount period, expected dividend yield, and time to achievement of a performance condition. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Common Stock and Fair Value of Total Equity&lt;/div&gt;&lt;/div&gt;&#x2014;Given the lack of an active public market for the common stock (prior to the Company&#x2019;s IPO), the fair value of the Company&#x2019;s common stock and total equity was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date and resulting total equity value. In determining the fair value of its common stock and total equity value, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#x2019; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&#160;the achievement of clinical and operational milestones by the Company; (2)&#160;the &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;significant risks associated with the Company&#x2019;s stage of development; (3)&#160;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&#160;the Company&#x2019;s available cash, financial condition, and results of operations; (5)&#160;the most recent sales of the Company&#x2019;s redeemable convertible preferred stock; and (6)&#160;the preferential rights of the outstanding redeemable convertible preferred stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Equity Volatility&lt;/div&gt;&lt;/div&gt;&#x2014;Due to the lack of a public market for the Company&#x2019;s common stock (prior to the Company&#x2019;s IPO) and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period commensurate with the expected date of achievement of a performance condition. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-Free Interest Rate and Discount Period&#x2014;&lt;/div&gt;&lt;/div&gt;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected time to achieve of a performance condition. The discount period is the period between the valuation date and the assumed change in control event date, with the assumption that all equity shares in the capital structure are paid out in cash. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividend Yield&lt;/div&gt;&lt;/div&gt;&#x2014;The expected dividend yield is based on the Company&#x2019;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Time to Achievement of a Performance Condition&#x2014;&lt;/div&gt;&lt;/div&gt;The time to the achievement of a performance condition is based on the Company&#x2019;s best estimate of the period of time to achievement of a performance condition that attains the established market capitalization thresholds. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company determined the fair value of the RSU Award considering third-party valuation reports. The Company considered several objective and subjective factors, including weighted probability of various liquidation event scenarios, operating and financial performance, discount for lack of marketability of the Company&#x2019;s equity, and general and industry-specific economic outlook, among other factors. The discount for lack of marketability was applied to reflect the increased risk arising from the inability to readily sell the RSUs. The assumptions used in the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt;s simulation models to determine the grant date fair value of the RSU Award for each of the three performance condition scenarios were as follows:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 38%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Change&#160;in&#160;Control&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;IPO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Change&#160;in&#160;Control&lt;br/&gt;Following an IPO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;June 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;December 7, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;December 7, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to liquidity event (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.56&#x2014;3.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100%&#x2014;110%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;70%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.11%&#x2014;0.31%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.47%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.44%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount for lack of marketability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26%&#x2014;32%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of the RSU award (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The performance condition will only become probable in the event of a change in control or an IPO. Accordingly, as a performance condition was not achieved in 2021, the Company did not record any share-based compensation expense related to this RSU Award in the year ended December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Upon completion of the IPO in February 2022, the performance condition was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period (10 years) and based on the fair value (aggregate $10.3 million) according to the IPO scenario &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation model as no other performance condition was deemed probable at the time of the IPO.&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="P01_01_2021To12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">7927329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity for awards under the 2017 Plan is presented below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding and Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"&gt;(1)&lt;/div&gt;&lt;br/&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,952,145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,145,794&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(288,557&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(210,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,598,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,696,109&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1952145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">8143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4145794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">288557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">210552</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">5598830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">7349000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1696109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">5011000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.77</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.19</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">6800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2021_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">19600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;551&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,051&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">4824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">551000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1051000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.3&#x2014;7&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7&#160;years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90%&#x2014;110%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;95%&#x2014;100%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.83%&#x2014;1.52%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.42%&#x2014;1.42%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#x2014;%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;&#x2014;%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020_MinimumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020_MaximumMembersrtRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <aclx:NumberOfPerformanceConditionScenarios
      contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_condition">3</aclx:NumberOfPerformanceConditionScenarios>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2021To12_31_2021_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon a Change in Control, (i) one-sixth of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon an IPO, (i) one-sixth of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <aclx:ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock contextRef="P01_01_2021To12_31_2021">The assumptions used in the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt;s simulation models to determine the grant date fair value of the RSU Award for each of the three performance condition scenarios were as follows:&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 38%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Change&#160;in&#160;Control&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;IPO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Change&#160;in&#160;Control&lt;br/&gt;Following an IPO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Date of grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;June 9, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;December 7, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;December 7, 2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to liquidity event (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.56&#x2014;3.06&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100%&#x2014;110%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;70%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.11%&#x2014;0.31%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.47%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.44%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount for lack of marketability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26%&#x2014;32%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of the RSU award (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock>
    <aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">2021-06-09</aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant>
    <aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">2021-12-07</aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant>
    <aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">2021-12-07</aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P3Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P1Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_ChangeInControlMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1580000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_ChangeInControlFollowingAnIpoMembersrtStatementScenarioAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14. Net Loss Per Share Attributable to Common Stockholders &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s potential dilutive securities, which include redeemable convertible preferred stock, options to purchase common stock, and unvested shares of restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redeemable convertible preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24,785,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,388,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,598,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,910,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested shares of restricted common stock from early exercises&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;41,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;952,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,337,198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,341,001&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Shares of redeemable convertible preferred stock also participated in dividends with shares of common stock (if and when declared) and therefore were deemed participating securities. The holders of redeemable convertible preferred stock did not contractually share in losses and therefore no additional net loss per share has been disclosed under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method. &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redeemable convertible preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24,785,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,388,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,598,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,910,310&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested shares of restricted common stock from early exercises&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;41,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;952,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;31,337,198&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,341,001&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">24785564</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">14388857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">5598073</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1910310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">41834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">952804</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">31337198</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">16341001</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s provision for income taxes consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current income tax provision (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax provision (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(14,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,954&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(19,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(9,625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total provision (benefit) for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State tax, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(29.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(29.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in tax rates and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The significant components of the Company&#x2019;s deferred income tax assets (liabilities) were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal net operating loss carryforward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24,692&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,826&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State net operating loss carryforward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,218&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,935&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-qualified&lt;/div&gt; stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;941&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred income tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,724&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(38,725&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(19,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred income tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred income tax assets (liabilities)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i)&#160;future reversals of existing taxable temporary differences; (ii)&#160;future taxable income exclusive of reversing temporary difference and carryforwards; (iii)&#160;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&#160;tax planning strategies. The Company&#x2019;s net deferred income tax assets are not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net change in valuation allowance for the years ended December&#160;31, 2021 and 2020 was an increase of $19.1&#160;million and $9.6&#160;million, respectively, due to the losses incurred for research and development. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On March&#160;27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act) to provide certain relief as a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic. The Company did not apply for any relief offered by the government during the years ended December&#160;31, 2021 or 2020. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had Federal and State net operating loss (NOL) carryforwards of approximately $117.6&#160;million and $116.5&#160;million, respectively, as of December&#160;31, 2021. The Company also had federal research and development tax credit carryforwards of approximately $3.2&#160;million, available to potentially offset future federal income taxes, as of December&#160;31, 2021. Approximately $6.3&#160;million of the Federal NOL was generated prior to 2018 and will begin expiring in 2035 while the remaining $111.3&#160;million will be carried forward indefinitely but are limited to eighty percent of taxable income. The State NOL will begin expiring in 2035. The federal research and development tax carryforwards, if not utilized, will expire beginning in 2038. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;However, the deductibility of such federal net operating losses may be limited. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law, if a corporation undergoes an &#x201c;ownership change,&#x201d; which generally occurs if the percentage of the corporation&#x2019;s stock owned by 5% stockholders increases by more than 50% over a three-year period, the corporation&#x2019;s ability to use its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-change&lt;/div&gt; NOL carryforwards and other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-change&lt;/div&gt; tax attributes to offset its post-change income may be limited. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has not determined if it has experienced Section&#160;382 ownership changes in the past and if a portion of its NOL and tax credit carryforwards are subject to an annual limitation under Section&#160;382. In addition, the Company may experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be outside of its control. If the Company determines that an ownership change has occurred and its ability to use its historical NOL and tax credit carryforwards is materially limited, it would harm the Company&#x2019;s future operating results by effectively increasing the Company&#x2019;s future tax obligations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has not identified any uncertain tax positions and did not recognize any adjustments for unrecognized tax benefits. The Company&#x2019;s Federal and State tax returns for all years, 2015 through 2020, remain subject to examination by taxing authorities due to the tax attribute carryforwards. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s provision for income taxes consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current income tax provision (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax provision (benefit):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(14,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(4,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,954&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(19,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(9,625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,090&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total provision (benefit) for income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-14840000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-7671000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-4250000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1954000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-19090000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-9625000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-19090000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-9625000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal tax&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State tax, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(29.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(29.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in tax rates and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.294</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.299</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The significant components of the Company&#x2019;s deferred income tax assets (liabilities) were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. federal net operating loss carryforward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;24,692&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,826&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State net operating loss carryforward&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,862&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,218&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,935&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-qualified&lt;/div&gt; stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,665&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;941&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;570&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;556&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;173&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross deferred income tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,724&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(38,725&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(19,635&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred income tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(132&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred income tax assets (liabilities)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">24692000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12826000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7592000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3862000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3218000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1935000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <aclx:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1665000</aclx:DeferredTaxAssetsNonQualifiedStockOptions>
    <aclx:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">75000</aclx:DeferredTaxAssetsNonQualifiedStockOptions>
    <aclx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">941000</aclx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses>
    <aclx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">297000</aclx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses>
    <aclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">570000</aclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <aclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">556000</aclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">179000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">173000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38857000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19724000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38725000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19635000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">132000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">89000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">132000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">89000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2021To12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">19100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2020To12_31_2020_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">9600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">117600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">116500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxPeriodTwoThousandThirtyFiveMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">6300000</us-gaap:OperatingLossCarryforwards>
    <aclx:OperatingLossCarryforwardsExpirationPeriod contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">P2035Y</aclx:OperatingLossCarryforwardsExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefinitelyCarryforwardMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">111300000</us-gaap:OperatingLossCarryforwards>
    <aclx:OperatingLossCarryforwardsExpirationPeriod contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">P2035Y</aclx:OperatingLossCarryforwardsExpirationPeriod>
    <aclx:TaxCreditCarryforwardExpirationPeriod contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">P2038Y</aclx:TaxCreditCarryforwardExpirationPeriod>
    <aclx:PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.05</aclx:PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange>
    <aclx:MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.50</aclx:MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationDescription contextRef="P01_01_2021To12_31_2021">The Company&#x2019;s Federal and State tax returns for all years, 2015 through 2020, remain subject to examination by taxing authorities due to the tax attribute carryforwards.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:IncomeTaxExaminationYearUnderExamination contextRef="P01_01_2021To12_31_2021_MinimumMembersrtRangeAxis">2015</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:IncomeTaxExaminationYearUnderExamination contextRef="P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis">2020</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:DefinedBenefitPlanTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;16. Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company sponsors a tax deferred retirement plan under the Code to provide retirement benefits for all eligible employees. Participating employees may voluntarily contribute up to limits provided by Internal Revenue Service regulations. The Company made contributions to the plan of $0.4&#160;million and $0.2&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">127160000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">30833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">83769000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">73784000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9974000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">220903000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">112809000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10127000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10318000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3248000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3172000</us-gaap:DeferredCosts>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8913000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2284000</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">243390000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128782000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1874000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1333000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13180000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">370000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">183000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">164000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">149000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16808000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14845000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4844000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1895000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">147000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">178000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">21799000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16918000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">29795227</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">5413272</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">29795000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">49402623</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8975585</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">85681000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">57224618</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10396707</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10396707</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">120000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">119118000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">233379000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35718764</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">35718764</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">544210</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">544210</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">384095000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8615000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-44000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-162496000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-130111000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">221591000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-121515000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">243390000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128782000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">24401000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8521000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8034000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2761000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">32435000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11282000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-32435000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11282000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11281000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-32409000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11281000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-33.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">20760722</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">337302</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5413272</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">8975585</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">10396707</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">119118000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">544210</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-130111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-121515000</us-gaap:StockholdersEquity>
    <aclx:TransactionCosts
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">15029000</aclx:TransactionCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">9487500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">127274000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">127283000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <aclx:TransactionCosts
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">42000</aclx:TransactionCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">590318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">9957000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">9958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-5413272</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-28894000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-8975585</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-85367000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-10396707</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-119118000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">24785564</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">233354000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">233379000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">24889</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">107000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">107000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">286283</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">307000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">307000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4481000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4481000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-24000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-24000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">35718764</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">384095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-162496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">221591000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5413272</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">8975585</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">333658</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-65142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-63720000</us-gaap:StockholdersEquity>
    <aclx:TransactionCosts
      contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">814000</aclx:TransactionCosts>
    <aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">7970812</aclx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">91186000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <aclx:TemporaryEquitySharesSubscriptionsAmount
      contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000000</aclx:TemporaryEquitySharesSubscriptionsAmount>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">7173</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">7522</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">757000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">757000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-11281000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11281000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5413272</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2021_SeriesARedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28894000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">8975585</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2021_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">85367000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">7970812</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">91186000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <aclx:TemporaryEquitySharesSubscriptionsAmount
      contextRef="P01_01_2021To03_31_2021_SeriesCRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_TemporaryEquityMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000000</aclx:TemporaryEquitySharesSubscriptionsAmount>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">348353</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-76423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-74232000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11281000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">416000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">207000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">60000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-110000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4481000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">757000</us-gaap:ShareBasedCompensation>
    <aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8423000</aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets>
    <aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-48000</aclx:IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">696000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">321000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2563000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">392000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-104000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-49000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-32586000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-9507000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">467000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1066000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">27026000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16850000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-10643000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1066000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">129156000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">81756000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">429000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">29000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">121000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">139556000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">81628000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">96327000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">71055000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">127359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">117850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">238000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <aclx:DeferredOfferingCostsIncludedInAccruedLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">42000</aclx:DeferredOfferingCostsIncludedInAccruedLiabilities>
    <us-gaap:NatureOfOperations contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Nature of the Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;8, 2022, the Company closed its initial public offering (IPO) of 9,487,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $15.00 per share. The Company received net proceeds of $127.3&#160;million, after deducting underwriting discounts and commissions of and other offering expenses paid by the Company of approximately $15.0&#160;million. The Company&#x2019;s common stock began trading on the Nasdaq Global Select Market on February&#160;4, 2022, under the ticker symbol &#x201c;ACLX.&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future as it continues development of drug candidates, including preclinical and clinical testing and regulatory approval prior to commercialization. The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company expects that its cash and cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2023. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has funded its operations primarily with proceeds from public and private offerings of its common and preferred stock. The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. &lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9487500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <aclx:AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1237500</aclx:AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">127300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <aclx:CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses
      contextRef="P02_08_2022To02_08_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</aclx:CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no material changes to the significant accounting policies disclosed in the Company&#x2019;s Audited Consolidated Financial Statements included elsewhere in this prospectus during the three months ended March&#160;31, 2022, except for the adoption of the new lease accounting standard effective January&#160;1, 2022, as discussed below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (&lt;span style="-sec-ix-hidden:hidden49526100"&gt;Topic 842&lt;/span&gt;)&lt;/div&gt;&lt;/div&gt;. Topic 842 increases transparency and comparability among &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The adoption of this standard resulted in the recognition of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (ROU) assets in the amount of $3.3&#160;million and operating lease liabilities in the amount of $5.4&#160;million for operating lease liabilities on the consolidated balance sheet, with a $2.1&#160;million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January&#160;1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components are accounted for together as a single lease component for leases associated with office space. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases (&lt;span style="-sec-ix-hidden:hidden49526100"&gt;Topic 842&lt;/span&gt;)&lt;/div&gt;&lt;/div&gt;. Topic 842 increases transparency and comparability among &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The Company adopted the new standard effective January 1, 2022, electing to use the package of practical expedients permitted under the transition guidance which allows for the carry forward of historical lease classification for existing leases on the adoption date and does not require the assessment of existing lease contracts to determine whether the contracts contain a lease or initial direct costs. Prior periods were not retrospectively adjusted. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The adoption of this standard resulted in the recognition of operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (ROU) assets in the amount of $3.3&#160;million and operating lease liabilities in the amount of $5.4&#160;million for operating lease liabilities on the consolidated balance sheet, with a $2.1&#160;million reclassification of deferred rent and tenant improvement allowances. There was no cumulative effect adjustment to the opening balance of accumulated deficit as of January&#160;1, 2022. The adoption of this standard did not have an impact on the consolidated statements of operations or cash flows on the effective date. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company leases office space and certain equipment. If a lease arrangement is determined to exist with a lease term of more than 12 months at the lease commencement date, an ROU asset and corresponding lease liability are recorded on the consolidated balance sheet at the lease commencement date based on the present value of lease payments over the lease term. An ROU asset represents the right to control the use of an identified asset over the lease term and a lease liability represents the obligation to make lease payments arising from the lease. The Company uses the discount rate implicit in the lease, if available, or its incremental borrowing rate on the lease commencement date to determine the present value of lease payments. The lease terms used to calculate the ROU assets and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases are classified as either operating or financing leases based on the economic substance of the agreement. Lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components are accounted for together as a single lease component for leases associated with office space. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For operating leases, the lease expense is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is amortized from the lease commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term, unless the Company is reasonably certain to exercise an option to purchase the underlying asset or if the lease transfers ownership of the underlying asset to the Company by the end of the lease term, in which case the ROU asset is amortized over the remaining useful life. Interest accretion on the finance lease liabilities is recorded as interest expense. Variable lease expense for both operating and finance leases is expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For short-term lease arrangements with a term of one year or less, the Company has elected to recognize the related lease payments on a straight-line basis over the lease term without recording related ROU assets and lease liabilities. &lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="PAsOn03_31_2022">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="PAsOn01_01_2022">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn01_01_2022"
      decimals="-5"
      unitRef="Unit_USD">3300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn01_01_2022"
      decimals="-5"
      unitRef="Unit_USD">5400000</us-gaap:OperatingLeaseLiability>
    <aclx:ReclassificationOfDeferredRentAndTenantImprovementAllowances
      contextRef="P01_01_2022To01_01_2022"
      decimals="-5"
      unitRef="Unit_USD">2100000</aclx:ReclassificationOfDeferredRentAndTenantImprovementAllowances>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is required to maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled $0.2&#160;million as of both March&#160;31, 2022 and December&#160;31, 2021. This amount is presented as restricted cash on the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;127,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;127,359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;127,160&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,651&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;127,359&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;117,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">127160000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">117651000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">127359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">117850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets by level within the fair value hierarchy were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (cash equivalent)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,509&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (cash equivalent)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,053&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These items have been reclassified to conform to current period presentation. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of financial assets categorized within Level&#160;1 of the fair value hierarchy is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. The fair value of financial assets categorized within Level&#160;2 of the fair value hierarchy is determined by using inputs other than Level&#160;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. &lt;/div&gt;&lt;/div&gt;The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March&#160;31, 2022 or the year ended December&#160;31, 2021.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets by level within the fair value hierarchy were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (cash equivalent)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,509&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;124,708&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (cash equivalent)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market fund (long-term restricted cash)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities &lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,053&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26,671&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These items have been reclassified to conform to current period presentation. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">124509000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <aclx:LongTermRestrictedCashFairValue
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">199000</aclx:LongTermRestrictedCashFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">50904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">14797000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">15061000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">3007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">124708000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">83769000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26472000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <aclx:LongTermRestrictedCashFairValue
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">199000</aclx:LongTermRestrictedCashFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_49525208"
      unitRef="Unit_USD">43969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_49525209"
      unitRef="Unit_USD">17072000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentAgenciesDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_49525210"
      unitRef="Unit_USD">5053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_49525211"
      unitRef="Unit_USD">7690000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">26671000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">73784000</us-gaap:AssetsFairValueDisclosure>
    <aclx:MarketableSecuritiesDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,081&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021 (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,053&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,695&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These items have been reclassified to conform to current period presentation. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;All of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt marketable securities held as of March&#160;31, 2022 had contractual maturities of less than one year. The Company had 9 securities in an unrealized loss position with an aggregate related fair value of $24.8&#160;million as of March&#160;31, 2022. All securities in an unrealized loss position as of March&#160;31, 2022 had been in a loss position for less than 12 months. Unrealized losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities as of March&#160;31, 2022 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities was recorded for the three months ended March&#160;31, 2022. The Company does not intend to sell these securities or expect to be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $0.2&#160;million, offset by amortization of premium of $0.1&#160;million, for the three months ended March&#160;31, 2022, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. &lt;/div&gt;</aclx:MarketableSecuritiesDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;50,904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,081&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,007&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,812&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,769&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021 (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,969&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate debt&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,084&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. government agency&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,056&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,053&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,695&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,690&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;73,784&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These items have been reclassified to conform to current period presentation. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">50904000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">50904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">14814000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">14797000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">15081000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">15061000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3013000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">83812000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">83769000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      id="Fact_49525090"
      unitRef="Unit_USD">43969000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      id="Fact_49525099"
      unitRef="Unit_USD">43969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525091"
      unitRef="Unit_USD">17084000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525095"
      unitRef="Unit_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525100"
      unitRef="Unit_USD">17072000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525092"
      unitRef="Unit_USD">5056000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525096"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_USTreasuryAndGovernmentMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525101"
      unitRef="Unit_USD">5053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525093"
      unitRef="Unit_USD">7695000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525097"
      unitRef="Unit_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="Fact_49525102"
      unitRef="Unit_USD">7690000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="Fact_49525094"
      unitRef="Unit_USD">73804000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="Fact_49525098"
      unitRef="Unit_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="Fact_49525103"
      unitRef="Unit_USD">73784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <aclx:DebtSecuritiesAvailableForSaleContractualMaturities contextRef="P01_01_2022To03_31_2022">less than one year</aclx:DebtSecuritiesAvailableForSaleContractualMaturities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_condition">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">24800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating
      contextRef="P01_01_2022To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2022To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Prepaid Expenses and Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other current assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid research and development costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other prepaid expense and current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total prepaid expenses and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses and other current assets consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid research and development costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,388&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other prepaid expense and current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,586&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,049&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total prepaid expenses and other current assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,974&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,192&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <aclx:PrepaidResearchAndDevelopmentCosts
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6388000</aclx:PrepaidResearchAndDevelopmentCosts>
    <aclx:PrepaidResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6143000</aclx:PrepaidResearchAndDevelopmentCosts>
    <aclx:OtherPrepaidExpenseAndCurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3586000</aclx:OtherPrepaidExpenseAndCurrentAssets>
    <aclx:OtherPrepaidExpenseAndCurrentAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2049000</aclx:OtherPrepaidExpenseAndCurrentAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9974000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the manufacturing services agreement with Lonza Houston, Inc. (Lonza) in connection with the development and manufacture of autologous drug product CART-ddBCMA (Lonza Agreement), the Company entered into a statement of work with Lonza (Lonza SOW) in February 2022, for the technology transfer and cGMP manufacturing of CART-ddBCMA and potentially other pipeline products. The term of the Lonza SOW expires December&#160;31, 2024, unless earlier terminated by either party or unless extended due to certain delays or suspensions or by mutual agreement. The Lonza SOW is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; for the first six months of the term and carries minimum &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; costs including upfront payments, milestone fees, and fixed monthly payments during the related period. Subsequent to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; period, the Company may terminate the arrangement for any reason upon 12 months&#x2019; prior notification to Lonza. As of March&#160;31, 2022, the Company&#x2019;s minimum &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancellable&lt;/div&gt; costs payable to Lonza was approximately $40.6&#160;million. Variable costs under this arrangement include materials, external testing, and other services. The Company paid $5.8&#160;million under this arrangement during the three months ended March&#160;31, 2022. &lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <aclx:PriorNotificationPeriodToTerminateArrangement contextRef="P01_01_2022To03_31_2022">P12M</aclx:PriorNotificationPeriodToTerminateArrangement>
    <aclx:MinimumNonCancellableCosts
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">40600000</aclx:MinimumNonCancellableCosts>
    <us-gaap:OtherCommitment
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">5800000</us-gaap:OtherCommitment>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Accrued Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued offering costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;793&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued offering costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;793&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,429&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,478&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <aclx:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12129000</aclx:ResearchAndDevelopmentAccruedExpensesCurrent>
    <aclx:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6626000</aclx:ResearchAndDevelopmentAccruedExpensesCurrent>
    <aclx:AccruedOfferingCostsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</aclx:AccruedOfferingCostsCurrent>
    <aclx:AccruedOfferingCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1301000</aclx:AccruedOfferingCostsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">793000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3429000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1478000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1824000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13180000</us-gaap:AccruedLiabilitiesCurrent>
    <aclx:LesseeOperatingAndFinanceLeasesTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in 2030 unless renewed. The lease agreement contains rent escalation, rent abatement clauses, tenant improvement allowances, and optional renewal clauses. The lease agreement also includes variable lease payments, which are primarily related to common area maintenance and utility charges. The Company also has short-term operating leases with a term of one year or less. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of March&#160;31, 2022, the Company had operating lease ROU assets of $3.2&#160;million, current operating lease liabilities of $0.4&#160;million, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; operating lease liabilities of $4.8&#160;million. The Company used a discount rate of 8.2% in measuring operating lease liabilities. The remaining lease term was 7.8 years as of March&#160;31, 2022. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s total operating lease costs were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;554&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, future minimum operating lease payments were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 90%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Through December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;916&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,033&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information related to operating leases is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ROU assets obtained in exchange for operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:LesseeOperatingAndFinanceLeasesTextBlock>
    <aclx:LeaseExpirationYear contextRef="P01_01_2022To03_31_2022_MDsrtStatementGeographicalAxis_OfficeAndLaboratorySpaceMemberusgaapPropertyPlantAndEquipmentByTypeAxis">2030</aclx:LeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn03_31_2022">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">4800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn03_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.082</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn03_31_2022">P7Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s total operating lease costs were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;554&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">163000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">377000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">554000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, future minimum operating lease payments were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 90%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Through December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;916&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,033&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">555000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">851000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">872000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">894000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">916000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">939000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2033000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7060000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1846000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5214000</us-gaap:OperatingLeaseLiability>
    <aclx:SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental cash flow information related to operating leases is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 17%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;206&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ROU assets obtained in exchange for operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aclx:SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock>
    <aclx:CashPaidForMeasurementOfOperatingLeaseLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">206000</aclx:CashPaidForMeasurementOfOperatingLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3308000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <aclx:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Company&#x2019;s IPO, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock automatically converted into shares of common stock at the applicable conversion ratio then in effect. The Company&#x2019;s outstanding shares of preferred stock were converted into 24,785,564 shares of common stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent to the IPO, the Company&#x2019;s board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to the shares of common stock issued and outstanding in connection with the IPO and the subsequent private placement, total shares of common stock issued and outstanding includes shares issued to employees pursuant to the exercise of vested stock options as well as the vesting of early exercised stock options. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment, the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All shares that were early exercised by the employees of the Company are considered legally issued. However, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares of common stock legally issued and outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;35,736,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unvested early exercised shares of common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares issued and outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;35,718,764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. No dividends have been declared or paid by the Company through March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the assets of the Company legally available for distribution. &lt;/div&gt;&lt;/div&gt;</aclx:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn03_31_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">24785564</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="P01_01_2022To03_31_2022">Below is a reconciliation of shares issued and outstanding:&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares of common stock legally issued and outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;35,736,584&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,967&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unvested early exercised shares of common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(17,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total shares issued and outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;35,718,764&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;544,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <aclx:CommonStockSharesLegallyIssuedAndOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">35736584</aclx:CommonStockSharesLegallyIssuedAndOutstanding>
    <aclx:CommonStockSharesLegallyIssuedAndOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">544967</aclx:CommonStockSharesLegallyIssuedAndOutstanding>
    <aclx:UnvestedEarlyExercisedSharesOfCommonStock
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-17820</aclx:UnvestedEarlyExercisedSharesOfCommonStock>
    <aclx:UnvestedEarlyExercisedSharesOfCommonStock
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-757</aclx:UnvestedEarlyExercisedSharesOfCommonStock>
    <aclx:CommonStockSharesIssuedAndOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">35718764</aclx:CommonStockSharesIssuedAndOutstanding>
    <aclx:CommonStockSharesIssuedAndOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">544210</aclx:CommonStockSharesIssuedAndOutstanding>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2022To03_31_2022">one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s 2017 Equity Incentive Plan (the 2017 Plan) provided for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, to the Company&#x2019;s employees, directors, and consultants. The 2017 Plan terminated one business day prior to effectiveness of the 2022 Equity Incentive Plan (the 2022 Plan) with respect to the grant of future awards. The 2022 Plan became effective on February&#160;3, 2022 and provides for the grant of incentive stock options to the Company&#x2019;s employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (RSUs), and performance awards to the Company&#x2019;s employees, directors, and consultants. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate number of shares of common stock that may be issued pursuant to equity awards under the 2022 Plan is 4,296,875 shares, plus shares subject to awards granted under the 2017 Plan that expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by the Company (provided that the maximum number of shares that may be added to the 2022 Plan pursuant to awards under the 2017 Plan is 6,269,300 shares). The number of shares of common stock reserved for issuance under the 2022 &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plan shall be cumulatively increased on the first day of each fiscal year, beginning with the Company&#x2019;s 2023 fiscal year and ending on the ten year anniversary of the date the Company&#x2019;s board of directors approves the 2022 Plan equal to the least of 4,296,875 shares, 5% of the total number of shares of common stock outstanding as of the last day of the immediately preceding fiscal year, or a lesser number of shares determined by the administrator of the 2022 Plan. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense by type of award was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&#x2014;executive officer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized $4.5&#160;million in share-based compensation expense during the three months ended March&#160;31, 2022, of which $1.3&#160;million was included in research and development and $3.2&#160;million was included in general and administrative in the accompanying condensed consolidated statements of operations. The Company recognized $0.8&#160;million in share-based compensation expense during the three months ended March&#160;31, 2021, of which $0.2&#160;million was included in research and development and $0.6&#160;million was included in general and administrative in the accompanying condensed consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options granted under the 2017 Plan and the 2022 Plan vest over &lt;span style="-sec-ix-hidden:hidden49526059"&gt;three&lt;/span&gt; or four years and expire after 10 years. The Company uses the Black Scholes option pricing model to determine the grant date fair value of stock options. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding and Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"&gt; (1)&lt;/div&gt;&lt;br/&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,598,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,829,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(311,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,113,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;44,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,767,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,304&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSUs granted under the 2022 Plan generally vest annually over three years. The Company uses the market price of the Company&#x2019;s common shares on the date of grant to determine the fair value of RSUs. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of RSU activity for awards under the 2022 Plan is presented below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&#160;Grate&lt;br/&gt;Date Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;703,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;702,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units&#x2014;Executive Officer &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Company granted 952,804 RSUs to an executive officer subject to service, performance, and market conditions. In December 2021, the Company added alternative performance conditions for vesting of the same RSUs (the RSU Award). These additional performance conditions provided alternative paths to vesting and the original award from June 2021 and its vesting conditions remained the same, i.e., the original award was not modified. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions. All 952,804 RSUs were outstanding as of March&#160;31, 2022 and December&#160;31, 2021 and no RSUs were vested or exercisable as of March&#160;31, 2022 or December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Condition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The service condition to vesting of the RSU Award requires the executive officer&#x2019;s continued employment with the Company through the achievement of any of the performance conditions and the market condition. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Performance Condition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The performance conditions to vesting of the RSU Award include (i)&#160;the consummation of a change in control event as defined in the 2017 Plan (Change in Control), (ii) the consummation of the first firm commitment underwritten public offering covering the offer and sale of Company shares, the consummation of the direct listing or direct placement of Company shares on a publicly traded exchange, or the completion of a merger or consolidation with a special purpose acquisition company in which the shares of the surviving or parent entity are listed on a national securities exchange (IPO), or (iii)&#160;a Change in Control following an IPO. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Market Condition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The market condition to vesting of the RSU Award involves Company value thresholds depending upon which of the three performance condition scenarios is applicable at the time of measurement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company value on a Change in Control is measured on the date of the Change in Control and is the aggregate amount of deal consideration paid at the closing of a Change in Control by an acquiror for the Company shares of common stock in connection with such Change in Control (Change in Control Market Capitalization). Upon a Change in Control, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i) one-sixth&lt;/div&gt; of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company value in the event of an IPO is measured each June&#160;30 and December&#160;31 following an IPO (subject to applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period) and represents the Company&#x2019;s Enterprise Value. The Company&#x2019;s Enterprise Value is determined using the total market capitalization of the Company based the average closing trading price of one share of the Company over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60-day&lt;/div&gt; period ending on the day prior to the applicable IPO measurement date, less cash. Upon an IPO, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i) one-sixth&lt;/div&gt; of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company utilized &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Monte Carlo&lt;/div&gt;&lt;/div&gt; simulation models to estimate the fair value of the RSU Award on the date of grant in each of the three performance condition scenarios. &lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon completion of the IPO in February 2022, the performance condition of the RSU Award was satisfied and the Company began recognizing share-based compensation expense on an accelerated attribution basis over the anticipated service period (10 years) and based on the fair value (aggregate $10.3 million) according to the IPO scenario as no other performance condition was deemed probable at the time of the IPO. The Company recognized $0.8&#160;million in share-based compensation expense related to this RSU Award during the three months ended March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4296875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2022_TwoThousandSeventeenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">6269300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <aclx:AnniversaryPeriod contextRef="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis">P10Y</aclx:AnniversaryPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">4296875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <aclx:PercentageIncreaseInCommonStockReserveForFutureIssuance
      contextRef="P01_01_2022To03_31_2022_DirectorMembersrtTitleOfIndividualAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</aclx:PercentageIncreaseInCommonStockReserveForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense by type of award was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&#x2014;executive officer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,481&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;757&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">3030000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">755000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-5"
      unitRef="Unit_USD">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity for awards under the 2017 Plan and the 2022 Plan is presented below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding and Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px"&gt; (1)&lt;/div&gt;&lt;br/&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,598,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,349&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,829,435&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,504&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(311,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,113,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;44,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,767,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,304&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="width: 32%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">5598830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="Fact_49525510"
      unitRef="Unit_USD">7349000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">2829435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">3504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">311172</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">8113589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="Fact_49525513"
      unitRef="Unit_USD">44630000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1767303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="Fact_49525516"
      unitRef="Unit_USD">16304000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of RSU activity for awards under the 2022 Plan is presented below: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&#160;Grate&lt;br/&gt;Date Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;703,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;702,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">703329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">702663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P06_01_2021To06_30_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">952804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Each RSU granted in the RSU Award entitles the recipient to one share of common stock upon vesting subject to the service, performance, and market conditions.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">952804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">952804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2021To12_31_2021_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <aclx:NumberOfPerformanceConditionScenarios
      contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_condition">3</aclx:NumberOfPerformanceConditionScenarios>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2022To03_31_2022_ChangeInControlMemberusgaapSubsidiarySaleOfStockAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon a Change in Control, (i) one-sixth of the RSU Award will vest if a minimum Change in Control Market Capitalization of $2.5 billion is achieved, (ii) all of the RSU Award will vest if a $5.0 billion Change in Control Market Capitalization is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if a Change in Control Market Capitalization of between $2.5 billion and $5.0 billion is achieved based on a straight-line interpolation.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">Upon an IPO, (i) one-sixth of the RSU Award will vest if a minimum Enterprise Value of $2.5 billion is achieved, (ii) all the RSU Award will vest if a $5.0 billion Enterprise Value is achieved, and (iii) a portion of the RSU Award will vest based on a straight-line interpolation if an Enterprise Value of between $2.5 billion and $5.0 billion is achieved.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward
      contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10300000</aclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ExecutiveOfficerMembersrtTitleOfIndividualAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Net Loss Per Share Attributable to Common Stockholders &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 8%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s potentially dilutive securities include options to purchase common stock, unvested shares of restricted common stock, and redeemable convertible preferred stock. The Company&#x2019;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redeemable convertible preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,359,669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,113,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,871,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested shares of restricted common stock from early exercises&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;34,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;702,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&#x2014;executive officer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;952,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,786,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,265,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redeemable convertible preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,359,669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Options to purchase common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,113,589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,871,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested shares of restricted common stock from early exercises&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;17,820&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;34,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;702,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units&#x2014;executive officer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;952,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,786,876&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;25,265,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">22359669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">8113589</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2871594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">17820</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">34647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">702663</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">952804</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_RestrictedStockUnitsExecutiveOfficerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">9786876</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">25265910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_49525090"
          xlink:label="Fact_49525090"
          xlink:type="locator"/>
        <link:footnote id="FN_158911" xlink:label="FN_158911" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These items have been reclassified to conform to current period presentation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525090"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525091"
          xlink:label="Fact_49525091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525091"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525092"
          xlink:label="Fact_49525092"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525092"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525093"
          xlink:label="Fact_49525093"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525093"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525094"
          xlink:label="Fact_49525094"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525094"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525095"
          xlink:label="Fact_49525095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525095"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525096"
          xlink:label="Fact_49525096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525096"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525097"
          xlink:label="Fact_49525097"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525097"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525098"
          xlink:label="Fact_49525098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525098"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525099"
          xlink:label="Fact_49525099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525099"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525100"
          xlink:label="Fact_49525100"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525100"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525101"
          xlink:label="Fact_49525101"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525101"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525102"
          xlink:label="Fact_49525102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525102"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525103"
          xlink:label="Fact_49525103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525103"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525208"
          xlink:label="Fact_49525208"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525208"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525209"
          xlink:label="Fact_49525209"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525209"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525210"
          xlink:label="Fact_49525210"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525210"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525211"
          xlink:label="Fact_49525211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525211"
          xlink:to="FN_158911"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525510"
          xlink:label="Fact_49525510"
          xlink:type="locator"/>
        <link:footnote id="FN_158912" xlink:label="FN_158912" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of March 31, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525510"
          xlink:to="FN_158912"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525513"
          xlink:label="Fact_49525513"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525513"
          xlink:to="FN_158912"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_49525516"
          xlink:label="Fact_49525516"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_49525516"
          xlink:to="FN_158912"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MQ)^ D#SC+!(/;/>)5(*</-^:16GQ'^PJK#D!ZRP5+*Z")8.8)N4G_EEUQ%X
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M_7Q^]M/?778QE%6/UY>V<9A4YOSQKFKRIN!V5ST>0#OU#@L4]0!^RTSMS)V
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M*1D^PCJ#H:/%G5#P *'M2%4(M5?H>-H.<+ER;V'%;M;W8NO#[M5D5YK3I>F
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MYX$O?X./TPI"]_F%#U_V\E$HU-[![S<%)9\*^8\+;J:#FVEP,_WG!WF9()_
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MI&["^R%^-N]?8=1[.ZD=U55-T&2RF$5@^Y=-/_&F"X\#.E9Z:H1A0X]!M&Q
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M(%28>T80]%CB#2K%0!3&QPUFKYN2'??'6_07(7?*)1,.;XSZ51:^O.J=]Z#
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MKG5A6-+%&RT;T/]S0_*W>>$)NJO\["]02P,$%     @  8;.5"XWIS!T P
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MM4%E'6A]+:4Y*':#[K(T^Q-02P,$%     @  8;.5,Y5]<BU @  [@<  !D
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MJ(_VO*5^\]N"GOJWQ2?EC!>*5!5T$%MX21Q<K5M+BMI7\Q$%+. "\NNQ_YQ
M/@D?4[B:CCYKCTBG#Y>M[)$;MH^XD^ET] ZMG<-:ZI;2-QA*53G/F01 &CEX
MF<_@U>@^KL #$RWZI!5MW!G@"Y@4UR._*:<Y/65.Y[%@RBM+B5V,TPE!"1$.
M^W.*TFS<!C+/!_.X)Z5HJ[!GH$E+0\<OU1"1%9QMN.".8ZP_<BW^QE5HM7L=
M"OG(.588EXW@L32B,J&>6ANKE8JV+6-!G9&%C)H3%3V#JW3\77K2C9)51TZA
M7,FKH<O0(YQ3-,A&^4V?E P)]WV/L$=FK&\@HGM\6.3!T)\:EX<X=-N*?0IO
M#WGB([TD*!J)5&JE^FMY:*2>^/<O9D5^\X,]I4@9$ AI1_<P&D[3_YQ0"M\Z
MT[.C.U.BV867@6]R*N%X?0ZSP^-C'>_<)_/X<J%6WG&23N"67,?IS54")KX&
MXL#I)MS &^WH/@^?-3V@T'@#6M]J[0X#'V!XDJW^!%!+ P04    "  !ALY4
M^2"'/M\"  "<!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RU5=]O
MTS 0?N]?806$0(J:Q,G:=+25N@X$$A/3QH\'Q(.;7!IKB5UL9QW_/6>G#1UJ
MHR'$2V+?W??=W1?G/-U*=:=+ $,>ZDKHF5<:LSD/ IV54#,]E!L0Z"FDJIG!
MK5H'>J. Y0Y45P$-PU%0,RZ\^=39KM5\*AM3<0'7BNBFKIGZ>0&5W,Z\R-L;
M;OBZ--80S*<;MH9;,)\WUPIW0<>2\QJ$YE(0!<7,6T3GR\3&NX O'+;Z8$UL
M)RLI[^SF?3[S0EL05) 9R\#P=0]+J"I+A&7\V'%Z74H+/%SOV=^ZWK&7%=.P
ME-57GIMRYJ4>R:%@365NY/8=[/HYLWR9K+1[DFT;FX0>R1IM9+T#8P4U%^V;
M/>QT. "DIP!T!Z!/!<0[0.P:;2MS;5TRP^93);=$V6ADLPNGC4-C-US8KWAK
M%'HYXLQ\D66J@9Q\X&S%*VXXZ&E@D-BZ@VQ'<M&2T!,D,;F2PI2:O!$YY$?P
MRWY\1'L( NRH:XONV[J@O8Q73 U)'/F$AI0>*Z@??@E9!X]ZRHD[E6/'%S]=
M99\L&Z5 &/)ML=)&X7G^WI,IZ3(E+E/R;]^SGR0=DB,\G:TZL&42?VAMB"R(
M*8$4LL*YP,6:O.0"+;+13.3ZU?D OTA6.DU17*A7H.QF< ,:G ?#\/>[Q[&R
MJ:TJ;)<,'G!@:<STG$34C^@$%R-_1$>#?3FR*$#9E)G41I,7SU(:T=<D\N,P
MZH)64C2:C"<QB?V$3@8?L5KUJ)/(3\8I/E.:##Y)PZJNA,,HK"+QDS"TB]B/
MTO#8X>I7=_(?U'VDJ3VT]N2&?Z6N$Q7?U ]'X2EQG:CD;#SZ0U@G*GJC*.X\
M]RQC;E3'24)H<D+S-$2ZM%]Q)S0N$A\S'_M)@H,!6(-:NWO!RM<(T\["SMI=
M/0LW<8/?X>V]A>=TS84F%10(#8?C,X^H]BYH-T9NW#A=28/#V2U+O#Y!V0#T
M%U*:_<8FZ"[D^2]02P,$%     @  8;.5 &:Z(=(!   OPD  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&ULE5;;;MM&$'W75PQ8HT@ 1:)(W>Q* FRG
M-R!!#-M)'XH^K,BAN,B2R^XN)>OO.[,D9=E1A.9%VLO,F3/7Y6*GS5>;(SIX
M*E1IET'N7'4U'-HDQT+8@:ZPI)M,FT(XVIK-T%8&1>J5"C6,PG Z+(0L@]7"
MG]V9U4+73LD2[PS8NBB$V=^@TKME, JZ@WNYR1T?#%>+2FSP =WGZL[0;GA
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M-@G -)\+S<;IRC_1:^WHP??+G+ZPT+  W6=:NV[#!@[?;*O_ %!+ P04
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M'$V43U\ITDUTC7P9P.B)KI;+DM#!G@7P?.W0J]T-&Q@^%5W\%U!+ P04
M"  !ALY4&_JCCWD&   F$0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6S%6%EOXS80?L^O(%R@30##M^,TFP1(=K?8 -TV2+;M0]$'6AI91"A22U)V
M_.\[0U*'CZ3;OO0ET3'G-_/-4+[::/-L<P#'7@JI['4O=ZZ\' YMDD/![4"7
MH/!-IDW!'=Z:U="6!GCJE0HYG(Q&Y\.""]6[N?+/'LS-E:Z<% H>#+-547"S
MO0.I-]>]<:]^\"A6N:,'PYNKDJ_@"=QOY8/!NV%C)14%*"NT8@:RZ][M^/)N
M1O)>X'<!&]NY9I3)4NMGNKE/KWLC"@@D)(XL</RWAO<@)1G",+Y&F[W&)2EV
MKVOK/_G<,9<EM_!>RS]$ZO+KWD6/I9#Q2KI'O?D$,9\YV4NTM/XOVP39Q:S'
MDLHZ741EC* 0*OSG+Q&'CL+%Z!6%2528^+B#(Q_E!^[XS971&V9(&JW1A4_5
M:V-P0E%1GIS!MP+UW,TCI(!E7DI@[[5:@W&"KA\0&S &4O;D=/+,N(I7N98I
M&/L#^_BU$F[+3C] )A+ASJZ&#L,AH\,DNKX+KB>ON)ZRSUJYW+*/*H5T5W^(
M:32Y3.I<[B9O&OS,S8!-QWTV&4TF;]B;-MA,O;WI*_9BBG_>+JTSV#Y_O6%S
MUMB<>9NS_P/O-UT3O2]MR1.X[B%_+9@U]&[&HP'[CS%]_]W%9+QX=Q#9M]J[
M5RS12D5Z;H3+F<M)I2BYVD;KEMT__-IG7$J&(\4Z#$*H%;,YQQ28SHZJF#:
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MHV1G['0Q7["SW:C>\#Z^Z"_.@_?)>'3RD=>->N"")JJ3$/@?M@#1A,X+N%B
M.HIX@L<X1_L!YUHAG N#AT>1XX?$[C&EF<#=A[[\T7\:N+F[=VBWVGJ5II!(
M;MI&/3Q)X5#(:!D/V"^ZM1$VS!+PS-B8H&W2(77=XBXWNEKEK&T)^M#QP\Y3
M@]8/>239[JD#S:58#"VKNDEW1E6+[)&EO >!/PA:"^Z ?W7/\347TA^,L^ 7
MY^BR"FONV/?3L//M6H!9^2]T?Q)3+GS&-D^;'P%NP[=O*QY^04!<5@*WAH0,
M54>#Q;P7!EM]XW3IOX27VN')WU_FP#%Q$L#WF<9^B3?DH/EIY.9O4$L#!!0
M   (  &&SE0?EW=1A <  /@5   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;,U86V_;.!;^*X2WLV@!Q1?9CNU.$B!)6VR!'6R0=&<?%O- 2W3$J41J
M2,INYM?O=TA)EJ^; GV8A\222)[K=[YSI*N--E]M)H1CWXI<V>M>YESY?C"P
M228*;ONZ% HK*VT*[G!KG@>V-(*G_E"1#^+A\')0<*EZ-U?^V8.YN=*5RZ42
M#X;9JBBX>;D3N=Y<]T:]YL&C?,X</1C<7)7\63P)]^_RP>!NT$I)92&4E5HQ
M(U;7O=O1^[L)[?<;?I5B8SO7C#Q9:OV5;CZGU[TA&21RD3B2P/&S%O<BSTD0
MS/BCEMEK5=+![G4C_9/W';XLN17W.O^/3%UVW9OW6"I6O,K=H][\0]3^3$E>
MHG/K_[--V#M>]%A26:>+^C L**0*O_Q;'8?.@?GPQ(&X/A![NX,B;^4'[OC-
ME=$;9F@WI-&%=]6?AG%245*>G,&JQ#EW\RA2@30O<\'NM5H+XR1=/R VPAB1
MLB>GDZ]7 P===&*0U'+O@MSXA-Q1S'[1RF66?52I2'<%#&!D:VG<6'H7GY7X
M021]-AY%+![&HS/RQJWG8R]O?$+>%U&4V@"([.,?E70O[(.T2:YM903[[^W2
M.@/$_'9&T:15-/&*)C\\Q&?E4KF^MR5/Q'4/]6B%68O>S6C49Z]3R#XKEFBE
MZO+82)<QE]&1HN3JY>]_F\>CV<^6?7[X%\/Z)[$T%45KXC,01XSG.4.96\=5
M*M4SLQF'&4ROCHHQ6Z.2CE%E:Y3U1O$*B.=.)I#^TNS$JE1.=S0DNBA@5'W&
M>8V\+'.<VVH(Q %AFM859#"Q6L'?/OMRQ,+CONP;N!%&[-L53Z+9?!I-+R<G
M3-Q1R#*>LG@1S1;3*(YGY'*FC?R35+2GWPS[P^&(E=RP-<\KP9Z$D5BZ?6T@
MW[8']E;>121_D\DD8]-H,AI'\2QN-'OOI+45=B,4.S'AWK"E!DY0BZ)8"M/6
MH]^,BV'P])1NMH&0).?6RI4D%9:YM@Q%*$,\XW#2@E9]&.$@>HMWNR@]5 TQ
M+4YF2#RL]D;*5)Q"'J+DC,X/<S!91)-A'%W&X^_+P=WWYN#N7 [FT6(&[,RG
M/RP';&5TX4-!4KA*?&@:6RY&^(L/ 3F+)I-)-!XOOC,87M[H0%Y'2#R*%M-Y
M%,\GKY(7UW^C]O=39>"-*;01H)V5@],;:K<4$7+35DN*$/5W'P19@ F@&!L+
MZY^L!'=5AYU.)0;U#.*O,'6XJ LF2G.25RD)S6J^Z9",#L ,Z!;<@+I(*[43
M@6LC<DYDX3P1'>C,M'4!I>@X_B!Y*S!Q"<PT59XRI1U3(DA8"K:4J\HD)+)/
M+-XB@9*_:W8-(Q\D 16X- !$MHN($/$/E6D"^@(?F*#&?0BS706=-$]GH+-)
M=#F:OR+-]Z^NH4ZZ[@_J**0[.#D:1N/%930;SAK]1/C?DHRK9\$03?9F!((:
M8HS*<TH7EA-NLUUBD"JIO )8ONANI<!9'IIE@HS9W;1*VU;;#@<>V/R7X<!V
M\11;1R?+)/)Q/^GA6TRE?NQ> _W1,<R_\QQ!"RMLU1L"7NT220Z[!6)I(]S(
MM<S%,UW3(N+BC/2)L'U,;6OXK5+K7<MTGJ(F3S9NU+5T><B9 ;(#8ZB*YZ@Q
M9+ZHD%)ZF+9B*<"JV81IPL=X_A-!8FLFR2/TI *9]2,'2,$ ]B]$)73"K]9"
M:9X*#+(=$2)Z2(KLQ7:Z^%4[BLQCB,Q'CG;AH7W,/R/\%*CHG*VP4U6^;K%U
MK1WRQ FAA##X43/1=LN)T<J/-Z%/>9E!N[3=DNV_*O*^T"&,;,'OLR".VTZ=
MG>,[!AP)ROV6=U\5&%]O'88Y-TJF@GH&!NV4+>M\-9P(EGN6"K%KFRJ B?_8
MM]<-_/,0E?VGWIB=%)P0&]51][%[,^U/1Y[!3I?JFWG_<MC=TS10K<2%TQ?X
M8?^4H)<TH/-AB]W/ 8UBW8'J6N>5<D1)D"C5]C;?RH@0(&NQTL =9>S#595[
M/!3MY_@T.9ZHT@A]SS=$,FZOK&I=8%3A]M\_FC!W=)_K_P>&=C8?"3I\/@->
M) 6O8],I*X'T ,^WQ.SI[WBOAQ!*%IE80Z\FAZB^MYAA,(1 X!+X:$*L?=E8
MB<:$EMKI2424>64[+$08KARK5,EENB6T=WUVZT>H3A1]^)8:O$<G?EBD3[X&
M_+^X'9?3(/IQVP9K OAR9*JJRYX(%![X*:P=.*J2FGC=5>L!0:JF2X9*^.[F
M&M'L@!F1*F"G2BS/A7>9LK4*?-NHVA6)U,#@BU36-?5@P)9AY/ARB,N#.9)3
MY]08)>@$*(7O""NWP@AY'E\VZG8Z=*8&62@[7DK'<_DGKSOM4[7\'><ISTWH
M,%T!<P%]^\JDI[(=E3Q-96T:Q<0[@K$4<Z>C_-9,VN")3B!,%/FZHU(=54HZ
MAK,^/>K,BW]M07.D1K -4#IL$U&@GC!@4]=A2Z-Y>D&?_-+PND$URR&> RUX
M+!&38Y^'!IVO<84PS_Z;(Z$$#!H^S+5/V\^:M^%KWG9[^";Z"S=H#A;^KG!T
MV)]->V%,:FZ<+OVW/;P1.EWXRTQP!(PV8'VED8#ZAA2T'WMO_@=02P,$%
M  @  8;.5'7O^/@L!0  &0P  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&ULG5?;;N,V$'W/5PS<HD@ PY9E.7:R20 GN\5NT6V#9-L^%'V@J+%%A"*U
M)&6O^_4=4A?+S@6+ K8EDG,]G#FDK[;:/-D<T<&W0BI[/<B=*R_'8\MS+)@=
MZ1(5K:RT*9BCH5F/;6F094&ID.,XBL['!1-J<',5YN[-S96NG!0*[PW8JBB8
MV=VBU-OKP6303CR(=>[\Q/CFJF1K?$3W1WEO:#3NK&2B0&6%5F!P=3U83BYO
M$R\?!/X4N+6]=_"9I%H_^<&G['H0^8!0(G?> J/'!N]02F^(POC:V!QT+KUB
M_[VU_G/(G7))F<4[+?\2F<NO!XL!9+ABE70/>OL1FWQFWA[7TH9?V-:R<3(
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M%_')KVCM)9QV178,_<M>SN!T/IL#/9+)<#%-X.PPJ#><QY,(IM/I\'RV./G
MVB)]E@:UAW R5 5"KF73SYKX<Z,]TZG0(W224WM1\U9I(9Q/@(18(W)0)!T-
M!?NU1=LQ='\R;'WC/ZO[DB/=-HBE-U0-*J."H=HNV Y2FD0NF=D7Z7-.)T(@
M:O7,])O>VR#V)),IHMJ;H/+L-W1;WBXWNEKGT"^'<(H$K@N=L?&DI(,;:KFO
ME<B:HC3DT5HMJQ>/@SVXSPOI& 4ORZQ%]ZS]VI)C&R8D2V7-0.27:#0-CD?P
MNX+/C @'DA!Z?,@LO7JA6.O#;TUDNVX.M=E%-)Q.%J_5/#$6\X2X\>*EI(,X
MD#31"=L?*C].SD<7"92$7UUR@0WZCCI&[.E$HXAN:E*&)%ZZ:(Q[U[4"S3I<
M2BT$DJEO;MUL=^]=UM>]O7A]:2: UH*./(DK4HU&\]F@)N=VX'09+G^I=G25
M#*\YW=W1> %:7VFJ^V;@'73_!F[^ U!+ P04    "  !ALY4,?[9,$<1  "E
M0   &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6SM7%MOVTB6?M>O*'B=
M@0W0-"GJFDX".+?>##";($GW8+"8AQ)9LFI"D1I>K'A^_7[G5!5)293L]*31
MP$X>.N:E+N=^OG.*ZF?;O/A2KI2JQ-=UFI7/SU95M7EZ?5W&*[66I9]O5(8W
MR[Q8RPJWQ>UUN2F43'C2.KT>!L'D>BUU=O;B&3_[4+QXEM=5JC/UH1!EO5[+
MXOZE2O/M\[/PS#WXJ&]7%3VX?O%L(V_5)U7]LOE0X.ZZ6271:Y65.L]$H9;/
MSV["IZ]&-)X'_*K5MNQ<"^)DD>=?Z.9=\OPL(()4JN**5I#X<Z=>J32EA4#&
M/^V:9\V6-+%[[59_R[R#EX4LU:L\_:M.JM7SL]F92-12UFGU,=_^M[+\C&F]
M.$]+_E=LS=A1=";BNJSRM9T,"M8Z,W_E5RN'SH19<&3"T$X8/G9"9"=$S*BA
MC-EZ+2OYXEF1;T5!H[$:7;!L>#:XT1EI\5-5X*W&O.K%IY4LU-5+""(1K_(U
MC*.4)-]GUQ56IS'7L5WII5EI>&2E2/PESZI5*=YDB4IZYK\Z/3\<GEC@&FPU
MO T=;R^')U?\BRQ\$86>& ;#81]!IZ>_5G$S/3Q!3M2(.N+UHI.B7K"H/\A[
MN$(E;HI"9K>*K__W9E%6!>SZ[R<V&S6;C7BST7?0Z\F5*(P\+3<R5L_/$"=*
M5=RILQ=AZ(MC6XC/*\4/9';_I_^:#</I3R5D&$[%FW_6NKH7[[(8_,)[Q8=4
M9N*BPGA^3[>78E/D=QH6(!"C!+V[A8PJD2^%;B;"+^(O(M_0?J4G,OQ;R:JN
M\N)^_YVYE1L0'VM#8$&^C5=@IRIT7&$O.VHKBP0OJIPWWF="K3=I?J\41B0:
MRV$[7,HL$3&V0N  G:7/_#?\B$H5\%M)F^29$HNZA(#+4B3R'JQJXC$7:KE4
M'-#X%5@U,AD.3\L,[XW,MKI:$3L;K.*H;\2VK*NZ4)8Y1YZ=*A8JEFO5$@ B
MQ5NU*&K$=!$9WV$6K5K*1ZOE02GRL@>K?2==]FBWSG15BHN/GWXI+XW:-JK@
M1 @&K'B^@^KE[6VA;J%PD=7KA2J(J9)\A14;Y^LUR#8452M9(9K?0PM"EV4-
M4C=U4=8D"K(*HWM+68VP6(@=Q6.2&'G#^<2;3<=V$T]LTKIT.Y;UXA_6)NPR
M+&ALU%VNL56B1WW=@$,!O>1X6VQUJ5HC9DL#&A K>:>S6Q"N,LQ01:PI#N@,
MUI:F-!G;DW*72M-NV!_/"@7VXA6'C,5]5]#BHG%[)H)>(<WI=;T^%&-7;#))
MS/*[@NF*L4=^CF'(;^(-)W,O"@*[^J71XH.ZL['06# ICZVH3TE8 "(!K7&]
MKE-)GI+>D]< =I4<%GC"4A=EQ6$!6RD9K_"DC&4J[I4L/,R_U5E&,F=G[S-2
M;!EU)[%]JBRA27:3"NJRKS+0493DYC;>)*3?OG47.01(HQK39Q_,[U@7759A
ML=C;:B,%>^S2AR8Z?N(VK?(*,QZ4-DP.4<&P(IL(F<I68G2OUVN5(#"0?"E&
M*!Z_(T:R3%!60GF'NR;*&'IKGC+!K::\7.7%3F F?ET2-$D][B9!>!&N%:]S
MOU$TE>U0;$&^I"B: D$C'&E23%Z78*Z\?#KXO"J4VD%" ]Z.0,C@TTY\/4=\
M#J( ?Z?CZ>!C?[B;S">"%3G\Z<@0^Q9.'-<F RR7.H9<IN-Q,_4SJZE\B-MS
MZ'HT"RU)'2  =XGSVTS_"S//1_X86#9-::;.'EXUJ0O2(YL+BV=MQ*-(/ (P
M#[[B<)Y'DMZN-!Z=AW[4[$-BA\NE=6+"%+DO3R0?211<,M\P#*/[\\@?'IUY
MBR1=0!@TL&,>)#EMG$S&L>&:J$9^2(@+DRGR5"?2* !_:$,V9E1E!?-L<TB?
MU )_]GM)+>Q*+3C!^VFI!?[D#Y.:<8WWUC5V'>54RB-Z=F,8HAJBUAV/)+'=
MN!*7 T5G85.#4H:F%' BRQSN@;S#8)K)6E M_73@:'_?#768^<9D5[E(U>!_
MFHCU5RY0,;NYN&EPQT5X.7A_$##_+#,&==91Q-@;SV?>C /(V(\F8N;/R7&]
M:#0?_&Q%-O1FP[DWBL8B'/FSZ>!MD]$O(F\<C,2E0"T0S09O&@QP$86A%TZ'
M],J/QCV4['JLF'EAB,5FM/O,GT5B[E,$&8V\210,.NSW3P^]Z01$!Q'-H>DS
MGAY.\&PT@"SV4)G.$ 2S4L?B3J8U 2^!]!!39@;UTJ2T1 ,0%XI2^D)56T(Y
M]-@A'4+NL7+Y@'6>LMTZDW,JARWI-2^\E+JP.]II.PG.X> &/!/&V8($YQX8
MJNY[)>"+3F WEO\+QWY"NKW&[\S0.B6R)1L],$'-=QWKIZRY%Y3JTN9].,47
M5>W*8A\[."9M6L]:I($)!O0#+C2)UR"A'5$1%_ZN%^+1@\YWRM5ZW.@&+,M;
M)6#XE7J$]]C$"$-S*=*YS#2(O&@X%^'8#X+!KQ L'KKA;G#'CR:3";D*CW[0
M5Z;!T)M,R-3-A'[-VUW>-"G]O4WI[S+QYSI3-N9W\;<SD_D8+@^_9MLA\,SP
M?@\9=*H* L%XYG5K*5,86>N@2*YMD,;VKX'*6/B')!@H+U.80F8R0[<^:]=A
MC9/!LL,9LRNIB&6:N30F [DAFS!HON0Z@6<C!1U9M2E =BB0E#+!I]O/.7:.
MPE/3:@;5+8M\W8J61Y$'NEF=;0I%S565-&1[0OO*]_I6I22:Y:AU<L0CK1)?
MO*&Z@+AS^K+1H6%84"E>I=9#J4[>:&6<C-H/[(<'Z+K>Y%E#:T>Y3.*W*/@&
MA<Z.!7$$.P3O>U9-JS6&X3 )/\WRSCIWQI>@??504L"8@P4!$@POL#A+,L<U
MRV'+2%??UKY:^194E1=6O@>NT8E[T$-&%;UI'3!*VJ_<*,;F]>W*XI^5!J+B
M@50M9$U9<\1@G2GNZ\$7'SH3=GD]LM0IABV*0Z5R:=-6QJ&8UR1"!2KZ[)83
M%7%=Y*D 'P0*J:):LK%;,VTQT<6K9M(K,^G2PQ9']FCK8_R[9N/5%4N*0_ZV
MT!55MIMZD2*OYY2[C=O=J08$\U,66BE3]@&G!5>5'MO9E+TBU59"A7NR267<
M*&QW-4IUTA*$C JL2Z%%?36RXCK48H!-JEI1KE5Q2YFIZ.!>AM-D.5)0@T]3
M"*N+34Y1+88QED:]%CV31 V29^]MRFF^JV'I=Y:'#=Z <HX7]]RN(09-/T**
M3-IH6<+"(5Z-51SUXN+=A_>7S ,T!I5)<:!-6^":D"DPWB<7)3O=-<A]XWW
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M%6E9M\L^GM^>9UO5*)/7]0&W58MUD[=:4Q$&;0WY_^7JZL/C\^RJ.<" $1H
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MU!GH-/'7&E(,U,])8!DF178A=QD"PU8LA6-U;DY%J,?[IW>.H7R)((!#ZC&
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M^DM+NN0D&,,\7!4L*BYR[X@5B+TH,N&I*2($Y6^%"P%1(X*CL.YHKL\'AJ9
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M3(XR7F-Z"N/1"23#9'2$;]Q?PSCPC0_PO9?OK\7&D>6R^7U$8-(+3(+ Y(#
MRG(?67H%H3.X>6IDS95-)_ -Z;W[/$YVXTAR06(&C<.\4:"XLAUPBT*]KX,[
M'1 607@/Q5WH+@=O# \MPYW,<7!EJKHAM'O ,;RBL&YPVU@MJ?$T3)S+%[]V
M<-X=WXG-'JC?1>Z7TJ@,9,6!/:,_=7"'SK$(EQS^FTB.P&E8] /%/X?R',!!
M58/^VJ#A,K*0BEJ24)W+?[*^][;Q7C]5:(LP-1R$$FE;J]_M!].B[<<W]W:J
M?16VD-JQ8,[0X>GY602VG12M0:8.W;DQQ+T>EB4/5[3>@<]S8VAG>(%^7,__
M %!+ P04    "  !ALY4\2\^![D"  !F!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6S55<ENVS 0O?LK"*&'!#"LS?(2V 82)T5["! X:7LH>J"D
MD46$(AV2BM._[Y"2%2.PU5Y[D#0DY[U9-5SLI7K6)8 A;Q47>NF5QNRN?%]G
M)514C^0.!)X44E74X%)M?;U30','JK@?!<'$KR@3WFKA]A[4:B%KPYF !T5T
M7554_;X!+O=++_0.&QNV+8W=\%>+'=W"(YAONP>%*[]CR5D%0C,IB()BZ5V'
M5^NQU7<*WQGL]9%,;"2IE,]V\35?>H%U"#ADQC)0_+S"&CBW1.C&2\OI=28M
M\%@^L']VL6,L*=6PEOP'RTVY]&8>R:&@-3<;N?\";3R)Y<LDU^Y-]HUN@LI9
MK8VL6C!Z4#'1?.E;FX<CP"PX XA:0/2O@+@%Q"[0QC,7UBTU=+50<D^4U48V
M*[C<.#1&PX2MXJ-1>,H09U8;T$:QS$!.UE27Y.*)IASTY<(WR&YU_*QENFF8
MHC-,,;F7PI2:W(D<\A/X=3\^C'H(? RKBRTZQ'83]3+>4S4B<3@D41!%IQSJ
MA]]"UL'#'G?B+M6QXXO/\+G\4M$F^NZE9J^4@S":_+Q.L0K8T;]ZS(P[,V-G
M9GS&S"/^Z'G-@<B"G#=I-S_4_E3)^TT]E4 *R7$2,+$EQG8._MF9%!G#'B+9
MP;H3X(-U]6[=G>] $8.$*>549$!<3VMBI-O5AAJH'!CC<H "[6IRP00JR%HC
MI[Z\&F#1L]*5K9,&Z[..?")A-!V&D\!*X70X2<+!YH-CX7QNG\&3-)2WB#B9
MMXA9$IQJK?\O<=CN4*7(93-F6][V?=";NS@8SN(8A?%DF,PG?\T<,@=QU.A/
MY\FI9O>/1ED%:NLF/&9$UL(T4ZW;[2Z1:S<[_7?UY@;"^F^9T(1#@=!@-$T\
MHIJIWBR,W+G!F$J#8]:))5Z$H*P"GA=2FL/"&NBNUM4?4$L#!!0    (  &&
MSE3N7(U-_P,   \,   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;,U7
MWV_;-A!^SU]Q4(LM 53KEVW9J6T@<1:LP ($3=H]#'N@I;-%1")=DK+K_WY'
MRI;=P'&SK1CV8E'2?=_Q[N.=SJ.U5$^Z0#3PM2J%'GN%,<O+(-!9@173';E$
M06_F4E7,T*U:!'JID.4.5)5!'(;]H&)<>).1>W:O)B-9FY(+O%>@ZZIB:G.-
MI5R/O<C;/?C(%X6Q#X+):,D6^(#FT_)>T5W0LN2\0J&Y%*!P/O:NHLMIU]H[
M@\\<U_I@#3:2F91/]N9#/O9"NR$L,3.6@=%EA5,L2TM$V_BRY?1:EQ9XN-ZQ
MW[K8*989TSB5Y>\\-\78&WB0XYS5I?DHU[_B-IZ>Y<MDJ=TOK!O;7N)!5FLC
MJRV8=E!QT5S9UVT>#@"#\ 5 O 7$KP4D6T#B FUVYL*Z889-1DJN05EK8K,+
MEQN'IFBXL"H^&$5O.>',Y)9Q!9]962/(.=QRP43&60D?A#:J)KF,AO-'-BM1
M7XP"0QXM+LBV[-<->_P">P)W4IA"PR\BQ_P(?GH:'\4G" (*M8TWWL5['9]D
MO&.J TGD0QS&\;$-G8;?8-;"HQ/;2=KT)XXO^7[Z;[C.2JEKA1K^N)I1^NF(
M_WG"1[?UT74^NB_X>*#*S^NR$?@;N:>R6C*Q^5D?"'^E-1I]3.J37FRWN=1+
MEN'8HW:B4:W0FSP6"'/K<K5S:>C)UNU/;P9QE+[7,&^=,^<<9ALH<86V%DS!
MA0,=T!0<%5-9L8$U*B00S&5)[8A.JC.6M68BUQ>79W?6K)7[[#='&D%SC;?7
MY(S.&&ZHJM03M<UY+7(XSY@N +_4G%Q2$5S 6XCBKM\+A[1R.X_?[U?'&$HI
M%N\,JHJ:'8G),X,Y6-H+B(;#EJ-E<%A;:* QJQ4W'/7E&>6J0N62LV1+5"VN
M%_K#L-O"IU(MI6(&J8?-3&L5=?UTF+96GSH/'5C(%2IA2QNH3XMLL[?N^6$_
M:JW=47@W8]D3[7R_J=8\\<-PS_THS5[!"ID]R3DP<ZA<D\0T'-!JD/AI_R";
M9U1;6,THQ%U]_4N]XK[?3>/_4BXXCRY>5JR;^,/^\+N*I7Y(NWZE8B18+WFU
M8*G?'X9_4S#*8C^-:)&27H/N01(I6* "UPC<8*6A8"N$&:+]NF<E\?(Y)T(C
M(9/"SAMN62MEXZ#$<)F#:Q7",/M)[\"Q?GRZM[D&XXJ?BP7L]#"V(RA3/&\<
M/[S_/.\WKS_"39O]_Y[D]L@TJO^H,_,\0>$_2-")^-ZZ"(_EZ97=Z3CZV$<X
M.)BYJ-X7;A35=-1K89KQJWW:3KM7;L@+]N;-J$P*++C0=.;F! T[:<\#U8R?
MS8V12S?!S:2A>= M"YK845D#>C^7TNQNK(/V/\#D+U!+ P04    "  !ALY4
M,:M<JGH#  "<"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R=5MV/
MVC@0?\]?,<I5IUV))9\0V ,DEEZO?:BT*KO7A],]F&0@UB9QSG:@[5_?L0.!
MZP*ZW@,P'L]O/GYC>YCLA'Q1.:*&+V51J:F;:UW?>YY*<RR9ZHL:*]I9"UDR
M34NY\50MD6465!9>Z/M#KV2\<F<3JWN4LXEH=,$K?)2@FK)D\NL#%F(W=0/W
MH/C$-[DV"F\VJ=D&EZB?ZT=)*Z_SDO$2*\5%!1+74W<>W"]B8V\-_N2X4R<R
MF$I60KR8Q8=LZOHF(2PPU<8#HY\M+K HC"-*XY^]3[<+:8"G\L'[.UL[U;)B
M"A>B^,PSG4_=D0L9KEE3Z$]B]Q[W]0R,OU04RG[#KK4=1"ZDC=*BW(,I@Y)7
M[2_[LN?A!##R+P#"/2#\KX!H#XALH6UFMJRW3+/91(H=2&--WHQ@N;%HJH97
MIHM++6F7$T[//C+Y@IJM"H0EIHWDFJ."FR>C4;<33U,,8^FE>W\/K;_P@K\(
M/HI*YPI^KS+,SN 7U_%!>,6!1\5U%8:'"A_"JQZIPCY$00]"/PS/)70=_A;3
M#AY<22?J"(^LO^BG"/]KOE):TIG^^TJ(N L1VQ#QA1!+NNI90P'$&N9;Q@L3
M[8YN_)UBI#V;P;E.7XUBGI=[5;,4IRZ]'PKE%MW9ZW .A4OSK@'.O!12\V^8
MP7-%ST[QH_B.<>DL1%FB3#DKH&8U2G@# [\W]F,2?OUE% ;A;_^2VDV"R5I(
MII$N\DI#$/=&00P!W 0CN#7+9)PXS_UE'S9BB[*BUT@#O555^A6"0<\?!9W/
MF] W$%(. V>N%.J[%4M?*$%U[%K4\X/H"!D2@E1^XCP)3:F_@5%$&80D!/2Y
MB6,RL,ID.';H8&&YHMH.AXO2O/W?],11;SP<7Z"GW7Q%3T(5Q\?T*=%;JTS"
M2R01'8/A$1$1P*BBBPPEO>%X< 0,"&!4?L=00@S]T-:6>KN5C&*'6(&GG X8
M<(VE@IQM$5:(9HBD!5.*KSD%U0)249FQ9L5&2I,WD<-%!O: 5IJ9R=&'<X_
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M;#;1:DVT\T8V9WAM/!JKX=+]Q3NK<9<CSLXN\EPW4)!/G"VXX):#(4?W;"'
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M1\=P8Y9T4:+Q#O2]T-J=%CY ?_5N?@%02P,$%     @  8;.5,B+8'7N @
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M-RSQG01E'7!]):79&39 ]_+.?@-02P,$%     @  8;.5$8 HTBQ!@  I1,
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M<DB/K"=2%')\8F6-7K0=C81V.$OLI,FEXT<D<6:(0=L/9M8':"PHU(,LSNS
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MCZCQI1DG1AY<L]Y)@ZW?#1M\G$%9 ]ROI32GB3U@?NY7?P%02P,$%     @
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ML@=P/Y?2;">6H&W#I[\ 4$L#!!0    (  &&SE1O!XF!GP,  +8*   9
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;+562V_;.! ^=W\%(?30 DGTL.PX
M@6W B5TTBQ9KQ,WV$/1 2R.;*$6J)!6[^^MW2"F*'<O:]K 76R3GF_GFP>&,
MME)]UQL 0W8Y%WKL;8PIKGU?)QO(J;Z0!0@\R:3*J<&E6ONZ4$!3!\JY'P7!
MP,\I$]YDY/86:C*2I>%,P$(17>8Y53]O@,OMV N]YXU[MMX8N^%/1@5=PQ+,
M0[%0N/(;+2G+06@F!5&0C;UI>#T/ PMP$G\SV.J];V)=64GYW2[NTK$76$;
M(3%6!<6_)[@%SJTFY/&C5NHU-BUP__M9^P?G/#JSHAIN)?_*4K,9>T./I)#1
MDIM[N?T(M4-]JR^17+M?LJUE X\DI38RK\'((&>B^J>[.A![ -33#HAJ0/0*
M$ ]. 'HUH/?:0GP"$-> ^%<!_1K@7/<KWUW@9M30R4C)+5%6&K79#Q=]A\9X
M,6$+96D4GC+$F<FR*A B,[)D:\$REE!AR#1)9"D,$VNRD)PE##0Y)],T93:]
ME),[416I3?:[&1C*N'Z/(@_+&7GW]CUY2Y@@7S:RU%2D>N0;Y&HM^DG-ZZ;B
M%9W@]2<5%R0(ST@41%$+_+8;_IFJ"]([#9]UPV>0-/"P!3[_=7AP"/<Q/TV2
MHB9)D=/7.Z&O+1N/TY4V"N_9MPX#O<9 SQF(_]O TF#"J$HU>2A2:H \SG?&
M-H85!S(790[*9?U;6U*ZK93Z?$UI<?UBK3%6V8J"<!!$GR%?@>KP*FZ\BCOM
MW6ZH6(,M1/KB7Z&82%C!X6Q_5S=>EXX)'J:R,) 2NVHKWV[3KGS#LS_>O#DN
MP -?^HTO_?_?ET>C2B 9Y1I:T]=-P8([/!DTG@PZU?Q5N I"HARPPQ-E6_FY
MS,Y+7%"MP;2VBTIIWRFUK]_3I-<+\'(][3O0(A3%PT;H@.]EP_?RM_AR1E>,
M,_.SC66E:K!'H!\?L;P\8MF/PKB=Y;!A.>QD>0\)Q^"Y_NV:,C9T?"]!*<R[
M FSI6!0$+[+M[BPOE'R"W&USG!6H2* UZL,CJE&XY\\!U:N&ZE4GU0>A()'X
MUOR#U+[0';D! 1DS&A^51.;@]A;(E!O;Z.8['(ITVQV<71VQ>Q7J>9?$ ?DP
M>'DP@T[Z=WE!F7*QPQA_DE@8GW#62<G4U2[Y"#PE^#B2LIUTK;Z+=:=(1=O?
M>_+M1(</WIH)C36:(2:XN$2PJH:D:F%DX:: E30X4[C/#0Z6H*P GF=2FN>%
M'2R:477R+U!+ P04    "  !ALY4F<%3\!T"   6!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6R-5,&.VC 0_17+V@-(+0D)6]I5B,225MW#2@BT
M[:'JP20#L=:QL[8AV[_OV D1E8!RB3WV>V\\SQ,GC=*OI@2PY+T2TLQH:6W]
M$ 0F+Z%B9J1JD+BS5;IB%D.]"TRM@16>5(D@"L-/0<6XI&GBUY8Z3=3>"BYA
MJ8G95Q73?QY!J&9&Q_2XL.*[TKJ%($UJMH,UV)=ZJ3$*>I6"5R -5Y)HV,[H
M?/R0Q0[O 3\X-.9D3EPE&Z5>7?!4S&CH#@0"<NL4& X'6( 03@B/\=9ITCZE
M(Y[.C^K??.U8RX896"CQDQ>VG-'/E!2P97MA5ZKY#ET]]TXO5\+X+VE:['1*
M2;XW5E4=&4]0<=F.[+WSX80PGEP@1!TANI40=X3X5L*D(TR\,VTIWH>,698F
M6C5$.S2JN8DWT[.Q?"[=M:^MQEV./)NNP%C-<PL%63!3DH]D,"\*[NZ$"?(D
MV\;":$@&&5C&A1DBZ&6=D<'=D-P1+LDS%P(1)@DLGLCI!GF7_;'-'EW(_LST
MB,3C#R0*H^@,?7&=GD'>T\=GZ-GM]/!?>H V]EY&O9>1UXLOZ'D#F>R<_/JV
MYP<F0%I#?LTW:#/V^.\K:>(^3>S33/Y_9;E+I,& /L Y]UNA+U[(/0"'-!RA
MSX=3BV_ 9-<Q;17!21.Z%P/O=L>E(0*VR I'TWM*=/L7MH%5M>_+C;+8Y7Y:
MXL,%V@%P?ZN4/0:NU?NG,/T+4$L#!!0    (  &&SE1M 'TYK@(  (4(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;(U676^;,!3]*Q;J0RMEY9LD
M58+4AD3;PZ2J6;>':0\.W 2K@%/;)-V_GVTH(X&FO( _SCF^YU[KPNQ(V0M/
M 01ZR[."SXU4B/V=:?(XA1SS6[J'0NYL*<NQD%.V,_F> 4XT*<],Q[(",\>D
M,,*97GMDX8R6(B,%/#+$RSS'[.\#9/0X-VSC?>&)[%*A%LQPML<[6(-XWC\R
M.3,;E83D4'!""\1@.S?N[;N5K_ :\)/ D;?&2#G94/JB)M^2N6&I@""#6"@%
M+%\'6$"6*2$9QFNM:31'*F)[_*Z^TMZEEPWFL*#9+Y*(=&Y,#)3 %I>9>*+'
MKU#[T0'&-./ZB8XUUC)07')!\YHL(\A)4;WQ6YV'%L'V/B X-<$92G!K@CN4
MX-4$;RC!KPG^4$)0$P*=^RI9.M,1%CB<,7I$3*&EFAKH<FFV3# IU,5:"R9W
MB>2)\ FX8"06D* %YBGZ@M;R[B9E!HANJR5<U'O+UY(<< :%X'KQG'L=@< D
MXS=2Y7D=H>NK&W2%2(%^I+3DDL%GII QJY/-N([OH8K/^2"^[YC=(M<>(<=R
MG![ZXC(]@KBAVSWT:/CI??3E\-.M'OIJ,-V>GM)-6>:FUDY3:T?KN1_HJ2*-
M.J4<=>K85]MV[7_?;^2F[ E_+@3E-D&Y.BCO0E#ZQ%@-X/\Q?7>EDO*UE&J9
MA]!VQG8@<WMHWXDNS+4FKGN*BGK$[''@VZ>P91?F!?XT:% GKKW&M7?1=2N]
MRG>?UTH@:(<WG9X9'8")!F"6ES$G#OW&H?]I74>=HNI*L\_-^WV%=OUS_UV8
M:UNN<Y:!'C%[//'/;LVR"_."\=0_1:UZCO2"R7FRS%9'5A]HV4AVI. H@ZWD
M6;=C*<"JCUXU$72OF_2&"MGR]3"5_PG %$#N;RD5[Q/5]YL_C_ ?4$L#!!0
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M_+*DEPR,"Z#]M=9X,%R"]FW,_@!02P,$%     @  8;.5(#LF4QJ @  F@4
M !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULC53?;]HP$/Y7K*@/K;02
M")!U%42"=M,J#0T5=7N8]F"2(['J'YE]E'9__<X.9&RCT5YBW]GWW7>?<S?9
M&?OH*@!DSTIJ-XTJQ/HZCEU>@>*N9VK0=+(Q5G$DTY:QJRWP(@0I&2?]?AHK
M+G2438)O:;.)V:(4&I:6N:U2W+[,09K=-!I$!\>]*"OTCCB;U+R$%>!#O;1D
MQ2U*(11H)XQF%C;3:#:XGJ?^?KCP1<#.'>V9KV1MS*,W[HIIU/>$0$*.'H'3
M\@0W(*4'(AH_]IA1F](''N\/Z!]"[53+FCNX,?*K*+":1E<1*V##MQ+OS>XC
M[.L9>[S<2!>^;-?<32ECOG5HU#Z8;"5TL_+GO0Y' <EK <D^( F\FT2!Y2U'
MGDVLV3'K;Q.:WX120S21$]H_R@HMG0J*P^S&*"605$;'+MFL*(07BTMVIYL7
M]]*=WP)R(=T%.V-"LX60DMQN$B,Q\#AQOL\V;[(EKV0;LH716#GV7A=0_!D?
M$_.6?G*@/T\Z 1?<]MAP\(8E_21Y6-VR\[.+#MAAJ\HPP [_0Y5OL[5#2W_/
M]P[@40L\"L"C5X"75AC+M$&Q$7DC;@WD*Q@:AF#IA3D"X]9R78(G<$KD[AR#
MA*F@<@??<<MWW(FU$%JHK2+&^C+G.J?NX6L)+#<.3[Y_ _<NP/F!\)2-^KUT
M$C^=()&V)-).$I_74I0D2Q"IYB]^^63T3WZ*0/H/@7'OZJ_\\5&_*+!EF J.
MBMIJ;%JG];:#9];TV^_KS=2B'[ 4VC$)&PKM]]Z2 +:9!(V!I@[=MS9(O1RV
M%0U/L/X"G6^,P8/A$[3C./L%4$L#!!0    (  &&SE1?S'P2XP(  "D)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;*U6;4_;,!#^*U:T22!MS4O3
M%E!;"5I-0X)1@=@^3/O@)M?&PHZ#[5#X]SL[(1219F6B'QJ_W'-WSW..+^.-
M5'<Z S#D4?!<3[S,F.+$]W62@:"Z)PO(<6<EE: &IVKMZT(!31U(<#\*@J$O
M*,N]Z=BM+=1T+$O#60X+170I!%5/9\#E9N*%WO/"-5MGQB[XTW%!UW #YK98
M*)SYC9>4"<@UDSE1L)IXI^')/ PLP%G\9+#16V-BJ2REO+.3\W3B!38CX) 8
MZX+BXP%FP+GUA'G<UTZ])J8%;H^?O7]SY)',DFJ82?Z+I2:;>$<>26%%2VZN
MY>8[U(0&UE\BN7;_9%/9C@8>24IMI*C!F(%@>?6DC[406X PW@&(:D"T+Z!?
M _K[ N(:$#ME*BI.ASDU=#I6<D.4M49O=N#$=&BDSW);]QNC<)<ASDQGM&"&
M<G(!*!ZY6G*VIK8@FGPEIVG*[!BWS_/JB-E2'<S!4,8/T>+V9DX./AV.?8.I
M6(=^4H<]J\)&.\)>4M4C_? +B8(H;('/NN%S2#KA\_WAP6NXC_HU(D:-B)'S
M%_]#1.Y$I&L%@*^&P3J94C'S1!:@F$S;9.IV'(Z(D+G)=)M$W=#^L!7ZBE^_
MX=?O]+4H59)9:G)%X+YDA6-7YBDHDK1S;TNX"C)P0>Q]]##%VCVTY!4W><7O
MT%V^'-ZVZ/&;Z/W _MI3&#0I##I3.!<%9Y 2EAM0H U1U  I-2X9B1=C6B9
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MZ9@!\/M("/UR8UY0'5:>_0M02P,$%     @  8;.5'O;/7\I!   )!(  !D
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M<2;(;P/.?UMB$9&4_RY=<#7")Z:0>:IHS;C*Z:G,R;Z2$P)?:2X.,HA<1C#
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M2&-DYBX3X+A=MP;X?BJE>;RQ 9I#X^%_4$L#!!0    (  &&SE2"J5U!^P(
M -<)   9    >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;*6647.B,!#'OTJ&
MZ4,[<Q6(B-I19JK>S?6A,TYM[YXC+,(4$B\)ZGW[2P)2M$AOVA=)POYW?[O$
M;"9[QE]% B#1(<^HF%J)E-L[VQ9A CD1/;8%JM[$C.=$JBG?V&++@41&E&<V
M=AS?SDE*K6!BUI8\F+!"9BF%)4>BR'/"_\X@8_NIY5K'A:=TDTB]8 >3+=G
M"N3+=LG5S*Z]1&D.5*2,(@[QU+IW[^8NU@)C\2N%O6B,D4YES=BKGCQ$4\O1
M1)!!*+4+HAX[F$.6:4^*XT_EU*IC:F%S?/3^PR2ODED3 7.6_4XCF4RMD84B
MB$F1R2>V_PE50@/M+V29,+]H7]DZ%@H+(5E>B15!GM+R20Y5(1H"U[\@P)4
MGPN\"X)^)>B;1$LRD]:"2!),.-LCKJV5-STPM3%JE4U*]6=<2:[>IDHG@P<:
MLAS0,SF 0+=H57Y-Q&*TY&R7FJ^EZH5.[*X7($F:B1NE>%DMT/75#;I"*47/
M"2L$H9&8V%+!Z1!V6(',2A!\ <3%Z)%1F0CTG480G3JP559U:OB8V@QW>EQ
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MN)O#)68H"8,9T0@3GL%%GJ,K3&4Z.$=-*%-?AY$VP5J745H'=E8%ENP)K)/
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MXQ-HO=+:[2:^P/!DYG\!4$L#!!0    (  &&SE2FD79]*@,   P3   -
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MBOF#5A"TFC_H$8(>YP]*2Y1Q29 TP9I ZX1<)P*O$X*=",1.2'8B,#LAVHE
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M/;AN?,EG\]_ K_X 4$L! A0#%     @  8;.5 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  !ALY4
MU?)9:.\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  !ALY4F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  &&SE2O](1"K0(
M $((   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  !ALY4R:O*J%L'  !0(0  &               @('Q
M"@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @  8;.5'H8
M+X^O!   >1@  !@              ("!@A(  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    (  &&SE2!L@EKQ@0  #P1   8
M  " @6<7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  !
MALY4>#)%\1 *  #?.P  &               @(%C'   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @  8;.5(=:41.+ @  I 4  !@
M         ("!J28  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   (  &&SE16P<T$;0@  &0E   8              " @6HI  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  !ALY4<QMI%(D'  "/'0
M&               @($-,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @  8;.5&90Y9S+&0  C4P  !@              ("!S#D  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  &&SE26UA<8D@,
M &H*   9              " @<U3  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @  8;.5%%*^J(:!0  U@\  !D              ("!
MEE<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  !ALY4
M+C>G,'0#   X"0  &0              @('G7   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    (  &&SE3.5?7(M0(  .X'   9
M      " @9)@  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @  8;.5.?-CG F P  UP8  !D              ("!?F,  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  !ALY4 <'IY@X#  "[!@
M&0              @(';9@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    (  &&SE1@]YHF_P,  )X)   9              " @2!J  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @  8;.5/D@AS[?
M @  G <  !D              ("!5FX  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  !ALY4 9KHAT@$  "_"0  &0
M@(%L<0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  &&
MSE3L>MMVL@<  #82   9              " @>MU  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @  8;.5!OZHX]Y!@  )A$  !D
M         ("!U'T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  !ALY4'Y=W480'  #X%0  &0              @(&$A   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  &&SE1U[_CX+ 4  !D,
M   9              " @3^,  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @  8;.5#'^V3!'$0  I4   !D              ("!HI$
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  !ALY4A*^O
MGMX$  #4#P  &0              @($@HP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    (  &&SE2/">^U, D  .@6   9
M  " @36H  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M 8;.5'U4_AZX @  \P4  !D              ("!G+$  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  !ALY4)Y4,:[@:  !T5@  &0
M            @(&+M   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    (  &&SE3F@7,:C (  +H%   9              " @7K/  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @  8;.5/$O/@>Y @
M9@<  !D              ("!/=(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  !ALY4[ER-3?\#   /#   &0              @($M
MU0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  &&SE0Q
MJURJ>@,  )P(   9              " @6/9  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @  8;.5,=Z4:7# @  J0<  !D
M     ("!%-T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M"  !ALY4]\0U'?,"   T!@  &0              @($.X   >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  &&SE2NT?GXL@(  -,%   9
M              " @3CC  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @  8;.5.Q<0BWK @  @P<  !D              ("!(>8  'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  !ALY4<)%A%,\#
M  !3"@  &0              @(%#Z0  >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    (  &&SE2#V>1<#P,  (8'   9              "
M@4GM  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @  8;.
M5,B+8'7N @  O <  !D              ("!C_   'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  !ALY44@^J<,@"  "%!P  &0
M        @(&T\P  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   (  &&SE1& *-(L08  *43   9              " @;/V  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @  8;.5#^M9-)/ P  ^@<
M !D              ("!F_T  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  !ALY47NZM:9T$  "-"P  &0              @($A 0$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  &&SE0<Z1;N
M:@,  )(*   9              " @?4% 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @  8;.5+V1JP$' P  D@L  !D
M ("!E@D! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  !
MALY4;P>)@9\#  "V"@  &0              @('4# $ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  &&SE29P5/P'0(  !8%   9
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M970U,"YX;6Q02P$"% ,4    "  !ALY4'"MPF94"   K!P  &0
M    @($=(P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M  &&SE2!<A,HM ,  &L/   9              " @>DE 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @  8;.5*4\KR9% @  )P4  !D
M             ("!U"D! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    "  !ALY4@.R93&H"  ":!0  &0              @(%0+ $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  &&SE1?S'P2XP(
M "D)   9              " @?$N 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @  8;.5'2/6_B= @  K08  !D              ("!
M"S(! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  !ALY4
M]:FY7O("  !@"0  &0              @('?- $ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    (  &&SE2 5]C 5 ,  '(*   9
M      " @0@X 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @  8;.5%4C]/]3 @  T04  !D              ("!DSL! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  !ALY4L%9@/20#   F"@
M&0              @($=/@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    (  &&SE2^?$06>0(  &T%   9              " @7A! 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @  8;.5 EO*"CL
M @  ?P@  !D              ("!*$0! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    "  !ALY4+D@4E,T"   _"   &0
M@(%+1P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (  &&
MSE2U<L\#\0(  ),(   9              " @4]* 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @  8;.5!'#F>3& @  7@<  !D
M         ("!=TT! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M    "  !ALY4H!@<[0<'  "C*0  &0              @(%T4 $ >&PO=V]R
M:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (  &&SE2H*0\RI (  "P'
M   9              " @;)7 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL
M4$L! A0#%     @  8;.5*"3:G._ P  ?0T  !D              ("!C5H!
M 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  !ALY4*KT\
MN# *   P.P  &0              @(&#7@$ >&PO=V]R:W-H965T<R]S:&5E
M=#8Y+GAM;%!+ 0(4 Q0    (  &&SE3&RECF^0,  -01   9
M  " @>IH 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
M 8;.5.]TUU3&!0  5!<  !D              ("!&FT! 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    "  !ALY4YY,!: T#  !G"0  &0
M            @($7<P$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4
M Q0    (  &&SE0&5)2_W0(  +D)   9              " @5MV 0!X;"]W
M;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @  8;.5!X;>VE%!0
MN!P  !D              ("!;WD! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX
M;6Q02P$"% ,4    "  !ALY4>]L]?RD$   D$@  &0              @('K
M?@$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (  &&SE0B
M040T2 4  $ 6   9              " @4N# 0!X;"]W;W)K<VAE971S+W-H
M965T-S8N>&UL4$L! A0#%     @  8;.5(*I74'[ @  UPD  !D
M     ("!RH@! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4
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M   ,$P  #0              @ '#E0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   (  &&SE27BKL<P    !,"   +              "  1B9 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    (  &&SE1QQ<P^\04  -(T   /              "
M 0&: 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  !ALY4M,4*KF@"  !'
M+P  &@              @ $?H $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  !ALY4+ %G.QL"   .+@  $P              @ &_
LH@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     6 !8 !\8   +I0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>222</ContextCount>
  <ElementCount>328</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/NatureOfTheBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Capital Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CapitalLeaseObligations</Role>
      <ShortName>Capital Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/NetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RestrictedCashTables</Role>
      <ShortName>Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/RestrictedCash</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/MarketableSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Capital Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CapitalLeaseObligationsTables</Role>
      <ShortName>Capital Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/CapitalLeaseObligations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/AccruedLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/CommonStock</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/ShareBasedCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/NetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arc.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Nature of The Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails</Role>
      <ShortName>Nature of The Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Restricted Cash - (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RestrictedCashAdditionalInformationDetails</Role>
      <ShortName>Restricted Cash - (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arc.com/role/RestrictedCashTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Property and Equipment, Net - Schedule Of Property And Equipment Consist (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule Of Property And Equipment Consist (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/PropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arc.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Capital Lease Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail</Role>
      <ShortName>Capital Lease Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Capital Lease Obligations - Summary of Future Lease Obligations Under These Capital Lease Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail</Role>
      <ShortName>Capital Lease Obligations - Summary of Future Lease Obligations Under These Capital Lease Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Leases - Summary of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/LeasesSummaryOfLeaseCostsDetails</Role>
      <ShortName>Leases - Summary of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Redeemable Convertible Preferred Stock -  Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock -  Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Common Stock - Schedule of Reconciliation of Shares Issued and Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail</Role>
      <ShortName>Common Stock - Schedule of Reconciliation of Shares Issued and Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/CommonStockAdditionalInformationDetail</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Share-Based Compensation - Schedule of Black-Scholes option pricing model for stock options granted  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Black-Scholes option pricing model for stock options granted  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Share-Based Compensation - Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Income Taxes - Summary of Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Income Taxes - Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails</Role>
      <ShortName>Income Taxes - Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d332508ds1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" original="d332508ds1a.htm">d332508ds1a.htm</File>
    <File>aclx-20220331.xsd</File>
    <File>aclx-20220331_cal.xml</File>
    <File>aclx-20220331_def.xml</File>
    <File>aclx-20220331_lab.xml</File>
    <File>aclx-20220331_pre.xml</File>
    <File>d332508dex231.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g332508g01a11.jpg</File>
    <File>g332508g02s22.jpg</File>
    <File>g332508g04a44.jpg</File>
    <File>g332508g08a40.jpg</File>
    <File>g332508g08a45.jpg</File>
    <File>g332508g09u04.jpg</File>
    <File>g332508g11i15.jpg</File>
    <File>g332508g11v20.jpg</File>
    <File>g332508g15a69.jpg</File>
    <File>g332508g15n13.jpg</File>
    <File>g332508g20a42.jpg</File>
    <File>g332508g22i15.jpg</File>
    <File>g332508g22s22.jpg</File>
    <File>g332508g26a01.jpg</File>
    <File>g332508g29n95.jpg</File>
    <File>g332508g33h85.jpg</File>
    <File>g332508g33i14.jpg</File>
    <File>g332508g36a20.jpg</File>
    <File>g332508g39b76.jpg</File>
    <File>g332508g40f82.jpg</File>
    <File>g332508g41x63.jpg</File>
    <File>g332508g42b83.jpg</File>
    <File>g332508g42q66.jpg</File>
    <File>g332508g43n80.jpg</File>
    <File>g332508g43z54.jpg</File>
    <File>g332508g46h84.jpg</File>
    <File>g332508g53o14.jpg</File>
    <File>g332508g55z44.jpg</File>
    <File>g332508g71l23.jpg</File>
    <File>g332508g77g82.jpg</File>
    <File>g332508g79z49.jpg</File>
    <File>g332508g88p88.jpg</File>
    <File>g332508g91e20.jpg</File>
    <File>g332508g96c25.jpg</File>
    <File>g332508g98u89.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="946">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>130
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d332508ds1a.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 222,
   "dts": {
    "calculationLink": {
     "local": [
      "aclx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aclx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d332508ds1a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aclx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aclx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aclx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 513,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021": 4,
    "total": 7
   },
   "keyCustom": 58,
   "keyStandard": 270,
   "memberCustom": 21,
   "memberStandard": 35,
   "nsprefix": "aclx",
   "nsuri": "http://arc.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntitySmallBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://arc.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntitySmallBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Restricted Cash",
     "role": "http://arc.com/role/RestrictedCash",
     "shortName": "Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://arc.com/role/FairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:MarketableSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Marketable Securities",
     "role": "http://arc.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:MarketableSecuritiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Property and Equipment, Net",
     "role": "http://arc.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Commitments",
     "role": "http://arc.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Capital Lease Obligations",
     "role": "http://arc.com/role/CapitalLeaseObligations",
     "shortName": "Capital Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Accrued Liabilities",
     "role": "http://arc.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:LesseeOperatingAndFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Leases",
     "role": "http://arc.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:LesseeOperatingAndFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Commitments and Contingencies",
     "role": "http://arc.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)",
     "role": "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:DiscloureOfRedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://arc.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:DiscloureOfRedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Common Stock",
     "role": "http://arc.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Share-Based Compensation",
     "role": "http://arc.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://arc.com/role/NetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Income Taxes",
     "role": "http://arc.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Employee Benefit Plan",
     "role": "http://arc.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Restricted Cash (Tables)",
     "role": "http://arc.com/role/RestrictedCashTables",
     "shortName": "Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)",
     "role": "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://arc.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Marketable Securities (Tables)",
     "role": "http://arc.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://arc.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Capital Lease Obligations (Tables)",
     "role": "http://arc.com/role/CapitalLeaseObligationsTables",
     "shortName": "Capital Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://arc.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Leases (Tables)",
     "role": "http://arc.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://arc.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)",
     "role": "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Common Stock (Tables)",
     "role": "http://arc.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)",
     "role": "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://arc.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Income Taxes (Tables)",
     "role": "http://arc.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P02_08_2022To02_08_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Nature of The Business - Additional Information (Details)",
     "role": "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
     "shortName": "Nature of The Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P02_08_2022To02_08_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment, Net (Details)",
     "role": "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "aclx:PropertyPlantAndEquipmentEstimatedLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn01_01_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn01_01_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Restricted Cash - (Additional Information) (Details)",
     "role": "http://arc.com/role/RestrictedCashAdditionalInformationDetails",
     "shortName": "Restricted Cash - (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Restricted Cash - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details)",
     "role": "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails",
     "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value of Company's Financial Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details)",
     "role": "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Available-for-sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited)",
     "role": "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:DebtSecuritiesAvailableForSaleContractualMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "aclx:MarketableSecuritiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:DebtSecuritiesAvailableForSaleContractualMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:PrepaidResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "aclx:PrepaidExpensesAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:PrepaidResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Property and Equipment, Net - Schedule Of Property And Equipment Consist (Details)",
     "role": "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
     "shortName": "Property and Equipment, Net - Schedule Of Property And Equipment Consist (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Property and Equipment, Net (Detail)",
     "role": "http://arc.com/role/PropertyAndEquipmentNetDetail",
     "shortName": "Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:PriorNotificationPeriodToTerminateArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Commitments - Additional Information (Details)",
     "role": "http://arc.com/role/CommitmentsAdditionalInformationDetails",
     "shortName": "Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:PriorNotificationPeriodToTerminateArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P03_31_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:CapitalLeaseAgreementMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Capital Lease Obligations - Additional Information (Detail)",
     "role": "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail",
     "shortName": "Capital Lease Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P03_31_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aclx:CapitalLeaseAgreementMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Capital Lease Obligations - Summary of Future Lease Obligations Under These Capital Lease Agreements (Detail)",
     "role": "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail",
     "shortName": "Capital Lease Obligations - Summary of Future Lease Obligations Under These Capital Lease Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "aclx:CapitalLeasesFutureMinimumPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:ResearchAndDevelopmentAccruedExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:ResearchAndDevelopmentAccruedExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "aclx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://arc.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "aclx:LesseeOperatingAndFinanceLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Leases - Summary of Lease Costs (Details)",
     "role": "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails",
     "shortName": "Leases - Summary of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:TransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)",
     "role": "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:TransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Leases - Summary of Future Minimum Operating Lease Payments (Details)",
     "role": "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails",
     "shortName": "Leases - Summary of Future Minimum Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "aclx:SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:CashPaidForMeasurementOfOperatingLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)",
     "role": "http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
     "shortName": "Leases - Supplemental Cash Flow Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "aclx:SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "aclx:CashPaidForMeasurementOfOperatingLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "aclx:OperatingLeasesDeferredRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "aclx:OperatingLeasesDeferredRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail)",
     "role": "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)",
     "role": "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aclx:CommonStockSharesLegallyIssuedAndOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details)",
     "role": "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Reconciliation of Shares Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Redeemable Convertible Preferred Stock -  Additional Information (Details)",
     "role": "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock -  Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "2",
      "lang": null,
      "name": "aclx:TemporaryEquitySharesDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aclx:CommonStockSharesLegallyIssuedAndOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Common Stock - Schedule of Reconciliation of Shares Issued and Outstanding (Detail)",
     "role": "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
     "shortName": "Common Stock - Schedule of Reconciliation of Shares Issued and Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Common Stock - Additional Information (Detail)",
     "role": "http://arc.com/role/CommonStockAdditionalInformationDetail",
     "shortName": "Common Stock - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "aclx:CommonStockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P03_04_2022To03_04_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "role": "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)",
     "role": "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "role": "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Schedule of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units Activity (Details)",
     "role": "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
     "shortName": "Share-Based Compensation - Summary of Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Share-Based Compensation - Schedule of Black-Scholes option pricing model for stock options granted  (Details)",
     "role": "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
     "shortName": "Share-Based Compensation - Schedule of Black-Scholes option pricing model for stock options granted  (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021_MaximumMembersrtRangeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Share-Based Compensation - Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award  (Details)",
     "role": "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails",
     "shortName": "Share-Based Compensation - Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award  (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "aclx:SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://arc.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "2",
      "lang": null,
      "name": "aclx:PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Income Taxes - Summary of Provision For Income Taxes (Details)",
     "role": "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Income Taxes - Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate (Details)",
     "role": "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails",
     "shortName": "Income Taxes - Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Nature of the Business",
     "role": "http://arc.com/role/NatureOfTheBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "role": "http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://arc.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d332508ds1a.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "aclx_AccruedOfferingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued offering costs, Current",
        "label": "Accrued Offering Costs, Current",
        "terseLabel": "Accrued offering costs"
       }
      }
     },
     "localname": "AccruedOfferingCostsCurrent",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional stock issued during period shares exercised by underwriters with option to purchase.",
        "label": "Additional Stock Issued During Period Shares Exercised by Underwriters with Option to Purchase",
        "terseLabel": "Additional stock issued during period shares exercised by underwriters with option to purchase"
       }
      }
     },
     "localname": "AdditionalStockIssuedDuringPeriodSharesExercisedByUnderwritersWithOptionToPurchase",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aclx_AnniversaryPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary period",
        "label": "Anniversary Period",
        "terseLabel": "Anniversary period"
       }
      }
     },
     "localname": "AnniversaryPeriod",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "aclx_CapitalLeaseAgreementMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital lease agreement maturity Period.",
        "label": "Capital Lease Agreement Maturity Period",
        "terseLabel": "Capital lease agreement maturity Period"
       }
      }
     },
     "localname": "CapitalLeaseAgreementMaturityPeriod",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "aclx_CapitalLeasePrincipalPayments": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital lease principal payments.",
        "label": "Capital Lease Principal Payments",
        "negatedLabel": "Payments under capital leases"
       }
      }
     },
     "localname": "CapitalLeasePrincipalPayments",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_CapitalLeasesFutureMinimumPaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital leases future minimum payments.",
        "label": "Capital Leases Future Minimum Payments [Table Text Block]",
        "terseLabel": "Summary of Future Lease Obligations Under These Capital Lease Agreements"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsTableTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_CashPaidForMeasurementOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for measurement of operating lease liabilities.",
        "label": "Cash Paid for Measurement of Operating Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForMeasurementOfOperatingLeaseLiabilities",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for underwriting discounts and commissions and other offering expenses.",
        "label": "Cash Paid for Underwriting Discounts and commissions and Other Offering Expenses",
        "terseLabel": "Cash paid for underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "CashPaidForUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_ChangeInControlFollowingAnIpoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in control following an IPO [Member]"
       }
      }
     },
     "localname": "ChangeInControlFollowingAnIpoMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_ChangeInControlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in control.",
        "label": "Change in Control [Member]",
        "terseLabel": "Change in Control"
       }
      }
     },
     "localname": "ChangeInControlMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial accrual and expenses policy.",
        "label": "Clinical Trial Accrual and Expenses Policy [Policy Text Block]",
        "terseLabel": "Clinical Trial Accrual and Expenses"
       }
      }
     },
     "localname": "ClinicalTrialAccrualAndExpensesPolicyPolicyTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_CommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments",
        "label": "Commitments [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAbstract",
     "nsuri": "http://arc.com/20220331",
     "xbrltype": "stringItemType"
    },
    "aclx_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock.",
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://arc.com/20220331",
     "xbrltype": "stringItemType"
    },
    "aclx_CommonStockSharesIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares issued and outstanding.",
        "label": "Common Stock Shares Issued And Outstanding",
        "totalLabel": "Total shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndOutstanding",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aclx_CommonStockSharesLegallyIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails": {
       "order": 1.0,
       "parentTag": "aclx_CommonStockSharesIssuedAndOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares legally issued and outstanding",
        "label": "Common Stock Shares Legally Issued And Outstanding",
        "terseLabel": "Total shares of common stock legally issued and outstanding"
       }
      }
     },
     "localname": "CommonStockSharesLegallyIssuedAndOutstanding",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aclx_CommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock.",
        "label": "Common Stock [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_DebtSecuritiesAvailableForSaleContractualMaturities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities available for sale contractual maturities.",
        "label": "Debt Securities Available For Sale Contractual Maturities",
        "terseLabel": "Available-for-sale debt marketable securities contractual maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContractualMaturities",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_DeferredOfferingCostsIncludedInAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accrued liabilities.",
        "label": "Deferred Offering Costs Included in Accrued Liabilities",
        "terseLabel": "Deferred offering costs included in accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccruedLiabilities",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_DeferredTaxAssetsNonQualifiedStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets non qualified stock options.",
        "label": "Deferred Tax Assets Non Qualified Stock Options",
        "terseLabel": "Non-qualified\u00a0stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsNonQualifiedStockOptions",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits accrued employee bonuses.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Accrued Employee Bonuses",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsAccruedEmployeeBonuses",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_DiscloureOfRedeemableConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloure of redeemable convertible preferred stock.",
        "label": "Discloure of Redeemable Convertible Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "DiscloureOfRedeemableConvertiblePreferredStockTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status policy.",
        "label": "Emerging Growth Company Status Policy Text Block [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_EquipmentUnderCapitalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment under capital lease.",
        "label": "Equipment Under Capital Lease [Member]",
        "terseLabel": "Equipment under capital lease"
       }
      }
     },
     "localname": "EquipmentUnderCapitalLeaseMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implied interest rate used to reduce the minimum lease payments to present.",
        "label": "Implied Interest Rate Used To Reduce The Minimum Lease Payments To Present",
        "terseLabel": "Implied interest rate used to reduce the minimum lease payments to present"
       }
      }
     },
     "localname": "ImpliedInterestRateUsedToReduceTheMinimumLeasePaymentsToPresent",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "aclx_IncometaxdisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeTaxDisclosure [Line Items]"
       }
      }
     },
     "localname": "IncometaxdisclosureLineItems",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_IncometaxdisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeTaxDisclosure [Table]"
       }
      }
     },
     "localname": "IncometaxdisclosureTable",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses and other current and non-current assets",
        "label": "Increase (Decrease) Prepaid Expenses and Other Current and Non-Current Assets",
        "negatedLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreasePrepaidExpensesAndOtherCurrentAndNonCurrentAssets",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_IndefinitelyCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinitely Carryforward [Member]"
       }
      }
     },
     "localname": "IndefinitelyCarryforwardMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment [Member]",
        "verboseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_LabEquipmentUnderCapitalLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment under capital leases.",
        "label": "Lab Equipment Under Capital Leases [Member]",
        "terseLabel": "Lab equipment under capital leases [Member]"
       }
      }
     },
     "localname": "LabEquipmentUnderCapitalLeasesMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_LeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration year.",
        "label": "Lease Expiration Year",
        "terseLabel": "Lease expiration year"
       }
      }
     },
     "localname": "LeaseExpirationYear",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "aclx_LesseeOperatingAndFinanceLeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating And Finance Leases.",
        "label": "Lessee Operating And Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeasesTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_LongTermRestrictedCashFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term restricted cash fair value",
        "label": "Long-Term Restricted Cash Fair Value",
        "terseLabel": "Money market fund (long-term restricted cash)"
       }
      }
     },
     "localname": "LongTermRestrictedCashFairValue",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_LonzaSowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lonza SOW.",
        "label": "Lonza SOW [Member]"
       }
      }
     },
     "localname": "LonzaSowMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_LossCarryforwardGeneratedPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Carryforward Generated Period [Axis]"
       }
      }
     },
     "localname": "LossCarryforwardGeneratedPeriodAxis",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_LossCarryforwardGeneratedPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Carryforward Generated Period [Domain]"
       }
      }
     },
     "localname": "LossCarryforwardGeneratedPeriodDomain",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_MarketableSecuritiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities Disclosure [Text Block]",
        "label": "Marketable Securities Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesDisclosureTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change.",
        "label": "Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change",
        "terseLabel": "Maximum Threshold Percentage Increases Over A Three Year Period Of Corporations Stock Owned By Stockholders For Ownership Change"
       }
      }
     },
     "localname": "MaximumThresholdPercentageIncreasesOverAThreeYearPeriodOfCorporationsStockOwnedByStockholdersForOwnershipChange",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "aclx_MinimumNonCancellableCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum non-cancellable costs.",
        "label": "Minimum Non-cancellable Costs",
        "terseLabel": "Minimum non-cancellable costs"
       }
      }
     },
     "localname": "MinimumNonCancellableCosts",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors entitled to be elected by each class of stock.",
        "label": "Number Of Directors Entitled To Be Elected By Each Class Of Stock.",
        "terseLabel": "Number of directors entitled to be elected by each class of stock."
       }
      }
     },
     "localname": "NumberOfDirectorsEntitledToBeElectedByEachClassOfStock.",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "aclx_NumberOfPerformanceConditionScenarios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance condition scenarios.",
        "label": "Number of Performance Condition Scenarios",
        "terseLabel": "Number of performance condition scenarios"
       }
      }
     },
     "localname": "NumberOfPerformanceConditionScenarios",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "aclx_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "office and Laboratory Space.",
        "label": "office and Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_OperatingLeasesDeferredRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases deferred rent.",
        "label": "Operating Leases Deferred Rent",
        "terseLabel": "Deferred rent balance"
       }
      }
     },
     "localname": "OperatingLeasesDeferredRent",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_OperatingLossCarryforwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards Expiration Period.",
        "label": "Operating Loss Carryforwards Expiration Period",
        "terseLabel": "Operating loss carryforwards expiration period"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationPeriod",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "aclx_OtherAccruedLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accrued liability current.",
        "label": "Other Accrued Liability Current",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilityCurrent",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_OtherPrepaidExpenseAndCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other prepaid expense and current assets",
        "label": "Other Prepaid Expense and Current Assets",
        "terseLabel": "Other prepaid expense and current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseAndCurrentAssets",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_PaymentsForRepurchaseOfRestrictedStock": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for repurchase of restricted stock.",
        "label": "Payments For Repurchase Of Restricted Stock",
        "terseLabel": "Payment for repurchase of restricted stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRestrictedStock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_PercentageIncreaseInCommonStockReserveForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increase in common stock reserve for future issuance.",
        "label": "Percentage Increase In Common Stock Reserve for Future Issuance",
        "terseLabel": "Percentage increase in common stock reserve for future issuance"
       }
      }
     },
     "localname": "PercentageIncreaseInCommonStockReserveForFutureIssuance",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "aclx_PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change.",
        "label": "Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change",
        "terseLabel": "Percentage Of The Corporations Stock Owned By Stockholders To Determine The Ownership Change"
       }
      }
     },
     "localname": "PercentageOfTheCorporationsStockOwnedByStockholdersToDetermineTheOwnershipChange",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "aclx_PrepaidExpensesAndOtherAssetsCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other assets current",
        "label": "Prepaid Expenses And Other Assets Current [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherAssetsCurrentTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_PrepaidResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research and Development Costs",
        "label": "Prepaid Research and Development Costs",
        "terseLabel": "Prepaid research and development costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_PriorNotificationPeriodToTerminateArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior notification period to terminate arrangement.",
        "label": "Prior Notification Period to Terminate Arrangement",
        "terseLabel": "Prior notification period to terminate arrangement"
       }
      }
     },
     "localname": "PriorNotificationPeriodToTerminateArrangement",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "aclx_PropertyPlantAndEquipmentEstimatedLivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated lives.",
        "label": "Property Plant And Equipment Estimated Lives [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedLivesLineItems",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_PropertyPlantAndEquipmentEstimatedLivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated lives.",
        "label": "Property Plant And Equipment Estimated Lives [Table]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedLivesTable",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_PropertyPlantAndEquipmentEstimatedLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment estimated lives.",
        "label": "Property Plant And Equipment Estimated Lives [Table Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedLivesTableTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently adopted accounting pronouncements policy.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_ReclassificationOfDeferredRentAndTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of deferred rent and tenant improvement allowances",
        "label": "Reclassification of Deferred Rent and Tenant Improvement Allowances",
        "terseLabel": "Reclassification of deferred rent and tenant improvement allowances"
       }
      }
     },
     "localname": "ReclassificationOfDeferredRentAndTenantImprovementAllowances",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock and stockholders equity.",
        "label": "Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure Text Block",
        "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_RedeemableConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock policy.",
        "label": "Redeemable Convertible Preferred Stock [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_ResearchAndDevelopmentAccruedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development accrued expenses, current",
        "label": "Research and Development Accrued Expenses, Current",
        "terseLabel": "Research and development accrued expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAccruedExpensesCurrent",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_RestrictedStockUnitsExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units - executive officer[Member]",
        "label": "Restricted stock units - executive officer[Member]",
        "terseLabel": "Restricted stock units - executive officer"
       }
      }
     },
     "localname": "RestrictedStockUnitsExecutiveOfficerMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsAbstract",
     "nsuri": "http://arc.com/20220331",
     "xbrltype": "stringItemType"
    },
    "aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsLineItems",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Table]"
       }
      }
     },
     "localname": "ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTable",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aclx_ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the fair value of the RSU Award considering thirdparty valuation reports.",
        "label": "Schedule of the fair value of the RSU Award considering thirdparty valuation reports [Table Text Block]",
        "terseLabel": "Schedule of the Monte Carlos simulation models to determine the grant date fair value of the RSU Award"
       }
      }
     },
     "localname": "ScheduleOfTheFairValueOfTheRsuAwardConsideringThirdpartyValuationReportsTableTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_SegmentAndGeographicInformationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment and geographic information policy.",
        "label": "Segment and Geographic Information Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentAndGeographicInformationPolicyPolicyTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock member.",
        "label": "Series A Redeemable Convertible Preferred Stock",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_SeriesB1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B1 redeemable convertible preferred stock.",
        "label": "Series B1 Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesB1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_SeriesB2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B2 redeemable convertible preferred stock.",
        "label": "Series B2 Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesB2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock member.",
        "label": "Series B Redeemable Convertible Preferred Stock",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred stock member.",
        "label": "Series C Redeemable Convertible Preferred Stock",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_SeriesCRedeemableConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Redeemable Convertible Preferred Stock",
        "label": "Series C Redeemable Convertible Preferred Stocks [Member]",
        "verboseLabel": "Series C Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStocksMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Exercisable",
        "terseLabel": "Restricted stock units, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, fair value assumptions, fair value of award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Value of Award",
        "terseLabel": "Fair value of the RSU award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAward",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Compensation Arrangement by Sharebased Payment Award, Date of Grant.",
        "label": "Sharebased Compensation Arrangement by Sharebased Payment Award, Date of Grant",
        "terseLabel": "Date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardDateOfGrant",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "aclx_SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of supplemental cash flow information related to operating leases.",
        "label": "Summary of Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]",
        "terseLabel": "Summary of Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "localname": "SummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aclx_TaxCreditCarryforwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration period.",
        "label": "Tax Credit Carryforward Expiration Period",
        "terseLabel": "Tax credit carryforward expiration period"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationPeriod",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "aclx_TaxPeriodTwoThousandThirtyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period Two Thousand Thirty Five [Member]"
       }
      }
     },
     "localname": "TaxPeriodTwoThousandThirtyFiveMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_TemporaryEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_TemporaryEquitySharesConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity shares conversion price.",
        "label": "Temporary Equity Shares Conversion Price",
        "terseLabel": "Temporary equity shares conversion price"
       }
      }
     },
     "localname": "TemporaryEquitySharesConversionPrice",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "aclx_TemporaryEquitySharesDividendRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity shares dividend rate.",
        "label": "Temporary Equity Shares Dividend Rate",
        "terseLabel": "Temporary Equity Shares Dividend Rate"
       }
      }
     },
     "localname": "TemporaryEquitySharesDividendRate",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "aclx_TemporaryEquitySharesSubscriptionsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity shares subscriptions amount.",
        "label": "Temporary Equity Shares Subscriptions Amount",
        "terseLabel": "Issuance of Series C redeemable convertible preferred stock for cash, subscriptions"
       }
      }
     },
     "localname": "TemporaryEquitySharesSubscriptionsAmount",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred stock for cash, shares, net of transaction costs",
        "verboseLabel": "Issuance of redeemable convertible preferred stock shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aclx_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs.",
        "label": "Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aclx_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen plan and two thousand twenty two equity incentive plan.",
        "label": "Two Thousand Seventeen Plan and Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "terseLabel": "2017 and 2022 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenPlanAndTwoThousandTwentyTwoEquityIncentivePlanMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two equity incentive plan.",
        "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "terseLabel": "2022 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aclx_UnvestedEarlyExercisedSharesOfCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails": {
       "order": 2.0,
       "parentTag": "aclx_CommonStockSharesIssuedAndOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested early exercised shares of common stock.",
        "label": "Unvested Early Exercised Shares Of Common Stock",
        "negatedLabel": "Less: unvested early exercised shares of common stock",
        "terseLabel": "Less: unvested early exercised shares of common stock"
       }
      }
     },
     "localname": "UnvestedEarlyExercisedSharesOfCommonStock",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "aclx_UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested shares of restricted common stock from early exercises [Member]",
        "label": "Unvested shares of restricted common stock from early exercises [Member]",
        "terseLabel": "Unvested Shares of Restricted Common Stock from Early Exercises"
       }
      }
     },
     "localname": "UnvestedSharesOfRestrictedCommonStockFromEarlyExercisesMember",
     "nsuri": "http://arc.com/20220331",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r228",
      "r241",
      "r275",
      "r277",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r471",
      "r502",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r228",
      "r241",
      "r275",
      "r277",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r471",
      "r502",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r228",
      "r241",
      "r261",
      "r275",
      "r277",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r471",
      "r502",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r228",
      "r241",
      "r261",
      "r275",
      "r277",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r471",
      "r502",
      "r504",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r106",
      "r110",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r258",
      "r259",
      "r503",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r258",
      "r259",
      "r503",
      "r533",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r106",
      "r110",
      "r213",
      "r276",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r155",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MOLDOVA",
        "terseLabel": "Gaithersburg, Maryland"
       }
      }
     },
     "localname": "MD",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r99",
      "r100",
      "r101",
      "r102",
      "r157",
      "r158",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r216",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r351",
      "r352",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r435",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r46"
     ],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r13",
      "r46",
      "r260"
     ],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Accrued vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r203"
     ],
     "calculation": {
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r55",
      "r56",
      "r57",
      "r495",
      "r512",
      "r516"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r367",
      "r507",
      "r508",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r319",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r316",
      "r317",
      "r318",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r278",
      "r280",
      "r322",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r280",
      "r308",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r71",
      "r79",
      "r231",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premium"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r166",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-Backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails",
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r140",
      "r143",
      "r149",
      "r174",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r364",
      "r368",
      "r395",
      "r437",
      "r439",
      "r479",
      "r491"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r52",
      "r89",
      "r174",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r364",
      "r368",
      "r395",
      "r437",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r189"
     ],
     "calculation": {
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized costs"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r159",
      "r162",
      "r189",
      "r482"
     ],
     "calculation": {
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails",
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r281",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligations": {
     "auth_ref": [
      "r22",
      "r415",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.",
        "label": "Capital Lease Obligations",
        "terseLabel": "Capital lease obligations"
       }
      }
     },
     "localname": "CapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Lease Obligations [Abstract]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases.",
        "label": "Capital Leases, Future Minimum Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capital Leases, Future Minimum Payments Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount necessary to reduce net minimum lease payments to present value for capital leases.",
        "label": "Capital Leases, Future Minimum Payments, Interest Included in Payments",
        "negatedLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.",
        "label": "Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments",
        "totalLabel": "Present value of net minimum lease payments"
       }
      }
     },
     "localname": "CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsSummaryOfFutureLeaseObligationsUnderTheseCapitalLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for capital leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Capital Leases in Financial Statements of Lessee Disclosure [Text Block]",
        "terseLabel": "Capital Lease Obligations"
       }
      }
     },
     "localname": "CapitalLeasesInFinancialStatementsOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after depreciation of leased long-lived, physical assets used to produce goods and services and not intended for resale meeting the criteria for capitalization, classified as other.",
        "label": "Capital Leases, Lessee Balance Sheet, Assets by Major Class, Other Property, Plant, and Equipment, Net",
        "terseLabel": "Purchase of equipment under capital lease agreement"
       }
      }
     },
     "localname": "CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r37",
      "r81"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market fund (cash equivalent)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r17",
      "r82",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of the year",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r405"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r95",
      "r96",
      "r98",
      "r157",
      "r158",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r216",
      "r312",
      "r313",
      "r314",
      "r350",
      "r373",
      "r375",
      "r376",
      "r396",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r417",
      "r435",
      "r475",
      "r476",
      "r505",
      "r506",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r95",
      "r96",
      "r105",
      "r157",
      "r158",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r216",
      "r312",
      "r313",
      "r314",
      "r350",
      "r373",
      "r375",
      "r376",
      "r377",
      "r380",
      "r396",
      "r398",
      "r399",
      "r400",
      "r403",
      "r404",
      "r417",
      "r435",
      "r475",
      "r476",
      "r505",
      "r506",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r111",
      "r112",
      "r113",
      "r115",
      "r117",
      "r123",
      "r124",
      "r125",
      "r174",
      "r217",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r239",
      "r240",
      "r243",
      "r244",
      "r395",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail",
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails",
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 35,718,764 shares issued and outstanding as of March 31, 2022; 185,000,000 shares authorized and 544,210 shares issued and outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r68",
      "r484",
      "r500"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment [Member]",
        "verboseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r26",
      "r27",
      "r245",
      "r248",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion of preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bond Securities"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r262",
      "r273",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt",
        "verboseLabel": "Corporate Debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails",
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current income tax provision (benefit):"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r347",
      "r355"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "U.S. federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r347",
      "r355"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r163",
      "r189",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r168",
      "r190",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r169",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r20",
      "r478",
      "r490"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r348",
      "r355"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S. federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred income tax provision (benefit):"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r21",
      "r413",
      "r434"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent, current portion"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r24",
      "r413",
      "r434"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r348",
      "r355"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "U.S. federal net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r343",
      "r345",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "auth_ref": [
      "r273",
      "r274",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined benefit plan.",
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions to the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r79",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r138"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendDeclaredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.",
        "label": "Dividend Declared [Member]"
       }
      }
     },
     "localname": "DividendDeclaredMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.",
        "label": "Dividends [Axis]"
       }
      }
     },
     "localname": "DividendsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r255",
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared or paid"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.",
        "label": "Dividends [Domain]"
       }
      }
     },
     "localname": "DividendsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r21",
      "r23",
      "r480",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividends Payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r91",
      "r330",
      "r356"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesScheduleOfReconciliationOfTheStatutoryUsFederalRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "unrecognized compensation cost related to unvested share-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r100",
      "r107",
      "r109",
      "r122",
      "r181",
      "r247",
      "r255",
      "r316",
      "r317",
      "r318",
      "r351",
      "r352",
      "r383",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r507",
      "r508",
      "r509",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Company's Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r386",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r233",
      "r234",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r273",
      "r387",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r386",
      "r387",
      "r389",
      "r390",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r262",
      "r263",
      "r268",
      "r273",
      "r387",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r233",
      "r234",
      "r262",
      "r263",
      "r268",
      "r273",
      "r387",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r233",
      "r234",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r273",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r392",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r420",
      "r429"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments under finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r171",
      "r172",
      "r173",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193",
      "r196",
      "r197",
      "r232",
      "r246",
      "r374",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures [Member]",
        "verboseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r79",
      "r200",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of Long Lived Assets Held for use"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r331",
      "r336",
      "r342",
      "r353",
      "r357",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination, Description",
        "terseLabel": "Description of income tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year being audited in the income tax examination, in YYYY format.",
        "label": "Income Tax Examination, Year under Examination",
        "terseLabel": "Income tax examination year under examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r108",
      "r109",
      "r139",
      "r329",
      "r354",
      "r358",
      "r501"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r327",
      "r328",
      "r336",
      "r337",
      "r341",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increase (Decrease) in Deferred Charges",
        "negatedLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r78",
      "r429"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income, amortization of premium and accretion of discount on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale); classified as operating.",
        "label": "Interest Income, Debt Securities, Available-for-sale, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeDebtSecuritiesAvailableForSaleOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r431",
      "r433"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "verboseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease, discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum operating lease payments",
        "verboseLabel": "Summary of Future Minimum Lease Payments Under Noncancelable Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesTables",
      "http://arc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail",
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Through December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Short-term operating lease, term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r89",
      "r144",
      "r174",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r365",
      "r368",
      "r369",
      "r395",
      "r437",
      "r438"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r89",
      "r174",
      "r395",
      "r439",
      "r481",
      "r497"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r89",
      "r174",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r365",
      "r368",
      "r369",
      "r395",
      "r437",
      "r438",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r45"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r126",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of The Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NatureOfTheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r58",
      "r60",
      "r66",
      "r67",
      "r80",
      "r89",
      "r99",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r114",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r174",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r385",
      "r395",
      "r483",
      "r499"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r140",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r426",
      "r433"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Present value of total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfFutureMinimumOperatingLeasePaymentsDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/LeasesAdditionalInformationDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Noncash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r46"
     ],
     "calculation": {
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Obligated to pay to Lonza",
        "verboseLabel": "Other Commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAdditionalInformationDetails",
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r362",
      "r363",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on investment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r170"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "negatedLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r46",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r281",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r27",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value of $0.001 per share; 200,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2022; no shares authorized, issued or outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "auth_ref": [
      "r11",
      "r41"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense Other, Noncurrent",
        "terseLabel": "Prepaid research and development expenses and other long-term assets"
       }
      }
     },
     "localname": "PrepaidExpenseOtherNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock (initial public offering), net of transactions costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of common stock (private placement), net of transactions costs",
        "verboseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction costs",
        "verboseLabel": "Proceeds from Issuance of redeemable convertible preferred stock shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r311"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r40",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails",
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r208",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r202"
     ],
     "calculation": {
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r204",
      "r439",
      "r487",
      "r498"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r204",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule Of Property And Equipment Consist"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/LeasesAdditionalInformationDetails",
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails",
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments of Debt and Lease Obligation",
        "terseLabel": "Payments to capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r325",
      "r473",
      "r550"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r86",
      "r477",
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash reserve"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r6",
      "r17",
      "r86"
     ],
     "calculation": {
      "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RestrictedCashScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r20",
      "r86",
      "r534"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r255",
      "r319",
      "r439",
      "r496",
      "r511",
      "r516"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r95",
      "r96",
      "r97",
      "r100",
      "r107",
      "r109",
      "r181",
      "r316",
      "r317",
      "r318",
      "r351",
      "r352",
      "r383",
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r154",
      "r257",
      "r258",
      "r474"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r430",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Shares Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockTables",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Reconciliation Of The Statutory US Federal Rate And Effective Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r280",
      "r307",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r280",
      "r307",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentConsistDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r17",
      "r86",
      "r477",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r281",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r287",
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Black-Scholes option pricing model for stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r49",
      "r88",
      "r123",
      "r124",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Anticipated service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units, granted",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Outstanding, Ending balance",
        "terseLabel": "Restricted stock units, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Restricted stock units, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of the RSU award (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Discount for lack of marketability"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Equity volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r289",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Outstanding, Ending balance",
        "periodStartLabel": "Number of Shares, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r279",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfShareBasedCompensationExpenseDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsActivityDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r281",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "verboseLabel": "Time to liquidity event (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r302",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate grant date fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "weighted average grant date fair value per share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r427",
      "r433"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r88",
      "r89",
      "r111",
      "r112",
      "r113",
      "r115",
      "r117",
      "r123",
      "r124",
      "r125",
      "r174",
      "r217",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r239",
      "r240",
      "r243",
      "r244",
      "r247",
      "r395",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail",
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r51",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r100",
      "r107",
      "r109",
      "r122",
      "r181",
      "r247",
      "r255",
      "r316",
      "r317",
      "r318",
      "r351",
      "r352",
      "r383",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r507",
      "r508",
      "r509",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CommonStockScheduleOfReconciliationOfSharesIssuedAndOutstandingDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitScheduleOfReconciliationOfSharesIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail",
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r122",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CapitalLeaseObligationsAdditionalInformationDetail",
      "http://arc.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://arc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/ShareBasedCompensationScheduleOfBlackScholesOptionPricingModelForStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r230",
      "r247",
      "r248",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r247",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock , net of transaction costs, shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r27",
      "r28",
      "r247",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock from vesting of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r247",
      "r255",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares, Exercised",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r247",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r247",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of transaction costs, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r247",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock from vesting of restricted stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r247",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r32",
      "r33",
      "r89",
      "r156",
      "r174",
      "r395",
      "r439"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Stockholders Equity Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CommonStockAdditionalInformationDetail",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnauditedParenthetical",
      "http://arc.com/role/NatureOfTheBusinessAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://arc.com/role/ShareBasedCompensationScheduleOfTheMonteCarlosSimulationModelsToDetermineTheGrantDateFairValueOfTheRsuAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r16",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r217",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227"
     ],
     "calculation": {
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary Equity, Ending Balance",
        "periodStartLabel": "Temporary Equity, Beginning Balance",
        "terseLabel": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract]",
        "terseLabel": "Redeemable convertible preferred stock:"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Temporary Equity, Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference Per Share",
        "terseLabel": "Temporary equity liquidation preference per share"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Temporary equity, par or stated value per share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Ending balance, Shares",
        "periodStartLabel": "Temporary Equity, Beginning balance, shares",
        "terseLabel": "Temporary equity, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited",
      "http://arc.com/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred stock for cash, Value, net of transaction costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r171",
      "r172",
      "r173",
      "r232",
      "r246",
      "r374",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r93",
      "r262",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/FairValueOfFinancialInstrumentsScheduleOfFairValueOfCompanysFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r262",
      "r485",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "U.S. Government Agency"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/MarketableSecuritiesScheduleOfAvailableForSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r326",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Unrecognized Tax Benefits Income Tax Penalties Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://arc.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r428",
      "r433"
     ],
     "calculation": {
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/LeasesSummaryOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding\u2014basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235042"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/subtopic&trid=2209026"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472162&loc=d3e58407-109430"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r551": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r552": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r553": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r559": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>131
<FILENAME>0001193125-22-173887-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-173887-xbrl.zip
M4$L#!!0 " @( !>&SE0                1    86-L>"TR,#(R,#,S,2YX
M<V3M/6MSXS:2WZ_J_@/67S*I6OF92>*I3+9D6TY\9UM>2Y/-UM75%DQ"$BL4
MJ05(6[JK^^_7#9 4^(!$4C0U=]07FR+0#W0W&D W /[TE^7<):^,"\?W/A^=
M'9\>$>99ONUXT\]'83#I_7CTEY__]5]^^E.O]POS&*<!L\G+BMS<WCV2WZ^>
M[\F=)P+J68S<^%8X9UY >F06!(M/)R=O;V_']L3QA.^& 1 0QY8_/X'RWQ1!
M\GQQ? H_X>GL8^_?0H_USD_/S\E_G)Y]^N[RTW<__"?Y[_[#__1ZR(&P9FQ.
M24#YE 6/=,[$@EKL\U%$BW)+8D<$IQ<79] .ER$[MSZ?W[ )#=W@\]$_0^HZ
M$X?91P0:[HE/U'*7&W#(2DDYMN?MXMCG4ZAR>G;R^\/]2'(58W,=[X]4[>4+
M=^/Z%R=8_$(%BZLO<_4C[&>7EY<GLC2I"HB<#:B=2 MZ?3M( /3*'T]4X9J+
M#7A_O]>8"$5O2NDBJ3ZAXD56C0I0<&>]T[->(KI/EA]Z 5^E&1',.I[ZKR=1
MH01+ $+.P0)-$%%I"L1F3G%M*$A59$MK5EP32U)5/>I8HKBN+$I5%HY57!4*
M4A5!3L%JP42A!&5)@0A%L. &]%"2D<2",PO[J%&EEVCEW'<9T+:"'ELN7.K1
MP.>K6_B=T.1!GD=X6<0>#TR-2HH*P.R 9\!2G$+Q"18CY"E"0B/1"U#/\P.*
MSD3^6BP<;^+C(W:63]BN,4 1?/CR?)?KV;+AUSXXO"<ZA<[B@*#6/Q,\-@.O
MY4@J9]#1P45ISDW6)PCPTTFV=HP@%,P>>C_+9U") $C)-/:F""JJ4@2Q1EBN
MOD5=*W3-!$Y2PJDL+<]F'N""!W#DCHWF=45=]#:C&6.!^.+1T'8"=*I*GN4!
M#!(_!S&/0&(L%OGP\6;P.!K<X--H>']WTQ_#CZO^??_Q>D!&OPX&XQ'Y$,9X
MOSUH)BWH)PIN,YBQP &.*JLI#6W0V<6N.B,?4G0ZK,-$C&(X&2YPTH63I[X'
ME>;0WAD .*_LWA>ENEX=; 8=?U=.QZ,Q_'L8/()^A[=D^#1X[H_OH +I/V+-
MAZ?GP:\ =O?;@-P/1X>.FU/3,[,93"M?7 8U8+0)''A\XFS"8/H#-7WK#]"?
M_#_S71MFTX-_ADZP@GFN8SE!5:MHC)S!;#[6,9OGP<U@\-"_NA]@K=\&S^,[
M? ;;N1T\/\OJP^M_ER8EGWX=WM\,GD??D,%?O]R-_TX^W QN[Z[OQM\>S.N]
M]%UV5'E_V@;#^W[/AO?E,+AM-(9K*F:WKO]6>1PK #28P ]U3."Z/_J5W-X/
M_]:]L>F1!B%GP\EXQJY"X7A,"*63H@*#S'_$!9,C+-<7  (_%"SQ)P0Z (G!
M.R'/43B?4[X:3D;.U'/ AU$OZ%LR\N%XTR<P;LMAD8A+UC5(_3(K]0@=BEU#
M2-8828RR$YIX9B+@C@4]&;V'DGCF7;%DSTZSDEV#$83KA/ANJ<-_HVX(+N#6
M\6"5Z% 78[]<QD4B"]Y6R2#@LZR $0^1B-!Z$U1$P]4)H3]0_@<+<+8T8E;(
M@:W85Q26&,1[GA7O&IBLH3LA4)AI+JAC#Y8+G%_@*G@(0Q*_EG'EH"\$BTVY
M5$V#P"^R H^0D1@;H9Y-)#X2(20*8T>4X"]@YK\"F>+D?H']^9$%L=R+"PVB
M_BXO:@4O19Q@^#,!')T0[K4_GSN!YI/U%P8A?LP*48/IAM#HP@FH>\^H8,,7
MUYFJ(%DD0$.A09C?YX2IX(E$0#0,G1 M3#=YR.Q[A[XXKC: %;PW"/2'K$ C
M4*+!=D*4TH B\47/!I'E5F"J>B>DI/DN&>262QWFK9=9FRH8Y)E;6VDXY$"3
MPM(),>\8R(O77[LA*5;7><&"+:9#-$(DH40D":E)G=@W1)$C'R*"W8@!E=!*
M:?695)1;\I5342?DC\[%]S0YZR\,\LRM\11,AZ0VFE'.KJB,&L]QF27I1)&U
MXC*#+'/+-PG>D_!$1] )N<+""9/#3XQ+,?2#@#LOH8P>C'W-,B.?&46+*P(9
M-)%;W0%>@H@)8%9J(3IN$O@IPX_0=T)/=QX\LC%=QO,<_85!OKF%GX(A$J@3
M4AO,%ZZ_8NR*><!6\.32R&44%1BDF%OQQ; D B8(W0EQEDMAU$E[;$E_G.=6
MB>73'^1#_-2-^5TY@8_1H592401A4%!N35I%00IU-]233DKI:B@L,8@[MV3-
M)*VZ)=,MB2E=R.6J%DO](K?R+)')ZI8FBA)7NO@WE!MDGEM*%J:WNB7E,MDK
M7>H5ZANTD%N ELYY=4TSA?FMM#(V53'(OR#G:$R$=4OBAOR-+O'-50P2SRU.
MC8F>;LD[G]G116TL-4@YMT0MR/YT2[XJEZ/+-/7&(,?<(E4!=4MT&U(_*7>P
MM9I!R+E%Z,8\4;=DOV.N)[T.:@*508>Y=6ICR:-NZ5N+\F;[5OJU00^%.=<X
ML-LM41:G+U(!FDTUB@7\76ZM:DIS=$O8%5,7NA;J@1K4DUO6ULM]=$MY6LY#
M5TS^M4'HN56LGA#IEB@+#GST;5MRAP&QB<_GDO(-"ZCCFD^); 0RJ"&WF%V?
M(!EK)TAP-9!@)QIZ'',E@6ZHJEQX/JEEB"^D%-DL2H.:<ROH"BF!5.6-L8Z#
M*>3TMKTC-X#'H/3<@KZ2T@_]/9<AVJ[,"O4-2LM%#[+9I![Y4*R:;SNM&[P?
MR@Y=IHZL8C !_J&#>J5N%%Y( VS06VU<!IWF@A5YG<8DL6_*5S*&@0\:7?DR
MEUWLE-*WY S7FM,JX@J+>BN1 *AL2,H W@&OP1AR48\RB<NT@:0A(C:^$1IL
MG._IE&T4)337BNN_@B2P\-;G(^A/1;53)M$<.H,EY.(NQ>G4M.X3NCUP_#T!
ME$U9V,[K?OMP71FJ6),?<P$>DR8/DZJ2*?-U1RM3.Z74]T-OT'XN?E0^(9_N
MVQ42^1TSF,(UKZ[$? 6\T<010<8T=D=D,(*"71GFE;*F]J&VIN[K-4E$]Z#K
M=7QCHQ:C*@;]5-NUH7!U0^)Z#G;KB%FVLD$+^9T<6MKV,#QNVD6S0=P;M]9L
M@C-H*7]*W;C?9IO..JVR)+1W&V)0/5O\Q;,9'\^@Y3I\?\J9NGVKA'*;H6 P
M@_+GZ].Q1<5+02W)#I'\9'"M6>J6X>3W:&DKS%Q9RA/7 S6HNLS)_^Q"M&AW
M6*<<M=K7M7W,+%'/H!;#[0*'D5)70.(#Y<]K7V36@UMK&82?"\\DPM=\G7)?
M$EVWA:^<_@/P-P_GT>W'WE16>J(K;;0IUDH%\&)U?9^+P12I*QJ:(CHD(13I
M,2;5454N%NI+'M2-K_W4?,LS<_%RT+&?UDZQ5G?"9%!P+LRB*7A-3R5%D&+*
M,48T<>M.1NE=4_:&+;?5EG]5@ TJ+;Q+P;R+]S#L;=-@L3]-N5$Y"7_T/0N_
M/R S"87=<*N^&R1EL(Y<R&:;=9@=?<:]JX5(BC.C6^B&3>VXT;O,SHCW(V"P
MGURPJ;G]Y0=/U(35K!>LS\R"S@C+2,GH<"(WW8H[(6"%B2F9,,"O;N''TIHT
MJEWH&VPN%SIKTN;TY7>:8[FE2_),%-,J=;1F^V"8.<-HQ&75<$L%.[Q*F4B/
M')Q.YKA+_0Z<.R*S RJ#G@N/J"7':AKIS9U3^/8D2+FZ!I7EXFT9E1UR':8C
M4B7V.5>',V@I__T%TW&JPS1M@\K6'J^X/-J%4D*)%3$5J_6'\J?DTKY357O)
M5XO('I2-*DI.&: K&RYDW[,"YU7.AK=KN 2X0:VYL-TFM6H'%*3+591(3.J@
M2ET7ZYW@4EA?@&]11Z=E\!B4FPO@E5.NMH==Z5G2/*BYV*E>N53.3Z&N4!WB
M"80'T\ 'WV8N[C]>=TKQ"Z<>R+62U]Z%@,$P2M_LFG'FDI5>Q OQ5?=?*&[(
M'-DA,(H3(:U&%0LR52R1@]VDU#J>L0<?!'--.:AAY,PC3J16Q=@'83$^=SP&
M%:56;VC M/,-\/I9A/TWRJN9TSO0-5A9_EAC.2O#CZ-)%HGBD8B$265D A-%
M=LRGK"^-C. '\L@$SU^\QN<OL/!Y](5(AKMF@Q4/XB=CSHWCAN#LM7WW@Z7E
MAC:S;[D_1]6%0;3^EE69G:&4/@R];RX,]IF+!M:\62 U>,9,ZR<+8K;)!/@F
M&N,) )05$.^6L6J7$VQ?KY:M;%!]+LJ7NM_@L##-*D0_X/[J"" '\PZMW*2;
MLG &->6"=!DUI8^^*P($*&2NJ^BLUHQ14QC$\6NP8>#SU1=QR\"/4?<91D_<
MM3^9,)SJ,_QM5&QSJ VZST7[LKK7SFAD K1#=3U&P@;Y,B(1(P0IJZ,<,2_J
MU<%()C=11@->JX-,(";3_M9=$!@4G@L<FA2.@V:<?('"^-051N&[N]VUX)[^
M[:-H5:!BS?V8BPT67OS__W]8Q3\8Z7QF$[*4;P(H_GP$ZY>%RXZB=S/.)I^/
MJ.4N>^>GY^>G%Q=G_X F'2_G;EP%,2=J?GM[.UZ^</?8Y].3\]/3"Z7PK!0B
MPC$*,(X<EK<+B>/L\O+R1-8")/*8%727DYCY(W+20(- XE4;E%;2U]4<E[Y4
M;0Z ,/?K:PF8=M669'I#P^TYH8N% \Y /7N>KTP:?T)C?!X0C\Z96%!K$Z..
MA]E7"Y *&";F]-ZW))H-(/BK%\/U\%7O[+QW<7:\%';$6P4&UJVJQD ,5Y$!
M'=-'^<L.2I.. 9#FQS+4)E2\2.!0]*:4+@#)^5GO] R8+28J8A8+(4^8&XCX
M36^-JW3#!;..I_[KB;P9B:\DTBV,%('$/R0+U8G+0]]6->HZ3/*K'GVVM&95
M:"?UY5,]FAYU+%&%Z!I /=8C*QRK"M&X.C[4)!@L>"6*<7WY5)IFMF->*H?K
ML2ENAR_7GUW.4U#8J2_1D9Q]OQ,+)=V)1C[8F70TEH"_L8(>6RY@UDAQ 7<+
MO\NSHV,9K)%4Y"ZE7YLY5<PAKHX/I8U!=Y4XFHNFO*Q$5M'-)A@%#VIS [ :
M)PFF'5AIA(EJY%/F90?\!-N &$\1QR:3V 8I?PN-!Z:.R4@F/A^-&,>#&R7V
M.3ZP^0OC1T3- 8&2DO,GVY]3Q[L+V!R7*4>$OHB 0Z?X?!3P$&>)P)SS">9E
MCF^/%6S(92..B.>X<N=]7!>7BSB3_$=UMD0(=)T@1,2_<#]<?#Y2E!W@;$/3
MK[[.IE=AJV[3K[_.IE=AJWK3QPS[(.4KM;E:8E,[+&]"CK=M2I;5ULM']B:+
M1-Q^A5NHW: %;9]05]1M?$W&=I> Q#@"-!9W5#:]/\<I:[K1<Q_&7@!Z[V:;
MN=G24O7\0EU<:0%I]H(?OM[>_E8MW$"[AA(Y]01P P#RY'%+RLI1;4HI=Y[%
M\<S5#5/_M]S)Y=F/P()^05<[ FB S6H2 S*V063Z?1Y/X"$L9T'=^'Q;.^+8
MPD)C38U1WOK\F2U";LWPDI/LKK5VVER6E\8:'Z<AAA/X#P.!['E@B#+;?^?E
M+_IH1PXUV&I,)(4W;2:Y@3%;!E>N9A!KIQ[$14U+HS1'U5V]P<<H?Q(YEWTT
MN2)?U1NNGSR..,Y,Q (TO(:'Z$*JU9F_9R"']6%GD(ZZFI=%WP_;@\+*LU2]
MN;6/8>ZUUS;*=76A*33R&QXE.-F'@&IS6*^WQ\>VVNWM.:H[,;\/-163K]$,
MU_$<B[ICCE>9XP@._[S$Q<M/0ZS4W[TTLQ9[[^+,]B>$.LQ5%\%@SO@4NAO4
M?@MFT?WR<J^3R&#?GR1VX+%.R&PZ5TNZ7Y@_Y70Q<RQM>\F^NT8]]NIT#0M^
MN*N^[2]@K:-]I8;['CQ:Z@K'?8MC-S;KS-'53<*X!2G0+R4> *(Y9LSNG=?H
M>VC[F:O7XJ_&"*)%!$3J6J!XW;PW&51GK8:72 Y)UKO_;&_":9KQ&J+3#P\5
M'P62UZ';,MHPGCG<7E P::P6L8;)M3V*\)T:4%V4ZQV0&[,(@R7CEB.8?;62
MMV&]<<#(Q=^<8*8.^HW]IRB^U48"Y#VXKN/ Q.R).O:MSQ/T>,\'+(1P"%%W
MH,WGCA R-Q$%/>(@6#P5;2O\V@ROS<5I*PPS+2SNJK%CD((=?)H!06Z%+^S.
M&.VA+PGR5A-*181KS/9C%-*,](&RU<9L9^/=9F;WCB>UFTWU[M$L-99JS=-=
M"OT>O^^(4.MS$\]JF3!F'E"_FR^X_RH!^RZ,]-C#6W)>NW'85-[QWH>AF/%Y
M^F-^R>C=@"C4YM]@4Q_>QD-3C;UA+X'VE:O,Y\OP*DUL2TC=!_P"<$$NR=P=
M=LLDU6"K=AX%I,PHS _ PF[8*W/]Z L_S231MVN[#!M-*5R.]^D\#<X)&LZ;
M;V]S*3X:Z]+:D)@;2,3>1F<S*W5,V?'YHQ\DSE--D,?^6-Y6@.<@.:?>5,*D
M-1QSW7R$H1)+U=L<K=5Q0X6\L==5(="VNNTF\N^RI2/Y'DKD]59*H.UHLQ0C
MU74(@[GKX.X 6+'!8(=G8K\(C"8\P\K9PLM BNZ0A@6=.H:6[[4X+X>"QK?Y
M[,IGG0E;T7@0[:*(EVJ1QVS%X*LQU%@7B BD=I6TV>R-]!MKI=HID=XBLVJS
MF9L9:*R=LG^ L3BJR_T=+"K=O"F^:GZC0P'5ZET2;,"Q<*("P[C/Y?&.$>[:
M;W4*L8V)G2)<#R"HD,O"X20=T6U]/UD-MIKKCMEO$JP7HNWTQDWTF^N,OO=?
M=.2_M3L%SA#=:6^%B@#?LREUW571=<P[QZFWZZH:.]6;^\5[A2D'#+&4NZLD
MV*U(R0_.Q]1;:&L%7AK0Z]>BT*8T67BTX<9Y=6SFV3BG;&T^6X*3ZLU[#+%'
MX[5HG%DP+HF!!PA<G"9?L8'+,)!UM1I0:W:-@;[HXMCCM$8=F&)/6>,S@-J\
M-:1EM34'TRYXC6:QHF7-AFVY'#.US\J=?9TGQBKQ5;OQYU]IXZOP]9Y'!=L-
MK=7@JT;CBR^L7P>RKE;K*E$80";Z5?>[@_[*0QD;D.NM\8QZT16ZT6!:D A]
ME]QZ2PVI/X@\,2[WF, <%A2I-@*,8"BDT$S1ZI"QA9,6C2C) /5A0C)7XM;V
ME<@Z[:S-WKD)347^^Y[GX$@'$F@S6%I MD9(7\W\Z)3%9PSO/&UFBM$X_HHY
M,;5S#>>HZBJBEJ:0M?FKL3"8H5DA>B_@OMOJL&*@76-:^.:/9WXH8/DP8J_P
MGC%/7GWGV5K1^ U*5O B]K,H8S FK-GNP>3&V-U)5%^C/-Z]T8G OZ)&E^%I
M?WL\6SP@U#S+>]X:^W](9@ULS&N*E3;WA[T#SS5GK2_;IWPOV2D??LEA.)$?
M=<A,OZ#@72:F.W.Y\Q3EUL>M:?),[=W"W^>$I9B3^E'H.-:K[4U;3_KP"PFI
MT'"[(8 =>:R5H\]])0G06O);#"I1QUN50!6&:NS6D%=C!W1IKX\[MS2"F$GO
M,A@48&W3KV\F7R,_G60-?2&N*>>KB<_1N8EU[KO-=7 5?FI,F.GR6N8V=<S[
M:6A)5G8) LC1_MKG&,V741/U_:TW#_,6^H4$Z6\I804N9LY"#0M[B XTQ7B-
M#8)TB5NRQC,8#)!&/F(AAJ^,][$"PSTA2D^8Q]S.[:W/]R7;UMM5X[*33(?_
MA7GH"IBM6.DOG3;\:RDNS..'[4"+1.0NZC3S1@[QK>VK*,5++3\;;=W50B"P
MQ@A6MS"I:#<>48J5.A.;Z#, S%WI,FRU<=N8J'&=3/;+*(^^]]>0NL[$B2:(
M4<ZFE3U-%;AI[GQ+AB0\Q.^B':NI9:)G1Y\.$?&VUOA3);X7-G.*LX:<=F;Z
MW<3YGCL$:PBJL9V!N@A.U$7+/_\O4$L'"*JD6-; %@  KO$  %!+ P04  @(
M"  7ALY4                %0   &%C;'@M,C R,C S,S%?8V%L+GAM;.U=
M:V_CN!7]7J#_P<U^]N2UV]T9[.S"22;3%)EQD,=TBJ)8,#(="RM++BDE\1;]
M[[VD+%L/4B0M6:22 0836R8O[^&YO"2O^/CYU^=Y,'C$A/I1^'[O\,W!W@"'
M7C3QPX?W>TD\'?ZT]^LO?_[3SW\9#C_B$!,4X\G@?CDX.[_X//AZ<GTYN AI
MC$(/#\XB+YGC,!X,![,X7KS;WW]Z>GHSF?HAC8(DA@+H&R^:[\/O7]("!]?'
M;P[@*WPZ_&'X]R3$PZ.#HZ/!OPX.WWW_]MWW/_Y[\-_1I_\-ATR#P ]_OT<4
M#T#CD+[?RY7Q?$^"-Q%YV#\Z.#C>SQ+NI2G?/5._D/KI.$M[N/_UT^6--\-S
M-/17,-:YF!A1OL.W;]_N\U\A*?7?49[_,O)0S.M0J== FH)]&V;)ANS1\/!H
M>'SXYIE.]E@=D"C UW@ZX,6_BY<+_'Z/^O-%P-3FSV8$3]_O(2]XYE5Y<)SF
M_NXT"B<XI'@"'X .?\*(/$$!@WPSPSBF=R%*)CX\W1NP8NZN+]98$/$X<^SY
MOI&D_1UH?1/#_\S0Z'@Z7C"39*8U"B'1?$'P##+XC_@RHLT@;57,KO&>(CH[
M#Z*G]J"))#9$<8UI3'P/1#'AK'U-D@"G1;'Z@S\?_I/XCRA@*L"38H8S'",_
MH I@;172$.LY\LD7%"10\KD?0AOP4< \(N&ND&[TRB5D!H3")5UG&%$*S48/
M]RX*;%@'GQ#Y'43=!_@&>PGQ8Q_G]!@]0B'LQ_.(W  ;HM1ZT%LLIR'B*X(7
MR)]\>%ZPML6L:QS/,#E-" $2TMK=:*:36J\&=EANXQJ)P$?&2RB$-;L%,\;/
M.,XK4TW ?))/8UWL+930U#^CA1^CX!)#_SR^#_R'M%.X2>9S1);0YI(X(;C\
M\QVX8'([PQ3G\X\>"$Z=<*J=RI'OM.B&]3+R/)+@R:6/[OV@W"XKO^GQO:7,
MADAX_6QJE7\]C:AN U5G;U>_E/5/?NC/D_EJE!(^\$17:)FCV%!Q$[F-1PL3
M,$;FIZ&QPDPD]N$CN*XI!C<%0Y7(^QU:-/\[BP(P9\I:=[P\PU/?\W/M_QI[
M$?1N@<]-?SR]F2&"Z06E8"G,]R4Q&^&SF8WN",.>8@WK] *F<'-\BYYSE()[
M?/39K OZQ]SO>G6QC< 6,4BK$EP;&\PF<426=_0<&",HN(;1+>L$IE/LQ3!&
M9]_-8;98YBYJXFQEA_ X[<FA=&,?VT@R1^6AP$L"7C.7@*& #C_'&/J?28:/
M%=GUN(9'#B*OH%? YNH1*58[4XN"7GQ&/D7TGD_+$SI\0&@!T_.CPWT<Q#1[
MPA@Z'!X<KF;GWZT>_U;4+5,MU6FE8%8N#%9QP+7YS2CWOC:FJBFQ)UDI,"'"
MP *;+9WA1QQ$JQ$3]%8"%4>GEU^U<I;-8D2*FD+&3#Q\+-A$-2*R2K%/F=-A
MTH8P0YUG^:<DFF]1@2MM(D-@"05-HP73 L&0*2+0\-_O'>X-GK#_,(OYQ\;<
M<'TK* JF+2-'*VLOV=%")J;GJ$K/?LEGM>G&FD]1NG=8J4I7 8*Z+"I>ZZGJ
MLNDW@UVC^$@B*FHQNADMMQ<U-UE#T074KA=KB3Z8SR5S5L,8_.Z"8"\=:\'G
M /-:#R>C>00C\#_X<RG&&J+;*Z)W)M$>=*6/'>[>R>XT$-*UX>>5H85)=S;-
MAFZ/PM]5)!=8+OU>8_)M"._<%:B5/DMP(] \O]5&W![KY::NB=[)3D!+=_4<
MRDR,XW:0L_6MJ%[CU!X=.\?X17C[%/T3IF7-7%U)T@OG/0]53/UQ/ZB'0G%;
MY.=DO7SZ<V#%!O"]ZP9P$<88NL'X(O2"!(:&%V$K8YXZL8Z;Q>Y&!765(C:?
M'SH=]"O?JW5MOFL-:FPQEZ;SYE5\9Z=05)38:E.H*%VV:)'&3@YJ;V8PL;[%
M9*[#@RBQVSR(-'9RJ/D%$9^]RM6A09#6;18$"FL/^CKSV09+"KIWYI1B7-0I
M>^.YU L[Z(OHW/2U5+O&<^2S&!E;5DC! -C8L2E>B5#+C<F,ZW);:P+<R1Y*
MMT(^0\N_?<+!(_X4A?&L;A"^O<B7;QI"V$YVF;IPF&W?/D4MV,-:TJLP@S5:
M)P,T1BA8L*$M_E-9K\<"4KQ.QFA,<)Q'2>/Q0D'4J[& %*XRRN*\ ?B/;?F
M5-3K,0 .5VP ?^V' 8RF,28M6D%)WJLPA1)FL3W\V.4,WF2K9^=+AF1K(<L)
MNE_,I+G85[2LUY:-%VNSLH"HJ*F3TUC)OL_X%!&RA&;'7YK4OCC2RN\ 2Y*5
MLH9 G)QRBO9LJAM2;2[W":M5W\FY85>;')RF30N&D].ZXD[XSU'H*3F39W&
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M(41L*W@[PQF9T%=@'#+HVI&'CJ<CFM>9VHJ)K-7*KTBLW4RNS&DMOK/6R!"
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M4$L'"!8%OFZ($   1.\  %!+ P04  @("  7ALY4                %0
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M[G->),T#]:N(%J6ME84TK1:WR%\&26^1PJ,7880H=!-HV$&?7TND&P;)RG.
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M/27I^.N+< <",%F=16+&A4$<_OD=5O'Z'T7!]!M6YQ?#]$'=X7PY4NQ\@61
MQ^JU*9/#T4A$%1:7R5RH#A:0EJ(Z3Y.[=&(+ NGTWMN]'53#3+>!$E $=,H:
M*,'P&1MW& YKS6_W<#U[([*N1$K'.F= ?B[^O>BZJ8R2\SL /*KS8RR:C7#I
MV/4V.WY2FX^/'Q/^X#F+U]H"6-0S72QNE3#I6 %;>JSBYD$+>_Y60*-C[EOQ
MW!=N]]DHG;"5+M_DX:[:,3X'(D4]DH4=+?$D1,>H><*>.!NE,@ $?IXPR5@V
M/IP*7_P_Y>\-@\BE.1Q24>-GXM&H'C;N,B%D-5T]EURE#X_EQ3V(0=Y'FSVO
M+[&&,>'[*I %JJ="W^.CG7P(V67%5:4:U(W.7MR?I$5U<86Q?LG9-)U-B[/L
MF=6R-6U%K5X(<D$]FO0];KI(B9#I5P8?'JT''YHL'<H&<+I&#:7JFWV3% C9
ME'\#V0GL%UEEE@7T@+><7TZ2REOO:6H.JG1[@4RM.QBB'C;['@&^DB%4_,/]
M7![$-@BS M6$$/S2ZH6;4#61UJ&!D0IO>H<&ZBVYJAZ'# W$T/J%C0V4"]%G
M@O&!!RWB Y=@"-48Z1J+)C%]0:_?:)>YFBP3(D)510*Q1,93-3Q=5@]5+\48
MM2+2%4A4#9AIIBC<%]I#C%A5!"W\LP*':HQLQ5\;B(3JE&A.O:=IEL ]*XQ;
MH>%E<$J@EO3)WZW0BH]0*13H^XBQ<7$*HA"IT*#C3"1$70:%&?W2+6T!+44O
M0BL_:K8=X1(J?:+N\;KKO3?#ZR^XW<--%-T'S6K,A(JEJ+OML!EYT^_P3I .
MJG=X'R/"60PA:JM$&"2^V4"M;6_W!J@&Q7BD&^"&J+H2B-P**#NO7)]3P/PD
M$E#.;69 8SM 2=$1J26I#E )E6I9=*R^@BR6'EW@FDNSV[U=5#?>P'/4BI10
MO19WZ$%N5( ?]?(<EFE?W"%JNV@T(K6OJO,R:V]4*0)BY3?HDRX?K"&JK6@H
M6GSL-.=7[&G&1X_0%7%B6TG?K^/*K74-Y W<;UN!)E0712.%RADGD,K*\#(0
M*;5\T?XJ*RL^0M5.%D/U)C\<_6.6<K;BD7&8C5W\7=Q? O@IWF6MC)F/3*ZX
M"14RV>CZMX3_P62Z<J?25T[MX<I.<1\.Q;8>,J$B)BM7[T2&8GY+2M';^<6]
M+^F^[P)I4-S3VPZ =O )53AQET>07?UV;T QE*8E_;ZX"=47^9YG(^CZ:U>S
M\?)<*T\Y+H<YUW> #*D5B#"=X?Q@$:K>45\-983%N*J7=I:-1 J&\=&L_)Z7
M?V>E*)EC<M5Q? 4L9+B:+C^2U$S[@;54">ERHU[$V%[<PW]%P*Y0L4%7)K.Q
M6%"<T@VT>Q% PW4J[L)C%\@:-C&B%<4>(OXG[@;/<(J $^6K8D#\ 82R^HO&
MDU4]J\VP;8$?I/'U9?289 _L"E; KR AXX+>;T=@3]PB9Q0,V6A2H&!$4G:"
M'VO(@92V*$M: *B: ;&81K'2#'X7=QJ1@O*1'<T*P%H4KS7XSK+[G$_KN. R
M22=%[RD&FYZ$YPY9!I7/WWXZP+!;&:MD?F<_Y9]:5Q!>ON#V,VXXLD'DZMGB
M XM.'L'KT2,;SY:96X_F$K<U3DC?"@#&N3H9@X;\V;(A"!A$A!+>&Z6&R^=(
M=RB_."(K=9KY:45&)]-?F%(AGV)9*@(5=)%"5[-E $0GSUXPELA%%06CRQ94
MA*%"[E;0Y3-NNDO#Q-"<XM4(Z"2Y"UO0Y7,D>UTO6Y09%9T<=K%+@GR.E:HJ
M0'$7286&/T=D=)+=]4 DF;TM'J.V30Y#1^M7VN4SKE+==>*H25J#$2*=F\;L
M\:I$,M[VES$!1_,?&7S])T]+QHO_3,O'*FK@)K^L7>IT=I'P7P+AH'KN.U_1
MH^(GE+^M,>@O>3IB@$N"<EMQ5YH -E0G%7_UBQ$(H31IJEBO,R'?9'(YNYND
MHX45S]'GR/@.0(]J'O"FT1-9B 1I6B_\XE%8OD]SOEP(X+O-K'SB(I06XK"P
M+/VPZ-ZB)(1N-0[S]MO/N#GS_5;@D)@)Y4"3Z!_S"?2@J.[25^P9?F;R#]=/
MD]1D<'9H+7SB/QU\WD+CA2LNI-IAU[/I%$[O "M]R-+[="0<E*LB'>)4D,-R
MD[)B^=3"D;GIP_R=E=XF/UU,B<Y/^FM1IE-1UNP\?6:%R;K7ZCU5R$60R"7'
M3^N,0=[OJ+H>*2>@TCS44<**5;$=WI 9Z7 .06K01_,;^+A%5^?0NI94G/N)
MD^:N"[FZHY$[:CIV0VVW1:>M&B&'UC5H;,.4%SV>#*O TC$M]L8P%<5?OU3;
M=($89UYA+9J5C"^[[6+V4K6HMT94+TBO::<UB9G1T;%5GLYX)AV]I9_QBW3Y
MMK*G;U1#1 UN"$"@"\  !D[-N?D\N;//),V3=?]0M>T="+"BHF.CE/D&Q)7V
M;/K$\^>JP+1UZAA:U2!1E>@!YHX3P@ 62LWD6?98*I6:N2',4\G6KNX[JAJ\
MZ\1RQTC'SJC%_*-@][/)>7IO,F@XM*XK*:!H3H/J#UIA)E2;RBZ'!8!G6PBV
M^WND)) J4_7+OAF]Q6X92^=ZFJ3\]V0R8Q?W=92;B)\H2CZ3V\:KGU/C07&Z
M3K)YL6Q0%=/&BK58]JSJ!HB\$5KW#1;7F8C%RZY$R#NO OJ^YQE?_/,H*5*C
M%C?*=VX_?T:I?2F[OD0B;#V37'3<I9"EK>WMYR^H]XX(!*FGN*,DZ.AWZUBN
MM0@N!0"3QL#U'0 >U<CMR(Y&<^"',H!>5W<'S;.'&\:GJ_%WRXYH+Z3F9K>?
M]U&SW;3BQAT8'27LX3/LA<*,<)ISX0OSFG#EA-V53IEL7%\!T''KLW69;WX@
MZ6A<M:#;;*  #O5:VXU!,RI"FM8 QP-;W&2P;X#$>S2C]WZ""BRG@.9WE$3>
M"VD<S:4\I'>/Q>BN;0,2(1##&9I@\RA2RX".JGI-&@K\$O"/++\K&'\6N,^R
MIUFYJ'9:%3EOHK3:<6-]$F8UMFG?0KO3BA-8'G0"?M[84*/B8T!NS%$,21+N
MPB)<0V3_AKW"*?9VXWD0**H%+NY"H?57T F"D'W@..=/.4]*MGHU<Z#9T YN
M":C>)CAT6P5"*(SIQ_5O^3/CF3A*'SZP;+1Q.;>. -=7 '94MWJ,P> G&T*1
M4Q+D43+Z@XT]AH*A%2#\IUOYK>(($5(5_II:RT:,V5/._C&#83MWO[#J6L..
M1R"W0]]75[,T"$56+?NLZK'[+4'?&A!CIX5PYL5"JPVD)<3JS=%*\!X7D5]K
MI754+6.C[\5R%;/['#LT!^RHA@SGZ>?.KAJBAE94W>+1?/GC_TP9!]$]SL_9
M,YNX;\R&%P#N.%9&TGNS52":@8"J^6N.WDT K59T[7M "I%N;&VV;"M='O/>
MC%C#.X;6#8UW@GMZ7P/ ML'O8NCGEAV6M])"(A^X[^N;K> &BIK/HL6\M/"K
MPZAA$4/=INKK;BL6=Y<(:;AEQF!Q!:.&Q85.(98/M:JLUJOC]+J'D^II+-=I
M55_.'5RAC>UNO^Q@G(/7Y;RJ0SV<YKQ,_V1C48Q%'@,]/.]LK[K],D"=80YT
M:+2/K8#2\6M6 ;>Y:&G;@*#B7%Z-+E>MN;/@V/+T]HI@%-LU5MT"AFP<G:+7
MO=5&EGJ_,R&BX^HL4WG>,RYNX]>,/Z>B4I8ZG$B$21;J/UFO)R$_ R*,=+!U
MO[6:R%6/A_ 2H.-/O:6#B,P5&'\TT2P$$,-CY0MNQ=CPRT ;+Y4O^O*Q&,:-
M']<W7%XO13K 5X<*!\\40SL B>J0T!?3#D*@XTL=WNWD"V[-OKY8MHJ CA/S
M<NDYRC,?EHWMJORFN+FM>E^[S8*@XSI<E=M=I%*Q7/4V'P99$/ <:G7+TX$A
MY/B[VL5C&%8/.4__E.YN]AH4UL8@'>R0$AT)+I3I(1%RXNV!0BIWH1A<6AUZ
M,'1D8<(MO@Q07:Y=YY)NG]-"(N0X:U&SCT:SZ6PB,@/]QO.B^)'!87PB].Z_
M@0"/V'W.V4WRTMY>X?9^D!IJTL)81@P?](2<;=NB.H=_Q1PS*^\'J:'Z^_4^
M9A3H"7GR]IETY,LNJFM(,.;- "WNN[$\"C2E+5Z="E0/'.=P0"K\ZU_$SA[H
MXE!@;UQ=6O=0BF%NB'TS_Z=S/77S*VJ4"*D_?!A0SRQ_C']5S;!GK?]T\(F
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MV3/<M5+X\9+74[Y*T995_Q4%)Q@OQ!VLG,.BD([2DI0QLIDG[MS!'JE\_O8
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MM+.=L]$)EX:]$)ZN^L'CD&#0\PTU(+R<E:W]8MM@U) 6(CA&.6A<^7)J7,/
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MXW+6HX%NJ^6IM(?+>4[*]6A:8*<3_BQ,;3FO<>Z+QU?#9>3JU5@!#:U9A=2
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M6Y:QXQSOLARK4]^N^$W7CW!7TMS(%BZN-N@2/Y:H)4',_26($VKK9Z3GV7U
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MGLEK=4HUC98K#S11TM'>BI-AP=26$.I0\F:.=RLVF-.9 ^&>OP''KY&K66%
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M,>BL&&D66-)<?N;A:(]FSO[M\3&)0R+ CI^N'AC_!&X<:U"I#"8,0,$'0".
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MQ_'-[B)+RSP(5?M*D\[.?;1&%IF;;KK5#IOVI,?5=5^8_><DF>Z?L[P\*YD
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MMD8XO]F]CXLP2"271)8@"GR88"R[\0%#0W%#D]0_TM(B<52?.]!B4]D.<<H
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M\_[;X)7=QSSF]-G7-HT^DG'E_S"Y3*+L#G&Y1"V/_.)&U0_XFLG"W(/<-C%
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M5N,AFO5>/<*[.(U+G+QV]^5J_.AZN7NSKN%^O+%I._2#+.!(,1N)P<MUDV$
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MM]OAD);M:EBZ(\8I.BJO_G2'J4KB).;E-O2QD,6^X-"TEM/*$,X-Y>[ZD%)
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MD537N"A^[(@1R,0 M1+SAR-^/@8172RQO-($?I7)Y@I3MEO7,N9>9Q+(PO.
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M^)7_B_SP&!3X/_Y_4$L'"#4^)Y^X=   C_T& %!+ P04  @("  7ALY4
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MS7B#G[V(-_A)^!J4A^=GO,%J++C/Z,OBOH04LN2#^-'C#7Y"MV%(Q2,P80B
M_(PWR,)W?78PWN"G/4^I!N!^QAM<D8&\7S66M"FXG_$&5V0@WVH;2]H4W(\>
M;_"S*U'K]/=4.[WW/-[@MFK"J7*4%D@GQ3W)*H^C]K6?J '@"OTFD"\_G1M
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MGA*H2>4/4!X@S^]GUY!8A$38G"0Q'7RZ[ZUY]8 95WR7*I)2R%0,Q/-WUSO
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M>#](^K*96W2VCB;ME._?UV$_G,-K>"+3:(@A1HZ+55-(RF.<$0$^CEB-Y_;
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M+ZY4DO,1V;_.@O!U(/8AE04UG^3I8DQ!7,= W L U7E.*J[&"$(^MEF9 '1
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M]^.->4DRL@^)!=N-&J#OKMAMOSLOB4+>]VG(4:  !@!M^5G[\0B]A(W]_LE
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MN6!*@!9[8THX/$ Z6ZH9KF=** #Y;DJP_R#V /M8J2,V@<35R#PW'W3R$/8
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M,O96?RNA)UK7W[UO46%@&Y?=UE\19;9\;KS>H%8&]TX\Q-5B=9>&W!C!'?>
M"@W[BM]M/3<C4J#]QC<S/I@9A+9([B&VK7%@KQ=4A-B1-9#'@G4R!>.A9VE0
M5+1Q#L-8P\&P*U2,_L?';'5,U&-4,#!Z=K6GXF[%#/JP,.H(%>$/?@G3!I^"
M(>'76^@?ZN3@NB>>-R<'H1??H.8%93_L/D@C0+,'3X/!P<]K3'M$"CSN/;S:
M?%93]FP\:=P3ZGH&OS]/XN+]RR*('DDZ/U2-A&Y[0X7Y UR-HI J&"$_5LX@
M\:0BHJ^C\.*ZO:'"[/G5+1JI@A'B84HA.QO/[:#MW9P:MK])!?/S)K@)=0*=
M]BNAD,4IP8W<$8.#'^!^N$WN!&K=_*(8,30#+[CKSQ@-W(9!"]8IKW_&:! ^
MZ!@,D;>*5J0LF&(LT_1CQF@8#+&/VY;%R%<6'NJ?,1KP8S0,AL@V4)YBV+[5
M4A+@>8R&EJ+[#X:N^Y;5ESA?Q70(^6'C-0P.L6_-.UFI.*!_U'@-@T-'WNU7
M9"$7VE;/W8W78"4H@TX8@L$0V7C'%<RV#&OC^AE>H8/P"H-#;#>13F9]:U3]
MJ.$55H,5-E"+0A:C?$;2QUD0<YV/V]!:PRY0?>B!PWBA=9:5NAZ3EF(T<,+U
M]F,$,%=C,D$=!'N]H-+#WMG[.@Y$9#:.\^#Y(V8E<;=)_ :';3)I[W&H:1^H
MZ+#W.KZ. SZ5MM*;^.L4:[B0[KC+%'^\@ G@*@C3UEQ ;/<1A'^$?:?AZSBJ
M1[6M?#%^GH1U%VGZQ,O- 6;202KR'CAD8>[63'BV%<^CIT-KO>Z[.;#TNT?%
MW0./,-S-GR[+MH*,</>%"/YC:POE612,_X0?H6Q6DD-?R(3QR]=D0B*8?JJ!
MKPIZR 3+L:RV/JRE>9IEBWF)Y32>?"7Y+)DD4?*RU/ ^Z^#K93Z]XR'&A+M*
M$ZAT-=LJR'KLJU&RCF@$<Y6 %K=<Q+02:=]3U@3W[%M_+U%^Q':Y$#"_+2=!
MQ]URZ-(7CS2Y>:4$0XHT/@6D"R2SVV.W7)RT9/,U> _GB[E4.EME&%HDIP4A
M]?L2$O3:DFM1IS(*8[6,JF486J0+!Q,9\7OMN2_0)H&QCO_ 7F&V(&";R;46
M*1T46"Y"V,^R>%LUFGR5NCZV]N96^5$VRK"-QQ)]D1RM6V;DAW9VDO'T1Q)!
M,U&8+^]!;ET=.?E?9^+"?AY>3X&[HL:2AU1_-/D^S/Z\2@E]:$E 8_(N]9CW
M;28J[%L&7"V6$V/)U<F%QZ]KX^7CC'Q- .UYD$9)]@";WZ@H4=@NL\?D@D!W
MYR ,*+AOVBWJWV>+@E!CFZ; 97JK<_Q/G8.L0F _C%\>9V$Z >7*E[08>^;X
MFJ32Y["M?*=4E'6&!Q<H$%DB[7^$@4>:/EJ6Y_;,TR9Y'MHZUU/VPYC$01HF
M$KLGMRQ#CV1@:U.:^_8%!0$>VE)70+[%&>P PVE()L(G1]+RC 5$.YY".!QI
MJK%@66 %"\OYC&Z+KN,B%%,2R9\=<0LS:$C&($W6.1.V @R6%59/3E=)%"7?
M8>HYC:]?$R.I\:H6L(=8(?^LR5 .S7>;[>(9UILP2)</0?$.BCH1*)[N"NL4
MK!P=(ETS=K?$&A#ANQ%X@XN^M 0>X7"6P:X5\*BC2B@K,YZPG1+48A3(WP"@
M)1LKEB)<WXV4(1_691AJ[.P0!M+ARY<#R/,GF#4#"='%;H 4S*7[:5T WI)=
MSMG7MSZ$%"ID@7R')U"/FG;C1C382OG<L^!"!3W85PRM"IZO;)JTV'HZYZZK
MXW" Y&_?K9F/ ]K6<RVW_22' Z0SIH!U@6AV>VSKP8_[CI+# ;8CZR[W^R(2
M]-K6 Q+W/26' X>\645"XO?:5C)56X946U/^C<1SLIT/L?6E]S:[MMFSE<[4
MFD;6]1NDGA>C:>&$(51""VTS"SJ2.UO;VL#3/:ND]2=):!U*+M]?P[0HK!?L
MR,8W&/=]<#U1*FR+Y-E*Y>EK)"^OW(V'6)E,$-6]*UIM9?7LTT!PTEMY>-"'
MS3'.()"3VI^TGK8GC8OP#20:3S#6@>JWF:SZX#2)NPKP2;65M=/7-4 9_N6/
M(O;+*F;98Y('$6[4'UF'F%R1C&J>#19+3+>6U;/-US*W)+])L@R0%=R<YGD:
M/B]R:KYZ3(#'>1(7%WBS) (XV3J'W$48+6BT^@<R7J1A'A*87L;1 KYY!6I
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M,2"?_1S2UUK<>1X.5(>7M6MYMHI)T%!)]QMD?"(?&QW211E%O<A*93 >+^.
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M>[YWXE:K'[Q./Y@/$L)ZJ!GS/NYG9NJE8#78+3:O+6;10TJ#'E(RSK!H0Z5
M&RH95]B\TTV\\#\1$7?C\#D%S!H,BXL^?4J9*R[/)C'F<0\#Z<Z#8W@V"HM@
M"-/R1C;2[?AN]L!3Z3NTB28NH57]2V==SYKH:/=+F=AV+OOT!2F@Z[=-WHJ[
MLR89PHL%Z+%L^E8V70\NLZN[("&TAGGA*R217IJ?OGX,O(;\9]=]AG57B*5-
MBTX\!]S7V:DX#[%63G3B4K*W!=\N"ZRQ9>\%L/>Q9>\YL/?L5+3LO2)6U6JP
M96DAE4O&#;-=<I9RS>T%X=0M[KI)/_&A6>\Z[O$(MT'$>TBX>ZXB0#9LN\]*
MD$WB$HNKO61<[?=:?RR_O3COQ&IPP^*=#*]CD%P%[Y$E?W/%]<59[.NPY.]7
M3VB92SXW*W8=EGP>QFB9E_S,$=$_'3\!C6:0Q/("(W?K^=5-'_@V3/_\#6B/
MH;Y#>IP<%NEOE]R12424E;>8MA_!23FEP=RS9Q'_*^&!.RP]X\Q&D)S6\ 2)
MY^# F(V<8T\_L4RKR<@8=HSP.&B=#XH0'.>$LH-#+G4D519N/V&X^>CJL6FN
MZHI%Z%6+^0EOQQG"1T%6B, )<++GT&^4X!Q*OWS3QYRMX1,37\VU_-&ZBTBB
M#)N!]SV$<S(8O;Q>S[5\<N*KN99-*7G\S7%_@GJS0;ORB6FOYCK:#*355LU?
M$$>^X?;:'#%H9Q_/>T9@OI]MV'AOVQ!4C>R8;7;A:Q#33VB068LDX(E[2L_L
M<[$Q&RMI8[YF4&,KFVEGL_'*:N[/YQ6U:20JY]:V6W(#MN1:JME3'$]V_VW"
M_IO*ZB_TU95R[Y=[YSWO0+0[< -VX&J=@&OH_K6;R6ZFM3A2+.+)ZB(XE)FO
M)D'_;@C@T_/S7<TEM2C8K]_AZU<8MU2<6FO\63LTP=OIWZ^Z$%P3N(SYWQS.
MWG>9H#K@?X=I4\_$DN>??5LNP?S8<=.X;(57G8Y+*WSF)@!6CPV+IUN>L=YV
MNIG4I'HN-:EN@]?+%+Q>D$#U%^0PU1>1PU9D%%LV>C;=?:'S+E?9Z))QJ"T;
MO7%EHTO&@;9L=$FYM.1EHTO&QK9L]+L?[^^%(;X"G&C+1F]RV>B2,:@M&[T)
MJVRKF)6FBEG).,-6,3,*R[M6,2L95UA<RW)Y8U\^IG+A6I:,O2VNY;OB6I:,
M&^R%]"8ZVRVDX9(A#=]M_0]RZW_PYVY-&[XVY'?#0GY'N?'@!=QXL+-;FP\W
M[OY9V\L 5O7?MOS+$LN_[.[4]F9:]Y%GYP&L:M=[\>L]&EV;K>";X\#KC1$3
MV1;N*0NF[@J:R#E&K>_4&_-,6!AC5%N"IRQ(P)91IS"J]<HLVRNSG'6UEO;B
M+>TE[5!;+*0DQ4*6J3K8:R![#51F1JT?66/,&F/S8]3ZT:(9U1ICUA@K.:/:
M2]'%IT<N<OVL,?U^QO0BU]4:T\LTIA>VDHV:U5FMSCI'XZJV:$:U.JO564O.
MJ%;G><<+A 6NJ]5YEGJ!,.^5+-21?ED4W9^;B)+WRJ"XF?M]!BEO;>#P1LMF
MV-/A_4Z'!:ZK/1V6>CHL<H?:Z^7R72\O;+UMP,\[!_PL;%VM1%YRP,_"5M+>
M BT!)'.!ZV<#>&P SPHQJKT,L9<A*\&H]C+$7H:4@%&30"@N11_AGS]:)SFN
MZ*L:35^%#/<:]4^?X5?3BODI;1;;F=RF)*C)"<WJF=//KVCW$B;2F]!L$D>?
MZ;=7M/DO[D13FL2?7M'B )Z;.G?\\15MPCK\"<OZ)^'6Y1JG=.PL#15?NDKZ
M/'+B,'KUHHZW@-^>\"#LBV!BRS.O:[&1CR.3>)8,P,G*[IU 7]J*Z0.OH/')
M^>WI\=WU;6M:X^D#SS0N'C]'W"? *-D3 ]:)POXM[\A?M\X<-_YS[VB_L5\[
MJFVQ.-1?7_U9WS\\JM>W/L[Z=OU-;S?>]/;NF][>>]/;^V]Z^^!-;W]ZT]N'
M;WK[Z UOUVMOX;5Z[2V\5J^]A=?JM;?P6J/V%IHW:F^A>:/^%IHWZF^A^?ZD
MOANSOSV!YB]X>\(>H[<_TNLR3"*72_6QQQT/5*)?/L()\/47^(?)>.B#ZMF!
MPWQ'BO_PSZR^6VT<#AZ_L+X3=46P$X>#SZPVB-,OVF$<AWUX\!-\^87>?."B
MVXL_LW;H>U^VOO[BL!ZHA[]N_1?HAEM?[U!U9&&'':->!+K<+Q\=/0:6'P3J
M3#N.+[K!9X:WF3R"M@I// @O[GUFA]5]$7QA^>=]WLE&&*G1.$D<IM_A _JK
MK?&IZPG0^#TA![XS!#7/%P&?]'3'Z0M_^)G]SU])&'^Y RU6LBO^P&[#OA.H
M+[^P'$D/D7H^CV%&.W+@N"+H(DF!QIJXCU\F]*H6:9Q,+VYHQ29KISQE,[#7
M#^ZYO8S?%0FQCB1O2M81/O?8@XA[+.YQEF%0,R?PV.FCVW."+F?H6!8235,&
M__M[$O#_^:_Z0>U+?:_"\+:MRL:7+[>(TY>21-.B5U))1A&@ET#18OW7]I9W
M-4PP+-A56%7KM;N[N],XV-__M/O$@LU7WK0=]V<W"I/ ^\R"$'[^4@Z2L;&!
M*3;QN!LJLIGQC@UO NW8%.UAKS0\FAO/2]M2O//<F03/[O2TXE.?>=KM, (5
M+%.B!H],AK[P6-1M;]<J#/_W8:'463PU=F>A1F.-J3&WP[O>&"7EWGK*?#71
MEP[RQ]7YW>D):]TU[TY;3Q_)[RJ>9YG=O.3SLAAQ-C6R),0=[[9U>OSC]OSN
M'/BF>77"3O\X_JUY]?V4'5]?7IZW6N?75\^=>G.C[5%I27OT&LK^[L@>/!B'
M086=5(^KH##O[QV]0(>8Z?B80H]<"V^7["_T3J@1TM#(T:"...VS:-3^5O18
M&)8IG)P'8X?BCAOZ8?1YY$ L/J*[J),4*?Q"(_NLSM2Y'WR3-.<)IU"Y!-):
MGH/-R].K$_C_';NZKK+Z;">A78I%+,7=]8LLS7=8A.<TQ>=)>W9]>UGTR_9$
MS(E&')64A\@9O,(A!D\&IL4=R=T=\;C3$QZ,\[/Z#SJ\#^JU?3B]=W[YB(]_
MK1=(6PX"KPBGWIY^/V_=W3;O4-<A%9HDR/II/?H0#,*H[_BOX,O)[6'XMW G
MV20GI[=+EL#K2LN[WTY97E$_OF/79ZQ^M/N4.\\JE6NI5,Y%AA^,<L%N:63X
MP:LND68Z,_>/]CZ!DGA[?'IQ\4>%G5\=5_7QN31I_\I;J'*XSL=[W3Y]=-R8
M!4Z?+K;-Y4, >U0R.> N!F=Z3 1,Q)*Y/2>"YC]8&W@CQ%4IE_%__Z]?8HK#
M<+GO#QS/@X9^W:IMT6?=,'T>6\A''4BAJ*J^<9,H@K6C=4F7MU[#]7W])M3+
M!HWZSD#"M^:O]*<" ;;4I*()1,O][(W$CNSN_8TNWV-OY'<*;'8=W_"F6IW)
MSYJV&E/:,@0!<KRQ6?@WFC1/0^ 1THX3=>!T^4X[XLY/,/FD\.![YSZDG?#T
M_(&]OGS);=9TOR_/A#_AOO/@8/QN7FS.OG)F&SS[1@GFVCC</=B$><[=;;#W
M::=QN+]_5/\TR238^#VT31D5+(Q8B+GI[-]))*0G7(J3"#N_M*./7T7@AM%
MWS+1HU'7"<1_Z/.'3>#*[9M(P(DW9$"MP',BCYT'7H( +XY/)*(4&5#J5%EB
M=AQZG%TEF&"R&?0YK]Y66U6FR[1'1)-SG86D:3*5'&K_P;^H?Q15)=?G3@1]
MQKTO?>?1J(!:(5JF.5+P[JV>/=+89[]S&;/?G?@GB"AV*7P?>G"\"FLE(&19
MTUIZKZ/L=T>@W)3M).I6V.4)&#&'GPY7GYK;C;W:A_D[\7<;GW9J![7=I;GE
MUXS=MIN>%W$I*PP.93]!*XW]1PS %/)XA6)48^[S02\,. M(X.:?!%W9T8\6
MO!+_\U^'C?JG+Y(-(GA8#!R?<5-$%)[$*J+2>B<VPSNQN)U7&E_JZP*(H1-V
MZG=[L,G")%I]"?\^9+P!Z47IZ15VW!.\P])JQ4R7*R8I=MQS1 3=HIS"0/QO
M(2K=\.%$1-R-PTC:!7AEDD.$'KW'"E@P[J0T!4M$JT];?=KJTYO!;ML(H0N*
M\_RT:J<+Y(5Q14SRZ!X.-*LX6\6YI(KS<J-UCL,!)E+&X><5CLZQ]Z3Z$O+@
M)6-\R8WJ&ULU0N?MXWO^EG8^';R.E,_=6C5OSYL7R[BK>F<]HWB*:%&V&LK'
M"=BW_PCY8, #1C<FMR&H%C&[J()U$<%3[.]1M72:[PH3_.\\"$2'1^S,";J6
ML//DY'OA,01#0Z0O2]=YT?5WX<LP8*T01'4@V/<P]"+A]I1>\C].'RS&VU Z
ML:BPF^JQE15S)'U]MU9GS7L>)-PX(9M]#M1WI"7S_,B\5YNBL!_N3]"[2 D9
M:>-+]M*GZO[@<>LKXD[2JISY81C9U9K?:F&#_PJCGQ5F_D)KI7Y4*AK7YT7C
M[4:]L0"?W='1T<[^8:TV,0-P0?%!KR.WLO]F[FB.H4MVB[YVBUX(Z; S$?'@
M/[Q4VW)N=/T[[W00>!KMI+EOSFM? )/N7(CUI-V[J;&@.K'C)/;A/S?"_0F*
M5-!EOSD^)_?Z21A%[.+BQA)]?D3_Q'X/(]]C=Y'C<79,Y++TG><=<(U]CS@/
M'L B8ZT8_HPM?1>M:]8FA/%;77,ZD^[6=@XS71.=C!,4SCE'8!OLB,-1O_:S
MF10OO_5:;%Q[<S"(PD?1QQ0)C_(D.LP-^WT>N%2% C_#$X-0<M!Q\32+0W(5
M#)*V+]S/!5HW)9-A&& *Z"!R7%2$\2+)Z< $Z"70:[A+H5"FK[@G)(ORT)72
M%,"H3KV#7";YER<.SCN@*0R-*T9FP*QMCJJ$(A*/8!V 2D2W#NQ$O)S'-6E3
M'*OYV6$>A\;Q0\2P&H<(DC"!IAP)[PV22":8JPOOW2:^AG;=J^^S!"@;C0+#
M-EUB T0=J#"WQ]V?]$0G]/WP 8?6#A\UW*CY]^C3WMZ79X(UUG85L[41!F\7
M"&W6#T,Q="7%_")C/ 5% W:4YCAEC0X:V^T/4Y>IP@8@S22?MDJDBOHPC$E+
M/'D7ZG 0PY8@*WTLV9/MY"FOX7R(CU6&N)J5Y9(I7.(PD+#Q3D95H%K@*4(2
M TUG!_<I=K!\L#%\X%D^F <?G <>YO-QUAYJJL%C/]E#CU/V*$XARL N:,E\
M: =6RG6YCU6,8)5PK2*,JYOX[?R5X" ,=G(]:=KI_B1HZ^B5B/@@C&)<>5#P
M!J!J5)@Z<V"!D!!=UHW"A[AG?JX"0W":L,<[(J S2^*Z8S)-H_9EVK3IY_H7
M\]BS#TP=GWD.F50_.V6HYDD1S)^VV2ZK-]H[#4U;S?XI7CYLF(GZJ@WQ*G&(
M5_U@(? 5![6%-%L_6DBSI<#:2,=Y@4)%L6Q.<*@O2'HLY)8F]P:=02_OY.5=
M-=][>M-66\-QD2 JMEN(9)[A%@WV+()L_;K5V%K5)DJP)>9^HNFS0#Q^!KV!
M2B\*EY"\?MWRN/A\2E5!SY ;CX$[NV$TW&*ZHN<M%K6ZJ=7_K%&=V<9=F-:<
M!>JB%NO$OVX)T-/ M-7U18FO7=T2#Q8PH:OIZ@]5_<JFN1A\BN+^.EB*^&@I
MK4F]F*I.ZJ/6BA8[UV?XA\;W+9&P0E*^G'\^=\0C]W;B*.$YLDY:2RO&5D&,
M+37H8NY]OOR]4VVHJ#>5M5*>S6E&]YW&=:Q&M/A-NI+W+TN^ )AFC6,^WD3/
MA.B,.B5ZCF1P%KIH<0<AN8H2J2QY(!X'VGD,GY1DTC-5O)L<--B7/\3.J4 <
M7D<$,,L0C?-[(<F"#YS %8Z/AG^8!&2O2XT9A=<^(596+OJI6IS MA07?]IV
M/FPW/FQ_^V!LZ*+;J> 2>HZ-'^_2:=S0+%[-PQW'ESRG(!>9^+4^J?(EQ"V%
MD>]@57.(L#T><>!9<F7*IV[\\.9*)FY/WPY&]%^)UXE]9X@W7 %W09M F#)@
M*[KA(GC9D6M%Y$J?6"LW"-D#?81T0N:P3A*1-R_UKE88**+0L4:N!9'J#]6X
M<,!._.2H5=/8(%=7G6T.&RE_VRG($1A&'NP=KO9685,<PJ:8O!VRBS>@ @V7
M>^2WRR;YY*C&AE(@L2-G+ ()W;OQZ+64=# E8G0>%5HLCP,A^L .SR(PY)CM
M+04&<BW,.3FXE"Z\0H2 >'LAOE*G(D^;ZRO+[)5ZKE.SKPM@?;P_OJ;X74Y-
M;W,XY5!-]Q^<H<PI4[W4!"CX:C.BPJ!S%*KO@_ Q_WSXLO5QZNZ86#B[7CWX
M-&&T^NL%5<]685$3:V>KTMFY9ZEPMAY=KD:V_B9727MK4FG;W%0G,%^M:)C5
ML\_Z'![55\=.] F3.OWCYJ)YU;R[OOT7N[J^.WV&628!.[YT7'BDP_G73"\C
MKT*LLK1-IZ*^FDE_U)<Q'TRD4*$P;2M_UI_AK6=KIXZ+6T3MV1ZM9LNR0K8?
ML%]NNIW<>CH&8<)GU/4I[%H.)[NYC(33#".;L'_X'1_#;\]I?XYS^=.:%BT"
M_P,X5 I@V->\S8R_!&AF[L(NX"1.8%>S[3^^W5Y\  V^)]JH],#9;2P"PMF_
M<:*8G9\# 8$$K'Z01E>E"U,%A0*5$&C6!WM"O5!!C5D"";$SK8(,(NX+.+Q1
MT0*-'I6B.)$:)P1^;SL^*3+PN.[5O#EEK3%&*0F45N%51X6<%7DC(F^B<:$\
M&+,*PT6,\36X*9K>2NH6,%)([K)Q,9M^EQ/&6Q,FE\( ($0QNW(B,)<+IDN]
M]CIM[2T!ESDF:NSNDVZQ5__P-N"1Q0: HJTF F40XZ85.K9PL@Q >8HN!7(4
M\%CE-FCC+-W>OW/Z"I^37%E&LA#0^*SM\O(B]2)G!5;9W?,S,+%V9,A,'"5V
M)6+S/.I[KB IF7^UG0S'WT1S+]#V(T:.1,KYHEY"W"2,H]7M#M!,@@7V)AE*
ML]@DK\2KFE-Y\5?Y!^930OHI7Y_=^[/L_5;2_C=L"N3C8[6A<2N]@ WM&BU\
MC6YR4NPFDV(>J7U_3P(3F[178>C;?+$0>7&9KK%5FQ$Y?GE5-<:JAE-<)#WX
M<C17=LNN68O=L%-VS.[8#S9CF?7YE6P;$_"-]:@N^SHTA4JM5L/_$Q8+GP22
M^XR/\1VDSECW"SDP"[>=[SG'Q4UQTJ9:[C3G<?AP[^7D^=__ZQ?1!]73CW_=
M OLP<G_=ZN[N-O9KA]VC [>Q7_WWH)O:C2GL&K5JK-Q/#;0@/Q8]C4N07WMK
M*K_V7L/F:+*0:R1T?UK9]0)'PGH#L,[W%F&Z1^WUT1/C>M^RMO'K--07(SAP
M\E*B*P!M_$S/D$K/"#L,BR*X:O]*W+^S@<O/B=K+TK*70^WK$5*B-P3SD$QR
M*V=7CO2<O]AW/VP[/FM1/ N[=**?/,[E.<EA'\1[>@5Q?/%'U>2"7 =Y\VA7
MF4<5>LMW9*S334Q6\R 2RJ$]NLBSC.?!D>R_&_7JISJZ<Q3'H!.*4[B,KW.E
M<[F=U-F#H/OY[*H<G>M1F'1[+.#=,!;**];F\0/G 4MDZG^G^3]$ MZ3RF&7
MI51E7OH7S3*16?=A$AL?8&IO&H=>FYM;!U4Y1^6439^EW2-OE4A.,&/R$ZZ[
M,WM2E51I7;#LV7;J</BKF)?L.P_$>!7]F#,8^#JO?P:W[+8>3NOT.+V2BQ*?
MRPI[X*SG  ^92#4XTE7XF?+[NCR*'>!MT)83EP+*B+OT+'+SPJZ!=JX?RB1"
MC_)?B8C(C2Q5!IL>0LYYTDKZP"1$BGKCBPF&9"H:DNEP2&I81UGG[N/,KWBY
ME<A4VKR)RV?FH[$ F=+Y7MXPKQ>'2P;W7%U;:A%8/%""^]"'!U@DY$\=Q(7;
MR>/2C41;W9GF[I$+-W#UQE%CM_[GWM;76WB;G3E4D >OVLQZ2Q7V!/(0*!_0
MW6E 5Y&LOI_>O&;R<[IS?^JMW2N#H>:DZ[]N2:RN7R)=?VV9:0GIJX=[KY;1
M^=BZQ::O?JH_G1"Z-V-"Z"Q_+Z;I=T]+F>=N?$%VQIO[G-;SA"2A:<DQDS+O
M2HE46A#$%."JQ/"()#>48HI4.VT?U(!9H,M*KAR]K@BAR0Q4MR33E8^E<JW=
M*7:GE&VGW(6QXY=P?[SE:%0ZR-2SD;4=]V<W"L&@SRO%C1K&$.P>PC_[^Q^>
M/4$ST.U<IY/V@#%[=RB$<TY!!U/W0"%XD'I< E\OQR%T,\G!]NY,^SK1/E&H
MOFTX_SV7,>0%.T6ESI%(;_^W!&0NWU%N.6T!G+86G+G 0]0>CV4['G^86S$\
M&_%& -/3U=6$F]Y(R&EQS*\HQG-4W<-B/-OU#R71'TNS$S=!0): S/8HW@A.
M6PO.M/:L/;#'4AM"EW-/5IA*W&3\<< #B<$!!%ECS]--DG(E(+,]3S>"T]:"
M,^>'J):3XP?O&B9P\*Y1 HN$M)Y+4,#,K@@]7@47O3AQ^$0H0#Q2]9)R_1>3
M?SP'N_V%NWRBHCAAME-O Q7RP:(5Q[51$TT5 A-R%XL8T0%TW%[>ZV."\ZB6
M3E9E)P]O$/&N0P@H%$D*VJ;Z>N ,259HR)I\@/7D".;2H%JN>Q3TW6B\.T:B
M.[X,P5K@D2L4L*6(6#A0W!$BJH_;PRI(R0 _8A6.C!D.BFD=G2CL,\*VB7-E
MS4;NV"HP:BF+G/&DD[%"++A;8YXSE+GZ9X6J9T]'AUKVF*G;*R[2NBPSQ*,'
M5/'$0'/DPMRSQ2/X5 ?+XMVK\FG09_:Q,X[V@8]D*1QB;'4QMR6.DKC727QF
M0%;AA2IKJD!VX$-86,>PKPIE#N((4_ZIP(P;$0* 3VP)!K+EES>)$[WU3?X-
M:%2>@@3S.-5&'F(L-S)*&S-AWLOJ4 E++X'/7*\H7QLR;D/&5RED_"WFX?)*
M'NTOIC;17JXVT9L\_6^+ZD;3K!Q8#\^'.WX+.TW%KYG>,ND>N90!NJ,&_CR<
M?,LC?>N?WV:E_)Q-O/EA9:V?6C;%.&($,5MJ'6QN.*7%_ZP8:NEK@)J7@AHJ
M/.AS%%9U+M V[X7'LN!TW-=MX>:WBU-V?<:.KZ_N3J_N9L1)LRKG^ZB<RTM3
M/)I3E<VRYQ(RO<@9IU;WW\RKK[R!7.907I!)]7KK>LPT+UC7$[.Q5D,7O0&N
M>XO:OZ2E?L=(Z@G5W&QLUJ)/\TEP&'7@UMOKULWI\=V/%FO]N+QLWOXKT_%*
MDCA7F@B-TD3/U$M)'BM1K$1I@-GP&QH-9Z>WYU??K2PIORRQPL0*DW(*D]VM
MKUHG86?G5\VKX_/F!3MIWC6M6"F_6-DM)7VL6+%B!4$ SUO_8&?-X[OKVY85
M)N47)ONEI(\5)E:8[(..<G-*FLD5ENZ\/?W>O#T!TX>=7=_^#G_N7%Q?_P,_
MM^Z:=Z>7>(]B)4[I)<ZA55^LQ"FGQ#G8^@HFT3].[RKL_.KD1^L.S*/FU0F[
MOOOM]-::1RLB7ZQ&8^5+.>7+IZVO/UH4]W%S>WU\>GIB]945D"<'I:2/E2=6
MGAQN?3TY_^?YR2GH*#?7%^?']H9Y!>3)IU+2Q\H3*T^.MKX>-V_.[YH7Y_^O
M>7=^?67%2?G%R6$IZ6/%B14G]1KJ)Q<_K"19"4ER5"LE?:PDL9*DWFB@:_:J
M^9VN>:@8X:<O+79RWCK^T6J!?"$_+3QP\:_6>0L]+%E8R_'UU<GYG7GF]K3U
MX^*.'KF^.;TE-<>Z859 .C5*21\KG:QTJN]N??WVHW5^==JRDJ3\DJ1>LR:3
M%24E%25[>3W'"I/R"Y,#>SUDA4E)A<G^UM?3/TZ/?]R=__,4S*#+F].KEO7K
MKHA@^60%BQ4L)14L!UM?CT]O[YKG5^SV]$+Y4'X[OVEI#PM\<WK";IJW=_]B
M=[=-$#K'ULVR(F+GR(;G6K%34K'S"4$5SJ^.SV^:%ZQU=WW\C]^N+TY.;:+1
M2@@6J\]8P5)2P8*!=*>MX]OS&[HG0F V%0>CI(P5+RL@7HY*22 K7JQXJ1]M
M?6W]UKP];;'3B_/OYXC]>'9]R\Y^W/VX/66MYL6IE3"EES"-FDTLFL9[&R%0
M)F$RU?"ZYN[T%N-,?E1;579V"O8(?  KY?KRE-TU_\#XD];YB0DUH9W_"_0:
MF(%,8I*7UW:YOMK! ?SR$9O^RK1A1&$N/V[1^7L)BLU$;<9*F5))&9L>8/68
M<NHQC?K6UQ]7(%9^OSV_LQ!T*R%.+ :=%2=E%2>-K:\7I]]!60(5ZLYZ<5=#
MGE@WBY4G)94GNQCN<G-Z:V&@5D&2-&RZD94D)94D>UM??__M]/:4_>OZ!SMN
M7F$VT0EKGJ@\(G+OG%W?7MI8NE61-=8*LK*FI+)F?^LK")?3/]C==2YIT4):
MKI!\.=LILWSY95X%.6V1] G=_LZ9$WA4B#X!^D0/$:QK)%G/N>>PKE1ANQ=&
MT(,'#P[#@$-K6++S'J0U&X8)?LM$T$&Y1F7M84UX! TZ ?X34WU[!SKSX*G1
M@I\5>MOI\\"#_\=8B5TF@X'/Z1-T-%H@%!Z 5O"E3L0YP]'"-/-/#"(^<"+H
MK3W$IV% ;=YS_ X6JU0-0+/ O6Z//7 U39!I/,)78#I5-HTBL?,3*0)/RT$(
MAU5;^"*F8O(5>L&%"1NZP&..E$GD!"ZT)M5,L"-?./J]L*,FK\B5)R!1C;Z6
MP&9#UA7W_.FAP7QIK?K.3Z0&#"3L=#C-5'+?QQ<DAS]-!5Q#PW_#9^D)E[I]
M@ XYM:U>QK5P?(XU6;'M 8_Z GC+J[)_P:K+7ICX'LVRS]60\=7\/)S! #8I
M#FA\X;%5QX7Q4"'8P!\BE:@@K"D.&]#?G0BX!UCH'@<T5B^VRJZ3B+43">PE
M@9DZ(@"*"\='IO,$CJ*"ZY7X,;4>PB1H;)+H:!I29"96<(%MN\ )T**KIX7#
M>;8LK!4P4P\7VK+W7,8A<&J8Q*CFF:7^$0 #>ZP5 XWEYW1#DMQY4BIY*(B
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M R*!5?+04R5(;@[0V=T'E3$:IBY88$,4UV'0#;&W&Q!9G-73<PNV VX[/%*
M1^YV/._;\653^]JXVBQF#Z+..8 =CXH:J&,1J=<PINAC]('UH3<Q *;K#^$8
MZSML^_(2!$PS=3%?@GVP6U$D +$,1R?P1Z>C1?1N/7>DH3;'[QT_48*$O.(=
MI GR'QP3,' 7/R@EVPACXPMD<+;XP&X@A5E]!U1>."!!O/KAPTXR8/=@>)!G
M'35?4(5#GZ$ONZO7IWX >B4L;>!H:7JII_-[&)%9\!U.[ ';/K_\_?L'W&#D
M =3W$R WR&DJ'!KTY:49&AYUG22BHQE$.CS51C(&Y$EC]=TZ'FLH9+)9I]1
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M:*X4XB4GU!Q\,?<,H'%G)X.,U=0SQDD>^Q7&CD/ 8*X4QC7N8=VY0200X]0
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M'HE5/#O>9Y'#7,@>CB*;(\A,(VO[7 D$I5@H/3I[4-^MH(C!FH@>]XK,B-*
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MTIV_#<<C*'!Y!9S'/81Z2D4 [>H/]B+)B@8K&M9%-)"]9(J;:(M,*HM(&NA
ME71-L!+F3IFP(P3*D]U&)D_V]E-Y8J^3K*2PDF*=) 4"F2ED2/19*>L%1B*\
MA IL:Y"#3'R@0R4*?901G^HY&7&4RHCUP 5_Q\L.9;?V=37SS+3T0J[,2718
M&JP6M"H?'-]/D8-&[%6AH5P,/ !&1U,J,IJ@!N*\ &:#Q8'1>4?2+HN ['''
MCWM8 *O*SE/K./56Z>Q$'=O$ _)]2$D7,SL/803F]J2(2(3-2;F,*_AUSR#-
M*=T5!@3C406F15 8A[:+/:XJ,AL ?$<5-BYJN(9@!(%2Q,$?X]AI&38V%^J=
MM\>!S86RN5!SS85:U-%2NJV#LA*=C$;,>YP/U!6IJV_?.*R(.V8.*)=FF],-
M.GSKXDT/C)\_.)$GC2,2W^1X Y.*Y/M0"V1?!;69NWE]^:2"4'YRO*\T&'BZ
MQH6Y,C/GA4)G=DD?P9L354OS@:M[KRIKRK&#3Y\""J6-RC?24+I8WDUC8/45
MJ)\([D/_7B$UZ4J2(!"PSH5RK:K+-DX(KD+V]-N&8.U(85IAM;4P<A7X>S<,
MO2Q%('UVT!.^$^#W ^%6LMEY]Z&"BJ>.M".;P:@2&#=6C1F+P+'1,[,P_*V0
M/R4P!S$U\B)9O:A@?=,!"3:N)H<6F;_U,A$;V?67P'*^[7]C4CH\&R1]'J$8
MB)#&5 ^) -PQD RA!:4+^IP"2R<@9*X@A]%^B/%:7Y?DQ15B9P[>YTI=,Q=D
M )4>(!@V!6*E+HM5A02,[HA1_"1](.6PJJL=TS#T?2M>C_>QNCU5-K((6-;3
M8#T-I? TI'?V:1FV<$ E,- 0Q2"<2*D:]!#L961EKQ!6YH<2JS* ;'*5G,(_
M!BIIQMS[@HAQQ4 5' %#] 'A57W?7/^2VD%MF\:,LH'JO^1<57#1$*2F9,1/
MS.R+B\"JB&,IE>*A@P?OA9:F"W: 6+%EQ9856\N[9<4@'=%1*DB(\:=4+4$:
M6%O0>2JIF*&2\?DJ/;@/=!A?)R&W5)6==TR$2J+2C3%^V1$JX4]@]0.J*H]M
M<:\"=@U&F* C;J V&!:I498-ECEH<V5ZD('C<1A[19?!09GX$4/Q%-HXZG88
M\1PI74V["Z>&FQF'7L7(M_&(7!-]@GT8NZ7''<\-P72Q4M!*02L%UT4*_I['
MCD>4>G)I!*&)$9<JN$PZ6&X&[Q@"*JN"Q6:DCK,;@D2[UQ7MZ6W]*HJ/-E=%
M6&COJ#!>_3;>$'C"4PBH"LT;U345M2X5(CAF!F22BWQ0%'&7QA"W>1>#]D>K
M*2#^*J9GDQ(G(AF/=THW#GA+LNARMU:>67EFY=E2G5]/5[=(;P]UBA$^EP2Z
M8($S@#\<M\>S*A@JD^DIDQ':\X2KDCMB5,FZE;3LBXI)EZH S+@4RBMFI@:*
M+WZ"9M=#9S/J<NU85_6,>!>O5\F<QF'>8RG"\R!515/-,9>VD(Z3+@0H3TET
MAM@:-3&(!%G4JF0FEL_$GSQ35P8&U'$$R5.MP6)F*2B($V1X$<E2ERY1:BRI
MI=DQ@(^B=:Y(&E-:$$9*I^@\10)H==R*:2NFK9A>)S$]+IQ1#& ]0;IK&'"Z
MH#&5J;08H$2IXXL_=FJUNA4)5B18D; N(N%W-!P1713WNX@\0KO00#AN&)"^
M,2'&2QNA)L^<FVI7(_J)E1565EA9L2ZR(DW)S]M/9$/X/.C&O6&%C"!5<4,9
M>"Y0&=,G030H<^)Z@BQ!@\58/![O4R%D-) <#R-5,9!*58DV#G@TKAQW:!QC
M!F#'2A\K?:ST65OI\[MVLP1T'\:CPL4@W=05P$Q2'PPJ,SR(@.7PZWS=V)F"
MUZW,L#+#RHP5E1E3;KY0CKA.(CG!-T@1$>]3N0-0+KBK+N$I<HK"'JF.+]=V
M$;I8003Y&%KED_M9Y*1( 8AK0'=RYID)GF3T6/^5"+"?*,+:I!212YONU'#R
M%17A97K*X*=2C$&*:E"^;Q1K^2"O@'<UI@JH5= 7(159(6>%G!5RZR+DSE$;
M$GT2-RHV"5'1$&!N0 700.8Y*IY@DB/'Q'4Z01 F% D:*<@[V5,OQ3!LNI;#
M_Y+D[#D!5O_64>HF\X*Z:7.03_#;/9AS*OC 2AHK::RD60])<YD'%J7((P.:
MS ,8.>>$N6;BE(0D "Z?/RK<C"SA!?>WB@-2OPQES/N8"8^))RK@*")A12[I
M'71)#_/>YDB.F((%8T^D-^6H3E$'T!9E:)O0J3;/#X<0&]4%NAHHU=MRE1]*
M!"J*X"<?TG3" ,W'*KL,/=*QU'O09P%UE7HQNETN:M54ME'(8JD^V!%HG$H3
MP$ AL4'^/1W,$"E#=Q%2U69IES75])/-TK99VG/-TK;ZB=5/UE$_T2YB#%1&
MET<2X'44(7#"R9D$'> )Y>KI<.ZU'?>GLG#.3IHZ.@[F82!1<"?WPDAEQ\-1
M[43D5I9PX$L\YK6K1EU-51!,U"3WDUO&';+MS!F=&EWF[NJ#3JO%<&GR,'54
MWBY\[5/)"!6F]T!^)N-&,L?_)$_2%)3W=#SH)D)\ H4)@ ZF_"6> ;LQSBY[
MD6:M."LEUU=*@K3A!3=QBI0,,D.YBD@4%!'E29@4D=P5)C>(R$J*L9VE(9MH
M;,KEDPDF^V'JWP//XINI6^-U)T!O*VNLK+&R9EUD#5[ F1CB*6'&81$X1=<@
MR&.OZ[?D3Y CH,NEI7(P?QA+4<@"UH_55JP$L1)D;23([W0WKCVU.97%'VI4
MLC&TLGP4$);^)5TDYTL502=R9!PE*G(9F]4UQ'/J"SF#95K^*:UP8CI$[#,T
M$@DY34& 3@N"'J]OKJ[>E,I$G2A-*4LEF^K8[IO*/=D83):<BDD ^D7)8'0J
M5B1:D6A%XKJ(Q$F()RIAM5B#!TTN03C3!-I(19,0AUI',Q&D0*S!Y#KZQBU-
M"C.";ER>4;214%%*TH6F3,C2LYWH^CW9N!!,( H=KV)@)--R/0K%,@S,=1V(
M6$3#Q@IF9"MRS\HT*].L3%L7F7:'"+61<%,D)1F'[D^S^^]#1#CW=:W&89AH
M;<>GXF[H,8\H<0U?'BHH.U/ALLI^!%)M&2#"3ZXL2^Z&0=@GO2Y0BJ$**:"8
M3\DC0N75,J<0.FDLUJP*:R<MZYBVI<((: (T)RNJK*BRHFKNHNHZCZV+>6A:
M,Z#ZLCV$S.B&:"L5+OA[(N:TS!Q;>HB<P2L2X:[_>7ZR4S_2C(Y6*,4OY<.+
M"I;JN/;"=-7;]%T#J2FU=J4<\'3QA[B8Z1T=E7<(_8*AEQ*!T#>=]-E\^!1>
M$PJLS5EE"Q)#%CS[23?H.2*MPREQHQP*UP;[</O\YOK#AF-G!^R,MZ,$ Y</
MJ1QI0T'-2YGHPN02EI,=5?8./U7V:S55WY7B\O#.&TY<.FWSGA^"-7O$VW!)
ML&,(IFT$ Q7M?(A $J@*Q2JS(B3L6X(62B*WYV!ZR  _UBN-7=5M/I)OR@A@
M]Z5.HQ3?,M5L_KN^7X5V!ER7J*5@1QVO !/M=C'2 *'@>*QR9KFJM/[?]<9A
MM<9T-7'HI4/>(4Y1CM!!.B.5^B;)?Y36YM75:M1G)5C2H:F,79C)P!$D.1.%
M.(=Q!8^BKZ##_[N^5]TUO5O\_-?P^"VAY^7KM&\X8/X=P40;2'KT9BB P7Q@
M"L%0%$XXXNA)>>CZR*-JY]H?ZQ6<%L?-V[L=S_MV?-E4*&4:SZ:20\ &48RR
M(A5&*(DLY+U5O*WB708?P?G(SB0=@4X9*HZ!E\<P*MCM1B \A-%/5:?D(@S^
MX[#?P*J/\?@\#]QJBE6?BW!1=>CA>"0Q\_WR9B2J'T.,1\1(/KI.Q\^) :?$
M*Y,)464MSDV5#E,M!3_6&U_4P(J)%2T>W0OT-31!':#)F'(>'0,W+0)TTNJJ
M=-:Y8&6<E7%K(^,N"4!^JA&$25.IG0 ":?^H5MFM'^8,$E.2RQ@EE$N$-L@]
M%<[R'9>;<I@(8>^X+D*IQB1$T6T*0D99,9G5<E ]VLNL%I)#A7&D%E/NG5IF
ML%@99664E5%K):-R*I@72N[E8=]U1K@&E[\AP5 ?A8O/08IFJIB!?L9?HX\1
MN[RTN8Z;E.MX:',=;:ZCS76TA[ ]A%]X"!O\%E7-@/L\35&\]L6]<-COJ+A3
MM&F?]]MT!:!<JZ$3$>2_)R).28A66[>"P@J*S1 4SF 0BB#5N2^%V\,83O9=
M^!(#F51-SN.>X!UVED8Z7:O$&RLHK*"P@F*-!,7?DX"3I$ '8+-U?#TB,0+H
M5$5F(Z)D>@U+ '-@PN_64WS=#'#.1&$9-T!J_>=O4I;L + A"S.%N871("0D
M]O/LNJDD00N_<^!,N@ASS2C1?<U.N.\\Z,J&)]Q5FFZC5M]3(3+$9('33Z_C
M3@/7B8!][WH\<@:4UB[5_:"Y<\-MX01XZ:B$#31V0-NB(S ;U6&(<:^@P,@N
MA\8#S_C7-58B[@/J%;[2'3<C/"X>BWTIO%J8DQ@@6,A(HJLJV>B'+DT6=FAC
MG_V.%1=_=^*?6#KL$A/M;RF?HI4(&$ZSPKX[ F\E93N)NA6\6QCZ>)70J!U^
M.E1P_#$8"X,>W@0$"9%+2+;=V*M]F'_@Y&[CTT[MH+9;U8R#W3_PMA2$]N]%
M.I#SX>&AZBCZ5-VP7RWP'P9 .M <V"Q!)8UX=)V TD0HU5A04HS*NE.I):83
MG8'BI-'B5(=X$(424PP3F9:#HT R@\<;3AIF,/8NAJ &\(-#4 ;D4<%,F(AW
M@%,IQ"3(\ TV*-(']BIB+:=;+V5]_$9_ +;NAKGX-(S5IPS,.'(\KCYI?_*/
M@.ZJ6K&J8IJ^0C%OD< $\+N1E=$\([.U2".+<NW3%9NZ>V?9-PA]VL,\@S;W
MPX"2+_%5%9X;Q 005&6MT,= .3S'H+-['E EP,IH\_21J*#'$JE*T^/<E(]E
M1-I@NF@44T1#-N5[(9'#-,7A$8P^!I4>3D"*>\"X8239- _U_C0E;60-OV0O
M'57W!H^D>'W:TWHQ;L*[2R:'?3B^8!#M!'.\W%Z>VBBY<.=ACACPN9ZTIZ0F
M):X-V8,S3.%H5?UOW*H2EB2NJ&7@%,:)(@\V#(I8)=1AQCZTA+L>I+_:\>1A
MU!'1//W4,49/^CPL=B )+1=_0C:=NF(4K.F%N7E03\C;",VD2$;RHL <%.GQ
MZ4N^I0)?P+M%KD/2]!&"$A.#?97!VQ,#6E&2>-!S&$D=Y@)O#T*< CT#O0._
MMX<551HE&\@8L(K5@6:J5]_G$>WY[RKA^SB7!]X"==T'^MYRS!['A\RO*)N2
M#8_O_%VEJ,*)R T-==*\SJ6OH'CW>(?.<BW;_Y[T!S+&LQE5 Q,KA?2,XF0@
M6=.E4QMTL ;;_OOUMQ9^\P%SO(QR9[ZL3.D6$^E165!(:HZ'4=_P#%HV!*(/
M(A65*Y=.$T)\BV&MG<B3)A(#ZXY0.EALA!+'(]]8+?E!,&S#5\)0X6BC>%/'
M2=:N0WBS5-)6A6BD(R6)0SEIY-!58E.=I7!8D PD68IA:RKS#&O0AIX^AU"(
MX!0H!&Z6&=+PJ#\$'D#9'6?83$RA&70,0+C*=QD;LYZS*2LNE*>9$.>HZJT6
M\-OB@]*GU<G \&REP+MI[(*#WQ;I6Z 1DT9X3UDU,! !9^E]B%)]B*'\)F=&
MY0%,)91.B\D84*]<E37SP SJ<MNXO](@0Y4TB.=!6U,@,@G9&3UTQ0B2Z+02
MI A-70T8D3*W50>.JF%<1*$869/G1/MRS#$\L2/>5VGH4U=QE#LDK5+*#52*
MV9$()Y]6]E)1!1TAT=DP1-T&NM  B7I[Q&%,&(@!JD/0HT3U"K2PA.OTB6KM
MD^J@K2*2F(ZDK.1X*N71,-<\LJ>'49BT]]#$,!:<C_6;R>+PN;(_T2*,C"V7
MV9M1XO-4]VB='E.?3W9*<]+BAN(]@8<"FD5Q$D"'N=MH01CLD H+1QKPLN8I
MC[=!J0-[5"-B>BI4E5+8D(DQ7Q8L+LYI@11&P+:X?W)5L_7,\@!(QQ,=A%8)
M H%9<U3-("= ]-\*6CS.66A")UB-)M]LBRJO5C)OP&Z=4HP^P;'1G,ZGN+%C
MYZ<&=XF=+O6,RCG8^ARQJ;S$I?^:PU_#?>MMBQ()F1!8'%-[,$](U\)32ED>
M?:_P)HD+Y#IZ[@'3EQ!I/:((XYSF2GE*.:E QT53/K'W/C\3\F*=[-;);IWL
M2X$HI@(I*+4D]^^SPX$_\OX@ ^&DPR.3#06<%P3*XZB(&+P!)8@RO[N3> )O
M\TTI;S2DI<SG2J$-&ZGJ BJG.+SG>34G$VT#&&CB9 IORXG:#FCF.]>//A^B
MOO3%ANEM4)C>D0W3LV%Z-DS/GO?VO)_MO-=NAM1JP!1]/Y2(/^FTR5,!YW%V
MWT=(:('4AWL4X24B60=?Z*BW43=60%@!,6<!H?W5Z,S3.C=Y?'J8<S=W)POE
MY6'3Z"]"8J+7I8T78D%7.SB]>R'#:*C9_SZ,%?C8%"$11JR+S05XL^VXO02O
MJG."8[&H/^M\B3'J?A]W"J6.G8ZVV,9D?-@&_LY*Q:FGN@+KR]'J%;/6R0LX
M*;A 12T8E"D:T^01*1?3,RXJ L4A"&1=?F[$YZW"(++ "^.Y-V>9OD#/L;(T
MZ%?9[0$Y+A&PKX]LE);FR=68T$ZL;)"9YSQU\V(#M!%Q_/%06:Y@_9; \WUZ
M#WM.P?$\Y"\R_DI IG6&%''_Q!681GR6,7K/\^\8+[/$2\8QZ@PKQLV<+Q3D
MH!<5[W\G,D6?+E$T;BO&8:3>!AVMEV/8/*-464MY/:G4HRY<I!</N)3J%M*(
MI;X/'1NLF:7;"_'FBVZZN%3X_[Z"9(H?0H7=HD%@<MYAA4>4J SEB9<P0F$R
M-I7[7UW'HJP\0R#;N<ON>FWG'YK?8"LB? RPE$,1!%.O'"M3B8-\3B+F&;&1
ME:":? )41ZUPZS8IG=ND7K-^DZ?])A.%M]*>G_2H6,?*-,<*O2@\($CHUAM'
MC=WZGXVMF3?<_+7O%8G[N?OME%V?G9W>GE]]?RZ.QUK,R[&8)QNCD^W@P[%=
M4Q I.XVWS>2Y%:[GOE,;&SLLE6?J.(\00Y?EW. _3O O$9&_[E5JM1K^7Z/-
M5*WWR>XENY>^_L@!RIIPWPEPLN/PL5-WFG$\=",PX'2N9@&V%HQ*W0.!,9EX
M-M"/=FL89B,G -D>Z,T[$<9V%#7*[FV[M^W>'CDG50A@F,04,XO6N.CWN2<4
M3#*Y@7YI1V UD?LN#4&;NLUWCRJ?=@\J^X=[9B=NPV[>JU5VB]_J<CL%"9"B
M6T^%KQ[?YQH(^X/=W'9SV\T-![<DET(*M?[4>:Q3?M((_!&4=AVQE=OVF+34
MY>0GI;AO=<<KI/+^.;*G8&;Q#W2WWCL^NC7(F:H"8N5GMETW(;0A[%R=G#@!
M]WI"V<%<?G5E_EY0@]V6>4(7UD<CU\=V0].#"I;I:P[)"3(3?\^3AO(P*5RY
M0E# BNP#H4+%30Z=#JYE:1XQRL]!*+G&[25WN4;3B46,.;_:-:^9YT9SP',@
MO5;>6GF[Z?+V5LB?6'V> E.G"MO1;3<A3[NX$ZG9,]6LV89M#G0("+4[(%>Y
MXM;Z?F[OYZ\W5;JMR00J]J9,++R92:1)"C>SP+M)V:/[-Q=T+%2OAE0R#*OM
M,.68!['D"D^G#BN07>SF2>,+U4@K-JS8L&)CZ^N5(SWG+TJ:IH1%RC2?+C]0
M;["!+B^NQJ+A/S#-:3J6^+@%K((?B@8O_-UV"!581;OL[H_:N9/:+K1*CR@L
M=)VQU5#E'_DC"6I5/RW-'+-E6MY=YMF(QG)%-+X7AG.E7M^%K7XTI48:);82
MXR<#%="HW%@H$70X4MZ)]39Y@5@_ZGZ9>SL.K"8&0Z5=9M4*#JN'NUF!@T5D
M,UF!9 62%4CO(9 ^U1J5@X/=:>)()NU_ZTA:C"D%D8 7;NJW)!"Q9-NWK1_R
MP[/BQDH-*S6LU%@7J7&T7SG8/9Q!:*!P2._IE3%DY8*5"U8NK*=<J.\?5CXU
MIFH3<S-N3+K-4Y+E109.X\@:.%8D69&T?B)I?[]6V:]/%4EX01XA"!5>8^F4
M/Q)3B$G\_[/W9LUQ&]FZZ/N-./\!X=-]0HH V2(U6+9NWPA*LKVUMV4Y)/5V
M[Z<;*""K"BT44(T$2)5__5E33BB@2$D<B_E@F62A$CFL7//Z%L.4(?<AW/>?
MN,#N38WE %AC]'N5U<D#^@Q_?!@KT"/WB-QCG[C'XZ/C]*E-Z=_-/2;9QFI=
M-1NED@_TG=^-?N-QCY\^_/[[P^MHYK"W,;J?,E#]1%6T#)FS&>PYP":; FU)
M6^"B6*Q5PT2''/,<X,IK92O1M\)^]L0Q1T+12:?A:_C%E6["=[FA!2=L:VA2
M:J5(W$MME[>XF"'V<"AT0&5'W_-K:0CU>5TB>*<T(YXK+ XFT$F'FM@JHV9+
M70MEUE%F%B=IP+3SMIPY\-?Q-*^?;+WM*Z_>5OJW6\)_J6HU+[DZ7RX!S%;;
MU@X7+/R,-;HW?,F.CF*-;L0VN_P2W"N04+?N[ORCKA"MW;%@T^&A2+=2ZH">
M$+^$D7(S4"M6,:,C6@C10KB-%L)O3>C(].*@QJF)M[AN$LQLI3_/.2PR'@Z)
M'H3('R)_V$_^,-ML5RHRZ-1%:Q2'#@@JK.I=QS639'H5OH1HE]U6W?+H.-IE
MT2Z[:FBDQQ$:Z=R;^.$?;]^>O/^?Y.<WOYW\]NK-R:_)ZY./)_>[V=E'WW!-
M2/CH!&Q:F".,.F@?9?LE4_<<PNTP9K#?Z48[\]GU 8,;5(IKEHK,\!YEG*_H
M08@V:]4*;F#P,H93Y%Y8IA\.RQ51SA\EW!SV^&C02 *^$+QN H=12NA4I=79
MDOOS#BW_R;4 :>CA:RZT*NX[! I#MS2+(XLC6-F16=FQ[?$Z\<Y95E&(0R^5
MZOA-7K9G,.BQVZ6^]O9I;-C+V+%UJ]99:^%@ON:-4I!# *"S3)?<9'5(3:-?
MQ7WCSE1FU@A-FA7_ZG7G>A=AXU+$&LT8>5C@<.#%Z[(NL64OH2PK[-.+K9U
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MAN@: 1?3GK^*%3B^/_QSO@2R5K 2S2(&7YD5IZK5N%' 9I3LDYG8T(%UGV2
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M+ F!"6;(4 AF4*J(MU/J;8G0:596S!B#\F#R5%-R%GZ_(G"KM9+27S3")$4
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MV)+8IF-'Q 9].[6&J@<T![*P[5WT!(T'&(D#D!V\?M9WRJM']-,I< M[[@?
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MG3QX]?Z=?IB.H)HFNNP$RM%'WA&W <*@E%UO?03DN)XU65LD#]Z\?_G0\U>
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M=Z8CG50@S?H%;1R=EW'#%LD*N0#\/.J#L 2!?"QO<<M %K&M;I@9_^9N%QP
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MRR_D=(!SD?,U.*G^)K1AGVI+ ALCN3#^,-6=27,MEI0%WM/+])-PZ=VZP9F
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M9BHQ4'I;0U/'SV.@- 9*;PLU,LMRQ3I:>2*<E%%Q7&!^+0H*[)68M^4,4>=
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M@2L![VH)S,+Z0_.,2UY$EL$]]A!%26/ECG,(8X?UBI@U*1R*T!$8W*.IU 7
M3-URQGM?197I"U2F>8;0MAY0H<] O*;LL[+Q4HCH F&6*'R[[Z1;^VJ=U;9$
MGM"!6?P2*# '/(CY2<=WCFI9)D&O-9"STB4X*CKDNX:]'VRVZ4!$9;NV^^.?
MG*1'<EJ'HH 2C8$/HV2OFU-)V'K7M_:IIK5FD$-$X:YT@?#E,NJV7WCH.^8+
M)KBL01M#7D68S[A>%_%"R^H3QE0<1*+'".P;)U"[L-2.8J4(?8-IB+!<4OV,
MSI3EIBFOPV -XR^44JB#,J?6AWKP\L6'VV-!'RG5DI(=.;\/8:DG;H.I(_,N
MCW]3\JS@S%PCL\H:S.*N]\"3*4]0LKTQ@S"W=VS=S^!:BS3#=$$U/@YE>#GM
M15EP2Z(.BE#X #YX1Z6,>%CS'3)D8Y'LJF[%O+(MC'9J;QB UG5!X;5@UDUV
M&DAM^AXFII>Y3<?80JEK5;F:868:=^I$?N8VU,^$\Q'&LPV!7-TTQ_G#=XV9
M<D72$KB+RQ2K;MH%D->?HKMXP0X+(GNE63M65T!L,J*-T6;W \W4V2DE$=**
M:R[<W:4GZ7H96'(?T\;K(RM.KV--]29 (2>SV6D):M()**TX%?AI!?^'__5=
M4R%4S4OLG-M4!V\WR L^@/HTFZ7)JZPM9TV?O"P;\J"1[8A0P_1E^!0HL<SP
M1\500)I_)#4-OD2E(AA)^@6TJS5]MLD*^#^\;=VF\.<,-P%^^/!?:?(&^3)5
MQ/QGLZQU4W,DY?^ (?+"_"E-?E4+:FG\&_#PEM[X^QPH"T;[O=$*;@?Z#,U&
MX:>MJ.<XH0]V%?!GW@F\ >_IYQ8%0M#RX,Q/G2#ET@AILCX<BW,D]N-D$I'0
M__$W1Z5XB$L(2_VO_^?_94,##V&-RZX7?__NT7><K\4#T^\R!]"+"]72"XS5
M06&5%TD0=_D&W8#?0$!AV5K#G\U/]J-@O=_Q&FSXQPL6 ?<O"PP6G39E81XL
MAG&3OWH;TQ7C#SV&)9TB<C7<,A-=@7U^\<(+MU"T18HDGNT8ZVABK!VSN."K
M)P-'' BZ)+5_BE8I1G)@ FZBN]^<QN@G'!(RNH>2F'&[2^2T_0I-2^=2,!Z*
M%\,()AX*_-O2OWACPNW.*] X?L2PS(M5]MEL@]SAR TB-XC<H!I>RTM7P#X>
MX.A"RY@.O2:%_L''5^_UPZ]D %=Y]6-VRDV(AL>/8G;*[NR441./V>MY>2O7
MG4=S\VDS469&F7EM&O0EBDDMUX8!&HIL34%"$WV[#O$7-=]XB^_E+;[.%)'2
MQ'+% IZ1R]GHX8)CQC75_"?*U:9&'@E#+]B*4U";)0<A6L>11T0>L2\\XAVG
M#:U6?:V$"=ABZIE)XK$0&V@@SQK,98U<('*!R 7VA0O\A@GQ695\*JE4X<%O
M__7P8&;U A>DC+<^WOIXZZ_^UE]O$MP;S$D];0*:IWP&/^< [KY#&XXW/][\
M>//OKKPWB4"(L32 &+I2 ;_?F:IOO0)U/VN2&T6Z[+5J8TLP;+5.*IW,#9#\
M(!73]9BAU,L=I3'PDOD\M2]PZ: !4*54 -@,4==$S<+Q-IA;Z'70J;=;K]L*
M(:"A X7]6*L2,2@3G55<34!9I$%.U2H+&K]XVT1YM!R<Q51XI3Y)-SFI7.B4
MZ\'N$O.'>?@V8= T5G%=ZCAUW\!>&$1G#Q;2-K*A$Y-=Q0K$#U+#*U7!&]-R
MR": V>H#OQQT+*F\:?6@;_Q(Z0$",OO+8N0L//@T\;?9OO\P>:N0+$R_'RQ_
M*(.F!^=FKTM"M5F, ]&A<FFJ77!5A#,EN:L87VNEA'5(]PP%;=(S!9&;6\08
M')YL .W-Z9D>I*)-M#4HT@[1S:S&I!A;BA\DP$KQC:!&(GXFW1.+>>@6OI7O
M#+M=\CRKIJ9B1<G[\T\*#[.FZB'"M,&$8-X.EQ28\I&T4DCB595PFZ?/>=4C
MX+6D=!/V9=/:YAN#!IMX3[@^RE0*I)1AW*9^V538.(<J>BOJU=KHKI+2\^G6
MT-1:5%+1X8DU%E=C#]U@UPF?-">0J*U+:DKF; M0"^SI%PHRK]PZ2E='=-,9
MR#<D27YRH&?-C"J#?!32<ULJI=N9X)(BGZL1 >5U'6$RXS(X*BN0,ULQYH'I
M6XSCA(!L5(2Q4#M*S*>ZSEH@JQ ^'V%E#!06"K$U=:K9D6A?(MM8EK-2D)IY
MEGZ&N%!@JRKXJAEMO=QH$!B"8:/A@H-0I5QRBS7E]=]SU>\(;C6Q^0V5]G@#
MRZ@6#PLQ :8O.4(R+9N&NV8*9._4HHT@ PHQ!<!YV>;]2AK['"8_8XJ3@WLK
ML??\2LK(++"23Q DI4'Z)@+Y_5).A*CD^(7'TP\% ?P.5YM=SW5^3\6K[UV_
M5I0S9E]':KSNUAY>K[/BG<\D$"N A*!K8-O4BP9)^O(K/-[]]YO7!T<_R!&9
M[KP!B)E3^ B,P_2JMG.TO>GENX@S6]:]8";,A3U0V88F5 S+K!G^&28UTFA$
MH)Z--+7MM!B<!(S\82W/34O5/Y8(&$H0*)\[403P-T'OE=^N[00-!(W?!=S!
M*)C"/:"UOA:LO)1Z O/9%49EP0:>RM:D+156SB.PN::N%&R]7>NZ<E> C/WY
MI,6L@9ZVNQVN?KR[B8<EX8I92:+3\+[Y:.Y#@!$9=.EF(B;KA 3M56^(B&JO
MX33LA\.C.2-L?5LW%2MXHG\R^B=OUC_Y&@%1Z*(&;>"W?%!^N2/#WS:$$(R^
M!-NHQ7B $"N#TH')FZ:IR93XB&QK#D3:2%F5ENI1M&7QDSDS"^=$@4&6?5<T
M9S3$:/MV8\\6=CE^8WI:FGG$]$:)$=;(QR(?VS\^%J)E^=WLI8E+O/CQXL>+
MOR\7_Q6A?+I>%-S+&1WFH#,DJ#2DW#'2="<C!"D<'?$:+!YI"-EB("*,IV\K
MTC'X#D<"Z1WPM#-XRMI@@S)03DF=6EK$WR_1-5OH$/*;F\M0Q"<(%J? U=#%
M(5H46[QY%D2*LC-$ND,K;]@$P$4YK6%&8"B%Z9QY?1PQUF+>2"WF4:S%O'M(
MX5%B1XF]CQ+[5Q&JMA5<SCT:5=T".;G&T::)+$-_"F93FYTJ\A2#;,L=<AGC
M?G&>1(LXXA[R^K(Q)16%^;[%@S,I*A(!Z-#'$."<MAA* MD;)&5&RR'RH<B'
M[CH?,I;#(.?#2PGT^G!1^Z:F)B,"<^4\MX+I.4" A0/5NY $/B\4N1^)GY)A
M0LV":9L*'U,S:)LVW9,P63=5F7NY2,9\X^YK/";A5TN^D^D;K%U#T:L.:9V6
M;2_)'1:I&RCF+:6$'C\Z?N0:)%*?N@(Q]?NRX*R7VB>:"Q!'*J#&9R"W^G5A
M\OW^LZ\V\K+_S.H>\\/@MR/NI-TO$& >?Z<N'N[ML(MY6\ZH9;NS24/33X"H
MX2=,#-TR;;7$+EW4W\TT# AXMX5RC02_U.07AN?>*G3_)P\:24S4"J0](D\6
M3=[C$ \EZ+N@+M(KE6FB"TM33!I P9ET^.!Q3;\8%_BT'4_Y\S +\CICQ"^P
MX5>I.?N2D(F%DH=I%=<UH8/69,FTC//I8L4PD[XN_]V[/MW<X7M>2E-E0O[%
M!,]R87H>H-^$]U_HSF[_LCGCG(,:WE\6?59)&IP>Z'A(]-3#614OY"BS:J,-
M:\7N!4BI1'+HY>VU=O#[TI!ED-W@$\PH13U0AXO#U$VD[MB!3!D'F8,['2[7
M:_O^-VJU1YGE-/M:LE4=.^LUTZO$QZ@'.XL.5EME$ -:F\"]SQZ:!I[N&?>
MR93@>^3E?-(\* \<.TFN&DW]>O%.,C=AW--26R;AN)=LH,+&Z[A4;@@HS8Y#
MO](:0:")I5/;(VE)2.@FP@[*UC7$D#0 FRRA:N"I#:'BFK9#[HW4]8*:%04=
M W#2]0+[:2Q5S7#LA,R?VN00[H6"G1&0#CU^0.1G^['F@;L03/^F8AY(73#I
M>?B'6D^O&H3"1;*&>6#Z)J[M%-.]N5V2[:'GVL1+7KNWOP(!?$'V;]JJKC &
MBQGAC#[;M*Z7%J)9-YQX2OWZO"8/_A60+@YX;Y:844^+5B %%">19S.8UV@?
MYFM2(+@<WG4CX#NK;RHER22S#025$6/&5BT:SY3$!QQI&-$M:M$Z8SJ6GB/P
MHYBPN5,[G?K345LM[%00%H^DR5RAK ;>HCMJP(#-,"II1:*P16V5G<%C;5_9
M^/9"NE %&,7_YD:/W&'-PB9OF].I:PYC*SM&_<U@*V>4_F:N-4?7_'<6V+"8
M"RBRC@Z:Q_,3=E7+W=MTV-S%;+_ANDUK5L<^]J%'GNXI^>$IV@\SL9D*K(#9
M!+_@#2DYYENK++1>!@'E.#HFUMAFP:G7HP+D"#-*FW%ZG=1[DQ?XS35?5)O!
MF9HV-XBYTUE$^(D;[#?8KK(:C8HA(S:M"+:R2%-[=TFX"*'@WRV-I]S T%@&
M1(8BABB]VS .D*1M7W;6N^6<7>EYT2633SC>7H"4!5]"^8I"ZFL/E%Q3&06&
MON82=AB>F_[(6E<)0NY#LU*A.\Q.(+R9(\4&F.1>":31T.JS@M<OC>.>/C8=
M'[]8M-F9H,WWK6UCWYIJ%VZ2V#"K]=V'[A$W'O6'"(S5K:^)&C;@]64H()IV
MDH[P2?0^L7(AY022G>K%Z=C4)7-6]L,IGUC#UW$"[*<:G9&HO6"ZJY10T9RY
M+8:GKW/ZJ;D@A\GO_I::?F)V0T4.F7N&A0JVYV7KIX^:(K+"7 V3+\V95EFW
MU+88;4NW"=]A^*-[ER\N70F<>R71C^V*).,)>@YR>-1T7#,"[,"W6:V73:'@
M'IJ:"V!U]8VRR '$O7A#*UPQ_$,*ODDAIY99S;C2Z_4/2? $/8[@?[2C<F6:
M06)R7;D.[1OIN;+MT )V@GP.E0358GF+;:71*6V+5R63D->P:+"@A_Z,HEXZ
M([9]F M-?:S0<J?T;3^Q7@@LR$Z<4]V<[ &5)EC6[;LK6'N^1E_1F&^$=!+Z
M88G=\A:T>7Q(N-.Z:LXP2<&"Q-E+[><PZHWNU$JGVULALDN^*$GA7,B@;7W9
MS+O+Z:")C8@=]J9\&RDQ:Q/F*#)W+!?!:F2[&@]ZFE>FS:@W>9G_4-0O%I5T
MW'V$[I/64RALK?)-IBQR7.K%V6BK>,)Z0%6L5>53!WJ"Y/.L(&6YDV)7!1>M
MV2CJ(=FTG\0>Q29]1EN_BN8J37V 2H7L,NO3*#QK*F0EM$*S#'.472L=?= /
MP+TNA3>@-X&-.Z^+).\+/C;CFL%*7<-*N)*=XXYACUQ>(Z4\;Y)%B59V3&&Y
MA2DLQS&%Y>ZEL$P2RQVGQDFI)6@%3;MAB .GSV*S3!,3<CP463N5,:"*LD1S
MBU5V+ARS^HS5&$XY:]&J_V*A.H_$6:G5ECHT5+5\M92\E:PF6- (TA\VR" )
M=0#U _0G@OU)R ]B)E+:1BGZ@Y=Y0:4CGZ@S*Z$DZ%YC47GI#$-0XDV[:T_C
M21,!+&'#@.>T<RF!>\8T]ZT5S@M#9&2Q9V+:,+)'8U!?Q*WF(K^8@ )[D6N:
M8 GT$';N(Q6.77+V])LMAY5#?)$NP;9'LFFG-Q2;7@/[,V6U-[]'G.C-KL34
M5R#PX5?OWPD0P7C[07QFNP6A%,48. W/[MM66>\M/ 3>8:N);6D\7FSW(@VT
M1[PD AI$]JME'=R(M^:2W0(SI>!DN"\[-J0<BV)ZY5A#E93B"XV[J:2 A9T>
M>U#M6IZCP8NAWGD;V_+8]Q /6[=A1 9?ZI=BM>0Z%:N7+C)05M/CA?0\K#DR
M0;:#Z'K::)U)L<BHJ23>91NP0T.E)$-5V4 '+AOHE_TUPZF@.\R>H.^3"%CF
MR&PDG,)6+9YCSXYW%[.@=^*V^\,^"!R"8+8!!\C:4FP&J_13JV5T4[-+/#-S
MW@AW%T_)^8^S0FW<8=3_F.;%7A\SK8>#SN@>VV>V*:U.12,WCGHOS<41LL]_
MS//PXYO?7O_ME7GZ(S&@D[7UX20/7GT\>7B@:L14(KN8LV;$HO3L4.EH+P:D
M?Y=\Z ]*,;&.5L8TFD@S\>Q6HNVQ/MTWS^'^PS@*72J2$1F+JIEQ1\N040_<
M!5MQUQM,=^!4%(PK>Z$J\87Z_,82+CI"&&T-DU$4T:,6KVU?8TZ?<:%**%W"
MOL@/V/E]CF<B];<#A?AIJ<Z0E"F,8%W@XGG#VT"Q,G&P&'=3M3$Q@7,\M=/^
M662*K6+X,[2ML6<[W$[0?11^/S.1J$L_JD(=A+$]TT5U+#+F%*HP/X[W3;;1
MJJ[DMMM>LK=K$UU^)U&&;M+5\Y$R*;*"Q1!)4DJ36F8M=YG=[I+M .H<&UZ"
M?00K/VTPZ%*-RNWKNXX!]Y?H"#5D#W*AVTQZX0J4FX',8YA!!VBU0M<E6)V?
MJ-(*#Y^?D-L"G_;U/#L%R4>*CFI70[4AH^02\N&C$6/]^3:T"F8# H!XT0>&
M2.0@Q)  *5,&!LF*Z]K:;0JOBZT8XC;<"4[M-*MZ-;:;-TWTUQ_,10ZHX(9@
M,@K. ,\4]_2V(-3X64S:W&B+3B.&%.?(V=P.1NK$M!R@:X4RI1[19FP$#'B>
ML0I0%&3HY47-JRCS,-;,S+-OK<83YF-Z^D_3NN;7?@_RW!K:TL)<C.,.[/7:
MB%5<UU7O-T.E4;82)JKQ80?!+\:\*1JRF#9P[5'*"LY-57EP1DX=%\.B:5TR
MT1!Q9R16F89Q"*,0IG[6B\1?#*X=ZV.)@MUJ5AN:*!WWF%)"C*GL))>0P@;5
MYM8$)0-:M\&B<]&U9IMA0:DO^V'UO57L@V[WQH,AG4_H?5JU$E-!B<K:@#U2
MN38M\OQ>#?"B0M"DT'M%T2^R_3XC_(B!''77V5R"1EM.S'X48^ /?#]AI_L'
MK]Z^TP]]C='S"] 8_Y>]=UN2VTBV!=_';/XA;=LY8Y(96$=4W]1;,P_<E+I;
M9UJ;,I$]?$8F(BLA(H$4+E7*_OH)7^X>X8%+5E$BQ6(1+Q*K*A,(!"(\_+)\
M+3J=<NQROH^M\\:)CJ9#JJ6\LG13!ZS+M6L(+,:^1C _ NSP+FRO\=-GT5K\
M2/C8/&!M=:_[W?VO-RV=K'[\?LWWAY\'O_VI+ D/W-0I>XK$;+K.^T%Y65$<
M[HT7.&#-I_<5E7K]OAG:EM8.KG ^'1K,]K[$M_P:)Y"X]T!RG39^AY2&(I-'
M^^I4\M.;Z:U%-^-]^,7^13\YYH76BOS?\X[(:Q!]1"JKB!/K&/4C4'UFYR2#
MW1QI;=*>\=ME3\U%?JH*/MC@YK=.N# 3:N;93;2X.6Q\]UNVPVN7HA!DCZ:)
M0H;)$N0NMFA(OFK.97^11O+"J!HAC<K#L\PM&K9&K&@+->D$BM>YF,-D +(Q
M3_E[7R9-7)2Z8J+S.KML9JW^6EG\T)7%/ZR5Q4=467SW78L?&6WKO^ -5"%<
MAM6'I\IQEQRW)O/&9TP(L\EY(1@+^.'OS5G)V0!D2QX6!>J'$OZ@DF/A@/7C
M)IU,O;L=Q7;]Z/3FM]5-63XE?:34XM9'X-:>ZFSA9MY3QK%NL/=5^?-0%GH!
MO;L!'5,"9L?I3JZ#=-0G0O_84^,7=0G9#X35=-TVM_TA"[X&_CK47&Y!Q-GF
M6@]-G-8M]=N'RP3O-4L\%Z!%!:_<<@6:7:GII&D\FP9FFZ 5,8ONUH8[K7&A
MZ";M:*XP"8@C#8Z&0!/B]UQO8_([O6QRH]NV\<,_1O\@\><957NU>>F?2KY]
MY *.C/!?-8!++_L\K2ZCH@8A">1H-7/><$9.1]N-4PBDL&#'%Z9I4FSOWV*V
ML]!]::P-*GZA=B>/$UY '+].C#J [A?OJK5;2@3-F3$3\6@KELAH3MNQM*)9
M.,K4-9(]H75^:1M*J5?6?[+JC0U%U$\)"DGBD_]+:C_D% 87$) ^=WU>[C.
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M.*D/IIV&$86H6>@$M0DB",FX1^3TAU[\KQHLFQU#"/"0";91F"/R/NA,^7<
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M03BF<^Z-!MK'N>G4 O_FI\9/)3%4TO=%(*2J_'9K#7@WSOG&OD><+":CK,6
ML:N E'O"0"_O<NLJZ,E$;X)/>+KN<,W_M,)8O>+2-+$S)Y%KJ%=: C\)_V+O
M*A!@$DW*$1581RPG;1#RED)T@+X]V>;44^FGNZ=9-&Q2J/:[,#QP<@&**ZS^
M'SZ!P)QC**J'XYWD&4BYO-K4E.IJAL[*@O)J"7R5"'O3&I"PYA$'I03*2DQ=
MRM$]4F=(CJ:"P,J=^6M4LPQ@!\@SLM*=2E5:S2Q5R$Q7J&"L6>)H)_P L8HU
MK^-F%U+&--LMNHA(:<6XJ(7;]@SDJP9.&73=P/:(TE7^;OU9BUM"T$E,!V;B
MD5HDB&(8+-S>;'/P9P20-?1>?B'TH2O2)\OL9E-ME6NYD%SEMB7;3.HK;+J]
MG\>P"J+FP;9JP""=ERU+O'KWY5J>&:P-!9VI?I_(L4\C81!_4>[WU.(D.$.Z
M'[T-(?L19"+XV48OP^_C;5GKGT>DRMS85;M ^AA>F?$KXW#]AV8XE]^X<VBU
M A-A@MYI#8ORTDTV!<NO^.GP=@K5.:.N"FN0P##@X-;&!?/^/^%N:"11]F7I
M;E>;9QVD&\DS4^'%>9M*PW_G9V\\:%4]];IU+B!PXO&@E,4TU4LB9#-> ^\:
MDH2Q!F=.7S)5,)/E+%(V0<H\F/LQ(;<_(&A^:5'R86=\9K#9LQ(6:6C2O$\$
M&Z=.=7Q#KX6&T]L)>6#%5G%C?N#_H^ H3)C=Z)33XUG.@M"C"J8Q_98_90>6
MTE&6$Q_?T$ZDW#5.EY_\RB7ASFXRG]Q>2.EQ)F54?PU?JU GYN@]K"HX^?$@
MGM6T79WC.>=XZ_!&#(<X63_I!T)42.M 3Y8HSZ#4,<*Y!OW6WG4A[IXYBY3D
M$J!ZD>5DJQIXQ/UA1#);&M]-;UL&<&#,<9!64%Z%&);C9*P?'N3J._/K!C4T
MR/!(N95 &\(4/YWF/-IPC5<C\ZB^Y8L4QI&,6J2R-M=PPEN^*QO,5*(15"$!
MZI*H5]WJ8O7OE>A2EQ4_<LE'(=7AK\VR9+2L19;KIZ$]ZP?VS<#*3_["T7H.
M-14K8,8+$3H=/;L]AT?LM&2Z?*#OCT%-<RWM'<D5<C8O!RE_8*"GU)9P/(_N
M9/["Y+U96D:Y]5X^KD"VL.WBRY;=)Z/) DD^Q0C"RAM'2/.C<C&4L(%M9=$!
MX1(SHC5T8"+G%B#4%Q O>+=,CRW'3W).<D[/)/0T&[AL@61ML'Z,=6B-RTX/
MM W )[QR<-Z^C9K,U>9;6L8F!XG!^@5S*Y)HC+6VZ<089' U-KA=?F]!9-I?
M]<=)9=:/J&1W!64^RL\U0T]V.IM?14')9R7L71$_*^+G(2!^OG$:<Q;N*-FI
M"V+K 2.IZ2+:UA+J?[U" 5?#L!J&1V(8ODLR/DGN,-;>UBV_;OEURS^6+?^Z
M[ ]%F]\R'?U(?3D4].N^^_VV_8J,^R#(N*]69-S'AXQ;CZ7U6'J,Q])W==F7
M(>DU@G%O0[=)T_Z.Y]+JCJ[[?MWW[W??/X>,(Q,C.BGX*V$%I<NOUQ!TW?/K
MGG]4>_Y9"DJ[!$@38#67IU8KL%J!U0H\%BOPTE3'0\-)?@L]>4)131)23+;+
M8LFK*5A-P6H*'HLI^$'*T-1K7A$MVVU(4DO+-C4L3+!-@18'9$R,&Z)\P6H<
M5N.P&H?'8AS^V3 836#<Z^9>-_>ZN1_+YO[VET-.K1>Q\3G2\45XO68"=CEX
M6]>,P&H,5F/P^(S!JW&SWV)+1@2L?@WCL%J!U0JL5N!Q6(%GI!Q)_T8/.K71
M')@JIMRYE27RM_!^QL8LUI9C&CO\JQNHZ;QD/;GE/D?2"*6^*1(]8-M#W>E@
MD6Z8$% [I)3H<[GCC)NVE#T07?:LM9>V89I6J-"7<.NT'2';Y%53H\F.B:6:
M]M2TW/"E[?%-RVW&U,4 EB4A"X"W>231P([SSJR:030'0XL1U>ZZ(50*=?G5
MU'_L9USX)] :0>H/3EQ3ZOPDE@2T<D7Z*M95%<HH5;?8<L-TF-? +:5]I#3,
M3/K$M(5;]0#-JU)_6!Z(B:SXB:1!3)H33=\YDX;Y1Q?*I(498W5T4L[H6/2A
M<$?N)./6.7G/3,Z8\:W''[)-[,&K!W6)^WF@.XJZ+'K+H;6;MV4WV>2__P85
MQ169K!V]HM90E?B=1=TT?F*(TZ&/+W2N_1025'XS^(7JC[;B#$Y41^M N+EN
MZ/(@YKYF*@.Y/$MIT7HE^[5AY@_FY^5_OW.Z M,LR >:WYQ/E!2 ?^/O+Z_%
M4OE6Y=X]Z0_HJ04!A4A>@<SD:O,--Z[ROH96!_46TJ>9;DR+.L+Q0HK&RAK
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MNO.O%D_3T+OH0_N>N4[KI!&1B]0+J6)QTEO&!"T#782L3')C3=MO]FUSI$0
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M'9,V@?$EU,%MOY-I66'1C5W3BK9]J#+9*GIHI1$NTS+"X_.9"X<V>I33QV2
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MP5&QR]"TW>>"!R*#$&%)"8*-U$N%.CG (A+Z^N5NO0O>RFI:5M.RFI9/W+0
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MS?T$VA5'Y?H?ZF@EUWJCO^WSE!M<Y'DF :S:\73J 9PD\0!$5*>S5E7:2X7
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MGJ&_5YU_SB1Q67U;-B,"7,8F GP";*)P.OOO'UQ^4X*]1X2!-W!@9N!UH[Z
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MS-&=$VTGV;/$?3"U 98?!%7_?4[BH-T6+CN10@GJ%QNK?H'!"5K5$NK>ZB4
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M!(D'<+P:+J/D8C!2,BN;SU@5PU#93:D& 6W,9_W"SS<-BH"= O(CS61XC)!
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M*]J/@3ME)D'X<4WFAP+T37C@#9E]X$O7BO 2I:NWD"*[Q]H,EAD^7(1/1_[
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M;=#EQX895?EGOG=@.]1\1JDFOG[^8M)]><W5,F\GA0*BF[C=V8E>"MQ#/+0
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MYR=()W3LU%01XXUAT9%.\DSC1H$8L+3;9H.!L4:J"'#F\6\0HGU3$A4+LD"
MKCQP2O+ Q@<U#097H=Y<X*_"\LL\9QP#JDIBNAKVZ/(A-("-:@4DYQ2[@'G
M=NV!7TNZ1=F88ML,FRUF8?*Z4X\UD*,P#2Y18.O;AI[J,*_P1BPE%\;[T<W%
M$N$;G\[-',QS1O&*<+\,*[76)>N)LHT?'E-YZ>BGF.G)ILDFI"Z9MVA;MT$>
M*_HLP*RE4Q^WX*P6MTT+QIW?@P\TTN(0!]XV<&M%?, +-VW1/?PN&I\@QF5\
MX+MO'&TU\/MW'(2C9<16]T0H>E/FHU??!0(VE+$0RNU8(47Y=M&Q+/L!Z<F<
M)S@>N6!FC]^=I?"A7B\2DFV"/5_B;]G7) DE&4#U/#:9&8<>-J_DVY$>#>-;
MFA<LYH*3I!Q$]<V$!4)*![:O;V/K_75SX0H)SI@T#[\9S\4XOC"9*W$488C-
MVW X^JS8>O2.*T8AD%I!=0SR$P-\0+!!,%+7]O>!XIA$__=H2>NN4^A %)Z^
M+\@FYI$*(4 ],0+V()M*]N^ 90$CQ._+DW"6^6QP K/<QW9>6O%1#4IP!I-N
M(E.+;9U@%6:2F*73/K)$.;!N18Z.%PI#938#]KXFHQA"O\I2Y-Q=((?$H%2?
MLT%5[DB?LHR"=C3<I<&"KJ-7T@=7$;S1FSI=YO,2]D&AIX9038 - Y. JIRA
M&)9XU>R<R\6/C4R@YJ-N'"..C!&"(*3I<I9L_H!<,%^EKS3P* ^X47^+]]*@
M5@!2P'0U/M/![)*H_[>NVN-"XISWX!!P&!9CO<X'K^"DWL8E#E85@-,%YB72
M:>[*_VBJ=Z93"<CKBM/J((X:NN- 74/\G+ S$%[WE.;F/I-AB4LQ"L<<N=;@
M':,&RK66JK$6C,\O$3+-2$X-,_SD^W]<?;;)_RNP$&D)HJ/J:6P6H:G<$< G
MI!>#/619$B+TU.ATF1XD]A"Y!P3EEY"D,IRL,T<903PH@T&#WY;PG5XW<[!1
MB*+UA(P(U&%O Z4P0J6@^?0N1[:L+,B5N !%M.>XX4_75)@Q9L /(Q^8=C:N
M;>)-3[M&:&#S%=S3TO#.!IZMJ1!M9FD,,K1@L?,L:.+D".EDC8%Z^?$<X20K
M:"1$]+-F+0Z;2M,!*1TYKV*TW8M?(5Y@^IK+CHB?NLAXR!5M?EM;?<*PCR5(
MAKN)3J XSP?> GJ[5-EJ]$HHM(]A\#90X$<:&>E3)!2^YL2?\((6]H1/2,-(
M%1AF>"5/%-KZ2,K$]$JF_'U-^6=KDS)C]@60F[[<Y)ZI5>(*L@)RL F*0@L;
M5R[* )((P36"^PUI.>^=Y\BYNVRIU0^)AU]>/+5O\T.RCJ42YNKZ2@-\'7<R
M(#3- DT_QU;2]WXU7K8E+,6U60I4N\_J&C8,_7FUHI9)3QX]^G;QX/N7U\^N
M'FK\>27QC-'2A!.-%X8UG:)HXK 3D=G[96>\#UM^?/)1DD)!Q*"N+D F8?^3
M %!6>.4FM[:X.!IP1B,<(7ES^UP?)[=U_TMBS_?0"526 QQCJ$9 [ GJ8\+I
M/9,.. L/T!%:Q HC2/QKC-#Q@5PY!$TX&G37>'=Y83+%>M^4HOQ4<T!?/THI
MRM,IREF-S56@GWCR\ISD-*B]QT]4Z2EZE/1=4QMLWGUT'GB^;.#W6S L'S^Y
MP+LN"/-8C!!LJ+F%RM(D3,':J"K%:>9J1\ -A<M=/=CI8 P(1PR,3HA;-),5
M;N9MQ*96CDP38/!X?81+6I(IX0@NC&GL:3ZIW,U5U86X-7@<CRLM1@U!&$F$
M#'D9>BXR)Y):6WF@331)II9 #L0W!#&Z14.>.=K?<;BRD[GDTA+/HT5G>A$(
MD$?GU!5.&N< ,LI0J_6-O\@QUQM3)_.()=5%1[ZV5**B$(4_'C[;<,,O3AVP
MD(@Y'O/VIC$%.L?6CS2W8JGNM@1V8E\K0--.[CE36>1S13DQU*II@PAM QEC
M0!6:3 R*=[[@!\1\@VEM=@PDEJ>YN]M2DO$1<MOGA."W6-#?SOH8.ZE ["1+
M,]GI[%Y/-G-GZL&PKAL-6-W8#;FU0ZTI:JIC@'FU;DK7-+7FJ# ^NBKWC#U^
MP>!RZ4RC$30V/JE>!#X2M#JV3Z!M$JZ)II.2]QWCTYDEF-UW"7;JUJ&,)YYI
M"Z1SV4@B[#F<_(VN'=RV%]XJ?K:U(6'J<;Y4*6>^+HB"O]B"2A"5)(RU3\+,
M3#45$*&AK_%V8\Z#%O/A%)U1_P2UQ>L&-N+$02C9W3^ DJ=">%,N7#@L0.-.
M;2$"RR<"A5\ETN1]Q*BQ!6F@GN^CZ&J"*.I2*]IQ5$Q]+*1@_5:='F4&"()G
M_Q*XS@HEP^C"B4=,P0IS^RP@3_,><QHYES_RKVZH[(7QPQ(\8Q#K*N4J[Q_@
M,&4$I_J$G.A8=>OL9M+%!5W8C#H/-<M*=F[GHYU8O%E,<XZ941\A_6[S."9N
MB5$T6'JQ-Q0;9L8"7^<5U[/1BRK1%!D'ASL[LYDX\U ;/8BS 5M&2WJ/$2.D
M.,W_N:(&,Q.IZGQ44T7OKB9GLC0(9;IQ\ &C.1J%H1C[<5P\8&*?;TS9E&V"
MM7CUP_/7;&8$('NC <"1BHNW  >(R#)0L%DD11R"8: ;W78SP&F?A2:/HWP?
MPLVDH5T0\TH11HT&A?%5%]2V2'.9L%G LJ:BXX+P0X*5W[E^VQ2S^")N%T<G
M.ID]DO)3['E3S33"4OOE-+6,;<@U-VUQ:<B(X*W*T4BL-SCDU=M\0_^T[Y3%
M9=7(OPT6#5W6@2SD&R=7]&7']X$SII%7V.&U6)M#_)9\?")"ZJUS5'UTCVY[
M1L&0Y4$E/C274]5GA4&91B(!4:D)B4FRJT26PPH1^BI@):(>;?02^#Y=ILNK
M#DE'CAA!>[S2)>U7AMZ4H4'LWZY?=MX8FGALLF4U@13AP2X7_^#ZH;(C%--!
M>H[>((H 5.U0OZW9A;Q;<T;UBJ,"^O5($V,]8BLE@0+P7!W(W/8/.$[^UQQM
M%Y<QAZ!I]GGG@9'%9Q;,/>BFC:P>C*'>=*EO5F)22TQJGP*3VBLY+5G=UG(@
MJ7*=Z(531K DFP.6-2K_"S<F&&U3#76/Z"A^1"&9/=^:%7-7B:4]J9JD:LY&
MU?R(\3O0$WE+86'^.=D>2%;012Q"J4M#VO]I_Y_7_G_EUD,7(>8LU3G&=T<$
M;*0;".87W/Z0"XD: 9<5IZP&^0WRE6DO!JP"6?D"2XE_APA,4C))R20E<RY*
MYI>)%T*5%<D%2=HA:8?/7CM<21!U/RR1,QZQ->ODE225D%3"9ZL2A'1BT;GR
M/YCC:)CZK?8$R:VX+91%;Y%$BHK5*7TFN7'ZU['(Z!_;'2FIC*0RDLKX?57&
ML_I?0[WR$0I5!Z%.<57>E%Q V%(1>!7P-W]$1YA4Y?$1JSP>IRJ/1$3WR8KG
MFU'S 0-\FJ6_EPM#CRV$=DB-.O[6@+,VB':I=X*L\ASV@D4$_4>0+,+.,$QL
M3ZR;?:;4G*V45K\7^)+*X>%/! XK2U?,OY(MZKP7RT[PT7"WV='RZ @4UY9(
M9(Y1(Z::@9G>E%T5BK4+!(DQONC&"=0]6PA;_+$&OSF1%"L[*L&2JX:J\ T?
M<)'O&1Q,T]PQZY)P?8R!F00,+IJ]GCPU2,SX&ET[;?<A3R:Z=,_M*@2L9NX#
M.,KS8E=-Q]3J,RS8"HK"Z[@+ES*?&5 J/5.("#A.3T^%6ZS+7GA9/WY1B*(C
M&1E1>8DD\3>P*;\Y%%6') I57NX(GD5QQ\#9_:PV!.&9$M;,U'7RW3B=$:.T
M$(\V=,Z V@WE?<Q]1#C(M?3"%FF,-.<6))/4!N&L;]M\_ZLJQ2[TZ;): ;*8
M*Z,&HR*1GIC66:M#&'#/'I44W1(CM)TU>N,//NQFO;Z@<<J8<4H]))8AF4\=
MKM5.=,7?04RQ:/K!TQ=_?\@7/*NI\@.&]S?N?J'1YOB7/_WT.H:_&;4#)WO-
MVS)7[FR'6,:5$$CEMYTM:B!E"A.S+9<E[;S3HHA/_T-FCHLT<E^OIR4AZV:H
M:55)&1![$2PV$X2S?/\APYO!PEL,/2@XUCH6:DDL@&+$$TI?K7B)%7ICGM]=
M5FVGC.7:2H]T"))_$L*:/ 0G-1I(>.Y6K1/64]@$>8T?EL:SX+(NQE5+MR@&
MW ==(_A3+/*CLZ(0JE-0JI44\_"RE*HT7+W)-ZP2E!>#! K5-$IAR3X*GT]R
MK,*%B 5=#Q7W"\J%GR:2-2+65DUTI$9"Z\;&53!'%D2HO>E'AEU?@+#X+RI^
MIT<OD5$6:5&H3Q@L5DT=J@UG:JJ#N:L.YL52RUYM$\D1C/MNBPQE"\O';,.D
MP.6"1:$QDPMM3I4P^O'RUS^7E&S4J@F;:'GT\HFZKK+V./[H]R* 8JP>>S;3
MF3C6RV@;X8828R]5O_P?4SS!M/OA2)LSE6U;'NIJC\C]J)RNG&\$M<,3Z*KC
M:I*A'A=WC'IXH5&*G:%$*CH\NK&H>;9.1QCI//B]'G:N16) _.(F;P\GZATR
M[@@H%, ^G<3;+(+=@V;;,Z''Y>)J2C$UX42R-%2VS@RF*C^@PQ%W,M.J<9V:
M9C(G=)B;F^)./G5C^&CH,10ZX_#<<[#O.4;\P!:G^^+EW-<I>%?R3FTRIZN\
M!Y.#.[5A_\[)43-IT35F<_-O,.9)L]Q@N)+$6-K->5+->KXY$?.SD<MV?/;F
M=1B).9DA"K>:%!YE=BAU$9_N\^REM G1)?2+980V$,;1[A K.!X6[2GJXG-#
M#'&1Y\KAA<C+5HHPJF+O3*,8W%DLNQNB*.**[4R&-Z]B;&F-#V)88@<E?9LP
MRG410;!\),88VU:S,B7^'=*\[<6_NVL7C$ZR9S5KN-%^.+8!LSDY8ED8=]$!
MH=DM!S"KR(KE4*/V QM?V^65S"F<XG8H-$ J?E_EG5:W[8EO2D]\)F:5Z 9:
MV:,J,RH")T$U]F$HK;J:>1_?^XXJYF='&O6O8V$-S8M"S:^= JLA-&:%/XOH
M%Y>3BO%P7I"R/[*^L^KYN!YM3+].(K-/[3H]P[3*"D80(UT:P*'3,R44BX9C
M!JYB:P)7!TV(8RN-6-/%J#5P;":,):MV>#+D<=DOE=*!"8%^"K8@&ILWXWU^
MN3C>H'1>'XC>CF6)#K9I8:XY>V;K/<%Z\9V62(&(*>1Y[&U!IJC=D?(*[H6>
M4:?M+%.7.?.#Z!78L9RODB=#H,OHL$ -T*M)N&JZ7F-J\@'>A0T'8MAEBY^I
MZ7N>%>/MVL421AM[$/[B.S2S+5$?YF9V7EV-EMZ>54394WM:%)IU,=MNXR>:
MFOW[F$&S-[:1ZA"A'NDZ[2YXW#.[AW&:>.L^U931UT]21O//G=$\)VD\XOCC
M@<V=2SIWBR16)MDUQW4R\N)&1 3S7E2F?'%R:J.FL_Q/>3]G;4OX.9Q(V""T
M)+=F2PT*,#J!Q?EH#JL-XR-C+;A0*\FA'>E=R.TP C]>Z,%T7"'K[;'!K"L2
M5="OH J20S#JE7W701@:#&/$8GJ.MB.;T%)7G[;KXFCYR5Z7/;5OFI68%*OD
M6"5! :,89##>[E@%,8]=AU@NV.*_*6Y(DC0*A\&E>4NFH&%&H8X6^0J\T^N[
MPA)C]_<](Q+&AQHQKHUC:OJ@F=#_W*]4)7G8@!C"]K&'.^-+<=37QI:B((]T
M4W:=#W?!+7&/*HN,N?ID#.IR\=JYMW<Z-1_&0='>D4C4]-XQJUA#+!W=OCI(
MYT;N7-P-.V+&>W7,SX+YI,D&,P6#$=+7F=>93EC^YV_TIB9!Q=<P]=WZ(,2-
MPG,V@2W%AW@G+YB-WBX+!*2<6[#,I)90A]=E1/R$0UW?-Y_$W2_#=O.30?[9
M*+;LV3<TD'PDQ#"S%<_,V7P?;KIC]U+6(NNNFJ1F:%;B]VCV6^VK9%7]6JOJ
MS5:)A W)J8$-M>@G[B($7E  !B6'*V5^!A8*',6BCLK:?M5IM3G<:F!EP?4&
M@: K\RKW-.!@U\"V3H83X@>(+)8:J1O7R),%\^1)=ZJP:'.KPGS7("N'>20E
MG="27?\%B7RI?RE'^K<@YP:R5\1B@/A(1%9E40Z:4HQ(,$R=;%9*QHM$M=A:
M2UFR]>IUP&/.WLO<@IH=,;K-O&A^ ZK)XUPH%4?DA 0;=%7)M'$4)J-D!.KK
M&$;'"H=SX^U-B1U1>:+U5*D\Z;"5UDSFRF??3D!E/COY?4/DU[YK'2L Z0%,
MJEV) YF#.@L*Z69"/XQHMZ:C>#;;/&(>9HNU*P@O2&N'X@RW@>7";&;+^P-^
M0;+M/ 6]E1>4$2M*PB(KYRUV*<2NJOI+M('B7]CSW8P2YI2>['^-Q,*KMF1D
ML: R2<Y8FU*KRY(L;D-AS(9>_+LN(E\T=JO!72/?)YZ:^8JZCI/1FM<=MB-#
MSOO ZSC&0&?J<%O^T?D](#CN"&ML7X93,";UL!S #:R/ <QAOL$(P,=T 3:^
M%#1V -WR4^VDRSA !5:5(RV(UIAQ"-##8/I+:41S=7W%@$(10+P+&(U(<ZEN
M:,"5XJ.TR:\'_V6"VT.7B/ 1&_CX/T8/"+4FAN6[D81Y!</\[F0^D6F*D2EQ
M4B8R^=\8?2/$HR2 M:_;[(F:Z"!3:6,J;?P42AO?4"/ '9D&1_E_LS@$.N/C
M)8J$I!224C@7I? B#HQTU(0IQG5I-QLL_,C+=@+K2@HA*82D$,Y4(8@=0'3W
M^49]X5DT)7>!$*V0E$)2"DDIG*E2H-Y?7$W#(6$*VH;:;Y^*B0(R?YQ*2&#"
MCP(F_"*!"?]\8,)T9*4CZQR/+.J2B]D7"J/G[USH[<1Y9P$)(/5??DA$?FG_
MI_U_;OM_G%M=Y7O$J?S./'WGG4GG9I>*\*,4@8T&$&SP.76"Y&+M"3<.^ 2;
M-M]UB[C[:>X;#4=W%YB$U%SNV_(&_0Y.9MHVJK- GKFT\)\9NO4']?(HN[?=
MXE5 MUP;X+KOM8$NH?+K7@<<XATHJ4]^BC]VS<%[=B<VQ?N=AWUO\$8*;R?\
M-R$&&$7M>[*&;JG8F[SI2#7"/U=X<;OHL=B>-BP[( 9+X %YW/&UTNZNX\WU
MF6*-GMU5,JFUPU-^"%I0Q>_7#OZH""XL:%=:V&Y +#EUN9VN\?)P;($-Q(R1
M(/=:SICF0I%Q:!KB+UHX3QV3O06,94/$#=@GMF*(']HNA.)?Y87;E:L@;%K?
M?R/D =1C=L4%J64O7R,P'1L%(1&W:8!,V/;F'3']+\JN&W @7=? FZ/:XIZO
MT3CG"UYA2$U-%0#.3JT\)1"#YP+<(IJ^^Y0!X4;4.)F% (4F)"%V=FNKT8E"
M2\^L2CHZ%V[3.GKN=-%/#*9<Q\AP4^&&(/&,P6^%0W0F<Q'4PVZ)]4OK!=*'
MT"GK\4T)RY.\F^3=?"K>C2\"@I,T=$MKE%?PR.&3MX'R)27IDDY(.N&<= (>
MYW Q5:\(?%B*S\447.R;O6?$;A98.X%U$,:8JZE4(5B19 ,Q\'OII$;/7YXT
M2-(@28.<BP9Y:5S'^T8$U,6D*ER0'&XE?\3VZ##,!YX5>*:#%+APA2PZ?O[^
M2:DDI9*4RKDH%31+0ETUJ0S74@ ,J1AN\KK/J5#J:+@,4P?8<H KP:VB2.9'
MTA1)4WQX33&"^]D0*3>EN>^N53*+^H:;+H("^."=(:ZO7EV\D9TQ\4N22D@J
M(:F$#Z 2Z!3WYS8R_N054<(P3P&\FF L,/5%)%I*?7.\UE!8SSG)S)G,][OM
M'Z=8(EH&T6I1<BDIG*1PDL+Y\WLK"FD)S<Z(<#'7MB+<2IYIWN52$!>8YPFY
MGS:#:%K/'\=)>$N^EQR8I#R2\C@7Y8%&4H_\OQL#U#C!B#B*C2J/CJ?=N7&I
MR#HIBJ0HSE)1*'U72*L0_#/D9E/(,RF"I C.7Q&,JU3R CP)C+4JZ4(V9ER@
M%FXE/H&[Y95M<8%=L X6VVO;$2>'(ZF/I#Y^Y_#H"'OE@1%<8?KAXY,?_(;-
MT%\TZXM]LP*_)=H_4B"0+SLG@'-/"/-K%5#B?S@[_H<O$_]#XG](1V,Z&C\%
MRYKJ5ZF>C)*$I<\J,AWT.NK]$K?&R./,Y+P?[IO_:*3.I (3ET32)4F7G(\N
M0>O>XY35OL<X/M90:O\FK>45]O9$,O';2JCO4;ZV6 Z]KXU6^KD/7_>N)!;'
MZZ2IZ)<J:4?]I&<+@*7P][/MQ:&D!U%_I:/+E\7%T7YJ/<>@-&B8%$4C_I#:
M@\&CL,0I]%J$S]UJ6\-)L]'R=4W2X8F/]\//=N!S@'C=-"T\\Z!5^W1!'0T^
M"Y=34#^4-% OA1J+QJ.7;99= [-V2@024<9<1_AU#BL;-=/C-G72<@B[6+ 9
M$;7M(<9[IH(Q?:8N%]=R[?SW]$#?/P3WO7^P=L'KN'W/<*3ENW1(,37XW'=&
M&&H8\4;M-T3$F0/$FJ*FF=()"E[JIR2M'+7_G>R(SFU"*_BCE 6FP<HN?PO;
MH0\O:UZQPP3U/:@&LD!?D"A!2.4I<X9M(Z2+ABO/ZYR-^U.:$)H5:&E'X^J<
MF@HQ30:MGK1BS+1-;"N-"=^+5N986QSJEU1NFP86&/RA@0F>8.%P?'"WV=&&
M!CIY6\)&H@T[L]N0/#KNQIE+ST)7$MYRMEL8_DJ:A05RCZYJ;O&;0/*1%_F>
MVD":_>3"FEC@5BL0]V:O@ T\/,;7Z.*95M3X9)RQR0%EYCYT(/+'6M5TW-1Q
MR@;C"0OQ.F))T0:JV9@UQ)#O=D,WY=ZE5I=H7"Z*9H>M45<+Z0-"P+2=MG_L
MAA4VJ%P/E=BV]^,6F?"(S'6VFN2U9C092<<TGCSJU+ETJWR0IDZS_#I8KXRW
MJQLD@*11P@PYWW4I&'G$"D>&'VV]H6]*-.I0V7>H^)G0138#F!<#FG-@#> <
M[K0@(I0W*:D+O<>QW?69*L&7FA"YW3:! TELZ; B:]Z"91O:UG5B2%=DAB''
M4#V7=*#&GB)-B[RJN,U>VRL:D_M9C4F"^%G^^9>+J_O*:=!W\ )Q#S]BN,NX
MR7?>!4(\O!/_4<HFMCWG^36P8R7F2FA:&FN[&OOVLY6BO\UFE9@.:B(28064
M.5 @N-1'34N8Y3-2V*YF[\%V4<NHZV/AQ$XBLXX?&**!Q-LEG01O1)N0$MQA
M)U_N?6H$"/LP6WE:PO$X'?^".PN34AWV=](S9>00HZ*BTY^BETP1-[DS!I8>
M?_-=!W?OD=^J-F>U\%OE >#<)>*G%(I,H<A/(11YQ?H%@U]P)(*!!U8NQA>0
M+D_T&/R@3C"?M.G3IC^73<\6(UJ_M4/W+)>.UULD5&&3$*4>_&O$2K!:H+1F
M4@-)#20U<"YJX KC&.#(H!\C7O*BVX-KLBY7FM-*.S[M^+3CSV7'7S==?^'3
MB0E8E/9WVM_GM+__5W);[MW>M:5$DFM,*=4WF&'8Y)P(3&"BW]*\DI)FE$V_
M1Q?;*/))8?[<)C9]1YMIL+9$=DM$G%P@%>9 9>"*$P#7#>Z)OIO-UDI64;+K
M. ",,BL9#MU4.A_@O3KJ3(#&7G:O<&RJ@O@H51!?I2J(/U\5Q%%A^5#2Z,GZ
M52-<Q(#2(N]S[]1-.XQTEXMIKR"OSKCS]@;OI3_@O ^WUV*00P08XJY:&"1"
M  I.C\?7:?8SP'[N A<L)%.EZNR#%Z:MF@OM ^:)_O(^5-BM2TR0U3X4=EAL
MX94N%T\'KTWQ@R,)X)C(*Z!#I5$,H5Z(!_$$Y  NPU7T*U)VJLX+!@':V<>#
M0F>9@&.4,(R;Q*#.9_A);[@"3B,*/J,S_=D,&"@#^<+&02"X.P;H'*)*Q9DL
M?F- F80'Z@0M/ =!>0,B0BHXN_<]L7<1 NE@?<WJ@C1Q-SLZX;D\M&DO%U=H
M0/"6S639Y3%QEE8MB1+A.:! [V]V4()ZWNH(U@7_6O65MEXZKIOL/H ;.E 7
M:KPXF$'"RV2\U6"!8/<-+>78Q1 R,^EW13RE-.IE0#]]MMB'7Z1/5L%@3/?6
M0,4:17P>69E2\%]3#!W.//85<Y4C.*&"POXUM&6'X#_$0"B^3HX>_USX=U-S
MTW>"2\_]]C3VU/GU[8;EOP@8VRS:00LK+.Z1(("(EQL/#4:/3;/TZ2O$7+2B
MS-$IA3NTJ,/IQP(D_&%HF[V##0JS@: RA>,*>].R)'SXBK:9&5D$^H$=U[=-
M12/@SACVT7*SVFV:OI17H&T0W<.B6%!?] C 53)]!A,BBCV'G=[*].-=9^""
MD>OBYWB$G9NICT"JS=-@OPC>%VNR#P_V.\48RJ4VA'YE%#4FP@\!RVF@W :0
M16I[M]BY'%$_GR\"#^N8KJZO8$Q(I/K.=]P+\'F"N;L*/FUI&052L.(:B:GR
M(*@P1B\((ISW8G4N>6_# &@_8*-*ZL!MV%/)% OVJ<@"CR_4;I#<$?0UQWW$
MP& G'5ZY"@.?7G=R\]@NE1&S0' ?/;P][EK816*B=;0O/4J9NL\Z;:QIC=PU
M(;_"X=YOVV;8;'V-0*$O3@+,*#$O\"2FBOPS"$%9!3;U_/=Z(U@1_QD( FRC
M@M<",1X=;N:Z8&2QGVHFQI4B (\[?(DPR*>"&0'CMU7,7%[7 ZB.M8._E_02
M:&!L\W8'%OO0:YW3/J_A%X(:6W1;:NZ[%K4!HUP[5%95)"_ZDJ,NDKT50J+X
MQ4?$(NA?^BG.^"N:#>PVB_>SY1$R]275=T5CAID9$"%'*#\=-T_KHBIU39<'
M>PNJ[0+MNAMV.!=@"8T6!.=FAZ;X$BR8@GF0L2\20\5IQ1$^JO!]-'O8-;."
MPS!51K_JM,5ZD1$]T3S 7>*U_#[T468;$L]/\+9!$.#F/3LL/U^^OHQH.#:N
M9M0ZO:J9HL5NP,*E=V1<!%E"<Z[N^6P"K; I!=O.IVJYQSF13?;%EX^^U_?D
M<T\&^-EJV]=E+8J$"C44;B[R3VN QQ0JMZ5S:#,5Y4I[9%R#%P+"U7$="&R/
MJG*^QDEV=X[)WT V"S>EL_[O"%]_\NC)XVS&V'L][+&, >X_@!1M727E(V]@
M?T;Z69\(Y_$V+]!RKT#_@C_0XVF,NZ4)%X67@EG8E9W?3BNLG4*;IQEZGZMF
M'/=0D:55BZ=3PP'>#[QQ1-WZE[I:K9H6'XH[2O4'O 8I<2SEX ,!_H4P."T!
MPS,?)H3\[:&FD/ABVV"OLW(\#XCO[<@\TLJ44H/O5.%A; DU(E"\=T.UR<4$
MP6%]#R9;/2(6X".L! TJ3<F7 \P.K&R&80LPP$JV(UEIB)6$IR*;8WO'MP'%
M<HW%(P><-#(BL68$L>&C(AI3X1)90+X>AT//2S8K+T+?7>)&H+,4_LK,T4S%
M9"#Y))K<9GUT!.LK?;9;_07M&;\2QJ8*VQNQ&PT>L.SI-GL4G-FBILXK#I3S
M6]B74NDU<Y)^/Q38W>^:'1'8*:1CGCQZ#+N?0QD^75%O/%B<;!7AI"65<OW\
MM08%;52@)2%\\A>D_@=Q[?!D/< ^TI+!6Z:MQ&/";T%X]A?XCJ +./P&SE,'
MS@!>:F<HAX<5_H&$98'7'WIM2LS[VVQOM;>>//KB<>9K-V ZT),1"RI?]&ZW
M;UI$R'5#MQ?;JL0)PV>Y0D[7&S"!FJ%;7+_XY[.G%X^_Q;J2TJVCW40VZ7.P
M">%QH$\?^1$\SUMX^2_XXR>91O],X5ZLOKF2#?40.G?U):PWCD$5E7DF+RH>
MRF05*&VP->7\,M$LW>";TD ?_X5G_\D3BE7N\;]?_L7;P"4.Q"PA*UCT;7%M
M.A!W/CS *,!;XBIF8'(Y=$-AC"^6^8Y#E"2U<.\JOV49W8%J0,?U3?X.Q@;O
M]8JG,LCBD\4#NO+-JZN'(CKSTLG&=S'SLA3P8%O1RZ:U!$TA?[G+-Y3M,UWJ
MCA7W9Q+]4 O>B"&.W7"_XQ8HF\+'P8Q9Q08=-[R!_\SO(W%PL(DWVLNX W 9
M0&?^0Y:?BCE\L>!L20O>B,I%8;N7-6^O_4!''0*_2<-07_4F90@_W0SAURE#
MF#*$GXHT2KR#XS&@FBN*YXB-CYW%07\-<7VC0,PC_6MT#[H3<.!277,X$:TJ
M%:.?LX\F *RETV \M9+6O%?QL19MS]?::6RRXCMR1:!2R/AHSK2B4[UEOOU8
M#\_21TQCCM:>H "55OVS&2ZAK7O:U_RHJ=<P5[!_B\O I^M<4&826Z<U0(M_
MQP7.L!S6:I+0G@8L<!Y[BJ4XK+"6!=!1<[NF^2)_XXG,&K^AUCWY%AJTI3!!
MQVX$ZVR'9E@DK=VJ!>^Y9IX:CLS?2!0)1E,S@4(H8(T#9&!;]<I%$NJO.55@
M-HF:_3@8]@^=I([8,HNMWK+&/&,9(K/!_5'F"A4G2D&(/ 5I*9S8FUC&.F<N
M+JG9,"6>P-NN.Z3LJU<',;Q(9T@P"@VKFY(;G7N2_6Y;[F%2^UMVSSAJQ1D&
M$QGSC=-]S):W#FUO8P7*]R/=LW/]MBF4:D@#PP;6$7ET;, _RA8__?2:PT#@
MEY5=-\ DJ,?"J3'/4L3!=V8JY"A#-%>2AW+6W^/D\XEX*4U@!29]MX?KT19E
MIXFCR!E&B^'9+7JX;.GZ2>2;'GQQ(@>MVVXRK1R\-K,L@U2P6T2X,1,0O2,P
M;#4;3Q6K)OO,"WD[YYM88W*Z[#@KYA6ER?T=>STBAMBQW1YKV._!LX+QC=^M
MRF7%-)1WDU<#6''D@^P'\"XY(FTG.9L1S=&->9Y&@>++Q7-4ZR!?Z+)U U6*
M^JC$DCQ:# UC,*TGP=.P'MY2I6X4:V0AM =$,;0:]'O3#KO]* PV@VZ8C9;A
M.^(8:(3$72->F7^6/TGVP[(JNRW&,F@T&(LOV6ZA;# /M9/Q7("B\:?O9WN8
M_.QWDG?;7\&T@2?Y$O>[=]DQ>!QHS#0HP &/+S/C)A.K3;['T_K4W@P9+<ZS
M666#Y.CHWI/^GZ3(O''HT(*L<PJ#_2#_]A IY,R 45@4VIT*#JZEHX,H>OSH
M,(:L^1EOJ6*>BSC=1P?AO!&GP=ZQ ?/CT*)*)C7_]Z$ZF"#][%X /<%1B1S9
MBMQJ$$ZY N]!"/Y'W\'\[AK:_-?*11LL*[_&/X"IV.P.&?WH\7<</-NI6C!I
MT!SDCHP]DQ9;F1LSNFF:]'J&HR5]*HB[LIL.&?=U>"<:<.NV$GXF^</;7Q4%
MV1#PY)\0M$?2]))M$Y*>9NA1FHG3 PSA?14?K'R,R_G,)K>R\]CPHS?$Z9YJ
MN2B-%IS?@S!'W0A8"35)>.((5>%_CX(HV T<AC5G\$'DN.SAF$&WQ4B/Q?X%
M\1&+C 1O/.>!!^#@-;X] 4?^EI\<YZ-=#&GSCU-M.6;.,Z;\7!J$+MF0V34]
M%$[E1>!_@P:Y)KL5%/  5QZ0NB5'PJ"*,)42,86M,]1OZ^:V]J\0G0UK!DQ*
MGE_L,!FO!_!/?#7V/81!#<=&=M+2T4$\)O04HB<XE/LI()8\TBD?X!PJ*[BQ
M]TKP&*^--*]D&7Y-3N?>7N=G>UA>]?Z@$T<WLQ&1KO>,M$%;(N(R9^TU7C<O
MI6,#U?@YBB@;[P?\O2+2. 0>>S=AWQO,#2QWWRH&KPG4D)9-JAO3%]/.P9M4
M#6X8X3DRSE5 446NBZ4F,C-CE2$F4E'9>0]5W4">8:.BH@>RS*N-BS:LK:'!
M[!)8[*C?*\/7B0(<V/9 EN$($H4&&P)C4PQ_W6!& '-W'A/"1C1%B63E\8D-
MWN46C>8-(>_#WI8%'L'SY@@7"0M2'Z;0_C>D>+V*TN(@#T0JW$[8^D:\L^,H
MV#3L%L 8KA,%6%,6?#=0_HX@A_/QMI%V^DR5P#]LRC+6OB'F&?PI0C5A/I1B
MJ&!E=/V%%X#(J95,/^U00R2^9X/.YPUO&'U#AE>L$X+\A.@?H6A;9"IS=,C9
M .Q,=MK;UKP128;TI]J_V&BJ;+$9X.!B@C2"(K<@5[V-("[UYGHS"1P&*X-V
ME@Y [.LIF/5.YLGZD D2=&2*A62>#XF)&4)P*&^IA1;-G@S-+Y2"YO$!,=R5
MZ539"B8[(>79/M7,QM??I#Q;RK-]*M(X57&9[?FL44:V2B@N@4<#*$D.+4=-
MZ1?3HZ5W 0#/_HT];#[;T_O/1&2-I31TP7SA32LV;052T+0"$?EH;-='A_,^
M%-A'G.)[T6+[/"&975H:]KZ\V![(1B:W^,%PS$NZX)YN\ ?BK#BC9@TA4$-K
M5#=V'4.]D6'9%4*[&^?):YD4@_IV^7X&C.OR];H'8P0'_O>P$T IYI0DF'W\
M*M^S&$B2GPXV!K?E8",ZA=D1T+!L"X:],P9;RZCP9O?NBC#?R<3'E/3WLPUB
M/F,%/I$E6K[,K"E&?U'?ELN!,<YV97^K8+T)%?"&K%N8\KU3/T:4T!>*DEV@
MEX2)\IE^41(W+W6\+"94CL'G18&1IV:/%>(S/[=[*-9F2Q=B?QS&P8HJ7R2<
ML0[O.Q!='^!>#W4 !1NB$Q5]K724@\^+] H.4P[]+X<2-2F\_FH@)VQFS&6]
M;G-8KH'2,=I9)%.^=E-9(K\.?C#MQNG) Y.=^:S?B5@KG@Y;1Z]PB'I)?7P+
MB7$>%(XNN[=X:-\TU8V2%%#MKE=GM/#PELWMO$Q-Y)]4&T\]:C>;NY_7;[!#
M*('"8M&Y]@93$:.87^O PRZ]5@5[AX-?*JEPAQ7%[4_)H12KH\2R<XV[*5B\
M()!;4NY<)N+W'W]SI.9UO/EHF*-AT;3,G _1W)6=3T*CCFG@(]3>#3:"\%L?
MPPVT^9SL/-(V6%]"MF5U8/-,N5M+CE.B5BM\U? XGJA5C1@<+'W'%Z[I9R0
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MXDB9]Z"T07P$+_E8D:7G( ;XHMG8=Q773T_KVRVZNQXR$M1@'!H5/S@^Z@)
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M#%'::M''NYE:T122W^E-T!SO51?<M =E99'[]P@ZB74;!XO6>!I)[T>.!]F
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M>L2>UHU^.YISHNX 1R)$D>*YOJK -1DVV\E7&*BJRJX/# W_FW=%_N_%WQ@
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M)ZVD I(*2"K@7%0 >BTA[@C_(.9CI%+6/N3V,\QQ$J(Z:86D%9)6.%^M@$Y
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M%$&WY3?\$C.9<C0R-WE;5";6+C"]V0&.U?^'D8)H?SZYO\S)/J5M.A&5J5+
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M$'<"0:4F';(N'XTC'I#3)TP"2:+S9&*L-FV:W5%I%!IKL!%9J;KT@%(!PBE
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M,P/U7GS6PAW ?YMIB<DTR68"!KV<V^'Q9NM#3N$F\Y'\(E*1*[&ZB":PCK+
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M_MSI\)<<C[KRADMA-@F6HT#M,AO"W/'I=S!^>#ELS!!/LMJ889GR(N/X4IQ
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MG-JJF_@:.CQ?CU:_V-(G33[/0B+ IW?VSYN82+VI\(W(8*\;9=ET[<@8C.X
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M+0NF 2RGP0@5VEVXJ':(3U8.D;NQ2&M1!GX=.1D&0F#$-Q3Q+9JE>?5A[;G
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MK1 _S>*/]@ZK NI56:_*>E7V %39NPZHS JE];M#FW]W<3ZPJ>'8BE$.*(^
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M,N0C)=6VS6O8(]8VOMZX/RT+H9F96%<.[E]" A@S35*1[/3K#WM)\NKT_&0
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M*K\10F:AA[:=/&?OWN]BY;J$&X"$9WA:! SW!%4>"\" XR$17DZ+D.]A>';
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M;>3BX&5SL)(1Y=G!,S]R<?SDX$%%+B!)-GZ.19\+\(XH9A0.I5P]$.._7%"
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MSI$++0#*)B=9NRV@4R]H>X.\%R*>NH,\#K>/7-+B\!DK!72$B.)T62"1!(Z
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MS-(K;N5<0#-#O"$UZG^H)Z)S*Q]-ML#_(@;JY64('*3WFN<<4-A-SD5$LMO
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M[ S]7.X?)%M/GH2SR'#VFEE$&+P3@LY-">(5]TEN/[;*N#DLLYW5*^F]TP^
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MWQB1<1W5)#1E+V]I5(!' 0)L"\GQCK*+O$OI(16&?\]\;"P+@U4<;_SB[A#
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MBOVO2=)7K&SE#G0].2N9.C&765HL+I=1!QS2YS,S4AQ:*QV/VQD,15B":#.
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M?_UU_X1V^BEVDJ,/\]LMK5T%@'2:;T V+%*R%U7T7MJ)S22^"  5$^/R'=R
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MJQ<5&F*;3#U7F1JJJ4T$:Q/!^OP(UN'>]&EOJ\7#@RB"=?#T<QJ[_I  5^V
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M;Q.(O#D0V:L6&%CRT$.4#S@<^36YI91.] &R['U-.G0EH.74F9IT.? M'I7
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M;T"#W@LG^83&KLN*ZV&9(3FH80;I/G(:11:,)E!HK,E\]+;K7(B)TGFML#-
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M\UGP9>553K,O#3VLQZM?)5D(GV7G3FF@BR^LJ9<DL/C%;2$"N)J=E,ML_$%
MGT$_&ACJ%>?H@X34UYR) (7HQ)+TB9&N)OT;F<-7[7A,8A,HWCME.%')\N?R
M<3]N.,0'PY+7@9_. ;>02)KV&R(G[[WG_Z,'3,R:XLBJL9!'XJW(A.]C1A[Q
ME>AT8]BD Y+R(?8V4\C;'>"V?[EWQ?[#I!=_9\M1[)CF4Y*,]S#&V,Y;LPVE
M90BK7(U'01"G4P#9<;+15V12<,^@ J43WLSF_I]77*:E&&@)HC#P>Y0%'<_&
MEZCG*B\TCJ0A%Z688@!<J7+E;L1^8U$9RZ1X14-O!B.Y3K]R$ J:$:&EZI]
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M6XA^U@G<MU_#4T;-5YST4U2<]7"U[/O$#=EOOQD$"X@VI*=X44E%+9\\'.1
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MT_U'3_ZFFZ!J%Y?)T;3NN1^N_7F/'OIH>S?Q2])9$="ECK*L3*YHEB;L0^"
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M3A@@LM!R9ZYI!LR%_KLJ&_&W,W@^>X;7W"^G0Y./U^E3.FM7^:*NPLF7;_B
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M,D5?GK#S&T$@O)6 %V*^/SCVP =,@CE!^#M6*Q<U%*+%"3708$WL(O<C3LR
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M4"-)&K;""=M5!1JUJ,Q!G$7IU-HUN&E3CKHIWLQIC(293O6IP94BE^+R*Z\
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MF0,[*MPB,^NF2&CF=)I,AZ!0V-*S+J.\XMYTHA-F::*;Z;2SB34E5+?A&F7
M!2;L(4$40+Y%<]Q8U\J8\B0X5P81.Z<H^7_7CD-E@/-7H>DZU!(&&&['(!2!
M3-88ADIKS6!M,40B4E; 6Z.U"S90R,M$8Z:JU[9AT(@W?5V0L@X<%08O$!;G
M1WKHHY*SQY330[G06M1N?#P>;++^;G6J.&%I>ZRD;15LG!Q7FZL(@#*%HOHT
MGR;7?H<JX4NC(KZ([>@ ^8)Q@+;+)8$ODF^)9 %C0XI+:U%,R<$H6#%'J\1
M#L.::$DP9T52^U 9@L[Y+25*:A_C>[(QOH,='^-;'>/KE-!<8?K$HW\/TSWH
M$=/'.N5LAAC0X@PTWN!4LD4O"T[Q)[''OC!E,F#4!M,68,(@!VLMTW6!0PWG
M>IIQ:$>]=4OL1ELRAVB0@A@=SRU,W"U.#]1>'G[M")O:A5RD=Z6X<=7,,+VV
M6B+DN0HRALFH%HF@T[,8C["KR!Q+Q&)>=I)')"G:*HWE,#WY/?A8,!O<WST
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M-^U3,8()<3FM?2BT,CMD$=F))O6RE=*+]D6VF$8H-<BJ8HP#S=2'1D!/K'Y
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MV=UA_)<D>FLE@20/6+/W*<(CDR.LR4<&!,:>J(ZZ%4V-/<HH DH"<=R4N;@
M+-DFOY'Z&)31I/Q7R16+"=.7H+Z!CK8"8A6@KR*J$FA"+]WJE3HE1*DJ8 ^P
MB=2TF5(.7;S0.@O=):A-+==&.#[:V]_N_962I$4W=MKVD<X4; RHF R6V]^5
M7\,GHD6/3"&0O!I6%*L #>Z&^+OPY!G]HE)>+LD<Q>?14+3Z3HC%RC#1I,YD
MJ-<X/]LDB5]@V5I1<CHU+@)_0D:V6;XN$S/PCG9W*FY48< !NJA/?27F&G*
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M4#[52VG&^'*E3/^19'$TNH?B?-B!PST1^L'&L"CKY+_%-!V21Y@3F.98JY:
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M,(OJ'>[Z7@TOJ%?#O1U'B4V+Y^+6YVS)>,"D0")V=!]=8,BOVFSYV*V]H;\
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MC4(EAC8+A4L;Y$6&9Q&DATJOPK%1[-A]FA27,T^AQ4S#PWY[WGD455ZI,&4
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MC*QL1 J'5.@B$9K0D]?:>G1NLHZ#E8\ ;%:Y%QSZ)Z='_M%Q.X QE9H.! I
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MF>0>1^[+T"LV6]U*RYV@RF;FV0VLK\95Q"2*QY@2F9$,;)D$K>),F"SX[<B
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M,L4LOWX@;+S0GGU[]A=_]F]CKU=Y\BAV/^*X'E[9U'977M(9  ,6[UHL_($
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M\&U/MUAAY@#J\N>%YJUL2#[E!^7GTT?HFCP>(X&E>";ADD.@CD$<T?4%MJE
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MB@U'(1X5C(Y"MT)$'>G"'0J3JMMQ5A5"%D)0X-?)T52;I;=9>INE7YG*N87
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M4EMJI%Z407AJHS5O;>99(:26$.2%_**S(^6%P'4A5.Y6!;5U:'SNJ#8TX.,
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M0!$Q"'X*<O*!8IK/>5!1O@6S0=KJ&-Q_Q1 N?\GTU+WH,7ST8N!1EA/-H.=
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MOR&Z UC3@:[X]*49 J7K"#G#@B]P8$4L/QW% 0'(68&#ON2&?P"@59I2U>Y
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M6^[!X>([;&\8B;[FF%_+59G_!"UO0<S8_%3GC3[!OAO%\$M_*WAO]MIBU42
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M"U86;/W+1N_/9DS2RH*5!2L+5A:L+%A9L+)@9<'*@I6%5]?"R/\!_%;AA?Y
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MV#+WARO'@T] HT,XT#"^D]@4JY'R&/R D1WL_<0K%8G;C2+4(A#FV2V;TK9
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MQ$>@E\)E'+ME1YX.#Q_9USZQE3L1#2TAX\0#*W)'%N\=0"0L&I;#<M0DUX5
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M*@>\%8I43X4Q/J,-2V8PD[JG<L%@J",>:N2"V@/ZYG2F)$: KHS$EPDKCO$
MZI(T3,E,/59Z9/T"\JG+=(,QZ"HC3"5X%/2P/K=FO\MYX56Z=O%5-J&BVI&,
M$S;BS9W&]7.1?*J8C2,P]PLTJF_YO5"\#&T%'8EUI]("&6@TFD3*P(JA46B,
ME82:^L"DSZ^8F"$-K!$51IE/" #VM"Y6,!8F/MXROLRGT!Q[$"ZC4T8; 5)V
MH-Q*,ZON '5#NL]":6!-K3:4>%:6<;TCMMN/#6'9(\VT[JAHKS%H6,80+0FP
M!C3X# W;#>&@8*X=&7(I/R8NE*E@ZS,A#K;C.LDV\O9W3?Z4)*41&K%CV+ ;
M(K.A,#@J@O5(GIJ1Y,1XCY$E(W,&[ $KT&&!R9B<%L>Q;-D])@^[0VF47!4L
M^]7-W7)LB:1#?@2P Z(58ZS_%T[SI*6N#:Q2G<+>L$= US2!L$*?HK*MF%/6
M5%@UH4:Z+. :@,O+C8F]$.+42A!13R/!F5_ZPI5/94\QB)$P2V&?'>M'*W2#
MA (7XR",LCA,]I05O60XB)^K)ZJ9LTW$GO_ 7%[BA;-W*:(6"SI&] TP(B]!
MUBF3#(&W)%%,(:V6-\5GB'_)4$PG";.('N"CTGW*(7\:&6( )<4CD*$<MU\X
MLN4!F,C>HXA]=Q$/S%3#L9#$-SWW)P80TI@(DI0GY/)U"]'\D:PLF>$F31F5
MKL$T^-0:([O^-_D (S081VZ4>0 CS ].G0(BQZJ>XV7[!&__ P'RA:-7<:2-
M!:@M#4@\Z1TW?K<%NAUBQ_B'8E!9^-"U5GBF0IK>ZWO;TI.<=T4I6&E^I[E5
M(<S9%M.E2I,YTXS+S'7C4F$.K""EW$>/V%C4S"N-DM!"Y;)Z=5+PU.H):<S/
M2=3=Z&*9*6 G1W@/2F9=*?=:"@(4NT*$;:B\CEN1YM,IY'VI06V<,<"H+&ZQ
M?W=IG'?;9HE7ZK5XPA=]R0BSJZSW94XL>"L7CX&4_!<IMQBNGT& XEZ #MUH
MA I7[CI5VCY7$BN/&I( =/)V#Q5 +\.>* T-:S+H;3JM09#$\W#!YT<M.UM)
M2&YGO /1/2JOQ%"H%?%]2H81SN;/PJG,-(R(Y5@6$M.XFH*LFRY]SK;9I%78
MM?+!:QIK%H?%<P=^*C<- \\+GF1Y!X',(A8/ 1K*?EM6L6M#IS+OE8&S_VK,
M7+,]=8B;=]]_FJ=>#*;21I'X::D[7(=PE'&- ^>PPI.2F_EH$\MDMEZTP,V+
MI%HIN7&?T=%=&1W2'LG&'1*4=:S.0Y$#I\Q&<P2BP\\^#3!O"U&'.AT-;%,W
M(XYUS@\VU.RG<\[K+/[AG=E1EA$$97GY^9'04NC)V.=TH987!5ID-@;9*?:C
MA?.IPB2X JHL$C@" P<IQH[SSC*5B1<S=87GH/WK44$1IT.N$X1A,)!E]@<Z
M!%44BF/%5D/1[WLK4+3$9$JEB:^!4Q;CG(%X#LPRNIH3%N1PH"D''N)-C[:G
M6*MD\$\IT?TS<1[X:N?+9&P! <'@EF;20QJ-IW(;HO70,G-&#R0_K2@D,TD5
M<VRE!96EQL]T[WEI"42@_,!V:5,<G68\N%CH2BFQ2TBHZM$ZLWE[!Q6_<]'$
M[S2%;_8KMJ.)D&DB9+81(3,;_+)&I$SWS<HQ.#/VT$V:9"IW!=U+_XTTX^?R
M6US-R<JR,*L%>6&,K/N:/ :/Y.0SJ>*S.&8N4_<C+3L++?U* &M19ER(GA!O
MJD;!Z&Q\73V4%O2>Z33AYAU1>6<9#(,"?<RREVZJE#: ?[.W6Y=:83VE]LW4
M^.GAP\7 C1E3CIOW8QM>\(0+X9=EJ4,"N"S]D!=69S.B-*--2=[/Z@42X,9%
M?LR.GF]N]/.2W$?X5U5"Q_;%OY #-4D[[*E#6%?)L?"IU)I/9#D)D'MPB0_Q
M:X+JM7[XN$9PMDDN_2_]D;C++.WEF<Z!N46DBP50.7,D6J$F=3&% AV,3P&Y
M!G#A8EZF#=DVI'^!@,,N?%7PAU)[V$1+?MQB2E!IDA][/J5:BN!,_"3"R \=
MB ,Q#:2#DBDW]VM1C2SD#G%C"8_1,W(GA66Q4YGV)I.G6,TN!FY(]"FM.$0G
M+66[RHZ#(.C[3EK9;*:@$::H2,,Q;))U8'Q+<M&->R,"7QPYUE0%88TH=9(
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M QOI7M N.67E@[N&DIC4-)3P*+W0P@KQMVCAK'WM7*>BF$K*T8\SV=Y YE"
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M+@"$4/Q\2<O $_6BDS1//#V"#>!I>H*51\)_\X<?S#(:2ZV'R%<"1E*H8B0
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M7C<B:RX&FYBK59U0&BZ$@EX38+77 5;M)L"JEM$O38!5$V#51.LT 58-RIH
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M$^[/C:?'S!VEF6<BF>0AW@H[N@EZQS7M#M&(93M-ZNV/ =*Q$6*07230VOZ
M/F4!G^I7OG9)WN?R\WDM=W[MVU[B".?:5[_L2IO:?,I&D^A9/^GF$/;82' U
MN2AN^68P'BTOH> +7\25$.A>UYPMP?(/A,K-\*N("[_O2M![E;HLS8U1M8R:
M@]ADDS94&K";#Z+(0BU EZ)8\%6RAG2&IZ4CO(B+K9-:TUN6*;0P\@1^XN#7
M+>SR!\7,2]?E9]<:N)X;N_E2V7K0_>? YF2E%0JLK@.ASA((<=PO*RX8 !S@
MLE6P"!S4=.&K9%T]'U!? ]]^=5C-UC]:!59>X#\<4;2Z!BT.VW;'$\_E>&O2
M$ T*TDXB#@$/A9/8'*5=+AA1ED=.CL(5E*. PM:N>3ZED'Z#V;[#9/?!-YH*
MEB3%#<)0&LH62*GD68E^$Q!R=(AG0LA1=YGCH233[Z_SX\[WGR6KA("QY6A4
M0$'],M\/26(>XR9>M^2$?A-JV)OAE1A@'L]JAW;;69_MUJSI<>VLSY?O;JTD
MT-/5=S>SMX59GVLD>Q[,^5!,+4UJ!@8,./0YJC?+?)%GB.J+G[V/"ET2C2<8
M!/@RH I$/OAZ=3249-GJD<;ET<1:]3@TF4; <U'TQ)1DVPX3X6C7W882;)O<
MV=EI+UJ&A+>A ;PLPGT1$N_L$=RC'BCNL\BK<#QX]<ZRPH4N7@+ (A>.M\R
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MVZ2_5C5QLTE_;=)?GY?^6EXIB,N3@3AS,_PF'!!"D"L 1R#7$OQY&\IZ)G?
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MP,FN5OA9HI54V-TZ', ?:;[R#E. ^8K^33;[7.J<G6TG.J><YGK/GTS'))2
M=^'+@,U)S@S12)RZ7,68,V$N[[\UVUQIVJ?,H%Q0X@HU>U.H@_<"KI H8"%$
MY1V8]U.VAC:V,V2SV8%4,>L&EGD+JTR+)MF#NR:3T+76?)T.HF:^B;A]M=1,
M'*6U>=>\JKC,FV!+V#=F?9YR:\+IJ9"N#.94P!O)QBX:0)M,7.>##@7K\S"B
M'&8-1Z*;@;]VE8^L&8GLU>J0U3F)Y00%J;"HR]VA=,#ZA-OKIM^2<+7*O+Y,
M$$[N^W#?B[Z;V \3\;W!3_P+D@;$99'$8#M<>$V:8(7(=2S+T1'JI=_]]?A
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M$F0[T<_X[9[A,)[@#V"2W]&QV#=@/PV$[ GI' 8HDE+Z:$%(G\[L\9&:SKI
M,X9**RWQ>,'-UBII2=Q2Q5*74:OA7QO=%PE5Y?N::8M4:P\K#9G>B$WK$"3O
MTJ?WNT>4DOA.B-V!K J7")W%W"V_])8C_H28C]EC>%=LK>%CYEYA?!+W1O#;
MY($VB !;Z*^.W\[SLR6ZWE1#VT;4!9E:0XFJ$=%A1[:<0*F<?;'GI8E3&#.
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M]3XA;:.F-AHMM7;=+BBJ+3IG$UAUKR[\*[5Q65.KU?EBRQ(T'A D-.  -9P
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M=6TAN;='K=M0VU<%#2R7ZC2[5)URING,[<4HK2.Q#Q>D>&2E0!MJO=:6"O0
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MV?8=7:<2Y\"(3\1=)?*?B94]\H4=-E>KIK8+F4*?"X9DXEU3&[+HTLFJ.#<
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MEX0,$P=DU8^#I1=\TRSJ^J5Y6.3WN^;J(\[C1@W(7*W7#I-W<("TH-3>P?W
M]WS--H!6,W$3':]OS_4*[N2N5_ N5?":ZF6MH=9;Q:N$]^7WGPXG*5W-=3]!
M0'AKZ8[ON^8@\%$&7IQ'H/Y<N^F"B,[V*6GUMMJ^OBR@U!1"R7S+G:3LHF3:
MZG6KJ3;;Q6L<4D EDS_1V5[)M)MJXZIX:?4%43+=W$G*;O5\KUM5M5V32.8
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MTP\=NW=]I3;JF=XR%A4\YH/M6=TKU]1JLRDOE^4AL"I);EVEKRH#!HNQT0F
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M+F-\I]_S30Y+VSNF@N/D@N8EH)0>Q?/RF@7<ZL%R!!09]\KQM8:I2BB?5DQ
M^._HBV*E0!I'-XE_I'[B6NV(^O983OEY2..I,?D486M</@FJ_Y?+B49!.P1^
M<2@4('.!=KN-!(XEGC!5>9AE!FK?I\&3VB5]EY.4:JYE4D@[_W/:FP0V\3
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M6J9TOV>[I56[157EA:_CEO?3<'B8DX<S4M]^G4,%<_*WS2@*VSL5A<H+E6,
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MT]Z*;X;:[R7*5BOS:=J@STEUG>&)@KTEO.G&1S\2B(SR&IB+T6L+3OXKA0+
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MNSM:HS: T:>!(="L$)Z@N1MHGI5+';V+ 57@9\!RO-Z< &]_**0XDR(Y "<
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M-GTLZ(8L$+Q?)WC4-V!6'J$BNT]5?C4\@K+EN[PE*9G9/_QAP"T<=S\ADMT
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M(G/^P21&P!@EF!=]'C['DZXB@A.>4\@."\$H]1L_HJY_V*UE.*]0Y\R,(!%
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MG3/:[:XGHQ=W[, +A_70VS=XG<5\HE?:Y+,-7C<F0I:^;"@N5/-DX 6'UBV
M\X$#QT(MIRNR&2JT\H\R"RU$%R=U";Z,TAMZZ]<38": ?5]RO9F\=K0D5LJ+
M>U,@'E"I?0 ,AY9+D*MIV-$R+[S&+F8WJ/>0H,MG@H? 9"_O7J7L=$A=J%<B
MUMPU#5@?DW:?7M-%@%U^ "M<F6,LTX-,"#66V4?PH_9%2L5UPC+D?, M8QZ*
MB.;IRW6=)C-0!*80"YF\<WEGZ278CWM4R8>IGZ"1Y^I).)Z8V2F A@Q+X'8K
M'I5VRA8Z8Y;60(5F+I_,YCKL6X8O$BEM %YNA%T2=2 ?8G)I> IUVB)P,O*@
M9.QZ\, @\MP9<-5<QED[/1)PR;A6NDJ'<K 3)YB3*<LLP>6T.0(<=L%RKNF[
M%\\^[-P9?E1![$XH5[)J]@!EJQV>,>I.;)%&KF\I\) A/W?V8=1DVUD:94$;
M: QS:)0"O6]7T3K)YV)QO$158'U5#TRX00^ZG5,YQB@$<IAJ9TZYE& U*T3P
M(_'!^M4]^K?^2/5ROBX2%N!7:D<Y= B</*Y3Q+6[6#WG\Q<WHW-8G$EZ<OPD
MXQS7-:N6=4'(;V[YSE6C!\M!2Y247E7 -3M)2)]5=^=X>_("54^63J5PB%+9
MD84+,8"7_85>6]R*BI7(H^/1MJMD](!I\YF46O6/AUR#)XP.1,&EJU\%IUN-
MX69DPR7WG7Y_3D%)+-U@0_D7M$Q,10*WK->62Z8^9!(G2A'?D-I-64X,66Q0
M\ ':VW4NCN&&N6/!ZW"N2SS^8%ZP+NS- QQB<^1:LB^<R_+<L_1T[_FY9<1]
M6,]>;M@G_KH'T$;H@6[M'Z#=!J=U=$-C#W"U*4I9K]NZH8CJ12$1YN@=NQAS
ML'B3:],W1=8-Q;ISY@X<V$5LE<%/CLZ-(N\7ZF!3#QFF)M=<:#J NR693Q>*
MN2L*=U[Q6I8<KFO,FI$&9(D#0H5945G,$LHZ>,OU[P:6M?K($O8"5T)9RCGQ
M"*.VQMBVS9HB/I]1.A<'&X<35^'S> S'0Q<@T[X?A;Z[YZ6QKZ\H/A>T>$_9
MS$W/-(Q+N-TK;+/JIRT->Y@-(F8[>5[O_M4P!1[M*["=[D"^NY$ZEEX0$KZE
M$#/6[&PZ@!OKURUJG>/DF@U;^%T]:#R)6Z; ;; \?\3EVKGNMS6A%!">7($S
M:(65R9+R(84 7<2=)30O;N^J2H_RD'8[IL$JW"G*E2,.N)E(6'BA $.1&)W=
M-_[PC6^!VJ:*M\S(0<5\ VL4=+3!TX55I,%6MR0$10]80)0CGS#BTA17UZ&%
M.UVE>D,+5K'@%H0] CV#Q +KA'3LXR,V7.O9QQCA* 1FR_6MAD6;X^+\LWE)
M:<GU(&U,R-:)FHIS'';%$U-C(\#BB/-,F- CC#HA!>,@#Z>>TY4INV.*AO!(
M<E^R8]=;96]CJ"<:<K8DU905.7]*":>M.ZVB[3;F0&S%9PSSTG'AO<=:SA7!
M8,4+ G9BAFHXB36*:1W0^MPNY 'QT/,Z5V;1*@3@7LK>E H#E?;!0=)$*4\D
M$*J-FB2]8@!-\%%90L[7R7-$=R=TPS&#*B+>+4H4+"%F:5(+U$,(B] $Q?O&
MT.XB7AA;5LUL5G% $U)LZCA#VT.W@>2Z8^37I2H/9TR8G<4.A@HC"TU5K-).
M7@ FTHH6GP"3(353#22LN5NC"M5WY!3" UCHV 9_[AZ#]J:)E8)_??U(';W,
MRDS&RY:!;)D<44J;![#6>X,"_15)W7LUNJANPAA?B$%D078*'0^%;%N2;V+0
MC)Y;Q<@G#]6#R^WA8"=J7BKK= ]+EJ6,75E@\O$DA ZQX>W"W Y9UR+5=U,[
MS2B'Y#LEMS9,<JB9;IXEYF[=$-M.BTF*'Y5V5QYF132CQ!."[@(KG2SG^GHT
M-7>6IPX&ZHL[JJF)%GFP+R8?-@!Q#&7[LM\2MZ@,HQ$F\+[FT_ X+*]+IBK:
MHG$,Q+.4@NCH9?6V*CHSFIKTR- DZ 6M*-;M@;D$DM-O0*-;[MBDDWJ@@<,>
M;X"S8N!0X"7(HT0P(^SL!\Z1YTNVY\&3VJ4UY-.\:].E&)GC)?)#SBGB;?TS
MB27%TA#+[+64F1T$23YRZF9>\(X^X!O7!YQS*V.XD,X:']LR/TRKN0\$8,/@
MM_*J&JIBK$=[%]#TYN(H/<WBT 4CJA3-^Q"LIC(=3LMY#S;4:8[#X;%2.#P;
M^[EFQELKQZNM-5&VFX:5]CT>(35O3(76#)+D<I7B .VOJ1=V*"B9C:!27)RQ
ML8<;9XGG9]O7]-?8QCN8LJG"&YX1U(-[<39P>.V!+?B#W-78  V6Q=TP-M7B
MC]B6+;-\WYZ4DVP;R@V\M58!:MZ))3EW.3_>"&(9:KE;'9)#I[O0.1#;*ZLB
MXP"<%1>]RKMJ5$X!D\[4G4V7,WY;,V#1S%':HVKF;ZK K6W=Q,5D#P\H$LL#
M[:YS5]YW3@U )W[M[DU@ RO58#[';W#RZ!]CCR&6A.\':*KV(%$?^2'<(L40
M1J=]99IMM0<:@5(?42\S;(>_M9B<D21[!$\6=7N#P4[:G9ZD*X(WWC#V_+G?
M_#YCI0V+*I'1;XDQ(VPIKVE5N,:-\?!PL+<MUT9X,#VNRQ&]%-.YZ+S:NI_:
M2SDMD'G(A@,0VIQG+:%N5ELL&M4C=H%"R)&F#8"GB!>D*Z"*<EL^,OK%/536
M[;QC9=TD%6*7(4.VDRYW%J@ERQ;,$N.X/:$.U3JB#'(CH:PV'/T =9N+'Q+
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M3V_GI<<=V3$!>/?X5J;C$\E&<P3278]T!2$E%6$3'M3-"S!$EQS=A>T=P0!
M[(#KAG/$#:<8&KY%>H+>8 N_LSQ(ZQ#(PPX/Y^"U1>9E +$':K,.B\,&!P[]
M[HAT048$.P/IDCG8M19TT7OBW)\(:QMF)F"'T, DV<&)%K*.MJN-G3,]"N.
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M\>LZ#\?<\,M>W T\S/!]0NFTC?KGYH(E/_]D=%35RT#'13&QD. $"E9O4.)
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MY9HB[O/XRGF>=<&;1[(,;]2LVU.Q,*!^>)B"4_S>NR:,(.%]"^;8=,\^ET>
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M"S8P_@<@!5U@ @DI^DO7&@/ZEAV5Q:_,R;'7DR%+CI[!^$_88"16*_RX<#[
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M51M1#Z3WJA+%ZZRFT2U)(BJ*C^EK7+7[VQL4*2JN37M,FYE,\T:OTU9$TX=
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M[;JTXI,W_/8<18NW,2SPB6<*EW3?><U+7,YFM:6^>>FYP<T/]9:X=!]P"';
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M'*I3L@^7B?2)/@8:2YF.23[,'1X#GQ[&4_O?;-W,XEZB808_7<E 0@)J,^@
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MF?H?8.:EH&TF/V>U\+OXZ[\%7>]1N^B($[2I1WXS]2T/LR/'._(O'*?\IS/
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M3F[PTK3$/TP2=&;@2#1J"R*)79H7CA?<W2JCS)I.NF25/U!7KN-,=[*$SZ@
MF7* <\XI.R2!JC"&\FY_'>?[)N^03J#]3A;J@AE^\B5KE5SOK4:G$I>V.7_#
M!)/:B[+]K21B#D=FUAE'*HJ9)"P^+;Y=]5NZ,MM.XULY3H)P; R,]%F:>BE(
MH-BWUZ0#0U]GI;BV7^K8*HKFI$^"M-4+RY\O!]PG:*# BUF/3[Z'(,2=I/2.
MX_HF49&P>.Z\:V9!#IC\%W)&]B6K8E-GF\GY_(W!"WV]EYRF I0<TX*-J=@\
M606CNLX4"14M"9<9=^0B*6 .SXJ60VE];-EQC!1^9;5Z^N\WHQ]8?[P:F+C^
MZ9"P^A^G4Z"R\^"' ]'4!IABCT$BBDKV9G,DE!3/VHS'=!#<HQ6^ ,>'1SS:
M:)O]5FV5QK$YYA,GO/@#7AHLS8[+"?'8C2*81^,CZJ+5^\6"[PM.1K5M/22\
M!X>06)6= 'D %V/*Q/S2?I2BJ);E;IA7ZZJG!L21_N/&A:(/:AKS,C>Q$@[#
M_/U\TX(!)G\8[R )X:+2GHCCH5C/F;35RV^$$T]IDYJ*@BJ^:MAP\_+31;7$
M*AC$Z^2V)9*GTI(&)[)RJ=Z0*G@5HA55 8*M _9?[_'N"DSC4VP,VG/8V7X?
M..8@D=P]>(6F2D-OO&%>LX8Y,#*J]))!)5Z$RW42LO\U7G&X<43$0I+"T.LB
MB2G---V:$\2:P\TBR<^KDI2Q*?8KN2E38,"RJ9S;7=*=2PZ-.@4BMD]#\R/=
M'"MZA$OY&_B6"L&=T8_0K8O=CS0'O-AD*G1?^E^-J(ZYQO^,:IG5N#L^J_2=
M?3:ZQ_Y4N[.''30403M,/Z\]FK=O:N>@R%CB^A#EO1+V4HQ6%Q4<RLX7^#_,
M0$!3@(5[7T(-R*4-D;LDP4B3>UQ][_7L]>QC6+[Q(WZEZ[3R6\Z9>]2R@[]$
MXV*9\@I.+8OZH+=SKBXRVH:#T>"DL[A%73W-("[14 %S_,6Y4G07)S4>WD_1
M&9W0G-OM<0]7=P0ARS2_XSYLGV!1O@<5,&G[/:E/;1C*BE^ZY'?4X>-AYWZ_
M..:Y!\O+L#@H)?L1D/XVGPQ[!J#J&H'AKS-:X[1N^T&8<>Q$X=>V=T\0+5A"
M6X1MAXY&LA7*F9"7TIAD2Q]-:N$\@YB,*ZO4/W?WR<HE_5%'W!*T)T,9RM/3
M1F"2@O=>I,;WXZ$H=(C*>&+6!(=W4.R2R*?#+*<TD#G.8/$-YKOXRHY0&;5'
ML=0+B (@3 <C:DZ8_>G'6@VDQ^1##U9MA/+$ H,F7,/"G^*7"^$:T^OZ\V&K
MO&!7T,"D9F>&RUCXSZ AWA7^)EB:WQ9*V;NX&4SFY-2NL+Q$N("EZWT%$G+D
MUUX@ .T>LTMWT7Q:ZACWJ=KAYH_='C% NY?>9+0?X#%J-CR.\=,'L!X7GZ;D
M?_"82_ (N,CAK*'(-F/QS_8MR\:2-&>92N7Y"6[O5VU7?JVXYC5K*UZ'2+7%
M[?S#^9!WSG2 0;^&NM9=5W:_G/XEN&2,91E%_IZLJY.I^ND]G(:M/^X_RAWL
MEJNH.,&RV37/()L-(_\@)T^/3I/FK>.Z7'L9AB/W(;(HW]3BJ[]N,ZF7<&R=
M0;,YA8LOJG"B/$X%:IFH50,:A5D$>8VD8Y]K%NHVR+ 0QIM2C@?UL>J5Q3$G
MH:/7"$)Y=# *,[3#9&3,ZCJZ.[.1BA]'FPKD:+YC*DT#\6+*,1O>\EN/ V)I
M]-K:H%\$Z+ ?,>H;3X4G!#P31:#LEF_*+=?>2O'-+/'JJ0\-HP4FV N<\1!*
M/"3$IPUHHP"L!X<0P_D+K':X1[V8[M?W+[>"R=8,1;%FO(0&$E(\86X!\3$<
M<Z=JDQSCX+1(/, +EBY>Y__5PIH@C\<$2\;_.R];_ONH]0$&*AL7YJ*O1RQK
M8&N_?WOOPUY:3&AP07Y8EZ" 8&H>"@1K/#KK.1D[[8^%6VS$;?2H^%*I%J"P
MUO^2]4L;;FE;5P9>3-V2\6VH_F@_KFV7(<+!UQZ$OQ^8#1\)+\O=7;7QVWU+
M9NI4H-SA4[E=F5!3US-<$Z]P<MI!@]B6].X?JN[YP*[AS0!\\4:4(<]]LFE^
MUA[R ]^N!4*FK#&F[L*%VDKJ[QPOQ\Z,@]2*W8GY;]%!X%E"I^J:3M\#F+IY
M$%'RPMP?<JZWN"6)F4\Z5<R[RI2&$X#TVOH4M[[KFN:BD3U+W50"7RI0U,Z(
MMG2W9:"^4G]7C-Q7>E3ZYV;*L$&@&1G0%^3=FOAY84L PCL]AL8Q<1P_$QY5
M,+$0#J1F'59LCDN;O\X@)/0-<JL(E$.CD6!%GAI/7S"/<$(7[;AF4-5<JF"@
M)1XFLJ::.6N?.0Z35.[CG3YR2CWCO]1@UNX^UY2J=1@N*]E$O4)>@S!9NZ8;
M(JQ%*7\-I*BV>%B*^'BMO19'$>_\?':JH#DD]3UM:(#PC- %DCY<7/E%?CH9
M@%U\K^V$7]^GJK5=8R&?[#XQ7R.>0*H-HYB25K'SIFF@CQCSZ;%?I)/(:LM0
M[$E1*OK- P]HM[.613!?53EQ$>MX2Y9U?J[1K2=X$]5J.BHPY;MMK16(0!KV
M(O&K#R383,FJ0_-LPX,H-=P1N7CB<58P+54\,]\<_EEIA.KEQ7Y*8(7U-IYL
M:W:9?7*9B;2RL3QN<D\W6M.5*,9 =6U]E4L04ZRL>WG6*1[]QXS:.5H*>()1
MG)GP%CS4 RLOJMBY5]1D2,K)5GNOK'T;1<#&GT6@T_H,UM,9XV454M3TB\==
M806]#(ND$+$0RT=3=UD:S'?9-DTXJ@]]X4$/288<G8H1NM80=,+>@0B)^=>X
M//E#MYNBQL-L_FAU.^W1?JZ%F'.SW;<E$YXUYBAO,G'(MQ-8NP/LM%7$][7N
M4BZ6C62=W$91+E_P&\1E]]8),3^8&J\):(6>SRM'O11Y1Z<L.4P@[4[RU=31
M3=J,4[.TU01V=O_FI7F8H/XB;]TW?4H'4.P!4\ &KNON0;LYDT/CZ->ZO202
MZK:O'>4N';D^LV7*K?8\1MD!/+(]=D#17:[PI+[KY'.7_,T0>.FS1UKB.8C"
M62AGF?='596Y2@;OHW\GGFIL >.JNK1:570U<\2.Q\CU@$*W!L_,\C3&D>%T
MY+.+5M?*'PT/=]XJ'SN\;)2N$1R1B=4261IN9[*[)RM)K!1J=;>PJ5P J\^M
M\F*RH4^A47O!;#N8R8H^:$D"AI'JY<'%I_K6&Q([?!@-BY-+L2I^^48VS_A%
M'8)81CV5>@JM:[?Y>*7 D!LS9?VG7U"$\*E\'R%<S GX?30W3N@+ULS0J1&@
MU=DT'%1H*Q@N^!>46:SV49"OE ^=.4&5AJ='#2=;VBL#YBV"W$]/A:T$J+KK
M!GR=<W.?__$^HG#UO5XY-0_(?EUCK4/M%'Z/9CN4F^G/?S=KEV'+O,AQP)D4
MF"N08ZX!.A9K[EC]%FDI_G5H7MT9\BZP#(T2+CN#2A-%1[]D(@<01&6XF)D+
MM@>Q9471_N )XEO;HF;'R?#:[)JH55">. D^Y^V>"PT0T6#2PU%RV7[-B'%S
MI&564?[2,82WP@G.(F!9SWFG>5?LISA='+OPI1X"FO2I6#HJ%!)W+U;T2H!G
MZN;9$.H1OL#W=SA#5\'\ "B\'/-S^_)3:>;ZPM2HG]+P\A220= 1BL4.A4KN
M1IVD_](PWG[2:EFM QT<M32 V6S=>Y3EAA@,Q%(B!N7QO1J@R(-J'[H,"!]:
M)*0-<C+%R0LN3?#J=5[-,1.N[D^P?8BB:+^#)2M@9]$'T'-N,,Q""=)/K.KV
M,[YIIQ."L*RTU3#9,<08'J&,ZS0#T(M7M;^4^Y=(9<K%CZI?&,1,%7C)C3:C
M0J=G^".^/*;4:03&74VKZM2M4I[\%2U?/#46O %>LO6D5W9E'V:RYL(W)=/*
MT[##XB1-Y"A<:+AIL?2# ("@@<E[*,.L;.U5;>N7F+J#\HUA$MX=&81=JU ;
M-\'M'PMVSJ$^JX9OOT,?GX(.,-R5T28EBT>*!PY\TB_YG5U)B4EHSH/N+]9"
M/WEME!T&9L:<'97$1:2SL(L*Z3,)@&ECOR!<+:LXTM+>T*W&0 2(E#@J06IF
MQN&]C;^!7J[M7P.V0*^W>S[XAFN?HJX^T\8D!1VDT40.+Z6Z.S.G$]IH?]FC
MAHK1=;GZ_YP _O%)08R^H>+K>TE'@O]"X#J</P>3,OJW[H8 \E#=)!5H/ML@
MYAN7>^IWO[0_6^?>V<:MVJ)NI8;G(-GTN']WQQB.MH'BHN2'$JP1AOP#K,M
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M RSQJV5X-?)L1GK>"=>3B^BM96('X?([=JNC2(>30(35^=B0JAP!.TZM1XU
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M8[!3&3AI,]EZ>*O:I__#C8*:.U:-]XL*""XVS89&E^"-GZ&*&7SL>C:Q7;-
M4,X@?8'H?$[[/K:(IB=TT>6;S%3F&Y'I$HH_^VD3DS)R_]U[4Q1H,JEV9H(1
MN7)TQ64F$"]CS.QA;5HG\[.A2:J<;XW=IM.AA'4S'!".AEEH?;^/3F/KXBMB
M%D$MXNV6PGD )*2;7L@C]5P;(R"7L#Y.;.BLSW7E=4'56A;.AY#+]U[(P-5,
M>+HOM5F#/I"6$7#QEM9>.ZOOR"O!R4E/]'$3V10-V[=Z7:>) 6,&'U>T7-YM
M2P>1JH PR#;F+_S1$B8'9=]\_XF9N4GY0^\*L2(ZMJ/6G[%!%U^>N>MNPB\H
M,DD]6Y'8+.0\R;9@B);RRSTL;.TUV4.BDDT(-K?R18'63"#'AM523,=4##SA
M<\,Z/GEP()8"X^<\U?L9AEL<7]5\,&?<>+J4M@-?V>F&QJ0A$!Z')=A'A]%X
M4"7=:^TU_M: LFFE3K:C+^6K6P9-S(+.$9= G*] ^$AA#, !@T=9V5485K"B
MN6JIU6WU@\KW,+A#G#=K0#T/48/YOG'F\W .1[D$4I";26+!\V!OWH"FRH2F
MT9M<^97'Y\/Q=X7T)&_&5T\>EO/A5,.]W3E&GN,^Z > *66)%Q-/[[T!Z!TI
M@LA]X/@.<+S0X78LZ+3=Z7_7.SQ<JY_YM?#>=H=\*V^/77HG(YY2S)K2N!66
MY_SLTJ TL,,4435JQMN4Q1&$NZP),^SFMZO@OTI*SW*>4"S%\V:1JMSQ.,F9
M'PS:/5/^U/IPHB\E/ZQ!=:5YLR&A.0:L\O-,C_(1(6A?^CY&P=TY^$Q6JE+F
M_'K03?$L6/CPKL(FP,=NKT]%9[&-+ATNM52S^/#TY:)R?6Q5IRT)UTIUQ*G=
MB9B+XTP]9S-$_RZN)=V?B\2J/&![.<F^ZI)QL;&]KD0&V.B1H@'[6<;^(7KM
MJ PM/3(.&$..I<W:F,2PIF(%.^$^$0WP,:V[BRCM#0AN6BC+H'LF7A"X*JVK
MW89_@CFHZAV1@%05YEB:E5G%>'IV.^-46E=["4IA;7.)ESQU%^],OS"U)+N"
M>A->GZ]L?#>KVYK?U0#I>-JD Y6OT'C]2W!E*H\KVBHPL)?4\OK.F:L.1O.E
M7>E0YVX1:QF7UP<3C8+[,=;6:/0(S.9HG'/.BN"2^ZQZNK'-3QT5#,89,K%M
M_.5CZ9,>+\:7J&XP[0GG6SH*]_)(53$ 7I_&.!N.K^\:V,J2L,:UQ]W*1MU(
M!C;?0<TV/F<LF.X1$?*$?W.".;A(4'XV_0<0HWV,<7P>9O=&SX!3B ^*A!!V
MY^*+ W.0,>Y <MLL:5<L:K93\B8XP[2&7SH=ZZB=HP%+3W0#1^QCE;G37T8!
MGACY: CN@^W[1JD'S!(^O/NZ)'"[2V<_EXT'N<B=#V%F5*N=X5AXH<# ) UC
M[[?6/[]NB(M@(B_L=06U&SI4F\I$5(ZX5V .^]6_FMG4$VZ_N\WKV#.1'^S+
MBDLP4]]@V;QZBC?02,&M*(8)/?*6J]47\>XR1SUV GG#1S*&I3T.CU>E*SG)
MI]]Z!*_BX055&*DQ,R$*N<3F*@52CR;V6?TNEDI(M1;U(SH4N,2WH<*-05[R
M-1N(A/0<7].Q!'+I53SH-RIK/LX.B"DWC2V+]Q-F#:</K]U1D\>N5(BL:,MK
MEY660'>A]#:ZS>J$_EBB*A_SD<]=E0<\3NF=:20,/00[% \:HWAPRM2X^MI0
M]09:V.:ZV='"J>?N..56?"DFSTZP,689XFYWC"@AH6MR0O12@L(</+1,OA0]
M FT:AYQSM3#I:BJ0VSC9=,4UQP*],J)<FYXK&O&I+QIC,W]^VKLLW>.UFM;M
MOSIG&[4-+.UZF*"2./D6S\QVCJ0ZC27?:_;OWG6S6,7:UY(8^2V\G%/RC?JA
M@LN=UPJHL:8$GA9W;S&6,(+CVA!VHNW#!YF,_R16G6OG7S@[F2N8+HHPV&\:
M8X^YJ5])Z"?:\OP#:!O&#QFNUN./ I&_-=4 $^.E6Q]>.ZTV5K2P5=<X!_=*
MLUC2;*E@)[@[M.># Q?UAS]TIO!W;L#C>ZJMGI1Q)X0K*M><3D22& [71,VR
MAP;Y$43@XD,X1:WJ;>5SQ. @UPRN</NYSY6>[?1.MY%GD_+DVI<_KBMQ?@YL
M3Y9L>MD%%C$*_"/53V#/4+3<PJQDWBY'0^)7LWL*=JW"5V&,G&U$[JM&;9W]
M(M4^#&,M\%"$0R3[$'DJB!R^4]@TP,[].2P)9M>RP#[_ZYT&==ZF!G%2[7HT
M[+("F6/Y/1%=K0/ P1ZN[<TE=E)?J'/)T<RXDL%C*M*WA 0+@#JGRH2WU.P1
M3MRS6VU/2>YD3)2WL\.Z4:3OC-)*_]H0"1%#%$I*P==@%&EKCF=J;*HW0;YJ
M]!Q7T3O>4MW11W"2/P .O+A:6:A(\>P@--N;?^G(;@OZ8#WK#:#?)3SL@A+L
M-.MH=\M5_P[15+1TM##U)TR;^5MP@9=>8)0R97L5AV<3P[UEJ(C/,.1-S^]N
M4UC!*^V<*+H59L%8^G';V?O(P2Z5M=8:Z2V8([7^=-"XZPEE%TG;!'?B1\T,
M9X24S(7C5$KUY^6OS^WOBUT_P*__R!C+. B%#V  PB2,US!2< X$?[]M$R@!
MC@7:I"G9]_>W_GV[7')U$$+2^?SV6U/F^5N=QZHZF9)?#G^@:V'C9_\ %)-W
M,E5_5EN"?HFG:DL> V>]?O?^ U#_]WK0T\.1?[;Q++'7\YM6,=#2&]/9-YWC
M^W-3U1L25:0AQ]_46IY(>LIYOE E6YJLQCA./;WPTB%Y04<;MM'PP@]LTQRB
M2(7((C-QI-FB0LJ)69-U>6WEV-QA5PO4KC;CR6%#Y\NYQJ$\GMM-A5'C-F=?
MZ[5KI.JSA)[\K6*&!;75B4;7T V^2SW6AS2:^;1WT_EMA=B\M_SHD;C5IXV6
MG%M]QU2:ZO7()13D%/@<(#TQU$2O1G;&')B4"DL6=VZZE)OMKFR62:BKBK3Q
M(36-72;,$-BB9LKHG(4>D'SYKPLI\D-9P2K?A5Q3!9!-"@X&X&W3M79R9?(9
M F!8K^:\9@/KS?+M$L_O[D".L*_P/ZDNP19&,VAVQM'QA/!&T"1!ID$,&&]J
M-G!=393RLBT'=$7798#K(5D>J;PL_#C=\;>R^".EG 2,<B[/4_I:\LGKQ.J2
M1=P^GY[CH[O[@4T/T.X6#;F?84CH+\;TK2;7TW_?^VX1-GHGTJ75<S);9=A^
MYUQ 6]. SO3<MS:)G*3 RYDTX5?D$:FI)IX@UQJ;(!=.^#.MQB$2D2,P5N1^
MZ32LV!P^!)!%,LT9A6W."T1-$,U*">K#3L(M0U\94W=G?%7PM&>V#:?$%Q%1
M2X^P&]H+Q"P>,/RS;)+<T5K7!ILB,>5M+2#Z^HTW]A_ =9UMR:Y&5_B>5K%]
MHD%Y>L4UKOX9[XV_$J%*#!?$ GW,K0$3*_ZNP!ZB:KF>.$X07S2?CP+P;9<'
M6NVUS(429@#H:1?Z(JPM[TW2-#S3\FQ5M>_<\P240%?BKHGO 8('1JP9WFZQ
M37HU^F4;T1],;+A)S_=ZA:E?)^+38S^7KE'VHF2!-DA.#,*!$Y/RY5A3IUH'
M7#<\K7A\;$K9^P$,J>=^"Q,)GF;U391_VF]!<FT91A>6(V?Q_[/_#OH?HV'=
MAL[?3<]=1)8Q^ .=@J=-=\_A(B].[6#2'REL?E67'I#?O "RHWEJ!3YD4HE9
M328\9K5E(5L;3'0[$O<U^PC#M2,Y>8Z_DEU<PM-4&6!1:?.UZ9VLA%#>0I,T
MU#0943(JA^$>7>1&2I:5/CA<I>MEV2O75?=,P[J@D%IA$'?@RBW9$P<G$VBG
M!I57=EA^"#H"H78"\+'R803JI(LSDA#Y3#L^WI^?8D3[[-QXOR9N9'U,'TII
MTJ) Q;W@WV2)&=P5&%/;9[C.M**OMB'X8+M[2,/-R9!'*35(OU^8ZAS]'*8H
M7;-"U2[=.(O1Z/[]E%X+&U9F7YV+6^/,G:ZB(D7\6\==0+@QP7<0'.V*!K1E
MCB"<CJ"(%9PAH^S%ND=*/J,1+O!'R@FEE[L#1!9I)DV,_N,68BS=KTG-Z#2F
MC=M/H\VYG8R,C;-PUW8Q3T7D ;L<L_*[]+O+33BUIYI?6-I6%]-&W7EP=]>H
M&,;/NMS6[DUYP?$_"9KFQM/V+A"CG02UG#K02Y_"O='?W;CS<"7%/4-KDL>+
MS.)'AJ=;BS\ESC-S1],_[@[HHP9_RL15A*DO=Q^,A.=6"]?:\RGB.=[#X@GE
M,=.1G)GRG!E*3AGD^V#BX?7QKN]^6A6OP"-!VHC)'V?/_G=_I* ?9O0*T=_O
MQM+#,;U): Y"[A]70I#PEZX^E.#_;\K!3^]A(J&/^4GKA7=Q?+9R%T,B8/M-
M(:JLER%[/X*EA[EY?P4N, Y+*4:T3G< UI,S9KP@GJ]BI6&!3:S2@[O*BP<+
MQ5]%8SQH->8N6'L@?5V)JOFN>?4_DT&\,]%P%C'1IINL9X,_5 \A.V@/59JM
M84+;O.>TL5W$J([;CR?^FY;L9.,\5&FR_F[Y*Z_CBT#%;'+QX!3U.P)U9_>/
M?P31&SI6DYOZG=ZI/YIMW,,(TD=,>+NC3S8",;E.W--6ATH2ATXXPN,C=8=$
M_MBSH4H4!U,2Y:K92M3[^E9ZX2^2]>=TNIHCOZW,!@(*OE[)L?;P[IJW6WW<
M]D/9\6#X/BH2 NK)7Y%9/?P#/%2Y?'"F+7[W7CV5(5HT6*LVEVIAW DT2M,>
M>>HEM;C](X!G@2<%18%KY+_>,.Q<YU+E6R*O8'ZX]D[,3]_>!DFK:AI;@%H[
M!KO2_A8EMR%DBCEB2V5_G:R_YK#IPG+@VWD)O*><":P/=)=4^*B!:<]\C0;6
M3V9T+TN$UJ]Q4UG3GH!M.B^9#L*UN6/^LNC8^>R_)M.HRC?;?)+[MB/<O=&;
M.9! M%2Y#6$FWU81_/A29$S_T7MD5MMG>71%YA_@U\-;T?V_8O]/:5\5%5>W
M=-L)P25(&K=@ 1IWEP"-0W"7QIW@#@&"!AKW!@)!@KL'".X0'!KWX!;<+N?<
M<_[_?-\9X[[<,9_6T]ZKJE;-67NO4?5P<W]3I?WSDB+)ZJC;>OP*6EFI,J5W
M&D\K+<>"JVW7D&*ZA1H>%Z&D;WU\+HGDR6$IU<_63EX9[0-WBF<;.K3 K5R:
M7X(%6[N]&0H<?1/TT[3!;G43;W?4>LH5+[<W7MK)D0:W9..5P*K'3GN%4R"4
M4P-3ZI"\8-J N7(ONA2!RW!0Q59+D8660[=V56OBE+%)Y:L9Q)#&8I3EQ>\!
M"Q1_==S,Z*Z#YH+DC7*.A26].9Z<=7RK3=D_-<RMW><RXG5F@]L\Y_8L<V@$
M1$NPN'B;'#-; WZBKKP6&G4<7%KQ?LPF,3C ?IX9RB=DK+[=-G->4JCML(%D
M]1&;"<<.F@U3>Q9SV%8S,%*+-9K7JFFW'6?CY8BDKP33$IX]6K]@K2KKU)[I
MV2*3H?](N;"K2Y<F$E-(&;KRH6D2>%B#G>7N4UY\P@$EF'R!]%&FHN+:U+!N
M7 CHYE:ZYV3+2[N3HE@_A;:T]DB^4H@@M0@FT\-PYCB$P4S96 KK>7;ACYJF
MWNV$BD6H#_A?YN;AN,D)IFS2PST#TP7@\(0O-D@.4FB(-> TLHZMV$M48+*>
M:YX?@N%I>=J:(IP\SOQ-BK@"41;9Z? #9^:PR!V7#?B2E&?"9<1W1_ID9"=<
MH3F_NQJ=2B&:%C9$(A;2X,4Q%,7>8:0Q"+TN@A0W>RZ<.6-GT%'FV+TT48A@
M:+Y.:8I(]2*@$97^%H2R)_@Y-H,J'%I/N(F9*T ;1(;+-C4TT).:9/+,;6H3
M=3+&4\=<H%;6#Y)06A]^?*E&-X.M2XZ#2.91I-]]^ECB0)-L$@A-O:Y[E771
M;D6L24NX% WCQSQ^9WECA)U1?KXMF9*7>?L1PEKA\OA?"J7WY+;<S>&$*BEZ
MI-/Q6W7;<EG/-49!KLF8 "UUJ$2UTJ<]FE-N;#%+&>:3M4XF#KX(Q5W8R@(%
MQV(X:FM+:U/\ZN"*$R0='/T!:516T&DA\,LX;515?;;OR,>:GRFJ/)G6EO:8
ML:'LQ+S=I;8@GE_%C^6$>"U-U9FF'^FV "X3GQH(((%I<:4ZZ_.T4E%O#CA3
M[6+B:8??SGZ+(>J@I=;W*I 9]EI?#4T/P.*!ALXX5,96'WIN69EU(&)$U&8&
M1['P'W!@27MO.=@_DJW!Y:6XV!?%M+>&<>-+VF<]C0>[:$ EK!_%YO27OA?]
MWYF/!WV/C*(. ;<[J8[-_DE;+>2/F2U7P*)Z&HUK^?R7"Q6VIPE*;$5SH&\<
M>.\[5B-/J\J!N"&)O\'MR=\.#EXZ_J#<3N8;%'*G'A@.6B)N5G?B<I$B=(?W
M;[8-OW/:W1[R ![*8<OCHZ\$PN+VHV[]*3Z $GA-8O2-M^L__?H#J9P<;1"P
MVW^E.D!6M4B?)VB6@(O3>(9,ZJSOZ_4Q\/V<O0/*J95\HPVG>V4$XD1^%4JW
MS!E6'(DR,PBB1OCJB \!=F)K@2[X9>#P\,]U86MSEC8D<F:9('E=)S].@RH4
M)7B JYH=G9B2J?O3U_@718K(DA!UP]$/VQ=;ZZ=EE\8.:OM-TP[U\,]0)H1M
M%25RV8Q7[X._L##.(K_5K\S?+NZ;R3;FS',FD9']<1F( 4U//-=KXHU/G9$T
MIS\MWC+D!9O3+S2 BCH0GBDVTSRD=>03I[2U1T%+V4C^HOV;<7W);0;3+((8
MYQ&\;[VG,J_BFF/5V4IL)P5NTI$RIF]___:,?0)(7#P(U.M_D+%*S1D)^AR#
MDMPS")<S,O^&Z&076Q#?X)S8#H/8[&@1(T*YWOH6?P-@F+V .1V/[>N'+#[(
MIVU%+^ J,H4OEMBYFWR-=5D@M42HLU>OA[/!WJ* <6%O^>148;2$=Q"&7O8H
M"%_?*LRS5U23_UV!L' K2.',V4MDIWW'\/Z?<\3;=N_9[]@?8.K[_[C=;NA9
M.AFI[K^4M<GN)J^#/FI[*-/S4R=^(^M78&^*?<E(\8>MG4[<9TV7BN.I6A6F
M0<4)4M)QVJ+N[EA>2I(WX8<T?DQ='.]=,R>D>1E(X?OUA$K:80\T0<JWBF_\
MNWW/G,;EG!K@785 S8UT,9,A=>QLAVXX_0795!U,Y #4J<C&\RYZP>!(<V,2
MF/)%J"'.6('$\6O*^GKN=BYRIF\*PDT=M!8T[,$9S8$N>R[ W#V*CPAR)*Z-
M<J$&5?3(@-$)HK]]9NF/%='O9)ZWV.<G!9@B9KAXQW=%8001(&<A$WXO\Y@A
MKL^LL$\DGIY0B:ZE6?RS9.[]\%:FIV-J_0 C#/<F3E[^EQ.'&DT'E3PY$L0X
M)^>CFE+80;@16<F";O@&S@6Q*8-5DK9KD".&II0@#&;IJ"B/\9(-;%OA97@I
MA2*"2_$Y2# ^#ZL&LQI_"!D-NS@$ 8%RIXEJX[8N^G,98ND*'$QL/P6_I3'3
MH)LA3B+DQY41P$!UQ.1,H37]&AZ-)C5=&T;*'I9X7#:F]V7O0%7[D%('-D I
MIA/S+DMLK!R)_^KJR*LE63H+'.W^UK3.[]/&1:_R&-]ZPQ. 9P_M?_N9E)=?
M7/AWM1]D^E?;$NUCM2SIMLWS,T@LB$DB6I2I=B5*XC)APDMPQ=(HN,_M :11
M>$A P*2%>$)RH8B?<<>HZS+9]-HDGFKD)>$QU_Z"&W2O(\_*K-'5PHJ883QI
MG;W*S%V<^DUB40S$R^3 EW9=]  X VFDP,O?:W:9MR&VU-06$29,CO"N',+K
MQ>E G"T62R!CRR\((VBW(M;RCIJM+G <";.86;4E@B?5^X@OM4MS&W;4]LTC
M?VJ3&):..HP4)DQU*PK?@,S%>LO0GY)&,RH>)Y!-6__VIZNKJ\TZE@U3:,'=
M(_F:O,[NP]SX60XOGR.UVGX3P/D&[0S[CA^BI=E<WG3/YV>J\..D)R2YR.^D
MNBP[TM6]<9IK03[#U WB9L&BB1\XS-DEI(6)@AL6J6[P0R-!3*Q+X^O:OL;<
MK[6OQE0;:Q 3TWF9GV#)'I1?[.-K6,ML"R]#J3&@@O2]N N*^81WIDFXLC03
M0M4MLC3E$S('LI8>M&FI6?*<N++" Q49 ]2#QTQ18S11HT?=R1XF.FD1F\DT
M\<K.MBD[D:?:S_YB,%2[WKC<N//\*=QKBUQU2QSCXYT%V)GEV6!S.CMSM52P
M4(G_A-$9DS-<!-.>HZ#A33)NU$)\.42<Z*4*B_!%JEZ9RM*T/8H:)]R1=I,A
M)'HO6#'/QD!M3)97'/];FZR4UZ.7ATE M;2^VAYI5UOL.+AZ#>GW"[YWMFPX
MU5&6'H0[ E#+7&'9^5%>,X=8-@PB^LV]28F:P4Y-6ME8B=>XJJMK>4GZ8U-X
MB:N=XC%$ZY-K-CXBJGG+NUFT;5!JD<PBVFX/^A?IG!AKLPY3+R$_JA/AJP1V
MH32K:"5-D]]6)IIKK?)"SJMNXY+LS).^T6"4.$CT?72*6J_)ZB%X/T&,'>$D
M%5PDH3:M6M%A1O^[FPP!G=HL)"P!-YFB-DP+XO!#,G=U8UW/7R8AS7:SFRLQ
M)TQ(1U>^:$^&)FS#(JX@XU"%AJ3;3F+H+4(AMG&KM(64^JB.%C=[7$Y(/*]5
MHCU8>RD6R 3\\5V=].5'ML48_1FUU\70V2< AT,N%1^.Y2*YKG^5O<.'&?/\
M*?J-)K[#:!NZ7J:!H$H!6EBR@SU=<R^I&L*;PBSG<C7G":$OC&W./"("5ETP
MR>_JC%">U:R;0SU;)D%<(E.[0G0:Q7H)<CT0@[GQ:KR2$I:P)^$%JY*2"6[\
MO7"L]MT23=$ >P$TK/O'JXC+/B.JB?D3B@_1?J;]/Q[5<=X/A('(/N?7C[A:
M0@D/Q2T&8X&);B8>L8Z(*1SL%HMOCF@E@,JBB<8N V7!WF7<7?(.8QC]<0=@
M' $:N>)(*+(":YS'<72#\0GJ*TOX3*P4'1VDB$':LO" ,W^^-*$<JY\^(94[
M3E(ML+>R086(%!OP@HP<2X9Y.Q@3E@@)*0W*G*\+_EK:TI"2+@O;  A]=4#_
M^=:W[8-++8;9J>[Y8EV7)-$KZU<XNIT(CG1\:3!\ZINEK7A9K#<$[F_%UNM?
M\S(*_"/;G%_>G]]5/0II\E]2I#T!(N_8H\PW38G&LOGOG>[G'_TAT#</[#>G
MVI1Q4"1_L]L'1.>LJ$?/Q_:33>!.X?F#Z%%=V^R4NL'\^VI;@S@DYLAOUM$\
M/*I\/R"R?P@YU^_[]U0U0A7P7A>MAG<Z5X5+./*N62DYE;E98Q[67C:@MY&$
M+_,3S-I&D14B6Y--0<4!T&G;W+V&6Z2R_'UOLTXR">DII@M!(O=-:0]3)[+I
MEKBX1J8J!O-10C/R"W7=T/$YY=#-MM#]@@=TK0/#"D-6#&LRK3E=U;S]%MPJ
M;LJ%:%O"I2V-6$QLR7*9MTA%#285Y!+OHXG977!9VR9T>:%5&>HG+;NW%KGU
M#;J*/6,_Y_?8W'#7W\5FA^K]AKEV& L8]\H5LVR .( !XX]T$^UA3X#>%D?B
MZ_T.UE)/R^L02,'(ABC>-4A=7C :70/* SZE/?Y\04][/7(J2VVCJFN#75H]
MP!6G][XJ\]<2L5-(/NC]KUIF/E7-)(BLKD:4.:-<PJ6JQC_N&8O,]_IN'([N
MM3,?C%7L/@'<#G^/[<3L/P&P&"9O'K.OE,$!0@%&UTY*V6-_G@#-WIPW&[=/
M@*Y(U\> PH?)\>PQBME'4K5_>J0M]<Z4\+X*"IHC!/A@:&6!N-:3ND??!T,B
M.<AE6>@EL!/+% 0*4,Q[81)=\0PH)ZM;X1+VN R8.UAL$HH"46LR?1RE&L%8
M&Y3!_>;&&DEAQ=7QA.Z4JY,/39N6<?U"=^328^E=^^EPCI?Z_+/YM'1YZ^N*
MP>&NVY2?+'@X)',P^$-#R[O>8[T?],6>V>BMEUL8DK\Q2KF);[T_(G%GI+%N
M<>_N_^ OEO!SH&]JAGU4EB9K$Y8>(HH)XJI?V&]S)^_3QB_YO9!2J5&G,QH2
M8F'PO=&@W>:E@.@K!'+6_)Q/A. ?:WQ.!UQA%'KEIK-96IT-N"N[92Z>0T+[
M?G[821/":]1I26^ *I]*/@D[#;SCOG3<J C[$X/N>7P'$JM6Y%4(0+\6N-?M
MHCG&T]\C)YDL/]H9/AO<''-CJHYKL:F)C2Q^^85T1\6(N/#-?Z(X[]JI6%KN
MP'_%U=VM,G,T&KZWH'OTD2#KDJY.VC0RI4WLT^\*Z&!:4I%,WG51 [%JS\>S
MLU]M!<AVW_B.T8\JFV=\1>DF'[(]3MTG& A]%*4Y<^WA:+4T@73.Z/WOXXM1
M'XCNG;$]2]X_$@7@'\ UG@!#/_B$>,MU%8K:)KO]$:&SX!]I9M+&,[<P))(,
M*6,:;=,E.G()4LV&T=YV_LE(K9AGG]]5]3!L4"2+NO/E>PYBES['ESKL.;@X
M_M&'(H#4DJ@O:D.T@F@]:X5EA37?%>%Z0Y?I338T0*.NE5$?;H^.FZE1)?CA
M>],M)\!LJ\&!H84&ENA*]X+\0]/G[K[[_7@&T*(>^39;"IF7DKJU-U)$KGP
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MEM-^+2<53/E;7C5#-YDZI/*L5S5Y4EXU394SB0=> ]M"'7U3;OE?IURS>DD
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M\_?/;2]G2OEAQ J,_J/MTX6*OITI3N7P[9S#@8P8_M.9 N7CVZO2/^6EN_/
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MJRA.MFSO(9DGMQONF:24DFNMUN!'Y)OB'(A#P&[<I&N><ZZ1]K)\R3_;)TJ
M"\V>"FUF8IM. XK%UT<]>WY\ZR]T6<9?=8G_V&;;O;1=ZL:\O<33NF3)/1+T
M]?,RFE>2J^''[;V6=W^,5'9O \^*YT(&I+O!XNH(U&S53D"&':P&L)R,3(G(
M5VQINYT8PX<G0*GFZFNS0X.8Q<>*V7*>$@!HQF]T_D5=[JMIUA"C0AO/E;!L
MTXWO&5$/48OXKYU:[@]'.A:<+8:E# W!KG+1JO@"7>7,W3+T@A2%SP5L3E]
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M-54'Y-''SZ:M;ZBW*>%(DIVH3MIE$7_[U/7_ ]#3_/\!4$L'""5'R=>$WP
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M-/1ZBG+E,-1%B%X5N\ROA;9:8<TFS %XD$><;<RU-;(-N\UY0D^*'EQ;>>R
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M*SAEMS4HW S+F.X;S,,B0; ;-MVRAZLQP> 0C;#7)82T#XZO=KNZ#=:[?M\
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MB>-=/(LI@(QN=MUF16=$4Y.>:(H W* 5A&M[I"^!:/<;T.B6.SIIA!:HP'#
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MJW$O0EW0C =9P9,$&!\!5MO-87^WV[,E6>2P1FE_2HTM&,M4NJ0'R8,FW]_
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M#L"3SCAV%4]6OBJWWHPU:H@'5N%S@1^KC<=LP<[(SND0%NVE0J+'&FP7GS;
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MWA(=P^ KR^8)%CD>.FS9/U0N5A,Y #P]'D*%,OJ(#0S2M;A00<J\+L>C(:^
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M5ERWYHPF7U)H^9L5/=IEK].U3;OQ<97<5?J[4=KZ)+MV0#C\)M90$4Z>$4S
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M)5XJTX&_]0*S2NI_T-ZC?+86'%;)- (A31JB/ZTT-)::4"L\\U;CV(?6MZ#
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MI*/6=8<Z]Q=8.HC]8Z$ !X< 0,E#80TJ"!")0V'!T9:H-4]Z>&L&D+'/LA'
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MCQ X'1EUJ@.U1A38X#C(Y<ICF:. -^E 0W3$4E0Z'AI$GC>I.:D=P0M?'_>
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MXIC% \L^$P;L9*@D9)^E*Y6?MK9,8*O29]1BJ\K2QO"Q8JM\DB$?/- MD2(
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M<K]O"%U^4,;E9&Z)NQ*PXCO[\A"%KMKD(G%<%=2D3"#__M[Y\H\CG\/4I _
M=JFQQT*Y@L1(LOR,J9^8@B2V:3^*0EEMUE<>'9 ?CC5'SEG-7!^Q[W#XKDN)
M;":5$U,-T -.P2/-$M%5BR=XRXS1@,QE*;NEY8(ZVA4B26F-:)#FVRN46 B?
M!Z)D)([=?P.#-IJB[^-!YT,UB\YXZ-R_S$:<P,\"MC/*E9)R2<>SG9;U#!&
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M:#"5K[;P'QS!^'W=FR-\EEOW8&RLO*0C6$':UI:$?@^"$*$F5E)!9*#]EA5
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MX#I);_63PA$FQDSN,K!<[J+;OR 3=N;8>AH@C97%$W5R=\4SCS"T;G6V_OT
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MQVS8BAKC 6.X%FW_08'$>PO-XNE*@J6)QHM11?#2N/%X5'=2P?@G*XCVD"0
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MP]7+^HH'#BT$#]8G;W"AAF&/6G:)D/8NSJ4HV5,-JTI0@!'DV!QQP\]7.!.
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M!*S&7:K!R*G++(L]-.V"J=G@0)8IM'N]3JA)&T #7*@F!E]K@J8(ZY@G-*)
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M6787UJW9I)%Q,$+LVZ,'%$#2G7M6YM/,D[,J*_?*RLJ]RN& 7"OW/;,R$RD
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MAXW6N5'O8748/Q+$V$>O62_\>$P(#*[=J+HYQBGQ00>"\,H<&9XP$A4JAIU
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MWOLBRR.7P;2D,)5G4Y@<-[7,HD2B_K+S9;<^$6EQKU,B"1G;U4J>T^<RPZV
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MY+!K9CK+RH:>X1.$ C)ZTV5).-?ML4'8RD/0<M3J<$2(A' W>KW&F(-M:0L
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M[J-P*IC,O!APA:=6F1PN%B=J@#-!6&;>$JW7>42^)RE<446GH-,62+T%S&Z
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MCV9XSXD4X/U(BG<=8 &^]P2+^W$8[SWRXM[VI2-,_E6/-JE?.D/E'2>4K ]
M^"WTG6>3K#>?JFT5#'[8/C]41&78)WGBM6X[/X&AMR#X4^ [6GVI!0[\S\E;
M#VW^>.)+X(-A'A9AV7>KS/ [90[\%V=HN'6=)[[[P 6LJZZ_\_P4^':+=W;S
M[P>BO.*8$3ULWN^8D6=ZF,QN_^3@1BLT^2!+OY/(HQCOY?@@1Y_T>?A%'G:R
M*NMI[I;73[\QO1F$D3OD_1O/KA#F8M@7XWVOX/X@4?!>._XKR-6&M9NT;SQC
MDSQ\HKA%^/1=G>[RON7>8:#9A6WYWE9MBU H1=V1G5SY;O[$2-[="H;?%-WR
MS8=C9YX\'#A#/,6>%TVZ\8KF[V@/P4^AS[77'\?]Q K;;AW\V[V0M^ZQ^>4S
M=EYN!!-OK9/CL0G7NG6<^$_ZN7Z9+=WVMZJ];R]\O/R]7_\=3^ GJQ/U8?OD
M,9!T3V)W#)^X3]JPJ_+A<;IX85[=GB $_M;;/8TX?!)5^?H@*:_KMW5>/'';
M\$F]]ELGR9.D?-*O38+*'QXFS=/'3F]+LG,?)G3RZKMO;JL\>#]6?I57[1?%
M:YN[?O9N3H>S]'X<DCXLGJO!"\/R292[UVL8K"T>SC1Z^G:W?>&%0; ^>=3<
MDZ1[\J"G5:C'IV_^Z_P\<O@B9]DK9M27+&2N*<10/\]!5#U87U]YC%77,TGQ
MP7V[AP.5P+596#[X>_?)5]-AR_X+H<.N[OI*"@\Y]?.=IO7ND[36<3]5U(>I
M\PQ^S*4OW7AO2][MK*1+O#PT6K?LZM6/2W]^9K1#^+G.[]/F@X@=Q["MVZ3L
MWX_2VPW>2^;@3@_BZLD2?H$G6'WJT61/;\\H8@TYCY]/@2_NO:IE_ S'WMTR
M?F7+H4SZ9VJU2MJ]:/AXZUV Y5UROV)4#T9^U?E=6_?ZI3F_Z]'=GCZ$OH?$
M\NQY\'H0^AWW/[@KZQ9)/K^J\_,GGZ^['S[3PNN0N^T[._N?C_/#$)\=ZS7
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M:\BY@K\<467.\.7X9L4C=@77@MJA^2WMY*OT?-#@@LL68QO5_>[6*\D7KW\
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M!)?EW<%L3-_3\,.T;BK)^2T0;]K!E5+..!I!"FGH<8*8\SB"&"N9LA;^W]O
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M2LQ4!B_B$\:/EEI4PXD9S$UH#?H^@I.[B*IZ+<)I2LG<@!K)CS9CT9AR4*/
MD?\%RZ?D4[*0M![NJT_OC(.OWU[+_QE!>\XK^X<_6SU_2.ENPV615W^S?_$P
MC[1\;JMO$6K1T;D75?2FXL>ICL=,\W]-I&Q/R?E$O6MHX*[,&?3?@+EW_P,X
M2]"-)N_LWDO(WA@?)Z\;0UXHGBJ.]$Z57]\M\!"PW4'_>L1[N$JH:F>-9 HH
MSD=;(_V+')$<M.P[W*$1'!X[;][J=S]2U9\%OWXB,6FDVH:M8;R;W'NU<RX?
MNK__9[Y"-,KFV\MTLYYKIF#]A2570_=:CW17?S/G[.TET4SFE!",T,L9MQ\2
M3N6W',EWU(;%,=6O,@?OW>R#D_R=7"VPO^R^%"-]BUIX+12RWLMPK+D3'EQ5
MA!=1# K#^6A#.*S0C>:)2_<]](Q;!OZDF6*90J?+Z.ZS.;O!<6S--Z2^]!"6
M?%+X%(-!UEQGF*]%()^U[-Z83DW&?.$A33N*38R6)^)DM36$7?XQL]9C1KNT
M[#$_FH/_4OPJ66FL''\FO&+"2"%%=W<9O+ P%2+)%_I<)ET$;?<!T0I>O+42
M>)F/X"E&CJH:<L5Q5*BWM]#IB_),MHYX'@#;C-<I_@&2(.@H)M: &-B#XEF^
MGDP;7P._5 2V&&SSUUIM!$($_1P2L)R[5S3]L%*6DKH>SO=LL_P?(#C* YM!
M&0<QP':?_N;-#^WJ#&$_L5N3GJ/[Q;]'H_--IV<;W_9MGEJ*9I(2UN0&J2Q\
MX2_@3!ITY[M6-?;[PA'\4'F]Z^.;[YOOLO_ R$).0;!T\S!?[(\OV..0121P
MMCI)]($_O/3X(FU2YQ]@X%N4X=WCMT!A7>^H_'\ BFH_V=HSV\M:VM+ AZ/'
MP.VL;T,NS(G?#5/^5]=SA)'J7WWZUJUUV6M,-]\'S^YG%<%<>N_"#6T=/EQI
MAXZX B"JPB;?XQWC7C&R,-+1K#W]2)N,O@57^7,:# \B&6\XMK(WB!8=ISE3
MIT@_8< ,+*BZB==X_<>%P#T]OR<JI@ ,0Q]!OJ_>MW);73+SND!\I;0#F91U
M_D(E;.8T1[,D[5@N8;57.U5U-1FZ"=J1B1];GV=:"KSV%!5YR-E[GC_?)5LZ
MYGFAY 3,Y1)Z\IS=I]U!>M)LYXYZ/;U$=62K&S^(3/*]^Y!B'Z'>KG]K4+_H
MI\MT QWWWA62(N_R&^V6T$PWZT2AL@T+[)6>FNV:N>6CFJ/&Z9X2NF;Q("6X
M]%150[1B]6&^IXJQ#?06A$-K^-V?B9,[L\1;.;2DO:4MX<77Y8:R7V6_HWH[
M=S7LU_Q\]?U"M -NB[JF=X3K7H1Y]_)_.V%GLP,H]H)!M^F0RBSWB5IXX$&M
M)*NJPN>[-A!)I;:3JAN2Q!*7Q)C;2]F(6$5H9OY:M-PK=C!T0?HBS,Q*8SS@
M>P' 8)9QNN_0:S?5N-7U-;NK-]4'"ZF+MN68.36&"\E(<M\3I($]^T)UX<PC
M#6CTY7"Q/6('2\!35%&V,R[N1RN=VS&/]I5]>2#(\CUV'9/CS^K7.1;X?TTV
M+@+?D[:(OD3RA//9> 6F65BT3!;'-PU.I1USBZ0)(G1 WMJ$G^8$<,9 ?2<8
MSBP!(NLJ)>MB5DG\$+D=D<V4M*[O5^O44"_7D0JSR7+I!#5NLWM1T2!'/OS=
MI36JWC7WTTCQL +O?>.%N#D>+=FW^19*3!(V$_WULDQ;.T1E59XWE+I RN4A
MQF#/%F,_&6,/N7UJ\_R;#@<R)9<T&PT6X26V$X>W+K'";;\)OBG$T66@3;O>
M ILMM=[R,G0<D::_W8G=HDONQ?C@^**P=O**-]NO1U?>^1W#1/DJQN4NG:VD
M&,9^559X5*6R,E)M6X;3N$C2N+YLK-/"K68,XP G 97Y3";?=N95C/>V'?O7
M:Z"B7,!@:>G]E5)HMMMW;?+YM"3>!C!_ER.IR @>T:2BTS 8U]A[2%2_H2+;
MK!>"146%9VJ^^&0*NU*P<D]_"@#_\>E&2<QTM9 K +?W9W+,68()Q \'0>&Y
M,"H=.(QKAU Z)3Q]CCG:Z.;A-_V?\+.IVH[.F5_M,NCTX/JO[..5D<K?-W0G
MJ[_.QL9 >#CYS]C^QE1JV<6<'>6'_>=E_PTI(UMX<KZ44Q_M5B!WB/;L3H69
M1WFSXR!=/._%TAB3@&[]L#J"*CMA;0^$I>-"B4(+C#'QU:96Q+BG3]C7SWX-
M:0I3J>758^#,M.(ZK&00AJ"]=Q)R4IBH,E-="M?6^?NZOJ5#Y9T+4;]<IZ:G
MD*9BIY) <) TY)KYR>^LY-^U5>PH;-?W#,T-O5&AV4W!HI:5NONE=K&<HP=?
MRJO?Q0)Q_30.G,+WA=,91ORA8\4';E_[QW<T0_WH:O9W&H<!LL$BSGSM8(8^
MB#2!1*KMHN.B]QA?<W-:^[*3*ZA!F?%6V1.HBCP';CJ2 C0J/B>0688W!46]
M,.(GJV8NB,(RQQV'&KE;C*[<W\)BX+:^#,$NP>#=#T!8!M\6T\YN_,@X0J,V
M.)P?-,(D^,ZMSTDM#31,WZ;G"/;9W(R6KF9J=A5H.O)]@&TUTZ.A4@8:PI%2
M\:EL+(IV.OY&-#5>4\H5;LW\K&1.V=KVS><C!T=5' 7S_?CR*;&1:>4OTL7G
M/ZE@-EE$+3Y.3G$HTS@&9SZ1_0^"KBJ[9*T_'T+/ GE<?>CR8X85R8$(>@11
M^13QP<PA/?UP#;0U4L&7_^G*Q.QXIY%O>T,T1@Z*C,MMCI)FZ.:X*M55#0<X
M&J[L9G&-:<-RC.;U<-X_W<(4JTLD@64T16Y?<UT:,_.8T>9 /QR ]==>B'SO
M>L66@Q][NL?_#N?T@^-H7'J')2X,EJ&CB98XS!BB2)4C;Y5\U%I7&-W>,.?$
MJ6Q8I&Y\O=[F\E5C!(<YT<=[?LZY"1?P8E(X/Y5];F?5*:1:#=W9NR),VHHF
MD_B]38]80(-$S!I:!GL9(+\H\7KG$BQZ)?(IVWM^5"D[I/M<KCY7V];0JCP1
M8)BG^WO0Z5'W*GJ\./83M4D7P[.4?J052NB3&KN],\[7DAQ)-%O.'++M&,QY
MA@J5P-&2:!O:<ZF:1/]Z.585QL>4[%5W[E1)P%T]/(,2/A&(XS8DQ=X0<S_&
M%_;S$NA>6J72!Z85?!?#E6IMI1"GOZP>//\XI]EJ%\ F&L?B"]QWU8_9Y70L
M0 NN5S?I]05[@!"KZZ_3/@<)_1+W2GC*RQ*P0_F'2W-%HY<.2EJJ[K1N'E@]
MIRVY07MY+A^D%JD5&F4U8$R1KM=2.'LK3<:ZA3,)=12'?DIYYI.)1>W&G:$!
M-MXO3EWU>J[82.DE:DT["OO8-3IS3B0?,S)B/4C3*S'^N]!CA.Y"7\K/1Z2)
M^5.Z'KF\:.B^Q(I=8=[^L1#R+G1M77:/ BVERH)GI86B[G]Y.#ZZG3N>H];]
M=1@J1(\QK8EV"E =1B=#P0X&CT0ZV2[V_P"\N2NG&-TYO2GGX\_ ./;D5^XZ
MI@0BE_DX69PN8.2;_L1DI^BWF>V D_4]]M!3<BRF)+#"\IY9@.V"!.IV1"@,
M?'AFV?M0QO(4T>=I8P! QN?-&VA:B629!G"G8ZY&L/C".<5Y!",_?>X8=.[C
MGW9,F6]:.AYU#_/$% ^9 4??I^7D9P5"2$9CNZ(U06&>ECHS<:2_;M]1^M^;
M0=C@O0@E# &.M'Q%<B#]SV87\PSFI@ZQY9VCKB]BQ4UE_8)5GGPX97RJZI*D
MZI"*@NMF<'^/36]V7-[VO$G'""($U2[8I<$H@O^9,%?^TQ.^AM=LYS/LAAFB
M6.#@[R8,XA=6([C5+/Y]#M@[6-&]&?+G(C!DW(0A2Y[,R?+=F^##"8J%J(:H
M[J60P*P%5J<>UTI+!X41-$6E2!\&POMGPK!7XLA?2-;U Z\DES*5A)? ]Q><
MF:P*LF-"Q<\DNKI=OQJ[;CN/J),"GK;=1K1;?XS>I\N&I'045R::\(UC#9 Z
M\@/:I*4OPQSWX<L",(U]<A&."1"&5HZ+7.69)V("=[I%PRGYQ#_WSV[:23C+
M(J3&_4M1%GW^/N^NQB6V<<PI^3'H;H=2:1BTUYI5/T4 GF5]]OKG@ZK'WLN)
M_W_"--2S)U:@, &5K0O<X:9@)S+VXPT2AO#42!02PV^P1:5?.C3K1Q2IE6+&
M_=!S+]K[^E;6SM]01/U0/C!;@U%-*>1'*OVE.#\Y,DHE6<I4I-]K0=4]\<Q)
M]2NSDC,^8ARZ]O1I6*Y7ID2F.G&,CWK@#P"R8Z6=(90WNHR' V))2]H<:#8H
M(PU"*]8(%#.5@W,8.:'/H'#07]^/6+(J5+S8!RKD3"J=;-17'LK:>?_0KC6
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MYK'U%WQ7Z16D8\!-0+H$&:,F[-_!)_:31NGPFWWM;;"V'!!_/1K'"$>@?+!
M?Q]_ AE.3"EG,^Z"KE+-I('9X?5706Y^NXFWXB-!<&6SD 6Q+Y-UQGH_UM:@
M] C^Z0-<8QA7R@+8D9J 3VW#[Q] ;4X SIW6$3F(I!X=#,.)FQ1&@W<H?$1Z
M"KYN\'-H^I)(L_T^99:LT01Y\Q_$W!I=S;?9='RO,!'\4B;*7!!5)JB@Z:RF
M=_&SC-*MF#/!8@W1.#\WWJ^5<_NS_ 7B1D/]D8=4BRE3B>-I,ZAA9^<4**O+
M1HIIGV+NUG5?;6IMKANU$&@4AO%K@IM@$\.[.9L^@R<@^ "$;L^GNS&!0CW#
M8#]81K+L;Z7SL1I=FDO[E1?5Y;I2UC)T 9J>SF2F[]-_S_@%)#XS]I1+P92!
M!U7H0H:_;3FZ+%(R%VW'GL(QVNN?>0"_/5NZ"QI-9S=@$(Q3.+ZR)5N#>:T,
M2 -JP6QQ0UI>D)0U^[:PV76SE/ ?OJ_MS:3Q"NSPN 23+^E,5?#2,OYB!JN?
MJ, Y--0@%CLIP")&(' ='#N.K[:V0]4$"QX^^P=89*ZW=(4CR;^2L"Q!<'[Z
M2 .O3V W$L;M7OS((1>;@9_/XZ4K_K_$N-&SL:W2T2-)LL _YZ/ ]_?/1$?@
M[!6+,"%L?I$*P&8 7)7:A?#3N^)F2T82W"F7M7\ <?@"1\(V5\QW475 .U>2
ME19P5)1F=ZVA(;]>#X#[:\*:@9?+/UUX25TN+N[C5_I9T-[GFMHE)EV9E7!=
MZ=[S7H$+=YA>S"GG^&0#8VRN?@PM08S4=X]CW=:FD*L256LS:I7%X9>C%VLH
M>=9IFQ^] ?)2NO5O)[>(NCK)8^ERGHX3#C[)?M5P1>Q$@S.^1KS8O+9H/T5L
MK3@), #:Y2/D+T0N,0O1AIZ"!?JS"7/Z]7X_#\YJ4C_:[^9@=IJI*#V]>1.'
MT.%#T3\Y&AP$)/'&+%"]8HE47/%[]W6WZP^[OY]DH,GR:$4!EY4$,, 27^@:
M=CQNH2(!2W]G.C7?V@;'NAI'WO%$&3O[@J:."3U.T,]AY?;$'!!V408>Y@[Z
MHRU=+W<.5/I$62VW/MIXP\0L5CLT&G381Q8W[(=)<7S[F3 I*4--TBQKAD+,
M7/R93D"NUXJ-A2I?-+ED!_Q%QPXE1:WG_J+$J)6BG4_QJ8EQ@(.PN9D+<HTR
MA.VZG&[BKN]_JO]B0R!:].H][<BO^0]V7@^"W6(E[J$*M(W$/MG.$C4>^3]G
M7HN[\X=7&I[=G[3I5%&K?/+.>**H>6Q-?'VU>4X1M=%>A7C)UA:+8?BI3?O)
M$?9[W995< FE*'UVD (WD]P:JB,+6;%N#M:/W3A<871_M;LL<EQ5&X[-R+C5
MP->HH<%6_Z4[PD,B%!%\_N&02@3N*:HXP:15]AFF+I:SLB"-P=2;&0GML:5W
MH]\CT36JGNO+:]I/<PD'1T(%X&_]$W/5$%\)V,H]O7MY<.]C[!]+Y96(#BDD
MQBME;!JZ%\6ATPTI&+NY]GF&)\/E2=D]1/!<;N&*CHI+9KE :H'ZM39EF%\F
M #7.)"WX>M"@9#S3;=0NC;)D_-=G9L]ZK*3> 3P"A)__3\*IJC^&?0L7%N@G
MC1RZ NVY,PLFAM,K;T\,IS;DD+&B[2@_/O9=B]?62D+=LXP:2S?XWZ<4LMYY
M1F9#)RIH18\]BGG72.G,=WQHC7SD\B):_OXI%LY(]/1#@]C'10_6!+M.F OS
MP%;#UV/^$G-OT;.<&89N9 C9'>DI4,P(HD%*\@7&8!YCJ14>GMW4/+M(SJ6R
M\D2G#E#.(XTM2O" ]*70@7^X[,:XU?@79)A=NEKC.85;5Y8YID#LAD^+6T0G
MY\]5&54RXJT1VE2<:_2@AH+S_IJX+HY7/W?E9$O6;34]@OTLMP30AQ@^[ DV
MGJM$'O[84D#BE#3'%SF7:K<5,?<G,GX4S<UL)M>!T"1[-@<)3N;5=UA]K^SR
M:7Z G[)Y+)]HE%T'&86#!G^]"3!Z$)K47:KX>!G9&73O/_,RD0(A_*=7(14F
M^C%R8/%CA"D<SU.("3CIH\&Y0QG2AZ=!$'< VRZ2R$X=KOS<^6F@MKZ]CF0,
M?U4I84_Z*BVIS2LW Z,1Q1C(-:_T:6'4H\!1T+.!;X9YW2V54I.14R:5>3V_
MI(K;#.O22X1(6/==S+Y2?0Q;S48XR-'D?L(KX-O^>=>L'0[?*XY#7(#0KFNQ
M+-+8I^]6KM!'EX;YP(CP>.;,P=-SW_$]+7XLF79)>8S#U>]L;V(M&?P%X>UC
MP8KT["8I!GQE?Z\+^;>.U=?%&703.&OJLM::G%Y^(_76'%0"ZL]##?UYP8!]
MN)J:J ?SQ* N<=]KHECR3TADB6A3*?!287A2I!" D9]XF01^ZUH$"BF*=F6@
M%58B]81+V\?#X-)%4'T@2@3F8;;P!:ROL(Z4%3)XFV'>8):AZZ=YJGG%N?#-
M#H 3 W.!2P,Q+<\33\_S^$V/3OI2S+:8GE$5C=>'Z^^ 5BI[[47I/)$=ST/,
M.=TGB9#\69A\SGI:V>G:!#5(M9]C<DG,('+8^%TLX52I-+B>89\Y>;_;G-.#
M(\O)@! RM3LIC6D_^TE.5 65>7_PHVQ*5Z!@X8_(LH[]3(^NP\JVGX#.FKM7
M##S5,UVSWD-5&(QPOL?1HESP%/9YECOM(%''O/'DNL6BRB)?"X1$O=>K>&LJ
MVYIUG^%'"X(H%)=?E6E6[S0[C!X[>&:HB7ZZ44*9@G\P8!8A':TJD5Z_^87J
M<7 60QLEAA(49%E#TT^F4E-V4:O9(UPRDX,CR*SWF=U0D[:5F8\T[)XBDEC+
M)Q)V$EID%EK)W(5@(0UBO7KC5W:DK,*7CH6WD_[Y"P]-"_T2*EXY#+)=Q1>:
MD\+MD+/;H(KZV?=&N1_+;,KN$H9\QKXT4E]-< -'Y6#JPSKLY-(AGK%_B1GF
M#9[G'K=@$]7+\*YEOQ#M$-E#V-&%5H:Z"9:4U"&#Y&![9O\ 'KZ<J(G8$"J8
MW6:L.L.$<X)*AKDDXD7%9LPNN!$+'8EFNRN[->[-DC-M]5[O&2Y /J=H/3;6
MO;WG*WVS.L%^H_[=9!AM_U-W:^0Q/F+7CP*:6QT\_J#V7\(Z:_F+)>[_M=BD
MX1]@P?;X<6>[_KGO[T?GCLZPW*/1H@.O%XRHAN$72M(T'/8XM.R^,M0$A4_U
MQS.>?@G/N9:GJX ;&9V,4@(I!]CNC$O)B35P4+V51;Q\HVK$2+@2B'73??;!
M[G=MQV$3RMJP1'0LXIL%OAW]V&=K:_VK!--X*%UR()#;:-HR%(>]X)NP16M^
MYKBXBO$ N^LKAP[)T_'1-$IC5W,-U]'RT_"X5K:X6,G\'1=(F?9+U%5UB;:"
MHYD.15^3R'.L^7H0O)H#[RS>/A^Z2(=]Y]$ .\QI?$P-SEQNJG3 9LZ<;0D]
M_WD1WT1GDQTX4:O@&CN,1UE*14KX:\51KT,=;<_@_C,/Y]IZZ*WGG5,_@Q2V
M5^$K*.YYQ> ^A ?9BP-:2/C(A&;D*M@NF=FOQAOP$NJUB\=+L0OM)!<5]9/N
MX='I5BQH1M6C&KNL'MQ:ZX/ZCSMM+=M3C'!>I?U9O#)L[IE/>.Y<N<,>IRGN
M"P&)-W >^_F%ZW;G[M"VO[5<*V/Z0N#3RQK!\OC&LZ"-Y6IVU4IN6;.(2B=%
MZDO+KIR=3.9/W=)2]]9%?1DM\*24=TC$T1NMIJ<3&9@7)WQ;"PZ^X"I[; TX
M>8U]:OD(-@L;6[%,]I(A_U=//J47TDE;F06J::/]G3QL*Y+3XB[ " 3PUVCF
M5(Y_9GHM1&;=\G!")&F=B.C@R8J*5CZIT(S<)TP;2LJQ4"407 L:H!0FDUC<
MR\6_ARR.\]F+457@)9#F0X^(JX7"JT1ZAUX&.D.UV0%=N1J?*STOA@2:]%[2
M+(D_3,7WB&[(GI$=RB8-9EH^7>>J,Y"+3W;FP]^5G=Q:DRH)P(;.<+B*_N$,
M)M:\00G[B,K"(PDDO%>C$#?I!K>052D]UYC?-4U-')X)>9R-C=6]=7\J.D>-
M YHHEY8Y4SF1Q2+X9HWXG)GRE6 \4\CTR<KA/P#>;-.<9KL1'J<^XPA'&XXO
M9V7=U17N-9"Y_8_JY8AXJG<, WQFWTY7A&'SZZE<3[N-G_O98UX(,L#%J>W)
MFVQ/_>,MWB^_.@[3$-L^)'N:E(V.KA)?N1RT2,;=R2*<S1(E+I/@/7,OOBM,
M]SB[AB!6Z^&1"G*KHNQ1369(SK5>L@:A7<-T?@JA345PROK,"2!#+=?$'%C/
M3S88+[P&I]8N:>NS^2/GZ!.Q;\;,LGF7*C8E$_L1=R:<Q.J8]#TY 3OJ6FE5
MM-5)W\IZQ%;5U:1KDM^/1*2TLZOQ7>IN"JJ-7F9ZYZ5^<5'G4%&I^S,!#^\,
MZ]6U%TQ??_&)J_@]AGPPH]O/$-6=BI5RC@6.^*4<AN U6++] T0F>YZ+K%V?
MF-+^])"BX9Z[62H)'/G 95.P')K]^>N( /$MVA;Z!_EB(AUD7@[R??=*_-K!
M!/%*HYI##Z3^LZJ2"2QAYIAPQ:B(LZ;8*$U,3]KK"/@$$.N$KUT#J_-"P=D@
M]8+R-K]Q-%NA'QIR\Q@H?OO9U!2<,MF=^/T-L:]Q*>U_6YE3=UV04K9.Q+2B
M#DWCKR,Y6^FB]]QY)$Y9J9BR9 MN71)+.M];.B=M[8ASD&*_>8R*(J_&+L.V
MS=/JW#WA%T06="$;DEY?M=QT=)YW01%/P<M+%WATL<ET,;SWEI M:PW=,M+J
M.)@?GD^ SC<"VF<*GX?@\$2AE/GVR'S@>O0R>2LP(E897#;DF%9'^.K2.(5D
M6X(PB:GM+Z:>-#O649E;,^-D.R9W"S% ,; Z$ U.D.[MKU+$BD7[:XX$K1>&
M2"@#+X[QI)Q^W71F:$"/+D[.EARHKU0+G2,E#SS6,WW5C9-_'PAFK3A^V5K
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M5!IUV!=72,LOG<R[5*V5 @75@46_5]Y2=0+?,SH^V\V"N@+%>RDL%5F^=7H
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M,.=FR25E7)W:R@-W@0"5Z8I08.P_*C,UK.&V-+W; _00*5%,G]=JU$A]1 %
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M0O.F?L',BL";9QP.)NN=&3 _[O[*/W>P4<>]1/,+Q8L5?0)]:=J)EX]]UZ_
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MX:JDC+P/6:XUR#!(W3'>%T1J+O.C9VI@8_"]60<C_(XX[HRGK581O7A7UXI
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M[ Z@H=J%5C0)7^P+NZ$N#R%G^MZNET!I2T)IRPZ. @ XZTB#$/[\T0Z'/N5
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MDF,A5:X[0]3,0?7=W1378.7_6]/_7\?U/3N84+DJ@!$(W_OM]_K%[?SBY1_
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MB7QY:>W"M3?+U4>Y/C$#V>;7\VO0>Q/]WYM^CZR.CFGCZ_4>=A*7\D:=G4<
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MO44NC37UL!'\Q6H_:Y$HZJ\1IWA$6>H\;"'[Q>(<8#SI;TR.2(Z-/<9"CHH
MAW:5WP5A",;V KKQP8IN_40/\TKNW_K3HY;2Q *$)LN<=KV?/]X#?2DTQ_,;
M3B0B^:Z&*GEW[NT02HQPK5^5(BNE*]WDLU@LP/.SU_2^-Q/:U>&2OUTXGQ<P
MNC)'S 4Q N&=HH #, TAWF=*+."(_NYHB"V[X\S*-5WM,N6AD9QD#"]3X+UA
M6G034U8GQ0;_C_"(]++N*6*+/.T#H)OH^+=Q/%%N_Y_Y9;X+W8V)EQWS)=.9
MJ8N(A2;L8YA #D:[FQ2>S@F\G9+!P>Z![E=Q]<6D2RG?[1\< 7VVYUTTQ-ZN
MH]/.3>0RX5MBIVDI1B(_B"E=Y-044_&]Y* B#-\&8#VO=U[2W>U_!?Z$YJ>G
MIZ&Y[X6^W&';=&O@%"6D('J>(!T?0X2[W\?N6;J'F)5M+&G]6J1.I(<B^BQ/
MJ)W2!Z?AI@GFTW HD"A6"#QX7^4#GG>:N1'N[_G#R!>+2P-/4=_ P*96+E@(
MP0;3,:ME-E;6]7I\:/FH*3QCX"CS%U Z/:\I)&>\U[G7E_Y,QCFVY/VU;K:R
M,V4BUV=#S<W&C(F<Q%]=PNZ";D/>K],.#9U!,;@<;EQ_QA.!\@EL0I3M_5AH
M:!L?<!T+2C+;#;+_F"P)&7+6,.B1U?W1)%,;_N%![2[$\/JP+$TU\',I4I0>
M8_CH *E\UX51U?H^E39ZT60=J"?\5O*H;\$N)D85?=[XY4:B[34!;/K;&D.B
MO%C!R!YI8ZVCH[V-/;1V3#2&^S583L"/; !<H/_._P8#G<9N5\,V(#FY]I><
M$T-#3:CV'WX81*[;(RG> <'#$B:'%J+YF86%C(OV9FB@9E\\2SGBW>Q%_WUW
M],3@U+^*=>RMMKN"-R4/&ULM[/K_%#V2'RH? ;:7+&11M['YI_SYT96MD/Y)
M79W#K+#\@W>/ ->%VS;Z_;52C6:),N48@T_I8VZW 5M&(]4F?$ ;>\36U%EB
MO2X?\9M4N+KH&*"K9-_50J!> ;_42E>W?B$:X:&<L6O/J\&9W#72DJ*NI? 2
MOL).DAZ%AME/8VG_3NE.H*M4Z;VV&Z;Z(9=(2*Y/+_<9Y(PTYR=^WC$M?5EI
M!7XVSVY@H'NZ5L:7U08:\P5#K<TDG]_B*7;FY/7LQL\@*>:64G9U:#S1M3SK
MS)<(W,-6["53W;#.0:M)*\+4"G3M7%Y1CE-V#BFH(VLLL[%_*Y'O$![T/(CP
M^%/;.JVAT]VK?%JCF_'I/=W,09&O(O;D?6HZF4@KP3KR'5YPD#G>:^;N%*:7
M)N$Z&GEBS UN+2SIJ[.!G(65W0)R21HG[*=[["?;/7F,E1;;0R#[ETCEQ4M*
M-D*]T>AJ8QHW@XB++O(+32<J.>=&LL21UK3CX0K0P(*9T[K0P%*<TCX!VO5?
M1ZJ('TO[/FY 2\2K>MPZQX1-)1JB\,OK@0T\2S+WP#?A>;73]9RM-Q]K!R(L
M#![8DBIA'?16\U05CG$SN#3Q7-:@]>+,+BMXA9\O&,'D5WSS,H:, OP20')9
M+@3LQ3HD&QWC5>.+%Q!45N$"MK]:!IY=;$Q)R6>_#EY8J L:6*Z[^YOQ")@9
M*L):D9 X*6O^+]?50*/W'QS_)KKDW_<-DPYLDU472]E$D3.WE8MUAH+82KQE
M=&&&UKF6@DEP+?VWE"GW[&O5/*PA .)OO@BF+U;V"N31- 0G'?ZH(RXVEB'P
M 5L1C-=@=[7/GV1U@0SEB32U.H0IUU,>"^N40)09B6IYW4\:0,!/-!#(;:N9
M0O6FU83X$6"S0>:&Y6D/-R0"IXS::NOB#["CNA,7? :C5]:6H[@,O-_Z\BYA
M&3.8N[VRHJ2<)C2B29#(R$B&N&JA]WM&7NJ/S#7-%+^W*0#*\!JF7B9I'2N$
MPQ=2]R;GN*H*] H FQ6482'](TW2H48^&G<=(]VGO'R6<:&D]/XJ30&,/Y9>
M_ >'] %X9%KH?F1\5S6Z5>V.OVZ^=_-(YY=XA75_Y,'D'LW4=>4O0@-C8COK
MR6=\=4\B/@):8._@8:!?1W%(AXELV#3JI999AQ[9:B?5[E ]7REX>-"OMXP3
ML0H= ^A4G-W\2C:2T7TG OKYE:9FV,,PEH+"[<M;<A&8CG0B*:- VZ)/!82K
M4RY]#$'4'_ B"H6P8BW;XXU"E4!2-+UODK21Y KFTJPM>G@?9!T(RCPG".89
M$0?-6T Q8NW:%T)G =P'!WVTQRQUS$7*_VZM_[/E8,[OS&#/ST5>PU:HDLWV
M[I0SG-AJ2E4B/_OKD:UP9S'ZJ+GWQ.$L<]AGZX?RXT*UBSH-#N+ 2:V&U,X6
M@0+CJZ_PDBI;M])V<6B9??7Q+#O9RAF*G+M33MOB$'1Y?$O*R"FJ,0WOVOJ6
M]Z&EE@G=FU9>NM*[:$SAO3(?GXTJDS,F_]C)MW5\E^_ '91WMID8[=BD^H9Q
MADQGQJ"JP-E0G#=-E?6C<FQEJ@PISZX2MO)TR"2"E;".-.H K_\5KW'=-%]W
MYF\;.YLFOX]5:-2'D:+$F+'P+:?RP&L&C'DV_[YW^#/!"A\VC\*;5<@*'<EM
M!B]62SB3D/@9YU!]O546[*8O,FZQ(+3+NUP_%:#GR.":_;]9GO_?]%0CJTLA
MA'RY3IP.(CV5$*VE.UV8:WA\W7LY?:;"P-]OZHYO/4E#XKI@\BB];GX=VY/T
M<,HC@Y1P)OP>]?V[?K2Z\SL';HO)LX3<C302(5@;4^\?"/F56I L-O/DG#D6
M\98(V<5HM%0L.R7D"'=6K]7[#<4;-I:_@V?0ZD0.9@$/U5?I@T&4J1^,O\4/
M_VTP;^@ZWP3[76Q?Z%AHW[R."1.3QOY2$/O=EPPWU)/<D#D(OZ<^!L% @=O(
M%'0".> 6CQ6VZ? DJKI34%]+ $IZ^*]2O$71PB8]C#$W#"N\UOB)[]U;.*W,
MI=40O2W,[[A8V +:G4\OI]9O3CWH9].L)2RC<1-3H%^/U_SB[%+IA:"<EN91
M1%'W7X'"NK!JA<[*7D\=.L(L^*FBO[(R(M>I"=PLZU^HP4(V$4?L!:UE-7@?
M/MQT;%GWE%=N\&CR['^H51&<8$Y5E7T^P;8Y[LS)(FA#NG@QC5"M[%=07\[_
M9&_E(\:'Q,(VO>B?%P3(3:"[I# 0(M'=#[%%W7C\^D (E&T@4ZY*06Y/OKE1
MT# -&;.6> FT1$6UJT132@X?N*"/WC&B'F#^'/N +3=T0=2]0HWF)RAJ/PS^
MPL9/SV:9D7GX<Y!Q>+O;X).V SPSUV-.W&)HO"^)@.@!TIH)=A,L,4/04B4A
MIV/L=2'1W,G8ABZG IX]9IZ+(P:3^N*P3/ZR0!=52!RUDJ,*#@$K8SQ]PK/>
MD$Z=).40P<T^7I8T_O979-_A8(LQ<(N%NI\;*O0 ":^1)Z'VW<<1ZK]TGHE6
M7.]V5_AEL$S\,I9#.63Y#T=/5O@8%H@E)G3WZPU>-DV;T*A3+;GL<_OWI!$)
MV*3\U0EYPWP]N7R)+]N'&BOB&%J_>Q@-L<D*XZ$SQ' <#[P7&$9PC*M:IYIS
ML6-@"SO)\!QH%GK(JQ#5KWCNJ'QI/^%O:<DV-F[^Z<Z$0Z5M'?.6J*Z!!U"X
M+Q!>!ZX  J(W'A[4CZXN-\+^R<39=2QIO+>OLO[J9>H5_>N'IK>G_SJ-9.<_
MOJ#;Z?GH/KF$V.-'0%MT14(\'+:\;BK6MOY0=GM5Y$WO?OT(B!"5V Q.%0E>
MZ$'E@J 'FT:(M>XM#_C?/SP"@A?NVX+8FDQOEU,? <]@8KKO6TH;Z\936Y-F
MXYK=>.;SGILB0H2.6GLXI41%HE5V[;?4#](:MZI1MPD6HW&Y+3*KZP(L?FS8
M5/PPWA,.[,UR3S1,<$J4?$U:T+$.]UQV+%AL0)GP($8C>5OW=Z^/:NSO3*_P
M:^A[+;RZ#[)(WGEUX]6R_4-SQ/1#[[K=(JBQ.LG@8PA%F S-R4,EN*>^9OIJ
M#S?[[=+W#WY[MJS3"_[JAT_30=RK39(S8"3B:[U)'X\%G)'>RK(3.%G@#6+$
MO027AT%TU9,<<4IC[6H=_NA-:,[PX=Z+J,Y8U;94M#)-3VB&&EI'&QS#F7M7
MFNH^0;FM63A,5&_!8TV^X9WTV6/C^1^;+=>#?ZMEUJUJD%ZI!0_2$_NRZS74
M-DZ45OOGV[8T'.__#JI@FK B;I.;4Y#2)K+'57)YOILVW5+B3P=SA-/,"%:E
M;36(Y*05%$;_QU50T#*1<1#PH_PV=NR._:CN+GCJ:=U)9P/[MA](+YZ0NVD[
M6OM*4'_W".C,7#YY!.C?W[TQOZ3/NGJS\""Q^P^L3N+KIT_P^ ?WW9M>GJA]
M7@P*7C5.UY/D EQ0_M_-=_^SG3:\>*61B(-=^UMC"XCM[+Z2I!;X0VL$IICB
M[!SB(:WY48#5.FH4)FM5/L!!4FG C! T@?U.8E-(<3:3M#;?'_057Y\-D<?.
M;P/;PO#9\_NXJ%0-OE*[Y]76M%6@N^'U\^!*EQS\ % 0O313@.!?=*'[13-Y
M1Y*"))$OXJ(,P4?O"WTXN",T4=JU8'?Q?>"'ARY2310:_'6)DQ%CX]_QKX=X
M@V#8=2,>Z5^X6JE]#QWR%ZP%O?TPBJ6Q$GQ(T<5G$4-V.3S66KU*VI3&["VU
M_#0M5VUHBQJ>.4K,P^.+RHT1\UXL\"TWBESI(WAJ.6_[**9O68X$,F><KX3B
M[%M2FD!R_@ZYQNIKW,4O;WD&YSOG?J1U\6K\JHE^":VL?V$HX.H-M-#@]Q;W
MUCW-^-]V9K5+>KD5K6AM:15MMTQ:T2!2<](_93F[<5_BJ:OUYB(;^1$30[&?
M(8S  KL#:Y>M<!A:G%O$BI?K@X<O1<\E+V=8-4'T^L9OD=;X0X"51IEXE9+U
MVB'MFR JPDZ.\];=ET47,P8][$D"R;$)<N\]6\DK8@6&_\Y6]J!KO\9=!7&F
M!A9?.3@7U_+B+BA)B63.[SDZNX>@:/ZJ .")]&/JL)85M&ELC?7^ =Y3/:05
MR_Y:]*U32>ZB U<FY#"WMJPJKE7RMO>C[)C*QC?;S5E_PC8XL+6F2-KV,>7\
M[\4AO2S,8+FVO_FW0C]$@??DCX#LK/VUA&/;H(=71[=W;]JN;]V58^\U+5)&
MI;(%*I*KR<@WUZG6Q0:XUYP E#]WRAPJJ!&.!^R;28*B;S R8A 0"T_])BW:
MC2P7Z;U6VE]W:G8<_/><8[K5AN16T4A&%G5K?;DT"DH$4!<,US/(H)6IG0:6
M'$B\F>3[J7KCM7CA4;EO$SKX6:VC5K$Y-U(1/:>(M8]A9JOC;^!4K/972Y\/
MX>^V;_OLK%AF;JR\OJ;I5A?/,,(:OW*8G9&'F?YZ(V5.)B]F;:"DX2PZ*3G#
M+'G2*>:(\>E%'4+ .V[6<'YV 0>C):-9H!PG+VU+ZWFS(VF@\9?/26M^ @S+
M?$@ECIAD^-R 91G?F*=H_%#Y@&@9QU<B)FDDQ)N=QJ&BMRGE0'%*"Y.,3 ?P
M(G8CQD6LJ.D&N=3A(A:5>L#M3I?BY.(>Z4VGYIDF$+;C;8-.<FB?#!88F=*K
M_*C3J>KU(4:T"\($'W5@\@SD9(&QFBE9*=J\M(DR*52V7*HJ^!:R(%C[:P[-
MO1B,*L5@A8<&4V@3WY[9,<WV"9?(7CY[<Y_>I>S+>_/J$2 G,=?#>E!U@_=?
MMRMC?^ON29]21]+\?W75SL1[^!+\6^/"_=^?^=\ZUOS/LU/NUH,YV)WWTS4F
M<677ZB]L@_5C'@$-U+2UG^*,F2Q*B;<F')U#8ANP;13A40Z*B5XYP^^Q.\$?
MB0PN&\IEH=6%M8)LM?CR*_@$]6,68GL<GBK8+@FQ])H\XKU6?SX#]>;E]6?L
M5S+7JE;^SAN^V*'^L9,'1PZ]UOC@HF2=>(A0 @>U]*5?@_T332Y;!DL]TPNW
M(;JZNOK)>FP(D__/,?^_]FW[I^D;2+#\$M:YQ.0%FI:*?^I.BZ5EXKJ7'PD.
M(NZK:9:I 6^Q!;YY?XK[DL4/#NXQ8M4K(,DBO.5.N^+L+N&P64!!M]Y'+ZV-
M.:_/OKQ%"6X.'(70VDV4=,\)K%>,J0V;FEN"2V ?9A\! JQKA3BALL?I$^G(
M(7,B?VXC>;ASCK&2H\-XLX>)DH?J<''')C8E:F&.:YR9)8@E_FW?#EK?S<P.
MR.1S-]69GI:IS _[&TEC;*LP-.>\[M_&%3##?)>?\F+RN^:1Z&Q(=LY#Y1F"
M__T0<]-T#:G[X'/K"@E6I?EMUD5#P_I#E:DZ[?E8-BK>#7+19)T]]PNDF='-
MBOLTMW)OA5]%H;9CJ($6-+,<A^*L3U^I,$FO8FDH($Z^SK.W0D6(OMCWUTM=
MRUU2MM S,D&)*/Z%#,RASM/=9,15L'I+EE;%^#L]1W;'O43KS%U*C<07B6^[
M&E?*+3.W)7+J! J)_Q\ M:VR]*/!$@2GIL=MH[S7;?<L.T&?'P&"+F\\3OO7
MVT"Q937ZCNZ;HA<KIV>7=ZQ(AL/>V]]^BIE:=8NV/C42%-RB30TDEW6-'E^3
M&5Q,,KM +'_%[&L:A(1H2,([Q$(O[APU!JE[3)$,QPJ^[/=_[[0> ;_T_;R1
MCX#XY;;C39_7EY\#?&CO6]O8G%T6U-W3S2XN;P)N]7YDDGJF5,G&6@;\Z8%'
M;E4=MJJ[!AVX6NDB=61O7R\?]&YN#PMM((7HMKX: U96TM'"PP)#SR78KC["
M?E+E'A<J%\+9E$?'V8)8J:Z#TO(/3HYZ-X6ZT#(784$)\XO7&LE';KXWMT'\
MBL(?X?%VK[9)7UM5<F;/:>:Z-]"=IZGR[, [H0Y%2?HM_=,*"R.C.HY:NEI"
MBVU_Z)O?/*V&N&M3Q_;.T97^YM1?C-!M%*<L36,0UW"Q\AZ!BGCE3KMHNO<?
M *PV4)RG5_>3SO=*5*=W%V(ESX!T*NE]_$RZ#MF"K^OOUTJ?+=*60$/3:6S%
MJJ"Z[<&@?.+!$\ZVF[A8MEX/&NN]\51W$,\S8S;;XH_.KP+!1#E.\D#=TSZ\
M<>EN#58@*<P"4NSQ0_ UG?5V'2@KOT6S"&_3P+)5:GVO)PCF(+ESZ)-)>M&V
MZC_8_>11SK)^W-#?+36\'1I+<5^&]\W,_ZR!<>5NUV%EY;>MFFI&D@U;:#QK
ME2]*Z89';_^#:^O;Q<G[PLB"K+:8H;X4S_X-#[$>@3H6++0P-U^6<O'E&/MK
M&=_KNTA1HC_/'@'>$J3!JZN;FPM#;7?O[A\!GZF3@8O<Z;8@X,58B[ZC+;6Q
MT"B79VR ?\">-AP5,FRXJL#=JN'0/_9"\$9=@_/ ]41']D'4RA\&$85AM;S!
M"@\/<\,G8)GUSTH,D,8R=:T^+FM:GC]@IU@\N+H-S+@);'.-#5K,>\*4=<Q%
M04(CN+.HI@%9]U^P\FDKR+<,RKZ<75J[Y*BXJEBZ]6T):.)?>EA*KKR\3W?1
M2J^$^FRXGV]'YTVO#_IMN/G1K2\?E[7>B2N.?7C-[YK&NVB+J)"@R/&_/-'8
M\3ZX\WL[="AB6W]P='8]@=6*SPM=N;RXN2M:(^:I*95FT&OY@^>A0E5S]/!%
M?Z@JXQ' +%)VO.YQN<CEBP6*/U K&4LXYO$5)?#<%W^OC24')_?5LI UU+*V
M]?T=C $7;9.BN&!O<F_P.\4700K],_SY13\-L7K1>[$GS\B(5ECQ4Y1MQWB3
M"ERL"V\;MP UM;3UM$Q<G31X8*[&SUI9W8OM_+>(VQZDKDON#^^A72F]S#G8
MOL=_>-O<MO$@T97P] :_NSH4N?4Y0A8>N![6.5V(M3QD"4_F2D9?%!_GY+@F
MQ!A21O<^ I3^EAY./P(HO-4%7XM;KU@]1=KV;,#N_PPV_-9E^U53GR,*>X/6
MM:"K6Y&S1\"U_TE#<'/SQ8:G=#%O(H@624!OZMJ;!;9R7,R56J=N?G?D+4$N
M<GSRX=K;L>FA9[^M*W&QY1(/'Z=_Y?:-H_>\AQ\:%OS(-/!*M%GL;_-=P)U8
MKY_OZY5' #WG _L]YU);+!#8*^^>;F5+]PA0=G:RQ0+VNKEG.=W>%6D,4/>4
M7A/Z/N'ATT3_Y4^6M>,_@"P_L/F8KO9NK@]##OJW=]1*%NS[-Z!T6"WV<;]6
MG6 I%=E.RE'LN9DO!)@]LOG!^F)$T84%41L_EW1%/")^V7+DT"+;+??B>W1
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MXB AC+Z>/.5Y J8N/(%97YD"I65AMD]SV*&,:WS1>2DR*!P8Y9Y^YX_8=NL
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M#M:Z45Z.S*IHW*RC C]-"15[Q*;$Z8E)U''D!9J##E0V-L!UMMOT4);5K+S
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MG%R.(C7U:&:V^-HXKT%8.3EV*]5;N/;@=>(WM[BG&&%!X&P*Q%&?DJ><55]
M&N %X/VDG W1YM\;H1*V;]E-+-L%\"$ G'\1#D@%5OW%@#:7N_TG0 \RU(B'
M]:7+;&%.SF>6Y)$3>#X+%B2-F?F^ 3[2LVA8"6CHI-ZBH]&?$W&)BX-A +)A
M2JPU6_(L,I:VGD &O=+@3SEA:J8/6D6O"!E:BLJ/_&,!I*T&)> 9"]Q?FSCH
MNR,N1,#XIUJ3P%FFA7E%XZV/PR>3YYY>J^=-O'=_Y>/6F_ =#=>-7]SXUD/X
M2[)[$8@FI[L"LT%4P4.DQ:FB=3T*./2)KE@@NFBIUUM9DLQ!^@O;)+Y*,54)
M^'Q/Q _2,^1?]%%I_LO)C _EHN)4M>Q_]QS2#+V1OI&8SR+9TO+!U96-/U[K
MX$'NK"4I(L.J=(XI[V7.H!VQR,'M<Q6,)@Z*1(^C*.U,UXM$JF>3%TQG"N@C
M9H_4'F+X8EB6D!"4^Q#%N[U\Z,_8Z:-_'2(M08;^#3.+)5/P88TG1@EFKS9(
M55A_4I:]F)&V7YRLZ-I9RO7EY@_OKD9&$JD!,[-=-M/7,9OBDY:H.T%_%(3+
MLB!GS>EH36XA4;M/+Y1"RMQGVBT39#DZ;MCSMTV]/U<7*SO[*J[@W!Q56_WX
M&!DN_2K3(3@Q*(2C-43'LIE#)FI5K+6@J?#O2?WF> T6"#Y(DVFRO^B;A3,?
M0\&NSV54)_[5;!T5H:8"G/KF#7S)"-G;#4269$DJL*E##@R/:P8[&WM1*NS2
MBS%,KP);<W-7R4KMHNA/:4![36HV&:%!Y(Z(_T@E_BO*)!^/=@@6J@KV55J0
MB!S1YXK'^;])<I7[<)C<!;0F?X9]POZCA-,1>T>5%A<M=6>[M&.XDGV^<V);
MK.@415+/_[5YDU;U3]-SK!]ZM:9F[R?*1 LG3(VD:DF'L@_I<[QI:9(I2S;)
MX@BL#R\U2+(8'*B(R)IJ8 YHO!/GCQODI=D+Z?=K?)$[Z#.2\2FB[CJJC/2.
MK.?4G30:ZS'0G]2>+^HV_BT5%TO 3NMKVU2]6;<3[5[ 0^3-.S)5!RQCAS9S
MW 7P&^!=,3WVX8>ASCL/:AVEH8Z*<;!19$A'7T >]^NG,UO^V< 3[3,Y6]^7
M-P"B$\1H]2DPD,P(B^+E:VT.:V1-PNM\[Y<WP,BGJ5F4U]KN3G_0]^?6J8"3
M%=_,B[D%GQB+,S-8E<%VO$S)(ZOPR%@A5Z!/'W]XU1O@I7Q[2U"PH]P]+:YE
MEJDBZ';#^J/D\\#NX_2/4HK7:1.*T8U*VN=788I-+9QKF4,C2X= #?*,@TM3
M6X2?Y'4>)/B*O,P$]%_'R:K_1(NQ^@TDD/@VC(?HK,++DJKYVC+9^<CJVA!<
M66?3--1/Y]9&'FC6"F;99F24*/C<@HN!R=8!9.)11AF^\A[V?>P6/;&@#!VS
M]BFZ]%.]B/N#>/JOA,:BCX8_QU2P^?-A,2_EE\'@8I3T%_B6,?7^_V0SR%M@
MHG+(=3A86\-2UQKRV]MA87F!CJC\*HK=3K-.8S4K?,J?G+AU$28?<EY7S#'J
MB@'SWJU]/.G84$K6D@*X;_B*]2Y1U!U77-\SLURWD2PR,3M4[L[6%W58%[3&
ME7>]=YE;JE=A!/UD61;Z/-C$^GF0HTD8:7:LB4,1Z62\=642$<W,KW'K<_"8
M505J>O]*C28]Y^K9:AB$_?L'8';U-;+.+K=LW5Y+=L 1Z(K!I6T:J/7SX:E?
M#^W;75E;54X:YN5IQZQO%3M)'';"J_V6@'+JKWLC'&WKFNT%,=K=8+((,FP(
M!^-I,HR-=LJ*^8P%ZNZU#BYQ=,$:N\&::SWGCSO0(XT5CDG9PG]OEBS%$4=2
M@S8.5<$V(M92Z2O_MQ#\HWM6Z^FYR'MT7S7?%],T0T%T4,E^E$C<2T!!620\
MD"6$.RUCMP_V\KGYZGO'[[-]*/,X7XPRJY,>.\ZJ[=CQ A<2R/O>DCW-TFX@
M1^!CNYPE#TQ?/B(-5ZL5Z)&ZF\DP#U+78I_X:G#A0H=94GX?<,#YN& ^/:_9
M!A6Q-FUMFKZL]-IUM^50HC8)U;AWY[MG%E$+BT.C-B AQ(ZS]*)M)4+8-^,E
M UO6>?^E<+?H^'+M.#UP.K%+[M=F=I0^%G(/_8Y'@.<ZQ/2%10P0Z7./SDAE
M1CFGA8X?.);L#O@@J2T9CJO?U- PR_*S5DM>XG?Z*G#('+*W1!(F3JRS@'AX
M@CX],9*+G*Z)++4^79!NRVNX4?85HV9D-*3\?!Q(&XQ&*-!H#B4UALG$PJ'3
M[E/;^OQW7[QRT!']+-WDG[3DT)X:V['2+J1Q=O\8]U3U39V*QI:.INK"AE[1
MHG2%*M)HP1!E48*1.?KM:MV9F>76_K,69_L/O)MW%+_OPMS> !^^5!KH+^NN
M&"R,FB8/W"*U!N.8MUBS(P;_..0$FLM=#!U4NXW@]+?O#Z:OSJ7092&J*>'Q
ML*_4=V%1A4M]6Z),@[+3_29JC_Y;KL?:#& <Q;[!SV79MW[@+FM/7O1M]=6/
M(^R[;".R\#P:>DIC/651T&)=7_M$PCE]ND?]TG)*T^M347O<]*'<K%9/AEK!
M>8E+>\8?4,7[I#MBUJJZ^Z)KSL$=> #K>[+B6JM2%N)D"G@7T3*\W%3WG":Q
MW.0X^T()(U^ONWD*> ,TK2?[1U7L/_$)=WWH>GV>7;>V?@.L_>-'W]X 3[8_
M#/.N-44$(+TW'E+ONU(2/Q(VD+-_UY9F#"BO:*\:*F7M/2Z.3D CV;.Y+],N
MS;%=[N7/FCINT?.FIDEL=<]"%0[GD<6[XT-R7K_(G6/:H/UAK7%/E:M&8NYQ
M%2Y%^$#Q:_:N@[@U97'YL:I8SF[OCJ9QD.O@L?N>USO P*J:@S&UMJ9N8+7/
MT#8><P7VVV5WH$R&\)U:!4U1X'!(\V0,A]0ZX(7-RTKI_.0TVN[DI&*OJZG=
M]X<5:F.3&6+R$;:>6Y_,+[G-)=YMK-V5_$JEHGM<[=99^QLXP3IYLOK&([AL
MB<^Y,K"S59#% BYQDI;E\@06;]F2ZR"HX[]-8,21)57IU#$<^AD%@<D"775(
MG6M*]SO.7/*T![CP)UR3B.=^EI92.\L-KO^^S6;)NUQKZ5"[[(9-@@[/BH\G
MX:9YZ+^<)4A,S4&Y,20 >06,YE>HOKA'!0C (.X>KI)F9JJ=FC[1.='RN(&9
MU[^(_^2<8,Z]KZ:8GR;_?RGS Q<%EPBV0<<:IL*?790#'-&V"IXT/QH):&PJ
M_U9V9S>N_1S[M'0O7U5;!0P:([;D_S28+I-O4W,87:"=][MT8%UAWGW\H!NJ
MDV%&+YJEL;/P6N.>AJ-H/)%UI]"8=OM#5=/=K2JQ!6G4@?S:]T<T*#@T#(<J
M#Z9U\XKO>]70U9XGHM(M A$)L'D5_!^53)(5EE'<A8J[R!M ./\-<&;8OM,9
M\YK@^3HP'WCNN_1G1J2VZ1^DK+O.;F^"4*1XB"5(UYL]I#L+WEW)@0_S;'JZ
M^A#&S_,N/]7JHO^=%_[!VXP$PL_/%: <R2>M82DM/RW^].T279[486X+&*)O
M;G5^^VRC40<1> ,8=+J#W'_H K'=+&(7B9&G4DC67LP'0?(Q*LJ[30O<2A7.
M-6ZRB_<Z9)J*G[FJ%MR(C/;\VC!3: ?=ST;*JZDKB06"C)P]B4@K.?P[FI_A
M)G?5][.W1P<#GI]\+@4"&4M(2!@/ .,2S8<'"%,]^BN%/G::[L$VGZK8]3OX
M70_4C^7"P>@&1FI)>V,UJPNGVSWAXV[N:T4SUVE(C68U"CU%<W?4)N;38/+U
M%#_,!?*''6.?C5DV%SZ1;"SZ>>@R2K8OP%5_<OCP#4#\!OC:]?3.,_!6Q,3%
M3/8-(''Q\8GX7R+^_<P8-R/2-"6RQ!&XR5\0 &T'5[3^#V\XO_PM P<\YR@>
MU.E?(TIVLMM>.B*>2/YMYA+=X-9U7!FX]/'?[;#J,SJ$?3N*^+NZ3#A>)DNO
M\D1P!QA1*N]'B",MK*X9O)Y3J_S95^6@S9#L/"[=:)CFGY$\GK?C-2 +GIZ-
M/\2U+XQ87""]RGSQA03D&,Y29;\!J'*V<S;O?9ZT; OY*>=\)72O7Q+Q4XQB
M8,=69D3DGMJ8)I&UNNTX3\7V73\F:K&(>3[JZ6N6YC[COOLR:5?A\KCE@K&9
MQ-K71RK)M9$;/"GT!L" +C]<7?\ 6ET,;G ^O)*5$M^0E#'<$ Q&4/3;13;W
M5;'9NV9M)R?HSYB#4_77T?*&[$']P\4AI>7#4@.U:JS.W.MQ\J*-M;_']&<^
M7\G2^A%4=S_#D3<HNPA_CW/<OJR:BINB>-85^G?NT-+ 1_')A,>[YUWZ%RW%
M-T OTR&]PAM TNBE8_]IMU_?,_ZFZ[_+ .V>QS= X+YT(=9+]]+Z30S<_G3@
M@W!@GE?.&\"Q,'!U32LN(+&KZ<\;X%8K\/E<XZ=[96;Q: /YVD)C,B[_*%9>
M?+OFS\HG,LQO0X7MO22P9?.;9.&;]AN*+R,_WI$1M'Y(/MR<XQAT&#1SF5Y]
M(JC:0BMW'\>5#?^,O?ZUS%OPMW[SHN#'KG?ORZ'!'U(G;0QW\ZW^2DPCTUQ0
M:WL)O&<1R!)0Z8 .^WH--T7SF:BU\C$_7BI Y%/[U)"BU%E5%0<##Z-E=9TA
MF5P.TC"C&=[RN4(:M4*Y%3R2=_=D#E)BG9_MUP;H6EULW9.2-'[\V74WFU7I
M=6G=)PBI%-\<YAR)^@G9]&Y;_WBDF9P\C7K]D$5_H358KWEJHN>(=5B]F!])
M.[.9#.2>$JQK#R1ST@<M+XR@A1><7+\7]MX#-RR!OOQ\9O!6EK&<9<K/2HK6
M:961'"HA;NJ5Q*M.WA6IQ^MR/5BA09OW>6+I+:]D8F(NJ\8;IQ(>44.L:)AP
MFT.J_05!?=?#=HW?E^69U,,VX_&$B%UJ<Y3AZJUBRT2SHNCE^8\<EY3::&K]
MT1O$4"HF08YFR1C%#V_P+Y31";O95V9R6JIK_WUP:@G["L;I>S=(46:MV:CI
MD4)P I+9FG4('>Y0E<\27KIP>E]/XG*I@"=-._)=\E &(NK[^U5I_I5Y-N6U
M)B_P4<\UF_X-D/CQ>7.SZ[$P[PW@:VT8]LCR!O@R^^_>YW*>4_"A3<)>5>K_
MWV92['I(5E<T+81\ ZV7H)*L[VFU7/7\K-;PNIP&DZYRW!B 5IU&#PJ_^BPL
M[9SNE?W1C=Z1U-"0TI%N0;A+SS.$Z':^%SEP_MU)!AC'[K^^"#E&0)'RX@<9
MM (S+#=I'<W5J>Q=S? 2U<_.RK-FM5HO7@(>RS+;*-+*DB[^Z</_>G_4"&VH
M4U-Y56E2N>\5Z0;QUUWOSY'DQV']B9YDFWXB[U+6:CB1E!K1OJ^@7<F6JX11
M;=LP>DW$])L+#F 5NXC <SYWN@>2@\C^,X/G+9 P4F9)V#GRS;=OFV9[B&'#
M]6#@/2IS*2G-<F.VSP:E*.]1LAW.X>%-(Q@K(KH7C,*]I^1]YUW=HQ]:SW=W
MO5Q<?JJ0, B,E[?WM6:+2J+5/K.GK[>F9BD/V\)UUR!$BB]2:/=MC2GS?#>)
MJIV&(YF^YC46K?-N>9+T$()7AN1*WC,BJ[P<TLB=2>MAM#/KDV!BB8M)I%;L
M<:_2\08@'!.QU-@^HV,Y.FGI.8YD*Q+C3%M>B9KJY%U?+<^V_"ES/*@X53"J
M=_2[KS.F9,%H>?1ZN>A+6?^_O-9&N#Q1_]@4!65) ^5(6/TCPA0O1RU,_TKT
MS=V#JS*)[Z.6^_RTY&.]_WS><"]%:^,IS4^NT#> ()M""$:5G96-C:E7Y(X9
M$?,, -OY>EL3!+(&'1B+K13J8$9/,BGE][0YEQ]P(!L'_9CQHK]-,_HJ]86\
M? 1P<PJB-I)YZMIYVF4 [[#5'W?T)+49CQ_CP?PY56V)GW.4-/0C([=SBDHS
MOVFU8._O9+BJ1F$P=%UD4^IDA95!<4\[9_URVBZ>7.D7"?*>E#Y\.S@M31^K
MB(/&R'@-WR)_(;I!2!^\_3YX>N 3_) \'6^U1_ZBCY4J,=AETT6?KY0[\?QW
MNF0,5%KQ4,\U)FU<OQB?Z+,,<!]0,-G=TPZ;(Q&H)8T>: VOK63<9)43)CQ(
M"RB(YSUO#S:#:?$P)"A6UW>%3&WMO>XK-T9/R1(O,IU01@LL"^QYQ2@)]8^V
M+0Y^P)&PI-'RH):HQ_CBR++? //ZT1 ^9]6LCOOY:N3$WMFF]!["^T-#+\*U
M5C[DN#0W=YA/ZY(X_W_ZH.)\TW50%+BYEBLD9X\1HW3\@:O1-[.)NO?J=IL[
M;#-EEG9&DYLO>%B<--I3"0_L1X=X1>C$V6#,YD5[W/_7\7KY1,7.H7[9F@LU
M0:&F*<DNJ+4YQ%:;@"AY:P[GC@WPUV.8Z1-IM,3 :1$7D;6WO:6#<7L:L_Z:
M_DCXSK5I,E^!-0V[$MV"!:VV@\R.E3AZ:PEAF9QI&X7U$>Q@O,=U-3B$ J*M
MK_O[8_0N'P&; 7ZA..T7_Y<DP1L4!"Z#L T\/,H50MP-ZC$YW>!8F)>MA+G@
M=6.3QT[Y[=T'MB%J;?/(T$-4=U4A3M4_XQB][/)XN9"+5EZ:P_P04&=H@&/Q
M]\)*$K>3A5^#+A]WF\\_V-F-AZA8N!CH[,#,9WH&7>+GS#G,M5)X)EN1>9FR
MW!VMOFVI'\'O9^ P042_>/)M4%KR"?^"=[&YU)#2+B;/W\!:\[JF: TR$U@O
MUE_4[$RP=>B(\CT?=*L.3;9CZES>BD-R]U.-KUG62_WS/<A8P@XFLR =#O=#
MJI_43I;7C=ER4S*J<"TRSC<MU]=7_6'8TXFZ,<IYV)I6 P'FK.MBH^LGF6>H
M=X/RS2S)(BNN5@S;.ZMK5M)2>/;1U^>;K=VVTC7N5&?#HO;F/<0]RD:7_SF%
MJ,'.KBZ_&J8ZKOM$: :3)/Q+R8C'($N:$,4_Q,[>)ZG:-_:X ATN43"%TDI"
MIA" "N3<OKX"OMX^+BR:DCA]F^;BP]1!?\? Y4[6(P?6A&[FEMZ[J!ME8>E;
M.FH^.1S<@ZI#OSA@&D'&HIGMT15+_YU?#1;-?RSJ6*P[=1/NF_,99%]H'L"/
MM9-CJE4@CE\IW?H^FB$H/E!I>M$J$SM46,%DTT8O_)NX]NAHA6391I3\WD:I
MZS7T6?['WXJ*19NEI,8LKNMD5IMY%U2J1/$F$/6S9&H8*=$'1$]-_UYC.V[!
MKNO8?!O^H.E*)GNZ-L@BBZ8)/)&Y^ FVN*G^T(AXHXY&R(E XXX5L1X?N%^!
MKO1@SXR 8R"/2,OINXJV,)TBW@1AZ]5O\:18:E1:-\[>Q3H)W-GB^X62ZV,M
M?O_+_/A):X_HY6VOG7!W3<;1%B)Y@!PGB]C$G$DF#F@PFZ3,$@1T_37&7=O:
M;I%">6(L"G10=O(:0B&";X,U-FJZQB:>),2G'C'N%-<DE@\,15"HSB?0V(S[
MS;&JEJ5?O?-!XA_B$/RI#_7,UO!H/>#G8&2T7K)A4DW;UJAOU("8?B!21OVE
M@QH+YQQ.A6>%SIZX;H.ADWYY$5.D&-6<F0S&$6=G31;5@4PGC>)"%.TCK!/M
M/MG\M7T_=#5E@V)A3X:OW]ABK?'3ZPNIQ@T^9444?/<F(OL I00'EQT[>\VM
M&3;&(W>B98O'M-NVTX!\U,*R;EH.;<PX%8.Y71V[%7 ']E41?GWM>@O^]*@0
MOI_P2'%:'T#P^<J>$ $]%P-N ,D"[6]P;A-+;E_3FD9#PX!6)>B6_7&$25!P
MKACL2%4?@4LBX-\]M4U004)5B@09/J+&M(U>NJD.'/:R2T<EL/*K>[2_P(RM
MM$D7])'ZX5CLA]2P92!K\Z*-O9^,0,QTE%I@)[G;^G73:T6,M^K;"]F!3WB&
M5<#=7.W2LWKC";I"&] BEG9E'-=4D@@JNE8J.P&'P.4?X!7K0_O_-%EIEDK/
M8W\6M_EFGZ!D&%-4:QMV#K7]YSTYP(#\%4)5Z"X^H!]*:#;F9D'P9S ^2BI$
M6_H\74JH5O<+V"<YS]'J\]82$7_5YQVK(HP/\LX@L_4B7( ,E2R&1M"2.VNE
MX=2<SG9<!?6Q]O8$SS!3% [65YYFH#D.' "\8WH>6.'P!E@Z=5YH4B.>A LJ
M.'O_%2[<6 ,,H;\[0>]M$E_P1NF,/5ZT -\#9;'/8N,#8G2$W1YP$93.?]HX
MFSTY!WI7-GI1ICV+N%M]Z_KLZ_<Z3(3"'H@7@7RF9TN_?2.U])Z-]!:>617M
M%,L!?31TF!0[FJO)IV1%2-RVO$O]9"W?Q>Y.?W]65=62L.9C:IB%QHUDG:1D
M+L&897K:&+FL<=2D\938*M%&V4E9:NO9;;F5XP.S(Z:(1;WM@/#JOC4%9*71
M_]*6PX_$.T4W:?(N^74%<_6"N/1V/]BP#OWH#5#L+Q!CQ@NAFDU;J*0*4U8S
M7=BE3?B\.FLAS!>G]5Y-205E'X+O3H,$7RT6&C:1)F/'SN7_!OA\M2>S.4M'
M\4A$-D2Z^[G#@=5(S<S3(5!0(XXVT>H-($..HV39,;U^V1)N-&19Q/K%L+YE
M8N103^5Z.=M"=](QD+&%-+7Y]GZ5YB\G/[5F:=]]96S=8+3'.UL#O%P.>,;<
M 6N,I/QVZ/'\=CU?K7R>&%?!3NWB8)[ALJZ\.UGK8?P*VB.)0KQ_$J=2J6X"
MD3?2V)TB3NKC%Z(5_ ;6W6A;"]EUY<9TKPWK]/&M@QNQ=Y0=L6:UJ2A+A80_
M,"5.U_"=7+[MDZG-.H@H5RF7N_Y@7-7%3NUP4$PY%:^CJD$V3S/G-02^8XMT
M3EF9M'>]'LU#$YH<+24H!.O>D]B2:LIRS<H/ANXJ?7L$V<2OZ;\!,MLU577[
MYN8(#MP#79D76KWFWGFFOQ\JL6)/ESR2167H69-<^S-@=$@](4/U(M?1HT29
MO"<5/@<,SI6VMM#>Z25H!DO%3LMB[G+2V+^W?N>HC5EYJ?3I8OZOOD_M%PVB
M:UX">3=;PK-6;CV]BC1K?;W4+&AMKPRNT>,H//7]3\LI>])!NJB2\K)5]_<*
M5+S;=(1N;;*X0B-I^J&_7,'I/]>__IA7KF/P);'E6'T85)4?GJTYQ79=_W9,
MM?H&4-7;ISWLA3^2&^6O4MRMY#)X31LL1^RMV:QIVM"A+6G2Q$].?9)V\\"M
MG?@%"^50A3EG7Y]K7'PUO7]A;5K0O+^[/Y'V/+N/[>B:.9L<J?43VF._35R]
MB@NO7\[YRB_PCX;:SA7B*Y6=:=WO@^^NOOF%-W)]H7U [AQFE'<EN5./'HFQ
M5-.*OOO)R%2GECI 709#.EE.H_:G.^BS_FFC"'+"Z57#<''BG,J0;X=>O/RA
M-K]HUN31^XO79L,=C$);67X1)+03?;GZ<4^.U'.PP"!N>GY&C>RH@#L)4;M!
MDS/]8,]D:A<4LUMCZ944N5A6^ZUTMZK6W8)O=LYI,FJ1N0#--'WD'K7"[6.R
MBX*ZB4'YM]A",6L/I!45@U%7U(898WF])V]FV)H4SJ\$.04.VAE+M'P]SPR[
MB,T_\)Q3O2H?89-P?P5^Q0_/-205-2316:O;0?/ :/@_ O)M++1[*0_K"-ZY
M5(JJ_\=10\JG!4WV@8I+[^S/?'6]73YP&6*[IT[*8I=H-^;(D9E'\C$%T(:6
M#:9[2DW%0EH'3*3NK,+;#_*,ZQP//&A49YB9%$8=FG"^>R\@:YL!VF'V5K':
MI: /Y#*_XQ%DB7<'*DZ&ZQNR=Z0LV*DLP#CO:JA47/"'1C^@J7L@"&A \+;%
M+(X<NV[3F]O?6?S-)"^&G*$*<I)CKE,2HXG(\1YC+G@NDM)!*6"<N](1?_IY
MHAGG)<_HKG)3%.XMK!K/.W\$XN1<#Y_NS3"9DV[FI4A E@"$QL=Z3['Y%R#X
M]U+,BZEA&3J-#?'_Y*%7+F1N%^W:ZX8N6[6W<:\AQ@/M(#2>V?/0>BY.W9=>
MP]JO]_.ZAXY:O:-ZJYG'1MZKI?5(]]^K<NW1]!&F$")G?W<%G:DY[N<6&OB-
M,GYQTAVUTE$WIU8&V[;(\]!C$A N:0G-]41=JX;"'AK27I$3H@L.3^IW-6]1
M635Z#H\:-FN1?P@(.A\*8JON(1@\4NZVPF9IOCQCI:!WX2%L(>PL?+%6;J&K
M.[2WHXFY[@#'&'U3Z7>A/\ZZT9V*'.2\Y=-V4V4,?)DQZN(Q2=B2T?:CM>;V
MMX^(7/L:V/8& ,D%/8('>G=U(>'8:5S#O[%T.D<TW@!K;P!VB;@\A*L2DRG'
M"DN#;'>$$A^_)8Z#L?OQFE2MC5G-]$VFB^/:Y)YAV+.OK1/L#< Z<-H?XK4T
MBHT2]R[>>.TRW'E7=&2;Q_PWCIYO"X52Y^]*^PH6EBDR\5,4O1_VN$I,RCKZ
M$A8E _SL;>4CK-,N82GYL;,&YC.+M&&:A^NJX3I;P?D-(<K&G+RQY'JIV5OC
M4= D!3M[[1 Y1XN#S'COP9F;_ZQJQ1WR^%\/V@K;+MGT]_8IA^O^!N%M.Y'B
MDN10-6& L'\'3>T-+9:R+?%-X,A$$]>^ >@K:AG@I80_Y ,BA]VR.E,^5].N
MS!-X$-02'"AY\VFFF.%9ALPA-G=F<SD-3?7: L4EO48C-%6*F ^!L1C.2NX<
M)^MD[28A#G!!,&M=T+>%$@P:F$5\'BB,\5>&J65G00?ESJXB_S4>@6%MQTB!
M'=A*^KMYQWQ7&BH"-SI-9FGI:;_"OT)C<VE(DO<-O@K,.OUMP[JD-)&"]C[M
M\S1D883UMR8X'FUB[[>]]C]QRSTGUNE]0+MP=CQ0\?Z <\XR?%IWN=@/Q=C-
M*O3X.(?L"-<[B4#6 AE>8Q8)J6;F^_26Z*1O6(Y@0^H;H-'XY@U /L.&79FP
M%02T@:2\KRSZ!)'9O>!NLN&_Q(-PM203?3A9%CB>B<^O=>U 5,5?$M%^V!::
M3?3=<OMSO=BE1FX EJ=F&V*O/.+&*!F86VL9'F&M>.::+[N3GX5**%C&+3V6
M-ACVIT:3ZAGJ;6TV'<\F2?9Q(@[+:$]W_46(P.6H$1&#>/YUQ6A4-NB\V *!
MHO3"]#9+Q3@I1"W2)^1ENE^OFR)S[QQU2_5EX4_X-?ID^.@6%H<)R;<^9]&;
M)2PR+W8X:^G.^AH9GJX09YC;'*<J-&%TB4^UKFACHKV^>"?,+P3Y6Q3GZLWH
M:I&RPRW,Z@'>QP-[[N4(B$BVAS+*9(\+V?1S9>'S8FNE/SN2%M=^85(3OY3X
MK$H#&F12%73(QS<%>:!M-8/EWQ&(ZWS5V'9W,ZV,(XVNE?K[JRROM!4:KFSS
MX\JP=OJ__2BF@;)N('W$DEE\<,J-[8F3D9"M84@/-OM?=5ME5-1?M_[]:1 I
M!>F:H4%D"&E$I:1C@)&2!H>0[A203DD%I%LZ!@80%(8&Z13I;AB:N=QU[_OA
MWOO>=3Z<M<Y:Y\/9S]YG/<\.H55C"X14."O7>H<AKT,@$$;PVJ[(<'%&6P-K
M*R2P7Y]0E%/QR\B-3,E%V+*RGSC8G(C0@3U#+I( 9$50 6K03S$/C04GZOZ$
MY.@X5\^FE%@7O$Y<:"')>QPI.H),;,(-AU(# &1H-QSRSSN8;& Z?\D U<!G
M.Y]"N,^;#6[T1UL[8F5JW^+,WU0:55=^;72&Q64S9 CM&K0>QV)6D/T53ZNA
M<'<+'/MZQL!PWGQS3/@CH\^A#.W:^E$!8IE/Q/;)[+*^V4W>$]#)WG4IJL;-
MU8IEQ_OI4G;A0Q.PC\G8::NE7J6VE93 -)] 3(^(L=6[W1A7LUZ&?C@G5>66
M2F>+I NM^L;SS1Y\H=5#E6K/V$7Y #(C;+<"J7F/Y=[HT-S,Y/)9TKJ.K5"U
MXM1E@OF7IQ)-<^ID^1G@QIV"']ZTP9WHPK]V6(I!CR+\"6+6I@N'XH_7HM,E
MN,]=&8NL)B&<_.*6;FYV\',FPSUQN_#P=/3QQ5]+?;7OE:Z9[=#8&H98XYXM
M_6S7Q:;;>Q6R_M$XS%HJ9NWS(?:9IW6K*0;H]$\N>A)C2DUAFRC?-F*HP(*]
M6B/G@+ATN$K8>N[MMSVE<T8OMR#-/%!$/^#4?%AQ\,%N.8.V/(0VBH*#6$)S
MH+BZ[=?!"R]S%18<<YCPJ-ZCW5<V08KO5#E"IFYXRCP__)K:>C W+XC"72AO
MU0<G/J,9(ZE6?Q3ZKL,ZC'4G\4MPPY\DE<ER-_OEF7R8&=26.5U$L?17X(RN
MY[P%F8JS]%C@=,] YH:8UOB_:C?V ?HF1Y9N"7>*_1B@B$M,\%O D/(]"9IH
M/_PR.S+>_EOFS@IU>S7;+EAA5&[G[M?Z]X.)^44R(UOD[/I,K.GGYHU-T6YA
M;5'A?=%I@3Z[3\PB/G3]WI(.WXB\E2D&D,CR8,7NAVOT_-)XZK[F7Z]U$*(W
M:MSUR:.#\Y[)_E"Y9F&K-W-V=*!9*/7MR[T.?GMA?ZY:B)]1O#7PRJO,=B>+
M036+(7X5;^5$/RZ#G<-$..VB%XP2]C7@<?/\2.CQ(8^F<Y@[VGV7FO1G>_]H
M5=TS@7Y9.OIC%1LU=<E$PGT?=.^!H5'JZ-ED86T;MOFNW?OD>FI_T.>/+$)T
M0@8\+BZ147/1<!)_CH0E(9HLP<_Z^'$IAD[K^F@IE=E<[@.3#[/P4FT[NT18
MP=VLK04*5+Q_>S+G)"KIVU;O#;81H.7^N!E9*HU\1SY<Z',]GG9J@ %H[LD^
MTQJW^A7"JU>5]-I(X3:F! /,TXZ,8X#:>@Q@ PM8)+J5$J,Q@(8_6;/  *OM
MKTRN XI-KB14G:$RISY:&,!NTV3?F+4"A $D8/]Y2^8\D[6:[V?]_FACIWV#
M'-N"NUC$.(.U.FZA;(T3DE8E[#@V@SAR@_&G;(\SK<OQ=7.&-ERUJAP55L4,
M>WK4/$,[YUM$6]G008+X_B*(>=)-T=R82O3L0?%8 P%!+6ZWQ%&TKI?0@HC>
MXM-L2_"GEM9\DIN-Q&[(PJW+XE'IGN,82O<S;$*WL:Z?&Q?9/.#LYVC\TNV?
MRB*42775CK<X?9PQ>4+<UWY-DR^3<ZM-%\<K(KA1[X_X?B*CK5?Z^9#W3^CC
M)[.PUFOKO<US7JN1F>PU\_<:-+_F43XXI&J[V'SZ+&!B+MJ?NO@R;=D'*XJN
MM ]R\PWJ-X,"&,6-W\T1=TBGVR=HSGZU$A\M$B6*KW"J>7F5$Q-(1]A'RQU1
M;L$X4Y_&/N76.Y)_-53":]\1J_IR;R16GMB>RY#8G!I58!&G.F;N=[2%UFQ&
MN]8%Z7L?=CX+$.\[.%:3/CGK++NX?HN/ 38:Q;Z>+%U#?&YK2P,0MI2?,$"K
M@\P,VN1 /-3J54_I_+_M7?+W+L< 45'E[<?D&0$8 "0F<!\^DXNG#NT+'!4/
MU6_Q',MESH^FUNG*W1;V!WOS45N\I9QYE3D]-<B/;#W*0KP!3[J<Q%WXG>FN
MTW?^J:OW_#:%R_T"5QA:OS<8G:.E,3YKI!]DK$+OK$2''ZD0@6)9L9*GQ@ P
M1=!AB9Z.&_?V]R*T/A[^H1A>F2F#@!6^F=.JCH^Y_KI&IMR7];0[*6W'JG>(
MOF=2MEPD0X*1LL?1>,$E<*= H*FU)K>NMGSH;_XW9(T#ZV:9]1[2S0@6+S];
M<*WP$^=YHQP$&?RXMY';B]Z"<:%,7W\Z["EO!?22K@O)@OQAX? @2[;C5+AK
MX,JE[S#IS:=GLVG"EK3O*&G.K#3?[15*68[#'B;O0?'X'^+&-C^2*>FO).SF
M[RDI[7W6K*^67^E@0E@6DL:NRL<V?J;4\6A;;PP+\GHJ%8)%HL R?XX&96>"
M:FNBUWDD]'ND5H(?2[K$0Q7LKER2H >CCVZLI.X-D+)K?1VQ/OGQ+O6_JLQ1
M?3]+ _)^8@"3L8#%O9TSZE5+N['_I_^Z=N>VSIVDZ4QMCL)4S+);<E3X+N-S
M3A#7( &"KK*4.HZ3XS)&(J$"[IL?,?0:KOGDU&"NH'G"8;?N@'0.=7AB()+N
MPM6 K*M'ABC.KE?%@>$NQ(6$#.3D:XTV!99R6A>:X64^=#Y1%5IZV_F=:#!%
MAY,4,O2)RM@,= #"G$R9F:ZEL4F3%MI//WL<5S94_$=4"^_E(K&MUE20X&%0
MM&T1*7XO,TL$0/T5%A]W1_YL-Q&V\NERJK[Z+A74-MG@8/)S5J)ZO^.LN)'I
M0SR<O+/]=83>FD& =1]IJLXXI=\3AZ]_?1N5BI#W#NS5>[F.9"0<QUN? MO3
M#>CHX[E;?DG/L Y-CFGZ#8?X]!I*%J\E"H5E0!0C1F+)U8Y=?[>)\/R9$A9
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MZ_@7OP@&%''K'XIR#H.C-JD#I12A5LSN&NKOX&>4JT;V_]\@W?-+^?85I=F
MU0-5##!.E*6TO;AIS(@!+-0Q0!P<6F9ZVU9V-Q*' 1Z,O><US52&'ZI-3CU
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MX]*[,V/MO?0X?LL\L?/K)RIQ=P,BOSGV-:'7T@(_$., 6CQFQ]]1\/F!\*;
MHNS!FVAWS[ZH@K?]SJ8NAJA5"9"CX:N%TJB;OS@;[2KIE)J46N_RU;O(R2DU
M3>P7^.?K?\?[UC%0O90*MRUG^Z"00TSZW650>CCD=NL,3T9*75,3 W2F<A8=
M,26K9W*-QJDRB';Q>G.\WAZ$BF'?O.(]'( DYE[],-XSB;-,>,DQ9;>D(/!=
M,:Z:+7SU6#[WW!B^\#XC9A?^<'#U^$4,@J]QMSZF.N;W+*KFCPB*1G$\H1L.
M%M%MV#6F!BE1FQ;,-5LQ#@ON)Z-ZOXX'K8?:0W&W20OVL[W+?R[]N H?OXB=
M[/K%K@T/[@U.4"T4\4PD'/R&K/Q*M^O;R0PW92Y5?D:0157#9>%#/5FXEI7C
M868A,AH*>UD^TOOX.=58::*&X=MY%%_=$B$;SF]1+25#"C@.>F3>;CN'CX9=
MC/P/5R[OLVZN7(L4R ]@CL&#A$2!TD9E\=BN5=!YU(HUZY,K/*5O0RQXB4[I
MA%A<#*H97^@BFS%0X>@_>+Z>N9 @^?6@W:^]GF_Q2PRI?)/+PI5W:+;TK=1S
MC>I /QQ9A6^4GY;8C5G'*Y=-]O?KL[<V6NJ:/J]LL' @P"<ZR0%L[=^8/'I%
M4J%*^/YW4QO=53!)GSO&\V/IF(.YO<69.RF$;$#1U86/,L?<LMM">\M>S"*Z
MQ7LCPU?XCP"ZXF JKW"C_?85$W\+5(_H)N- Y48E3;&Q:.'+PP2Q[YZ([Z-V
M(+(8':A%;XAYFF'/%'KWP,S&:$:O:_#:O7A\+RE-2(H6_]0Y(^:/S"V?@F9K
MX,H&.?XX;4Y=>E.2UCC89#^L[J/,-3HEY3BN4S9.A;8%I;; =;HS:L6N^VBL
M,.^7FYJ4N>BO.;G8"(G= R42,3/BZ$^L=:P_67NL2;AZWCDOO,TZHI7E8S![
MR:ZP;;3]Q&-!P(DU;8F8)9C:M*'AHY<VQ\O)25'[' BE-DLD&$*IM=80;14\
M^<!^'<RR.C>>H@3.L'7?<-3URE+*)T0$X[L34(?^8,]_(K1C]C\'<?YK-76'
M,,1;3DV'"_QE%%KZ2ECU6L,*3T<M,$&9UEV)$)O\P2+QH0JJBU?=U5E@P#EW
MOKRG;W,@-IJ&04E75XOH7HF4<0'!!,R!LH,:@3_*@+X?85K_X) '$TB2*> P
M$I19[)G(JZNT_O)ROU172L-5120J"7W:68'$6$RJ<I=E\W ?TNUZAT*'G!$P
M/IUJ+VX$Z'@7F2J.SN%X+C]T&_<G56.L[GHG%0,4>+G8LRW)R(3C;[R5L9JM
M)+N1JXGMA7NXV1-A@-^-81:-3&HITE!J7AF.)V,$,RGZ'Z1R]">,MW#])UOU
MWV8'U' =,CRWP #)W)4S$J6WUW/H<HX#FV;!K,L+GV(,P.D(TCPEPC4Z="9Y
MHM&NN3=^KPO$^!;:Q0_N^6_OPFE#?H:8ZMAEED8W#U2A1Z3;==KR]8T!ZPKZ
MLR#:X^\!85H[0M/_IG)VR>O3F]^FTI]VSQ"H8?N3!98K2M \;4XUWVT!^MO*
MM!%U /$<+[$,%FEUV4?7ZQ$%^5:>M'XC[+'"VBF]W[*<U98O1IM7!$-@*ZZO
M8TAL$X?=DE^+:8KI&Y+/B[!^0;,DHM6F'83]7JZS-WK]TAW2::WX2H6FBM59
M>ZML0%VQM_ YNDQ2+FB53*ELN;H^4A;2;6R)PWM.H>PF'OP,:HWPLH2"@DO_
MDG=04SZ]I#/X=[/#_SGC/WRO?%XQR$SYHUJVY1_V9FP_++S1_=[(["IZYN 1
M;HP;KLOIIJ40EV0?-3T!XW,5P%$"66A]Y'E''U)F*L.MS6Z_7[Z_7%L];E>0
M-H?76-=<UT*5A'H\13%/702SK[3?B.!HRM"9(WZT+B_?9#,I'/=2T8$Y<7E]
M<HE,11>VE$6"5-EZ_.$@.K_AN'OOL6:>0Z(B,BA$-DK0M'6\J&C 3WI^&MK5
MD)U<15,0P9Z$:P\J0,]7'.L^?U8O[^5^,->[T.Y]TEQ[2]U5_.*IZ:1%@WP'
MN9)9(R^D!9'LL!>$<MP-\SF:12!NK-"C0A#;'1Z6#E>$ -<52%: Z<8J5_YY
MD<Q]>)7=K%SX[X8/!VPQ@5#-I1[HMA+\@)^'YX_N_.WB?K.KR?21:LBL5_H&
MW"AOZ./'GL1=\C3AWTK,/\( JW=0WS\14K@VS67L6/S>F?6_=G)#'SX3KU!D
M"PJ)[6Y0PJ/]T1I%S*H,@K[MM*@0J*ZTYAQU/S)V?'O8\&6I1AJBO*"R"C!G
M, @[*W;_1<]&46XDZ^F"1-W Y()%.WK>58/-!C/1%-XE;$LKV,$ULX#7WV1F
M[X^PJE./T3#$9G;1 %.1JJZ#@FV$*9>CI/NEZ4\F/T?; #O+A:Z@41QJH#,I
MR[6'TQ07!PNOA]G$W^J-SDWFV5)KNL4FRI%>XZ<]#CD-#6OP'P%Z>)M>(HPZ
MT%C!@RW?BIM<)'=@SB#*L^^,4<\+G $S9+8%)T=)V,N]AM(0199B%6LHTU<G
M(<<J(O^G /SD9^FJ6>8]W<DIP!=AGV(N0NU7DNH9"_U$BT/EQJ&/%\0H]L)P
MRF!L=D)?CJSG0P@V3<21F9M]IEW?9?;DQ:ONMY7!!VMM8U2S)A'ALBZ.;G22
MVJ\K6S_\1CK+;\]P;E_TGN3%<I,:C_ B9=^G3,4(^7% 7O&24*XXMZB]X@&5
M4,^7(U;Z^KS*?9JC3GU KSM3@MWHJ)2-59S5.'%MIW2_2JJZ9$R'UWYZ3R7F
M[!_GH4JIJ&*, 6SHYK(N<_R_<$P$Z#W_9!8KQ_)6\>SY]*_H-7,XEHY+- W=
MCK%EB7_L2NT)JDP"A 6E[7'0D'H0]8WZII-_M*)-[>-G'^$*P^;GE4V;]X)_
M<$I81F[7.@"^,V32GNK_YV!W;_%@,7/D:$L@0KJ//GIE1;U-XH;C^+LM4H@R
M\L94=%B&!-_.VZW-3:+9Y31/IAC+S,P-AQV$_[$HO:S8JCWYJ'L\X4B!_[A$
ML2??QZ>^IHTFHVMW+>RU.NZJ\.(8;_-+ 752\&!FJ8&.!9 4^"9&*@+EBT>S
MEZ ]ZQA(<1FV!\TS=&"&X8&Q>_"74W&N_ZY,3[[()/=V?Q\;GOEY81FA9IEE
M#:NW=)-^]=D2,HE#3^E6\,8.FK8O\88Z=Q)7(+$NUZ(6<C>K9!81T_"N0A;Q
M]T[XEGF'\;D/M#UL='2T=]4'#M?Q_?09USK%%I:E,"L2DRL$9$_LK[?R__SS
MI.IP>\ ^/\MKGY+*MM"T+P?,Z_0-*M?;.W0.]KMQTL/>P#?Z;^(:@)GY#U!+
M!PA&=:>NDIP! )S2 0!02P,$%  (" @ %X;.5                !$   !G
M,S,R-3 X9S X830P+FIP9^Q\![C39/OW05 0!R^*(J)R0$&A0IJ.M#W"P:YT
MKZ1-VJ)"VB9MVK0934<*B M<; 4G(@*B(DX4%T.1)2 R! $%!45!D2%[?CFG
MH(" ^O[?_W5]W_6]N<Y)V^>YG_O)<\_?G?3I\:^.?UOS+R?L@&N:-+F@B=1$
MJJDY_ATV,"6*7!T Y/(]B 0;(WO$V2Q0)C@ [*$$:GKV+G-$/$.*M3$R2>=Z
M==KQX>Q.M72B5R=<ZU%Z.#.9HNT5@40KWF"\DHD;$IUZU[?L6:XK9[DL*1*U
MY2R3R]>5>W5J9%XGOV]H!CK5-I*(F5Z=C T=M6&/O];,"F2MMH>Z>UP)@K40
MU /4:"$(O+56I015@%+^@[J#FCHM5*?2U9XX.M6WE,\]A015AUC@$]/)GWIU
M.K&N4JG4HZ3NP0I) #08# UL5*KN,D7WO)03B7+W7/[&*I.3?"QD/B[0G$BS
MN=J&ST2,+8B].G5J67O*49TH$?]]'JX@,(VS).( R9!9,B?F91F"P._,&_@G
MXG44*V0)L9[@.(:.$PVS !R;%ZMS]@3^H#A]F$B+#%E_VC4T7JV1$4]O/=G!
MT T76<<0N62O3N7N"9(B"HS8J3ZIU!,:94^@2G,&1^#/+!LOZ<S9&ZXH\8><
M_@?7)9 <00N=ZF&:(6N]1):L.V-0, PJP1X$W>7&LO&V4)X4<G\F$@30H *5
MFD8:-QLGF-H@?285J.ON98O=54H56 NJZ[3:.FUU@!4-GH7\='KH%'JT<=FU
M&"GDY;7_,4K5 VKL=S!,(2\*A,@*IQ&!4 ]E#V4CB4T@N!0=KQ4E[M1I3810
M:TX1@MA(U'CJUJU;,$76<@)),70R)=;&4V0\4TOG:V5'Y1A2)'O4^AF2R).U
M9"Y?D#TH2^0*L@ :Z?*UA-QRDC)1RY&"S(J-D_E\#YGS'],TS$&Q#,.6Z%Q2
M?B=;;^-0>=Z\;,JU=*Y6E$D2;+S08-IUC8-.49) )$@;*\IK.A?/.,NPPC]B
M:F+DT'-&F]D3<?TQ0_?_S:-QAG.:95*III7JO[1+E4&MT^C/:Y<J37<+&3]A
M9V =J*]3&\YGEZ?2*\$ZS>_T_WMV:13$$BMD_I^S2EEX>2]90EAY=C_:W<0R
MB?\:;F/\_U\P7)6A3JG\!X:K_9W^OP'U_Y^ ^@^!QUE 1I76<I:.?XC>9 #Z
M.WP[*_P]QR";(YL\_\ D0&>3IR,_>5R=1X:^"4(D+(1(UC>X07=0U5VE"9YP
M'HU"J:U3R]#L3[1G\F$3-"7]+2Y_4)[!PRR0<NO?X7$*Y=EXL$*099GZ*HP_
MU5/-*%1["T[G$FPIW_445B<&G,$KF"ID8SF"9O+_$$PVO'"$D">#LNOWZH20
M>;8@Q,E.?QIP8J8&[=65Z(28JE=IH<;K.J7I?(-29$.\J%>!IXPZT7:^82?@
MO--OM?TQ[D\8_\_CZ"R1).L!0QK0&(T!-!-U(DFCR9BT&E&CR6$T6@!=P)@/
MV5+%A,U0(6R&DL/B*7B,1DT@PWB-"J6Q\3 99?J&PVIL=$!CH&&P? 2,)D"A
M,5HR<":F<C)&6[ Z@ )B1H?<F0Q83<:0U90,P:9DQF8*1)SF4M)F2B;=%B/K
M,I?8:N"PF(P>B['4\!^P&#5^JU'OLY@\0=@4"%K+I9BMG(_;RWKJ]_^2U6XJ
MQ;T6HS(BSQ"QI4((C+"-?8T,3R/^A_^ 7EYH(&E4R<LUEJQ(=<E&!V(,>!!Y
M:58CT;AZN[%A=0&K\8\C !M+#ILL%KO9F)&7)_<E'98SZ4[(T&B65RO+)>XP
M!UBWW&V6)[ 8DP&SW"9+1&:4\\C*\B"R_&$'XB@',*O-JK+2\8@UY.%L*5,9
M+P=HOZF:AD5[RE..TGHS(B6+5B9008(9WB5%U'ZS-Q3(92!?Q9M*A*+VH$59
M<#B<K,=I3B6C*:<L.AY58J(7<YD$20/XK8T,05]0&0WC,$/@8#D19@QX5)7B
MB*R8C^':8D2-@(E<0D.&.1UE!Q64VF=-10@[[<BZ:(WD3;,*<T:+8@Q'1K+1
M1H9\+.=4D3FM*\VY\"P'T1S/%_(" 1591):OO'R'Q120S240L9IE@X@UR"QE
MM9C,5M03LL(AQ)MR)*/E9-0J-3)D8_82[+$C&M1KAC$G'2]:*TX+8DFF"#0D
MX71$YS:;U'[42SJMR7(BE"DE&Y?L3$=A&YW()."06L_[*B4IR34R5"K\E903
MS8B>8$CK1YA$!,>X6!@&R3"(,-%L@B5P3HC9P$),]5?+;V2HL#!.'&>T=#3+
M%>*Y*$1E>%^&(X@<[\KR/"2) J\H H1L:)8&B[ VF)A%;S2$-+P.#D?D$R9(
M2#D)J\Q5LY'-JFSD*[:D#8CGX)!-48 <M-KBY^$\KTJ;W#).]9B=-&K,,T&]
MTPE[]1AF!<-!>Y1!]:EHQN#QF1PIAX%,5M&;$-"17"A.V46:=Y4QE:OP[Y\:
M&?[^T0RE(QR)( ZUU6OQ6WQICP\QT1F+CC1%C$)87<;2#*>U$NIBPEDH"K1D
M1Y,EC<V5$_1I%U$@$4T5:-C(8D!'%ZEHD+")E*3V9D#.'8'HB)M6IA$JY GS
M+CV/V#PHF7-47*P-A.U$P8#:,%P5S>1 QA[ARPX%$H;-0!77-LKU?WS"'&J,
MKS),5#Q)W*./VMQF6M1X")V=@C&U$  C)"MB+K[$>VFU*D#EPC$X;%< 00"+
M&0@-7_PK&?ZCD[88(U$1$V/*L!^T0&I.Z<D0U7C(JF)0/I^!.'O"#6526-JF
M<QFD8ME#(FP096TN#!2T3GT)BKJC095+<+O-(BM*F8I#'\\H0^XXES*D"F;4
M&XA7S097.XT*V(.)D(W2&?P&K @*=(JBA3R6.//$JU#4Y_)R3IL98<V50MF(
M848>1<FDS<51^FH\U&3U(E"R8*H\H,C0;L#HY,N86N$LNBG ""<$/\ Y:$#[
M1V,#9<ERLM&.@Y58..2JJ)1\L)%AR1].N6VEA"6@]-IP%DK#6/#OZS8%%)4
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MJ)3$"F8GO>F"RV^3-5'4>"PTSYW( "5 #5&00 EA&%.<[@,:G8+(-3($7"'
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M "V: UAU&L!5"9/*W\C08#+H2H"( 60)X $N0F759(-0W'X)RIMX&TMP$0_
MT3JEBC1*1LQ%AUB&B&%<V.M7E:B@75W$%5+4$ ?B589*M@@87; A+X=UWB"K
MA88!K5#!J1QG*%&!8D6IT/@ J(% (8!.0'+(J=4IE %_4)<L:B$J;J<,9H4J
M#&#56WL90&MU Y5P6D'FU":J8;P?H5R%I%-+*<V@,N%,Q]V$ON2DBU:QDB&"
MK)G,N;*1O#:.Y M.7]B*HED5$OE+])4NYG!(J9#R.A]0=&<A$1>%-!-#5739
M4\J03@U &Q)AVJRWQQ(\Y8=#L*(:OJ"R)1@M1\T! K,!K"K'%PF?EG!F<21M
M"-%( K)HT@[ +>@R#![6R* ^[X8S&40@G9EL+.?B$-0>H42/*Y:+50&GG"O$
M&%ZQ,FPFPI0=!&_1$TD3KHBP+CN,5P"C_;S>)J=;.:H@1;M"S%=E:,E3D$6G
M3@&$H#"D  Q 2X"WH)<]'(\U1 DIPY3E\%]*RQ';*?F]7E79X*%(0TSGHL(9
M0PE #?%*H$C\ P3K,E %,2"R.D07DJ%@+(504@"QD9C#9['Q2-(3Q$I\ELXD
MJ]5H-NMB_9(6AA6,&"JX\8H'3OL<%KO720 A.5#;_=D<G*$38%B#VJ(DY]/J
M7/ED&4O%PUFJ8HN)"7<!,44AT>^OHB_$;2S3M%BQQR46<#I5AG#.@#D@+DC%
M8)<M3U6,8*2"IT!43>=UA$+VLJPKBI$AI\5M4Z;U!8L/Q,V4&<=D5ZKF92I=
M$(*^].\)/>36GQY(RFH]Z%>$. #R:@!0S 42:2! D7J_#J/4>3]4A'"[5E0S
M)Y-4):;GY,C,.-UI(&NE@(S6GLWJ(HJL'!E% ^,7)%)#<60ARH;%OP"UIT;L
MI)< "3<J>,)QCI;K03B"5I 29A+R:90)N74Q5\6MUV,H()4%4%Y*A9?S9X9.
MBFJCJ.1*67.^HJP^+D(L#EV,M48\&"H& U8SA\F@R(2YBWJO(DPAF22 )#C(
M6J%1W*UT%"P%D?!(>L)*<VJ?')"RLC,Z7"@>LJ2S52C"V-)(,9T.)].Q-,_K
MC(84S3MD$9P=(V6*V:!DH(BR(:S@(9 D$,CNSQF"+@OHHVR-#'/^K$!%-;J0
M/LY+D8H[0\2%($'[?+J4+6$ $(U.:] 7PV!*T":SH*0HY@RPS4#$2PQDS<44
M.LCBS:D2;+1"$]5[#L%T49FPJ PJ7;(<== X4]*Z[3@ YN,  I8!,"[KRNAT
M (:07N779Z.4 <]"=@#Q<I0BY#89!'EX7,Y%6*E0C8<*5,YD<+ ,9"IN@%>"
M0,ED53& -I"WJ_(ZP"F!3$I?";O]<:F25,72:6>)]:LSI$;#%R*^@C*C#YB8
M#.-3&-3V1H91/U%P8[9 6>,AS;PZ10)%4HH*N83O;U61<MG.)1C>@Y;#A*>1
MH<2JO>9TT2;E,9<M769P&(O(T+!$1'BAC.NM+D<F1+!YPNPULD:6-L#VO*=!
M4:4L*)<&L9 !S>:]+EI4)W2IJAW&S#@>T.-I@XW N(9[99A"R-%^4S*HB7 <
M7P8\.$F0(*K/@WF'H(T1A#K#1&DVR00*.D\)MN2+):5*[:7RU:<RM.A1_IW<
M9G3)CE<RQ:)*>T1^/6MJJS(4O$5)3BPHJ@&T*3M@] 4S)!$3TU!$QAEJ54A1
M=.I2"@;29E,G2H-SGLY6/*(2I,\3EH0M5,%1V0O3J(\)1;(>#Y_QI$)I33@2
M2]!Q+"87Q1#LD:NR2EKVEYBKH)%+H6K$MMM8HU^%!3)Q*J_+Q>(:/EWY&[6$
MT?MGA%4M'L^ 6:(BE -<:-@.>!PRZI?BZ4HPD3^9T'.@UA_W*XMAC]*M^M.:
M&QF>6R+RR5[4QW"_7*A4T$HAZH9<6 03K0839W=S3B>&.DDCF[=D4BJ+I:2V
M52LI(>+W%U)HT<A9E<9"VF((D0F,QK%H";=PE0AE9A4@G@N%! G&B*CQ#WC-
M Z?'0WVB>B/(&P08E^R+#9#'"%?CL=$J+]"B ,,&G44A*)B4(I;0RD:45P$N
MF?Q$*-8;M3Y$RQ54?JX!8E/1:N$#Z7,%.Q06L@2L^V?W;IQ1OU-!2QY])EFP
MYQ),I!JQW6&L%&4T9@3#G&; BQES&=A(J=(T#\6D-&N5'!DFCV8HSFUC$Z"9
M,]F4*$*G+1IC6M3[ Z#/Q?$GY5"5X0EAE'-ZR1 ![4C141"@')=7LV%0M-J2
M60VOMF813"C'/9S*'X\F.(TY).O?B9JBE)<"7')Y853*%E&%(H8<P-E%2L'C
ML:)<R87CVK VGM F9")! KQR2*M2%&4*OSZG*6@I2:.3Y"J>I+0<8 CG 8/#
M(,AV&<J?J/7\Y80$,&4U ^FTM-)>\0H"$>4S7MX &B)*.<[C491.2EZ[1!&\
M4NU/9;UL(IPNT0%&7;0E"@E&*P9]GGRDF@)*.B4G7XU)(5^@$',"I1 %&"U8
M5EY*UE[T2PD[P,9 *F'7%H!2X\E\@DQOK&"R19BYE*ZB9^2 8:G6RX*.!;P,
MI8TI\$1"]@&G0 -YE:C!Q2PBRS: N]F ER9+%=S 0@5;R(A /D!GTGDJ!!%*
M9XR&@!V#D"Q/,B>CS7G"QYF1 PU64IPU)I4]HN3..L$ 7A:YE ?@W0XI3U>#
M Y'G<', !*0@+0CN"J.EBAQ&Y[6J;$)%XPZW#2@K\C97G@FX>!:ARSJC'0YI
M_HB@6&,]&HDJXKFJIQB=;G=8QGYIHPS>S8F@)XW*B(4BLWX/:="3464E7W4N
MM44;!+1(&"DJ(C85H/4(.6=%P1;R=J<W3C,-MEX-#O_P]F8^');2?"1'Z'U<
M690!23 14$=%&K>[JL$!M2O5H4HH"J<9-AE.!^B"(8AA2 9P\Q63F!4%3B!P
M):Y.T=ETP*5-)67DH\\&."D34<:R9 ZF4BIU2"7EY4JU:H=5 &T&8"R?3CE4
M\63CK7<XF'?I+$8T8Y9DD_!4]"6#"PQ+3L&6*ZEL7$E26QU8U$U+#$W#3MA?
M]I78:H -FC@Q;(TZLEQ<H54E=4X)]\OFI=107C\K:M(Z/611A%BJ$@6@4"$!
M./. 5BECGZ!)7>VFM&@*\,K>A%89ZK,RTG?*B<]C)VDU[2^6Y7!FUZLH!>/R
M:V5"7PK@D@HUY9(K*#-=2,L&[;'$*'T6JR"23TLF^ PH_>U;56>!\%J_UY9R
MFKSR5>))?=RJ%9U^%-':#!%G-1ZF$ S!H[15X= '$L5,'$O$2,)K*G ^N$@Z
M76J7$]:8:)O'0-J-R1"E<_*8@*;DOS+F"9Z>S:H5/6ZC<@TW+61K-/H;K-$)
M>B2O$R#+!BBB+^O496TNZ"M7R_ZXO^'&QKFLL>IZS+_SL"./4Q(H<$4=#:!Z
M$2M8*"HLA*I/*UP!UJ6B0&<F8^?-15W>E$34ACP6B !NCK6)3K?9 '/^*!<K
M<5Y;VE4IEP-9KYJB)3"A\E):PIS3!;&0JN( U%49_F&(LHN5*GIMP^U2'"_*
M[F@S48H@'Y5AM,*0UBG+VK2ZF)98?1PBU)%X1*?&[.DTH8_H5'RZ7!:K^-#J
M,QC*9 A0A#!E#,B:1+D0STB%>,X/T9 FWF 2?_LYR*EE1>,II=.%W.92TENF
MPM:$:#3#!A1+TJ _@,F(/T2*D-]1<=O)$NI)(XX2BN .(JZD;64@!AAM5/4*
MX5#HS.0M,@V.2[BB<"8=#T7MQBCJC\M!RZY(BI:&B)V0[9J. %"$=/ Z@U&&
MW&!,B '5LB)H!X(V2?0! 3S5\)"A(*<CQ$,9/#)Q&L.PD(LU\RS+IR-&2]YC
M%C7G6?1?/$(*":"J5-0Q@EF31ZR&<B1LREF]I8K3IB',N#&9YR6KE10E>TDV
MBH@(*ZHRS'(XDH\F/(6(CH3RK(YT2/&<JQ#1X.D,X_+E:5[ME9TBX!(D'L15
MLGU4DF(@ :4C-DZG81-E>]&@+6-J*WG";')P.([H %)V.;E/;SSQYG>B?])?
M+6__'I.8D?OK)';.YRG_[NE$&BT%Y0);,@#>(.[W&0#>EBQ71"[.EVAC69V/
MNT <ADG:ZTK9RTE#7D4R%4VDQ ?4AHK/21MC-IV<S&/N"N:NWNX3F2A!NFD?
MZ0YR6,&IT3(!6X(%$=@25R!QCUGM8OR4ER!C1I>"+BOB,5)38'5:O^"A\SF0
M3&B33%&NC5QEII@Z\?BCG$6R6H8*<I*%+#O0E#>J5%?2[CB1]D)*-1<L!RB,
M=?M"^@B %K!H)FS0$G(E0F.%6)(GO &KTN82G#JJ4BT>'3&+7!4H1#?G1@/A
M$!UFLREM5IU!71ZWVU.* E@4]Z1=J-GHRIN#-._3\W@QZR'QF.3&(EJ'(< 0
MH0 B!;VN0"-#CL8P34$G%8QAD[_L!PU\)&6*&+1NO:"(NRT52TR-<XCD)ASY
M9$86B\.53QD55E\94JAB?DRKM[*8$7.K?4E=M7A4DOFR-NCV^ND4HLKG$K8P
M7)2I$KI8&9&R)K=6D*NNC-^?4F12GB3MS-EY5RPN2G@PA2;#WHC!F(YD]*I@
MT(97OTJ8+&BRL6#4H2WRRGS 4A%=7%J#B"X)0=TV3@N3.KNFF II>%&,4!ZY
M[HD;<!5H=FF3*3J,"4FU-8;8TU;()R!D]4Z[Y--)H7@!<W)H5E'"@CDI6^ X
M+E8FTO8XYV'*<3)K4.GCF72@Z-&5K:)-ER:\C%W4YT,>LU(&)EJ#"%3@&.:N
MRC!**3TQ2<-8;%J$,3@EP&)0V9T 89-S%5<I9V$CR4F<UA--&DU0%@L&R*BU
MZ TF'.Y"..0,9\+!&!-+(1&DC%9OIEE3VE(V1*D39"RGI,$ 8:6S$2'M3"0@
M1 MI5%@1=OLT2F60-RC=3%()F4F3!M>DV++7#=F]KJ#1A5LP**GALU7T)405
MA->CQ#6XDI:-5LTP?C[L5;OC<FPV$!$G% ]5;!ZER'N*.I#(Z7 71Q$J(*?*
MYG"E/IY,*D0AKO;D=">^T8OY6!0M.&U6K<L4\0<U;,YCM0IZ)N1DLUD%%<IG
MTG(M8O 6G Y+O(R$:3&!QB-VK&)WZ-4E 0),65GO?A.!F:K! ?&H<E36''$7
M0!GQ*K6) %.,Q-)@R8F)<F5B%3&_BPWQUHP]EI;"JC+F]YIIO52&R@FUCTUE
M\PG$Q*1DBXI!U6]B1'(NSH;92@;4P>,:.%7!BG;8XCC;XVJ<TC!*/]0@2RYH
MLKO=1ETJ['4Z0@2*H$:7SM'(,"7G,Z8HJ#)AN."F;1I+B=%$DAJ,C^N2CDA*
M"1!6'G 5%"Y1K1*A<*1BLT$Y<U!._U*D)'C4G",@>)$ J3,:J^$K**\"9?02
MY#5'4GZ/WL2$9?^P>.UE7##:@IFDP9\).<*Y(!,D"BXV%Q1#>1&A21R,2OE8
MW&[-Q#-!$\W&,;0JPU L$3;95"Z!-2#YG @(+HEW^$,>/^_%$"B9,=C3>DP&
M2(E<2</3GNKZ<3-IK7B-=I-< R98"+#"D8R+J'J*R96#,5X=LH2#*C8&H XE
MCBG91":>Y[/%8)R5ITKYS=%LTI*L./B",D'1YCP*>_U&1HX]882,&JQ9,89#
M=*%:23E-9%["*YS=H7:P@(D.P#S/J\I1WJ(N8S NEXQPV94)>8HNI.S"PG2)
M=Y,!!#4@"DG+T;Q9+NMPR!R1(+6E4*U3B'@HE8TVW.F':)Z'LVD-7>2-<8J"
ML6C1X\L(L-L-"9Y\B"]YK#232#N@%&AV\$R.3YN2F*GA^S*("71)</61.DPJ
M> M1(1DHQ)H<,5"%1:"078?$(SSHYID4;$](*)H*Y8,HY+101C29,4(4K'>G
M.441QEQJ4!UTIS3*-!/Q5GTYD^<5G-UI1R)V@R_,5##2B:0#/&BA>0G4EPDD
M0:8A&:A"95<D4@B%>"QCI820WVDJ"W8]FM%9$QX,R8/@B6K4;8(=:ANJC91+
M0B"7D=A*)I;PIP(Y><E2I21Z]*Z"Q6OC"_J(3X-) <YA4#A/5'AQV9QS$0L?
MQW"D4I)*589QI&!/)1!'AM8E>21D#>D16L"*\5+8*\*)0%%*9I%H1*V&0Y%X
M,@%98S(.\\>),L<4X6@%K? .08'Z;)6XL5K1YS.9DC-M="4!P@CE8C#F4^E+
M1#!>H ,5#Y[)6$-AEP\Q-@ HV"PE/9PU&(I39B(1QXB"WV/+X(:TB4*#.4BH
M@G:ADDJ$,G&&=,9%V6=*(9<KC[HL15F"P8J7Y<V0.^@MYZ&L)H*@>2,<+^>E
MC(.,(*5 &6?#Q2 <0F#>D';R[FJM%^<RL(JV!5B]AW>%0BE4DCPLDL)2!B9-
M\R:P(FD5&99)TDQ:=,M5%.5W\24PH8VR]J1%GY32$13TE[)%V8FJ:90G@VES
M7@]S)(#I<&T1+N:P2%))^W)<GJ6C69=;H4]K*6O:G.*"<#@,9,18 2 -5,@9
MM3.B2N183J/A'&H35OUZC"^ 1+(:?4:;Y_-^VJ>V8B:7Z-:BQ8!8-+LA!YYW
M25@25[N2*.K3\4K,23@<*6>9QI*EL !"+D'TZW/.J"*LJQ:/J#67-JN#^E*(
MCB!N)!2F(VHF$V5B2B!M]Y,<%.$9@F)XOJ"S03)<#::A,(AF GXP%4NG2P8\
ME3:%TV6?P6*H/K"V@0BEL.BR2J494"K,J LB#45'+$<K [C'B)9MP9PMZG.G
MTS:T9,)E'6!&@!&(G%)-:#$NDT7##!1C63/"T]4[2\DT$Q"@J,F3P!VXZ++;
MP)#6+TET)J'V0K(F_%#8YD(HU"HIG6A&P\LEA%M?"*A491%#M8 ;KS (JV12
M.)RLQD,KDHQ8TH9()H>YRE+96P)(I2M)<UA0Q:4)+L4"&<!@ SBK&<*#D,$:
M*412K(;7"WK.%E4;0FFPX!""&LQ8/J%E95KRJ;*E( <GRF:"D#)Y90Y5NT1;
MF"$1/)!%TF531HT6#+ :]L2P@EWR&<2H$%6I6(\CHDN#&CN30KA(*814$[U#
MG?:$89Y%;48.H6U8/H;9(4P;I95 B!)XM363SLNZ0+)Q#N \FIS"A">88+K,
MD@Z[FX^;69];XGC"6LF%JH^0;,4*1-NT"EX,E%&A[(+]84[OATF[-6DI>8,I
M+&1G?%$W#HFLCO>GG$Z3D_ HXWS1''%@284:]ENU$<[F!5T&1?6+9%Z/64AK
M(YE80"O:/))-;<%+8IC!M*607*,!15:5P!1>39;GXT@ A&2])&-!R1E7Q95Y
M@TB5D4HAA3E31#)?-1NO+4_9R4"R["QKG38D3\2R6:T8DD3*;=#%)#PDXSTT
MAKNTZ8R=1>V@K8!;L@&&4Q-%IQ'G@Y(:PE1F/L%I8]4[G#;8[0=CD TGU46_
M$-<#)5,XBF>!A,V:2D$5$Z[Q!,S^E*UD5MH@/BU0&=" @B[4@$(T'56Z0%)M
MS2=--&'E*M5X*"B@B#_$!85BV,QC105N]!;M9@:PR>(S45!!5KE3BR.9&$@2
M#,R8!3VB"I/%J!BB2#+D- 3 &"9D,8V.K-YF@3 V$H73%K208?@,HO57@ (8
ML2JRF+T< ^6 E@3<!95H0&%MK((@R3"A1GE'V&W"$EF-.<^E<5HL84P:AG55
MPU;+%N\/4E(E[_;X*TPZ&Q'-6+R4QXUIBG&'Y 2EJPAZMYYP QEE@WMDPEH"
M*1><ID3 [W"P+.UT)U3I..(ZL54DZBB&-9Z4P9]#&3(J2+J(BH\V!"FWY$8<
MV0)F)3..?$S/D@B#!>@,IK7(UFH6C/ID@,RZ^(16:R<@924HH\FJ8=O4MFS
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M>==UZQQ<&?*\\N+3JSX?V^'M-4N.U^Q_YI?9NSY^??H6^-#XU/@W1PT:-V/
MMXLZ?[SA8<WX55_M<AVO69\[..?H<[.2QVL^VD@>KQE^V< I-TQ9=_,OB;X_
M9C?J@9=7/]R_?8>#Z]G/F_^R][?>1[<<!HYPF>WZO?7+>\<[':^Y31Z^MVXY
M$(_+[[/G8W7#E&CG7YA!/V9GZV^S'!DUT/;"WAU7S"KNO63R(P>3AZ?<,?BG
M[<\^?M^D8]=?WGG@PI$S?W6.W?'A@CN>6+6X/[9GV >S;3MF/-=Q\OZ!H[>M
M:#]PR-RNB]Y:N&=&9>SFI]2/;KQU=!?;WM]BPW7AS8\ KSV\8GK0T?F[2M_2
MVA[3.GW$7-W.ZQG[^2^?!6=<MVCX#0<3HZ#>KS_5AO]@P76!^)634R^-=J7:
MK1X^_=Q:[E2:NA1].NC;"'2)KWFE<.^O5T(Q%](W=QV\:LC>;=;[/GUY96+6
MX6'P@Q<TBZ!3ED@/<1/MCQ]VOWI)*\62'=<3:^J%S]Z_GAX7'8;<]3K[5,&Z
MIT4Q_56+L1_6;#VR] /DT'7-+IPZLD.\BXDD[AUU0>OK'&L_>+B^_>N//"85
M7P[?^\.,X9-^] V^9,I#A::WI+<*BU^2]G7;^J(N^.J&\5V6?G#[V%=6_&!]
M\<YNQ8?[;;IFP)';BQUOFC0TK9G_]5>/_U;\JF^_^1V_,EY<WTO=NN;;)[O4
M/O_ Q2],>;&=/NL9^M0GB\ V#ZU]F-R3=E^\:^+2(?N>N &]=-;Z89-::L\3
M@Z[Y9DOO;\=\O_&G*Z<-6CA%?8CINW>LCUEXO 9K>NC6\7N+?1G'\1KDRN>'
MD >?W/G]^VT?ZC>QIM_U<XY9^LZ9.&CR^HW[KOT\[AU_(%(9%#\P[,GY-_RK
M9X^9QVNZ+=IU2=<97V^=XCFWSUVSXX=AEW^SJF=IVQW'AMX26'S5&VWX2R^^
M=4^+AY[3[MX<''@O^JCFP(2QP^XQ:M'%;>BX9=V*:X;NP#1X<*3VN\^.]-_M
M&]YG3K'FH^>65^ZY]LMO)CRR9=R54_-S[YSW[=&QSRQH;_UPXIX%E[XRGAW=
M;>N2+@]F>ZQ=LG;^;TB3CNI;YG[7KN6]=_6Z,SS@H>_:[;SR>=,+O^TJI'_S
MY[Y>.=1_<]0S]+WI/PV?NL9LGEA3G!%Z=6V+)2]=D'OSSBT?][WSK>6AZY:^
M]$4/;\_1/X0^7M_<?E6=$']Z6L^^-T>F>Z^\<HKQ^S'ZF<-=;QUJSURS]@ER
MX66W/L-=US.R[B/SVXJA;_9]AKPW&-9#]//K#_1<W$Q X/?VZ"*%^*-+CUX?
M?7C86=749&*/H[LG%2_WK:LDM<U-/ZH_79%]8.H771ZG%KYUQ<2/H_X'?WBE
MZT]O[OOMN7';[YI_FWW-(<WXF5LWW/Z3KLD(]Y[TW$G*K2W?4"2P)P=V^^7R
M_F-_V??PZ/8['ED)#)VX8T":OTKA_"#X\:QK;YO./-N*&SP@U6;[!=/[COH&
MZ;'V>$UP<M\5ORB]^+"-R1FW#.Q^_7J:,S@']6=G?3J1VS5ZR$>AU*#<S1\<
M\[R/_]8_>=0S;L;J!1V^8^KW]G[N!OQX3>O#LW?AS 'TQOW@YGV;^L_X?N/C
MQVN@=P>M.K#WS04'^K2:Z?OQ_F,W[A^TZ;6U.U^T_1I?MOW3_7T7S>AVC&6.
MU[S\YL_Q$3O?[5 9OZSY$=NOQVOFW?GV=^X17\_;_M+!:8-V?SA_A-[R3;>]
MUQ[6;&S/6OK=%F'FYAS<3'ACNWT__/24J>NZ]NXNJ]:\N=*YXO'9?3.K5VX[
M:&MQW?65<1O;7C9LP_C0]9M=O@$8Z^KJ#+URQ^3F;6<MY:'UCPX+N:_2/L5^
MO7;N+\]U8'1+=]T(OYA:U?;"_:5O7K.L_ZS]9PHW]K!RW;,_J"[I/,HUI,VJ
MZVR79C^8-]_YT+;^SVW*FJY[HM.N2]OTN[3I>QT6/GJ@#;OGP_['YD:6T"N/
MUUP"^'X9U/KM:^9^TGSPFMD_1.H[DM#A<9JM$\\/@[;-WJ X\,JQ:=^V[M;\
MBZ=G;+%W\#][0=\_B)I.V?AT[\&#1G:8M+CYZHE0\SG)=:LW']G^XP_M'2\,
MW_[Z!S>[>TV8V'OJ?FFH]/.+-\L\[_*VWJ2_:_:RGBMG+]U^EWE%X@O]PU.G
MI]?4_;1\:J']30\]S^R8=.%[ZC&;%&"X?VSDJE'VIUI[W^DA:#O7;^P#U^R'
M=TJ)^[VWMIVZ8J!J,]U\P+N?OW7;MK;]/OA:_?W:KY]Y>LFKA3<C7RM+:[HO
M>?;K R^,& 9/Z/W%C@G3ONG3?]&WF8.7;=/-N13+UGS48WN'M[>V&= A&ELQ
M\\8Q]7>L'X"_./:NSX[7^._:O^2E:3V6=5E_X>C/GG_KL\>Z+GIXSJ9'?1OS
M^WH_L'KCUK&S%H_OO>KN+4?Z[9R\<SCP]9;- ^_<=.3B;S=^._C#'^?^>O>"
MG4^O/ZI:LY;?UCM_M[*,'+"U_97?MJ/MM[Z+CM<TZWZ\IK[#'YQ&! X_L^O^
M3Y[X1#\[/P(OS[Z@K#O0D3VX\_#X-X]T>?=XC?N=?7=41GR]<>@-;6:UGG?X
MV<J'\PY<^?'LCR\9M&SXZN,U'=L.-_T\X,G71UY6N&%)\"G3C%GI6>GTMD]_
M-5\.S%H^[,C/]WKMU%TCBOON_U?OS1_VV#SHDB?J;GZ_TG?E2[L/K['>NLXP
M:<8#4&:'?<=#Q&-=3,./?=3K-E5GR#,V/[QN[:O;E]QW2_^OWSOPLKGS>ZF?
MYX/W#WGMZNUUV>NVMQ]A+O=^_]9][5?,E1;/$O.VF[_!][YHP!-;+U^4F>&=
ML:[-^DOO&C]<_WTEVKS-8NWHSJK1T1%O0#RX\]R6!N<Z+[OWU;$ _O)G'XU_
M8&[NLI<_Z5';9J*OA[E[C]LZ+W,\U.F*IXD%I)RDHUD[X;FQ?V'^BN>5 ]J.
ML_XRPO'J@[M6[[WM)1D\K*3_=4O@M8^V[W.\/=^$+=KS\Z5][H>_["M<EIKW
MDK5](%RTO#^C=->EZZ()B9X[^(5U*]:MWG#W@-UZHAZYZW;ND='SHEN^B 0[
M7OT&&KQGV5>MUGJ1]SU?^VZ[WS74L7FCW@VN?;G Y7M9'U*4USZR&6W_]45=
M/"W)63/O?&O9Y'8'KHU<4?/ ,J6BGVOIE1=%;N__],?=A]S8I;W/>]5;(/+0
MRGUUSF\>?/_-+X9TSH[/K4#6/[SZ@5M6G;5(:>Z;K1G4\GA-;6_'V%;38*;5
M/<O>F;;@X/IEGT&/6:]?WU?T/MG?# _"?_WMFM_6N+VR"+^:/7C\_?L_ZWB\
M9LSBFX^\TW^)Y==A.Y\QSWQ9]]D52S\XU/ZNEO2/6X<M_7XM=9_ZS6<V/=AY
MX4?F"^5QOS;?W>G8A>V/]MAPO.:-U?EKQ>,UGRQ>>;C#I\Q\Y<Y[OROL.(CY
M'HIX9OWHJ4N=&[Q."K?3W73Q>WM??@,.;_R78V0SQUSNGN5;Q@W9?>'2CDV>
MV#2SKHWC,^*@?]V8=HMNA3;?,G ,X+WIT@Y''VK;LCN[X.7KT FK[]VSH6/@
MIW<Z%?L?M4]^Z?J]GR^\9_*A@>^]\?SJRO(NW:FZ%M>47GH+(7ZZ>W_MR+6C
MGAO1?<:F1X?,>HU]['/XUN=J/M;9I@2^>N="^KG(O%>^/C1$\,3[MNU5:KT-
M!KBMPD6>=CV_BAAO7/C:X*G#NEXX,OYKZ?W Y"/.?A&3T;+&(_VT9O$F==/!
MO\6N>_"QD/2=>>%;WM=5R=RH$=>Z.RZI?7_3@OA]S5LRFY#OL&V['GX[\NK<
MQ^I<RQ6;+EK +XO,G&)=__;+-]PTZ]X]7:8='-U\U<TU3WS[AV2V[M\RXKN^
MWS??JOIX[TM+[]W9;M\[[\FP5CH(KTA-_##SZ\,K6Z52R[8=W1"_H;+UX;DU
M_=JWW?GVSKL/6GKO?C]QO&;LZ])#XY;/NC)5>J?+05-D1E]SYF-/SZ/@^Q\]
M<^L7<%$]P/^?PT/-KU=M>@W](M"E;LO\$=?>\1 MO>.,W;JF\]N7NY;OF?;1
M*HF]_=E5R;$/O'MXY.0)D[L'GEM1\WWCX%:A8[OZSL/WLC4/^^L?^'*VZO9#
M#WQ[Q9$_9KB^_LCR(XHC]QSM$JY_I]T;]4WK5\_H\"/;^Y9UGC:E[,#E=<3V
MR]H=[?OADOBR.T&]G%)BQZZ^N]7&6QX\AM\Z?O>7.\ K/]!]DKU\WZ2-M[B@
MGW_*EKM.&?^B3O<8^72+S^>SC_P'<]Z"NF4WS6R^_>K^'U_^_A=N?,J*@W->
M[#1J\$+_\O<+/[<-U]J;8/<+WUD[/=CZVE6=[&OOV_*HHH<1\7AZ&%_B(_?W
M"4Z^FLUM/[3H]:<*P85+!M_*CIXY^(Y+ANRIG[YPQ CORX\\N)/;9MG[EN7@
MYALSVI]6C.QVT^ZI][T]Q/9KQ?KQDP[_.S?Z.RU\XMU(^!KBSMW/O+/1A1S8
MV//#W2^,>^7CVZ:.F?[T!^7C-6L/]MO6(D>&MDQ^>DJ[S:7%"W,//'/9L^.]
MKWNO2C\M]GNPZXJ[;_[7=0>S@\9=/:[/&AP+;>G^:N_'?6_,?;3O>^L.WN-O
MLWA_CV;>1^Z[??L$Q6B6.KA ._WY)<^M0-@E]/118Q\[:B%?;=/:\>XJ^MEW
MLRLJDVJ?WS7ZDS'I9]]_]:J[9KF%+=#49;>^\6N;:R>/ONR5#TNI:0/Z[^B3
MONN5C&VAKAWXV<A+/Z%&!?7>QREJI&'K[A\N18+U?7YU#MVWT[SC[-6L>/@W
MV\[7=S?=\U2_0ZNH.0<N/1S]>M"XCXY,I#6!;][9;]GZX'1-<N_=.\ 1O<1/
MO[M'>=DK YYI<_'1Z)@M#X)7U5WSR<!6#[[X>,]1S3YZ3]EE[7=?-[4^I05'
M?C_8.G3/ISV//9G-;9^D\$QP[;FY/.B;KNJ/ME[T\%+7T!_NW/?PL]&5PSY]
M=^Y5"IMSQ9B)+\[-U3_8[/.]$X[4+IW2?N;6[)?J1Z/XPX7?^S]9??<7@P8<
M>7=WJRU/]-[9\[?C-:&79WWLVC\?>*I]Y8X>GSN EY WCM<<:GUD"?M]JQVS
MC]V6[""7RE=O??UXS>"/*M,\^UKVG04.6%AY;=F^EO@LF6S78>/1_;O7+CA>
M\_0WO>>\N>T=W5==[SXP[[>.VS[L_577NP[8?E,OV]Y\_[+%;.TQ.G^\INF"
M5U9M[#?Y\.:V2QY\Y9?C-?TF]_^NPY*EWQX9OZ'[N@'&;_L*MPT>>>%+"Y9E
MKI](*K*C4KD7GN[GNA7>ZX0?50CMOOKAY6\.7Z^;G1K6T;F'[;GAV,QQ!ROK
M7K=/4JBG[Q]_L%O\Z>=W()T7'1OU,3!L_HX![)9NV),K7E\*'%ZGV+?OG0VC
M[%@R+3PSZM(%6N.&2<Y1#RQH-J-M^YF[9C_Y<C3N_&C#LN$#^+,F]@N6%P\O
MK^]O7OO\RI]?:#GZG>7=E,/[1(N>]*RIDY=<?Y?GGD]AY_U%L=_(1QQ=[MVJ
MZ7C33?-&7+R):S=P$;/JE4/"UZ_8[OO\F7VA+]ZZX_49?7<4MUYE6./K\,X%
MXX1QN#I^>3JQ^&9T?^K-1\PA8/Q-NS>O>$KDC6_^>/4S^9_:ER>I^6]K1K0-
M=)D1=6"CI'=B!R5E9WXR[@5N'COYN1G3E[RZ2:@==]NSH0^VMURV]-=1DYW3
M^C0?T'/X\YX!]#6?9?=1<VZZ=6BHR^V[/W%8A_COV!+:WG'D@]>:M#-G;/OE
MTNR@3RX7CJU@\6/S%_B*'_>KQZ?/?V]X\L5G#ZY$FUI[_NOQ[]?<G>WT(309
MF]:BGW_=>_OFZ9L1(Q=WZ!<GL6:3ICQXI/Q\DW<*"][X],+P#X5CUF7?FI6/
M__P,_O.D(=?TFZG=_]W",3>LMHR[^^5;EV]NU6[ <]ON#0^<.>_ 8\VLKV<'
MWG;)TJ72%Y<';%=97GWUT4T/O+IDG@?LJG:UZ1Z#O$MC*J^+F3_\_2VO=FEY
M]=@G1W7\F#XX7'U!&WWVS783+A]X]@)OY8ZE'3Z9O;#5"O+^GP//-/U6O3W#
M'RO^MGO8I.6VXIIOKGSQAB^6C__R\$?S>^Y=>>60FCFZP&[54<VO&Q=5?/O?
M/#)WUM;7WXZ"O][Y]N;4>G;"XF]]+69/UK&C [.'SE?'X^>]]=QW[<6+6RWS
MC!J\],HU-RE_FMEEZ*9K"Z.[BI.@9\=UGMS\C47%6^#5$U5]VO:M(YF/HY86
MM69^LP&35@Y*M]Y]\^*U3\;G;^_TZ]%%<]0.;D.FVTM73\Y<97Y%&!P\U.ZM
M+C]^\^TUTY9V7&-<D_M<VV?8':WJ!VS[$9IR!0J%'[[CR5O6N\8L6OWT-X75
M4R^'5P.7]EGXR)A%W= 06%CWV*+TA#=_^59HN,P;IA[=-/N1U[=M:'+%\P,O
MGGIWXMZ]%\_I?."/M=0-/#CQ 'ZPR2'W&P/3ZGX#+AHX+=?[\PUW!Z8_?<NO
MZPZ_(,Y==ZWZT.S2DPN>^R#&S;GFHFWU<-\7QZT_"#B.[>O]9.D;[;X,W&OQ
MNP.R[;-[# ,N_J[MGA?_#S-O&157%VR+=A)(\.#N[A9<@[O36 /!W=T)P=W=
M@DO3N%N"NTL#C01W]V#O>S_>>V><=^R.>\8=9_]:/]9>8^P]=]6LJEFU3Z_D
M>2\S!NWL_L/<S-*W)YN/U)4O5,^Y .U@5YGE1X_>Q[6T$=V2B8:H2->Z(+B#
M/B5T6L+F2X*JT]^E2<+-:RRU UU]F[.54R2/FV"T>M%4-S?."<*CSC= X3K?
MCH/"=+@[,D#!3%H9*CZ [(*,6WLC==1CVY9D)50RK0+5B<A<F(6D0I2S_.VU
M-%"BI5=_9*5B5982+0JDO;Q05[H5U<@H]!6F0#R^<%Q'#C>02J(=PC_$R^,-
M(_LAEZ%7*83+L10F_&#%.$3CG)<A8);F&J;:85L$J97(15,T%_.M-,_>'RR^
MJT:ZUVC^=I8B2F3FMKX[O(K@.MSL<UIU^C?=K.-H=_QP-6Q9!4!4#@\7=<GH
M^=NG3YLAH1"-6%<9D !X8A:/TJ+NL8;MEKJMZY;ZQ5V= %@MYV+UUUD^-SME
M%4]7X/XL+OQ$JI<Z"$@XM'?5C"&.P#7N8H[=:76!LV-GXKD69LI66SQ^IYLO
M4,F">U16\RVR)/S+;I_+JM[.Q\?12BVD5;!03VQ\)N@?>B4*V"R\2=(X]*!E
MX<Q(%6!^@E. ]RM6WRE0S@?DW'VC>.^WI*Z3<K E5TXF;K.12>XO[H08\/\A
MB)8?8/6*\_HU()F93"]FB>Q=OBTH_KHE/\6>-DJPN?L@E_TN+.:U9FV/8[\Z
M(^<?P-OC$],/RSQ>%68#N^+W2.Z5_+-FXEU.\XFD8?YHW]Y[2;TP=/@EQ3Y;
M<&03_8>E9K7));'%3^5-,;47)@G/5I/)3 SE5-M='#O249E?S!A:9Y*>TPGC
MYI)([)M$CA4/ V869W^R!,4MXHO*A$]IH?3G"HDWXMK'1I*KB[SK"/E #:YM
MI!4+L^LODHM"T]K#Q<8U.D 3F:I^JOI:+_O..M3I=*&&$>HA6<UUNKP];>@7
M2M4\&FMX;\"@WJX=O%*YMRSI<GN]O8V#+I>6;Z.A-![$T6+ZJ]2<O3_-W^.^
MN9AS[O24M3FT&-F ;9"-A&YVT+6B4S1-OO C&^=OQM(7TLX_?'2RS4_4,4/?
MRXG,X1'K:"5=7%\,1JA([G6RCD]:B^T00\[DQD9J+2A( ]5RT?K4<,2^(.E@
MS))/%;_7AW[07 \Y1HJNO!A"F'!!3UN6I"7V5Z;(9:%7_YJL#08>.;V[C?HI
M!AP]L,J.H"?7X0B+)B.2!V7;4-/'-O8Q@*KYKK/%N<H,G8=R5M:<;56Q5_ZM
M0@EA:?>TB,ZR9W9QM>NZ$"?.E!F,69W^QTD*>#P;?<5VD)9?^WN HEYQ1#VJ
M!$(YQ^@O@OL,#U?'UK%JGF*(@?*,Y1ROB&\#Z$R6>=)MR/*'7;1$-DHXL;+F
M%\*DN3@"/R"14AFF/4],3%M-WNZAI]0"Z\OT*_8IWFI'<Q_\I56M88LD+L%]
M%:ZNZCI6E:IBY^[XCQ&>Q3(9RQ]FZ#(H&3_5Q%#D2A;!(ZJD)I+G70Z\4EW.
MA2UIK+NP)HSJCX+X*',,SB*WY)K>XD7#%I@+!S"ESC$'.L-\78'QQC_U!V=Q
MN07:^A,$L]VH5>E"&BS=:8D^!IY5,#L,)K-=P>XAVCY.D)JRV@ \E?W763<O
M%B-/9>N: @.SS6C98J?XWU!W^].26EU6&2]0HZW\C<B8FU(JSHQ9U !JGA)8
MKNJZ(,X@<?2';Y0F(\/TX*:S^)R'Q*:(;"#28]F-L>/%\XUH>>Y"?E@.EN^4
MW^N9T*?'P .! $K?^E>" ]$W@)X(UD[X14U6H#3N&^#ST+SRT52?,F+7?G>@
MY^?=-\#/PX?(L[$'RY]O@!>K!Y4DLMYNZQ=\T+,HF9H@6!25C_8^[_%E533]
M-;ALBZZ#;3,O^ UP6WK?+?Y@(,_V]0I5^QI'W2E5N8CV@_M! U7G/(10N 6/
M0MV4/96[N8M!.:G$$7KCN+#8_>JE@HS+BEWE"9EM5>CF4K_/)=G@7G.V&DA:
M-O^AV&3M_TJDWK1\<L97&-F[VXJM*;=0F>F[>A_H2;;A0Q8HLLL"OQDOOB,[
M*V>K4+!I\=C&9IUV6+?F8K"!,WUFNW*C;I3Z/@N"Y.GC+(6-1LJIG!M_/1KO
M]A_Z %! _<"B$G8V-O:X[KW%=XD)Y(5O%AO5] \3H")HDX=$RNG2-["?04)6
M0YD8CYSS'/^@WOJZ0Z4V*8R3JAH"+M*UYF?#HM.-5VQ6O&?WZ(G\\MY+ E Y
MI(94P3=#$_.=YH] ^*=\O9QJ>G'FB[8@>OV2)\:IL5!%RO'A$$+>?#OWJ[U#
M?9=^#19#!QO3D1]#7^BOL(V(W<<CYD#>(VHP2V5?EO:6%0D]3^A=P)@#@YYR
MSNT;P/G(,:"EYBE?INS<B/1U.=^JM*O!<('E<('W%.,4<_&^RWJ :N[8NNL<
MM)C>92VXW@)Q_&<C^C4G5:&D)RA \*1DC\R\OWULO#V6I4S/G4B=V+Z?@4DB
M0FNV\5Q>^1YR[ 6G]]^5R9<_$@1D>3KN=-$]+;T:;[A!ER'X]ZS+EXWV+=.[
M%W0AWV:S6T;H-P9-">KJ_C-Q\/W$(T"E$G$'3Y=8O8-V8J[X<QPGY"-VU#86
MN2R[.'Y;LTXL+%;;-L1\/DPQVR("NZY'#4T><SB<3GI^P^X[E^.PV")C'4.3
M"I5WC03&MK!"F_<J>XKR&(K!((?@3N%MZM4CKF/6_MET% B& )4EQI[?QP'D
MKFN&,YBCC)+3AP0Y7UHV:/G4[8C4MWT#%<]5:'O1GGXYV^DT+<0[IY(-Y\&\
MGGHLB!(EWW/4M%OCH<#"Q3[[O<&38T!>L"#B,IW\I='-8EC8(NHC]2-,[_C1
MW5)\7_KN5'<1,K.9R@3V[L@G<4#NNB0DB7='T)0FP>'[>C0,&5ZB+P##CVB]
MFX(XZ&,D>6J*$ L1P6LXBL7M'8=^=+3:*(,"J2:>VZ[/5U0._E]Z%?_?*4T[
M%.V8_[5>^Y5TDW]N^ACN/_?-HM%TM<-R<*9Y0R+]=QY&H+S#!G51($&,Q>#@
M?T77_53Y!O"JV0+_;?DN^3\M!/B_E_2XV4H!R89,MDTX,9B=F(REV QLMG<8
M.K/3*YZ-7.&&WE!#YV:JP;BY>K-A]_++%?=[D/U77092T,,^;I)@P:^%=X55
MFH]150R$$?9]R/7:>CY2,50+6@.L4/14#VK/LB7*<:2^[T-49E%'U"2ET@L5
M5L=*?NM"43>BU \<[^=Z>X\:#[]\5'>?*6U?EK33X,H/^M18_3NY0SFH"R-J
M(*K+/ 4&9Y"*V>W%4*&VC*\%5_%.1OX(PC]63_[["4',LK]S)T@&7IR=4Z+.
MO,?]<F>+FP=K4CROWWJ&V./+*<398C">52"UN9A];AADC5XX_=]3G7(GHV*;
M4SY]3B]^ _B2C0N>93UQ%Y'NPD1X8IO_$G?#743_U?!XI"%Z&#?EX?E/17]Q
M <7>::NT2/(>&+.Y&\M>(4+!./AWNU %HZ2E.7#7@"ZZLMG)]+. JD?L5#SB
M,CO,' 2*XYD=T+T[V!^>O^?<]G\#I(".<U-?^6?;9?&%/XVZ]Q?IV@EER7CG
ML+4#=C2"UP0D&_4'KR.OL9Q^KAR=%0O'SE)X;]ID!Z(EMYJ1#WJ<?OM#-+ +
M9JXM!>Y0#CQC'E*VW0L3:(&QHMU^7C)B*"=D-(N5,K:\QL/Q"I7)%<Q4WG&B
MS)=T4H+'>CI,**PB/];9*XGFS>W6OMC,3>N!4IH,!6P*C_>&/NDM\-C'A[;-
MK>TL: L2.7!/IXQ \!73O@]1%QR*Z');*@]65KA'+&H?Z<'=%G)[!GZ(-W;*
MIDR*H#=&));[UYEJ'QNSWQO@TK27WTU'1.8&<3Y2F%8X#BC6JGD<6K.EJ+F*
M,++06EDN@1A\%J<34B*0VWJ4>"ZXZB]8:G@K\C)4>'^6)"C?QOJ8=F]VKCQ=
M,D3[B47Y//>T^XD3Z;)C-7 "PA#+"![@V\Y&B>1DX8F<48BS236O7V%1JU#?
M2H=SI=3RUN!+*-\;"ZN[M-F6)]Q6%'_IKDG^<'7C^@:P_'O^@I,;/-^A(OH)
M(KJM*^H0\)K6\H3G^S3G];QT^>0?2/MI=^?\=<K]_"\3:<F*]X.P]1N <.3)
MQ<=P[<3@\EQJ]UICZO36+X,L/3G_210:>%#EDVZ]_^>V[-F6[G3LT-:SSO-7
M%V_\1'3DB(CNM^2-5K=V;<J]M92ZCGUQ4;0&30RJ#+<9E,0OHC;S.M58+)IA
M/+BY*[PUCCP:*'0!L0P3/N[Y UX7_B7WP*@9+T,\YB?NN+%/?ODB_,V6**U\
MHX1-< >%7OVI%*&=+J+\M7K,%^6GN$R#$RQ#<-U/5AV0>AKZO<&?Z2@:%L-A
M^JQ\6V$(7C/46Y'B=5:SG_^%B_TB\R^$"LF7?TNH6),9'KN9ZPBD.11='[I&
M>RKMGK ::O.8BBVR[PYG"Q*B?$U9ZY:3?OV"/Q$;\U_IF?GWJ\]H/T5WY?Q9
M+K(?!7?H[O/QQF// E^3Y=X E,=O@)55_Q?,B]"G6/N'VR5WJ?%D8<E_3%LD
M0$'T-NK!^:][6:"5IP 9XOK[0[S&S3> H=K\#?0$.^# 0$2C/G>M'3IB/"&P
MH=#AUNLO<D<>N][#T\=E]<"];RR>R"^G$2/EHLC=7:K6%;#M4*%PX[_+Y/OT
M-(1*N!FMR*6^7[_JJ:CMQD-$E8M=(C)8IE3U6#>9L96QK;3(MU7XSS5OS(N0
M.TJ,Z510XAF6>6B0])SKOZY^X@+A6#K/O!,4Q>PS3S5M*&>^^N/4NYE,"X\%
M=I;2R3/O>"F=5'HT.G@#S#0%UNZOW_9>!-_?RW1-OTX?DM:^ OSC9QU#TG[=
M?5ZQV]E(0XM_(=)^0A-VZB1_>9DY=Q-M9*N2^/[9M#%_DP9\9WJ7S<^[&UST
M!I!>>.V+UV=#$ UT\UW[?(IX_/D/\M(+[8.,[1O .&V=[D%.^9*K:;S)Y-"R
MJ<N5F-RM.7X0BZ35_E.R@(*R](.=AV939]N80A[41EX]Y&_[S;GO9%"IGF>
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M)@[(M=Y8(9D,[_7\WBYURA<(37$7YGZ")VO'4TDY*3L,S.#Q7OHO=KZ]?[=
MX?9#_^B/8$(F!"I@]B>I4$,%5B!/8X!D(5,Y1X/X.22<+",#%;+,L>U+E^%A
MZCS#D%YXNC>/'.BPNEK>PU@3E7L4C94,LJ'F&WZ%C-TN]2E[U8%>0MBD0E=7
M*C/:W9ABX[[J6.8<,G4OF.ANF/\\^\&$N S(\(.3$M>9L<V:/ZSP^A4K(F\?
MOG.GBV1.6LT^P8/AH#)PA/VW:9U=%V"??I: O$JE+#H]&60B'&&N3J[&&EX>
M@>37F/6<;2S()!*\P!A]BJQ97^UH*!_+ZN=ZW<#'9X V,M[&HI7H4'<VZ\=$
M"V3/*\6A[+>0)V4VL_=Y1Q77:9:0];T>O=)X! =FAH"$B&;6.D/F[ZQ+[&M'
M<_,_$:;_L!T$!?$J>.?/Y=A8]8\OI>X#-_W+(?/AZELVN3-*\Z'/V+JF82:G
MFT6!XX*"&\S4PE4+@;GN\1[FWUKC8A[P2F/76@8*B8 -<P9WB.S#X9TK%G+!
MD7"N5, ?GV3P",V T3SE3:1#/6\ -!_7GI(QJU8W:WW6'NO.LO6Y@$I]#X71
MF<,.J:PAL\R!?-'CS>3U*DZ^^O3%/C*_6%,B@9+G#E*BRPW$$U*.WUO1'?9Q
M<60U8W7/CZT8[6UEE<G>193=^)OV]A)J1SH13UOX3[,+9Z.>YX..PBH_1.!O
MOL@7_<(Y.N^O4EW2SY?;T.I@_;)6(;,A"/O[!CC8W((^ML[Q^,3%>VI=@!VZ
MUI+\!*C6NTM7[,FN;O1Z6$4>61>,4S]#?\]M75K*Z+@XQ+X!N F1'BX_WV6\
MVDV] ?3O\D&\'_/]2T01[?=];T>=$N_;.2X\AEXW+[?(3CF>E_-?6V\;G*SO
M5S0NTM:%77*H_<]B_$CJW@"M?E[A3XJ!/)9O@&IANU5"_[N49YJ6>/TR1#+?
M(K)/=H%G7Z [K5_XSU,D^@;U88(279-YH7^KN%)].A+.[@^TDB''@;XO NON
M+PQ_R,2XU/]T-OXXBI8EV?187H7QEK'!S*LG!N-H:%F?+#-OD_$PS335S'$H
M=8J][Y&$A _W$@Z4CIT-T0_NBQVM6\RCH(>^46.4T\7C7<S.4NN6O:OJI5HX
MLIL#IHI3LV AA &,_V(?+#S:!&O/^VX3<U5F(I(T]D?68#C%47!15+*"[SV?
MZ^1/XS(X<>]S;?4(+O*B&9W;-3._(?6(LW??FQR9GGBER[S.:#/5]H*?R.S@
M5UEHT /L\QQ%JB,VFW&9:"@_*Y+$BZB[QRRWC[^[,I<C'5ZJE\](Q=4K&$)E
MUJH -E@ZK LJ?=BE;:$HX %]IHI"*G/8^QFK89*0Y&11:OC9M=K>^4=%%W$Q
M?:.2JJ=1\X8M_$@SC/IHL_5E] &(%A7+9Q5.+E^=>M+0F[ISJE0PRXRR4@&,
M)OI4>1>261.3=QJ6S/*E\J.Y*&*)(H5N>D6QQP4_YDO[X*GK7GM&A_5G.>]Y
MR ""S_^I$":_Y-5H>?\_E&;^Q1*))D%S^[M".($)AQJY/%R$T\GMG=@P#^)]
M8B./(@A7]0Z -A$%>9)&UZ>0)3)L.D?/ERDA^H#\]8$:LTFM$"KAN7X)=\^5
M/YTJ=Y"XMH.R^D/K;Z6NSXO<+.&.5>54#0D+H7 0)^*BQ3)<9BS.Q=#08#0I
MDWB+MC:L95I1\<%@#!78,T="9Q<-*G:)>@/0[Z'KY'#*/S:JNH9C!&S!S_;*
M-<J?N'Q%ZK.(UJ/*C68%L(7Y"5/%Z9KB(W7IF.JW^>W>[?K-LU'\1/@)R-$I
M?L>:EW>I4=WCUF:*Z_O.%AC2^ 8(_8W-D G/_'%D2E-,?# ZM((PC >.3Y&#
MI ZIZU\E(H=O@%?-PNEHRY .O:18O_4K+,-4)CEHV9;^MX!XY7N(CS_AQOH;
MH,\[4?^=4CJK13)_,GE:#IX!WV4?JG.+^:!-&72FPSQI*+#\U ,LG(9P%FW'
M+F.=SRC)(74(J[LTCK)3+2\L=(ALD5RC=Q>_.PG<X'X#E,>_NE*]<%O\8_B)
MKUR_[DFC;UUV[TR.[WM'GHQ/E]X W?_$8VIDS[LW$_E_'T6W>EXW_^T-.S<3
MV:];,@_U;X!5D6K][G&#@ ==43O+C1&38]M'J4Y>>6+QU'OWLO/IU!+0C?5]
M2]=?[J[S<UO0/X]TLMC%/^.ED$\I_&D6WRB7D2\WCE "99C2\=6O*LD^UU*A
M1J%^P96?QW:PQRH79].=SURV:7EO(E+":[DPLH]5?[C0!E\CBI%.5L,1;OFO
ML04Z"?7_2HO\[;=SG&=@H-8%0NJ_@N0G4<5"%2P&3&,%'Z1Z<U9PLF0\T(*G
M<MKUJQR63RB]- <SAW24=AGP-V??OH@4^A,7Q/$Q#431V^;CTH(5P=)@^>XD
MKCQK$<W\F)\OHVV!.^NA;X!/T%]]#>D!V2]V4^<#^W28G[O"G\#C7D\I5^<C
M39]>T:K? .&FOY1>FRWOMZ[CJ,E\/]]K9US?,^Z^ 9)]\)[)#/^AJZ'_YW9B
M69$[LK,:CK'@2>^#ML1AE$(-&96(+<-( 50C:KE$0Y6R!0^AC N0=SK6X4;E
MMJU\T^%&D3?Q<BS7GO3<!-^6]55I;QA.5!CV77%G_Q@?<=A_=:K@P^?.\+J-
M*/?NSWV'N<3GE*&SP1X*]C\>M?#4:$R5VQ)\2ON@TF<7[Z>^1>,'(<</*D*,
MR?(>5HX3"D:_1ZJ7D*.Z#ES=CU6^6.:Z@\3@1#Y47BY2:TT'<=7CX*['R^\G
MQ+@K:=B.=RS,*Z)>PIKRW'A);**-$2WV_)X_G*Y4)?(2NRB@ JM?4DOQ@=<"
M18Z=-C><CV-'6@ L%BT='S+*+N:U*C] <V;9X=R>!D2P 6EQJ.5]'^DX0J=&
M8I%8+&*]G?P][LN4G:-I)"=X( ^W'5NQE8U5=G/&1*3U7!S$Z)Z6%'I:TL92
M4D&TWG)TJE3D"_VK47-CA'/N'7CI-@4ENSMY=\[VRIKY=_MU[;OP/]@,S(GJ
M!\)J/W7^>FBW/(Y_\@#<I[\!\!1?G-\ #K])K]X 6X?YU:*G2Q_6OST;?+D=
M>ND ^(Z] :)+ UK? "U&G_^''2P"$=C.7D\GN..&^+BW  GTM%\)[S!)-\J^
M';XL)M<\\7:]G'PX_W<^$[VSDH$V3UM\9AG5LOAF"02QV:![FBMTVNAL6I3$
M9)+OJI(].UL_OX\DA27%C?=+4XM(3)<U4'Z)LC4I793!](3?+@Y7P>#-@^9C
MRN3&[$PAWWN"2(AR/CGOA\U+B5OO;</AX.RK7ZD2E']F.0@V<-\GQN10>U]3
MW;FSF*D(OEX9;G=GYU+%^0D9_KKI='>U8JY!*TO%?T^:='Q5,DXNK5\/1Z<8
M(+E\O2N7S7&_*W(,QN)4^6^8-OQ?' 1[#'S$V_GL'K[ANZJ3.U;3%_^YP=UK
MAG+@",]JIE FUJ?V"RF7U3B)?<:)C'4CUQ@J3]B*/:(]@KP&Q);7S5':S<8C
M9K5A7S]=<DQR+*^/TVPYC8E+@RH3)TE?3898[>NJV@ N!Z\6# RVM.RHS@[S
MB)>P:91@9#+34M ?WI-RR$>9?$+1>*B)@K"7Z[-BIS!BIV+*J8<'^IJ_#NA?
M$O6;F+(4P^N>\N1_E)C,F+$DY/(#%A6Z8&CSJ0BT=%W$N(K)HT=X"\*ZKY'<
M4L;6IZ_N.YE;)%!X8&;L)2CL*Q#T/A0&>N-0I5CJI![J6CFC-(0C#ZVMAN$H
M6I@+33,,[,QOO="2[4C8"6(W"=I)]ZB$\0,%"VY\=55)QB:>C%EM[3.YK15M
ME) ;;TE=Y_ETZ^7N9!\0G'L.6@C[&;KKJ3]Q&Y/"VJ.!YO^P+)L#3 76L!$'
MR=6UC,PC!@]O-ZW0*=;J,*R%5_<0K HUKRK@$$L2Q9 O&'I"'6O!"Q"?(5,\
M5_M0+&QA(R,U*;=F6#1&+M5,\8'B.,T>"?)P//E';U1-#*A]W5].G_OX+M2_
M+]_WU?Y0,MX4+6PN@MX 6(5KM#-)AK6K5D\^#:@'A;E,IDO+GBQ# 11XYI4.
M4.6EF>IEW&R;NE*=G;SF]GIH%FM)<+GTH9!IF&WJS3I,]AR7B"4O?I+QBR!S
M!_U2<5L^*%_WB$2E+,]_8.CPN;OMI]F2V6G)<A&S&&W0NV^?2(>=,R(+'/46
M/#9O'N)S\<"WVGY_XC:C<V>U*6H?B98>OQ(Q.G1D*M>/5%WQ&I ,X/0UL?F4
MGN4[P=L*3)F;.78MEVJN!O/(P^MMR[G#6AS_S'>N=G7'.+2,=MH-DQ$$3\ 9
M_92+/FJ*.$XCCZE+2B4Q@L2QA,J&7'^V3X64+C;?_5*3MT=:\6RD\[F91*@^
MKK^=@Q7V^2Y7+79TNW4$!B;:JK9AW'=@/R8]/%ND+TZ$?4)CK*.N@Y"*W*M]
M^RM31(QP&'M?Z!G:??SK)%"MB\JA@U@>1C/9??:(]32%B[\!_8?.?PB(O];3
MYV%70EM&Y)Q;2*Z<4K \QCC*]7:;TV]1ZJ[ZMP[WQA>28"OQ/*8GA_,TMO+$
MLUR-A[:S0 B3ST:5TV.1#XOS:@OV&EG[V1C<X7W.HT?$";M"&'_29H/SSS!>
M%#41QLCF-*12UOO/3K&] =F'RCFZ;F\ .:ZXY_HE!Z)V_PW:IRC;5$H_6*]9
MVQPU_:Z"OE=)N7%D91,J9T7J96?(<8JOI07@LITF+LCSJN^7<\^FNO0(59W&
M,.\PLP&"01SQ N&2V@)[=N41W40:^/6B'].Z=JAV\-:-P:NQ6WM^N5YDK3V>
M6&-X=H[ONX]HDK 0.:/J.68KKX-IY26R4BO+'OH<7 MPX>."L5]!7QB;QY5Q
M01T@58Q[&]<Z!"T(EU;H85PE76%D?ZA9,F>3%*9\V=</$ZYIN"%\*1&1NIZ1
M.9YEOJV'/VD4B=W!MKK-2@<VLHN(2>S3/^>45^964"I)?=?Z_<,UOM-YT%3V
M-_19T&/=4/Q+1-JU7CM1ZAWRH["6;AW!%?L[4"62R^@T5:/V']< ]V^E[2L?
M^@XX[7P)IHF6,F!"//5\56/&0(F&[S^^BEMN!G4(+05(0>US><86+-6>,SN!
MH;HL<_T*7VHQCHAO4G2&XP!>3D72/)(%,D9Q:-1>K7G+BR9#*I5=I[ 6.Z17
MJ2WI7!$#T.E6T<*#I%[)Z()N+%N>+EDZZ2\C9I)(ML)AF)6/A$3)D,1D29<U
MHG-_A8_,F7N7[;EEV86MAT%ZRO&:H98@"T0NU=0%6*J/A8W&=\K(^SZ:#@\7
M'@N$<;A*:.!IL&_55=!YDF:K_X^+I$R"L$L0!@T1WQ(%QR9'2B"Y+44W7-&X
M(1]6"^]2).U5>39P7RU4&)&3\<CVU2C:U)BG#"_%H:=2.,]*:WJ=M)5JQK*
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M5B'G_J#&77Z98Y^_:@0\/5VF##*^W @"$;XCG>EO$XZ,^EG\ 5QKFS<_TF"
M--?A7P=8R:#90<*'C6J4!\,S2RE4:D3:RFO=US(%/YS38'DES\&[$@+6HWG8
M6L>Z>LH!D8[)6$N4K-M=)B8?S'.LU4 .G$D5OK/;/&$XA]:(TM_3R*H63YW4
M.>>^(9H1IL-2$O<'OG+ <V8I1-C(FV#$TXKD6Z.UIZW/^3C_XZQ+]&87(%=A
M]#_=?] 7>&OA;KHM:\[Q#:!P5#,[]6$+4LK33,])$7_BVT^5&Z73*IAC,DLG
M&8XB?U^-(K0KY6[?>F*N0/*1*W;(V:ZQA0"6;6]KW<0@N(+5I5,Z'JO.G]@/
MUI,B5F,\+;+7W$:I4!7H8=5'2ZEBET N'2W.19(0LDR4:5'Y53?6=LR;5#L2
M3^=LD_O-85(<L:3"?$M)(/$O'2._%(LO^=R55F:6WNQKCGPJY$)4/&PH+D!4
M^IU1Y> 6<9JPQ=)79UMA[SQO#2N6D)_QVB:RA/A!#"'*1A-E\F24IFR"J(;U
M115-#* E8N]N+J\C672!'C2,H7VM8[;D5(-W;#F:U)_@J>?&9=G(^:"2K/C[
M4;*Q!%MH_>:IX^YA^@EEV+,\">#)UE/&Q <RU$A'J%CTD'>([7J>9J[^]@P3
MRHH[A9,'A^.S=UTDW6F*H._W,N%CJ*;PF<A]<\O1/_A/">^*AP]ZXS$GJ'_[
MLOO\E"_/$T;(09NJ\D['#^RL=9R837F@=I&3$7$F=+6L&,J7MG@<)=W4!/9]
M7V>YK__WY%E76X"&9XT66<$$.UK8B.)^L_;H9CMFP*V*P$'&>HB[!-*<$L+B
M,YN2"S;,:;*EG=&PI852V?:[@+%]@#29SH>I2%U2D6?--WM,.)?D!%G7]!IV
M'2P%:I24"A *&PD'H=0*!/6DW&/0>@OCND-!\Z5]2U-[(H(0541,;4H+V@[Q
M('SYLLXG15V*&5N,.&P>1E\IZ?0\8&)$-GT*9@R[/#,T7S\-@7-^<54Q;?HL
MA":I/"5R$?>TP08GTR--BV*Q*DDLQN_8 6!VXZ3, UP:S0G_P&%=7\]B'2C_
M?>'[F+/'+.+XW&]*-09V8N(3PE +HD+FCZ<_<J)03)&)K.J;U< X4>^S8E(E
M^=R++$"L:K$M7%%(B8HMZXHCA$Y(YANIKJ1IM9-NAIZRW?P& 9H):/J,/<S1
MR)2VI,<<FS8<2"8_^5E%&N=#I6 @;P1'99_U"=)RX"F?_-9SD,=2^N[5NA=X
M^*&P0*RU,MMP+0_[J]SL^\$H3]-7.I)$^ED0,4Q=-<.^ '5HSDI<H\#FK@ZX
M31P0V]!1<M7MKKY64+:]# 250-]7]I J+U9@Q-HY+3TQD-SR;>7&\SK6[ZVZ
MVDK?-3F: $\WIAIO*BZ5!<4ML'U$&?<U[SZ1^LP*5TYPMB.V:NE2(8;Z/6O&
MD! I$KAQ)&UIR=5H&0YBY7]8>:IJ6=$A'K@RU-E!WX).'$03&<8*X&,<5?Q8
M):]#(L(RI\/6-.BY0Z=*J -\]'#E %FWF??%4/[53__X92):N^DF:>+[IX:*
M1CN^KF55BM\(M0XHCK'41 U$E'_<DN\,'PML\\8T@)]4?.M+FB.);%?*%'J0
MFO]56;[*$@(M[CUL,.UC;[Q:E.TV1NMQH>M79;9K2[JC6/8QC_1QL)HM2#DB
M7G5+(F((%2WA.M)K' NT\_,+J?;M''DN!OZBL#GBMH:[,*VC67PUK_R2A/6.
MX\2J6:;P%Z_18F8E"%QN6ZR1;.&@X-P\&/=9GV5<X>G.1D ;U1]X.3.MK773
M;KU5R?KS6)]3"R8L5CX+RM8BTJ7CU,@;6S/CMEKNDG3@K=S*NTM\A:=:]P?;
MESU?BXPH!YS/9X''%E3XJEE<W%]0FOM]!RS@XOI7/B8G8L4N#I$RZBK'1I _
M1U;K;8UB(KE50!K+?J163'ZT<#MW(T%8+$'3C.VFSS+5$^*]&QH:9JQ;@WW&
M8U -7MC!KXX7-*ATF&N[1N': FL=!1E]H @V9U7.4%\?T?P><Y2K3BY)&,FF
MXN%RW[(<)4 A+C$/"V?+;HGD]C =V3_=MN' &T&JNL:9N0A.7;7%6]WE2.4Q
MHABZZR[YB($$NSB\BJ+MU]2GGVL$,UAAD$20;>[?K905-ICHM.!LMW<9^@,?
M@99$+#>[0QX#D,I;SNUO?T-E<B0EFM\K4OJEU+>^R_;/Q<P+C^C%3B>P7BA
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M@C*D'*%S\5CVDROW*ZJHY,H4&AJB*O<$855!7#P:P[1+#ZI6Q"R8DUB7&BH
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MD,%/LXK"8HG%Q0DIT4(*7RJR6W"",-^HE:J8$BK"QV*Q'3PVQ6A0&=F0Z%P
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M,+:1X)%5)YPP(VC4HL5^#-?KP*K4%"R-B331)0R+RZ\.*B@>&A?0@!2]F>A
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M@D$3%R,R 62D2LK42(5FHPP!MYH50JAD(2$]*+O>J>++>&$_RX.I?DKL-ND
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MO"O?^<>X'W]34J/.-=B!Q?5S=S4HCBLO:]UP;<+)WET+]4?[17:N,7QE.E*
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M , 8 P#_V5!+!PCW$&17GT0  "QQ  !02P,$%  (" @ %X;.5
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M\=U @(&:HM+)!\;9N1T3DQW,PU8>M@CX06IPUW_P%*'_;*<(MS,T<D6JLAA
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M_EHX=ERX>63FHTN8#"O/+7L9;.[RQR]U^M!FE'UCII=D$D3F<S)ZE7K733U
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M6QY[49"=$$@<+"8A+'$6$W\5_X=J91C8XS2UG-1]S]UV,/")^I]33%+"7D0
M8B]BRR,F A'AD> 7%N.Q%143YN$'@45! D)"$!#(]@?0+\K^ ?3]KAD(^DN;
MT[[8G8 )@D6$!05.LC[83DB01UA V)['5D)8E,=67-A.2$B<7P@"$?@!\1LU
M_X!2/PEL&-SG/Q>@9VN &PB..+ME)\/\(T<Q_T/@5.8L:TJ"P*>KARP"Y FQ
MD^;["^]?"SG]<S#_/0?\0_Q?8W@Y0ES_EOQ$1$[2Q8]<\4NK?ZWD=%IX@> 0
M!8<3/\M^7\#__)&.H!"OP*\)XW<R_UHWV/%D)D+L9/E^"/Y@_&-T?CO7_N\8
M-I"HN*BXG:@=#T0 !.(1$Q 6Y)$XG1I"$B<;&HB@J*V0 /]_8=C^F>+_>X:-
M___M80/#7$_O'_\GANX$!W2R'SU9N67MX3 7)I";&]0)##J5XO-TM?MC9_$S
MY3$A84R_)N9_*/E?[*P=!.[TGXG27ZS\Z2>F_]<Z_5^>F/_>XG@^,?_&_?OV
MZU^MIC^V#M]C4_4TNOZ]P98^NT+XKZ32OXG_3KO=_^D&XQ_BO],.^Z]N8_ZE
MFG]Z_A<'_V4S_W-O=O;KEY,K!XBLL#3?[]@_KG?Y_G;!^_UJFN^/R^F32WF^
MG]?ROPNR_WXZ!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y
M!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'
M.0<Y!SD'.0<Y!_EO!L'_\U_'0USM9)B]F.5DCV< 2@"T_R*=*OFOZD [>R C
MFB&Z%08:Z8\',G8"&$Z?KHB.CO'+@UEQ<+'QL/#1,##13^IE3Q^XB'[ZS$4,
M#'1,+ Q,#(S3)S4"L'%P2<DNDN-17&9F$;BDH$\I"&0%H804#=P#1<H_4 DK
M;RO9MIW(TZ.=/KWQEX<Y @!8V!B8..AHN'@GU1HGIIRJQCA]GB(.&C8&'AHZ
M!@"3%(OL,K: PD5F?7(0CJ![((LBZC%%^8=+0"$#V[:A5\)*U^!!V[B4K,K@
M.$1(:&96Q5^?B?A^.^(:>>X5*PK]BPVE=KKO(XRQJN!66;F6^OKO$N6<4>4/
MW&_HN,N >A^8T$Z0#M/.97)&2(?K^M"\1*=S(LLF5R"8GSMT$=W:(;B7XMV)
MFL[W:?4@1N5=;QEG8>'. ["F3>E3/%AZ7+JW*7:UI6RDE-6[1$2,U.P8@*T6
MK:%%PB+(7*9ZV7) EI24>@6IA]=1G_3@8<^L1&]3?);Q^(Y]5_Z-3\;)XP_-
MRL<4V5Y5M >!#=?+WLV",8TO[5)QN"]'Q;&EALAWA+/IHZ/[#;\C.S0L+VM,
MJ_K,Z_HXXO66.M#=R76'<P ^]$K#-#9)@O,1NF6" HB3+0RM69E3'2TX'S.]
M'_>%1F\K(-T;I]IC^D!G<^':MR+?I[.^]:MI+;M:;]<&;(:]9&6F;6>,UDW8
MBPE;#=Y*@Q[K*&M.F?,,*3O?'!N,$3=0@U@Z@6]#'&!X:;7;S L?C@%/&EP'
M<ZL*34NJ/4Q+BF$V=GYU Q74,!':EW+WZ&<UE8V='_0_F ?>$5_RG>(.1<.,
M'Z2_SR 0. A*K:V*#]RBQIN^)HYEFWOEJL&#' %-V_M=5\Z&Z7^[F$"+8.?0
M^Y!T$6["OTE:9+^1:IWU[G#SG:1[ETA50[%QNN7HF^J@%%Y,05T4 S46:5QN
M9_1RDXMP;-1UU:VW-1=O-$3=>>BZG7T0NEI]7U< $@ZL?WA9[7YF8XC!8KFA
M)X".BX%@Y2OZ[4>#]/6?5Q"OJV?:,\QU GSZ'4@WDA>XS(S@[ (+"F-YXN.?
M=";#JO3?B8I>* RSJ-$J"(457,O.OPN\)R*J00)$5P<2*X9K9C;<L+Y##\K)
M+92NX7\.R6[_='%!P0=JDXS[4GW'/+N4:'3&Q-WN .+!V=]/_/(6&0 S5B@2
M8X&]K5M>8CD^Z/85%NR\C'&U=-^=F7HAZS=<3W@OU<:4(OR)9#NL7\NH;KT2
M):CM>0@2 SUY"#$W-?(ETK[:WYW^LI8LA:E:N,*55J(ZKA^WYGT'$5^6"]1^
M@PAF%*'5?*64S(5MG>I6^B2YZ6(=:7\IS\<*[E"0>FQI(<?=TKR &O5]H0HR
MH;=;MKHKQMQB6.\S8%5!-SL#! 7%K%O]55I&D0M=7\&C^Q/ZSU,32ITIW#[=
M[-L;)/=KG.1E6=(EU<D7WO?03Z,AJ(&HBWJ1O8K[&!#(Z<-"D.!L,BY&,Y]U
M\_%T7\[;W5FI:7,89M=%SK#KO/ID:O-+LY3J1D<4#H:$[KKD0G<T2+2HH8',
M^<#(5V4 _(XZKB!INI7TJF/ =:6%#]86:<0OENYMSD0'@M Q8YIO[,^ GVEM
M[^@Q)3I=E=B2[1"DN-X6^%$YV8C'_W[ (C%]2K+KJ\_Z'\W#-/>NF]^_-%%4
M(7B R)8@H<7VH+;KU*>^QG854((1_Z#-.G$\L5QV-50LUDC#EHK.1G1)BQ_M
M[B25'5D3NG.MH:= T V!HAM\7IS\CD 3&?_Y/5MF3W>&-=*CD8;Z_H+F,<1N
MZ4;?%SE&QD>MC&6E'C@[85*MR\6EEB]O>!\#8NNU_*<X^#S?'&30=X[1RQ)G
M%3_/*ZJ=A!:)W6S4>$0(FEHP,E$.H VG-!;,X6LKDO8> :H9M'QI5G(KIF\F
M+J^!N\9D;Z503G5AJ,QZ-GM9S=&"?(C)IP]\)%<V5"?Q)SO*0T3;P?A+ZG&
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MG40QU/ZA/5),4MF[=";\/2^[(+ H#@LM._)!$+N-3(B-@[C^P7*0,]M;5^"
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M= '5TE;Z2 +U(NDG74&)XJVTPR?)K1(%]X9+C0+7]0_S1DP\:VZ:W[;'8FL
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MGP$:#QX??]1>,L8H^O)5;N2%Q0(];D!4 R[T9*19GF6$/+L$7S5I!T_LKS(
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M4I W_S/@SU+\ <N4VFG\V8=G -*Q2M'SX171I@V$4<)([? 1(_;V3\HSH#V
MZ(#((V;6*U(I$-(/$_5]S]8L<:PCB=1]^36CW%+T[$[.[&/9W='7QUV666[2
M"]OTZH>J6\?@3\^ U8,/ Z?ADLW]5A^CIRP9I&^1$YI)RS/.-77T9H8W^5P3
M@2-\\-G^[+)V]KS6$Z#-C'6*D*"QUK+GP]"\>D]4^[=%6.ZDT]5@]+\=/V77
MR?:5*CGY<8+*90B&FEUI%^]0(/NUE/ XEQ/9 6 OT>WOIXKD1Y[9$[A 1\X?
M+N-$]((J8\_CS-$L@%&@]8-R,S@+P(N1*'R<'?C6*)!U39762&1>/K^!HQU6
MNFJCN'6H0'KVH&C4+C=O_:"A0ZSPYT+^\=/-N,85X5<0YC. N#%N.?@;OI-Q
M=MPW#CR;!-[8BZ6?J_^(/S,OR3BK00[?I0SCT7RGH[Q:-LN3.#653_G'U8P9
ML5X/EV8J]Y+HE:V1!Q[@I9<URUN\XF?G9#*08YN__93?P]L#>>MYM-NNX5]D
M]?&.,U&!;148S92 8VGE*GWDGA]+3R\HTUK[LP:9TU[?4I>F2$ ^0[(\G.]#
M !R$X]PRM0@(&_N@9'A5>:OS241*(3B5_A %_LXD?07\.-@L<:7K8)R.K@CI
M',0-D6E#YW81#R=P.#;+N6[L48KH7C*025%?Z+;"+P@604M.P,!_\#@.*'RC
M8<IT-'$E(J GQ%"/-,$__\K"_ 'C0XK'IQ"$TERL[106!BU?0/$^&#/@TVGB
MW*"CWHMS"MU3UZ0!&E2ECJM)3RQ^RD<U'T:8J0/)+S(GKO3*P_0OAHZ-K_5P
MQ1+ B2[*GPP5J98M4'>X3=--6EQ]0P<HE( =($&^ID7&/26"0,G[C ,62618
M'L*"&D;9%LAZ4DYLICA6):%#L2WX0WGP]>3URYC5Y2#18PX(0>M0(Y\W[.16
M*%6=I)7A4KD8)?.T9(PV*C/^T0_[>M[W*VY#A2*M) FE.70B&+Q=!DQ(36B&
M&#%3(8XD>8G3^H$@:E7;+6*GXJ_.<4<%>F#[;L@[LZ7]')FZ1M-8;<_VSQ6.
MY<;L23*NA8-.*\)S_=$\/.,:Z#+?:4K*"^;2F*1@!E0(*SZYG<T%WQYHGF4J
M0TDBWV0B/TUKPD#)GR=R+QLW@MU2Q)$4LSYY4UBW9+\8?HED@LV*"!A-ITZM
M<.T]Y/>-8^O-._<P.T%IQ[EISX,[3$/Q)H\&N!8*V<AW5+M_99C$<1BQ9&@9
M[\ <BIG;K,PY9Q/7V-::UE,+P-VCLLC+'DW@ ="Y?EZS_[S9JSQ["G@&$#11
MX714OY#6$=91R:>BZ88=[6%FFOVA<12$WS1*+UU7H$YT^U\URKWHVW=JABGS
M!921XG,FYXA9B95,_5R[&296K[#M$8 T!THJ'QXK*^XO_TNK;ZJ%B_YVI;O,
MCW/M5 ]E-8^F>.<ECT?LR<2')9M%O6<UN>1GO&AO\:;.;)*\,0[!P")D(\M$
MF=8,2X1YCBW,)/ 1POH?E6@DDVDR_--C1/3<-E-FW(U(BC&_DCOB<)B)[#/^
M6XC>Q8HETN'[(5[!B#YPD>JX(-9BT1>6Q9L)BP6HL5X] ]A;#]*/W.3)7&5?
MOA] ($?>N-RI@5\%S?MEMF#=UGK71?Z.<2LS,=4=B2+')7MK98RM&YJ(%C//
MUYV .#Q)I(@C&<5E>D^ 25&KH-80(=X?":*)%K]8SA;>$C[.A(F4.HWE>+F&
MRP)^G"P_ W2E63NDA5&J 9GXN\W4Z1)BLS;OS'<Z:-,Z[5"1U6CIM&OC+D5S
MRVO,;M(F9@^&LJ@&/\W!E#=R495R[(A<$<I-G+AZVZ8;/_*+@_?B1XWOWF+_
M&/N*^0-E:4#E/9;(;9! L"RMCB6\4I'G5U&\GZ@_OE\F5C/81(.9" &9F: W
MZK3+K:1Q'*\8X0L+/ /@L$7/FSI)FX*%?/O:N;MIP4ZG/53Y#P2?9C-V%:,2
MB5PMK<8BB1N&]64ZJW@?"2A=:-#+1G/URA)A8F+7.%1B>$%^_+U%.3*8R)-_
MH]48\N4TJC4$^*6#3[^QX?L7BKEW2X;#3>^=\W.<R[F_9ZUFD@X&C@C^5%UX
MQ[3X.]UV9@"(X,<N"U.<P5K4:L2 Y2U76IR&<G U_)X:N7W)L9]H[#'JB</H
MZ:#_)4KDMW B#Q8J$\?3C))R.[^[Q,0O0M'F4Z&9UG3V?Q8U3&X>FFE6YC:>
MCOB6UVI!BV];,9WR+5T] F?'05N_,A"Z\-[8;VZ$;-\=C&[5TH1@5G0].) J
M#XMIC3H@RIL_,I[L6VX'O[TZ'YXC FDLZG8O@>=6U$>8!A;BL;IC&J:W]!W/
M;?0XQOZJ18J,\<02,0KQ^6]R.U,%^VXC"I ^5OJ)RM!P5YZ^+.R$3UV[JENY
M FLY4_7^;[BV53ADF\+4IG;"\?6(98%N72G\V6,/H%#A;8)'>?;*JE/.Z6RR
M0.W[^JV\]<5G0(G+3E03NIAN&)*!9(K68"*>C=N>24>M1-PXI+G*G"/2TC W
M&O(:Y8[.T=M.?)5K(/-*W^8_Z@Q;CHVE"ZJ0__B/[K+AZI<WTV+],Z# K-"?
ME5A1V!A+\4N/EP54V#4'>18)\G+)SI-H,1E_XC(^=P'S1;\[]KZQFG8J%BAZ
MA=WQS4"=HW6_X8JD:#A)[:*D0$)ND825R^K3(>>Q"A^8LLC1Y*M^EEV2-;G&
M9)8"?6^<+!OG(S#V[^L7F0FEE E$^(\*DX[W"AI94TO*T<?<G'W7I0OW$79R
MI==GPSD4D*_3G-;+E'#^ ZB.1E95-L7LRIR=@,O"RO;"\0^9U@6FQ@^+/ Z5
MY3D#XN%66C:9>_%&@(,_DSV5]B+Z=X2P#^XW(\6JWUZK3C+E\^Y2!M:4U4-'
M:W9MIWC!OXA:AK>#2WE*?VAX&KUQ= 3!-_72=[6N7C-G6<>QIFD/D=>J<(X2
M_+1T@C/L2.,_ ](6TO $2@W_C\^3(/?A^TP7*7=8>8$S35&&Y9%\K=RC6'.E
M.L76A 7X2P_4._@; EHRZ.4V<@S]P%@=/BB5>)S0RFL\H LP:BR?%XWRS=!?
M1>S3<?'! 1%2/TB+!'PMGSAOL)Q.*&C;51HS%KB52=29^;+5JUJ"W))],VG[
M$>J6\W.,QN#\%<!,&TXM\J?O;4QIW=#@C'O3T/KP =UV"/S3 U'L,V MEP51
MF&*0"I@:/.?! /#76 #^\GVB>V&/70Q/Y1 >2"QK_/[R^OA%Y] "YY'@5KE7
MG.Y2S4"6[5FYR4HB;($SK'C [ TS_#8J/U$W;<PQ]C5-0AX:<CEB.V5, 50-
M@D,4!RGOEN"[NU*(TV$(#QI5U]Y ]H.;X>VNQ+O"EE4AT6B^;3HRF9#IW1AC
M6Y2<>ER1G:%U>[B4DHP"5:K0H'^@[:[(&I>!OQY;L+^K/^'CWO%6-@C.?[-D
M5TDNWH=\> 8$6)YU'9_U6_P4=*I(%X\#ZT^#WZ?[]_+*[;#_[#]9Z$N_.C-#
M_WH46VEJ1%U^[A  C?/>CC6R YO%QC\)4P'A5U$)"V.^5."M&F&&OV+/@/68
M#"MT?,7:;*8Q&B.J([-(M/_T_,WKWAM1**FVTD21MW">/TJ!U:U%ZR(+$4WO
M:$8$?X0-8#_\ZS67PJB^?;IX$B5>"86"ALJU;'YZEI[K:H]^H@=_+AJ*+3EU
M>/WW$N\9(-'$(8DC9U]&/K)1?#*\GMB"L1Q[<R<^)HW=>9BYX6'4>!;:ZS-(
M:7XSD"7J@1(Y'I43TLW+"3$Q>%F3P"*$TD:F3O^,3!Z2B>#Y\LMCA>7'2ZH7
M5%A1%OE-C&N7E.F#+6 O6%+6:A3 AI6V+G[^5%>@#OX;(.K.GW06+$P;[_P4
MH2;XUDWY^%JE$*O*JSJPL&,Q4@X!SN6GUHW>QK' 'R.14%1>#([9GS1@#LB+
M/DY0%UQ8.]LR#O98@#W&ASQ%*!P;OJ96PDA0&#SM OK<WFU= ].;'_V[^+P"
M-9<M6^=W7(XR0#:5"[2R=!^^",J/6M[_U9\:J*TH_Z;G4_D8HH2DZ_E0#76E
MI"24?V-<_8VZH1>*IKM4A(V-"G"5WO#()#HV$EIR*GL&X)Y6;"1_L46LZGPM
MB\W1W*@=;M:H)Q'ONS:<J6)8=;FWOO&J,#4"$Q_6;<_P2,%?5>\#QF.2R*LL
MVDD\#,[5WS[)7->K.7SL'QH1"82FR(C_PCD=ART_;%\?7Z0O4^@>W )X,3'"
MNN^Z,&*#C&/#=,?S,V),L*U:MHTX\!R$G!I(.,QG>R.IQF@SUBGS4_+<!?,_
M?5PDL&<$,%)F]?G=LCHY%(<)_3XVC^!4=<>6_'$[IC@  L\]C5YF*[6Z:K^"
MR+*@K:B*;;OZCF/NB6V)K:Y);@ZC#/H13Q1M8=XT9P9Z3J]Y1W O&83!H>(.
MOV6SYB0,T^5:(K%M<#CQR,*ORS0% OMVQO!@SA)J(J?CUV,B_?*)C9/W;5&B
M5,-6D(V7WT?'=TQ^ +!%,\"O..PNFSP%OGPKY]W"C*&>&&83H^8CP9.J-%_H
M?_,RB"+Z&+0$?X+.^.6V9QE*S_ ";:CVQK#%/++X1(.DT_-7NKV\&L_"^%:4
MM'DMNG@=S1)+R=QYA"G'L,FELZ_XMVZ-"VP&$CV_FLUJ.VI=)7VLJ(>H>A;S
M1V.OO9?IQ]''IK1'?6G<8A?4K]+H'%19T2:@#-P@X6^BVKH:\UA'\2[E?RL0
M9%77@O$"PO<2I83'Q))"!H).@\]]9DUUPFH"PZ*]I-?ZO^B]G#=;^<J2*Z(Z
M#S*A*RW$I><)=3EP*%)-(EZ;.:)\02)PNA@Z"[0V$(JUQ.QV#,A\!B1@7QT1
MYGH^/? JOH)T(<*^B=")=U:-FG)GW!V\EK##7\C $K>JUS$[-NL5899RB)&-
ME8]D&*5*=@Z 1>7ROPKA,5W<Q>NS<!BEC!Z.6&GO!F'3!W7N&[Z>X]<?+&'[
MW<WN2X4!^*LP[O*X1T'/JXO\W_)>\?Y)Y=9#-6(T*"-_/)OIO&<N22VC8K0B
MQ%>#B9+C%/,;V2$3Z1$;ET57=0:=W[P:IL.G?)*AV,*H\(# ([MC5WUH'P,
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M^Z2IX<;C];>Q/E7Y7@Q08N/\D.N@Y-M$<5R C7.JJO@06YS^_),AP[_07$#
MF)<W5!]5/<?<C=9KYVEU_$7/;-6X\GO?MR@'U,#65])Z(5]2;"Y&?5($3JGJ
MZ3&*&4A4;(K+,9VO^!78(_YN-[S_DYN/W,5[T^F#]59D[]NO3M4[K7'#!P83
M0LN68(AQFYG8IU_&&5">!+QX,J^?@S5->V&5>[1!P24UKX+"U@<L)W?RUH>#
M;T$#$'I-(-:S=-FB>3/!3Z]:?T\)0M?HD/FR(%.>-937M907V+>9$^PN;$;I
M1N(,43.XK%2O=E/'BZ8H(-^>'<J2\CE.)'LOA2+6:\.RO4D#>+#!/"(GCSI:
MC1X !,TMCF([OJMT&P@)JA@A=6B#2I1P<L464\,P$*'&JA/TA[/EQ]E&]0@L
MDN<PP5RK87DYWRL!8.S@Y]9(_0Y3M6,;G;"T6SWMR.>ELC)[Q2G[4[-YL>*\
MNE"W*\KW?<ODG&FK73UQI0*/5IP>O0@W.'5,0B/"WN>WF-$LS0].G_&A;CF%
MW?:S3AGFL:<,"9#/I:VMUL5L_6K$I_V%63F40?Y"TB/<2$6C^(3"]44UG=4P
MEJ%0V4Z82 5<*WGW<3$"G+' 7^ G^VF*V9FZEB4!+QU+%;QMF P)NPCAG78D
M.<<U#!;@67%M49.G\C:?"=J:79UFCWFG6>7,#^QO1#QJK[7FE'HUD+HM^462
M<49Y@V=XCP[,<OUB4\TK;!#7\@%@\N-<ZPD4O]29OU%0-J>%_J7\H6V&INH=
MF5=U*B$[0$7K>J_ ^?]P0;YC<I?2!@TG7MC/-BRJ:@QMUK++F4XDBBVHR=,G
M5;XZWGI=GZF)^:& PTY8B+L=G(80QLO*6R#?,H)F2&[DZ= RDH4%G/9BCBR,
M]=1$O^L->\&73^'WC9=7C-ESHM*!O&6D+Y9_OO"8OW2_3"D>7/*MJ\(T'+UX
MQ_J&H0/CR>Y(M997'<N?X03E>V]T1_\ ,$A>ZS3X$N5T$B7B94A&:)"2TD:+
MO69'NLQ4FNT&^6;$7'@0GVKR^0L>K<3/2BQR]GH(H>1-X1<[/0<6^\$T(\%B
MWN-4'\#;$"VF[\%Z1L4PYD>/S8N@M)O&E(M#>NT5XI+4]"*I;P2HP5RX>2%K
M=Q>W&Y*8>];'_1T'TF!@*W/(]?5]5XIH2MRZ1ZV0]HB.J6Z'_,"C %[\ZA0I
MRIGCO!&R=N+T]0LC(E4%C.O$(</4M%A;L,L"!K*4EL_US4OP^.)X@_H7F? .
MJ\FF(U,G,>R?Y2;,F#"'Q:GYEP7%\[%(_BJJ0#*0Y7,,T"HOJKOL'7PMH+WX
M@JV[8L;E6L9B:X](J1V>2Z8=[BEQ,![.+#SD0'2(B](Y^DE['R8=>3P$H7[N
MQ0=4;XEC)P."S]494D[(5'E!J&D=&O(R5=%#S[#?.@0!,I;HYLYJ,M[<]#Q\
MU6>RSZ!CX3KYK;5&OX!YPC\QXR&YB)_,<MKS'KT^W<@!H*'.H\L7X:S=%C>6
M<S?+93HO7EP4%#0;8,/ERKVEG"192!\ 'J"=-E3(-6X$U. B.X[:D'*M5>X^
M!7,P1G#$S1&2-4/EO?&Z5B2-W8=-]# D6BW<ENY;,7DU@Z68])"1Q7IB68V:
MWZSIC\]P;_6-LP< "+86P%5?O>!!"[^//\H_#']'>P^S>/M+MN"7\[*15M4^
M%/5'RK2N$(M$@G>?#^",O9.T\[(<?#6HJR29>%+U%4UKM075&YANF]CD,Y/4
M#[9.06R<[[0"-XUL?<P\S/6_/^-@ !52Z3[)K\=#>!%A""+-#W<TM("Y[01.
M2\C(Q;-=["&3NUU*JE FMSD'3U.$3FJ@AD@@"&^R^^COX>$HIZ=%KW4,*W )
M#6S;J .E1.[(>9S2S EQ&PG1"4:8=>;-CX'RX1!9 FK@7S3EK/8ZJ_F/@[G%
MD@> 5CT_8^030GL%?LA/"O_LV,'W;%1?>R7Y&#@:4BGDB02?3P$[A!5OO=@Y
M ;SCT'&;)7C(VO$RW'C$<K_M<:]@'<>U=*15 $'4LZ?I\W>G%GQ(\K,_!;M3
M1GP74=S13V0^7&N*L>O8.=!>E#PA0J1P^C06KMK9S N*XJ,?CYG8T25G15->
MXJ(ET%C,]6U8!O,E;Z6FR!,-)3+Y6Q/7>OU>H)@V1)>@*3(3M-%^N>@I_E%\
MNF1:U/$@YW&&NR5J>2;W^,\/FK*Y!'8$*SVW$KMQ769<DW 4&^YT?12J#7%E
M0^P=6LJ2R82Y)97S F_T%HC0Z#;!M)*\3/F$>#(=C(')"US.6#@*0$=L>IP8
M#3GK7VDYA"R(:]7Z3__:6^+$.C=H^+*XC80,-:>:;47P7),5RKNB62J>??BC
M)JHZDQH%RTU;^M9!_N3+LRYB"K^##:8Z!?0>J> 2TG5:!L+?\D:L-Y40#K[&
M[1&'I$>B0 @<@NR$=O'?EUTJBTR00<843:B"M2%[_-)90L;SC!BC$S;V"HTD
MGB73LL.]Y^P\N[CT3>Q$,TFL2V)3%H]YY2H^T3(C@=$7ET+D:9= T+\.YQF3
ML$(LGUZ['W_L&O%I9)O@OVOTJ#M#$6G6\Q(K.=EN2%VX@5LK!8' =K\4K2\T
MFXH-55U)OC@ (O_)IJ?^N@^G^,->!8#8EM*7T]>? Q>/D=O-XUY; N_.;F-S
M6K:T?*3\>P/F*S4.8=*" DO^+0[:QGA)T-#]_P5R34FXR6U>88"K^\?.D\Q=
MFD9PVZI 5E_FE!]MJ^]7^)*#68C+ 7\U[ ^_R[FZ8 4G*P\CI:PP5[9/_Z?W
MG/_>%[B8SU83TQ@_IT]-"3E5\Q"G_=*7;!9IAZ,,SV*_VZ"EO6>=^@^QRN@)
M<:A%=TUZN8IST:(5[T*3_LH[V:&V;,VI]IJTT>Z5X;A/;A1\4"7ZB$+C9=CL
MHH=YW*YSJ^OFLL.>KW&Z38Y9+0EHTGRN>_(%YZ%1+)QP.U*6'(79KREEW_G^
MCAQUHB;9FG;E5.D;3%KN*(*_1]4Z=>^LK.M\HLES..WXE.5<I6=2]A,=,7;O
M*WD]PNXZ?'9% 59Q]EWF6:@S9W+1.\[JN><.*-Z1;DV-F^#IE%*1LBV[;-[*
MZPT*;-D#X#%?HGF'IE\US.GOT8OS8%]LZ]9LSJ")D4@+>:Z)NYY]=C O%_ %
MMQS+9D641"U/X^RKJP] QE\RU5Q1E14RGI.OSQ#9[-&63=,."PQ!7BBV-/^&
MS?C!4[%EZP@OZ)@.WCDS?"^P8\#*J.W'4=.2XWGABM_7#3MR)%"Z4/[[_-(!
M"5(--]>,+F=_Y*V7#T4!X:DY9_R% _0I]ZBC_^OWJ3OM5A?-YM7W;SL%R<L2
M5['*<7_^?(VGTF,K([[/PESW<K5=HW%%/1X >%I/;DZ<'#,..&TGS.UNQ#;K
MAX=H+QZ[Y<*#&]0)1%E<R6V6]$QHE&<7U!$XZ*MMB#G8B8:-5\_\B(Z[5DVP
MV+BRV]VEW6@\B*.@3Y5,0VD?A7-]BI;S6#E>;"\U?%;2$>AVL-GB')&V0SQ<
M,YA;@)/<MA^"NP3(5;$0?Q.BXQX(ZV@T+4YHZ #SV[U)3)26]..N?C5,F#8L
MPDJ8:$9"B3\EPW@J.@Y+<Q!]FC121H,3[DO\DOY+G.1;R!/\&5K]+Q$$@!T0
M_%2/7J#4W8;'<MDY\U*<4][XUX'>-DDG :40#2WMCG_8PI'96*&]QZ*T%FO=
MGR$+>J\^1A0]R5:Z8/3YA_<N+PDW34099RL_O3>YM#I0\?68?1P/LJ"JO[B)
M.?$.7%D6W)?UAJ[69A>.EZN[AE(/EC,HFYN*4]2K$?*!66STH+GI:3N1[Q)R
MP]6U&A29!^M^4=7=_SO]4)+,K4B&*8) VC6FLC"%>@6=(QB-Q*3-\@MW*0D'
M$U^<^MR7:_\*0>':=_>(Y(]&H]#2U3YKE?ZH"7R>'*1"*I@B6%7H2:XWOI .
M]5%9:.".&+7N>DQ*LU(OSZ49GTO9[>-J(/5PXK]#2M(RO8H"Z59/E--G:@2
MU@/$3!H^GGO?/FJ3+6D^N>J:R?_O("<*T,O^^;LB232S7[#.KME]LOO0Y;)M
M[&&L9 $BD ,2!L;\()^D\F"@U@W;1ANW(UQSJ_?%+OQ_^;_SZ=W_%8&5<PO
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MA<4'30<T>Z%R6A.3$VZ'4[,_&42215AN3%ZQQ][+X[QZZFEOY"WAZV9IWO8
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MD'@8%Y9^' 6"T#)=H7]2DQ8E_F)W%9TJU.0F3&,"*+2]9#\@Z6/T)@ ]Z]8
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MD69&$9%!@)^W>\8MC+S::4'$%]CCI5;:,=G[]O(,L#'AILGWE#90,'@1!Z4
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MT5K&<JC;&@Z1"8\A3I32KZ(9XXR&W!HGTYTF]].@(%,=@D(Q-@3XBW1#=1\
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M8RR_&G%GK]/<=7\">\]'A(9?/@#&926'-/9H6I#..[K &<6\HF#MY34*[T
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M7SEJ,P^)J0@LU,SU^R3]<*6T5\^H5GITE6;/#P_:O4@U?44AI17PY"I2K<5
M5N(M>X.>RZS_L]V:J^66&0%\Q@V0.Q]UX[QXV/U5;=F6*84V0>3Q ^#G!OJ%
M2ZRS?7(]6,2',[)/CR7VUDY9E8>G*26H7IKK5J_:1;R!+:# X:HY4$A> K3#
M)8$F8.KT+U?I23 ,1JGB2\B]6 (QWX56E#$DMII94&=DX,;6Z?7G"[C]$?RZ
M<M$G,0Z*&B4#9OSFWE/C36"*?:JG1VYVI=S'$;66Q;Z4!P#9G?:" D AETSU
M)B325>X'7\CBYX=5\7^\UK$9DQ@_%-P1]9:4%3CP]:]Z\D^)]\O<KGGO[L8
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M-R<>W=%W*$]9#8QA$++NG_X3(6].J1N4PEYQ*;GL$><IE(&RDQ8.0L)X-=T
MGJ"T6ZWY*3@GMBWT*//P$>[LB3[@6K$-'X/0T3$!JTQ]NHJ]T<S-ZKS'.ZC<
M(?GQG;;N9@!T@I1*7$WK ,)BE4!)&/X(2-4]^PUN,I4RSX(LYT+.YZHO-:X#
M$C<>UV.W_P ?*#F'YW<FF2 \XT.>*:!]/LS?$5$GB#'!-[]:=5W;0.<#[F-R
M0/QF 7*/$TKYV&@]"?=X/0'KX,]HU^0WG>ACJ41G!1FUT9@^;"3$(BP4U &'
M:>M74KR_C;K@S2,^5&.\\8L?8>'?T]QGR:WL&46ET'E'W//AC)X%,FTNT/J,
MUO,IK%4TYV]9EH97:)1BZR37L3(D\[7T-3U#B2-\=$=MY"3)\C[)%6*>8SHK
MG!P-)ZHXXCG-/I[35=I"F43#%Q4" 13R]C?LH,3]CC%T;NTSVZ_M5JXEH$@.
M^8Z)7#7SGF(-(P= AIHX/A)"6Y'H]QB.\>E^1 "*:](L1X>$2Z*LI'P!\IRV
M?H43L]-(8(+UVKV(R2=1+0Z&C?Y;5!B%$# '+YPK8O4?(":S@-]&J-F.PR_0
M,$1"CJ\E]]/'[>G&&G5B4*.Q-.GG2B"#*,^Z_1X>[Z?3U[XB2%<(VY6,'6M$
MI:(!!4-JB?-XB &5M7DM<N-,$]C'&G=ZG1K<H&W\@2J1H^*##R=3?<%7C7H?
MM0+;P4G3(0DX]4=TID]F(HV; L%IS1=XN)[(1,;1%J9"?6QS5Y5F:>HFZIFK
M[[D8[CX*$Z%+CQM = EZ@3Y;X<63F4,(+7WGW5?@[1%_?>Z#,+&)[$UMDZ$Z
MAXIVKM#P@*S('?J\S"8*.@7J*BF_>9$E"_>N\GML^D U/Y(9[1Z3@R^?]AA\
M(??VFP+R5!^O5BN]9^7\_A,1SI>E"&,087P_@H7JAQHI<X0TM]F%!L]OYW:1
M:!*NB&35^IWOOO /(!,I[M)_KF"[[=4&$-M=T;2T*>^LQ35(NEB-7KUK""K:
MV#V6E00IM@Q?.SY^&F)Y_M@UNJY*_5'4S0'PASJ99?Q"=$Q*A*+6%8[[8&@I
MZ]?5D@K0?><(0T%9AP9(80X(3B+R,DO9H,6.+LI2%D9G0'LBL%VBAE^CY,+H
M=ZRRY!_RO+O'"H$X[<U-1QF[#;B^_3$GB+W+0G0I?(*YX!_%SF*V%S>_%Y)W
M8S_O[>0!"/DC+FB5#QN/#NK<D)=OF%)K410Z!\(?6WW+HBN<:=/T+GC*L+YD
MR."IB5KX]$:*N/#C47R)'>AI8E8T)_I5XIJF]1D[9!O QU^$2DV=E@J5V,_W
MRQ82%L,;5A7QD>M)=R;?Y4TY3B $T(<,(^MZ126NM/:6?#MVY:%7'E6<=Q04
M7:GKW>)F7F8_1ZM73$]E%R3#: _RX\B,!&+O\XG(,BII^L$9^:6-OE6X_$X:
M:;I81Y(!-EH]^G('AP-0#R5TIRD1L&W&Z;K*Y<0A8D8):#'R 5.BD)]R>--7
MNI9(P:E/D$3_;[KK;KZ20DS1B3]E%<V&V[YN8@:$T4H?2*;#R)08VMZ_?F12
MM#>VY>NI1 *Q6@;#6K[R;6^93<\W3]SZ.I.1TI48*U%Q\CT@R7S_D$5[.0W:
MBFM;:<%1NOC$SEQ>%0?L<AD,2L L(!ER86?AYDTF8)Y'LB8L9H,NR?7 YV,B
MVF_^FJZY3'739#8V<C"N7Q<4S:09*?J8F*'3Y%>1:3L#"S9W!YB1RCZN\C&I
M??_O(*1"68WA?=/NW7Y07UU^.SY_+O 3?MQ,F^[WF/2I[?NN L.Z?&/KHINE
M7<9Q$I2FY X'Y?&R^HD8Y_5+FN$J-^UWUUY1O#+HS]1)$M8W4L)/0 ;;]X--
MG18==-C=_[6P<KW\/A=J+2=/Z]K6>+0J<1_)QYC=W,5@D28TL;SN*%H?'U8D
M,@!P7&3$Q%ZQSY!6++K'R'3U4K#^2WNA4=S(43O'@6]ZZS#,==>D(.".;]O\
M,).N&KD;0\X;7I&S:.)7)YCOM;7AH'DGI$?T5S*?GI/2?U4P%9O**";ITY?1
M865D6PXES+TL5<J2ZP9:F4/[XK[_]G31O-907SR)E*SH[3<'K\IATV?@>!;S
M'[$6S"#'QV*/1K(A]/WP'FN1.8:DO:V *:DLQT-">I3&SFSNO5*'4KE$_7>J
MMWNM0@#%W\T&*ZX-3UE&+84;,!JQP_FFSGCE"XZCYMW7I!X]/PJ'H[8'^EN;
M[G@1252GRFREDKD?<,?_&W/QOY25OU\.,L[( >^XE>2YA=GW?E%A'-V]FEZ2
M5:9E/7<&_8>S/@,GWT00N7KM_U]6JHE;#::X\3])=BYQHJ+=(0"?,88+T\14
MZJ[4MQMEGCV-,6L;GI,AK?J</1OE::WI 1:/(M&"FP/1'[X8KW8W9>@_!,)/
M_(^,=LWV:86.7 57IPP&Q&S7^$S3/$;%A=FW/E?OLO84V$LRS]* =ENV;492
M16F['NPVWM>,V2CW:-36<;:JZSX,Z\U]RP]K2/Y=9?L]\&LL%[ATWNIW_0X;
M>,>E?F^BW>S7?9''.S4[[ODTJR7!0H$MSKQJI8VIL:6+Q6^.IZ%G))\=GV;Z
MW]=6W]?NB#"'-=S] \!#&HIL['02#T4$M4V6T79,"K+8C#QF1\RH:O'"K)>/
MY8KGBT\W.0L$5/<]7T>?0XJ?,T<J727N''#4R^(HP6CSSK4XRJPU$%DC_(:W
M=J3EN%S&VZ)1SM]_XM=\;I+[P24\[Y\<E+;D_JR6*T1=P.?)U?E:#W+.$\OK
M$#!.T&L^]QP<::Y?_3(Z$GR"V/J?$>A>,5W:\H^0SO2@OI*IL0F/X?X?G/JZ
MP;]PLA1,IQ(L;Q0J*<][\KX:N#0A, F:1_;8123*2H5:1)O\H7)"GN%\0_]1
MP>/U:Y_#W-C#_R0P/&_MQMW5LJF:5L+[IJ8%#6.V9@6RC'VX\]$:A7U[EBW=
M%0F<)LPKMDW55]6EN1VXSLYVNE*WM!C7RHR\*0"\K6:.]P?_1T?TL)5J@\,^
M:?R*AS0]HM3DT5J>L+T6_-'1':Z)MBW9\6.#5279OD?WW!HHSQWV'"Z#*QVC
M%7Q=B6F&U6+WGKYMK+SC9*S@N'4A#BU;6S$,DYZH7%?AJV:\=F,:I*4U(/^L
ME,=.^;V,:O8-S$?XHV-N?:W#4@@?:,.-(4&[]^-$*\'KP\^FJ":14@P^?!LW
MQV?_-*&3'5GC7C+F&ABJ@:X%UY"DE%-YVVAP#G[\^$" ;AJ0MKY#'4#%6L>*
MGNA%,NRTD_TD=6VU;-?#VZ&::62_9VZFP1.]D8>FR]'$ ZS7=<<$)%J<&:$;
ML4MR]#C?QS$AIG+42AR.TX<;2]ML;5LC>2F?)NNL!G2.^,'X"VU=]<*I3:H9
M/K3I_*= O5I-ID9DQ8[!]X-RO=JH(R+K#YV_#I(<2VK\KOT^]B[E?20KVQ)
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M?[Q_S?W.H$P7D&ULO/UKS_+@0E"P->?\;H7WW#E9S-A_E:RD[I$8\R1]!C7
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M3\M$\;T@JW>$:B0S2.#**\H2SCRF)IU!)B&$OF'Q3Q6'T.#B FE@'/A(_A]
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M);.1">LR*)^@P9N (??4GZ)KZ+Y47?]7LX]>65FSOYB!V2F<Z\<E)OWBO/\
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ML)C",_I_)EJKB<9C(*D*IU6D/]&]O67BI+AQ>V_@ZG-FY",T$$D2:7MS]Q2
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M!-O:C@?8'>HEPF(0F-@0V+.3/,,4IT#G:N&9R?.D]A-I5SR)*#SBG!^L1I"
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M0@="]F>"@P]ZL?1X-#>[)"M+0TL5HFW<)/!$X68:6'>>1&<8!(L(ONY4L.J
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M/1X$\'*5EVU[EAP'_M.<R;X_7X@!-7JG>V<P+YIPB3"*4>A&_\0:AR\KY1M
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MC"AE0UJS&8_R1;"4C!#BTD[R B40(W.U<=;@R=(FOZOO KP#['-LF]=G\H/
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M"F6@C60L3XW>I0N9J5G>+]=S]<JMYC!-?!W25_ IQ61O#FT3H.2<NL.Q@7[
M\I++!UEK3M!F2K*^(E($82(%88U)*)@ 'LD3MC/L*N"4!-20O1UXT!S4IMMR
M]U>E<XF\T\?PB]1_R KZ#Q#_TW'R_&W*T++R+JJPL/AN_$[*9,IR#9 ,D!?O
M"YIT]M]\+7%/4WZ,3JKP  J$Y[,S%G0:7N:D_"DMVX7'=O[GO6(_R)F8C>TF
M^_G2VTLYTW:A^ED&YNU1HF^WGP&L*2A 0#P\HG?9G@0 .A8*8&::< HTH=-5
MGU]I.@ASF"2.+T&LWKVK8Z9A0N\DUD93EK@Q4^1H]ZS"<]<TL"3EXS,<K?E>
MRW_2]3E@,-[@-M%JN:/(R:[D33K^.]9=!0(EEA#L+BT-O=RN2X6E$_8"7:UQ
M=YDIA2AL!7Z+O[2@>!)BR@<Y?3D%1@'(H[X4]D:M7XH\TPSM:^L5RJ'31:_P
M.]36W4F:RO@G]SAT#-V$(@/6'I3)-7]Z:\P)=HY-G+5(B=2),6DEE:PXHFY%
MXO7%<QY]I4HBN+"-^_+6$^T"*+-2X7,0*27[#_1)%HFH((_P59OGU]ETT_!V
M$<])#W>UH1.9=X-'J$-FLCMN2? NH/756S20U!<=72QLDZ],I\OR+JOG)')G
M\Z):((; %RGVWS;6XH'5[JU_<F /3,7OF;Z_!:W^1-R:7L"Z>_VD)!V7W0 W
MJF$2>'BY7JW(=;[W79C)*+?90(/US] V,2?=JO.V-1N07/6R(K7R//JM,)LU
M6;')HC,9?$'HK@ Z7./X,R/QDZ >!ZQ9?UQ_XMW]3(4TUW[.CYYASC2&:M<U
M(Z$B\$7T9B.>U'<Y*F-%NESB>&@@W5:AEZ:E%US<4Q[OA,ME7CJ<-32QFH?R
M.5('E-!VDA+""VF<H#:3S%]7W2*@VU<*#1]ILR_T1/>O8-WZ!] _UA?BH^=?
M:^]TS>)CLUMHBIUOGHR@?WUI#80J"L#SI.EW@50KR,Z..CPN[C.7\,VF, =&
M KT]570+BK)=(FQ:L<QCV1O:1XM+/[IS<F#<M!^9Z9FXET<UU]<$DS1E) <-
MAW4L./K3O?=T2;IU7>'WRC@7%$;!C:UO2&V"Q5\%<FK?IJ5ZP;/7>_.&G[\O
MU' 7D@2^Q+<\3GRGY";VPSV7&O*#F>F6?-JE$54-/)Z4U4>N.KL6CBBZWS,S
M\,<"$N:ZC"E.\4I\55TK T],C9$7Z:3N0*X5_5U:B=VX![%N$<^"3]O+7+0=
M[84B-,I_.3X'&]!.UN%=C+[9C7YZ\/&ILIY@OX](WM#4G#_[0L#E(J :S+B@
MT>7$6D\=IS=KT^1KH-#Z> Y_TX5(.2*QP!T1#'\@_4 M>_2VKZKL*,=J0RLC
MJ\3['I3!$AF(G;R58SAM!(Z\W==-J U6&;9UXG1^(W>%TF00G2/BT>_ I>XC
M..E0G6'/MXY,-M8C:9C>RQFP#K](\EQ?W-5S?]XCU) [*S@[X&@W?V&]D1C_
M*LBC:N] )9.T:EI4.^KG7AK*!\XH5%)]TT3QTU!!)&%A&2.3('>ZH#7Y=#/9
M85WF/^$H]59A;&5B<6>IW8^X+U*3SO&QT:R4!(H'O[_8-<$OB.S[^(2%XK8S
M5JGP:2 G,X'P.6AH_X&QX=7-A%BI^2>7(_I5Q6R_G>;3Q 5DT(+ZK^L"/^J_
M&KLQ,5M?ON_$TZ$U'^P \,*-G#VRG+'W![.W)D@"^'!FL0L'=7E4/+ O@PA=
M8!+C/(P8'3-L??LBF(^FI_PM:;\CH1)[(A9>4!$1290!K,O7QSK$QHN'*5BN
M=A_GY<<T2/ 0SS_^]'I(I0/.0 C P;O=!+_XB/[, /^MULW&EEC(UI6XQ'</
M\@_!!;8"E.8Z;T(^\.XF3 ,_VMLTHBO3U$4[V'FM=%8?D24M&WUP:!32<HIC
M=3!95_[AY"^G3CV8TF7C7NG\I\9</L=VA1Z+PSSB$PN$N7EV65.G.W_R_HL]
M#N1Z=F!Y<?V(C[]6E6EM$V]LDI//90[CVLI8@.>.3/4ZQ8W_ML ([C-&4RHZ
MIP]<ID3[ANTSAV!G?HI9&_](QAI6' BKUF='#)%Z91=:IN9J3?MHZIM#U"V9
MV^&3#J*<7H,>@?Q;^035"+F()6G+9!33'4P08PM)CM0,E=E0IPNN*K(E5E$P
M>=EH169E2>GUD2Q5VFW*F7B(,L6N7CGB?<VWQ\K2+(R@.V5ZI<5NA+)GOD2\
M)44*"%OO/?W4X9/9W(F^^VK"ERSJ2%RL??71G!'L\V2IJ@#)SW^;X0-ULZ)I
M69SLX(13N]3W\O0UF"E'K%T]I>AT'C2MV89\#BLV]X^_8WP8"7<"FEW2'%9<
M%9I?U)P=P!Y88;%]%%%G?Y/@)46Q\#UU\DC-TC<-/5W4R]7<OHF 9'$+Z"NL
MEQL_1+NQ=T0.?W,#"A%G+5-2C'V*B!4<&(^@">V>W!O>G# -[A=('PA7;3*=
M=KR)DBC*>TQ +"Z^X6 (8KIF>C:9-QK-@=RA?%XJ9TNT>;@"HNOPK"/<NN;G
MXV76Y#\M8NQ%N<M;'WA0;,(&6<(";:*Y[&A47GJ<(J?<O .")TMZ_00Z9]4I
M1["8(_;?OYF4+/@^9*%DM;Z0@QS7E-XY:E$R9;!O\H)NV"%*B-0QJ9&Q- KU
M]_T1'!8U'+(._*!T@9X8M30O8W<C^I2/_CX6PJM*6>-!BF*/:JI)74FO 0]@
MM-7G\(VD=P9<F/D-N*=4D\]6/;@0>9\F_"-P:)'V"6NG)MF#ODP&K8*;)@;#
M.\"XSBZ4_YW-PO&"3$$&AV.<L.!M'826(+UR(2TF1;"_]1[31FLHRL 6?4HS
M23&CM!9J:X4^&9^HV]'4U!BN<?.YRKA \)AL!Z3V5>DGNF5&(3J;U@^$!>^D
M0 "59)Z]FX]?.=;Z_/RZ)0],7U:6O9Y D QM)NE58@"U#7KVYG8KZ;7VU*#R
M-9"ZZTFPL_#"C]7HB+\".>6WO5S"*SM;K)8F,HTV2&TP8UW/W4X&=W;OATJX
MJ@=:*E6?)-C\)(0>I_B\-A)_[5!Y)!I/KE/J(C,S0^7@ETPO: 99D7=FDHSC
MM!E):.<34:#_!Q#^E#Q3;'F4\^F\Z+K<A:_G;%<F 3W0IB5RKA!;/)DWP%2=
MLY$<MT/!>4)9Y-2K.3VVOD-_UL;@M(P9J?_.QLQQI8AMP[CQXJ6;C)>,>:'T
M0_^?/&VW#V7[Y<!.J@&AEJII\:-FSRU:P>GMP(!OO6<W.(-@3B%YT7<HARI1
M[$?*EWPE>(4\Z(;GH(A-6 D3&4F W(A2,DVLT3#U:\_:$$W@FU/Z,.G')G.K
M14%7GFE[5_D0]1/1/3F:A]2J^)KNEIY0(#5KSU"$N#OV;0*,61A=!Q^F@4&]
MSH)_=E<*P55MSC?]WEBWT@'&96HELH))Z"NRC\:3Z8/#D[#HG1RHXDV*O@II
MUVR,&?*F)12&'7%R_E%A3#::EW-5J8 6&1L;PU+C"S+U6?XWT,G_IZRP]D%?
M$H4.49V3UO@P)7?+X!=3%]4RF--\Q?T'4%:0:2B@7[L/!%::]]RI9PGJM2+M
MG\/\[[P:P[KHW'>M188.8F<[XD?M/>,>,BEYN\0C6!#HP%L0)OT.Z6ROW8$&
MVUJSM=TO,T.O@=6?YE[LO(= WMS$C_YRM?CL:=U]@0,+BHIT6QIH8)[@R.F<
M$YVWO_\R7EG)47Z-"VWXCK=)A'*&<K[SGSQM88@]YXV4+$2$D1PP!9:R(#8W
M/Y<( _-(C43<BO'3K7V*D'4>KP;&\9Y0G"*M\Y5@%% Y]DBG7(2!2GGF/.(W
M2H9N;9OK2=S"=4=M?0PH;!\;E ![4T52SM[4A3>:M"*]>P?:@8IP=TZG&WHH
M,[7!1D5MIXEP^*.-B.!]7_$TFZ67"ZM6P[IBZ>Q5':H71XI;*S,,G0#EM'*4
MW?3@KS%+NN/0OTI5C@6PH2KK@=U TE.O#[6&CSGE''RCU!RL'U=Y>CD^ZQ!@
MH36+-7>#J$,P$]:[/9S$TZ[DID;IB, AY66[@*[-@R&1 [&Z;+1;W:-&H=H,
MG*I:M4-T+Y/N0=P)>:]44K%Z%T\_@VH?0U^YY^HO>^2YCLO0RU&*X9/7M'QP
M%$K<!M_0!@6L+MP'!=:?K4V2.0T5,V.!G!]WW<63L# 4/P^*H-O3+YO1%5;V
MK*&P6)Y*$U;9U[S]1-8[VYG^M@C^/D:;_#X@J%,J[7.J?+GHJ-C;TCZ\$!):
M !T%P&-X ##PB@=%2.+MGW\ 2"<']P_KFD9A)@(J3_%L4JWF$^5)B4'4JDZ@
M^T3C0+S;$D<B>'3[,(TO.S*+R>P>E#D HEIXW5_]48X9M'C7$+W].?T,,H!@
MT*? 7\W>A84/#]/163[Z_F[YHKKX$:*>*=9TIPY*GE9.ZH(E-&&)T5.@>:!Y
MB-6-GV&[.E(K:AU0N1Q5?'R!L9E,^5Z*Q+:W =[$P&,5R[6!NW).N0F.9W(
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MWE(3+/O(E%-P@_/9=2[S?H0#Z\F6L5;J&5RZG98"EA;!V+S]H7(HH*OW\8"
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MR(H8=:K.Q=U46*<RJ?/+F,D7;0>3XM8*[[,,%[BF9$9P!01;O8:0[^.=IDN
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M]C//CO>63='3P<CVFG*JVX:3KPL"Y"*2K;./D]HJ=#HM7#B\/"8R^;A**/\
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M;?'(=:VS/7VIA<>'*M4J6ML]QXXF;N'R#_L$=?SCOM4%[4ZPZQS%0@W6RKV
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M_=;]W=^]]WV?__]YF.V.-6MF/K-F9JV]]B-P,G$R!X N*ZLI R@HJ"B^*+X
M<+)^*5G+UL7#Q=W6Q14LP,,'B,JK::"C TBZY--$2!1VBSEY2%;VM(TJUTR:
M#4#*]=R:P0# V<G0S *@8 B3K2@;&*)B>*4^-JC>W5T\E9?7.I5'N2AJ.[,!
M*IO%H%ZU!6E>K% X[5/(/NW#1TJ@G#Z 3B] #19KZCO%/4,5+,-3J%-U#"P1
M)6'6W=WF4PGTU'?*!@;O#(9^>SX50!?N8CUM[YWJ*@FG12(EEEC3E$]U?MI4
M-F1>(1O35]0/E_T)]ET!"RD'$S94,43?97W,AV0W8P!88,PMY&&."F#P86IA
MR6)I89UI /D_I7_XC,[:I;SRFT>=; :I7<JIRZ="YLAVVNF#E>#KY%*TLQ&7
MGBHQ#OTZ8A2V?XQ8<0]+.77W'=('%-=3RR)8RBL_!H$NW,G&^J.!P>HM./:S
M1X1U2?@?8N\4_]'H9.WZ1V/%6\7Z9\-@K/UG?)!Q5/EI&IU5N-KCMT!\CQ(&
MLP?S:8OO#%@>%5-YSX 9\QOP@]"]61?^Q&-M_;,<&ZN2DL$[14LAUBY9 /A%
MME,>XR_X&&S"7=_EL2+:L=CW=7[CYUL;B"CO,2N3*Y/]J H,3$\LX=]R</K,
M]_V.SG<6! .;OX+%4-Y#_4M88>'6[WPL5D$,Q \V"J8(ZQZ&5X3!\EDUI:YX
M_8C8RFD'JX&((NN>BO+N6.?NBNMO.IT_>I N*/_"'_N-K\2:ZA7Y:T?UCP[E
M/<P?[+/*D1XZ\P$@B@\'(],"_NW.=#;'S,]TYWZ. &W_-RW9,RT .3JLL]DK
MA_C11CF;G3)\9^V?8P2=:HVX?6]D_Y9^X#N*S-E,1@]&W;4V!T"8G<CK=US0
M=PX.97KV#PX:^/2*D8V\_N!HG4D._>00G]D,/GU$SBR"D[^B+>G3_O]^W_?8
M!'^/*'!6YLS ]_-[G]S<CSC]UCX="2"@]=/[,V+8 @ IV1^A _Y,O_!.Y4[E
M_U;@!_VR%&*^,^AL1MY/@VG-NF>PHB+X^WG)*J( ^LW-TV+&_*60T/]0<>AL
M/ROSS T,UI^%=S8$&^'.5&%#(>OVKE/[)+_#,3SM.UVE3QWQ/FWH)?]JV\N;
M=<\0_7<LZSUD9:?^6!7;]<^4SGASR/88N:'R9R^#%4-6<F6#,^]5TC!_+.JY
M9\+Z2,[9TIXZ!@?^'XQ?Q)"UXW>OAM/@_YZ#/B[L]?O7AS59EY(RF>?O>"O"
M2#UEPTC%-,%PQ='.'PM4Q&]LI=\)IT;LL>62=:9Z_8C4Y^^1^L$^#9:7LH$U
MN<'9"I5F;<BF^&=Q_1_L/XA7LWH([W;NL?PCN"@DW^TS_^PXB_'*[LKI/4UY
M#QWY&A(V_#5PCY&!5/P3M_-LJ1O]$[_F=$'[@_C9#)(//NMO1IY,)]]EO\^L
M[X$ @;ZW9,]:I]?ONXU3>52BN>\!PSG-&W*MHD,^.B/YA&"48(#^./X;N.-6
MLJ#0%PSFSU;)[5I(8\B2N]69NK+%@,SCV#L5%F8/1HSPE$? S3GD9$( YF@@
M )-,1 3]M2#L% L]68\?2XC9 PS\@T  @9/Y69HN\H^&HZ("_SM"(1/!8D/:
M)CT=J+"RH3"R;"F0;<PN;Q4LY)W^5$:9M>;T&8P\4518PE.RD<49?,KW/'MF
M;#Y]_LYG/I-7'EM!RK(@3RQ,Y3%EY)T+>6)'VAB<3B-!I#RVC76JX6]%C:K<
M93"&C)?,F<TQ W*D#Z<11551-A!&\A1.'>UB43I]N2L@^<&=GK\\_\+O0A;N
M69R$][#23C,LCQK!GXA&G)04BAYAZ-5IJ"+_&I-,N)J<51Y=>'<<D^P= L#\
M/N:S6+ A8\N(#+( E#@):OF*<?&7=>^?=OZ+=);;,R(0 IWEC-"QXR?OK^0P
M#\$ 6CRRZ,5^X7$@ %P?+0 E-N\G#_4R\K(O"^ Z[OXR'BMDO6!&JJB@/=K9
M\_:&KZ0:\*^<!O3GF/XG@7^!?HD?ZA+2'-J/\!"A?Y_A\LAM&2/FZ3PV9,02
M089?!W7D#T7\;RO^C1\=K ;6AJP&*\(Z&,@J0Z[O<&2Z5Y33D'O6!<S4A;])
MXK^I]@?"^E[7R."*:\ZA*.W,H>!MRP+2T\V '%\I(-0SA^PB_9$W].84<PSD
M'</MF]?WNC^CO[#.?OHR8!-./7O)H NQR&.*&+*9?^^3/;UH(?=!6RBR* B4
M.50^U&#4(30PFBM:*3J KH6>C;Z%(8N!P)C#Y,,,QAS" F.Y8C5C@[#-L4LO
M !>T+F1?V,*1Q4'@S.&"<5UQF_% >.9XI1>!BUH72_&1WSWXI00 @3E!*0@$
M<@4-$?(1(@BWB+2(2HG!Q,'$<R1:),VD8%($&4#F2C9'KD7>3,%'44H)ILRF
M E$AJ$'4"!H0#8(61(N@ ]$AZ,'TV6 ^<#.#+,,0HSGC%E,P,XBYE$6698C5
ME0W$ELTNRS['$<P)YFR^9,X%XBKEUN(!>$IYM?@ OE*(.3^(?T@@6)!/<$LH
M6]A<!"PR)YHM9BX.%I^3R)9TE>*3!J2;91"RYG)\\H \\BM&,5A)2YE/!:0R
MI]JLEGTY6-W\BJP&WU60)J YIS6DW:Q3JINMA] /-G U=#4R-S:_9FZB9:IE
MIG5=ZX:YN;F%N:4KU-4J&(:PSK8IM6VV&[+?<@2<0,Y\+EJNKFX(>*G[D,>6
M%\A;UL?<%^'7[+\5  [4"@H.+@W9"@/?,@_/CIB[#8XROY,=/1<+CG.-+TT
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MW2V\8%:2O+_C_;V2W5^D['\<_)]4_]Z^MRW,^2_64/X?:^@O4G]OY'0=\[:
MP^1LD#&6_OYZ_<>OWBCH"H/9#>V<K5R\W3E^6/R]RM^;AMI:.-O K*1Y?RC^
M8/PI,7^YM/Q_)&-R__<S)G:>L7]D!^KB[ 6#>_POLH;$L4#N$V%P=VEKN(L3
MV,+5U=$.:G&JQ>OE;/7;BNOZ,T0>+N!?7T!_,O+_<+!6,+C=_Z9 ?_'R9YS
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M)<7HS2@C?3(%*  H_R&=&OE/;:"<- .$V$ IBA0:"B& 2HB"1HART@[0 R@
M*BK:J<"//P5P 0<+&P,3%QT%#14I( H"4-!13PD%#4FH6  Z*AH&)@H6@'V!
MD(B8A($4AQ%"1L[$+*?-PF\AF$!!*2"D8.F&U*1!FCRS_(^_,H")A8Z!C89Z
M"BR#= )I^-0H*CJ2L  45#0 '8.0B &3&"*'Q:A-PF_!)$_J%I) QJSSD$7
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M$-.+ZL\S++UJ7)J>;(_'W:Y7IH%ZB.T0\8J/>QB\?,*&T6SH/@D,K>B&+YP
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MCSC),/K*N+WR8_W!4J,BA1BZ"M(QAR\[2W@)5M \&$]+=-:BO-M%T(U%/.G
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M1C&M]%4/6^;52VR6$N@W?8W6@V<7]GI'S<1YD19FV5=G=JD8>'D$^-PTKG&
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MEQG2=S\ &/T=BDXN?9(5*+B)0H8(NSMM84R#HYCW4YJ5$+'X4;U!9E"DH;Z
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MU8W]B<9Y6GX=PQN*]C+4#[O*)-C<:!:CSF?DH,PP=CA'Y-7-\BHE:J#H2H[
MZ][%R<J1G].\N=H?_A"MF-G\&B^2_OGZJ87C?IZ'G&HB3FK]RGB^]9._..*C
M@/,^^AW$=_.H*G6S6H.6K._>8<JD0H]0_.:].RLJS^_1.=Z;WL/<M8AJ?[_Q
M9F9=<BX^,_MHNYD2N9]MJJW<-7E#L&UF):"H_O2&#X3<^&(6NP2*Y7_1HD+^
M/5OC/Z6<W=9AXQK^M/Z^820--!!]T-FSD)2$T\,L4[_:?-2GF^*RJ7S"5MF.
MEBT1A/0C" QA2XSW?S-Q7E.O[3Q=RJ;ZTC2/W5S)-XR5<L0W4^5Z!RL#UZ 4
M])HL=\MVI>ST$)\0>]7,G7T_[6*EOW*EI7)7C,@N1?%;>\49B^5[;R(Q+#0!
MP?(0!._H86NXDYW$N6<D$?9.28$FHN[%$KVJ:\+DJ,":]6R<)2>ZUDA++L]^
M?LRJ"9<_((FAU$XS(.@RCXKMB8+5(OHG,2]2L$]EB*#KGQHL@&O4U[-]\7.S
M^)0'.*9<PTZ])4MC8@R+HMDP0MC#1Z'X:%X'EIK,%8UJ\@.030[6J )!&T-+
M"::I%];U5J%XG;F$DBKR7 -5)G965NOQ3J"+BWQW-8%?O^SDM9)N9*HUT";/
MRWAZ;BD-22+\/P YNAW]VI$U:Z?"&XN^3A!##^["0I4*\*(6 WA@=[1[E1'O
M\[/F'*EM,[YDL&8B15 B;V%.0PV)-KJYRG!,(!KX.(5E$9UYT-RAANUI[ .@
MM2!/R#E'Z8.4^,<,/@XOPZR="(84&%R]$&"ZG_X:5@&!C"[P6MQ;:)* 4V[(
M#9(GZ^&:OWU[W!*?R,F[DM;P^4,XUU%JKOT!6!P,/^L]0_)8:S&F5OT[K>^$
M(\HJ,;>;FO>4F5QO28'',*VV'R),?V]L\@H2R$GVFN!3D!'U744.669^8?H!
M11W86OBUF!(/#2^ *!-.69F+[(!K3DABTI0V8SO)<F 7N%L\SQ,C$E[)ES1*
MNPSKEKMZ<C]!(PRXXLIJ!D@*@K/B:Z70&^R1A[5#*Z:$D(( KUQ^=>_D6=C[
M[%*LQ>,$H:5TQ^BX?<9/^TJM!)5GSQ8J)#R94@VA;C(A!-Z\KN<6AQTDHUU7
M^8+*PY>=/CQ)>QR^_ISU?[W@:UKJ7J[F=;])@3X 9:$0^$]JLM58-9+P75'E
MH?@>.A:QI36Y%B7Z\M;**S\BM*O(Z>2<8XX>S_ ?7Z9=X[UG@)Z74]&3&?CU
M?DJR.N"MP,(L_=77N >!;Z^+$71O"L*&*# ?@+"M>F:9+10;?,]5&EM^&N.#
M)1^IV[C*^),ANO]!Z%M%%LG=-IILE\,GW<&22BW&P".Z#BQ4F&%SD4=:BS 1
M2?I>7_M=T;(QWCX:**[036"TR9,Y[O8I&X@WR_.$4V>UMH&!TSF[0H(H_1E(
MDQ!_I1^Y0UPQNIYPNS<A2FN"_]/JC=7 /$-WM[TU6G^W;%E-#NX'7$(B2 J*
M"*S),^@]QD"N\'J$;Y-NZEQPWG):>$V1 K*N=%IA?@ R8[INE(0.%-\@IDH?
M@- W+^,)D1[=ELY8&GRBTGP4D7RX3R*>Z*HHY^^(8ETSQ*_V2ZT'(1Z]6[_<
MF89 J'B[(JI\=M+YZ"1Z)&M7-4T2<O;Z+0V9<2UV^O#-:B<(#T 3FNUI"G8%
M H2$(BH%?,I8P65#FQ$"U]U#]I9U/=?LEVF.XCH&(/O@[) ST:B_S&$L571
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M9<OI6>WQK=?'E FN[]90IF@/C0LZ2<[CQ@;3I8H-B"B<*@Z#J -WX(Z@'TW
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MU ]Y5H3_SX)#K4^FC9K'=<Z:/GY!6)7@<&*IR54FY_P!<:FHF#\,--*:H.M
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M";(PI<G-6_RK>UX1\IUU/U1,X[?)1 /BZ:0M]LN^:75""$X&!YI5<0LG7*4
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M4H<822:TU"SS8\M4GW6] W:X5/%5)1]+^Y^<[*EFF?;HM2EIHS$;M..# CZ
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M7:KI(G@1N$;1&B69S#3S;*_*%VJR!X(SAZ'+56/>K$*N>[\V#>J"&\:3$GA
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M^AR73S\ ,:I;NI0[?T6)@Z7W0S!5"L&<J5_E9$"Z7.B(>NEBR*MBC?&/D7=
MZ"J$?9IR8QB"!2X>%KW;(M/D^&0X'^H_]K#@]&L5(?*"8$+/GF-K8&>_EBJ6
M^7'JZ6  Q_(\)5ZRBOUG#$FW$J'SH9W>87Q<)#NL9S'-I:&'RB#EY+XG=^/9
MW[%LR*YJ>.5#<DK52D_0S8ZA]3@W0:D9D1HZ%Q$@"<',+B%1]8SR)/:NAT >
MV+8+?UZ4NKZB\!2YAZ!,"=C0KD@EDT7/TG,56[*[0[\@<EO$^KCY4#JGRV9.
MDCF#THFCB;2A$8_U)\(.A^SYL!9NO? =T&RY&<-0HDXQA:I1&)V"%9Z!G[A
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MQL+@%@<SV@*5+U6="\ 5?1#LE;I2-)'6ZGX]"32_6M]P 8XJL:%.,^,T&[/
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MX1[RG&Q>TAAW2;X&*TAUG1(/+V1%_TQ<MS*YD[2%"*4R147$>+28"@@E&5H
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MR9,L1/ZLBC).K. =H+D'" +N@'Y]T/"0<BW]R\W9YLG\RKI0AU)0LC.!Q[?
MDRFL!UKNI+1P^P\S9<W?-,UDV.K#.&AW&.M@WN*:C?<<I>/>L;64F67#6,W,
MR*JC#&-9@>2,#*J:P'(O$N@%1XW%4V(JO@AYHDJPE!5>))<87)8BV?9,Q'=W
MY9;*/$$8&6LC"TX[=0?2Z-64%]O+F2OZ,X+-3I7/Q%O![?^;?TAR,J[!<\*P
M591V>_VOZ&9[<\O\:=[)W4'1$""# QJ/>N,=B*^N;)H4V>&(I0^A<DS>TDQ.
M>YM&HW?D4=@#(S<G3-JR\!ZC#;3SX8HRATI4! #XM-L(CF9Z,R0E+;'Q81!'
M'U(>T0[7/:;64EGYC;*L:/4JXL_F-I5^LV^ELPGU#'_SW+[0[&]6&"FB?[@-
M4_3'7C]W5D?4R$M%S(A(''R#)F'+>P[PI[@=Y((\"&5H0'-@W]@N-C#[IPV7
M(#Z8X>G*2+S;I=,^_F3*SL-,L.Y;E-0'&]B#9,36]K3\/D.L_/)2>H5!=[GF
MT1T>^Q63D$G)9V+#P!ABD=Z?>#\+AI%,RW4F5NXXLMN:Z8?WY553TA<;QCF;
M&F5OQ@YM;]@]((],0TEOI4WVEY2<8V<70ZD6U.E0=Q"M*13$O=Y^:(C]_]@Q
M^M6>J^>@^!/6Z K$".^?'<R$,/UDH+>VPD$Q4SQK@TM[K?"ID "HCVCJRZMD
M:'[.=2H)V]*V6]YP5_G1/^Q%].B;LS9J[#0O3=NN_ [ <0+ZS:UKT\0#PSXD
M!EBJAY%!/\K6_5-Q(33CX/T2-PB6U93_'5J<^>=;YKH.V1QT_U;XS[VD\*'0
M1S:T=E^@C353O&$S5<Z$^#:L9L9>AY!ZWE!?4F+.K>0K&(%?U8= &B6:E"AA
M/:2"11+W%#TW$)^K1=;1TW$^1;IP;L#K3>7WQ+8U7QV>8$"1P].,VK;^%FB<
MB2+S%)J6:_)9#QL 5VO_?]5QW=]L, HT;5%5NVJUB(=:H6UL8K6*Q"JU8M:(
M/2I&J5'-AQI%/\2H7=0N@M@4:4FH72M&[3V"V./U_?!^>N\[]U^XYXYS[KFP
M9^^B]BT2GR8VZC+9[!Z^5$D!_ ST]>9EG!3X.08<ZEZL25A[0GJ1PS +?VMV
M!=#.:LPW)X*MZYN02)18!#@(-J7#70K'VGA]KWE#]7T-#!Z/)T2Y<D '[W[3
MM5%*YNMH#8.DEK4922#MEJND1\.F-$ &A+ELK4<CG_D%8148_VJ9ZR'#&&A<
MVXAV.R89_Z\ZIOY[&KP?.=0S_>MCS0M,)@1TCS-?\;5,WDJN[!$#HV5K:B8Y
M.Z:M+'S]W65U61:B+Y?JR^PF1RLFT1FERLU[E27GA]#S2\42R>;.]MMV)/P$
M->;R %LIA=?Y*&+P^1J0KD5%,H *4_9&7=7?AWDAE8 DBM67"2NU[+V8TR]K
M??$^M@^]\E$Z#JNL\WBA+<YL7EXQVV[3/D2 \^>B:9%E=/X8E;"D#YP_^AGB
MW/W=O$QKM[Q\,4T^R\D((2J_Y80BS314"*58J!RX^(QZHR)0(]]QR\O%NL9N
MX6*6>$KN[HTVAMYM^36M=Q(!O ),&8:H?I]^N^;'LZGYM;\_^OC_GQI5+&_H
M* U_:"5Z@M=9B&6-8?7#Y14<,*)7[8*0&6O&D@BL*JF4XS^/ZY +"A0U/Z,J
M!1>CQDN4 @6/G9ZG"^IR_YAKP]/%C?E,0[^?9U0,_Q"EE990@&/@_>J1T/=P
M&Q?>&(;Z_ J4N-$3*8XL$+6&9+2<&.AH03HU>V>[FL\40KE1?4=^VM_P[@K)
MD! U)'8&K%''"N"^."N.8/A9+:L1"=KQ=F>;!*;-JC)L&[UZ*MZELE,1'VO4
MTV@EKG VL)HB+@V3.$LWI!D.ZW8KYU%^V?+4.&&L:[ZIP*7?ZOJ8*9LR_Q(R
MFOJ8U>*0L&*X;-:Q=:[\"R*P]\:$%3,Y=6?@DV]B.E<HJWI\<*;K-C_#E,M/
M7+!6UY2FVJ E7%-CR[7?0(9_E=X UV7-]<@],/&YN0V1>7_H"M#]P]5)NO 7
M&CR2ET<'S)=#+XE> 0H<J>_2"P><R)^M>4&]1?K+[.26AW847TN\K_ZF<G3-
M7P-2<3^&Z*,[_E<%LD\:,'!<UM3/'U  =]O%9A>/4=0CXE[ZS3H?X(6W+OKR
M#WQS2Q+%[LSJ>(UL"5(*EA^$^S5,VQ(KWSEN>;1CXFL$G*LTA.<6[F]<UINZ
MO2 W[\U#?< K>O0&FI32!9('A4MYQZO?=^+MO6745WKWEQ48KVG[\8;EJ<06
M&SZ0I/#%R%VKE&J,GYG?X]#*'@G@=@U'D1!=I90@JBA=:C6G3(:0;ZL/S8HF
ME19LI[!U]@Y32>B8CZF)6:GBND8G@6)9;O-);DD9F^_4%/GU$_;XBQHXX";Z
MJ)$Y$2A]PV$Q.$9X]%(K2*?\75W'!"4C40C8K1A*IJ9L\.+.CYN\$1Q7ZNTJ
M88UW=W9U%<.*]UC%8MC.DG:^:JN$J'E N4(!?U>57"[4T[UQL%7ZO*Q;;4;=
MN4V%=\71<='FARUBE$14U%@8E^YGL*ZS_6TJ3+IQ!5AG2V'J0CBGM%HX:\4#
M"6X0U5^_V]O72.X-S]G,0#BFZL-BQ+B<\]WR\LUANV"Y[>T>D:E2T:<+NV@1
M(@6@RUQ\JVKF8_:T.>^P4NV6TK[GA?=8,-MS+&$49$(=(1V"BXD*6'71H2MF
M,J^W6':(@MGB7FD6WGK$>_LQ/P_P6-\&<T*/(<Q?ZJVPLF\X@T@>_$F97-P6
M:1JL"4^@%%5$D2N LX<\T-!.9G'7;NM+;54:PD%^T6=J'/#%1-E+H/LA[L[G
M<[W)'!XC2[ORM4^O+8=JK9K#F.O4QVI3WZ#-:%F'!D@#E3:2U-H+MWZ %TJ<
M,^2A]$%90BG< N3R%0NSHEM?$N;A@NB8'M'J)AYDKY_>KO*-<?KW1KIXOAZ^
M'E[0WF,_NVUX'/XKN5_D'\2@D*7D_,F.5AU4(7<FAFIQ_:VS#&(LV,TL*-O*
M3SWE5Z&;?$N;\4T] ,UE)7<PZCD7_WI2#D[&AF7O\4G:J7T2MSDM2%G6W;'*
MWR*(;526"#$$WT[=$3Q((;]0%JZ@"7]@G&AF;9NW16D4"^NX_U6!PY$;-MK7
MA[>74'V-Y-/<1B =&C5#05LBX3Q.8@,WCCAG/+*<6P:=)E*R5OU*ZKDD/#<C
MA=9#L"-\^"\!G'P&$37IT8,&14^?WG7#:,XQ)[\.0]1(/@'/L!"B'T @%MNZ
M':#@PK@Y^P3SVW"S]5/2V#O\(NS4 :'GBXV23E[O0F@Z3 "R03_4\2#W5Z;)
MX DSPA&;25E6NKVGA1=X5QG9SDS/R)>EPHR[[J(9P%3T4[9 O2M%ZP7:D\<R
MAERQ?08(I!-Y4O.411:[O+A>T1VW/U '%6JKQ1 J5.$4X;V$O($36QI=W1YG
M=EMN%ZUY*OX]VF!<W>$QN29-/&P,4B\7-9*:$LF7GFN;>Q"+*V6D\VQV4I>0
M?M&RR?I@R+ I#M[)$@#\FUVM0/7:%%*T-PP"JP*,3I"#TF]ENFS,&8_G_2ZG
M<%8T(T>SZA=4"=Z1;%3CS%_(-_6BD\6WIZ6\%TNYY_YCUAWW)QHB,US (?''
M?TK56FIMVX:X-JTN/K)W&:QY!/&=[6]QV:D/P>X/O1R\_.)][SJU$,(VGVDT
M<K06/IPJ%?._6ZC_PCH:9IA18-J14(;XXQ,?"J!]BHX</]["?WB=]DF<]BG#
M%XB3Z)STIN^%\2$=4C;>#KZ"T'0%!/NRO<<C%G^7\.&]^+.DS6KC3Y6#S%>
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M$.H:YJ !JDIEHQBSG1PYCG-EC]9DR1;5$ES5K(*+"7H7ZXSPU*W4JO,$Z!7
MV[(Z6^KD'[AU-?%O4$L'"*(Q8D?]S@  >"@! %!+ P04  @("  7ALY4
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MSPZNS=[&A.[<[._;#.FWE?8!\V/,W'T- )"82<%N!N %;%M_N3X'V'?&$>N
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M\WHN.?L%Y(V<XT6)2+9R#P?1\UI!AKV*9[S#;7,)<?).U^<'<H(=86:);H_
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ML#M@B+6$WS7[<F\"@S1R/X7ATR=V*XL>UV39_%C[H<_XT $+!=R7H5JM3)<
MKY9LU-3#L-*:UCRKES$\SQ&O9[JB'^:^*J5)I[1%9E435:,.0Z13Q%Z!2ET8
M\F^?GN(J&..E(7?UO:2>8 37$ZV?O J]4Q(0#^HWN8Z!_1R9@*I.2\H97>1M
MYNM$4Q/=1:.PK,KILY?/<J;6#N8.S3\Q@>1HS71[!\,+>D*=(WUJ'$9HT4%7
ML-U0\E#P&9=;0\9Q;MC<9Q2Y$PQ/$CHTCB8B>.[!)1ZPQ2578YD<)QDGU5>)
M\+32C.=5?513;GM0W1?&(9)S8IC)$Y*@)VG9KB#:@Q%9@W)S3V(_<PWK+K>H
M:/PI_]9:EN7KY^_'UJ;\>MZ0UP%4VA<9XW=/I]W"CAZ)\W1.5:EF#Z=)02WG
MX,_=YF5DAB(?RNR+4W;"#;^^VWR^EB(DN<]%A<M8N.,!+- HMOQHSI<.!XJ>
MO!\%I#]W\T">&=E/DI! )TY"K1J=>4..SN;,#X>E=2UQOV!<\?#CKMU/V6XQ
M[$[XX!F=6A1OEYKSG%X47=L5UW6\<>Y9J^NCC%OMMD9YQ?+0W:@^T?%G>@8E
MAP\4)7.-5;N2O.<@>*K$8_<>7@D'J2_C[Q>&UR[NS.T$.8$AEF'$GR>,/*[W
M/@I5;>\(ZOG4\B&QJ6?RYW2+J;UF+S%GS=,<706-S:AS\KT%$F+2YQ>/U.XT
MOBPZC^BTCLMA+LU[.Z-R](I]EA\C#_HH!%H)MC0+9L,0 OY>.?A"HF56@G96
M]_VK3S#ULNI9/ACNUZ,/"CY.M]%B2N0@=:*%=/3+-U;D)<WI;D<02"!$,.%V
MPV)7EQYL)35/[8KT0BB(RCF7]DJV\FUP[HQ1Q.,>\];R9BGENPE3-*OM09=L
M?G[;#[^H6;)7NS@R:K*U[MZ']KY?<YOB![L\B3&9@B7X$WW/U^X,89\'>UY0
M26XZEZ40<#8HUJ/KV6R8W) !D3HD^#0S'ZEJHLT6%;VM)'IZX,.YBAM2;J9L
M4_<2_C_NW@(HKF];$V\"P35(<'=W)R1XX]K0N!.D<2=($BRXNP37QAT:=W>'
MX X)&CR3_-Y]]]V9__O/U-3<F??JG:JNZCKG]%I[K?VMM=>W]SZGJ[]W[;A\
M$>)N=J#NEQ&&BC;4I*N0Z.8>%&7>]LSW/^[;*IDQ#Q7&E5_C95SKO_XNXA_?
M",W8I@"RA]2RF93E44B>587C+82U2,H ^2I_4.&0L5"4V)Y\ZQ_\H>'.!]O]
M&)YT.=0$H6F>OE9MH/E:8RO!_XY.R\V2"76Q"-D,57!)VL),O#H^;GE!WH;C
M4]A N,UPVEII%K1T.- YL_RZOFDO]Y[;:]B =4A4]I[W:^/-\E)K0?LDW9MC
M9TRB?)OU.:BQ?95;&0,&O\C<)Z:Y0@)+DUJE<'!CT!2_BYM %V*\BW;.>A[C
M[S)=+*HNRU#7(<WZ>T\!T["(L/;,6F*KF=+)G)Z6NDL)M(S)!<,2%2C\*B.I
MQ@$WHO['UGD$?993I'OX%=U,BAMGE&! +7L$G-ME.(J.:N[7:#X6K761(B\P
MJ38*KKE]?PB)2>H:]V3BHDXA5OK4-I69IGW=UH!JP:P3/G[]T='I8LTVJ!YT
MPTJ["\Y//LN/L]L"X=RC9211;ZU3)^E"U>NJ@Q-PW8C#% YH.SP#528]C(QT
M=:S5/\@I,%CR^<BK\CWM%10=N6HQM>PK\+5W\5CPP1MF2Z.M=S?-\$/&RR!+
M<7$X%RJZ0P(&R(%RH\1L V-04,UE&7()JW0_I[H!R<ZV4-_0MIF.@A:->-EV
M\=81S$X]D/YK7AFJ[J$%?<(^XVR&A4#PC!X_9!F#Z.#K9JOVC$.=TF?"!8^%
M<A_PTU[<\ 3>$8J8-= ".]'#\&@PVE6%,3^!'U;I8ZYOEQY$[&-M3EIYEL3
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M['FP?\B60Q#"DLOH%/H%2*/@?$3:&YNX[UB-;GIU]^>9#>BJ]H\?*V%*O+\
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MDM+959*YT1S6@NS5$J)M$H$_I].6RF^)EM,6?"%LSRMA(;@$F254TF%5N?M
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M0F(FQZ2#1[EE*-42X,UU.3RBQ.>\AY$POKZ&A?4#PZ3N7@RF)]HN2:#UQ"1
M,LRZGV=+[$U.]?@-5:O.+2SYD*'U0E.P>*ZE8H<_+!^K%3LR+GCNE0_926#S
M!'$-O["OQ Q];5A:%6I@^,B*1^35S:'#GJ#V50S$(+:*U_)KS:3)WIA)])QF
MJT7B6M0+\@<V(8O-+%B;9<.Q]WU<K'4EF#<P;C*XM%M+6PM$>;8XW)O&JE7^
MT?V#;_;W'1:@U<0>N/]YT8=\;17RL9]\I<0>LJF0NC+TAH;I04\>0T.??^[5
MCVJ^^_:IF>LKU:04*O)3B$755VK[**)U(KMAK:S(#T0-([8K9&[F1-1'\7D-
M$^SC69$P!(STZ;)ZEJ]WO1!;*4.;"_[3Y>'P&BHV#DIF%[<U].ZLB&-PPXV"
M+GWER#K$'7B0)EJ6&H\SIF*TU, C#/OT\OW><*M_QX,__ZCK?N/EXO($^6=G
MCZ ;]1G7C:K+'Q.VB>%X]!/KE[Q#*+P1\:?AY?52OJU&QX<_8Q48N_6IS*WV
M[0.E:\:)FI,76 M6\,WSPHPQQ4<:EQ[GH:NW&2L^DB'-ML%=Y6J'*\S)A8+R
MVWI >5OP"$E<;?H*:*CI_9@>>\861@80.,B"1">=^&%(0GKE^ %E5+9ID75R
M1(["SNQ\D7ST*67]>=6GXULK8(_R!=6@%'R*']PC(=7^O^ ;F83A7,>_+4?<
M@+.3H>H/VI'4]24<8+%Z6X4\1FJ"$0;(X:^26]SBPI$75"MI2G?-;IUJ[<)J
MY*:M2F96F'4'V#A(QV\7(')#[;.QU4Q)GSD4/*CWUU&5$U<:6_U#85A6T2O1
M-(:K=T0=J]RKY2*O@Y\I&C":#\VA'E":4GM^ZU=\-H/1)P3>M.BS(],\YN'N
M$-0CZ>/$X:5<Y(:W> @Q0-Y0"8*8L=L_TRX"U/9MDDAW,*WJT! K]A@%K7O1
M!V\C. 'V=R/;HV^]7#"C:\]/5R"U?^(5PPG-VAHX_8"Z1-.PQ2NECX"3O\>_
M,VNGWZK+RV*E%,W%OBQLIX)]9&X&MR)\9ZXK7T=[7+RK]2F;26SX$6?&(#MZ
M;5<EY\?%5/ES9WQ$K?VR_E.("S3/XD:O#!3:=JZ^ #X> QHGSRQ?*&C->;C>
M0+U]V+O,,6R3;(:1M6VGKJ<-[1% ?$U-Z_.BF2(-=8V;KC[>RL]OO0*0/R (
MA8R=/W>=8MW^E7!>Y*CBHK!FLOLFW6UP< (>)@TX,?6;;SYLT*S\/@+T?OSN
M%=[C"&A\5;T=8GCF@H:#F=&8$U^Q->X/:-Z&.<D:<R/2M-.K.=EM'BSZTS"5
M()EQXD'MC.XQ_ICWDQIQ!#*>0XME1;T=>!VX!C#2#%D(9/;B&VX#]$"OZ/7L
MO9%]+&,X>7NCE'K6B4?Z*WZ_A*<Q@A!)PTBS+W'%+S#K(5\7EL)&^,?6LLT6
M28?DZL*1HJ+8K.S75GT\HV:JW@5P8D"V<>]9SN&>\58[-)J[Z)KO*)J&EVOO
MJA8H5H5#GL7(/JNO/U:N&W'^OA<S7Z5-@$APMM5&@?_(<SC<96EFN=)PWFWM
M0;*I^>@F?[.K?<;6L_8HG (+=T&*2F=0 @R2.!:OWZ5Z86E?N+1++M&^\W;K
MRM[PP^G*[D!K4?Z*/1J#^\L!-:"1?2OY5.W72A_$;Z8SEPMRI;0&*2U@OM1.
MU0P@9DO^\='EQ<I*%VR)ZTRF;OU=OL%F!$LC>S<372"%_7J/_9^VH>9O8.DP
M?6B^0!'R2Z8B-QI:>HMI3/:)])GT&7XDV1Z)?(W%'W++YOEO P/?3+A/XHJA
MXUIC)?&9*7^'7=D<?HJ%"&,YKBO5(J_WZ T*_3@;U9S,Q4E9^[73BZU%NE(J
M_@SO>2W<SS27"8]Z+]9;?1J>0O0T?=?:&\9>P1%G/:[BE^7O$TP3LZB&-Y"R
M@56JW,I)A!MZ%U]')MQ#H1RN=R$MZPE)HY7%Q]JZMD[*%L>3]8=N,TV"?DUH
M$0X&Y/,-7K=W-V2+2#W;$P_^6#?__8!V*VPS=VF%GM7P;EO@/?/2BJQ<X69M
MX4C,$/M:-QK>(>NGH92ATKA ;AOL?JIA.ARX%U4-'3E-T2&AAO%JALQM: @(
MIG--%C0;7=W, OI42V2QZ3(OQN:T7L*^T(J9,A?'WDL)A5$JTV%@?XSEQE$K
M3JT-44Y/I6?3X,;,QMOYL(M#+8V7(4I=BC/=>U"\44I:1KCA O@869HF M9@
MU]8[H3/D3;(=G77=^?P3W6Q!5&*JCCBI7CK2>+U?VIA:NW3Z:UI;I&F)7HL!
MW;QJKM9':G%L([TYFU,Z$F4^:&=#F@6>'+T+QN;V5((U<FJ8LR1_C%*S00Z>
M9$P(K;<"3HZB>@H.'",RW,:<?'.^><&87@!OW3#KBL(P,;F@N87>0$8IIP3P
MH.$U1ZQI#FH>;R9S"0EI 3<=50 "(%A%Y]A<E[6+S$<6&/Y%9L:>B$'C(XWT
M7NJ7OOR6L7!RY#+&64U5/3G28/> C*VX/ER2%')[[[W4*A4-W154H"ROK;GO
M>OZ/J&\#L,^U,O6^Y/$W#F9D/&Y'F7WR\MTC \REL?$QSG&JM>C?I#M<IU0%
MDZ :E17YY33FY5Q^R]DFY;J4X'P/KI.8Y +VS5VI";!,Q51YFZ\-L'.DNWLD
M_Y[XC74K2M()"@-IUXPC-\'?*I87B$./((KOC"H+BIPH)W_59^A0]_:Z 1W0
MIV"0_]I R,^MZHB$E)\2I:C#T@^C@VC?/!BKPHK,CI]2CI SAE "90'Q=DNM
M_ >\[S^QZ?))TX^E\\N%"MBMO<"G57V'%Z8Y)8TWK#D-Y$[X$E- A?H2 ( _
M_:-%PYFB-<7D@-3?.8GS^N/$5]+=TL=0,1BV4#-*^*A0*/9C(  !P3!:^-''
M*]P2^?</NN+#(]),M[A-A2+J;&M>V.?M+ OX]0VA.A>K"[X_Y-,K?RN$ZLC\
M)06PRQ0@%( ,UVFF7=[77X!%9/ I*E1Z664JS R'?)J/85!(:8M#W72M!:+A
M'EZGYAH?1XM&OTN[0-6E.6S\PN-OU>8O0%NM[^;00U7VTR^ >,=>C>0,!Q=%
MF\!=6ZL0DC$B_-%/SU:G9?T_,2,X#N;Q1H;OC\S\;,4(L\-4!3K:GU>W0-:^
MHL9LQ"?M/UQIJ^26RCSLC*N==@K&QCC&!,?P\HIJ @NRH2R,[P=O(C#HZ#?R
M6;X0P=F$29S?[RIQEY\/E#N6R+T5#GX10DGW5Q9IC% YJ.Q%NM5P?E+>1TC:
MW_';9K&9V.O1]W<\HKB]<L=0\+GH\/K0]?M>:@RCCZ(M2? 24L1>[S=#0'93
MY9'LY<#$EV,$^3&Y'%BD+ !6UHBJ!ORW>'@M)A. V'_I/\LU BAQ;KS[F!YM
M&L9*HU20$AZV-'4BKQJ0.Y$W3K& VIQ)7OWC6WC PQ\7:19)9H;%B09ZR2MB
M<6(:4S0WJSYL'J3'8+UY*T;M0OYNU.M*2O"V90KR#Y7_)1A/G[K, X6^U6U&
M#7\2S%T:-EBJ1EW"'-O9J\:';(8C-:[&-$RM 0@(-<9QNCY 3J A[GO7TU\?
M!'2E2I?MY[8,E&>7C$\PP['[9%T%['1G3U?/EY:L?LMIC/O?E^*E4"L$D!:'
M&:YW@:9*P7& L $\BM?%M=E(]F^:$<W1$_"A99YL\(/C1162;D\S5A0Y"'"L
MXT%UWC/<26:+N?-&T$L''FJR&C* Q0)P*Q>)N=W<-<:L#W&F(!4MAYNO.I/<
M#DD,$/[?%H%]V:!J$,!P\LGHXC;^\KI3_+%$QN;B%V#W%R!S\N#RKOER1[39
M&/>?V(273CX<(JX:T6;D7UAJAUQ]'6_"XK1Z7/:/[JD&<>\>9+.MC#'AS/Z)
MMK/PA7.4L/[D-WW3,,%=Y:PC&<-8C0!?+Q[J?(I]0A'ZP1%-X/_<XQCN6UN]
MF+<FWY1@"<#C>H-!F+@NXL'SC##Y!YB.RZT?=A?QL&U85\(U-('D. W>WQSW
M/DQ)BSRY G#H74R/<.C\!PFRV>Q_\&#V66FWL6^G]5^5?OX_L-V%0%Q/2$.'
MV!FQYI45)VK7:&<^7A@EW,-K*RI!Y)L08_\>0,T_$4ZD! N?FKRH9];Z.:H8
ME[C$ZP"?VB>7!$@[Q>1<O<G>A(9P[8]D6[W101+Y)V*Y@=9?)\[&>?<8E^K.
M97^D4%6 W5_\=U1M$*K/B;\$67.(6Z:%5;Z3*<VMX>&)PZ#.3:'-^_J.CUSN
M#1@Q,E[X*/^+<DT^4Z(:;Z?4 ",RJ5/69Y3.\HA153 B[4R7$1'B1UY."W>=
M2\5 (^C-9CC+)7[,H'>T.9(EXE9E!38]W(^:I>/9110]I5++-QWZG\W+(]IF
M\Q*6966YW@) [J?#N2BYGXPI&52[7P*P]P-\C<NQY]__2/P8(Z$L.&%!,WS:
ME#V'M@@6<)R.[)G'"\:MC3<]3<M]>1!63"AG%B-O!L?^ GXB)N#B]H+\0\=,
M@/KA XNA'64"'^:U6@L!CC-?"A^H#_>-3B-S\2[M9 RO7J/T^YHP'O=47'TY
M,[*:74:4.%54I*05XM"+];. ^26$K:/.[S->.L![AE2[?'UID)]4.#>\]Q91
M MM>-OT&NBI>*ICZM0"UF)SBRXD4K,ZW_MNW?H1(&?"=H4B];X4^>$7!1=_(
M#'Z:QXZMN63+WUF=T&5Q+9U%>(61,:YS2E#"FV>::SKI?2&6K?C5XY4S>U:[
M93_S*WYUDX<$PH$FS0!S3)-;R>V1+0J<6Z1[68 +YN1M*-*;MU03OP 'OP .
MEG#1U^W# 4L_IJ>K0H$#S17+)W4^O'C;YKI*"Q M(!V-1:YYC-WN\3M<.+VA
M?ICY^<Z'.MH(_5Z7(G1:$E9';DPX$K9'[([3V&\_3ZM06'^G7RQI326\6;!9
M+&T<U:R6-/I+:NM"-:YQ%\*WJ!)X"/V<H0  <NC%;^+5>T[RU:K .L8QO4A;
M4=$.]#(A9T#&D"4Z<Y5FUH5Q['5BKYX<L[4KJ4A@FMWLR4=CURUB,,%SO=Q"
MP5OTS^ 6378349O(K!?C^+:\,.YA3NY1BT\=]@'"P'$0O6^0V].*.+;;)&N"
MPH3Z74IY<AUE=CF#'!K_G_7[5]^&WW]OP\%R4O(;&O1"$D*F:,,Y"'41H,*&
M$T2^0HI5&I3ZJKSQ>RA1/]6C,%++ZADP8+\6CG] L\4=I$]20-"G^1*<B&Q1
M#BKB*@$*VUF%:E.2-*5G: &$J+=4#=\=QMK$A26@YI%3NMIE(FK8R)Z.N5_J
M=0V^HK<\6U]!A=HP@[7,IB28)70J7^8!99E'>F/+G8]PMO/D^WVXF1^ZBBK@
M*;6@;NE]WLPK2E62RZ67T'<G?)\ZJ.=UR=6^9AQZWW"C)X++$H9+;6B=@)+>
M]?%J-%>:BKL AC\,D&7NS)>HPOR5WX&%EPL<9HQWM[.@"Y/7QW83S!BL:8H4
M-,P_\V.D34Y8.?67AP<C\SOS6BC$M2F((!"!0KTWV0Y\J[YY_IA)VXC5!3(;
M,328&M-2'B\:.72(ZTN<\\0"[=!0//RF0&\T5GU.05"(N\V@> NO*SH,8.'@
MUH#0(KUL0-E?3Z,MDHHW)#C<>3UC&3-N%K%)),".+9TZKZ:.UVE9_ALDZ'!]
M1E>VZ]F;;B/7+&WPC+;?=S!H'G)TG^1' (U_7&\&"VETL\R'$%R^MY,W;+?E
M/W1WPF3G%RR]4%<FSL4TI!^\B$J'#S!??->SBWM(.]3TZ2PJ3 ()F_N5#8XZ
MCF:4-*YJD!H?+B=I&/8&(M6@<VA"+Y<4N@:>U)_93$I!I(8_0$#_ZK<RWXK@
M]28&F]SWXX/RK5"H"Z;OYY$-L;R)VBV RI]R L3VVL:--D9^%<)W7PKRX>5C
M;RH(-@@4=FEX>+4/@=/Y(G(]R1KXN!)'UJ:IH*9U]6D7+^UK:;9/P#M5]SWH
M\F=!XAE3#8X\L&<X&K*FG1//-OKI0)T/MSH5X>%@_4V'N3L;9J6T@/'<8*/P
MUT\P ,-1HW#0D=@JC'G*J%&:*RT="HN#*LJ.55D;0X'-0=42@A[$F\/((^\4
M:CU><Y#G!KF142ZYVT\#NYGI55F;?I= V-7;#[;BRV11-,^.>Q3U@UCO77"P
M;C_Z(P,>I5#^^!Y5Z<'\^%0;0>_-< N(,7&[W8$P8ZS".I#4N88]M :Z2+WW
MSA47O#78X-Q,0FM6SLCOW"$YVZBS [_:2F*4I9Z*K- G=RE"S"[A8M3WJN^5
M-4D;JP)!G'/<-;^%.SLK5^S4-+H1S!<OO0$*AMGL6LB%!T8YLO]%A^%9ZY_1
MOSU)B%^-!%BKO!8V,*2ZLA^909!!F7X]TRT#K*TI/446^*%D[Z@^3WCXDK F
MQNUHQSAO1Z=0:ID4WZ ;R.SZ2CCJE=@$R3W<_'7>U$/O6LY<UHI(8ZG+ Z)R
MB-8</#^X)-2# *96VBA373]SR"]0XZKP&;%P"<\F:%G#IMVPWC)4_:'&BLJ[
MT;P ^4O YRIOT<:=K-;4(E$5L-&WQ1(XHQ*Y$[(1E[>>CIXB,M^=XZ/G2S3J
M]/&DDSK$=:NUCX\%)& 5&N;+5>/%YPG77(B**Q_=FQQ%>M'; J<SV?2<?;FL
M0U)+#$_2C2P7RHF5F46^L+0O9(472O1,TJ4KO]R*-@X)33]4FHLW5(H]CL\Q
M+9'I2S%H=3]"'/SQO=LW7NY;\0*W>,!O*DCV@-$*BJ@"FY.?D"3..$S9WWM#
MANC,8F5,A/&5*OHK\R^D93"/WR^N=';6^R*W%$7#$]9O=%AJ\R;%YS#?-+=X
M1[[/S%[4C;<X"6?ST=9]E52^N)FC\TXGQVWT*D^G5&JVC(25E'2-'Y@[36OP
M"U!7FQP9^&%5Q/TB9:H1L"I9!^PI\B%(M4Q6QVD5$E#G/Q[5:ZUAFO04*E?2
M9"AG*U/9-_MZAO+CR:]X%/P*9.I$/!:&:N%YZ,50RX4.B$G<4/$;DF6,--Q6
MG'7B1QFIF\ET48<96K*T#$$=ZT4J,>>.6._K!1E>32:.+>FDM.IOS59JF:H&
M+][HMM$0":848N0#EAI(F?0RWR_=E\\O-,M 6,9+%W\T='<;,&39!*<K0/J6
MR5?*J['9TSCCG/#)W!J'!CN9<\RR\\C'.9'GPHIQ6M[:1,U.M<FO_B1OK#[Q
M52FNB+U9R7OQ9A;Z\\U8[+PD#G#S%\"LJ]W%O2DXT3B=&ZA;J -\)R.G2K]E
MU&K9)Q BH1])U@!OE6U#EB@YJT^5Q^CA0S#2L[=4LF1?;DRJL*C?!!V=O2&O
MC'4P=&*7*CI%KX]PG["B';LJ?5FCLE#"#-/Z<H*%/-II?(<EJU&D):0Y0R=9
M&==B%$J8#()?<:!,A_YT;&RH.EA+V^W201WP*2<6S+#%M2:PK)K&]9;!)V G
M3 A8VZ$>'_VQLLO!>T;<]+'PC&"%M\36>NB@+&JP0<DN64_^JOM;<VDCH_7[
MHZ2$%NTW>W%5]?+V#1YLF/<$UH&PQKB693C/X3;)ULQ$G2ZEI,WE1C/CG[[K
M=JH.+' -'FU/W1UPM"$U0PUEVH=U!EHH;/2C?D_I9<["APIA;*1PY T165$2
M[PBF45KL8TCH F1&_!$X'LP]GA[L7BC\1;7<?-0WTT-;PN[=JVR2@K,6EI?5
M%8PGVB"U;/4*!?L6M8LDF#,5:2J"]%$U]%N?*Y>75Q2J(^65ZN(?P@OTR2QC
MJL(&] )6Q^@J('A,9&ML[T4)V>H:><:2":=1WUVEJ55'U[?7E3*1W\W<>FJ0
M'>'BHYAA#_()H\DRD1\HAR>N<EDBNO^A>I_T[I3(13L>4:T:]YXY/YW\ CS\
M E"$&N/^28?$NQWU;C,FP]9WPRKJ!+[EIPNM"BG'M_(L1DE$3_CUU[V\/OUJ
MB@;ESV)Z;.MXE]"(6JJC(^<1/G#/3MI &SR\;297KR]J:I,N067QKM5-PY)O
MW<O L^^+,Y4FP#G?=VH25&S%A1EF%BZ"&#:@)6&W+OE%IK+E?MO2!'.Q.*XO
M.\:?&SL:(:UD/?SU-4=L+.I?]59EFJMZ19O$/^2;SV9F<B>->=;H@K\^K_'@
M&"6W+))PI=FM3W@F? R,:=&93JP3_1+MQ)JG&3#QA][BW_\"=%L]=#'] GQ7
M^068 53]Z0;K\9$I/>XQ]RU,^S(!_="(==W:D#')[R\M"@D7;:^/(B=<*!P4
MN1%C'+!E/-_K*:)5C*?W%,*@S9&<^3P$UD*>+[?FRJ >*&)ZFB#^;+V9M.7'
M_M$]8F%[977U.;3*LO,H/E[=6%NMK>W-5Q&+$@JDY=[.-25\$I^U?W,<*K,$
MBQ>( W\]J(C)_ N09WCU"X!6851BL$$D:>1/:4VQAKIP!-)YV?$G_TO<3F].
MO'>0=?W9LKOJS=1W#%VKW%U)-E,\^I+'5J^COBPC:CB#)K'(,JZV=&WR7>_Z
MXCP"NTI$MYX?:]Y)2X+O@*16-]H+1[^R3ZYTR MY4*[XYXA,/0'7B*AY%^*X
M5K2Y6;&E70*8)K-,@_%KXUL-*64G!KFWZ7^!)!Z.R&8Q( % (7X(N-RCY/P>
M &AK%;K<H9FHC<&:& %D_KFK2U3BF.D)JE+\=H$@6'K7W^, (^&*0;_U_5@O
M9MGJ;&2(J7E8>5X!/F_Z@?S*32QCZ6(D*9!U[G74$I]PQ12\MG4:2Y@L%TEV
MN;@33,1O9;+*^YG]H:2B(3Q0.6\N(=B#]_K4,KHR_]JP!DF%9:!6[G,J@P!C
M(_L>N\:-SFY.RH*M:T^(G<_H6%=_2*OC,92-^'F?J](B=-O.CD5+6LP:E%:L
MO64- JJ+?0IWPA$QJ151-J!$8C?ZY%R1WO :*)MX4A,QEQH+;_=GA8:*IC>/
M[0T <0^3IK-;'$;N-(CLZO?X#4#^#<;@,.KP#1GWSZ!,_+.WP,49? "AJ5,T
MK--]]IJ-E1^KWJ>E5)&L')8>D=!EXV6(8"3![G!5<00.O@--,*#K\)OQ'LF\
MCW<J7YTK"I@3ED44L<ELKP/-6GC/EZBYU=*[S?%M#_>E.4]57J^2QR7-7S]!
M));"%G.7P::O:D;$:^7'%(^7RQ-J[P2<*Z=<6;=,P!^7@O^:M1EA\_\L\ N@
M&OW$O4$(^_YCP/^4Y1=@[@U<__]GI17NWTE(?[OX2<??=:IK9/LEK^A=B!43
M,OFX_MW-Y?YO5N>\0_V":A1E]1_DO( 9DIOP+8W\E&2DP";_D*#26"6;+-XI
M!LO,60G0<?PW=?]K?/]-*@)ZBM\**"1O(OX0<]V4C&+9XZFMA68BNR?FBV1C
M-A?VBU#<Q7\P!H'57]Q[XB::XWWTS@O2 '';F/U!/S]_\0WRT1>V_VC6/SJ'
M/-ATM!^7J,R%L)N>*PBO5TK**S3TR^_/36ATKZ,5B"-O^7Z"O'.@N>$'[GT3
M<>SFJ:_9(N%/_O47_MKPZJ)BE>4^\.1[*YTJ1QLVLB'UU]'&9JLKGBA/^AAR
M/V[:JT_0?=(=X,3+/I:0DR_,BWV,=H%L,%P[\M'T+-\/5'&=0=H0GBL0\SU]
MC'1N$,7&&@.RYSIGH[%LC__OJ!QD(:&WB(!C >U2>':'<$ISDLNDF&H@<7)T
MRE/#W[Z5XM3":^3P$OE7$9_^HTQ*U&9-<UNG;!\.>6MS@XLBIB;\PCBQ/(!0
M,ID]!I""*H:##4\H%,(%CU9:-<_/WP YOWH**OM7@0C_%QWX/S6068N>#5V!
M0JD4?GA%6/TJ3G$U%(W^Y8M+N!U5S$X.8Z1. /P62YCG\&K<X:J>[[_*5?I_
MYM6T;_UH_%]^U':,IYLC.Q^EQR3TR05QR:Z>2:8@XR$@)6]T.@'YDXA5"GYP
M-U28C]Z/&)">ZJ7LY6HJFA'A]?9SE9UOF1%*M?V.$2DI'RD?1[",D(^P$3G=
M\?][SX.UTDTG6?&J6-S[&(=&[KN] W\!S $5PRCRXM71WY4&GW(-IQ^EO/"D
MYZ*(^W\!.&0SZO^N.>T_*(@M+*GBJ;(;$L Y@U%; *'\E.0&LNJ07,, 5\F4
MFP#D2W*SI8DDQ-+%ZE;WA6DP[#\Z5XRK O  !7_]/3)F)P"P X"[!" 9&T\%
M>!:L*7NZ3_J\=N'Y!+%PDXL.<PUD65!G31,#@?JP $;63EBX8JS(#40.MFJ,
M@]9"2"_MV99JP=TE,9*-N*K/ZLC"F>MKTDM7.S1) 9ON/*%I:\$U9^-R3R&"
M]U-5E$BJ\V4_6X*X5Y?/[F#J^&.6;W2IRH,29T?#+;F"Y/'&#<*CLM::?BPU
M6NO,OXF%1/KEM*YAU4% N!JSVX).'C7I\59 D<7ZZF^N$!\'[_L.K%G>LJ0&
M7KH;-%!T*OD $HOH,/N[56%FN=1 G@49_^S6'X0KT=SGU^Y#< -&!6K1R#Z^
M& (O*P@-]P?T6JM;/WPWMV%$/#ESU[/L*+0Y>@@M(Y\M6URN\6=P='\>SVLR
M)V- 7PO,$*B3#-SIY6FT7T$4]A%U&'"P'V@D2;8],5OWM,^U[;_@=$Z^?QY9
MXP_EXK.;J;W.% &5B]+G2)@L=)3%1)\ECT7+A&54<SD_+)4Y)6E^S8\%;UOW
M4[L_? CN6!!L75Z9T''"Q\'"1<GU>!.3J[!(W&@X@2;$0%=MS:U16[&15*#<
M^S"Z/*?#."RE=03I9J.E^?;-ZI"50E*?Z7N^KC#W2$CMP$+D0U2?&ZPM'<E@
MLG*(CP?O[*JE'L8O(R W.F3QV8Q;II#S)F5L^ H'%ZM7CN:3/7O*OPVME';9
M?2;/%X%/KCV K#^[PIQ>-]L+N_7''!6HOUK-FE@])R[4?:-L,,H;[CPQ6\'C
MI+R1B5,;>NYI;3,#PD1C-2<J'+NH\'4D U#E>3ZH/QBB-CQ%+]88R[&SW438
M1V_3F-C9@-K%\H+DYRHT1X[U$';#C718KV'R!I%\E=VFH#="QU^.\*:_S)Q%
MYPV_W_1TSJ3N ](PH>'+-=2]6_0,WL)ZJR?HL2 @B!S9\[K:C&C!W#X?)65D
MM\>8H1(B4,8;KT5E/>7MG#M+OZ4#8O*^EW 2,:@N3\WHQG=P$F0Y]T]6V83=
M-1)R9QZ*+=;,B? EKA<4Z:4=N[KV?7,<F2P\L]N\]JM;5GL-1B,A:FBX;T5I
MU#XU?/XLAF)B%T]_0B[.@SA<%Y3H6,YCO;)\OG)">'&Z5 \9']TG:4LW"K>N
MFQNG/)M98,=F/QJ4XBTZ)R6!!Z^X?:#==3ZD +9+3Y_ZV)2P*GR0Y!8B$44@
M>S$FO1@S. C[I&ROE$-$B_K.IU\YYML'N #-U8#K/4(?H9>@?OA;KXAZH^2Q
MWX48UIOU+L#)*?I?6W%:3PX;?K.#2K&!/OZCO-6F<"C(QML:YB_SSN;A>.QC
MU9D[H9Q<"\9R9BU=/EZU]("T4%QL39GC@M*1V\'15BEM*4&_>@7,YER^3RZL
M[?2'P1NEZ(%L',M6^[5TT<O/3<@ZS9%&)JN3/"O1YJ!DNVZ9 5S#^>4]YDV^
M8OFZ!(U9[,2T-MTC-_#^:=YT,IU39@857G@B.#\<H/"&;5T)UF9HD.XVH'=^
M#G/@G$W3KZC-5VN*6$XRL"+27- >OCG*Z9\I:RPEG^D0K=<?L2_M5YK@M G.
M:@512Y2'43Y/$+I/HTKS<2N48I%1?#]9VO&WIGMY2-A125>$8COU Y]Y?"LR
MQ.2U9\J2W58I3L.M#ZW=FV4UKY*4XBNM8DW"QI;FD%AA2'[!CC'S%/OB0-,2
M7]:[*!+W;2O[15_D50B5>U/;<H;\45G@(93)-AVF.R25J57N8E5B"ZW4DAG"
MU4X0U;"$D L7@_/..*<<HN8$SI@.YV3 O1G51HIR\ =+$96-MOPN"(0O);Z^
M0*BY!&"ZWYUC2DZD>%_=(=\@45%DB/A/"_ZI;LE<'._ZY_*<G1C>SZ@G'.U(
M0P#?N@SBHM1W7D5&YK@7V((K3T%$I8]^L$4#9[J >=R",JM]_ 5ZB[F1' 7&
M#3SIE4;R;,ON*_?+.]&'GRE9(WW?<.:*#R,_JQ=65E-6?)!UHJL #UR_>K"M
MM(:Z]+#./C>_NPS6S2UAL_5@J3KA32=K45:>O#U-+Z$/\L,+1.0Z/X,?Z1&W
M%^T(V0 G;(]8*2QE#!Y#+:07[V'7/\\8I$'D<^(D/C"(P >&FJTP1'NQC @<
M$[,# H3L'!G+I:,U4_OJ+Y:.#N::U&&^K28WR]+;BX[1_7[]R_IB3BR^T*J@
MV5:28.*=S*4^__+K!_3(90<E)@'C93Z@<'F&:=RD[A:$^<XMKWD?*+.4<_J=
M'7N(#4=,YF;@T[:]"&3UWL<U,_?=,)T0&@[_)RL@2FC3G92ZJA!CFCH&CGN:
M#=*H,XXQ4\\A8".P$ [:9NHO[4<IWIV>?.0A2-LH3O.32 _DST^\_1"B^@LP
MD%=EH_<M\6%D#]F8G)X?E@P\2M8CJ$1#,O8@<IZ/J<&)GS"JLL\GFS$%,7&/
M$PE&V^^J)AHO=W-LQQEPOF\Y_?B:F3[MDR/FF@S;?/J(:\OB!UD0?Y"+-H?F
M%#[S:(=N?6!B\T9SX[B,SFF<\+U609P8@/;4+W@Y_GV<"'QQJFI'%VTJIAG+
M4=_FR@_#-_2PGG.57@+8_".MH;U3HNTJ%@[2;(T'49'U8MJPA(K#,8G50 D(
M5*K1'217:,.\&TR7:6IDM:C 5:L\5V]0]K/1"C$VR0N1)_OU1K;,4_MX@M:6
M&)7/X?4[$AMAU&1S^<,"FS8EV\7[N3V#EU_KZE9W9NUJ]/AF>U'94L$Y)#2:
M!KWYE&6&;V^\M%5"IXF3:9CH^'\<W/SP'Q%[X\X%NZI[7/L=K[>CHX+Y=0:Y
MMT9K]<E34YK0R'8C:Y_":@<N>#-]9A^,@@"WQ+A!5T(Z >7ER?'-XLMXS:X8
MN<1!ELB:#K.(N&0S$CI\29UAGP<?"NWL:CML8WRA<0.3_$L SL^,#BJ*+_XN
M<9D%SU.87<]=I"^6_FQLJ"25@SRP)U4<*V XHV)V9M:&LF$5GRC19[='J67Z
M.)TT85ANV>"#E#)BK8ME;SR7>(G%F17)>&VN\5\#S;[:X4,>**KYK=$KR47?
MSAB<%1\;AA8IMDS5ZO;K&0N5+YZIJFF)V7H&KSC?$-6OKA^I5D CCEALWWNZ
M-DB;?*D?"[INGDIML^=MI3'?\[AM3";GJQ>%Z,T+>PM<W8E:&:>]ML$\G$O,
MC,HC3+'BI\UL=C,(KQY8)BB/;JA@W6!]A?.)C7@E;QN],VE0 J4?T?/[UDLK
MRM$*4*%A_P(\YY_E&!#5W?6GM9_=XKN.CP%>SARG/ XA5#BGM]&<F-]"K.SA
MK/[PTVG80$<CABQ$O]X>5C#%@(&;DR- RML7=#UGI=0E%@53/DD(LLPVS,RH
M"92VIE&>MZW7Q!"W29,M*U 77\'Q"VU:RB872Q=/+<>? "(.NY 4%D+3^.O!
MY6<I].C' E^4PG2(/W(H50#[].+2O,2PY[PS,"P3B5R:1J27XLV</L="^7/'
M^OCK%W-UBMDK$=,W&Y=NO6YY&A%FE<P'2V6I2Y@EBM.^I!0I28VK<F%*)D@5
M40U3FJ;DTG%)(2"\=33_^1?1QS-(AEJG^T4:+Y @LO6.O9E<J[5.V7/1F!L(
MQXF_B8N8LQ+3C@^NZA6UHNY+[X_>W-5Y8[?98D.]$8PYN6KRLXW,\9"#02^C
M9M+ P Z?".IC&E!C1S+>N^@.<FDIE#_FJ*1+KEX[C;]T5BG]?D/798E)1P%3
MDY O7-IHMGV-&>%I'ARPX1!,W%NNF,_>%F\7P7B\"Y[77O+1E31B?M#LZ^FQ
M_9)J8$'GZ5&Q;\?;CW] W;G$P'S!,YHI)3L8)V6NFWORU3P]&K-%VW@UO(K=
M%3G]9=O'BH!:K(SAJP ^OJ'GKH4-UM@8>4&)#N=8)T'2I6@8*6T72J5G;5BX
MW2BF>^]L!$<23-;308!*I^[PP6<$@37!E"V9%N;G]_+)<E\ZS6X#4*9=?JZB
MURR8ZYHQH//5E@<:Y68RO-3I?KIB_1FBC_+>6J=,P?L#;U1KM;XU 8:M@&-@
M=JV\(I,23$DP?G$KW/KN$/FS(7LD'4/>NEWC^<5KR_X4K058)KQK.K+[$?\]
M-?,;5&9N3+I21=.<O"5I&>ZWPHRUT5%V\3)*:AP.TO2GL4"\GI0+*@ GRC_,
M!V'SJVQ5_0)X2?BUF 2H&*._^%S%%T3SOC; S#,$9$!<'POM;G&_Q(VQWSP9
MS:/+61JMB:D<DA8';NO<#4GII9!^P5$;%%(,<EVK.?@8P:C/<'!J57RJ2Y]C
M6$M34L&7JNO:QSQ2>Q/5_46F7HB(#H<#!U$IW+F!2=>"=MCP+2W)0D($\"'D
MQ?DAJ0BU+39H95V;69_41M#C2D0+AI(94EU\[F:IH%]H!TH9?$CHHV\[R]-J
M6^=KXPNJJ*RUDRMMK3=5:QF>U1]KH Y[@/;J2=2:#_(\MADZFT*[?F+.'FV'
M)="][#H^VZ]_"NK]</W-1,_7+%+U"47, IW]U+VYJ*] U:A!>DS6,''HO2,J
M[DU#PVHAER*1?X@];,<--Y!-N_Q,]\(O)B&#SPC4KQ><+:6KK.OUV39HG!FS
M^/Z<2LPJ/KU&;EC2]NC!P$?-.#_,R:VT;$EG#S(:'@P<0(8H SJ9E>7)?(+%
MV2=+P6C3.Z*=&!P@'$Q_S/50+*K3DY-;3+3)Q[+STZ6D56QCXK6Z6[G)]"Q(
MWY__-,[T>G-D&F3LQ*6WY*-@-,C"4S9DP=X1\UKX_E!;DU1+Q:&J.?Q5"FKZ
MSZ'!4BTCV?XF2W9'%4->J9>P_N08"(\0+EO>B?4P:->HW<<Q-JU2O&QPZO3J
MP343>I(QE_9F6RO1,; NH[=L*)$A37(I4]2?CIA\DNJM5>=/]*D?SMCHQ;6G
MZ6(N:H[C6F*531)K6O(!UK5JN6Z[)PX][O-\+5YV\YJV?! /X[+Y3>+%$_3M
MW/3Z]'CIR69_2^_7RK\9>,8^^)9U,VX35*'!4.\B799P+^K>6%)M9MXLR:13
M,/#&@1)[[@[9%A>%T"G><2Q%9R=%Q('#UFXJCX7GSA*B]S7&XN&I%?UC2=WH
MF]+8I5J(!?FX,D1D4&\O6TP:<;!_0%K;^-!UV)6&5UC:RK!8XU@-)Q)7N(SU
M6?&29SQ*VT7YE:+R6JMGQ%  )ZJ;8( $N/EUWG331/8O0)-BBY'O+\"=\6M2
MN !C5 %T8CU](_V3M$0;<&3BNQ9BKM>-/K.[NL60:-'YJ:IHJ3QE,*VUJS3[
M#;]28?F1)J5)0I)?2NE._TL0=8":OJ-1<2'B6??4/#AL+MM:KV'7G9YZS6EA
M^HJ$?B2,(-V0N\-U@4"^ .J=-)CBPF=1J[5#FQSFSV">8?_T>LI&EBL2/9G0
M$$_0O\*.\#0;KC(NN*&GT3)!KE_G]*0,)YKF(-+-A007%<WGA2M]LDS+4C@S
MZNN&Z_RS+S/@>FB2)S5)_F2 Z3$6(..-:$#U.PV6\?I-^WIDJ)F[+QJ7:8)A
M7ZG\5F[B=(I[[64-3L2WDY93:D2H!ZRP3Z]MU4Q=V)_W#$QP@1R>M=+JOA$Y
M)XV7GA^'3"\5^XZ;.@R8@"HUK?A5:H9*,@8OD.IM 2,2)0" .8I];TR\TL]P
MI;T%_\C4[%?D\DG!Y4+<*;'>ZM*D0KS)#>O16P2Q '9GU-9N'"1_+EUJE[92
M&K1,);2\O5 5QYZGY7J7BN^CGQ%9TUW!3I/)XZYF)H!#>IM/\ZFP.OT%NURM
M!8'T6\&Y3"?YHOI&GHK.1M.@FREQEZ;[ :Q\_*HENQUIHA*AUZ^4LP0UQXGY
MK$C7<K18"!>36*EIB&LC3*=R*6TA+!_'&'0C%NR*TE3TUXX*$Y>O^1Y&E%K:
MY_HH])=WV(1-B_S+0:Q.FD_%49G@+>#43@,ZPD/3P)B2Z"S4TFA0V)'=\!OY
MQ0Q\5S9&8G'K**U,$Y[)C:BK/GXIUUK_$W.?;C[O8V*N\!>$9=#T-;-?DXRS
MI<5%VGJ&#C%-54J2S45;JY# V +ZM;VA!#?+9XBD;K/ZB18!AZVC%ENR> OI
MS&1,4I*)Z7(<WVM-^:N'A1L4H)53C&;::-L]?JDHMLS<]H[1P!"OZ>R/L5A-
M2;LJ1#CUS-UY9MEOSM@)*3NDS5<=OZNHC+L0=B.*C\T7NX-O*,E:G=C^K-GA
MM:ZW%MH-%C>)C!+S(Q?;NO'_)![RX$@K7%^H+#_W8 ZL2A.;D7Y-Z$/+:IX*
M;A*>^JXX2SQ8YSFDM<),UCZ#.N_)OSE<@"O^$N>=9[E8HH$?6.?P>+V_OOZG
M3%E5:[UMBZN->[I=YSO;TL#'P/!;B!72V:E?2)NY;EI=GL#92CG1Z>YI1_&0
M< CPF U+ST=M3JNZ7'N'7C/+??"2Y[(()#>EQLF80J&S2_<M?RH0#YV65--&
M^0L9+A8N!0GQ7!E_";7JN&+9G[)0)_195<\'07QX2T3J[5M_Z[1' *8)IA$<
M')-0M ,5W"$RP8<_NV'H:II<9U;<M8 /NUJCD8&3,7,W#8+I6OT%IJ$F^O4Y
MGA]U86*J5>\40(4FIY#8E.CJMZ*157SZG\*<+=Z[D:3H=]A_V"77^#1.;,D\
M6;=POW'T;H$EZFC2L'3?WY8#GXCA0\C2C#UXB7@YMIK!M,:H[,>\C\%_X^TM
MH^M*DC3 )R:+F9G!8F:PF)F9F9DLR6)FMF1)%C,S,S,S2T],%GG+55T]-;"S
M,]/=^^>=>_+E38B,C(RX$?%EU^8WFX;A:E$;9Z4PF!G.=. ^L'E%(ZWXF*IX
MF/-+.&/XEUA3=(P! "/1*#=7K2TVJ^@'"D:RE5IJDC2L04:DP'%1;X<_#F 0
MT,((/G(TB0''69DCF?5$JE")+RBQQ/>!XUP!-^<(4YF NS-6]QGG'=2);GRS
MF&<&'Q+/9K#RF2VQJ6!Y#H!K!L]QRU7XX39"G;@O)C\R[SK(HL5E_E$O968
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MNW/$=*4'_.\JH0\7<_9-KBJS.!X7G%)!$[3X&4"%V3@[OR6>0+\CC/\F"W_
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M$!EGA./_I?6KS?JE7.#M-4>NM3,WY3F"&':=8KV5NENKW.>S?TG59D@O4'N
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M!8%TB-=R"SP8 ]3^D_D2I$\X+@$AMQ4&XL/'F/5=>3-B(0&%]>AN0'<5RUU
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MA<KZHR9#*B%XN9U&YTJX/E?B_Z0% 5"WXJ=+YS#PN(?HK-M% _K/67*4W"#
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MEU^>:/#.:V"0)U62CWI\6^6Z"E2O=PO-;8L-R^UXF@1_>'6/8XSZ5#,1FJ0
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M)"&1:]Y"Z$FTP'L.!T-3IXPX8X!IXJ-%'J@7_>3#N[O$F>A)D%!U([Z=NZ4
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ML?1/4$L'",B]$UHWV@  #4@! %!+ P04  @("  7ALY4
M$0   &<S,S(U,#AG,35A-CDN:G!G[+U[L.Q:>A=V[XP]8\8!/(G!QC9PN&/
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M_MNRLZ9^^XTW/O+@WNNV7TG^I*(7#N!+F%@^.;^:\0P'R?F%[/F]SCW#"@H
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M0;L@UO,%N59VI.A.$TJ.!$/<\)<UJ>F[#4D/&F!W",A,X_4D].,0EM8+*FB
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M[-S '?WAPL#C9KN8+_?S/64'FP9U"F25R (K;W>VY*I+]W2.96@N;SU8C\
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M@$J-:RZ<8NHJ<$+A]9+1X,TAAX>*#6>28>*9YXL2>R@A'&++]<(Z,ITDDX-
MM?!JTYZM,4C!>B5#'8S[0DH&9E6%O5RR<3PYQ,GFXO1.[U4N=.11<K?&!5BD
MRI)P?$)8@NQ03Z$8ZDHX-BD41MW-^C8N+Z((0(T-RT%['AYNF#AH=X2G>0 C
MV&Q%FH1CDE70=5:91U'(!EE]Z0[IA-9H%\E H$W!0.7A[-92%A:K+8'W7850
MOO+( HSX=85#.\(D)\*HVK<0L&Y'G,DHT#[?VWM#YDDPJ0;.!EZ;^\[MN+V=
MT)/#Z&V.\?DX\+OMA> SC+0(1IBTC"\OF,[UJ-++X:,G=&$G*/BV-CUL/G7H
MS%AL%&1Q9J;SY"RX")U[07S%':/'MN )0/XMM-'&I8WQK=9FH-7;&NX*27_R
M,(8;D#%I($LPE;O5U"N7OIA6XGJ,>B[F$F>08:HF.CLTF8T0NY#GC%9IQ&H-
M04LVULG%F%P8H344:+ZRIUHQLS8G1;M@#+;N$C.)E&.KCJF9(BQ<<=,1WJJI
M]1E>Q%R,]2+A(S4?->W&(;PJTI2$B*C=H$N^FRT1A&H\'UHFUW7\^*CLKOD%
M+((L9%PRI:"<Q+#UQ5PJ!A836.X(7!I'FZ4Q4_2E)8$HC<I+9T7PTP*DC4ZY
MC::KHL>V)>8V 5Z++KO%(FG6N^/>Z+(H13XM5(PFM(U>K.-YK;5]OQ%X1ERF
MMG,!D)$UT@2$ JWG-N$@G!(],7OOI'1IOJST'7-9H(1L-]CM,:TI0A4SHKDH
M)C650<(ON2#?B1W0&=H!>-4],5#9M\[15C!RCW:"0.SB:(D$ )1DJD<'C8'O
M+0&=[F\7@O8Z;!&'(RO07!#: TRS<)AK#-=U,9^JT<0C\@D&DAX0M6D3K47*
M0$IC-E7GF2RBW3%8\TI3.0W.-(MQ$<.\+GT0A8UNL3TPJA[':2Q:UA!0;@M/
M2@2RUSL ('>97B]GD,=[87'V2 DZ7-->U$QA508C2R.$ XVSW '%AZ6M  N3
M['K4+85S#<I!^*11(H2GM4[4US.:7 P3>0=+>$L@7K*"H]G>FU[W!9 <!IF!
MGPX</.;+5CE<$0+A0=;)&[8BY'"$[Q%;E(/R ;Z2EQ,N]@:5FM'5-L7VR]QQ
ME[-.50J_I+)FM]X#T*(?E"4VHB\.KR?I;(,J/>/[6Z%-=HJ9VI@Z/^KG$"!1
M85T4 $"NYPF-;;8 _ D]W]H1@)=S>C6+O?-1/-RM#][&E)MTW D*%*X%^)H1
MI/?3;RN=7$_]7;.(PY,LP@8(E[N:9N$!- #+ *%U#E'=N:_RNGX J_H&#"YZ
M;+<+^>1CD AO4EB?MF#P\_5-9H3S5-\ &A.R90@PP;1\91KT\*+,@*(%MP+I
MB4>9UT59*"H '!;N.#N/J.!I>PW^F]N4;,XU.JBJ!571*[>\IG1CCN6"1I3M
M:'I/ZB/I9^N#AR/PP^4US[O/19JN?=WUH:Y;3D^2R)NJQBS@Y]&UE_7J=I/K
M)5VKY4V;5 WMV"TZY^<R6M@SN#Z02Y<PLVUF[<334%Z%1?U0VU)QTL<U!SQ
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MAS+TB'HJ7!1VF\I*@>(PL]O#R>\&C]__7.JG>5JPV$8!U=-7Z/($HHS[RZ_
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M+'L03E>POXA2HYNV.]2&)S<5C\:>X#J;J:=2(9(VY=6%7)+"]X=0N!P;IVV
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M]&4ES1&C;3X4$8. \;2KE-['(L\:+V@_6VCSC60=2/1\&1OA)F#9U7C%5J?
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MV3DPQ[K43TM::N>'AY<6A;>'AZMQAQY65SL9AQ[6*]47I=/,;LU6&?244DM
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MO77,FL224.=PR%W'#^_U#Z 59HQ@CM).QI 6"H+!PR!2=F2A6-E+H=0AM8@
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MDXJ=U)/0G#K^[OKC\Y;&8T"?N4Q0PN]U V>##8/449BYP2?82>J=KVOB;AV
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M>TTXZ5UDI(,C'T;-4=5B^9E(.% G'[()<9CNZ(]\.,O\L\K.+<!'173*%&;
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MXY<JIF5#O\:=9F"T4SHW:1[>VH6U;H16.&(^JRV0,A>DO)<2!*:>RM9",@5
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M-,\F=)YEO&Z\M,G=15_@11)+[]2)GF9C"!( 4WDH8%9;X$;O;$1[_\KQ5C0
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MRB00Q\8UU?)(*7*2]9"&16TI[^0$ U.^5(>)MW,\R)3L(0TMFUGOW9HB7/O
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M\4Y8/WX#Z;X[#>@(%GPS\AZ_/,ZJ*=%UA90O1418[ @7O2"@@X+LC)HO:6X
M-/>[7J$X@2KW<C USC4PC'2BH@.I&K;7>QFO;0+;S[U+X.$VKW3QETG3(0KR
MS,[UUP4WA+' 2+BELPW\KIO:6IFWKF+&YZZD5ZD'</BH*4?N?,3V@PJ-V"A$
MOB2&8O%OU%\:/3H,VF)_[RX1*(=JH7\8*$U/5:QKF+AP&VO_WE]+P#6SK3T&
M(C#@;J.HRLFA0E=( 2(X^E68@MAY\&")'9H6B]D< -00P'GDY/E+*RFKESJ\
M"TO::L#S<O,6&7,2C>!VR>)$@US8U_)L;)%(Q0CAOD $PYF\U0R<3G>.V_9B
MU'!,5H,!/[0X@BKKBJQN#;&=<:NP\?A3\8T/A4A;[K]]@3M>OX;MHQE8%A@!
MD\>Q[]RZ"GJ-\8.K3<$'LEXPNKL1RL$XTW:!9?J(36KT-3.QVY9%"C SN957
M!F@/QV_N6PX,6RQ7R:=6\O1*UH"A*.#4!-Q#ZUF^7WQDDT\A !)85"V6:["I
MBR:E>[-]BE/"^#M5Z%G7P>X5\,>P&VE?_.!!V-<+;B-%=KF#0'N" /]"-T1U
M_&" J;&XF$/:[I7JMV$W(A)IXZL^G@ )>DO*X.FHD[?V$W%,;VBW%0%A(T$#
M96PM)0=M*D=XS?1X>$&CFT@86 UDD0C]Z_#)=._]Y<2MX,\V*RC'9W_<=+(8
M&[PWD",[30L7DR1,VU8!6O+\F=J@6IFR(=G*2A1@ +<<)+8IP0BSD$4GU5&=
M09*&D^LER1(,%E;SL/!/SMXD5X1J_1K[&YA\","8 :1V9Q2G4<IJY%92IY]0
M*M/Y*64)EA16,V'P+U@ 1.,MO:EF ,!C5/_JC+1YZ=+%"PTP(@5B!/-*9@>@
M0RDAF%C!F15X5 C8HF%6>NSRE!<6E_.6;WQ,YF0K[?DP4/RV559CD)3#E=N+
M6QY#3- !@ GIR-PDUB@'3$<U?WX6B>"@0C!/_)04JW+10AF'XB*S"=<HS]UI
MV]:B:# B.]!AC(TJ#Y5\3#E(Y!+3M1(-D4IA"2PN[:S*_[T].V=#*Q[C/:$J
MH9.[.R]"5LPWEF -=R<MF=&46_@\1?</P>PV>"*:CE/UAL)?J#>^5#;B=HR&
MEHDS?(7@DROIB1;Y)TE;7\O6J=V+.?\^D?".HP&LN"Y2$H-4";-S^V5MN(Y&
M2GM!DKZ V0:GP)0DA3@:FZ19 @.[ W6]"*CKHA9$5MP[MN*\HF"7B)''EOVH
MO*I>99'L*49@@/@I$(4(@Y_)6+'F5NOXPC,"1/SAK1_,=UE9(X)O*$&(D'HX
M<=(A;!"][;O#T%RCB4%R"+9C$JPF.6GR89R[3)'*S\*;[-+WV";\F/NI<;3*
M4]F<\?&-J*RV6<(YI3>[7^2TI %#B<8#*T(8%GFZE%+S9 5#-HJ4T]%R[H..
MN\V,;*97M0,./WF"/T#JEQ*^ Z#QB'',DVM;""DR-9SD'-3<*EJF40<'ZKD8
MVPJR48AGU)<&?IE:>"7O!A-W9"!*MW+ HC& QQ:S$#JE>->ST)?184Z42%ZR
M:/C$$R6JIN[S\UX;AL/AJ%7I<AI;<%&1DK:',"JK4J>8J=$ .ZB16Y6&%L@>
M^T6--];C1XD@[CQ:#<@YWX O(9V3,$95I:;NRI_0.(];W-3H-SO['W0A+84%
M=4>Q;MG-;V:"7-DD]KAQH"9-V0[I) 0GL-_T?=*0,8\W]%V(=,\NF\ZWE)#.
MX-AFW$<EJC-;<1;B#\O;6Q#[$HL IR'/LFDI3/-SW"8CQA2& 0\V*8/D$)."
M(1&TJE+)6'_T="4\-I%3WJ]C^.#=?9E\GF/F3+%(=&[,.5V0-N3*-([HW]&.
M?] !@W8T*'B9MVF-NTD8APU?T];S;_P-)S!.ZI"Y/E%5^)&-BSCW$-1*84>*
M2;ZE78DO-1 ,$JU]M%,-38WN7Q8=QR6<2$W^<O][=W"()$H>G8$U\]UE_)2A
MI//,D$C80!+M#>+^Q)%I\' PN6CU8-TR8PJTKI8L\4!J$)GL?2!V@M(/"MF:
M1$==9]:H;59*J58_]RN>G^2.6X+DAA6@:29:$=E2V6HB:BV%KD]>WQU%-/SF
M0HYTLI1I,+V$II?%26FUH&@U%2O(0^\BK1)8Y^^^=+Z=A/%HT9,!R&A_(SKL
M/BE8-@B'98B.)5MBGS?%'&4A2M"Q*&#%(6*L,9-3(O(P-,J[3E$B2MX#J>6K
MV>3?]FVEDEN/39KQ<LH=!(VT;,L*1>TX-4T>.J8X+P9'_.#X@TUML2Z49Z+\
MP1E;RR4Z.2;G>*H6PRN@*]DVQ!@P7C=94R<GVB!NN@JPTI*N62LVE^)?1JZ/
MSG\;A&E!U>N<^SU.RH(J;GL!VQCW[7SBJ.;]@"DY^$XVE8@BR@2E(2]H*84X
MFUO296\T)HX,R0A1PCZ"#6TDO+;A4#ED-BT]( M;#\/2SQZ5%\%FECW&TMHC
M]IKL*$69BE$8LS-:XBNF*47:<6&_0IJ3NAXOZ?_VXSUO')U1<U-/^2,Q9[4V
MA -R+V&#4?#GYH?A1RL.!\UZP8W][^@'N )H&@":-VXF/\11U+7N]KT<NNEY
M_.]J&NS&$C<YB'E0K-2&8CT1;1!;*KFVPJ*6$)YRJ4,N%G%5\?VU=&@P]KAD
M)<(62RU'@R4JXI?IAC$BJ =1?D5<,XAJUDF<&DE]EK9L!9<Y=RZZ@P_<9#X#
MK/U;1BMZOL^3+P*6.2VW?S;S4D0:&.,M#I5E+$(8GA5]Q%YAG-H<+D:EM+\6
M85!R$#64#D8=#42L3UC0*19 M-7W6S7 U#V6';$42-*[M*EU^S.4,I8\Y/6T
MTN59O*[)^-*A'.A2SRVWQ8A W+ S,H0N_Y6'3MR_56@(^_9DQ'(W$GFOQJ+D
MB7CE0TE:IWKPA/!W#=H_$8CD$-D+%)3@?];4@CEZ=Q?&^3MSO8CB,Y;6?R:X
MKMGWGC?JC[,O*WBJ% <XRU!FPBSTNRH6KB8Z29&\(L6)0MIT8P*C9$M*CCJ\
MS71.Y7+"RJ'Y?CK]U=IC3[T "?<]_I@E_DG<4*=&T=!VR82NS^U<M<^[8OT-
M7@$X\0>.4:X'Z'>2./O8[2VY_U=?B^!(Z"UE!-7ND$'C'0:JW&A<CYN18R53
MNX'V_8R+LUXQO<95XP3ZY00T/T]/3&P;&T[H^ZL\)7K(+UHNXSMM$DC,HV__
M,EO0</LQJF=-.W=(:#U'>I-4/U7KY2*!>/,"5^^_Z9J(6DO@[]];MW3UHMMV
M4-G\BHX!!!I"Q%!JKSSD#DKK-]W;H]I<8ACVV>.V=>ZK3BLTAP&2.UGJ51;
MA5VKFU@K![7,#LLT= ;^.2WE8J"DI51:ZSSF5K#X2EZT UXZ092$RV#2/E$I
M]MIL@<K-025N/E>WM+.Y3L .PS2GFBT=>DKL%".0>J!," ]K?KW*Q6A!=1,G
MXGC^:EG=>V%N7N?AY3SG(;B=$+1T.'];2C(C?;=Q@^4FMMWL_ R:77=AGQ=H
M;[$0R++KAV^J?3Z2N$9_X?)J%RY'.+7[ZGK2K/_@>3T[_PH3^(- ^2]3@!K5
M<IN>[(Q7&'A-W]ONR(K"+GUBWN*#]++'JL)YX=86"[T\N[[@>:WFEH*7(K/^
M]_\,R&O".MZ6NF;S8>>8*SNE%2Q*.N^$TMHG]$<</I@5MT$+RWYZNDVURJR'
MHS@7-P]%'N9YV6\G".<C,<TNG/)/VG7/+\HX^^CZ3L[.EMH?OOBT=\\_Z^H=
MZ2+=G.=Z)+7CXQ^IN\:1S,K<;?8O*&_J1\J.7K5K>*\H_RM@XP;S3GU[^JLW
MTQR)*^9??@<TS:[N2EPK"W IC3@QV4^&\N%8-->3'^E\"YB7YS:M'INSO:K&
MEIL]E-<UB*L2ROXYUT^W7M$-.$Y.W$OG-HCYT] *OJ*IX&U2RI_<1?2W7B@4
M[*>&/JF,5K_"1"+%ZR+I,+:^PH2VU@-+9^]8XZWHR^>?Z^;='C-^K!R^PMA=
MR35AK39@MBLSMS]V8Y35?K7%HI@=87JYZB<QD X@YK_%F2HUN?64=:)K[DKX
M0\\7JU+M-95(=:9MD06ES<!([]ZK8DWOM6E=I).SW(?"#%S\([7;.(K9X;N)
M&\P&@^UU!V_:.7W7FGGAYA8:GR*S/OBFV=9=R6O'%W:'=N%(Y(?GT<L&!KN]
MVIV'J;]M5'^VF7_!_C-LJYO2?UAAYI@K/:65*$XXS]ZOR.Z6)]'V/0#5/+[[
M+]U1W,R/+&V_2M'R]OLO#&1"J<^F^^?6'V1+!3J5_]7=R7F?GZB$U^O%/L=M
MY7M'T596Z\4/IVO\3:\P]47KB\IE/[_^^!-3^KV(\UJU+1:"@TQ;W0L*F^.1
MJ_57H=K>@7^:;/N8Y]'HB_G'9'TXU3WP22./8:*Q!S#RT2#@=IF;W8FK.G=%
M3ZC,$Y#*:D]&66@4EPGJFM/E'+L<)JQL<]=%MOMY7H>D33,O7.]Z+Y!4I7_J
M>/<*LZGW;5ZKOH6&TW8C(67ZV8[CR=,O'TIMOW]??[+\(%+:UKV4K8NT_GZ:
M7Z<]Y,_X:_?%/$%>Z.UO,.X\MU]AK+V>RP1ZI_]"8)2UFKDIM<>K][ZOR.A>
M)WDTVC]VN&%,_JUV)Y!TN/ND8%6NN899OAMW+@2E.KOM?UFX?]3Q#OWGWLVY
M_J2[-_%2N/?Q?R%QUJ_<@9^O?85)ON4M8[*[69I8L?,]K_T@AK2V*I#DBN$X
M7"Y+4L$Q7W**I XH#\$K[6[#.(\)8,J5^ 6Y53IP*H6#+V=(P8QH9*2&Q:-L
M^R+\$,6E;$JOWR;+V<M6I=E(6JUXQU@Z^665SWU8Q(HV/IR>@P9%(J(S>9J8
MA4>V=+JEJFP7NY8!#$Y64(<H2.GV>LR8C2SQ&BC5!!L4BO:XG8_,*6Z;H"]'
MI.W(-<<Z=&M-Q+#7IP;#Y:ZHEXR81?I$,_E_]W&P>AS:+>/OWF$9^O^;W(6Y
M4/6Q9?SKZ7?(SGLM\*6 \:($6D-4YB,.=/L_3_+5-!9%8^5NZQNMSX9)NL./
ME8S=JXG[-D\2_5C'4T,N1WVL+K%])7#_1\TY_\=S4X>6$>:()CU+=, P?6!+
M/Z&U4.UIO":GTEQMJ0G_\MIM;:G=?BOC'YJ96^JE8P,UP&&*S%W,8Z($A&>X
MW<CG S^L3"(T:J46C3QUY1UO6LNMEN_++74\ P<,@O[@51ZO@KT 'RY#]=>4
MME<$1#X,.S5*\OX/OZ8]6DH;SO<MW7;F+.%#X:&^E1C5Z*6R0,?$+BO4H5=Z
M[3D"=S?NH?3$*/STCD$5$(EFRM]:1H$,7F54="#[JZQZD6J53\Q-,+K6MW_Y
M0KA)_F[T:2@+TU*U5EK6548E.6A\0F_V/Q6"@4>Q6;,[0.6R#N;#,"IDZ+A\
MZAZ,JJ!^ >(])+[PD7[UW-L[75K'(9HB6S>-M&HW^@D9KVXWFXW,U>1'*E6M
MR2TJ%Y/EVJRG^2TUK8S*V^BB,%W<B(>U%L94[UAIQB?F8OT*PV^>_2AK;I+Y
M+L=V:.EZ?JCHF9'!X)U,3IZU-Q7#@6)2S_FPX;YC5'I/&#Q8[FV/6QF= [3<
M0>1RF>"W+7%B64KOI2@)5-%#Y@77O3_2Y;M@3QV)J^+EIQOUALS[X_ KSH\R
MRO\!X?.L07P!5CPV128&5K7V?ARWMLML\#!,9THF?84Q#)TR.^O<7OTE?\X0
MN#KCU<,?=T+MXVGDC=(]C7GN-?G^$5,O1C#@(_$QK&^PM<!)]A[9/WF2'[H7
M)+B0=97TQ.QV:X[Q)&UPZTS"\M'$,X0D?6%=Q/ZJET^?7>BE%R=G?/-'?_/G
MC"WMC\T%]T&>="L*3S=]#P2!>31;]UD?;ZA;*7V1B?F7X%YAT!>\5R5&1!;U
MM@+WZS@G5OA9Y'%&/_E6BAVPW7TY/YF@NHOO/CD4,"0>NL44Y*]L"]@\"'%K
M,__Q',($SNA^_Q]TH(D+3F7T.E*<62_:!"ZS4+];?3061'8XIHB((-U>O=9[
MA>D[<2FZP;WV)1#H)VYVOEZ2OO&>A&L?R8*2/,C<# Q[(@@NUW^.>87QJB,
MOL)D%RRQ"J!A9?Q3[R3^H_\9_Q<R]-\3,.1Y.+ELP7O281B.ET(@RN?LCZK(
MO9Y1DH_-^G#T9RDU@URCQ?"W2D.\7XTQJQ",DAN-%C;CC@WEOGF0B8<]^87+
M1$>9]->T6 8H22^RXU_(_*WZN;NK@0TNQ$H3(GG*BE=SNASZ.21<&/-MA@4I
MYJ*,V'0M/I[$]T_K#@R8P>591D.&=.)9VJ?&<[(@*0>QGY0F:4=%D(N"I=_4
MR0.E!#%%(8-F(<&TD$A#[KPL2P//C;_]F02XK=WMAA_'<_[)J_-A-+1"A1_
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ME[:R $K^S ,5I/[DYP@O'[6X5$.K.HSH9%"AWQKC(W?.4^"5WC#" ?A4>\N
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M"B.+ YB1A?@9X9"J?F[;R+-^CG6.3&SOBI)ZG<]C-<D=K>IP5@+R@@,R:&J
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ML)R,\1R&4<FU@K(ZR0T;(OTU&.CD 6624[!JH;[[9V0$SNA^Q^!=7KUGXQ\
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M2S*??+?_1OGC/H;D[<;&Z%GSNP9\?V\VK9_9S,2Y>7G )3S*Q25N&D.!1MR
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MPKRR'U!2=9;2E1P'%YM4#)J^\QKOFQH67&(N\[BL87Z68I^@HP)!S47.CGM
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M.Y-?8[GR<]K*U<3)Z!$F(C9<$VEH75'=>6X8 6>WC3*.JI\Q3O ]K^J[_).
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M,#.I;&- +[,SK[8BCR7S2$9H990Y@,H<9BMIAGG$O#25-7''^($5<( ;9&;
MO:PQBM]\>GKX2\&%S=&>?%0D1V? P<Q6(?*XZ6W8($W[Y=:3RNE,(A,1[QIG
MG@KVS@B/'TE\E9AI7YZTF)\B>!N]Y9[#(K^O[EV+X3N94[F:ODU@JGZNBA7
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M[3*F[D//<ZW)ZH;#@U^O)G_UF4!9%ZNLMI!2*[EK6IPRYLDWP1W(>=4@5UE
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M2\=_K+?^-7@<JV>UHGR#S(2O[L)[<L$LYSF/VF PAWK]?&Z*Y8_EAK1<:]M
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MMQ>VU+"7MY?W:YO8#]T(,9&_#;^^[J@H*?Q]DZ!.P"C*%1?Y\ZF.&HJ9@ <
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MV[RJ[$?65Y$VG[=5OQY08N?>A5E6LU"XK@I37KK65;/AB_U X$BC^1.)_G(
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M)[S+;!W JLC?H':G8;ZERLY?_,P\'#N7FEHWM41]/F8J/>:;%9?!YL92754
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M\>AA[G\ 4$L'"(3%8X&R>0$ UO8! %!+ P04  @("  7ALY4
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M3YB+!PQ^ZO*X37"JK:1EJO$M_=(G^IC\O_28\J<>7W7S@"'@J&/NN=-^N7G
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M3R? O_")D"?3W)_8IV?0I6]V)^4L]Q;P!Y_B]!#CV\R#37W:.AE0O-/VB3Z
MXL+O"7MT_#(^/EP  #*/BX(""T 'P#B:/-H"$"M $+;0:TI: ,RC;0#I:0L
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M(&<@9R!G(&<@9R!G(&<@_V$0PC_^\1\*AUQF\V:3DSV: 2@!,/Y-.G'R[_K
M.'VR)08VQ@(6!L7W)UNV YA/'E.)B?7'4RL! #P"7'QL'$(,+,QCN33YL1@3
M$P,;$P,+"PL3&Q<+"QL3!P,7@$>!3TE%3<-*0,L&9%?0/<<!LG&GTPN*XQ01
M%5-\K%+>>FS,A/'[0S'_>'@"#B86-BX>!C[!L5CS.(YO7K&QL7!P<([YF%@
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M&DK%AWS0]O-GM:)S/AO1YN4&X,OIYSXR^6@:1A=O^Z7'' &JXQ:T\ORTV(X
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MYXK-FWG;:2B$SQVG_DIC$B94X>LDT>>AA/FN7GUC2'_S(.@X[U1QOK .DW,
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M Q!2^JP1%NQD I6F:_2F?,!^?I++,YX\0)$8S!A5*40WJ2]#*?Q&XO#3UR.
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M08^I0MO.\B(/LIM]B\%8K)C@@)\B"\^ Z'':YA?EC@^)76[%0PH8@V+W<ZH
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MN&MV8D)XZ73?FR06\#LP$J;8+ K:-AOF'/]H45TIZ(AA1@U?8B%C=$7S,PY
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MXJX250VC515Z&%?7ON#_7QRO/LMB^095CTS?4" 3'M6TJO=:^JY7ZFZJP^[
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M<;.06(6M9F??(#\O9^LK6!+PL.H 6\]VW+44V$\GW;8P^OO@'_DX&6*<N1Q
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M0Z"M*@Y^=A4RTQP)W5X#3YMYC7("E$?X7O^9 &.S]-N/^2S"HRJGAEVY<:_
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MDI%6BGFB))1+J-ZM*NZ,(<Z9,N/K88(E6/%S?V^.HQ=D9(]NTC<%=".EXP,
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M)D_5NFD_)X&%T>O13)/\$-=6"OE<)I=>7,?2*U;Z4N7X'_7W\&\4B963!$3
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MH C-22$*6VYLR36$?TA2'QO/H0CBP7I10&6 &@)4"N.II7.W$W[J"&P3)AL
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M![.!RWG>267H9D9&6 *K#)W=;7+T]6ZY&K>^&P7$?UOI\7O[I0$0PZO)RG\
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MYOJDF".6\;8>S9,<TN$U:G9<=-/L@'TO+"8SC,ARXD@CZ"]LVBDIKG^S] ^
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M]L[E3^?^EZZ->TL-EL^=_6A8D[TR)-9G7NC012W45?:86R%*QP>CV8?"<M_
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MBO+*]P%[.\V_MJ7)P.&-4N7ZR6LXK?O!U)I%9XRH9C4&(V$'R+@(,DXI6;Z
MXA8]S)/ $SU"-N@&]1WF^9<EW@WS/%S-Y%0?!Y^;^I8*EWK9S>D4F=O9I_M7
MZV\0N!MTTNUP2 H@D< F4%X ?'VR.%)N3_(2-AR03:5Q/1,[RX2W^?*V6SCT
M,NZ-44XS+0'.SDHW6[X ''W'6LX+KKJBMECVG*68BX,/KU0B(WF(Y>6O-]J'
M%ZG1E(8/+ +4#6JJ_NL3G7]#?%>45NOF0Z_?PMM5PC8*M Z(J8$U-FW]/1;E
MWBNS68(]IDQ&BRZ4:*6W*,UID"P(9249>S'!MP:6,_34&41U?)AB@KQ,9R.*
M#2V^8O_ND&UYL4GVV0:Z;Z./SW>#I47ETL_%5F9#YL6"T=(C@.H4=8'(5ZH6
MVJFT]\C(G^EB_N3S0$\'L*O$/(I3@B<^KH700N'RQ&%BA)@/;H;>Q76K1K;Q
MYH1"DV+?)9Z*9&JL)EB@Z2(HH:')*<*'3C[.\QNWTT>GGSK*OV>V+GKOK=F?
MNF767->Z2=]_^K!L+H<3.TF+BG+*T\ 2^?EDFQKTU)@K(/=VTA!5\=O5S/T,
M2X*8QT%K)N<V##O&LET_GP1-.!IE4N,:VB"6BX?$,+9E-O.W33]M)_T/)9(E
MDW$HSA;W* /@>XR,.2$P%$5S@C &35'Y8^8^4-YM&L)A YP6?F(%#2Q*9+;T
M+*]M7(I/5,&=X]:K??3CWJMI-]0O7^Q6H_62&-+LK"W-L?G:00.4APATY;^/
MJEU-VUB>$7%,SY8[\HX#@_DLT\<80Z<EGV1=[^\JO7ORY_@C-\_44V2 UQT\
MS1>O\2T&?Z)+6D@J;XKS577NUJVV><C/W3Z!<^:#XBSFEF,XVC4"QW9Y2'D
M42BY8Q$9T1G0_:PM_8S+S+.+;5D>L^)_Q L6U*\T"8FQ21B=5K09H)$Z)O;T
M=R%TG&U#N/3_"]WYYUJAA(ZN#?.O'96F"*$V^?+Z5ENCX^Q+0PHP_/9-B6>>
MX+CZ9M&JT$05Q\G1G7JA\T#Y&2=>PNUY88;47-5DA"Q;OTFPZ>USKTN@&Q@C
MR(M#?$)[GH-_RE^7U#A&>JE+T^M\Q'E5LZ8%\0AZ+EMV$1"]?9\>Q&Z[M-ZM
MN&K9MN8<YUN<+FJ%8@ON6+INC>VN@9C<!JT^6O66AV>8S/_:,%T0+%A<6\S:
MMO+IF/EBYZ/7#*GB_&J*;%3XQ6*Y=U[X_6$=*/AG[*EQE*FUN?[E-UY^?:TN
MO,U;.L2#D._9PJ+U9T\J(=]?+X#Z591%<>\I2J^+,?A2VOHZ7/0I66D-UY%=
M=_.]L?Y[YHA6%E'-N9HY062F!JE2_1_$M3*WTD?S->+J6F9O*A:UST[*/W]<
MV:\O=:"LOC,+?&=?@ZMM9=8YFUJ0$)MQ*R^= 1W5..2CW+GE9,.5(_+@YQUY
M-FH,442YKBNG6)Y!2@MS?YWD,QU[^J17;),F2]8[?Z&<DX-9ED(+!J4IN7 Q
M*3*):#+P$W%$QY8B84WHYG^1C*NN53!8IOA>YQ7I?_C!U*9W-=.@*#9O/*R6
M?*DF/1O2W-9EZH[J[&%1*S-MJ G6Z1M3)OV#@6/K(!0DX.7R3(_84Z7#V0<K
M*X+0SGM@="/HML*TYWM;R[['-/'^)C4O@'XO7&H'*EE0)[RY*<M9]V <?%$J
M>.6SA[\V8;NV#YUA&Q+3BEBGCS+3G7O*F-4(K"Z=OA3WZ+H8-90UU]9NF$]3
M<<#=P5BM%F[Y*3#1]?%TT06/@P>Y\7,-.&F,/+A=.!^<I!GD0](5IXE% A#I
MMP8DZA+#C'9#M@C]J'>:$KKG!87N86_$91VYMFRS+Y9\\H><]O-DHT&W% $"
M6;OKHM6D]Q&1S/H_V 26#4XEEE,T3OE;B>J5NZ_G=J(@\BNUNF>^K,C6R=4%
MWIVL:X4ND<Z67C^_W8AP+Z@13[ZE''+B08[)<Y_C31D!V'B[[1YII%[&Y@CQ
M;JS*,LZI">1R-?7![WFP_>@=TVRC"=E'V))/Y;'&P>'4:J8VA>_DA#J]2U7:
M?;J9N\5#'=Q_G-ZR/QUDVL74 9:=<O!-,P8C6N;'TN,9N7^;8; =&U(0\>9.
M-L]O^B1<_T7WG7;:90-@\37N:>Y=@W52%%#':"'Q?Z5^A]MA&Q\%4=\8]GM@
MANMV@K.^\P':2 591%7M-755TK!*HA3?F/,*=+G[MX/^LZ,Z*-08"UF<O59]
MZJH\B1:Q"X#41GP^92\5TU_%R]]L.C\Y^1VKR5KPJ:>CE%"?MS_'<D '_ <7
M3]DV@P!Q M<>!VDRF4V.8'6/;G)/:B#)"C,E8J'M]HW&+6T%Y+$]D"UT?47'
M*$S9!H.3D"9(Y:P0O(:BKAXF,N&K=Y[[:YUSFV/#OZ9V4!_&R0Z$EYKE+=E.
M\'!)M1YES:(^\C(';1-]CNI:HY^@D?+<OQQS($W9D*"WH%4J8?BI:X%,9X:I
MGYFD48%R'<2>?'.I8[N$N%>U=S7XEFP\@,S_4YIZWC<9RKC#A*CU3 ZG.-?>
MP.*+DJA];]DAP1>]8\(@@B?QVYIH!@X>]!"V$9EF@OK>*TP'-=U0VD@>YAU<
M(%%*)1<HB8R@[$*I@WG(:#1'QT3J8TVHE[:0R""YX2.-TU(BTWRY[F[&@?T<
MN_>Y$)X;:+#+G^&@U:??PV*/7P\?>W\-B_VY@MI[5'<1A-\CBSW:Y./QC>1:
M[H:I@2\ W'B8,PPBPZ\E=J&'_2/M=<K;:1[1?X;%7@#'B<"G%T!/\+_L]F;W
M'BJ9;GV(GGA^/I(8N/M8 %A%J!SFN[Y&L0E1]]V]!5 &(&<W/!<O7K9NID\L
M>*FI+_OSY%OM#M*&I<>FIQ%FC&H-D&FS#UZ$-*=],I+,'9:D:0(/Z$A[QC&&
MBMJXH?"@1I-1Z(D(8R?QY5KBI#@<)T;XT[8<=]SBEFS8>]SK,K,#;8LG/Y98
MIOZVY$AU$1/) )B]<O+X77-TH])T^6@_#L?5/7G?17[7;0\>6BQN<'0,@:%7
M0XC>6O2QR2 <D^T.9(Q? )%@*'C2:JJ'R_[NQP"'YY&IT\;BC/L^@*<@'8[;
MYD])5<\#K31#)ALS'>?Y]7K@Z=7UO$YG]U?%;W+V**) 1E#V7B69)1-H"7][
MP3^UHS4L=>KNYO#A]-=_T>+@O\35X0N@_/+?WE9$^9?=XJ[GJ:QL>%3>7A1&
M1 A^;R@+R#%@S_$ZYP*V<'IZ[4T8[3" 2V#1'*IBJE/Y7._>?E")SH1P;:*D
M,UD[\N+LNI+]X_BO<W]+]&&ESM=R.F=K>KBMZ,CH7(#&^@\Y,"1X$EYOMK6
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M</,& K] 5(&3YKEEI<3Y0WG;(#/9M_O= LX&JS6$G[\T/W(66=[VZXWQA!&
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M1NB-GV6O#D .Z;H(VSXI^)ASX**8[UIB<AV16%]^7+^E4 N;UZI#"!S"J^1
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MX+6;:#]*).?I.D&CE1YK7C\P/8V'0DD7L$>^WV#+T;'"DHOSBJX\%S+MAJ3
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M<N]O+\HX5,E(\%.(61#F0^Y-07O%D_+JQ<4$QS5G&A8D07[:U!FSGX$)VP8
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M'+\B(TB5/0.K9$P6. F5L!?.+OBO].:=>&Z;LOTJ**/PCE!D&]W'!G@" ;X
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M;XCGV9L='4_[H7;6K5:C\?QNHGSVP!YD-[.6>TM36CK^Q9U:U3AD5>8^MW[
MI3&%L.=I4L(!RZ!>F!H.<_7RDVX,HD6*T-E&5^VT1\IEU6S+,/\#\$O('M)
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M45Y302@AW"KGPK8:!SON1Y1NVQM_@6G90-'51]*!4;_CWW5LCH6VU!D<'8#
MH!!;GH29J\?3*0SD1?D'&NB'QJY!Z9%,YW7>$Y^?!;.XT)GR,?Z9X1069O')
M2D5"]&VO;O6[$\CGTB#=M5"[H!:WN[C@&<'V3<3:1AS,>U&4311KY25<BQZ<
MN&[DHRJ4,R2]X%?2899".DGS5C[Y"S]G6"%A"PQ"8<0JNE%O&X^96@)#F#Z7
MVQ@L<D'^;R0@-Q'E_RP#YQ:&NH^L35LZTF'_"$T")6]Z'PKF&K*EY;K'%!,7
MRH8D@F7QHL@-Z:,+\KG7W)Q3]X3=/8W5BD30/:?CD5E"9=O%I6IT\F@^/?17
M=+8!(&V=2W.&-X;:@J@K\('G<?X"^[8:?K&9R8E'(4N667?[&S_OM-Q\FQ<6
MD4W_ !E_BE=E&$JMYC?%JUCST]R?&N['2Z%*8C6./\<8MDW;N@U6RLVO7"#V
M70Q21AS%#WJ_4R\M])[RH,MB3U6S_89#<;\/_BLVJO%O+IUD\CU_)4)XW$EY
MY9?SC; *WGQA(OHK/OM9997MFP>G@9#SCV];78CJ1KX5@V;X [%J2+V<B//5
M5V)-AUMAEVZ31['U:/#J:8(X,YC;\%ZQH7]M?[E//Q)^&6%BOSJ)U]$*%T24
M73NQ9]7L3D)+G#H5PYM%PU=9 R'S+ORVRJ;XF.8!7>8#>>MK!@/=^-\N8!^$
MX,>86(*28&JTV/[/OT8="/'7/T>(-MPMM-->Z*Z([&A9S4M!9\;\H>0&\K@@
M#_.M8%;*(&P;7\H=QN#J^,K?CMOV$<)+5[ .C0<H3AO=EH)-72/A\&H6@#G/
ME;P-@3Y'[**1D*/<GGE#X!Z73*XI6LPR#]J;Y?7IFU':63'.()@SH,<!@.68
M7[[-QRDA\GU]YR&+"'&O;;L^0SF(I_]]4U+@Q8KC_YK[8.>X.RMW4/]XLLZ>
MR%+I183=3D3L+NXYU]^@5I%D'!S'VI_:=GI='2*AOSX:_')ZX&@,3%WG8G"$
M6<2K8_G-SV(I2M$)%9/^73=9[4J1\@='R'[B5 6;OB>TRY8J;%=Y#, *[/G$
MYC7&CQ%2>6[)M?2'"V)%[1Z:#>I11Q&:Q_?\\I'&C&J+J8T?A([L2(V,%IU0
MP=6KR\0NY\4&-3L]"71F\KJ?/OTJ[2MJE(HVM(3AMSISFXD"!>-N+"K=6RX=
MS$V078K'4<4T'0*<E)3U!IT1DL<)FMR9,-BH./6?7HD% 4&$\$CAF4ZCY'^%
M@?O"YW';GGR]:*T4NO;JA)SVS""@9N:DCUY%3 ]'C]9[KU(;?3_5C8"N%9 *
MU.'^)03&]>J/C4=X:A><>FY.HNXU+":G2=E:1]6<))U-?,9,[]QWTE-H#)A)
M'H-[E/J&YA#XDSY8'.'2>Y;&9KJV _V:59&'>Q6_9*$JXM=4D;.S*6T5PZEB
M(2D=6WJXAC*77WXVB1S>QI,>2N_KFT=<)UR7]K>41M!>=#B42%X?FX*7DJL3
M?"=G6LPXE*DG;'2H<6_L=,"7:F(@\?@Z&^'OY"JF5UF^8]+$*GMLXCC)'2O=
MK[G 4L4]G,%\7T2*U6M(^J;1+Y.Q\UX=12Z[ SJS-*;4 W?#/1<@2W]H>CU*
MQS9 8FEM@6*3OCT6#?K.-'R&^IO,"I*H.N4?V,9JX8<*:%8<_D#MWHK!D#Q@
M&=&R^PZ[<U%.OO?V^9LW/MR@*F1/^LP[A4B;6O!7FF,7(_J<Q"K$7/)'*1S!
MM4M9D?,W?RB\ZL^+J-2^]8FUW%XD>!@0#&HVWH74FV9K='2T+7EZ7-HD?SHQ
MU6_QJN@ONL)M!09;":S3Q9^=5O?EM889_@]5-+!WA?0%;U$@R?RIULWZDU[E
MU<F-.2CG\MGHJZPH6"9/FOOV7\PH698W>Q#]EGNL4].+YT8#MK$P+0597WVR
M?T,/TT.3F CP7J=\$MD3]O/"B_-*1EU^'8:K\R;V90U9R;$P_*P"KQ[E+WMF
MBQ28)-F_MV((,)74QE!K(&Y"P]_1M-)@J5!.[A/\ZIJ+<5#5-7#<R1,^]G=>
MI2//! ?!]@\ H;FM 55-8K[J#ZS1;]CH)X]7!C3]TI/;9Y3;7S]]Z/=?[]N%
M!<_[HP*:WF]3#I;RM[X,/#?!/C]Y.];3,T9T]^4)F.U7@2_7O)C?Q/W_94 K
M1 AGT/PYE#88LA5'2-M1W_P#T!L,E^#Z+#B0C)'F_S48]TG2G/P'$//)$/H'
MN"CY[SU?.LSO-(/^>0E,?/I*QSNU1OI77"V]D\""3XF3X,('G__N0XG)U%.:
MA;<(/X2N]*_]/PB_V.>H#_I6Q'B846H2_X4X&]LW;[6I!Z#)XT28#I=>>4-9
MSTL/_ZNSBC828I-&'AKBNBC9%OUVC1G^= ??'B%6L"Y.8D&;LMVS$*4Y,:[6
M+88A_$W@&\H#T9RI"DQ?<GI)L"(IP!J-VU<"0(KE$4'2,JQUKY(-G?1^:+41
M ?,V4A=@AX78&H&%*1#?2DMX"[I+<]7]DW;>F8 ]?C$L-/*L/#B"7,]>'4IB
M=3E\W%5T6'?==BPK.H>@6R\W-H%7YHSY5)E94-H.48 *46T.9M;AWC(?#_83
MJYE@U$E(*I1J!E%+K$#?0$AA)#XBI8.&&7WO;LZ?+K*^<H<BR0I(4?=:HR.'
M?=2C_;,"SP^"[?[NY,]'-QXHUMN>.I$+='#,,OO5WVWC\9X(UN"_O5T/\FY?
M[;"TZ](T7(L-*-(8Z.W7O[RH=&G;U%\EW<=[X;35UNRZZ4W*I8:6TJ @?$#9
M*RV6M>$\+(CU&3PW(81(+>ZX,)9I\Q%,S3LVS4-Y!FP3F8SJ9!L/#YU;03M@
MJSG(>WJ3+?\@\_A1\(RZU2LM'ZK+I,YG%_P:#S=I8DD">'>Z6=;_T]I9!L45
MM&UZ")($"!8@6)"@P0<=W((.+H/KX.X$"$$"!!D@N$-P C.X#19T< @RN"2X
M$T*   &6O-_6UF[5?OMKN^MT_SJGNJNZ[[Z?/M5]I0/5CW?,<Q4M->-\+BQ"
M#]3>$EI!V*;%\04H5(GZNA1^@.U(AFL.[4 6T94LLI9)3F#K)H@0$"]::-F7
M87GL'G!N2-K\>#[GEZ*DDF"9>6/X8EQ_Z]+KZ=F+==+&9ENK68_AX9B[,FBG
M./EY2C?#$TT@M\^EY22_20JG'Z31=KZZSO9[?GSZ;$M0TUS >&%?L.F>_HQ!
MCE8:P;OG>%;LO(83K^BWE!HC#;E*/4V/ZJ 6!L]&VY3IB> 4GAC#FU! :.P9
MV#=M,;6Q,4=[WK2.*$GQ^81K[6.#XAC%T2^O!CAKFWJ$BV&(ED\*IDL9B/D*
MKD:"G@5&?_/&SOX.'&[JX>-H;]*WB]M]OHS&5O/N&UA_'K']<!LBVA7]/0(A
M#A\O]H_,=WL(:KBMD-%Y@KBJGY*C7\R F&A">/W'@0;!!(??[P'V6R<#I.0(
M.P&M9?$PLC#?+*(;3!/C-X90_+[1PYC85_+4JOL*S-]>NL&-C]K2SJNT("LZ
MYU_-6_2WZ7,#]AJ$G(:)1=]QI,[C?J<V3[G<FHIL'Q"W#('UX0A,PLMK#RDS
M<5,Y[GYN&7A\$J?#_$V?E89NS/S=U-3T(L'%BZ4P\NF43<H7TRYQ-QJ8' R3
M=JK"NB>2*6;+&\U3#K[]B*P^/M_;'S$[%A*;TSJW<7G?%M\VGHH/=#"TEM-M
MQU3?6V(*_V9_4MB[*>DX%'US-!W[2=2TL\"5!W&22$+>XN5$8UI+TH-D")5+
M,H]GZG6E)27";]9Q#.)B'M"H2O#S\G41N &;.NEWINV=BV5?&19ZT2<)R!]&
MVB496[@4&JHS)5IRT17< U15UT2F%C,N6J/U#I_&S2#^;O(;H0>%M+.V2#Z(
M$.O4C= Q>1$R$KO[],B%O!+Q.]!6:Y>I3Y7.*VKYH8#>V6O )WR8]Z'FK#XP
MH-R,48*504FDX9O3"X5NDF%,W]S'FZGJA@-I7,O._)]8K Y$?XQ%$LJHV )Y
MWA,X-J@X@^\!V=@9S.)VMW]OVJ]N[P%Y)L WZAM4Y-<IVL%5[,_<3A+%' )]
M$S=>-B(S=6B!-2 3Z!+9LC24U .CAS?<(PK%BV*D&*!;!\:+6X$&;J 4*!%W
M  Z@BP8@CO$;KJW,',V4I\S*E/^%-?EF[K+?W^BYXM[7#G@@M U^:7:Z6"E:
M[^^2Y$AZS=)W*]$HVM]6U8H8\[;NU)XU19B^UEY FCRG/=>9MTFZ66,X=6\]
MTGPQ \#*>^=_DW/[-U"W %EG#'9ONAT9W,3.4K>:Q\3!YS]XELI>Y* SQ/2(
MX"J>CH9>7$7G0@%XJ2&Y-X(2#RSCH;@$2VT;GMZ,>^49EW\]'TA8_$QPL^"S
M4Y&V)WUQ*)I>?Q,DO'^]O6"$=JUZM4]B&CF>ZQ/FHC?H^>(VY<Q28-.93PG"
M3TV!(_<[R"/'G\[M_);CU3)?2W:=;3Q)-7O8L-#.5:Z[OF0?+0''H]]>>^;W
M@(C5#@GLX_4=FY-TH6=2=6[-F(G.R^$C.660^OC-BXP*58-N^GINTF#O,3Y@
M+$L:_X'01A+@&N,[Q!51+A\LVMB(;&R2U_SDMG*P]#$Q!$,8N$%O9T_)].>@
M&1&T[N=S%'];?$E^ OGS&_@;D6ZR>EB^GP6?1'G5,7L_\W*9FT,WO7,6\=P_
M\5X(09@>QV\)5:1.]U4VS VIR4,^._N\;[J1JN:0Z= Z\EK@>-JD?A''7'GP
M3+EUZ5KE7*]RE1%A/+5_+1$T]]"1F6?)\(I&/OGQKN&+(S22%C5/<>-5KO_Q
MD\=V%4DG%M5K6$L*&%OFD8(YTB*1U$,<+.FU TKCWWFHI$[Z TTZ_]M_O/^R
M7O;?.+0A5]5^4+J\EGW5RHS24>#[Z!;=R667KKL"06=VY=+#@%P7AK2 BLMG
M<WSU$.-GVKM#''COL$Z+V(S0UV4M7(S6TH_$A/UFYETZ,RZP+.3RMSG;9&N[
M!R1VOFLO@BOWR?7]RBW0D#6UCBFF+ Y^#SLICVS-L(/MC39_SB:E? Y+)XG1
M7Q-NKG72W('?_F0MM"G65PN-70:!E:Q4CR+B+LYK:@TZORHC',N79%$]^6;>
MCN14]X!EBZN*B+"K9$J32E:#4GK9\*S4\%^* CJ<JH/'<"--+3+B7K[D,.FM
MCR5*DKH6N-?!%=Z[>?,R/HC^,L6R;@'/_A*3$8FQNS(O+$B-R8KL+\:5Y3XN
MBRP0-Y.?'<'<"_SA7[E_RD\D]#N]*XX7T4YQ"$,C\V2=^@**>\!S[*,#I_UB
MN;^6(EHU;[YEX.'1@#@IRJPZ4FQ]ABA/C*JU<]WT6CKBQ\6H_4G(B!D],A+U
M X7(#&,B3"HJ(O2P,-O$Y7[,]6:*$A8UW&5WS+JVQM^AG*Z>:W929I1LS31+
M1$WF&3)&!$8T@3G'F;G?1/B^&FJ:$T/;MIM.>AU1-8653JG,-2%LX<V5^JLJ
M?=A?7ATS6^"__DGBT--QH4KS]_VNW3'M<YK"JA/G;4O,XS2Y$(_()YX8(_@;
MK ^6Z/M.S)ZHHH;YTFB2C&"*-I936D/J[&N[)NS$9<-A+P_<Q+K@7B!@B<6T
M.K)'"'=3&%<MV6Y^&=G>;%.^<'2\3$ ^L;8ZJY:6*TDP[2YBYN]X#PB,!&*S
M_55(IKV2=:ZU75_@^E1#">G]I+YN@+^9-D(;=)83FH.++-Z?,MOG76H?LF1Z
M^HMH,!'/&.PD#!R@ 1HO5L@F=M/@T0#EJ,(UM0514U"S^B7!H[!/8E@^D&J!
M?3&2GL.9Z,0<+38D_L),2XPV .*J"F90(('RBC(;A-E?8;UW\FT=Y;!C?%15
MD,L78>R@B?$8,PQ$L?$A\5A]J-I;LWUVEHVE+6Q;(,SJ3)[3P_3I<KB37QJ$
MN&JR4^=5P^#^[K>!#W&7OR>+%H\6,YT;7+1_8"V/&L'G#\O'Y-4D8KH+5?5<
MVD%C]$FJZCZ[N6?51DIOG&^[JT1Z$[^M+2G%LACF9IRHIFHJ;[!BT20F6"8.
MA&KE:F!=R]^.Y6YM1?%R@/&=/)Z-'2S)5M@BC>USJW)=-L2VE K])Q7>J/>3
M(3Y.YA>UWRD:'Q-TEU6*$!"[^(RI(?EM>\?!SZ9G:1X]%\11R5*;7Z(]9;T'
MO+;T<OS%DS<,=ZC6 98X5 =YG%UZ.#?KM#XQ"<Y1'F[CH>\+L2'].3'$!'"*
M?:?^)Q8GN6S-VS?4WWNN;3SSRZ 5S-A8T=F5L2-I"D)LIBAQ)C72SM\WV/0-
M/IEA\ZGA8M7ZNQ(A1@Z:WC(*$#+.<!@)W,#\=(LDQMQX&/DJ[J,>&R0?:Q+#
M?R")?W]/H'-;ZG\W6$>D;,&$[]E]MB_IU7;&89?;M3._24)HS&&E;[?D#:HB
ME)Q?C.0?<_6(NKH4SMQ^ Q]_!^9+-LS2^L5FU?61M9<*?/3W+^%ER'#"S#V
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MHH)I>(K0Z'L0>9=_*E7H(;7!&VX9*U%T-'T!-:7%6ZKNM#NV*J[2K$6\S_<
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MH2^!T.E&.+L?7;.RNB/^*8G_0[._T+>Z1A-EWE> RE$(('M&!6"N]@-8E(0
MIGTFN@?T(V_Z^); T<JS8GG[K>Z/Z3?'+4;<T9NO^_$A ZB9FK-"_)#^W_J.
MSQ5L]'40*4 %T ',  =P&GT%(P:< >0 94 #T 6, '/ !G  (( ; $??,P0
MP< E(!RX =P$DH$[0!:0!Q0#Y4 54 \\ )X G4 ?\!P8 :: 5^C[GF5@'=@!
M#D @$"Z(&$0)H@.Q@+A _" QD#1($:0!T@>9@FQ YT"N( 3(#Q0,N@*Z 4H
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MW@'F\-"1U!'L6'T.^YS5N9)SG\%&X%SPMI..4[K3.D0-D@)9=E9V3G)>@BI
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M/4_\[E(]9>T;BF=+=PD,);#(M3N;+W<$Y,4_HUCBYB,DRR^X6MY>Q -W)[E
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MWBNHD=[(Y[6R"_R%>Z9$\'C3 $+ZLA?P@1EKSADLXIB$X&ZK=_>HD3"*\P^
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M^YDS)&"K@$GCJYRQ@^+(*#$QML:Z%AG(1*?XVCSC%SN[Y9<_-M"R0^! /.N
M;>00. 1,E\(. ;X)QJ_(0V#H_F?7)\^^3!6'[3?<V<NZ-JN'>PA$'0)M#(X9
MH8UA>\_?]QT"#3//#H'WU%>RZH(I#H$W]4^>?6U?"OL:*_LI,^T0Z-ES/*@)
M^TQ8;OWV^7+]3[OWR*C*?$(BM5@,3<)M<L9+V&+X^N=%LA^DYXR;B,SWMKO%
MWI51BT]MI?.1Z;6,GI?I$K-6.>\3G9*&&RJN\G3L73-,0?^1&5/WI]AL0 H
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MOGG--F&@Y*,KXSR4E5FYEAY/)L;'*[$$=>,<,ERNRG:)<-I.^URZ:W=%^X:
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MDQL/MFN9!'/TOFPF)E^0;QIP&UB2T,K!B2XJ&>;P)JP *H&;A!2:;^'H:TH
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M*9L';K1]K!FI:&$[3;9U\=81_+Y&_9*71PW=P5$%'\I>[WRV$VV':"?'*9?
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M<PKT68:7>=[/E56ZTX?O:LX@CS=CK$1KE*T[6;HJ.I>S?3=!&I^'8D;V7$#
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M/QI[2B9BN0:O2%O6AQ<??:OM-7<'9NQ^O!<=^&MWU!N#K;AR/FJ85B9KA:C
MCE'2]^0!969$?QR&_FF\?;:>ZCF60+>0X5,G)+FRN1,'Z[7+87NU[0-=TFQP
MGC>-+C5U$2A"D:/AU6PK$7%ZH#@FJ7^FJ3'9HIN9]ZB%F^$B,8_]JWVVZ)XH
M/1H(9:O46*DV;O=+WYD4.P8LVJ,NGNV?T^5L8MI5':H)!79RQ6/Y^W#1SS>\
MA'J?BVG#':@,GNAV<U?2JRZJ-,[;\E:Y[N/J[ ?+\>K@HW6%2P^M^XNIZRM"
M]UCZ42,0$MV36X121%D+Z)HV(BF/'_JBD]$8X;5^/4_FX'%"]KR=.05RM[4
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M>]H+'(2<5]$I-JU'Z7=S>:IA^#T-&YBXC.F'H<MB):<_DZM0*V7'>O=!'*O
M@ZKQ44@PI#O15Q)@H4][6".O_([^FTK.2JKLNEKF&K*T_E=[Z8$08F?H+,.Z
M0<[KHQ]3AQZ<\Q=JH.D.0KG\7\2Z]BKEDMDB W57;EQTD9'R,QC5%6TRK:(,
MJV9DG_3M5;+/]^T"2S<N7.GUQ/2PPP*M)2-7-T>TM8 QW+@N8RW$TY0K-V '
M3=X&WAN2KH[)5BJ4NF:M*!]*UD@$+PGX(#WGJIV6&*X>Q6.ES@ABQ^Y!(7>E
MM;H@0HG&2&:CUX2E ]PWQT5-]Q8Y>^O7L$P'?LP4-Q;4$>,8MDDSVT8^2O&T
MD-K:MZU4-,5X$Q)LDA2=!LGS)58F%YZH"BNGO-90\&E6WT=4>E*OL8AEX/28
MZM6*NVB[.8\R7L20L(>8&Y0J-Z%AYV#DNKS&W">RU7#DP2%JE&F/&NM,)H6%
M6?8Y;(#A0FE;1,HFGXP6P"*/E81<;$0^<R)Y 12Y.E6Q%-T"7(730C=] ;<5
M4<35(C=_D )N>S:K9G2[CW,V:L ]^JP9%ENZD$B\>=F/WXMPTDBW8$C4: W9
M&$6?&=H3V,<\/20,MLZ%11LX+]HJ,U,09VS_/&;Y3V!L3/KM7/!-Z^?E=5GI
M(/'K\:1<[7)S%6LL(+YFL>VH;JZ-^*3#E,I?G?U#:5BDH>NAY62CW*/9L&NQ
M#V(1CQU.=="R?*:(X\0_2'H<=Y=\B\/??MV\/3WL[1G-]LI_FR_S;-RVVKZH
M6:V+:LEJU)28:RD,3[>"06.9R+6;<H\\N&/-A69<"^S)1ET++-_8571K8,W2
M_*XW.MNR*X_:^XGXL#SI[QO'=RW+N7701;.9X$0MQ+$9_\6^[;?HH]>B!N'0
M[?BGJO3'!PK[$8S@6&L5%Q^=! =E'@.A,4=?[LW<F=&_XN#M9OX,WVKO?U)S
M^36C5#B56(<%'@X1*U&1;.2TF#H?,\IN/2(KQ7K"P\<P@8+=(]?_(4_;R*Z$
MPQY(D'M,[*E4/+_&2MO4]189(,4^_/LS,A,08&,MJSUS3JR+,\F+3RSY.$&/
M)-$$,WQ:GM1\MP+^B1$:I/]R@(\L1@Y78.G:ZD"0!W5%BU9'@Z%2R]3NONM
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M4!EN W:<E+D[?:_8%OD"!^B>$&1PC[-RKRFH0]2D1"A#\G0WY]8?#.?#MC\
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M/0_DYJP"^@HSOC4[53N+KO;Y'?]%W5WDSDI\KD"M=K7F!K:6(B:>_.Y1&T*
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M98K5ZUN+D!Q+ $B0R9O4A6EK7TK/CI][)8+62.T^7AE7=-Y,K &XGZ59BIF
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MUUR*4\@B31AZ0#:RGK6>]_>)X>5FGYKR!(%$DX?_P=6C?CP#@U7 (@L!D@
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MI#D<0>%E8IB\O4? RCXK]R9*54^-5N>='LZ>CU0#(D$41I-(Z;YO>.]^%P4
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MQE.DRBOP([H1^%5[%BNDXQKIP3DK7S\<:/+^8H+M;J"7_RKUH]Y:U@%48Z5
MK^)4Z?=X?)M^8*O&1(@-ER3<(OC1<!@_"T]KZ^A/D*R'P9<"@^;"=/N:]!-'
MIU>>MO97SCW5^M^L(N74IZ5$F47^-&X_IZ3N30Q4V#R^?VXT=.Q^XN>G99*E
MD(L']8LGVD\<0?'B5L<B\HQ3E@U2VTG(9O&R4N><Z>;!3,P*$V4W/ N8WAS2
M,=36E))\:NECG-$0F'O^M .%:RPW&L$V@+%OZ-&9L_>]/=LU70', K&^'Z3"
M6ESA6?.G/@[LHQNB3=/./YLTDZ,1-%ZI3#7/(VIL 5TU;+3J,MVO7O?::C/D
MV5:#'27?> J/!-KZLI&1\//I82401VJR$X&QV>5@L^H]\SW;!V2P3EER%FIO
MZ4\F'U6M[[56I]7>]6X&OX ]!>[VP@$[3M7-@S/' KZ_/ATW&6E5;'P@U<AN
MCE,4,.&=ZDF"'&;&?>(8="HC\O'5&+S[M*:X!O)%ZP U+B)K"^A%^$3 NQKQ
M!G@I\FL,R&$Z=%,;(\7Y#6-E.L0;<X!"90)#,O$GA[#1AG]/4M/Y76HN!+Y<
M=]YOK.!,3AZS.DW^Z-KEH$TEB>(\[9D4^9*N14SX7?3CL]#/M=X$5 &>%')T
M=PZW\+T!;^(5JL[;%$-6[:W1*8.*T]RG*!.B2X='C&OK6NM42AG45 Z_,^V.
MG^+)F$=,WV]K'@BUNKYW]SX3W'<%QK&Z^E?OMK8Q@)Z F]D?GL,V#"2(W!)6
MSQ<RYI*_>4OKT(>L2PCV>I(Z_G=\5E^0 L#D@V7K8V]XP5G"]N^ HI?GM@N/
MAZ]E^^#;OQ7^ 35R;.-N0'JW H V3*>N'5VZ' D'3*<^#[6C7 D' J>S'/EV
M8##_GMK+.^#Y';!S:/KP,>!85$E,833W1N0&>=#C1E^SJ:Y"P+59<3! J&Z/
M]*&#7^USX0G_6/-&TK8K2<CA.T#LSZM9HTH I.^B^@_+*SV1_;\C!Z.)@#ZA
M%R:Q=+,WO$#(&U<B#Q]C0(?88-G&]S>\H.TKWP53GW]O\)_0E<F52,'"#'VW
M+E;AT=?9(\7[]*25(*#=$T>RG=A<DMC-<_3A T#ME?L=\/U"Z,.6//G=2M_4
MUE-RVO=Y]\K>-^SN2:$;DRV.*!N1BX=517 ^K8%:T-F@3@:(8-9]+;]"?]0S
MWZZYZBWDYGFT[]ST83$P,S@]D?L?$ ^K?4"WU:-T"$OC"\L;&OW5UT,7L9NS
MMZ3IUL79@XL@N0F[(_X%U?^/D:9N5L")V"#U.P ;_,CRI_/%M6LTM^"?7G5D
M"8/X: JG=?45%>Q@AGR)I"H8UFWNA[YQ3GK53#IE]1SE<-)&\D3:<V++$&O]
M&%X&O<"("1"W8$T# \_. U='KB\G%DK\:8("31'$!:?#,NV-7)Q)\QP*XZ'P
M*J6O4_9)^[CMJ0UXW<DM>.E?8UQ1V4@*GF>U;E!K3>F"BDE[(8G\@%>KDN;'
MN__3]ZEI<)F0$X,[\$NZ1UV[LK<FT.?S7XM;=;$FH(\/4"J)6>\@#V%9!<SJ
M$!5',!G(V\_@3L%TBDRJ8LIL!*LY+JNG/>>VB8_HI;/F"#W(L40%*O*Y5!HH
M6:Z[U GPK5?:&>#]B07^4H>G3^KY8]/K&WB92(7B6F-3HDB2;VOM8R#]L::S
ML::3E;\Q?6"?);D)<ODI5<?5O:B.3/0S?0S+5@KI+R5?Z/221#J%2U(FU(*@
M$W'UT"%G4Y8 U0*3"N)O/_<=27WA?/M:'&K68NTH7CV^_B)NPB,$.#V0LQ(P
MN1T?%H=$*@SF&,M/*U"T4_;IV>3>E.QPK'.7N6!I@9Q8==\!TCI2RQFB>%J@
MQ$%2$\SJ74^H:A5<N@\-&;GG5AR'P)RX&>S1VU)&YG%2.^I?3;JP6!%V(_G<
M&?SE"+/Q"2)$3H1U?'0TG=\I(27+-&->'3GN I.ZZ_/EA_RS F5E,ULN%2:$
MJ8N/3)/R-M1WX8B",Z2?XGY+45?;6)PS]6/(O4HLF?U/!FBH_P\R /T6_H@,
MW*QG.I-VF1WV$2GZFKZQ\7S@??\..%A[!XAR+Q4]Z;P>!'O[_I=(MG//_'OO
M0X'3,5LASXVUOZP,)OLE]+?,ZLDS_QV@1N0X^]_;>?H_W(X:5>MC]U:OG0NF
M5Y4UE3:G4EG9QY/6EEQ_+/1EC2=-AY0N%(?L%1=[=X)FW2)+_/3L/"-!?^E*
M &Z8S=KWAVRT<_NS&/Q/;ZC8M78A..?7#7+OUF3TTYX(OP?L[&WGA91]/HAS
M)\2U<V.[\^'DT%6RQ_+!"=L>!+EG85UR0P#=R:RVS78T0SLQU3G*E+*.V^=J
M1T<XO%H?4&T0C*A<1SG ZG.P$;0,8G4@=!$N*F_MHRKG]N.=IEFH"WRG[TI8
MRAWL!S8GP_)!(>!.CE;QXJ,(6]=QNA^F>// &HA&6-TWI)<92L-0:^B>GH_]
ME?BJ3)8&MS%!%=!9M8*"<<0UE+<B/3W,M\Y?J)+4"P"()\#1(P\XEV,8&^?P
M+()Y1144TA9>0WG_5D*+& 'K=+PV??>;U)'*#OM:U&EE_>9>6O1L20_TJBI<
MN_J5=JAV.Z-?C,DRD*^.*^PUZ;8:3@?1HK8R!Z=W%4_%K#L&7(OW5U<='N/9
M!233M ,DLD1*Y"D6B;SWS3WW2SEY7^+\,^5/2$RD6KQ5;TE,22E>7'+86DD'
MC"(03)L /(H2ZZUI&;%\#J=,=^T\H7=YN/!H25+EY2JLU+DL8\B\<+4B6:6;
M:]A=Q@EO)1' ,WY,E!&T]&H2-_90/-G00>_T_:P5J5*?VLBZFJLO6N$R>0D+
ME3O[TU,"OP/K-C 1!8)MAUC!&J:^I7+FDA!K;[:^JK59PLSSU^4@M:-V$ZC0
M1+TE;5?;4[H[]QE[7'<,($%2GT_\F_.<G0CC:2$A[V#V$11R$5^!UL\U$\%T
M)JP_I$KH=?6=I:C"^;W9T)*98T,:\?8<,+VO8N2T@Q#.*DJAH6J56)=943KE
M6%DXTH^(>\:5^Q4W3*SXZL$V7&<)*$K!9IH"A8U_S4VC[0FA-Z)W )^P?4WM
M_<UKUSL@F'OEWWYCR_?O;S%D#&+Q0O(J7U708</IDPGHU'6"-B1ZF1MCNOM3
M)=N9?3"604KYQ4;</C:U?,"/D[+[F7%*E?4#7P%!23S,.V#^<BGLFI2<C:N4
M_1T G,M1'69'\#+WIIJ$,G*](.ARJCK14W;HYG_JT%,?<I-+ID@F&O$>L.99
MC"Z7F(OZ'EIFS_K<Q>P5VE3(H#C4<IS>!M3\$"O-66>]5&Y#=>/YQ9@0TGE\
M8& &)&2=B)N.AEO7.<:5=E@@1[;$E&;YY8??<C#/>E[ %XV'67ER(W 7S^=P
MB^:57<?^:S9-Z;!TN95"N?>G?;*0B_ TWM=/6GM]8<P,YQ+(5T%*U5_+62WY
MO&IUTO8TFM4?5!LRA;0VN.>ZE>;'3OWA1-:WU=H(LQS8C^X)SPU^"0'.8K<>
MF)3WL!J^"M9K":L+ 4CIRG7UO(X%^ -2-GOX6FZ-ETL0L<!#P_%W,BRV'U'Y
MBM3'"QBAB&U'[!6KY<:D%JZN,U+J+C52E]R3]E(+.#U,! .HD GU:(W@4?%&
M8WMYWJ8B0EH_6S6'KJ^X=:\K.9WI@$\Y!FW!9%,&LD7@,VS%3\2?7-&6F?,0
M::'6D[_X:C"=6DTA*BKA4?/R6KN$P?VFF9YK5&RF[?^@>[0IAX+LUZ9#9[E'
ME:,A4J@.4ZV_AQ>ATH9W#LNL;;!,JFJDHF 3,SLT.>$D,/>%+V4$ X2WWNI2
MA-=I.-/_Q#'Y?PBVS&][S6^<WXZLKRHK_UW%_?F^^/5G^X*/$86%\X3_F^_Q
M6QQM55OZQX6RL>UE4.5O>ITUGA5S<D39$><K&4T*RL;DZI0PNA*\:9!3;],O
M"LQ89<O%B<_4J:12%58Y3L9)>1DO_M&NSM[NIS=\C8'IPI[A1!'MRXH;U'.)
M,SJ!.UY&<>G#^:?Z]>S-,!UEAY_HP@$^'D'EI62.5$6R.FL)AP3W/9YKKP5?
MQS[6GOR?U*U@=CT=\EB4E\2]>/XORG<40!ND1$VV1W1?&Y0?LN_PR.?ML)'R
MB_[Q2R>A"E$3,HH+M&(<],P_7#T[Y'7*??1+$4?9P*=C(#A%F6>+07KZ0D=<
M!-JN;ZYN&1\#N>#YI#?#>. RU U_($Z!$@KRW]GI7CZLX_%9O3&_5* Y^'RK
M9*S+Z[:^\7$UDW:/5'"3FZL=407%_C 6N=[DW)*4394+719?VW<I3=> B%,[
M,XAXCG7)WN:&I6(V7&, 6DTOVMIA:$+**M(-!D/'B-^34=1%8$[1?$GLC.ZR
M4P8&B,FT4,OX]*PU+A H@?HV,2(@H&V_R%;@HH!=5\W7I/,.H#C) ]7T+7@X
M8Q=C:'2UBQPTL?GS-F<GEBCY^H0ZJ6UB]'1J"BO9E.M%@Y!3GM<<<W0,.);+
MW-&34=FH0TQ5V*O"4A2(71EV YQ\TWJWV7AR$$B.;4VE*,HPE>Z4;)@CWBX(
M/8[RV-&?ZYE3.#Z$BF=XT$JT99 0FYV0)B[HQ-L9[3J$67M)(">V2/M?2E9<
MK%R%.6K6QY6>..S:$-,YK4TM/D2NQ@Y],N!PR>DE(&2:@48C:P8DZ9[KP?"B
MPW%RT>II/S$ZO9Q "?M_/8"U];B>U=GN@)NH5/6MR71>(:^T9,Q*M._*V/%"
MW\#>&!U+\^&<$]<[5[<2EY4G&L,GQT:=ZDI*5IW^P0T6W).U7X>+7>P-!M9]
MNO-TE,KVZ\5%,B(1#5 128((3F%9=0ZQ60D,)?)&60F,NL^>5NJ-UQ@25;M0
MC06=]<->\%$9 3L?B%/IO84*'E9085C2TRXM47 @9-N\'S<@OL(";G]//@"T
MM@Z![_6M>RJF0R%$:@_4;X&%W$OQ3*J<=38*9^=9K_PWX'\IDH4>N?RBR;'&
MOT)\[I#^NOED3T6HU6_BI<[_<4'UC,PCA)GLZ_]_+UKLT$VZO;A(?\E]!UQ8
MS7Q_>5Q0MS0VG0X9'KMO?@<D;!^Y5_9==A9%COVQ?0<H)7+_)\S#F 4_=E&P
MXZ9_T5#S$#!9UK9M:F;G?5,PJK5-:F8KU(&_WN9MU:T;P#'6X]SK?/Y:=+MP
MLGTB>G-78+G4[855 G7E-0 UBAZX=D)F7N*;2AB!%\'E)'<@X6 UCR'0(B>?
MPG++\9@(AUVE%!0SP_@@5'Q;]X-<.=6.XZ[\1R%DX.$R19BF_(R12='"AEN&
MKZ9@8TJCJTOLV*.V;C@@0@QCD0)&$0]T7=;3KI80/VJFRRF&G%;>H-C\<W4Z
MJHQ $>_-_;2WE9Y@4/N7=OD>P:!G@A5)<..J#WG36_-SX <QL-3A]E/[.Z#G
M+F3A/J M&;]V/AE8G\O.KGVM ].X=I)&YDD@/T436LX<+PRQW9+6FVI';)9P
MEU>RE<[60%26YB.8.F>F/'*Q&H(M'WA5TNR;I8;4[4B"0TG*- ,[=6OWCDUA
M"VGGQK>/"#VX4(-.XV:F*6D%ZK:3!90;-';<Q9"2KV?>LHCL_P,Z&+7L/E0)
MT33G'[3M$0S-' K,:A5.6Q'H_>LKNB<;G6?18_7;5LA5WBL;]THA/O9E]CN
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M@E ]L_9Z9G<LM?JJ44$[)"!WYW8A<L$:&_7R%)BNM+1 'AR7!83-Z0_^S^\
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MN1M.@)$-"Z_53E<[GN*3PN["6CM+SVH9=&C-YHQD]?7&B/7MIER-;\6OC29
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MUJKR<]S*>XE\ZEQ0_0<FU)BT;WB%>:1[!Q0RDP^KM?W4XEH["^@<#;D>(W(
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M9I>.3Q<.:3&HG'5L"J(;]B5'0@85+1)9O8MMXKX^@\6O3$M@0:U[.<,?M%(
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ME JS\L%?6_:=SOO$-WPG)&EZA!>I)_#>JHO(FGH&N;1M.ONH($M2-@+5B83
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MY$Y7DOA#R]B5L;_VK!=*J=%Y?J!:CM"M4^<7]<TPQNZ;U(>>"Y]11:U<J!=
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M4A1A4ZW-IFKS1BGJS4]XZ_\N"Q1'#4KM^(K09#<Y?L81X(J$/-SO011?WTS
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M9;)#/M8G=\"KVRA9P*IB4.BDD.0X0<%3<$+A*\P=P+]N;?RYCUN"BQ9KVN$
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M[-JAK#X5R=_/&R=3$(A\JI7KB2 J>C/C@_UW#/J0L@UG!2MX1NZ9AB:;Z=Q
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MC2TF,CJ1RK>&*^/[;4XFMJK0^E#TH*/0<[PFH)=)8@X2O>4_\'L&OO?ILV$
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M*/Z%16Z61HU]Z-8L+XAYA14$\QO9E_="'H[+_46;Z%GJM9%^O1X;/X7C0YS
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M,!8L8,E*P7.A=0O:^%MJDBMM0$*R4T(7(G.MY<[S]\S!$UQR.\$R7&U+05/
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MDG+GO^O_ U!+!PBTV1US8W@! *WQ 0!02P,$%  (" @ %X;.5
M     !$   !G,S,R-3 X9S(R:3$U+FIP9^R\!UQ3V[,_&IHH @HJO4E36N@M
M-.F&WCLHA  A)($D]*:B(")%.@(BTD% >@>1WD1Z%00$!*0+*$4>X/'T<__W
MWO-[[_/>^S"2O??,FIGOK%FSUMX[.^[#X<,/@(LJ2F E  X.+HX[CCL <+A,
M=UG+#H5%8>Q0CDR"0#Z F!Q8'1\?<$2T7VN=;O_& C3H<$P >+1LRG2X  #N
M2RLZ7"W 632:7UQ81%2$#I< P*,.@Z!1&)0-EDD+Y0I%:Z%@2"P3#Q._@+B
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M1X<? (#W-X[DC@ J ,[A\.$R@%C6&F4%O26O#L ]7 &0GG  ZSO'=H=C@/L
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M+5DJH!=*S'724H!^=]<K.,6>1G:XEF4O1KIWA%Y--U6/JUF;;0<U3S_6IW?
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MN9T@ W!S.)""^-X8^PJOI%.T.!P"*C3)W0G@X>/=437/FT+;"&=_?\+@G#4
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MDI@KQGJ5?=D"::#T&J)(O/B97F)@BO!URLI<D4$4CXG7!U5.(9_;)L %4$T
MN5%M[@,->^25W"2%BA?3\53J%^UU+F"&1XN_V1?%7UPC%A,CNO#D6\Q3:79Z
MP\G86XP6C-V;GGDR5@VYT7+;\D3]76D/2_>L_5&9?J27PG0. 9WOD2CIV,R2
MEJBK@GICVK4P[=118T>7^W-FU:;:?=7V6XL&D*R><H1MQ;+0Y"& ,RWYY>51
M+PW+=EI2O^E>.V/'TB"3T16$W<)JKI/.=,K-%#.IIL]"S\"DV?+RBNQ5C:SH
MC8]7,!A)UXC*J_.B!=6/I@<).[UDO$K'7Y@G2T<5=@[.M%28\&YGI/.]N3:R
MXCAI8PVMH^:?EPM+GX"I@XII$-DC3DK17%KI2S6B.JG;H/BGUL7A[9'V9\*-
MM4-@\#L"+<34QK0FNZZ78,QI(K2Y,EJIN\CTN88@,(93Q]-DGL;92!:&TUC2
M19"W(Q^%66N8L9.";)F&K!LH6\:'0<J7^M#2-\,N9BR'0L(NIF7#RPS"/NJQ
M+^[UC#U\ON;6%39^6Z$8-"HIB<@,8>P!KBPO!GGFV;ML]S_KTRCBTNO @R5(
MW8LW<X^]20RO:%"[^VCZP.DI,,C=8"+_KLN0P.A$1 M7DV$])$M(U:)>/6UC
MZ"+-64\36;L1 ^^U:XL@6^![IUJIKJ^#C$2JS\S*YN/4]JH?OQBS"I\;(AD7
M($@M<JD:BS6&OGIY;XAHNK0J(?Y"]9/TD3V]GCA+C9+9M+TMD:+)TC(H^YA>
M-N$<I69NMWJH^"%@>XNN;>1="?R6_5.COH7:E;=;HT&PAN5/(A&(;'V\S?,Q
M>KSI+543H0W]W+& -Q,M#7O)W%S/D62)C6+-IE[=Z1^-A3XW<'?P%HS<V6K>
M<BP=0R"52DR-/ P_;%,Y(8+91^!Z"RM-6[=T(U+%%A,D\Q^5/YU_5,+;,JZ5
M8=^.?7 >;J_A.:;TT',"Q[.SXF/UIIAP\&L2" V>\O5I#:;R:8EU3Y,(Q(A&
M6#(*V1Z:.2HD/[$VX>$/GG./);%[#3<!$#WZY/I<>??&QY!43-Q^]/Q5^=GJ
M[4VG&3ADT#:WT&TL>.4;SY((E63<RGLD8TBL,8.R(U)HHU%93<RA-2SCXUMW
MLJ?=Y :#0N^O:7HS7CBHN*^?U7FV_ @(D27))^3F%7F])&/"E=\%3_Z&8/;2
MEK,JB4A3?Y ,+IU]72R918:?W$1\@[SRM0 Y/Q/HVSD@'PT-SL@5.)?%O_R%
MW#$34$88'FF'JQ&9^Y5!2$)F?BM3L%?ZNN3Z0M*4"G4KN#?,NZJ.);_GFKUA
MJ,^[F]LL/IR8;=]"1MX\&=_WWH)AE^_H8$N2:_Q>/<@%*T7?N KBNCFRIA(>
M&>Y"(+W#'S9AX0]V37@(L %%+LPS7DCH[E$_!!A_8_F6\_VRY.:*_Y/Q<C^&
MNZFD-2H7)!FY#YQV@5PF[Z)XP 0<M%?9%$T8=FDV?'89-%]M9N=D)"&39#['
M??7XWK.7XQ2^[GMI@Z2)DF[HL=@>?Z7(:__X$$/_&>/+_8KPW<$948$EQ--#
M0$?&D,Z[=G,2-E7C<T1<^?KGE\;LD1DH5V=DBT1L7[*32:*HV&L@QFCNWB<
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MX5U=:<V\@ZF>_WSR^/_DUF$G(+5Q09\#D)4!V-'>0Z!E$<6.=T#E^5HK"/)
M<6R\*FXZ=QU<G&;#Q',2JK8TPU"[E.V^+ZCVVR>(6KPQ05IQ+KF46CJ?T=/L
M!XX/=FCJY-;:AUI3;\.KV_:[K96+M<Q3QCV\/:KMG0;B,\G=$FK);09TYC'
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MVH9D#TQFFQ;%'U[?<CWI&R:]C7FGYT0LWP&%5:A[LO.HXX/;*W:"HN JSG>
MU(,/OB_V[D"+#B_LIWYCW68<@CKMC8% GETE<%; D/@@XQD_YM)ZPB;?Z_G]
MTTVPCYM=J0_9T1?LZ*R+6,I-K[Q(:9#.BR)FVV +7C7PHW:^'GGM5K'6F3Q
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M>@G^H$94>+[L>?E\*ZXBE(]X%XPE=COS#O!&O"%>_E827[TOKDOD3%4O\*I
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MP4-M_$XU5W3L* K2N/U&7)JYM 1&:\VJ#^- D%;\,<]F,O45J/ N()GG%S)
M@V5+A@@MKS:S09MK+F1S"V*^NXN1\].@Q1@J,H AM;QJ:U>10+!_E4"!M,0Z
MTT$F;HNLP8;!O 2Y4__>QTE+'AJ]=JY<K&/$3<SH0TC<+_CY#CL.KE-Z8$5%
M&HZ![(.+URZ/1J2;8KB -A''D;%V Z1LDS7:8I<,\ZI'FIW6EW%8=76J[/OT
MQ6$X$RUEVID".'[F>>F%D&O$8<47&$GG]7QZMK/A05SVER,9B,%W-)>RG0U#
M5+1'*,KA%%0F[@9YA%B@L2(2G@O6\;]JA-V.[>_O50\PQU0$N_6<>F0L@YAK
M"?5&C-5*V8GDW,UJL</@15"I"K\6&,<OY2(T=-#-,T(])=L[6W<N%N5".+MX
M"(JJ& %$-ZR_<[*KEY4XCQHSI>%VXL-@QYP$%:7(*C7:Y8?=F<XV3))T[>H6
MW$,VQ$V*$U)0F' QE3CP39#M[_D.92?-&3QM.]B=SS^!]PD.EB ?-3!F(+:P
M@?"TM6E&) "2 ]@44BJ[^?S%7)FYB7G3+XF([HDT#HH_O<($Y]0O77$G>^>C
M^UN$=I?6+6KR6(/*T-L)_KH)EB= *Q^(@YD8BUP#XGYSX.S,K\PQ>T(.6&]>
MF&08K,KZ '<A@1VFIAX3K[@5:OVW1-OIM$*=:V9C[@QQ)DS)S#-:DH8GIT"9
M.&'^CPJ->>>OOP3<JAT:2[318\Z5#7V6ICV=SSM_K[WXG"I_TOXO[S4P F5D
ML):DSL! ON<B\0_?PCB^WRJG 7*Z!$C)*HP&.]NQ0%H"92[+_%<;WQ-.@LJ0
M3\+6QX125MW(K<0LJ> Y NN?8RD][_.]3TE]*HC<43C&:SH81TT&H6,2RFAA
MMCHX%$NSH>21#<-A-0$%0512&:,HMP1V)M1GLQ6M'E1JZP3M<8)6-417-V>2
MSG)E\@.M_+8O6+ERY$F_4S<_Q#4'#<F9Z<Y/7UY,2='+,PE :,TI2]X!<8B-
M K/&MF:"8.)VN=?[QUE$^NH(GDG*48A\;\L.+M2NU:JVE;+I$OFD=BL1W[O5
M[52$*B2NB/=74H!B!,G6/+N/OB%_-TY3ZC%)>B6 B.# CJLOJD\N5@GI2K#E
MKZY8T@_V&(&>VK&<@3:7Z_AM]='VZ9%]CW< :C87&XD#G4S]EBA_CY\W4$N:
M@ 2]6D!L$'AOL,T;1[8_X1*_OV:)4+,)<>67RC%<GS=?;QO8U9U:-P.+2OJ?
MKR@VPY[?+;R\ P;**.2&24(_+E(YY<Z?STSSE36J2L$>+2@F*,RTQ\+>EBDA
M\X>]_IM'+9E?]I]RKGHZO+\D/HAGH\@W!$JWH$*_+>K8:7H,YBD,*OIA<_)7
MM1E>G74/7B.J]8T]G$241LA-_0SF0@\4OU\A7R6$22$]'!N'R J7\_#7]9MC
M$[<# N_HBF/4%L:E]S[VMD =8Z?LD&&#&_0'!+RQHNG_Y7,PL:Q.\>Y5A,UQ
M0J9SA<.*25-<J$;+>CV$76'ZAU'97VB)L_3\#6_:O"+4^Q[1CXS$O#L0BK><
M:+74V%P%FKTQ75"ML;*N0%1G!.\AKD88 T3LG6"G9;//>F8&1;V4^UY6+<()
MRQ1XQQ?L*('^D8Q-5;C+QII,U,6J>K*H13>,UD%EA]:5N*,F';/^^]Y;DQ;:
M13*,-7\@^J/84[W*4?Z;' [U"5QDXNG'Z[9F73XC-YAT>E;<:L<_U*KVVZM*
M8<I4LA(#XQ;9*/F)C"%#,L-N39N+ PMK,'U08YWV"KIA6QS&"_S.;^3]8I(E
MQ^/)%&()5%Z],C?IR'0R*:H?_-3[P;(=.L]-NAH5:@W$1#L)AC-,MT.GN\<W
M*:DF=H6'$L&XT!FK4<T%?',J#B.X,,"9 K(Z2KK-Q%[6?M]V%$,J(;I)]@[T
M=NGUX]+]F(3M>M'*N8;9HFA2Z9FX1=7B65(1$-QWEPR4M._ZWCP9"N=GC(S3
MG#W@;;;Q?<EVKU#_*V(KU4^IH6]5KU'2P4Y/SQU.QT'BS3]L73R].GR&*[$(
M_;'A]K4RBA.PQV2S%U-PL<G%W'@_28$)W8L3$E?S)>Z[=!E]^PAB*7G3C9$S
M"OF3_)#\)-@\;I+'O(L\16<>%&6,PDWD99/;4L9WF"QXAV)LN@$*/7*>19:]
M!0SW"0_7V<W<235$SMQW/PU0A3O*[@NY$2961T[A2S6 "M1%U#;+J\[H+<.@
M7DCCIFV+)*G]6W;)H0L?=ZQ(LH5@M:,(FF.D"'4S.W6MI_\1=+"NBFZ+446O
M9?[ XE9_-$+!3(#'CQ0VK0L6 083IL^ 64E TZ&191EKS,Y\Z-S!YG0BT^4G
M/\MBTDT_/KE4#!+J[V7;HK#P>W!QRN9UR^/ ;93)=KKL:O$<%$ 6CFX^S![_
M326+&<*1Z&(-Y#L=]S9#$&@+0,; H)(T[;+MM=[5<_*=6WT'J.;>C;NIJ_RZ
M_5:@NNKQB3GH Q*E00"24!\I'.FZ.&@:E#3@10VPH5-/B),&M0\IUB@+^:JH
MV])V5: Q"1'F05[Z!@#7IWOE!O"G<%U4)E:1R2;MCCN+7)G!MY$ZK$F]UJRL
M@U(W"@F@.,7B$5WX[Y)Z!7HCTH"(AXHEW,2^%ZU22UQ5CN62!T5G/DX2.@$.
MQQ-N?VSP+K4-@<EJ>UVS+H'<9!O,@?!Z_2, >=E92:?FP4VFLEFG#F_4&V\^
M[%M0C\.*S;3-53X%ZO[NA!ON='!+\=28!,%'^U!29?*&>= =\<FVTH8W7;NW
M!(15_Z8U([&DGZQ%^-[/B1O]QB*F8KA2?ZKJ3,:K5BH,)I\V+0P1CU!N++%&
M58C_LQ8B4'.Q9\EE:'+K1-9AJ2&==;/+4*B^*!QK"C:^UP*$N?2L _#SK_Y\
MPV^4W!'HJRC4J>:7&WI_^,Q0OVM%_ [X*BZ@J_NC=J&J9M7AVE563F"U@T/4
M;\K&KHRQ\6;P2^?QYT)RJD]Q7E9>BD46!!W9^LN:%9O:" _58%=Z][(  %5:
M #*<K8?9QUW:.:/EC2$PB[MTPLJ8P2/L3'-?)=EXY30/I'\%O%),?*4*[S5:
MQ\C<,3:/@W4GAI0D&J&^;[EB(QVEU#5O9\XW+S#CUA3HU"XKN_E&W-10CK>I
M -'VP8)?Z6[>Q=1CPCXY<T7D)9BML@2AE^XKODH+QF#(-XVETZ R9FY<%^J#
MHQQ.!7]3KU1R+5YAUQ1QG4#!.3J6TE=(VG/9N=ZD1NUW 7NI<5.$9'Q<?BZD
M*KN+1JA1^'$N0L4*^VZ(+(ZUY3_]8#, -CT*(8W.9[[LH#(5U?_6S !*> <8
M=MZ6O@/,E3_U_L)=^;AN(=K3ZKI:-=.Q:GZNO\2_WH"E_2:]0^]*O.7@P'L@
M-[BL8[\A*C;.=3IP]IR30<&BKV1GY2U?">]V(QIK#CMZ?F[\MO;#1Q:I>3NU
MN']++I6BK8 H;?K4HEFQD3$/22C2([H_18/=1J@8-@KA!W47Q!7W?@,O)U,Q
M99VXY%Q03R!6X5^.J%]1O*U@L7>6Y\'5^_@.P-L:16?.J:.3OQL?O'8D3*XB
M/L<=M)WY9U7LV'ZY]*2[-?:9;L*[ILW3>TP]Q3DM]\_^16,AK@\41# SIWV^
M_YB  8PRZ/)GGV;'X<W]OD*4;VOD'IFZ[Q:5.2%KTT_8HLWR%2LM*M.D=W>[
M)5U1N&W4<"4"YU=+R'GO;"2ZC*B0&I)[ T5FQFSI<OO.!SR4VD7V#BI;19$1
MA*Y;H59/[52GTIGB*:OY\A$&1S^J+ZU)GHN47ND#"M-RMKD^Y$1B8Z@.?>GT
M4 /U,X)T\R;C,^,A%07QQT>:M;AKU/HG3_SFQ@H'% =D%1-F1AES*E3!E ;1
MVV3=:9K$2"FJ"51QNUU$(1%;@ODZB&^HCJ',56"TSM.WL'PDWF("9#9I?SC2
MJ V&UX;5K=7M!J%YZO2[0S1JY=W!^&LTH7DK$R:N7[@SX5<=^SKV"5*R!5
MV^P:W6]^?$%TRKRKJ]<"/OEQPDB9CL_J/)AP#0M.Z2N85(-N)Y)J(,GGAS^G
MA*3Q+YW!ZI  J03*T;-/?S\5_><KOU7.C=/'D6B%C&9'@K\^VXD-S^?:G578
M&I$8)S*^ ZYXUG?GS^FH6+"G>+/$X]AG2BF;,FJ]>IUK-S1=P,,5O[N;]6JB
MA)[)K72EML0KG+Z6I]D4.\25+(=LEZ/S=5$GC\!;BJ;NU2Y1TQY]F5-'AWI^
M5>TP4NP0$Z%-XJ--BN/KBY5&@>]S-9*?X206:5SC]%!O("+01'8'P*3EZ(;C
MI/$FTD\@<(^L*CD.^!JU;D$;]2N<RV^Q=Q&^D"RLVF'7B^84]C8+6ZI^[@M3
M'W-5)TIX=+:@ ]L6 F4_W]R>Q7:W<1?H:>NKY8'N( @1$A!MTY)=%K&<K<T$
M.8-;S Z!:9[0J(8WIAKO[)A?JUS)W9R9=A(5YBH??ET"3+@:@C!<Y/ I,^$"
M[/9^S/2B@T^;Z$;KQ)=YF6':3&Q&MY_WI&9F/INTK@;WT ^9-.EZ4/\QP/S9
MHDY#*O>K,<'_!P<?A,\CN!\!Y.PB..E,L3F&HGMH 3>!%!6%\]<[9B29U,2,
MJ3D?!LT3-FO8'L"?7OM'8)'RL,V,6WBQE]>4-VNU&AKE9/+ .,(%)*1,1J"S
M3952Z,*(Y-[R*2D/75:2K=4Q.4\E(U>(V=P>=6>"7A RVACP$E#_PFJ#\9-,
MK>RKC*:;/=2).W?LSG'TVZ*M$G%-.T$_UM(SV!!(G&7^9OPR&6FT^+TI3"\<
M@Z#)5!GB*W"=>*F%0[&F^;W]5_YJ\_!:+4%.XF+C;$W'GZKE7ETML: ;TKMR
M\JJY\H0-;4#I,#O,S 1KX#XE#LH>">U&RXKW *U:.5IQH#3$J'R.=,;=2)AJ
M"%40"2Y[$-0(O#C<4?@Z6NENA[UP<?+SCV^?3E3%U68=B>I*,4,PPMCQC=J@
M7*?*WU-I]WN]B()J>61X(-%^-)-;P-%5"L3M*:9 -Q8CIV %3X$\:&!*BI*&
M/T'#>"/[6PC'LW:&4+CZ4L')Z])D_@#G!*70"T JVY],#E+%BB @$4_,P!6R
M)*HT32@EQEB??<<51&8A&'@' @#LNIX/%=P]1[.9P-BZCLTX;7?X5U=Z'[(Q
MEPP<X]']8.QA"9$(O2CKD7(.N$MD7LRC?3I;'T_> 03%B(97:J4-7Y.^(TBT
M?^%RXE?,MOM159[:##'*VAZ9FI8^H70FPQ8F3%P3:A=41W'H'XTIV&?/]>GY
M._$PRS)SY+Y;ECRD:&_-$UL:,WM'W[6>_2$[@,<7QU-I^L%5M;I81SNB2<$J
MZVG\@WLLZ$QK3.)A,F-<^[!H0Y4JIO@G;5+4SHGT2O>_Q1+>B0G=)Z48M]BX
M+:N7.0;G+'7+T9ZQ3J>E/)0J!$(^I#,-@16 YN1%)+/96"EW/_I3L[1/Y=:6
M"4S'KG6:-]*L<N;2F' >B22XX2:^Q%PETQG[S5TC!>(36BM((),8(9:/KJ6Q
MF:=6?)[-'[<S/;1).L$UDS"@\ HS^!4TXBSU5M.80V_S432,S,5-ZJ]S*G]"
MA046#H6'.]8.Y;/,X%B+0/C3.\!N>Z)][].:F59>IDG+)FL!;8<73YZ,4(9*
M":Z6S%2R7V$PQD?*8<")!LI=>_$E>IY$=G$D:$-HJP+8G'0$9:GI[AY,$D!.
M"\<[J;W[#)P934/QBZK'@6(CPP5&$3&@##%Q15K?I_HV*,9;FH)&[U)T7=:9
MC%K)_4JRS.&X9G88YY2^0<@^5*U=5)+6Y1IS0K5F;R'@<>?E\%+@+,P90D':
MQ:%3G"0PL&WXMOQH9S:EI@]@W$T)D)3"'YP MRSM$;T U5&H*CPBXPJU;"9$
M[>,\\_%.(4G1%F3UH=A+0U)G9#BG/R158/ZHVMYQ(0IS#RYHIMIZ#M/ZE%0K
M)I06>/*^I;\#/K:4J7#\5P5W]!TN>/TIV/Y/PCV5N<;DG,YWBO30J3$8FW!Q
MBX>DZ$ )R0"G7SF;]W_(L%:KP:I=\><B?=+\67*DND\NR0R -FQ4GG#K., Q
M;(FN_^N-UJ5IT_[\&$XH@[JM>7C?Q665N._7=KTSQX[O6@Z;U.FX(7KA:#L3
M\A F1HMD++24%&S*W$( Z_U2,"3'&25D627W$(JYYJ/[$Z,K,6:?K?$-9R.'
M9MNJ):4%(=39<U/8L2Q*+ 8Y+$$NC':$?\66^IBYJ*HX3WR#X8B)/6XO54#V
M8KDLT")EX%O"A.G"DRD]<4HC?D(3YK1N'$69%)B)><9&(:E0G5YQ"X+]M#G7
M>%]9>B%ECDZ50!7'S@9@IY$^8>&>H+Q#&]3]1]Q@A+)"76VMI?BMU.U>"_*.
M"^I\V# \1#8YM.K5S"SH.R#P7!=^9F35Q>&Z[>?3'&&L3AXPI/)A@$//?)4M
MI+"(/%+R57O2TL3&XZJ0\>)3(4>>#K7HDE>T(?-E+?*AWT&J GG[79Q9-?IN
MZ?U'3U6K40-L&EJO]*XAP7OM@H?(V[RL+7>TZG"WHF(6%S#\D(>$PFAX<@)2
MZL!>(WFOBZAJF/V*J4[\7!+C1V$Q.O7V3U;BVZ=BRG4SS8P6.1Z5.T305 $$
M6#+C$TDEN8WT'UKO@.(8G(TSFFT,C AZ'1 NI$0[N[U7:V.<;#[,PHY2=VN1
M!GG,K@/X(L1CE,S;RSERB?M341+7(9"K^%&'+A/(.F]?K\E4T4;H1 W\:;P<
MO2?KRW"2-O*-;K2:L:'122&^FTM 3(XU(ZU,/GGEZ%<J#[0>']!BBGJ*?XIR
MP'Q+V2\TQG&$6E+(%KW67*SL#:D "F QP800XJ.%\R.%)6(=.\:PR.E$L\I*
M? [5UJXQ<L$KC[9I8FG2%4-2R1ZA<][_X3Y(508_CQ*+W>!M;",^;V<$3V!C
ML" \0-67X+H2F_"RTME6YJTU[XJ]U$#T:-7T01J A(?M>0,WI$'#BK(4VM%0
M<'?]TKE^^L+$,BJ2?JV/GS7 FEW2P0=L*9/YS_I2$?$I/1^LP<'#=3O&X\M+
M1+TBBQL>@Q/>,0"/]QU0=ARSIDQ2[$"U[=AD_18QXXA.M.<]D.4?W$0-1=]Y
M@#P-I5?':0<_)"%24H@ R;\#P1:.];E'LSDWA]J<AXUEH.AQB-7/[]K.>'L-
MA?5?%)76NKI8PP\J5T$%8"M'A;-OZ!;-5> AQO#CJ)UNG ^4%E-KL$G\?[B_
M\!XZPZ.+J<^N[(MT,YS2O&7VK_&/KKCTAL7MX)K)Q5(IQ!]Q'T)D!&,UU!HW
MQSTC;-?!WA9JIQR/S2O2 MF\NG(;6#"==_SP_;<*/)LD:#7H,[9I]*!2R:!)
MYVI/Q4Y&\P#9D#>_9%.PK6GM]6K/:.;>9>:VEQ%WQUA(_S!8*]/5NX 7*Z=#
MZ-R26D&VB1HCQ2TDPY9.*2[X*W^[F=(TTTUD9,I'3CK!X'&KJ%0.CA0_8BC
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MMG,2$I9 "$FBDG8NMUO-MY;%1=WE UU@&DK\1*).^=;3F5(=98[3X"]M[>,
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M%N[0SYL9>V['?OR)*#7RC+G5\1LCP-B/B8676H+F^3=1\>:P7(S2RRACR 9
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M\C $A:(S?'N=/J'0?/3_EAO8>>1'D=WEF29 >$!!M9$[J(A,-&WAS.? BB'
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MG='B3XB,:.9^\?D%'2<V[@OVT,2O1\@!]V[T#4?\\/X*%D&NV0[6GXFA6.J
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M,?O^<>G_ %!+!PB9<WNZ_.$  %@V 0!02P,$%  (" @ %X;.5
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MS:#0_$)WZ_UA;CG%<VT;%(9IXF*0Z^:23CYAI!_F4[(V((25\'6 GVSGP?9
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MN/H\JDDQFXD5'4Y(>LYCSY6OJ,]:RL/RNB=!B^I.<6YD(E."67IG;[&!]L=
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MS,Z##G6 :O/E[T@C. 5Y$$SIM0;/_3>Z<HH3_]J!1U^4XV43_P8*6T[YNP,
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MI'4"TK04HB M"KQ:[>-!9VX.VCZBA[M'25-7V=2<]_TJ.B-!V;,3^=3<1T)
M38/Z<==]X2#W4]LOM["UB\'5R\O=[FEG=IP<51W=(18J;QLU39_&^KCL&Z*
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M[DVC(N:$AQ9G=SVW4 1J<(5+C4,Y@L\<?,K)V:O$U0HV.#=U3MO.:' ^'Y>
M&'(_\/A86E5AJ1%?%CU4WJGJ$6\1V&\1U3>12=<N#)M4>,-HZ0W P]Y#*WJR
M0FN[-JH$:GCJ&FHVC?8@'??+J.>VS9$G]Q!(>\?&QN@*:]B)B@3-07&D*HL'
M7;'60OH/>CG4>X\W]LYDIF[SX7H5?)R2"#C0J2;;AHEF426+FI@7X\A!'JUH
MOB_D@G1#QSV2T.2QLIG@X.W97=8%D!?6S)/U4(IXM-&6 M %24T-K%F/&VJ
M#&4YW#M-RD& N%@/7..>M,B"K7$-F33ATX3L>)6DR'&D< Y9, ?#*HY4^EV4
MRUL!'@TYE9BYR'44Q;0PD%\N8;AB5XF\IF+88*5;U,W"M1"SZ]I;G;$ $LY1
M=^WR'LR;1')T.;/CI.7XYLMEMYP 4K7#^"1T??<4%CO)9M]M CI_GI>NOP5:
MUQ_M"GO(L\2TJGYL"\5\1 /B!,@>[5$:Q9Y=9U#>!CA54V+G,' #A+VH BE!
M_*TS-3C?LPD&<GS*-\>NE^3CH(D.RN\5\XQ?-?$B2 >9RF?JVG5/RN^1BRN'
M6Y?8=(95JKNFN&4HV-YN=\F+'=(C+_30Q,V\O_(6*Q.F=&?/"G?7Y(7SZ][L
M4C>^]\"["K&D;3KRY6NXI5$3[FU<;L^F>9JT>XI=T2N A@G//!RO;["A#2M-
M#4UC(<^,WCRD7(HO()+'-9^01)>)2.WL[_K^&?C.%F =UA0>T[.<^'N<)RKV
M5%JXR5WK J5MH-MEY1Y6^Z$\(OC K@1T/K@XDMA+"UC$ATO:-*O(:)=CPS/B
MYLNAW4X@^*V4WU$N?3PCR-P>U+@4I&J?QN>9C&6)DQIMA)0!0%P*08I;.1W:
MA\_9HR4$S#WM+K$,A]IN:Q$4!<LXCHXXG8B6V*%NZ_9H9$=6FVR".R%1U-TF
M6Y*A>KH[IF<.GD$L;-WFJ9EU0B81^Y0_[?%5XHZ'[8\US!T)*L7(??#R?%UH
MRR9!')H&E(*PG7/WUM*LE2==C)9BV=G <4W3A.$8Q)#292W9VSD+?) +[*OI
M;-6H[1'99<=X:HE@;=;7.8,>B:BL'FAJBT@#G>I9S)3#$A3)P:/U\.!=ZO6Z
MO]>'+)BG]70M&UD14[9!/VX^\?N!@$T 4./;S*5^?VC3$>0)A;,&1I_K]I6L
MH/Y@6U=0W(-*IG\^UMT, TA$-4DY>^V"M0L)&];!WNX8?P&%A\"0L1$E*,@^
MH%[U/>8F"(K135J[DT'\,==Y=[F8%Q#:O5N4\#J"=6E^OU9:,6KUTZS/0GJ:
MA<T.QQU\@/2L+FI0*O6(^TC:WG%.]FHE#1MV987+((\,_(Q?;))S*/)^-NLW
MUL5^\S;!V.5O?_OUL7?;,^U^]R@_>'N6WW=/_H-__^B_[3F"OW]6X+_;,R&C
MV]<G.[9C7[X?E1G=X+B,J[@>'C#Z,_KM<QVCVY=G^05M6V:WX"4%;IO'L,G\
M*_PKQ;?#AFPHXW_R88= R5_*H+[_[:?Y+U&<!&,Y_/3YCF$/#/MG%O$'TE\:
M1;]?OW^#7GW<!EG_T^=#5L:?M*"*?_ENT*;OS\%6LMN/N*]_3]7W&([0V%:?
MJ<TM*#]9V?=4*/87>:S_\GKLY*>/!TYNN%<PK1^0?T+17^E1]A?\*[WYGO<G
M)^X?8/*_CL)^WM#!;Y_3^5LBE/H9^1G_*)N#-LUNGX:E_:U8KA^>3;\]$^#]
M]G_\C__3)QK[M#]=E4]A&=R*3TV8Q[?A\>F6@A6,HT]#\^G>!\L#S#G^^=>!
M5AI_2IJR;)Y9?0??@#E^"OKX4]O'#V";G[+ZTP!(HN8VOFSUE_>@7Q71F[;-
MZL=?C/@^ED'_W=E]\'KR:O:775-&/S[U]Q2Y-673_U.:O*;^W:'=:R%^E?"7
M_R=?;PG_I+?\V#->/G/;'M'Z W\QX^[O^<OG+];]1VI\._ZMQG?"_CV?A&OI
M?_),VP%N[S]\(NYCX+/JC\<^7L]FA0%97+]<Y_$??\SG4 __")\#,/T?<GAE
MF3][,._W#^4%\_Y%TT%6>GQ&W]GE-P=^3RD&#R=[9&$96WU0/UI@]?5M^7P(
MRD?\=?3?(?HC;N<I[ML^JX?/5C_^B-.O!+]G<PKFE[YFML;_X--P__K>LU^>
MGRD4^QEYO_X*?SGV(\KT,\U^3YG^D'($=>1GO0&:/KX0O@]]E\._T_L'LWKM
M\H^>!;P+[O\^SP)^V]LOKSCZ2E*??QL!7YI_<_*/QQ^"*BN7+QQ^._CCS)\-
MO\6?OQ?[/OC'XUZ3_'QNX_K3Z]MO![_/_/W!TY;!S $8U/WS1S[[1/V,X5^8
M?$OQ]SD!WP)0)QOB+R[P_>$_F3F "._UO6U+%_X\#,DWJ_"%X!^#C)_^74WA
MOX 5?"3G_]\;PO\[[. [R/1OLX</)O\?M <"!'SBOY0A?+?V/S?_MPQB._IM
MZOB:A[[/-%\RD%X&PUO(C]+0'Z&[_1+4?V:8GT\@]=5#\*=TU_B%M/^4[(V@
M_QDX^4>3_+("YC,8;NFQ;\;VGUR#?_ZQ_+_<7V+>>\IOE>VG3?RGM_RMA_ ;
MHC_F\S9TY+>#?FCZ_X8%^]&:_'L"\=/ICR%L5?T=%&[$?^?_W_@6/7_9"4#^
M=V"X,/U#,/P+(V&*7WC\._,YG7[A/^H_B?\,#OP<9=$ON,"0*$_1/"&PPAY%
M68QG!9;9T7MVAQVH[;]C^';H[]A*]6,(ZEO\P3;[)]C^9NCOV)[[[)[50?DC
MK??_&/L?L/B=&".NH^QE"OLR>#P^?S1Q_B_VWC.JK6U9$R6;;, $$XT  0)$
M1D1CLD$$@\@28'*6B (#QIN<P>0,)HDL@@"1L<D9DS.8;+*- 2>V]W[[W.XS
M^KY[SQG=/6[W&.^-<6;]FW/5]]6J6K-FS?6G_H[P'U;_LTN=?-T"G!RU?+V0
M_^NE_E^15G#[!T[3^)^]U7]2_4?(CO_ 7_^+R([_R$__ ]GKOQ*1?PKQCYA\
M_TE0_N'J?\@)_^^H_.>0:;OY_75E#_J_F3[_;<LJV#G\6^;QL_O+E+^9_N_F
M_KG2/_HN_A=\^Q]4_SE^H*L3ZC^VA9%4$)?^>UN8?_?4/P?Q\W+V#_SK%JWZ
MMQ/S?]XYYQ\I_7/P__[735GL[XI_G_B_76K^'XW9_S0!_A=C]N];^?S_/F;_
M]'S_S]OU'Y_L_VT6IJ&E3/F7WM_[>_TC@__/CW^1_(OD7R3_(OD7R;](_D7R
M_RD2RO_1(?2O*\-CGD">)\I_;A"H$Q#^%\??0/ZK&(1_OB.@)R>$$5D3$](3
M$-$3$M,3_CE$P$5 2$!(^K=U@K\/4A*R>^04Q)1$?UM_3D= 2$)$2$A$1D5%
M1G6/B.0>*1$Q"1GA/0)R"GJ&!XRL6<M,S"P/ >86ENB<%1X):1E3L^S6MJ55
M7E63]/E%/@%).:/ J(S,EG9^*0C,+G<!Z*/FYQ^ 4]<T=O!-^YL!?S$3DA#_
M.WX"4L*_+" B)J>@_&O=B9Z D)B(B)B"BIR4@HR$D(*"\"\#"$C)Z.\Q !XP
M,DNH&IF:+3*Q\)C8I:5G9&8M&?N$E\[-+WPFYW5N[I>4@:'+REMWKR@>\DFI
M9;.JFR_[ Z4U-+7L?2-S5O@A?@$1T4/#?ZX34!,3_N448GJ")P1WW_>R,%O6
M;%MVE>Y)LU4H.H5B5>'8;M/&JGPG83N4H3*?B,S9>6SUYFG.1_)%8+91%J*H
MR@C)HG4PA!WFI$B32A[S @WJPXOT1U_QK]X."R9N5G^K@>W"MZ>7*+KK<W%V
MISJZ=J4/=7*X - /QHFB@!)'[DJ%R+OJE*HO7B%EQBDRG);5EUTS$#S.6\#<
M;XM#/8@I'1VA";OYM*A1D/;+N&XEB*E[O?F8/68IK??I"N>*KV=&3;>A0;N_
M#M(1SY@_G"Z4\)CVA,: U-OZ'7W<PQISAB,U<NSI1.[4IB@1;W;Z])%,!YSY
M>WXV/?_VP<Z^\6U+ZD ;45FC@'I:D5O(X>_MYAZBW$BQWDXA2$7E*GW"-]NP
M?=(+Q]XW,9'9R#=4EFU\EXE_P-K6FY<$#+N]@MV&3Z%HM]5O?<4_XT5M<M"K
MT2H>^5<T=HO)SQ$J7>D\;'GVRJX''1(<'"+:IW<4;A 8929<234AP'/C^ZMI
M9*O5'0;TN3JG3EA_(I&TO;(G_JO\@QPF\@!C:MR$64D[!^*@SENKSAWV17-]
M5]->.NPN<;K3B,@*65%S&%N*W5NE]*& $LK7:+K\(.9+QV:-=AUSL84:.YXG
M%/45B,'.9KJ+-UOAQ0,OMN# @DJ6MG01\9W^=RJID!"!,@;'RF9<GG.5-/6#
M9Q -:2+22766X4*>?>Q8))F>FTZG_@!%VV0:!5@;\3#,2I8)&](RV9YMMH8*
MH1&"<AFKE"Z55BX?TB.%=).E]U'WMO#DE]B2K$S]K38*A0F1S+2,,1T+(X-A
MNE13-=[6/?$ D2]?@4]MV-UIBSLNPN9N^*>E<&\X;$HN0@M/$Z<*1'M6!B/6
M/,4L2T9K-[BA;\S @NCDO!.2V?YY@VL_0M#\NTA^/_@W.?Q'TQ=ABP1XS+WW
M_O; ^ 7FFP 2=*T&&LC KI[$B!H>QM36SIA6L_DL'MUY"DXXB41PK/P*4:7M
MP@ 4HK XXGA*+?BP!O^W4_.@V[JZGTZG!A>R9NX3I%UIY?J>"<PCE1>DGD)-
MO.4<!C0F[XDZSJ!7>0&S:HQ7Z^-D0F3' 1_MQCB"D3)3FJY9F(2YZ :6,T8-
M*]$'O+K=;62.K&97E.I3';2'@)SR9Z$5HT&;>:G1.NZ.MB7[H$R9Q% ?7D1Q
M'DW3W27^(!-W9B#5"=8Q_V*E5A"D0U-C";3MR#$J=J-:UQA9./WFZ_XXTFC%
MK->N*CKKC4G5FT+X9.=]HUIVKF&/KC5A8YGB^)X-=.JZT72X*36CT<D[/&=,
MA,K!'=KSX0ME=4G-? '3MS3P2\.*Z=?>G1WK?.-.-$_;6B1-F'F'[6[>=P\F
M/_;-BP6L6#G=5W.V9]5PNZ^ =>17Z) @4KR0._/2-M1-X0/2SY\E VCP33?9
MLU<^8+ N3"U?O92PK>:I.%V ES?J>!VU5FV_]E3=X?FYL7G^4L0GP<BT-%T9
M^/)79"&-,8\];WV?X X<.$"U8)/S0()*DO8!S>1+'+L&#6ZQKC D/1>>-*:O
M$9H;KV*4N7"=&_89VA9.*WW>,4E.8=;B=,AIN";C.N0 Z"0ER;'4]=!5<;:"
M;JD+C7W\O:)F9(R5H]]HK0Y.Y]6H.#)^4CFH)-I35 ?Y\9AS&3BQQQ1@JOVX
MPLY-WXMQ26UH$Z^!B_]XSA 0D")%1C7&$4>/K'ADKTI*_"<!Y13K #WW!POU
M%B,?O&S (+V#PL,EY].Z^D,98$3ZKJ!3YKMNZ;;D!6NC5$I#KL^.:9[(/%=*
M?^4!QW?(-G?'>'[U85'NB/)T&&MZNA;>J8D6OB'6T>MVC@69$"%J>AULV C>
MZN84W9E*-000"F]51.:' 6F1E6EH9E26'B?9OGUB"(TT2,69>OF+:8N]\XRS
MM-P]JG5A*M6N\:!NZF_+UR\B@,7JQJ6RM(KV1^=#3[.81C 3\'WQ:E3I\C:R
MZIOD9)PJ+'O2VGE[*KI:/<@=YMS&--0U#U?Y0.D/.7,2E=-U!0L*@D$VFD($
MZ;#"3]K;&YD!ZR6G*24RI@R)LEY+HA#D"W.$Y\ = _>7&T@X'6Y6=+IPY4:6
M)\\6=#1!CB/H]R;SY;L16*<\M[WDBLUQ;6O8DMQW[IC*3O3,G=)#^9/M@I"Z
M8H#X9EUC9U+I*LO-+;N+\:-V,Y/TS\:E!2Z\3T44?C??\A;'SY[:.($9<F0B
M.+U,5_QT8&B3Z-,:A7'Y.AGWG9"4VU-XWN(]RX25Q9\I$ROKSZU/$J]O[XZF
M)71\10+=6(R7H=N=4?S1O@EU-.ER3YW'08ZYU"+VU)%QC2*.X:SO^'G616#U
MJU;Z6?PD&Q5G%=*]M-N+365 #:?8C^#Q--..IJH(A@V*H"6(C7F8X3I7IX8K
M2J/]LLXGQ_$QL 2?IYN7NJ^C5BR$;JF.*"$R9"RCG!E@8/FMO$Z_O%EWZ^#F
MMJHV!VY6@_$XL]Y[]6Z-1- L\@BBW$[?KCEW>ZSJ[Q%7-46]@E>8 U6"J\Y*
M#A\]H<1/7NUK@1W87?HG7_*7\=_ZIS&;CIB,7='3$O$_=:J6*L)WBGHTZ";L
MP7T][N-C]G%W-4Y9?3 ,\^ISFRNGBK:^"G#[(Y]%:39'A2A,56:_SQ)H>::V
M2.V=KAL\PM \C8][HZNQWGIZD;Q+NA>($=0X$JY"4O5!,LRG&YS+J>V0WXRR
MO!O<UTE*X7O+5WN?HVD+!(MPPVQX2C9@6-*F6V.J2.V?!.A1:OCYC*[^\IE$
M:^+AT7LO\8MI'42R)89?^!MKO*^_[:2NCYNN3Z[Q)Q',(1- T//Q^'?ZO9HY
M'O4:(JOJ^DL]X$#%L#>D:HLRB! DQ$W"C7T*+'Q'L=(4X]6[_01',&ITN_#C
MMQ=1)P87+?:6#3.:19(4L]PS#].=0PSBFZE$O>F^BTT]Y L[L4UF"R?1L930
MT,M4>[QW_C7K!%S'?G[H&DBO$59]190>C;N>:LU.54^2VQ #VXDJ1&..\N&;
M2"$T2*W;E%GB+3]/6J:3/C(]YIH XPY54UU62\\2#,,0,6:F5T24$+ZQ63@3
M?FPP4;$BE)\]X,3)X[$5;E?-NF%.$%P/+G;>V02L9UD+LYMD-6<V;X8E$"A;
MC2_9EA/B>>RW_!/L:1(0U8C/H_?FP#]8F!%RV?[\3C+(I-O^U6,\? L4VF;%
M;H?GZ3F;A-(#5CA%*PB271@_< Y\Z(FL0YP8_.7D"KEL=N-3E90!'%SW1,UP
M?;&, )Z)M1O. [5-?"U(D5[N>*W2>/IS-^3YL_6S:G9&ZV^M4X8 &@=G;=Q
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M\)"L9;MTYQ?+'/^ V>J&8:L#\:%L_M'4]45^N7%UNQN0#IS],>=[.T&?V['
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MY_G8V<#MG\SNI9R_9I9D0W24/PP9U5*,_YCS,)@O!(W]*B#C*X:PD^4<K9+
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MJF+.E,G7]475J^/#2[V-SS&'O7K2V(I6I-'YKK:J;DT\V^>"?:AN>!#FZC%
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MX5F]<<EK(R999+DF0\[S(8B2"-J+)XVA\>/P=E^#:[?(><OYY!M8NXF4CEO
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M(DZLH(]M1#=TB.25+>NWLQ";73[KN8LU8[GE&)]B$QQAT[I)&*YQ8"<)9L:
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M0UT)?/4W57]"D!)[0G"&_=4HQ;_B!"=HR=-GGA FX[N66_XF\:\PY?\OO1H
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MZ$59V]J+=XM%*KE!7TC@R4>KT@O>'K0*-$]]!5,&:H7AC"PFT]FW($-YF9I
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M!CB0K8=-J88D7IV&A_.#B4[2.RRV&J0LX]<,!<N!'>QEW!R^0N'VB!T4 V1
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MPCZLU$$X>?Z[2--$7!UA'@LU($NM./F5MEN<UC5@^-WPR(*QE"/V'GJV_H1
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M$S'TWRS=(/E)&&DE'8Q&P(],P8R\WZ.^['0QC@ YQ%0I-/<[+)_><J9QN*+
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M1VG3;3K=\)V,W]X=/ .^7U94^7#_26;JC40ZCMM5K ^=TC\'Q%F"6?]Z:V-
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M!7C5^P:?\*($M]U:7GZZZ^1%#/:\M[C\>=?H0W(L>[!ORYMQHP6&R:!O+&:
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MT\\$*2,F!0ZVR'@4DL,,.=8L^GTMX.=J5(\UJD +BN>0T3^9"T7?QM-E2\.
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M'FL9M#^Z<<C5-0H=U ;&0.IB8000O6TIK.6L'>AE@ D),=B?)JX.RYM*.?.
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MX. .VDXRW]Y6[)(22,#%FEE/GN*<1H UWTBG2D,@)LS,H/9E;"+)7SR8T2L
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MGLR\*N*.F=P- ]/=S_D1:(C_5N-Z4X;4<<BI6S_IOAZ9=\=U/ DU)PZU(_:
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MB+>+4IFV\D43OA?_$I#3<5F5X*>Q.9,6O<NCJ)75CR;_H!5R$GEF]G-^46K
M<3F;PS46@\5JH8_GW0P#D-QDGDWE<8=F3A656.MG/QT[2=*UKKQ&44N#QNP3
MT+5S%MNY4L,V<(&1=!KZI923<O:PCRF^5RK58,E^1"*.+4 X"8O94:IR=CK4
M:>'E,W)'GT:_=#,-)'/W&1Q2.OL;$M7N@Q03M)S)E<(T[%C:XHB2P'&4@)/4
M&QT0IVMK@*OD*=S'O.SX-K9F%_W'G<%!."UY"Y=0^DDJN1!%.%>6V8%^:RAN
M)'G;@T$JX>J!CGR@=$!A#OPVSSJ<6;U+:#Q1Z>Z8TI2$L7$U-]N-C'[S],5A
M=&"EIBVH$-7?9 7F5TE-\/)/ 0YWBSEUA.G^(D@65/G.U5P \_>T5<LI<A*#
M4:\#R)X^70-#W%F5X>N28UO'$1,KA6Y^M<Y.85-!CAX-/<:B;2+ON;@NZEY@
M@:RD?WN*KQ0G_LG[HCP>3BR0_@*N1662+M>=48JCO8[<]T1V0EKJQBKY=NNR
M6EWT[7M,&NX^A2FI"J]<-1_*1L/"6[<E,LZ7+3W/A1"A=*17P'':KP[6WK4'
M;;_GK8+3/P[Q>G$<PJ$NX%IU\(ZITTP+%XN6H1:B62[32FS5!^D997PO%^C4
MM$0,=A\1U+4,NT+H0@YW,L<.,-KM*'R0ZHO%W GLO96]Y6CAH4P<MYM?3$7T
M80'9MR8=.LDHDY>T):LA$);)C)*5=!_=M_UHV^BD84$EJ-UHJ/>JH1FHJ-Z4
M11E1R=%#THMQ)"7O;DML> .$U:3B%DO0$P]#5/$,KE2TVMR>*#;\:4P!WZ-L
M4TQJJ19;%8-E_JYANAARD;0('F:!0TE),;8B_(!+35<:UT/9^F:P8_'3SD4T
M#]EI=>X/_SZ^5HZ)=%8NJZZ;1>\L'))L(S1HF\L[5RL=%)KE(V\GP@G3&\0S
M_^?0LQ'%LF1?MO9XJF&377.EB8LL9,NS^K4$'?+->_3>)(-#>^89$-&(245]
M6T3SYS=H35PWQ5H'NZZV7$D+ZR8$?R#B;JL"Y:%$(]85['^#S.2)?V$-_S=(
MB/=J.]&?0=0E])I=YQHY+G-DBO48K</P6)U^.9/:>9/5HWMQ_^1Z?NT5$%_P
MN31LKD3/C5&FNT'XW+=1M95?9J_/X-*W<7KEL/9OA[[*9*OB5"NUG&C$^EIZ
M;[X"K(J=7&(G0CIW7P'6Q>US)KXOBK'"18P&N8[+E90OOQ[[7V84M_>ILC&\
MQE[F/KM5#;P"GC(IO>4U.L6V6G4DGW-OPY_+,H>GI(4I;].?JSI6U_2CM$'+
M%"24=QZV[M+^18Q:FH'K>S]/QND,WWD]MM>_9 DD%A@NDKEW+Y;^.W^1Q<,!
MU/LC%WDZD#<)E?N19'1PAWEJ9:D/#PH5JKO5&#+?R)/P*P"9;]PYXW:/;X+D
M/Q10.U&,XSO'Z\@^!JO_JRB0=:H?^0JXYY=X2*GT#!QT:@A_%#_%>U07B"^(
M^BIYRO.HKZ2P)A1UX."J+2U+BF11J"*(PJD[("@=!U'\:LXN/ABP%JFJOS_A
M(\CZ5FCE;L#A?R.Z_8=HV2O@OX&)),D!5NT#@CB69,\^$HC7. 1(@NAIW+HN
METU*-=X;UOTN;+&# !-]"7BF)]:>G+53+ *.&J@D%-.MI.DWQN8N1D\LT3,<
MHU/Q4VD:H3*6%?BTN5EEJ_,QHIA(+JQ/5BPIH%)_VO?G)R4DS5> @* X9Y][
M>2KA8=D+I*J0R7/$5ZV3%6'_[IF%OLFX6C?4MO*#9;*YON.,7">53F"5 8WY
MV^L;#GQ]/]FP%/>",?*?H%$Y1^CN)1/^YLCHME9UE7YJ7%%8P$R\LQ%[[SHM
M1=K6N52+MVY^1 LT&'M)LNB7RIO1W8TG-W-S8YODP:HCX/)(\U*@)BWZD!?U
M ):>)S^XMQBLR\)]&28NV4!=@/2@,S5U53'FBKB:33H[837*772X %VH^N.!
M$'L$G:DFU4_0(<=[]'U-Z DRH-6K83']GMHQ9F>%,2P2/,>/GR=XVG/;[>,'
M8[5C'WI05]0Q5:2@<8QRRZJ.\LV24'DLY[&55\ ?0)8'3O(K0.O34IGBE\B<
M'6W-)!P399L7?HHK+=_9\;_. ?_+K'3U]U(N3T?63H2S;T'/F97,S#.,7.J?
M-RP%(HFHKY43\=W.@")$5:_G[3=SMTTC/TI1!J'&LUA$#A",J)7Y)\]='Y61
M9D5:,TI5O;&#$J%W_<I=2K,:(H7:?R&:O\S\Q,N6<0&/H@5,IA5R2)>3232(
M>40-SBJ-& XD--ZA8B!C/1G)?ZA\!7"-%W1#:==? <5-+,#Y[FRFM=FFTW,;
M:*7__0WDV=;N%8 _!IJS?AJ!HH97J##[R6KU%MU_DO.'G2>L&-4]8-K%!]/H
M(WX1MS3S==D2'F1E-3EQ.#3<<::</# TH#9C7Q5'/=7VX-VBN?(C6D0VFJVG
MMH'7,QN,W:R(EY;Q=D]-&/1X+]!)$[,5D3P%L#'G83ODB^-^6UV?,C>LV92)
M=B[B];#G?Z,\]MAYLO(!;R7L^/HW\ZGK/F_7D:9]9<L<K:)$$1H+->KP+/\H
MF+O/'12?*5U#V-"V7][O4R3.'(I1$I:4T0[W9.;N0H#F[XV*4<&ACD49521+
M342:!K&*:UKV(=Z'Q$'D;,OI'8\76JJ&I.SX'&P;@O*89RHI)M>%=>E5M@/X
MHA3,"H&Z=D*H+GLT'%-+5B/Z7P6AFMFR+ *.M@TT*>$>UH@N[FA)(]BM].))
M:\J41H=S=+^:25"??)< VMQMO7:G<P@LQ"HA!(2>T\0#:23L107K[KMQ8LB8
MUMLK 3>P"5E7E,)47:.-HYB)MJD8F<-]-2\: 3GT,HPJW(U..K*$A_QA]!YO
MQ%ULW\A,=(TTRF/.V*;B9/9#![^&BRE7%(U OU6L#/?%98(S);$[YI56B$15
M.&>[;?G)-GUNKR?@C_+C=5>/IQR]YZO65-/_XTF?_@#VI<K"RTZCV#H<=J'R
MF&C+::>QUA&E5$79@C9YFP=KT26:5GS<2)$BFO0V%%BS%NG\\^RRE4U"X*'&
M#EN5IT7A8P6?N:H"PXB^JFVZBU, _>I^OHL*5ASP&J-"JJG,><A'V67/]4<E
MJ%A.0?%G\Q^O-B7%)5%JLX7=:R4?L,D8XG&S2<SSP8MB#B8IB:?W,4X-HZVU
MO,*$BV_D*ESU;DX=F<MXD+#1^D,<L]U7_YAUA^O[G?&?X31EGZ/CGB:5S#A2
MWM-8)654LAIAJ%+L5K._ERUI+F[7I,/:8 %W1O[4,O'.D4UD3YDDT<$!0\4(
M8RZM6)D*N)WH:7H"RI"E;^48YVZE4'J3ETCVTVD>[)ZDXOIK=Y8J9U,UD0ND
M2*5P5@P\Y1&JFU(B:22O#N&YJ KW,)+&K/.2=@^4*[B<@M/#51)RE.5.YVA:
M]4,P6P"/C;A?QO+N@8@] ->*9GS4O@TVDPDB3".9TH!')<>AYI*;:4<GXKLS
M2#)M7S/5E[/YM*/2>(J\S6*==EA<DE143Y521G.Y<K-;PJ@-,)+7E^4SFV6Q
M".&QW5ZG=DIATIAR71X2%@:QHR.=H]GT]A2/EJF:K*/4R6,>.<P,N^7E$HS4
M1)10S@4,?3ONBD<3:#;.S>>*9<_8T5> A[%PMO\)UKG.K^?%R35EUNS;*=^;
M2M?\NKWE$T@9?Q#QF%0?;2M=H3%)B#,W5I.Q9.XP)@B5'1G'[^<$%2K[EDDW
MNK638=HTQ)KW7-NQ6?"/T:QW,-\)[+L?553)60X'FJ->H'RC9*E1D2\5R%4F
MWP7"B$*HLL#76,_9JDR89ZMQB49U"G4-X2M^,G9FA^U ;ZMO#G2Z=K0+-LLP
MF-AQD=+@X=E916W24J6=0^-WR,#"!/>?B>HE<4BR"08CH%U&. IL"EDITAJY
MI.6/8R$;E%;!!/+C;AQ3,KT$GBZ::Y>@"8ILW.7N2&\4 HMZT)#37GW\Y=5L
MP:FGO07]6*Y1)G1[/!U_D<"4\S,5R) A\5"SACF [$A*@[<_Q'14=)R3:FAU
M5(_[1- B7.>)^-:,VT.KO\0(5V(U@F3&%)^=6G#@ .SV&:5)3['[ AS49&+^
M14/7(CYB(0C#1.'HYXH>^8]0BM^/I1"7LT6SOL,CQ9K949O1]_W&:,X& V@C
M0EC>UK^$G+:+7J:DK]AYV@MOK!+6%H$O072W+JMCG_^*V?(%43W@IZ],/7+Q
MW,1UYX8)K?#4JR[/U?I?1$NLZ5RAZ;6L+<J\!-'>NG2-*3P75/\VCG93.(+>
M<AU]><J?Y)GM?#O'\B>E2&YHYPIKO:HOB/$!/W]EVHM+:,P+7X3N2N&Z6O0:
M$OE<$/W;V-Y-[@CZ=R(&]M8& ZS8IW[2>;YH_=4_3A:OWN_UG#FOW_HND76O
MK?P9::N)'F7A7R(43NY-7@'7I=T-R<_OE4_V,],Z<JWM!O1Z0Y.'KI2W+G&%
M#<[3=;X%WBTW1+1N;/$06R"?/3XQ6>"/<ZY%;!';'U.C/?S182?[%3#[1Q3#
M*W;I]B)7J]+_CBC^.^2<*>]4GG]D=GFV(=+1E+F:@;[KJ1].#Z'8OSF'9YS)
M?9-!<-3:GLI0F\_Y+G<4)_0] "HEGQ^_XJW WX=A1B,U7H-*-$7*V2:$JKYZ
M;!*(X?>4JFK"OQ2&S"!NVV^VF[8RJ_'NMUBCCBR<KIH?N"KQ:L+SURR6 <L
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MH]@H$PUJ*3,FZK-8^M@ C->@V.^@;20B<?,8[;89GTFIH:_%=.3/K;F+KCN
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M@S/,:>FH#5XN.KD9%17YAT0B4OVN(1LSP7TES> 7VWM;ZUR.%J)=2TH2V$/
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M=O_D)^*<['HFRTRS6(A[VY&2?V!-0./;$_\ WN2XVN3M-*J-J=M:$O>Y2>N
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M2BZ;4QS]X/W9)/R3TQY[A<$/%7^.E#.K3)SM\8]<3%ZK,9?XU(DOGLU"KB>
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M!1"\\G=37WWH,<_5_\R2_GW>P,K>_S/B@07[<N+QW_U6_>]?^OK+/:SLU\2
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MV$Q)62,CE9N:#V>_?HIJL66HJBM@G%O%4RHG^9AM+74U1:0^LOI]5ZF&5'-
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MD?![UU2HG%&7E^/%'%O7J_5>.T&/0':@)*HJ9=\OW[(PK:+1I!B#9S$_#E[
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MVYMX'AZD#:2V80O2<9F0\\!!%YX!FWE*:$&*CB,.XCI91):#-91%G*A*Y[.
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M=S_SGRX>*:G_EG*A>^4S8>G_P]]XG)V#VL(ZY0BR<;X(G!D5U2NRD%?2\Q3
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M<- E(@>0IA>3V8:#]B^]8GZ.[G!U 9GTIF:S8@)SU3(?"'$@Q59%ZXLKWD^
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M-@'A8\>PCCQE P6>>R,%@4<GV[%P>_/]PRL;&.(%E^=/P8(\5^907LG++NF
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M1MW\U%JY6NBC-(LJO(,=ER#4<D#]MO=9X6.F/D&(@W8$U"H]223$2 "Q/%/
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MJ.C_;SG^W?E?4$L'"+F%&%[U^ $ ]W0" %!+ P04  @("  7ALY4
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M2TM(\(L("/_DJ'\Y^&_"<6R_M3:-3F(&HNK]$_<[.G@.*O]0.QKZ[3]Q3FD
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M)"PB*(3Z*\$O+"8C+B$C(@G^ U@4\%#O<@@75QEC-8T_U*%Z\BP__5(3*"H
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MB 2K0?V04"\O" (L+"0@+"#\%U_^A>-_VW@7YQ^V^_@CO$[RU<59$.(%\8;
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M81]KXU64?'@X/S:77JHJRD3X?N'<+@7$GG;/SI[/.4I.4YL_A'&_?_#]^[%
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MI$EYQOA4GIWG25D]E+2.R3%!,[AVV@2Z$^K+/7AXLTC&/#[?TY=89P^6=;G
M?:CU67M;4MHX:4;%0FFAU,.@ZKQWE+T)*UIK57#8-C1,/1M*QUB3UZKYM!B-
MUMJN@B]U8#876;%1#=$MI-5J:QA5[Q:93/./MUG>EDGL)*D4+]S(LM(IV.CC
M]\+54$VPW2 B<[QU05&G% $*+@(VB4K71Z7U+WM^S+R$Q4 [-_A&2HE,G"FR
M6G-:Z0$I2RLY[)8E(SRAL-=T5_),8-E-'K,^QE0NOYK]SU-]A1XMFJK]=GL0
M4W>["FJ-7",/Y-+]Q7NE$2R,!-(DO=FO/.8$-)\-FEZY0"_^K;S0KOUN-V/8
M"WMW?NH(N/J5M^L(("!-(%95D'T0;++SV(^YM85>K(5_-*))ZD.QC%PJBD.&
M?/?Q^3J[_2]6A >6$BJ'8E_,HV9I%5;(1&;.,PR$%=OM- %+DM*OQPAM=BO<
MZI(&TSZ(6Q,C4FN0(092U(D&1B$6MU\? 9GT(?;JU6J6DH$5GRI9';G\;UGH
M)YW/_0S%K?\";;Y&W%#B"B(3*3?2I, 5?N=,KNJ3^N3A)^,+X_=*,[4SA3D%
M7>>I1?AO&37X-]_C'U3H&6%S#<&MZ7$W[#48>5ZAVRO @J:$D]H%U?29^:"-
MIJ]/=N$=Y$: H;M$^TWQ'8Z;.TS8)%>O^K9U)7T2$)-L!1*7"[\RC[[:T>-]
MPT^XKSU ]_7F:A/8P3-E(;TJ/NQB *_;4VH<07GRPLG%6>O[)*\G7(WSN<@4
M.&2T."='OYAVSA>;7A'^W-$6K;90!MSC<X=S[CUO*TX<TVMXIJ+F_T0CH=Z
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MO0>O[IMQ9\K8C9!2&Y:3.L<B'CB XC_E77BT=2\_DS$BN9O6;OA*74'=FGQ
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M ,0&>XB2E:.;HZN5HQ,U%QL'@%]<3@$='8 D=H<&PIO I[0OOHHKG8]1 /]
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M]?D[QBOD^T^.TH7DUU^<'S;]S[\B5]9UQ-_1MNCY_+]_[D=N_']D%'#1YK2
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M02!E$.@Q?M,Y??CQ\4\(_VMIZ=>97L#,-Q2QF9EO]Y!OR/<+E0\$_PD#/:<
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M+F?VX?>YXKAA6#-#!Y=-GK??26YN4)P=SIY 0ROHN;-UYAL^.5VID,$YE5
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MNO+)D,:'WYV'JQ& ,>C2 1Q"N[8AZ0I;=3PI/P.;B$0J4+A"P&-9>^FG*0A
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M:;E?*^"UVFEEK*ZJ8K%#&,^!EGD;]F.)!R\CX11C<<D9(XA(<8  4NQ)("J
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M*$II9UDD^EXY4A],-+"S*),CDA7 1#!'),B!U_6*P4 ;@9-K; !@KMW;<Y/
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MXEK82J(C4\L65+0NN57<P=\,J3;E3L6,FPM]*IO! !DC # #'@8/!'U 'G/
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MW J\M%*]931I+$M-%3O%-$%#RE#^T YR^5/&/P/L,=4Y[ZX]UVK=ITV&8AF
M-A8KF;8EGA.45L=[Y<NNDRI5.^!8U8>Y@V]5-C'ARFC7VI""0P6"\G#9J(U%
M,E9+;9(7@KHJF2#TI&$FZ3<5A@*QA@LSR85G,A5&;Z]H4MU1I:<I-Z05BS.
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M]:C-)Z%3-B-8:Z.22$1@'Z5H_1D>1P"S1DX'TJO5>J98C/&8T:.';ZKU#ME
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M#F#")[W/1K4[N5WW]= :JS^OI*ILKJU4LEKDH_\ :#O:9VIV0%V 7+,^&+#
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M^IL%BJXP!^/'-&7$S:-#@.0=0-K7!L#;0QNXPC%C&48']KS: +LU@%CF$5)
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M7R>[W*Y7*G97W/-63EX6IED+F4&%8DC6)F?*8 R"2Q0)43322).%3:WZ@':
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M.6/49/#QAT(&49'B%O%O,<QZ;+K 6I8%S:A<-M8>#%/WFOF"!&:HC/C'D1_
MY+KMG<W1MSHZFIAO5)$M(D\M1!42)'4I%"SYE^7#.SJP0O&(PS,I0;0QV].O
M11/()T:)W51O8$ JHR"<9R!]).1SC[' Z O<$K4F>WN RL0VI4!6HJV"G0K?
M'\B!.E9$Z^EFD02&@U\VN%%$ 8(]?9I.D"L EC'4$17&&/5#N=K:'6EWBJ*1
M'2BH(YZ:FW;F:?,O%0%=4,<4T:K($91+&Y9'5AAS$KI:>;TUA?Z8T<9*MN=B
MQ.2< @8.%R2?LHZ]C'$?OBF,+^G^3U+]O_Z;&]8VZHO3A]'1TO1T=+T='7C^
M]2W((V+]5'E[DDFG@Y""EY.[!L'4]@U"09Y(M_)>,,IBM>PHFF:Q[Q$:\;U'
M[9&.;Y-5#9.0,C(QD#QG/)Q^.<\CSX//4F,[2K$!L8.#X/'4*<7]DYH[DBS+
MR9!:#R#+<8VM5WEG'E&C2),"\USDX),=SPN;X1 L8%0QVM04<4<# L8T3/%F
M15]+: -H*$?F&!/M@G'&,^V,^1T[&=TA+9.003X&,'S_  &.H+P_8>3X0RPC
M5<MDRCMHTR'=8S;C=88U<@G1G1I"SJHKD#\OQ5I 64?X]C&.,1X\H;QM7TLK
MN/(&1SD'GR>/(_#@D@#\\'Q6*YQD@C)!Y'(Y!!^_W'/ \X/4E6]_C.3MXXT^
M*#D@R#&:ZKQR] 0)FC'?FSLEE$D1"O5[#MDOGMD^8>Q!N<C"M\VIZ\P0'+<A
MB2/?C'C(QR!DYQ@XR/&>ED@^F5\@<Y&>=RD#'U#//_(>V:WWE]I4\D=YW5)(
M8 ]GF>P*26XD<9PR8-K(E5=L H2L5CDD-]U$>K4>PG8HU:1$<GB &-,XQM7C
M &",$#/X\^>!TIN&<^,EAC[ C!'/W]_QY\]2+4;2L,S=R/W%]/2DM(.B:3 Z
MR/ (Y8]?^U%YB6!26PW-&)P R:A]K[8?NH!'>!'$8WUX5QZ:'ZMS[B<><#=Y
M_,#/N"/P'7I);U&X&$"CSD \<'[#W!QR?Q!Z%;"LB?B^25D]\B9'JC%2KR,<
M%!ND3\7L42-D%6UA%0;VV%6Z1%5%<Q?(B*P@W-1[5D#G)R3_  &0,'Q[><>.
M/;P49VD?;." /(P>.B'TWG1<NY:XAD+@M%3V63NJJ^D;%&"NC8J&JG0J;'1U
M8W%BBA0X08@F16J9K9 D-[A#(IEDQU]?2/#4TU9405%(FVFFAFDC>G5F)9(F
M!&Q'+,6081MS;E(/2TED]8.KL"N OD;5PQV@> /P\>W4%:VS:/@^:KD5F*7*
M="KLT2H> 0Y1*W([NBEUE;;,%(()KB1)IF'>9"(8#F-D#1QA,:K$Q:4O)(Q>
M25S)([$EG+N78N<8)9B22?)STR&Q(6;)_;.3YW,#@D?CG)_PZ?..S3?U5-IP
MAJ_W8FV]:$&9%<A8\6WH<MC64=A6^+TCV1JZO68'O[9WQ([GM<\:=IE-=+E2
M0U%%2U]7345<H^=I(9WBAJC&1L,T2, ^T' W>1@'(Z6KN(757.PLI('']P\<
M\'D9XSGCIA;OS/'L]S.+D.- E!B.P[":F>Z5'6.4]W28W JK<Z"<8KW"?)C*
MT)WD5QQC0RM;Y^*0XP5&#@?4V .!@G\O/N ,9_$<]-R,&8$?\(SY\XY\_CQP
M2.,^^.K?.KBY%XD=%A.Z*J< *CNO?O\ _P 1N3NO95_BB_Z.Z*B=^R^E'^/(
M_=YQS]LC\??IE>6;\P/X?Y]5XTVR)6RM';/QJYJX([37VIL#@UUO%8X4FRK<
M=VE3ACEF,;^3WXU3>I7'*BJDH80/>B.8U&N+5U=/3S4<=5.E)5N&J*82-Z$K
M19>)GB.5+(P&Q@ R@D!MI.98F<Q/&#@;%##_ (@KY&<GV./'G/V&.AKQ7*\C
MPNU%=8O;3*6R8US'R(CU:V0$B*PD>8!S7 F1R-54?'DB*(GZ/8J)Z8P#D$<8
MX7/C/WYR/N?WGVZ95BIX.//C\?ODC(XYYQCSR3UDLFSB_P NAX[7W!@K!Q&E
M^@TD2*%8\6+#^269(.H&JX2S9THY#SI+&"645&*]JJS[)5<9(YR<\ ;O(_'(
MQ@ ><#VYY4S%E((QMX '  !!\9/G.>..IWVQF%[B5IHJ52R_I]Q0\<\'JTD+
M' =WQ[^%>23"<.2(HG>Y5W7M-<X:N&QZ.&K5:QR)4*?4SD9D8^> 1@#..1SY
M)QS^_IPY5D.>1&.3R.<GD'DCD\GC&.??J-!YM2)I>3K=U6]EXNR8F9AMQL$@
M"US<</3FA22^\ADD1S*(D1C /$HSR'.*Q[6HY6T;B2<_01SD@G)P??R//X@#
MSQUYE I'!.[<3P3XQ_B?8>>B0RG8</36S-,9I#I&VKI7&7&&V]7(.UK+"URZ
MDR6NE3I!#A/W85SX<J6-B-62)A (1GO.7U5KO?KOJ,TKWBN>LDH*=:"EEDQO
M6E@=I$1BH&\@NV7?+D!03](Z=>8L\;-M.(0.."V2268C&2<C+'DX . #TV1<
MI<STQ2R< XM9KD^ML-NVXC=9M=4=A;0+O.\QHH;#_4[!LH[A5E? G%EPX557
M18T<T)7@G$L &1OJCA"661L[P<HP8 IR"-I!!R" <YR#C!7'39;: (R0."6S
M]1./()Y'CQ_A[.SE5O?/MG8SQ:V+(G0Z>6S!;:;*;B]3#QFN)M#&<MFU60Y2
M6NJ11X+[BRA@HI$HS1-1?=*U@Q-DF:ZH5EUN=R;_ *RN%97F >G"U3/),T<)
M485&=L^/ISDG;P<A1A<T\\BQ[Y'8*&(!/AN-Q^Q_LYSG*YSX&8_SKD'007OR
M33=$S#,_V-AZ5>V,FAH8+X[I; 0[?'L6@#0%95Q[MU;&O;NUBQ"R3S)0PPY$
M902%+%0F+ 4L?U;(Q=@0'W,2T9&"H" * QW [SG&W:@RA>8P [H1(<C@G@[/
M89P,^_GQP>G+G.UTKKWB]DV>/GY)\G5A;79;ICC3I^3QLEL\FQA\NQ0DD3K&
M<3&(D832&,QTEXFD,5[R/>ZJ5^H+U=Z&DMU?<)ZNCMC.+?#*5VP!P"YR "Y/
M*JTFYD7"KA0!TY)4R.*=97W*J$G@9^KC+'&6; X)R?(SCJT3B@L;_P"CM]4%
M8J/;$=R[T8L-A5_>MCJ+$/C-(G=?SH!&([LKN[D=V5R)W]4T>/.3CGG/./W\
M?NQ^'4!L>H,>.<?ESU0QIO(*'%-HX+D>4OG QZGOHLJUD5J/6;&B^!@ND@8/
M]X]L=2M,0(T<0H&O$UKU>C50^2A ')' ).3]QS@_OY_+IV,A74DD 'DCSX/1
M$Z\V/DV4Z)Y,:6G99DMMA=?0X]M;"Z6?<64BMK[7"L\JJTQ8D&21XHXYN,Y1
M.=(CH,8U)& ]PT()O9MEVO'(JKN)*,<8SE2?X@KC/CSX!Z<7<RN"<KC<.><!
M@, ><>../PY/3OP?E+F?'K5E#$U%EHJS/=AXLM%GSJ[W)E0N 55_92*:@R.L
MF%+$EY+..:>&<10M%%QD\6)&$TT@TE[]+//1U<=5 QBF@99()  S12HP99$/
MD,A52K#P?(P>G4E:$HR'$@ PQ!8H%;( &,9SGD$8!X&2")ASSE]G6N]6<?\
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M1Q/)M97!CQVI-EAC_9C;"UEJ:=92W(XYY!7>3U8QC6T<* 6 Y\DGW/' \Y(
MX&/!QD<#J,6SD> J@#'@<$\#/D^3^/VXZ+.XW++H9W$;=5]#D9A&QO3>1X&*
M#..AFDR;$+G**4I3/DM>U3-A7^.39$GR=+*-H7>?N#'V\<O)O5Y'<@)&F]BY
M2%1E(UW$[8D((51A!S@8)RLR-F)V9GQ&4 )R0%&/[60!@^![>/;H8+;/:X>"
M45%B8K*AR(V4W.6YQ8Q5?$9860YK2X>R!-!*60Z+C\9\@L8) A6)8%?)&\I'
MM>-0+*6PV%9=HP?(&"0<<8R W/'&>#R&MX5 %X8L2V/?!R!D>0/;[_NZ?W*>
M\DVF6:UL@D(($_2>KKY# <\*2[RQH$;D-TYPW>3I]C;Q93Y\E%1Y)#2*[LO=
M/55N%_O-[BHH[O7SUZVV*6DH_F&W&*$R&0*3C+MR%#MN;8J)DA0.G*B>64QA
MW+!4&WQY/)8X\L?&X\X Y]S9M^&\,4G5ATVA3$)XZSY%*B%(]_97:/SE[E;[
MCG=G+V5SNRJKE3NOW^_JFKYS[8..,'D?E@^<?D3@GVB29V\Y\KC.?^(?XD?Q
MZJ-V_L F2VE#31:\54+7:Y#3QI,5_9UC/D9796TBY(YC&.')D.(!%57O<C@H
M]KT\D1 !5XVMO+,S-N.,?2% 7 V%/J+$')R <$<NLY(4>-H\^^>,G/L>//[_
M 'QT\>6%U/R/?F;6MK*E6$B3%PYOG-,224(VX5CSFQD<955@@/5Z,$U$8U7.
M7Q1RJJM)^SRQ.,Y)8G)W>23DY(]QDG[^>ERDF1B><;<YYS^S^!^_^/WQTR:W
M80J'6<W"L>J4J;W(;J1(RO+0O;\^UQQ@0CK\7AD:UIZVN20DB1;!$_VK571T
M.CF@1J^[<MEN<#&"?V?_ %OL2!]N1SX)/0'PI &,M]3 CP3X!\X\9\9_#'4W
M3+]E#QQX_EL $L!OW'L;(I8F.&"7-I\9'AT2MJOF$"9RQ8TJ1:DAL(PP(IYA
MB-&KOLDJ6XU\]/'035U7+0THWTM)+/))3T[N"&:*!G*1LPP,JO&3C +9?:20
MQ1(79D1F94SP,8P.3YR<Y/CVQSTUZW;&+FR[>FPI](6NR#/:/*@X+$BC62&@
MM<ML1@F/)+:\*@*"@//C-G,8_P!PA2L]IJ'_ "Q C?0"?# L?&=N>?!\GD9Q
M_<.FU89=CG+@[<#@9X_<<>_\/;K*0I\@_#C(ZY2&<.LY&XF0**YRLC1[/7V4
M$, ?W5!BD3*\4IPD\6..!IE:KV^2*,LO$/J.(3^N,.YO3]9<HDVS(7U CLNX
M#.UF!&..O<GTBN2%$BG']D,%.#CQG! 'D?AQU]X-N'%).[*?9>P:PD45+KX]
M'%?#^7.-)RJFPHE!CUQ*>)K9"GDR6"5Q!IXPRK'(JO&!SE;9"5*KSE@>0, ,
MPR./ ^WG(P>@,"X9O9"/&?J"X'/GG]P/OX)/=TGFN3AX]\L,!#<V;:%,$Q/-
MJZI;),^#6WL?9N%4%K;P ^7A#F3\>N9E3/D :-\N$9P3*J(G:7!75E&SK1U4
M],*M#357H2/$:B $2B.0J5++ZD:MC/L 3@MGR*62-)@CLFY=K8.,KN7@D'R2
M!X]P<YSS!X\^8;64[7%Y5)<(#(*V^Q"U,1GOXLUOO#R*MB/<QY_IU\%8RDAC
M(*,*7'28HG%55]1\#<&!P2"&QD D@%2<>_W\_GC/3;-].TC/C:<>/'X>_N ,
M>WGHE*[84*[=RXN,)L;N+CN7Z$QSY]<8DN,U+(%Y@%9-BRP..]DI*\R2X4>6
MODPL=[T C F\50-R>D <$N<X)&5*D\X\C&>/'L1YZ<+@F4J3AHQG\3C']V?Q
M^WN>@?IU\;FH_@C;. O\FIVEB5%[KV^W9/O_ #[?Q3T\3Q]R3@<<>_/\/OQD
M9\<]1NO;ZQ'LN*8PJ?HN/4O;^/V^FQOX^E]1^G#Z.CI>CHZ7HZ.O-=ZA'66W
M+J/FWRGUI4\6. .35N"[GSG'(.0YQQ3P_)<NMX]9:G ";D>02YK9-Q;R&L:Z
M;8':TD@JN(J-[HGKS('DX\XX)Y'M]^?;C\>1TZ$4@9)Y&?;[?E]\=.K3/4(Y
MB9YKJ1M&EXN=,NAG.++K,9JEXBXA"LLBG$J?ER:ZLEQ)K_WQ:V2V-)85X (^
MRBPWD(0Q!LK=_71NBZC2UGUGJ2:VZFUC3K7VJV4E :V@H+=-4+24-PU%<%</
M;J6OJRU-$\4-0\;1S2O&(:>=TN33^C-9:KI]6W#2NE[MJ&U: L<6H=;7.@EH
MXZ?3UKG,AAEE%3/#-65+04]56-0T,=15+14L\Y3Z45PPRKK=\C\6DM@V7#3I
MN0IPP&-)C&X<X5Y,1)20VHBK-:CWM,T["^VJC16+V>JHJ(]>]-UUBG%-71I%
M4K2)53(&W)L>H>G0Q28 F+.C%S'NC0!?UC,2!0&C&Q'1V*O&) P8X:-]NPK[
ML&!#<#&/?/1"Z3ZI7,7:E!D&88?P=Z==J/&8,RU!(K>)&"5LFO/7RANAS0FD
MV 1R3^8#K#APRDL3DCJ2.%4$Y[9?]5X:>RV2]7C46G-/1:FNQLFGH;Y<!0S7
MBX*Q7Y:C9T,3/(58*TKQ1*4422H9$R@&,2?+JE=4U(I:FODBM]%6W"2DMU'@
MU=SKUHH)_D;92AE-3<*H0TM."IFE0$$COE/7/Y*0;&?(M^'W3C-,-,N2R9<S
MB!A,B1,E1);@2Y!3%L?.25TU#*8WD]Q']W.?W[]J;=[!7V6=X*N#T]LE4B,S
MIB3Y*I:DJ&C_ &-RI-&5&U>0 1G!Z6\6/J5RRG<58.K!E&.00<-G.1@_4"".
M#GJ:]*]6OF/M]^4TV#\*.GA95P8:&NH<3B3@\"-,?!8.PJP2AR;,()I&2%:>
M$!Z/*^1V2(U3J-'.TVGRU#^DKG>-/Z<M[5<-NIZW4-SBM<55<:F..:"BI?7
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M>H_9^(>Y8.\T_JT=/7NB1^R)Q'Q#O^\C&,_NBV7W_,-J)]_M]_LOV]4?//\
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MKE >*61'3R$>0C94%SJ;;7T]11S-35$#AEG0*98BZE!+$Q4E)45BT4B@21R
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M2#N?)E2S&]Q_[QK&$<]Y'[U>*VYU,=35.[;!$K9DD9%"J(T5%=V5%10 BH%
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MHU5T4%%#N[R9;8#JC[PI;>MVI3S9T<L:'8/IV5PC">$L=L22-A8QV$8QZO\
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MV5V"Y11@@%G+5CO7J>Z:]^)S7NMJ6FI?T/JRCH+X6H9Z::"A%\M=MN5'2>I
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MN%85T>'"G59P/;\-&Q0&B,"H2L[>#O5(>:>>4R5$C2N0JAV))VHH55P>0J*
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MUD=0A5%:)/LUJY8TQVYH;]36F:HNU522WEYOE8HZ.*5?1IV$4DKO+/"3^LW
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MSTY3;N.>'&O:XM?8.A.E6!V1ICH,@P@3P(R7%]Y[HY1%3S4=(@J#.=R[G&"
MC*[84')W J%?( &6*XRN2M3+DE9!G&.1CSG., \_C]CCCQTT2<Z>E<%KT_P/
M6.*C"1!M1.6&]_%6F>]BKW^J?\A&)XHG]Y>_?[?=?!M/('N?!(.?P''D?;VQ
M^Y/ZP#]OP0/ \??\?'[P?/W[E1S=Z7-W/AU==T<:27/GE9&AQ(_*[>Y3R))9
M+XX0!&EIW<\KD:UK4^_=W;LB(B)Z<>#^'&3XX'@?X>_^'JB0X ?G'C:"<YP
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MYWBY2W#7!8QCG^"#3Q[N_P"0J_>;11VUUF^=_26Z/#H*"*"5%C! =YS-(A0
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MH;\V#9VTXA-_[K0\>+$M6UL1H(P[=[#'D!\#F1",8SNBL4B?=:'#V3GEJ:6
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M)!/6D4I*5E1R?]\0?8D;\X/\!^\9ZV\\$XZ0.5_"_7\:\:N(W60ZTQ>^/:5
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M8A5E/<Y@V,8K_7<1/('5_4#$LCKM4?2AC(YW%B"<A@, @AF#=-2Q@E<%MVT
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MXEH!<JI9GHZ6@W'-?75HIK7;Z:=I 42%ZNJ!F<?3Z)<DEL#JVK]IF]ZW&G-
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MH3,[JCE*T9V+(_5124*+NWQ^TO".KO(V78MN)8DG''OR?W\CQX'4.8D2LJY
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M!:%%9&F2VP2UMBL=K4G1%5)+'*K5]9GTU0Z;UG14FN;O:Z.IU=H7]+T]EO\
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M. N8N'(9D$G%@5P#5-&8J(.R6)5SQELH[#/?V&P$4;7I'$U)TVANU^G]:?\
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M6%%@<!F29>;+*79MA>BD@?9V%<UHPUXJB197DHXXPCJ*,"&?W7,&ZBLI=/\
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MO=0MO9$5_-CC^SLY4:GD_&Z9OW5>R-3NOW55^WW5>WZ>I>>"<X /G\OW??\
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ME>%X\='XN<PKGN5S7JI$:J_R7+6G- ]QM-6BXVJ@K=)RTEV61:LU8NLTS&6
MT\C*XV %TRQ)!RWU>^.J-55F)12O#N:"6.HW(RX+("RAF9\[3_:P03G'GIJ)
MI+H&/:SM7]1UK4=W$B91I=58KD3NYO;%E5C53Q<YRKW1&M_BU.UCS=C]7 1(
M+C8 (7!B$9KLQ,WTEU)@)4D!=S*!@*A)&Q2*O$E7.D;A(T5N4Y!*Y4'.0QP-
MO)88' YR!AW3\2Z$4_%Z_#I4'J+"JZDZ262V91IXDTKE85$:<S\>(KQM0RN:
MU@A^*HWQ5/%$6]:[07<RXZ<H--2W?3BT5%,LT50DEV-?*\8F5?6JI-^<-*S
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M(-SL3NY)STQ<Z^.FE@2JAJV]*>.0>E#O0. -HDPY9D <,Q"^>=W!'3-LM0=
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M_P"O/3_QW='X?K',%V'K:#C/4S+2[)3%@799>0:6/.AAPVY)D,*-4%;5,CQ
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MG*,W&2,GV]^K%.C=C_1WQOGF&#Q=@<U1[HJ].;P0@]N9/JJPPYF,NUY;_M:
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MK3H(B3'1 UXN.=4N[LE*"0V+H#D= ,8?E&;(L8NM<EJYDID(S13&));%&_\
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MD\4=UK]+G'FV5Q9 CD:92Q2"@PH\R"QBH<:E[O1PD55UISZ:8)#9) R>1QC
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M>Y%%;[;)VST#315\6ES5WFFCLNC;%#33U*S_ "E'\W7UB6ZIKUI*:G!2.>*
M&29'=JTN:;J;'MPI%QVXJ\JA'D8]$M),+WR5[LC!1U0;A8C56&=5KYK)?E+$
MCA!DN4!@JJ?NNQ';F+4^G>Q/;*@U1:UH;W#9ZJF:U>N*IX*5;A73V&64TTS
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MHUZOUYTSJ2V6==56+M[:[A<;7506^:\Q]L:FU6Z6&L"?+[+E.E9<*&%Y \U
MYJ44JL@CZ.%R:N'EN.2KJ,*95  C0-R_"Y@$GQC$0(2QDD,\T*545&#;W\WN
M<GBC6KY?E[^M9;K'+-;JV.%Y(Y'IY K1#,H&,L(P 3O9 RI@$[B, GCKKQW,
MI=25O;S7%)HZIDI-5U&E;[%IVIA"&:*\-;J@4!A$F$]8U&Q8BQ"K(RL2 ,B#
M=E:ZM[[DS/K[O+*$T#.,VM;V+F*3)%O31Z,EG)E#2>X;'R0/@QD#!/&>-&A\
M@N&KHSFN]=?M'=^NTEE[%QZKTM#=SI;05NL.E9[#2VB6DO5!5_)4U/1TT=%5
M"D6=70/4?.0,R5+15+1F2H5H^OF6M'8SOM'3VWMU4]LK]:^YEZTU<;];-.7R
M:AMEPU!3TD,\MTN=%/+5-3S5,L\=5)Z,DL=;+.P1X(WE7,Z9M8P;?+LCLJS[
MUTNVF%@KX^"+$]U6@5K/MX-4;6JQG9$8Q6M1$[=O7(\32U#2U,PD$M5/454@
MF?U)@]5/)4$3."=\H,F)&R=SACDYSU])?8K1]S[?=F.UFA[VE/'>=*:"TO8;
MK'2L'ITN-MM%+35B0N H=%J(Y%W@8<@L.#U!VZ'S:BIU[7R8S8H\AR >31CG
M UACPJ<[ZB,8!W+YI"?+EV#7M5J,*6*Q[7.]KOZWJ^"^QT\EL[P:U!5Y;?89
M])P2I.'$#RT$M\N<3P1@O')B"T,9"RDH2B*2&(Y3?TD^N+;J_NEH#M;02M<9
M]$T)N=]MRQ/) +GK*LMM)04C<8FJ'M5'-ZD46XI%6JCX>10)+>YSWO>]>[W.
M<YRK^JN<JJY?^=55?6BB@*JJHPJJ H^P P!_#KM5!#%3PPT\$:Q0011PPQ(-
MJ111($CC1?[*HBJJCV  Z;W(.(:3I[59ZX;31:[*<U/D:QWH0D&5.^C1*B3/
M$QSB1A2(X"1P&>P87O1C$<I'L\M\?@)N=NBNW=ZT5-9#'=JU]&U=NHI"(YZF
MVT5'>%K):7<J_,1TU55 U"QM(T#2HSA58'KA!_2+T-]@^)ZPWRYVZX0:<J.W
M-HL.GKQ-!*+757&&X7:XW2W4E4/U!JXA4Q3RP,ZS,I9U5DC9ESG7Y8P^O.D4
M,R=V&X-86)Z=U5JL+,J6$17(J*GY'+]T3O\ =?OV]5K77_[X:HQQ_P!=W/\
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M>W1TYC81-)3Q0F*-5^N-) "02W7S@VZ-*6V4%.D;0I34=)&D3'U'C"0H#&Q
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M^(DAK127 D*^Y<4?FL<-420-4(-JIF+X=-.WG5?>G0PT^[J-,7RFU+J"OIY
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M<VM76K*6:3';,$Y8E+)K:2<.TAU4B(ZN\T, ;)))#D<Y@.[W4]1GC<IA5#$
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M?7H4 L1@%B">/L,??W^_GD_N7\PQ ! .T8&3[?Y]/7-?PHV2Y/8P+&MYRV%
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M^#BV-)GS)O\ 76PA/E2I,E!NU9?.1J2"D(C5_P HD[JSS_5.R=T1>W9.WK%
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MM]HM5/-6VZWT%M2AJZ2FK)?0JI%J9I3,J.S,H$<OIQJ[N4*)A@JJ [)7;Q$
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MQA#_ (T@,A&)JJZ8CG">U?OVOU:J^VU1IW3NB.7[HOYO4):J0>H2Q!;)7:J
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MDZ#?F<^'T6*B&$#$;+)0@"HQ&M/+0H4W1B))2E^LN H^G\O#&U)EPL1E@YX
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M*,;3;I_B*):<)-.R,JS+8&*T)J5H-,,5"P6V:(WX$IP/CIL@1/5#!.@(N$J
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MT1%+4S8R9W$2]51%AS<)HHJ_(E4T^ 'C;"+!I92DYCM P5462#:7H.*@C-&
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M8+:GA'@XX:HK=:O%KT39%BAP%(-6S =$&NY;:7YJ$FQZ<P22\V$F9BGGP@[
M8D1 4SFV#Q55&9UB86-5  X%_<9D+5_6+"?9,T$%=).LYK]^N];:.PVU2HM@
M(":[(3+"9SQ!KB#:,T8 <H,^U5LLZD-64TP$ZAJYD K Y7(70T0P9='Q2A=B
MZ?K4RMA@T1RP09D*BR(ABY)R@*R:JJ4;^>WWW*7V<8>$ C'0G:Z$"B40L=E2
M(E>/6JM@:U>D&'! -EU90U, :/2 $--P91%4')I/Z&,)Q:JZ39HK4P"'MLJ4
M.Y@V$[$F$""3=H_67F?=!E>S2K7:"C!NM@;2KJA.'TC21KY*N77.E!XC4(H6
M#!F34K7")![(1C&$PTUL":9-HHFW(W9<-MH\((FC5#&?3UJB.;&5#S%6,<-D
M-%-/.)P*!U@PGO=8@SD$ 8WQRC[_S5J%C-&IY*PF)J4Y*>=NH&<*9=(*$!0<
M8!6)VT"U54;+4DE30 '$6,RK>*@B5R *Q4PJZP:UNEC'->>%??K0/M&U*+8U
MHABPN>*64L5J=X!:%&NM=%Y+@DV"K?LPDHUH0<PD/7$-L1D3)&IS"SH/X@8L
M:-VK*UE-(567<LL^P,3!(<51+P4,,&]!8PTT6I= 51_OBI0\HFB6"C08)2U:
MNN)(A]-8\$6U<A#-Q,0HHBW6Y)4N-7C-)(Q=9MK/:].-/*%6+%LEL.I122,?
MSE@L,;#!* XDXTU&(TU&+5DD8VDX>@2LVG[/J;2?4T>]A1Q U9C,0UY-L>$8
M)J1T2A)$_&(\7H2S9HJ*1'&S-1K6RJP_XR_2&3)CS#&B)0!6/*!;JVK&!F=-
MIFJY%L'2?LXQ67*[<J)HPTU9)"Y65%*K=W(H ,M@36>P9K/E+,8&(W2%PK*$
MUY_4(1[(8:;U*((2<(+RHJVZC.6K:,BD5TDUC(H6/9! -$-0>;<+)[1 =&6E
MIK$(+=2ESE 7-&DH7Q$70I9FL0K1,:OJ,V5:5G:77$D9BA@PC:%<K)0$\Z)6
M'AVNAC$: 9\)^ PQ6-"%@;#L]Q).?:E)4'%VR2_LE[\%YW0F$(I8JW5WRFH4
M5+"6;P 2!<^#G+L!J'G8P&=A)9:P9]U6HX*W8MT+,@XX[;99HF#%FW%8JK"I
MGFYA&RRHD@:L[(7-()RF?"#BJ?HT#O D!L%Z1I?A"-9=<P@)+%NR@AH]Q,MX
M_3I#LW#%#&DP%0%"1HXK-7AI^6$C59:"UF##!]W-JE]R@UBHD29#4"5B@YC.
M3,240)35,&.HB1F##@,'IJ* VYB#ZD4+0VA9J!5Z9-P&B:#)(JMP 31E*V04
M$AA3A@L?Q-F^DDH:--=R.S-Y*Y1(FE,9F-?P2!AJN4U#6XA74Z+6,WMX,^*
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M,[6!:4M62X3LOCZA9?,FP9;A92SFQ#E;+85%18M+$&0]EH<C1;.OQD-"VA:
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MVQ4ZD#G$;=H'=%MU^=!HUPFD,T!00D$U&]-BO&@@ZY!H+8&8& QH0+>K 4%
MB-Y?]UNQO*_X*UIZJ_GV^\W^73[$[FM8R L&RJEX(]\U84E%:W\!#3/Q8!=F
M:A+L!$[N4G ?9LJZ?Y=Y.DL_[FYE'M(6LFBB:K'GP[W%4JL_JM0S+1VVFB19
M\]_]35+79JZA3&-:UK%9<WBS^-<)GYL2+'R48@20]"!Y&Y^)Y LB9$.2A:K8
MTJ&7I^-B$4<*A /=WX<XHD+0F(V&])K[";S) .CX),16&G!'9O.Q&ICF".(
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MSA03:I1 R79[0,\S?*OQ(;Q%;SEE4'QL/AAR^%(H)I5J)9XVP%*8BM,ICU'
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M>]NZ^>><%]IT\@V7C+SAA>()!NKE=8O.O.2L[O<5GWSS@ZF$ESGJ=+V=NJ,
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M[2\M]%ZY_)I74N?-[%C6:\%RJ!R^QG/* VL*B>VO;GKPQH?>?-*[\@)E:G2
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MM439#99NLG5M=KV0B:7504<-&IV^9^4[)2R$^K*[U"7E2;#,M3&QL[S%!-#
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ME26:-5#A5%3J^Y29VQKW9(_S90H9EF_.0?R3&;G$@Z_S7C9Z+G[WJZ=$I*3
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MA)(6%MA0;P\N@_'S*/+E1LRI;?RI:Z@1$5_MBC6!7SYS"O]8@GZTX+\PM$O
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MZH3G<6,R[4?;"Q2$9B,K;6J9EOE@-71]-F'6]+<A%ICB\Y#&V_CG(J<GN/5
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M-3R*%$CK,2O!D<=,>D'<,P8U'JX#3_S2W@)I7FR'DUYT-3L"NH!JKV:Q-45
M1YU&55SB<*4Y-Z4*DY:RQF-;')E-^9FZ.VT/QV.Q?*O)3'!%9[6A_#0EG7GE
MWG1LQDO;&JK8RZ93R^C+]_I%2 HQ^UB_V!Q="GJV)O<0OP+:(==K@-K<S[#
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M%SQ-F?0C*[-91PU8LO)M>-WUGMKNAM^AP4GE%[<(A8@QXO6V%]-Y"1S+#\-
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M\9BZ?<"E_G7YH6HQP9WY9PAE.><Z5LL-21#I3X2^:D]_@%!=ES]H^>E6U'I
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MJCZ[<+.G]Z.SUR@ %@^5/_+.5,*(94,1YB(;),44"!-73IU(8A&+EI"((FO
M8:)2$V2?K8K\(UB)-3!R*::IA]C=^8V' ,*5E0L 5LZ@FX/?F5-U)J/;KN/J
MX3/;Y,MLT&"51VA/B(GACL]NH+J\\\0.][8O&!0<-.-2'DX_^UKUG1(BHTSX
M\QG] 0V^;8Q7^<^?79[XU'1A^^T<=XKJ< [O+9J*)6[U+[X2'$!-A^556[/V
ML@]G"^M*CC>2\UK$)W=%-Y\4JA!7S;RE421EOO(*M42J;B'R3U_YB6!MIHK:
M'G=DE"C;5;GLU)--%L.^ D)C:! /<(:,44X(\E\?:^J>N,\L^CMR2U)_+P2?
MAL;5*Z_@Z=:!MV3>HBODBR1AU6W-C'EZTR'W'@D,CW+#6#F&FT;;?R+0E<<P
M])7U;B^[L_4U#"F 3Y!%(^$<O:M 0VQ$&5(469TQ%S51@>+6;_LYU+F%6R1\
MGP7C'PF'F8WDPO.=VCTR*:*&2M&A2%[^W!CX;1#VX"RQ[&H;KMKT\8V32TII
M\OM==#\5S-RZQ11T7.++^ND:STT*MFPLZ7'JKYXO;9]BGB=-K!B#F9Q9WOM]
ME'._TMUX94/^2=2MVJ/LR^<%K\LJJT!#U*\2MP#G;6ZTD<A!XCE;5,9#D>IE
M,O]]@A#1^6;V<_)/*@WUQQSIQN(\DV,'G&^,?$IX#0%[WII4PZ%:==)/]^(P
M99'8DYGY20ONB:)D.^0(AP@A_X#H4C8W6!4T"MKUTGU5<[I7SU,%07O;R^;+
MCJO^,.MUD5!B<10Y9G"^H^./)U-^5E.<@0%GFWPK(40*M]1MU'7#7:&1](ST
MS!-/P&Y+X)ZWE+^,,HBI U1J'OM)@]$.RA2_RUI=<6I9F,EYEU[\*[)]EVSB
M0D1FPRC52B1HY&6J(H8MUT'L\\.4WTI*_](+:J-'!!WAJF*OK5&('@,T-(V@
MYM5 A!R7;W$O%7.$I,Z1$8(W.ZR-K+.B,B^$/KBGC:C7U"X?C6;1#HTWI?>Q
M?=UKJ8K^0B/V$8A"_;QA:EECBEPFWY$'@$EXSHHNCWQRKD,"DI?G_8P]<8QA
M(:S8#)A<?FX"9.2**AGMJ(AH228S[QK3-UW:#D6],H>/RP18#A\=1@A(86/E
MYM;XWD9_/_V.X(_)6/,%:94]8'5!K'IE6AM0:",Y9;2X]?#NS=80>T@ZF]^G
MC3XU?'='OUV#^.IT1E'?-3H49958MWR5M,\KT.8%#EM*:@OXHMB9 7\S<QRT
M8_5QNKY*N[PH?NVVV?RN]69Z)0W%C5DZ'X]VP*XN&[V0Y.S;]H5QIQKZ7U<D
M(;KX3W3'+;N/UB"C=$V>L'KM<Z_%!CG$J+[+8N..9954:&3$Y\5 ,*^#TT/1
M+6LKHRYYY655!W+(^;R2GW%#M\ <PP()7M[, 8S=+U7IW*'<JQ9EA@R-WHU#
MII:(KT?[S5-]'3_;O%.&"=EJL'/05<J+RP^PF:*TAUWNQCGC$?)GQB^\?;OV
MEN'-$%R:8M$>"N,^A[IGSP)&;Q=@\U-I>@E; B0"_)<C;FQ#K&TO6D&QJ2U(
MWOZF/)_S8\.,W0XQ>*PX69IC&/&G[]6W=HB0;>"+ W*^6<3K<-<5FWALGW2%
M*%_FF=.YF*JB(=5Z.*'CBV\?*QA+V#G8^FQ7'[XM=X(F[A3 T-K;F?0@3.+,
MJI\((&\< #MH.(8%:? JP)C]S86B(&T%2]U$?)#87$JU?'Q%,7419IWAW"!L
MI("&M!8WRUI$*F&?#)6#V,4ES;G(:P&5#2\J,TS]O8%+4I)2E#-ZSZY F03U
MD/-@1*=QLL'*"(.5@8W>RB:?U"I*M='@(M/GV(6Q1N%RXH>GNSD*?T.U/<J;
M89BQC#OB<E5OP=5@:Z9J@$- P5 J1X6[!E:7*/U0M BHF#S958SNLAB/:2ER
MK70<\(%HQ"V Z;6X8X<2[6 #9H.[^T1)-92:N=HV[YX9K*J83N%H.CA$Q!!$
M[(;#0P5KU,2XS<@O>UQ,YG['_XV"]4F!9;PY:],R"_N+ZUWN5XVXKW.4\K06
MG0\UP CLNY*HCQKO]2AO9L/YWJ"$7B!ZIJ9T]$Z9&P,TRB[UP(DGG)?.ZG@A
M>$H0IU7D:&J6K$5@14B^_3./8)5DG=   2#*@H+Y0WQIO20Y.,1TKPE6Q>[X
M]M<4Z$F$GG,HYICYL@V&VI-053=L8:\?MKO$MZNSB["UT@UOUVB13=)6<1&+
M%Q&UW:=;M+(B8S_E9CB.];'!_CZ"G"]Q=T&-21%7P=E\1S;NY/6K?P=='/.L
MB,1ZM F%"GJ.+D=ZZZHJIX?T+CG/U(T^&+QYMJ0RVWQD5P"@KP9E8.'*=8/S
M0"NRQU&7'S^\)<.*0V4).\.6OU#O\D!YHQ/FQM#%ID#\FJL6$GU112_4X3#$
MV$5'C.0M@WFEO[VP\YHXE!*L#I#_IL[.HPHHXH$W](-1G,E2G-:Y P.V%Q:6
MAYVWMS_M "??Q D(1C=]H.RI&F*9GNPM3*N#Z?)3%Y(T?>-T.7^W*7!R^QWN
MR3Y95-=SSFV4R1U XN[8V]PX=&9@%>Y,OCXD:9B1H$\MY%5'$&^ XP1\E=.S
MME2"\BC$D*Y(^7 ?F7;W_]L]2/.MZW9= AN-@%K^"CPCM==GZ3G.@(,91_E\
M<]/=O S^/F9WZV1794T'*_IW/#4/2H%:RT7!1F8"1NU&(XML.79A9[28'2P(
MN<6.9ZYDZ&2=505HF1FB4G2*::/-50MX1L;F%^G,0?N6.8$E.1@I/Z(ZFG$+
MX_ VQH4!3HA[+,]S7_*ZQ56R,CF4=C,&=H/'Y\!B71PU'D6][.W]5J.N4#)(
MMMXI99F=OLWJD@K>5[^"Z;N@7EQ748@@<ZP'"-4\]V>I[PWC:2X*0=^KM]&=
M0*"5WKNQQ%[L7?TA\@[?P98D2IXF2"%NI@Z7%\![$>KD6DVI6MPNXSPRK!!%
M=R#G*C<0=9M"W2]M+=2KY!'#]QD<E%XM\-:^YE@K[ZNSZPIY,YS&$9'M976J
M3Z?G6ECR3D)P_,LG%+@OD5/@:>S%-2/C!AZ[Z0V[3ZGY2^4?><N5E6$%U2L=
M0JQZ,@F2W^LOOR_VIK.K/^5 R4%3?![68THIY+92A@^:Y^0[,%"1.XDHK 4[
M]5&PB?3&L>*@^1BKHC(P36P,"KW\/BU]KNJW!0H)O::F72%0*FD'^!M6D,\:
M?BOQ1;K1XA)#$P]@6F!=YJB=E!<2[48<X.4Y.4,=9B=S5,53-ME(2])*<.)+
MEH6UW!]^C"]JO)[1TQ5L7]]'WY<N\*T2T+.K9ANIK%LQIJ^<&4@$(*500D_.
MB76W53VPXHKXZ^L)L/K3Q:$%=>WD10'*0W/A!Y)7[98"!C?<FDI-/H2SVU:Z
MBR#^+ULW!-'CNM]711[' RU3]8J.:EP<>UN;\-53=8F+9,P-E8WP31!%K>_S
M7D'>Y,;L-O(;4(O84&KFJK@2HNGA3^_%!L]+E5EM'\;*<B?R5<L/"^,.B.+$
MZR_>!DMGA.:&>VD]>\IVB5 ":B8().?C>?%H'/O5M?*VLP_V7ELD.CO:N+A9
M;W%HJ><P):&@$HY$6RH'&1<"?C^8Z&4UD   'SP\4?2HK2G*/U++HH&+N_IF
M$N\'LD>U( K_U#@O:AD[4QY=):_>G;JZ@'BDG4SOZZ+N:*&9TVKY$NBV=9GG
M57VM))WWHU33$M NC8P:.<9$;V$V3,%4+$PRU.M%](RY0 >"38"CD"N2?E$R
M (M=G=K'*IV)_U3!#IV,4@QDH*NCN^/$^%7-)O:Y*K&XT:5#6*#DXDEG(#*B
MB\W1IB=]Y;[.>.PQ]/L(A#Y)P!YR(4:ZUP?JHA43]NE:V.1CV+ZU79W.,$A8
MB 2JI44BS9&J^?)(I[QH  8]<QC 6$)&0,#=COJ RN>&R L\K?FJ9>.U-"=.
M$CMOZUT_1C2HCL5-9[(X)!+NR\$ZR&RHVEFQ&7XU9WU(>(GJAL$6$:6/-K!B
MTGS^S/%ER%9-C1??._*"MOA..6/UJ>$34/U L/G1?.KV5FSO<9M8NKN5]8S\
M?A,10M@<*&]J>LW0VN/1,6S!='4%R_\MB%'"Y/F ,9H=_(-^2_BGA-CRLSEG
MOV%=\=R&?!N T$*;)_+I'<6R1V-MNUIKGY&+CA*CGH'@RVJ+C^FF.EG3]-(R
M"DH4?*WYHA6?#]F2?TPV.7Q,\!A%&W=*7Y:$?6JH%]C&)N&I89R=@DD=.&["
M*8\;.$XXU"W<>I<(M^.&N:(RA]BBCIU/5Y>,UN5O-L"IH.:9O;I><2,XJ9<<
M"@FQ 8JFT9N%S/Z65OWYG3OZNO:J]*\5$9U&3.HB].'T_"G%JO+!W]J6.#X.
MAS6^.'>J6\$[*R.$RN-)F=9P%S@YNTBS&F1AV$J'M@[75@W2)O/:8;<V  2;
M910]@JV71;IMO,(5S:D>;4*Z$*$\RIJ;7ESJ]3V:(:O?M_K8+"VCILWU.^^>
M&F1%-.FJ8#\6V2SS+ZY1QC(M2,,WM&LDLJW2R.18TUD.C3P(F;#(-D;F0SW8
MLVKT,?'572C+=84W@=YZ='[J>\^H^UOTEB@%^20$*U:>E$50V"CI",E%G7,L
MN!4O*YE9$$A(8MVL[-[43R?9H#%>!PM]LWENKL6@%^QF^'N!@^7,O['=ILTM
M&'M[PZ?9B<B0_!/=B/V'9O.I)>E%=GE'E6A9UX@!2E4^8;RMM-E/AYM)4_U5
MR >,<T[ER#N 9R&6A1CI1&^\5)FO@V3Y#QLQ\5]KG=)8L^"%SG,C0"B_\5SU
MAN!,NWOR7$NFK?4U#PAA' TL@[ 01A*0)B]LMYM.+(;F\#6;;(0-,,Q0TDJI
M?=-^I$WQ\28()24+QS)<A775$M?/JE,VXSYW+,%XVWP@5U$*&X+JBS-I8")J
M&2NX896 D.79Y,T'>Q*_)HCXU3A3GZUZN,M86X,1>9=..1?7K&[N2P:1HPVW
M@?J7B[F>5'$TJ///8@UBF;WXD"-5>>6HE+:02 >1XDYV>MGQQH=@ H6()Q4K
M)MV%9=5#AQ>K7FWQD(. ^-)RPX]TJ,WW2OB:SDAD=$>#]>0Z2C2LC,UV>;F,
MPM "FML5ED:]IJJREA40YV"-D/-&**#^:(DF1#2%GH2G2PI2!R:[73*GM2X=
M0QIB7RC$<MB_701D%00>>_D[5!SC0VJ=+XZ^%QM[K@49OVO&RV6D<Y;[A8<]
MB=L#U*!IFFDR87WE44H\58@3=_!;54(<N,+5F$:DK3EWVDQDIBI+A/19EU'$
M !T?(V$].V4:<U/_M731%VL!IC5@S]11<#U[2+BUUN@^,]6!@(L#CP/;JA7E
MRKAT-M7(B+TO%C.AN901^!5=.+/N)_F^V232J004),G;*L0>S#<8E#P\59+-
M@SW[!-8" 1BJX0=BC;U#3:,CD:NQ!Y??=_)6RYWEAU>$G?6)J.A@N*%=6>/R
M7C%)!8UTU:\9U8/ FC C*:DDW=W&;/LPG9W&&RNM.1.][;G"7!-](@=M=!KW
M/F1_$?DR1P?:9#[0]%P36S8 -0H[9$6$WI%D1:VSUY8T5N+Y0'T(TM"'_E!(
M='Q;C6:]WR/R:?#01B+/EH?.EL&R@3Z.Z8"4)?=6I+4]^V?W8&9G\4^GX@<C
M;^U3-TE'6BT:M;6>91'(&=K*J0U;%535UW*7TX/9F7?JV2$A5)-OK/.\XN^W
M 5Z=%B[0@9P8)]M)I_F):5@&P@!S_5D+N1LG=D7%B\;V)18$.\0TZTU '(.'
M9M5D",H.=SQ]*/'_:^ZKFMI@&&9QA^($=TU"L>)0W*%8("%X<"O!K7TH[AZ*
ME^(2+#@4B@:"%HH'*-X6:Z&%0FF?]WO/#_BNSKDX,WN_,[LS>[4[*Y;GK:P!
M^=_J"_^_@='QX'7NJSAW[ '#,W5S,&G!3_HT03H!.!0;'>_&/ZP$M<XJYLA,
M7#+89/L.:5XL;(V0"[%RW0B!II?,4 +YW!%O!,:P'P=T#"'+W78=53*G;;JZ
M 0/B+DLF=RWRR=(#&;1YAAG:21!<DCXS;2/JIB5QUFSCZ_9ZCR>H6"RWOU5?
MTEU7:^&+0G9*QE,O69I/3R? DC(2&4TISN+H#E?@.0Z;DEZ+!-,^$4-=#O6Y
M=B^M$5C<Y !\#QA 13KQ:3:&U5%J-$MK%@K:LII/5+Y6G*+B.FXR_7 2U18+
M,=DVDO7N>K6YH3^*Y ON*K*1JK(L^?HKJ];=2[8Z,ZRK+ATNK:$2'[L7@P73
MQ$J!H1!KVR:)JIU>##1?%CQ_(#G.FV4O<O8D.]AX44$.^'<P@-W*UC85 ;A4
M&&3=(%K;L?>?_P^!W7FB]#DH):6K71[4,,M*P+ZQ+8KCB]#L;FOKV/G\9G1[
M741WAQ:+>RS6Z869J^?:FH7_+N\9FO%")IN=XJ0SAX?>XX(,KF;MRG+LPWQW
M-N2YAU4?[-(I)=@8+EG5&0-4[ 54[Z_\[RC45?KMS60Y#R+.(H.4YIM&>XV^
M(2ILN*AR'"K ?9SUV9:J?/IC38[\F=7H$8, A1AY6[5M><+==3:0T.:Z'M?]
M6<[@KN!=SFC'E*O?2&O0_&1HW9D-N#R)U\7UB>LZ6Y$L41XU5X2J1Z=4BN;I
MU3@(1(!M3.Q%OV\R+'WFI6^ID:SFB[PZ8Z/NQ*_W%U\>;1\HW.F&>HB;9E/X
ML?MHOK!VU+!@CG H>OT$HI]E@-,,@/R]H^&*WU=N0(?JQZSIFCH_40P^Z1]\
M"7;EGNJ!3+ RC:G_..8"KNW@OUV8TKKA@QVR7,<\>G7M#/,LLWP)L71$'^#>
MG*9/TC_15#+F3FQ2^-I]*15\',653-N ;7"9W.&4^CS]LS&D$ZSJ-9&F&V ]
M'^,S 6-(#8D./EF,!G\B3DORLRP$Z2[UI%Y&F7QUAPKJK%2TS*!XYA)F]3[/
MF-SJSM4F!3X=WFV(V>9F>L?EN'__IW0R[=NEOBFBUU9%CXP3=?Q@BTPZ9(X(
M6CT,B;B ,63:]MT_>L'P4LP_!/5$X0.73AQ9(^FLGG4?BPB0)HHGCU+,)DET
MNNO&#.UJC;X!1X%:"]WUA4P3(<5A.M:A^6+H)35U%M,471Z:.UZCKMRA,U*M
M55E;F*=^70-FUM/'F[$Y")W2T"^.JAAT?VB>6!.US?G(^A(1W!^Z[V25#L]T
ME4LUGS[KZ0^B0O]T\<3/\K=I3,ODSK5YQQ\[IVKG%ENE,65#VWV)/"<R@M_4
M!HL^^(KXY@^#"Y 0XR'H#ED(<F*O_"J+W%/LY\^U]DFK(I;AVN7$*'<1-AC#
MZU%;!-X7GN?.K-!= /@[6\Q<(._B]N*8WG/3C"[FYO9"]+A,\XJ[^S[L,PSJ
M&LGCGFF*>$/=4X!+P2%L@5=^8W,:,*6?<M";PJ<T*P@;V[C"PN*8?N]B4@B*
M:3DPNQ'$$KGUQ['T+IBI0G8BZU^V/L$#^6A/)SXV]BJL> _SO;KBEKTU+C!R
MO*[HL_P,$)0%^D>H?SCA3O/<$Z>MYG9@JX=7,3)?/'2DN=VZ\/_KH=$E !>^
MM'A'X,SYWI\^+/>3Q46=OW^BH/35L8!)W4#>2(D(&:]K;J&[XD;R*4$>$0+\
M%U!.TG"#:/:!F:Q)NUC; M%G2@XE>*/^3CQBS%%:+/#N(-5KA[/&=O,+KE!7
M[ZAU +CSW*_D]Z\Y^.1+^.0QS^$>O]O)UF)"P4LZ?_QA[52K*3'7G"Q<693R
M=0L=#7W/NDD6 ZE4F>4A9SP%NJO^?2^G4%S/M>N7=/F7C]GJ%1[.>.W;8A03
M1\)]@U(E\OF&\ T!,B;_D!-*T]TT:(W%>[*VCWUNJGW;V]3*$A0S7;_U&N5$
MF=LC2,[!@4%6+#JSWU^%W487=_+:!8@I)@C\CI6Y+2(;+[%SQ9(Z>%L56@P^
MJAL8[1FX^,GZRZ%LK334.[+ 4V,5*JSCD/..<;GO--4MOX8@ZV7,?PAZ_::Q
M_^LD^O\2IVO=J4L(.^R/X/XG#(W+T:AOX4(Z9@'!99\?9RY ("=-S94J_P^(
MJ-@&^^N.#FSQGO"$Y/A"GG]>_YXI,:E=GQ<9QFT,PPNEON35XI@K*Q5K]@=$
MJYYMS:;IA%MQ;E5:ENP^!FJ@>\-\XX\J[;+_R84<&EH6_5PM;KC!SX9W52I7
M6,HDHV"*B<EVNH?710VN068PN3EEUA&5D:9;SJ].9,(][$\\'I5NEP\J47?8
M/V=T US(ZPBO0.O<"U&DRT?%+&I\B"2Z1\$D=;2!?B1S;^=MSNAG4I()#8,D
MY=I'O#=>JJ0<A]? +G9V$0:_<)G9,.Z_9EM'*C5S;"(E- F=7QX[I1_:B!I]
M!4[3?I<G N)4K<Y20!29[UE9(M GJ;G[L)!U!W]!H@FQ^*GT(>Y:_^^PG44'
MYS^CWN :DJ!]&JAO2FS5 D@CD7FCQ*%H+R9H0;*Y\:R3\DL/7JY+E+=M=J9*
M8,;>M:)> D@R.'XJ$YAT%B3^W,>-#+36BE5PLEB];2##<#!;85,L-5J@2>?Q
MJ,_LZI_F,]R*AOX%.\!=36""'5?1"\2ZK66I7R;I?IX!HV:6T55-C_DHV#L^
MVV69F]L9"NI?\%G01&>86$:5&*NFL\TF-(FD4%.CIWVV !TC?AE;*IF?_8.]
M$7/@ZXG<NZRG2)Q^6R<CM:(>X:WE;0_]!Q'?EP(9E>]']W'R#_R3C4%SP?Q=
M.4!7))P&53O9-TC\RO4X[8\O>*#275KFFR:)@Q[LHIM])4BLVI#).;22WJ\^
M;40_;HU&EFJZ-;L2!_PJ8TR\SLN:S@48^A?7PTA-O/6G#!X-^/;XN\E$DPUB
M;RM'+&X-]?*)#T<\'\]6%KB#*TF?-GL/G^SGGJ3KE.7R78]5CHN]472QH,.S
MJ:L#-][0Y*RQOZZ@EUS K>\S4V^#YGOF%AZF1=XNR2_LL7*1=+QKI?C8B9WT
M;VBFAI:>"Q&E8?:EB-8=?_"W/2ZK,A'ZC5U+]@!17]3A%'$R?R$AX0TP%>"Q
M>7&\??J.7)@.[W6E?>TJ35/T+E"KA=QTJ&W;Q[+473LZ9VW</I2[(0^08ETX
M@B.-Q=DJ65 SQ!I%DC/? CH>&IWR_/]> )&BCM19\&KD8*S+NZK]@=)_,B>O
MG4?G#^0&-XCMJX0J<I=<C[(=[)AA( ^.ZPU2KW&%O&QP[^)7S^9>K &^)@D>
M>9ULN2(_UJ/;Z7/T9/5R0&"7QB/@JUC:PX.Y1GTGY=6B?>3S."P?0=7\H3Y]
M81YVXT7O]K)A?8"U^Q (Z3RGR@'2IYGZ130EX"+D\7T%:L.0[N:"LMO""]*I
M]M6S$G(S38!R!"(?LQ2X?MH\@.Z0%K/NVQ\($H:[H=Q<;5?K+D\V_5\&H.JL
M'/-=2!<DS(X(N;IO7[V28\V(.-'\2#%*_\B[#+8?M\[BR<I?5@1^4N[.:J^#
M.-2RW>L]>EV6'/RLV %V5+EL;IJV&,?"<O/J5MHR6UXW11YH6/WN+)%(+?V*
M'/:\\*-+LOFNCHUVX67/$UC>.^42>]LN_X5_RO=Q%NPVD7(3VT=,F@D+;JB?
M%MR>4N[)T6!A76\133,209F#7JHQS-P@DPI@'NPYZ4NIK*),@1PTVHX]_=%^
M>N875;YTE"$!BFLO.WB;8&N?:7T40MZ]Z%H;'O%*UME>8^ES_VH6@3I_B:4=
M1-N;\O-6NIZNU.N[!^_2W$-A;MUHY.9YTVQ?(#T*Y%\_(%!Q:F<L.);T;E!*
MO/P3&RJDGW[A#27.==2S:EO)MTWD9N ,-"XXJ9#L*^]8INJF*/-Z&-/WIU-5
M,=AS;F+*"3#7@$'LLX,%8A\-7 7#"=D\W_2R5P*Z;5CB';'>P.Q'H9(690%U
MD*[0OIIN$L=Q3H2LV%25NXT^80+BA%!<01:::?*[^GPD[9]C1/8P8QVGOX)&
M00OV^Y^XG30Z(>IFSP4%!=$MOY>O_IZ]MGT;EGRLB'JW7TB4G\VF-7JY]R[0
MG0;SZCM36@[8C49H5!9D<(WY$PY(W-2X*\^9FAO\8=Q>//*V3K:L7(@)H?2B
M(/;7JX4$5_XO#BO).8F,9% >AKO9\;KZMHY2@FV-[&G2$72'!&-Q8GC2LV=]
M78/)+S1]V+5/K#ZNC<3ZFX7R(QPW(1LZIQV"SGFF/EQF1(J\C-^/BI-V+%R+
M;(RV:#I5T&.7F+("NYD4H!\X3/TP"E&5E&5\XC[FI@7YO9WQ:Q/A7__JA_VZ
M>/D[BS4-U1Y5LU;IO !N,\/>>\UNQ>'PG/VBFUO0#''58/M43]#[B-2W+V"1
MJNS4U^)75]>1$R42!F(IYLV^@'\BBU?[*#L%/WW8VQH<6AZ3;J99P PJM([[
M""2<IMW)%)2J-8R@6QL6)4:KAC'45G[Z1 AW6C.1CF]?)AU41?LH^<PD]M"=
MN--@56I1HL @^YEL1HFWR*KXF5GL#[0H(1OG*X]9Y>]!6L\5'K'16;6ZUDWL
M"$WEX1L(VW*27TD]33,Q$ 02#4W\L$=^Y"Q>=2.#CV?J6Z7M[)W>=%;+[/GE
MI.%G\Y,0?N(^2)GGY^?-1WZY),M5(.G8=-=MW<-^LRT/?#D=?YD-Q+D;XPB#
M0-=7AK>P>:HQ?N5^#34M ^WU77J09[*>C-2.>-(<LO4!TG\0!2/B2S'.A[]R
MG[%NN?[J=R^W"4TZE!^=Y=9 +MH6>U8=%.W?"+_.(>!<5ZW*R9@B43U(;GK,
MZZ:/-Z*:7G(D^60X*2+Z DR<,!$<<09*'6EJNZ1(9W,N,M/OAS$H%HIG.Z;-
M51C#B:9Q9/XN4P?=][125,ZZ.+?OT9%\!+T'4C'/@J[_J("P66QL=?VL);W*
MS.\B?#1-3=]T[(QKX]SZ<1IRH@/5O-.%U-"F30U.<B(5N+1UL6<LA8,"&Q2"
M#L2:\;ZQM$-%Z0FQ@!OD0(KGHX6<06**(WG4.<Q<A3:K^-KT(PVE(ZS,A\F7
M2%FZ E90"F4]\8$@[_96QLDBZ]2U<]6D]#V&8Y K@9"_'M=<T?LA 8)\TN,Y
MS*8>Q2XB4[4$E!QO:V_FBW7)Z7=AIG)YQ 'X:_-)&W6B2.;M%$%JRKV@G;GZ
MGE;J]L.&,Y_GYQ/K. 6Y$NVK0)^Y+_./''MO?C0<XFU2:C3E1JRC_/^$/1N
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M-$6;&V&;+H.U>A86'X_EM>U6=@_[5]F%A'4S;C7ZJ2D/WN:$<)%,/6+P8,/
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M=RLFZ9(P3,\4P.4*41^WEI0B7I!KMZ4+-5&CC,^:&5/DP7(8&9$GQ?N&?6;
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M ^]_-O\'4$L'"%.A[9KEZP  52\! %!+ P04  @("  7ALY4
M    $0   &<S,S(U,#AG,S-I,30N:G!G[+P'6!-=TS<>FO1>5 0ITI$N77H/
MU1 ZJ)0  9) "/VF"J(@T@((B+2$C@A":(*"-$%$NE*4(B(@H-*4^@6\]>[O
M][SO\[S?]?]?%[-D=\_,F?G-F3-[]FQA#UX=3 'H@-IZV@ " D*" ((  .!@
M^:RGB2L"A?!V17AR2HF* ^34]0R)B0%X.@MN]G/ZK0@P8B.P!A"=X=5A(P0
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M)@6_&66X^8J'(L-.VD>^9@\$6[=9@RTB4CH]!T5[C.X/Y$RF2O>>YI(6=OZ
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M142TA$!6^O"Z\?/%-O:\U#)T!/%U5[U!3^LXB(,?+7:>:[(LG;(F?V+2MW0
MN+A_&85U&T#_"TL*%@C4!GO-)V<C!H$6&?7P3-]7^5T5MCXE,(98RMIY(6DK
MV),;_=81-GK!&UR\HR<CJUJ9"K.M@*SJ0]5Q6IQE88EU]\Z5T\BWF[R7W5:"
MN27:+Z?.OT5_W-2I&(1U?*@6%+VMZVS6)YHLW1%VKDK#DZ7U , (%^%A9Z%@
ML3'A<ERE_;JS?V\#H,8@Q6$\(NP5M&2*D;G2Z'O%5Z2+W%)*Z-: X"BO @4Y
MT7NG&&J0G19,QE,WUC!80VZ9M(O0@"+H !#B5F9U)MSE"GK>G26EW;#<].6B
M8W/1[>FOH"0F"Y9\\JF)1:>A><HHD]MM:*9IPVNYQ%>'U(AU)15OW7Y;'H26
MBSX!\EZ-)R::2@@XO;FSR%0>^'^][S;E&"P[^B7^\+; NP/ DP, $59("PH\
M7")5Z,^6Q6L%\\.==S0+)*SJ%JC[EQN%TJ4XSO%]>2246'3AY*+@AK5-]9CM
M3?TR<'Y5M0H?M?S7C^4T"FGT"?XVVL8WI/<4@5Y #5DQC'+UM%HD<)*<AXX%
MPY/+$T&(OGN6>O5I@\E(32:UO)L =&O@K FG\#/CYU-Z<L 831(ZWV1QAP=7
MZV3=]MZ4%A37[63Y#%<(M\ZE[FD76I7J(]7W]$3+UU@H*;P,3*&)L>%%%[J@
M;FP"SV WEKEP ]+#A@LC@3:"E96U\+'7D;S4N%=C7)S4/>*4MTL(;&)21$!@
MIXS%S* S=O+7/WXL'\?50KC(H-48>TX^/4)PU8DY$<UBS22]<N+P9W(<WA72
MDK1N[V ;)^Q>/YZ\.(Y"\9DY5#X^HT=#[ E,G2W8S2D&"JI:[\FP M\FY%Q;
M># >RTF\]O[;T/B'C/$76>6UF+?%3@F)L7XR$<:[:'40#3@/\-R,YL&,=;^/
M"UO8&&HG3Z]5C[J$D8<.> M RK/%YUVP)%:@6!BR7,JR\'KIS=F1C9-5?M:(
MK#L3;I&D0A=NI)#.B*8A7X]ZZ':!%U*5/FL&=$-:6$[9%/O$P%2U[]X1#A=+
MJ1:!*.C7&MK9!#_6'RK?[REZE?(MQ!UJXI66@62>FQA7("I3 )5CBH6^F;NG
MK<.N[(GXB30_>32X^DJF=E/+AJC7Z)W<6,[U%9$)@@YVSH]7U,F+ @)1'$,%
MGY9#5FS9K7U, R:WEN'MCV9LSI@^2':S\:YDLKA<*T0U\.'+!V1Z8&VPE(QU
M)KQPQ[]-:K:ASKB&BX)F<0\Q$R=LU%")4/^TE_)0Q%:\$+&A66@RS"X80"%*
M&F/C/)1__2G9-UU*"HK2C8J8\ZBE6.UU&,VSZ^-U$/='0V<,-S'3-+D0M3D/
M^$0AXMD<#U,12524P0S4"U4Z9#0%8HC1,; 9]1=XI_&-.K])2(]FCS?T_+8K
MA+SK]"6-<&&@Y_W/\[ECHQ>$?=I?U&"JKJ5@QW?4./487OL )?@D&HRH440-
M'=<CM-Z48KG(><II)\=?2* 1/.FW:!?/Q=0JN6.I>V[6G8S8DHSR]5@.[ !G
MB$B^*GO9RSH?;1U( 78""Z18+H2<U^8V7-5'2/9\L0L0=*^4&)IM9BB%7=Y0
M2(E[J57X(O;D,B50[QNX;PP$9(KB Y<7:,\1>B;6F^,\^LOLQ$QK0KNJS:<+
M&^%TZDD,!8^&;@A^.0!L$J#?9=_AE:S?@"'NK:[8T<)+MN+6;+-EW3S<C :M
MD#/R0K<$UF/-84#-=R#SMAJ@/O ^N%!38PDE-@=]D%<]^R#WJ1?H]4!96>\7
MK8>7(7NS:18#Z.*T^P"J-+JQ9$&->U;^7$$QX,4O>7E8VPM[,@.OKBBDTIUM
MKK>I?8(5@HZGQB?-=JE1$- 4"UL2WQ'F,X@2S3%\TS2UWI@U:==EI:Y(9]NT
M8K:)<2'7,S-((*W28?OZ2?,2=N$AD7%EA-,!8*:R[\H!(%NNI,71\4Y5S2DI
MW&0B3_8!@-UEQ[?"O5^G[6$)/+,A(_^RG\STF[1L_86B]IHMBHX&. 76E\2(
M9\&CO<@NM51:C]%0--\YUSTC75S#T,PN9H-]8(;ER\SK7<.I+)7+U0&Q-OJ*
MPDM!6HJN.S++,CM;=P+.-^ &DJPLSQH-1S#4(#29GK4]TINFM//*S(5!H:X;
M-25QI67C,H.U)V]& YD*!I)P.6?\;9-F;L*!ABYK>B5JY8.<YH))=[(,2C1B
M+Q4:Q<Q<CI,A?K7<'2VJ6,0K*L6G6/YH8"#(?&P@MX5U;IC7L!Q6EQ1]QCK3
MBX*82808J\<9IJ9'3/_RQGVX-=/84!0&ZPI*J"Y23\(D,271$M.IL9/=?WK9
MO?>?IML_I]V@"&WC<*QP[Z3THEF3:LEH*2,]89I6+'>^LON3$_DZD6/W?(;]
MILX#$AC0$5B!R,(4:@$E2?_57JT=H[;,INR'M?P!@O&Z!8KG1WQ7W4K(#@ 3
MYI/R8LP@4=9U<2_+!C</F>%+A4("U@(<XC<2\ZO7C!3JX-:RZ%,@-<",=Q>;
MXXVEF](?8!3D5N^=J#2-IQ/O9<4%-K4NVCC)1-0P3#Y&6*)*JJO%)P)-O0KZ
M[KWTN;)N+U(DTF5K= !HC=@^3<,K?YK-G;/_XKD9$6C4FP6<Z 0N"5..9$ _
MD5H33KYS\7:_97/M+ ?-!W=35NP7$;,H38&-SLDD"6*B)&_F:4$E;U0?<H7]
M<0UXN<7T9%:O98IJKGJF9NG@[+#09WOR5=-S0YAV./_S7THTPKD^V7()J(&J
M2& '@/!=G8+7)?M?GM3"P_S8IX%$PX+9&B].!!D^UOZ:/+7G M+.+%QTK6LP
M.6/"H"I)3OH^P8E6E8;*HK)Y\Y[=6;LKWK[!5.-!:(H2:6M;\Z=@D1=P8?U+
MN9-#[YAT?'])O>F6;@LA*S)UHJM:JQS9$6IC.&$T6<B6OBNINFV.$'H"JJ5*
M##MA9,S8M_JF9&3T+;CWR4.HGRUQ>?Q=)XE+!75 3+_;2[U8<-YS-7(0GZD+
MUX=5$IF(1Z1T3(-QY9<7F4$,#Q[-7G24)PXX?:KK].P+N=T7Z'+KOSVE5U=\
M*MTSW;V-+OI<R[_?Y#<1NJ?\]@!0Q1?:"03?_#Y#LG^\P&$8F/FIH\G- .M&
MYQ?M9!>L"]@VJ _2BC'WGF)^!GO\&/GDDT^Z/_EGV$P0:8',M[# I#OQ92.&
MTZ2/XGS[7T<DO#N5S"M!Q$U^)_NI=%ST4TKLYO;LXW>P-MCD^'(S2[L"->A=
MK'F=P!>QU^+\3AW. P_LBC3*;&F*R?CLU,C@\7K =/""MN8=SSG$ZIFO#8-/
MG^,687>;&^O4P=>M><]? !+6VMD2ETF2FXQ-"(XJ\' RQVW,9)\:<Y4I4XCU
M$UOE@ E1R=:+2#(E^$U>9,B9>)Y+KN?E=@\@?!JR?*4E+:^')9M9%E+K#6^'
MH O?"Z6E](.CZ;=42=S@41YZ>8,V[N?(X>K. N<(C,JM+O7['0#H=_5]:UA$
M3P^.\<_!7U_O#HLXUQL@*J?W#HU^U@70@HZOWCS+VVB]&_WJ 53SJ>]SF3SB
M.VE7]&\S3D0D7@1(F-9Z*-@MC$.R-9M*7Y<W5KJ1J7F8N<JTBTI#=07)N;H'
M$R=+&B<2&"I #HW7O=\ML3P>J0DV@ U)"_=4>\\U><YDMB3NCTR](<]N?.Y;
M9GT L!V1%C<-+;:;R$G_,AD *<8/D>^24N=?<Y>^*4]QJU#RG=@<3O$8A>]T
M/]:M*5=T3E.H]YI((]'FY;ZIGC=X3E$TWZS4C+_AN5"P,I5Y5J*H;:&-_763
M6C9K$_(AT-BD]1F8D$VLB;ZKJA!HI(P8>XZGY"I!^DP3EY!U4B1/L3Z7(%"-
M5_,NX(0>'Z>Y0I/Y 4"7M' TQ[;1JG\X8&E_-X3ME:,OQO1*P2O?F3/ 0<E\
M]XQ20[U&M\1\['QNEX'<.DN,S;UT,\OE^T*;A5$AK)>OU,7V.N6]Z:VEJZCD
M5;.0!7FFH'\IOV# VU+W2"V,D<O1V=_XB=$56^YY"VMK^ZHTD@BS^IU$XK :
MGF48N8G1.D]Q.T]B#3=80J?$YZRPV?:>^D(<J)2[&)PI[8<_)RZV;?$JU]XK
M,C.5;WU7;WK6INIM N])-M%[[T2>8"MR2")$,M2MQR)E(G,%@/;5D5A!<EU=
M$D$B\LA$@G/C_I3715Z>42?RD"$RY,6$H:L3R0DJT+R"NHKJ?NI 33WF 'AL
M,TMFX;"?OLS[_>5[4U;K0+,6[S=TL)W ;P4C17%ZN"(S9E5I_^$2E%O))*BT
M;&1:[B;ZSDT1-;AJIJ"1H/MH"-?7J +7L?$QG_;2+7)8K$^]MQ-N(GI"31AJ
M4&?3I9-:K)_$5)7TBM/H=.DO:H.H.+- ;]S]B:I4*\NZAR"F:KD/0B)R3YM-
MB/F8!3W+4F "DVM"M/ 7D\(PL>WW;X!-9<*;6@V+N>;"9Q"6V5=PF<6XV7(@
M5J>\&SN07J1"EBN0L2$MF2NY/<ID +[SQ<9==+ B9-)Y>!$F^O'IE BN(D-#
MEJ2*0#\&*BIGDO(EH2J%GD)P#&2686E'N:2],HCP<8M.KL=5G-$0BSPE:)U)
M::7]L=6,0I# A##*U"U*\GP,,N?Z&4W4 VL-PUQ!]3-D9$ Z=!A#0@*A*MM5
M@I+W$R!;RB0PF)PGG4\M*4#)Y;%U*864W-WTV_E*YW9?N#!GT+8D^RUEUKR\
M_::C[BY2RP;JGK*783L?--00)?1<2WX'.B=BN0JV<:C4QM8]*JU?#(H!H:O*
MO1%M<?+E*NU^V!O4;M0/BXD)SEJO1#QZ]V36>[EABIVATG;T,Z6QN_%GI2D7
MZC=<C7O9G^PZ#@ 7O(;;1+SNO&6,:< ] +9"_^F- (^&,-WY\+OAB?.GNK;V
M?,C9U]I\LLNU:1TSMM,8\L.?[<GMQ*]V9O<I7/\83JK25U&!5:]9&A9,\ S9
M5U$)G2O2W?7'PAJ"3'2?;#W;!##H[CXACM-.8=U:#[5\!X-/B  -A%?VK^VX
M*3RFB@UY'<LWD\X\?5?P9OR3&T^7&33*ZS *%&#M'#5Q'3U^#M50QF^CR0VF
MU9Z0RS<C5$"T Z6+-H(P$DQ"ZDMT=61D867U+=YJ ( Z,BPR\<D+(^DY;;KI
M^3FPLX(#^9VN>*O$WJ#(\K9T3GKB-3[)P'=)QK75(V(' (8ZFI<*:](D=:8T
M#UV6FZ"I07?U[=\[&6.[1"&7$Z]X&]Z:K9[O4E9X.DVZKQ-A2T90F^B-3"F1
MQ"P#P^XZ9D]+=W.P#HAL1-\U 8U]L?:,?,?O&:&[(17^_$9&T9[*^K#%FY5B
MD:"J=%.'>%)'Q)C1_- ;BYQWZ6Y9FN*.(%-ZH!#5D$H@6\);5X^J!+T7I-DW
M E]DVT^SO H-2F.]&1 +&C,[,\8C9_Z0BXM;G*?E7#HIY5>QG,G%9ID@<#47
M2X;;:=_YYYQ,WV[PDI,E*J)I3YV2%'<_)U=LNER7EX0M=N/)=0I6+89N/[R+
M01<"WH7I=OMT1ZIQWCA'RME7=CNDGHUUA:E<7UWO'#0I$7"*^-:[[+Y=DS."
M7AY9ZQ-+=O!*AO2 E\O+7>'LHYD.4F:>A<L[Z>\M00EC5#72P. W+1/87+A8
M/9"X1)K;NG0@PM,--277N2<C(_$M9"U\D[0#7>Y<HTMZHI!HXUO7JWWE^_CI
MVUZM#L?7<L6SG?..5_=5MYL#AGC\..*$=9:W1:5VK#/D6RBRF#CZ.)K7B@8B
M'FNH?&T2#WDX$UH_BQ5P7Y<X -P"=;[*B%15P5^GJTQCA8'WA2B\,GK%LCEV
M6OE5?@G9 9HG(FUVM\P7!'?\P/:WXA_OX=#E?/.U:BWE Z$'  @I?KX'!7Z%
M9WJ>=:\._Y9QEX[T?6AH]J>!E$^3OD]FM]LU^#\*O93:I0K'"H@V7EW;L\\C
MV)*VY-B?!9JGV*5VD.T_>-E'FFA>..6U$N*X4XTUZ2W/H@CYBLA_Z:R9T9E[
M-=Z<+957)B5&,\<$^V!F(.46,DEMJP-=_/V0$AIZ?(8]N6AU_JE%L2)?4I3B
M)>R B-(3".XU.-J, [X:BUPM3<U4707V:V"&[E+J6A$(=3.1LSZ[R&ESEJ\?
M].4I3/&7'@HK3N)OG=TGC'W.$W0$2(=\ZFAWWS:%GY>)KF"]6G:'7*RT&WAS
M'13I)ZXP0CKN-[@1KY9.. V7MBN]375]D<H\WU:ZRX=LF&^$S> 5<MKH]KH5
MM9P4^X<57 $H=:!?5744]!CB$"7 E2TND#6W(??9VX\+Z@/4TSLUQOB %LU#
ML5"Q;B=!?,V#366HE@VTVZJ7PK0R3DJT$D7&[9G1R#*QJZ[P?.R&>/%FGTEC
MM&BF ?1\1Y3_<-SN2WM204@G0M."MR[QJQKXWOJUR/)S<8ZR(=2?>K_<]-.M
MAKE+6KA=<RV^,:'\PMKH0SHOG_&;9/.>;-*OSA\YI+0?JL<+V9^8U)R5?*8F
M=#>9YVXRO[283/+LTE!3?;V-C\>J4FRM1<$;V]J:"@^[DV!6U)+1AWR0\+ _
MNGCXJUZA<;+VG66N8FW,.G]1I<V=";]3FM>9JAO>2)?M"O9?3PL.PMI=E@IP
MAR^WBIC/7('85Z>H*9N@F.F(H\G9PN,S:4>;3R]00T<M,FS28+8/!K)8>E 7
M!R*T 90>#<!AP-/(FPE4IWN6*8 #*9@Y(2 XZ2)3$2'M5H1T3O"2%ECU:\1R
M]>34!_?2K(<%O.W#%:)9?H%QNC#,5MV&_1)K]3)O9.$SVB'KF.ZP[1B6G.RB
M"&'4:/O]?$>DPZE'M:@^)X4D?](<E9Q>LU<-IYIJ_/=&WD*!!X O++(<.<E7
M4JDS+^>+ANLG]=AG7+NASF)EG=D*>NN4;<>)OOT9'>IT;\8,'<6ST9$9 -V4
M84$G;,?8Z_$1 K[58F;?)Q#,EW4(YY\7+==ZZ*XJ$&QC;UBN>P:<Q&*>H+E"
M\<TW<>*6EIW+].M^)<JRIHF<2[+\ON?W[HYUN)FPEQO6"U<6;=FMD3,RW,2-
M3+1GC#YKLKR3.GF]!+-UYJ:AZ.Y3^D7D&;HTM9D^!EO7;9MXJX4MV5H*C^OH
MGLN.5.QU@1\P)+S5U[BXB"M6,#B:]:>7ARHN[$GT-"HI+&Y A(%,/5JNB+FP
MM2D.\0LI5]&8E2X2>9-GB-FF!EF$UAZ%!TTO:F \R*4ZK7R.%.*^)B*;5=B3
M_PIMHP #QD$'7)X&T&K'HDI2=Z2?+7@AA3QG]6_RSJMX &TR3*=?XH9VKVSV
M.E'6MIB-:4R+\OJ1M&'DJL\S)4U$O.3DK6($,&'BC*<B>E=OAKPN(?#\<G(S
M?)Y'(&#NB2Q:&("[RJGZ.BP+PR?A,+ZX9F2:QT4!!*5F$IR++*P&J)Z5.T?Z
M["+CW7D[P2+)7]K/,ZC?G@F8H%%;3\P>'<6\B5!_0H?IXKQW,D&5YQ.5&G_U
M[$F##\DYRX-+P ^$-WHV[P]?>I\;V^?-KP7*T?RH&S F4C<815B/O-A/0&]U
M*=:05IJO9(>Z[BG29^OFKI7]="I7JZ@T*6/#6+L0@=M=WM&N;,'TQ1 7,D$/
M!G(CCIDKS O[K+5I8%&QNWH[TDE,LO?5"#H=1223N]$$MAI7TV_U;8I!<#N%
M314UFVD>KN7](L*@TW',V;G>0HR7+2I Y69S7+CGV^V7'28S+V7,J-]+6(P
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M:?L_[]X,?7P ",R>GEW&<OHR*;&N#^6G>&P\3+BX.^R>W/>@A.#9S@&@$3]
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MA_.V:@+(PBV KRH6*)NNFKEN=EJDMBDTG3#M;4^L3V5B@=9TNP1FPJ264I/
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MIDCJ*1)7I97O.;.B/+Z_N<SQRV:_UF&VN7Z9VT,WJ+9>"9U@TX&CC@G<C%T
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M%VE--@OH%T<@Y)C(Q,:[ZD<@' &J>=5'(QJ\,FR &G>_T#.0@(B_UW1'QB"
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MMUJL?EVS6B[O-<B=NDYM'>A'>PP5=+P7 _FJ;??P5^IJGN/CPJ_?$[P"7X@
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M,3\'_M2RBBZQ2F5S<=Y(#=3SR+U9]31.ZXJWKXK9B/JPGWH^K_ +PP6^AG^
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MF$0=: ]B+CU4<'5+RJJ9J/4 @? D,73>S<8%GZ+45+-:-R2(BZFQ18W[JBS
M:(P61_*CQ3T"3L_E76L-9"!;!IYA>)Q'('LB8DI1YY"(\L"4=^;E0/(6Y;=7
M"\3+QASWTVJO3<00^^W$JK<LVG5Z)[N4K\'MG;; V[=_24+/5T2SFT3_+\*^
M,YP-/VPWB-T2,?ZH$<0(I7;M79+8$2M&%=7:JRA*S99:$6)OB3U:>[:HO6LW
M5FN/H@M%M>?_GO=]K_.>\^5\^GUYOOZ>Y[ZOZQZ_8@8SUN.\GL^PR LZ'=$B
MZ#3"^4+AJ06E;6KXV;\ QF.YS)]L1C6QD,U1L?R!QL@V$ U.:8M<5324G ;(
ME?)NW<K.I?D<:8'WP?/^!:3_;Q_XKA?S7X"]S5[-7\!%*,!I_2^@=_OY2][-
M\OM;SV_\0?]6"G\^_H>5_[_-C4YVUT(,>>ZA'V>->M9DS>>=!-S.RS!BYDA;
M\['KA'MO:T7Q<N:P"@1M"I/Y*SG.K.SD2AHO3Z0 7\]6#-]$ZM<>Z>-WOAY'
M(RT2^U/B."S=:G!F]OV,>(C7]V?;?P'#0%:AP%3KW?>#MSH75IO\/ME<+!C5
M-H*);:/8US&T!O6NJ!XZ;+I"!9^0E-'R<7Z-N^(+GISE\]L_'_0<V8G'53S!
ME1PX-%%X*1!Y-MK=TT,C4*'&^7](H+[ )@69;I-FO)^YL@;.O]/KXD^CS=FR
M04LS[Y.NMT&=K[&A,01@RE_ POYOMXU.P<7GIMQ06';HP[9YFI:M1Z"M:K9/
MF.H,0\TF4+@UFB,YQ"?].]@&+#)E]B@BU!K'4B3G,M<E7/HK+MW>FO"VAKZ%
M+Y? >_$/BM8*.+F(:O*##Z .UM@_G&ZEW[?F,SKBNVOXO-DGY<]( .19I2+?
M U=^JEE+C;7[K_(_+P;UV=1_<_?,U_,\SWC?TO+#HP[^Y" ^'UY-NOH<-.O1
MD?1!C^%?]'I/CD1W',>\,6<=_&0#D[YRD9J0(E-9UT7U1)W]<8Z;5])$0<F/
M29+2)7AFI-G3B"V?1LQH=9G<#F0A>*\IDMK [I?LOAILYN=9@=U \V%=U4?O
MN]L*^C2HL]O.GNMO:'UB6&^.B1-N;%"TWC+LEK?#+-?/;MJB$S(6J\S$+%8M
MXL6ES+2J9P3?R&>:$L>3?W@.X*F<;@P[(GPZ2#G(SAYJF\I\68F5Y?NUY1PH
M.DOO'3Y#%B8ZX\S.X]1A$U%TP2]2S5ZFFZO!:NFX*QRE4M22/J+U8AX:T5T%
M98^";E&D6?<^DPJ76Z@[-VQ5<CN8O]1=#J"_6?&34_R(7T?T87R'?XF.AFL[
M."^X@FW@!*6%(J#&HI)\C'S%;4[>R#MCA)K*$_]PK;B231CKK@:7U=G956DM
M^KO$:DKRZ8>O D;3F7=D"[/GTBF5,84#X53/D6:M.8&'"29!BEY8B^LV:Y )
MF#8 BQ@_\>2W[!)$<C#+$RIA,!1:67,8\BU%$9CR>;#91  0N%GO/982LFCK
M;_$7\*MV]52,^7/SPL2L7L4886[_6NE8&U1EPN5;^7JM:GJ]]&5)U\ST(2/4
MF*_]IKB$GBDCGR:<VM*0E<:^OHPXU>;-GC=$3YW3YJHI.E>CU5#8U*S6J[&X
M:_J&]>N1$!W+9T'?'$4QU+MC+$ZZIH#.K%>1QQBRV\C^\F>U)3,H!JBQW_2D
MP =.+<,QQ?V0*"ZQ[Q%),9:N$0?H141.XTI_RTE4G@(KN2IV6P?]-Q,__?K]
M%Y 2G623D7CYI_3['R=2R8TCJ7VI*X!#=N3AD?V5:XO%^8%34(U=^G*53LY$
M[U/+RC<[HK)!SO=::Q=V]5@/RSHV-1&1VB4:9C@7_3!//J\7D :B829KIJOW
MJ;X=O6'7_!VNFXT>,PFA^&9C6Q;0V$TC]&%"'PJ+1-%-C>*9-*L/+$CRV0$5
M=I4BKF5<-,A_QSJ*M#WN\J.;JP$ (Q9'<(GZ/3H=JGWT$LN"QHW9SSI1P[0P
MLHK4Y>0(ZB7!-RG"[%,KWP[2+8CBNLAT-&(+#RYY5*^^+F.;V,Q:ZZY2BS3]
M*2KM=&B7T;68\W\L+,O($;I)*FF]_2_&PM>D"!,57B^](^3L 1>@"%RB]A=@
MI,@!=(Y2'<K7J! 2KO?^\5OV6KV0U%:'$)?=R"!$S-!E-/@!CD2%IV(BZ%(.
M_(\JRMA>1T"S$HT%%M]*K>_;HP/Y]%6@(MG[Y Y9FS]XYF]*C+G>NK8W5]IK
M*T,%'MQ$+/G4'O@?)&_O_+;X?M5,C:HW1<^IZ<,=8.)MMQ FED\7[GNTREJ\
MK[$I7IQ;0BUL:.&65#0BH+2)S(MQ-7(#I59M9EY=9=G(] P<7M,G<=Q/4]68
MF=QMZ59W TWS.>=6 C@.]IHS8U.V0HI/>ERHN$:0;&\+"DRY)[(EXD<[:!30
M\OMN]>OK5VRM6@L@W.NG/#U/KGM.\FY9S^:W/"6*4X)*!*T$I1VV!G4T/WVB
MJ^,6^;EUY[#Y'R+J#M'-^KM)7(F!PX&8)4A3NZZ%>"[=X@HA.X#1JTMOH$E#
M#SC[56PV'K9\/UJ"D.-O@&]D<U#$GX,%$@>NM*9OCKGZ]MC (54 P+^KWD#/
M'J'"\_(NS3K=DQ"&%8,D(U?)_8D![.%J/!)M^Y#25:(>:]) ,^@;R^MQT]&>
M$W,<H+MP,$>,PMZ8&D5#R8 N?KZ_!NR>6<6XDF!N'YN^W!\MT3,G)\/JJ5OM
M*<V7!@:22N?..??>'NYY$1G>%\W7ZSY06[SFJ1<"ZYOHQSYC6_X7C14G5D!^
M*2BM8;:W!]X6.A%),,-JLX!JN0ZU'PA?P]A:4?;5UUEY-%'2FA\ZY&(;+8,N
M\7TJZV]>;Y,X))_U+6&C)/V(4*Y$!R:YL:;+K<ZCJEIS1FWB! &=L6&I_;QS
MRU$/8XO$)$2O#&-820T%WVMP6B_D^ \_KS8?8 ).5Z0/?9N_W3HO]Q#ID=8<
MYT*HT&5Z?[MWQ:JTS$;WG5N4[N&6ED %DCP&WAN]^"VJDZBZ.KC"V=]ASD/)
M/E^ EU=EXY_+,HGP]+/7EU EE1X$BL0\$+4IXA.Y?-%X!!-W#7$37^VX*Y@.
MC.VD='9A_0Y,'-($A%I4+GI-ME96?;Y9LCZ)FM^2+T'=S8[@=^"B&,%)4PG$
MQ& M,K63;HLU(\0K8? AR.T(^B*G]@;R7$6Z25UOBQ-,5_8/6E6!E9];W]88
M$=%6$Q.=M151PAXC\3NJD;W#0QY^(9F1OQ5%:;\^XWI.\*&"3ZH.)5Z?'FNQ
MIF0%25'SJ^H4'BT0=._^!: 'UX14%3\9("Y/+\$VQWS!6CTP/3P>H$ZEP5NI
MJ#Z%JHO7P H#!AV,G):,[=.HB_,F-[(%1,<!X6_?J.ZJ6*3A3(I[10#GH+#Y
M7JX'5KUJBK^;C5CD*<D1%L]Y]RD*TJ[,/[PXZ^7BVJ$V\.<]?[4Q8J79PS$,
M,P4Z@ZE\"\L%5$)Q*K^4TIOCCY;+PXT%EA>J%D8PCB&(W\',:JLR!>YCM0.#
MZ?J:?2QY7!4.%Y!-'@T5AT<G%?+%/\;SXI@AT<O+K6TG%OJ= 8)P#UY\KZC)
M5B"M\*R0_R_+ +T:)>&&H1I;K>FB%F?&4CZ[I>%>Y&L:2@6U]6<SJWST'*"\
M2)61+3+JO%U^!W^SIEK3"? ^F>1KHA#=T,]AQ!Z_3 _0G^HFNF)N^,=F_ <[
M3$,)47;Z+^!- " 1"B7K$0 FIDZ]K9$@B86@2 _I1*&G1L:+4A?."]\_G.H<
ML!W5'*TXY)<'\3OJ:$Y]/I);E".WA=VL_*G0LGJ)+'SH'N */*N4" +ATCXY
M<>T*"UM6WW(D.1P)[SEP_617H% GU1^NR$<4H 6$KVBO^9\*58<U&[K5NI@_
M4"-9P+YC+S$F=#PQ38*MG+Y L78DF34/V>";>N9E&,(4#@SV4S7H#Q2@?G=H
M?D/\AAK^6,WE,RT3.#0YO+&PLB(SZ,A//#=BL?)#KLM+P3NJBL?;3(:V%GUS
M+\$TVK?%7Z,CTK>-8!"F DE/J4RV?==^+'EWQ_E6X7.G%=OF(\U.5:D@"2P2
M9,Z5#<AO&]^L1WZ3[WYO4:OJ)\O_AFTU'&Z@=PL>:#;B2N9YKD*'+J-[C2Z0
M;"C"2<JEKQ,[E5EE1].Y@X7]MKQ 4M3QB6<*BA-N*0QN1H>8T9-"RD 1E,E[
M-R !)L0*2#L0WN^I3GZFLFJH'GR_N<J[PM3[T+[8>_+!EXPMV$+"U[PO/A5\
M.T1YT%BY&#!YQ4F (3C5LZRMJ^V'.R.?NZDH]C5<!0Z#,EU$IK9X3M,/5"Z]
M!!.@9(5Y(!Q9%@Q%8(H$]-.UU5MV/I0)5Y)H/WH5^V#A^+BP+MB<K:+Q\(Z9
MZV(_)[FM:P<E!D70/;'#8 ^-M 2=Y>3*7H$.$VCFJ5_491;_JAN]&"1K6G"
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M<% RJNXHX-*PJ"+-X8G[M[ODBES'M#-"#'.-BD;M;A.'4,&4#!U<OJH,+*J
MJN<?/(7L@NJ3D_>?[$TBP[K/&MU<5)Z4M[=9_,8O[+[5'$7UB[!<@.W5X=KB
M8M2=G'7?Q"J<^G@$;5XML1([AJ%^FP,B6CY":"+9L9]&Q=/:_N;/GL'ZDC>C
M:RD129,WD\H ZL'Z "VMD//ZZ13;)%OB_PS%MWCYJ^"96MUD6T6@2OZ[%<Z
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MS6#1#<"YKPF8+X]JV!+Y1)"/MD4/WOE&)AJ[\K^Y>:>O_$OO6#QJ]'ST3;-
M*L^,@3^_P;V@W"1XW+62,]N#H8L'W(,YMADVOK0:[ R\IG0 RANQ-V *0!ZJ
M\CU+QA-D0A5=]H4+;30ST%A2^%!1SO,;!=N(IKX'1!"2-,T/B!SND0S_8C G
MX]AI7+HRH7E*A)I^U/&V); MI3?A53;L'0C*E(]-;TK_LJ8T<DKA:)AI!9B]
M]$&+3(U%KO,SUKD#0&@'3Y$>"(->19XO3UKR*75E:/%8*/'@U"V31T;F^-X]
MPE@F*5TISF_.A\/T"VIZUX%,6%!UET?._>M\_?(SJQ@EHGCU$X4KN/ 6 Q3
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MD9\X83@EFP\K?80@:>F33-+.)\FHLM,LKGC26,C'?Q+E4PB#E0@ ,0Q$_9W
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MSAAV=!><9+\-I@0?]"9F^YI.G#1I$"S7I_SWQ*.XT]Z9C/XRHD 9ZGP#E-"
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M 1YT[1%+Z0UE8NXE$JN:+YE^HKU!WJ3-BW'X)R5-SO5T>WD4:&,5>UW@+S?
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M["KW#FB]UO/U=74I-J"98_.^3?#O&[S#%6A@D-#J4B7HG+:9^N;-:R.]Z+^
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M:W<<VT\Z2>#@M[4AO4<<RP_<&Y6KL9QQO?]LBFDW^YA@XWJ'[NLM(*S,*=0
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MS=?I$MP\2CX6YCBU%/W^/W[.YNSO-)VB4.ZP^O3.L27#ZA<,IOZ4%:E\W .
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MH3P^NS1VX6BW[(;DK>]W?-$3]"&$Y_]/:>\=U 3P?XN&HD"D%P6E1 @E051
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MM:I.-"B*/BEE<?$(8'Z+SR, :?NNZLVKS\Z#PH573.VQ2Y(8? O5=NW:U N
M*G(49OK)+"8;\G'QI_6TM3V^<T<OV@$?5ZK]E ',PS'![$3PU!M]1$*.WK:$
M^=<I&-,R@,345MLG=/D_0=]O+!69X']<Y8/]C)Z6?^==!]++)#2MO]05,_6\
M<XW!EP# G6\CI!27*CY.8$GQ,<;4^G[97C3%,"-IQ=';\T".W/PH04ET9&;_
MT& 9;:_9=4]643A(L6B"$)I"8%#C+3I*@=0Q+Z0"@=QR72VL"'U=NMA_AVA;
M99,0)7,^U27;Q^B[A1+:JX(BDS51BYWI)H1*Q]>#&[<#7DRX2/#B+L_85);F
MT4+ /GXLU[?QE=0P5P4TPR$O0JA&B):>PL8AR3$AFBYI_^H-^,]W!>L*.3B<
M&LXX?!. ]\DS6[[,L!,?2)7>3V-/'64.I^ISX,W[O-/_KA2<%2//KY:>I=+*
M>Y!963)F^0JS;]$,9\60 +\4>5-*1+D/06X",X^!^AUN*GE.4[G39:Y&/ )&
MU33YYTH]O_B;)M5?>H9(L.4N$FL3PM)S@==BV%DPLF=]OJ6?M)5\G/O7GHQ]
M-11*44WM$CH>DUT@^T%M"N*67#0:K2PWYN+P1&5*,ZF(WY .]8R-.PK$'[N3
M>GHR#*3/RFY+.EHHS90^'GO&CSB^)%$[E*I8%!<7/<7)XNT?QPO&1X#XZ07\
M2\/?]89IKZ[.;N.#**;="Q_,-/&3O_,?".8K>WD8^>JUFAJX?=((H8='<4/E
M?O]4Y2!>062'$W574[2,Z+*XMT!4'/ <8:'S.B/;L*2.5/N6K_W\:[)/ZV]8
MP['YXG4,O,SLJD CSVY0)#N]X67%M1Q5%(O0H/P.+>IY=ULU_4R%&",C%3CT
M@.V@ZHF7##J&%;7<Q[%9R)6]R-'.#7".M)_85@-DW0VY:-.B/<!(A7 ]V$R*
M7C_N/O-5:LRL')'EY$2LM8, :-3P3JI GL#)^8=H&@;:9Q@6M;L^@I(]A5<Y
M*^/0A53[2E(^E_U[DD_Y4"MO:?\Q-1RCD#&ET_87L+SR%] JOTT&<;>!.A*[
M(I2"E=P4QW!1$P61-<I'K$9"8V/5+18&]9/'9"XOH4<2<1#-D\Z:B'O"$5],
M]#)5J<  ?%31QK%3Z$79=&5,?Q9P L2O*XGZ"UB98-I3'ZRJKGXS,46RG2)@
M0*(8^84L6F=_KLW0N$)+4\_3YZX-ZZD(B!18_TU9J.G:YZA,3ZF<##'.1-\<
M*^UA6]4^'5K&M<\_R0><=4&E5WL\VF@>^E_R0$=AH\%?'0)ZVCKWNO17OY9]
MZJQ[_@%#0_0 58#1!!Y9'NX^V5S/;.0*##4KS65:,>S\\NG7X,Y]F/'D0!CN
ME_SD.M\0OQ@#7S\-3X@P@\E-Z^:UCU*&V=^]ICT>A$4Z=T3YQ_-NZ%#@1CZ7
M3-T_,C\WM>9O>DIVU[EQBM>,BV&D#-#0\-WF<=S 59))'4-(3T5+"4)^!EAF
M0MG5"G!QHC$N;I,,/I(!&J=_TN:^_MYXI/J9MMZ88:7F-D:3<5LH'Z#9T\%_
M4!\P+=BOYW[_Z: 6 'YL)>A<VK;"P3U?IA_8RXHIB#^,TO)/Y7W.EO>%4E^9
MG9*ZLJ>,>Y:XL%M=NK5E#.%>F:39;3\[/_L%X.:L7$P!T-/PMRT^3[S^2GSS
M_Z%4,AP13WMQ>X3V A_Q;S'DX:4/@YS$N)JKRD,>V$^)A[ZW?V7XTO*BW)[K
M.B>DAU"_)J@@"(X\O%)1._^&609;<;IW<$DEK[^O'O59C19RXU4+@Q#Z\J(9
M0N4X9L+2^#25K@]'?W1F=%2=\-C&0F(S<I>DC3K=5&]3.=L!)I[+[9QXF%3G
M+<H\-KPQ73D-,P*4K;&PJJC 07NQV6B_B!;LQ7,1S_SQPX!F><7$5+MK9H/@
M'M._@/L!?5[AF;]^;[#]\"W.U'%GY<RN)[CUOC_@@N:O_A??VW^'";A%"J-3
M[AR+2H:KS^7PTG1*S2"N ="VP!M\Q+/[G];F)K:R1(N]D!F8N-+'K*#6I9TJ
MOUNHR9VY,GE,MZJVGKI2IVVW.MZM0- .Z> V]J+?><V==K/JE^D %BTX A\_
ML$V!)4\\PV<LR*IC"#%P[S>&I,WL4GUBH2K(+U.Q1(X"D53.>1I:G-*7CRED
MYP5@,Q<IO-Q*5 ($FU#BX][SU#MN3T@,@0=;[J0EU]E(M^(FE\^ ICW414^I
M],R7WX'LQ1.^2%WUY A7C/\K8M$Z4G'M]H/X>[^%.W;5V.J<+^FG>'4YE8K<
M-Z\K:GG*J5@+U(6T8[+_43G]7)].#.";IN?[P9O"RS/"A+MVS&2*'^([G!/!
MHJ)'A+1??*?I8ABG?P:D,FA'TQNC%)@_J$EV18ASJL*5S1)-P*B(/5"8ZKD@
M,>A8(Q6HQS;K:^G?>%LVMI?>GBY;)I(BRAO&IP_'5CFUVLX=2$\(C55!4*+_
MZ)UN ,.X0QT1TOFH:,IWF5!R/8 0@YV+P5["*(KA DN/>',-5:27<0Y0I^K(
MK*.SOP V^PZ'?9YS5Z/U7-QFD=Z6KYZ):=L*7]R+-CJ^3EK_R;0%1=Y=+3P;
M?T)U^,6CUHUE?9W)@[60154Y="CW_9'IJZ\$EUXFJ-\T@%%Y.C&! #6Z_(6[
MV27G-U=,@"F\J5U*)0)&>YH-:@NBY*'C8Z<WA6;777K<RN!+&@9: MYA9F)K
MFQN.I""G 2H]7>[-/D.=;:7B5R5">>XK62LU%\"CAE+]A;PQO-/J-X1=;6[C
M.RY$^I<]');"_/R'5%3N2$D-&RY%K&2'NI %M- [*$0-.EPS$CCJ BSGS]U0
MXQ9AI%JE*59^GQTVNIRK"F"D9M?EZ:%I$YW=.MHANHA6JZLTG$--[N)\?!A
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M&B&0WS M=NQ."EMTVPAS$WG*IAP*M4X2ML6$CBXXDJ0&;R!OTL-489H 0 =
MJ9EA6=KNLVH< '^(-J,(^/?ST*ADS.X--[VU^9^3:.)H%MT._A?BY'\A6[;]
ME/.E#_\"LG]I[L$&2!@<H(*1_[+R;+BS!\!'$#?OI:"%\_LL6>8C]'&!WBI)
M?%"[FLU9_*CB#GD8:?4)MUH1-!?/)0HQ,R.L'Z)"$DWTV1HN&2X>Y*(U4_9S
M18AWGE9N68M9!\',:*,"2V,DATAI?PZNNJR]="N9Q'GB#&^)QMCKU4(E:C'8
MYIFJ#L1-<@Q!"R.Y+A/]FO^2'@.=_$PDY^CU5O*XW7$] )L.%J,2=%[^5^>%
MY$'EFX,"[YK@L9Y,A(<P2)0,1A7$B_XG9MWR._-OY^7AS<&=SYXP9?!MZ.6[
M,/0(@V,7F?VD&&3[:FM5Y>3:>R[^ G*<'/(Q67+S:H#0F.>R*_F"S3:&YY'9
M"V*(V%]<C+7S6#P!Q IDD05EIVVM]!E^B ?'J-$RS+<TT-"L9*<PNY$-WQ\/
M-Y.]N0??.!XN)@R2\N^RUJB?HC@1TG%1_NU=P0L;;$!>_]63@+RNI.-$D),@
M/4K!E\]-T6FBX+VE:<NKAC68GY&G'[P^=5Z76]98]M,')]D%D]U&!=]L_0ZV
M/[%Y_FRHQZI\@BQ&I8H1LA33F>;[L-3;"FG.XDT**;*]F=R;$'^)N-AX,4"A
MD0^O;Y=B"$/Z;K1"BS:/$)E[P]Y9#>[$8R'$YSO+UWPR0E[P.O#V"+(F>^IA
M=^<HN)O=:!?,5H" 742RHY7.;5H,D!J1CXV-D20NB0 F+UFQT>55L!@>"]P:
M:6D>KEQA:Y+Q,XN2TA+%^'=H*P+?U'L=35R3UB\6MI:^?8>DV-%Y]K[4&H7(
M;H)S*M1PH,)9ZO4<.QAB0I,$\&YR/:F&=7!;#]4XB2M1DHIL RF,'=F[_J-/
MP#=BP.A(L^TC+V;C?-*"+%^9 .SC&<=FY$DQW"P&KGGB?W;8)0W_ZL,)GJ=N
M5%F157YW?U*D=+ F0C,;'!3$FC95S=#=/W(<QIL:H0=")6R?G2=81V/G,-(
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M@""+!^/JZ?B(.C2\8AR%.0V@+1._$.LD:"I1EG=9^C@6B0>\&(R2!P-8J@8
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M(AQ'?)I"O0QD-[S[X"_@,YT77_W0YDM4PUN;!%X?B8=P+OHHAFY>-HR(@U]
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MQ_:V/CIB@ORW*:C_>WC^]\?_!5!+!PB9):RELC@! &>. 0!02P,$%  (" @
M&(;.5                !$   !G,S,R-3 X9S,V83(P+FIP9^R\!5A4W[<_
M/'2W=,, T@PQE)2TA-(@S3#DT T2TIT2@B H(1+"T()!#1W2)5+2Z* (" HO
M6#^_=>-_[WO?^W\?ELXY>Z^]UOJLVON<X1%/ITX7 ,37E%25 "@HJ"A^*'X
MP.D._\L;=BZ>+AYV+JY,0GP" +&KJAKHZ( SXB]\3DH-"0?>&9:5/9^C+;XD
MSP> X+IN?[DS 0!, )27; "4(IL,[U4#<)0W)7LJ.CB28E69G1*L7T_)3K%\
M;NGJC7-+*$0\C#JJC@"_I7M3(N+#7'9HYVOR^>=KA&<2*.<#XO,+H &+/6--
MX<! &<O@W(ES=0PL444P^_[^RW,)](PU)7W]-?WA'^-S 71P%_OY_.!<5Q&<
M&74FL<*>J72N\\NFD@%PE6)"3T$O0O87V'<%K#,Y*-A V0!]G[U8X(S]$@.
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M?((%) +6TM'U3*E]Q2KLY5U31P44D\,5]/"I9[-T<[]]M?K,*-T9&BK:[Y@
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M?I%/4W) EO32&>_6G1>=RR>?KO\V;,M\P]^W_6:80.<XIFM!%./Y-?.EW5.
M?\GOX]\#6T;2AKYAX]_U/04\T_G#N.B@[\.QZ!Z:[LF2V[^"+_W7\'' UJ1+
M"[M41EUNZ0U)7"[TQ^,J=5.+QJ;R-V.QA;&A"&?(!YNV"453^;NZQ56]0I3=
MYC%!HB0K)S(<CLC@VP$4V-54SU)88W9)%A\D$44C>KC[F*P*]'9?A?(4KX&S
M[1S[9UKH%LRZ0CEWC=FF;3H4(V*8.R!YRMF.*S<J$F3EJIN>IZ.NM:6_X;$5
MV_\J*LUSV.*;[W"?(OCK[O(#B#3_*:!+RN5?N3&[_UL.G@S]3V:J]%#[^.WG
MP)PCE,?!;F*_=\]_JI'N;CWK0SXTJA.I\2.:?:(T7MM&@ V""1F.,"T^M]RK
M+0Y'MZBX!NS#$8'NDZS+L0XF9YK;UQ5PZ;LE@9T)D0P$!5'3+C7MD.K+UHG8
M)3/N< 2_'SMHB=I2#=5#1=>0+.!FRV=?T9?1;DA8U_2FVU2XH')4$DGMBAO5
MLY7D8N8,JCV.*T4H@*GLR#\TJQ3_;SF.^M^;O?]MV[!T3?\ K0W2('*R.%TW
MV!;'J#TB,@'SH:['#:H+:9A)O6L4R4,#<>3<T10":5&,V;F;A<[,N=U9O>K:
M4BJM*1/V!7?Z<"#W=HZURF%""2B*,'D)].1.:$%A)E@<5Z'IMLV-%8"F*7<_
M NEQVY?.;*A5 VY:37M-AY">I6,YKU.6[X,Y31'K#>=^-#N"VW6R;WZ/*J_A
M]ZUR_?_J<A4'V+I_N3PV8*KRFMU[:]"1/H)%@6N\5M%6A9YAD2K+8P3CTLO8
M.UVMZ?9N;^$%")H(?J*V[*[LC]5FUV[-R6#Y$L5T6=7# J[@>^-CYA !CS4Y
MNB=J4W:S(D@1\IQ#U-":TF=9-!\7%B91053;FH-)MHG&X7I^^7[[]V D%1D*
M_-%ZJ4)>XLL\]5#1-=S_'^^<0-:VE#<&%!FS;SPFZLIPKI(\J=/.J..6!A9Q
M:I"):]?<[XR'4 ]Z'%8G$J$<<J%P0"^C:6OR,UI(#!WKR9QQ1+>_@QWYM"6\
M\:8SYG=)Y7DZ X^B\3';K)]SLA^*4;E)*=^67&Z["^5"",6?\"PGBQ&U:J/0
M\F*S+,3;7 F5:*4J(Y%[&82;X@9/#FL\8X7M?7C\\0\!WO___K'Y/UF48..;
MVB_-IHOKV(I;A8#7C;S2<5_"0N\F4>O$W7T<RW+-!M)N<T5)B!V6F=<',K22
M-#)/;N<5OE,@ YC14L9\U=5*NA)+Y\QU.77E;:+XBH)Q-8_[X]O>P!R35*\G
M(3MBD/8=W@)T[M3+H*E&*[6T5+%=4A;>J0QQ/=EF4HU*58G)W:U%TE/ 1)=5
M\%K+*6!:X>.>#+K,NXFN4T#O*>#$B'M/&?W%N_FS:4_)A,.L=-WF &>Q1)KI
M#GO/*$02!^Z]/ZI?-3:&!\S(*4E,OEL3T>7;;Y]EV%6HF<?T8,XW3/"FFC@M
M?=+5WM6^KMOU;L?7[5U#G2+"9OCA L8R:'UNAXUR8E$F,:S8TTY,V' FW/C"
M>]OR(65F%%-=3KP/&]Y.^?(^..; JD'2-=M9+1HOF1"7ZX/KH;JJK*S,Z'D"
M]8Y<8T5307DX4QE\3Z752O<K\ZFG LRJR[R!1\_B]*9$TK;JGTF2 "?D)RO#
MXQ!"U,1T*;2XY3C$C[;223T&I6CP8V[2LH9K6SR8603OT3''X=S.H0U35Q [
MK,Z72Q;(5JWJH56:?NG2U\-D4?Z@,W0=%D0B34$/)W-N;<-&^N+L'HIDTWE2
M#3=ZW>B3[(M(9$^(>P3.5N5#NXR2!32R1EH/ [U9RB;IH5.^^EL/WSJ%>^OZ
MW#Z\/W%)0%YA@)KG 40LNK#\;5Y>XUUJ!F->A-=Z4R"!LCS<Y$U4Y%3=M-!.
MO',W3)I*&=7B+G1UV4V[N>PQ!:4*!"^K25M%OVXJ@A:)'+H$OG)L2P]G)(HT
M1&Z%L6C!O+EL4TPAZ)2)EW"I)#EY"K(<KB:1/D/?PHC3VN=PM#L9S)TNM\MN
M^?PA]*C@-C]7FS2(D]/&NJF_4V&!30</AT9%4I/Y6I+0UYHI'2/UKK:!!D(9
M:PMP7D<<JG?A>AQSARV=6JV#D9X:><:5 \_DL$%3S(:L0YWZI1E:5I0Z,-"7
M8B;M+:E[(DA!F;\5U["\VS@OE:1 F_<1:7'.NE+L:(!0>;(HAP73RVWZ02=)
MB]91^,;0W4>IU.P>[F1Z0%-\U?C^GL:$*^I^X7E6^$LI#$[1B5T?'0*&9FYQ
MS>2HH=7/VL**G5*BC) )M0;$K!U*BTY=A7YWTHW+TN,I%-R\,3\]K!73J]V/
M)')Z/CBM.<N!VWB/UHF\ [N:FZM 1]@MM5P+CQ6>S_?HY1N1ET?3]$05[S2[
M#O#L9PBH)H]L#6$JY%FM7H'4LXI5XZ&F#M4B\H[I;B!XAZ\6+2?!=-*28$JF
MK:49>[:-=606'[E&C;<H5I6 (@._W;)KJN;(<O55*I8(-ZH((N'!Z3A0 CR^
M/3O*CPL/IRVF/JA[X1TFU7+G#D\0]B"TRRJ<RG?)B$T'^+%;34A<"9??X\[\
MRN/Z,!_E1T1>)I\(70-XMB(;9M);C#;8X]'2#.$"H_:Q3:VP$!LVHB1^C-)A
M4S\\^X@2TJJ^78BJY6KUA*MCN+R+8JP1DPE8%$V4+"91G,)7E2U4%?^QBN_4
M0P(<](KQNX8TF[Z2#8C9N$NI"EFWG%$]HCJ5+Y5=86N:AH;J@7WO<P.<O72L
MY#"?-HWWL1=M8Z:\J.HR$*X+KKPYJ6NHP(AV"2*:UV4$MK!D+19UI03*NM5H
M4<!47VP/2.%MB!5/MU?D6?% &QA#9ZN6]S5'V]+J]^\T0Z@3(U6*^5R;&>@N
M);'<DXR!>O&4UX,BE_J5$.PV:ZZSSKP%\/H,DL2Y&?>=6][#MQ<]F-MAA@+:
M*INN(^65W4:"M A&;H3RBIK(K)J_?W$=Q[7FH1<YO0^N2_-@)A9+;()B?%.L
M,F:ATY9#-*Y%2VPAMWJBK[78P_1-/G@L7=,;04;3%[1IXFVGV1KFF9;$ #XZ
MX:9&1.DM>NDX??#W7#^4)90)OT4UK=^?H@H>Z_!KLI#O)%OGIWU4)=$X=O,3
M[Z'$T^E'I1OCQT+P.\.4'KE)<"GYX:/>"2JMW4T,!CJX/F^>'<FCD05QG#N$
M*@N#W?%;T7N(0F47Q#7A1_/!^.")X8Y[SGA62^SM\M4%5!5E">T]0'Y$AFX4
M!EVUX',K<^';AFAW(L%7:0<7@Z9FJ&XGML)@ZHV&]5?0*.M 4WX,',MJ7*VW
M8PVG321M!:]=FL+H[<KNGBO9]BT(:29XUH9.#Q"S.$ZSB2,%FJ@L(_"HI#>=
M@2CM^0I.657Y;;&C6@\4XD>UE@5&8? 9VJLZB1^MNC]L!Z;Q5'Y08Q]XV0-,
M!?D!?=HZ!M]MJPG5D/;WJUJI M-,)WI\TJ"P'J!WJBHX"&<E9:JY^3D-V-;;
MRNAN5FJ_*C!5%3CIM$>DY8D_7ZY3Z_7NH;Y/[;.D,4D.YQL\*^$*[CTFW:N(
M9FW&2^T#7]E0J&(;%2AQXNL[(A].&VG7W./F^]+GZ!KER#?7L:/.SN)6M2\]
MW&H!NM'%O4L6)>@>:=?:O0)_:B/*E(7]QO)C8$5#_6.G?J71=BMV6CS(#AWA
M(.(J7"#66:"JHTENP+W\FDE.J"48M4H&*S(2RWZS_D,5QQ.)8 _GV+SI)+,G
ML;-A$0TX]30VM:T%<,+KEBY$#OBV?1J6X8TS]'DS-P<%2VKB=UQ?./1AOIZN
M]C.WVWZ=(PW0$,[" 0YX"V6]ME)"Z2.A21L.3WE:?VA<NQ+F#&LDG)BA%;6U
M$A!4$\Z1RKU7)9B5I92_VG^54UP56W7]D5+U:'T VY1TM\V!*4%!_OHN2N&T
M%[_9RZY&X@PY^2G+QC'9G98.([L[69MY5Z\*O,^4N&DD;]]7YO5"VYF$/@$.
M%F7+TRB?U51%IY5W[)WRU!U4%2O%MC$I?'M#!<[;,S*^8>4KZPWNG6K'X\G1
MJD][VIXT,THG&,$SE$/)J58*V+4KY$V7XU"CI]NAR'ZXP1L[8&L.,P#3^_N"
M5I/A^;;C%>,Q0MI%S<9-!M&"?0\'.ESZNPUR-*G]8GC7L*^>O;Z53!FKD=<)
MV-PRP[=853635.8:BLK5W0 S6 .OV.J)C@GFJDAXYE#:67DGX@_$M>$#^[@[
M%-P+#_W&"<(/[9/O[8+S;6HP=8)BYX,.+ >\)BMC/A6R[*+6B9K(SM1;=UQ/
MGLYQ*C@%*+8:F?$\)"U4,B+;M.4ON 9M>F1?MUB[R/FVD4>)W]&UQ*E;:#"K
MH54NZTU<*+$AH@']$8O8[5Z8>T[L:B/H9+*N4:L>NM;?N#:-7!4%+5;U4K',
M?Y:_*=BJ@G$GE5_[K@O&D''G.R9_S.OV,%?O\?WD. W4"J[(NSA^B"AJ9F:E
M/B5MQ0;Z_;#!('3VE<[L%4L/>(/[ERS\IB)&0N_^' G3Q\VX%-.')BIAY!)+
MT2P[I+?I8$*I^+'4<'CH5E%Z][ FK5/4](@3=,KU.1I.K "$@ZJ\>,[:#A^4
M;)*^?$F26%>H(E(O);+.(2_R%?/6UNK"CMGZ8/:D"&^V\0U<[Q94:-9 Q@J-
M<4IQ,T'DTO-5C"(M;+]PL-1G%U%46,DN[A5SVI,)F0C?XLY%[Z#6Z>?:G4L"
M6CM8I+U5780,>O@%B19"']-$7LOR/!82LM]>/KP>*]8/'IP*D.P5FT:"=BC)
MU*L4"2GD!@8]\+H]V#XORGFA@9S8>I^$=C [=]4\MMG9(/L4T:PF\_137M^3
MV)C,010ME!06!)<$I,Q&8M8NEDV*G351A)VU:J4J0_\C<MGO,)&^CZ'K;5_-
MN%N5$TF-6Z-XH;C5'6#B35$-0]*(JU48A@+ $.J6SX<NP "JY4G;",3B?M9T
MUO8E.%FG.GE?UFL KWOX93!S&"<0,$"X_3QI$_JI)<G"_^USX,ZZ;D[54X:V
M4*L2ON(^Q6M7!/'<MPZS[EW355<3Y%)3S8ZH/VSJ#2#3XB-[1;<G8'*Y*Z&:
MH7>6]C)LO]/R/GFXW2Z>^.50Y3X^,Z</G2RIA20L4Y7Z^%)TC-B[)S=-4^KV
M;R[0DD6FD8?Y[N)%M[A%V1C!/WI$)(RM/,MUNO,0J]Q]=Z%E9[#EX50]?7:9
M09)1&6JF%8A%I/M**2]>!*.@M<284OJ:F1O/,E?[Y1.:FB]TD*[^0V<Z9#!E
M3!0._F%DMI\^56O[M<>FLY<QHGLQ!HOWZ^LR\=K-B)9!-Q86.GI'A[C::>B$
M>_'C82@V-QZ:I3H9FP?8EDL3[007/*ZOK-4-(*H%UZ'K=TU1!(9E%!$QT,U,
MM'7J3N5@QUN.4GE%985OD1B9>"\O69>2,MR[)[*PJ#FWZ"SD,(0YTP&+)T2[
M='@%2*7>^Q[H'W7O(6*PT+#1ACD.>J- !%E547]H$#=3L[C??\R*%H)0#6V3
M"Z=(60E'0UAA<PV64PFA3@#OW"#G<WXM5+*W%G0 WMZO'$T<FM"N+8TC%(F<
MQ*<:?DF9M=HNL%86$^17N*"SW1*OH%NRRT(&MX'WIN"H"P[RD2SY*L,;)<--
MO%\M[3ZT!UYI0.%):9G2P0]WZ]1GS36D:U4RP U_?9O]'G.':Q34U0,?-*NJ
M0]-\C4I3$O!!Z8/E37&"U57ES[)R_.GN57KL.^[N9JWKN<!G:->F36.WGHD6
M!Q ,'*B7BIA/OEWTW<D>U-V=JB>Y)6!;K.!(@JHJ(:==38U>((U*VY0>O4*"
M:T:?5N>=-=-83H&8.:PD6<3L[5@2FS-Q^8SO\##KDNIE??$B$B:3:;IK?9F"
M%":2K/8[_-Q6KL8<,"LQY5!:#I)H^VHMQOU;[E$KZW!X*=MK*Y.FN]109V?K
M?C@6;&^PI&)3<GN3Z-JGW(]7EW));>!OGC(@6"F/6O8CA5?:)P\^](<I8W0*
MMGR>@W_VG:)DN*8N3NU<I.X (WB8E&-G:4#>9N),Z? A4MVF=Z:JUS6M-+6'
MXI(-B2*K\M,M6ELN"#H>O<;M6K?1961IW"*[*$Z=$G.DJ/6."F/JX-TI'D,Y
M3Y4LA,2U>G=<5!2LZYQYCEJ^/#;/F N9NNR.&2[AJ>CX?H1OU.DB4E@)+8.N
MYS+$I%OQ<(NU9[4C4N-+.NHXZ0FYCN6CF#C9I:*JB^XD>YJHMX;.!MZ+&=YP
M8L'ZY.S/>0J8/70-<63HF!I1"UAO+%<C9TA&B.M%OA]P69<L@Q_%35A*W9DS
M9ADM5Z@N\=^=2 BH*G'HM:9P;'>:Z&,]2!+^LHKASYA[%3)AUE_X%I'&I9-,
M"7)12&*1G)O "Z=UUDBH0=Z %$G*.^Z4ZY.X364*J4:%DK>]OM&3/6G?60L$
MM,(Z2 86]O=G,JVV^^FH)C\D3LT:]M,L5V,EWI)F0,.T:&K'"Q.,:'SE@=&K
M ET=G-MV43_P?E!+:&Z0OQ[8S3O65#&T<=A.6SYD^81-Y;9/W!JJWUZW<EX"
MEY522E9Z8\<$@PLHDT+9OF9?!@=L,WP;,1M85E-(@5"LI9$7)/6Z!;KB%/TJ
MW>/!>N_+57Q)?,SN18J!&6*QV80ZL$<H*'D'?\Z?-(B!^HZ*\' $7RPFM+H?
M]UV)K/_BI+[_*4 U=RI;SZ'5=>?MNVG5L8^).#%7<EWU_*O\ZG'PTD$MS\DW
MBC$U.NS;JS,SA2/L.Y]T:PMVB;0-U-033G14=G<,$3*&'1J"Q#[%*JNL^ME&
MIZ?HSB@JI,ASKY.S'_D-DCLE5+\UN;9]2[W:\E JO'UI/U3IK;9/MF],PLL1
MV:I&GGBG=/;Z_ G:A<,M_1R+$B].^H)'>KT*8QHBYOQ6$J 8P8W^CC0HG<4A
MR[7$+]6$!=$#Q';AC&0)11E #JYV^]4N/._Y5]8+$]Q65K;Q.P ;%<N4=#?\
M-LQ$SAO$<+SJJTD%39B3%7D43@D/( OS')9+[,HSA-#$R_-],4_E@5HJX1&N
MG;&7G BZP<\"&3>@/E>]9)X1>Q-(M 0-*3X=MMX<*+K,(\YNEC^EKEN#7>?:
M-NUV&).#:M((A;0'#-2J @O*!MG$M5^Y9CA5-!SR3:FKOY*+;;?*I+]M9&1%
MU?BPPR;1KK4&"E6ZVO895X1YD:[9P 5I5)458]6^+-"XF_@R"BH7%XHO9[>:
M)*ONS@(GY=-A)?A4X_V5,3_? =!1ZZ-9EV2SAU]ATY9D[K63!3&-(/#\2"0I
MG%-84KN;R=I!-V?D$A]RU O7OK:;O!XZFL#=V;ZC47Y\57?F'DL73.-QXVCG
MHEMRM[?\8B5JO@*+@'KXX^;+\0CAY&K,%G7PZ$Q"K762@VL4;37X49<H67CG
MXM1VC&L#-:N>2?6J#T_!U.-+-.+NW%>/U'AI94I-WP][XS>SU)D_D)_S[/Z(
M+)FKG.*&<ZC>90'?,FPGA4HP/(]J05"W?1CK:,RDO?-!? QY5Q/+!6GL*&]Y
M9:IX>BI##458.UR/H*(;5;7"'2:XB1OWZ0JKIF+#(6\=2U6VB?'VG*HI^O!@
M"%>#H?I(^G-'TD*'!U\:BI4K^NI"8EPU8KSN*K(@1&+3;JP8N>'*9]D[XM$$
M"1&:['':&Y,P]MEG%!Y),UAJLHWY&&;<=?T(9HQ9G@#;?9:#A@G&G>BEW2NU
M<&Y?>%^-VE770:V/<Y.0.]%P^N%R'[8'BAL"_C%=>$V@2:LBH=P_PFY#PZ/B
MV=/-ETWU3+-H!DXY&@HM3*(%R4S&S#C>LG,IE-67BVBU617]W"=&-;OCLMP%
M^Q\)WK71529]3T"$4SQ[A6&VLJHOO,M"X.-#C0B?6Y)B0^G(K$*)*EP<E!J
MWEBZDUB+#/;J+"V6LTKRN1Q31\>'1=-YS'2]#])$Y-3-Q)=HN6V-RU#U;E>T
MOXNLRA4UW%?,-2B7P!%\4CG?OD]U5)G"0'$*R-<>UN04PX2FW284<$/H\G&]
MX1O38V94XG+40AY]V7+ZV$*+>+!<+]X%:=1.L^HL$)N3!_=V+KG?\6VKN<O
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M;5E[R3FUZV!=S,HV -^(1Q3S.G\<=@L&HZQN^26RL%IM]ABP\%MI\6G$C/-
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M:/I0C K=SH6YW?1FX#OLB%%+WIP"+#^?F/BAI(SH($HKX]EH%00[2R _>^.
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M210P?+4108;6S-<:#:QL,DKW[_J74T;W5<R\4QWPF:/RL0--?)X-&QZK,AW
M";D KH@E&0$<57#F5:E-W]$!^HKXJ\Q6?L7E'BJAY6UE7]2D;5_BEE6QG!N1
M"YDI(J=97:Q!UR5:']E#^51)*I)L1IPF26M%&SNO>WLDH6A"PO 3H!(J"RI
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MN+ 8A/<"Z '2O@#87P"/-LV+!01_VX%_VRS%QO5J74N&"IJL_SYTUF*J0S>
M"<"/$+\.KC9P!RJ:>Q[9$W%'KR3X0_N=_DU7"C_!%#?Y+9E2J::.1*58K"Y)
MY+COPE9GKEN@.'E\1,;-0Y!$NKR[1@8.M<)0YAV7'N74;'E):[+;QRV_.+=\
MJ;^<V*.6!W_;Q,/BA)$8?2;R CP#7A?WV6['7-^X%'MOV1= 87Y[U.<YXV[.
MK:W,8'T6!+GV+X_0T:)?)66 >B8'1OHJ^CA,>DI.GOT'7%$*>6-<V;ALO>5@
M'TS7_7%41):5B<L=26'"R!.N-!!IK"WYG0HF?]\1 L69.&#H [\1X=D^_)0T
MS=+"\<C'BVS6 #=33"[6G#Y-CC2=X'IT]%6A9PL2,=8:TM*Y2\$U^T\0JYD_
M;(4SX'#"VCM<,1/4A)<D-*#ARN966&K]"9(Y@"..+;;BRP<_['FK/N8C)ZFS
MEF#]H-36TL-("/OV$,N;.HSE[LY/;PQ]+1\JPC*K@AR5@(0E+03CW:'??#!+
MB=O& ]&-RV"TCHW.5K*,!A&%BO3EYB0.CX7O1(DAYOJ,5)^TGRYNZL_I&FZ3
M-/K7OEJOV&V"UXV#A(2T]91E9[J_D[D?0(U8GGSY !%QTRPM,43;7RM%W$VV
M$2.UKZA(<$R#'K D^6DYZJ.'#\ZPS'19\4-G9^VD0]BRN].Y$(0:*'$C\:^P
M<%""O#8X)+D=>D>PH\.#'D?M[YQSLAS+=41.]A+!T@RK]4LPFH4HO5IS6ZU&
M]>6O%3O8JM :@9WX]BS'1WQ3"@P=DVET#?F<5J-9AW[W3V(SL<,>%6=4/TD=
M+$V"%(G=W:@4\45VU"5 9^%\" MLGW+@ML+. +37[P/54H8D'A+9#DM%$MDX
M<G+D$\:E$Q'9ISNZ67707JOA!3CSM?V8\+@0S42]OZ[?^"YV5;-XD*9"6#<?
M?[FB\CY1V5+5CC[G5O47>YT/$ZJYX\3.+6&!E:1.1B/.YF;GZ"AV<?+0X6GX
MZ]0RS0JNO\:&D2[O'XJUCX=\88$+N_<1T.S$\L$EYL!O:U42$P(B@AY5Z/DQ
M^0'2M KJU D7F/K7$^I+?1Z57RGM""TP3(B#?VAETEIR3KFE/I*S$V+1^7XC
M[S"%\)XI$Z+3Z-RNZ=VZ+7]]_$WK0@[GNWH+C=O,"9E1HU2+&F6W C?:F%YQ
ME"?144VVBB[M8TLO;HH[)VU\:8?WO[:3>33&/QT^1+0<-&0+5;Z5.D%[4*:&
MG0OKAV/\> 'X(FZ\\M9.T@^@A"[XM1)D"W4KO@T=)YI9XBF-V+'&F5?*2?Y=
M9 H62V2NYB\XFEI(6-%H;F,>5DE)H8T*(C)1BS/6&R.?)9D?O-,$(>=M3Y@%
MN%^9Y7,1J ?Y7;+O'R+-Q!FGE26/(A8.M>:GE4)7O..;V[V;6XCRNB@;>S0N
MG7;EU7\J9$!SZDC"&9#N[=X$IE5J!/,9VRKG12E,9S4(9S]I'/CK9"2N8<-:
M>76K*'';6SQ!3-(W(S0,0FDK39;Z<J:[FL[8D,:ZU*NDS-A"GA8(%M-&'"-!
M!>]\$J/B-!6/ELHJFK/KM*NS'N."9A_;N<_".L5%TQ^6)3KJRA5-U[TU9:=S
MU2]V38EBH(@FDBR34*%*IDC[(@0Q'Q8TO;A%OI7VQCLCM=KWT*]R!SQ&.W8;
M!US+.2!W7G!A>&.,N@"A"I%?KU&__2@;7]P'V]2ZOK49FBPNROC!(]Y 8&2^
MIG9L$6=FRP23N@1?K_LAM#N7:129,<GHME//N2JM<*QMPBSIF\_E=9?9]UV'
MW52%Y(ZNI*A&U%X,2C&1(9)7HP=#7MI&?#0>LK0)%$$@]3-<9B1KD"JC/8Y\
M6J3+93"9)7R<U&&!BD!.:"[>^'BXIUXB=3SQX,BM%#R&@0_2CL\HQ[P"!Y/L
M^\Q3.F@0Z<AQS:LP9V,SLJ8=RML3*([DZ<?ST7QPMOOX(>>KDU>*U\<.L]^J
MVA?5':P0OTER5#6M>F9;1=M\M,[C Y$G@4.]V#@#6E.OVI,SG,Z17,4@BP1*
M/QPB\*S!W/ 5A]Y'\,I8^PR17VTJ@55J^8F+ V3P,P(@8>T4,S)0G+C-+5\-
M7R!04L*><DPI/D\0!$HKMZ0X, KO6'9C^'V!G+WR//B*52_"?TVHST5HVPE;
M*\)^ #7?N%'AC>,3?-P^BVF9M[QUAG,RYU=K;RUO67][I;%21F'E]F\&HS,P
MEQB6\\%^!MZB%9-QE4VBZ7$2.E.Z;'+B+ +#C]8>5]OI##@I.0KOMV\JL7YN
MK1S+1(FF)TGH(!5ZQ6+TT"^-XUM%.%O(G@80]OZ*RUUK%Z-V-B3QCD'I)G4:
MCD#DH#6//\&#N>D31+,&6<>)'33R:Z8N$K%?->)$"Q0\"P>_C9 *22%&3UP:
MM^!=Z=)MW@I,WXHFICF6L35E6V6=:.U$8TR[B%ZB8KKK'K6(F :/CH(??)K)
MCQ^+;'P]R9CB2J>;J0<I4M&8\!JJ>;YM%%K7?B_B-O_-,'9D>A\"O&07B.5C
M9_Z,Q[**M;Y-FXUY1LZA_"2JP[-4R2=IS6L]2:/)SY?O^R=O2^] :(\Q<@YV
MSSL"NF<11@?8%DD *VXTBCY^2E V5KC-UADS1D=R0H/C0MX-"VW]ICIPSR>D
MC(A2SG6W>4?5-!'/F)#,5ZY@IV-F1C%*_8/H0;Z=6$[AJT.K=SUK2CW\1$1H
MO5364734ZM6EJ[J+ELCFK=N'<5HAQF39E*C.SG([&:L)DHI'IT_[P6NC$(VL
MF22F(W@PBSH.:UR/\@TR.[NSQVRCG3-@OD'!Y9N:$TBH:(:1PC5Y\R'7)Y@S
M^9$YE)4@?R/]\T7.QJN#242WQ=E:U7&>2G8130F5<<^" Y'G1&NIL907 -BS
MON6\J6Q I/(?(<3/S/T%L+P6\P*XG&]^ 7P+#7J"PJ6N(+4O@)JCD$>^]9/"
MMK\/@UC\4:-^ 4QG#:1^1<M^AHL3O@#>GCU/ORXN>:!_ ?C I9[_YDNW4Q:E
M(LQ_F_=2SQJ2;0;9GA5-\04Z_S[@S>4ZC*/7N*9,T^]S/FYLZY/2I-&O\,UP
M5F3XZR9W'Z9O.VA*47R 68E,',W[[W\K(=F_W]!'SME_#0"HO.;:1ZEX6CWX
MED.R_[RICQRWN5$"0$KW@R\BU$H)^I2[73&LT/0]J(.],)OKX6/W-HQ6:@A<
MHYZLX3KFC60:!]P3@4L\N8A,FK&7.?T2I3$V_CCT1K?+=QKY82FDL$YR%&[L
M":NG)-8L46L6B:D3=#QE-'ARW1#0'U'U<6]A<")^JQ<C@3CZJ,0LBCY=U)J3
MQDL=2)?*,^/MUH 8W$*A[Z:1I_QG9(@S6-A[="8J&FJ/'2SYZ#?%H!XTW6!,
M4+;)9+72676J'CT:ASVKH_6]XF25D<M>]%@M3+GDX)J 0\A4@G^$A0"??(J2
MBZFNG1URGCR-L1,EU%>7OI].)8S[+<VJU:HL#]TM#6V;022MP0H(E%XCEVEI
M(0$8H*N+--YY?*O^;$Q)A^$C.2JYWVBY.S\^*X(DK0<F43Q,))"5W56-0;/F
M.:J2$'@;J\T,8\>V8W?MW)MGP&]U>T+=&D'E9AB6I:5R6\SRRO,[Y+BEZY"4
MRSD%\;=FON8%7!V6WYI3AO;H69Z(<!!A/!Q%1[8I<;%CQ_2F,X3**3]NYC;F
M#@'/V# ^LQE$7BQ$))?=CR_/[<"J+1-462V+K66N7(CF64S1N:A#.\&<]THC
MN:QT\23)D7P<Z;3IN6^<6&RJW%JY5K=V>$>Q:!9%P'93TFE,+!PV:2^ UAJ'
M\O3!'K:;6G*F;F-EYD9UC@283P>6_7&@] $TGXU8.8N0A,_H[TZ;P_((Q>RN
MS1+9+CC75ST%PS)_"O%E5"4:<QHJP6I_"ULZV#(X?09&HARM_XX0A;_R_AU%
M^461IE/;<C@BDT8/K1X@$<A#1;9OH\ TDNSLYO4">!X7L1S! FM=)H*$!.%!
MVW_]]0M@LQ(1-V[2$#?>SEDA=W3V5/J">3$L(L)%HI((SRJ;G(36YA#_9J'-
M=K-SKM#!%$OH367+0[9=NW$*V;RF._/'.K^!75FR2UQ/6%';IB %*NB>JV1U
MS@F89NV.,I%-95DFPD.E<OQ+D3$=XDK_E86 "2\I)MTL9T8YVV ]-W)$C69Z
M_UJ8,F(4="^)ZW"4+(5-!;XD/Y:C[#74T0^%;=0)=K9^^@"]=<MQU+5Q<Z9,
M&EJ(WWC@"!:%1U.(Y&Z:J! I<*1YJM'M^M!KU@23]=K5J[)E%Z.B%.\&JE:V
M_F95WA3F]PTDJ\>2:UIW&JU;&QVD\3K/(%_I8Y/(VQ'*%*TR9VK1G'\!.&T9
MI[WVC15)Y,822IX=7 C?V"B@(>$0X,94&I_/*>"UBZ<S,E:=O4I-+7 P0Z=S
MB<5Z,">'8.>'C5K"N=B1D8R,;*+*" \9TZENY4C@6L-VHBZDR>B]? W>3;YF
M/=:0 0P%1,M+40,*+#::CTDZS10\(_O[#%CE84J\IDGTL^.VK*31QG)N+<U2
MIUO^?NX[_K/7H'L76M2V3MR$82L2*N!ABQ*^@'8:>Q:^\BD(>6K!TV?7 SDZ
MLR]A,P=,@QKZT,N";S7F,5<\,4=EHWQPI&+#GXK@/,FE]C?I0("%B#S]IG[O
MU/UX@*R6C2$E+8P70OB]S403IBD/URU0B+!NPD^\X5U@Q]!5GU:TD1Q)?#0W
M,25E9;\Y:!Z[ZT=/BQG]UF&O,C<ZUOYZE)CE<G$ZN69_@P3E;[X5K!UP$;Z?
MBP?J-&P[/CT$;;6!5-.Y%A>HR[TI)T6YWZ]Y[VAXG8'O7YL270,T&Z]E9<_.
M U?YWYDY"#'-AV?5!";7@'/#^"BYLHEB.3;66-"JGV"<9+F?%_=DZ4D8&FZ
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M^YYO\7SFN?D$^I9PO(/JGO![+N %D"B)'Y01>>T> GGW=Z9? #/FRW]8UE\
M73O!O'X*MRZ(G6-_3HO_>UD67=\$O!%%QOE[A*K<4V@3R-LN7@ D$B$3AQ.U
M>QQ^?\WN)H3VOSYU>A%UO<34\JOB*,TMAY?B;Z<AZNF8R0B^_-J,QJFJ8J1I
MM[%#1'A,7<:4W!QIL>M+V-#<-.M3-1VRD431ZI2#!33W!Y5OD,@(K,Y(WMY.
MHVJ5< +^NO;TZ3IJET0/N^D)5EV0(.^.R &..+HDWC[C"!<]EJL0A82L9LTG
M+$;EI;HS8*DH.L8$JP&4&!@S%+-N=@&]HGQG];6O2'$57)S;MDXQ)IORBE(9
M@B5'QL5P[EI'-O01Z,3Q9M-_56C&<::I][; W[VMTQDN9(Z#A8-K:ZF#1LIV
M&D-D-L74GLXSRN5('6?GC)E1 @ PVG];!O_+L6$JEO%A)C*OR="Q!(ZM]/FK
M\<3Y2S5^(].,$A)B\N?_5XSX^I^%",__PSW(/TG_)Y+JH1^<.J<56 K5,-GD
M]W]0P *:6, 3Y#ZF0Z%(H\2O]*JM!49]F903\*LMW*.-;5T:51VK/GXHIQ4=
MTWPHT&0D9(C*P)=HFZQ#T_>W<237XV4"S$HCI:/<:L+NP*9?X\9 [GPU*KQD
M<=5ITG3L,XS*YPA=",:Q@'2PX!J,T#Y$"CSP*>W90.KM$^GGEN>I7W-F=@M_
M,'%_0__,609M-4Z[J_[/Q.>WGH^]J,]8W$\)5,>G3Y<#O2$-SE&CP6E27RM_
M79DXM@T4PRV^3KX V&D+23"_&X78_+%KZK%_CHKYL_%\VB(),3CYQZ_3_J/P
MHNEZVD-\ :"0/BLD>W@&^UCL2:T)#A]**1?_7/KC4Z/S2;;I0RL)/9=_5<5T
M:C:UB[B;Q[#^*<6[N-Z>%-$/#QF)+P#,FX>[XC]=GP]N/"K>Q$-32T*!@L_X
MGZR=[MTZ9U6M#N63">K@R D[H9J_\=@I[^WU?Q9&G,>$5/-[?'F:'%@_ E(-
MD&[*7(10!/+7_9X?^B$WL)QL)I5+^NO)<>;F_0>:CIOJ-K'FWDM:/?$_(B?+
MCVDAS>,%_Q3YI\@_1?XI\K]/I#&/9,0]&B=Q*:NJ?#!V1-5S:B0>4G,%CQ*-
M? &@8D[K)M9//>-F%CP,D"84\:?/7WIQS"I3-JF(&8JR<G(DKF$MB=*9KW.H
MP'[ ?EH #7$R#FC;>PYB]OH0NW%7,S5DF@*^8;I&#F302[P=S2PI_TY"@N-U
M""<R,*6-AB"9V\:&;= 7R-D:I[;3OP"XG1@X2+TSA/ZH<,G\X@0^&*NT*[W1
M3^$1VTE7,NY0^5SS3OK!2M9(.#ORNQ1H\OR]\[IDM*G3D'.^.F+,Z5QK5&L^
M-"+Z9H+']))?87*>A O@D*F=9B@1AJMDQU_GWLNP_R3^&:]FH"0A/233UOAZ
MV;[%:"Z,6NS[UZYS6'=P7'WC,T53W'UHTOV '-S".>L73D?+U;IC(+LY1;GQ
M5=YY X/*LH$)!X._7B _/HJBZ8!\ F_7]<2\+3_Q)'@Z?90=18BTDQ2*1.E]
M+HS[:]F$A45XSCD<P1G?.6Q)[!RM_@5P0_O WG#R&02%7^^3]:GJT1IQ;(U/
ML[6]*\QMH^<GN':=FXPE7E\FKGT DM.-:D?2S=%]%\IF_%C'+ ?Q_1$.^$[8
MJ8=ERK*5BJNB:]4(.[]XA.T"4=>^8G-'W,'R[]\!?Y"LLW.#Q(EZMWK65/VG
M^RPL1U%FEB:5RS8P^68].?>]C*,8'N]+V/PV/"IEU"/Y&CRFSR?>"$OQKI_^
M+37J]9?Q">$*$&^&_5 P%_A=N46^2;A+R)/",V:\1IOURADDH=3[PE$710UJ
M*-@8VZ>Z!/8Z+9E'5VT1BB[-+YK79]/E$L]AG!RB%M*J74[[7)2)(H^4<'V^
MHPP;%(\CO?@LF;!R6(J4.*%VCA*]JU15XC(2<H-U_H=_9[[#T5U YZR=9GM5
MD#K%MZ]'NZT'&EYO@YP3$$51"8P2Q\-2R$11"/ER(I%-A?<]'%+KI,<EDXJ"
M"?+$#'\K#"]6A"F.(:>1[*P!LABUWZ\!+CX&-_JN'=W;CY3O7Y]'[^>7W[O,
MM*?WKB^)"U=]UN//QOMU,NR76,5@II:L:HU;-,TRHO<9+S@]&\$#F,"95?6H
MK<MQ7E$KEO2+$+)]=?<"6,N>?,A):TUW=<['/.F_V'[<.G:L5*3\.:P;0'E
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MW]WJY?R7 UOE. HTBP)I01&H.=7B>4>9X'Q;;>K*X@1>&VJ9K]7#\R;;7TN
MR4G"JWY=D?:X8XB>P7R':W-Y/S_ONN8=E<%K*1)@>SC-&"X'W0XNW?I!]$E?
M<5J=S!S?..R6*S6"J77Y<M76];[H<H?/]#KLFA38F8DX,O!-HX4CA?*'%3@-
MUH85Q["=\:2V-ED.(4 !34"NCO[HP1\6S:SU47YVS+I)6'62>$A&"(U?^P?/
M!5 UA&]'9'XD0-\6?U.[[E9,7SYV78<6D2@VOG:B.,.KQL'@H.F#)" >6OB8
M^BVL#\\RDE 98_7V<K%#2?9(,H\DRL)!5A"_8;"P@\[]=TS:,B@#_[!LXV1!
M.JD;B79UV?[3H+-9)&]-$)TD[O.G!X7I\V;4ENO'B^>?&Q-[@B>+<2;'\;
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MMO(VT-HLICX;61U&G\:7@$G^+L,QJLU'JBX-:R1X[[JCRH2/W"'G;54L29A
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MO2MLCN $S3PQ!$C5PZ(C<&15PW7@5>N='#GJU?;\;A/=G+9S%:V3615&W*&
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M:RLP\>X(ID MZ^)^>ZR:[[$9R"Z@F@ZM%,RZ&%FU5B#LHJS_>B(HT28QY[B
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M,J)HITX7'#-1S!FBJKV<#=@$N&.3H]G;H==[BK)[2N#$8O;QS!JC&"V2T[Z
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ME'9(;+[9ER2[UJW-+'+'XM2_^>QS%V^8>VW6W%<N(IG@'V*)L?1B&K;0MUF
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MF)6)70;FAYJ3%*B"@('/\W0V^J>\XT.XU>_8[$QO:YQ<8HA36FA1W1E.4!Q
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MI%6(KW)"8D50L.G3MLDCSN-@L8#P,+CL;?0W4'66QRUWAOSIN@X_8)HPM+B
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M2.D@5I+V5,Q\LFK%!C*+#D1G&2C+"(?PFE$9D@CM=&2Q>+!Z/QCRK<9AOB'
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M>"\ME^VM<Q3KDFH,3AUS'$>:=SQC,Z*4*%0&Z)XL<]HAI!]ELD#_5I8HRO[
M%B7A7'#U' W#C=N[/A0%<^I!N_$QN;@$)L0'22Z!T*(%8$,O-JCT;9VH[JXJ
M896NH,RYRLAREM&WH(?(!9Y,BK;I=K))N7)#B )DH,*^+6FNAMD^OA!<5BE3
M9[*5$G//,C6H/XVB%J4E@$XL9!*GD41!%U2.E;\C@9+E,)EW(M9:+% +6-I
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MTA+'309F(+HQ^+Q^^LU5DY/2GZ2,^ZN!8U&3M< /7=@/!JO=W<,?/X\![.0
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M3:(=U1 H\ S^]6PRQ.3LO>950Q?[2$ET9GXA]]>9GZ8>$#/DXEYP*&EGR%/
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MGQ2,^=T"KH2[^!@$9>"B%:H[; C61/R6E;R^W5!D/)81$.L/*VO"J$7O_.%
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M\:\L*F%B&\'^"XN-2OA+&^;U:M^4;%TFC;RB]'45-,'%[+'Q[$J,S*&ZYL;
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M/)3:_)$'4R&;EI@YB",,M@?PHNB%.\MTK!+IL%3P]5EO;I ?E)K)$2-BZ9G
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MN9EOI.8^;2U'72J1- @GW"?-FR"A#1DKZW6T,4A<G:]GOO=<,O@UN?M 8GV
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MK5)P92G$W-'9%0+)+%51:2GHD:!,"!G^ C[Z$3)*Z4N=IC;E^4-24.NBL.V
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M TV>KBZWO8C(*[V@K-7-E0[S*;06MH"B ?QTKZ;$%APX:4/I(%]DF%$WHO4
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MAR4TX:\J<.&0\,<! $2'CE  =@E@!TD41,UJSF1:-=STJD<9 $!=L+$$$.\
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MWN__?9_?\_L_#PO.S-EKK[4^:Z\=9^_99\Z<3IZ^ >"I*:DJ 1 0$!%\$'P
M@---<C\=>Q>XB[N]BRL-/Q</0$1.51,9&7!&Y#?:7-'_3 +D*!#, $CDC,H4
MB # V3\%H@X '0;C$Q7@%1*D0$0!T&HZ &$N[BZV<!IC%QB(AI-&5E[#A$;+
MQ9.&5Y@+Y +TOK#&>&$-[V[AD<F7E=!:L?M/TV*]H@(O\L0N\E;.\\\.A(L4
MEBO, 0K7]H"[>L#/DBCG/!UWN+Z-BPOD0D(5"@>#H1[.W\_/W^4AL/,T[H6N
MOH/WN82< _Q<YT^;8)B6M3/80-'$X ?8-P4=F(N+K3X8[N&J;>,(/&-C W0
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M\+%@YX/;W]@7O8GEF][9@2C]$? G'__B%.';*(1,=)$ZKQ'DB_2Y/ !OYX^
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M?VP,T$G]MYOX$MS?U/\&QOTKF@3W;QP[=Q;XK4Y^XZX^V.V?W)7Z?J_!?^7
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M=#V2H[N[_F!#0<%(WB-AG#S1>L4G(=/W:Z;1-GD7A;.QUEA#!2JJ+65E^G2
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ML].WN6*L;?;XR=Q(X<L-PW6TU ZW];Q;TYJSF(\K-FQU:XUTBN!D4LW7YQY
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M>?.J[LS<N7_N75V]>U7UI[O7VM]:DFF?%JIHFX%?R4N@2>7TTME8:+3I@.,
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MJ/Q,J#+&=U)0]E&D\4V5<_#^;1U#DYPX7&:!N8Z-Q$*+F]F@!\S!2\PL_";
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MC *D?4)ZC0$[Q_2&JJAH5*+>4P.$+.#VJ28"R),_?-"I9;93F)TRLEN:+$F
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ME?\"4$L'"+7)N0Q3;P  \<   %!+ P04  @("  8ALY4
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MYLML,(V;(A>I27DX%<T8;W$820$EQ+3O\(@:N-[4I==CY'THQ*,KPF7H)/U
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M44100B&YXZX%'%4@BMUV*0(DP0&U1'S6ADOU8*B"3:_JMK.5GV@%1:%609O
MP')L@F$M:C=8PKU7<,2'!Q4\.N<UBD.^)\Z$NGC!Q:$*>8;1/IHXOM_"4<U3
MACEQ.-U%'1%@V #KVBL:/71N1BUZ+!PF@PTW6M5X^^=09 .M-_:L$M=TE"\<
M%%492C\IXZ$*KX%O3,>D&KG?S PMVJXX['7(R5KPSU=!J2KT6_K'84?!>;EB
M+1LX#?5 J.K%--9Y#=^!T?9A;R><BLAH/22VG*W0(<+]\^MQH\584P(A5GZJ
MJ^<J6YPXOJ[8%'7O(ZK&LGR*'[\IW92H$**[2)C_1DW6'WFZC9+2@3V\*BZZ
M(^=9]-9'=Y[L5<M[GU(TPOWFMOK>R"0LKC -]:!5\P>]^^_E.LM!II>IP<5W
M3^5\I'Z \AM=^-#34SK#=_X@. IILVCC.+A,-:.V(1*.LMR?)@MA$;Q+_9!E
M WWV-H]$T?TAB 5?H;,NO&*B^J)#D2HZ9ECW_:W4,'59II%5U7CLLB64BS_R
M[ &N<X9E*=35)-&$/4OX S[I7/2PY,ZU+2'?DBT7X=A.Q;QS&:5>3^=U[I;9
MZDH.LLSD49IOE8R'[[^Z'D/+%9!#/7I8= F?9(&K H@46W(H8V0C]4=8#Y>4
M N:;:RRK(E>RS2[*,#JJUMT,NCZT6V0;+M*4"5'R[C\',W>4::.PGO;E1;R=
MI6!WZ.[G+]P+0PB5:1V>VQ@/2]=YT7]1YO0\WW@<#L3;]D61QZ%CXM)0&,RP
M), -\DF/=66_"=")5RCNKZ35R[%\WI2 A#>:7J_*14MX.=O>)>9%UZ*M1<L%
MJH9BKJ<THMKS:,ZA+$J1C N57_CE0!%7E_-\'Q-KN(UFD;A4*%^U=LOE6&QQ
MUG48=BQ?J2N7NG! [%!84171AIXGVLXY4^V]T6QB-2YY)JW'8(<=WH!/WT(Y
M2.N5!I*,MN"6W'*XL]6OA+JFRAXI^Y# _&M'LLEFT5Y(8EB%-599PDS%)R\I
MNJNK"1HJEB9?]1)LA=K1U>XA+^3PM9)Q"RX&1<TB$+D2S%VL!$A\<WM=M(S5
MO'O(2Q-O3T]OT3/8\_U^DMUE>O7>\R1%>/'J W"9&W+CH&V!/2O#9[%#[T->
M[_'D;W<=BB D]UCUSH/\I=O9RZS)BLB'*/'6YO=XRHOFT)_H':[HD3/3)1J'
M>4TN%9D/36I%;0MTCU943LT;UR<2)\2SAB9(GNTDT%S<2<H)]KX- <GH>&MW
M$.Y]C9EQ5P';+6B.4*8S&7^9 ,G81V?@VXIT:)'S1EO:<-MEP*^ 1&L:B@86
MEEH\RL#NTAU=52!TC;/[/(FT#?_X8!1UMVT17\.#^E(1:7/.HIX#UN1==-4"
M#8<AEV7ZR/S>;'>T.^LR9%A'\H,R<OP]HB*YIJZ@J.RP9'?Q/2I<BZ*?GP5Q
M#Q1C4EU%<;U#9-BQ6P.$GU5TNM=9#IHQF-_ /#D?>776PEXD?,D=><'&PE4>
MOG@!!>_1<9=OAB=0N,HLPPN>6J0MH*47R8;F-]TST7B1M[],<-GSUMGYSXO?
M1U/7H ]85;3',8=4;O-ALCU^[[;JVESMP)?^,Y4Q5(VP/.]-S2B!N3QJ >:"
M[L^S(-13963G,K4L<VK,-DJ^ #U10=WM+N">&KPYGMS7XUX_9GE1( HU;R%K
MX(3; +OC..-1]/6M4O5@#_^+PVPDSLK[L:0U2UVIQ,W(I9N^5=HF(M"#RB&+
M(E!(CW#&=-5B9"F(W[>]88]GB,FZL,G41<=#:W]F=+EQ.V5ZL)-<K:\Y!^:;
M7=]JK O5Q6L>,NDK8S =U6VY!1:)U4O40UXH*>CE;R<1T2:/?!;D,S3JJ^-4
MI$$A:S]L,<@<UX$$()8**\;\ME$Q_LCSM/:G3*DS\F6:J/S#_9&X6@QI@[TK
M[HN&43 ]Z[$A'3"IF^VH>*C68="&>_S]N7>S]E2).B:,=#WI5$7%YS(NR8AJ
M[;:K6;2+(+'U&!+/J;?2+"Z#3D=%LERA+!4OL!R7GSM81>(YNQNC7]Y%E6PY
M1.KNO5*].@>)-6=3=:PL$^GA<)5>O'_WZ6/[0%\_ L0#:3W69 \]AH[J[)1K
MKGJL[RHE5.S*O5#N"A:[3L:HI6&98; ?U,$]P0%M\O7->$]+%7BR3(!&N):<
M%8F;^;S?+6AHN6U_5B@35J(S*EPNPS[Z3K>M<-6RWRJGW59'//]P4404):^V
MS>V"KJF4DY?*'3%/&EEDUC?GY7I*5CV8NZ*'Q,%<?)\?%='#TQP!O$F =\4/
M_-O(:GOFW[E)M?@C+Z9]?'.1D*'.F&"NI8OUG?LXDB#/MK06QI;'.:@KNSSN
MN1#B7.A"N6A39!%YK6C^CF_=0JC=DI96I*V.11]BON(KN=R@GT@T^L68?U]F
M;6%ZI!=:8W."+V0(K]IP1%ZVC%(FLK"(<RP9O$1B&#'2I:*F8GO.8.74VRWN
MCC%[WI6Q<#^:ZG!GH^OGB'>+T0]S'V#=QF)A-TZBJR&'?K66F;+3Z7PA7'(Q
MTEVUL-S 9\3;>RDW,^LCM]><?FZ_6_!6A;\&Z/3D1N7[192?2FA?$)@,48 @
M;6?X6ID\7R6Y5:5F4M@B$J&)5BOUEZ];5)V9-?(@\@==@QA4(7(2!P4<!6PK
MG*O$W=!(0%5<YJGVO&=H[CQG58%1U?V1=(O4MNV!E@O;AA?0;9R[2:X?_!S0
M,ULW;]5)9SQP+KB*PS?*7F1L8M[4UI25I-^3;N&.Q Y!-)O:C%N80RF@VYIH
MY/GE*UL2%NZ/,A8=-RG$X33.%RP0EV: "(/*[%GW6LUQ%<R-SZQ(OK34PBEW
M7&S0TZ?S86VMF<5J,I1'8)\Z]1!3SM1(;*^O*S6.O?L9)OPZ@4$RR!1\U=*B
M@A*>H9V#:[K1E3$'XS&AYUT_/O8DK)*?O_UZ7L-1:_-)7^2[17Z/!BW%G+%P
MDI7<?A6HY<BV>>9&::1&59]2S5Q64W*V44RBR^UJ^.9MZ-+'$K^/45[)/7F@
MJ*&T/8&J2:I\\X7'3OEV3Y@$\W35Y-,6&:L@'WRX/?@C]$QV&"M;S4<#]_M1
M6B+2>3:E9>(ZF 4\O+6=.^+;%ABH#E+?,RMX-H8:QYP)\:#M520!7G3M*6%3
M?[6+!R+.51G)7(/AX2:B=0X6 \O-\+2B(<M<BBI&EB)UM/L,T"[LVL4H=.:U
M1UZE,;)AS W<( \-\_:[]LS"VWMN'2#M5<?]J],Q,PJ' 8L?,@$G=$(G=$(G
M=$(G=$(G=$(G=$(G=$(G=$(G=$(G=$(G=$(G=$(G=$(G]+^+T!,B?*9V=M;\
MK*R6MBP&1E:&8!:0E07K8P-K5G86-E: H,AC:P,0%&Q'8P@V@5@*T:Z65='2
M0(R$:-6 LFRRUJ)@4\@#9QA8R5E.&>0,!?$9T8H(GQ5\S/_8PMH";&= \]C"
MW-*6_[$0[;%Q?LSG(S8K+<VQB!U4B/;>T0"-NJP"C:@5#$S#P\+&#&)C8Z/A
MX6-AYP3R@/C 3#0<;!SLK&P\K.Q<S&QL_)Q\_$!NFN]$*WP6TPK"C(SY'XE)
M?,?#](1HOP?FZ.C(XLC)8@4S867GX^-C9>-@Y>!@QD@PVSI9VAD\9K:TI?MF
MY(<=,; M" :QMH-86=(<]0T,K>SMA&AIS]+\0M^ K'\!^E,&,0.8#'*R_DX)
M$_COE7ZD_7=*1J"?.M;V,//C>(Q K&!SL 78TLX6H\?^3V"RLO\:SL+BMYJV
M=N(.=O]:TU;9R1K,^@AL:V4/ X'%'3">T/W>U"/P/R3J]Z8PXK\U9/WC1Z7_
MD/4?P]_2*/R'!4',A/ KP*R,[$%@F/ ]$,S*T,".1@QB:P<Q-P?#:-C96# 9
MY*:YI0:Q-+)RM+TMR/HGC5\L83+*+PH#&]A9P92MK,R%%92.JP7(8F1N3J,*
MAMD>U0V0A8.%0Y#UK[)_,2-K900Q=A(SL ,+'Y4X,SOF'X\R.Q<_&R\_)Q<C
M&Y"?D^V;D5\D?^<*^&\V./F!/+\:^$7LKTY@%J21@9W!O^7&K[*_V#$"\=M!
M[,Q_Y?U83??,[?[,_3%@#CF:5'YS TL3(=K'S$9@8P-[<SM:85D(9G9LK8SM
M:-2L8$8TS#3W1!^JT\A9.="P\[ 868$>"[)^4_\+&.O?T019?^/8D;.@;W/R
M&W>5P#;_Y*XP#,;!Q\7.#?Q7#OQ9_]B!OX,=N6!L!;,PL!.&6!B8@%G!UK;&
MQ[+?N7^>(EE9?BE+6SL#2Q!82DP8PV"!0(SX#?D,#=F,N=F9P4 >(V8@B O(
MS OB!C)S&' :<O,"V;G8P,#C6?NS^M],BUF![(_V$,S8MTT:DV.,^9]KB9^/
MPY#'F).7G=F8CX>'F9.;RYB9#\S'Q6S$:6AHR,5C! 9Q<?\ ^L78WX#D81#,
M&6)@_HO,42Q&&#!N-@,@!Y -Q,S&;0!B-F3CXF'FY63G8^;A8S?DYN8S8.<!
M@7Y _,;,WZ >8!:V%<SIOS:_QYN]M0',%GRT%PG1_MB,:/^F<*1SO#WR&X".
MC@EA6P,'L)$@ZY]X_ZP$^?MD_GL)^)OZ/V,XFH(M_[Z:.?A^K.9?I/[9R-$J
M=#2 @>^98/(L_.VD_N-W_1P<+,!?-\S?Z?RS;9 I9N&#C819?RC^8/QM=GZ[
MVOYW3)L!9C?D,>;F8N8Q!+(S<[!Q\6'6(!>(F=L0Q,7)R\'.#0:"_QNF[8]-
M^&3:,%,$LK)T ,/L_@M3A\$QP%P\,8>SL#',RH+&P-K:' (R.-)B=; T^GZ%
M^+GET=A9T?RZ,?_-R/]@L$9@&.2_4J6_>/DS3S3_?POZ/UZ8_][A>+(P_\+]
MZ^WEGT[3'U>';[4I<51=_]YD"QX_"OPG6^E?U']GW>C_]H+Q-_7?6;?Z3Z\Q
M_VCF[YG_)<%_>ICY>3<3M3*W@F$>#L#"7(*LOV/_>+!E_<N3[;?'9M;OS\V8
M9W;6GP_MORNR_WXZ 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!
M.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y 3D!.0$Y
M 3D!.0$Y 3D!.0$Y ?EO!CG[Q\_@P99&0K2.M"+"Z&& * #K/Z0C(_^I#2QT
M-8#H--93K$)L+"+ *2(L;"(L=!V &@# PL$^&O_Y:W_\TV?.XN*=P\$^=21@
M0(@1.(6%C7T*&QOW]/DSN$386*=P</'P3P.(+ITAOG[V,@DM.^D]Q2MD=.H&
M5V]PV(2$(OIOTC/PW5=Y_"SP74$?^2U.;AY>AR+D;2Y1\5<?<FHD)!\I&1J;
M)D\ 5=5,$C$05!CP8R?^^!\'L(X03F%C/,&,BV/\Q3B A8>-AW?JU"G J7-8
MI[!Q<(D EZ[CX1.SWU-$TAK8G+[\+/!##0D=1T[7Q/VU,Z0W.*^(/C*\2<\%
M5((]#XI##P'.8V-AXL8F H@ JN"R7'8]DO^R44QO%E&CPEFC,)HH!9FM/M$N
M<P>VKIFS")?6FZB-ZQIV<Z2'<4U4#JP/\P,O%C<L1/(5%B+(HROX!A^=X?A\
M_Z.BBQPDF6!_IUCMP*JXXM"]0!*E7L'5]0M#'J71(TO=X?W*';'G/3Z[IXP&
M)$;_KY'HSLG<EH@9"5PV-KN6G5F8P$_7X&O/JFVB7FE#&O>PZ]W'R2%J\OQ\
M$J?ITW@WK%NL']B\]B?610@I)H7QI,)35." >=X]CDB27C483U97:3]!(T_2
MC Y)!C)$Z;/C;J[VE$;'DILI[XNH?+WGM6>@>+4:\B]Q>,(CHKEZGL*=(/Z3
M(]QO6D9GZ<ZFUIO9[_N^B1F88PJ9#"2[9BQ$:C!(/WNQV490DZ325O)B3EQ>
M3FYF_8NM4R217KB^FA Y2&;__?6>^^LP-Q<"\9GE 1M@#EO*KH2XK+S=B'B0
M[3YWG@A\T8RCQ'YM#G:.^XNC,J)?X39#>[ _]U I<."]3 @-7U)$2.7FN<9U
M*FO8%2\!:E&-^7(9R;7/Y6^R!W8EH**VCF$3-@ZXA1=E/DWL%&<:@)15#>/R
M&U,B!6X%!UX-#+A@(R[+[;(X 8\1UAN&[_FX\3N9S*-F]R$OX9NUPY>04;8&
M0]9SQ3'X33'"ZT$PI-4-O#;OZ'%S&6%>_=#!89N*HF?*H.!+;%)\B1=$)NT,
MXAK7'2]=)]<$G;4YNQ.4E$#=@QW$!Z?GJG2QSUD?V,-FJN$.1^XQ+3P=6NC0
MU<MUJZSF;)S/RM4!D5+QN?KU>'/L4]DFY(IODDI>7"0KS2\*?ECX* +"-'$E
MK>ZBWKKW8],SSE$17Z_"(;",55\M6@F%D+5=NG2V"V5AD(?#O"FIFLY;W:>*
M..H_J5O7@.QVWR&ZEG3OOB&;Y.J!?I'/3'(MW\*_NE@(OXJTL$GG@P2NGR/M
M"T\BKJ(U/]]#'@NW:YX"JPZK:734Y @P02]'$Q/F/M'VRVU?H!1GXAFXX2!]
MB6^U=KSR"5=/ZQ<&WMV;+>=\Z(S[D$N/LR]P+V6DVELN!)>D))E_FKR<4>+
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M+P8-\-AMW^LK+NQ [#ID%:1-);'"!9[0 2M2RAK,UQ9;"4!=%HU.22S.X>=
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MBQPF+R;UPG[")&)D*L,#-,#2ES$".N]IF_TJ$D]&WR#JXV26J%'EK877%$$
MK0]\HV47Q6];O8*258E<#SPO866W?M5Q/BEJV353)]^@-2WWF0EA*P3[3J61
M4Z 73QSC \Z&ZSA;?"0D6=#@-"\OK]0>69>RY#5YE%)2Q.'&_\=SY?_C1F&[
MU$U(W"$9K+Q:J\M*NY\-%A^E_"37'!NW;]=O"+ -(/#TG\QF4<P$-EA2%[79
M'Q*%2:ZINI"K,H@&>-8TI\WL.6Q^)1]L3DN+$0I647'7C9A]-B=R/4%]A/7+
M\,-=94TMPNJDJK)H4!J%27)&KU?%P6J=/=B/&@A764ISO%:_XKMTN"PN$6^(
M<G<?UT@;Q89XWRG3A9F$#1 ':GY^$Q4ZL,>!X\A3Y%^@5+'DT*9YIB+PTITZ
M==/QQL"NV-"D>/U-D>0=Q"B5/,_:;'R.G\VHWDNSOLM"</CR[? SC>.'?F*9
M)K+Q2V>!.^*J,F=&WHS*SV2Y1/BMPO'G#S<+Q*;44D*X?,U?CP@.3U(<ZIHM
MPS\82QNZ18]?;7&K?3V]O#[3\*Y7146BA+A&\_G+Q[8H-]0H(]]TD[1#T>[=
M":SE0#\86:EH &H/J!;'X,Z;PUU!_YJN:QRIZ40TOA><4G6ZU\)*'G,47K,@
M=)4#3L&X-,8I=H.R^HA<YR_E"[8%X]R)WB]KZN(9UNF@<'D2IF]=YF8$*Z#,
M-#L;&$- Y:8Y>MTYQOJAW^E<*E'#(<2]<LV!X;ADYFX)".645?[4,._651''
M)L7*(2*=4441E?F4GJAJQS&?H?=2FK6V9IF^U#4)2OIEYRZUJ".$B-2S[2^4
MHP$$K/1;DCO9CK0.*RE'C^U3?6+*L#MW',57HH-%O%A7Y2*@>Z,B_O_355@U
M3C(4NP[\LGV(XO/LT0G</:2N#,RL:=IG5# )D\N@OYWK(-'2P;X?Q)Y:8Z_+
M2D%?]>:EX24HS52X;SR3Y2U]>%+FQY*,IXUKLS*5^9',.:D0\]=T^;(P8SA9
M1VRE<*FTN>N]?%^6Z>(>-3N*1^][M=P).T.T:'6OXPY5LHQVY)Q=&B;X9#12
MUYAHI&"BJS14>QYZ[ORC:S1+8Q_!&G#GG%5(L0F92*AGX_Z!??+GF*0A'GUE
MO(5TO=6(G=#2K^9+H^8MYA=]DT?(5@)"U"-9N NER]M[.=?/NW[9ON1-R\TI
M7$= SBC)VI(+I-A'VBSN3$ZO(]OSWF_>FKS@*WYXST]K.OP5J4!V/L*6I9\8
M3FY_50=.DX&ME6(/A&(;#7+RX.E#V*7/"]%])+&YB2<[6J]?44\A.SF[*KS3
M7IFU2=S]*LVCN5725M<\?C827ZNCLW>'Z;9 Q OZ/O5]P3S]PO67)91/+(&Z
M CY#G:.57[@U.$H1W)+WJ#S$,WW?7[?K>;PA[-1!11F+ZJ_<ZV40[01IFAB2
MYIFJSX].,^C>K=L&ZYZ%+=XITTED"AZPD% $L7PBO:=CP-$*T3 :X!W-,'>K
M^^#I3I^_*D$G>TA.UM$A^-CD*^:66[H+?@.1#7IA)@J-KLG+.WCA:5RR?!,O
MJ>$6!]^]>OO]YM-\0)^)T>GB&LH'N1R:2?79:=<RWVTRPB]=ET.<]I72%WPS
M*8A9/Y6%VC+O*!T["@JQ\Z\OFY.6X0UE!^J]DFE;9;1.O;*U9O(@.;^^5C8L
M)JX&9I;^.._V\AI<3.N!JJ(_X9KBLCQ]^",LWAID.S#+J+3EE<NYFTWL4=EX
MDU0ZD8;VX[[3P:3Y5TO[@75IKVO"B]0"V\@&J7C.?&+S:M%X@W.'XZ-/X&<Q
M%5.'W<DU$7FDR 6H.O6UXHH@98([G24A6E)B4AQT=8V\X\TZ3=Y?4CFN7X:!
M/+BSAKJL4QE>2[J8>#D/BEB*B]&$H0%]*4/)U8=B$'7OK&T$[Y0#;GN6^J0!
M1>"G]"8+KI6Q-#WJKMP;%FU"X>!D$ZM7$M,U:@P[<K9E?%<O4TE29Q4]<*'H
M)2:CT%!JS"3)$>-YP@FUR1W"S?=(MFQT6=8HL4X+X5,1X8R?."^WH@)]XD*0
M]!X^9[OC7F%!\J1D]A5%PTC\/1MW_7J3&F/]O0XP=)%N:WFWWG^ZU)8EVWL:
ME2_6"GYRJ$9.7#;2?\UW<]^]'5@(WR1K7Z!$F#RY//6$O@ASH0=EY58*FS=7
MSH^7Q>-R;S&^"X.@ME@8KXH&*GWBC*F\QG6GMF4=,7VN=]OG T@GL@]&H5*!
MOT*Q>__+X?X+/![+P]FR@,[/Y*1,\03@1\T7)@S84[(UA$]GS6?Q*[)3*[*<
MF;TDB4T]W4&M9ZJ6_S"I:(@WB=TYV7G+W#Z^:0FR/,Q0NI-A<A\RM+)LW=68
MXLNU.+?^!$KO-3@P)BH5\,E%L35<$HHWQ!BQ&E*22T-U5R5+/J2$>K!I_>C(
M-=Z+R[8:/[R)!DSNN]=N;_3HC468SB?Y_3L-=.:^C]34(S:+'7F&DJMCBRB&
MH&#BV7U7KO[I&W"8(\1C"KDM4+"LC%Q)G46F[PK$'5HAW:[,3CA#LKO)Y)2A
MNGVPO!$Q\96T]H/R+N)IC5%%HJ9=M=(G^QL]ZNG:_M1QKP>W'8,O=^JQ %WH
MAP9%LU_O?CT_@)S@%LO#80F](SIPNBMP 13>1ABV77(U$Q@N+KXK=^19H)_D
M;']$LK]6ORGH_%/M(&W(:&CTY&0^%ECUTNJE6A:KA4$0&0=MA-@5N6QL\--'
M\835CRYXGHMZ"96]5YB[Z3M 9L&263P-=KBIH,W@'14X0AF;TE\\U:^II:/?
M,4FE^'ZU($'KX;OG&0E#I?  .X1?>F$X"].3N 9Q]NS/Y\AS[^1W5P2B5B!,
M4,6L^LCXK=?KUTU*0L[OTUNJI=Y>S#CW:F&@S$''@S4O,^^U\R)'D*U?N[>D
MKV%8WZB'B4LT1^VE;#CF>>,5G:S5+AJ0OL+L9?YY[G&I*/.A^OH%C;?3O!5G
MMO B"AY04'G?U5C'M4>X2-[+2023*7GZ]K5E K-D]<0&2=>(G@)2E^97D[FZ
M19XY%YMK[LO<7QY=3;\QJ9[TZ?-6P52#R[,)KE[5]5OA4:NRT'23Y;21D4CI
M)@-HA-FUIZWM<EA@WX?-Z3:O.4VTC.)*GDO35HV'5FU/)Q4=I"\&P=O ;)T@
MLXKTJ </\]RJ,RV!##A^X=Q8<,$%O)QV;N'K.ULJ2GO*%%'[1;QC9]XHN;9+
MO:,F*WW7B(P[I))JXZJT:)>Q.H\&A$1 WXR8-[$)Z8YT>.^*,',LI^9MUL_4
MOMV7HP=[Z_.ZG?/^;//5U7JN<$N-G-R2HT7 VS,B)NFR*>'BHR>S3:][-%70
M@+1#HF?3&E3L[Q9D@VR\#08;)KLXMGUID*49^.Q3)M1V!8>S@^IX?)Z#LTI;
M-X64(Z)$&5+@'%JEM8K4M,]V!#(3)!5&FB )!+R;(6T9-D](5=]_4;6GX&_D
M1@/PS1@,7"09$ #7AM"9<N_[T/ULBJ+Z0CLO=3YQY-I>Q"W@-L*'E-%^2Y5<
MUF6!FF%Y"%+GV<=],TO4_I5AN?9(B82EW$-SW=O0A\XL4JF,Q&;FF3SW@L'#
MEI_BAE;YLS/A;/O4) WD^BXC'_M8RG*+O"7]1?/"26O6-*'#M99V ^O;0>1*
M-F>X%>R V1?R+R[6(O?]_"+PU'Q,!MU&IZBJ!A2LS*%2O&_!U8&9C',)HA?J
MHVD2NR,LV&/(9X*84SIX=XEW0?L+RB@SNW^\3H3%"N\41<*,X]Y6Z2VVF2WM
M42<5Z.@U0BU*8LPJ/L!'9CX]=/"^78<&Z"-EYG=U;M52,;_<-Y10\?]4'*E+
M9OM\35 )!&QZ)@QXXN=$G;R[B<A)$A*^IU3!(S<US@T>=. 1"-6Q<'U(.E,2
ML/;,:$<N\)-]Q[I_*)2&*@_?H9Y45#:@(RE?D.GEIH*)V VIB0"BLYS:]XFC
M#JE+]A_O3ME^M7CBN+$TY7\Y?F%I44VF=Y >D=D9Y=U7<F!L'VF\369A;! Z
MLQ6)+3N-ZMTJ;FN-TJTP3[B?.'R9=]J24<-=D9)#%3>S_%X[G6SR=&!@4^,^
M+[7PQ8)]ZNZBQ_,Z[B%FOI!(Z'XL45 N;TN+-DP7S/TII$'M=@&>O-_P\A/C
M<>3Y^X_4%J+?4SZQ74LG@W#4XD1-(+RI(K$:!")\,Y\+%@MKQ_!VA/#!][H_
MR-94/IR(K'=ZY8\OKVUI'@^!"3 V;QPDN8<@/G.%92WU7^T!-!AT+P5 WVSU
M\^R\ ;((V;A!R$B8*-9TM=74$K4^WXLP3H;"'O-U>+8^V?2&[UQOHF01.9]_
MD*B:-;)O_D7NNO<44SW]\A-OC5B1*7.^KQE7],&;;U*^;FE/\$]MV1I#,X"%
MP2TLB\LK,'(K,NQ'I/&029_)&;ZO7]?WA=S4'8?WY%:;M#]V4P9V[[3GM=%!
MHUE+"UP+^3YR,V^5.6LNI;<Y6<@X7@73EPS(")>6L,T_S'O^(>N=T=L;OK>]
M_-QE8?JVU93/183EDU>3B$WF;<K71NXWO/5KD;)HB4YLB-Y-="#:NCSB>>5]
MW]Z5@$AOVN%=^KX^X/M:3B?2@G<]N7D]SST@:]!A=L.P\B]ZM<XA7-S%2X*/
M'[MI'U8R;.Y"NP)0>JO#9R]*0)E8^>N0S"Y%]L D$0[7) ,!?0USYH*=F=Q@
M:OURTHBT(H:>S9(9D>QIA$6KZD7WO)SA2(H:Z?3$/<VP+RZRGM.KR-YGR$C?
M<*JGSPHM.4^;9#5O(;3\IAR[KICVFP\8!_D:]*F_A-Z:B>M"77S^<OV]JIB'
M*;#X26ZSIX86;<,7Y3H7G'Z@-G8L\>K^_+I=/_,UKJX>64R#<HOF0IS=N](
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M[64\!$[X'U@]1@-&A;C&7/$7#^W<_RO&]3AMAGLO\8Z!1I#%M,24]R\'.;[
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M\&Z#?+4Y9A;OI"=G>=VJ7&]4)32;B1@P+YEO,,OHES. Y2X%:U7)OOK4.S@
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M:>%LR>J?(7Z@'R)/'R.--9B]=B!,![J7(6[M6-_#P[4WYA673$>[+:]?!1Y
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M5Z7KW$[Q91Q!V5;0(1I9Z?0UN;VJO0&3%(Q\"BB"O?<;0QR"G<MOA)$J/()
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MV;5E>90+##-#P%?:=###5AQ';_(GA\/O[':'[O MML;%)K]U7UT?PAL2J%-
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MG-\!"U^1GV *3FOU?.VC8NH6Y6%*RUVW:; 5HJVIEXCR<YZGTP&D9(79.&B
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M($"RPA94Z3H <% A$B8A)J_&'5'/))]J)PUB:& ;> ?QX52V[FK3^7FNMN[
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M,)27#&)!*N7A+YI@%RR5"W,@"99L9"QL[A] *(FAGM5>-ED/#TI,0S&!+N*
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MR"%;$@).77@*!S]M@41,GU9L#'QQFRY<_%[ED&(YC54M@.&4\!K$(BHA?OA
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MQ_,%"#M+9 5ACG(TX/C=C$[&=*4@[,"Q9MW8660*%XD89(DT_A ]WX:KG%B
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MIYC?JJIH$B"I%/21(D#TT!!*L:&2*5NY7&V.1V52$E*Y'=K55WJEH'#-%-!
M)JBG7('>30PF4A>"2DB."NP;%. .#AYKYEHM;&H)$HB5$.<>P&PAG)%8>2V.
M)ZIY*@VJY0C153LCE1._SUN8U47=F4$;BNT+CG..21G@\>/./+RU@\'2TJWH
MN*7_ .1+%'&\RQG<T4+2,B;@ QP9&./$ \<<:<9Z3.<5>3>J]@..U11S 8;H
MWD=7RK!I$(AK*5K.<LR&-Z?"BK$BBBN3NOC)24Q$[,1>O*';'U/2W>_4%#2=
MW(_3XF6HE7#*:NI>GE>G+*>?NZP(LN#GO))(CL:)L[,MUN2STZTR',OWAZF8
M$Y"RMM78/3A T@!!+$ C*G+1==YC7["PBAR82QX9[Z/,]^K5_B\-C622PK4(
M!D\2& &0)Q1%8CV_;E$]7]U<C=]]+]34_4=KHKK3I)&)4V.CCE)HB$GC5O"1
M$DW*D@.&&T\9QKHN%E8P2U$9$L-03*P&?Y;L7!60'P.\,%.</@E> <9G(K6E
MP[&K"ZOYC(%=#"0QBJKE(5S6/(V.%C4<0IC>"M&-J=U5>ZKV[JEXN5ZHK:DE
M?<*F&FIJ<9>6=U1!G@*-Q&^1_!8UR[G 52VK;0V%GHVAP8T< /)G;M&0 2V<
M\<;1D G &.,,+XZYW6R-K;2L9,#\.H[>EO\ ,Y#@C0@*6%26A; CBHQ&I[+(
M=@4:^VQ5(=@V"&Y7M3KSYV>]<VRCZKZLGJ2EMI.HZAZ^G>3:(X#2R54O=S.@
M"[YH)Y),@8,T1C7)E4F_5-N@N4:T[R*&A82P/-\*LR)MRY).'8$D'.."3DXT
M^QEE3+70K1+VO;C]R2$L&<26)D2::85!PP *][6/,<KT8T2=WJ]JM5$5CD3T
M@E[HI***K2H@:&98C!4)-'W,JU 40F.7<5<3;E6+:QWE@%#9&L*'2%2UP4!,
MIC<&(!SO.5PPXPP(*^;9^$<Y+;(6U8EKR+'!IAQQXICN/WN.9G>9#81Z.OJ/
MM+&/)G7+5LC!3PB3Q0ZU@1C)/L7D>..!RJ'OI.[]K-!3=904\;//:*>DEME;
M61.3$M5+412FHA4'NY8:7N5BE<,2RRRF,,8$6;+J.S45,OW68JRR2F:24-E8
MJ@*$0C@_TJ623 \7.!A#N<VF08?/K*[)!9%3+1V$@4:!:OG@##ERCD:(449#
MO'_?3GJC5C.1IFO5$<QJ]NVTX>IK6MO-<+E0_<6.T5;54"T^[S3OFD6,/D$;
M"V[(( R2-4U3TR:FICE0*\:GX90RF/QQ@OG9C=C&2,' )&<:8[RWVC7SY'\F
M-9 DL-6SPS[VQG1CPG)+A!>*-!@ D#&4@D2:]QYJM:(BM8V.IF=R=:([5>O+
M9=Z*/INV.E<D55'5U-=$RR4T3PEMD$$@RLSLQ#RRQML15$2F0R.8KE#;X;:]
M1M*O4SK%'*Z.K1!(CN0 H2I<'&X@_".,Y)"^33.V:[4&N:^-FF1UF0Q;OW[/
M',-QYIY^48^ \LR%-;2WH"G@19SV.E KW3"V(WO>1XPH11I:^SSM1_\ 6J.6
MV7A:B6W0JTUNDIH=U1"SOODI6CD:)9()&>26*0N6B8LAWQNG=<:JBI;A&(:Q
M<;5PD@7+ ,S$JP.,J,@J=P.0 .,:=)?;HUUB]?B%I9S;!XL_IDO\?DDKIA!.
MJ22Y5<EC8.:U3CB!LH4N =T<4L_OPY2""3VE1=R73M8Z5I((9DND=4TT/?Q4
M]"K3R#^6'1*A44_=7<D*(ZC8ZMD/& IVVJAZ6H*0 331&-R "H[QN[)SN 3(
M4[2<*^PGSS@X<!)VF^IX.<8;#8$G&I+,MY;<E\=K,LI%\J9([M>Z1/32:R25
M@21H4AK65,W[IC)(R@;]YXD87MKWI;M%I[GUFD]TCHX)KA;5M@JTW]TM5'<*
MJIIH899U218)H:F*GD[Q5,E9#$1A=NKZU/3O1-;J8" "-5C*,0CM$[,L:[L$
M"52,@@$RG 4 \:^2K\I*E1?G\J]NW[U[*BK^[Y147]WQV7].R]>A4K5$(3((
M&<G(\#@$>1'AR,9YUAD]@E:L[TQN'PI7((!(Q@YY&,>>[&1X\$:CWYLV5<2[
MQ&C!*]ZTK$?,L@-<UZPV6JQ2PQG1%51$)'AI*:Q_971C@,W\A&.=YN[;[W0U
MC62T4\L4E5;_ +]45*Q.C&#[P((HHYP&9HY&,;R&-PK! KGAUSDE';'H&GDD
M=C+5]T_=DGX4B7X& \MV\XP.0K8QP2\75@84K6N)+3."6K6D@M$@%16LD,"U
MM@QWBB=C-L$E))3LGC(0J+V7OUO;I:>U#I^P-:Q$M(+51K$8MI3(A19 =IP9
M%E5UES\0E60/APPU8+C1W&>6M6I9I8'G=J< Y"4V2850@8P$*C@'GCQSC=(X
MAQHLV3+.V+#C"*65(.Y C$ 3?,A2$<YK6#$QBN<]RHB(BJO9.K_5U2)M<LHV
MC?N)!4  DEB>  N<Y. ,Y('C;K+:JB;OXE1PKL8RNTJY)("X/U_I'AGYZ;QK
MGD%C6PLBS"ID5TFIK,=986</)'M;^",QR&\$=9M[)=XCJ9,J63W@$D.]N6^8
M.*-4DC1IM6V+M:L%?<:^W32K;TAJI%HZNK=(J2MB0[ PG9@D$DA!:*&7:'B"
ME6+@IK*+E8J:O[IT?_Y,%.*9WD8 3=V,!P[L!NR6"@X)50<$D@+1+N*&!*Q^
M%)M&RY>4E,+&85<JSI%K[$0DQY(C8WEYQT&-&MDHY ^\< T>CBM1<[N_6-DL
ML,$]PN%)1I4[NXDJ)559=D33,4.2&3NQRYQ&6:-"^^6,-8*/HR1I7^]L(8P[
M* Y";BN,[<D;BJ\X^8'BR@IQJ3:H,QHG6V0X_;8U%+%O;2+?3(<M<;/!K)<L
M]C$);.$R-$GT490BFQSO:I%1KA/<15"S"+)VKV&\;8*BLAM]2T;U6RJE6. (
M))1W9J7"Q">**.-YD=DR) \1D0G9D;V"CE=)*=A')]WBB$;L%RD4>T<\*#A<
ML#@C@Y*_%I2S9?AU!71L@M<AJX]';R8\:KLTE,)%G/F*B#0!!JYKV-1'FD$^
M!Q0#,60X8QN5,RN_4MGH+73W6KN%-%02=UW=5WG>0RM,,PB$PA^^[Q,NIBW#
MNU:0D1H["TVJPS05M9'4 11;@1(_PH48X7#^!+?\2,YR#X9(99:9IG@>5$.S
M;@5Y)6+72**LQROBDF3[K%'FDJ&\@$C^]%F1[!SOQJ#/CE6L(!8Z++]I'R.O
M.=5VG+_[^G4*022VFGH7LJA>*B6WM*\S5:*^ )'G99Q PC+1Q1PLZN7DUD@I
MJ-8ONHCS -P+8 .XNK]\!CC+@8!Y,8 )!;X7PP,VPF^N,CHJJ]K["UP^HD7^
M0Q81F3OP^IKH#+"WEN/#=(CG%1B>H[IT<QF5QQD%(5JM[];IHNT+I6H1V2_6
MZ/$:NRU%0E,RJP!'_P!YC4LN<,JEF1LJX!&NJIL5/)W;13P/C#/_ #%7: 2!
MP^PDX R0.,@'!.-/!)DLF7Z-OJ"Y!$J94.+*R?AAEV-R+ :(VVK+?8D:PA2'
M1_'N-!F 2.83G.\D:B]T:[K0?777=+>KY9KC98Y2MBJ.^AFJH]L=0RS05",(
M=V]8]T6TJYW,O)"D@"L9*:&-((,R*NXR,5*HY=$4JH)#X 4C>=IYX7C)9/19
MIC5YCN$R[&7'QNVS6L+-J<>MC,@VAG0C?;RUC19+F'-$=)1WX=,\&ALP=C0W
M&\2H/T#TUVA6/J$PFGK8H:Z;"FW5$B1U?>+&KR+'"Y1IT0$A9H4*.$9@!A@M
MEK.G*>:F$=&5>/:=D.1WR8Y*[.6)3.=RAE8 D$X8#1]QY=60,$SG%\<OL4+F
M;:*:&53V>1U-7-B5\BO*2PDCBSY 739J5RD^SKHR$ER))0HP3E7Q6T=HW6]'
M:+5<J*"IIYKS4TIIH*%9XA41+6QR(*F2-Y%*I'%WDBAL!R(Q_3(":BU66*A@
M$DI D7!BBWKN);CO,;@Q P9!@?'@> ;</-H"\Q;*=5XU'Q%X0DQVLAU]O4M0
M0Y,*W&/O-D2 #_.YMG)4\P4LC$^\0CG*ON-(UM\[.[U9:OIJTQVEXEBI*2"D
MJ:==JRTU3%$%E2>/ 8/),))DE*@5*O\ >%SO.+5U+:IZ[=4Q;S%L011C^E'C
M3#J1Y$L2S$CDL"!@C*QN"\$29-G';!CC$0\F25S1L  35<0A'*J(T;&(JO55
M1/'M_BZS:LKZ:$&61X^ZA1W=I"$C1%4LS.S'"JH!8L3@ $DC5AM%BN,B,D8D
M@:0@*R[@5()Y+<  CELD<<G4<^#[)QFRVEJBM/%%18_B\[.V4\Q\GW0N/D,R
M0^JD24<U@P"&_P!F,PBHOB5S2D<T;5[><K/UU8KKUCTQ2"D6AM%FEZ@@MLTM
M0H@EJ;M(5HG"! L:=VO<PEVW=]4@810-V=U-,66H%#(\59411QF;@][)&J0#
M;Y_S81)@,<EY=@\,M(S+@&3R(J]U>K%(OZI\_H]/\?;X_<J+\*JKWZ])4]5&
M1W8(P =@X''@?#]^?4>.M>7*S54;]](#O9E$AP<$D\D9'GXX\N/32%\E[:-C
M^G<ACFCR)$O(@AI(; @<9H%^X%//)E.3O]N&/'B$<T[T[-D. Q.WGY)K+M4O
M=/1=(76"8Y>Y#^'TR[-X:IG1R&; (1(X8Y9-Y&"R(O\ 4X&LNL=L:F3[])N&
M*8TR,0X#B7^E3GX2!M+>1)48.<:V32.<PMB:RQ6RE%#'M6(7'9$4I@C?,M**
M*'[E\42-"PBE@I'L7@CC=]L$Z(OY&HY:OH?K&COUHM\OWBF2Y&E*UE$)X/O*
M2T[M#+-]W4B2.&9E[]"8U54E51C&NZ\V@5X:HC5Y%9][)XE&. P(!8D;AD$\
M$%> <@;-G>?8YB.)9Q="G0;*RP2D#:S:J.99!H9Y\A*RC;8"B>98P)EP\$5[
MW(U0H]7$4:*CE[^H>M[-T[!6R5-=3&MBII)4MJ5$7WVI9@1#$D&XR#O795[Q
MDVHC&5LHIRBL2;(35%46(I*D9=5?X1_+VIN#A69< [2N,DX ..BSQ#ENL.*7
M&B>]K6/GZ#U!-<QB^3&.E:_Q\RM:J_*M17JC57Y5.W?YZ\95]8;A7UM>8^Z^
M^U=15]WNW]W]XE>7N]^U"VPOC<57=C.!G NKD,[%5V L2%SG:,\#.!G'AX#Z
M:<1U2:XZ.FFCIIHZ::C@]7Y>WIA<Y4^>Z\=-@]NWQ_\ 5B_OZ::Y3^'5LJ[R
MG&J6(QQ)EO?T]9&&U%\GR)UC&BA:B]OE5>5O;]?G]>H/S\N?>=-+#NZW29O'
M:ES52RN839&52($P+U89/9O); 2!D$Y%1S5&UPWC<G;LCVN5%1>AY(/.1X'Z
M<C!\L'D'@@YQJ1G(]?+\/#_6E.T-E.#ES@V0[$E5M3=1;DV8CRHHRQ23I%=B
MF30(V,@'715%%':WMK L9YGM]F<Z$V-,&]LA7)6T%QK;76PW"AG>GK(&9HIU
M 9E,B-'("&#!@Z.Z.&!#*Q!\]<DD>-MR'##/)P0?7(/!R,^(^G.-9_7^4Y5?
M<>]]Q).06)UQ"/@,ZK<4KWR UN29_%QV_A?=^2F9$*&7%$V.KG!&R1($QC6D
M:Q,M3M!ZC-AK[%-5S5"5 0)7-.5K::!I%[Z 2$,\T$X!BV[E>%7<*_<G8O>L
M[;'8HK2CPJ"Q$J[G!//BQ)+#=G<%)&<;<8"^S35>0[KPG+;JBLI6!5%%@E=D
MT"-#&.7:R,:Q>-636MCI+"KAGF1PQ3>9QK(AB(K5:TK/'"9999G,L\LLTK8W
M22R/+(V!@9D<EVVC 4$\  +X :Z'=G.78L<>+$D\  9)R>  ,>  P,#&MZTE
MMJXOMQFC7UE>-HLDJ<MKH-7%*"-#KYH\=N"86R##<Y8L4=7:,KF((+$5T?W1
MN4JN^=H=+=:=;7*_T]%2W6*26OB^[I!7H/X>OW>G+JRPPH#!)MB9BT"@ROGO
ME<$XJH6:JG59>Y889LRI\*%$9^\41C>7RI)"\.22^0 -(5?YM6Y'K"AQ+(*6
M?/S3'<SM[*-DIW#>BXU<PT+95)CNDODR9!<A9^(C>02"&Q%1I.Y2(NN;E4U]
M55RFY5<]950R2Q22SSO.0ZS.T@0R,P53*TCA4"H"S,%!8DTSO(QP[LQ7X>6)
MP 3@#/@ 2<!< >0TLF+;9BVG*+6F78I7RJ/%8>1Z^Q:MI;!\5[(6*"6LIK"F
M+%$XT4T J%GF:%WFU[I'OE_OA7/3JI*RKH)3/0U=31S,C1/+2SRT\KQL03&T
MD3HS1D@-L)*[E5L94'7%7>,DQNZ'R9&9&X.1RIR.0/7]]))DF09'@5GN76H>
MTBIO,DM\?O63B.D$>;'LIEN#8@0B^+++SCE ^4X;S)'D&:QS5?W3I=WED>61
MV>21G>1W8LSN[%G=V.2S,Q+,Q)))).2=03DDGDL=Q)Y))SDD^9.<D^9TX_E;
M>7>'\:/2YM<?LI%3:QN.&]Q G0B(.0 4_E7NN,=HBM3NQQ(T@@G/8B/9Y.<Q
MS7(CDXZC2&<4\PRO^4:=!_%#38-O16DJY%9S"R5*ZIAEDPY4=LA[G'L(\CL)
MB*_Q^U-*]Q%1C59M[L>N5UAO]504\P:@FMM145,$\K!(GIW04\U,"K$2][/W
M4D:LB20RRRL"\":J8H$JU[B=3)"K(P4Y^%N\0*4)!QRQW %<@^> NDJM]DY[
MD<&;5W&67<VNL9Q;*9 +,+]H645R*OD%BM8V.Q6M4<5.T8*M:HA-=\]8!<>J
M^I;O%+!7WJNFIYJB2HDI^]*0EW()3:A4FG0J.ZIB33QX #- S+_<D2L23Q[Z
M0(8@0$__ $414&T8POP@$(N =ARN0,C(SI3YFWHV-U%)0Z=KYN%P@!IY.47,
MM8\W),KRD(P?B,J;-59 @4;93"I!IP-%&6.0GW8WN(]J=EGZMZ@L$+06BN^Y
MQO+#-*J00N)G@9V'>]XCY$F\I+MVF2-41B0HU!G;N^ZVH4]&17R,GQWAL$Y
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MPOEKV29%'BT0PW1J/'()Y18MBUHW3;V4!"SR,",8$O\ 9^K>H["HBMEUJ8(
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MG(GRB=XJ+:E+%(YN5NEE0(4IX6JGDF2384>&3[JM.4VOE@TRNC))&P$JE">
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M3!]H+G1JZ6552&]4$A5?V*&0C?=$]C2C>PC$5.*2[6#12LK%64-%(5;:ZE7
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M,PHXL<;?EY#'>@@M;^_R<1R-3]>ZN1.W7;!!+53PTT"EYJB:.")!XM)*X1%
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MA%E^_--4XH9K>!D.?8HA*\,L]<2QJC3XII<1DH8GOC)*@(4;O=:P*H]1RB
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MIQX<!IR()Q'B&0R(Q2,R#I_KZH/5]FOE_=6CHZ22T][30JG=T\T=4B33C?\
M&(IJDO*X^,1[]B,<#7"<I7DQU(5%DRI,8**&8[@[Y8X =06QC R5 &1K:V\4
M]W?R=76QR8+;1Z''K,%9;)+&D&; 4L %@A30YSHTDHW@E <QT5AT$UAUE_;*
MZ*DG?<O6_3L-?#2276EC:>%JB*5I4^[N@D,>X2@F/;N##+,NXD&,,JN4KS:(
MXZ98FJ(1,Z*R(9!CNC\) E8=WWF[P4N %#8RV!J$SG'8NBYW3X-*C/CVF(P2
MFMPE5B2(<^_:&2R%('W5P3!@1(DAXGJCV)+8U6-<O6F^U_J2WWBKL]%03PU2
MT$%5--/!(DL(:L>!%B#H3\:K2%W&=NV9#G*D:M@I4H8S KK(TCM,[*ROC<%5
M 64D94*X(\?B!)X&>HWPT_\ 5#XM?\G;2W_NYQSK3>N&G)]--'331TTT=--1
MO^K^O;TPN<OZ?/'387S_ /9B_I_CZ::YJG#;>5YQG9LW=>(Y.RMRZH@8AC5/
MBCI 1CRF->9(*=;/F17D:>7"K(%(47G&8YT619 ,]S$1ODTU8PY(^OC>8,?%
M]=Z_PN= @9EI'%;J\SR04%A>8W9[ QJ/<U[L?I2/B1)HJH,T!98Y-D!9)6H%
MBHT?=[_?OW^FF/?OZ\^?UXU"YQDR+)M"<L,=Y8P<]Q_-, H+NKRC+\WR>R_!
M9&20LPBW$+(\=-4H^TMS9U$9.F3"4L$<UPWQJ^88C*^<![X^7CP0?Q&"#]0>
M?4>.I_WZ\@\'Y8\0?KCG5G7&_79U-.XC;3V;A-!=V6=X=E51B4#!9C'0B39V
M5WDBMPFPDS?%SHE-; $LR8_P<6,\4R*J.,C?*=1[]^_TU!SRGY>YACO)/9V[
M-N8A@^:Y!M'&\>P7'M92#V,BOQ*APZTJR66:+9 E@E5]S:G'DM741(QT>\=@
MZ?,*@A@$6ZV:]7*PUR5ULJI*>3"QS*A&V>#O8Y6AD#*P96,0 )4L-S;2N2P[
MH96A<.,$8(*LJLK9QP0P(R#@Y&",<'4EE?ZF.F-&47%K$N(&EZ<V4\AL?#>9
MC?9#&9'LA5D*XNHJ8];6T<@Y=O-BY'&EUS!$E>$*!%^X<CY)0N=WWOJ2\=0R
MB2Z5DLR(=T5/N(IX&V*C/%%G:CN%RS #DD#  &N=14O.2"$2,%2L:*JJN%*Y
MX&XDY))8DYX\!C4&&$;Z=KO9^XMQ\D+:!G>1<B:2^O[# \:]R9DE;EDFX9-Q
M6<:[*J5V* K&QCP"0GNM))J(S(QH[) T0;I[J*X]-UPK;?)XC;-32%_N\RD@
M_&BNJEQ@[9!ED!8#Q.>5+5R4K,5"O&ZLDD3Y[MP<$$A2&#*0"C @@Y'(/$AN
M=\WN.G&Z3QOW7HC +'*\MV1"/FBKDI#5])A<(<ZQQ>X@#J5D38TZPJKAI0P!
MO48_9@!.?WR'(27DEZ[1[[>*!K:>[@I)XN[J.>^G<B16#=_LBV[E0A\HP/>M
MM"$)LJI[B'[WN*:"G,J[&*KEA&0N508$:;@H#G86/.&&3F";EI.S>WY&;:N]
MC78,BS3(<VNLCO;F*PHX\XM]X6T1X0D<]\488$J+'2(Y[TBH+[=KW(-'.U]G
M'X$#GYX^I\_/'E]=6H<?/ZZ5'9&1W>+1/3YM\<8LJS%QWE1P05(00K)DWE!R
M)A2*TSF->Y!3PG?'>]!E5J/:1&/<QK5R7I&Z5UIZCLU50?%.:^" 0-*T44ZU
M;K3RPR.J2;!(CX[SNI#&ZI($8H!KNB42N("H=)B(F1OZ6$OP;3GCQ8 ,? @'
M'&ID-;<J,4O*>IUOM!79#+U^6ILQNQ:UC3L@HY<0#$CU5U"(4;+"%%$5M4Z?
M'((SHH88#(R0-AFWKMJ^RQT?VV]3-U18^J*;HWK-;>MIZF6"AH[O27&AE(E5
MZJF2IH*BDN2ABT58TACG4)WE,Q#EJ?LXZ[[5OLUW+K:Y=DW\'K[9UO;*NU7*
MR7Z.K^[VVIJ@WW>\6XT4A:FK:.4M)315$$M.6FG#*8'$*X':W/ %R')*6-EN
M'XOB<D):4<5),&RRD0)!?8EDL#Q#FE@DS7.(RU8P+(X0&*%RB;Y'ZV=T[V3=
MB70%BZ6MDEOZ:N-RZ&EIIJ*^W-*)[K376&11_$%8.TD$@JY.^AC.Z&DEV2 %
MX5EUI7I3LKKH[E#?K]6W&2M>45=91BN:FML[.V]*62G."T*/L=VE4SU##$N(
MI3"$HH.94[15I18L[-($R'9,=*BT-L$]QCT.%-"<T>W(4+H[Z9+%XT5K:PPE
M<26,GMOB/>9,B[1+1V2=8Q4G3':3:;'>?O0S2BX1)]XI$D1R)171[):..0P]
MRCBHC$SE%*NIR,MO_9I1UUV/4%CK:SIB^B6.HCK[9.:"N>JA8F.42 21OLQM
MBFJ8GD1E_DM&_AE=E\NLNVCD=AKQ\ZJ%(I\;L+ZPH*1TVII)4B,VO/70KV41
MTV7;>\&0R0Q$)-%!$-A%C^X]/'KZ(Z0[*>SFMJ>E^SGI>RV2Z0VQIJN6FA_^
M<M.9*?N:>IN<PJ*PK,U0DO=B281(HE>)2\(DX]/=F,5/=9+]U'=+EU%?9ZU:
MII[S,M=4+)(6[VH8]U'$E14,^9)>Z^\S*S=],4(4I7I/G%G \?LKEV3VM0+$
MI4%]O03"3;^A%3'E/BPSD YQ2+5-$U16K7 8R )&D16!:(C+C;.K^D>O>FKK
M!U):J22WPQ]S>J"OCCN%***IFE2*>8=QM,92-I:B3NHQ2E))I'6)%F-NOO8Y
MTU=JJ>OMU%2T-3+WTBSTD:4=733.&??'50!2&+*SJSJ5 WK(&C9PV^;ZYF2;
M>]Q2MR^X3':JXAC'%HL:ER64D:"=7M=>V["2U.:/929! ^[_ $BK&:8;$^WC
MO18M$79QV-VRU])6&"GLU%7U%3+3H@$C(:JI:5ZBJEW-(M.)YVBBEE+1QJI4
M'9'(XIND^RJDH*B6X7EC<+@)UV55QBA>IE$ 01PI(L:)30(8D<LB@23,TIX!
MV)HO(O8VA\6N;.QS5H 6L^47#Z[%Y'L$R**]0&!*<XCS5\-D>(>*$TP ?NB
MC^\D@[2 !UT]5Q]#TR)U%U=T]TIU%<( ]/8:FLM5NK:Z2FGE,T<%)4W&.62!
M$[\/4".?[L@62KQNE"#/NH>BNG>J&I:BX6^2FGIPD<SK+) \D:$B.D=8Y8EJ
M54EF1W)1$9F" %EUJ6Y^=VQ9N'ZZBV<R9;"R>DBY',IY'LP*U(89:"*R:VL'
M$;<3GG%)#$GRQ*V.%!S&B*4BCZQ9;[T'V<6^AN'2'0]HZ?JNK8H[S716J@I[
M<SJ8H@P>2GIHP06"QQL@2#;_ /)2.4,5DL]E[,>F;)7&XS137"0 ,T#,O]AC
MH/OLT]8]+$\89ON[U4LIA)[W#=ULW@Y;<JJNMP]*R\QW)_5ST=D6+J[\*NH^
MTK'VW!>'[>PD<?=@+:1D0B-<]!6'W37G:U@RD1SQM0;F*NHNNKC;KOU-672U
MR][3UT%%-(=LBB.J^ZQ)41@R8W%9$)=E 0R,^S*C<V>U 0,H1BX6.- <$8"K
MM Y] !X< [AR "8E]-9MAN 7\G(LDQR]O[2&:(7'"4>1_LZM6=AR??29!4AS
M$F^['<P+(I0OBF$L@!VHAFE%8[/=*BRW.ANE,SK+1U$<VU)&C,L2L._IV90Q
M[NHA,D$@VL"DC?"WAKKB<1R*Y4, 1N4@$,IX9>01\2Y7/B,Y!! U*_0;MUY;
MZ(R'>DVV%2@H<ZK<!%@\H9S93=VEA =:NDU"1@%KB0HE?_?<E\J9&<T;2M;Y
ME8C'^BD[8^GVC#FFNJG#_!W,)<,H5E4E9S'M<;RK*Y"B-A(%8J#WFEMK REY
M =QW(8ANVC^@KB7#%B/,A1R2P\"WG<TO&.05KC@-:;-I 4=;-JZW\(R&OGXY
MD(+#*"1Z<^1)+L'QZ^;'JY,CNR% .AXL(;YABN4CO:TYUIUO7=72B-@*:UTL
MVZDH@,O(Y1X_O4[8(,FQB@085$D8#=N<GC*U/@I3H8X592N\+W\AP<R2%1M&
M/!(P2J9)RSDMI>L<Y8,O,/Y01,EQ>+G=[KK76,Q]5[ N;*QAY'#_ &<M\0U.
MZ[ODKYHX61RIXI43(R#LA24;+:Z.TC@D(Y_7:>T#J>RT=-04=;&::F:4HM1
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M<V;!LEMNUKF^RT<$K9.+4U5/1R]]32R0S;6598I)(I$#*0=KQ.C@,NX, P#
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MQR=)-OBC=A=Z\AGC5CC93C!+#/H /+Y:[<E%5E:1=\>#M=ESMD<+X$ $#(+
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M':JNP"6HMLL<%YML]OJ+G=8^]HVJ*.HBE@N4KS4M8AEIJ9HBTKJ?3QR"X/S
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M2IDVE(PXVSX,*4PP)'OG$1S56,]2L A2JB#8]R0?/]/K[^7'GJ<\'Z8S_LD
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M2BGXGKJVK; JQ*EA[JPB74R]BAA=P.=.K&#K'LEO<]ACD]D2C[$\]JA?=M*
MHC2$.P7<%'(4GQ;T4<G]14JI;."!@$\GT4L<>IP#@9&3@#QTWCZ@7A13<?\
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M];CO(+\;9"%V$"BM%'2VRA&5 R6I:2*1MV7#NX8D@Z^UGV&.CZ/I/[.7255
M":WK2X=0];W>;<2)JN\WBJ@HMHW,J+3V*@M%$%7:":8R,HDD?/@S:@NH& )D
MDJL1E+=68*6!)F,(U)94;-EDE5R-*-SDAFJG!=)<TD;WO<C^)'M+[6Q/L7=,
M0=3]L,MV=IF@Z"M-1=99("ZPQW:X".W6ZBJ9 I0O-1UM?6"F+!V2F20@*5WZ
M:_\ (/VXVBP]&T_8Q9+Q%)UAUC)'7=16^E>FFEM?1]N,53*+DDL$YIVO%=);
MXZ..-Z>L:"*HJ4E2%0)OW"]YE'C,4R/1(F/5Z!]Q&(Y13T+<HJ>"?+%)9/\
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MZEHJ@4]/%%!1U4,3D0Q11,Y6.0&25I"-CS":7?F4(M=+&E1M:E<S-$%AFB0
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M:AYHEE96$T&TR(5W?#L 7<C*26/>!E;D*1N!T/U1..%UPWU=,I,EO:S.ES'
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M]6VNBBCJ"[33R2)#!'#'+45-34RN$BIJ6G@1YJB:9G"PPP1R22'B-6/.HO\
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MJVMFI(ON])-65$M- 228:>2=Y((CGDF.)D3)!8L.<$'7;,ZO([H-JL[,H\"
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M.PH^1<#MXQ:^%]Z2NK@6'<:+W$&+;1),B2WQ5%>U6,]M_=O=.S'=U:U51SG
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MZOEN5SG:>IEPH RL4429[N&&($B.*/<< 9)+%W+.S,>AW+DDX'@ %  "CP4
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M2L.&V22*P!Q\+8P<'!XU42TPJ8(U,;2)L8, "W.\D D @<'T\".,:^SM%[W
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M)]3WB[LP.',K]"2ZNSH8MQ43K'4]^QDL9ZKWY+XDQ,T""?$BV8Y<5IQ-;[B
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M[4O3$?7]R7IR&FDIH1332TUR[IZF.I$?>Q!8X#WBLSRT[)DMB.&(9)\_T/\
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M>(VZF]VLG2(41D&IB.:*/%BQ(@_:"QSSD?7] =!UG4_6-KLM-4I-?>K[M;Z
MS5,ACH*2KK)<54].KAY88IZF>IKZIF:>JJ99"&:1A%&OH[H3LK[-OLI]G'4O
M4M!0M+-:.C[15]77>EHT^_7H=$=,QVY)*6F3)@:M^[3U1A,K(:ROGEFF"%G5
M#,$D62QI<XTU[WEFM.$C)'<X);%1YG)X$4L9/)(Y0#[#1G9"B3LY'=>K/M?]
M*]%](=6=&]+],6F.@EMO0]#37;91I3T]PA2HJ::WU<S+'''77&:.&K_B-7M=
MYB8EF=I%95UI]AGKKKKM.Z%[1>JNN+A+=:.[=I-XELL=9/)5FABJZ"AK+E:J
M1)VE^[V2E>L@AMU$K=U /O2)&D;#=M^5YI;"JU=;75K9)]S++!BSI\R<);2R
M7W)4I GD>+7R7C218R&N8:0T2J]Y#*-KM'=C/9)-VH=>6SI>STL%!#.J5%]N
MM/30QFVV"W[1-,S+'@NBNE';H7!B-94T\;!(6D==W]M':'TC]GKLVOO7T5CL
ML5924MNLEBM--3TUJ:]7 =Y#9;*LM)3=X*2@A-55B!$*4M!35AIQ$3G7WP+-
M\IK8<"WK;F;!DC/*>QL5Y01%[R1LDB6&XQ@'C2EA!'+&9KAS0A8*4,@T\5K.
MWOL]Z/Z([2>H.C>G6K:ZWV>&TT\U;<IZ::O:X-;:>MG*55%3TG=_=)ZMA  B
MRTE0LFU@ZAM8OV/3-]HWL5LW5/;3T/T372=627BIHK5'9Y)Z:"Q=]<[/;:@_
MQ=ZRJI[E)0U%Q,5925";:.N22F>)IY<R7<)-ZY=EO(S L9OH-')#9,V&99\:
M-,@2XWEK[+)8Q CQ)PZKV@N'[+'$KG2'A>YIY)7]G]6SL?JNI+7U9:;/1]:=
M7+8*VHJY;C8)[U45-IN,_P!RJ9Y9ZRGFW-++/41I4R,TC)WZ*Z1KC&O+?VC?
ML1=@/1W1MZ[6>DNG*OIWJ;HZTVJ&UPV^KB-KE'WNBL[RUD%32SU;U$U)5.TT
ML-;#WM0HED5F>7?1H\"G)]N$!3R)9EBA %JD*8QW>V,0V-17O>][D8UK45SG
M*C4\G=NO:>OG#Y^GOW^^K=_I.>E^.)Q<O-D;$.-E_N2AM)HHBI&+'I,>+ 4$
M<$P@7$*.6]AGJ=BJK8CU*SVGG:1&-1ZXYQ_8G&=5@N6>C9>AN0.<ZXE-D28-
M3D1%H)KQF!%FTME(2?#^U/)&GW'M D1XA9+7$9[T=[W-17*-K3R^?OW_ (\[
M?_IC^F+C57Q'GCL[:/8WFWZ&U7+YM?)-.KT%=AC2_P #*HQ1E^WC!E1?>5H@
MG4HE5%1G9JM-52^8'$+)]#<F++3=$$UP7)K+WL%KXHY,FQ? M,D-&@ .PT<)
M/N!2HAD>J^2!")I#N8J/Z:GU^0]_D<?X\1JU?P2]-+&]6<3LBLUR*X#F.<8E
M96&>VTL3&/#+NZ='W=0V"P3%9##[\BN-%;(]\JHK7F\2*BQP/?C_ ).HU3OY
M,:G74F\MK8#]PR0&EMK18[AA>!B0;27'M(*!&7N]PE <*#(CGC,U&O&YZ*B]
M,^_3Z^^//4^IS]<_GX_@?VSY6P/2C]*;46P-&+>Y/F.7VEX.3-L,OH8]/.Q<
M9#V:>Y$8@K:".S6*&O:$9"!<(<DPICP&:)WN=9]9.N+WTI8:NR45%#3FMJ9*
MQ*V>&5)M\T$,!**X".8XHD,14$;L,4(W:[PJPRQ5#TSBJA5A3RN718UD969^
MY("LP(PK,2H! (/@8$_5<X$8KPHW@6IPG/(^1XWD<Z3,9CU@]@LLQXE@,MG%
MD&C-&C)&/3B!D)5V'P]Q8QXY6=V,<N!9/FQ8GDECEB?,D^))/))\2==))8Y.
M!D\GD#)]?Q&?3/.L/G:^/I0<:_E%\N;_ "8?W[(G=S]/Z$>ORB]U[N>O?]/X
M=NW37'V=)#Q0UG197DMEFN0";/!A#JLM56*YR,?<R"R"QY\MB,[%CP!QW."%
MST8^01CRL<P/B[=W8STI27>OJKU6!9/X;-%%01DMA*PH\C3LHVJQB79W();$
MC,Y53'$QZ*^N-KH'K5C,D@D[I./Z,C+28\\Y55)\,,< A<O Y":Q=M[ )OV<
M4DK),;BS9^-H.20"*A1C_%J]K/)1$6?""K&(HV.4XP,81J/<O6TNU3I.BN?3
M595101F[6NG>KI9RNV3NH"9*B N 6D62 2]W$V0)^[8;2&)MUCNM7=)*A)P'
M@[MGII-V7250'DC(X(#J"N#\.2KD$KD-[X!GF56:YQ9T\TT(U96-2*)PFR8K
M2VI2PGR_8DL/%6;%B">.))>-9 7G4P7-()KV:V[$G?O>HX99)6IXTM,HIXY7
M6+OFFJG[[? Z_%FDB4J'*RQ%XGWQ&16J;Y8Z3J*T3VBN+O1S3T<TD222Q%A%
M(9"N^)D8K*8T65-VUX\QL,,=/YW'Q*/R TOF3,/I['(-C8-B\K/,;?4%68%D
M 3RLR7'YPHT8JQ)\VI@FEQW39@FR7LA!C!(21Y+7=L[U5=0V^I(B6&CKIU=9
M"(9W:2*- \ D=3/$2P5TAC=U,>]B$4XO_P#"*>VVVGBIS'@;'<B6)\*5(15P
MVX$;OYB_$22GAL8ECGIK:FQ#)]^"S;:DTF,X;@S9"QK6SH)MQ5ERT<:-$'")
M'AH^0&PKXYOO1$=$D !*''?(]M!(O6G[1T;U#U#2-5VZW-/1K(T33M-#"O?1
MJDFQ!++'(Y!=,E%VKG#-D[==4%-+,28Y(T8 X,DBQ@XP"%9R.0IR,C!'GC)$
MEWK":IX][)U]B&Q=,[%%F.?X#3SF9+%B5EK&@DP^'":X8$FV%37!636JXCHD
M8"/1XEE,>,7Y'+>F[-.J(Z.X5L\*016^!J@)4NBR5,<,;RU B6)YR)$1"R+)
MM60 YD4X5NQZ"15E;OH7[H%@$=9 R\!F)C:0)\1"@L0&=@ <\ZA\X7X%66V8
MW6?7$<I6X<RL;3(H"NC-OY<:2HY#G^VX+"08@7>TUSFN;)EQ2(YKF,5V1]D?
M2-#U%5UU?<J5:N"WM3PP03 -325$ZRM*TB'X)ON\2H3$X9,3H[H?AU;YZF*A
MHZFME:+,*@(DH!#,V5^%"?YA&5 780I<2$@H-2 [>PVDWO4NAYVV3:V@(4J/
MCE],F2Y$ZHE*$PP,%)(Y7MC#(HWFA-<L<HG*US45[NV^[WV?=/7*W24K6JA1
MA 8X9H*:*GFI<*HB:&6$)*$3 '=9[IE#(R%&(U8+=U<E94_=:V*,1G:D3*H$
M@4DG*; NS.2 #E3P""% UA/25X)BS[?X\[W Q8&N=:W-E#A$!)4IKO.Z8L<$
M48(@6OE.@"]^,X<Q1, 24L<17!3Q<[R%6]-7.@O,]EFC!J*9_P"=+'AHA"&(
M^\@ALB%PK,A8HPX1PKY RJ*EDEE[I QX9RP7)6$,Z]Z02N%(7(R1NR,<L%T]
MWUXN*.-FQ/!N4&!2+JYCFKFUT^Q=%<43*2'8?@8H\F:$D@2! Z**5$$\C5BQ
M'B8UC6F1K;;5VZ>ADJ(:AX5EINX[V,R*DI^\ E.ZBD*23+&<),\:LJ,03QG$
M3TLE.\B2%=T8C+ ,.>\'_#."P4\$@<?333>(7DGH;^JJJJBK_+)Q/[IW7LO?
M,*SNOZ=E[I^[X_YD3YH=4VH,RHA&C%[@QD*8#1/(YC!-*XK5&I7O5HVM:Y$5
MZO<UJ(GYG=NZ]0"#S]?T^FIQCQX_#W[XR-7)^-GIUU%;Z>@M>9E<D/2YQ14M
MKEDG&82RC%N+J08U-[<QI##?*K_NA2P>*_;N<H'/:J-:B2? Y\,'/T\]1JJ+
MMOCY<ZFY!Y'HJY?*);U&;'Q&%8RXLBM98Q)B@K*"X#'DQ_N&194:0"2J^!&'
M&]S@D<Q6F=54%+]^KZ*A$B1-6UE-2"60XCB-1,D0DD.1B./?O<YX0$\^!YHI
M=T08!=U4>@WD+GGQQG@>)(QP<:F<+48Q+XVLXP9!25AJ0+*XXKF.1?Q2NN@0
M'@_&HC2.,-9RK,FO0:E&QJ2G@*-$:]%]#GL5M+TY>GK[B6-,RQROW?=M4A9
M)G4(I:'O-K]TI!*(5$I+;AVSU-IIZ@TLTLBSJ%5U,L98EQE2R*!M==R9B[S
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MI1#+1Q.(Q&[2HTU3W8D53&5D.Y0>]A))#(*K8>Z#B*I242!I#\:0XC9E)8
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MJ^S!Z)+?#3SI5SB6R.)G:LB1$JH2B.0VJ66AY5L#>.HOP*4.%;R-EX? @RS
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MH[<&%T\#*\GUKF='C%K3BOZV^GX_8"I9M*:L?<AL(]G[#H3H[JX9I7E[WDC
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M)Y/!-]VE]-S1FXL#F7UYC-]^VH]?8[CL&YK;9T".2UQ&@&&)8/KFE &1(L6
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M?691=/;1T,NV7*AXM: QFU/% $1*JF$2*.U+9 BH<SGRZV'$E/"5M;+G2)(
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MBQD9\]E$17>/9?EQY^/!Y]? 8_(Z D$$<$<@@X(/EC_.JF7J495QKO>:/$C
M<4D:UQO)<RR_9$/(;NNJJLE;C<N^@5^)8H7*F5(PJ<)\D%)B$ Y[Y<9P)2>+
M#(X:Y19>IJZANUJKJ^JK*^FMTTI6&6JF<PQ5,;0U!I=[LL,I1@05 #%%5LC5
M=35LD=1#-,SSK%D;9"90$93&V%<D$A6.U<XR !@:W'"?3V=_)SG&S]O[-QW
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MJ*6202M3L)8FI*FEGV$LJ2("$?Q1XU()!(:4?).4&IJ[7EM(QZ\AY!?3V//
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MR2.P"QQQH6=Y".51$#,21D8/B3C6#6ZCNE=<(XQWR@RK++(Q*HB1MN9R6(7
M QX^.>0-;GIO)H68^CSZP^35K7LK[GD'Q:F04(/VB.B/S6K9&>4:]U84H&,*
M5JJO](YRK\_'7A'J^ZP7OJ6[W.D(:EJ*G%,X0IWD,,<<"2LK .&D6,,0P5AG
M#*#D#:TS RY&/A")D?\ +8JKN\!RVW/(SD^ \-1*<6MEUV#9D>HOI(X6/Y<*
M+ F32>2,@6$0A7U4DKV]T8!YI!(IB.3VQ,D(4CF#&YR9IV2=5TW3MZFHJUDA
MI;QW48J)'(BBJXN\6G63(V*DXGDB:0XVR&(LPC#L*6IHX[C2O1.S*9'C>)E(
M4B5&RH!\?BY'/&0HX)U,KBM]FF!S"Y%A=O,IR3H25TB<*.&1&D@D>3QM[R1&
MC/>KHSC >G=['QW%$Y%$YS?3=?%9;[1-:KY;K?=Z)Y8J@T-?3PUD#24\J3PN
MT$RR1DPS"*1&*DHVP@@D'6#]2=G,-[$/WV"5XX9$99 ]1 \<O=R1$I-#)#*I
M>)I4<!L2*75@>1K0\8)?YAO>ZTY7 D666PM>.SP],]&%N;68\RV\QL42]Y9[
M(5#(_&#U[?.46*;WV1T5CE?A5?VB6:#JM+"\\2*U,-]7WBK!#7-(JQ4#,V%W
MM#B3=OVDLJ APRC/;39*:BH:6S8CA,*HT2MPD1"J(X"J!@C"/<X&U=HPG+,%
M&W6=9-JYCH5C#/"D#:-Q(\D3A%$A!,,SS&1$<U7#>UW941S>_9S4<BHF;05,
M<L7>QNCJ2?C4@@X)!/'! ((SX'Q!(.NNLMTD-0D+1N-Z@HI7((P"NT_,$<?U
M9RI 88&F\<=85V9<KN0^L%RFBQ;,[;6M%?XO2W-H&J%>Y? CTMA*QYSY+AQA
MW1ZHJHC#/8L,LQ4E."UDEX?/M5UK1V7M+N-5'4%K-5&CIKJ(BLL#U=+2I3I6
M*%#EFI&+PN%9<CO<JQ"#5S+&'OJ,OW:S4ZT\C*<&&7:JY+ ,4,>%28#C*L2I
M9!I3\AP;+,*N08QE-/*I[4S@J&+-:QGO-E2'1XQ(Q&/( X#&1PQ$ 4@WJU?!
M7-7NN]OXS:ZBCGNL=5 M)#&\DLX;9'%'$A:1G)QM")EFW 8''CQJ@AM==0K3
M4$DAJ($PQJ))%F7!&_<SAF0# R23N0 ;@H PCGIX\F[G3W,'D7EVO9>'2K^_
MIVT-0_((+G5^0XS3Y?C=?=08#I7V3H?XQ&B19$BQD'KS1JU9DUYH_M*K/-$,
MEIZVZ_N,]69H:2K@G^X?=W,<S2T=+##!*=H+R2&*!ZCN8U=FEVQ*)$Y:ZT<=
M/55IC<DIM"Q?$$+LA4 !P H#*'*EB-JA68-AEU>^L^0F'9/@-1+OL@IZF!D]
M# C@=8%6F#838Z'%8#@1K1[9#VS9\:4RN:CY/W$!C31C2@F:=^N;A2/05E32
M,H7N92H =9,*P$B!F7"EQ&Y<O554'%P3+#I(@"#!">X2W E.D$$#@PWN@VMP
MET#0P.!N"3+ X.X0W"&XNP5WM_/]ZZYU[SKWI1_[H;IW577OAP[[TCFU4X+P
M'7%=C01J@[,=207@LN?8KB,"8)[TRR*@]F)CN1K>R"T*KLWL!1P.55VB&R+[
M#J6M,*O)\THG'!*ZX5/B(D;1RM@L[*%%@Z6:.%D-RGW<OXZ/$U T 1=:P9KQ
M"8MFOXCLJ\G2$H-0OO'/Z<3]VMXD)L=&5-B?N=K>$A6MGU$*77_,N=!X5=$#
MO0$\%M8-W =4C/_?JSO%FS?^;P!?[*SLSM**KC= 3?:TLLME7X.#Q\=2H%*8
MP%*BU:(575/G2+[8+U]N'ZXOB='J<XJX"5^61K\GG+ %;W)9B?KLBX9;RW:)
MOKP!G,[NO1Y J;$'3P^8&UYO@!#ZY]0;JET.L$.!$X.] J^SOA&_V:Q&M1Q?
M_#^',2?29>)Q)6N62\FT(^:KDM@37>E,TNX6WH5/>'2^85)B;X!LV3HQA"$2
M/XWBH0?N@9'.!:R0)*!X96:9-$UCTWT9NLZ=Q3"ETKS.,E'2MTW)>&/B"6<2
MER>T'U7TLIA FY"#RV=_?E%O[0J5B8Z!ILR*FU,,0^W:.PX1J$7SS=AH>$X*
MK,5BME _?ZY/UGLXU20I!9\V17KA4[4QB283W?(2E]BK\7(L+*/20VWD^+#3
M;G?Y51PD+,=2RWI\^<&NFMRJM[+_$$3SR41C<V;RZW#B]^L+M4YWZ_<A$?DQ
MM_%ZS@V*L2^O1FT! 3WKG?-7TVOP&]PED<S0Y*5YUUUN<S5(5MALVJEG=E(8
MX>Q<6S5%A1(C8<(\@@BI@O,\6"$!X?,I;;R!N96KV%E@Y?;@'=1MQ@+)<M/=
M6YOFEH(BIJGV>:Y[CK*ZY8PYX<CYN.9RTO6]H@F<IV581=3Z9B-!^ZD+N?G[
MSRTKH6._]M<.'QOWI97F'4JY[HK/FRGZ3(SFF!HV#L1N5V8Z\C^=[BW)J%"^
MFLO58:3S'>CXA2VHK5W!FW]!8[5%T=I!G0$#N; BJE22!RNU2E]&]]V"(PR%
M6K;]D3/:KT/A;,T\YEFQSMC4^Z[#9NUC0-^<7=?4W>'BM56^<U&J@?6C4M=O
MF731QJ!Q[HWW BV$,;#\!;S2;/,W@*W(!).?H_Q7$O08ETC"8]M;E>%;_A-(
MVY-[HKN5Y:K2TF?3CQA60/4I\ U]-HB2KC0G)TVLYG.13V]11K$G]TP\]"0[
M=9/C,R:6]WHQIY9CXI/DM;'632'[5.<O^\OK/I":NJZ9C6."NJK!ZY-6W7>+
MT/2]?-T\Z36IGTQN7ZM1;/"[J@0O(%&9**$:H@(N+AHRQ7%[N(I]]0GAO#L#
M=K*S\LX+)(B^8+\EP4W6>&.:5TJ4$Z3:#]7'TW!K8947)0K#J2M)+/\2]JY5
MBQ0%2$'""L8GRW26 B#T2UDM:_I'VZ"0$]#B_!N ;I5S:4+Y=G]V5=?R%=7V
M>"JAMJPL:6ZK%CQ[;::L9 >KGQD2/4#.!C[KY84Q)K7SL\O,1VS)!+,(6*T?
M"79F0!(AYFGU662L4591YF@D6,@6D;0Z"\7P\P2+)"M?!L]F$D6F^_@0EGO<
M&*,FN05/6S%)JPK%G*2<3TN,^&K3*S%B_C*2?],.J,QI9=WO&60S (?F7W3U
ML4K_*\+POJ68FIK&U*KNXC[X>EYAG2YCT7!F561V<B*@06W6DE<7BYRHU+4@
MOM_U4T$+'[RPM5I I-%PRW;HX99!7&4^KX)P8?\K=3CQH>X'.Z,"W:U:EP:3
M]V+C6L0.7"^]^/+.#_41HB.PUW%MX8!QGZ)RX3BMZ[9;$8=OM:K\;&XN:LME
M;DYJ8D!W4A%),$F&0%BRY0@;]R!$A%[*#]_Y24YNP<K.[?H-8-XQ]3AU,:7M
M=:R-L=*NC<G3-_.BH&?!7]>(00%LR4C>ABG6_3[K.+8-.&?,26E.TACO-'"2
MVM;)UBPE]RC^59^&QQHC+*4[1F[L31GWCBT/'WG*5UD.CSJO9+HO7#U&N].P
M]/C._?##*%NV>?*-)]F+0['QOP,M;J D&R$7[]2?.ML!WAGU*NO=XO2G9DL$
MQ*(^^(>UCF7_6H]E[6\''ZK:U/1\!(27O.#"*EW =PQ-<\L6;X#[C.$B7<?D
MT606"VZPUH@2>75^ES(^[6;>2;N=P+MQ]P1S"7],>@JR:IY(NB&LI&UV/\09
M11(T9FFOS;I]4P"3ER#:NLVQ:WR&^I'-(4=6<?WRJ59XXS D\M1Y=H -B'PM
M5=Q./U@CR=LG0KP7LVJ ><;=0=B1_Q(N/D7Q'ON+A\)"JLK\2&"[QHJ(1D!A
M CP'OLZI[-:>U_(&F"6J^%5B&>5#5-2D,:LZ6<X'GA+%'^&SW]#8?:VY8;!D
M1D7(1/Y,8J3+Q%'T;$M"@^RUL$$K+%GZ4B ]S"J^(452]-4+^9MHN8[4_1E4
M9GXDVZ([Q1Q6U "28V<G<).%^=:"%8?C1RU4XUE%[9^HOU-LQ]&AA^]_S.1\
ME7R4J(.=I,Q*F1R?3D]GI[B[WQ7X_"RNT%0U=+Q;XM,3<=/4Y&3I8_";T"8$
M$\*22UG,N:HPGW3>#;AN(0U^$WD/;IFGBH48?6GY-4.H9&Q'D$(TF2W:^\PO
MH^2!"V-I\F!+&SQQ:<-"?R_JV$ Y)-PP!&12[7^1$VNA"-Y*G@49U/0&J?\I
ME5.M:>?I/?EX]:DU;V%T=#M -/S6\,G5O<=C?7HN9_9)ON#W\>,3H3_[H=VR
M6F%#F.*'W"8E*V=C]6+V]I=^=$7/C,^15MY@QO6FAOAA+'Q$QU$4'AP]'6VU
M;7>M16(V>EEH#0=C'5SPMQL0LVI&\79*SB-R*J@?CX:>>Q>YL%U76*E".&'K
MA5]!*FY]_XQEBB'8VBAL<E5]G %.2'%MHU.BC<=L3W<7R3.]2Q_J+_<?C3Q@
MV@4N=N?7D[&GA$W,&FHO86M>?[:ZKN=I=Z/JML>=G-&\<9!QD:V>K<<DO)YQ
MT>!\ Y"OVE)C4J+MAZMC]%)@8!B=25I\R?@W>6Q3\Z>WT$SH3]2^Z5TO*[&T
MT-ZWM#-GJ8K 1)2.I0</U]39U:R7[);,(GCGG4I^11&.VTV' C/S+UUE,-#0
MMKQ#%NX)CI8D<*WU0_*K=6"C _?X;1TY-6+K>[P![(YS:S_4-B[!3ST^%#4;
M.5(8$WS3T%X_U)KW#%L)6Y4#*4@ZZ.G[&\2!_9>$L/SB)37[LY.G].@/HBLQ
M_Y2=\MJ=KRN/7#3\R2W?T%A:4.W_FEW[W$E8UU+"Y_MI\A!10(%</AQ:.[@+
MO>+.7GJIA;<K5K3<<.TF.7YR<3X9UT<!GH(JN/5*A>]CPGDBTTMJ2AI[2H7%
M#@<*'<CZB,]<=P;\"GG1*^RTBT7O'[RLLO /GN[]W<Z9* /$45]?MK]:BU8M
MSS<?\,;$)RX=A^14++S7B%<B*X$8R/_X-Y,:7*I34/&TXF,+K*ED =HLZ4@"
M17SY#X1S>W9S<P('B)_=VQ)-K0C]*!P%GV&[LYF?$QMOM57G^A4;NL4EPN;D
M,X8,1U9&<UV]B<S7&5R(__:=TF7]G%8K8'AJM6 4X<2H'V*OB9:Y,:^,B=V)
M.,Z UQ<BY-,<ZMK=<99DXH T0QD1ONBTOP'R-9W,#V"%L;%^N\L+ BXKK%JG
MHBGS6!/WA3;D32]U(;H26 M-*OE-YE:]Y+T\6OH-CCR(N'2X^CRB06W_*JR3
MZ>;7L*<O9_;7G_;5W@"2'>?WCY8+VDF>J>30TN$SCIO7D<P=\[P/!EZN+JP?
ME?QRO>]*S%($"/M%S6HZ_(IT@+Z,^*OD3V^ 3D.Q!Y_7G&=H WA-Q)AFH_T4
MGIJY,\U5]ME_:]I8ULX[/.SQZPC!R!X10MB5T%GE5^AWI@)/UI"[!,T<<2>@
M=M&@B5_XX^7UT,V,39.+$F=W ^5,\_"YM<O6Y$I/WP@S8]5W^I^#"R\&(@=&
M0_)R558UT>YF[8=7MVZALB7@\NC]0>C[?<!S>^!\VH[-V9K;3@-2]L>IQIA0
MC#9*<3<7DVX7K\J0Q6(WC(R]^L'RYPI;%D\@:*6SLY52@COVK.1<U ^:H<+>
M<LM@J:^6O&#QT3.\Q*OWWVT*GN6 8@UA>:8Q$5^P.!OU(&*;@WSWQZK]IRXU
MPC(Z%VCZ86GL5T/F4X)+)5K/I /M]V9[>O)+#!F?9I=;=4DSZ-#E#\=P>NB8
M5>5,F.E=-&80&/B.:KQR&87PHTN^GJQ__V'OJ!%4E&6KZD'%9^]LQQ*OHZ.W
MBSW$M:0;!<&C7]C]7<,K2^SR&Q1"BYS/4\?*Q8L^,.+VZ^<*ZX?K.+%=YZ9;
MT\E4/<4,HZ1J]176=)\\EB-P2EA&^:$3H7UR*E6GAB2%^H1!#)CM#3"!V, ^
M4V/!1+T],4548H_KM@IT?V%W^\Q<>I)$</>TI+:\IZ SK0S\FDH8%MN\3A/&
MXB:??]]K&]KL*#1 JQ7@&AQNP&3-O=\O($=C1BD:76$?SB9_41:RJ@CJ82UD
M0^&CI/7^04OW]?Z86] =U:;NRIT3M"QL93]3;DAJ6(UQ L\H24F:PAID7)6/
MH?]1C''W'3W4&0/)HWYJ;HI?!NPI5"'EK25(V,#&5P>O[H^7*L%KY4M *<G0
MQ:B*;T!9^$THMS,@T'@3-IH(CK8GLP_(Q9J_/X4AH^]&W\_5W23=O+<_^C41
M^TF IU %FN=<R+^#1OL#T1<%/F_SH88M6]D?ICH$>K>U=?Y'GKM_>IA2.U*6
MB)OUDP? 91%RP8MOJ,9:BS,ELIE^V7M^%GR/-3AT<3/E[3M*\5-.H3+O\'GB
MTZ_AH^I'B-4R (5 M))^T-1 QZ"K@&VSNH"#-YI(/]28Q+]KS'1PB$6^C-QT
M:U?R G /.3]_]@O$KN '%3DW-=?'[\[IL4(NWX<MA=1NA:;1F-4NA>35C#OR
MV-G[C+L7>/7B0**Z&^*KBTBJ"^H1(4&2DMEJ3.O59P>PM+F801>LWT-M7(T"
M+JRECI="E7S$,M:LS-Q--P(:%EVAB,)R(:0U'<C:K$'$FWC1XH=Y8O@-2M/M
M(-<J@_)ZU7FM*$7FA7KBXO22&#%IJG;JPC-D"6++N'>2D;=*+TK9FG*?S.(U
M]VR-#Q*(+!<@9I\!S?VR2IPD:Y^1LBCL"#)/!X5>.G135:KJ(X9%81_$M'']
M,_ZYE)&&P$TVF:RWT;&K,-AZ1$,AL[O>'SO]MI:70GW=^=VG+K1U^>O4#6D;
MU(#/3=16;@FAE!D\U4-T;$I(FIKOUWA.^X9QM!O2#THRS&,0-4SJK(LC=%.
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M.R)7:>C?4E40!SIXR.E2]]CLB+TNA/7#FZ156E.\IYAI%".G2,#J\EHV1$Q
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M3.9S5%%3SEFNVMDZY8O;&\"(W%="XJRBL8W']G.$J(ZM7[[74:%>[D"M>[]
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M5G(!GY5IG*DI!V^V]DSG&$:NG8A0P):PU ^(S#?_1EJYW==G/PE#4;$'+Y^
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MN-]1?R#XH0D)D\5OX1]LY[L[$ZY_ Q1U?G AN+Z>X+\^UD <+;OM)W.;Z?P
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MJ$Q<9XM?J9I&BZ<V'8AS^> -X!<@?/ASH 7=3MGYPW!:]1@H45*WFB%4;Y_
M90G&17BTBA.B3ATQ[ZDR!I31=.I1!H\\L W4#U2^[J3ZBEVQ5?!1.,J%A&Y!
M9L?K(X$_5T*-H'(TIK-:7V7KRUUSF%$@G:S:K3?_VX0M:ZE&EL+$<\9L%?_4
M=)WB#2< \0L'N&37&V]G1='ZK#)15_V,]TZ/UG<A3X%S$H$#H-P7VP(_ONG.
MFK46L@FBP3)]9QNDCQV- X6#9$9O@/<V4G^J=1^R)FSK&-!_/6O:!UIY. 44
M*>N-F!TUK*B*BVQ'TAIHLY$A8@_]T*F0(AS\#P%/7G(MK+/3<DV[236-O.!>
M  ^(CHKZ_:-W+OX?)F'("/E^S_[$T]#SS3AD]K,B+'2O8Z3K5\=8O18];&13
MIDHJGTZQ[2Y_Z1=!5+DK%D1+O2T&8E"A239[2.#3(1<2Y!SG14=]#D)V$9,3
M)\T].7L)@&B'7]?TY!L^?COPD14 &PB?0**6OR#E7 QQ=6(3'+SC?3602]OE
M=(8S.3'"6?B)9V+G)ZB6;\B][&+#M_R?J(PUBCL?0[B&_3*#DQH3%WAV,D+<
MMC DV<;/^&=T81(00U<2RFL-0>GJ)QZA"F,J+YA+ #Q;I1D;-]9X78/N^K*9
MZH"PCQ#T!I!L$ ^L_VS4"U1Y W0V'KT!)$X/SM:KBV=FKO__&WHY9?[2?:J'
MU-0WP'&'Y!O ?.0 UO0&N( *#^Y8QD+L ]&I;RO(393/MD\48GV)+W I5D7]
M%Z4Q SG> *DKI[E%(^JBKSFO.5W;PH>>_6W.C8^=U"-*=D(IRVCTU:X,0BKU
M*0P14M5[5Z[&#! *LBVHK]B??-E.C+V$5D^.<]W/6,,?,#@"&+!VY+<%MP<.
MR+VC7P3IO8/\:H_@0I?[<GMZ@7/&RC"(U\H\W6"9L]CW0#LBTKF>]T? P ]^
M&4V'\. 0=#%I-M-0\"'_)<8:T#;YII&YV*H\1]^==TJMMM(91)=.R:>S_54D
MQ6%\M.ST3Y N%#'ZTVEVG@W&ES#!*D+-!% WG#BKEBIBM[JY.LN*M!5+A<+.
MO>#;T\:BE+V(O4>+PB9*]0_Z/)7"&IQNW?&$ H@AAP$K"@X"?O<_4#2HB;RF
MS0W^M\R>DLA&5^>]R)YFS&@\@7L$  VWK+JF5F O29X+ I[7[H$B,(WN1]^;
M(#R0/UP%N7_I4+86B>$\W(6::G6<F^X\;1M9N25\"+5JUTXTK[:7S>>=)91B
M_:(2# 4>KUOH[8)M:6\.Q5Z7.M;>@XC.,-R>&%PF0LFQ<A!I6?6%(O>07?Q8
MOS\0YP&!H%#//1FC<]?M?UX/#SX76;D@MHNLSO4<L:?S68"_];5A2L%>BIKK
M2='FLE9Z.C(N/[QC-HM.-E*86J,+5S8H4<_#JRA!7'KAYV*YMDK&/[HN3*DB
M;><19=7ZBB>WN?M?5#3&.QL@"B\#V4'()+RK=0@1ZFENMU F<Z%IE-/Q7ZLI
M\VNMEP3 MUG%-._YRBN+Y]/I$<?(39M'?<\6&:L3UV1Y^\; JMR'\!DY^0<0
MQ[]RU%2)V%BJSK-BR@GMD2F[F%R)RL_>?+EP>!XL^Z_"LT2L^<O(Q7KCV7\M
MW"D&^GZ7>[(EGE&__MO>P&<Y6L_R='Q&<%PL>LMER%5@3H/5)BS.2L_ G B:
MX?*!C5B-DDC8/$$,&3E:@V+LN/V!5H%U@("[K6:$%DC@7"HR1!]-B$LH:6EE
M1@B69(@ X#D7T3^/ RB+_@#$%#80'K$^2:CR+62%7:^-WGZD]# D,@T].OD>
M@VU92]'F4&"GI\=\^I/Q\TJ?-[$G6%_^NXG.97P9FT6,Z#LWU^_]\(I& _:$
M<K%A:%Z81PRC#MS,.CLOC@+Z.YSEFQPJRY]\T^0DUP2FR(;!5@428I9%U(E@
M.53JZ%T=G&]_OM]<DPU2.1^LYM_<$JN%TBS;'['U?A-KNK0T'!OAQ#I1\=)8
MH:W!V6H<+"ZD$Z$#D\X \^>-&@(-$QS0C2B-E/M*'%T9ZOK_#V-O&11'%[W[
M3H 02$AP)]C@[N[!-;A#< \RN 8(&IC!78+#X.X.,SC!W2VXNYV\5>?4OV[=
M6W5N?^A/7=6]JU:OY_GMO?;:%<ZM.Z%3([@B@@+E)2P]IJBAC"L?!S1-,8OQ
M2@? Y,ME%ZWZS-/75[<1%J5Z7L<WNV7Y81LK^I3R@>M?M\WLI>4^]8R?13%^
M[-+H?B]?BQ?#*!TRPS<<@M3 (7Y%8KX3>/9.=>NJXW")+NTV3A\'9,$DE,R5
M"_N(I P*';BZZDVY1,4E@/&=5IDI;QM38TB.T^3Y&EJ+?,GR98>P&KP"5DM>
M 6O@ -;*_<,2T+5_!;:G7.N!*<8D,S-WEMC!WW50EC2):PT*[>_6/-A&JO[*
M,6T\?F=O?*>_["CQB;2Y209'7+Z%>PQ*=[=!T)MM+)3N;=1WY#&^PD*BXP?L
MA6Y_L2NL]^]$0T4TM+3U+*([!M,IUB7P^I.T71B?U\@&]J!UY,2X Z=_4]?!
MTKDW43RX54Y'0P1G94.X*0C*'QAJXH.<4*X!54ZH&[YOA-# 3JA=6T*!AQN5
M^&6A'<V#=\=5I<X+6(L/;?IT'2V,&+$3-CG=">[B"1/^:GQQP-^J6<Q$GHS:
M+1B159Y4O.'=0%*R3Z?'XUE"Z$"BP/$?MQD!G46TT=*BD^OZB!=D,6S! CY?
M'M]%25M\VXZM,AC$3T6EDM,Y=F&+-XA=0)$&:1Y!6&13KFY),H5JA.[_JVED
M-90[AX?RO0)$GMJ$ZD57*STSYO5X^6/U=O1)*O$'G#QG GVRY.C=WIP#PI%O
M5:/QN_M G=U.J NBC,DET^C#-S-*=V!\V!7OM5Z4Y5T2S_YF^/O55T#.V[39
MC_MK>T_X]0$!X^/G^X7MV2K=MN7\?O'K/'C5AX56=Y3BA6CYX=%5V:J\YY(_
MX+(OZ4,R#3 ^U;:$<FW@?/$LE&LF\UGZGK:5K]<LE^VC,?)07(-LT<ZME[CU
MJBW:P(5E$#G;;P5@]'O'C;.M."UQU-BW-F@-;E*_F,,[OB\;IEPE@E\!7WR@
MK7)(%W3RGC:272KRH3P!'1QOM:,SS^HN'!EZZ,6_2K\U5UJA0E*+S%-576XB
M3P1S?+5B\) ^XGW2EP,@Y/M^^;K6U6X5";L6WF7^9 >>6X'%)YGQ_.R["(^]
M0 HTR=0D9G$>)84Q<-4<E#$3ZUPFD4=R>[-O@O?HTBN K2M,IRXY]0:%^85I
M#4J[<>((*K>6Q4%9FK&$65S6!@TSR39J!;=<ML.?K^IJY!,FU[^[+:?K9)!\
M+A.'N9]I;*]CJ1!--'^.VYQ9*N+]592SM$7@IJRLBZ-)77\[C.P'%"YIJ%9"
M@@+R[.'?]#S80A/?(V[]J#&R3#P\$DFHUYB9+R&ZLSDX*,H[.<C7 0_B.<<B
M,N6!****O LTJ;XICV"6&FM<<R4UEY1,-,JB?=[\& E>(!^LYLA_<B T_8 A
MPDJ"1I9G\=97Q.C"YQ.]N(7;30K,3Z)FT<:._CI5D-4 >$?*E:J6V[$MKQJU
M]05'6:*YUSNO+=8OT-NQY-3]@";19A]J1^<>3^9I#?VZ23X2)Q.+ RWN)TY
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MO>E;S6) -:7V'W#&G9E]M)&2,2X".NES%)LS^*Y!YW?5601QWR6EA<R>9(_
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M> 4(DI94PHR^E*"_;V$NWH_!A_D[R91VNZC=^..^J9*J$S++<%S.?1SYNZ"
M(*1U:MD)B0-AUL_\G HJS_PKR![YI?0BA?CGV%R:?5ZIY0!I<YW<]S_>!C"6
M7GRF+DE%-$TT%-."F4<A'QJ5LZ\ >%UQ"LO95[YN& NE[I6F5^Y&6T_V)9%2
MS@\KX\\#H\CQLQ9;C>003<$<[LKR*X#.P@_T^:CQGE#5&7- B2_^"I#_EL^'
M"+K<+[(>5CR^EKLK@"P1*(4M/@O8*TX/'_"H#N?L3O["Q)HY/^&O8&,1/SH0
M8B-QPEE/!15MVZ[MPET,:R]I7AQ>G[HCXD'QM$/R9+.&EHT#_4TA9J<_JSD/
MW*3>U"#(F>WW/'R=- N*"F?!?;+D:]$%!8L@T 2C2Q8^WS@]A6*<;BY.G:I.
MP=$&?U]2>CAE*T*:/ )D)K9H9$R>H].:Q/9[3GF!S#SF;^'MP@=Y$<RA#TF5
MO^ZJ'+*'*L75"TF(>?.8:7,D_PM;4EDEP1Z,'=SX:#:YZ.3/TH8ZUU+3\T9*
M^,%Q?O2_)1J$F,ZZ(.\SO213>N*IX*6,Q9%WM+AK5F;JZ-M.PAP[*S^@$*OR
M"O.8>.Y$G5.;&ZC"W2-01+$)!D@K.#2.1=B;JHEN/:0N@0I\'F.RK#=^?D^2
M9;L8LJ1V5RI)L:LOFG3PP)K6:#.^!:0/(A02B!?2\K"<:8+[$O+5Y%R69\[,
M;$>,%95J:E]:VFX4&*=<!/SV\,9$?Q:I!(:T3*SI"N!5,1IK.Z.R#&2 O,[9
M$!0L/G3BN6VG&CCY:5A+IF/FN;"&V2NNA(@V\NKVOKMKW<Y.C-+)/QHX2%=D
MD]YKI+&1R1FW=2^_[ ^W(\/$%;FM70'B>XN.,B=C4F_\V=E3LG9$]N0)TNX*
MWS$!T[5;SW"BDY:D1^A'*B%-*T7B0QI:"A-!J8F!8^/.Y#D1%N%&R8&<-.L$
M?][7,:YFBC0"K<QO+66Z9BO]C"1^CD@$Z]BI[))P9\:1W,Z,C46Q2L)?<4$M
MIN=<=(Y,B[DRGW3;^P+#,N-NO9BX,SO770U$"#W:D/*H9S:.@D ,FXH[6*V>
M!K\+SA;SQN+[^Q56Y#<X8LQL,W_^]<8.[TBM(T22\YRK][DFN\+$/&B;QLS#
M38H1CVM]RF&XG".%)24RUA/0)//)B2/7K>R"1@FK"Y6%]BL J\(ZY'(HZQW\
M$C6%M?1:#O@_A>5L)GA"17WO1?"7LM;MW9BIX ?6V?U8W9>;P_>1"E> Y[:G
M5J63WNKHXK=#F'<YCGKJYIT_!HA%@@T67+D?BK/-4II"Q'=<C4Q"RCQ9/Q>-
M7EP!0 ?Q;']!J:5NE4$J/V5(#-,W,].<%WSD:6%,LL(_,4+<W[-UJ+Y2-F^Y
M*.?<U$D,\\SDC3+G8W0\A+7.+N'I<HURYG$2PM6.P%J]PY(VG%.X*\9QV%,Z
M.;?D(5OX4E[F.TPISPM(C.73.G"$L8Y8+^^+E"@&?;$<,B[B)0B$;BDY#5)N
M24,7LL7WFY!U$:T/7Z4]7I--L=)4K!M"Q&]^]I+.X:BRN.A"DWXS4"D)).$0
M7I)GU&! BG^R>LG\KE9#HH79+W#U(KA@S,TC'OPB='4\ )W,UVD?W7*3IN3>
M=!%7&[>W45EN!B39TD)']@<CB]O[[;SH#U7 G'A6KL^8XC'X^[. \T-E>R?\
MT0%AO9@)<E:^=XO]#Y-6X((\T6G-'7GZY'?AU-*#E''#E,$0 U-)(RVO7V8B
M'[3O4@7*J >RDOB=GM03@]?\+Z%L>GK(HE5!^9:&&E"!%1SGU7""R'528);E
MZ'*O?.[PP7%>AOK;DH]Q:JW$;<:S]Y2)728R'R)+/S D &NSB,/%RL1SXAY(
MV,\/,<26+8Y7J(C+/QH9#F3CF_:SZ_M15E_0*5PEA:0D'@,1)$RE(K.][N<W
M<EFA)F0_3+7HQ&X(/W5?:$181B>0S ^-HI3U"7N+<*W_>>%E7#L:^:7^"J!T
MQ/LXFT?;_;=WJ)O22NR8A+VZ=W(]P:LK)6J:17,<2"GX:#N![2(!/: 23N/J
MTI E[2V*1A/7!@4XT0Y/W;RLMXUF%<E!UKC=K"O ZB7P[$W0Y64S45J*^/]]
MD]!^W+Y_= 4XMKH"7/:E874][B[F[U.P_0AHBC*,ZT4A_\R$>O,<!JY+?RJ.
M:*,W_%=U_^8;ZK_V(^S+,JT.=IB=-G;4Y&>L\0DVNU%.1J@C79%-),:#";N<
M*A?C;N.G7?^C)^>V\3YTHGZ(!CQ6([PV\KV78-[3FMY:,!K/Q$8RA$-':!,I
MXH<,8\^@JV<PI: /%]+6N)?-NA:>YW:2@<;+4AZ%[Y7<3[9A;,?&R1G2(EZ]
MY!(6F9XTNR6/QM_:-!8O5_\C5<?7FG!8)IU?-L"?\3T,>NXSAQRE3W>K8M^*
M%ICQZ-^O[4780<W!CN:I2KA&=$.@51QXRBB"J7U"ONH.1SQ$ZU/.^T5<Y#Q^
M>2@BG8 X(ISZ;4C6BDK47 $*]!QBL=OW!6C-9N]T;J',%*)[]W;Y:Q*X^BHC
M7P7'ZS(GZ]?"'[2Q[#K>L.M^V6QJB:') CT%7J(620SQ&-S0P5B2',]F1H2C
M][B"[+MD"(-/P[A&!:^UL:Q.1Y5]ZX;R)K>#9<83G0%RT]Q>3YX!^G!E?F:;
MGVXNX$7BR1ZF/')H_VRO8%3D+._ Y+UG0PMX=.$G1"ZU*G4F\OUHSX\,YKLA
M:I%F_6AT;Q638SWG>!NW!XQW[3?U /9%U"-GS_(PW!/_H<9XBM2PN*#3@%7<
MQ,MW[2#+!VR2B'!WG VF$IX<<Z_\*WK(>;ZI[AB<!(8NN26H4M,*+X:T?](H
MSY#AMY8O6&*'_OI+H%]5NG1D2X7!D 'G%RVB$UBXNK7RZ6)B0/A&"=9Z,YVS
M&./M8RNJB-*Q<^39L8@&5]ODZT.V*:'4VZ3A%3^*^)LW1#SMZ*E(8^6,O;#<
M0^DEA^C%(G]?+4]T4I[>%>!>P;;*UQ00Q&KS_)QPO1N[ @()I^OX#M;+!IAR
MBO*W=PM/T+?)45H"R.^_WDIK E.ZM;3%7*O>=*8D='\@J6[V_OG-V4P_4Z*Z
MW7XYCCUY3GL\^WK3-YX<_>@JF%^^<!B6X,?+O#6+RECJE[#VH_=^-:X!H3SR
M"H[J=B>M&7'A*>1H;'NV^\+4_74FJ8D<^#)8%!1<AG1M3K[\/GFM]UX[Z<-,
M&W5G?SDB*UTK2P0/V*/_\&P)I-Y&V$H8WC[N=^##3>KF6SB%VLO^E5.!\ZIR
M9#%L!?@O3K!)QN^A6X++I+DRSX[@K=5/V!JE+TM*7V,&=MU\^F(_(K+73N8$
M;#-UHE3N2J?$,!I)3WUQM:#X>4\.Y4C?)?!I@:Q)N06'Q2V?P/59B2A'R/)A
MV1&PSX\BO/F+<JG;<=:DQ3WM#FM25E]W\)\YX7ZA>$Z5!)XH<T^P.HT7D[8O
M,G#FM8+8Y.D!X>1:9C8'I84^7 &.OE9,336AZ/Q.R4;E'PS8?XU!.J@[_EL>
M*-WK&:<_,H4^^-R=UW>Z,6GL8/+1&%.*IP\Y"(0J7:*V_$\/UD^S@)<MHKA^
M,&&=8D.Y.;NN#!RZ_[#@4"X["#DQ.S;@%<HFXBX2.IE*\!2O@3MH="]D,^H$
MG<8P\'+,]*BE_(O30J7A\?%^6$/IWR 3%K/0%5KS3;I>H0-X2*48>*CSGT:%
M=C)[F"<#'[2BU.,65X[)LYZ!E9N-+QF'%6>A>4IN">W<E\W7FBG-D)TT5Y!4
M5Z18IN3!QI16[D88/QR44+# ?BP'NF5[>ET;VX8(S<I=9[C?IX*\FG<S$3J?
MH%Q4<@D[4,PJGI7H1< K$^7&?VVT#<UZ_WIWT,S^STQ/R85_#.$NL2I/&?/X
MH4.H,+5NP?//P;['QVTVKVAU!"6>LB#/'<5ZE->PFY?!W1EIS.+]L5K#AF.U
MC"V?*]X*R*)H_DUJF%04<,5(%%T,\&?NT=O;_0QEGUFAL;=E+)K@/,2:@]"B
MA1'5\[%@PU_W^^TF>GX5UO[0G,2T1"I#6Q7^GH9IL+@6[?V.;GWV@:3&RX>.
M?9;A7^#G]J8SIV*5?>H)ZK@S9]3MKLVRR*2E<PMK"OYR)4_^@KV-<W,L-7T2
M8CI4Z8=*_#MQ2WJ\JR$QZ0OGB[9/POL;RG6KN,5\D#YL:.B@! ^05TQRC\E2
M+/=^.Z#@/[]"4\^JE8GK3&%MSWT<DIAYJNO69_'M'I-"L>R=%%JRFRH4;PQ#
MN0T22MDCSC*O +AMS'KAZJWE\X-X_-G&@D&0GMPJ?&U+W[9M2*A4_"('N3-$
MDYN/%^R>)A>S_VNN'D,9O1H^YNJ2.#1W;'8#E*L8/K^(15FC)PX)J-1<"'+A
M<=$AO7*>9?0RS"FZ/Q_[RXI7/F[:*LL\)K054XIANI/EW"8TN6[\$B7R/8IV
MR._N(NUG%4WQ +_+2%Q+3PBZ!0:[#/CAR ?4]BK[.79H9KC?-Y-OK!.'$FRM
MZ),/J:D;>L;XZ2?<5L>4I/G%VC!"AU<]?< XJXR+TI*0:_PA^%IH5R]/5U7V
MA^(W\1U&S@L3RJY>HDH>,%-[T].W'*Z*KD@9?3#+MM.BX7(B<-1FFL#U;(TS
MBM2>.H5VT8FYTW.XQ O&RO9W&=/?&@R7=MA1.?ME6$LVG!)@2/FS-Z,);FW<
MW9;H80AIASU-*/DK<Q3ZICU$0^$N(UEDLNFJK1$_2='0/!X'BD"B:V6/C77J
M_!7K/&.S:WA$.K<2=[X=B1F41%G?9V1?=^$B>[@/;%H8OS&TLS,H8+G"%XW6
MOS[7NMJG?J<P)38,=N^@NZ%RMXE6+KCK[16@_,!SY)H#(H.7<$P:V\0LZ?^[
M7EV, J*DSS](E*]/B9@WW1ZW2+5'/E8HPNR5>-2\ZMJ>S2Q:9G8^*ZJ[J31U
M8 _\H,;(KVVG.%]BA73Y,O=C?K7 2M+"^V/7_"IG6YRK4(G0WL'O$46R\(@M
MCQ/#^1=P$0%U1%"*^(A:S K/O=-ZQOGJ-:Q%ZNI\K7(9H6;H]_I);9\=78=R
M+\_HW-/1<VZ/X(=N)1]-A(5(1]<T,?8W/H*->%6XO1@I]GWTD)E!(/'R0=UN
M$+BD&S&:QJRQ].RAZ?I??RBUIF/E$X_PKSH=:%X=>P51GZFC^725>)PSAZ58
M>H_:9WO-W.>\.0NUBKM-]U-NDM#4WWP0^7!F&FMG-R;3X*(@.ZNC#$J%^E1Q
M&K.FM'@E4+K8][(C"9H!W8HI99KRK,3S[NQKI]W$376"VJ![[>KXY7-F=(KC
MS^]=*8FS92F3T(IC$J5CSZ]:[YU,;W3^3'W:;#.<E5*Q2%YFQY4"W= ,QI'@
MLK.)YY=G,^)S- <!,?#SYZQZ?!X,KL</>\:'+8QG02@%.Z/YE%.-I?J5B.2U
M=]47FNW9DO;%1NJ""6X>C<^BKH'SS'^]E()K8;50#TPG=5_OB8=&Y:V(41L)
MC5O7T5L[Q((GM7^&6-N\:V/5 :)[O'(I.S44)T6]F<?%"^FO4U?C@T4<<2/X
M"2R[NU9/:M<767<Y\L7!I7-.8VSB"L!G84[)HX\]G3%=%B8ZI#R-(<^3YKI[
M2IW/*J7=IN$YQ)Y+.KU:7_"C .LC>JO^>/H8*QO%G'/!C;9?-*[5VS(*-6N+
M^W</#.6ABAK1?)P %8HH=V%>R6TT*;B\O +4!#<CUP+73,H]2\W6?;M+'CO8
M3BG?R!B1?2.#HQX0$':?B2C'^USZV]['%VY#NU#4._^>Q4B FN\&#MO?7MQG
MH%_. I[OC=;_/[\;:^E*EZZH",>J"<8SJ\LO0=,^ M0QC_+%77@>J-)/1J\F
MQ'N:=DO3#GKDFD<718VRJIRQ2/?>R,YNW-52O )06^D*^M>#371<I? '9T4B
M-V'X,Y@RC#(@2SDX,NV8>+B\;T5V\)XY$)O^\RVOAXSZZDJ@A6A-V<.LP7[.
MZG&R2(-QXJZ9]H(&=\&AARX+VH79X J@+67L8_5UE=GO_#0>GX\8?D^2]>PS
M:N @<5M=7<-YW2T4-Y.%,-RE2+XHQ+4$GS8'7(=V(7> _?2GD6EEC%U68FI/
M"Y$RF)3C W$36W$6WE'DM;"(J&+_I\K@9([5RZ"O>F1S4V @S)KN%Z9*ZY2P
MB?_CE!?-=E=^^Z6[F9&[8M)1#8>MJKR!UW%'/#]4+H9YBX%$,]Z.GH0_:J%I
MCK,^9G=9#ZU_1L"OSW\/@V=RKW2#JFUA0EVL6L:MO>XB49\&*K+0/PH2%I]
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M=,Y"_J# -]-Q<Q,;^@N=HX/Y'ILE]8R'!C&L+Z#P\!L1>PAX((3*F_%JZG\
M4$L'"$=&#4M)Z@( >4H# %!+ P04  @("  8ALY4                $0
M &<S,S(U,#AG-#%X-C,N:G!G[+P'5)/;TR\<>I'>04!Z;Z'WW@+20D('I800
M2@))J**B@B)5NC25WHOT9J-*5;I4I4D3% 4+%F[ HT?/\7_7>[_W77=]W[<8
MS9.]9\_,;V9V>W:>D(-G!R\ -$;Z('T 'AX^7C!>, !PL,4R:^Z!PJ(P'BA?
M+AD)*8"B-LB$D!" (Y:']UWE_ZX")-CQ[  $)_D-V/$! -Q_=GQS )L5 HZ$
M83P"G=$(+AT/9Z0;VAD#\W)&.R./-/F/-&DD/%_,6#F< 63OWK56?[++==2F
M?-2V<MB.>^$=U4[XHA%(K)D_UM<?BZL2'?+,,5A+%Q3*^T@"A,3"8$A_GQ_E
MPW<=;_1AG?I(UQ(1="BAC< >ZOQM$X8V=?:!0?1L(#_!OBN8HU$H=TL8UM_7
MS,73%<>F )@#T  4[I\[@ M@"8 !L !_@.^1"KGO3^D?9K2]L<B_/*)P\4=X
M8Q'((Y.X.MF1M(Z)K?'WM*H<RN.+_Q8QW2\1F_EB$2@D!L=E/HK+%XO\$00N
M2!?TSPH8CC'YNP6-U/F[@L3^73GMXHWY63&%8P-^5O1\O'5_5G!Y_-NTMJL7
M_*]$?'<0 #;0UL&]$1R5W;BXW%#^+IJH%X ?9(!&_HNG[?UO.6VT&P2*Q.KS
M@KVQ@%](V]N-ZT]\,,8;>\0W#_+6=$PT>?B=31X <\6BT+K.6.>?H\(<;H[Y
M,2H.RW^]ZQPE >:._9-Y"&[ _XEOZ>K]G6^.=M6T_<FF<46C?*T]8+C.Q?47
M @G_D3&JPP8PSB=M%!:+\O%&(>%_J5#\:#ETX1<^Y0\^& 'W^+7AQ(\&G&\_
MV8<CAV#KNP\$#[[)X:8>WH_WHU$E<-1&]7<$&F%_:;W]GC#<-#^B[UQ"RB/N
MX9RV.ZJS_JQS'FF].ZJ3_;"&=Z0E2/.7+;P?["/9O:.R(4#2W1W7XHV[$O^E
M])V3DY[QDR-]=+7#77]PY(ZNXG]SCFQ^/"K[_O#ZGT2P=MC\/]]VE O2[WD^
M\@N K_G]]5<;Y\\\?:^S'98(M'YZ_ST$=MQKZ8@'!\@"@( @@#Q !O!S,OU&
MO_ .=0YU_Z/ 3_I[Z0 @_;T/AR#^(9P+RA_IAOG'S'7% G^X?#C<?QEJ@'^,
M28#VS['[W0WPSZ'Y/1R,-\(5AK'R/GTXN?!^PR$Z:L,5Z' ODJ,*2/<7VR1P
M-,K?]S<6,0J-@"-^KIMZEH=*9D<\7)W2V1^+,H A86AG+,SMR/M@WQ_+/OEW
MX4/.80O(!\[U?R%^ G^T]V^;QU'R?^>88."_;S#$SMY8B#/\-QZ5*PRG!PO"
M@C"&$)/3/Y8PTA_LWX3)/%#H$"WOPSWV>_#4WX,W_,$^S*X;S-W9_V@-(PN
MH;%_$+?ZP?Y=_(0+7 ?EC4+_DES:[PK:!C\;#MTP12$/W\FP*%_<1H6!_9HX
M<F]<(O_%I7 Y6@S_Q3^!/ESR_L$^FDU"W_4.A[/&&\#??-JC(M[W58B0X:AV
MV*%$1W6*HY1J_)6P.[B7$Z[X @"HUL3Q>0$L +R#9P=;  HM-Y0+[(R."0#_
M8!M =50#N(4=ZAW, ,(!%*2DI&2D%&1D%+0GR$_0,E)34% SLM#3,]+3L]!2
M'-%?;W\F/,H3)RBI*&FHJ&@8J*BH& XO5 S?56C_*P8.'@)H27'.WR' XP'@
MT^(1T.(=S.$")3_HQ,.%AT>$=T1_I9$ @(=/2$1,0DI&?@+OGXUX 'R"'XTT
M #Q"/ )\0GPB$F)2(@(*&5PC+0$A-QV02,O"F9['[Y(T,4-"SEUM7CY&\",7
M&5GTY6$=$OY$RS<+.ZX8.:;<FBL"NDD0-[WV/*P\\PAT$?:V-KQCU'_IG;Y@
M<GY$74KGV/)N07W7^,J>E7O U=3"ANZ)E^\5#*SA@=?2BAI[)E<_T +P\7'>
M$A[Y1$),)'?D C>0CA#G@1\//9'TI02&0P\>@8??R/"Y+* O)^I8,KIB9'?X
MB0\=(!&0:Q_!.9''[*8'E<?"%G^Z\)\]$/S;A8-I  7!$28M0 .PNX_('VFW
M&0F(ZWAD]K3HZ\D++U).#4Q^M?C$:!Q2+]=6?;?KT<I5^6P[A0L?5GT. !JC
M99_ZP9:H[Z)I.6;[\E\?466U5%:- 1HX[@[RFK\F\9F-;@O^VL4OOF;Y+?:!
MK_'PD6SQGGKKZ#Y27E\O3H'=\?*^Q[7IY^9=3@7HYV:!7R0ZO;\5Z!,3-7^0
M[H$:JQG(Q:B\Z'FI G]]KO$K]1.#\/7"EY<]&M3(+PXW;I.RQG=W]@3HI9
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MKS,:<_1 0HWGQPSG^9?"H<[1FJ/L['JX]JICG -@;JJ2O_'^LQ+BWYWY7TO
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M $X '@"/D #OEY^=)"8D(B'%PR<C(,>U@VAP#'P  3[)"7(BG!P @'?T4W,
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MWEM&Q=ELZZ+=N 6'X-)8X^X0K!L+$*QQ".[!)6@:=VL@N 1W=TAP:%R"6_!
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M4?^A+:J<[AN]H2;3N0Y-FA[FL(3@7UDT%WFMJJ.=*HNL6JE)3<H,NGK8*QZ
MRKV4,=:=_L1%TO&Q?AI*")OKXS(6N8.TH'-JXW@(Y[31LJF?1_#6JM-N6?2J
MJ%!RG)]N=DB<,\-A L_6#.% D%\HKK 5C2@:-;$LP1Y$6N<W0.PW8.;3 \&G
MC?N[JYF"NR^\$E9:SM*FOH&A".Y<;68KQ!OF*A[C/,QFS*@HZQPA@YJ00VUO
M(M T)*&$1@:&2&^&-',$:ZKLC(1)G!KME[YMY!EA-8*&E3(>S*KG,%KKVKSU
M&M9-L?UVOE[##(6BD9" O/"U*]S/4).Q98OLE//5BW5G&FJC,Q-F&1'L#&B5
M%)6D15E*R+W)$D)B^!6=.4!J=*>/0WIXVG^D/?@<M;,!5UG7Q<Q$TOW#&@HA
M$U8E[76?SQXK3Z)"._$]YVR*,9 4>/J3E2_*X!%PMMY^R;.U^UG:RKC7%[BQ
M@MYF^\Y%'J1E'_"S=*%+:T8WSKG3'"<N!D54<S+%8$N%C3G- SM%[H0-A/7+
M\!D?T"A"8,":2."!> 4ZB;!LQ,D%I,7& '39_]&[4AD^X.$S.('RHQCF\H;)
MYQHGW_-MR1Q BUC%1IPH15C 6>&WJL8T;975. !NNS\BI9\" ;U4!I3M"#.C
M6QS),$)EQMF>*:%\/>?Q7!+N_NY&.P5W<S3Y1CI@&N=" L!*0Q?#EY=Z#Y!Y
ME)D70R_#*/9P)Z#K.;N=G3:% &;6VKF *=#@8D"*H!^[ALTQ2M*H:(G21[CI
MS[_@)+](G6)'T:[X8"_$D?(US?]T"'XV'YP]A3-&.K%?>)A=D;>:1C>Y$9\E
M ^X%PKL?XG)O$EQ^;F!ZFM-094B@$SV)<_E#V0"GV]),$[/T3#^9X$:%54_9
M".?BIC^]PCLDLXW9S_[3CV2YG6B4)A7J,0Y/M:A#=+K97TF/43M]_POP[U03
M)MF,VUDN9^T%%<5A@_U<F/%LS/I@LFZ/C#&Y*1;J+,_,S<Q+?AQ:BYGD$-_O
M3\5/J#8?.O /^R3R,Z30Q%(MU\.W=; !.G  "8! &>N>>A9%*@S0)K? @\^X
MIY?3:V3TO&H*%=DFFXP!Q;1EP!EC=F5AGXR0X0/?1EV_V9?!!WK_Y:/<J%J=
M]T$B.T$M>%B#-4U)$N92YDT'_J'V;2CWG+_&LK*\U5PF_6@B\!L^SS/\%5,"
MQ/4$MJ8!TOFYPS*'*B4QI1B ?1&%0H<]"KF#+)-A(#JD"Z%7#A1#)Q66W^C1
M]?_X].&Y(=0(Y(>!1 "0A:=#0$.A(<L7D^%_.G:3DXDY0A\%Z SX)_#DKAZB
M+[T8UC</"C9^ U+B.]X?PR\*N.XN=#C-"E@\3J64U>KU;7X#/.?6WNPRF 7]
MLV>8'9TS!DM?-_M\18!V\(I-&DBK4?"]G0V7N^>>>@XY %F&[M5)?4T]IGIU
MXJA+*GJ0DS)M?NVQ#S#[JVDI?$D8$P?K9GYZA:O$TSPP6?>. :A8D?)N>O((
M$Q&W8&,:0BSFQ8Z,)-HW,_F&V_O/-@%_19=0F#HG.O*YQI]9<I &"KUH]NBC
M)$W$!>OV15YJY_9IH4W*O'4=YWND!P#_JFIN D=1H0-&+9N@%D[RSGT4FX%P
M.+I1BHBM)%!6*LWLG>%G5=5@^=QHD$SJ1<-?&P<NJII\E_OAP]VA/NN23+H-
M0-N(2L:ZI]\FNC8GI@KS4TS/M/UHSL@1)\#ZD%EF039N!<\<2&(.'^5525B%
M/ZU02@;X W!%_KIEC2^L/Q79>4M<?(<6#)3^C_K C*\[1V9/OLR,B0;>H9\Z
MZP9:6]ISLG#S\]UCK52TL7CM%&NZW9R$(S@2-T4<8R GXJ;,.N+CZ+08CP,_
MZ3D.6JQK2!."_>5;95!%\% T0):231)3&5(Z]V(''V'=D=-KG=8_QW';W! 1
M8EB9I2B^<"LV8V&LLRC,^I(O2_971@0"6ZWV)@VQ^F7TLH,('Q4$\RN!GBL=
MA.0(*?3CG5X-#<?8.+:DP/L8<I^SAX2@O&Y/ 1>@8UY.0NW A $K34J)+K/G
MF,I3#BR@ENTP:H?);T : XJYNJ 728%@KJK\%?\?QE!6OY+2K9U.\CHF-B?<
MALOW&,$SLEJM\M9125DBP91M*JLG>),LP*>*@H2S%$\;6TX6!/<:)WBQC:3
MX#%VA.98\-:!BEA8;8JU$_3Z?C97/8"1])R@XK?@V@._BF-*)3O[Y&[3$KS
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MLUWG8^/!D[@ Y;E[909MZ<XJ^27]<Z/\EAB8,^=B8NV\@?XYU^'1DJE3.7)
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M3+BI>LL0>YKYJVJA5$M+[;WQIC%3JOJG17J%T>-+JJ696.[R!M%3(!C0RX!
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MS*3;?F=Z[F"9\8F^9$BZW:E(^=Y+4JVC6,<ED"H54BCZPH#JE%P25B1/)+:
MKT'_[J2ZL5>T'S(N(O+JGOM-^>7YF:W4-X.<=6&4,K5+Z_%>9I/ZTJ/<U4C2
MIWVCS\TG!41%TL/!3,!1NMQ\(?;P,L"3X3C;ZQ=V'4NA[;F8I?L!VF&9)0:@
M KL$_8 J =,\NXK"4BXKM[NO5B2\2D[)R&:]4G2[$N[55[ZN*))>@BU%C!:
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M8-U\:AIA?PG"5<E8M7EAL.6A8.'0+ %WX],-?;DU$T--PEP6.;  '!.@<\E
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MN2;_EI[N08<"UV!@"WD5EL&$6/$2F50<'/6NC90B (!/KB"-!R"0! *D%"
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M.6<O-KMLUU\O00S.[,,*1N2)V?/] -9IM%X,F'(=#WW",4I4=$;#(\ZUVB^
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MH-2A(:%[S5#-A&#5X6#BVN8=$<@5"@!;BLM+,5U"E]M6'%%N4ZO6R-6*TPV
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MH:'K8* 1 ]")T3"(T8X[  P -  Z.L:)P(__HP$.+A8V!N8Y=#2\\R@!32(
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M)TU@)C"Z077"4.'B^'M=0B)J_?UCI136 CDL\<0L<:HLF3T':R53-U0?FF3
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ME\+^-$,2\7,=HYY-KY"<P""Y@PA2^QADXQ,-1>^K-I"'N[FW8A#5_'Y)QL<
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M6N[YU9=W@V.RQQM[*^AG[[?62:0(9SC?MCU*-FKCH&MY$F[@5/="]"IKO>A
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MY7C]_-0EKE568A/78HN$G4>G4C$*G7K /C7H4$ T42?,Q%$FG^SJD1=WGK'
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M2!<'3$=.ET2^Y EGFWB$7CP\^+H!['Q_RY7EFQYF2FP5Y>N0@9)D6GN**&%
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M-J.Q98)<ND$(]KJX2NFJ3-1YG@]399^9"II7J[;2P7>^Q.4D9*:6>/W!Y(F
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M"B<W$IDR"N+']GQ^_AK(NJ&6HYHG8[RS#TTT*[W-BS&*D+V?^,]I4KO5MAW
M:?1!NYW!4"Y[&V.=43UC%N[$?1SF^V8N&6.:>-7A-^@3M@:K6>XEQBU$7'6G
M=<7 M1)8=4U]>=V9G7 ; S@X1'(']432D30)1+[2TZS\@RG %I*]&1ZF= $
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MBU?0U7;#:5R%>GP?\\@A$/_B1)]+]F;^2FRRJ=,CM+S.^FHZ4;FL):UFFN[
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MQ9(-HE?U@ [Y@LLV/5R\#=?YSHJ0#B0KUB:L7I(*K$@N2&(FA%U.4G+QC$R
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M,0'CI[&FP,DU/PJ% 8>GG#"T!\K9J;G#@3:Y;R:&$J$A5:9"+]PLP32FNJR
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M'KL&RN6S!2;HNQ*8IL8%,3&H0M&SU7BM*-ELN'IY?\M[ 5KKP#O:/9^(#8[
MM*Q+4$)"=C)EFE]C'TL:HO+6E<;P]"LLR9ICWI,W1&V_>9U]?>[C*^[[<%[\
M.VUF4F?9B/]M;D,N.@3';Z?W#2S/2Y."VC=L^#=CC<,:?I)2DXTSBH;NR2+#
M6B#^MGKA<8?;2OG73;7MI'HT.0:0D6G,J!W^HL0>V+M>-<?K.GO9-5'DE]4L
ME2.VG<8]9O4[@6)3B8IW%&+>K4,M1A7G&2TTX^#5<-6"E].-C(U'KGZP6CR
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M6)3,YB9^M'?BEA.]A%KDST??,.(/LH%%T^*KM^Y[;/52%4WWFX->M1489YU
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M="1@.6['JT?J#FT9L*J'6.&Q0QU(9/K948F]\<?VF\8V*$'5NA2B&NDYD:P
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MUNT@L6%UC\^6_Y=4\R1FA,G_C5TO9X1_-B.("&DPZ6]27\1+)/W;,V05?^V
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M7EBF[@LQW5/6N]8&QI!X7V<?&&7X*;^VY5_=BEJ^,E9F:Q![=RVB*O1Z95'
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M=FBZI^5$]"D0K>"BL=6YF*LH_YNVGQXU65#JP.N%F';CR959:N^[F]:LP(N
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MLRZ)Y*998516:7(A#>PO@217QN;/C?4(8-PZDW1QP?1^S@BOH=VOH(W7?(X
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MG[)KWE1_"807@@U-Q*GZ$1G>]^*F1=LQJ4TD.^$_$E^6+:X16P;>9$,71\Z
MW#AMWYJFL2MQ32=Q-F4C=-!U:KCXF"J6P7'7/H?M#S)4OB8-4N]ZE[_<L0#8
MU'X@?1!Q(",7)#JA&.2-IX$GUK:Z#;S^DTO^80)HON%A,M6TP@3ZI/2<8%]0
M.BFSV-C>I(X!\[JLR=5->):F\4\?YRP1PR^E[_  WM._!!N?K R7 $\N*Y8E
M0K3Z:!_*LX<T@GK-KLU-UC1#=\3JK/H@DY_R[4-N+-VXTUZFMMQA-QN1+%7N
MJ=*=UQW55"?#6GM<]*U5+ J2272WXG#8N&BR](PG+N-PAV_%GRLSNS>W7"9\
M?5MK9MI.]N$"LQ&R/=H7W\3NXF:OV@=TRIP))$M$/]744T@?F] B:B/E#.8K
M8,07)*0:+V(%3-6?:9[]Z#;\5#E%X_8NB\L48I?H4-4NCV95SAKG, R - -T
ME/1%"4E!&L8;'7-J%SN6F"9MI3*A76UM$I;7>XZ,_*V/2H1ON-]RU=H'70V+
M-GDS&_3KCR]P>Z]'K3T"KZS6>]( &&3/@6GF%$D@H=!QQ'KBIKP?^0 IK5*Z
M%:V^.P/1Z1@%F8>N6:Y'_ZP!$0^S<7Z2X&WQ/ D>8%6PJS.7:7=_,;^?'<:R
M%R5MP YF=<P(8Q2AR2YL9FO27G-*LW6[&,#7$\OY9RN>X28U*<5,I5I%I9PB
MB X[[:SW2M(&@B:4TCSW7IK8X%;Y":D,AEH>*KSG_US\B.[-4S3(VVV)T1($
M$4#)#2ZJ?*85X".'+)%RVR,(W(1[X9)9U&1&6K3Q/@/1F)9(1BE83++/,\,D
M(J+WMFZCUJT&K%%\&G!$LTJ. X!%=6RV>3H"N'_V5F;67TRO2!VA%>BF%*?5
MFMUV][MXKYO;8#;7V/(TNC;GQ[I:]BBD+S)6&N."-H2M,]4K@[Z$T @V>LPZ
MUUZ\SS'65?.5W0Z[QAF%?Q>A*3UN5R8#\UH%.UBV ,R[+U+T=V<X2@Z">:)8
M[2 ?=MH^JL4\7!P%/&_I/'""'6LC/%N5VK!KG4(V]BP[EDV+-_S,UN_1.)ND
M)HJV)+=]S_%K=I>R$9IS"6%=DCT1B? /O4 9M%TV.P>F1<@> 5CL%J)=\1%W
M#74T7TU[ZW#/=CQ?SG<D->1F1'C##BU_OQH#Y85).:TJ&E\U[2L#CJHD*!5]
MRG+:*"--2#-O[E?EY0[^2@L_Q-*RX7W;PU!7>L]9W*U;)1P!6/8J@U*%%;YC
MN0:]IM>U3O=?!7UO7'N5X(- <C##=QKI7M@SU D#L79#^@[_\Z ZLV2GT]U6
M)8)OZG7M7'A.A>+V1U4YWP42I2VVI?"/ 6]HDWT&N4K&#3>^A9UW_;IW\(;]
MC#LR:PP]K%!>_2ZTVW']WE$*E[+Q7X+5?<Z8;>ZL%Y1?O9R[D@[M_==.'&J&
M?@:$]MUH +?]/?B> _I;Z3D#'[ZQ!G8_Z7_Z '7'\T%KNUG"\\O\( :PRA86
MFE.8ND'?/9HB9K^^&&&8KM,$4:?-?[E))B34F?@3@?A=+#G_&!\HO488#"96
M5[ADA<]/Z_&5[[S0VPE23G4/57-'+S8_0NJ"BAYAW"0$B@0B_)&VDWHUE?V0
M&E$<K?O=L"XE$#=.0/L(QY=AJ(HF-<MI!#)42OXE4#_+GV[FMEEB6?EGB)(V
MR?JR\3N7Z$H#V;94!#'DO38ENY0/7G"_3L\$8**K%/8@O#36S*3-I:Y+<R"J
M/A=PZV+MO]$Q7G@^[^!\1(#RR-P%%&>,];%7-5T2[(.)8CGUX,+[/BO<#6-/
M0Z$^X]=S(M&SK.^^X_8[[X7)L%]<RI*ZJ"9KL2D=37]Y8?^+K11?TU-:6"0$
M;!2.'#.N!KEZDGVK'C<8/];S^;#?/1*46PH.N+X+P+7N[739^-L>7"O=0@8&
M_/.>DVCFS!H7O,]@ 45L7/C2:2'_\ Z^FCVX"SO^] G)/>_Q_NCV8;6[W+4Y
MW/!Q% @^&+E7^.HV['R@K>P70"H<^9/"\8'F/P QRC)!M@L+4<$'H:9O1W;G
M^30N[8;V:BXJ/QR#-84620U)<]LM1/5@.AS;U-(/0B\I,D(P_DA"85O&7G-J
MJRE](4HO:QMV<8OZT&)1!GU[SB %"R4'D2E+/_YW7M2!.,*,=<QV=3:G38VC
ME*3!0WUQ/X;WY;B#-PXOD]W XB5&" MC;Y9==Z:FQ91)^.%FQ+\DSVXOBG5
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MJS?*K$DMJ8CS]H-MO]N*.2[U<AL)^IWTKV!IV&-KFY8\4_=6GI9TA>; +IN
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MXXDQ.#.*9ZNOC/@EN<TE#-_;.QMLP+?@1&CEG[\./4R]XN$'BCUVFS/!CS;
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MJ3]HK4M_T*+O3WY3W_Q!@Q;\0=O\'33T!^T<^/[29^3_>B1W2A305IKM ['
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M'XK68'_<VK:%1N>,1I3L^P>Y)6WHN]*OE:]+OC/E)#D45]#Z-,VH-K6!]#]
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MQL'Y!BT92NK.O/SZ7G2"P6K7^#9QQR)3DX I,W!"CVH1S@8S[B'%DW2"OJX
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MT]3SB+ %39@=%A%*-+,H/IN)GJ/AXIQ?/VO^QQ;-^AK%R&$\\"Y405HN"%M
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M77W$N&DXC]HS]JUF$\&E,R_HIL>-U"'*2IW_0@/41*D!RG_!EN5"].F5ZBV
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MW/9HW_96Z+1S3.PIY([ K$-2SB:['2JD!<K*KY[+8=^@ XCZR[/O:%T0Z9^
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MF\MJ6,6M6>9M8%MJN8@+G_]DQ[#OLIR!<G9GT#=35NF"L(36)T2,4NA9?'+
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M<7.">_;"P(2GIW<$>RX>J'P<^V[=?K)R& :^(D,^-OX]L@"T ^IC<(+ :TH
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M']2_ %!+!PC$Q:7V<-,! &AN @!02P,$%  (" @ &(;.5
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M_KL^@-]^6'(6&$P*I/_QPY(/ 9Q[OQ()!)#^]0NSY!0'R2@/ $FI2(ARB\,
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MZCAC="[9[/R;(H:\X7 9EC:N.O]%'6L^06D3[@32M).Y["@K=/N=@A%48E-
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M#M3-&(L4-"V_FE=Y*%4SD]^24BB7Y^"#1T4T>8+%QI1V'WG,=4^U)D= [\U
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MY,/TA1!O#)<]*'.OC3Q6YG70$@FM@2X]-K;/V)1=SN-J$$':]+!$2WWF$EN
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M1"6]073E_^T>D*:N#D0?SB4"SQJ9HX+)K4&KP$:/&'H4!&W+!(4Q1'H HCD
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MQ-SQ19G=@YG27&_375/=:QHVS\-28B@:.EEZCO4E&A)6P9:LA%]Z;T#Y-Z-
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MH*N(#*7GGRD2MF.Z.NZA"YM1&D8SAR5=42JF]P!ZE:0ZN)!2,-*";T(5SKN
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M/69Z5@D,Z@P&>:O.'H2DO,&?U3YG-1=!:@5654:4Q]8_R;]AXF-E9;V;_^;
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M6B).8>%SZPJ=@P2.:*GQG>[0D:(.4.W"HH!+@Y_)6JG%CP^Z.O)+Y'-&JY#
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MH" 14&$!AJXJU$).'N_E($WKWX5=+^D0UXQ;E=?Z&ZHS\A=4MNXO+ TS/2Q
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M1*^V\2\ A+BJODB%SLP(Z5^/YWXB!C_(C/2^?D2K?W'!?E_3:2&O.*8FF3^
MI;?B]%H4N39 2)%D/!<JR_\8)JY\BN?'=$PU](;W&6EA8;*11LCAB@(;C_$,
MV:@8K>,O%-LQ"\1EMU_1!4<@\/HC34G%(7W]9PZ$X%>&/QV?WO=NTO3Y!EDA
M1&'U#)$?Z$HB1'S]8*8FR+"7?D<=-ZL^)%/\]95T:RUKHGSZST\F/JAO_V-?
M3DY^16L^^I6!EJ"TW%!XL#/>GM\?:W,,RA-%OLYE0B&)*N_(SU1"%E<F6N1-
M$XL4<,,U#7X_NNX%244%<Y7S!GR2S;8N1TP'A03'%NL8TVIU[]%$/S<C%9N8
MS_.BNU,AK0C\,Q$@(.BF]>CV+U[H_LZ%2HTU,N0JQO 6]-?"^P<'C#G1M>^3
M2&XG56@7*W6Z9"SR*?C&*K4!IVBZ1S1YR4<O,GFM*_\&OETBM,;?0C]ZVZ3R
MUH+M'SJ5AA)K0#U)A?+,P]6&RUOEZWOK5/@--AE0<59LBG<-^:#DJ*3R-V+!
MF"P\TN^01Y;ZO*83 +1HLH2 5[4 BPG)R-LG%]R _\.]4+=T-/V5U[E"9M.-
MZ:/LB4:T:T2Z/@5(A5!JSDS,HM"T7C,==O,,I#%$A&!SSA;Q91#UU%6'&TDG
MXM380[L]<BAK6\LHU(QQD]27MI)+1SPV5W >J1Q5O)1.!=$5T,?/UZ"]B$T^
M,=1KS49*OT::?,MWK>TS_%T9&07/8W[#O3PTXH+9+)<I6>NL7!:):  1*=C?
M!0>,>:72H#HMOW+E&;W61JP"C^ GL>-6 M$Y)<_1,64VN#66*I\5%C*A 4NE
M!--4I,<%B #KW[ =IHHE&=7CID/DQ)EQV;*CR6V!WAH9PZ.\%IDYX@&T]WL+
M=O-%D%3^BW:70IO"3.R"&7": N"NT6=!L4@?_5%CA_?]%FG<IR9]$2[C)K=,
MF--18YBZ1[I3!PM]>77R5%9T1AE=G X@BB8'2=?5M;2IL:F\HU&7<M." JL4
MVEQ2E%HO8::M-=#I4\1-@"6$ #3W#'L#/LX*G;U4IT6=#S9C*<VOJN>Q<EBH
MU_KL +ZP8#S^))089Q>547S6Z76OD$V?D3/,BEG&BA$'CN3#0T ZQO7#G2::
M<6OE(Y?"HLVH'# @_Z[/NAI-=*P.L;O/JA(V"M>*5!](B4#,B:"]Y5, 8%?$
M@=-&^()+_HHP1T=0U<(U,T>_!0  ^/CXAPA'5$@*KHV>V>)K=;C.2Q_OZ?RJ
MM6LJUPHPW@J&6E<I<U'O]/OAGWAMRY)BP^UP%2&YA9WN296E!:JHY\N+NM.&
MW19':'%;^:D?$]8KLZYR6HS"H6@XJRJC0 N8^K VDPY?5 &V#M& -D(?G].E
MT$@C_GWZHLOTR7%6CS?Q6T_Z<39?F'8)77%.?2S4K,MO.9I8W:0Z!)/^2R5A
M'1_@Z!@MI-6W>),$;@]NA3G,T!HAB97>/XV->Q928\#I#%5*:([<&_1&9,W@
M(BCJ(_SL"&\4!0!HMV=;H5902!)0,5U;4%LA$@J%B^D &1=9,\Y9"X;0Y?#R
MF<6F:,%IR IO ,J 9;E[A6_&]M\,SS^ATB_K<FP.>+'T%Z\)&YUR[AFBV7TU
M-<@_)%(XS]R!9.UZ#/4%F@8[JE2GAH%=MB"KLAYC#1R,;N4IX^Q:XG:E!<BJ
M'DMT,6Y4A4Q\"MC:>'A42'B_^XTL.4B-4K/"[46DE2,C0@)HQ\F!:0>+[+.S
ME&0=PYZTV8QQ4./,!G9X/;9.-2," IZDZZJ=1]?/$AC[LDEJHVQ2I7H?;T:B
MKP!!YE"^_+BRB$M1BR)? CBX#2C3P(M6*_D9)^V$WH(_AJR8#M,\YX27*(SN
MC;HYV0@>8EH^(C-O% " 'G6+C23GW=3LX>F)5;45JF0-"3R]N:I16Z==^.!W
MWS'9(B'\7<D/FZI-=@ W61Q#5#R:/>:03]5B"8#DZW34.7(J8=/!G=6A*(*3
MTPJ);74)&4+!-T9)X4N%$NOP@?YN@B$Q;%2VL$*D8'NUK0KD1@8E=_MJ@NV;
M^MS6"AXA,A(T#<RL6'*/ B+7'91D9##45(R2+#]%62?O300OPG>3;G!-(C-#
MY<KY=/POS[F&3^8H8N3LU\2[U KAU556W+H&4B[:Q*GGN?@,]]'L(&/&&0"J
ME8$).Z+0X=1A*KI/U"'NT<^<HB8RY0:G#'?QZT_BVLQ7"[1!4X651 6'Q])&
M2$K>;4+8%MB.[;^G5NOO*^[3Y=C'KK?>VF-Q=S*PIZ9EJK'_C-LNGSJMS@YA
M[(AP\$BCSY<GZ@.HQ&^*^&RA.9(J+NJRENXU?CQ/MJ"BK4=0^*AH,66Q#(1,
MZ9068)M112 1*2"C 59*K^^B,&QBCF+6]".R&UAQ=@N8F8O(@!J5GIA1#.0T
M-Q,@1EQ/$$0UVP).6.E6K$68@4EK\9Z^CL!7/"^(;M)*4K\47/,XG@2B(!>:
MF%LHCKKH=!E)GH_Y8A(:. 4=PB=&D$7<I7G"0,7G-!Z?D+*EINKOJ-V1>;_'
M'+?6_":D\-I8S.BL, 2]5(<:"A53D0O.& $@4"%I,,^LJ,)0GW,?TDI$*S.3
M:PX;!C[U8"7/6DKP97/TFZX2G]RA.J[[#;3]CE/!].7%F4Y=<5/?4%'N<'J*
M72)TFSY03'597O2,0E/TNB@V9VY@3^KS6%(?H9N@9<)'Z!-ZDNAF9NXGULIH
M@9G7D"!/V1@LQ6V: ]O3>DO8(H29)E.D F7/=7E^BF-^Z"AY(W9O#4"ZB.C1
MMBX]LOM&\MPU'-&#J)_U4_W0\,S'1>/-FWXZLOF)VC5$NRAZIVZB?B$% A&%
MG['!#C-;S>^6!T]FM*S&LS#;O:X6QEL=UAJ0^6.Y]SS5%9(5&2<LB:'R?]&O
M,,)+A.R" ^AT!\<[^H\+*R+;V4IP&F:;.KHP(*?>OOHRRL/_JA.?.@ERC$/D
M@D5:?>;Y#O685@7'6.C]6N<*2,MG>IU-S.ZJ<KS-X:CCD#VJS:F#65R-OL&*
M/9H]<RHKC$]='D/AK[VMO@K:D$=E3<=LZ4;FUI,1A'W(R(XU91-V+T</T:Z?
MI2H^>DJH^$!?NL6D</X*IL77E8'VB.57_.68V7[YPM/*S:_-!=2/A2]&SL"!
MZ@HY16 R7VO77_+M.$Q3+CQCC*Q1/PN:D2<"%'7]EW=]_NN>$XQ.4TX0D\?]
M  G*?7U$YY=:3AC%D%Z38/;I$X5&0_6"DECCD6&SWS6J@6]8GI5$&#'JN)C;
MTK';%B,4B6YP6-HKMJ+J_H52X:!$"70@ZN,!IQ\*L;;KT./"3P(4RED@S[DV
MXM"GH1Z3#&D7C'U11"RE1UX-AN;:C8S*=#H^5D%1_9+2U"DG4%!2DF\LHV'E
M81/@!6%R<B\>8H%H?T@;_B19V 9^DZ \,G;E!7!,!CFXZ0N*][ZF\;:P(Q7\
M/*:YC#,5+"<7V&KY-<NQQCB%:VV7OA/B"D.>DWNO-R[ZUQ#3>9DI..GB*IC=
MO(Q<,O@R")7-0\0EC<(P5@-%,V;3(A2XRW+CCU,K1RK:K$F\2 A8&Y\^\O2#
M>CZ9#B%AH2FB4A\;L5=F>^7&^2(=@?Y\W:97:]@*!IKQ+NSCBU$\6[$=EVH=
MC(3 H,B*7,2JOTY=&XB8"XYJ$IN@-=Y$[+J1 #=N>?H,0++&JEA).MYG[O23
MYZ_EDP]I"B2[OZL23M9F;7U +VQ%P[^T1('A8J.AX1@'(UF^>?&QKEBOR!KM
M6D6=(8"#-]S3&9[XA95&WUF+F 6Q;P\[VO1['I"M,R.LY4XVQ1 QI!CUKV7R
MTG52 $"$&"T&S!HL]8/<TS#<14\B"*&'+?.)K%QU'R4GDV)?I[IZI%;%!R&_
MF0]#F*9]8@=UK(]9.4Z]F3?R%HQ<2"XWA)PU**A:ZEL^,LV,7#-L DG:IO3X
M=B(Q\6FJU-^EVZNB1A9G98EF8KW96!\>'MZU4:!FB]0UK725?GE.T>C737*D
M7>OH]O>YA^I[6T3+O@.PEP_1[XDVI=$B6FL4J&<@(!<$*W72=]R#&#W"%UB,
M)B9*3!*Z1@QJZ^M=Y7"*+EW"$T/?7<M:VZBT6\W_ =@:>Q5K0/1#?N6CTQ?4
M7UU='=Z%GJ@I_X_JSC0:"D:-XX-!,=FRBY!=UB1C5S,8KZ6AR2!+UK'&6*-$
M2K;(6,:,+;N,G9EAS" QH1!C'2DILDTI\5:B^WYZO]Q[SSWWV[W?_U^>__^<
MYSG/.;_G/"Y^I)B!^3E#O4-)1\?S#PW;N-9,SZO$X34\X#\J?X[X\SN?[=P^
MP/YAWVVGOZY[W[O'(*:2TE1F',/YL+UR9"P^D)JOTPC?HAO#/AQWE?WE+Z62
M/-H9KHOV)L<RAY6L.IJ]8%YFYN\GM9=/+;O!0K=N\+Z,_@"UT24N#X?ZO=XJ
MQO!8<J9:6N]SXW]]^>.IYI%>H]P,-FRO,6'0*>BDG7C1)ED!%?6"L7%D8A;^
METL'?.E3KC:M=0CDN/P,]87:]CD81$*E<DSP%M.$HND8UC!HAQ"R<Q2O 0\[
MB7,4)47VJ[]YW31L_%92:>YXBZ(BML6P/-2;2J=#2[P?KRVOR?L@P7GNH[I6
M_J/NZ\,4[V01*!![[I7<M""(P^$=I;A;Q2F"&-B./%D/I7M,4]2]>;ZLU(2V
M7YVN5M>==A:$8> #0B"QD@33SB?W#B^<=4*"=D!>"0D)=[2OP;ZY=-W%W9 3
M/M<HEIF8.6\>DCF)154AK%>T);J$'J][RON0ME^("WDV;DX+J#X K!E2BE&]
M,\Q/?<<=YUVI,QI5W6LBA;66,PXQS0.+UUP0!')3/XSFT4E+#-.-D_\XVJX<
M*0P1@MZU$]XP#>&VT'MY:LS'<2MH*4-&K0_,!FMZ!ANP:.Q(2R-'M-GAZH?N
MCI\R0K(6,V1QAL_#!L''+1A) .3RQ00;R<5;B]'X=89RI:H> [\D%9MY76:=
M="+KB-V;!JHB^\7E=2'5(B64[<L;-5Z;X1^%/ZU*').6V5:0>?N<*JYYNEX,
M2?"GY9;5]M209F\9$QD= 3&-$0PBT[&TF6J<!:Z:17H\U55,A.VZB-T+HHS.
MO^0,@4(_RFK(]!<4IM3.^RT'_?%F[7W53+2@8P@!(E*,^2,7I\?-?T_J@A9J
M<QH>^2TKP]<P71!J<U&<QT+=>7YXX]S4RGKA!&^L8ON6.JE9@6#1Y9I_@9O-
M)##2]0FM *S@1O-LF]TZ46JDRW["Z-#+"*LBS=WO_C  2&]J7M\KHF.RSA"(
M2!6ELVL,.]54EKR/6VM8"<:ZO@%& Q8_NB9XGN]BO1)[D3D'[^Z1[+T_=WFE
M*6ALRZM*^^%7U:N/&\E;^5+'/GZFX*,Q^D\]ZMKD/TN!?0,EUD#5BO[9T/33
MH,G%N&^I]A9BMN:,0,J#4/,OAJ&EOO95X)->R;UR.D$Y'N[']6VE;<PY9>JS
MW*8+H 04*FY*09441W#6F@#K5N3=5%+)7#BX77Y9HZ9[MXM"NPN]'SW4O2O^
M8'QAAHFKN#;1$_9ZDYQN_CG+TA>Q.20/A(]DI ,/S^5 JI(BYZ/+QA.D'?K*
M^A+3B>K$SV[*UR'F5G/(T=:.191=<+@ZPN7%V1]YZ_$,ZWG*YM< 74<M>ZW5
M<;P7ZZG-%HMU\!L0KM5,TGC5*9D>H\HL^RJ@\PYE)&LMA?<2T H2B@8<BQK\
M#0@373[&LQ3@","::Q\SBVQK9Y+L20V8=..U^X(F5^=CU*N-Q#^FWO%I<)!>
M,FU0@J_PGRFRA#TBJ2XX*=2+)#ME>6-J'R7ZFC\PN#/=8T/HEIH/R=V]SCY3
MM@!%X58@G&Z>ZC?(]''=T"<?JLIDO ,+2B1$AE(&[O8AZO6"YZ^F 8RX93VV
MY#,4/?$(E>=Y-AB=C;ST'"[+.[+A81'JEE ,7)0KJO4P$TU%Z*_4YXMH"U@!
M'B-H">T$Y\(#<!""/N8:3*S=WH38%E*--/]:#MHDDR9&K,A13#GOBR\Z%:(,
MO3I<V"]1W0>&S*XZG>(-?+:J%ND12!$QI$,$<*EIEW,DSB-/Z6>(Y2P-R_$L
MH9.4&@2:EJJ$<Z< YH/^[$GL)H#^,YIG@F8)A(8/(J[=J%M[G8>:T<I !4#P
MB(B<ANVJL/U:S_T7!C@YMPZ7K8OMP.P 7O+VW?;2" "_)2T U7JCQWUESJ*L
MEMCBK!P]WJ=:1/^S]#!T+%LS)O[E3WCQ$%_5@2_5-S*MJ'GT<O;#'$2L6N;&
M!5@M$/SW842W8>:!\NSIC57U0[)$DG7<O\:ON+@\&,B6GK3K)C[)]VY?C]/9
M =6LOG_O/FZF:OA,)RUD;T =9JP*Y-/ "48GI4P)H;\NGU;HO'JEM<G1?@A8
M\X1ZTP_;B/$PWA?VSJZ *^!?U83KPI[C?'+E:4;>)-U4538+G20@Z!.@7R].
M&MO"$NUQE^P.3RKN@MN^Q$INAV3PK:H'62L@%A0U%TZ*OYP)S\U *[0H H"&
M4)4?.N4WR%^]W@#- 1"K1]SYD-M>_"'A_,L9@H[)#+"P'+4&#.)639E=XU))
MX\<R3W&X=;FKQ1^QK3:PKF<0G,6E&QS\:]\HT,$-.:7R(SA1=%L&#K3*7"=!
M@#?KVZMMJ2^]0!P!;&Q\7L;]MQ[+;1U+^,LD.M3NTCC):!Z,&BD,I$0-644X
M,(=)=ELBXPM;YYK'$)@SM6%.\)[:-0.U);2THC64QSM)@D,%9W]1_(/J]$:T
MKTX&M]/C4V.O5-*.4V1EE=:3OK*M&:< CG;^#0/'-F'Z']B0?TH-#%N2FKK@
M/M9J$+ZCR^/RK4#-*-[M71WR7'B'#6N%/9N.3JUZCDK*Q;07'JL^XQ(U6(MN
M>&ZA(ZB="C^X[3DQMO^#.X_!^/'QAS"3JV<P4)]S(A-WVZ(-MWTX^4R)@4MP
M:0'E:Z3B\5+J;K.H_,O%-\2_;,%FA;O$"J.EM+UNQJ(,<AW!%(=LI]K]OT9S
MSBL36F^>UXQ.B4>(?+!-*7UR,#JL\4*V<O(OJBWQ:]]9HD4A,;TM:%I!.825
M&68<OY^+$.<69:\QCL2A^MU-,?6KMVFTOE=^BIJ_O'4:]3/R_ ;5%\,&IDM.
M6UM8/[6<%_;A-'+M:3WQ827B/3R,V:$A=PS':-.#ZRW95GZNO')-7@VG_1NP
M6'6$^LFZ(CU6CY)BN0*5#EV=?2**B3R-KT,)WH\F"_1<3!*<21(%T,RMD&)>
M4$7Q\X)O:HU,4S1(I"2FVNE,K:QU?-.<0.&61UO6VT]QI:B;1S+$3#7'*X^+
MTPF4WI%+#E8L/]+7+QORD_F, +4. \)U.$=GB.6$7)+O/6#_)<-W)ALU4?OD
M5(+Y%QMT!>'[XUF2S1<W=\77]!M@T9V*IK=T/32Z>I24+A3^E>8?4B$[/ZRE
MU*XY%4Y9E8R]4X?^Y.GLL/RTVVZJ"]^VR=KS+\&_Q>@;N'[FB=!3"R8S-*][
M=!4T!=<M7G27W+V'51@<$&*=OD>X'[^<%>-RWCS=*(IUZ8I,S]F^D\Q)WD\K
MT3%O3C@&1[TWR20Y?2[MJW:./@SP0"H3KSQ3^_4$GA$$:3HA6493V^CG?=9@
MW5F2(@CK5BF+G/QVD)!WY%6<@-5_H4CL78]-6!#;.,"EN/::$GO=]*5K]MCY
M[*O]!+#0H2.:LYGS;;QE4 3?+E02G'>1G D[F#HGWWT9(A(<QF@.WXV8)MJ4
M_4EPE8O#DIDDG]$FT8F3IN^MD;%G\[:D6*$!QA&NL'&#EN$+,9AP/E&<0ER/
M2[*1C9] 5=S/GJ.7!S=-P.L@8Y/3(2/;,A(Q=M-Q%;ES>[3W-%GBZ^)5EGW,
M*=/>LI:!<C?3^0@4#YJ6>I4^[I)2-^N;1LB8E&AMK8<("W"3R9X3FYRSGV+Z
M%E],ZD/"F&Y^X]T/:"EQZOMCBG@E^YW)0:< AVH)1E-Z++W$DO^*7L+WHH_M
M(KF)^-&Y$@ZMMM&4BOE_W3FYC;___5%9DBCUL(_[B=YW?E'W#FITT"^SX!U&
MQW[S/J33CVF8 YS;-#RJ:MJ,7Z7T8B\U.54Q!/3+G<N?.D^4/_G.,?-Q!['[
M<3,1L'?SE\BM'S_+DTP\[G!ZFB;6+?/_WXNX-&\\3 L^:UR:^*S&ITZVMHB2
M591:2"(_RLK/CD]?I'H?9C:X-I5VHI/',:PYVPTU7-:E?'.(]@E^Y!?!^F\=
MQ\7'[)Y)FWFT8]W%=)\@ I"#>+N8D5*END?N1!4"=3M=I3*4YQWBV,QYX3/H
M6@0?%_OE_YWB_SL1V]7O!2O.]);D.S^TJ";O=G)^6;VUGWMKO_,;< 2*A4_'
M]OP&L&;WWOZ\[;F0_'OA'U!+!P@&*V2V_Y   ##M  !02P,$%  (" @ &(;.
M5                !$   !G,S,R-3 X9S0S>C4T+FIP9^R\!U237;,V''J5
MCM)!$J27T$&*]%ZD5Q62T"&0A":@TA3IB8* ""*]2N]5D2H@501$E"9($P04
M!?Z CSX^[;SGG/==W_J_]3$W=]FS9^::/7OOV7=AY7#\< 9 I:VNI0[ P<'%
M\<?Q!P .5YG4#9W@*#C2">[)(28D I!6UM+#QP=@B8FOV2'I]R+ @07'"H#'
MS*7QES,N (#+OL^":P@@1B#$9$1DI"59< D $GK.$ 0<"7= <1C"?6$(0[BS
M!XI#D ,L*B2*_1,1!5\V]83:H6!0#BUW.T<84LC3$^5WC,AUC$@5MR*;+9SM
M*W FZ%(X9B.W\+A.]KAN]Z@>N^,<E\@\$5C;!MXH3V\4MDAPQ#-$HHSMX7"W
M8PDM#Q0,YN'M_N/ZZ*SBAC@J4Q[K&CO['4DH.Z..='ZW"4/HV[G#3-0L3+ L
M4H 2  J  ^P!,  'P!"@"E _AO]NPA !ASL8PU#>G@;V+A LFQPK@L"*PP$.
M6'%CK!(*X WP/%8A]?PI_:,5RFXHC]]\)+?W=G9#.7L<F\2628ZE5?0L=;YW
MT/DC>5S!/\2 YI<8&'BBG.$>2"SWS'%+/5$>/YJ%;;8]XF?!R!&I]WL-PD/E
M]X('ZO>"KKT;\F=!WQ'E\[.@YNZF^K. C>SOII4AKHZ_!>*[@P C#645[ GO
M^!K*P0&%>]M?@,\ ?I &PN,O/&6WO\HI(Z FIAXH=:"1&PKP"RF[03G^CF^$
M=$,=\PW]W"X@)Z(N?&>3^L @*#A"U0YE]W.<&#H:(G^,DZ/KW\XJQT& .:#^
MSKP)=NK\'=\8XO:=;XB 7+#\R:;"3@I/<R<8MG.Q_>7LX?@C8A1'%498GY3A
M*!3<W0WNX?B;"OF/FB,7?N&?^L$W<G9T^K6"[$<%UK>?[*.1@[?ZW0>\E@,)
M "X ]\?Y>%2=.ZZC^+T%BC>^:^&?.BX>Y8'O\Y/Q9YGMV.K6<9GDAQ[.L18W
MU?<P_^C^[RAXV\?7F@!A!P=LC1OV2/B;TG=.1G+*3X[H\=$*>_S!D3@^"O[.
M.;;Y^?@:.Y,._Y;PWA]5_^?KCF-!_#VBQWX!<"]\WW^K8_L9I^]EIJ,K/(F?
MWG\/RR96Y/K/T/V5?N$=R1W)_Z/ 3_H],0 \O-V.!ACN$:P]W-L#BOS3O(2@
MP#_</!K,OPPDP)]&'$#YY\C\[H;1SX%WW 1"I)LS!(8T<],]FCHX?\ A.*[#
M7M!@=Z+C@I;J+[:)'!%P;\\_L CA"&='YY]94<WX2,G@F(<MG[+S1L$U8!XP
MQ-$B<NR]O^>/-$_Z7?B(<U2CY>[(\7^@_7C>"+??%HM?@O]'CA[2$?8'#J&=
M&\K$SO$// H(#*L'\T-I(35-]'1_)"CB'^P_"),XP1%7E=R<'7]$BO)[XS5_
ML(^B"X4YV'D?9R@2'Q@"]3?B9C_8?Q0GLW=4@;O!$;\$E_J[@K+&SXHC-_3A
M'D=G$A3<$[L,(6&_!H[4#1O(OW#)[8]3W5_X9(BCA/8G]O$,XOFN=S2<%3<
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M( M%ITXH5"R,M"V3HXUCAA72L\:JMM%K;W0F'?/W%(=$!XP_N68L&70&V"Q
M);^R%M[820P^!!"N#TD8-V2B"H4KSA42R+A=*?D 3614R'D96MW4=P@(^;0O
M>;UMSR6<H4[ZR_A.K6B'9$>Z43E4_$'XL]A3 99K!@ &M+=.13^M"!B?FK@C
MT!9&O'%],&HT"Z-]CAX;<5YL%V@;80]W"^:\!71]W0.B'LRTVAX"C&YC]HL
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M+^JYZ7N?OVZ*EIM71!IC-_,"RXS@*-!F)[F[@=#Q$J#PYI[,1=JM??/4&UH
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M8ETK6G.8YUJ+N_N%\Z]5>^#KNA^+C.[WIJTX9=#(X \TBYM^*NAX96IZW@1
MQ%#4DE2HGVH4]?DRBU%]Y+5'5T."Y/<&Q$:%];1(E_(E$F4\)IZ]B<@CZ NA
M=P7XCM(4%/86UG7VG!*L2U@)*^I[?E;G?+9')%WBEX>JT"JG<V90C#CFS*G^
M%WANFSZB,O:1Y@)DGJ::CX?70YLD"KX9?9: ;TP6.-3>R]4/=LW[%)N1V^@N
MF<QTWU]H9=U(?DA#P.K)0)#CJ?=.5<P6V2OX3,B=G$- SK4)WP)K+Y2,6>BM
MBBDH/V6 SZU;-G(4A#,;Y)E9\F5]\LG*F/=SJJ?/44/E(E3"P\OJ<7*XG02
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M+6ETQ 9-XSL>(R]N-C'-N[EO[@)M\J+>!JI<29VA#;X3G$I^0^LK>72Z2Q;
MX(;!4I_SI>DWBS/]E^R7?"N,?81"JJU66OW>9@ROJ95)\AY$M@J\>*^ZPAC+
M=CEEK/NA<2@S5VJOU8YJUK,6F#M0BV73VE<0XCDLWO[4XZ+F5 RX=4JI5540
MR$;/\-&Z&IV475-?6RGVJJBUJWR7,P2F?![M>Y?"4]V'ID>3RR#TYM#ROG%?
M$MZR;'H)7]%,07@XZ^/5V<MV9^-CB^XVD#;6V(R;2OI?9J*6?N)DQ=3-GTP=
MWQ[Q?JN12=H?'.0STY)QMM0V7-^/1L\' Y VM,)M1R@!B>P7!,]***-M!R03
M':,K-ZSN)IQ%,,%N,B>KR-PXK?F\I.EU1NP4VM;P$&"H$V#=/R1E66!XZO'*
MUQ%E@8K9"8U$ZV2.,$'Y4]2+O7)0>JVKHH-)%W*2-P,A#VC323R!\-.&#((3
MTQR'@+ SU;&&/2K7AQ)&E4LMJ4-O]"1-^>;!^J[5' ).38RE8(\"E6LI]=2N
M$YQ*V;WN*&R:$(_MV35*T1-=VYGF?%N\7LSE+S '%8FZE38A970G/-E6[X:N
MN<E;I-J3T/'A%Z=(8I#RF XE,EZNLC-/^"VWXG>UF/S4 B !Z$L=_ Y%%LU<
M1I8LA"K]C!:X67'Y^.2;&ORI;-<8/A\"1A/WS3\*ET@P@&BL!DILVEP0##[B
M^_5!=432P IW-@I*1KGHE#?2"DNK)7FWEDH;K/GJ<VB4/#+2SA8[S7$DVX*-
MLFWOXC\1SQX S@M=B7=>3#3O^6)FNINSNA"3[7*M<!+DKXG7')YQGU1$D>:<
MV97,<,I: & R^+*$C?L:FZC?AN;B(2!]^.OG\L?:S8\%SZ=\*B)<5* W*R%]
M)_!!R)GNYO E<KKXTK9Y_%RTO'LJ=?^050>#178;HSY\4)901?'^MK!^6Q9^
M;46:EON<9PS=,]T7=?@AK+B%'9X:?"6-N.Q<A=;?#@$RBNO&O0E\QI'_>C-[
M/.&A5?2@TK*,U?T1[S4>@G!FSG(U V1"GSDX(KXC7V!S *02QY29@\Y;>"RU
MZGYQ9,#S=>V9@7CK+D# IA]#M]QL6TDK.<UUNYG4KP?I!B5\4LM7T_TK02'"
MVX/$Z"K#-SF!,06YKDT]GQ?J>:,8=\"Y9:S6UH;O[7?J&8N)$*I+YXJW>01O
M6 =<UU((!Z*&/@-VVIBIMI;]95C" JEDIOQ:6Q6>3FTJ3+$S' *N#GM==8XL
MZ<=[+VX;FET%[;.(B*X/? 9:;O&VR*R$W&V;/@2 OUJ9I 4^JAA(GQ5)68)Q
MSEFKL4T;WO:P#0Q%D^XQLVSFHO>8.CE3M[JZ.L#;;5N?V%[-3@6\9%7TW*74
M:S"V37^6S,!QJ9:9BIS$+93T+6&L[W,!^_A1UNI'VF!T'^T+?N+7C$")(9E-
M13LW<4%(F<!N6/>K+HPH!'EZA2!H6<=GDL/#MH>"[,H-:1(P?LGP(N,59H5
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MRGR"'<X8?;M/54-%_\608G4Z\O6GZ^_7+5^P+HZ]>4,5<B]L8)6)UU?Z2WK
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MW-;1FX_X^0H^D/3KC@,CN'Q07.F8^\3@IB&J(&V3]2W79/U9['ZGV_N)X?\
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MG\7+X;B:5?7$S6?G6Q%7"S+@]-CJ\T0?Q9;Y/7HS"?HXUX72ZF?YN\ZNB%[
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MU1\0\\;%@G!ZE;'8KJ]DIV)"8H,WXP0&?U3Q?J^Q:637\)R>\E-]OVH?>\6
MYX8T2@@"+OP&5O54=DN^V>GJ7T90PXR0()\KQ?G(R.W.#_5H"Y=D$0JV C;[
M6#A9WX"):BT^S$FM_#>U<I\)Z;#VNT+ZC9%^O: .62[[,WB)D;2[>SM3J[[E
M5\W82/'(2SDEQ=-Z0@J;9=W\1R./' _6.W+\PQ-UTQ\G<%KFYKJW7N;\'/V/
MD:]K'^L\2*\:W&$#/"U-(\=?68+T[#6G63@803ISS:OCQ5 ?3FK#=5#+[  Y
MGY6U$2J5D_HP,Q$]+I>$^:2O[:5\Y<U4M2MR'?[[6HMNW"^D7_?G;=G9BJ']
M)XL):<K!0',>>?!'%9B[.TQ8Q#R#? <'*#>B<EG17 UU*S28NZJHB(R,>H!"
MGQ@8/D%]-6IC*XF1QABG8B&/3?E5(38V.P-2P3F\&)PLL-?9\92NV2#W!AG;
MWQYJ[L:'?RIJX[QE10?ET%5_%Q%(8GKA2^Y9M)SFVSN?<2R1VCN=[;P+1E=.
M+(@)'=D./ES-.,D_4JM1^.0WW=+T>@3NZ5DXJXXULK9D?WE[QTQ)7UB9"_QK
MN$3(L8P'E0,55<7*)/HBG']])1Y&8SV*V4MP4_IC :&=3*;V)Q(YZ-YZ86@_
MGALO\<!''-7]U#9QN#HWOG]\GD]N(NK,UWCKE VG//J-2&&+J5$<IB@7A"S1
MA/^G''6 *N90JGV/Q@7!F515RY6RZ&+MM-&0@#@'($F$7!_BQWZZ"'-4H:7E
M9_*XNQ5!!0 XCR0=DQF'C> /9G;8V6.\PY]IC>B/3)(/471J 9?3 B]96?&=
MI2?Q)A+/+A[9P[)X*$E@:5[S7'->35EP=(SE.1NS*QEI'7MR^;M\A"V.T;Y'
M(98P'3O[2JX<GVO75*K+(E:T?K7M$E//X>]B]?)WPPP?])9V7T\-PR4;2 4$
MGWV'G_Z3I%UZ:0,29K_)P#,$W%Q#$GN20.L('R8+".Z,XJ .A*2^K=9RZ9#[
MS$VP1J>";4:!/D$2C0@+B$;8BT8KB3E2DWS^_[?[[O_-*E[3);TUEC.@UB=2
M186<7_E^8Y*-'R_^;@,41C[H^*J]_K/E3O4/P)MT=FBS,G5\UK+:=[4;(H<2
MNH=R*A4B+\"1=(KGHH *VMU\A)K>83H>%K4M.RAPC59X"$GV!2$R2= 9@<5,
M7CP82R-@5P@(.%#7X,U=G<R@ZZ/SH/3<G<ZSLBK5H:.W-65XA=UR!3%*_,AK
M2XW(\B6MWEB96(7@!?<<VDW'4UN]65Q[THFXU5_*]E].-_)D)=<U\ZM];VCA
M.14R*VIDD^76DZ#IX&C/3[K_%LQ0P=/+N6"WEMCBQNBNC#C5\+?W,SZ+2>4=
M]]Y(;\E&C#([8PI/U/-P*NR:4^/B6F;\N-'5-/[52O0W.WM]_GDNY7*Y9[I]
M2J5J?S=G/A3TM#0TYN-A]VWH)&5=7DBLPZCE?-4[>G9IY9 Q4T1.XIA=Z?LJ
M'DKE5C<1@(@Y^K#.8!=>L5&OK%QLS.>/=0KT"./Q$BQ*8F>:/1*^!VC''")V
M ;3XKT9$@H/$:KX:&1O*-,4V_6E:5[Q32G<V@_F8G1^;I4:[@LH8]5]9Q=GM
MNQ/$D0^0"VL4%-][KZ[]'.^JJHBYOA'R6V&(X*EHL8G2YW8C(CRD(<)V!<:\
M)MH5LH\2^F 0R5<_Q&==^-:!*BBZOB)NAFH'-YT->]]WSXQ VS+(=>BGP\XZ
M&[]@3(.\2\9").+H\4]#9PY6K7<^G!?:$)5<$+UQ0/( "X^17$TD+P(T#3!V
M/LK<DJB59.OX!\I*>&4<*LG;IW<5ST@T??.>=]ND;"ZRO'FELZ'7639:2>MO
M65KEP?5M]/AY2.)>"8I7J?</(!!G!TI^IV"CS^ S@BA\Q[7^QSN/8CU9/<!"
M0D[U@N)/<*$AS,\,R1#EL8>L!M]6"B83^;>M'(RQ<E8S3=0CG"DGV[%Q@_5W
M7Q/[>/ONNCY^N>B2-,A>Z#.KCS]^%C$_.,>?-M0W4'(ZNB'%7,)6*9V3_%K%
M,LM=:#3$Y,=FH=+&\G,' YJZ_I:A\"C-8]]PUI,UY]4Z-)%S94B19P@)@K-"
M(=%DW[H'H!:J@K6D7XKY1L ';5WSMK/G.\00I]8/_43_-8EP8;)I=_&=L1 @
M+_EN5!KOHQREL5_#+0Q=5V8X[V9TY<_Q63A3JJ@*/-E'^^ $M:I1NH*L^D&X
M1&0%I1(WJIB0^QM2#LPO6S@?VB>=@JJ(;#VFB55=L8G:183EI\EWXNVH'EM;
MX;[JT;DEH_VK_1EB[T5\XKKJB9>5J+_6S],/5!)M8CA\M>V5013+(/8!36><
MXE5O#ZF!;T[^A=/I+Z([8\:U>]$?UM#V_]#']>C%=S(B+FA2>&\.PHI=*E11
M*&]7*B4:]0YK!U,^51 :"^]7#5O5;O6SR2ZO>NOUF:4K7(%?ZE6B)&7D,P[E
MR$P>6D&C65"A#Y;VU_/Z\E_CU;WVM79D[2RM37%]B] &B4J7#+<T8/).N)7H
MSH?\M,:ZOLI]J88^AB:_9XP IR3?=/LR-KZ>935;2^U'+O?%+_[]]8^[*24X
M,^Z?C9T4E7'-E&OX9.KBR(W1XA+'$@9 L&WJ]5UB.5(*HVDBHI,PO%4>/[D%
M<)&MO06WYF)ET9%N@J=.?JVIT=%B2_0BMQPH P8AX\7%,DOB-C)69OC:(AVF
MIW49;)3Q37"",=7&IED[C=J+SGSU^7T!/@[^9>FYH4+3A[D'N=0GM#_4DX,E
M;%1LVQ4GEC4XDIJ'(TJ5YB ]<L7&34K;D#&]XH[.MI:Z.7I&ON6F?X ^?:97
M5F^)Y5+?67$.KGRD=EH9IG40^O:K#WE[[C2K,O?TI>'1#['&J!QQO,??2S3Y
M'<)@RY&55</.=K.Y;E SW88\%J[UFQHY:X]K^$&%W%X/$36^8P?ZFVK8.[M;
MYX]@$>1W2%H:FAJ%'IU/"OE,())3JJ7TB+/S*XY^+D<6UK7"E+!K"H3*6\"M
M/ -(,(R:I]&VI7@Y0^"N,E[S47)J6/W7AW;C'_[2.1M4=BFK#TTIK3RRWF#>
M-.ANZWGW-5MGX8%YK,:'-"2?E?Y3RI?&(V6Y8:1KX'V\:[;\ZAT-8*,GLT[(
ML5*UC>5K\D"KDD6_/<\0Q, #(^E62@W[U7(&V$H4-FZOWBL,(W1(53_N5VT'
MJM>IR*P&-#\.>_6]<UTQ64.6)WZ ]J+3D"".I?#9IW;:R82^RX?7G)[5IJ,G
M_]GL)DDKB],(;AY[,<L#+&\]C?Q0H<&9_^.( 33#\/"??,GDS9X[\N?5BYNY
MH_TJZ9Y#IH0#$U7I(W8:+;5/ZIF1RS)')Y/'!LS(GEL,';=GGPW<DTWRRMJ2
M( =)O]&%VE/;LZX48/45$D!5'U %S; %JXUUMD;+-N\*E13PUL>*B[LUL2R)
MQ98T7NT3N'RTRG*#E&O]V>.7^Y\YI:C;C2^_^=A%C!O$3['&%,]_F2J7Q$3C
M\WN="GZ:;>IN@]Q1PXGZWR S'JB<6!YQB/P/VC]WC[B+P,UXQ\]&AT^VB*??
ML-F"MM(QI)[1,M=M;26- FNR]EUJZ0>RMNK?_++D\LO9[%E[<O@$5@2WT#NY
M?=E#;;GD/DX<[A[.XU#QI^QEJ/QZVILN+UE;E\J'M"VK(.SK41%__TMMQ-I&
MTC./7_RML%@I#6(5;T,T7-?<LOSG49)_%$4R #FKJ6X7.^F%#E#-H+Q;3 )X
M/B!(WQ"+),],O9FC]%1IF#I_4FY@T@>2S32@$:1Q>M?#S]YZ85._,V_TNI/J
M&#<[@SJ7^;W993;V$)<T6I9TS6-6-1BU+_UJ[FSEZ:LR.#^YUS+B\93&61JM
MD4Y[HHG/D#TS/L*@9[,]?8(;+S_76+8]KCV^]'TU^,5IKX)^XB8PA&1!30?)
M/Y@Q]II&]TS'"L-L[ 2=@'[%1R/=EM%!W(W"X+1K#ZGP4S%HT&:"%S?,3/"=
M4J?B>)M\J2L]$<9OAHO'PPJAG-OF3+AD]8VHY0^*G[14QAI-@8CA=5]S)>?<
MC#'(KES<D89^6"TJ06;ORNJ#/)F?4\H40=)D)7A5TV/^+#+OVF-A5FS'.VTI
M$VMFF1P9DR0DHA*FBTG"J)PPM+3-C"*G3^D%+J<,*I!2XAX"K$&VX%11(-M!
M7YD46/6]7\Y#-1R$!#6VML]T>7T42F_6;ETW*R2JTR"B41G'/EL>)T,LP1N<
MOAY_=R$Y,;,L93L?*DDL'J(=21R^:Y?\].I;LZ76+LM1]KL#J:\[@G3$="]@
M5;GY"T[E*VKB>OU(VM5XM/@E@  F*73N_2<W6[M= L-[ZT0J:QN/,(75Z$)!
M< \ XX Q$Y #H[XE/&9FGC4CSNDH65C>.&KXN&=M7C3UU@5O<M<47<7$@%7&
MO3CE;NT)2UO=G-;TE92&S)@P!9%:?<E1HTG[.)5,O:R(A5>B56QA?*JO@IOH
MZ\AA[Y >EE'^=_EVND)SQQSGCO 4X4@B?6>GQ&5S>?"DRV O"A8ICO(?80Q\
M)"II[!]C<9AEE^AQE9^W]ZPA[J'A=IRG%^V)H&_Z_-:/QN]IQ;G"1=^4=!4Y
M3G5ZJ7TMC]PM$Y4'Q@ZS>JU#M[[EL%/<*J1<;;Q@U]2\#1@%N4NZ6'_O2:2'
M?L9&)*"23 9ONX\NM2OI\Y<M0C\JQ/O,;)CJC^/MJ%&.KQ(M75+S,!24Q3OF
M*Z+_+8WNYZ*Q#JS[:+N0_I.[J?A65;ZF0(K%H^4QYCSZ;J%[0Q3@MH;(+ HI
MF&-PR$N(_E, W$J[A>03D<(L$N%R..*I'=FV/K6''6:XA+V,G0J_+%??^JGN
MZ04 G32A$/18ZP5/JM6<^>?U^<G=C5%A[(L/7TOUU@#7%OH&4LOBD1NEO8RY
MH+3GKE#IQ3NDYKG[G> )^OTH"@T.);=E_<L@6^?2.HLMWKFV[#=-)DN0J57T
M8FTS? $/'DB>.+8C^-.,2U.ZTE+8&)^&BES &BU>?2<OMK^]T?(L1?#E1YX(
MM5E6G.A-;/4@-)V;1W '0<,>6*W+'5!0&V^9^0S=^%SQ_EGK\6*22A8U8II^
MEW;S<]GCYX!#\N$U?*RA0)%#.N4$#/?@*;%_@(4.5(^]JLP*H:/+"K!][/30
MM,.#C"-_85_DU_WQ[7*ZL*N*'\X_-G-8RUP#?8?$KWGICO?^ 28=6I,>,Y9%
M9FM8!_]OR;[(GESEUDQH5+[=#244J=V=SJ6S^EO[Y&OZ8UN[;'7Y/@V7"E+?
M6DET=1-1E41L<9!P (Y&-/X#?-Q %'1I"IC'QMP](2CG' )+3LG.M]BJSIQ1
MS-"5:P)LR7M!6U9)HR_/WZ<4[K9>G1V.'N8NBN<-P3+K3ZWGB'3*P&4)^V!0
M7%DS6),, ==K:/C0=AHK)FA, B.)HVAXYD,PCPR+GN"FCF-@?75RPIFHL#)"
MK&.Y)HT* JZG1)[,"'^B$P&_,7YT$_W^W+E%((@JYFZP@U]]%"!!V>;ICT=S
M1R7QNGN31N]^,(44$B$W26KT/J@RI$KIP92:6T>*D%>4L!RE77P[[OS@2G4M
M&K$*H;#K_T"KK_T/4(R0D.#"3.R%,+N@+99X-#KXK<]WA\ZV<V1/%8O\'D<_
M':1/'!CX\U'E,_BGX?*J'!8LBE._NJ]B']7-;-KBQEG?=(,F^E<[["V:"HD;
MZN+-V\4$S(2I9Q$GQL64XO3;#X_5I,FA,"Q21SS]<W!!,>'O'D!L(@_.TY([
M:(I4B6O-4A-)31RN*E40I!^W0:I$IU';)20FK()3?-J,_Z,%6=C:TOTAE4:I
MRL# 6*7F.)68R@[9P_+>N4C/4((I;J^(LX6LTI=M[)JGB'SN$;(\AZ@YP9Q9
M0>K;OA)6^/+W?#:5FJ,5ZWC,%Z4R<A9-B64@3:%&24,NFC(WVIJO(.MNZ5T'
M)'%#7=I)K#$A1Q)7[M0).P&+EH='CE>#R/-"X4BHN[Q2^K.KN.(MFI!7-IPQ
MMF' \?"A4I]TI(V;*(&\9H]@I$_? K'PP3I<(IMGR8&'3Z_^'7*_(<V LW1H
M;M*]T5'_<8;=*Y^P[92<3XZ@?Z]T==W>"9<-,T)@07D8C;$LL1,2X;OTSM"7
M,7T??Y9_[VJ$\+\/MXK 1?] JALI4VQXS>PY)D:ANIDAE'(BVYE4EK@RJPV+
M57R!J:"L*GK.,3H-.VPJ1(MTVT10:1!MM"7/,&?H2?"$+5_>B5<Z*WU<,5+B
M(?_4OJ!CQ8H[=G34GM1X4WQ[@#SN,=@J._<LZ*B]'"7M4O"42Z+@I%Z&Q-;'
M[&KMT'JY6Y+.Q#VDO 0N\J#BJ*" 6LKT4N,8F+/U%02@.E!-R J$7L?C''$,
M8Q0R:>-&DG1ZCWM6Z ]RG)6WZ! Q-F+;6/$Z0WWZ8P=8K+?F[QXUCW)5:;/]
ME(B;@]UN;8[=/+Q3:;XTI92T+ZRXL>GT$H9E2<7@2D4KSPSQ.T:!=AN/5;XA
M-[G=?O(KG4FK=V:0\30,LQ=YS6"RY'W +)8 0P")_:$/4D& ZY?"N>987:WV
MIN3B9/"Y302[86"#+.TPMQ,=I[#C=$PJA49VF500&Y7W&[.#@16O3_>OJE9N
MO"I]EVETE>:,\ZDU;1N$UF[KTOZ6K(RMBGJ!2766MC2I:-!UXF5P8%%L**\+
MF[_TNI+R6\)%?J\:3))\1!BLF$(\'=7<[ S$_OZN4(A=@Z2QQ P2$[U2GSE$
M6#3-<M(C^3I.5OU5_/K6-ICRB['7C/5&SH ])3YU)^SHFR"N4:!,"9"/7C'.
MY]/O&YK%C.[=@=W'53<EI8[\M3OY,OCSMYTUO7FD'6.IITEY&3&LX;;() /O
ME*+"+O11SZ DA\8?UN<+/+7/EO1$C[DVDO\6E=<\"Y]7C+)6W;*#F%TU#%7%
M\H7MH<N *7J$'IUUL3@R'X8RT9_C<BPIO5(%/5I\>>GM:BC2:YAD-<,WO?;U
M^LJ-!VA<E4S?%&\D?F\Y4U-]AJTUB7XM?QF[%1O:OIU8(C_>4J)CMBT;I<4=
M$/ZHKPHNF80G,+"GL?4]:J(G4L"^VNQ/3%8Z$!:WE+J:<U2AP$:(?8)YQJZK
MW KA1"GT7@<H/(<Q!#W#ORRUCBO_ ?9;*)..QJY,3 WU1Z[^MKI&)JP:DJ"O
M0**+=.HG*""O/Z)^;W(?-+A=U#Y8(0@4-:TY57[9:FALH3S%2X[7/FTP(*;"
MG+D#4(9$-J%%'P%?7P.MH<8T9=O$I+X<48;LV1G'VQ?,6.^ME?3?R5I'>[QU
M69/+^])JUR-'1#3*DW)63Y5*0?4IQ#24QGG.!<_==-'/4F5V*"/B7B54KTGH
MQA)2SUC#454%3.E9EUU-9"6MU;U2:'1,"F^6;,T4.QUX&S/O?6AT8Z/Z],$8
M+;V[Z@1&]"DG:^4?(-^@>?EDRA/N\SL>&)K>[.')MMTU@Z7NI*,X4E@J6ZK<
M2F#_MKWH<B0QJO:]I=J SH:1P6JMFY3"V#GB]P"9' 7FP3+4HUK/6+3#(63E
MH=3R\SN&2QWC,5N]W._Z(^.)9VUQJMN'XIBM3SC(3\)O<I&:N<>\99:?G-&C
M3KLK)4\_Y/W8L0Z$?[K^R!'30S2$Q?M"PV@\8*D$(EA,(/%BPL:=0=K_/K[_
M^)Y0R/B%J:.]L1LW88OH"@)G&C3C<;/PZ=UK:*0'6;9S>6)4BMS-K-IK;JSQ
ME<SOK]I2C2VSD]0>0SF5:!ZN%.A==;B&_9<6_[@'3L*Z:F1A26N1W=3S3X5)
MT^&R3P4/LON&?W<13W1^M8@0>6IJ%S=Q"P'@A8F1+LE.<K67 :6L=3)VT3-W
M?3_N[R[=I8/Q,\?^<:H?'.[&VZ)G3\U:8^S&?]::XK08%*(IW*3?"&IBF<G/
MTDH.P1I\IT5\>_X!Q"=R'7YZ?"KN'S?@%5RJN@N]:G)M#I%YT.@^K.!>M)";
M]ZZ/?5+P*3MD;J9AJ<@%'8F*JS8/R.VJ[=?IGQD%J5$,<+I@B\VTT<DZH2Q(
M$XK4\ Z7;@H\<XE+#_E,P:2]MR_W+O+/.S?AMRV5S;#@\N9!;>S85G%IVX2@
M,PZ?9!Q^>;.WZDQ.>AZI.P:F*MGE8?UF1,(XY@I!NI+(7OV=5+6<H2OA@!%.
MG'%*L-8.<.WUW=CZ^HQLO?"4%"]<'M=A'MEN/^]\QC=^==<NNH[L]?5GO^,X
M@PQ$J!Y%:#*^3I.52?X-T<NR)12?_U*&_?A447F06JK84OR]O@M'6]Q,;S:T
M6'6D)"MIZA.7X\QBA4F68732!0!32E1$'HO^$LM0*IN(IE(94W2\+%E2-G((
MQ/:;,%G3B 502ILB5I7XT??FX@O-ZV>UN46+<8/VNN[9+:*5R9(A4&.H8C9C
MD-&QIM(RPF-4>6%AD7<EBC',^'Y LPE&M?C\YD3TB+?*^'/\^1L5XUYSL024
MC#[)KZ)JIA8?PJT95D9><3@--A/&B!1:E#? ZP_0!();,,,DZB7(O.LZ.\P\
M3KZOL%BM3,19X3!8OAX,I$=[;<!3"$J4Q&0:KPG 7P0N;"/:3THW#F;RXS R
M#_;\M2/CUIS@IQ-N#9QX_7=SDT!%/2Y!^)3N/P!AJ;'N@M:AW]=9XZSFYB!4
M78/G5(L(E!@LZ0&6A)=-2.YWCUP20OZ<VQ994P?VSHJ*:[H7HF\1B?Y[Y]Q@
MRS@R08YC4"-/&05S.!JNZY"KZXQXV-+M?YRV&67@T?H1;/WAT2F6G7>2E7.,
ML:.C&2?1,!@>)+?V:N?@F<XOZ/B]89M(;1F@44+G3H<!)Z:W:4]OTN(3?>40
M#D<6L/X7GQ)IW4[?MJ--K;DJ1:,TVB^1AH#YIR4GC_/]A+1,WV60"T #./@=
ML*&JWN@G#1?4 =*C/Y36/&J5B5'#VH?EC]^S2<S*LRD0@(2*BYS.;#U*YWL8
MPQ!5,?6JM51D+.2[W?6P:Z$/F_-0"\]F8<5HY8'[Y]',Z'&19OU8G>!O'%.,
MR;AN:UY$:Q]XPNJ'\L*@L28/,>!'Y$^2'&E9>XLS)="E: ?_L,V45&)*S@99
M:CN1<G6M8[BY./YD$YM"VRH=,HF_)!_N=E2RT3/M2CCK24R"4)3MR-D%#6JB
MTDKWNNBA9_#W.%HTZW[VNQM_R4T?<VHX%=&QA=0Q)++XU0K.M>0#UD&.:>H8
M0./D1CD#SU-F&FZ>_,+1*HPQR;A'S35#4Q1W>)%8&W#=<$V19#2SI5/')K)N
MBB$=8AB$@8$5CO#:1]GZ^@_03Q?R#+T,U>SN0%H*Z:KH&PD[9+P4KZ4@^\!\
M0PO8*/)_^^X$  /<=\G:A5._@:R"5C3)SBL5HH<6FAKRU/-@PB9U=(I7D=QC
MK#:+X/VBQBSA&')?D"9U58JY67K"0%5L3%I+7=P4/UDMVYCJ-;<%G<_8N7$1
MVDV]J2H^-B[DH/-'&1S<%"MWUS?DRUE=?6X3S9[^'_;LQBX#$;N:.CS'J#SO
MZ(E;W<V(\^]I,^HIOV07#X\RB?PT*'K&)1)ST"JQ^!M%+.T1_=L4&% @HAN
MU3VGH7L]*C_O5! C[7+@&(/IB &]!\6@7HP*7D&&25$=GY%J06_$I1-\AL0V
M J-ZT/XT3:N%ZH7/Z@&JS1-1@XO5BZVJ==HF2)!;M-KR/J96_3P4A:9]0W<5
M; 4%UU/.2Z+[_;5?DC/CG]=R2]OXEQ[$R_\!!*M')Q5W_N_7+>N?3N06FOB]
MEQL5E7)^_.H%L#2KB<>W#\P]_0.HL>7&><OBNGS*^M2&^BL 1>V8/8'W^1^@
ME9_D+JV]XWVJ:S/_EX.#Z7Y/3E<K#[<E$H@6,5;1)-V77D,2=:Q[,6PQ"YHK
MB46)H;;IE)84S?7(0'*W\.%'4OD#=06JT2D>A>EZ:G74LU/YV8OG@, A7FC]
MTG-QX]FPGN8>I)B,\E;/OIY+0+$-NSK\N$XL. Q,3Z[P:_-]981&5>#FA *8
MU$8/GJ)"&H4[\E*8^KU?<;4^9CQVHJ+GQ9$48)9\/U+\IO@*,[[AS]V5JOP-
M,_-&8<!C"%,*^.#G5Y/.66)^8ZN]3#V)*H\"0WSO?J-Q!;HGV<&TG5&3$D4*
M(.$K'DFNV8?8K^Q"\AXA>HRH@.37R[%1<G][U5APR'KI0P"C.).M)45=K2G[
M-\\T?O^'LK<*BH.)H@:'X!K<+3"XN[N[N[M[< A! P2;P8*[NP[N,+B[!W<+
M3B#[_;6[+UOUR_:IKG[JAZ[JNO>>ZK[G)/"SE';D3C)'Z6O9N=02?=EB3A(W
M,*Z=I_9L#)!5L7ZW6B+K,*N\%/EA_#C,<BWC%/U#1V<Y@*O\FH]HORK3 QT;
M!$<NN:4E\66^W->%$WG#6!AS');&NG$"1I@%OE,AD-DFE9<Y!C3V.Y1&#IN6
M,\[(Z4-35N'17W"E6$WV9'9J]O41M#B W[#LJDGR4S6S1]I:HES:IE=_^<HI
MHCGP%_YH?@IF8X2UQH"C9^K&M^D%W7^ /5B^^8Z>^2^HT?&1K<GD&PGM^83N
MMRO*>D>',.%I0BC\V,6+\Z*69=GRQ!L(TX?@EC;>1R7*A2LVJQC%SHUJSX@T
MJ6<0I,[=7!ZMNQ%PG'JK=%84Z/ U;>%$I?R4F&8 6KX^P<638ABZ[IJO4,W:
MJBA.A>^/FT*SI,TP(16?+OUC;2LUON^1+7"9!?$J[3X0G6,KX=:#J!OW2??E
M;<*$S+MHHG0)QT-%\7R]!O/QDV"?$.G)G0K)7Y3W6TIYFAY(8Q)2@4H2'(+"
MOC4VO'HLT:=.9[\U9%TT3VT<S0!?8Z42T0+6]*+31CFA-6,)VW7K%2Z#]8VA
MQ@U#?3/F&)K*?@;&L_&KN^9&#M:+O?W2=\Z ?X"%*#JIU2WO57[CO\TBP1X*
M%GEKYEPJIU6.U!:6A&\->(>G) %:>+,KIQD%M".<H[$PB-9:Y8D5;)H*@4#=
M^?7QAI8!3I'NH1B?VK)Y[4HHEL;A/@<\([+M/L_Q8"4;CU,KI O2UL&7WKUH
M[UIJM%H"RK*4_0>X7^?Q@=_WJQ\O8Q:@ CR4RK65>[ZCFR*$V)&/;8W5)6+)
MN?E';B<;P%-^VG#<DEH4W!U*YJNJ*<7J486 4OFP2$PU8);-"+2X>0-_U*<9
M[0-;SXD6?G,I$:NY$A5_L=SQQW]((Z*A#"!H)])5-V1?:T7B_MJ]A.*HY.'(
M'4G<W$ S53CHS_4K MMT@-:@" <+'&N@>K!&"T68#W2J<7C:_A5V-;W[H[M:
MB%(_)'#(@N^5DLOFV)=K4H?7G>AV;?R+1WB?]C\ \G3"/I>UW.707WR-NE'U
M<X,%ZUP1X]-UOX4W94.!XU!#_0.(.KD>3E<- TK^+I01,$BOO1N+<G:9O[VU
M(2$2W9B'[\O'6U^S"EZW5;E$ U\EM^'>:"P65<"$$I6#DD<?_P&*B1SI>6UW
MN=6?R&N+%%:#B5;.ZK8WM27'CC5A:] <7\_.EAFP[:2F=4$:6=$HOZ*M<0;)
M!CXS>?N6G<53&U:_7;!L"QF-]=MKC,5S\N';?1.*,L!70+8:8RQ^]<E;:/JK
MUA1Y1=9L0B$3>9^%4;,,YT-,-PDE3?]I5[$-9 %.S\IPS_N ]ZYX[:UHBG.1
M;!=ZVCNY$QZN:MNK)N&+SK(^'?IJ'#'>U]:UYA&N,YZKT/[Q>O]5U-LZR3D=
MVRK/X'0.$#6(:R,EO"C60_@^2&3CYHLKN2Q@D:1"V=8!\FK9I^2L *4"+5II
MO5D_(7R3$ZAS>=:;SQ0;_)9R]E'7WMY\]K,J4 ,_*Z0@JYSYR"@K^NL&$Q,R
MCXC@A$;D@XK"(:2]TXE^6T1P6<)1R!>L+!:P0;#YQ<7^+IAID?VRPI-[X9$6
M*O_97'_#H?:R/W-03$)D27?@9>2S T.)D;Z4LB R]^G-)']='2$;SI\0MH:X
MH(O8G#V+Z.8ODN&MDE3>$5$JG7@E8SJ'?+!)PG],SFS.WBETEWFV(8O-60^9
M&^)SS4Z7PD:G56BM<TJ5!<D*FTD;,=@:N(W *:!CF"W76.:NMTF=];E3ZX7[
M:S7VG/T*FV\I0MMZ2?%<"%]/SSJR16Z'9!?'E1]4LFF"Q#K% (NXR=-R^PPH
MO\P FI>^DBZ95YF#C3]!GNZ3,%/HXR>\-:6K/O'-M-8%;YGH;_8'$:Y/V/F3
M0;UUJ(,GL<++AQJ2AERV4K?:V(DFA,(; _C7X[5]$?0/7*VBU'WY[VP /Z3+
M9[Q8G?2E^W\]%C9M#ABKWX7(,K;7&,^7U/S%2-Z0$H1.R%$A,N2A97^*W3FU
MC\7*MO:KK'X\8&?*VSC/E:-^['^:R5[JO4>LF CN":C=EWOS"6>U%!>\K+04
M'Z^FU98=R72,$I"+I6O7:,R&E4W \Q05-R+HT?7?KBI<IVZO]TTPTT(5R/(#
M:7^2Z>KBW>4,]+P"HB%S-9,:$<+FN97WBWI!(1L/;];3M.UUC@*5"4X@O%J9
MNX3_"%9AV9J&UE5LGHU:AV>%B=-3K+;) \G*JU+ ,R__ZC'G>BZBE(,Z5Q#(
M2G_I:TVV+M_@,3.=OPQ1KC6E+Z-D'K-R@D$\U1%]Z:5R/[[4B4^?3@B @WJ>
MY!] 8Y?4#I!L8&%.:KU+CEQY)'#H)'*1DR#7>4FE<.4TMZU#6BOGYV6\].9G
MAO3S4?LNN[O?O;5(V-RK;_0USBH,Z>DM$8\][4R;-^@[)R+BS,O!\::GUW'R
MV<]E"F&='_CLK1X)/''J:MS,O#!QT;?F=/NZ[+]D! F5R1JIBH&#I!?2:;R=
M.6XM@0Y)OKNQLI(&J"/(FMI5>'3,J S]KV%R85[;%-E-(.N6CDSR#:Y\ PRL
M'&)>:T0AA?@,PE!P<860BJ=H8S#P1$AH_LDB7GM@:NT3W>-T7+29T$7)O(8"
M60KV3R&]LQ!WD5E^!CJKGD)IABN]'FGIPV\S&O6!SU_:XC7G#O0/UO.=)3<Q
MVP#P,XENSH$!O@.JS>TGV\WS/'QMNM^;,X/?FS^JG.)97QE8W%R.?L #HS?&
M)ZEL&,FY^>_COH9?&O,.E-Z\;FD0-YK '&6N;QE5 SF[]@\"5M_E?4Q?PNO!
MOB+,Q-%CN*WM"U3CP]KW1D)"0GQ@(PYD@^^R8,I(&G&4BE'"((9[CC%Q6:2Z
M+I[:\/!XS?DIT_$[PMIJ5Y<TNC C78EUC@ED>@W 6C,V-1.$<C?;"NLG;Z"$
M71B1$2EG@Z:,4W=Y>?F!S$V"7G!F9;RTCN_.@+\::LZE3DKKIW>N;)B'F=![
M40'H959I@)9!6UM,-57:%Q(FDK"Z#9EI7RZK-9W$%12Y[4ZD (*KX*?B&?5@
MI^()[7/N+;WU9NXEDT1-'N/A*H2D>:>2^N?OKU'2P<CL@LO=!_4.%"C)IHE^
M)>P9#H;+.623V-]E[SVM/,+347/E85&"%?TIOY.$Q_GWCGQD-)[7L&DVK'BS
M9L\+#I:QUJ8KMZ<],-<<)C ).0VUINT]S(Z1E]@Q,]M*6B:<Y(.H_#+QKG2)
M^M8^D45'2,K;H<-8@*'41;F?K)SKE8C+7K*HR5?XH(=DCZK^@PQP59]0P$@'
MF'))(6HACG\/J.'"#T@I0B@\^M^KRBAJ4-J>\JKP?I$@;P(>NZM6DA95W =-
MB0R"9K_;_@[KD+%NX*5V+8^._FI%B!/M7YTFBYD+O ^F^FTQJ\N/Q Q2_0/?
M)[39A/9VJ/[N%0J%S5O*^Z%'T"%VTUU4I]27KK5VO]WM6R?G/$H;ZZ+ ZDW7
MG@ZO %Y??EV=),V (X.HG\ H;=<-[YPXAQ9 5V:L.&6(0<(LN@!<Q1[,<.60
M9UB9%]VBG3NE_0U8FI H+T!/V#86\Q66/U*QS6KH>.$+D-0Z <%?>.5PI &M
MEX,NR")7CTY@VA<G.9NO?0:R(6I;9OHU6-78(F9N<@I]Z!O%12#INON!M(Q:
M*=9)K':<;\IK,E;0LYPT^]63?Y4C<1<D88#F0FH45@#TYZ SI(R:/(7_->V/
MAN.G^$K^I_\8P(A8;[=;5$N-M),&\7)9A+0:4G1>A/1'=-Z<6-F7\\SW_Y69
M<DVG,D[91%*PH\BA5H&=(#[C6QFV8B= R4H#*W@"U^;=DNNB3J,[WHQ5ME9?
M'AM]^S-%.V4B)(E!G2YX??''X4WC3S>TI58![_,I3.<O(*6<9>VZ19V2[[4A
MXZ-L<C9QXOCQ[@M=UDXT00FZP*5J-KB9;GT$*V:7N&I0J\27*'$F4)+_&.PT
M@P9&[UQ/(D2.]1^@#$+D58SA*U$P<C;56-Q=("@GM'X;5X,]3H*2!9>@<*X,
M9GP"VM_2/*4P8!RT+T6&5YKT'1K;,A0!JFH1DR9+3#AAZ8$OE.:Q5R5>4=/(
M1&[NHKV0A8<_^F7ZKP$J(5:&H6?B0L2.">"Q#>>O[4=9%C9?3R@LT004F^.>
M5!E+0XGLO8A)<>1NHQC[+8#PP+D+TS/7+Q&KN#X=(,N8&:9.(D\YTA&?, QW
M!3BRMCKMYD2S4_(\HRT"=9_P2E;9/)M R]_X<K$$1@=ZC,D(,33XDR*,W6.X
M\6M#)O?]*R:_^6JG$)]P:BI+YYOJ>/F\G9QP#X[_O)0SQ6%GLY2'H]]']'N7
MIU.H2O7#7-E7\'PW;Y6737+I5MR;/>G;D;Z(.B*,T80#*[41F9+N@[ [O_O4
MJ@[T8;8\0(?&! TI?E^77O%T,W*QE%SF@L$R0Z\)[7Z:YUHO1&@Y2RT+U5,/
MD\%K&5-3+6&;QLJE>T()@X)['="%)TV8#9.U)&A>Y91Y(V&\R2-;W7Y3?1O-
M-$9ST(B[-%)6NMW$'.%]115SU"=J9.>A\DOG1MY$E"TSDZ"2[&2X-'^:6 %:
MQDJ +>>H)R;G4'%G:#9LW'-=A'7:D^%2[27W1(ZD/ML#4U65?9WK/P"QZD7M
M*<\:1GWW6EPX5_E$SV4['$I1CF]97*+5ZT0Y3OV-2%7N!?E&M8EQ6VY28;YA
M K@@64E.(JYW5L5"<=W^7)O2^<('O_IY2G ;YN@3(2+3;^_7'<VT&1F?,">2
MZ!KQ^++>-&,3T3%3/W,J&=#AF 0V['>N-FR8*I->=4=!GV@<)?PYH].G>-+7
M[$G\)\V.0?G1]F_'ML(@1+C=-%"[M &1[\\'=)DS.=333.CB4NJ*]/Z%9RI/
MQU8M8[*ZO$A3X?0);UMVRSTM-K-O&M[]/1L3^Q1-Y$<0U\]I447$S/%[8G:5
MXHG23<>J4I^Z4@?C#:/-,>(L^X,HHL/X5@%I!YI/$L3 ".1/HPA'_//!1 $!
M+A;..3P;IZY8!6$J()8X-URN+<F/TO!.[D(!;&[LT"V;5!R$ICJM;KTYT126
MD@>25=$B(?QO3U&()@]CK3^5?&U5?YLG-)Y-_3+\S?!'-7]N 5DGO254O/(U
MH'\'C< SE=DY47)!LV.1DMB9%[]A]=CYMU L'.!:YEK^FO9YLZM2JO785=V*
M!ZK$I^Z-W'::@RH#R83JIM%?75Y>#BI^8O?+<"O%GDY$-MUE/N((FXYMM]#/
M.7XM>/WY '^?46)K5?TZGM8<>"GA_WIGWD6[%^> 2N7/XEK,G^EGX5YL$&^D
M BS.5TPP"B,7+/[C(XB+#U]+U>9Y58<)FI[5F*''_%P*"Z$CN@\=#O25"\*H
M#_/7,IYS"\A\)?E%$VAD]%-WX>)^N2U49J/1N'!S^LCO<I_ Y*=:AG7\7A*'
M%AGCFY5=/N75;OWV!4J)7.1;[O9#LL$O8=I$4WB78/G'2-%MICVJ>MPW+C*F
M:RM\.3FT)7 S$O55O121D=^^GMWTH@P]$B(_/T5Z^'=Q^._HV2YU)0%D@B$5
M-HO-JU\#^8OFW%3C\^\KMX8QTNB:$QX?7S^LF[_+B-E+L^3N^>8BE^6DLF0R
MN&X;;[1*-5?UWA\9_=12:!IPK5E^'ED%2_L*VG^'T)[W(4IK+],STU;WO(RY
MY55:J&,/@?GD'3RJ(7R<K+C#5%_4Y4IP\=0Q%J  <YC+W95?CNO3/WUOK.I<
MZVIL&YM$5!8(,(=+BNT;-GH*RH4,"_&0R2I-E5PVM9I0;E/(X>U$^-JOJQ4,
M33?*")3A\36WV<6Z!%';T),,=9/$OS[B%TP_+\:]QQ5.H\T9QO#3YIY4Q2J@
MLO/;9>6]!#(:[ RCW9JX:;BQC]J*5P_0D597D@I>? 7)&B"A# 6MK.!W?+:2
M6+A_5Z'-#!8^\U40R=+/\J^3['+'1 .E:\M(Q/#5'S8:UE05"EE"5E8<-32O
MF'^)VM4(SB@@_ ,@8!TAIEX93559E7Y:C=M8])8>7Y9X&W]7FN2,>G7T<J C
MHGZ-ML_<SJ!0VU!B2;,UFBCOT?W=?WTZ-YSNIYQOT5FM[#AH#^9)$DS[H] U
M7\O-@C3E;P=79I!*H-K)#&[IXKT 3P%MR#H]%7UD6E)LB*4N8Q>I[HW?;1JO
MW%0(_O!.AT70OR%6.-?\BN3?C&Q0BW,\77\$2JLRGXH(7'H1"M!&:%?AR(%Z
M?+YNV3?K/J&#E4B<4K3BJC#4(.$_" _<]OG+J_C1;P"?*7X](T.(+.7[*$)(
M_*95X1KONY?<[_E4[>';G$9]EJT-8_ED3XMS&JGSR6[[#O3:%;XV] FVX$OB
MY3'I3 696E[_VMHIB(FMJ2*B2<E3M@J3H+1BK%3R0W$O(Z2T6C3=::.&]&L3
MVE&<F6.H-8Q(]!WOD+\T9N?+K-AR+1U7,O3-+R.9M02U()/R6V;4F"$?DE"3
M+OZWX,Q$_!FO&:2>$8YF3^1.*+J8EO\8*3C/.R+6@REJ\=9'.=$:L^X]C9!1
MHT\6J/4=/;CI,< Q/*X,F2Q?#IG.'B-V=0UA#)MZ_>RV>;N_([K4X(*4J:/[
M]WO87]#I3.AW5;7$!3JJCK&/XIY6MW?RIVF$)K&T\E7T:J.LX%4ZL(K%$(90
ME0&,=VG<6#[Q4!,&PYV\O(P4%ZRS:@+0=W)'8M:%0KTIB>,+-1,IO\ JPD5H
MKF(<*R*E72)M3\;)3I2NB=6"Q@Q<HMTWNLM!3G@P=GA\\M#JJ#J.<_0I)3!L
MR!R9Y-3L@?&$=:-A1EW"K*5@S6R4LN H=L3$5%XF-**>7Y9XD)[FV?5%(4 "
M=L*=<[).YIGZPW3+14NR/91<<[Q!#FRP2=E')+ ]^%U@GW_7+@GC6_,'Z0?=
MO6L>>9U7J4- 5"1/=GJ10?T*]U!+U#;]N@/Q^?%Q8Z #=:2A I6[8KF0DGDL
M!'FFXU(Y8M\:B%"9H,7BX'+%@G=3C;V@GZI06!/L^=<'DQ"K@)ST)@.I?.V+
M5X\NWS[(D82Z)9D3A_I[=651HF%4_$]/#"F$T1G$:^C,LIY/IFPIA,^#9S'M
MCKI8?30N,6HSGO3$E%:6TE*:DX$T?C.<^"U0[+0P<5%$)KU<L(M\XLUD#H];
MBG9%R*PVXDW1Y=+;Z3,LNS@!$PP^4U&"KSX"5QJ,I* >9O\NHPRXV452A;WD
M1P '^IO 19/T>*,1&.\ +2OL<08M*(GW,,HED[QW>>[KX8$)76#M*?Z-T]UF
M^]QU;;4F(4U#KI4#SP&.47KL%TP+U*2$-Z+940M4_-9W_]/]BEOP1D!@"U0/
M325ES#]O]D$7_UI- TU/=C'3&[W:(+;J== NEVH")4_)TL:C?#:%T,D(R#[%
M8<=:Y"L4=*?0K7=SB#,.XABH1\M9CGFLG07&>R)(N=[1[9_EUITQ1<QW5#Y5
ME+6\.+!4[\^_9FDWU#N50 P*7[(<6&NKUS<SX-(3'="P?Q^D-/7LZU-H>X<2
M4YLW0 1?T2W,<:R<58(;. QTT_3:W$_WI"EWL=E_)8^>/4G*8^%J>$@*8M2/
MC"$?8Q;A/]"!#=P)V03Z5D4C<"X$A)=(*EO>DOTQ?MBGW9X(2K8U0&*D&Z9X
M!EUS7TI3?$WW3*G]%RN\(_D.!SFR/<)Y$1X3";8%:]QL#6RO7BO/2VX$1JNX
MZKC.JW_!K0##564$+YS=(1:K:V8]0XU,C'\&?CJ0*:MQ3"G^X6A/<,H1W&:R
M/TJX9;NBF^SD_1YH<8!6SS(@'R822E8B4G^,VBD^X<924W6*_[.LTW!S_>R)
M#SNK&&RU&31D'5=3[+61(K^O;GTU,DP#Q':DJW.I[C8(V+?)69()CK(J=[U_
M>M!KT%PI:59).Y820=?HP"5BIBDS4N*&? JSI(TBH>&=M95\2MN#3!4;^N1M
M*A#9M(DWRAKOUO>YJ?+>1.P^$_43#7^+?W V].W_!_C>:*B_)2PBLQ)@"BK>
M,D1=>T,NZXY*6WG2.#W2^F365A\L&'BR+^?TQ<6-GC\1\E5LG8S E&TBCV?/
MSXJ,WHOOC"GFD:/BR,+XP"GWZ-ER"F<O)U[-B=9*"\KC<EESC<D\UH8M[CT^
MFO&(/K:_)F\S-J9EEBW83J EU!'6]^&&'A9D-RWR\O8BZH-!O10E.](7]'$+
MLG:)3JU'=S[560NG]8VP]B2BJFZ^&ZWZ'2^V3?$;'WH8:&G,E\/EA:OB83UR
MA0N?*TR1(2Z<5!23$GCQ$'HD_,FQ&\B<O9OZ*/I""&?^K2?(LB29?(QPC=K+
M%-I""FW1F HTSC4\:A<NRCS0UM;6^1_ZO+?C*XD\45UM_XO.[V\"Y4?MM=*Z
M[7BU,M+_[;LI+^_1T- (8F1;\RO1AE3\ TAF_0QT$G&3GT;_Q<N6-%@ONRJC
M[#[<(RO_#W#Q %(<GT<(?)\?(<O0N4;66A>0?HD'&7+7.*[33]46)LQA168@
M'$D"4!03/ $CVMARH ?M+[!\YV9EKH6S2]YNKCHG$HXK'W\R9P@*PV85""8B
MFQ/%R/ID!PZ<3( )S@/5#9P^S-8M"=;@;0?-<+2[00]GZ!=K(2(U?NNMEKFH
MH$0!RD-/U#Q7T;:/]J>GQ_?W]J1@-Z6SZRZVUE1!M!BBJBK#(&<2I<OQ;T.[
M9\8;EER7+EZ9YY+&SZ9!9X2%HAH'\IC7I2\63UXB5Y%VN"RN?+_6M7 ]XL=-
M6F.0F3UR 7"M@#'C._BP'2UV(X.1N[&UUC0#\W@,'X4O6DR%'"@)PSC,[OJ5
MR4GP^F8E;G)M%$KU+BX5%RXMG1_C3?@S3BVS;09J:2C/FBAQPZ16*%R,=RG.
M!KH=W9J>UIG^"OR-UL_$/%9:2ZX\O-$*K?R4:/62X2B=JTVCQ^^>[7^GH
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MU!9<%D=RNE_(&5#BJV&9K5J*2GKGBSPX60A7^$H-80TL+7_U*3?EU."7&OS
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M4\[?/,:AY:!$W[O ]QG?5,\ZX?&#@K9?^3!H<>+D"*KR%.(8XN0#;6)'HO\
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MT5OC(LV^Z*8I<^B-]_ZZ$B>@0]\@=QUFI0?*FG8W(R)']R*]+8Z6*Z] 7$2
M,<Y#3+0XIA:%\E?Z\$*;NE%>=WXV>7$9&&E?]YLD2[1Q+\=73&XDK?+ROY$0
M92LW"I-H_#+'&1\ URS,928I ;\-K_3$KFA!.*@J"3&&Z0EF$0^$9#<!_/P
M<]+W7L4/"CK%?P"L'82: +D*RI_*9Q@)]1\F%I6K@Y\47#QC!P:U+Q@+QTC/
ML'A(;#A\QU6EQ^>1"1JXAT%G>E5-W0T+OI?1)C0!Q"E\<7ZU4E%W\*G:0R/@
M=[)XCX)QN*FOGN'<LX)^HZ_^5JE+@4P1"Z[D)&TQZQM*I82UJA+0UY0P# FX
MSU9Q>L<_#._3ZN:V9"KO1VH;H!4.!"IN#/%/_8*8C1)>J+5>>%.=Q7.N,&&C
M551%5?319P@]><J;'\=B5GF-H'^ W^S/>#*<8IXM\X"@$,HTS,"N?X!HYKO
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M%9E8J.)W<<>'4Q[V"[\IO^)S_"ZZYL0ZLUUM\DY&VBTQ3U4D7VZ:>N&$@:[
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MH*+XH/@  "=;5$YZ#C D#.$ <Z,7Y.$#B"FH:Z.C TZ)2N>I8]RO)H"5&A4
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M%GB<[\)GG+,>=5=[^O\+XT?S@+O\Z31Q'OP_<[01]G\^E6 "79!&0/L_\0A
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M.=GY!3N#JN&<W^CN?*P*B)+=L0Z9JDEI[&%2('@O?P(0YM73\FT<4&W*DO5
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MG",J*90BWI\#4<9(F0D)WBZ2%E8W?6+;:_JX!=V?,WS7&C2W\0E6-R/+,W<
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M;U@E\]>_08?NX(_?^'SLQ/E5D>H$ +0].)2U??,%_V$ [INC]@E_G0!VW1/
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M4)T TDX U*\V@S4EY.'Z"9:VZ937;W^*BJ5J2Q97P:Q@KU<N2*0N$PQA=34
M;; R\;_"?45):06F9Q=X.+^A:9"<@PP9MV&.E:KH;#8KRM>4QBGGZ?8<475@
MS3@LGAQA:-Y\2%&K$Z4,G.5LX)C0BTD14R"&@U<9;JGFX?<KY)<0HT,]8R0^
MKAFKAR_AV+D+?6B!VD;T)6)[?6*]H]]P'%'$M =:UDTH3%-A<L=&M(<U:VQ_
MC"Y]P3N@_2HM*3H1G3?8VS-!:-:Q LJ%-1]LX+A&5LE M!''2>13U*TK:)I
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MEK^&!UXDEG(>N"I!U(*BM!3)A"FT)!432I(=^XAJ9HE<CRA"H1>/%484/-5
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MSC["5L+N#'%2=WB4U2LJ;,+N#]XDGPE\(1@5G,@=J!O_O<CR!=/KIA)<4W/
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MM6N!&(]4009@I#W[YG3&*O2SO& PV@<<S F:#K87U:F*[1]X(S4A@EF(+"4
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M' X%P6\@*50)3FM,AEW1O%ZT>U@4CQ?:*ZB&Z+$[]0$9P#@#!TRA76#_#U]
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M')>Z=.3P=(@#-RNE+0[*VE.%Q;&Q7U;^1I*M#2XH>UOKI;I%$K#&9+P5.1-
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M%RFB+J<]R78EC?AFW/,TR+C'W-(>O1YY0YXM;_G/\A'KX&HD\//5LWJ=*I&
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MLJ@FBAQJ(,H5E[+9_!+)>[%(H 95W!G((MD(S'9D!.:RQ7B,?P_2QPT*CKH
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MN;332]CHS#3C('_+/JJE:V6!2J/ (I+T!0_";)GTT3*CXD0[C>5R&M40]ZQ
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MZ83RY!]!"B6@=]U^DW]GA?9&(MHC3N+GWX!@<N@E%&SW0OQKY0!U:5G1*?N
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M765ANMUGKVQ[W>&).N8"95S]))*)6<.LC<H&W*Z1VYA8HNTT (F(*V"'M=%
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MQZCUIW C/$O$\N%RL4M8'S2.-5>1M30S%;6(%;6D6 ;**]9=%33)_:P-1*H
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M@L;TC-*EZ7S+WJ%0<KB4"@PJ3T9%]0G1 O+LV7("1K4RHWEC*?V=5V>C'I?
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MC%WYQ"S,Z:UME.!]]#A@Q["SC"58;V#Q=5!9)+3!HD",ER]@-CS,MQI-J6Q
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MBKD59\>WF_!<PMQSR?S\V0%43")*U=T?ZLK H&V7%=T;L&/E,-#_KEYZC:,
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M=^$B/Z$]WS)FX.;L"\KD!.'@J"+F?M]2EE6[F?0G8X%J&E&R*D)#<M\-W'^
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M7^B[]\D1P@4)1<\JRFEW,1'S44<=0;/U3.[?("#AD5L&599AFWF< K<!LN6
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MK=*+?M3G1M.#UI>!?T7WWU5%[;WH9TCN\^9$!^G?%Z[C*>.+BB$7K:_'%<O
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MBD.?*\0XE18*(]8>YAXS:Z"WX7MZD#Z5T(A!Q&I7/%Z=QPE3/M;!V)S&*:I
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MDJWP;Q#?_H+H^O9O$%5\I=-O2MX!"PNOW?\C)N^ H;!_-?+Y_]#H_(7F,3:
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M'Z/(7'M(5AB58?$LV%1&AP>&J'J^EI*K#!K[ $=?QEHK4WEHUU;"OY#GS+*
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M#]<4W48>8&\"\.PIOK0$*ORQ+%&IT)JOT(A'A,Q:E49;$^?2V4X:XHT::^,
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M4TUTWSRN]W<>.)0H41D,B'P'"/VSJK-([QV L"]RB+I04,)1\_?NC3E^_#L
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M_V0L-$9DRW#D%>JY47-8:_Z?9!OV7[^Y#';- C;F\/7^4=,7'XKJ02@O32]
MOZB$PS_CORV1.#8LVH193R#M=IXE33M1($>;HF+J\<?1*;NZ=FAPF- )-<+!
MO;'+-]1^Q1#S%449_2II'8:%GD&P'2VW']Q)_Y,[<ZL:P:%RBNF:2:W<@J$"
ML74C([#0Y1N^?Y-G$X<8ONHTT?E@&"(!5_S(5[D]26#=QXRX5 S129-A@G=
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M/OB4QFI#>DT"J@)X- Y%Q=VJ,)(!]3_I::94K $1Q3&"/?*YX,E@9GSR,+O
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M@6Z!=G^0FT#>%B=)P>D39V1PM%[#=W?"A@7:X!=1X-A@'   *B8 H!$&F.,
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MWZS86TU_QF0"S4:3-XE(_)7I==.?<1F<D%WC3>((Z<Q?^5XW_AF?V:XQ@DD
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MAHBV-KUZ"7*[5Z\A-(WOO[K!@=,,:(##PP<TA0<'"-*Q;H)4B$C6:@Q$E0I
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MXC5R>!^.4Z#@NI!/@>PX,U9,L00I0C9+YX@,BEIMLK)#%-[KER /L$G\#C]
M9@7AR"!;;&$UX.!K/?![@D7)04B%#A)#+S.;Y&I*T"J3NLD!"DTF-'/=-&.D
MMA%@44"R"F4V6'$X@AI-#8J(3@D=PN/-)B<3#6!Y+"+&HB3B+%J G"SG(D"
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M(FQX&\Z&B@1VB*37D!F"D"!9C<6Z_!!=B I0 *G%P2.R(95#1U-9J7X>0\'
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M(FF)NCU^-41O_D4F_87XAT4H$E<K@=5C2(VEV>!E.N][>=YOV3-?:K]EE_#
MXW?6-WI.;^'8H8O?M1!?5+I4 ,1.:LXM@TDAIR]QS5+I=C6686UE@)VQCOG(
M7WJ-DP!:/T/_6NDHY.7'.W#51UZL1_J+N@#/+8O]SFMVS/8;PE9.R>F\+N-
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M-M^7Y-6NJ\NWV[;-9(\X6*K7DMM=PSM+$ XRK0U1W[A'QW!#J\'82KN$,K%
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M"&,JXJRW?EKG22PV),N=@.^41[$.R(T@VM^GN[@S&BD_*XRC:*W1Y^2+/\[
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MCV&>:C5K4S*Y($I=14%?AWNO:>]4>Z0J>\>6GUT2%(K(ZRI5/)29>V9-)<K
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M^@Q?P1YP?;Z3=>\&4"JRT1WHM'(#,+&;&@;0MO^_;,!;9YSVW.=J4@9UOJN
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MP7L/.#A0@Q!'V]4!H_+7SJH#* ^]IM608*$89YW^7HYP)NRKP?Z4B1%K)@5
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M4$L'"/H_K@>L?   T+,  %!+ P04  @("  8ALY4                $0
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M-Q_LCMX"[+'>$MJ3'=%$,E*SEO*("4Y=MI?%52[54H$=F:9;J=@?N97Z&MW
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M<;\KX+/@XJC[4S4OF.',Q,OQ"ECFM(/!4$.;0<[5 \D@Q"/ ;<4'A3(("_-
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MQ-T"_=N.%[I>7*Z2"+]3(\_V8B/YEE<^?9(G<%7DW0I<MY2@:Z31RNWD>O;
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MF>N2':"F1RWQ2D#.Z%I$+:D*F@ZQ0.^6;'?4BTZ.C%+R5DSS]>!$ *TM<S8
M(U$+06C^N*3=7324G1<]6M_$1W>/PN0RT.HV-DE$0[5"SQ.?OJA2-.DWW;VE
MC%1>H^QP%<5P<!M,K3NW>-[>H)'F^A="5V^G-3$KIV6F6B8$=F0/.WC5U(/#
M.B;?,I9/B>$0>.EY<;6N&-"7PD(%@WBTR$S4[Q 3^HJ]?R4$P;JT/<>']MF'
MOMM\<1;_]4$<5Q\5K16>C)B8BV=3'!C[TIMNOL D_;W@'DG;*R?OEA[>OD]
M4QY=,D4R)LXNZ(P=K_'!=O 1YD,D7AUX>X2Q_^& :G=D5OQ&EB:K^@*0$1AR
M;2W_E?A.@@6RS,'8:[Q!/.QUS?-M:BYS 69'+KMM9D)F1!_-\S(C&5%,98HZ
M]3(3#FF."]1J[ A5;&TU1B1JQW/#V8$:CHP^3TY-%Y61B[*6B7QEYT4.>A/
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M=7=V?$RMZ4.;KT*&%6M!$TZ-UV=5A-O>O&=#UKY(*=]VB:!BT;?B7M_U#;I
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MVIX82+6-:J3\V1><G)BXNV.<0X"A03=HY^:Y&^W6D/-G2^(J[W454PVN:VD
MH! I_G>AB3^8D;A@L0AVJG5]&P$Z=-#B.;9E/ECOJL,/L'2!/*,^$:;03J"F
M OSEBJ2D$/L1\AZQ"2(H"P.:O-V,;9.1J;VE"]N[?>"M>RJ;ARTN6RE93X1-
M/+1P;?GXD*)^&T/877L?*5$6(5=W1Z[YKH&/3>S*QMC\FL%+@B[JC5"HXW>B
MF!H"%,S)SBAX46FGYA8BRG<QB=1)/^^GX^O+"N7.SE^O58Z2B,U=S7V=:#OZ
M.A0E6<1PD\.+]%,(_1\/\\5&$4KK$5=6.5H*KI@^-*2$$-YZIN2^EO;!7>3-
M$8;G,5&'C'WWO2:[4R*)AHPX256+X*5U9-,/37 55F0D*UJCV$G%9#X^8+I\
M<J$<FDL\^(HGEQ0B.87'*\!O#0@>.'%R'7/-==6W^S!=/<<*^W8K9.(VYIQH
ME_.AK-O8C9=I+9*WF_S^*"PMU@.&5@QUBB?!.P4#"W228V*$$M,3[7ITR4ME
M&L?+-:)"#*=.B^&I%%YEVP09I=/FBQ,V2/I&*L[P@+KY^F@$8^^'X]VQW(2R
M4!GJ4BC3T8A%]IE5S#M7?^:1)@#A?8L^CEZ6L6&#./>WS@G;; -7,;I!]?;K
MGQC@W[>__EO8#:]^@;$%7&\L1/J@ ;X&L1^<-NO)NLT/-Z(<[LGA^+0Y44\:
M'6IC=3]"U(*S\RK*-:;%\'+ZA[9D3Q^IFOFA!R7NQ/LVF;4ED6O>VG@3="P0
MN53\ZP216]=@U<J=?X#R@0]3>'2X$D'UGK9<D<YF+NL?;AR'$Y:M&A135O.,
M6U1SPN1S;"Z>PA9,ZDN!JH-8#N/=FNJ5#'PPP*DFE+F; !4M&M#[FNG=WF:?
M50!C8P/&?R13 C&T>ZC5_ /8YGOF93WA[)$B2?6K]/T18,M^\/Q)CHDE'CF,
M^7-),<$+WO^FQ<3';_M.?\UC8MP'A>"^>K/[G;7/X";MY;MF<7ZO[UB;#\QR
MLJ<EP6!L_I.!N.YYO7EY,85 _+>'F#JZG7:=2T/VH%QUC2,^^GJZK8! <]57
M&OIT0:NKR*^^V_;.;2Q")MMKY59M CFD5Q^=,J9/#]99U6/,FH3(OZN,$S%<
ML[G;;2+EUTSN!Q]JUM.02W2H=BY_R=%4,NO]5+]SMU/>S .*C7] 8%W?L-LQ
M6H^C,A]K$>D,';N>'X"PECFUK"YDV;:)JO,P?E*0]T&?^8DG$%$77U;J:H1S
MF5\Y@"3B^_"R-'9:H?8<O[_)#,(BJU_,.Q?A4VS@=>LSBLL=VLS!_-EP45+7
MBFDQJ]JRSN*X)G80R6ZH1V>DO9)O;R)%EB]>A*^96:6ZV;5B\-3DE[>,%TG6
MIL]<2XB5ERVN-+4FB UG26*@B60VN:+H:#Z9X*QK22RU:$RG3=(;9:NO5ONY
MJ2$4*Z>?!M>[$H:N\?/^9+J]-O+'ML2L@," D85P17UFWXE'$AW0',QLF0T;
M$\A(IT.>*%TNHL\GT:4M7";02ZH+(BN&BJ*ER4^__S_[T@,/1^]_^(86+_\!
M'."^?/L'^/HHLQ+X_%\D6OOW[P2U!?QE__]#%5?#WXW0/J-I<*FJ<=5KO-1V
M?6U<SJK-2VDGRU3J%OI!'T])(R^O.UCQ*@VO@XL%36H_ZU5/MFQM<TNTZ&.!
M_8?EV2/HK9!.279 !WNM2R6E!!]\?^?H[M=O#C0+]]U^$_6U]Z_$SB?$'3T1
M*ZA71Y@0J>9B- -.$J',"#I&H*;S5-?W_[M,IX\Y\/KKQC_ [YO@?X#[H?._
MV]^=%V.TH*3Q&2RM?\U%\&WN"TM@S;AO)PG!41,_-G[Z=_->93 FIR9)K[&:
M>U+'N()?3BYBI;&HQ/QX'H.+3C?8ZH)KMF7+YQS=N/0,A-4P;/<ZDR8I_=*T
M8M#HH++Q.WO%L4.XO']16/2'VU$[DUBC\DE+KE"GNKT=UYAJ.Z/H8^( $(C=
MJ\/R2O'0AZ-,S0+0U>1 O!EQ8[SY]%L)6%]_H<MFQ_(7,=D(*!4?#>WS>$5.
M$SON\#W&G;1*5D+/8V2Q=.E9MFB!2%NUESO4=I53YL(\0B@3^$%0D=:;G?3C
M9EJ"S"8-W"2NT90S(BHP.:V.[NL'$QE^2=H.6PS ^*;X$=RXU1"..*'U_: :
MS0Y;>J18C>XT=U/M78@J[5=Z?,B/A*PL<1SFK;PN9@%:VZ1)=+GBHK]RJE<"
M7\T$\W/^ 3+"H1C>#QCVYXUNQ$SL#'A<$Q^68@(>/Y!%(9@4Q[H4/FM]7_+,
M(.K2"\AMD!/^2J'=2-\>:=)W,PX*.F@Z8"0FFN.IB=,B[WXKWXW/%@Z'+'-5
MNM+&"KNHA3*,$ZV-J9P'"R6A;'/E#JHRR[9=7V*=*_X#3 ;(K=; !Y8:C5!1
M.W= &1+6B9(4)ESF04@3.]HDQXUY0M8PW1I]&38+S%4):1=%UC "K3$L,%S@
MFQ0 2\FLKEO6_#FWXIMAC*M2T=J B8^WA7Z7&%9\7@_&@^(:+'6792HT5$3I
M!9ESU=#$A05_NOQF09"=/;]W^8'J_A<;4JJOL8R![2E!S)2];[9GH?*)[)3A
M(*E4IIQB3EP^$["AMAS\R7&_(Q..E7.&;CPF\HME((Y^^)HWE&E=W,%IW Q,
MWTP]B_H+N&A(C<L\B?"SX?'R>JL"[JUON_<M\F=#%+;3%)GXHTR,!%</Q 7R
MU7561H"Q?6A/3V3:JT0GX@IGSP*N'3"VO0%)@#L00/0\.6;Y8/.QTELD:0VV
ME&TS^A&\)))J)<U5OEXHO6JF^ =H1/:;QZ&R][E UU4)U^,0F8.I"N##'K_T
M(AJY^J9=N@VVMW#.4>@-.=[;;T_0)O6HX1:S3$[V-UM ,Y. /.<@MG]HL>,E
M(CW.7%GH5"A+4H9SJ:86,Y=R2-N9[$9GFA!.UAUQ&O>TUU-U9KMC\%ZH)89*
MNS\,>8X"]346:<NY_P'P,DF3X9,*]]1SHS,:PV2_?S?SN=B+SI:-I@7-3O_!
M'2UQCUO DZ@BMH(,>UHQAM@GV8C@\L:R%VY0YM"'+6YW*^U&$_ L96&.E\4$
M0Q60-CJ(WW/- 1P8#K9FLU[=&'!RBU4;EA9G8/B\-&&AJ)$%WR.-,(0E!VF*
MJ!:5$9JPL\RW[N!)([1Y\])6T;*S>*VIBUL[EB7!O-%D)I=FD=25]/2GNQ&\
M M\5_>A#FU(3[;=;E:-X+PS+/CENNC'6"6L";22(85W;< :^C/@1>3/+81I]
MD]"*/\.Z1+?&6Y"X6B0DM6_L AE[Y!F[O2'RY.?SL,#Z81KEMO;[]&[C!$4'
M15_GW)@PZ>KE91W-4FD6'-:1,@XY-PL>!A4M%@K5B'+!D(=N=!5=NZI*0M25
MR*AY2.HM4WE1CI"?GL=='%8C0E/(A/ML8E"DNQ02MQ<_N>QAHNTV3^G]8XD]
M>Q9-RIO>N697A])K^O+BA>Q%%,P3-L2ZBHGR@)2F&OV[GTQZ@3"!SV8:,CE[
MZY:<LI<'X^_'U.T3?<<VC:I:7Z%/_=E7IB 3ROT)K@TO5%3<?X0HG'5&K2Z5
MM-P*=NB]FZ!A<U.M3@TM9*$MEKYPO1"Z;HH/E&K]<;!@W=O:MG2X5&<@SE+C
M9N ]A1TV3F8#&5 TL<@M&C,U2AI>&&FU1(2.]7,A.01QF$N(>YJ. ACCX'8:
M\;^43WY".*S&O+.:$B]"KG$!7@ZB96T-5VDZHJ\7@\B)#%W]573*';)#MD@K
M.S+#Y48_G-=T15;<U]*IMJW0AZC[F'IAZOGYW1IV]^_1:HC-$'NMMYD1R+@R
M'&U\\)&U,P^3OT6=C^9GW,FQ$9"6O.9J!\WT(][-@G)6G[U9L-C%];I#\ZG3
MF8\^(J9#V.(9FB;\-X=574R? UMR2F?64T"V3S0QM)FHJ)"[X@<E;*W%?X"5
M>S_^BY^:^;H/Q F++AY(M"39AU7.3V1#LBJHA@DU02QNSK A^IEBU*<Q)S0/
MTS>G/;&T,H<&+K\2T9LGUR"6\*8V.;UR@G:1;(#Q\0&EM#0MP]=5-2WQT&'2
MRFB-]S6K$<(\&"+.ERGJQM#?04&O'I[?RW\)BI;X5,I'6;;E+ZS0H][-N'GA
MZ]/JCTZ7;7PAF&%6S-P%6XB>K:;EM128TH*!<JA?O4_<:RB,>"AB_29K^O'#
MD!J#["E;?,?4O"+,JW&=R9H:1AFNY">W^PDKA8F@UZIV]S&Y\K*44+$)* P0
MA',L3G/%P)B.OX[573BQJ*6G62+%PR9 ::@,E"3?$5F>?K7VK^0.11\BD\M)
MXQTCXW L;MA82:XT+K+7C\AFRS%:,F$5L\P 8*;0P4.XOIK)(!G_[19!TAE;
M63Y)<[K\VABW]8-> ^MF@E[1>Y06QAR=[K0L2UDD_^L0),:,)E](C@[7[1&I
M]JM+)K9JHNJ/FSY/S@A]%<BB0[_),?US[$NFXO7>%0*"0WQR8]2(^S^ LN$8
M6U^1Z*M-[96P+C+J=F-#I2P)%Z\V1=L3 -Z._3.E3>O6DW%!M.=1>!?M-@6-
M7K)#(;":4T)PLJ1LDI%FG 77Q(3IB8KZ2R#E/D7L[<]F/ZR"I59U\ZI!1JB2
M_(*A**^GBEE[TXIE9E>BSQ+7!C0\:(?(U33)JR-S%-KC6M-4I!U-QD\O"=WT
M?ZRGIO+RY+.J('E>$(2@I E@SGC6S0&M17KQ6S3I1=W),_>1N.2I+<4#.6\X
M,9W9![8$'N@7='M3J]PHNC>BUIWP#F56CG%*O\?13UM1!V7<(/<77O%7*SBW
MQ(N%S'196@D8L!/G;4[ N89X66_3 7>UNB&NFIU_+T9Y!3946B.AS70?C]0)
M*EL3I'6E#_ $5OFC<([ W2ZW_)GB8O"98Y<_#W(<A617?0>/!S>.W&<^/JDN
M]8U >&'Z&Y6=V3^".1&&')-A)3B;Q+2O:]7]L6P#TJ+G<OV$_<03 P9!'&+C
MQ%0 4.!./=-1&$BAKCGU8,^4+H50V16/-R;1GGR"H'^,HW2[V>I780@2%:(:
M-8,8?&K17.N+F]+BO2/OJE*K2J.>6-L\)1\7K;E;$L"6/.26D\2*]:M +0K,
M\GMGY[#\E"-1!*+U.P-^HY\/.6;R5NX!S_3J9)S=&_B>Z_BHGX9!8(A$%C@.
M4+:VDSTD[2@]++H'$ZBD^6:/X3RIS,08[9M2NA;8OPF4?T7LNLB@<69M\1NO
MO0P2.D[V8.,8H19J"VN/.+LTI@Y9Y40(0?;<!NW[=>.MXH3QWHR1.Y3N#=4=
MFW'W1R<5'2!.=@I@%$BRU:^PVG;Z/D%;"SBR1Q6=T\SI:&M.*J>@R*/9N!]1
M8X4(S<J6+*ES&-'D!SE4-(08D02E5>D8U\5QGF/J[/$Y$L%L*D-/:+DI5DFS
M^IPI98T]C^3VR6UC/%MW>;#ZZ$O..EI6G?=,/X3R&T(=DLR31-TOPL*2MI;K
M?9[]%@,A)W8@3>Z: +)6;G7( Q'O03?6T":;=SN5H2L[7\145M]8BNU]C:H;
M2Z"PN5;=>I++ G(>O+L!9=\@C\P40TW.@U7>#/%,>%.:_+W*Z?RGQ0SMNM3N
M8229]C2N=\?Q+*MS-+E<-YLZ+5J@95KT&$%F-<L*9UTYB>:O^1MPUF"</D'3
MU\/^JMQ!CQ6UNI55]]REM\%)YSLL&6UN]3K/+@0'<'KJX'/Z:8S971^MS?V<
M^LAZ-E?##2+[YP,*Z1S86@D%L)I'_L=M2*P6DDV9G"8H2VM,XZ45/A&)2J=<
MS?['@WP9A!['F03)L'ZL/38BRB0(]46)[F"CW2X8<92#(=D_SMR+HTJ3[W^C
M]AJZW+-/%835"<NJ)VZ?I=Q'4Q9A&7D9+MY53SA_=BA_K=_!7J6/UD<Z+(7,
MW',0BLO,VDI[[GQ06,VT$EFKAW5)Y&M;%=Q:K]W/>&,CX-H4E?F*-V32?.KU
M*Y\<K'W*=95PR4QL*2R+#^709V"LT"1NW&:<6Q9I3(-N(@GODSH-AP?>20U"
MCZ/KEX$^RH(__6@_;_^;C?D'&'H'O+Q_VU)K\_L?*9S_3>3<:5HD,5%8JDN%
MN$,18)!R554/N1CFX 1J>(]TU<]0QD!Z0@%\:K1I%1) 2A :/R, SZ6PF5(X
M) 1\ 0#^9C96EOXOT1&+H?#ETJLIC5MMFQ!59W!PL9KC0FMYF@_ZA7]T#5MU
M"E9);F]^DG?0-*\KYVT%Y^:(2#SJ(1:4"550R=K^[UWMJ_P9\4-W:T,ZF3V9
M4*=C28N?3AE^6<L<B5\T4-*E5G2K:X15@@<4'?F![F_X\K=-W[9%6"M& 'TM
M6TLOBVI'HSY)+6WF3FW:T  P0UVNP#:^#M-!0G\"):1, ^]L@=?\RSE)M0K/
M..-=Y>;[37=4O(])4*(ESC:Q .,'-:%'Z90FI7Z^;^LYBZSSC)6 \D-\4%6D
M>1"*[&+7"X7RSO;]>\&9DM;1,-@5.;ELRC_)H,=N#GVR)L2P3KZ.0"B(F &5
M9XGV\7H!JJ<_09'>[N/[6^S)TS<@,OY1/YI."_IS-%_?/64H8!QH["G6G=3
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M+=I0N8PA>0]2C#OE:[8V?2\']G3 L_4I%0?VL+O/G(.J4N&NMK]<%A]_Y/1
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MK.%G&3*Y/:EXT8[7E,L%5"2E'[_0D\:^%\__H."9<1EN;.6AEEP /#+=S9#
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MY,=^?7;#7A&P-LKGE'32<)T_V"NE&F?VF?@R3#6Q@G#G;:,N\/<W_'^ XLS
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M,$8'](3Q5WY1?'FXK>>XGD^7NQ!I?-@5>45Y6<BC6M\*//=^>O'Z^[W@=K_
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MWQ!7AEUPYG2Z&4;K"[&46Y294 R0G1A+Q=O-O^=7&T*3.A)*T?"(9A_;515
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MF^KU,^G)Q[RRWF>VC(YG+%7M%MYJ18^;E4Q< ?)UEA,?')P?9&PSH[DF"X0
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M]4T%YR(=YV/S^<VK!UKX)'L3>5BKJ8MFJ[",5(=P1Z;.6.F)K:YI=6L(["(
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M6S*3LF$ GPA[<]U5PWN,A<3!'8,$>*23<7QR<T.U[>81HP[HT!BO;=#LEB2
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MK(J.@K^V-=CDQL258W L)\O-2FC!D%HF?DOMZ8XGF[:J=/'5A[=J7.Z8,:Y
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MX:W&4G-069=@E5]I_#ADB7'C'1%+0#17*M^BHQSVNPNU[9#DF$I:L4C-,FP
MS4]1N\.?3W_]_NC\_<D]/Q[7\2C)*[\-UG5ZA^@H+IP'@X73C65CM5SL<TW5
M3!7+;19Y' OQA  -N2/5N1Q:J5KZ@-PHJ!U[:N'+9]HO;PU@JGDMZ@>4;'JX
MJ[,\JQ[PB$TE^3XLM+G]ZG5.@>C)F- Y1AC_(?9"RY$N$-P1"<4)BXU.AOKX
MDXLEW;:4*M2SM45:)<HH4F:SP\ P[!BNVF)H" !9E9>ZE10$P(*D  :H'P$
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MLYV8(I%'DR="72*BF]&0^9,W 7"]>-O0-KWE(C.F\V:GO-3)7P;AG,+&XM)
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M$,C/7$^5#80'P&#/H&'Z/Z=++W\"=GC(C$,VZXN5DR'M-/V]O]=ZR>OR>OD
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M;DF!!EPU;]F\FVE]RC2B04SU<D-9O19S%NL#MD]\0VBM"5VR=6[TOI:F0^<
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MHTZL_Q)Y/?"CO+/(5W[ Y8]Q^VZ#B?''@ /*@:#V@!1%=#L9[+D0#?5W&M(
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MWW$C@OO^'W$Z8DJ2!NXH)'^MGE%%FLA)C&;0@?IAM&K_H2#Q^,3M;9$IHZ)
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MH-K#15WU4?Y>?>G^1A@L6GPB+-WY$"DZ]: #::XE)V\T_&X#/VM7;Q(7_:#
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M3.3O4&QV@)&H<"71T#3PPCGEA6LHS.K-H:-SVQB4>LIN(1YKA2O<85+$H];
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M%!,RE_GE\N$IA^RZE/_LALS'QQL^X?U1;+4OGUCVNV6\XL^T$O@S8(93 4U
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M_Z]U^E^?D__N+NMB3OZ9^^>]U\_]W%_W:C^WH#_*4N&LL/YCXWSG?%/]7UU
M_\'T[SQ;_5>VK7\Q_3O/L']E8_Q/7?PUVW](ZK]]7_6#JRVG((%_:OOSQX^_
M*Y'_?KH N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y
M +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D
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M1J%$I<FBNBK"#YM7>CD]P23_7<TT).[-*A<4SW7-<AX>UJ$D@D-R57'DZPF
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MZ:P<&EJ+W_"NX(UEX(\M:8?9%5-N5A6 M_.?MNU$%+OS%*/,"&9JS&K;NTI
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MPF,CLG.B+76YM-,*R.1:^\:=C=DE,RP!4X(4"LG[4D*F]2&:CRM\"G6X%DX
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M$)^%NOLDN<FI>,&.\-Y6<4GOQ.FH))EFOJ778KY5MERADA[&1,JDN*N@)6B
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M:U%:P)3K?M7L7G)DLA!ER;T*DKQ4(G*H-<:08H33)F:W-!/+"2!J_WA^_@3
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MSW;CS3](-?6P']#K#=\3JD>[ =R^F[MB-?06&/K@VOW]LZ;K*UV.\HZJZ?5
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M<_N#3H.H+FC(+=Z'J4?)F9O_TII-D'CE]^#G\1>0JW3W%^!9X4%P]2^1-$%
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MY0L\,%UN6>@2W5Z+Q.Z/]SS,R_9P+%F5,@!%'3**WP%UP'',5>R/U'"N=?Y
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MK 1#F+_#NKE9[Y(NEK&(]?PBDY:"B0$-S4%2SBY.!@@N?9Z(=U7W"&-?]&R
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MC=/WDJR*6(ZY>](!_-&L"LA\HA5U1_'20TW3J$]/F3$U)2P0[7U7K5 N^Q<
M"]G[9]6NU*UXB>Y#&"\XQ@.E2Z#AKGH^,8?J,[TEGSCXP0<E.;?O7C^N#%;U
M7764$T1B(]LB67=^<^J$UF3.7LOG.]NL%[O*(*G[%]L78T>7]FI;BVQH+FZ.
MEIB_=^Y63J:RW(GS<P4+ 5N3$._RT+OM+C41GG/J)@DU';R!OGF&07G.KU^"
MN?SAN3D(OMK(SLZEG,#U4R\#94HG6NE=<#Q=>#V 7J:8N =N&WGL"39IZ4)F
MKZK!52("!RAW-F)^X4"'0J-#+%&E8D)4=E58GOKGJ\7$)M$K.JU? "&+P\:6
MQ [..=:M!9"U\%'" -$P)DWRTQCM?4XICO4S"QDQ*6(P0K!WT<PT&U/.P=#2
MV6JL#!>8GN)/-'G0QCV5G9PT UUKL8=-37;.#U?]XR,S!H$4#*GGQ,S !X?7
MWXUM=(<<VGM*"JPI:->N+:G6P\>[-J *68=N(>N0CA-<#JY"08<!%65-#[K)
MKR&G!BUT/D:.8^GXH(8XFF6.+H6?\\2&G"HN<FG\21^ Q)F[S>(6)R>S)[JB
MV LC0RIU-258F3;QD1MGGGV203^@M<;,"(8;0;!;VB'7+$<QK9<73%';8/#M
M9_/1^PR5'$K&;Y"YCPQ[R0* S3+TCMG*,YIJE4[C(4\M/U*J8'X\8G*F@%?3
M_C -T?/;S8&O+0;52_[X/2(,[V0(FNU[R[W6R[940A9YKU!?0G_^KDHW/_Q-
MXE(+[CTJPH\D$1;8;#=K$UKJ8%5"__GEX^^:\^%JQ_3SC^6VB-^RX5VPF!H\
MXX=T>:Y&3636K#@[:I:IE)SC;Z#9\?O2DU1'EY6AIBFWKPU+"\,_Y(;;Z1*T
ML:^@9I_"")KR[),[MKO>$SU);!X>J2-F*+'"H9ZS,HLYL8"1Y#0#I.3"H+DF
M$SN4-1K"7,\"9CP$+- '<\ZF6P;+RL<20/,I >=(C"J*5PV)JV+9&]\#BBF(
M4;%R)<JJ>F??Y*@WF1$O2AF2 =?SO#K\9&G;9WHK=-9,+_" ^I32 ]XJAK2T
ME3!O4F=#%KLA6)9HP)U1Z,9=.PG^HSHN^(L$-$V5A%4]"G1C;>^X9QELOTX,
M6P*;7.N+^WL5O;MLRNC01\MU@U/=)+>0.^M_ <2<$<D!;_9;!>"]B^1)ZCI"
M$AG/([+X?:.V,L6*E$W1_$1D#VJ@,+[!M<^E#2_$\_/7 QV7B4=^K;H(@4QR
ML>Y&_#IS#A--\8AD=#V)@1)!)95QFH=2V3-WV&AYD8@7%"3$TSX[ PEXUT,(
M>P4,"[;-\X\(*4.-CG"]DE*<<.;MJ]E-C#5DX3Y>2,KGD?A%.:X7'#2$K)#Y
M4>12(CD5T.RW@X3QFP.UDAZ9-10MPQ:]=%DD/D;-3I\IN[GZ3;L#=Z:F1$.%
M6E<3N.H[QU"C<H#RW+1A_EBU!_S\94#Z%;Y<G>"VSA=5@:"5"B]=F[J:.Z_.
M_I)%='UI#-6C@Q@ZGQT_,RZ<3;5"<3>9](X>MA5:27'1;;GW:4/ZU9_]GR3:
MJB\4T50OH"4.V^P]F2_>K;:CG/=L.NAVZ*K?[+*I-32%\L/P#3XYWI8F7IY5
M_U2?[[%<+-($>H \%CU"6*>8)?Q/)GU%OH+!55/6I"(C398N;5(_XJ'<:TO\
MWBJ\-)WVQ@MXL_AYXF3NC\0U>S^O,-'M^!X@CRE>4ZCA:X93I50>T&!K&L39
M\IOCBWQ)*P7&WMM.7MBWGC@Y4KGMK\\D76 M^Y[VA],\#$"#-09#8OD+?LM)
MK%@M#\RWPO'MXP[^U),^H+GL3RU^W7M7J!/O;Q\T.-< OA9'9$G6.#R_K33U
MG&WR/(3"3@FR&;;H7"B4#B3&OF#*5%ZDI7]"&J"!R2X9OX9C7CS?UP/U3T>^
M#+ANGHP;#WA39347;K]B6ZOE,9A41\5XCDP;"8">=,[WQO/Q27PXC:J /SI,
MJ<26A._,7^<VM4&'?,?&=+L^V2,[C:W']Z0'WBE(K.LY? [!0,[U[6CM@7%+
M-X(,D'>PA;M(GPSCVN5C^NCG6?M'&((1NE4M*".JD4U52E;@V^>I"]M'.%MF
MS$E)"7^2>AKH/I0 +:H9:4FHZ43:V4:&1JN6SMX=+=*G^]8'UBVR=I.N\G1;
M/^7W>QUNH.%$HU)5NL CP+V&JH?.3)?[6RT]RWDDJMX?(TD9[$KV-;-LV%-8
M^LPJF3Q',VW#-MA+=M]HX96!38"G;_!8AZ=)<\E^-12Q,2K7W"Q'!L OR/HW
ML\EG?P$\;&+44K.:$S!&?H3Q<F91*P$HM'GZ6;0Y[[*[;W_IP?[7' 3ZGX%$
M^M.9@<;G0+IW$VN:MG"3: 7\K"K,HS>73WE34&5#?GK\:.2N==K)V&I:K67B
M19'O?M9W^+W:[=;!P?9A^TQ^L4,=,SUU/;6U-Z73 _WE'$2_H,JEP# %#H>O
MA.Q&1^6/_5(HO'X7Q?T^;0G^"X^5A],,$M" O-HV#?M@-0H\&(K*PRGPDKHZ
MO)]J"%QB)QU;TGS7;#(Q^?ZQ;QL.&B ELY4%)(4Z#B.32)6_GNA"T)M"Y.+4
M8ZO!J'=6JZ\)4TA4*4U';;H%]-$GL\D.L+5H,18A)#87 ?BY2]7P)2+P 9&_
M4*C.D:ULC[7Z!'A&\0#5B310!(D@:E_;QE(*%PFYF#\N&?01K*=.-&UA[KE[
MX3:'H;1:Y/*0A .@L9TD%C@7&#HURHET,GF,Q)_Y>S$+]=ZDT=;:I&<NR"R?
M!5Z_Q]P?!G6KB @9)7_U"'C*';3:FKGLK7KO6'W[=C&RXKQ&,$)FL;1=PU2(
M?#:F],)*^ES.8+(J Q+8QLK,_UO(U0 X"O,]WO0YFV2X?(-?55</R:L28R#<
M]6%SK2W?=2>)$CON&#RZ,[>I??:NHE/3=_$:DQ=8M_==IMDB4C/;!L=8R!NM
M<B+,=SOBN=-'.+3'Y*,K52"+]IT\S;>M!?[\'7]$O+WO\MWS!=Y'\^H#CNN.
M=]<R:J2H^6MK+NG W%_;2(LEN[)WAW4<3ZAS/>6D#[S"&<T^#4M(!;*BEC!6
MMD+&38(W<RC6T9#>.1AXR9/C:E#YR223O268\]7@A:#9E%8\E>*<^7NR.D%)
M94'28K)NL8&)Y&CIUS.P,"[J2,4&Y<R<NG(.ZJ?1G<@FW,EU^MS,N#WP$RLE
MH8G<?"]Y'623<X#+8Z),!+XV[]?)^H9J>Z/REMJ2';JK6=^4M_DO\F0HG+5H
MWQP6TZ!;OY99"Y>9^Q@/)".M)78Y1%\VXQ(Y>$D1@+\2VIF5"/"Y^Q6HY/.&
MBJOW*A?4Y]'M=K?USS12U-^)-NC)G7C QIW9ZY@!@K!-S.&+V*1V$QUIF[CA
M";V0RXUD6H85C^/N6NJNQJP/??WO29KQ.>L@&>#UB&<@HWK,@_%BXXNKR,EW
M7V05[&<FT0Y[W8L6JH#E_N$"K91?"\Z:*9NM%:IQ^;3R%>VXV].EK+@8.6!/
MK&5[K;Q9L-R36CG^9W<@.:& AG,G?MS!) \IB]8Z_BRZ/"@1+BS?Z6!*BEK>
M4VG9 F-NHI "<Y?I8UL:MYIZ><KPIZS72@TM._&PK>NQGDFK0[4$*#.7#IP_
M3I:BEFU\2E/%D.6R+P!PX3,M7SPA<D[CLE<36Q'D ]XL7_/643>9<W 2>!S=
M<[@<INSBS,#P:-DQ)23'L(]8"V1]FTG/DLE5K>0N2F=G!S7E D_@EZH6FA0J
M08H>U>I"7-IX!1,:C@?(+[WA VF.RYY6&VLK;<'F/IT$B\(0^_J>4TC%J>Q&
MH;Y*G\V$Q>LZ5^&5+HNX5Z26G.H,-BRN3%*R+<-2]#-R;4>>7\+=N+L]$8@V
M.^C.'D8_8'TZT^J!7LJ;E(AI.>F;0$*%KE@_E=A0X!+BT--CO-N+IKCVXTE\
M/1M3/:>3LZFE\>UT4A>_%"H;,KPDIW(.%874GY \\UJLAB'J*@JSM I";<7F
M^:>CWC,'A)91;S_>P>%\F$NZ\C*7@I#,6U'8Q%1>.].YT@9'QX_DR)JA&IZ;
M&S>>AF+C2,UI]X,=J0KEHO/8R2I/SP8F<^1UA!+M75SDFNM _2S M5A5L:;M
M\:]+7;>#^B55P/^_3<[_&=A)FC]<&9P^\*$9K8IKDH1V22(OZ(V<9*T>'29D
MQPB"#ZQ\??:4,[DFAC8TQ N:FQ)Y#7OD5]P.+1A*H>:%J;95DU;OMHS7U>0R
M//T(01J.7S6WP@J"BQ2\JY][?1@='UWR$;W,YZ&9EFP]5@T(L&!U J80:L)+
M5DV?#+A.RR=^=Y_M.RJEM&Y8D5A7$K%9\13Q.!1G>@-ZG!-/W=['KFV9\GQM
M;X9/C)^0,OAER4=B/Y5[4/U!9O6A-(-+@'EB*A!B*Z#=SIX,P4MT1?3C%XW9
M[<7?SNJRBJ4^K/+W*AD:'I[_]FKLEXUL4^RAB="-N54U3\<B[K6M(W&#T\]3
MKD_9TM:&+Y77I3X+K;H(7D@*6)G\JL8UV8A8UNSW=K40B/7*@R:Z:MAI4VS#
M[(]A#N3D/^(1/-(Y];H!):X]$I8&Y?JU6%M=1E;2>0.L*$PF-4"[+4/L/7=5
M2U2O+R]6%,@WEPS6'$2B)%"DZJO S(/2L_9#_;0G%25 V!;HRXG8.0N.W")9
MN Q1LCKOXL8 -0_"7_^MA6GG&'2V'8^>H;<<]MHS@1^_GW9C5[19!^L)NC2[
M3[+M:$%-XW@(Y'Y8_.X>-+22+&?]71#8S++8S+Y=W?;VL1Y6D3O7Y329TF06
M-9CW9 4+?^G5Z5EC;5_:EZ\NX<0%Y:(N]W91F$Z1AX_45TC#9EZ0\X/JTT;T
M\F[L5IK6[Q4:SW.") N+GWE28&@94W-!%)3SY!(,+J[B*AKXD: 5_Q0Z1)=Y
M_7"*$"?G<XTI)Q&S7Y3XXX5OQ>E220Z)J%7#>:"!7E[3NT%8?""<&B@ I\('
M=-&BI@1#H%RK$RQ <J F-=! ,RS1<5E.7"+-X/002&S%+ICNV(#3AO_>ICDA
M(H@0E#' AL\A)?Q@WSJXXY&7GIM)U;J*G4NU2>Z.]"!&I\].=+(..6D+KEWK
M(CMKJ(@S13!&R:<_2 P0#"FQM!:3_04R4<55_J]MC;?I2>'9\W>,H2?]<"W1
MX]AO5,84 IQAV35/N?=&G/>2VBR#6S49O":G5'=R DGEJ'-4@QVW^_T1 3.;
MZTM6Z[<!#$[[TE7QPH(O#=23)$^7(&515XO!5(RX@3A3#Y2ZDF7CS=H(2@@F
M'(#"%A9=\-D7-7D6I">M62/AO4J.*@T8P@PQN8\O20>-206B2^DFZ2#27H(!
MHV:@^2F+Z_)'#MW5)&WI'CXY6](_QF2*%_J 2WE/UVT3K+%IV[E"=X:E?P'@
MA<I805W#FCIX_.N?"?8;AJ<<$T6'33^O_%R199X,[XZXC%GDZHQ" E"ZX01T
MK]Y-+HCN]*?=1KIJCR.^TOJW%#,90P5;P4RRU-V=MHV&I53*.%=4FJC]UN"%
MK.<7V1I[H4/ZX+A*N>C%7+38I<"X$B&R"Z )7Y1/6J]M>+>*^]M\LIEA6X:H
M6,1TW0FT99M[@:BOR2/* Q[KDJ]R2^J.<KWY-OY\R#KB,@#57.K?=%4!X$]P
M@"KPO&Z#)/4>LGH4>I3*+]I&\MBM\ZOL?(Z?A4>QC#BL;D%2K=_G1NEK[9+0
M^OW)3P8I*@IKDK<&H9=-CDV7?D(D5U)34S,PU8$L;4"KC8.F 7Z3-16<Y(QK
M3+;!;FO^IOIB3Z);M!%HHH^[E6C$#VQ-C%RR(BZND0A?J+6 M"ET=?.<)C,7
M %W[ +PZC5]WS!?50#0./_0:/C>[=FBI=\X(8A-I&;49Y6]T6@%D<QDX2:3#
M//Q,*NW$1\@!)U%'K$HU%2Q7[KK6=GV<ZP2Q&0IIXM*U[2G.RH,,FF., $R)
M]C.0"IS9930O6BB@;*USL2?E^PV[^7\4[C @HW@#$J:3.U;=TT2.L%"@AY"B
MZ7>CBE"3X1PL/[1]W+WUK8W*A[&$/^;O-5FLPQ/V0<+J%B>C6$&;S_V 0L.B
MI!CF7WR#4\..AHC]V:Y07D678EBH2LQX%U.4]O,&.9K[U,V/%TTW3"KOIS.W
M?9H/47P9,</IJ&?;FTQ#IWH\ *]Z/]\#YD!2*=YFYZL/Y/5]]'2WCSGIOLWE
M++\N%-U]\?7ZF7EQ2OIK5&;U&DH,"73IK-'S(1CAD_ (L)H<6QR]>Q;VSX'S
MW[J@QEISJ=Q<V)149:O(/;7EHK:^K>,8?X'.(]K:>::_F10[/=VE'L8P M@=
M2>.)5-E'C\:L^;CY@?'3!A/P5[;+XYFS/K6IC_U]<OCX^B]\3'.Y=)I]ZV@>
MSC^_FT)?"UA[P4AT,+Y5O:/56A(K]ZJOD#L=9]9NJ>GIGKX[I;DOJ8!LE(^^
M.YP[!8J<L&VN1U'7LPXFR1M6N>C]*#\4&9WI2F,J-*IPK24E:+/ ;Z46=/BI
MDZ7ZTJ#%D4\0N;T/IU'3AYB\[S_TH2B82-=QV6F0J6SI9A3D/_[N[5HEAN.'
MM1$*20TJJ<,^>$CU@:AGN"E/2$B]:N/+](39;G5378('&W0]$ SJ2OYG"GP<
MQK\Y,T$O6*J"BW%3.IH;*<9<P846M>.1\.R7ND_VL"T28H['Z.7&V"=''.0E
MP$(U8!S#K]=[;L_V=EQV4"_LW8/XO/$-2ZPEQ#,LH1OSC34H'BGT)1X52(:%
MNKHZP?A56_MK,4L9<2C1-A0E=U+<P+\^$LAD&/H^<@(S^R<SY^XQH5_%Y-K*
MCMYXLI@<QT3:THQ:U$G%GJ!!4M,M6N]JDKEDRV=.$CRN"Q*-(CLH7Z*'8;&>
MY-3/2Q7CS#4D@:XPN_YX*'QDK70IIFUU$I3V\+:M_E=&P76=*!A;AP/"L16)
MJG78RF]+2)U06!07R_ZY%)_XBU4?,91D(E_:W$0LJ\+N-%RDY%7G9225M<\T
M??&*&DZ@$F*UD(*L8$AP)&4$^15HAZX=N4YCW3P*_5-E,ZTO_1O6+>#'J/4N
M_<[*!LJWH!\*DEXO6)D'A!5@3$PGU8)= F(.>)98%NTA$BK4AB0";)OXXQSQ
MZ >&D3V!]#7XA/ U=P\Y>JR"9,F=GXT\KU6!*50TH,+>"ZE*-.2W:"8J\TB%
MLN#)H!VHM5B*OJ%AH,)]/*&!D1FRE"I% Q"P^ 23V*K#^%._-,DR]+4! YS6
MR#\?N(B+F@CQQ<XV*0SB#U%G_)F9;>/PUC;MX#(5#":*M,#(X8AG:+_.==9:
M-\\V&#$#BT9,.5C- +$D$*RK(S,8SU6<1T9GLH&GPD8QD+$7<D]>S3"C@DB!
M+'7A#/F=$S"439QE?GVZRQ#TBRK^:FP*@R'\OFK3D7?V;?",&N.URLJS]N5)
M#;E1\^N]R9,/PH5.6=)F--#9?E9.*/>V0T)T@-7XN^GJ;]_I^1?OW9ZKRC!L
MB-/0HD?BAE($^#D2+WN0)GI8%]0QH]9"O:ZTSX?3I5B+W[3)4/V0CS;K"\?A
M]RLG&P*GC56,+/,)Y7)\EC)^"--'/=UI.P5@R7H?EMS3RM#TL9GN 5F7M!""
M*N%5- [P@2>9B[2(5UV JXMX[M[0@R8WRSS(1Y.FELKKF*=&,5L5;XR-<_.I
MMNNQ'C.5/U)E_^S!'8DA2Q$?&"&U=<TP$WUM!+^7E(VV_)E#T\.QUG;?V<G&
M)'POPIC0%*F-L3.'U6;4'_4W M^D/_[:Q*I4A+N[)FJLT7X0P?RT^X8W=BSU
MH._":/[E;2/UBO/LSID.Q$O_EKOPUC,,2_J39"MNM:I[VK]B<0V$/QM:[&SI
M6B-LYYR[ZK$(&[LW>LK#S^A3WH653]:=\Y3V+<Y*/KPWX:97'08$/DNX#KGF
M0C6!M;>&P0_/J5713??'<F)G'_I$3?H(70G:?BO\$#_^*K=;_9)[Y=O"<;K'
M7P!EV-#E6&=(WPN+7]UO\T_"DP?.OFU]+YTQW)=YNQ/T)_.7@=OE+[O-/1NH
MT-F-XFN>>&';-.E2>!]Z<R\4^]8[]/V?-[]):]!LU$$II>4AS\BG]0=QR%GK
MUZA9]]@6$7EVE VQ)2"-VN$.XN/"MZ1">4V:E)BIF2Y)5Z<>7:M#"ZKVK9ZK
M51BC=21^AU!G;DMX"RYKJD"3T]KI.TZ*9.!4";:8ZO+>M(I.>9Q,DB\A+T1J
M/;#I3.E@W.M)A8OD&,Z#3 'P"9Y.B<Q/45MN*6#+%W?AVE9)>R^\8V4A60U)
ML@J1N;C)!!.[UV+JXR &4Z!U<:I#355FM9$  NP+[$30UCP,@9Q[Y)-;>Q$S
MZ$OA/F0T\WK,K0!CS8,"2S)@^7I//7D@]08;#+@[D(@FV6"Y#W+@1'W$&!T(
M#^-F;YBG*M),AD5TPA\,. I,^?Y(\B!MB:$_H5#)9O'>&*8S!:-B28UN+G>.
M%;W$K?63*]R7*L-F_;DZ$74<11$].ZY5-XVOHI:NA<NA/%U8VQQ:EL]IU7)\
MA3\O$-F/%&P,#B)L).J_L^2=<14_&1CH'G3/D\>WZ#Z%1]5.<A9.(&J\Z@:J
MMJLD+<:=14I=BZXUX-C?([)?J N&2QQX^1/>(?QDVM<OO+^F2H/X)4J\SN!H
M8>O\(,02J:'_$R6\IZ9C$Q5]#8IV&ZN&[R;WIJ4"XVA]A#'0_E^**[AA:D6I
MQ>FDM %\SS&,V_&DGN"31WY?ND0G>)Q(ECSX'2A N6(#-"['VDIKKT),\[9V
ME1R\X<1V;CTRTVS#M%+T$-10A?MLW@-"5>LZHEK>1ZZUV6:Z$TVEFST!L$?,
MK?5>CW;6C,G<7 3X'"&$L;/]8=%Q0Q(1[Z8&6WC>&CLA<)]CF)8)Q!G!)SBD
M2E$%67NDC+#U-YB?5OE9+A365E0IBWM<%A#]N+2GW@C"2<W*:?@(;&84#G>=
M?WX<FT>KAEJW$")N8H:ERI;J>;)\V5BQ[I!#:_2SLBP_(H "7<R3J?38P7+O
MK;\/^=#=02S@DBR481/WV=5HMZED;N&EWEA7^5=@67G[4[L3[=D1 XK?J[KB
M\"E#M2R947-1LJJAN%@W:58*(@7RA#HIAI: ,![#GL+UV+Q56'R]S+JGLD&U
MO@O_M<I55^8?Q(FBP\6IJTE'!S "1O31@=JQ?$KJ-3DF^ZX)!'SXC3^=$GME
M]!W%Q* QW37&F%BO,Z-=P+ .W!/YM' ;W<RMT1N^\JTRE/H*JU_(27E5\G-A
MYU;B1ZU-MV\Z6M:.V'H@^X#A'U?QF*_;DHX$$F<"F91'3DOC^3&SEZ]:,%CZ
M0C89@A/\X5.PY+J4=-4?'F^>GD\3J_&IW<JU[Q,"N7;!QQ/*OS)%3X '3Y;A
M4;I^)K<6B8EX$E^.I<:8\ZUM)/B':SW-7$54]';Y=3CU"PO.TU=MG^'627_\
MO03U<.,($)CXB:E939Z<2?"]Q )<3RN=^4SF/%:Q,H7"78@3Y#;1M3W4=H%:
M>%4*_ZWU>"[3:OS3<%]_#-G5)[,>1!,IM_UJAA/*R*O>!;=2>]!GHH">&([7
MOL7VRP!(\M&+G*P;_E+>;'>+4!^TOV,A0%CAONC3*NCTC[>2'[,GB^5N*_N!
M;LU%L8$D\5Y'L[N#3FLE'6XNEA/TFL\'F>CN+'JZ96_\_]2$!Y3>:VU(7A 5
M.B4#ZC6OEP>XGB8;%R>8O%HWPW[3=?@+J#_>+F:N__(X>!7^%^ X,3 P:JE*
M?Z/JROE>6_H?=5=-&S*KS5KSGIE8US%<XCTC:V.4T!4RBE_N2>9SW& N51!I
MOX9UEIQ4"P/,G0=)0&-^1MP,'P05A+"Z!)LQ L'OK*K0F">\CM>S_>'@Q!0=
MU\&OZ^;19!;N]+K1'YMF6YQQMR9 /CO'1:0.#^#2P^YSF!O)#S.C4ESE6@NY
MU/2D(FV@$_3PF2 48K3[4'E+Q2XW(PR(0$>,M8 FOJ^J)Q/0Y R>\>)-\M(Y
M-@B=Z8(^]37C;#-7H;%/J!PE9_L=P<'I$R&#G_\E=\K"8$)=ITJ1ZY8@7+81
MD-@.<0PI/;Z0SG#A/.,U*F-FE%:A6FNAD)Z:0/1?G\O]9V -6R-G6M^MZ(VK
M" 6)6FSF6,MR[?=5Y6@:R9C!,Q&.01%IUP:!,Z+EQKXN\FT>4T&_+:)DUG^\
M34]SN*[,BI("=CP_3NNYLLX"(JVF(_9?)J6?0"D>![V:=&,Y%-W5NGJ;]-TW
M:ZJT)55V"9%3"?HW75P,-HRX2WCDKDT>_(<LM]\@SPT305\C/Z:<5/ ^<C,;
M%'+G\;%19'S*+T^Z!I+\K9Q>N N7'58?%TAL/?^23>:O)49/)0?J7I41[?D+
ML!@^*5FNL@6G_ 5 Q84^-*13I*#2(X1IQ+J%^69&ZRU8M18NB?_I<ELO6%4E
MI'V^--4@PK/16[G%TA=[(_26D95E16!,CK^!%Z;"34XZM#%ZYH!6;;OZI\LA
MA^K?^^8DJT*,=PN<7#<(TO4*#/?KB A0/D1K27D4OR6T.!JK5R_HTJQ\7YLE
M,W"A:I]]>5/S2,]YK%+L8H$5N69'@O(-^-76;$H/0#@VCL(UNNV 9[AX*4:Q
M=ML6NC1Y'Y?;VL7%C*5,5X'#$N NKZY> =OF$]WPMHS=(+&TI\'I9O(SD1HV
MJ_G!3LV29O5F%4HKA(V5B:S6AZ1Z!45_).I$/H2IO3&G=C7&_PT-!_\*/_C3
M@;S ,!D][Z9JBZJ>%2HJ'!?L\G8W7[2F+#X)CDP28$HG6E@8YFVQ LL4"I84
M=N'[RBDQ7RN94]G^T^7:[1UH/]?O?;/"I8Z1PGJ%H5:_(?G;TVF+N-&MKXW9
MNKCH5<7+ZX51Y#(F\772?@Q<,[F$GJ,B*DS[]]8S_T'@I-J*PQ]BG:+(N@"3
M,ZJSI:8^T\ZFO% 9-4V\>^OE-^-ZH699JZL@W'K<3@= 16HTZ08SY+_I\MS_
MJLL'4XP3Y=SL:?QC]/XWWMXR**X@VO>=D. !@KN[!QO<W=W=W6%P2(*[.P0(
M[CZ#AN .P6: 04*PP""!X 2X.>>^5Z?JUKNWSOMR/W75KMI[=?=>:_U_J[JK
M6R&>_\.FP7*:I_5(,P-RJ4$'*=91D ;OG)8+;1RUNLH<K?4&X_)L?M?<"N\1
MF3\=9._(O*?5%&8C"BKT5S5C.LSY#RY'10B=H7N?:OTXM!>V7S/.1".;^W&I
M0>)4";[H3+0YT:P.B^-1;VUC"CS\%T;9O+87%BEA%SV-C-&"U&S3"U9\Y"8*
M;W;Q6QJ8=.*C&1E)9,+?QKE,+;<[[ JLK/,G"^,2KK1"-XV6G-V[^I,>RBW(
M!HXQFFNQ#[N:=ZW&.^AIYZ8<;"J,=#$+7GW=D=E)F'!_,D/X "E4[C<+W%-I
MM=C)':V8?)39?!KRR.N>K_;T%1Y(WH()&_G,ORV+/A7DF@(B23/_(F?K29YH
M_#>Y?.<_N/SRW.L?E^]"/#TS3[U05[IJC*<W[QYLS'G'&:QJWIX6?T32.B_\
M@R5'7@=5NYV*P.'):-2 ^LJVWT O\EJ^CC$ *6R%M2DTLX^8W\R.F7JT_HO=
MD?98#*I-(_W4P4"(':R.<793 G*^&3[[\^OZ@W7K*4L"7UMV9BX[X?M$^,29
M<,RPR_BK(XMUPZZ_H? 9@BJC"2L/.O?B#_CO%10^LLJ,'4/:;'0Q K@*&&\;
M'<PY\0MC\?(YT;Z53JAR'I#D)4Q/^1MX"(3-!2L41_A 6T/ Q\-M22C+AJLK
MK%L5J]F" 1Z,J:)%WH"[&PBV\)K^A;S!CSS%KN&PD_ #RD)1SV/"W\W?=DW^
M@;E"N56!?@8/./F7G,(%)N8;H?!V/[W4A)B,9XM < ^+MS!#U?+>=JE]$A!2
M_.U$RO,M>$7@P+92W=39B%CXL//&N [3,)\QL-$D6R^\YAU^-F>7]N89E=ST
M?X)YIDF*9)W<,$O@!^S]"ZIY"S@8BA4O)I3\X>F90/PN]MRR8GH 'NXX]9?Q
MM\# SGG9"\ PM&3A!?!S(#;U!2!Y(;@A.2V:_B?P!<"]^D0<N;DS?"A:4#+C
M\P(8NWBBORQZ 3A.W;P GOZ_R/SO?Y*Y'UH=%9FUW(';=/\GO&QFH:;<CTVD
MV$F2T4\,E;]%_C)&LD:?C=G:.^I5[G>$CJJ.&48W38^#TW6< X7.?SUGJA<4
MF@6>=K.GUVRG(N PL-!KWV_,R=D++L:S[;SNEH;'#6;2EL4W?PPX00_A)0T/
MP=U!V]&].IX&,A?,4$'.9@ML&TP>.R14(QA*F7K61JVFD/(1Z.'C9:-26&Q>
M#)A>PP&/+&:I4=%#M<TBN$&M3X3-;F+QHMVLV]I_C71%I%8?J:5KC1^JK^3P
M=L(LEZ95J]1H>F3FZTIHF"$S,B%2)__N#Y.4P;Q"TK96CQ8B9*VZGAH,-*W1
M^-V3X$=;$HDCK=Z#(UV\ ^LGD6]3,75TXJDIPYS*0\PEY03 @<\(#Z60XPP+
M8Q^9!>)?O#&%'CU\7BX5AAZIB9E6^_TW=L<"W7O*YHM%/<<4KS" #1X SFZ&
MPH =1U/OMD9';K+V<;?@"[_#!F^ 8--?50^Q"8Z ]K$][G<HV^U76'$&,Q?I
MY.N'1FA[<9X"6M3:*YFCXPZB;G1R>GB"2HS6IKK0I::^W<I<VFQE;QYS:ZRV
MG.4#:\,4MG:ET:_?&[!5]X[1;8DX])/][2L!I30 MI^!GP;C16?OC*%VY"Y0
MWM8CC@J;*F#1]8=2%&W[U1P+V315?&?Z= R]5Y!?G:C6\YTUOYX.?5!>\^VH
MJ+-1JAJJOHM+_RHY2?JIXHC/;2U%\4@\=UN[:,YQ7_CWWOB#6QA+,Q\Z3S1W
MA0T\ -6RT*U8VIUCHVL-WLS*<\^TFW#3146? 3[MF>$XG!1D:LW6%UOXJNW=
M<5##=K%OZ3.C./'SD4I]ZT"8BJ.7:XB ,IIKO7Q!L'C$/(3AI_HHE8"JH1)V
M'@=KT@3.IZ5:WD;21%$LD=R*/:A29SR7 P>8-\9GC>]]+GG;N@)G+FA3PKW-
M'QE2Z+/KZ<X+H\[P0+. O1[QT>W>N MJS-PRMV3K$8U[ 3!UK?OJ#P9>UG?=
M):>/WHA"0O+V EM6W>] 'ULIP$_W_:>^-@.W.1/AJ/**!AP2*%]D*(W>$H'2
M>B6'_+/JV*KLH*J,G?LC&JIWJGGI^5$\O<Q*HZZ]\A)N>\=(6SLZR)NM.3SW
MD<<[ZZ<90%9(G!O';N86V9C)TB;.I2VYA@!H&,GYC$(V_5LR+#>DY]6&Q"/)
MV,!J%_CI473KL. %L'6I^EO"1:3YU?-:OG$$X7FO37JBY* JZ0B'^B-L\Q(J
MT>1XH%F_%GI / V*D+.Y?30?*+POENW=V(5$0/Y$<,_G-L>Z=@ZD4(0JW7.<
MYY^'YT^?W*J7L%[V!+A"IKT5??>>;3]8*DK<!GB*W0=]MOD.I"?:H(H(,3N
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MJ\+_EQXF4T,_Q\'  ,I7U!7=CWQ2+3&E:PK@5\-$N%RYWKZQDPGQ9DZ4!*>
M;<9W(OR&RF[ 4"_G;5I1ZJE-5>^JK_K)]N*[P3/JD4;^#\U6>J!OD_E*)\B?
MAUD?"C/U9-__4&'/F^?=8FS+O+U]?@',/]H5_T#H;_!K>H D:F'FWJM<UV[
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MUP(WE^F ^.GG01Z5H"!@RP2ZK 8 I &@!F2)LZV.\JDC^VP\N_L]84P9&>5
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M@X2L38I=?C/G(=%L6I-$F^S)2%OGVSOOH51-[AIHH[OA35.TGVXP^C=2;SF
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M2MXIA]/N4O1?CB5OQ1U7^WWT>D:'NSF4H46Z0?+VCEYA)ZUPOHC4LFJ=YA_
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M$#F^EC!N=L@NN[5W[TP&QM2S4X(WB=]-R5[(>/WX&\28WS_N*/2H97'T.:E
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MX9Y5;A6TB=ZB\REU^1BO/:?9[(%_*2Q](]0;WB,-AR/_D#!!6QQ1)ZC#%\_
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MUK!4E%4LB7-AY=0N;T]:9.7,WQ)HD5<;Z"49@$'B0$A)+'@QSXHD?47EV<'
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MV_GVG8 D-#%A)5CPI#D=)^;W Q]-+IW[NK-&WC'-5%N,YLN=ZVJ71R.J81F
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MO])^W6#LN&#E;XZ!<NOG?L&AR>+T"O'H7WUM7F_"#[F?P%^3?2M[H<9"N?\
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MV(QMAACRO7*SLL J^U6+\0'F4*>).TP-7"M]YU(+8M'J!).[C] ,2=JK_HO
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M2,_*^M,,I57CET'98^&X=^.1%;NQ(.MP3L4=XUD9'DN77>KQ]U&&"/<_OB\
M6;#YB,^Q@ =\>SQ+-A]O>\GI(F!=[8 E\O\2P*3S6M8MEN34=*)GB>;N9-<3
MDIL5M'JT#\QE%W2XL]1C]5\CW/Y>PW3!IK%X*W2MQ%_K[0VD.><WCI&<$X0Y
MIZ<Y,N8)!"!==4S1X-V4DTV?H7CDM;8>A336FO<D67DDOGOC3BOM[38$[/R?
M,<GO68<YK9GO%B2>35/JPP0S"- EV>D_I9-)$WS@AB\/50$F7 J-%TO@DB:K
MPW\PO7>QAX5$Y<-LWF0GQSNY^ ,LN^[P)/?XOJ6[P8,DV[[_!K+EE;^MXGX
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M    9S,S,C4P.&<W-V<X,BYJ<&?LO&=8D\W6-ARD66@6!.F"@M)["01$FHB
M2.]"" @!0@M5B.465)JH@'25)C44Z4*P$9IT0F^"M% "DB"AY M8]MWV?LI^
MGO<]WN-C0:Y<LV:M\YQ9LV9=D_P(J9\T#F"ZK*FM":"@.$ 10!$  ) 6U1.O
MWH#YP+QOP#QXI$3% ?(7M76IJ !D40^I8S%4^^W,TXX+%W;;@)5ZYN< B1(C
MSWH> (#\3[G;=_'J;A<%W3 I>S B:/R1*:W+/,Y*>G*W3^WY;A]3$;E_[V8/
MI8*6/VY&?=U4B]9T%W;7G9I63D.6GT"HW[6@BIO1-#&9,>GX<;]K0"6+YM]M
MK^_Z:LC&AY$MIOCC-7=]?F%JFIZ9/HDQ5C>^1\:EN$ E3L-$,TZ#HQD_ *"^
M0"U.>962B1) "3@ H!6GN4K+0_.(?!7?&])W6%HR&D365,N4BL"?M=M13PT@
MF^'(?]?)$+M.%VBOTNYY +)_6?^<&14_6G/ZQ[@;!$SBT)IQ7W:-KI/;\;LW
M#M*]3XOV8J96M.O$V_'[N% (_",NZNNTFG&$&?(8*#QVD>5H-:=_3I5*MD&
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MS7?,6[NWY/WV?=1_%ISR;O__?-_WV-SZ'F? 7O*? 7Q_?>]3'?\9IQ_MW9D
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M<WQK,]*6/U![5JZZPJ:YOL512N+9LDT6,%ZY4;D@@75$27*^'^V6E>UD"EZ
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M#]*_W*=<09)/HO.,IQ\SUX%-3V)4<)0)Y]O>-Q'?;$:-)CSM$JR8PP/478N
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M) //S;4U(K.<W(+;W6J\!PH)D4O>**>E]6KR(PR1L/4YRD9@(/!J\UAE'=I
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M;=Q9_G-2TK)R7C'% N=EU-0U+UTS,K/W>_%60\O4\8;OO:?Q*V6=$V1\+@H
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M,XB3G,C+&PCE=$Z96@5GPUR7 ,M6CNR';"U1I7#ID;?/[%FC.,L^NX*TH\S
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M<)6H>>&+!6NK)#'%ADQPAQUXXZ-;Q%555^&7=3V9'(1#!6<,2K1[X3C]MR1
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MIU3G]M&5\T':I!P[K8N#?UQ3/\Z]4)(NJX:O7T'OLI VRK.Z://I>_2ASNV
MKYLA.RK?L,=W9OI.2[8I.&RI# ]_RNM_$U#:[1=H'\',X7WOWI+\6L$K9EE*
M6+SKC%MK8O2YBG=\[_.5T@VA$1)> [$+,GGU35)4WKGPWUJ(3HMN_4F*_%/1
M0N<(RKTMKZG%.,3S*PY/8F5"Q>Z.UP^8$3J;%_-Q84MT729VSQSCOY6Q9IME
M64<9&GU 'IQ;^38Z]?HIW/I;'[8N[>:3N2:YF]/##_M]:HK\&0RJ\OSO7%'J
M@N=YS2_"XSQ9;EB[$H5:[@NE3!:V"TINQ"WFE*#O"3" '"Y-*04-A,IW2?0&
MO:'8., XS[@*G,,[O95N-WVV-&RI%.!=E8WFU'_NRS)'Q_.,_=PAI"=]:?C(
M-.L0Q-'\-FO5>=\7BX*OSC[]U&!]Z>#C0DE'O?/I*98=?;%K)8-#X0QMS@I'
M6BQ #YXT3=CT3CB^:))05F2T,L$.^\%,)_%5>DTMQ0U+2ODUW/(Q[,?1MXJ?
MCXZSMO#1?'IT/L_!7-9**G?Y+27V*_X;$1%MRF)Z9+$LMG=TN1;'\^'>LG]0
MR/+'*/&@NK&D;93WT%?<5T0T@EO.=RG;:)YC3%YVMFTE\3Z;BA?8 G;F;N!
MQ7%O757;ZJ*M&O:SUD\/]6>I/F 7[\.\BPB0.CUXH)W[TXV94./K8&US_..L
M>H7.7F!8MNWI-?Z9"1$Y=M\1:\Y4.4B/*71QI-<)W6]^,BFS-8#OT9QK<;^&
M;VS>@!EREDYPJ9ESRBTXZNI"7$L&@_@4J*!9Y(D3)Y=*.@D055QC^.+*XMT\
M^$YF6,MYZ@:)%('7,G$:C YSFZ[$ES:(RG(]MS*I[47DRF7ZL4*)*\>O6T\-
M+'[0L!QTN\_*N@9T>9C>E\_7D@BWW@GJB[Z[@8C&K_3>&E<ZTP:7E6O&83EW
MA,'7O>1.]/JPIMYTLU+4GPT=,[N1[W19H^E]]!.E*(YFUUAT4_R%![SM7)'&
M0".7@2/N!]5CY6?'T',H["3QZTH=ZJ;)W,9]7+>3F8.%@*2R8D[)".C.A"*?
MO@YZ[+I2MQNV!Q[L=#HE_CBO'=1[.)U=Z:';TW=@@D-;1D-Z35%YM)W^J%TO
M\$XYHU:!4(4$@Z&9ZR;!82MFRCT@U?6RGM;#4&+)Y+4IJA/R0/IO.VR@6X$M
MUU=VLCG>CO=($WJCFEHBV0Q3H@IR:=[,UVQ5[*A,[H L9149!FNXTY&H<N;M
M!;; 1C_3YTB+1]:6FK\QF0W1Y'2[QKTVD>QWOGNK7 K#?B4&XY &&PWH!;8&
M H$V45'I!<7W'-@9;<<^RV<UM<@P:#L1TKL67/E!=*W1IXJR:PIJ*#[7-PLB
M)88N&:98$_*JDQ[F/!)Y-3-@DNSJBO1QTC+"UP =%ATJNP>B2D?8CY\;,T>J
ME(7Q*3 VJ?;,M5I@3WS$A[%49*5]*#PODS /+5N8!_)-F<5)V(7W@:L85)^4
M"I27EKD^EX3$:G=V]\G.CB"EFF\"-;7>>%]) ALOIG16R]+ BLH*XP?E=SK;
M*MX(V^>)595W#U$>1/6LG3QQPM]12K60O]-^7)1>QVR6>5$^Z]-Z6]3]4?FU
M;Q_DWRFQ)JY#(%]*^I2 Z,J AP.6)N#IFY?I+"4;O[JX+JE?5:?2/G4FZ,H]
M]<LD@*M/9C25R+=/Z]JSL]B)=*(7E $T#62WQT:T2]Q.FW\C8'^]1DWTV6"5
M[YM$Y&# @9F->^630>DRI5Y2BV'<X)X1TS,!TB:R)WO*$%QWVJ[0<K)CZ1OU
MTN2&TGW=%M^&K?HI=ZVLDP#<'@RR[L(J''V)I1+WGHRS$9=AEIBXW#%E-"P;
MS.)UK[KDFT":A8"_A% FG2T_'T>8UBH)8+NYYH?E](N8%_&\[9(OJ/3L64CY
M^^(W+"SALG8+_%KHE<O^/O #\<HZ:;RN<1?NT*0:)&<J&'P)W% (YN14#OY^
M5%(\A,M]KO>Z^/$Y.+YHJCU->&F%SNSJNXUC&0DC\1\N !JO*980P,9!Y,PX
M4=G=ZBH6>_33(^B(TYL;9?F#S,T>P6^+BL[UIY8-LD[F6]JR35*_/KLU]!)=
M!!UPLJ!+O'LJ33G!I$WX8@-TN#L7:ZLR@9\M<NV'.:<V>:8V-A<\(B3KW> 8
M^Z8K%3-_QX1@,XMWR8:UI^?"-RP/'J1I-B\^)M5K\/CDI:N,)F5M7M*C(4.Q
M;.@J X[<2' L@MX&K75AQ[A'*]K,=:0@RD;4BS,\QT^VK-.$+5F^D;ZXE*/%
MJZYJ,-6W-DO'L;YI19A0Y]J2>S-!Y(7INVRT9$[5@6Y^D$-]"J=R@$C+@F)$
M%4/BNT5XP^>A4Z,;-:VS>,S1S&(7X72^8F74APS'#:LJ^T:O-Q?KS@BV>@D_
MR)TJEDY@.'Z7[;S.0*X/_-PL"(M4.)_C2=^9YV2N^UY*OO0(=87/UQ4LL0IO
M8GA>[(;D82$)&CB(H!)@#=;UM/$51!?=\3V8S5CNQ<EY13DJ*CX]/7-V=N[[
M#OQ?;!3[/33*K###7ZD%&O>?N]%X8V7 R^@^S#UG]2S?R]MQ8BOW)[6AZ0_H
MD)+G!G>_P,NMV^IECS?QC'_ED**66<7R4>]4XS@M3WZI&S7*F^/(F??%(5IF
MYQ;.9:ZX<YTM\M5MD'E0\D+RZ[0JI YT)Z%+XC'8;$I[Z=E! >-MI9 =!+*/
M"+JT;@4>+N;UJI']3 +H79NK#4Z899"9KZE3=%N!ML9Q30Z:$99*J@>&/-BP
M3"/7&\IC0RM[RK,YK18F'>R/R>D.7R9:?JVNZFK+-II#-NRD)B%%WL$URZ?$
M.&SY=#'XVTU^:P608&394OZ[W&\S8MEU6F'U=4\RBB(KRE:$=1A*IV22[W\M
MVPX!/RIW5(5)-G]^=%1X 7QK=C9F:-AD2FG'=S)%39R>UI;K25B";-UD:'H'
M4U[Q07/WA<EA8EZKE+L[L$F_E!,")]0Y?CRS?<C0V5F'7Y8ES$DFD\-98<V%
MD&*Z@T+-;(<@)CNI>QEU7;?O5<FS%'GD*SXQY^=\Y1VEVC)@RG&IT5/8V_MS
MD7?M:4C8Y]4<)\@ O]3Q14("W2.,58;S;T#C.%O/EPJYY(?RS3GOG/*ZJ,\G
MQ?)E&V0@]Y^PM1%JX(4JL9<:'!=F@?8M=K:#\WU+>7225Q8NMWM_^CBCD5;B
M6KSQ=;RMZ:S.XXUN_L=6=SB-R!6CDP1H-^&<G4_YKW[W"V>VM^R[Y#1PXHT*
MU7!BGDS+]<-VV?;?XMY_\%)ZR 2-:L30Q&OKPR3;Y)\W\4RVGGY9'*-'.#C_
M3J' ,#W'M+.S[V%S6WE<=?#'C[\))B96>KFZ+@IGWJ&&PV^*UZDW=4\W\Z2K
MA9V4;PR0=#AA!S!;C5T 6TT!@>YCKAQ'3GX\KM3T]:8:Q]N1DU28:;\!$1G-
M<[.^J<T8G2L/W[D&W@NW?TR!.W.FW<6ICCMJ-2A_%0ATFZJI,?A\3-PL@>%=
M T_30#9=\$T:\\.>4M0*T%L*)T0*-Z#*M3HP([F!\%J/% CUD?-IY[B<M*Y1
M]_;**A@X/7*0[7TJ+5T$L; :&=$/-S4P-*<2BY%M:&OV5&6@8O5L4&N./_<N
MFD,XX+*F1"%Y!\MZ%:05>%QQY((F+2BQT[]WY::";[@;QW6 ^UL_6U"LYM$R
M$$??<1K%]W\\=>;M=4AM5STZ$<CDYOUH%GO>-F&"\*WRZ\-\)%OINQ8+R]L0
M_'J9MZ=7#P!VOD +P6;@8FMQE.XWX>D6LW36T?58MCY!3LX 7"L)0-7?*X1
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M@5?KEW+SOJFKZS<C%U*CHB)L*)>L)YTJRPDQ7]S;/ZTJ7S"9I!NX]?ZV98:
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MT2;]125>NK2>(Y'*]L\8.OM9IZ9A]V("MJRP:1%!]IU3 :-(J=IGWPNA\U<
MY#=554C%B[C+R#?OYDD\WZ#OY"X>(0K)\UR]SXN;E89)$!2:3P)HHAM9ERA(
M%_Z*J$<4IJ\ PBM8C[52<28S8QKKAK$_@Z)7I%D8F])H$2V[KFN]8$A(!PLE
M%K/U=_'R%:^VN6OX_<-I,9E$#2<'QHKB.9L?0Y16K&%+",GZ<-*G5\"#Y-;
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M .WNZ24D]_9RJ_C;XWD(^PO!0]$I]<%? 8+K$))[@]0-C<FAIU *(DG)G<<
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MN[?6*]':%=*R'Z9=OAV= !SVWDB_51R<[#:IO9O-.6PU)#.-UE<OKJN--K%
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M\;6H<:@)DZ>UO;:IF?[XFGLO!W2ZI],.0_)FA3=.]14JU8]=X4NB:,O$M/[
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M*XA %^2=E=&NQ;3"P@!A'1&@B%@89>8-.J;*" _;$15Y0. X@V-!G O!L(&
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M?&TE$QR@1(X(I@C"X\8JRSQVLI2W(/1/G7R15)A[(PE7O6!/4?"8>T9.$_7
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M^9[!FED3(UI-D0@V#[&"CRP8460: /W0.<\K><DY'E.392UD,G;GG]R622K
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M2%"J/P@+I=^/G>B=C0.]^ ?%^OU4'^GAI5%_*IQ#U)W_ )]_[_D_[_X_LO\
MAW_Z?7/]8*>1H?'[>-$>/]/(\?3S]#3?HC+Q7.-7%5>HE/6873&GR,HD >R@
M!%$W^XUD^0 3TBVT][2 JQ>+R6<AK0 &X[E]20]/_6K'87$X_!<AJV4%$&M5
MO4H8VA%10#&L\"R+,9%)96>.-E<=K-IBV]E"M66&:*<LC.-^YV]T8TO:FP-E
M6&EUVJ=Z)UOXGS.+C"=>X)7Q[@BWF?;7H?FZVBTUF#[=C](4XT@9I>GCMD)*
M#?28TZFIZH9H\L3HTZPFA020T)G^I/K)7>LF+X?<69[=>.:UE(U)%=96\5HN
M\HT=H("\C]C&(E$&G#CK)!AI11QQF.29X_PRJ0P1"-#XT YUX^J_4 D@/VBQ
MRIVC58$FL8EV?,I.L8^<["PJ[C0:Z?C#(TBY'8WL22^T..?BCZ^M9;MGR&0)
M<*!(!(GP@BD *7H^!^LV(RN.LIRFY3P^1I^TAEFE"0WD,:+[L09%"SO,'9JZ
MERH9>TE?BKK'=$,A,4#PLKF-B%TIVO<N];V=C2D@#1.B1U&&Z'4U#1:YEZEN
MR[;MI%S[F=2<.C-GT&/2X5I*K0XL*;^+ EC;D^$:)8'KX]5)CR6)"/-0S7IP
M?,?7.:S;JU^,UU2I4N177M75;ONK P9(?95PT$;D2>Z>[W&C,?:4)916:>)&
M@:!!(\9),AT?! _NPPT5)((/QX[3]3M['B8ME.SLEPK6DRSL38M'L)MS7W,8
M,:SK(U%4?=,M,B19$P=E7XTH+ <F;$\R$%">9L9S'#(5R.+>M/&LMAK5G-30
MX7(5 S/2EE!-M%5FB>B7"+-)-HK]W5N])".Y@K*PH4BL6XK,4D4 A,@FCE;3
M!&7^*,G2R:*GP"3\?.P2S<FN8.:[8UOL7%L;NJ;CY)PRJQBSRFVFUSI]-&KY
MA!97:7]E.DU],R]B6HO=K:Q"@)9T(:^)7A=(>@PL70]9,]7Y18Y!:AKVX7KS
MTAC 6@B@J3SP3 PM_>.DAEACDD[O<#.7!\_C%KVO>L1S21*\,:]J@:4HOD=W
M<=Z<,=DCY\@=>S)RXM78Y<[)QO)8V6:VJ[<U*#)8,<T0Y;(A9GVFHFU,Q!RZ
MV\MH40MA$KI"=R06NEM,H!E>.0-7ULX9+Q]\K-;E@MQ",288JK9$S,(RR5HB
MR+/"&;7WD,L("L79"I7K'DJP/:6\)E$ 4]Z-XF[]'M4*-EM[\,/PC6]A?@5^
M5@J<V38=<8B*Z-@U_@>-V^-VUV*.&1:R9,-JY6C&1.X1MJ<F6PI4$JJ9HH 3
MD56R!D?%KG7.+7.LK%?GKI4AJ0&M6JH[R&-&E:1FE=CII9/PEBBHH4!=$@]4
MMR)(R&./VT"#0)!))\L6UK;;\'QX  V?!ZZWO3X_T#N&'_-9T+_LOQCUQ/6L
M;Y/[G_7HP/1U3I>CHZ7HZ.N<1U)^D#8[?YZ<M=KLYX\!<";GN]<[R1F$[!W@
M6BS3&!V-FZ0RIRBK3'Y3:V\B.(X,^ A2_'(Q$0CN_P#"L\$B1)*Z2*KMI2R$
M(04#J5?>B6!)[=>% 8$@^%0&&B5/:5 !_7R?S^->1Y_30UY&O#NC6[&<3V57
M+U&NFZM_F%)38[5R \AE^+%JOOT.VR!9!7XRA6$EAK(4 +!#<A!2I32/8B(U
M^,025/C2DD^?TU^0_,G^6OKTLK *W\6V4 $:T5)V0=D?.@/C7Z]-R3T,,IQN
M36'MNH7TX:TLF-#NZQMAO^0)LR"1[GPYHF'Q9J2(1GQWHTC/(9481$<JHJ>J
MD[!'CZ@^=?I\:_K_ #ZH&(UM7\Z^@'QOP=GR-?\ 0=3-@W29LYFZ)&?YAU"^
MFU=2\G%F$"RKZC?:R"'L<IQFVHJ\5= DXZYK4B65A7DCA0OG':%B@[O&-JW1
MRV*VS5GDKNRM$6BE>)GBD!22)BG:622,E'0DJR^"#THLVG[M,NPP/;H>""/H
MV_K\>5^FM=1.WHGYGA%\88^H_P!.[&,CJ"R814%R.G5%O7&<U\25&<X>-!DQ
MR.80D<P_)JN:]XWHJ.5%M/D>>TC]3X\#9^A_7]AYZM]S6B P/Y_AW^_AA\_3
M74DXGT<KVVP'/M=UG4*Z>619QLW+,*L&?&Y"&L3SZ[&69386(RN_399LNPFV
MEA DL:T1'$2(9ZO]Q&M?;V'O5AK\*L/V)[>T  ? '\_/[=5$@[6':Q+,#O0.
M@-D'P=GR?U)_GXC>5T<<N_3$?!9/4BZ:@\?K<@G9 *L?R 8(P;R;!BULN00_
MZ3;*[NB5X!?'>10C43WH-"*YRW!?.QY)\;)^!Y_3QK?Y_N1U:) !KM;7<2 0
MO@D '1)WHZ_/7R>I(ROHXW>PZK4\?%NH7T\#7VKM8NI;PD3D 8Z1@T&5Y'>Q
M+F(^-C)"LA0ZJWKW29!AA2+(&5%51(PCK%4J7)[=.Q.B=?( /G7T._\ 7Z]7
M>X#V]JL2%^@ \[)!^=_7\SK_  T_^&G2-OL1YM\9=K7'4'Z?V?6.-\BM79Q9
M46,;])=9KF$NKSNGMY==0USL=!]TR*X()8]?%<422IT@0U(WS54O4:^@_37T
M'CQO7GZG^O"3-L$D$G>R3KSH[_YM[/U^?.@!KJ;^L)TGY^_^HUR8V^+G!P5U
M<+,LGH9C<$VKNLF,9[C_ ,;#L>@+&R*C2AF-@23+$^4$?R"><0\<RJGN>"7=
M6 ^ =$CMU]#^_C?U_;Z=!;JSHQSL>#L8$7J'].6SR/*-=7.*8\*MY %E)&2S
MG5<C))LIK<90PP!Q*#>,<00R^+2N4OM!0A6V,">WX 5@Q\GSH'0^/S(/[@=*
MJX7N\,25*CQKR=?.]?0'^M QHG1+L_;4#^I'TV$ USC(+^L8;VT,K4:I$$N,
M^".<B-:]Z(CE3LBJJ)ZN_7QL_K\_7YU^7QX/C]^K58?4.->?@?(_<Z_R/[ZW
MU+>E>CF?"<\AYG9=1#IT6-'3UN0P[]*WD(201(.1X[:XT-IW$QM@F".>T"!R
MF*QJHY6L\G^+5L<%EUXWL$;/U!!\>!_\?/R=*+* P.F\;)\ G1!\>&^/KK7T
M!_7J+4Z*=F@'QDZDG39^*\HS/C)R,,@'&8UXQF>']-J-YF,>\;".8KV->]K7
M(CW(MX&M?UKX\?']:&_SZIWCQX?7Z$?R^&_S^?CR=]2OC/2$'6ZAVAK^PZB_
M3C*7*KO ;_'W@Y"(^""UQB5<!L?G%?CK'@^137!FQW!85SRA:PC6#57HF4/>
MC=V]!@=_)# :'U^H._TW]>JAU[&!#GR->!\[^OXM? ^1X(\?0ZQF#](O)**^
MUZRXZF73OFX7AF;X]E'Z=;R5/(A '6WH+6<ZNKRX^R(.4=B2W)X^TAC&<I'I
MY*Y*LOX6.E[BI'<?S(U^7_;\OKOH636AIM*5^0->//QW?X?K^W7DR#H^Y;/M
M]B'J>I7TY8E'L*^F6-U$=R(<Q;6.EY*NZX5@J8P1RK'D2&G<$9_;4[4<_P!Q
M&L5*!?"[T"HU\_77DGQ]0!^HUL$$>:F0_BT&[6^0 OGSOR=^/Y>=_P":U)T5
M+.AVMJ^]7J&].2S;2;"PJU=6UG($LFSL$K\EK)2PJZ-^FF?(G2_90$0"N8AI
M!!C5R([R]7[!\;'^(/[_ "/Z_3I,DL >UCH?D//SY^=_]_\ +JTWKV=,2=RB
MZAN6;9!S'X6Z8'/UQKBH3!]V;@)AV=QEJ:R4'Y\ND;1SD%7SU<I*\_R'*<3'
M.\6_SNW\_M\_X[_;Z>>DD\#?D[.OV_S\_/Y>//51MKT:\ONJ;&,?L>I-TT#5
M6(PIT&BB"Y!N"V.*SGEGS"$<'%F+(D&E&[O.3R*X8PB<YS1M3T(0&V55]D@*
MSL025UL!2K C:L " Q !VHT5^XD*"-A=@#7_ #?)^1Y^#_WUHS%N?I YC*WK
M<[7I^HOT]L2L+2TJ,MQ&79<@2P;B-$# @AIK035QDHE\VP&D 0;S!>UO;NYJ
M.3TF(V1?:D73CPZML-O>R&!4'ZGY_/?GJYW_ !ENUP0P8'0WX \$$C\MCY^0
M?J>OGJ7I'Y'$W$[.+[J.=.[)LAR*/FT*0E;O]LBUM\BS+&[FBB*R,/&8XG.D
M6MP!##"UG@-SO8$YR,$MKIM0!V@#M V? 52"-;'Y#_+6_)Z!("_=IB?Q;T%/
MY[UYT"2=_P O@#IHXOT?=BZEOI4>#U'>FY63H5M!)=4%KOXKHLFTQ^1*2 *W
M@$QD9'&JYASECM]P1(\Q&E8Y"B&K+F <>?J"/#:UO1\>/J-;W\#_ #!+VG^%
MP?!\@:V-Z^OCY\>?!\^#YZ>W'GHX9/7;MQS((O4(Z?&53YALB%.J\>W\>UO+
M<5]074"P9'C?IM"27D'.*8_N%_(FE(]ZHU56DB[C*[ /CM)_,$$?S^/W/Y=5
M67\6^U_&]G0^/(_YC_Y_0'IIY%TH-C7.%4NM[3J6=-P=/CA#A5O]8=X;"?&$
MR.&NK+4Z8NTDB!0QXOM5<%W>-&5Y3>TLAZE]5]LABPT&)^"=Z/GNT"/!/C9U
MOY&]>.K3*Q ![_ 'T7SX\?\ %\#QH#7Z[/D.NPZ-]UF^I=:X7C/4 Z=]E=:D
M=L;*LLGQ]]/D1X^/V=GC\BIG&E!QM\GX-*C3@(Z6T4> LP3 .5)#T3(-NVT2
M59K4TM2+N]BJ\TI@A>7O[WBA[NQ&+MW$JH[C_%L$KU<9F9(T)D(3N\:&AL[\
M L0OU_3SKP>HUV#T@\EV5F]CF]]U%^F."VN)$$DH%=R#,",KX,6+7M48B8X4
MBD*R,QYGO(YSSO>[OW<G;'1>T #M/SYWY._/Y?T.DW?O8L5()UO^'Z>#_P 7
M[>?]!U<)U]^FI.Y3<M=8YX#E_P -]+,I>.6N\2=C.[MMOPW*+!:F9?O6^KJU
ME+/]_'Y_R4'7S_=;[[PG3VV^'\2NB0= G6B?R V!L^/S( _4@?7I%/ .A\?D
M!X _GOS\#Z;_ )]4K1NB_EX,>EXL'J5=-AM!8VL.[F5X^0SD9)LH$:1$AR2%
M_2?ON]@$N0U@?=]GR)[GMJ5K7)9X)WX[@-?/^/TW_E_X5[CKM_%Y_%V@?) \
M;WKZ$_/^!ZD#871SF90NMUJNHMTY8SL'UOC6(O,?D,X9'V=/87-G*DQO:QLB
M_&;(ME9'>YR$5HO)S&*J(EJ@CNWV^69M;^AU^G^._GJ\MOMTKG2J#X ((W^N
MM#?C\]>?KM[81TK,GB;#L\SS?J1=.><2YUEF&MYQZSD!X2W0[S7=EA5:5POT
M\ ;U$8L"7,?YM4CAG.UKGN1CK6C!5570TZOHG?PX;QX\^ ?Y?._GJ_W"6V5<
M>"#^%3\C_P"[\P/S_P NHWU_TA]AZMR"-D^%=2_INT]Q'"2.IOZ?Q2X\B.3Q
M]R/*A3<2DPY('=D7P,)ZC>UI!.&5C7MO90Z]K:(.M#>O(_(C]?T_UT+0Y!V%
M<?J O\Q\^?/S^N]'XUG]9])7(\%VUCFSI74;Z;T^1!R5;6^"WD21KK6MM#&!
MDU>]J8RQKAVU5.L()!.<@W,DJQW9OJCKW(5.@"- [\@@?A/Q\C0ZH)?Q;[9/
M)V?P#^?U^H!^FQYU^F'R#H^94^LM<!Q_J=]/9-7)E=AD-+C4SD4H(Z%>0H*Z
MPF0Q8R5JV0ZYPPO5T@[!N5Z#<O=7* +ON8+W%=$[_/Y'Y>2#_F/U-/='\(#]
MH.P.U0/]0?\ /]]]9JEZ/ZPM+9UK67U%.G*MA?YU@67U!A<A%?"%^FJK,*FR
M'*>[&VD&8P,BBNC>V,C7^T1'JQ6L5U"-NK?@T%8:W_S$$_3X\'?Y_.ORJ) %
M(*N3O8!7\M@[^?YG\]G].F%;=&O-+JAQS&K/J5=-R72XDMM^G89>0:?]C67<
MH4ZS$,[<32004B4%I4$8I!@7S]AHD(1'7 +LG:@M\Z(\_E_,>1OZ_4?E1G+*
M 0Y'DKX'U.]?.R1O7_0]=)3A]B#M?\3N,V"/O:#*'X9H34F+/R7%)ZVF,9 Z
M@P.BJW7..V2C"MA26:Q5F5<U1"65", WML\_%+@- #\AKK%/DD_F3_KT1OJO
M5.EZ.CI>CHZY ?6-(]>J5SP1556MY-;0=_@GFM\97=E[=E[)V3]U[?R_'9/6
M1+/)*D2.25C4!0  OX42,'QO;!$0,2=^-#M&E&0"2JCZ #]M@ ?3ZZ'GX\_S
MZ&CCMI=NSL]Q:'DDN)08M:W%?6LM[=RCKW&ESA 22=J*UQ($%Z>_(;Y#;(5C
M8Z%8TCWM=OTX]/;&3BM<LS.)NWL!B*5O(U\=5C#V^06:<3S)0IQ%A[ID>,($
M<JMAW6(-HMUJ,YE/[&Q=R^L)LS5Z[S0548!YF&^TZ\D1AALL QT#X_,XNJ7H
M;&M6R--RL&8KZ@>'+3RPEL9,RP!'CV1V@F3()_-:B+.F3I!@1A*&*R0<R""Q
M2=W-!Q+E/)O57@W(N?YWC\&%DQGJ%D<+7K5<%+A$I\?EHTFQ%2021H<C+2F2
M6O:OL>X6)5A)9>P)@X/)S3V+F(M2S6;^*BI')V6OXK*4I,A921[:XF_AI)JD
MN*C#5S2CDDDLQQ-W3.6<JC$Z;W#LF^=B#S++SD@Z_P 6]^XFGKK*/!M_EF)W
MJRQW&"=0M=*@D5DD8#?&&Q\I?;>P/N[3E&2K>E/IW+ZC96KBLGF<TPQ'IYQW
M+4LCDL?EL[+81"^4JXY4D,(K"<4H39A^\W&@4L%*[P.5<I&!^[4ZB33Y.XSR
MZ@KBS]TQ\ ]V_:9)'CA:2"LK2HDDBJH!D?:*VA;Y9T]?6[LR<U+.FW-59V<X
ML6\G&'(D6Q8-H84JP-(&][)!9'L#.Z2QR+)0PY3AB<=1L[OU8P,6'S6+LP8J
M#$1YG!8[(34ZD;0U8L@T(%Z.&%E!A]N4J'B(!4L"P#,2>@PMVYD,1CKE](UN
M3UU-E8E*JLJZ)[D('MR%"K,FOPD@ D$,2[Z6NCL;V/L;(K[.,?'<4%)B=F.$
MK,B2DL(5UXF97VT-@A%FG2+8'C(Y(Z(2*5K9QGLC1RM+SEDY7B?IED^=XJW%
MA\J_*.+8;%9"?C,W,2]<YB%\_47#UQ&T"W\>PI_>Y9=0@2L.TLC=<[S+,VL?
M7J4\=96I?M&U,)WNU<:BI2HV[7X\A>*UHMR(CI5;<^1>(4*O;9LQ$ YR%P63
MAFR+H8X#HM<>YGQQ=I/S1BG0GR8D\#I3.XWO0Z.*SVW.843D*+LQR-9U'JUQ
M)>/YV+(4*:U\+G*\%RF8(Y$KI9D@CDMPJC@FL6F9YHJQ9BD3@*=*0.BQ%\9'
M&T+9;ODF@B:1NTQEG:/S)[;$LG>"#VD[#;7P1KHUN-'&?9. :<V)R*RIPL-J
M['& X9CM)<Q %L,JKL_".JED!#.]"P?.H4UC6RBA)[X5%*" L<BF'KO3K"\'
MY+S)."9C+37.5_=+V1NX/"WJA?CV.I01:GY$W;+)6LVK-J""M1AW/$W<;@@)
M6-M;EN1V,/?P%08:_/6SKWS#E)J]JMBI(L63#=%&\T*U;\E:VOW6XM:>1*<^
MX;';,!&8PZ>M2M7U-.&E8QLGVH7+[380?+"H9!8X]FXXHBO8G9$4@1^:^">*
MHJ*U?%4]<ER3%#"9[+XE!8]O'W[-6$VH_:G>**5EBDD3Q_[B!75AI74AUT&
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MM'8)&@/!ZC??&A,DU_E>1'AO->8^.8>7&MWB.&3-K;)"-K;P$8T<!9%/;1R
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MIV>G='-1G@J*BKW[]_Y=N"DC>*1XI$*21.T;HPTR.A*,I!\@J05(/P=CJA+
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M5'N#4; *I[5 5%8*/"]QT-:V4/'NJK7T^AX-:Z>.[L,K$2U=!,8$P))&9E;
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M!!^^H?M",]WP1&^?97=D[?R[^EC=LFL*1M3FFLIG%7WG^["9E[6E$(/M^X5
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M'G>CKZZZ^>:W/._8>=7N:YCK[>N6!OT/7R\4R7 ,SM\1?C#IZS8F,-QT]/\
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MIKD;G&97>2/T-N*/$ERFQZ>#_1QF+V56/UP1UV/U 5^RM7V:NFBPX U\6*Y
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MUS(WMUHRS.Q5? +DGL#'N(CCC0,$4 *2/^&-3VGL3Y&MMW$G\1'EF  7SO0
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M8YFKK2JO$L=.ND[F=V-BR8T>><*Z?W7]X9(P@VG:%8;^67*II=+Y[5WY(V2
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MB!0MKP-Z/G]#^^M?7P/!^NQT-#?J:^KPY"(F\\-_A6,J+_1+@WX0L0IW=_\
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M@KYW\C3 ?&]C1^/C2<RCW/[O6G (_('NT?)^/.]?'G]M];=G#/I/:LJ>%3<
MWMK;(JF+=X7"L\@L*I3V,JSR<D04G(DF2Z@;9#H[+ 5B"K4K2L!&9![#8_P8
MU)!,\ADB<,S))_=2JJ("&[%4!WTQ[6617T"&WKROG*#",)''V,2I5T8Z\GQX
M)^3Y!!\'\AL:ZTF.3V!ZOUSN/-\2U3-R>1C518QX;8.61"Q;:IFQBR0&B>^4
M4<D^#(AJ"= D&B19+(LT<:4'WX[WDS989:\LD,IB9HF[6:*6*9#X!\20L\;%
M2>UNUR P8?(\8\\:Q2R(OT*AAL, 1\@'X(UKX)T/'SX'7%Z:GXZ>?!]/\.*>
MAD_]&M,;3^7^'_5$]6+\#]NL5OXF_P#N/^O1@9-82*G&\@M8OA\JLI+:PC>Z
MWS'\B% D20^XQ%:KF>X-OFU')Y-[IW3OW]5ZMZUC^-/4CZA-SB/ +;NU,YX^
MYS@_41V=L#0F,X70ZJO,2S#2>>1HV>K@^<2+ .=6\?8&(0IN%-3,*_[9C\H5
M?8-/%F#(-J$.JGZ_H?K\_P!#7G]^K#>FENKG1NK9_*L7(W8>BMDZ5TKL!^CL
M"S?4VK\DUX7-MLXAX.VZ>$.]S')UD8G@MM(%A#9SD$6URB!?($4>-5-?,.J=
M<V#J"RRPNIMS EC8Y71^6^W3>3 J=S6AV5:E>YHD[(1S1->Y&_ER]^WX7LJ=
M1PZW-2Y+A+44;%DR=$EUA]XK&ERN\Y6/X++ DGP"^VV/Q:(S(2.Y-C\)[0QU
MX[21W?I_#OZ;\^/.M7DXYOK(I/%W3CH1IE-DK(R8LDA$9XRJ# S.@0[)H'QF
M1R-L7?$CD9(9)1WPI"JY4*OJ//VR,#CX?7>Y4IV)34O\6H9S.4(F-:%<CE;5
ML5HG->193,!7LWY6=DD62Q79==JZDS_LW_LK<%]4O5#UCY;ZB\;QG,.'\5CA
MQ.(QF5A-G'39_DXLV+SR1^X%>3&8V,?=SX:*3(1S(8Y858P_L/9T_.N9&D1Y
M!)+/'BV%0\A/ AJX$V1:@HCY?*C"]EK0,+/D2(Z+']M0.8>.)!JU'HK^>D,U
M[TW^Q+D,CQ^-X<G8PGJ%>J2.TC& MR>SQRID%=O=98<?3[+\COW,S0O.3W$M
MU'KU#](<!3];/5+TDX_/#A<)R/UVQW!,=?F+VH,1C,KR#&8>!PLD@:6/%)D)
MHU$LP=O95?<# N#2S'E2/%^/5OM:-AKY5B#)Y>-PH #O+64MS.A2),:?<J[P
MD3X)T)5,E26NC22S9+_;(%KWB5C/LL<4J^L?-)>)>IO,,]F\[Z>-@^<\6=LA
M/!-)BH;7W26O& 645Z^1BA(A4F:-%4M*RS2-)SWVR?LB+]G/UMPO"N-VIGX/
MRKAM')X[+WBEB_DIJG9C^053N,15;ZW(9KD4*!X8*5JLL;,P8C6>SW.+W:_(
MVERS(XIR3'Y3\:62,5[GDC0QP!$&+WD.;VXT90QHJ'<8OMMCM1SNZN;Z$Y.1
MLCZD8%*5.>M%@LE=H5Y0$6-A#6JF>611&55))95,G> 7#PF+2M*8\''XF#!<
M6CQT"JD=3&V^TOVA>^5))6+]O:OXI7)8Z'XCM1K8ZV(\%RLD;?M[,MK6V2#C
M\&_)25ORS 8=E+!$V#!2.\GMC*^KBD.%K!.<^P%'<T;E5$]>/<E6SFO4OCLM
M^ZE?*9GU=Q']K\@[(A;JV;G*F#VTE6-E3VKSPP]K'V8J[.C'L4@^H_JSPJI@
M_P#90\=BX-P_!6[&4]-?3W*\EM18BO/92OE#2R7).2M,L?OM;ISV)[37992:
M<!FD[TCBT*Y>.ES-VKS9J[[(I"A@W=C>Y(2-+GJ7W6P17-O!QQS",8XK%6OA
M!8XIE8J1&B]A&>7KV+]>N29?T_\ 2?U0S^%22:]@?3R1L;+'V]U>U)(*C6UA
M6,D>VTK7)9.YNT1$(GSOR/BXI#>XUP_B,4T=49?/X+CYO!04JC-9"IC[%YT7
M?XD28R'1#?'GSOJP.MWYF=?K?D'GI+ <R^J*$$O'(DIK"AI!7<\]7,=7!:)/
M[*%&DA8-'L<)'C&60U5*5S_,/[)'%<&_KWPK'WD,J-A.075FF:1Y;N;QM>G/
M#:E=W;_U+0M>E8@]S*S*I[(@%]"_]IU]FWTU].>*_9TK^G_ \;QS'1Y;+\6S
MV<Q%9*DV1AK8S&7,97S=A&]VY:MS5+]A+4[/,";:+*!(%ZHRX-RR3>J'PWE'
M'*"8G*_2KB,E,:UZ>>W*E[5:K41'#<UZ*UZL8O=5;XN1/-9D>JE@VN77)GAL
M0.YG[DLJ W:+UWVVC*^&B,?9VGM0ANY2#VAFAL\0@$4:@J$AC0 GN!"_A7SH
M^"NO/CR2=?E.GU O_&^<RO\ #]:8Q_L]Q/\ _P!^FX^G]?U^W\^DU^!^PW_A
M_G_T\]7(?3K\<K'-]0MS#%*&MRS+![0#;FA9!?,K(]#4Q'K$EW=3"2/(+.EQ
MZX1'-;V ]\@@QA>J$*0.PQ]R6M][3[]9JQ3U63VX(3*EB2.19(Z]ABT8BCD<
M;!!=0K.[)OM#;*"7V:S=\K(CJX("EMD'\*L?&@220=:T23^H(=?["N5&FLPT
MMHSD=MNNVJEK:["V1A\^K80-7C-;=7=-0BQT 25%1[ X/QBD0 !.@B$\:0_;
M\C(NZY?FL!FKM2; 8>3%1U<?%6N&5NZ6W:1G+3$B:8%>WM"N>V1V+E]@*>DK
M=B*<+[*=H/@NZJC-HCM5E#%3V@D!C^(Z\^=:N>Z7Z\FN.^"Z#U]I3:>%4FAP
M4[!Y]B$EN/S<PRG;^0V,RW@0RO0K+MTRS ,$6,RKDCIX%56N!-!-D,,LO/AI
M\=7B&89<9E;_ "!;C/C\K&LT%)L>@BBEL!'4PK!$ZL&693-(S*T3QJQ*9KU:
MZP'8,K(&56*LI8?A_O$)_ L:DD%7!8L001OQ2']1/M?(LFZA6.PKZJ;4%P#
ML3F,6&G@*3*M<HR&YL)4=W?Q=XR8[@^;5\?= ]K?PU.[=5-LDC-K;LP(\_(
M&_@?GY\:/^NK?2"-020 K[^/D['UUXUO6]@D];R/!_(,?R3C5J/*-;XA"CX@
M7%06]?4NK11F3TL:MA)19$9!JGD62:3':Y[7/1H1D[JGCY8\1=3M5/<A8$^2
M2WQO8\@^/S/CXWXZLFVLA!<[.OCQH'XUKP/'SY_/8)ZT:>M_AN6TO5,P^QPG
M'(U+F65V.NI>%Q8+QFDGR6+DU3"I!&BM'XB+%LWQ0,;_ &C"B<G;NUO9%ZS
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MJ8^YQN##28ZKZ?X^E6;"3)?B][=^22"P0(Y ?=;N>=))R7#L#TU#<4Q3X/\
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MD*">6Q>5$=HWDUN!A*Z.K=K:"JW6_MU$6)8X0O>B';+X#:!8[ ))+:)!'SL
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M8JH\!F+_  KW1(Q$@]P!WKN&_(^"1O7R/CZC?Z=)LK(Q1O!!;?S]&!_P._\
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MHRLLW;(&4ED*O&"K+K8T5[?.@2"!X\]; ?U3ZJG/#2_9>R_U0M2]O_Y_*/\
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M'\SX\)1N6F4$C8)/ZZ._'_7Z_'T(/7)LV]?V&4[?V5D%K6Q*6RN-A9;,GU,
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M-S1LN6O*C?@LNT.VOSS9V\,]U+"G;/FALXTG-+*WE85]ZBOQYPZDD!UR:7.
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M'-0J*Q)%V+F&K8NSG&A6;'4X+-B62OC6GF:*G[@L>S52 SSN'A<(D4;&709
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M)C\/BL3)4BL5\?VR&YR._P#>98Y$QN/$9,KQ+(5+P+[,IF4+RV>Y75X_;QE
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M/[)J+)VN[$,\22JK=S-KM#?A4!57N/:!LGKHX"(ZR/L'4>B!L@$#N_$/KX^
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M<O&CC]MO<VB;X.#DI(=#0+CTZ=4V$B-$G7=U78^L@%=",D8THQV0I3RQ8[I
MH199_P"+Q.1BI."/U"X5P#$>G>.Y3D8L/D.0X^KCL1%+WE'<QU_<4A"8D!F:
M%&D(+=\L:CPQZ:#FW(\1@N55'O0V'LM65$EA5FCK5I/94S2*9 @#2QZ=@K2
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M<O\ $Y2.5Z_NOY]$/H9AX4CK0<HY)##&BI%%%96.*-$ "QQQHBHB*-!54*H
MT .MFTK5ZJRFE+"J #V19B'8"I8!0BE1H [4?'[^.LC%^H#S@M&HY?%KB3%D
MUZD2KH6:>=)@)[[F>Y[,K[J"/"]U6-<5!Q%\U&WR\G(WM>/0O&Q2#V^1\E[7
M"B25;Z1N @(12H3\879"CNTH) _7G7SEA;86#%H5E"B:P;Z1R?AV%#**S&3M
MWI=R?4ZUY'6.@]?[91)@!6/$'A_#BD<K228FK!V!QJC55/"(LR)[JJJ(B-^0
MQ?SW[K^RJ'T1QI5O;Y3REG V$>_[8._H7[&*C]>UOV/6?D,E:IUC+'5CD?R%
M1KW8G<HVW<PA<C\)WX4DZ*Z'GK.W?7PVG#BQ%7A]Q?(9HP-C1[G2SJP X!_?
M*%\:0^XF^('N88@VL T3O$Y4<G@_UK,7Z*<<G-ZQ0Y1E=R6I!?FQF5K6&EOP
MJL,HNO7BC+6XD2.-_>+31JJ1MX"CK#AY'E9YZM:[65%$,:55;(S.4KRRF1!#
M'-60+79[#S QGVV>5W )=CUBZ;KZ;+L;($";Q XA1 G]Q?>@ZE;;'11M<]5;
M#2;"4J=V_GQ,BI^5[+V];"3T2QPAD:'D_)I'4;6.7)>Q&WU_%+V2>V/_ ,XQ
ML-Z\$GI?*Y>WCH&ECK13/Y[5DOF%#^((0T@KR$>2?A3X^0/K)F<];_/\-Q+'
MKB)QHXEV)\GGV8UQ>PT-98U+@'I607FE62S;.1&53!N8Q8!!,*I@G*JO$K7M
M=H,;Z+T+^1LSV\AFJ[TZL:5,O6S5;)&:*Y)*;%>"9:L$\2))5C>>,GLD?VVT
MQ38TF$YKE<G<M8J;&K7A@,$\A@S:V:TLCBPD+",5XP98PEF(NRAHNYE!(<[<
M_$[K:[$VGR:T%KV5Q1XGXR+8>W]?XE+R/&==CKLCIX^29'75$FRJ+!CO<!:1
M RC%B257NPJ-[HK47NER7T?Q>+PF;R(Y#R"Q)3QUZTD<]E&CF>O5DD6.9>TE
MU8H0PWY4D?'GIR%KJ]03B23;Q"3L[R5&TWVD_P#%H_H-_ UU%75>ZZ>S>*O/
MWD3H:CX?\/-D56N\BI*V)F&Q]7 O,UO&S,2H+5Q[RX*5%EF$^<^,%WBBLBA
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M09(K_;T7BD$=B8*@(V. ,ID;[F422HY4%&9(<Q#L(B-1?+USO).'>C7"+U'
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MCKH)7>P&_"SL)D*CL3M8LB$NJ@[7K]D<9]WW%_O%<&*01B0*I4H[#YC;8.M
M-VZWH]0WU5N#.HN#^?T&#8G99[#S*SK16LW'LFA_(I2U$M$ENFU%O\>/('(B
M')$$2+,'[<H93EBN8D?V7</'8DL232/%'$&D9PB JJ=[%@@5B?P*#I?)T!KR
M//6-,L?AT_#W=Q !)4:/G1\ZT?H=^ ?GKI^]/A.W _ABG[I_59T)_LOQCTOU
MAM\G]S_KU79R)ZJ/([46Z^<])@'%; ]G:*Z?%!J3,MZY7)W--Q+9L_#]DZ_D
M;"L[3!\./@MI17$S%Z:KO3%KYV3UCIZ0 #"9A9?81T:^/.M_G_/\M_E_7STZ
M,KZI6Z:SD'H77^-<28MUJ'E'95./\?\ +Y^X::#M#8/WS3S=LQ]K-U96T-V^
MCT11DD0</R[-;>^CVE%;R%D/H##^/&DG5/Z_K_/_  ^O4R<#>;/)?E'M[DEK
M/<_%S"]+T_'*VQ_"KC/,'W@FWL>O=I6E<"]NM?5\AF!XD EIAE%.JI.5GBR)
M8:FQMH=.;O.;*'&.CK1&YT6Y:'J"<GKH,>/++5<FME3AQ94<<N/(=&SJS)[)
M8Y$<,C2(BM1KD\O)4<WL]&JD^\!BXLUZ<8_#SV+56'+<3BQTMJC8DIW*T=W&
M&L\]6U"RRU[$*RF2&:-E>.158$:!ZR<D?_PPR!86:M#':1+"K+6DDJE9T2S$
MQ[)JSM&%L0/^":(M&X*NPZD'+'O?D-HTCV&<&2^.LA'.>62@.PVR997.>I9Y
MVM0DXO?L26IG(B-5$3PC^YKCY;5)9'E6M>O0AV9'#>W;F0M$R#M,#%2T!!.X
MBAV=[Z^G;T3O)E?2+TWS4=-L:F?X7QS/KB172G6PPS>)J9/^Q<=1BAKQT,3B
M?O/W#%44B5:F/KUX 6[.XQ;CM,^]W_CL4;!.;#P3,K:1Y/\ !RAK<6R:4YS>
MRM>XK7C9X,&JN5J*J_V:/1)J\;RE?&_8C]29;)GC#\HKX^-JZ,7>QD<]Q:M6
M$AC!_N&EGC2PTFD$/>KG6@?(O[2LUF'_ &AW!ON:UY+4O,?11(TMQ035PA?'
M_>6=+(]D.M43M78_C2P(FAU,(ST^)4A91E,H@![L"-!1A($+&@",#/ ;>Z-5
M6#:YZ_N\BN>OY<OJ%KNTC%W(9C\D*B#0&@ L:H@   &E'@;.SLGVLX_@ZO',
M7#B:<]^U##8R%HV,G;DOWII\GD;64MR6+<O]Y*6M7)B@.A'%[<* )&H'F67[
MESFPBF?*/)N,3/[YE>\K!Q\$IE>QKW-1&#+)L#O5C'.5SV*0O\2M<]]_59J$
M7IG]G;'4:S532X;RZ]84UHJ@E?,\F@0.T<:H92LV'M-'.ZGW89DE$DC2N1YX
M?8KQ%Q/M _;0S+Z2B.?XO!P1?>7G/NU,QS2<+IFD(CK4GIPPJ7"UHV^ZPHD4
M78F.N8AI]-<P8Y4":;46D1A'(]R)\B!("K51B.>OFUZL[-:Y?XOV7]O7!>EE
MR''^IOIU>L(LD-3G/$YY Y 543/4"9"25']T/[P;(&T&_'4K/M3TVO?9O]<(
M$[>Y/3+EUP=^^W_\.P]F^?(!(/;6/:?C>MD#9ZA+CW(F!K\G KB_$6142HI4
M\VM#/1+($Q@B(U$]Q\9(SC-1[7>*!<J*B?B='V\X<,V)]/Y6LUQGXLCEHTIC
MM:U+AYZT333N W<E>"]6KI&S*RO)/($*D/ORF_V7J9>UZI>HE,XF6_Q&_P %
MB7.SSP>_BHLI4SF.GP$5I)5>N]NQ%/F&K(X,GMP3R :0$$&$C@E$5B]G"(PC
M%[]NSF.1S5[I^W943\I^WKS9=0Z.A\AE92-;V&!!\?7P?CKW0L0I8@G@D&TG
MADA<:WM)$9&&OKL,?'UZ\'$<J%ZEF@"M(TC9'+O7DE'C<CQ.25LVKD]Q/\!^
M<=?=58[T&SR#X+X,14:GMCQJ9K7V>^-6)$5))_2/"/(BH(PC'BE4.HC&A'I@
M5,:_A1@578&^OE.RM%<%G^7<?22>5<%RCD^%26PO98E3%9J_022TG>_;8D]C
MW+"^Y)VS,Z][Z[B-G7X:0_5^Y?1H4=7V+]@XJT+T>YRF(3 <-;&"@51&)XE1
M5\D=W?[B-541J=X@T#(]G'0TJP;(_P!H1&"0L7]Z5Y(%JP>T=( LRDEM[D]W
M3$!1UK4V>W0\_AU\_/\ 7Z?3HU\'XTYW;\1\,SHFW,MQZXQ^!D6T:G'(LJ<[
M&:R! 2+(+\-L1XYL*S,%R64=X_>:QQSJ,36*<ZOYC?7_ (G:^TIF/14</I_[
MPT.+8_\ MWF;_P!GUWM7)XZLT.!A[XC:OPJD[LT33JL1K.?:<)W*P_(#!5M7
M.2&I@+6*RO*APA:CV8FY%:M)3-JYDS2;N4XBJ[UJ%BRX0-/8K("[=J@-N/=!
M19'LFZN[Z"RZBX;5V6:I3G80\.ZD!M8%?#BSCJU7$KVS;$4V>U7*\T>(HB>/
MOH].K^T_ZD9KTP].+&9XS[<.?MY#'X"A?FB$L.*_MAIQ+D!$P]N>Q%#1DCJQ
M,PC%F6!Y Z+V-)ST&]+JOK+Z@\%]*\CE9\#C.:YMZ.4RM,1IDH,9B,/D<S<@
MQID!B3(78J'W*M(RR)6:=K/M2F)8FD_EA35%93:YRK%JJ/05>SXEQ*OL5J6C
M9C%5D^)V8*LDJEA,5Z51;>N-$E640;A.(1!2"(]'C<WDOL>>K')/4WA/)(.9
M9&++\AX;R$8A\JT/W:]?Q=ZA7RE";((H6&65#-:JK8A58Y5K?PK(DI;%^T3Z
M+8WT*]?N:^E>"M9G(X3!U.-Y+C64S[+-F;>*Y'B8KLD,]R&"K%D(L?DUNT8+
M*P  0/&P$B-T$W!B4<_./&9KT)'E1LQEN#"*/VWE+6S:]D-'L3Q>JN4 '(B(
MKBH7\N<YW=>9Y3GKM6O]H3D6-7_\0I<'Y_+3H2*C+++CX*<,3O$A#?W0B[V)
M![QL%F8-MO.84*]GC4F-R%AJ]6Q9H4<A8 0M!6EG@KVK0$C*@:*-G92Y$?\
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MY*JN57+^[E55_P!:KW7_ /#ZXT#0 'P !_AU(]55%5$ 5$4*J@ !54:4 #P
M   !X \#H4-O9'(D;$!\:0GL8O$I(=8X+O%P3C!'N9R^;'.1#MN)TUJO:C'M
M00F/;[HW.7V&^RGQJ#%^@.!6S0$%GDDO)<ME4E3N^^QW,QDJ&/GD5@=QS<?I
MXM%4CM:, Z_&=_-I]M',Q<C^T_ZN6OO@NU(,CC<!"6F$T-:'!\9PN+M4H/QN
ML4,>0@ORS0JP N36I&6.21T!8EF&L2/L)#E=(G/=+.Y7$<KC254Q'*XJJ5RJ
M][E5Q%4BJO=ZJY5]>0N0JPT;]ZE7C$4%2Y:K01* %CA@GDBCC4* H"(JJ
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M23R^J9@FF<_=(UL7_P (E\4-/0([7+_[Z>WR6.)'*U/V5ST1>R?MW5$]11F
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M4Q)9;MA##)&DB&R*Z24P!>EO*<%57)^I4M?'5HLED?3_ #J+5]U+39&G8I+
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M(J?E$[7-]HK,'6N/8]=*%T+=GR!^?X/KTA#'!$&!@CE)L2659P"8WD^0GCP
M-C\_/Y]?I/I<M(]T5>4&SE_*+V7#,8_/;^7_ (;^/_\ OJS_ /6(R_\ _KV/
M_P#WNQ__  =9)G!V?;7?Y[WK_$?&_.OC?\^G;G'TSNELTR*1?EY*[+KU-"IX
M+(@\4QR2P *:G@TX&L*66UZM<&"PGBK?X'.5K5\43UR_#?5^]PW 5\!4PM.U
M%!<S%YK$MB9'DGS.8OYFR2B*54+8OR(@!)**I8EB3UK</53$4$HJS6.V6Q,T
MTFED=K$SS-L*.T=O?VC0'@#K[8%]-'IC \GBY/%Y)[(GR8<*XB@CGQ'' A0E
MM33ZCWWN%,5[OCMG..T?X0CQM:KFHJKZKS#UAO\ ,,#-@+>&IUJUB_A;LSQ6
M)I&=<-FL?F17*NH7V[3X]:TI\E8I7(!( *>>H19['2XV8F"*:6O([QA7;_T\
MR3!0) 5TS( 20=?0=,W_ 'KGI'\?]U!LW\?_ *F8QV_]'S?_ %?C_+UTY^T/
MES__ &]C_P#][L?_ ,']?7?6V6=%"A84 0 #1/T^//SX^?RWU+&C?IR=0:/W
M)JS<59R,V)>6&K<_Q3/H5--Q/'8T.UEXK<P[D$"5(#+>8$>62&T)2B:X@V/<
MYB*Y$3UJ\OZZ9/+XK(XN3 T(DR-*S2:5;-AFB6S"\)=5*Z9E#D@$@$@?'60U
M]FC:/VD'<I4L&;?D:WH^-CZ>.H3Y\_3$X]SDY;;BY3S.7=OKR3MJYK+@N&Q]
M00\C#2+78_4T2 9<DS^G?.0J5:2?-U=&\%,HO%WAYN8G^OZ_^/Y]80?0 U\?
MK_XZ&7$?H^L4Q:\B72\X;RP6(.6@X[M&PXW8IXAXPC(8>SGN10/*A?'P5'HU
M6*K>Z.;N,!F),#D?[2BA2>9*EZO"'8JL4MRG-46P/#!C 9O<$;#M<J%;7\07
M@L^S() G<R@]NVT 2- ^!YT?.OC\^L,/Z.;&Q%8<?/#(&&8]"L*S1,)A&%:Y
M',(QS=HHYCV.1'-<U>Z.1%3LOY]:;1_/Z[\C9W^GG_S^OY6>_K_A^N_XOKO?
M_+_\?GT^(_TCE'^ELXQ^RYT9%;3<UM\5MSWDS24,LZ,?&B7;GH]Q=F%-+6P9
M<JPCW2!*/XPU5"]T1BADE*NG>2LCK))LM^.1 X5F 8!C_>-Y8$C9T1L[O%H]
MKJ5[N\J22QV2N_)\>=[^OQTQ?]YR8OV1/Z]M[V1>_9-#P$3OV[=^W]*'[]OY
M_GTEV^2=_(UK7C^?Y_T-]6>]YWV#XU\_/[^/^G\^GQAWTC&-XM!S2H-S>O+.
MFS?%SX[:0/Z$8D/Q.&;#N**T89FS"^9:>\KH,Y /&HY06'BN<)#^ZRH!^IWL
M:/A=_71!()4^=;71UL?!/5RV.T,.PD.O:1W*/KL$?@.B#]=;T2-^>F.OT<>+
MJBHG.R]3NG_Z!X';_7V_I03_ *_CT:/YC_#R?\^K3.?^4?X^?K^GZ_Z_GT\I
M'TB.,2M=5^ FYO7;EJLRM,K@6Z:/A(00[JFJZJRJW1/Z3%:\9BTM;-&=#-43
MQ&'[3D/YLIV_C[]^2H&M?D=@_/ZD?L?TZ&FVO;VZ_$6WW?F "-:^N@?W_?IN
MX]]'EC-!?T=ZSG3>2%I;BLMFQET3!&AUK9P)J 4B;/?[:&4/MJ_P>K4=Y>+O
M%&K4CY_7Y_K^OK^?5GN?I_G_ ..CYZE7T[-1U$.2TKD3*Y3V6JR2,(Q##OTI
M&U1$RH;?TK 6!]Q=;OSFA*19S483XKH7MQG(Y&O)Y*[UTM'D<U&C!1CKQLL,
MTDI<MKW/==&8.%4,V@BA%=VB4[<QLVM+16C$@0(#IN[>];/Z_A)^/'SKJ(JC
MZ82CQ_5G]&]-S MP//:,L[*YD:@C2FS_ (HPCKXKH+MAL(*/#492-8D]Z/*7
MOV:UO@[HAZ@N>88/ELN)AGEXUQ>]@,'2FM3-'2MY>Y7GRV6,O:&FEM5:=6C'
M79 L$:.XD=GTNVI9YZ.)R^,BK_CS64Q%ZW9,S FKA*N2AH8X1!.TP):RMN_(
MQ/\ >3BOM/\ TZ,/YK[Z7W&<%LI5F[E_?7!B5MK#@#-J&KB JY$^ Z)&E1@A
MS=PW-AD\#_'(U4.C7"4@VO547YAZCR\OXS:XU9Q20UKF0PUN9C:,D1K8O,8_
M*344KQ05NR.['1^ZM().Z'WFE4,5"'.XURN;CF=H9J.NUAJ,>6C]C[RT'NC*
MX/*85R)8T[XC$N2^\J5!)DKHH*ABPP*?2R8[\E9*\R;U57R:H_Z'82#5CG->
MWLU-@]F$9V<U'C1GFQS4*TBC&K>W_P#KY<]_WAQZ$?([/[1D[>S:D ?^E_"R
MJO8'4 LI'=W%0>M+'DVC"CV0W8H0$R'>@-#_ (= @>-@ D>"3XU^H_TL^/B3
MN;F1<F>XSB$5NFH0VN;^&L:QJ[#?X*C6M1[N[D<K45&L_/>Z'U_O1C\?'JTA
M:5I)/_72*&'PJA?NS!3K6R/![1H#SNY<JP__ "*G9!.V_P =?A^OU_8?F>OH
MOTL^,=U5O,.\:ON.>G;3\)41JO<[P[+L#\HJN1SORGD3NY45JHQM3Z_6>[N7
MC<"GO[AK)2'0+,Q4?^E^"6[C^;[8@C2B[^U='8@&P=@ESO7_ "[T2%W^+0^3
MX/CI^Y;],_C.38OKW'!<K[>N+@U%:TYK'^B>'(?<DLKFQMVS'@3.HZ0UCNG,
MC^VTAWD'':GOL:K&#X_COJC-Q_-\YSJ8>*S:YOFZ.8L=UR5/N:X_CN-P$%2,
M^VX=0,>;;2(L!+6&C[!VB1L"K;LPV;4\\\EM)@J58)6TM& 36K+P0,/(CDLV
MYIV\ ^X[-_Q'INZ_^F+K\"SS#LYB\R+2:?%;N';D@OTQ%CCL&Q)0I"Q&O'L9
MPXR2!L?'*9T>4]6%=V:B>37W\N]59^7<7Y#QBWAH((.0X',82:PEIV:J<G2F
MJQ7((?96+WJ4LJV8PP_&\:J60$DHY<IEL;;QTJ>VEN"2$NK$F,MHI(J@*.Y'
M4/\ ()(\$;)Z9.>_2I8]EUY96E;S.NZ*'*M+&Q@0'::BSGUC9<AYX\9D@>QX
M(Y#(G</BI(K6N(!I&L&JHC5K7J_E;6.J4I:*-8K48JWWQK3EWL1UHX7MB,1A
M5]R9/O/LL9$60@ GMVRE*Q)4I4Z;L9S4K15Q*3VE_:C5 Y4;T6[02-L?U)'1
ME]2WZ?'6?4GW7A^ZLQY$9SK>TQ/56+:N;3X[B-%;PI\;&3V4@=N\]A/ <$B6
M^Q>A(R(08FC;XD=Y+Z:%F+,S'Y9BQ_<DD_Z])A];\?))/_;^7019W](UI+.<
MHFY,?F!M2O?*AT]>.&# <7**/#I:2OHXP6D?:(YS71J\;GHJ(WR>YJ-1O[V1
M&2'?MR,O<KHQ4LI9'!5U8JPVKJ2K*=@@D$:)W>TVV+=NM@#0)^- $> /!U\?
MD>FDWZ.W1#>_?F1M9?W_ /S>8FGY_E^UK^4_?NG^?^7HT?T_P(\?7ZGH$VCO
ML'^)_+7U!_K?Y]/C(?I)=*7V/8#CZ\OMI0@X#3VM5#DAP+&%-,);9):9&>:3
MO:M0!FEL61F-$O9&1!D\D>]R):%T6._XCL['Y  #Y^FOY_OYZN-@D =@\;\[
M_,[&_'T_E_+IFO\ H]-&$>\A.9.UR$>YSGO)KW%7O>YRJYSWN=;*YSG*JJYS
ME57*JJJJOJXC>OIK\O\ #_3?5#-O_A_7^+_^7KTE^D TL>+$@GYH[>-"@.D.
M@Q"X'C)(T-TLB%E+% ^X44=9)6M(=1,8IGM:XGDY$7U3M_;X_(>=?G]2- #6
MQ_V/>\ =IT/ _$/ _+^'Z^-_G^WCIT9C])'I#,%Q5TCEUM"(_%\,H<.&X> X
MN59<>A9($"83SM6^V4@C-8X3.[&(-/%?ROJ@0C>V^6+>!KY^GG?P?C_'Y^*F
M<MK:GP->&_+X^5/Q_P!OJ!TS/]YY:-1I&-YE[88PK481C=?8JUKVHO=K7HEL
MB.:UR(Y$<BHCFHJ?E/5VCYT=?R'\S^Y_EU3WOG\/T _B^@_/P/GSOXZ=F??2
M.:/SS(69%*Y>;1@ROL.*TAQBP#%C-.N+XQ4XP.8YQ+1%:2;'J R##3NUA2/:
MU5:B+ZM52HT#OR3Y!^K%OH?S/\_KU1INX@]OT /G>] #9.M[.O/^O6U+HO5L
M+1VE=1Z8KK63>U^IM:X1K>#=3 "BR[>)A6-UN.1[*5& YX8\B:*N9),$3W#$
M0CF,<K41?5_21.R3^9)_/Y/Y]?_94$L'"")!8K#B=@( BML" %!+ P04  @(
M"  8ALY4                $0   &<S,S(U,#AG-SEZ-#DN:G!G[+P%6%1K
MUS\\="/='2(-0[=T=X?(,#/D# ,SI( H" +2$H*(2@C2W8B$-*BTA#0HTBJA
M"!_@T:/GG.?-YWJO[W]=K,W,['O5;]WKSCU[,\?CQ[, $BTU334 &AHZFA^:
M'P!PO,[TSL )X8E .2'<640$A "22IJZF)B $V+J>^9[Z\\BP(P!S0J 0<^I
MSH . )S\,: ; '"12!$I(2E)<09T+("8KC,8B4 A'#Q9#! ^4*0!PMG-DX6?
M11@H #SY$P(*7S5UAX \H1 633C($8H2<'?W]#U#X#Q#((G:SY__^&U_)Y1\
M([&DZ'W?F4SZ3+9T*C]YH9V5"-R1)[[UO3S=O3Q/BEBG/ .4I[$] @$[T]!T
M\X1"W;S@/\Y//Y5AR-/RA3-;8V??4PTE9\]3FS]]0I%Z(#C41-7"Y"?8=P,#
M) +A8 SU]'+7MW<!G[ ) 08 ) !Q<C@ 6 #& "C $^ %<#\SP7?_J?W#C1+,
MT^V/B CMO9QAGLYN9RY/RGAGVLJZEMK?TR]SJH_._UN-R7ZIL;Z[IS/"#77"
MI3ZKE[NGVX]*G%32'OFS8.2(TOU3@G13_K/@YOEG0<<>AOI9T'/T]/Y94(7#
M5'X63O+XIVLEL*OC'XGX'B# 2%U)^>0#X^P<PL("07C97T;, GZ0.M+M;SPE
MV-_UE) 0$U,W3S5V(Y@GX!=2@D%8_HEOA()YGO$-?&&7D<]_L/&]H6!/!%(%
MY GZV2L,' U0/WK%Z?D?G\IG28 Z>/Z3>Y.3@?%/?&,P[#O?  F^;/F337(R
M!-S-G: GC7O27LYNCC\R1GPJ,#J)20GAZ8F PQ!NCG^8$/Z0G(;P"Y_H!]_(
MV='I5P'!#\%);#_9IST'8_U[#!C-1V(G0Q3]Q^=9K[IX)B/^LP8*-_ZPVOF>
ML)/IX(R^<S&)SKB8/WQCTOXL,YU9?3PKX_WPAG:FQ47RAR^T'^PSW<]GYQH
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M ?^,W=T+"3OKL!"P(!0&A4/=/%$G\0O_'C\$+ W^WK#RO[D[ S:&>OS._2&
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M'.0<Y!SD'.0<Y!SD'.0<Y!SD'.0<Y!SD'.3?#(+_YS_^0]T@<FP^; KRQY,
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MK. &9G(D0)P9',PT1I:@YDG)HF_&^>WIMP1[#D6F5[]]GBYAWKWRE;X!SYF
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MQ,K:TCXF1HI];#Q9MKR2WX\RV#;*O];EH*]<UHA/CST^RRM&B0#3VXBR)YC
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M/69]\702Y/I8.2-NC'INR!(&Y^LQU.C&$5-C>D\K1CD4D+1E/[_O@4GMBA_
M34693+[2YM6.HQ-I?8GP@:W[0'#YK4$QCDYV7"E,<(]$%(1\!1+]P)3]O:D-
M^R7S;?)$0LHQ]=>E+?JENP";$&O\CIZW(T$BN(.\/%V&!"M7#$>!.?3&Q1AW
M:T#AV%D=7B 2<23S18Q++CV6Q QTN73&\VIVD9)VQGJH;%V6X)L@3FV3%+$N
M9V1BF,RK:GI5=''#@PI'B%\IMFFBT#!4Z7I6?O1E-/-"Q]8-]*@K&%CCH=$#
M ="93QD54=XW0&I*Q8 7EE'+FT2U3]M8P+[M$U'!%4RI.!(523X\75*ZDQN.
MB>)E=CU*_!)6M]MB# "%4>9X>9<4/W,[]"G"11'":1I+D69F51'V^/;AF?ZT
M'81Y-E+J"'<SUO3U1UM@S/C,5F9/_,)%,*>1&&0S%\'6S>).<?,B'IH)?])T
M%*_"9)C]QQVZB.%XE*RWN'D4F;62:EWG4N)\A#/C&N\Q(,R/$,BBDY7 <;DP
M?%8);_-S5<SH]K)P?6WPU9Q:53M9(*&(VFRHC+>"7O?','9\MLVB#*%:'L6=
MZV&$$@91!E%1C%?TL@G1O<>*\OAR??+7O%\2M&;.CD_;FD9!)/:\9>(I<FQ*
MV$-<QD-"E1W7Z6I+N8>)Y5 &V1"DIL]3\&/"V(TI9"?'^F>^5X&R3M6W8BEH
MX)!X4@W[@?*'[([$QH3TDH7:=_)"LTD"I3M%=1@W*%@E=W0%I*-ZBN>O]A&Q
M&G_:HK!OPRFXL?'A76&F>I>--D/ SKTWPMF\ME7],A,O1$V4T:+<TSH:$?9R
ML6IBD6I5)4BS3=\Y:;(7X%2/#1NJ-\%EH*=*05HW;Q;C8;"8DUP!]D3(,W$S
MJT7?X.IH)\R'YREE35#/ KR,BEC>=+X0;#>ZZR;@W88=G0A-?3(^I<\D$W_1
M$(1M$H!>N.T"7MBE*="<9+^!CTK3WXT,>VN27VV,+[6=8=H/%EMA;1':40U&
MO&I8Q"/H$]HP4]*/WC5DCM08E@)+)#XP8=8WW+*YTB.R+;2_D<@;&L%HA32H
MC.!PY+Z[[HI"Y[:SZ;(1-1)O'2^^HIAF5C_#D#%)M]L58)+XJANW9UG(@?;F
MCA*.QFT!X87^FY)$'+RX0+#N+3]2/;;Z'#XCI2]:H?2 5:T$&78<(_<>13/C
M,#4L&FPSC"M7WDR-]\XVA+<)/*[D*[S<RXV9)4084\00KO>Z*RJ&<O@F**"C
M"V@#[EPK7J"OZ_*(Q_[J9K_\QH%#A)R[K3JY%^G!,[W8)[S2@9GJ7B0<6)B2
M8JM>'<*D&DJG&#CM2P2LQ?!Y8,\4%H38._HB=L%'$"G.WM'(D:H><6#*I'D/
MFDR/4(^7?^A_OZYJ?'EFV2\'2KL7MGK;PR>R 9,_6">5GCGWY<Y4<(94\>:'
M^T$^KCIX54B*=X[[!\> T:+^MZMNMHL8U/+7?8$*%<B VHZRWGWS!D?Y&9;,
MV_,34Y5UV8P/7_K@X#WI==Y8Y^?E:"^N#]TIF#-Y>UU939M+F2X$Y]O1OL+A
M,UX>?XH]!8BWQR8J8V_=]FW3IG_2@/^#"!.IEZCT_&)4DND ,K\@R=34U%QK
MN?@_OY]<TB.6UYC)QA,8U/;%->K"WC?ADTW>V'*2FJ/,G5!X#N'40^FN@K)\
M_%%6QS?C\>NQ)#Q-@9V?";/M# V[=@HHHQ92I$C]QM+OOB#GZ69[[)8HC,&U
MN_EX>T>#F7'/LMK&:X\3:#UNU>\E&T4F^5AI8$,#S21P?.61C (BQ$S!/:!G
M^Q@ OR1T6,+:-Q& D*RR2J-/\P6N93+VH673!1E&WY:#>=Q\^YYR+DW%U*54
MT-&Q1F!P8O[ T5\C8UX&LJ//X>LTKSLJ9*NXCMEP@YIC;YS9F5=?!R41BZ+P
M#I."JR\KR_ 9I4C)BZJM=>=7S*Z*J>W!0X6;MZ6W&ZX%O-TVH%=>>#8W9]''
MUWNI'5%!FTK8<'ELV=\?;Z.*4=?TA2BO"D:$\X& $H<L=4?YX2.2" $60BC_
MV-;F<(!"CIR*5(Q]S_+'%D<49>Q0^/C$V[Y,8??MKM=KLA>=D,5%S(FUYM K
MH+L[#T95H:![XP% AKGA8)&,<+GKLPM2%,/K6\\/;2<;N>QW;>O9A0*K<B-J
M3$>H/$H68_BQKK#:3$XR%&O%B5S4^IR,XGU,!AELTF4;-%'JI0 ,U\T8\$WE
M3.^Q=,8M"[JIKK^+5+UIES";JH0[2&7#0TDCB>:>1YP3ZX8SU#A6R%J["$H3
MD A.M)VTJ)@,A+YD&]T8'=03\2%H0]=B9+WBC:#UXY"AR7J^\>E(X B\X<#_
M8 U6-BLY?66ZLE[*TDS.U,/T7F2<6<^>40UK=&)YI+16)*FY7D6L >5#P"#F
MO#JDYH']AH"2CB5\_'*/0QRW@_CJ?CP8!W^0TJSS/2$8ZQ[\XR=JO'UP^W;R
MH0^GV(?^KM;JUY9M 5L$;GH;DHW(M]UH-P\-:;]]$7U*X4,8_QBJ1AG36]!;
MZRWLDAL=Y]ARK^B!\,:N>:5:Y$J:Y54LO U51\]8SF*>AH;;;Q@^7_&W?JMX
MS3YM^F:8,&_J#>$+3#<>A/  -8H?TPAA!EUV!?,QW"9?9,BIHQ91>_H)$A&;
MY,;$\<6'<T%8@T+:Q6,!8RV;5F'N&)!Z77--?%&+J7.1M&C;4.LN+_OS]2.3
M* (.0H>PVM$*5]+MB^T5*8,2F:LYKP72,PET#D@F-&('PEHW-C2RJFYI# D^
M:&77V&:E87*(>M9T"8=/2#_PKFF0J0<#C@*8?T:,FIURJ4Q;6W.>9T\*.?A-
M%D,I6'*\F]4RL8.\JS=VQ'*U/8A&K<%E9Q+^?.+UY>G(D+$+9)TG6^$$8;X^
M\I[H5-9D(X.=IP^5L!L_SO=Q3XN\(2TC5/",O;W@ >>L+"&\MZ-F N2FCWZ&
M9CZ$HS#'P1P[A3_<N;6TTE F;GZ76/P]5(+\;<M\<E=['?Y::.8]'21;O-8-
MQ2E"=+>2R&- 9 QMHZ5<,6_#"$6#!I1! IR*M]YSK_U]F'_'-6WG42?!'MA0
M@3:V9L0!9+1RSO/>3L*E)R \\SX[&3STS>!"N::'M1^*._1P][_B7[N[]3)^
M;HT\82'-36M86#N*PY4G,%G#D*;R]9*-!HE(YXUV"HXG5BTL0"61&YF7=#HH
M.$GI%"E47&0AM#3Y8]%K2*E8EP*;$76V?!Z!)E<+$D66*-(XQ7?!TBRQ&;']
M@95_;+P#=%E(.Y[$N=_0-5&G:+<+&T%F647NU16IFO.PL95,Y+,%YCNA@4/I
MF=.)!Q0"\$UO3]"53B[Z/WUH$VZ\N>RFIGW'>+SGDZ:8&F=8EX."M;J!R4:I
MZP,0U<2$"4C2[:ZKL[3.DZ=,[9"JP[7D77%#$76WZCA]/A>MPC%S0,_'GBQT
M=?S7[5%O1B6'!;!15G-%9*X#UDEUT9R-U_4V!B9\T#7YU_@B)U[ W=K)"?4Y
M4/H\ZGD)SE<6WY2J'@WK6CK_\B@)+[J\U1':5Y$ELX,-QSBR@!MO83C"TS*7
MDLU'O.++Z*.<B$/-C4UHXC*9RI_USF9Q/^[2^,B?4Z WT'_-DUKK(>=[8H6[
M]1D[SAL+:0M&\Q)W]%UX )2/P=$F 768=[>$>'VN:6\OC%R/FZL=(.[HC<AX
M&6%)]3HW9M'F M]'&QG1LJE+,WZ+:"/4^%XLB\,%DS,8P!+& -&0!>*QE=;I
M_#0^O8TGWLP-(TGS;159%I!D/TA>IL6CBI0(]88DF9T[6G4JW676^)V:>.]G
M^\I3/65JGM!-WF2 T3[ 8>J?:ZZ!"RP(<L0NL5I29K!S^TZ(4,279_%6/R9.
M.519.FBV0C&L/"6=.^F"R?Y^,S'>8,>F="%5,D7Y)[YTBG"2I/N]Y,OZO=$/
M>RK\[7C$!^\XNT\$9K=^J%[!*;C)5EV#4907H3(E[Q7P7@BQ7??9O0[3NE[[
MW:YI2O@@<U.A\ZT#H_AC $O&5.'>F$UT_TM.+_[/BP-,VG79SE9SELJJ/%W3
M][(CXC,9T6AM+G7PH@^\%^1?J(T"WAZ710;Y$[ZN4)<EBXKC#(8F<%_FP\@"
MA;<4].9]Z?YCZ6SKZO!X8RKUK=;UP3'@,/,8\"''78-9@?+C :O^]#<%1$U5
MG^K*,>"CVH=TYH>["B7K1UX=SP/2@PS,CP%?.K\<!HE]!H]_6NL4Z][;'5'5
M+]D9H^QBV95AKMU7>'4,&/JRW&QE+OK]"P$=!X\R/XL7;2AQQ>O"=/1K13.0
M1<BELGR;2=%2[B2KLH<6%B&EL<*QM(\UH[@]>MAOJ2"RU53C"3EOI;:Z[FBC
MUQ\#6$-(3@:18M?%IJ*E#-J%Y#?37&;M<&8] O3L"U-"G)9ZRMP\BIB18]:=
M^#RTXP.+$#-3I>9"_H0QU<.NHHQ]RCWR'/TDEI?(N&8!#KI]/N7*WDM&&@9/
M,Q9V S^D--4ZPQ;,G32F/[.K2==4,F"ABSPH>TM"5I ?.36ZO('+&KF!=".^
MZ, 2YO? N%P:$YY.DLO.UV2?.?#9:-AXL9K*HM*.@#'.L-#B1A(/R-6VI1+"
MT#G "A$F5MD-SU<GZH\3+[L>YU;J0>@&(NG2'^8)#@@6)4Z5>WJ%]O- GY#7
M<'*'AV59SV5LLPL7<158J_C3[:(<66Y&$;?LKRE/;0CSI>6KU^%],)<K4;4U
M#1^3RXN]EL];Z^AE)L60%_X"=>\%/ $WM (KCG V>0\2RI)G5Y^^F'Y4L2-7
M]\Y/_^"QE@CIEW+4W=AA_^?=SVDW,:N)742A* =3N2N[@V+&V2F\7ZKH!@SS
M%_6:IH8W8ERD\F8<B:\U/'D"9W--[JV@Y-3D$=*S1G/'V==_#K +L'^\P2F<
M[Y4 :!,RI0O6BIOQYG!\*]W"-9$]$MY7_A46RG;D#(;:3=0JEQ13U!E!@!0D
ME'T,0D^CO @-2YO:J-BM::-]7B7%F/A4]I4=J-9GJD59OI5LS>JA"7Z9F=!)
ML[8[WM+-"-;TXNRYE.P3Q\9"F@ QT7V@!+A2_T%2.-9U3EW1I7><)(S+GL;>
M-9#/L*R3Y1NZJ\5H/GO&DGF^O^U>IIAE#^O5-U%7,9,JD>V[SV:0T'0(V@UM
M@#]?GS@^K7EU2SLGX8TE%'/X,<!7@U.3,%.L(^I=U&H?-2&!W2P&<L^:=\(F
ME_-12N5DH(R;1U>MF]Q5E"DHD)<]'I[8?F>U:X>D+TU3FX(*J55,0<6(K:#?
ME(7W]MW"[71MLBZN!UP>? .$'BUH))6W.JDB]9^)LF!S//2NG\66HHYUENV!
M9?G.C0P'>T_H"V ;7CD&: &Y?:#$ILM>]OUIF_!RYUIB;1/S'0Z>6V6<Y/58
M(SODPV'A'?$A:!UJ!19FR-TZZ2;2XKFD X8([13,V<?C.'86P0S^-_$J@B+N
M@-RI&T=E:$&6#K&L@]C#Z421*L]O/L6T$\@?/WHP7[.\I2^9.X6@$]\3#<'/
M9QP9%JD !AJ@4Y3UK"XF9[0NV^,5F<H]MWM13F ;;<?2$T''\@)36$G.NH<O
MPE_4;6U>I! 4(:V&;!7"D\35Q,%<JK;7)M-EOIN\:ITY9J3+Z[L@++HVT(I]
ME0-D<9C;^#5,6=B!H\S> 2,M1H_Z(&AW.%!]1,(Z=)[B=1%H:'Y\W41[\-Y>
MO*LS+TMGG6RR))+(A>:UB@Q9%WVZ"!E89Z=LP'6D:X7MZ95PR6(Q2W3**VX*
MVE<MK;@!Q<4AYM@<-(#D0: %J!W3HS.26X?;DL6.9MR;=)W7)A;)D[1VBRV&
M]0:&G1*5D!+)O==1RO2&A33C[:X6'6*DA:Z&=*.98J2DY%KF8[\\N6>:-P7O
MIN('WB9]K&BU(6"'O$#72<\P='6+E5?;*WXR1BHKQUM&GY(A@6]%^R;A*%=)
M7BQ+LADI.Y5QS,)1GJZ7>P>Q]"N'U<4'./&)]^"9TAJVR]XT,6+179=WY..S
MI,?JWMIKHV'%,D3X#%PMOT- AG%=JRMX]<M20-S^6A$;WX[63CN3/F,C;$B;
M 8YZ7%BCBI%;BG[O,5D/@[UL62JKVHC,92,A%18KVW=<<6#VL&CSLF)3E6BX
M-YR XDTE'WJ9S@-O0"E1% R-A>&&QD:N/?!>E@@/7X<HL%#G)5UOW@Z?6T]4
M%STK;3QM"F9^PN6U#T77_O+HHI'GOE<\AWY9(JX!Z%8"9U\BJ#.:3M(BFWN1
MH=BNG;6LV+]K3ZS(U73 1,5TS-PSFDZ3UI"$RM&>TO1R-U_G(P!C@H=MO"K?
M3B<A:;?H8'TGA2&[)D=,)WYX.(&,, M/'D?&C;R*VF=@N#Q:@OJ+L ^%]7U5
M[L6<#REB+:4S,[!BL^,6K:WZJFXRR4"4X[@78)[)>RK^N%'F%,H!8B\5.JT3
MJ*[* (A9>=HX3OJL'1 I \CC>QS.@>$SWTP<J-\S(;8SP9^4W[>%"+#%H]-(
M35:-(:*SQ)>N+S7IXF9EX7/K#8YMY^JQM%Z0'Q"[B$$Z[L9>&[]U^>WX,YT"
M/.I$WQ<.EMYC:!NQ5ZGBD+#1)$@+W]";\>?W:1?N4 @O]P27-]R]MY3M4)&B
M6K,>'X<+QJ2YE9-XVSLIFW\=$)R?<V/BV<U/YMESGX+PW:X..S-^GN\N2A=?
MY4RS%."L\K./TWNQ'IHY*6R)2:[BR!?X)AKDK;Y8/ NU *Y__OC4=3M/B!O,
M6.55.JM!=%%"7#6:$M-?/6ZM\&DVWWM8!!,!=KFU9-F 479\4T/!K?I[]VH+
MB!E+#J3XES6"=9:GC7QU)(CA42Y%P---V@H^+6DXG]YK<[/D1EA)(.=,A)6E
M0\;J^VX_6P=-E0J@QC-G 2::1^YL#G::QJ^+=]L/NA/@UT&1ZZI!"9:>-JZ2
M/7,M;O1AXW0[-;1H-F-D3;"2#\T"G9-!4H_#%T#(& \FF]M=GJ9<O8Y%*W.W
MBUE+FS]CS4]L3_G08ER]TB*;J=U=] C$^7*(0U,Z)7)*D\62$?/>+C3F2<FJ
M]D.UG4;H)]FKN?<3/JNV"\+!UY-;!_O>]B^&T5[$\R 'JLJ659;;7#Z2-!$F
MS*/0DIN95K<=!,O0DK.\\/C6TIC(;9AC9=%R^X(00_CF#??>&KZ[7_0QYM)D
M"J:V-#QLQ:5NI?O<K+>]KAT;LS/AVA .KEVB6![5#)IO?/40&Y/G=9]L?"&P
MP\+E2(F=T/3&_4]7']>%KQU$K$G*:\?/RK$*]Z]7W7GI"H=>;TO49 (QAZ:Z
MK336U.,7;[^ +R:Q!9O&/8?UNGH$^$L^J*G5?0'=SLIOKZ]WYZBA<'-V9L#C
MKGK(361_Z%VLI/ZI*RUC09XPK*I(G=W,>6-"@&Y9W2]>,0$ATY%@HU56?8>J
MD[E@FA:"T;E^I<9V<[3EP!85NW@@SVDK41G):ROE!@TC=25)7:CUBJY*,+VO
M?2/*ZRX[)^G(Z$O'!J38_5KRK:].3^^L[5(+I8H]6,/SW"JY?^<%A$PW7[-$
MJ>&KJO>.N7E4[+5>2\6$\9M*U]!F7HG[,!P#9-JVS"1X"=.K^F*10]:5\S3C
MH@FN),D74RE)RQ]_I(4 )95LK+]Y\:4[YC(/!QP#J*@(G'P_R+,-MAXPJ6NN
M<),TWN\4')IJ%6!+"V!Y$W $Q(_2WFS[MB\^MC3B3269Z&I2^] X:@/3&T!+
M40JA(B7NC0*&<GK"6!?$)$1X@*E]4<FJ#WDT\O%>";^Y> Q8M8A]-)E4$8PG
M19%&;UDHP)*LK<FE+/N$/JEB^E9<ML?]%T2>L['X/&6!%P88@KBZKW-J@[X]
M[%-OL9Y1[WL[D9UQ@3*7_ 4&'(<KL%O3>:/^,[-XW*0'B4J<]3$ DKUG;BQ:
MOR_0F5+G-@+Y&BJO]JKU3AAH?(UE2"FON"-49T^??5&^CQ=0J$9"S.#^:"UX
M1\VC]:IUQHPB@77=4K'@(G6H0W5#PEO<G.2]]V^M;ULL)ST8 G)<%\V@Z6F@
M%:$:!_!K?1$<])&E)H-)/=.44^7?$POJBH=[=6DD"Q5,6D\J,WY;B5G>AB03
MW*_V-62+7;6EX #6A51"BN^ZOO-\5;?S4*HSV2Q\,;*+],HVX8@ZEZ8CG^\6
MC1^^"BTT^W9%%HE>Q,/NTJU"9-\Q8*N]LWK[,J;'G:2U2YZ$RA L: JL^%9T
MFZLKQ>B.W"+2VMJRM>:U.C*_6W0-FE1[0( 3A%%QH, +Y [W8>_E-;.0)9Z9
M;LN>6J^>U.H?KTFY?)A+TX$3 4FN#LL,A#X:H'>9R'_CR"%<WSSHK9C& <F<
MH*I8J(I[]8&=V+R^:G$VE$FSZ EQIA2G9@99L4$J9,1&YI(F>@'E^@U)3E6<
MD>OILU)!ZJCTD3$BJ'/OA#+_>'-I:<+K%=50 9;XP$5M>HUU5XZ$Q\YDXLYB
M7D0"_46V5B-'1:HG%PG&7CN!J--KR-"OJOJK=W)X,3/TC@B\KULADC?<8I;\
M4 U5DD],G7458+M'MW(K\EH,A%T3EA+L%\4'7:=I=\":<#$W!;)$(9*L!VPJ
M%6SM;K.?-N=K/W42=7@T!N7L/Q4H J?)?'T_8F0]G7K(:84[>EFI_,#6)_4A
M'9;I'D-VW78FS].>%2E)YKRXRS:0FS?O[F'NZJDJ+*\QRS=>FF9LW.'M^.!'
MW[00+2I+#R_7I[]4UO"5/A5%=-4R5J=7T.7=_#CZQ@S[@ZLV+0XD"MP/-46W
M6>71YIF>C\Y(7NOY.&+_A<DU.M4Q6.J> C6#$5!+ .K')-5:& 4B7K)+!L;"
MM&Z65_ &XNQS.>[S#WC(;F8VP5\0DR<O8TZ%-A<>5;_%7N"LN.-D'?7Q'OA6
M)X)$NUA^<6KR_^/KK;^B8*-HX2$$!*0'&!J&+NGN&&8 *9FA>^B0D.[N&AH1
MI+L[1"2'%J1!I!$D!$E!O._]XJY[?_B^=?Z"LYYUSK/W.OOL<^E1VRHB3D#Q
MQ?X-64=K_TCSY&0-R*]]9(0>_KY!V-*OI7*W0W@K0G^-J\4R[4N91C5*3P'E
M%\UJG2^-QNUR<SI>Q!IG%83Q0D#F(O[,O'0C8,Z7((^O#L,-0Q6C:I#^D#VF
MCO9/_>VM?>:0^;7+ P)S1184=G]G@CV4?_YYJ!BP.QYAFZ#99W7E:02KB35O
MC_W?98[FME/=34Z'DPT-P6TK%T0.BT,2NW)6HZ+NNP('JB0%!B&9X'\ #8-3
MW5#7 *7T<5Z/2:88<?=&+KT=45;,$34DX2'60?/9?CZM<WS]Z?3&A2IXR*6%
M]Y5,0EF=DMH-LR=FC$MXP=8CO&8EOW9%PC4Y19<^[9*N2&3:,Q"JN[.B& ET
M]>3ZGH./K0'!]PN_Y^1AL!\GB>?W*I_1)=[[LPZ>^BOPD705/;^NZ.I(J"<9
MU^OX!I3A12!B&S6JF&5SBL4A"7QV!/F8DR ND]7=WM_W:<_-OI/ O7GDX]XX
M231_28QW\A:T;#@=3.5KW7]V#BFIF?R?:9M*WYB39VW[:?^\?G!47PY%-XX<
MHN6)@_:?1N^E=U5O-OVT_27O$,S=R@ULW_;;JEK@WW]J$:EJ6-FDKAOD\AM1
M2GN GF7K[[J]B!Q^0!_6O._QLQ@R)U[H3Z<RQ94%GM=:*_KZ6B))E<FD=A]$
M/V3I^94A,!!_,]<U/%IP?@&SI-\J#(!/#%/BP;>X "0=UAF3Z_*(?0+1C]/I
M[.\&9VV\RY1BZVM?%":<O5)G/@A3Y:6LCE+T/(2;IDU%-=F.25C0U>C?!%(/
M:]NDYR^\M JFWRL(-#8EN"M'/>=]U+XF$%&I2Q=1H"*,UAJB!\!^V#4WN-77
M?4 =G_FYUN^8[1?ZDW'JPA@.?)GUR11 LBC N*CRO#^P&:0RJ%B[T0?O2,+:
M;\$>/R_MR,!S&&&]$W"--9,+=E@[X*FSC%'!5FO-X/ IV9=_/J56<''+2T6;
MN_N[S+9(U8B&;U[<[B;:L[[34!1']O51!=SG@->2:!CBQFZBEJ,O)!COAJVG
M'B%@VN<T7I+-5S5M'K*/2ZS&^\&]()T\0Y#J/ O"H==,JNMG+?JCJ!7ZR9$J
M3/LD]$VS//43\?5L:"=<MO5E<(_W"L.6]'GC@MQ?@,=W?^ W$#5"],3+=)F%
MFP=.EY!0\)<[Y.@OU?W/U)_F81%"1(IW\C86'WGR'=7'#G=HNQ:Z&E9VNLP5
MW0)D0CV%EA9M7UMG?/'=R5R\Y#MA$E*234V:-('H+L%X@+-WGGO"Q:1GY/MW
M@?[(;.>X=/I371#P!CQQ7B*@&S&B8*_[A2V0*3#J.V9>GU#TFJ$.M=1,JS"G
MD<<#I!@M;S>FLM,\G55$^2YU7[)0MIM*$CL>-1^/)R[%^S99T<R83C\Z1BP*
MC7)B;G_&51\@$<Y3)M.B:4WC!')C.%A:.AZ5F(.E;<-L+UO]!U;C")&>(QHD
MP %J:O4-GQ:0=]@0C82BA"OYAJTCPRM6);0^]&P$MH(+X&:"4W_90*TT*,I!
M'R9X!]/&2.;@#%</X,W/GW($@7UYNJ9R@=?7[@L:G0RD0" 6=[4<+PHW]:,N
M; A)EQ24!@DMY >R@-D4X"[5".QL">H3%^'?U>8SS]1D8C8:G6JGGM#+?S.R
M28$U];[/ C<^PKX!2YU-5D^/YAYKIQT[6KIZWBZ:-*/.B(H5.6SY3[3*TH37
MMN@*R'4S3,MT]Z_-!W0^5<>O>&\&C_2BX1*S]CW)>?NMY7$E^W(KGV_U:4@2
MKBS.?ZFUI[AO+#5_H_]6<]ONA^">'D=:1K]'FLEAD0RC!R@)PLJR5ZD+6I*(
M%P2<:#1:)>?@':RV\'?/#-;<"5S#O!?"!,0DI2(1DR)K'P=&;\Z)OCD[M26'
MG=&MU]29G_BT4Q*_!S.R$!W+Y+K;D[EZ#+\6'+(M\$M!4<C$?1Q=!OXJ.>8Z
MR)^C[NO89LT6(ZREF9I!J/$6(^T!0,/W@RC]CB'</*9\'MLN(1[68B+X.KI"
M[[C,"NYM13>BE"<*O\UT24AI-3\('W;.,OUNS)+\[=O-/HTDW9)HB@?=@N[O
MQ\(^\6J+96;K8=4../H4K?.)P]0R" =+)W! D@T*I-U?^( =?>\>WH)#WD?:
MG.Q5I60TSD0R5'-B75;^XEK[)HXC1Y4!B;LYVBA@M0:M<$'_M*+LUPR'8OOO
MQWT=C6?;9=K-.E%K2G+.JZ*-AT^&K4J][RL3AFH!K,Y8Z9OPBR'<[PB1-BS+
MJGZ3R5L,PMP/!"TN8CPHZ2]1<(B%.X;6L$"F9'W%VC>W5Y$="90F%NUIO @(
M(Y94#G[(:X8ZC]+ 4$$^KR<"A&MECSI>R%XJW<[S\MR26Q2AK3J,2\T;[M@G
M^:N5'O]N^!U:=KB6ZJ$H#*";[O-%N#D^E&]-E#N1B3M"@/T+].PXDJ_AM*"
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M4ZIYZ5O#N\V7"2V8; 8H#]F3"H7\ULK^3=9G+5LBGL&1E*#9FJGC8@,   >
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M2"U^5$IZ!.X8HKF&B_NP3[--D8+T8EJX-_%=S W31EB<\H-2#/BC!6%Q7B;
M'2I4&-OY,>'X6_L:8)L?.XF4U/,MDY00ZD0_>P7PD8(7@R0OYTTBSZ%^#X5&
M=)RX09!R^/SPM>7F9K+[XL77M=''= %-VF '^Q?^\)"WO_F&/57Q1]J',;#5
MX7NV@@6EF &+[6P0:1"]M\$[.0$UUI\>UYY#%/."_GK0'1AV<4M]6 NNV6YR
M;C8IZOFZE1'S12!/66** O(8<R ]QOIV=U8H$!@O!2R8?$=]1D_^4^6N97E'
M^VTM5,VKH)EMF0RF\P.CM/;BN9L>M88_F</N14W&7M*Q^X'2\Q6YX7 47#UE
M);_B3S]Q>>'EGOS^K%^M#68# 86"T<+[?P"N$N[H57>SP23;]K'"X$Q^W2[_
M>E2,CNN>9G/&:ZDHBV>9&1@"BBKX0^1F1%W;2@$X,*%@;=K@LXQS01/KGK;P
MR#56<7+J4TRV+TH4IN =!=,74)Y-$^\7EW6&/_F. I^TUI93WMLGN^1O&Q^O
M[2<5GV[*?K U,AW;CX^#/P?9ZPP(-0C_6:.OF;G%=6=:F"DT@;FT-\B6AZ^U
M#-Z3@PN5=V%"XQ05:<V[%$D61ABL-J@4]\7^0?AYW5E=D@>CQ\R! !K;\^7Q
M11;<E_ CR8@BD:?7&2U'^C4N]A*Q/S7E@[$&=D"M6JZ-MX**9@68!K8K*=5G
MJZC-Q.S,U=O:EKFX_EH8/"7D?)2=*J4\=$!93_KUL^B>JVKPY#C;C@V37,<(
MR$%<17&94"=A%<O%0V/ZZN&2&%WSF0ZBDJ+F?0GX\0$G6X0YTVJ(>%)NR=+4
M:9VTM/&>EG$*3Z0]&VJ3@YT[A]871O+\H(ZV2]N*\=00:AZ5_7F^^\JY1/8B
MX0](C<W#.FX:J:QI6"[\Q7,WOB&S/($C*PZD_9>09&+!0]\@VH_!P#TAYZ*$
M*5VCE?);'A:53N'2.J<BM_2D[2M+<U5?&I/AUMF7+SSG-42$HC,>NH:]VJRI
MR(2$_% <B"AA2EY1:A'*[<+^FO\JV&F\2-+8$?6-=C?(X^.Y(PXT[J"--<4Z
M/IGCJZ:^GH";=8D3>697X;==X=$(Q+<BB!%%E34&T[,O@FY9S3&O4?HX_^'-
M1]=*#N>WO Q>S@2#3<,7LW0U!R2'?-RG7-KDM4)][U1^*!)ZF!]\MW-G7W_5
M?:(\UI@$A?/P(O](Z[P)JCJW66$FX7,.9O,DI2@<OFI7/7$-.;Y9N]$)9TW!
MT5ZFZ2 \+H[W+&4F<5')!215TQ0D+N942FK)3</+8TRJV>,/8':8RG:H)I4D
MX5/6U#)75J=#,XIL#/7VL8I9H8)W<C53ITXLYF(UY-762U,88Z9.6_BV_C!V
M6+G(Z0T',6:/'@#L\'4AU9?O<T?K"XJ,CQL7@EYD6K)Y4#.B?L&YU0&03BDK
MX4.T_>_7:AATLIW$;DO.H+ROW.?T(U/X1^YV=KBCZ0X@>C-US%+""N6#58Q;
MKTYF8D*)!2YLT2C ?/@\'O4RO3.].8OL4_>SVM-GV/90&S)0?DV"JO]J9K/&
MLY\06Z$Q?TJ$_;AKGCCWA(!,H8H=4XS=MTPQ/""=F\3/&?8EP^+7'B-:S=-V
MQO0Z)I,4NEJLTE0ISI+J1;0A^G-HP"IE/:51)\; =LN,QWNYJ"]AJYXT4:EL
M,0C)./)A*VAA1^;GE,,47:EQZYI28 JXZ8R/GTSL\<>>B3\-E31R>&* -*.P
M9T5,&AO'10RWS;2\[U87[]2^/?^:[ R;- ^<QP9"J,)INM@2JW6(ZK\WY2>L
M-CAW+%8.$:>_E5W>SZAS-CP)$*G$Z4'.CT93CK[-K4NCJ7T;2'AID!09R +E
MRA^^;G=J^I-5]\9\34[/F8?+37ECFG!>M/D+YVIQ]/NR/.&XL/@R':@==$CJ
M5/C'O7\ACJ-\B^N]R=U=4\>-KT>-:8;G?IK"U[MMPWV.WYU>I'&PW H?TH[M
M0D(_@Y8O/M(.OPO^5+IU5O(6)0SU%O>I&S\4,-+4=CE7*C8,<Y\42TFR?D[E
M K]"\UD7WO\F0T(/ZVN1 54/>9*U<RYIQN;?RELY)Q-C?V]@9;3]!F.N/HQ&
M002$Z&,.?Q,L/@;7]5?ME_7L;'5T=_8&^K8'BH3S571@@E00AV^HA<!"K1G,
M>D2Z)HI"-B?1;EC!8NMVUJT81%K#;LK*D&8KRW@G<-+TA%FTA%M%H@<+QV2D
MG+DT?H/W*LSTH5H(%UL/'*@:2O$E]YZ5RI4</,*;+-CKL&CTHF:#)TFM66WJ
M\R"W0")VE),:\Z@GY@&HR[FSF9@N;9:LOM>P+IE5C^]D:7YXFC61SG.PUN5+
M&^H5*#=WH<^3$%I/2SHYF4Z>9?'S\1_@3>-=*)_R/\"GVZ=_@/DZY:W0Y=W#
M\XOE/P;GZ@>E8MMO-HV2S]9<;K!:<Z2+TL;6'4S>.[.SV\3MZ'R87]E;6NFC
M5O#1$)*?;959<T3JEI:JDI@^X^VH_?Y3KV\J<-*LOSN5<O3H2\<:\%7(R2>O
MFENQIU:ZR9O^<_O)6/;7NMZOS7]N>,[3<>8EN[9-H6J%V(CWL@U'IBGZ4AHY
MX_F%BLZ?NAC/[X%ZM)/$#+L[S<*2TEDFE"DARASD$>/>1G0F1WETW,V;KZKB
MXQER_4WS=*J2I(^J: Q:V,CGCY7'C*;*]'J_/I9<7';,$E5G]4HDH&>W;!!=
MF549\38:CB;YFH^]+PH>$_K(JGBL]V]D#*S'VELC9!)&3##??V7K+H;S'#.R
M=Y L@^IIW&*$0('>6.#6:;8IF5P*"H&F^\C&R60PYSM*.1%?ZVQLUQ!-/,0\
M4D=;;:B# @9FRBU_^WE?.]53H-=L@.%H-VF4Z^4'ZP[[S'5.GPNA1,N85V)B
MC\:F %O6_KYX=IEC;O>O9*-G?=M%<!JDD,!Q>8@/+CI) QWUS7]%;2PGY;3B
M1XXKRQXI+YF+:>;%S<.;UG@?9:R2X70M!R&ODET?D5;C!_P'=5#INXN]KK22
M:CWB_Z^3)T1_<U)_?+J:SYIKU%<DL;#XG,Y6P/(/X%%C3Z*Y'?H!*K]J8-KI
M)]^%^Y2U3Z5N\*3F_11IK1_Z!]KPU-5H'&,>?$I1?W 1*SU6RY.]=!:^V#TB
M&DA=EBX$><EQ8*@2(_94\BI'Y:??EYA-4R-5O/R$PTJR/M&)M4N2UK1J3@?Z
M%%%=SD7#PSK>?,9=T(-!'1EU18K"5#0U?6::@B1N\:4H*_ A83%@5J0I*T!&
M_491@SY]BYB>&:JDEDK#2SU0"TT.J#(AFL$#,].-=B<7)'Y/W?'P^>-7$M5C
MJ=X/*?#.>0&&,9_#.5@S00"6%ALF>V</7RM\%3R!">7U3P.$PTG22*3 E"=&
M,V+A6 !6QO>AV-1C7.N]Q63&5:GZC;<6W0PI3M5!Y7PSX;+[M2?/UT[25SO+
M2NII GLNS[E0&#/%S5DK=/Q87-2U(%N4@ \6B#<*8.!BX[%.B/NF&8!$XJ=*
M^HV.1R=<"$*$7K*^A*N5<.BKJ&KISJ@ZAZS-U?:RU+#4ZHV\<:<1E/*-K.6N
MLA0@2)]CHDMJT%8I2HYAJ>#9(U4?=J*(O.%6^*L>JGM^E8[:0GW'K(^Y'UPO
MT#L'Q7=TEVV<T=4IQ9PS-?'1%?@OY'FG00/['# RU>1&VLH#U![1KA0P;-X*
M5:[=.&%;) =8/.F4;!AACT=%1"/JL?N.E=,@+;#MLR 7QK6EKH<_3CB#2&30
MB]LT 2LPE</B* 6G/V:.P%840M\.FP*ZCC+?^+X"[4+S\S:XE'/J:3[ ,CA6
M\M*&)70-[U_C*8.:P2DB5LS2)=BN-#S&"S:]H-4LA07V,B!^'A/J4!7[F5D\
M/U2SF;=W+QWH)3W.?OE^C_7$; 4%D-^4#CK^ *!EO5JWW-)%B]K3<14<=AN/
MR98:B";4I#K]Y?CABWSC_: G:IRD)FH*/4)RM53)DLT(9B%LQR464$,<](_1
M=V 1Q%^IK4<<=SV![\1SV(*6,I$T!3PAUWX=OHP#+X5/[#K?"DEOO,0IDE]&
M(3/U!S_V5"1LT6^]QW^/SYH]"J/013O315.H2JJ L&EM:$=68;R)M..-&09\
M9'V1O!]:</$@4+V)(2;"FJVD1$6"V<38)2:4T[=2::)!X3HJ#(M0NR>0@M*J
MA0,/DSM]5\^T)P;B<WN>,^7'F5AMH1^'UB-CV^H()<.YO<SX9Y]&;LK]&.XN
M$M1$:VYK>"XX\JQ=RU#:(,_F;#WW=Z31*R\\ ?\ 1!X16@J-HC%NB ,-O[)\
M!TLA;IF3]5P$!(GQG 5<39VL=/S\F6<98E ^&C&$GO3E[<Y<>;VSW2L5Z0*:
M"LQCF)7P-_KU023%9DU'*:Z5EX.0.UJ-SPN*B- P-GVCO\E624]?@S>U;)2,
M ;)M_ZNG\0\@8&_9G-2LF3/P+*#Q<J,@NWER=#WS(FU.'>0CU=.5QBFALVIU
M]ME6OBSE)Q*G$B_^+WEJO;-ZU2)I[AF.?"0M_8LC<RKDTI&&\4$_F!J%8HT_
M8,[6SYW1@423:9;6V8U+*Y')?@@0G<A;,@T>^;/1WH5[Q/1[ B_M/6$\67B9
M&Y8(BH5_GZ*UBE=89^.3M-4@+4;03&3Z1Q-JD*8BXC5A:ZNZ;3:O&IW ),_=
M, H;8IL<@>+Q:42J/E4E_@U]>V@H*OR_5(O<)2''\4\!>O7]!MWZ*U=+.@.I
MTIR36@M!IB8,-FRKWKZ<L<T\A6C]7__!*YB/)V#8GI^<:.]'=_:-WDR,'<^S
ME@+1J>$Z_W^ +"D^GJ=)FLY@,NDJ!HT%RFQR DZ;=ZA]>F754<,/^;NOTUB[
MK"=?%(#^OC:#T6R1A:-'].*C#OW/V38T;G>OD'\T:5]D6S)'[)^$HSW?0K0*
MKYW^[(W4WNF8/1WA%70'/U7,+]=*!,TG_0.,F %6Y'^KXCI%,<[/&(7=Z^I6
MQAUT-X;*!E^)N:(DS%GLDX2*HC[MA1D=LGFVJ+E817*LS4B+:]"/"$YI8?$(
MKAD?^[EH-RLF#3R8S7+#L%7TQH4_?1>)36NT.)?TCA3Y;2KV>^*R<Z67//SA
MY:K:KRZL4P0/D=A08IB)QTV:T: T%[:5F,3HS- W,&,O=&KL#%833DI^LYQE
M_[\N^=2EIM^@N#K4W.U'5!Q7X902>UU0.T3=0\ /HAZ!]T,6#,DH,P_F1GWK
MB.?2-<)9L)!GOOLGL6I$)\#6>'5E<%QP7?+]O@J8D,C4<M%YB3#QJ,$ S3CZ
M18VV+^ <?]*#\)6GF('%G<[!7C9$IYE,$6CT3;E]M./R@.'[YV1QILIAE^C8
M)>V,HUBAXQ>P^12*5>Z$B%1VO]T$13C-7%*4[Y$3A^$XF_\!RA'ZDC?I/"5F
M:KA#_DU!*-!RM][59:>UQ:RTM=.0B?I6R&2L!AFRQR3Q%UVOJ_'1B QRW@//
M6V++M[UTX17FF4*1;K^>?L^+%O5^,T4'O:$D#SYE7>7%V'^,DIXWM'H+,6 8
M$"GN!D7D;;+%B:=#5)(N0<_-$*)?,79Y$\IPP#O]62UTOA%^?HY^#P]N<BP[
MTB9Q'+VO;'09_WM&(YN?6,,_"K\H(M).>!A!M1T_,7LW>,\]QN[-0A0M:$1<
M:BY5J*G1^JW6=%Y8]MY2+76_/U0?% QC?Y7M;Z'D-1*2XR'3D]?P$C:7+0+9
M^Z.%HBY4W5":=2#D3?T 3=2+I'A64TLRJ*4:PX>#^K.[)\'Y0,.0]^6KU+F'
M$E](K #H056=@:P?@MC[ZHMMEP*TSB$;X& F9/OPNFG/C!D]\=YHD33G> @F
M$+7?PY4M8GRG*3%%R1 XQ$R:2$=J_7[:[:-]R[Y$@]+/^#TK ?.+60IA179(
MJA2N8HMD^&-M3%(U4S'"U2MA8DLR-H5=VRN2*E=JE$9$%F.%P"/]UZ!,M*2D
MBW5Q@S(C=98$6;.[>K0%TX"AHPVW[LFP$&GZAC*0 2%9_A^TF]LG*&V*4.[;
M['".+PZC0%%:L:[2='E[OYE?*QP?3E!PG1 B?^*UL;P(*F)UW3>I.JWL6"#G
M>U>KHJRVIUH@5(O)8HE/SYYB;[9-<X+:%A!:V7'W)-3B2ST0'XS*=L=@5QHJ
M0.MJ<&9H$]HZ%I['W(?FD@(-):H\93YX%>P.&6V8&DJ@1/F3-,UE,;)@06EE
MF()_8O I,=[A @D"LA^C)U<NA48H$*..]6YTR3;VNC2GS;AP9B,%ESR1B<ZU
MO*JA%I9M2:"JCZBY-#KCDW1%3[IL0[IW\GIZEBN])D;NXBWP%T?6J<L03-CY
M&^GBCOPTI-F5U,(,N2EDH>HHDNIP?"'\^<5X NRMO:T"@\0Z,Q4V/S49!4W4
MNY2$I9LI@BXV%6W6$9R6ZLX!A*66]9^HI)SO*X?8$;0XC2L?*[J:-G2W6ENA
M\%4Q50KW[W"*KW9D? 48,P5DAN-1B?2HE2%@911Y]RPR-6GY02>2\"4?,SM!
M93!J PJD?1B'V2)\;V)>1V FI9_>8BVJSTZ8_ /8F:J^L0%_IJT6?^)<6F.S
MPD-&R=7]0';HG#1'ZSS7\^3^[>_7/:.<!ENKJ31"BOFYNPC1FN1WMQ3I$QK"
M=9"$N"F_,>FD>LJ"4'6C/DSY5DT<9V^M_';!*0*W[(XLV4>42ZQ,6>^'!$[G
MC!;2U@KX<5W?AXF^&&DOC<[7,)0+D_&45E?(!L$,C."TNEP3OC1=^%!"]9AA
M^(?A(6)@4RJW,#/R)1:B86U@U'X4K).J0(1%O<_#P4("%K211,^_H#UV1QMH
MP5Y,FI2/]'W>;;>A'<,ZN:RS_TW2FYPX;+3>H7,,4#(Q/6@$6U$Q\V7>( FN
MU%("NR;*(.Z4E(;*?1"00C(U%GB$!QW<5'WQ!63'S4FJ9I6M>*.YN^3K!=A5
M)&+ZR(V=,HY!7C@F.:]D@..^4< 3 P'3;_L2BI,FWN>5$273"C,KWRNDZ<GJ
M9FF[=E"D*5?+ZL]6WM-.2I9OW8W$;"ARFRHUC>]_[N)N8- 6[]=:'HYK&8V]
MW!LBRUKZ?/3K^"1$)$[GNS?[&=P=/&1-;9/PH)+&F5[:U4AH/Z'4NJ?%,[J7
MHL9$?=@9X53'IZ&29Q<]4;H^#%A29/VLT\4:V0'11]T_BP,<=++>WF+::<0F
M,W4D['W;Z"!,QW,=_LV^K:B:3.%45<D<1MS\.>>WHT? %YV=H1J1INBK6JO_
M0=A;Q;4!-]&"P2E6W((3W!T*%/<6#Q:@0((5#4YQBGN"%2U>W-U=@I46MR(!
M6JR%MGCA?M]O]^[>>_=A'_[O,R_SGSESSAQW6Q(^-X:[2YT<)D+T.#VV8F%1
M,NLE69EWOM[B-9]EBSK-?P*U3Q[T(XC"52R.@0&BR9O(VL%*%UW,=B[@!A[&
M/_XT%[)Z1/7@UT,V]#JQFB6:[[%?XB2U8XEA\#NRTQM[/EP.=N'$%Q$S4E=@
MQV,Q(LC%Z;"8Z\)/&.F378=&DWYHVA!YY:J3[2O8.WHP67!9ZW(OOTIW_T1$
M6+0Q24=WC]'7!Z/"#E=_49NJ+3KUXZ0F)WL\V5^B,I>H]O+EY[>__G#8<QM8
MA=2:87;Z.[J<A#M^L+7=*]K6KH'4DGP_\+,QU_-NNOG[W/DP.$";6H=5 (^-
MCX /5_%V*%'0A>$'@>:(FYWKJPXI8M)XNY9?K3S)5J"+QBSP!MB6@K1<24;$
M!\!6+V4BAU3M]2<+= ^D\W@] ?26<Q:_L!IA2*MK!73KQ#L^XU,2T8Q!:L*F
M!3T'.EL#^W]ZL)2M%MIO,RKC0E?M7KV5H2 >>\UM7-?"5XADA$,Q:'5^>(6
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MZ%:6]8?4Q2C68Q&A ^;W''#VG2^S]S(RPGTWOSY 5!/9W-7OKK5EQJ>NV_5
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M^BHH%\-A#O7QK!PKU?*NL7?N=M8>/=K;[3%L8D2,7]7CQ\5L\^5Q?RWC]_P
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MKB$N%%"'1F.FI4VL.IUM/ $./_CWBV"2GN3062A4*9RNW=C^^&9Z:1KZZ:_
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M^"?SP:^PZP9ILXP1AF;JY-3-#.G5QXTDZ4=:YKYW+_YO;M1P-=?Z$^#;[R=
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MAT9,$MX?8E-)A703PS;+G/,M?6>B G^T"-.PV?W3_6BJ:*#%U37\J=E0AR^
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MT\U0^3QVVZG;4/ W;'QDG!C5QX/M!= LN.2GG:"9ECBW6>]NJT '%FO;_D.
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MCGE$MCFS)AL0I>J9JU:G"F?3L"E5JSF+GX:&$46KK2QA$3X47BY:2[%KRKT
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M."'N^.GZ#J<0E+'E.A[?1=)]@'YK9R//D%\V$_AFBWC7O<@F)\?@(%]A:'Z
MHPVAE:PCCZ_E=R1'4U9O=7!=FV&F-F;S@]1>YD9\?[?"?E:\F35^J3_O&^>:
MG]CGRC-XRF>M"MK0Y9.A-YHY!#UQ"R2(3"Z^1"S>8W&"0";GSR[&N&),+NNB
MHX_&*3:%F+L+HQBHIOBD^&?<%-FO/9&HX/)F&J_*GD5Z@N=OS4@I6N:. \;(
M[)*WU#Z,;PW*\+>^6=MQY)@XAP=,/2FB>?A[13;'DM[J06_!NBP#<4[5Y=5R
MDV/ZC_0S5BY,X&G(]946[)$\S6Q 1$7!@'O-P"R=\KS)5Y,SY8XH(_C]__9[
MT/_/*X"1HE1-^)],'5.3S32!SL^@N )<NGSAM:310N8%%^/R\>ST*,:4A(6Y
M@'892U).Z#>:P1?QQ@3P:PV46ZQOM]_[](,[IE/55$=920ULF^B-S"E,MHM?
M]<(:%6F13EB<2-S0(PV[(JKO_JN\?6:T;4)K0NANJ9KC/$C?V=@LH;?&LZ64
M/MXTLP%X8RXJ$;(O,75D/95PEA3BLSL:QXR;N:*K=WV=0OC^"?^7F$<VKL_7
MC[-'P\ 9;(%**;_T%$V#Z;FVUU8GR)W[4#CAA1CMD!"G%ZCM95=(72D^ $HH
M520K'/3,1V2XH4&W0:LJ>I-_2=I0 _:7P-#%:?O8R;I!2[6ZU00]6.4U25%P
M@V72&=9%LC5QVR56:88;C3E=<_7%B7XUDT]\RP!O?1P-8I!(1WCEXWQLDW]2
M.FZ@O<;W&*,TF#]YOJ@ -8J6@AAK:/YH/:W06(UNH]_PN=@G^LEBPW,]Z/\M
MLXB?\40U+TXR@ORJWS3-\'ZUJ,.N*:"\Y_Q\)<BW0WNWG'("/U!*V=*9B$!'
MJ.(G)4W_/'59%L=U\R/ZD6>QH.1 2PN+J0M+*S"N[6%^Z3R7R"SCPY4K&;@U
MS<^1A'O<J%(3TNK,[BT&$^><L/3V0U^Q+.G4[(4_OOXZ'.+4[9Z8F%B7F'1O
M!#<*PO,[ Z=QV"78.D=]UM/'F9S\\@^@=.#:MI0%&6<44?G=- -]CO?](UD4
M1IFD?C9KQ^\2I18I*][ 4MGN07P<LNK6CGI&YTD#3PW!^G[*L.AGT]S/=D)B
MM;@/LW6U:9N-:TZDV6LJ*@B_'2/0[Q]+84(Q-*!1H3!B2UN,&FNSFMBI!.K$
MA!S&[?28.OB;RZ%EF3]H.%XJ2P'+1-W 23R819,-3QX0!T/S6>5]@2H,J7!4
MN)Z$^#JJA/%(U8.GW2#75Q0C[<^53EH&%4'7-IG6'7CGX &2B$6L2"@V924
M-(J:X(_#(ZLS*%P8B_(V=U^<6(-:TW@CQ_713Q]A[J<C/XNQPX<K<_\ (_\
M'+.\BD8'ZH'L)[2*<5U[,2<<\1>4O?P(KG<U,5\102Q/*(1+:H\'VBVY3$#^
MMDR/AL .I9IY-J,UV#%:#5IRVNMTLZK2(V]YN:UU2IDKC%F\NE*[FJJ41D+P
M#^D^]%#6Z6P+'SZYF'362[80PD)(<?3!G?CQ^9P]^N '+'/I^[AJAD\\HRX>
MI0)$DMG[?4=G0H*A<]8)\5Y<1!KBRFPH, O)"1WZ2?:D0J[PEZ.?KY4&/L]$
M,>HBCGR7%MO(@&KY(TQ#JANRK3'65??VMJ:*_IOKO(@+^O,H$)1 QO]8-C>
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M!,2;\QLB<\8?,X1=-=R8#[^H#*W[QKVL9@H87VU&2$_3<UN-2Q/+#7-5T,;
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M3(8WLK:-_E77T1K8=0%^;RXPNJ[C3XL)?]57K.5-[O66P^"B06^0WEW]Y!_
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MEW=RG)IF)=^TCG"\0Y":[.595-(K5(FK#-,+U2>I23GJ,'Z&2,EETC]BDM"
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M>[RM6<9M53]@:3? AMIIF,GT8)N5P8F;$3WM-OO<\?GZWE8XR8Y(O'F\P7P
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MTX.J)BO [_%4IIS8+M2H*L-L+\]S9''-)9OF%$I39-X?F3"R(=-PN^:D7[S
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M*<.RV<@#!5_RD<=H[O_]!_AS6=GI)V6L&.7QW!4R\@_0KY7M\XQ'ELQEYPI
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ME:>%X)O H@NH5"OM<<CC-J1*$B6PL;._.*_L$PS6\6</'A7-->$FY HVYR1
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M,NX2M@YYW9;XA$!X@UBGL+;:[(G79,!30>=M9+$AK@CQXFA_%X?+?>[\F'P
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M"\UVV5R*L@WEZ?I<R95]1/PBEA$LMMWM#HO>;@YYBXM5;Z*!-ZCLJF.-[66
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M$6B&5N0[[1&"]O.S&K4B= @_[S-MI.4R/V=%XX27AT-_$I--N_S?)S/14C@
MTL I]MR$N\2-V:DD+M:X3J$;EIBKH6#<UR)K$2Q!IX?V"LQ<&JI^A"@_UAFC
M<N9#7]_XG$;,,5RO?(279$@[>,[('^^C;<O!]02^(DMX=]XW+-S[=,=H&?[/
M!>G@2RG$_=;Z;D.$MS07SJ94Q._+8R&AO'Z.#SVLIWTK%HAE!+QP>T7'1=$A
MP>EB@BND"'Y:Z2.3BFLD=NSFP(A0^[J_<]64TAJZ=1]X";(&DD9P>=X=L,"?
MS\VZL'2Q>>?CFVQ'1;+?V2=ABK@*<52Z@<DQ=[/G;:/5#O\+$SO=;G=GQ;A7
M:,7(%9M74Q%T-'#N>6I(G'T6'1?YQAIUQ<OD)61#34U=GHVER<O7P"3RIDZ*
M@WA=%'<*C:>&IS1#B2E1.);C>,/7\G -??2Z=!;"?4;@]XR)9].-=5%Y9M.2
M_SL/]-66<<WJHI'=PK;J!1TC]DBBN#(71>.0+S1 OWC90B&5JJ;1/*+KZO+.
MJ).K[^@? !,HS&.2?>S_["$,?(],9IH-\&]MBNNL7C6W$AX2_#W5-/@B:,FC
MJ;#'VG+:8(& D64YY[T8V.OFT^M2C=H&W:O'=P^;)Y:S9AODOY?60S8;9YK-
M_'D9UG1HA&13FUI:TE/QY]C&ZX[:1KR?_N7ZH5[X$?LO1;NG(E/H,-4S_J-*
M,^(7CG!34$\:_]O0S6.Y?X#SQXA5-7*_^;--9]"W48GE,J&S<M_J)F7&I9=-
ME4M :HYQ$:9GNTL/W8TK1T6C:=\2B< 'OW_[8F@!R381<D4LL4^WW@6[Z>LX
M\!BB)\_+=38_KZP>-<U,&SJF@7>/'35X1N56/KYIZCJ[LY@<WZ'Z!Q *<R'>
MQ821P7.:-S]\V$HIC8E_I6O(1^.M-EMN-/H_%4S\?XU1CMN;EDOO\F0[7/%+
MH=*7M560EKZZ3^3U4XQV_$!>=(.#6N0=(6FV-V%TXDT]4R"9/4$;6KT](* U
MRW7]^7(H6>N2-J8R5EIPR"P3E*;F/C5H[C&KX?L.Q$ENAUN7>IQX"5/1@];"
MP8V!+>V!**L?&PNL7N^^;T.)Z[\RK,R^U()'!!7SQR;HO)0*#2$1"\XN=%5"
M^ >;_BI]KNK9TOT/$+%]>A?Z)+EE<IPOR]-R^6A1(6#=:=Z2=%0U97%H!PJG
M$QRE5U&$?.X.6[Y^]N$WQAL2-_3JJ>ZO5Q=*(LVBM?IT8T(R.^69\Y8ODQU^
MJ@AM$I\PM%5UE8O&]^MI *I<'5[$_57G?#/!DP6C?TP3J[F=1NOM_3>;XO/#
MCHB7?*8JC_Q9-NX=LV>;3,(92NK+'E77/:_X26UK3J^<;R50$U8GP]E=SE.%
MZ(G=!O[]N[TYE0U>"ZU1L<'Z3W5<LY)9'QFD"<AJ'P2E)KY=T+:/3IB:$X6Z
M>+DET%MT5)R-8.^R8XO-ATT4.[')6S$&:OG^_6C^*OU)5[[[6 "I9.!7?=CZ
MRN)<=P)'=YZF#7*C(;M;5?,FBI/O&_7W%UBRG\6K4G7<GWW2/GA-_)[QOJ'X
M;M@=07MG317QV?5CF N_^0V0K^%U* :+#-B>C[!Y,Q,#A6CCM[#<3WR04_UI
M-$'F<6UEXD+>,44XGXQG/B>8TV3@\D*!0OC#9=8.)6I(D_1=Q5LUWG+$7XT$
M?D9R#99-V>3TOU&GJR%WE'<V6H/65&GTRGF[6_[1(9-V)VMA%S$0QQOFQNMM
MH2OA.=GR;N9$9,:4E]J"=KU& YJ 09 3H4_DO;!N DB'#<J]R*#2328#U##8
M5Z./IUINV&^7W 8HQSU7"O0RSO#G&;:2F54YD84^=?*5KG.\4G]:=L*K@RIS
M9;[665$HJW@K(BJVQH'Y>\_J1R804^M;Q)]E.L_>V8<NGXXR+*QTU7Q9&7\8
M>[9_%+"8Z0G0P"K%L,>:FE=XO!\4A1L?5@3/4AQ5>B30]5:GH<#^U3#;>G,!
MKNFKW,P=Q^WCY[9?S@_UOET9\8J8]X\QF$ (E1]>216X4 3-/W4>BU9D40WG
M>&3_\P\0OXK^<F[%W&OI]]BYY91H)DT.82OYM1U/(W,Q?C^\D83*('* -_M=
M\&).==91/.WFX.VOC.%+*DW=5ZRX(^9=-"VR8A?<,=A\Z&FNUX;J^GB6C#Z:
M]*)_>-3]-L;B]=[S0)R(;I=.K4S.<LR-,M*J!SI&VAJHB@L8^W".C? TT;)Q
M4GF)UZ:;/V1VBSO]_/I\,YX/KBV,;&^F:O5/UJC48UA2-QW]'5[;OL-#1UH;
MB7?%:ENT+\6PGG\? +T..C*0ZI_PY*13A7>KBB7*."IF1YMD"N%PVZO58[-L
MQ%#65S%-ARK+Z]Z>L;).D$1P4+WT$VF>5F<W^45<G)1/\%6M/_ZN.Z750?*E
MSEI$M!%KQ79&<.?LJ?'B /&9!,77IDS%;"'N!(BA>A9V%IW*LPW*0DP^ADP[
M.^Q'R<(:3[6-%\I")\;TQ$+6P1/+S): .'O54-9.3HKWLG7;P=R,Z/#Y'3<D
M-3+I)'Y(PZ1!D565[E'2,RC$<7-IDA:!2 ^MFO(LF+#E<GS11!JY+ES7 \A>
MNN>>V4ZN"":$EB$__1^T_554'$P4[XDV[FZ-2S?6$(*[!6DLP1L)C3>0X!+<
MW=V3!A(DN+L[-!X([@XA0( D$'R^\S#WKKOFK#5S9^;4[[F>=E7MO6OO?]4H
MCS-GL]MM5C:'1&)'E3?^B/B^?JRQI85IFN?+\@43EBEW&2FQ,YIK\_WR4>G2
M?R_EWE8:C)7].,BWD<*X? :X"THN"OP&:6O@!L8/DB$2!V'NM4OX\0O!GCM;
MJI4C'>T#]4\D?Y\!M<9/W0;!-+CY=YN"K@3ALZ"]WM3E_XXM^]FGS#\Y>1L]
MP1^7B9W54B>R98DPL=DC,Y;4A#*(" 4DQCG:F:[])[\D]59&\V32G0RU9!N>
M*]F34<6^1TB.A&\?Q*)U%]7A<6)TH3NX;GD8= 60O16N6BVLTN9^SY':UP=+
M?'4C\)-/8--5$Z^LVHT@<:"J<T)P^=ME144;NXPLCP%KAP[NOCYE5YPU<$DZ
M9LG[@T%S'ORPM 84!2V8.7E1A1,V]/AFD#1M X6F3'O&JGD%D)&X_3<9IP]6
M<KVB:1QFO_37$&(;HPH;W]E(;_:/3C901*94_H(G!MA)*:RK4"Y75*\/?CE_
MHXUE[&W#-9?V<C*!&AV@Z4:Y'749JXMHJ2,VUULOJW47J#FXNPS"GMMYL^]5
M+S,N.[X*B07+9''A)C:FJ7I:J<K$K04_ T@?38<A1FX/9_/X3B/E;(KN_=B>
M>.!9U&7F!#_K[YYBJON[^^:.90,7&^-D:Z-A/I$W,1.JPJ]+$^@NXG!Z=/8C
MPDE>^N^GS(&E#U@)/61483PQ1_;V:Q'IR5'<)C *43I6X!I?2>YC:<V8P76:
M(KJ15>7(KZSVM+WT[MZ/U^=6'&WM^89IUKQVVL9C5H:O$U6&C)3Q2W4.:[:U
M'J*\R'^ 146K+:F!ZE6DCKA#NWH,2=#V8[G6>AVZ!2NVJP-E-1"FU]S:.ANV
M3_/X]KNQ-'[L#5*A*$Z,OZ2J5*'O><S<Q<2\"<?"8$:(OQ7EXGT@]F3Y.O'C
M_-A"",0ZJ=#UL80UF1NA8"CQ<]#,K&"((I,,NTP,TMO+O<&P258YE?([ !X*
M-,G(8D?+L,;J.&:Z&.U%,M@!J82P,GXZ3C)V7Z62\?9EOBCP<Q31Q1NT2+I$
M'E&G2[X[*185H!/?''9+,F@^NQ8HJS'@ 2:[\!D45H!Z->AB*F?.:#S'-+SH
M.)0%HL<1Z IAKVYQF&7V ':,UF7$NK,LSBLJ)^QA>\ZA&" 6]""!JZW1X;HD
M'R],+<?L>C)Q>AWX,\!2Y[CZ %96  ^\ZA8WH]K0\4ERK#T%W *L0=L6 83>
M]T%[9SI9L\5)BM@CDO3D:!(OLCA!<BR!R?+[%MZ@]MX<*%[>.;U49Z$$&<YU
M IV$#CP)9MA>MEA*M/=?H$.F5QM.$35^Q/*9L^L#L>0O<1S'T%E:3+K,+/D2
M"E970]YB+\ Q<QT.:*\K?!-W^JT<]D\.PR .)O!4W(V(K8U)IL:+Q(-JGU-1
M>L^=(GC\(#)_&$^VW8[7GHV-<\O!TR8E31/_J8\X++D.1PZ0'"(_.JS_^&Z,
MDP3(++ UY*KI^MH;HBHQ0JQ),L98T"+WA:_1 ?;]?Q)%Z;^^4N28B/_HR#&]
MMS(5M0C[Q6><8[!O$@FERQR?DZ6/6#ZHYV=@\WP@\'L;T"@<($$1+):I]9Z/
M#Q1G2UB<3/SG[Q(, BM:?S$S%6#7-=#B0#;N4;TS+L9B_.1AFGK>(Y'KG,O_
M6@N="<OX?;(@]I!3?V- S&*K<;/^QW8)C9%5GX9SF]=C)?B,V$(6-9+_G3Z_
MGC(1#04LK7:0,; Y8^[AG%K]:"]QKI[7B>/]W>B>U\IHGD3+^KDD-/:]:?);
M=B^/^'GTLKDS+JYJ05YP)FM72:UA6H-DQ!^MB^ ?Q@%S[?_G8NG_'^$TS0^J
MX$*^C"KI\P/FE)6:GX=!1COWK+<KUS1B-67+N]-350)=<TL.UQVP1[ZG!?VS
M(:2HVHN27YW.-_C9=(H(S^9;+H'$S/&<(1OE@'2>\(*CIX(?C_]%VKV/6":/
M(P-B>D(C77.4C!]'M%KHO^R?2PAW-K\WSIG<G*0AZEF58_RLL;%1MSJT]EEM
MC-.I*:<8Q>7((X;><YCVE+0YSBX3V0,Y]5OX;^WVWB#U(X9F&MN(1JYW9*&.
MU\I9YT&[OV0#O3EVG?L/37H)?.MXNFK@B4@;OC?*40<9MN4#UQ?+/81P@\WQ
MLC;EJ!=V$!L$I%S@UYE^9=XAQ\MVVM&X)]C\?ALQ_8?@OPZ?!E=1;3J_&AT;
MEG4K2Q/D)/,'2:O831]"B9MIS1/'NA7& D):3#X!L5)*--^N5HS[C!%_Q91<
M?G=$5F^AC"D^Y<M0X[^*NT<Z.^1>F7_>C3PX&*\LX?GVOU<OS%?^LW.';M.'
M!]CV,\#VX1EP53.T-9@IQ;-ZKVK%R<7-7WK*-S^H<)%X'M-@J64EPU!V@+%<
MK5DYM?5=+^;%Y!?8*O=&)BXF^1A=0A00-1*D$CRL*Z-B[^R"*8%0J\XTG6VV
MH'Y/7[323[2,(?>-_+7<"FH%? ]ZN_ FVV#Y"OU=^LG&97',CFM/-+MD>WZ6
MU'[JH)('J>IA-V5,I:5QU\&F7I:@@!P!LB"2(,%BCWFI:WO!ZYJK.DPASBA"
M>2'9!Y!FCM/@CV.=YK& 8.(-6'-U8!3SX!G,CV+@4"8V9"0O$(X8K8P#?5P$
MD3FB1(>M@1K" C.TY\H>=-V??M!_=N03* @1Q+E0 Y.K+!\='1U^_KK*&M.O
MU0XDS)5)^"^%N6=Z!DQ_<3YQVDJ1H#DT<K(X$_S(-LD\XO1:R,AH+DW,%NUK
M99S8)#.+'O]5BAT-+"51D&8^H>72?77T4TQ#4CWP($F>4M2M;CTL!Z4+P-@F
MI'A;ND!J?N6SY^L/Y&@1JS<UWC"IG" T$[7!-BK"]BEF@JXWJ)'%%LB>&MC(
M$6G1MMH-^WS>0'F4Q])PCB9S_?.,L56><BC1-QYEF'3N3]O!FG@5:*"[S%JH
MGH.)'.=.H)L)9]&I]YU63#JL1NSP!7U^LJHRQ$)KA7I:$\VS&W=Y# L"2Q('
MJ),GF +<L6N9E2^>BO[4\LGHD%^J':AY-S9GQ.>RAL'4')WC(9_BU<Z0<),9
M>M68)[P -0_,F';4E+3]I<.$4<[(P5&G@W+.5.I;K&A7E678VPXN56BUS%B%
M3;_P?F5&&DB6*+U8E#(5J?"J%&&J3,(SXV?O4".Y>6ZBFU:7QD)N%&_A(&RE
MY,FD.MZ ^DRC0*Q:^]6EF^>XUG1X]#<RF\!N3/4;=VM')BV?KB!0IFF&H%(L
M=F(4K"M4H5J%8T&7YN-%$^=T+F$<LP-\U'R9\%W%\6V'I*I\;4T$=NF-(I,4
M<'K&S$RWL_ZULAO^3>JT>_\Z7,M;.)M&2$WZJF5.@R?;2VX,O$T2@@U@!&#!
M>4_/Q._?59U6[S0WAZ(K8I)5N8T4;4/*,.[2T[00Z09RX[547IT3W15-JV?3
M(0@\>.-E5WX]0#J:" 4<%10YH"PB.K.D2]*>BC#H8<_@).=-K67C\E_=F+)[
MF44-VI8,CE+&9(1[IBZI[ >$\4S?#6REQ ]+HNM'Q\D#TCB9"1/#]!^3EY-B
MV)I_9)K\2WEBIA%T#;A!):Z%UKLRI=;E[9:MEO6H.@6HNQ6"+1!_LM+C\YTJ
MBV)[6@>26E+HH&TBJ0?0=X=9:JOCI[Z@6,RIM1$CI?Y8<"1$H7<]!.KZBC%N
M.)2O6@ZB!OX Q.-TN0P1748B /SXUT$D/JUFT%L3&D]1!^[HK"=(0ZND8QN1
M(V/AF@O]U9N*V!3F_""1A5N!^M<(V\#R0A1+A/DY=]#JF=4886PR8V'4-,T8
M6QUG%<)1Z_?*DQ2C_A(]+S.,MJ,C:Y7=5O -OCJG-HF5($@2N8U>6=!F(2\2
MN4K06I=B90C3E/Z*TM.HJPR]XJN"P8#;E>.(E/J[BZ/(&GJ&<ZJQM4BCB?CW
M9A*R7XU(R4X3D;PZ9&D$7/AXM_-IJJA[_!6X'6>?$1DG\ZB[82N8W[^EV?<P
M,)0HMMCB1]HK2%S\E<#R9%G3!HJJC2@1\]1$JJ2^ 5>AP4G@<#CV\M/LOCNE
MD*:-MU*PMZB48:1[A4C07(>XL=TGT1M1,0#%F4EJIQT&W.>R)1A)#B5VY^&^
M_<<$\W5JI]?7Q;Y::=-)BE)O_$"RS"T^.NU N?:WO6V?=Q%0CXI&V>D/A1A=
MCS"LMLEG[4HJH71V\L(+A'DED'C8+#O"40X93(O-$5X;?[(_V_4V7%T)Q5N<
MJK8TXLD,$EU476&_L^(M@L1Q!&1:87O2DGL8>+]N6.-YPR88Y""0* (UF =0
M0T\A*:L[&AB+'FJ68O&Y9BJ?L2QC?=^E//%_OE?_@9/4W[1K]7)-=1:G(?7<
M R:#JG51<FCLUCK>5$QL"C^NX?,EX/']>V=,+II/P0\7%V"YJCD'.99S_0-3
M+9<T1G=&_?0IB;7*VF6?X.$GCL\9@XVQ9@1@:IO0#A)^[/WM=?^R/))[4?@:
M%$NS=)6$&G;81=OWQ^%%77='QER!HAH!BJ/O&:K=Z,ZA*2\'-Z1)A-YV"0X"
M!0>.QX?XF?YJHS>0I7?<0_DWXGX$#\S8)TO2*CGN#(ZV:JQ< 6#=X68S:^>&
MV)V_BT=*PXF4H"T"J661'IF'AFQL,C6&$C5T5]V=;@OP6CLBY9\5Q=>17DZN
M?HP6)WC3*M- DB-.G)HZ]K-?NN*?$W-$^44MZS/LW4(;<OK["?W'\SM%[CA(
M<#@KO;32BX:3FLXP;2SR#3/]_:GT'<_WK[VLNFHXS<KB8@Z[83*G:1)PDQ3I
M-I3MC_H5U-@8Z!\.L_6"PE7:L#</3QXEU1*M5OJ=/,Z3]?=3V4>FBD&$>)"L
M%"V!-MXDOG@Q_3X$!+\6&7* #KM("R3 #M:OE90U*V)J&I.8-E6S 7:80@X)
M9 G(AZ/]_ [:82OVPL\<Y'=[$ 2+4R8F )=65^T6YWK:/ID1H_S?QX9(@0AE
MQ;N"/X*7*]7>/#.0 BUW(C**3,VWY5/>Z;NKPRV)D['UG+VA:7W67:'(!%%7
M6:&/P(T8%)8G2PJ@'T<RA60,?E\'_<]X9,:Z#S2[LD>7+R^9^(V2$? "]QK\
M5R(P.KKNZ U?R&X%I"@X87G7K*L9?OC8K)<(E3?D-&N0HGT*=B1IP;N]K<BN
M_#X\]!D#76/9\U=U@) L@//</0C'HB"I\H[A)T=SYO^QLU^X1$<JM!7(<;*G
M6W<V,G3<*&V+B-%[HY5BB#X <N0!QSF9(O6%]%.<[+]&"-E76TI3BZ0KT+JR
MJZ2Q9E; 2I\!%\E[T=<??#J]HDEM+!IT#]^DH>;64I\!#L7Z7^5 '%Y6*TX3
ML8&<3 X"*Z)#7<9'HSGC%*KL&B9$%7L8C\^ 'X]R<56OZCHER*6!;J);I-'$
M#97.[RIWADH2J<%T3H5C4Q^=,A'BLZLLZ$QDF2B9)VFTQ*IPA)4JG9=[8>7'
MSH[_R]WO_SM(SK,!MT>YO9G'H&? C+KA467PG<DS /S4]0Q8^J5N*/.V0'5^
M)[A?;B;YZAE Q*WL ).LX"1X:+N;RYPYN___OFSVW_2>C&K^8*8N6S/N(WV"
MLKKEYONB.B.B'<(J)47XKB^'6^PJR'0%IDH7LCOYDLB>WS:I=]-LM>&"F.0C
MM3BMP3\4+8H3YUSS\[7LRC\J\\,OM'';=@A"8MD@_;]+IR2FZ*)/]B GN,_?
M93/A;\+6URH!8[+-_LAT^E^*]\#Y ]0BS5[%8R$INKY??;6*22X=UT##R38B
M3"!%GB5YF2&\($S@_K#YSV_PDBZJAM&;J[3Q+K 8<:UV:EU4\,.8<YE^QC(4
MVQVSVLVZ0U4]Z5W$"BXBQ4IB6LE>)6;?JJ)R4Q!@]6YA$O*S2MD+8YLA\&E/
MUP\UZHO!+%Y%T&Q5?,02-=(^@M:'PPQ.""Y=C^O\--BBY_5'H-6%FBR7ZRC9
M@9V'\'@#@Y5I5!DO9)$*?5C?4*K>+/@]0XW+"VN[%S98'ZQG@2P/A$];!P^!
MC0\+ZKMR//60D@Q_-:93@#O>3\ST*X!.4B=\?KDOH&?MS>4@/V<+53-4)Q$V
M6-S-.L"*HER43M!W&"D-B*NT3=SGBA/(-!LHO602A@RMN:6_-;TB)XC9I/\4
M#OG/O0Z&*)*JM"BQ5"#K>/)[(-XI!P;7H[&19^QJ52]D<\\57Q[Z-/"WK>2R
M*S I(1);']GGZP7#1U^?B+YH6_3W2?/?7=D^W/>)95#ALCIP#1O8FAM5:==_
MW5Q)< [%>K>ZXFGP5>GZ]7WD7Q>F&4+IJ(@WN$;.V(K4D;&7KU49CZ=VU^1*
M,@+0XN5V;EXR>,#=L.4M\_)WOY%"&]D.=UED7_G,J]5@TXE)2/V5HS@C"ZXI
M@[6\+^&)=# =ER#3T8M4U@S*SM"_?_H?WQ% %H_HQ5J-%R52K1>7LR3[]SWG
M+#3SF)+J]!8:Z$>;V1N$-(L=VKPARF?7\?<_D4BR1HL$IAGKVU^]OY\!DK\P
M'J5GI^AJ+B7;CHGG]ZUOGP%:FTT"OZW?90\G@P0#A(B:U$1FJY+YT+G)(I)H
M:'\N#"FI_'4Y/EEB:Y=X^MV[D?1Q@UZ (67OM(CEJ 8%8OZY*(]QUB/NK--N
M)LIQR>*<I9\:0]B1VJ+U*O8&X\H5VV-!Y1G TNK/BFJQ Z%/_;O)HA+Y>YY-
M!F?K:;_65G1A$F3UT9LL^[ M5T]7DF0=_:?<=_[HR^EI=;?QH,BQ>6G2P:??
MJO/P3[Y3R 0C>_G.B\RQOA2>8,Y6"?15M]??_GPGQ=6KH$()DNICY F%/X2G
M258I-+P>5/=NWQ>@JDV8R\,M8?""@* #,O#/T,#4<,6RM5&\^];6A?H!T(:N
MB.[I&E<,6Y:3FI4"%M\0-J'Y@TR(*R3R'2QI"-(.M ( 1[SP^Z+$';=)O?I9
M;A;MGP'8M=3E7057(YT4O7$_8']R1#6RD(F@2#HR!V-38W-!W?#5"$)C&G0A
MMI?0URG]RJ!NA#NO=[7+IY _3>L1?@3QE1,.+*Z).<5J'"DLA/*VJG53B2&V
M<BRP&B9U)K8Y30/'L3^;['&B4C1>GJ_HHB#8^E0X=3'&,7(@GYS>Z*>^H57_
MQ#H.6>Y49X=-/(.Y 70U1#;6VS1L+&N%12]]7:SQ"FA0@0,5\##@\*EP/__,
MA<YY_AG@)53)?5P^)K%,+OM?6HVS6Z$7Q.:1[DZVD1;O'!'50'LY0?$!=>JN
M074LRD^R'.;QY64.O91O/?U1NXDBM=UAJ@"\9>0K:_]=1O/3(BH$FAH[6W8,
M35RA*QLE@\>.KG(X/;A*&!>9TTW'"I:A6%2_U"<<\;2THU" IX$:O:X&5*(S
MLYIUW*ZPW";8HU"];&5:Q.#=VF<\7;>DBIB16EZ31#GJ#&]6LQU9\;B_[O<4
MY=AQ"]X(%5 J_:P?Y\E1I'V%LGQ9>GPC<J340N65277HSVN6$*'+>_P_2MR-
MDP3B!O,4!<[N4CPMKI*8J=] 9V;8EDV=$<?A&8EJ&"Q2?RDR'TU&N0?3,_W8
M6L_H%R;&*]NM>Y:8RG5_,H!Y[8/-!+6V '\?$E*"/*ZI]M-G1"L;"DFQX_,&
M"3,DG@$ 3'2WZV5T+&/,$4$C*TFU),/*3)1\ZD:[RW<=R5(B?94*,HF#BIA$
M,_C"6;0<WW?HL69_M'D;YU]1DO6$VN5DY+6RT:E3GHZWX03Y**NQPHX?1.NA
M+R$!F>)W*]'[#%"1<K';?P;$*"&C$(;%,E^7SX8F@(;-,#27U.7=92S7SEH;
MZV18!L*9=*G4%K!!A1*S%]RX2=/%:7;%0!S$YXVQ/*"%ACX\ X 58KN&2?1F
M'%2/WA3K</[1)C!9E;V*SYA#-,8Y_W;XE??HHJF]_?_9EU?_3UD2>F1-S/R4
M?K:5)/5=S>R]7MW&2/OJI[U1EW5[QL4RHD3I=JVC/P#?+#P5-=II?:O7XT8B
MCRI*QIIL6HR[M:.YKWWO$:0G6J;7(<'Y<O;)^V$$QNRNN!$T(-J??Y %=?A#
M'P>Q3&UL!9*M,^K((O+P4]RO:(FDHKBS/8QN=75JW&\<C=Q& %RKF\4IHKV+
M\RJ7_FU=63M#:76\Y.)7E #,=V62S'VT?:</N\V.U+%XJ5;$]4US'3P'2!SW
M(8HM7W'FNKY_Y1A-QB7N6R7<[)B6Z4Q"!Q42>Z_NUN=0="V*1C6WZB-Q@B+P
M!!5UR6YXS1ZCR8N$_#HU9LXNICN<FUMFEZM?;FA&BBE0$US<6TX@1L_ 0_KL
M3YS#QJG(/?W.],9CH]F]J13U0UPK7]+CP]AQBSI>GLU9T-MG@ 4P>=_90&)\
MJ5 DU^IB4)@U"A1P<,&/>QQ<NR7G<OS&4*XQ8=94V%>,M+<9PZ+CB!.C"DDN
MSTCQ\->(9 L;D2_B7'^HD(P0?U&'BQ1E#7SW,F54!K[XY]Z:027S>('&(+LR
M;X-"MX'?QMBP06!+A>?*[S[\YA=E/0'_.W.T9K<LQBS:X[\IAD!F' !&0=/#
M0.MYX.*FMHLSI4U3>LMULV$K/PCT+9[NJP:^"?!XB6RNF/\%V(&,2&[UQX%6
M3+);:MEIVUYT9F-!8F[=W"BO*\HM9#)Z>>4TY)4/2D:5AG'^=:].GWO+0S'7
MASB?XH\">4E)E?M 5C_,6#3&X:WEQ5%Q6V.-O-V<<[ND-U21Q'H:QL$ZPGP.
MHVP]BT#;81!\6/] R;8H_<9A=LJ;V+Y9../;F(MPG7H).')53%>*L!0S^$J.
MZD]FUR6\GVB(&!SU;DXU3U,11%B.\_BQO/G ;'XN<^!IXDFCA$=M:Z353I 0
M-&9,F[M+]>>6USM+N,F^S?Z&;-\:9AC5V:D#?)I1AGEO<6U6]L/#_)X!N#+>
MB0WR$C]!,J'7H*[=%N^B6[2==_I/B'=JVJK3V+V T$6HT"S8;MN FG>VG=U9
MDET'?^3K7=M0C%5](7\T*(H5>EU;7^PPN\&P> WEF?7W@IU7Q.P7S/6=J*B
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M-71R:1N[9<KCS?,$9G.2+)VMG"ZE2_!745]VB:O1&2,PA%H J%1%; 5]*OS
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M=- 6 A(P^#G;/Q&4U3@YM2M'-,)':7/UZ_$$=)!%W*X1^V7@%#1M]^*82PV
M$._^XEMQ#LKO?:E<=FZP!G0>8%7*:-=+?4.1(3PJ_V"R1%=4S( W<R/<"([:
M'1$B&,1+,FV&Y12'W.H9L*1]B=]//5,@F09+A,VM7:9I+!0C,YL\:I5A"$/5
M08JHV1)6%7D:A,XY"_/7S;?&>W)YNRTS*=6AY .F%KSY<ZZH=$)TS!<.XU4J
MXB]/-\<78,$J$A64WG;_>?K/D.'+%GU24:;%_KY3+HQU58PZ367#0!G4&R</
M.5I4-%E9OL:;Y<0TZG>;HJQUD0B#%]\4VEGJ0$P,8SD/G]Z6?QM8MDE)XQ!A
MVBQUKZ_1C5.D?']J,= =RLYP*%4$19QN6=?MILB?S-2^J<<,H0>D 5 XX+WM
M, +/%-4Z8=$E;W0C[Q@U6EI:@>TT#55<*;1EA<1SRW. 3;)[[=58*[7P3ZZ8
MR\3BA/U@;UK\Q4JZ\VIZID)W+E212@7+[0Z,Z<Q_\G)RB!73*1++=>*&5N94
M;K+@JBJX5'1. C(($#6Q)2QE(>32I@U: 3 E>\+/6B8/[M?:Q!<GSD:D0#SK
M>6-=B8F6?Q7=$TMRG(=S11UK*L97U251O\]KJS4K(!T^0G;TJR'ZP=1EBTNI
MZW:L4O/$#4+? Y-]4:#K$:&/0P>WR^)KM)QVM/A*;@PNPK7S;B&X%K+[1S#Y
MT9:^VN/,[9D8X,OP3;%M?YR(NU*Z.*&S1L=JMB3PY$]7/B#Y@83CM5@]7;H-
MH6L%&W T4%/*5$/].R6LR&]_@F<*-,$Z@1K^5 706D:[ /1AG *J*3S<1#:&
MEH3J?;^F%GO)M?_#N(;!(0F$6(SZW4MY/O__R-+^[V/ ^ R@9AX4;9URI./;
M=T)*GLQPB*X6]PVS,Q16A;?[]#%SO/=:XFST\!L!:;'!3YGN3#* CW_:=;[R
MO'-Q;DO;;2<YO2_)4GVX/CO-QW@2=FY1W&Q@O0%9G\*ZB^.2]ZOVNYO2@+8.
MOE=,M"KV8+V4AI?_BES5VX"6*>->.F]5UF8W=E:(5>+W2:O?_;I<H\VXI98*
M)%TP;/N[X9;'%"CR%Y[5H!S8I"BB#.$&5IL-<N6K#J/%>O4P!%E_2NBD,?@]
M AXI%E8.?2C' (RQ7==$B!9;:H"X17K8-#5WT9'5R=\VUB8O4A([Q/62P6_2
M:BG#L<!P9T%< \+P49O48EZ?];O(4RA-- ^\.W@3]J2ZJ1,TV_MNR.PD)GZ.
M( *B?11@UWL;/7IVN3P32 W\)9(K\LEEOP_?*/_"*"0XZ6)T.^@$ERU)R)Z]
MMD>1*4*(;I9;?/_U_:MNG8?6K!L7?7N(UX%<5UG[& 2]W080@*ZVC P D-SM
MDP:'&KUQ L>MCIRZW85%]H_=@L,&SP4%$E(TH>[#VU$Z1*ZGVP*K]8NL06Y[
M_,5_1*3J-X"C8G6KUU@)^BY6W6]CE@*O%])#>'A;(7)Z [3Z#-?1H*(K*2"S
MRR-W4$FKSQS8PF-/POJ)8Z%G.P5;T^_G_DVX8?3%[=6Y2K29RWX.MH:%A1/Q
MR6%Z?4(,-N1!4HI RHKO9=J=?L6W*KV/,A_:&7T#,()J$NGXJK=BD(R]<C]R
M]B.H#]I4L:9:5P[J/Q"Y.7H@*TBF0KB!^/+'@,!N/)2&8U;-=KS)O.H!F!_=
M$Z:<#;9(,X2R/(:.$(@X9PCR%UE"#[L0#F9BS?XBI^Z@CX?MLIDURO\-?7TS
M'4/S%]Z;4'[59X!B\M/G:R)GR<?_H2N<SWYD>5&?J=)];UR@4*X]>[3FZV;D
M.T!R$9]KM3B4=2/Q-M%EFD_&:HD'7JT7@=^=_GVE*R5?CA7#WY<<(2XQ4+=L
MQP(PK-VZ9A8)_)/X7<W%8Z2Q@.I;VJ9._=.Y3W>W=R8YQY!%0H@J)V!;(?"/
M?X)D0U=-TGL,:R72YL$/H:I)RFZ;.ZWU1L+_1GB([1*3:942[.^-UT;^%N;X
M>N3L3^.R9!&Z6\_,-)W0>O["H+TW[99P\K:Q%U_1,5#M<JNHZP]$9/AFQDBI
ML$6E.SUV$\D#RYX!J?>TO%Y44S\D)3-12VQ_6,CHEF*JK%,K!%\B.!'NE=\[
M/U9K3H7$YJ_:($90)IC;49C\$,,'^:2<P'D&DKAEG;5^#XOK;(P)RGXH,( 2
M,KZ3%,Q/SJ@*X.ME"86Q"N(C\\FG"W!U?N&B1X';-A<C!E-PVGW_BHP?U26?
M'N;NF@W8%^7_<?XZO.JS4K3,$P5F( 4&U,BC8#BREX\DGH;M._D:$0XI/?[&
M\%%>U=E<RE-*LCR&M*??#5':53.IH?;NZ%E >04HK]>@/P&=.UXU!5CJ"UUJ
MSL')/A=RG\>?7#)19\8!7E;.+)3FO@S!L</I2@#(KOQB"=H^HN+&ZE0A0_,,
MU&?!%ZSI.9Q17 6,5)U$@_ZBXSTNCK2-7\&M.DEK&MLF:\XJN2X[>)UK8"4U
MBMZVYE'X?B<Y3KPK0J4:7 I<_;J=UP;U)W%*2I-S?*7KN'V,61A/CB%N*8*J
MQX1V9Z:W$DXOQ&]?^N(9X((B\!">$D3+.D#X+U"=P$B<^U58!<E)]=]@O)>#
M8#-&R^%-QMV:JD\'Q+O?HH@FK'M$(AA+AA =X(.U#GHT\;YL-T'XN^\>DU%D
MIG2+ V ZOSG5DJ)8T9%WC;($UHZ$>U^0WC>_&MP*=GO<#B54#IP_PBE;%92[
M5 Y(T\^=IQ$!![U6ZF$J=L)^NX7O_U??0?U_X"&6BVW=>1GJVVS*XW&]"=-<
M\972,>"J$\) VQT1@V!2?XB,=_9A 32,'>.#WQ(NDB(V]YS^ F9K?J!G=*!:
MV],V&HHSQ3<$Y2V?S#$#DV\-#6"."'05:Y"XW*^SM^K.TS/.2\F=>4XM]%-A
M6T[7@4J6:1,,'4E;UV7L/#D\'^E5(T0,U)+>N&[<>BDK"WKJ3]<2@%OT?5-?
MV32U15DU0#<J\N9;&+5&^X&6R&NYO"A^GA'YM]QD(9@I^F7'(;AFE\C]M%=/
MD.QW;)/9)VE(8MUV[08JAMFGZ=,%=Q')PEHYC9OKKLKVW>^C*Z->\N]U!?'_
M_!OC_.RN90ZV%[I\=-/9OZ7]=U%BX2O0>O-:<.H<3)B:]9T06XJV3UQ$1EJ[
MOFT4;#90J& LNACWZE"%7&"/\EVA>5J-FPZ,[.U1<[&^O@J(K"))6;G=C9JZ
M14R>UL!T(?U+0[:KO*,=&&/EUW; 8O=1N_&OZH"O&T7S8J_Q6]NU%#]3]0:G
M;N*84Q^-=[1K>TCRQAFV\"(;J9GDEX: </D4"0XU>*W'("N^F$@S(&4^;38S
MIC_E7;6TBD:OQPNZG 1\=5Q=*MUB&@)T=47"S'D\R9L&9,-9BKYO$..Z](.^
M]OHQ6)$K R/MLX3"N/$K1W0" /:PJUN:YOY6A$J6PX%8K'AC;=6:E-MUR>D:
M\G+(XPD^)D*VG+$$M=0IV5TLW4O=-_C[X7->UU5\;8Z,R= SP,;]-R;.C_/?
M'F@@.([L']"ISC7S=V9'.\_+;"8'#WI2FQ8/S!R)Z=Z2QGO!FX<]D8P- XCZ
M1]WZ^']U/K49MV]V'R-%T:G'9^I,#&S%YSDN5JAYZ, QB[#9^ FS@8D(NWJZ
M47>$,L''_6#8]ED8#2U+:&KJUN7OK:>MGQ(_GJ"R8BG&MIC#;/_V^_L!*1Y/
M1D\\"@&%->?9+-G)B#^-]?[+U)&1-H1%TBK8<+LV+.MEL:8B[?9I%Z_Z=>^#
MVG>;-?-^([ <<D-F+M%OZ%!5H%R+N]!3;O4!T=SZ,*U>C,V-"@=E> AZ)(N8
M.B[GD<3+A/1D_!X&ALS?"?[1PIDEX@<ABDG?!13LQ!9_UX\?U9-1,?S!194M
M2KP=8*7,XT@$:2M9ZDQ8]MV.HC D,+=K7&5*.S+V#AS*P9.G5R8HTH&3(BYW
M_3"JB&YT04.8HP3L+)%5T%G.U )-A?=S1SF<9+=I;(5IJ?M$]61:!S;C872N
M=%W!'R>6F.!5-.=-],6 Z=2^&%V3_Q7C8R<G",C9%:XWMS:@WCA!WE$#'4,2
MR9M^Y*>ZQUD7)%;?8]FM7LO[M%[ YB'YIF8E0'?/HQ6#(Z.F<-C>&GCU2*2O
MYI75B&O95U14>R.<E9U+^(_24W6$M[SH="2=:VV&SW!H-HJS19?T9HT: X=6
M!J.@[E8$;]*]RZ74<6J)U:O&/2A_A=GA4SE W.@;X<]9 ^\A-23J1\/'C>\7
M=0^,_'(XEDOGUZ<?LSVDBQNJ64Q35-!5A[RRL#(^4#ZX.&$)<B%DQ^69C&A6
MYD.4FMOB?ALLC91_%6YKW*\^2]MP[:Y_U S2NMQTQ5FVNSMLPBD/U$/Y9>W+
M]%\8#VC-&8VL))%E#:7QXW.TV5@QZ7XFS$S4(6[^-*])D?RC*J[J?R8?_%^'
MOOG5I\%:YBY4?SK6EB,U$Q2H!FX;T</:RK SDHE(;4(T#KJCJC0DU<!0HD:V
MYL/R%MPU\I.6<9IWTZ=)EW4^RT4D8:4X-\\ @?MP."DNR^.=' AT_?-NL?C)
M.@A+5ML1_(FAUJI ;"RO/,E8"(LIC4&5?B+!L)YJCVJ1>@Y;U.5R:#'\]XL>
M;F=>U1H#"Y$^JU1'ZH!O="6;/Y>9WGE\D^,=:S6]_F @MTOP<3B-T'&V4,CZ
M3]OT:$V4WXRIH_S8:7*7\\7A1\;7&V.$,5=HWDG60JSK.D:&TU6]HZ69@22A
M3FH(W&NJ[V]U/_CPHC')$ZPC,."C;DV!K&#O]019GL@V_ 1%[&6,S+Z _9J@
M_A P,O1MXV*<TYEI_DN"UT-H9;2F>.SR*$[.C? 0OQFKZFSD=WG3?YE12^22
MT40#+5=UO:?G0"PG.8;8#"/61R@_RL>](?:28I-#5H+.:(NYXIZ^WN6E=%GT
M7Y8TY?EGP!C#%*8CE2N_=0(Y,;0:F6+??CSAE9S8&OS!75V4TT+$&"^C'&<C
M[P">.8V>GIKTU7S;>[_P-#A[X9._F^TWRT^W!J\%C2:#K GXPG9GAJKDG*MX
MHW&;SOV11Q*V>#%*5@(T9GZ_8FC6I<Q42,48_&^]\!7IO<91I?^T%:V+4M-G
M^U<"1&;#+C%DK3H36/N.7Q<0;@7& ,$/Z:$KU;OI9V3!%1Q-,-/*/&XXQ.-O
M"8])[ZAA/V-3X\J$.:3.+W/$FYZV\RN3_HDKKFN#_01%!QF'9MP(B-826&*]
M(4!&.65&,/[8!B\C"E%_0 1GD5S>/P.8F9M- SE1ZR+S 0[JFYQ7:G@S'1+4
M@OS1#1@8ES<L =OX\_1HQ0^E @F%GI%=$]D/[)\))2BJ7YRQ9R985)9O$WX_
MG,H:,E2))18.$S].)#6+6:P1^@E"!T"T_D$]HC 3]L[2D=;BIV@F;*N[:TEV
M;>W[!@OXR#'A,%%C]/P-W(W<&%WTQ'@!D&7"$6BHH.\_&[BP(?#OO;DI1O+R
M&J1LLVS?:U%[72!@5ZJ[[3F+&REE;6%9@I\QWK?5EC54\2BSYYC6T2S^8BZ$
MYJA/%)9C*=3S#CFE:0( ^]9H2=A"%_:=4T]LGQ6=!KGSH<RY@=*.*>%+KJ\X
MV-U)_I4:?=N[SWZ[AC,4C"OM=I&-#0=9\G-]X$.*/P-6D=/?EYP*CH1 G!='
M-NUJ\MQ9^&)M$=&&M"EED,!AQA=O7)EV:H(T 6 D(2%RL;JSJZ,W[]R%,^O0
M^T=QYD0+&ABROZ/C[JF,IO\!0/7B0]7_\C[-_R,[.C0_] J.2B!B+LDQLF*^
M]'/07TY\+]/-1Z/^4=TV68R/BA$7@FX/162W]P3?_X:@*BIJ L2SK:-@=\+N
MK5FUW<T+4QD3;N_=9*J.W=/6)L"Z?$'R'VS$Y5PU<7\":PGB'?S;/A*4L;9'
M/@/T]8;21H)6YI1M9GXG+-)UA3X#5+YCKQ/&LTY=QX]M?!ML<$SRKW9B<:XV
M]?KY;3IGWEQ/U@:!Q.$B ):!&>)Y$J+D4YR\==O+/K88W_V>IQZ/Y?VV!0V!
MQ)?U!P(PL%6[G(<L_)&-S)<4.CP_ICE8*IV<7V1J:5 PRO_CJC@8^,)(J4W#
M".!A] H.I=E%:[I]06S:0LLQX"R2Q9JFC_ Y79W\Q3GP8H4OW_40[[ 4Q1\*
MBQR29_-+?Y$VRS.2)!P5G='$N6O3=7VU=L4@76(;^R6U^GPVG*?<0):;1?D^
MB]9C$\!29AWVA,P$W#E\2VC T^]2^4J(>V;:(#"+Y0^2(;2V[7C))AT9K6'
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M[N:\D0OC_]\$ %!+!PAC=*I ?P<" #9A @!02P,$%  (" @ &(;.5
M         !$   !G,S,R-3 X9S@X<#@X+FIP9^R\!5Q46]LW/( HH"+=("+=
M7=(]P!!#I\+,D,,,#$,:**!(2TLKW4B7*!+2("TEW2$(H@+""QC'<X[G?N_G
MO9_OC=_'@CVSUE7_Z[I6[+7WAGWX]G 20*"J!%0"8&!@8GA@>   AVM4-%HV
M2#32V0;I2"_ S0L0E0."SIP!'!4JP LK_3^: &8:3 #@Z)<&4PM I6]KC8 Y
MV[A9H&SIY6TL$%"4A3/,W@)E@3C18#K1(!C/A6,;::^,[)<2/E(I><!VPA,_
MX<T=\X\.C)/6>4>4+0*MZ8)V=$$?-;&/:5K.:!U+)!)^(@%$H&$PA(O#C_KQ
MMSP<==R^=**K8^M^+"%GBS[6^<,F#*5AX0#35334_0GV34$+A41:Z<#0+HZ:
MEG:0(_(%@!8 !4 >_5@!Z $Z !@ #7 !.)ZHX#G^E/YA1@Z.1GSWZ(*EBRT<
M;8LX,7G4QCV1E@<9J7U+Y[5C>4RN/T5,]$O$FHYH6R3"^8A*?A*7(QKQ(XBC
M("U1/QM@:V?0'QP40OZ/!@+]1T/=$N[\LZ%AC7;]V5!T@"O\;!SE\0_3<A![
MZ^^)^.8@ *PL)W_TA752A]+30Y$NEC+(2<"/HHQ"_(TF!_^[G!P*JJN'0"M=
M!</1@%^*'!Q*_SLZV!F./J%KN<-ES%XSUGTCX[G"(&@D2L$";?%S5&A9:SG_
M&!7']>_?\B=)@%FA?V=>]VB@_XZN X%_HVNA(#)&/\D$$!32T< &=M2Y1_UE
MB[#^D3'\8P;XR"<Y)!J-=( C$=;?52[\X!R[\ O]X@\ZV-;:YE?&^1^,(]]^
MDH]'#M;:-Q^P7AX('4T]C!_?)Z.*^82'_T<$TG>_:9VY>-(\GK7&)VW*GVVZ
M$ZM;)VW<'WH8)UHL!-_2_*/[OZ%@?3RIJP!XK*R../"CS[/?E;Y1GL;&_:3P
MGWP:'WW^H B=?'+]03FQ^?FD?C23#G];L!:/V?_]O)-<X'S+Z(E? $R9;\=W
M'MW//'UK4QW7L&1_>O\M!)JC8^:$9@T0! @ $ !1 "_@Y[3Y4_F%=JQSK/N/
M C_+'XL$ .$"/QYLF,=PED@7!-3Y+W,4@N;[X?+QP/YE4 '^,OH <C]'Z3<W
MP#\'X;=PG.&V$)BS/ES]>!IA_ D'^X1W5"$Z.LZ=-( *O]@^9XU"NCC^B706
MB;*UMOVY0BKJ'"MIGM".VA<M7-!(91@"AK) PZ GWGLX_EC@\;X)'U...4 '
M:_K_#?%CN:#@?SI-G"3_SQ20L_6?3R5G+>!H70OK/]'P(; C/9@[&NBLH@M2
M_[%8X?P@_TD8UP:)\I2%'Y]-OP5_Z5OP*C_(Q]F%PJPL7$Y6*UQ7& K]&W']
M'^0_BY^WM)9'PI&H7Y)+^$U!3ODGX]@-#23B^!L7C70\.B4YPWY-'![\*)%_
MHUZP/%GV_D8_CSI>W/Y"/IE-K-_TCH>S] ;@#SKA217CVRITAN2D==RAV"?M
M8WG I<3O"7MR=)@?52<!@&<R1_1[  H QN';PS7 !5DHTA)V71X$P#Q<!^"?
MM #0N\=ZAZ, 7\ %'!P<7)P+N+@7",_CG2<DO73APB52"F)B4F)B"L(+)^7[
MU^\+QL7SYR_B7R3 QR<@P<?')SG^P"?YID+X[Q@XK ,0XAPY_P0+@P& 28B!
M18AQ.'X4*-YA(X;TD9?8&"?E>QJQ !B89[#/GL/!Q3N/\5<F!@ 3ZP>3 (!Q
M!@,+\PPF]KFS.-A8%P2.F(189ZX0\6'+:EL0,SC=XS]+$O:T2.XJ(RGXE:6
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MG[_]M*N@0N3F5^';PMD5N>AVB@7MZ]G%;?9NI<(7=[[&O3Q*)W+M$""[9'1
M:E)R'K\M6-AR<#?!3;R"[WYZ3X63Q<[ZR.-)BZJ*X@[7MQV9@3RPNY(%C@Z
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M3XD/4R0%F[59G_^T\5ZU5\C!+IW6F#>7RK4WV\%>7X.W,K]*,9MQ>F%Q<FQ
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M'@ZH7U>4&P7W&\ D4^%^Z5IX$DGFA\^"7>\$F"9HW+?V6Q:WS=V!&$G^Y<@
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MJSS[-R"/K#@;YM>>VN"_,1"$O-.VSZ"(5HAL!"S6D &Q83Y&@,_TR096FO<
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MF"XSDP>1%"LQ2C2,ZQ_WCM]F4--,*\Z!.BB<*=X%OYQHCS187M//91HYTF0
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M(;KU9;44MAC]VY+EM.4>4.;\<;%WUIH^;)'Z4X%$RN!H@LD019QM<)L"9:_
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MHB\IF[27(4S:.AX/7(<R6IHJ5JAT<-?UE8PB&YK@K0PR:\T&K]Y\A1\F:4V
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M.!T@%1UK;MT$'I7]5$U NG9K7S3Y>/9\K'#=Y.H+1E"@*B ;5.O%/@H3, 6
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M+5?" :.J&Q",O7JPME@TS.:QS$0$MTK6$"N*<RRP[C?+.2N."F:K,/#.PJB
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M8A5DL^7L\-EL+O#@]:>+Y89&PCE;954)S44M.NVJV',VF]J\V0.;TRZ%M[(
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M=TW MYZY-W&\.]75=(8B-.S-CO0MG(/@BVON&R,:TA.&LR.N=,N%EDEE>"3
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ML;VA*&85)5%:;J705[*FOU3\8<Y \V6E!.,%*)S:L9$6H=/3<$$:RDBO4>\
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M)8W_ *SAY0<UK'NEU%.3NT@<CTMR7CT@/6)*_&#<:S.^IJMLJSV4K[K^6LJ
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M@G9  UVQKW(>MFH<81DOTRNZM=Z-P$Y'YI7E@GGDH=\4CT_^SQ<YALSUD'>
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M!7&.=>AW#_T>VZ"X.0/[?;]60]Q&[*F('+O$?*YRCX1%OI%Y8EAQ/OB;(?:
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ME0,3S1&_KYN8"W+5;Z;U-MB-II>[>^_[F&N><IPP4H:4\$\J:WY6XEQ0Y3C
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M _B@;;PE*@+CXV/;JBAQK]PW1_;SHQ\/D)\3KWXY,L]]WC8_<!13+'L0V5N
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MQ#4$<!\*$=\=*=2NQ0!!%^->/-\.6.A!VNAY0!FBG?$+8U[+9:9^A)."RC'
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M;)\[Y)W7:,=]A2Z':Y^W4%A/S+\B?$%'1-&2G03Z^*42[%A>71!<3_2)WXG
MFU?I7B47'!^I1'P_4^%0UK<2^W6L\OM4Y^9=&[>GK]-+FOKG]L15#,#NS]YD
ME#8/S.]S2MPRM/4(C,XL^S*X</#7PY?1R=&RW7N[*Y4]A!A 6C;LW'V/H1P?
M@?M<@Q?CP=.RU>5H3G?+$)W%RE"3T^;\A9>40PQ-OE:1BG.,YEPSKNFMKI@^
M?+G!,K))R^?YPAL0&;)$J-G>Q*//BI!A#>5K'[)-N$AGN;!3_M;(&X7W83W]
MYKZ[/HH9_EYH"P/<D]Z*N_I!MN?0(T8<$D.TA@'T4V\%0G)QCXIG!YXXNX?D
MDT>Z5Z#?K"/BC800S*,AA) EF>Y][;A$_JE#40Z/VERV:'&+%Q*'YE.,:BTO
MT[JEM+17' ZGGDHP&;NYA7:.[%?OSNU2+NY^N[M3TV [Y)!W!&K'H]C6Y\#C
M\%HDS28EQW4:E4DBKW MT5H-;AE^ Q&V7^H>;N6Z8QT!:R#_)H8PBRCKAX[@
M;#^/]?QAI;[*PUSXJL\B\O\Z *;]9"B-V<+%+,+!R3<3G]&I@%Y$L(8(:;6Q
MA=1QLG"PA5\'/ >S)#E9PNO:<<)5-AALPMZ%VQ :"J+:5FGW>3=<BPZ=29YQ
MBO0XPI;)*LDS]&0J!L@U_8:Z&HG#%9[O;=_H 1G)70I&= ^-@KWCIJ9W9H="
M]*:5KY?[RDTBO59RKK*]BR;9DU=@J9#BR3L\6(J)V_;V/%,]T7 C#P-\%9+0
MP0!%"9 =I/ZHP\Y*ZWRF\667W<?.@:2UTG!&F7)\OU N509':>9H#XEYMMS$
M0\,W5Q?P7G"_E>!B%(IWMNQ;&]R[HH6<>J3('<8I]ZY!VJ,IUV[)=<0U?(?!
MU\[B@6WZM_";FE_$F26 T PYK?</Y#4TVR^I;BRFNEY1IB]VTH:L3AP^9I5_
MTE!FWV3+2/(^Y38,K+_3',.M57#*0E))'!;T:'LGL\N]4/#S>7\#AM?X:M>$
MB\-M60+/C^75^-X=@[^L*&U"[41%BMP8&5BQBM"DNH5L;7BHTW!U4^8ZY2=X
M29\J0FQTNJO=6ZTOEC=_WK/?(2Y_T,T[_GDTSYLO]2@YOJT,->VH"'J.5DZH
M;M9EX[J8-];F/E7[D]\0,*8*=BFH*=^FSR9/G2MWPXK*L,_:#:KR<V<9+MSM
M?5K=H=D1M[A[>S<)/@QQI6\N<BF-5K*2-7ZB$P?,C1$0-I%ELTYHM%:]W,_*
M=V4\F+^U7'M%%NR8X>(_7K>R1!5C[6R^\3RX<>:J=7IMFZ8FYZ3SZZ57SEIM
M6;?++._1B>*>K^S=0;P]BADI6@Y]^ZZ8EM8ET2V.6*&]S,ZFGQC -90XNW@K
M6V?M_FW:%>7"X;[E>XL6!5 =OF<Y#G4=%0)N>1)VELQB@*V2U@5P8$;3?97W
MN[1PANW_&Z;%?P0@,!TG$T:W ]5Q>' O<"^V NSD3IX_ZEW)O. 0O:YR_GVR
M9'1DVF%/;-JS(WL^>IFXHON+%A=G&.58-G>1N2^B8KT[!D&5C^^U%)+GE. Q
M<(]]6+-@1].+!]NXY50S>P1(;\SJ3'U3*E]+[2I;X>&^WY0N< KD)#ON%&"[
M+Q*OV1O/9$$JQ:_=U9#W&4_S,]6M:WFUYSB5GF]O)7+@H@BK<O>^L@J%]#BK
ML,^X80"9/-K[,Y?./Z.>>P?(?&ZGV.!Z7]T9KP%AR-, XD4558X6!GMU!8)V
MAD-L"Y.?Q6Q=S.'/!+M-1^MB '*7N(_7U[.EY)1,MVI9-[89O4&N>??FV-FA
M&(#'L4^4SJ4TF:98O/&QTPT[H<EQU?'F#1*D'E-M<"C*SG.Z>-E2(N^0[HFV
MQ87N>>^N./^[5Y'D$_9ZEZQ?,]4VQ7W;-^PWN2>\3UCCIQ2- >A#^:=T;7VZ
MU,MCE^^U;<<L]VYRZHU\%DI+"^5@]GG0F/$(';;05!E:%G]0S#25NR%<ICIS
MF<G(ROE*E 7J=6UJ;:8_.)8CXY#7(55>O$^<B>14L$&$[^W(BY+DVKW:V7N,
MZ_*K+Y?'9C5L4F<D);V-^KA;'1\!MB)0JI!E+A2'@F"[$T63UT%#6Z4&:XC]
M3H/)3B^I45'MU1(\LDD[GM<K>M4U3Q2%I2G:XHWB/2>+C0L61X[ZRG:KX2N5
MJTC/7,_=>R> OETTE0:J59)\'^XE-0C# $R[?C1?]H4W:/-LBO3U5VS?RN Z
M-7\426V_Y3TT6+YRD7$^L7EY^/FDTP.M"5;#+^#Q6T%36N#N1T_\EJNOR;7&
M#!UY,5X9<(Q.-OQPQHCH2391+E0O:3PMEC2,!G:'X.;D/48O,?."'"[U3%<T
M92-J!6WH]6[_9:4,A]?,"D>Y3%K!P<A'V-85]>+[]C)536.B;8;[SN4M(&&>
MUJ$8DRQM%_O;06]L@NWAYQJ<0E@XPF/ER9W=:6T&BSR]1^_GKR4^J_F"*]EC
MW,Y_K16?+A!(JU/)Y@?K^=TB[V*=;?Q6=>_5YF3O4MS82,R)]EWZ:*I:5!L:
MACJS?WD]'H32WL?7[_(4]=R2V1TQ:KM \&G189)&7SI@M/N\AU1R!'V?C:-4
M,%?7)#O_T_GI0!8>@PM/66QVRB-<>.[G#X.01>M"S_AT5^#O.M/6\D/O,:]/
MAN2>)>5,8"B[BZZIGI6F(N%NQ "GV9O:VRW3K^Y^U250]WW.+J=+)CIV^K(B
MF5(DW>#53YN+SU)28R\D.>4KU25EEN4_G@D=$+;2X_?'>QQ3Q4J8-@]!9V['
M[IJBKE43I?'LJ6& L-MNPKP*Y:9C,N!,/5EM!7X^G489^3LTZTKRQ1WNNTFT
M^>HD 2%I!_H6^V_)VQC %4#R(VUTKB'YC,0%'VI$331:;2L>H8DR0#LSL!+>
M[<ZQH"@N)G^@O71F5WWU6]K[M@K-<5'"!W":>_;^3*)]!NSI*F030^&=G]44
M2&]HZ=7G*'".>N<-04161X9CW*P,]6O/L.E-/C$+4^20I\W22P'8V!.ZC.G(
M5EF(]ZVI4'*O=9B8;R)'XA+C\N-(RE3&,U,R_3D#;:/=M3P\ MT[+/W=K@1'
MBR=$BYQYGYQU%8_>\PD1<Y@BT:*)179V4D-'SY2S,*P$Y2,3Z3%X<# PD9*4
MF)3R;#8S*RLS=M(W.C*::&#JQ8 FA0H;SNJ7]TN9F:J4UPG/>1/>6U1MFZ''
M "21PW!D+&^#QC1WKU#L:,6&I*]W:-#J\+?N89, Q2I1>RT55>W O:[.(?W:
MN&4Y#2VAS_&YD5*Z"B_*N]K[-/<6V:+=70=+ZM\AW8L6YY<+%M9J\3O)<;GB
M WI>W?%C7L03" YZ*(>CCB/<=G!'H+:[&Q#4PDG0KT-A0Y2?&RHH1?U+F^NL
M#>S06G\OXDI_&^K1 D]8;N#59^%B,=D'4;96'#LEP "8JU57\SFQCO!1C&JY
MIWQ1<=?GXGJ^\^PU[AQ>A\,,IC9L'HR9XUEWFTF43^D3'HUC@,G&Y-2E_02L
M@G#TG7B[*K3!>'[E:KL._%5\8S&AS<2.L@?<_HY.=Z-"5LS*2&0HX8"WKK1E
M^-.,3%>B6SA:'2-7"]V0<T6F=ON54J2INL7#-FI4!6J?VO$>)#R<J+\35M@T
M<8V#6E[$645*YL8[;L(WYD]P9FNSLS! !.UFP-XBJD=BEULSGV.A+*MZAT#&
MM[@(+;GROIY&_\%R)MT^3624V]+P-K<T/KOY=JR/7-7(M7IN::F"PLN7<E.2
M(FUAT5=FOFD,NVNMUI;(7'YY[MP=#OJIFC35LYSX-UD*V++\UNE4M!^C<Z>\
M$3S,CQQE:DSL<N/8O\C.)*!6=D,W[^^KKCT>=VTR;K!@#]IG'XS!32KS#<V5
M$=>N\(183L0_4'V:AJQ\5F"3\>2N0[6<MJ3&J^8+EA0?-@2I3=T9/CK'L\I_
MD70YK%K^PGK@-J@BK%9?$QBA))S%5%.2>T8_+8%((:4!EWQO(7[M97LQRA1-
M8X$!..EWL4L)!%"]B $*!J7#T1P8P&%4'?$< V16>NY5HZXUHG5$5]$>:!Q$
M'P;PZ5B*6E<^=#S8W:L^R.IYAP$XZ## GJ:B1BN":5,R%>F$,L$ \D/;CT%S
M/IS:[7%M%[SCC[Y5Q$JL5J P0"WBV1PME4O/=+G;TKE9N>5/@[0'Z=J[48&%
M::$F5,+HKJ*W,CZQ@CRQ*N,A@W1')6G['B4:,XLC)EGK:?NVJ/K5D# D)*_<
M^KT$@KUTAV<YE,*W38905.-5O7:C\6OOK\&M]^V0S!DO;NAJM5$/3I,&?%#F
M-#!RE*HOO#NBP#BHPO%%!=AY&7M9XZS861]O@:FG4V9U5V4_4/8X(&IL9:"H
MW/WQ]9=3+NA]AR'2H9A:<U2H)*V=%=G7_D,.\Z+< Z[%Y3K^JW)Y+NB1A"S3
MR0ME;RIZB+D5I[ERKRMH6I?1$W2T'!8A(1\'GMX/']*DB\T<[-?+:74CYR2/
ML%7M!'*NG\< ]Q%9+=EAT@TFHK^R&[ JZHUL=.,F[KXJ:J(\:9+<Q^MQ%&)+
MJ;<1514#61)9=,P:>LS$:^!*PVJWE"KYW&ZI568V$TWX)-/MK*I>#<A!>S^Y
MP-=A5D:[7R1']0/27F2=X;# ,-[8O^S52W_GQ"JWR1?)%KFXNL8/>#' !5OR
MZ=[%>^,\O],KFU%4I^QKU\U M,9H*ZMESTK.]A<O_[VKU:*PH] >3R/HMJG&
M>,P'CQ6ZSJ.(]3;^?GJ(V:0H#=-'CQ:F5]H!S=GR*F'): 83K?S'IK<_QG,Z
M[[)O!O ,-U+[RK7>++N;U3+836=)\NU. ',X*6'=0U(9=B/#L#N 9;9RJU6F
MU"/&>TE/J;A[IYCH913AHBWWGBV2OSBZ4)J(K-0?BM%[[N)PK8;9-P.<>?O5
M]I[75_)P_7I'Z=+(U/3&J;G8H (#$H-W"&/K8>%2ASY/M>UO2&^:Y^DQJN1K
M9[T^4W%Z?2;,]"7"<Y*6V&USAR,:?**7XHY6@KOD\P^*,W;B]-U7U1KOC2DK
M/JN7S_VL@E]7>K%!*R,I^5WB$V%%.&Q=NR;W6GIJI(BH9,1TI=];CQ70_4P9
MZ]9X9@(5,>"<D\0Z\RF5=XNJH=/3J&8,\)9V,QAM$5/+U,4P$+7W=<T:O.+E
M@P&6N<O]%T9BAR_(I,SKO.>S]\D(\%ZI?%SB[$ZVNA)MK)"8:AW;=YZ)U505
M2$M,>S238S&=HSGUS;"8MO<TM)5,*(DVC!!15R^?3O*DC^1!"OVUB_WCNC>3
M*S2:W'&C;67</J%>8P!,YTF&;)B* 41&UC& JBD'?>X#W6IH@0?NV2$]H4!E
M#Y5#<F=E^:B1;9\KNJ>UGR6&,@5=XP5?2K]CKU$5?=2[+WJ0O?QI-">AJPP2
MOM?#6F)89\#=6Q728) QUP3NXY;9DIE-X_?,Y>7N'UX8+/7A3?N\+.KL%S[5
MU2N\EB#;:8#OD45\'YO"[HYB$[\K6AIQ'B$BZF:ICW)3HS.49,2YOGVPT>E!
M#UOI7XG;Q ]D)HZ\H?4E7H\-9WNGC*2%1>F)K3F!5]:,1MBV3*QJN3)?VI,6
M5DH*+5*QSC=I;5UMR;)N*+DV+XX1-W11VR0B0-9Z^39OTRU\JC:UB[@?%3Y.
M[T07/!164S:9GC.E%+R+W_X$R"DV6J:5<%Z5WJB:+MWHTAOI<BTOB$SF%U 8
M>U\RSE!GGZ] >M,P,)S<] X33'I'_?YAE?/EAG%F1YOBYY^&O7TRKG-^-0[6
M:Z##W>N]1:G^" ,X(PS8>SVD(JV)38/:',KV^8VB'*<?&(4Z@%A<0FY;30SM
MD]@WG&;.B2L\E,JFTJ+WUKV).DSN[77]8-SOR$?LLO@T[D)88$"@#O^75^AP
M0?*"ODQ5_.QA41K7]F?7K(,G(LCDE5E>O4 ,L5+TM8=.A'J/5VEXP1=DMFKP
M_"1QK2>=W;V<^T4HX5I9%J(^IQ0V;G9444([=+L,0A+S3EVOKL([3&DJCAOT
M?/S5ZX6'BMWIXINC1_LXJ[YW;#C9_%ZL!W6UY%P[?-[<9_SH&ZKYBRC\RI?Y
M"/JC?>)5?[F:*K;;P:&&[C S[X<2^/^^#MM\A09=6(K?S,9F 'AP;"S_&O,R
MJQD6I0WQD W6,'GZ0/HR3=VBQ'PY[@SC4:H'6.:; 9?=.MS3)2[M&XU50T<Z
M\P?M%ZA".F>-XBC)UCE\U!P(>*1EC.^GIJ[GIT)GFQ+3PMI-9Y Q[(D8'"NF
M#'-*H];N"D5QJ&:(!FRTHR$FY*A/$I)G7M\FMVSKJYS_.)<GQ!4\M.[2UWC7
M9:1QF;'<-S*2//_09+OGPX2A+9PD/U7]_=P'J]U<QY7Q&1_UX5*7_4*5LS 9
MAT23VZ%:<M?.YV=L=')ZE?4#6=F"ZV?<@YCXM?1Q.R,6Y^@[*TOSRW?3):HK
M)";9:2S,7&8^#WH'%PAHJIRIAA;OAIQ[+ATD>)XM4FQA(B5')TY:H5X@7_C-
MS=U0UR+H\FZ4GBB7ZE-+2[--+3E47FB4X9S:3A36?MU8PT4B!G2]5#! O?XR
M^='^7JX[]5(\ZN6NQOX<TWK]PAH&<(R?9T)=[47'6F, @='<ZK6FP?C#A'>[
MH5&F*[IMJ&[(6ERF6UPDNG_1!*R(S<,O]YM8LQM[,2QY9%Y4D[77<^&UA6=.
M:5YZ+!R[8!OL/Q3E-&&W0*FHYD(.6<FTMV]/B@P)]PKR$RJ47X@YBHR;0JZZ
M%%YIJ55BB<#9/BMS/;^W*N&Z\+N%CL#F\ZG$S!.%^"II3><(AV[!\XHWH$CZ
M%G=LRK#ZD/XE0LU(M\R9B?K SRYS@[.FK"@DP/;.Y ?X]K6%W&N%_72WP$'!
M"R_OY:N(\J>)*5))=54KDSST7;A-!KS48WIY3L9$Q"_PDAE2SK2X+9,3:QBL
MNGS!C1U'I_MD"3PFQ?4?M7J]JUWQGAT9N&W<IA'Y?+*J-3.YH24?S.Y[UW;L
M>9$K7&.@M^!:M@PKK8G2;DAV=ZAWTG1_,6G#I&>98;WM]2"MPK"IXE-D?BD$
MI'<%8F])?-"%IH2"B*7LY!I>,?%)!1.G>DAB@+7X^&G:#U5X*)L!Y/J I#QM
MV/Z;T4->BM+=D;GF=NVVEPNDSTHRKGZDMTXHDFR^@%Z>Y+O;#!YU*N0(-"Z"
M-%F[WT])N$DL73M+'V>&9,_S-1?Q=.7,)$X.2O570G-&S^6<F@(,LO);ZSYJ
M:VYM;>!.R7)&1Y-L?U@MF<V&(5_73KB2L5]]V#:Q/M!* V4P"OAJ!J72&9!2
MMZ!\F1KY_/+S+Q9VYG&AET*:-+^M:^"EKZM2YN='L'GF2S;,LSGJ*3+[DA*Q
M,OL*$$F1WUN\+3V+ 8@W]M/6<?<3'$S?(+XD"7=*VB7N-*S5NA P99:SY^_Z
MM^76F(M>[.QPM6Y,T'C:7QX=Q=]ME$5E)8;@UH&:]^:<#\AEP)=OS?-\]-$1
ME7&EY2O%K<-')J<4%<U\A9I-KOM3X06>-4 \F:=FGB>YJO@%E>4KV]G%['Y6
MZB$NK/!RQ-VL2YS$2IT&Q+2<]1?:\X](GS&U'_I+%)M*( (1N[0^:*SK-^XC
M,$ 5K>=A,W<7^NT$HNUR\9%Q:)H%^MOL$1\&"&$W5<QU&^HR^1E]>I00,O&'
M4&Q^A 'J<*(Q /(;>?_'%XAIAWX,,%.,.D!J:2QA/WLW1\>D=<A1K(WHIJ'I
M433W* ;@)\O8$=M-0ZO&R**PW\1>Y7F%47I$5A.\.+0$DOI[*^'M*HH]"CV!
MNT^. 6QSX^-19]W(W9E6F(XD*S\>"5>CG+83UM*&V(^,%^?J5R]*C/X,BC#%
MZM=]G^)2T9:RU**[#3Z]\L%>-8JE$ET(+6U%[;<+.0.?Y'0.V3]\,+_AK\(O
M',&+#^=P:U"FU-55^O;L3BNY.Q11,5W92_KM:[ 2@U<LJ?#5":E,8CP"H+TS
MU@WUC&G)"0/H+R^JC$X%;Q:7(%XVMI'5H0T08A/I TB#?N]<Y7QHP0#)@&RY
M]*4-7"=A4IKF963IBYP0HJ%DF1L3UHV!T;T474H]YU$Q*G2IUZ6&VNA)H\3M
M15!=']+M7D]>>Z 4SA]Y@U.I0/@=05GAY=.,R#S""H#3,X"$?W/"TZAEMB&Y
MD D1K[Q)N$P^$[LIFHN(@-0068]*(_(/?4A?=8SE\]+03]$V!]EU=TYSY9=R
MNLL,PT(;Q<"+5AFYSJ]W<E-SFRK"/\O+<:0Q;VSG<BY%7416<1A$<U^G>)WT
MF2J7\.5Y:H@?/KU6<113QJUT(=R>@(R-TPU)K=I/$X9#]\TP *_,![0A$V61
M1J/#$S"T/!T#5)>7E0MI<C-J%$EZ"JO>*D]S[;W$:&BO<R5:RH?N:3C_GH>$
M#;$[C8JEOWO\:\?2&)?X!R5LBH9*3_INX/H=>O4'T5QY2()CJJ6F,N&M<5!]
M_U.C*:9K1&.*'3)11IGBR5KL/'[YL:6#!RJ6FC[F3*J+HB%W>8"IL;T1;UQF
M6NK8L#OOWLZU*77=TEE'R#1:KY!->OI+$A^*(F3>M&TL&+OXX4E:A9<>U YB
M8WEI>;PHPQ6&LJ]3BE=\58+/$67>1/>ZA,B(]9CR%+QHUIO^Z'XQSE7V[OY%
M]-@7RUT"STM<%]AROUDM9@J\\:A97H#(W,A1 HZH'NWM]GO:.+S/7G[_WIRB
M_S.=(MT9_!!AHN?[G(]VMC>/[%J+8X*G>V=+D!=<Z=_$@8W?5N27ABO)"BRI
M>5A%4NQ=1%15'S+9A6L,=#\O@+SJ&NW(VZ-MEY]2_K*2-S! 0EX]4'ZKQ"7-
M+*FNLZ-H:(#Z%?QUJQI822E0NKD\Y5UR'JNQS'V9@&'0*D0J[L9.X^M=&_:.
M<A/V#L,PFQHC/Y"KJ3;5*?U]D=![^2_[I7/4/7?)S0<OG%[N'9UTE;&H>9BA
M:^NT;L6?UFJ[M3!0'4_>*+OEMU[KX.7_J?U:>?QDJGO:L%;-B\# G+11ZO,H
MGD5*,:8'FF1#7Q6#OCRA>^+4U2W\\)KWI,8P9%AVF''"\=[HJ(9:\>O[R==?
M*E85D;-17<2)%A2BKC>8O/".P9O$NVU_S+YB$]&L_U(;,C*>?+_7=P-H(Y5Z
M%"EX3;?>(,R#K/#R;D].F?))5I//A&+' %/60WJNY'7#1QY/IUU75G)]W5DT
M%(U?G6=L^]SQACPZ(:'YHHNNN9'?X6 4 #2.2LJ@[XWLA6V$ED6>=<4Y+-MZ
MJ*XC5.0LS,<9)X07)W/1O$+B<VB5->O>"^>VDIT[NSA;M);Z+3J1^:)AF7MY
MY]SF@O0#C$0\9_KN4OQESUMW%-5;9=V!PM\CWV"?>@N5.]H<*A=QR.UVFP<%
ML[7N,AY%B(0:=M12O6CE3$H<+KUKMY!$HM&O^:T/1Q6'EM,^NWKUT&5 H\,Z
M"Y5T;Z;M!3.8J9,UFZ[K5%J37H3,C6K!D$(>#/#DW7:?\G:.Z53 -]X7##W=
M1LH>5OU;A-J(Y)'6_D,HW/+=X0+IT0CR"7],FK1&3)IW3SGG R&NNZQRFCO"
MM@P=7Z=776:&>6CM^T6&+HP@"0,/6,T+$^XVVG86=-\<7XLF>PN[5. GI'D=
MW-@:C>.KP62(VU..J'GFA*"I<D#P<*.0\ W*R9&%5=[@_4"FL%BUIS6N3 9]
M*PRU1YTI64E+WA'/_.-AT8//BC4,+?-]Z&RT##B=J0H"\S[B?Y =BD3N\("*
M[(+SI^US")],U8V1FN+J9..?Q]&^Q26B;(CS64]7XM'649(8-37U1N[U713;
MQYE7WJ5KFQ^JZ%?LBX<=,<"S\CSGPU.<&?TZ?5M,CGJ6NS3#@>'$W;HJ!"VC
M_%9Y^>=:F5,C R69.4FJ75UDWXV,(1-OR;F\LM4^=QGGT]@%6-<%SD8ICZZ<
M -C&QOBGM4]C!-</N7H'XB;4"_O:GJ-I!%497%NJ PJ<F\P"TR8P *AF(U@T
MV+3@P:V[=I?$"#<<5EF\(R1<D/W8!<4Y0M0#CPK9E1N(9,A:VBUC<A1GV[[O
M,HKL-+XBJKC(0>T*+?'3>JT>->4-M>2LM,;)C RS]U<8*\[.9X5<8IF[EG#7
MX+5'H(%T>G]RN K]Z[LTYFZ-"SXF B8+" UT#J(W)]D2,6Z  5J52$B:D]#&
ME?!@MXPI>)/E>O65*XV:U%J*:O:FP^\AX=&\6>0E_F,^A0>'&YXJ+4MS::_9
MF.. 1M,6!G>#@8=K>Q@@#0-DF^@U-@9_KD2,*S"UUN;DR;8R3>=\60RN?E'?
M)E=01(-,>C_8'UO_<<X9T2"( 1BJ!"PNQU_U^[0J/5CP?L#X&^*J45S<&]Q/
MI<1@\Y2'&N7RD.4VSF_NK@Y@-EXEJ))PPNJK[G,T;RE@(:M+B^DR<PET042V
M@9/^MDG"&RN3&VE17:-@![72/)&<@?Y#67+%XJ+(KT-[#AF%'\[W5YQ?8AP>
MZE^P5Z(D#_5?'D]LL."8\+U<VD6'LTIK%:GZ#!1GS2V89\7^C*W[Y2:[M&C?
MMSXT%?H40H(W5*,_3F/+ RFX+O[N<.@H=)=;1AF25RTEHS%T:,8;LX)@4KNW
M(3N(1'0[M,QA@.'X])@ AGOGM/>=%B9-_0>YUMG)MVJJ(\1067T=";<BM/QN
M4>/?&E(Q\K@U%"QRX-GP+:./]U_74QN-JV\#6EKU41RBTW'R8\*7U5Q;Z1"O
MO3$ VO\JQYP+F7JB[1L7!WNC.FY"L"JA:1N=O7731ZS'P!6O&\HBB5>OB=0/
MQ ]E%[H_>90?<]/+N 3-(!Y:/9E6BR:+\X]V%/:2"$ ]D"B,WWJ)72?P8X X
M92SON<J]TQB@3\-,(W5'^>B0Z1 YNE]6/.<!7_U;-)\#B"5B- \#5"(Q0$RN
M3T":$3<&N.PUNWF]S0N\9%@]4Q[2,BFYP;,U##NDN_B-/NU#!&_WZ8\N;*_%
M65/F#4!# G)'\U%\"0L:HS1:C.M/7]=7K+W-8IRW%U=\-(3"R?27/X@>J1[<
M]9)PLY@B5;Z=I[T6^ ";QN['\^XEU*8QS79AOZ-NZ/N(O8>"IH>EGP\M_DS\
MA-EWM(\G#F,F(9IB$@-8.FRL8@ :[/4Z0.?PHB>6^/+7>+0;!EADW4J$!%?W
M3$D,-0Z+_DXN^[ZYHBE;,, #'%0 !BC4;VM#$TD15H3NDJ-C1P;0T:-H,8_V
M/>WEE^@<^);Y;@@#Y->YTW'V6""+7;OXZ'I)1/F@')+KE*SVD1K^N9(CWE58
M$<>IJFE2+E@U:+J>RZ<K_:CK.9WL_>8B^\HYBBC;AU<M'QOO+S6-"*T8-A_5
M[\GE[O1G:'""]Q:CY[L^'SC3N55Y"<[?7L]M"XAGXC:YA.5V23C^+,LJ(JS
M*)^"Z>NMV/CK'C)I,@^>%[/MK6N0$NYB *;NYOGTT _F2+LS,;&,VY#'AK@J
MMG<W]! C(*1::G][_*Z:]H16X;K=H&F+XM74^.<3;0&],UW95U%B6VDM+9U5
M7ER!\.K&"J_YG&I,=[_%?JLK?&P1$5+B\1FMR[GC?QARX>R'U(3(+-I\?C@=
M3\ON!0H#XW5QT[W3N/V^:2.VWIVE,N$0U"&<MD8FI/_%S.=[XXW]51?O!Z(<
MI4*-D]$;$)?ZM\9OEM!#,+SP^!'1!/4;5VVR66UQ_1%T^EIR=,P>9^46_-B>
M'T'V'F, *IG-!X858MLM1^5PYEP7C\=LIJ8[H^LTD/7BV:$OR)M&]S;7.LH&
M!/=%MO@&&%A+/;L$%5B'I4=?ZWQ2N:8RF[)H$BOM*(C'$H;><IK=#+<4P%=[
M7+<FRGQUMRVW,E[29W^6H?PE]^5L_Z^D(& ,^8UZ*GWLMN;31,*F ,9*%\H5
ME68!!Y\14RAZG)1W=Z!:*8D+Y&@HEF'\Z%J54,&[S-??G#R*U-8_BNR:+WT=
M^"#J0&*Y4[4SY%Z949+7B<]EY#=\?N&MGGK<2DYF9T>/F%Y>ISV"<3W <D24
M[-Z(2/:A[=OZT@%C92EUV3,OQ& RQA>4I/;@;\O5YSWS5LH=-XM:+8:YV4-L
M^GUH@Q]GH%Z3%^?&KCK!><;G9(:6OH4@E52@E9H5F_0"MLTTBFC>H'<O.$6^
MC0=]R=Q0+"FJ-*%V\@1N3_E('YW:"!5>1NU^>5O\K?SNJ1;XQY QCK3Y<A(U
MBC1<JA8V&#K4Y.-TG&7^+(]1OWNQ(V"P(I(AIJG>:*9BT8A[,6$R;<N#[.BI
MA.0<>&]TQ%TC*/:H._8HT-97HLM5<ZJ8X;+@ZZF6I8O1*GY+%[GXSAAPN<1Z
MJR;VCR2>#WZFN42_PLYFY/FRR:NOR57.KM100*&5D[7LEHH=^^#'S%.(1Z_=
MMZAG<S2+9U?49M352DX5[]2;LU_BH:P:P "#K>G$Z'.U;;D)D93"@<.OC94F
M/NMK3_.YH^[)"OLW=^9Y&(=P<:E0NTB4O6G"GU^89U<YVV]RUW.,>CFV%^GN
M6CQZO>/>9RYE%M&ZD"#=;E3/(\(9B8E89':]7\_7X*DKDB66EG IW?8(D"S?
MI\>;#!*>:IT^OPZ6Y5;W]$);LC\/(5ADQ+!)O7JZ,'U(6NXH9"?U8+"D+U*[
M5'*H>-K[>;L12]$+4)"JT;.A <,*7WR\W%W_-[573:$8H,!(P<7(9[:U[S['
M?<WSW5I"K<&&C)TU3_9MQNQZPOPL+LD2>-6K+-]Q<M)88F8,VCF-ILA:'^(M
M=NEQO8^J7,4?I71HO81L-]M15M<?RQ"]U*A=Y!(*Z085!2NI?: :T'O#4;>A
M(CKDU]O:QY8*<7=EHC,EM'E8FS[/5@CK[BS83&.*5[L9QT7CDK&?R=3"H:%Q
M%@/4\*-9:X4$>;$1+^QIA^K%1^_Z&2Z<^:+YF,#?+-^XGH.ULU="0V1G]&#3
M<<1(NM"G=\&76NN"&A$Z"+%%J).]SL1:*OM">7,G9?[K49FS(-S8:"-TLFI_
MQ-VMBY9F=V]Y@^X:F4:&I^H#N6#2$!61WI6HTZ9AM^!N&9D/MN<"?<?(BG/)
MXRNK1-N5\,<TJ'7HYB,E C0#=X&YPA0Y0FD.E]Y'0Q-:.&UGNY/.$C+<O4A8
MYP;?ZMX-8M#/C4M#7?N(_I(UH8'FK+9!K+;5>S;E6F)3]_@R1-MU#!#"JQ]P
M",, -[&14KUX:U%V/_((^R'S5^K& $A2P@JO,@S@G(.824(\V=:NVRK>:31<
MG+V* 4ARYF,?KQOM/T*Y[9]N=SL#T5\=^;KH[ID$[[9?$.,3VJYL[I2.?YPQ
M9!)/=7[+GY-[_$5:;FI@53Y^B&%#0B!8M?6>4C,O&,(^(D+:8CMLW&(?;D/W
MC$UI@?.M#\5;)M:T\4:]( +H!8;WQ%)N&8:( )D"W(>+<Q$%SILKI!E%@CW\
MRJ3J$(B9\_;9VJQZJOUK#L+V>8KID>N-;'7<S2*,ZPV6%%^OW1^_&]H/[O'H
MKD53OT!5[+)[>2$6V]XRV#W*&KZ  9Z+!7<52C92!/K-MO2@H"/:G99VN\$7
MSRH+@V[!KRPF&_L9W@AJ']\0)REFD5"6F:X&NX=PES\H&> 9"4.&6<BN=01+
M*0IG"[[4)4G2)JL@R;*]?ZO]\:W>@& .G^L3J8\OS&'3V!IOV9C>3_NCZ\56
M7AY+RY-!C5Y?YQ@BG@U)ECM.9\V#-Z1[^@X= ^.IB\J[S+F:"*:2OYB;^4HW
M4E^-M->SO-F5#.N!0:XJEWC%P%L.WQ[Z54@4V05<>_^N4\1"FQY!YD,REH-S
M6<.(\\M-<^)])]:FT!>H^9JT[,"CAB.[5._:$B=Z9=QHI%&N>, 0O87#1/X%
M9'W)+IGZ\].//IGQ"^7W@03%WS?<\K#WX:4.3GPTDYX>=W/<G\W:A81XUVTR
M''R.P\(ZXBG.=;9P)P"7[>4G,FG/;)Y=)A0'Y2SY5\A,0"&:$0-POH=H3$F0
M0QV'];[4NKA:;-^;0>[?KNH>HA2VAGJ%OH^,=W5H*AK5&^?/YAP;ST@]#'KG
M&Q'X?O]\1B?(%++C$!7!Y#$#MC2IXTF@^W J.9@_5,2<""^(BVX:7TT]DXM$
ML\0B-.O!'OA14+C44VE'[&<D,]*:\QVMPZ6WC\Q;*31Q1;O[<8Z W=/;CE58
M9Z;" "L\1T?8 0[=P  8P(MG=S?<*.U(O Z;IZE"#DJ9U!N/8ML.S## 1?6J
MY_?6BW]O:F4&H;UE=V9#9P@QP%-<80Q0_I8ISYH% WP9.OX//\C^=EER_( :
M^D7U)X]TICWET*,7Q2W5**-JM#F#]M*#50U4E AB'YM4O0_M?%8E@@'TPQ8A
M3$ZC:K^6JZ;BHWL:O$=UA!M,Z!Y36=D]YC7&#=EAV0-73^L#.\3>^*+\N$:1
MQD%I7\?S$3%XU<_@.N>+ 02J9_![9%N,)B+W]R\-!-,8\=ZBM=VF-:[79^"Q
M*))T%5?5<W&IKQ=D<-+6:5.]?$_K U>0"V-X9GK6ZR>.B!;C:O?6\O?T#HFQ
M[&5*I\I8\6PMIF?EM'#,<9AU0JV;SOF8+F  B[YL7L0+TT_WAM#V&$!,$G<_
M"342E^2^W?!Y>6[W*UQ)GW'^X6KUBSUY%?TBEWNGZ?6GGL 0C;<D//"I1(74
MM%5#&XBF R_ZON]JBSF*OVJOATK).WO%+3":[G52C@K+0\GH0)1N]TP0#H21
MD=I.?A@:N<748;J&^GQ9#AM7<-$FR#>H0A^3)<1,Y5I<8JZ9O<GH4#]R.2Y]
MZ)6SBG([$X<S-51'-28W(4B*NZN:Y7)Z1EISQ^W<$.-"$Q!5HIC J[ LGY%-
MZF)!^\T-GUWE-^:<*:$[+[#>NS>YK47WRFSX0N,KW /+#I5TV9H!M)KA6:FV
MK'.B %H/T6J4C0'>Y-9]C=G M5&6*Q9=IJ"7K#S(I^O2-^V1+GV6\JB88,3E
MU?["SHJA>%+S6%9(2DZ=[J<E/7@<1\(*>'HHS@"Y(C*?V=Z;5TK5&_#H4)F
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MS>;C!\M!#5!RTZ.C>O.,38%,'9JTN+*;)KI)K,/0:I]5R<K#9:V (63+95P
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M^[6Y&Y4&<EXT-C;6S(^+W6F^Q;$V\#IB@#5PW(L!6R#ED>8T0@;F/@7FX.8
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M'CK!/>C!]VEK__):<.UT^.+6\[(C!EH5W:J3ABM-#A,OWK$=PYQK?"%_ @^
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M?YGE+_\!4$L'"+";4:*Z3@  PFP  %!+ P04  @("  8ALY4
M    $0   &<S,S(U,#AG.3AU.#DN:G!G[+P'6%3+LR\Z!)$L(#E)S@/, $-&
MR3GGJ# S9&9@R*"(2) <)">5*)DA(Z" Y*C P)!4LI(4%,SZ +=N]W_O<^XY
M[W_>O>]^'ZUKK:[JJOIU5U?7ZE[ZS7?L]Q< "BTU334 #@XN3B!.( #P?8<J
MU\ 9Z8/T=D9ZLHD)BP*DE#1U\?$!1X4J]*$ZY(3D/B8!%(!_*2=M,B?5M3_:
M<4XH$D^4"\)'W]?'T]?GB#QSS#/P]C%V0"+=3R0T$3YP.,+7XV?]^*GLCCJF
MSYWH&KL$'$LHN?@<Z_QI$X[2L_> FZA:F/P"^Z%@@$(B'8WA/KZ>^@ZNT",V
M*<  @ (@C_XX M@ Q@ XP ?@"_ \42'V_"7]TXR2NP_BCQZ1.OBZN/NX($Y,
M'M%$)]+*NI;:/T8L>RR/"_S+B*E^&[&^IX\+$N%]Q*4[&9>G#^+G((X&Z8#Z
M11@Y>>O^V8)"*/])('S^)'0<W+U_$7I./GZ_"%4/=Y5?Q)$?_S2M!'5S^L,1
M/SH(,%)74CYZX)W486QL,*2OPR7DBU^3J8Y"_(VGY/YW.244S,04X:/&:>3N
M\WLP*+G#V/Z);^3M[G/"-PAPO^02[WGW!YO8#P[U0:)4['WL?T6%@9.!]\^H
M.*[_\50^<0+<T>>?S)L<A>T_\8VA[C_X!BCH)<M?; HH"NEI[@P_FMRC^7)!
M./WT&/EQ@]%1GY20/CY(#W<DPND/%=*?+<==^(U/]I-OY.+D_'L#R<^&H[[]
M8A]'#M[.CS[@/?HF < %X/Q\GD05STD;^9\CN!CZQPHC.R&/ER3K"<WP5QKO
M[0E-]%,/YT2+]\=J)?XY_3]0\ Y.ZAH $4?'HQ;WHSO!'TH_./>RLG]QP"=W
MJZ/[3X[$R1WX)^?$YH>3^M%*^OZ/!>_E<?/_?-N)+PA_>/2D7P#<2S^N/]I8
M?_GI!\UX7,.3_=7['T,X6A#X;XX; *"C$8L!?BV8OY3?>,?2.'C_B<"O\F=Z
M "!\W8_##/<8W 'IBX!Y_\OJA/J ?G;V.*1_"R? O\0=0.E7?/[HAM&O\#L9
M"(&WNPL4[FWFKG.\@'#^@G/FI.VH0G5TG3TA-%5^LWW6"87T]?P+BP")<G%R
M^94;58V/E?1/>$<TF;VO#U(=CH"C['W@L)/>!WK^3.W$/X2/.<<MFAY.;/\;
MQH_GBW+_RPOBQ/E_Y>AZ._WU)4)@[^YC8N_T%QXY%'ZD!P_PT?36,-'5^9FF
M"'^R_R),Y(Q$!2FZNSC]]-2Y'X/7^,D^]BX,[FCO>Y*GB/S@*)]_$#?[R?ZK
M.(F#DS+2'8GZS;F4/Q24U'\U''=##XDX?A+Y(#V/7D;>\-\=1^Q^Y,B_<4D=
M3A+>W_@DJ..T]B_LDW7$]T/O.)POO@'\R:<\J>+\R#_XU"?4\802G-#'\@#"
MH#\<=O?H8C^JO@  Y(\N0CL /0#G._;[#H!4$89T@%]6U@7@?M\%D)]0 %CH
ML=[W>4 X@)20D)"(D)2(B)22A)B$DN8<*>DY&OKSYVG.GZ>G)#TI?SS^N>"0
MD9"0D9-1D)-34).3DU,?W\BI?ZA0_E<,?.\$4!(>=?XN'@X' )<2!X\2Y_OB
MT4")O_?@7#SJY1F<DP(X+:?EM)R6TW):3LMI.2W_[?)]Z9*VLX^/IXR(",);
MV/YX*R@,17J(!-A[BH"$144 <A<#/.VA;G ?-@?XT8%$GN-UVR,.-A>8/(>Y
MA*ZHKJ<RW-E%(P@%-P[2,X$&N4&E81P7%8CE F0"/#P]X#[V; $>[@AOF0!Y
MCA/C,D?U8[8(!]N)B(^;/,?)!I3-0M> 31F)@K-!A$6!4%%1,!L(!!$&0<0E
M(1 A-K H&"0B"A8!20/!8C(@41E12;8_"H<"\=%=#@5SE#%24?L#[XB2Y_AC
M8/[^_L+^8L)(E-.1NK3TL1DP&'@D ?0.1/C8!P 1WIP_C/RTHP+WAJ)<3CXR
ML1W3]D<'*A]Y#@YBMM_*'P/S\/P%](\>_"<E&/27CN?16>JD:S"H"-P=[@%'
M^'@?Z8'^4<_SYW?$?X;\U?P? A_U5E?W/^^OA\<_:GK[J/KY_.>:WL=')!$C
MN#?2%P6%J_H=#87SGTT9P1W_.Z:.Q/^<H.,Y.AJ&C#(*;N]S="P[.C,J_(B@
M/[^R@D'"8#8^<Q<$#.GOS2\G\J_R_V0*KG)T*1S%&1@H"@*"0"9@L(P82$9,
M#"@J*2,J^IN1'Y+_8D,7"7-Q#/P'&Q)B,J)_L?&;Y+_:.%H8,'L?^_^2E=]E
M?[,#@\HX(E$>]CX*+A[V3G 1N*>WHYS(G]S?1'^%B\S) ?>H7W %<3F1?V+_
MHY:FLK(!"NGHX@Y7\#925V+35%6&@*0A$"!8&/2[F=_D_CI@75T9382WCSWB
M^!N)PA%#V,4%)B,.AXE)P"7$@6"0F /005P< K27E  #):2A4#!<5%H:[  Y
M\<%?U?]F6@4)]3U>3D=M/U(/# D],O]GO^!@:3%I<1 (Z.#@X @4<Q"' J6E
M1!V!8##$WEY47 (F*BG]$^@W8W\#^O&IQM[]-YGCL<".P$".,+"4.$@""!<[
M2C=B$N+B0"E'>P<@2%I,ZG@<HF*.H)\0_V#F;U :+MY',1RH\)=5=9*RC.%>
M?^7^;'!W.4EAGO8H[Y/O1/(</Y<5Q]\4CG5.%KJ,/?0X^2E 3^(=)B?R%^Y_
MK.;R]^G\K[G@;^K_,8:_,QSQGZW3WZ3^8R/>2$<??WL47-'IR-/_R_SQ3SI_
M<[;(#V__?S$+2,3QQZS_QCP<X=@?O6;A*&\%1Q32@^U'+O!$.+'Y(-GL/3W=
M7:#VQR9$_!"P/]+OKW7Q$^0W&_\;Q^IM[_?OQ9N4N!@<!G:4 H)$CZ(,(BD.
M!SJ(24& #O;V#C"(M#U< @S]=^--XOCO_^%X^],VU-D>X02'*8C\5/S)^+]I
MVB1$[<%28!@8" ,=Y6$)Z:.L+RUYE);A('$X!"PF#I6"2?[;T_;[2_1TVOY'
M,LO_(ID<YYO?-R+_)U,+#(YR^>]$Z6^]_.4GMO_;!OUO+\S_VG;L=&'^"_>O
M^[&?>[R_[]]^;E9_Q*;:<73]UR9;[N08]>^DTG]1_R?KL/^W6]J_J?^3=>2_
MNW'^#\W\W?._.?C745_D7\[Z/SXDB/SQ)4&!^$CWYV>,?PJ7__ER"G(*<@IR
M"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*
M<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"O(_#$+\
MYP\#P!$P>0Y_CHL*W^<!R@"<?[,<&_EW;>#\^ 6I(%PC/!S*G[\@U0-@!>
M<''Q?O_I*(*S9PAQ\(GP<(F/V@TH #CXN#BX>/AG"/%("<_B /!Q\<X0X)P%
M$%)2G:<FHJ%CIP499DQS*%K8>]U(G^'D>T//Q0N65--P=/)/1HM#I,S,[W4]
MY>91BHQJ7E(^LLA\!/570 #^&1P\ MRSA$>MAD=]P\7!P\$_<Y;H# '^&;PS
M)]@ 2BIV@O/4H+,<BH;VG*9>-Y)O3]& H:GWT$\GW]!R*:ET<8LI&RWMB3OX
M]$@8>]\L,/$M"@N/2&GX/@<@Q3L"I,2C!%P$?/LF-:DG/ADOOJ)K)DOBL^FA
M__)V'83%*/=+1M1BY^@(L7AN O4Z0W=G3/<,EUN O\(9*='J>PS=[:YZ5-73
MV!%R)['Q?3OPVMJM':XDI1UJ)X2U)J2;2]87)_?\I/V4Z\-OUDQQ!C.[,^5,
MY=$P'"RR:8M^$8M<5TJ2+RUIS GTU2S=: 1.0&XT<YC"!>1TB!<4J=B&&5BG
M[I[#<CJ0^<D#XX'\=@@C&> :L))M/VH\O\]K0W+Q\"(Z<&ZQJ-=BZ 5/$&B<
M_7:/.C5F FH'+Y7(#&\;M"(I:9^\3S;$M^!Y??2BR+O$>5+Y_'ZG,@=9I;1]
M;TP\IP1W?N.@((GI/*==W@VZ@?G&!&O3"@T&!MXTXD$FP);))O#]/0Z_!S")
M=U/I#Z<OG$OM+9=9?!<1R8/ 9\5[DZ"JIM'&H<9EWXDP<2DSV\>.KQV>58K9
MG7^Y%:R._8:UW9[5&77VOG9/NMC=!XLI&3>F3M))[\VAJ/+9!>JX=FCUB$=W
M+;8]LCPW&,P[_UP]DWR1J.VB7S]<EE%6A$OZ06L6F(<YRIF[U4@'ENJJ"WQ%
MBR&N2(KE#M0QU'ZN2"&VG<*SWN_+?V]-CU9*M]BD*[)FF*:>S,:5U?LA*)S[
M(ZWJA;[*#7HMDUWJHX>>6.X*\T?3_)[#NB(C786S;.@>R>04=M EF91A$HU.
M !%OXB4BF<\=(MH*\:^QD54([)+.(5,XD43D_;I'BKVPIB05BQ3<&GEL$C65
M'^99&K>+UI.B*F(]ZC1>*2.3-.B#H^LA.'=%:DPL;H.A+WAE;<PFC B?0A%[
M\TF87!=KM\0[-D5 &"$;A>("15 8X4M%%D76H(W,:9\5W5^Q]_^KBH0Y8C$F
M7O4^Q''<8"2[G)NGWXF9@U5C.]?=Q!X_E"21W[F;RN4^L\V:P..LMU>!]GIP
MHM%\I@L?S8'Q??LPNNJ9RK'"VURH@0JN4'=_?@:G3<BKF9)/,X*9R\F="P6R
M@&O%)DD*=9#IBBW<H.NO/J'/7W\N>\&Z_[5M#A,#$@L97@S##Q9\:[PBP;--
M#7#*5JS%,'XN=N2AXN'F2[RBR.C5*_<I??_!2-8.G;/[8&(7=%\_K$\3*.<K
M0V$A84:\ZW >ZZ.J684EY,ZWC$YJJV7BFS<U5$R\UU&1"&A5F-!WZ-)[@][J
M(MF%QH #"G@Z 9+[KVH;68N"?!YFO.2?SS##DN^&%]%_OHH[XBW,SZ?&0.,(
M^?R-NR5R;[7IT;"5X3<P.NZ)]7:_BW-I,)(H/0P8#9:7)1 E6$WW53/=YYWF
M'+CCV-2?_GCDZX+_RX;0"$+':)O;M0#!--XR ."<<7-^]1=(-SJ"NRDU=X6A
MSS/5B:$OI')%JM]]Y6*.U!J1$PN)Z/P]_/R<8,@'U_YPIQI\A95>??UZT_0G
M:%?&55D\C_I7>T_J8[C8LYH@M,KR'@UI*<-\_,7%>I"Y)XUP^NZGBR3=Z%RH
M5$?G2IMF<MW.[-RLK%DY?KI:OW^5$'MFN",HZ9(C/MDGEEML\0>#?H^ V*NJ
M^(E-TV],]F9&:M6RT#;FM:8F0[=XS8R&JL-WZLFFPLCG[LL@&KHORJ-?FE2$
MTGD@37L15HEL0I%PPINX?5GN3"97>_V]ENZ-QEH5RAT #V_PIZ<N/TFUI^NH
MZUL,:^+D3>NSZ'44"1@ &^CB5#;!2Z[LOBY2 50Y2'?>"26$J[$K\H9<>*J'
M9("RS^6/^7E?U&^P3>W^IM4Z^]FTFF0"6@$W>WT](KU3:)R&A!H[^=JR6&N2
M@Q9NNM(D]^+@,/Z/L+U0;U4QA8W:<-_O5NZM;<HRY*Z1&BY*:H>(.HC.V7!-
MQOA+.1LHP_>'_*4\(FWL//.U"Y76M;I-"NVTQ5H<"4.#[M],31G85E*E=B71
M%(I+[KM;7W?C807X8ZX=05P6<R^6SS@^F702M+B6%J:,3\GFXFZ9-Y! _$2=
MZ^V DBI3*YYI89O=$_/WO?Z:[F69X^2T"S<J[ILN\+>_'Z/E4DT9O2">RR]?
MEZK1W]>6N]%=DGRPON-)S7D@[%=(9!5R[UX\RCP=PB(UZ)A&5)Z7F!7IDDI^
M-_\N"CDOU_.</_9=\-S6 80TO=2=G*54>295'#6;G46S&!31:I23<HE/KB>F
MIJ&B2=-D>IC6M1!I,$:?'=]WD>*M2DP_TL#$*.FCEW%W8NYWP-7S.+P\3[ [
M*2;CL2S+ESL7BFT6$[1:F?T#T,P)$"2E*=>U#^I7J!-Z-2] NX!=>)KHW<?N
M?O6/#_OITAZ Q!XG=3GIB%RY\A:CRAQ>JUZ;XNJ>HJ_.2ZJ2\,G==A[]^,'[
MT0O<SP;7>!Z,FEIK^[I527')-D<W6Z36,Z["E4I)&+CA;39K5FYC?I!B_5!:
MI2XY93*X<';M)4^-:>J4HD%2N]?+W9'"NYI%- ZD26PIH]&P!.+&0EY[[E@Q
ML#+Q[1:#748U9J@YTMRH?!+MD:L46NDV9&F;+F6O>[@F5$<3CW.(F&_JX>,M
M*7,*2IU70.B>*Z@NT*Y<"AAOM\E\>FF\1=@K84U,3PPI"3PL8T]Y42>M[BZD
M]GS,0C>S&WKX8K&TNVCC"\NT[1+9#,:-/][YVYE4,/(;A[R'SI<\<X\<T"7M
MYO4S38/#(3<?6O5"WC>;LN[+Y'B;O?;P;[Z<'5VEH=&W(("E>Q72UJ*L8=)$
MHSW]X2M3?2-_D^IM1[GMAEU.)WSW 2(D/T95*SMRJM+\<L]B/V%1'I76M'2
M6V.QMGCEF_G,R![50N&<A'T>0?'@A'UQ+C*5>K7>2XD<%:K"7Z?V9(;QVP :
MF@9I0CC,24E;W[@96UJM[V=[E>2ZU"3CBW*>HS8>)14=E?J(K[#,8!]II6;C
MNY'GS>]1DJ-DTLQLE1+.RV!4'P>5WBA23YZ6PN0MAA5PI/L[R@J4W^?.B@8
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MK[H/KW$X"QK%'W@ZS)0HX7.%0;_Y_B8AIZ?BC(?:5Z%BF8^DO@_>WY^/=JQ
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MEMPSLZ5<IU$R[\U$]*WXF]C>DXE0,7EX=30/7*Z)+X[ML7P3&#()=[O"9V-
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MW"+K-R]8-V:BS:DCEZ.\MQR9D1G$\?$J[3/\6R!N7DX-41/J[:1KS][$-:_
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MN&MQ=R=(BQ=M@0*E]NSSO=_N7OOM__O?S#UGSLPUYQ![SJ3T;A[F!QU,D*J
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MT=H=PNS$A&E\[RR@-UJ=?#P+D <47-:U ^;>4H:>Q@V#EPH5WYH(LVY==2!
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M(.#&J2PWC<GB?!BBZ$=M3QCU#O9U^6L'L:43@@NC: U\5D()!W=+)=U$V9&
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M&_L+=3YW'RIJ7L)T@ENS.%-;B(&?@OA.QH00KJ=0&0.?IW75@IX!C$MN-AG
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M>YR?G5GAP@:E,RBEZ%.I/V00=,>'(>_[!44, D;A:%$Z/NWUG(X4\Z=(XD#
MQ\;SP2@2!7VP#\8:59] @V9>$[+"[K;0?-="(VGO:J''9Y;B;E>9OJ_CI[X_
MXV?&<JPI11[W)1:.S&M!+73.OR=2FAO)_$/ 3TO0)P)3'.M%H,8K7LTPZNQC
M7#H.TW!H/^X-,5ILM/(U^)7R*N;J&%:HW,))$+U3K*2Y?>V-796_)I@B@&*8
M1$9+VMJ;GH*[3S&MC'N0EXYYI\BT.GDG2#*-5%HE:9!;B+F1S X*DH/\-KWE
MSE)%Z^*HC[+$E":'90A@8NW[#=,X\1V>H0:.^AO8Z$4;GGVZ_KND8CKQEF#[
MNA;D(S//LC%G"Q_LB3.'A<F0Q:(RDQVV62^YC)L1F<'3VA6J&ZS,S$_TT>".
M"U#$Z674O:!-\_F^BZ%/N\]=Q)5@:L-TG;K]0^8D-F??C.#!,K_+SLPQFD][
MYLW]Y</2I?M9O0K/KVZ6;Q^^P37*^^NS7D%5^RNS"';\A"(U4WOZ'$-0IU*,
M[F9<[%MN!/60%AII28UX+ ;\1"W-J;H?P2?Q3/RG44GDW0[#,.CX97TM7:XY
M/O&!IGCNCY-GX4  I/1Q?;WF,EN,AH8[3[PAI^JZ9X=!-4KA?O$#1D=RM#N,
MTW::,K:]W;A#86<TL"<PP0"VHB->,OK\T 3I38&,"^V)P?":VT.:3>2(V;NR
MILYH#;=262@79U,ICF5B>6H%93]E>B/K_E=N>VP_-"!-2\P"@IIZ=;GCI72Y
MT;UR];GZ>X,ZVY3FVYJAI8?Z*,4V2-*YJ&^ \!8W"?K^>2BCVE+?$=$S1NN#
M'A@:1E7?G]54T-QN\9]%UGZ">16Y($)_11X1^^-HK0)NKI>^SH?M;#$( J8'
MZA"L2=5H4UA+7F,,A+:,D8Z2W[):J)2!SPK*7PP&O(U.02'N01J,*Q]2Y3)[
MS<(O7L,]W@E/0DJC U(G30W?"HS=2):!&_T<GF?173SX-G+P<(7@LA9/!D/I
M6FPM0T/?3_+*Z9NDW"@98G,EWA$*:L/9S-2@@EM!V4JI,YTP4BJS]&M973Q
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MAY<'G@$O3ZSY0,\6C/\=0L>;B,.OOU!RUWY,(ZBW7'!U[XKQ2.3AT-A>#/V
M^>\R252_RTS0_EBT$@7[\W[':F61:;5]=OYTLO..^W:6^YKLA&=GG;..Z1D
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MK@9*X3#@Y0JQ,..AY2KBV?"@\8%$VG+F>MU9ZE]7:K8F9>#$DP.E= C(/XI
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M?*#3/-)=$X5+(D+8QV% =M0+0=VQBO3X#$!JWY^TK1B.J"W&0C&O!;(??D5
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M78H2E (H(6QU9HC*G'ST7FI=<@K"*S[*M$(BIMQ+/+?B?$=,X/N=H)A"O?'
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MDRU;D\7@KV3-A%5.*HF.2>',$C47%P:X8S:1FDR:]*.!0%W51V6N$5E.>S(
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MX%^BYHM%:T#VBVZF+)?FY#113Y4;[6R!FFS(MP,29GEO<O@E ?F7;O%LI=Y
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MCV'A+.TS;[?KRBX.-8[;^$*T"+MQ:;M.IQ=+Q8S]^^H%&M,:_2Q#6NF#';O
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M>"TR,#(R,#,S,2YX<V102P$"%  4  @("  7ALY4%@6^;H@0  !$[P  %0
M              #_%@  86-L>"TR,#(R,#,S,5]C86PN>&UL4$L! A0 %  (
M" @ %X;.5'YA9P+X00  2F$$ !4                 RB<  &%C;'@M,C R
M,C S,S%?9&5F+GAM;%!+ 0(4 !0 " @( !>&SE0U/B>?N'0  (_]!@ 5
M              5J  !A8VQX+3(P,C(P,S,Q7VQA8BYX;6Q02P$"%  4  @(
M"  7ALY4IKE56]=<   Q6@8 %0                  WP  86-L>"TR,#(R
M,#,S,5]P<F4N>&UL4$L! A0 %  (" @ %X;.5,'Q0,XD @  $P4  !$
M            &CP! &0S,S(U,#AD97@R,S$N:'1M4$L! A0 %  (" @ %X;.
M5&MR?,&&V@4 W90^  \                 ?3X! &0S,S(U,#AD<S%A+FAT
M;5!+ 0(4 !0 " @( !>&SE0E1\G7A-\  -</ 0 1                 $ 9
M!P!G,S,R-3 X9S Q83$Q+FIP9U!+ 0(4 !0 " @( !>&SE2'AJQZJZ\   S?
M   1                  /Y!P!G,S,R-3 X9S R<S(R+FIP9U!+ 0(4 !0
M" @( !>&SE1&=:>NDIP! )S2 0 1                 .VH" !G,S,R-3 X
M9S T830T+FIP9U!+ 0(4 !0 " @( !>&SE2!B\#6]H(  &"X   1
M         +Y%"@!G,S,R-3 X9S X830P+FIP9U!+ 0(4 !0 " @( !>&SE3W
M$&17GT0  "QQ   1                 //("@!G,S,R-3 X9S X830U+FIP
M9U!+ 0(4 !0 " @( !>&SE3!.!8;W_8! .). @ 1                 -$-
M"P!G,S,R-3 X9S Y=3 T+FIP9U!+ 0(4 !0 " @( !>&SE2B,6)'_<X  '@H
M 0 1                 .\$#0!G,S,R-3 X9S$Q:3$U+FIP9U!+ 0(4 !0
M" @( !>&SE3(O1-:-]H   U( 0 1                 "O4#0!G,S,R-3 X
M9S$Q=C(P+FIP9U!+ 0(4 !0 " @( !>&SE2$Q6.!LGD! -;V 0 1
M         *&N#@!G,S,R-3 X9S$U838Y+FIP9U!+ 0(4 !0 " @( !>&SE1+
MC206_6H! %V_ 0 1                 )(H$ !G,S,R-3 X9S$U;C$S+FIP
M9U!+ 0(4 !0 " @( !>&SE2TV1US8W@! *WQ 0 1                 ,Z3
M$0!G,S,R-3 X9S(P830R+FIP9U!+ 0(4 !0 " @( !>&SE29<WNZ_.$  %@V
M 0 1                 ' ,$P!G,S,R-3 X9S(R:3$U+FIP9U!+ 0(4 !0
M" @( !>&SE2YA1A>]?@! /=T @ 1                 *ON$P!G,S,R-3 X
M9S(R<S(R+FIP9U!+ 0(4 !0 " @( !>&SE3%$27@H48  />>   1
M         -_G%0!G,S,R-3 X9S(V83 Q+FIP9U!+ 0(4 !0 " @( !>&SE3>
M7>7UIE4" 'VP @ 1                 +\N%@!G,S,R-3 X9S(Y;CDU+FIP
M9U!+ 0(4 !0 " @( !>&SE13H>V:Y>L  %4O 0 1                 *2$
M& !G,S,R-3 X9S,S:#@U+FIP9U!+ 0(4 !0 " @( !>&SE29):RELC@! &>.
M 0 1                 ,AP&0!G,S,R-3 X9S,S:3$T+FIP9U!+ 0(4 !0
M" @( !B&SE1X=$'4CX<! ,$@ @ 1                 +FI&@!G,S,R-3 X
M9S,V83(P+FIP9U!+ 0(4 !0 " @( !B&SE2UR;D,4V\  /'    1
M         (<Q' !G,S,R-3 X9S,Y8C<V+FIP9U!+ 0(4 !0 " @( !B&SE1'
M1@U+2>H" 'E* P 1                 !FA' !G,S,R-3 X9S0P9C@R+FIP
M9U!+ 0(4 !0 " @( !B&SE2,O4E.E7<  ('/   1                 *&+
M'P!G,S,R-3 X9S0Q>#8S+FIP9U!+ 0(4 !0 " @( !B&SE3-W$H!(X4  *K>
M   1                 '4#( !G,S,R-3 X9S0R8C@S+FIP9U!+ 0(4 !0
M" @( !B&SE3$Q:7V<-,! &AN @ 1                 ->(( !G,S,R-3 X
M9S0R<38V+FIP9U!+ 0(4 !0 " @( !B&SE0&*V2V_Y   ##M   1
M         (9<(@!G,S,R-3 X9S0S;C@P+FIP9U!+ 0(4 !0 " @( !B&SE3P
M*%@ZD<D  "(< 0 1                 ,3M(@!G,S,R-3 X9S0S>C4T+FIP
M9U!+ 0(4 !0 " @( !B&SE0<I.>%Q%$! ,C> 0 1                 )2W
M(P!G,S,R-3 X9S0V:#@T+FIP9U!+ 0(4 !0 " @( !B&SE3Z/ZX'K'P  -"S
M   1                 )<))0!G,S,R-3 X9S4S;S$T+FIP9U!+ 0(4 !0
M" @( !B&SE1;9K/(>D,! #6A 0 1                 (*&)0!G,S,R-3 X
M9S4U>C0T+FIP9U!+ 0(4 !0 " @( !B&SE385(G]3*0! #D! @ 1
M         #O*)@!G,S,R-3 X9S<Q;#(S+FIP9U!+ 0(4 !0 " @( !B&SE0B
M06*PXG8" (K; @ 1                 ,9N* !G,S,R-3 X9S<W9S@R+FIP
M9U!+ 0(4 !0 " @( !B&SE1C=*I ?P<" #9A @ 1                 .?E
M*@!G,S,R-3 X9S<Y>C0Y+FIP9U!+ 0(4 !0 " @( !B&SE3F[(B<)WD  -W6
M   1                 *7M+ !G,S,R-3 X9S@X<#@X+FIP9U!+ 0(4 !0
M" @( !B&SE1(JKU*NJP  *??   1                  MG+0!G,S,R-3 X
M9SDQ93(P+FIP9U!+ 0(4 !0 " @( !B&SE2PFU&BNDX  ,)L   1
M          04+@!G,S,R-3 X9SDV8S(U+FIP9U!+ 0(4 !0 " @( !B&SE2:
M0?F%">@  (LY 0 1                 /UB+@!G,S,R-3 X9SDX=3@Y+FIP
79U!+!08     *@ J &0*  !%2R\    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
